PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Andreishcheva, EN; Kunkel, JP; Gemmill, TR; Trimble, RB				Andreishcheva, EN; Kunkel, JP; Gemmill, TR; Trimble, RB			Five genes involved in biosynthesis of the pyruvylated Gal beta 1,3-epitope in Schizosaccharomyces pombe N-linked glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							AMYLOID-P COMPONENT; XANTHAN GUM BIOSYNTHESIS; MADS-BOX-FAMILY; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; FISSION YEAST; CELL-SURFACE; CRYSTAL-STRUCTURE; CAPSULAR POLYSACCHARIDE; PYRUVATE ACETAL	The N-linked galactomannans of Schizosaccharomyces pombe have pyruvylated Galbeta1,3- (PvGal) caps on a portion of the Galalpha1,2- residues in their outer chains (Gemmill, T. R., and Trimble, R. B. (1998) Glycobiology 8, 1087-1095). PvGal biosynthesis was investigated by ethyl methanesulfonate mutagenesis of S. pombe, followed by the isolation of cells devoid of negatively charged N-glycans by Q-Sepharose exclusion and failure to bind human serum amyloid P component, which acts as a lectin for terminal PvGal residues. Mutant glycans were characterized by lectin binding, saccharide composition, exoglycosidase sensitivity, and NMR spectroscopy. Restoration of the cell surface negative charge by complementation with an S. pombe genomic library led to the identification of five genes involved in PvGal biosynthesis, which we designated pvg1-pvg5. Pvg1p may be a pyruvyltransferase, since NMR of pvg1(-) mutant N-glycans revealed the absence of only the pyruvyl moiety. Pvg2p-Pvg5p are crucial for attachment of the Galbeta1,3- residue that becomes pyruvylated. Pvg3p is predicted to be a member of the beta1,3-galactosyltransferase family, and Pvg3p-green fluorescent protein labeling was consistent with Golgi localization. Predicted Pvg1p and Pvg3p functions imply that Galbeta1,3- is added to the galactomannans and is then pyruvylated in situ, rather than by an en bloc addition of PvGalbeta1,3- caps to the outer chain. Pvg4p-green fluorescent protein targeted to the nucleus, and its sequence contains a MADS-box DNA-binding and dimerization domain; however, it does not appear to solely control transcription of the other identified genes. Pvg2p and/or Pvg5p may contribute to an enzyme complex. Whereas a functional role for the PvGal epitope in S. pombe remains unclear, it is nonessential for either cell growth or mating under laboratory conditions.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Trimble, RB (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, C-547,POB 509, Albany, NY 12201 USA.	trimble@wadsworth.org			NIGMS NIH HHS [GM23900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Alvarez-Buylla ER, 2000, P NATL ACAD SCI USA, V97, P5328, DOI 10.1073/pnas.97.10.5328; Alviano CS, 1999, GLYCOCONJUGATE J, V16, P545, DOI 10.1023/A:1007078106280; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; ARAKI S, 1991, EUR J BIOCHEM, V198, P689, DOI 10.1111/j.1432-1033.1991.tb16068.x; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bahler J, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P13; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BEBAULT GM, 1973, J BACTERIOL, V113, P1345, DOI 10.1128/JB.113.3.1345-1347.1973; Becker A, 1998, APPL MICROBIOL BIOT, V50, P145, DOI 10.1007/s002530051269; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOSSIO JC, 1986, BIOCHEM BIOPH RES CO, V134, P205, DOI 10.1016/0006-291X(86)90548-6; Bossio JC, 1996, CELL MOL BIOL, V42, P737; Breton C, 2002, BIOCHEM SOC SYMP, V69, P23; Burke D., 2000, METHODS YEAST GENETI; Cerantola S, 2000, FEMS MICROBIOL LETT, V185, P243, DOI 10.1016/S0378-1097(00)00099-9; CHANDRASEKARAN R, 1994, CARBOHYD RES, V261, P279, DOI 10.1016/0008-6215(94)84024-5; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Chiovitti A, 1997, CARBOHYD RES, V299, P229, DOI 10.1016/S0008-6215(97)00017-7; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Cutler JE, 2001, MED MYCOL, V39, P75, DOI 10.1080/714030992; de Nadal E, 2003, MOL CELL BIOL, V23, P229, DOI 10.1128/MCB.23.1.229-237.2003; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; GARDIOL AE, 1986, J BACTERIOL, V168, P1459, DOI 10.1128/jb.168.3.1459-1462.1986; GARDIOL AE, 1987, J BACTERIOL, V169, P1161, DOI 10.1128/jb.169.3.1161-1167.1987; Gemmill TR, 1998, GLYCOBIOLOGY, V8, P1087, DOI 10.1093/glycob/8.11.1087; Gemmill TR, 1996, J BIOL CHEM, V271, P25945, DOI 10.1074/jbc.271.42.25945; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; Gemmill TR, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P405; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; HA YW, 1991, FEMS MICROBIOL LETT, V78, P49, DOI 10.1016/0378-1097(91)90253-7; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HART GW, 1995, ADV EXP MED BIOL, V376, P115; HASSLER RA, 1990, BIOTECHNOL PROGR, V6, P182, DOI 10.1021/bp00003a003; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hennet T, 2002, CELL MOL LIFE SCI, V59, P1081, DOI 10.1007/s00018-002-8489-4; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HIND CRK, 1985, BIOCHEM J, V225, P107, DOI 10.1042/bj2250107; HUANG KM, 1995, MOL BIOL CELL, V6, P485, DOI 10.1091/mbc.6.5.485; IELPI L, 1981, BIOCHEM BIOPH RES CO, V102, P1400, DOI 10.1016/S0006-291X(81)80167-2; Jamai A, 2002, MOL CELL BIOL, V22, P5741, DOI 10.1128/MCB.22.16.5741-5752.2002; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; Jung US, 2002, MOL MICROBIOL, V46, P781, DOI 10.1046/j.1365-2958.2002.03198.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Kojima H, 1999, BIOSCI BIOTECH BIOCH, V63, P1970, DOI 10.1271/bbb.63.1970; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; Leslie MR, 1998, CARBOHYD RES, V309, P95, DOI 10.1016/S0008-6215(98)00103-7; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MACHLERBAUER A, 2003, NUCLEIC ACIDS RES, V31, P383; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; MARZOCCA MP, 1991, J BACTERIOL, V173, P7519, DOI 10.1128/jb.173.23.7519-7524.1991; Mata J, 2003, GENOME RES, V13, P2686, DOI 10.1101/gr.1420903; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Mesnage S, 2000, EMBO J, V19, P4473, DOI 10.1093/emboj/19.17.4473; Miyata M, 1997, ANTON LEEUW INT J G, V71, P207, DOI 10.1023/A:1000166426509; Mo Y, 2001, J MOL BIOL, V314, P495, DOI 10.1006/jmbi.2001.5138; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakai K, 2000, ADV PROTEIN CHEM, V54, P277, DOI 10.1016/S0065-3233(00)54009-1; Neiman AM, 1997, GENETICS, V145, P637; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen O, 1996, MOL GEN GENET, V253, P387, DOI 10.1007/PL00008604; Parolis LAS, 1996, CARBOHYD RES, V293, P101, DOI 10.1016/0008-6215(96)00190-5; Peng XA, 2001, APPL ENVIRON MICROB, V67, P3413, DOI 10.1128/AEM.67.8.3413-3417.2001; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Sadykov M. R., 1998, Molekulyarnaya Biologiya (Moscow), V32, P797; Sambrook J., MOL CLONING LAB MANU; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Schaffer C, 2001, EUR J BIOCHEM, V268, P857, DOI 10.1046/j.1432-1327.2001.01961.x; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SILVER RP, 1988, REV INFECT DIS, V10, pS282; Soares RMA, 2000, BBA-GEN SUBJECTS, V1474, P262, DOI 10.1016/S0304-4165(00)00003-9; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; SWAMY MJ, 1991, CARBOHYD RES, V213, P59; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; Tanaka N, 1999, J BACTERIOL, V181, P1356, DOI 10.1128/JB.181.4.1356-1359.1999; Tanaka N, 2001, YEAST, V18, P903, DOI 10.1002/yea.740; Thompson D, 2002, J MOL BIOL, V320, P1081, DOI 10.1016/S0022-2836(02)00514-4; TRIMBLE RB, 1987, METHOD ENZYMOL, V138, P763; URBANIKSYPNIEWSKA T, 1992, ACTA BIOCHIM POL, V39, P177; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yabana N, 1996, MOL CELL BIOL, V16, P3420; Yoko-o T, 2001, FEBS LETT, V489, P75, DOI 10.1016/S0014-5793(01)02082-8; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527	109	28	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35644	35655		10.1074/jbc.M403574200	http://dx.doi.org/10.1074/jbc.M403574200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15173185	hybrid			2022-12-25	WOS:000223303400061
J	Sansen, S; De Ranter, CJ; Gebruers, K; Brijs, K; Courtin, CM; Delcour, JA; Rabijns, A				Sansen, S; De Ranter, CJ; Gebruers, K; Brijs, K; Courtin, CM; Delcour, JA; Rabijns, A			Structural basis for inhibition of Aspergillus niger xylanase by Triticum aestivum xylanase inhibitor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; XIP-I; 3-DIMENSIONAL STRUCTURE; CELL-WALLS; PROTEIN; WHEAT; CRYSTALLIZATION; IDENTIFICATION; ENDOXYLANASES	Plants developed a diverse battery of defense mechanisms in response to continual challenges by a broad spectrum of pathogenic microorganisms. Their defense arsenal includes inhibitors of cell wall-degrading enzymes, which hinder a possible invasion and colonization by antagonists. The structure of Triticum aestivum xylanase inhibitor-I (TAXI-I), a first member of potent TAXI-type inhibitors of fungal and bacterial family 11 xylanases, has been determined to 1.7-Angstrom resolution. Surprisingly, TAXI-I displays structural homology with the pepsin-like family of aspartic proteases but is proteolytically nonfunctional, because one or more residues of the essential catalytical triad are absent. The structure of the TAXI-I.Aspergillus niger xylanase I complex, at a resolution of 1.8 Angstrom, illustrates the ability of tight binding and inhibition with subnanomolar affinity and indicates the importance of the C-terminal end for the differences in xylanase specificity among different TAXI-type inhibitors.	Katholieke Univ Leuven, Lab Analyt Chem & Med Physicochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Food Chem Lab, B-3001 Louvain, Belgium	KU Leuven; KU Leuven	Rabijns, A (corresponding author), Katholieke Univ Leuven, Lab Analyt Chem & Med Physicochem, E van Evenstr 4, B-3000 Louvain, Belgium.	Anja.rabijns@pharm.kuleuven.ac.be	Courtin, Christophe M/Q-1916-2016; DELCOUR, Jan A/P-4182-2017; Delcour, Jan A/A-7636-2013; Gebruers, Kurt/AAW-8622-2021	Courtin, Christophe M/0000-0002-1203-9063; DELCOUR, Jan A/0000-0003-2954-1022; Gebruers, Kurt/0000-0003-4720-1515				ALBERSHEIM P, 1971, P NATL ACAD SCI USA, V68, P1815, DOI 10.1073/pnas.68.8.1815; BAILEY D, 1994, PROTEIN SCI, V3, P2129, DOI 10.1002/pro.5560031126; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bento I, 1998, ACTA CRYSTALLOGR D, V54, P991, DOI 10.1107/S0907444998001048; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUGBEE WM, 1993, PHYTOPATHOLOGY, V83, P63, DOI 10.1094/Phyto-83-63; CAMPBELL RL, 1993, P 2 TRICEL S TRICH R, P63; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Christophersen C, 1997, STARCH-STARKE, V49, P5, DOI 10.1002/star.19970490104; Christov LP, 1999, PROCESS BIOCHEM, V34, P511, DOI 10.1016/S0032-9592(98)00117-4; Courtin CM, 1999, J AGR FOOD CHEM, V47, P1870, DOI 10.1021/jf981178w; Debyser W, 1997, J AM SOC BREW CHEM, V55, P153; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fierens K, 2003, FEBS LETT, V540, P259, DOI 10.1016/S0014-5793(03)00276-X; Flatman R, 2002, BIOCHEM J, V365, P773, DOI 10.1042/BJ20020168; Gebruers K, 2002, J ENZYM INHIB MED CH, V17, P61, DOI 10.1080/14756360290018611; Gebruers K, 2001, BIOCHEM J, V353, P239, DOI 10.1042/0264-6021:3530239; Green JA, 1998, REV REPROD, V3, P62; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ingelbrecht JA, 2001, CEREAL CHEM, V78, P721, DOI 10.1094/CCHEM.2001.78.6.721; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krengel U, 1996, J MOL BIOL, V263, P70, DOI 10.1006/jmbi.1996.0556; LESLIE AG, 1992, JNT CCP4 ESF EACMB N, V26; MATTHEWS BW, 1974, J MOL BIOL, V82, P513, DOI 10.1016/0022-2836(74)90245-9; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payan F, 2004, J BIOL CHEM, V279, P36029, DOI 10.1074/jbc.M404225200; Payan F, 2003, BIOCHEM J, V372, P399, DOI 10.1042/BJ20021802; Prusky D, 2003, MOL PLANT PATHOL, V4, P509, DOI [10.1046/j.1364-3703.2003.00196.x, 10.1046/J.1364-3703.2003.00196.X]; Qin Q, 2003, PLANT J, V34, P327, DOI 10.1046/j.1365-313X.2003.01726.x; Ramalho-Santos M, 1998, EUR J BIOCHEM, V255, P133, DOI 10.1046/j.1432-1327.1998.2550133.x; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Rouau X, 1998, J CEREAL SCI, V28, P63, DOI 10.1006/jcrs.1997.0180; Sansen S, 2004, ACTA CRYSTALLOGR D, V60, P555, DOI 10.1107/S0907444903029330; SATOH S, 1992, PLANTA, V188, P432, DOI 10.1007/BF00192811; Suurnakki A, 1997, Adv Biochem Eng Biotechnol, V57, P261; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; WALTON JD, 1994, PLANT PHYSIOL, V104, P1113, DOI 10.1104/pp.104.4.1113; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; Wu SSH, 2002, J BIOL CHEM, V277, P49055, DOI 10.1074/jbc.M208804200; Xie S, 1997, P NATL ACAD SCI USA, V94, P12809, DOI 10.1073/pnas.94.24.12809; Yang J, 1999, ACTA CRYSTALLOGR D, V55, P625, DOI 10.1107/S0907444998013961	47	104	108	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36022	36028		10.1074/jbc.M404212200	http://dx.doi.org/10.1074/jbc.M404212200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166216	hybrid			2022-12-25	WOS:000223303400104
J	Bjelke, JR; Christensen, J; Branner, S; Wagtmann, N; Olsen, C; Kanstrup, AB; Rasmussen, HB				Bjelke, JR; Christensen, J; Branner, S; Wagtmann, N; Olsen, C; Kanstrup, AB; Rasmussen, HB			Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROPELLER DOMAIN; PROLYL OLIGOPEPTIDASE; SERINE PROTEASES; DPP-IV; CRYSTAL-STRUCTURE; CD26; INHIBITION; IV/CD26; LOCALIZATION; EXPRESSION	Human dipeptidyl peptidase IV (DPP- IV) is a ubiquitously expressed type II transmembrane serine protease. It cleaves the penultimate positioned prolyl bonds at the N terminus of physiologically important peptides such as the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. In this study, we have characterized different active site mutants. The Y547F mutant as well as the catalytic triad mutants S630A, D708A, and H740L showed less than 1% wild type activity. X-ray crystal structure analysis of the Y547F mutant revealed no overall changes compared with wild type apoDPP-IV, except the ablation of the hydroxyl group of Tyr(547) and a water molecule positioned in close proximity to Tyr(547). To elucidate further the reaction mechanism, we determined the crystal structure of DPP- IV in complex with diisopropyl fluorophosphate, mimicking the tetrahedral intermediate. The kinetic and structural findings of the tyrosine residue are discussed in relation to the catalytic mechanism of DPP- IV and to the inhibitory mechanism of the 2-cyanopyrrolidine class of potent DPP- IV inhibitors, proposing an explanation for the specificity of this class of inhibitors for the S9b family among serine proteases.	Novo Nordisk AS, Prot Struct, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Prot Sci, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Canc & Immunobiol, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Med Chem, DK-2880 Bagsvaerd, Denmark; Univ Copenhagen, Panum Inst, Inst Med Biochem & Genet, DK-2200 Copenhagen, Denmark	Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; University of Copenhagen	Rasmussen, HB (corresponding author), Novo Nordisk AS, Prot Struct, Novo Alle, DK-2880 Bagsvaerd, Denmark.	hbrm@novonordisk.com						Abbott CA, 2000, EUR J BIOCHEM, V267, P6140, DOI 10.1046/j.1432-1327.2000.01617.x; Abbott CA, 1999, FEBS LETT, V458, P278, DOI 10.1016/S0014-5793(99)01166-7; ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; Abbott CA., 2002, ECTOPEPTIDASES CD13A, P171; Ahren B, 2004, J CLIN ENDOCR METAB, V89, P2078, DOI 10.1210/jc.2003-031907; Ahren B, 2002, DIABETES CARE, V25, P869, DOI 10.2337/diacare.25.5.869; ASBOTH B, 1983, BIOCHEMISTRY-US, V22, P117, DOI 10.1021/bi00270a017; BERNARD AM, 1994, BIOCHEMISTRY-US, V33, P15204, DOI 10.1021/bi00254a032; Brandt W, 2000, ADV EXP MED BIOL, V477, P97; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER P, 1991, BIOCHEMISTRY-US, V30, P6142, DOI 10.1021/bi00239a009; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; DukeCohan JS, 1996, J IMMUNOL, V156, P1714; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Hiramatsu H, 2003, BIOCHEM BIOPH RES CO, V302, P849, DOI 10.1016/S0006-291X(03)00258-4; Holst JJ, 2001, SCAND J CLIN LAB INV, V61, P75, DOI 10.1080/713783697; Holst JJ, 1998, DIABETES, V47, P1663, DOI 10.2337/diabetes.47.11.1663; HOPSUHAV.VK, 1966, HISTOCHEMISTRY, V7, P197, DOI 10.1007/BF00577838; Hughes TE, 1999, BIOCHEMISTRY-US, V38, P11597, DOI 10.1021/bi990852f; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Oefner C, 2003, ACTA CRYSTALLOGR D, V59, P1206, DOI 10.1107/S0907444903010059; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Reva B, 2002, PROTEINS, V47, P180, DOI 10.1002/prot.10076; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Szeltner Z, 2000, PROTEIN SCI, V9, P353; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001	35	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34691	34697		10.1074/jbc.M405400200	http://dx.doi.org/10.1074/jbc.M405400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175333	hybrid			2022-12-25	WOS:000223134800074
J	Dave V; Childs, T; Whitsett, JA				Dave, V; Childs, T; Whitsett, JA			Nuclear factor of activated T cells regulates transcription of the surfactant protein D gene (Sftpd) via direct interaction with thyroid transcription factor-1 in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; ALVEOLAR MACROPHAGES; RAT ALVEOLAR; SP-A; BINDING PROTEIN; HOST-DEFENSE; DEVELOPMENTAL EXPRESSION; TRANSGENIC MICE; INNATE IMMUNITY; MESSENGER-RNA	Surfactant protein D (SP-D) plays critical roles in host defense, surfactant homeostasis, and pulmonary immunomodulation. Here, we identify a role of nuclear factor of activated T cells (NFATs) in regulation of murine SP-D gene (Sftpd) transcription. An NFAT-dependent enhancer modulated by NFATs or calcineurin and sensitive to cyclosporin was identified in the Sftpd promoter. Ionomycin and phorbol 12-myristate 13-acetate further increased the activity of this enhancer, whereas VIVIT, a potent NFAT inhibitor peptide, selectively interfered with the calcineurin-NFAT interaction and abolished enhancer function. Gel supershift and DNase I protection assays identified DNA elements that bind NFAT in the Sftpd promoter. Calcineurin and NFATc3 proteins were detected in the embryonic and adult mouse lung epithelium, and the mRNA expression profiles of the NFATs were similar in immortalized mouse lung epithelial cells and alveolar epithelial type II cells. NFATc3 and TTF-1 activated the Sftpd promoter, synergized transcription, co-immunoprecipitated from mouse lung epithelial cells, and physically interacted in vitro. Components of the calcineurin/NFAT pathway were identified in respiratory epithelial cells of the lung that potentially augment rapid assembly of a multiprotein transcription complex on Sftpd promoter inducing SP-D expression.	Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Dave V (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, 4403,3333 Burnet Ave, Cincinnati, OH 45229 USA.	davev0@cchmc.org	Dave, Vrushank/K-5262-2012	Dave, Vrushank/0000-0003-4044-2658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63329] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderibigbe AO, 1999, AM J RESP CELL MOL, V20, P219, DOI 10.1165/ajrcmb.20.2.3348; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crestani B, 1998, J IMMUNOL, V160, P4596; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; Dave V, 2000, MOL CELL BIOL, V20, P7673, DOI 10.1128/MCB.20.20.7673-7684.2000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146, DOI 10.1165/ajrcmb.23.2.3855; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Haidaris PJS, 1997, BLOOD, V89, P873; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; He YC, 2002, J BIOL CHEM, V277, P19530, DOI 10.1074/jbc.M201126200; He YC, 2000, J BIOL CHEM, V275, P31051, DOI 10.1074/jbc.M003499200; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V278, pL75, DOI 10.1152/ajplung.2000.278.1.L75; Ikegami M, 2001, AM J PHYSIOL-LUNG C, V281, pL697, DOI 10.1152/ajplung.2001.281.3.L697; Jain-Vora S, 1998, INFECT IMMUN, V66, P4229; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LeVine AM, 2001, MICROBES INFECT, V3, P161, DOI 10.1016/S1286-4579(00)01363-0; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; Mannervik M, 1999, BIOESSAYS, V21, P267, DOI 10.1002/(SICI)1521-1878(199904)21:4<267::AID-BIES1>3.3.CO;2-3; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; Mason RJ, 2002, AM J PHYSIOL-LUNG C, V282, pL249, DOI 10.1152/ajplung.00027.2001; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mucenski ML, 2003, J BIOL CHEM, V278, P40231, DOI 10.1074/jbc.M305892200; OGASAWARA Y, 1992, LIFE SCI, V50, P1761, DOI 10.1016/0024-3205(92)90059-X; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Palaniyar N, 2002, J BIOL CHEM, V277, P26971, DOI 10.1074/jbc.M110080200; PARK KM, 2004, J BIOL CHEM; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reid KBM, 1998, IMMUNOBIOLOGY, V199, P200, DOI 10.1016/S0171-2985(98)80027-2; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; Suck Dietrich, 1994, Journal of Molecular Recognition, V7, P65, DOI 10.1002/jmr.300070203; Tino MJ, 1999, AM J PHYSIOL-LUNG C, V276, pL164, DOI 10.1152/ajplung.1999.276.1.L164; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Whitsett J, 1998, NAT GENET, V20, P7, DOI 10.1038/1654; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002; Wright JR, 2003, J CLIN INVEST, V111, P1453, DOI 10.1172/JCI200318650; Wright JR, 2001, AM J RESP CELL MOL, V24, P513, DOI 10.1165/ajrcmb.24.5.f208; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Xu XS, 1998, AM J RESP CELL MOL, V18, P168, DOI 10.1165/ajrcmb.18.2.2824; Yan C, 2001, J BIOL CHEM, V276, P21686, DOI 10.1074/jbc.M011378200; Yang MCW, 2003, EUR RESPIR J, V22, P28, DOI 10.1183/09031936.03.00117702; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	73	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34578	34588		10.1074/jbc.M404296200	http://dx.doi.org/10.1074/jbc.M404296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173172	hybrid			2022-12-25	WOS:000223134800062
J	Junutula, JR; Schonteich, E; Wilson, GM; Peden, AA; Scheller, RH; Prekeris, R				Junutula, JR; Schonteich, E; Wilson, GM; Peden, AA; Scheller, RH; Prekeris, R			Molecular characterization of Rab11 interactions with members of the family of Rab11-interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; CANINE KIDNEY-CELLS; BETA-CATENIN; MEMBRANE TRAFFICKING; RECYCLING ENDOSOME; BINDING-PROTEINS; IDENTIFICATION; COMPLEX; DOMAIN; RAB25	The Rab11 subfamily of GTPases plays an important role in vesicle trafficking from endosomes to the plasma membrane. At least six Rab11 effectors ( family of Rab11-interacting proteins (FIPs)) have been shown to interact with Rab11 and are hypothesized to regulate various membrane trafficking pathways such as transferrin recycling, cytokinesis, and epidermal growth factor trafficking. In this study, we characterized interactions of FIPs with the Rab11 GTPase using isothermal titration calorimetric studies and mutational analysis. Our data suggest that FIPs cannot differentiate between GTP-bound Rab11a and Rab11b in vitro ( 50 - 100 nM affinity) and in vivo. We also show that, although FIPs interact with the GDP-bound form of Rab11 in vitro, the binding affinity (> 1000 nM) is not sufficient for FIP and GDP-bound Rab11 interactions to occur in vivo. Mutational analysis revealed that both the conserved hydrophobic patch and Tyr(628) are important for the GTP-dependent binding of Rab11 to FIPs. The entropy and enthalpy analyses suggest that binding to Rab11a/b may induce conformational changes in FIPs.	Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Sch Med, Denver, CO 80262 USA; Genentech Inc, San Francisco, CA 94080 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roche Holding; Genentech	Prekeris, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Sch Med, Rm 4520,B111,4200 E 9th Ave, Denver, CO 80262 USA.	Rytis.Prekeris@uchsc.edu	Junutula, Jagath Reddy/ABD-4753-2020	Junutula, Jagath Reddy/0000-0002-5942-4428; Peden, Andrew/0000-0003-0144-7712	NIDDK NIH HHS [DK064380] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064380] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; EKLOF SK, 2001, EMBO J, V20, P6203; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Goldenring JR, 2001, METHOD ENZYMOL, V329, P225; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hickson GRX, 2003, MOL BIOL CELL, V14, P2908, DOI 10.1091/mbc.E03-03-0160; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Junutula JR, 2004, MOL BIOL CELL, V15, P2218, DOI 10.1091/mbc.E03-10-0777; Kessler A, 2000, DIABETOLOGIA, V43, P1518, DOI 10.1007/s001250051563; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Lindsay AJ, 2002, J BIOL CHEM, V277, P27193, DOI 10.1074/jbc.M200757200; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Meyers JM, 2002, J BIOL CHEM, V277, P49003, DOI 10.1074/jbc.M205728200; PEDEN AA, 2004, IN PRESS MOL BIOL CE; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Prekeris Rytis, 2003, ScientificWorldJournal, V3, P870; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	74	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33430	33437		10.1074/jbc.M404633200	http://dx.doi.org/10.1074/jbc.M404633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173169	hybrid			2022-12-25	WOS:000223039700051
J	Michaely, P; Li, WP; Anderson, RGW; Cohen, JC; Hobbs, HH				Michaely, P; Li, WP; Anderson, RGW; Cohen, JC; Hobbs, HH			The modular adaptor protein ARH is required for low density lipoprotein (LDL) binding and internalization but not for LDL receptor clustering in coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; ULTRATHIN FROZEN-SECTIONS; FAMILIAL HYPERCHOLESTEROLEMIA; MOLECULAR-MECHANISMS; CYTOPLASMIC DOMAIN; HUMAN-FIBROBLASTS; CLATHRIN ADAPTER; ENDOCYTOSIS; AP-2; CATABOLISM	ARH is an adaptor protein required for efficient endocytosis of low density lipoprotein (LDL) receptors (LDLRs) in selected tissues. Individuals lacking ARH (ARH(-/-)) have severe hypercholesterolemia due to impaired hepatic clearance of LDL. Immortalized lymphocytes, but not fibroblasts, from ARH-deficient subjects fail to internalize LDL. To further define the role of ARH in LDLR function, we compared the subcellular distribution of the LDLR in lymphocytes from normal and ARH(-/-) subjects. In normal lymphocytes LDLRs were predominantly located in intracellular compartments, whereas in ARH(-/-) cells the receptors were almost exclusively on the plasma membrane. Biochemical assays and quantification of LDLR by electron microscopy indicated that ARH(-/-) lymphocytes had >20-fold more LDLR on the cell surface and a similar to27-fold excess of LDLR outside of coated pits. The accumulation of LDLR on the cell surface was not due to failure of receptors to localize in coated pits since the number of LDLRs in coated pits was similar in ARH(-/-) and normal cells. Despite the dramatic increase in cell surface receptors, LDL binding was only 2-fold higher in the ARH(-/-) lymphocytes. These findings indicate that ARH is required not only for internalization of the LDL.LDLR complex but also for efficient binding of LDL to the receptor and suggest that ARH stabilizes the associations of the receptor with LDL and with the invaginating portion of the budding pit, thereby increasing the efficiency of LDL internalization.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75290 USA.	Helen.Hobbs@utsouthwestern.edu			NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; Cohen JC, 2003, CURR OPIN LIPIDOL, V14, P121, DOI 10.1097/00041433-200304000-00002; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; Eden ER, 2002, J CLIN INVEST, V110, P1695, DOI 10.1172/JCI200216445; ESSER V, 1988, J BIOL CHEM, V263, P13282; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Licht SS, 2003, BIOCHEMISTRY-US, V42, P2916, DOI 10.1021/bi026059v; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LOUIE LG, 1991, AM J HUM GENET, V48, P637; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Mishra SK, 2002, P NATL ACAD SCI USA, V99, P16099, DOI 10.1073/pnas.252630799; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Soutar AK, 2003, ARTERIOSCL THROM VAS, V23, P1963, DOI 10.1161/01.ATV.0000094410.66558.9A; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; Traub LM, 2003, J CELL BIOL, V163, P203, DOI 10.1083/jcb.200309175; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zuliani G, 1999, ARTERIOSCL THROM VAS, V19, P802, DOI 10.1161/01.ATV.19.3.802; ZULIANI G, 1995, EUR J CLIN INVEST, V25, P322, DOI 10.1111/j.1365-2362.1995.tb01709.x	40	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34023	34031		10.1074/jbc.M405242200	http://dx.doi.org/10.1074/jbc.M405242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166224	hybrid			2022-12-25	WOS:000223039700114
J	Sarkar, A; Sreenivasan, Y; Ramesh, GT; Manna, SK				Sarkar, A; Sreenivasan, Y; Ramesh, GT; Manna, SK			beta-D-glucoside suppresses tumor necrosis factor-induced activation of nuclear transcription factor kappa B but potentiates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; GLUTATHIONE LEVELS; HYDROGEN-PEROXIDE; FACTOR-ALPHA; INHIBITION; MANGIFERIN; CYTOKINE; KINASE; OVEREXPRESSION; CELLS	Mangiferin, a natural polyphenol is known to exhibit anti-inflammatory, antioxidant, and antiviral effects. However the molecular mechanism underlying these effects has not been well characterized. Because NF-kappaB plays an important role in these processes, it is possible that mangiferin modulates NF-kappaB activation. Our results show that mangiferin blocks tumor necrosis factor (TNF)- induced NF-kappaB activation and NF-kappaB-dependent genes like ICAM1 and COX2. The effect was mediated through inhibition of IKK activation and subsequent blocking of phosphorylation and degradation of IkappaBalpha. In addition, mangiferin inhibits TNF-induced p65 phosphorylation as well as translocation to the nucleus and also inhibits NF-kappaB activation induced by other inflammatory agents like PMA, ceramide, and SA-LPS. Mangiferin, similar to the other known antioxidants, NAC and PDTC, inhibits TNF-induced reactive oxygen intermediate (ROI) generation. Since intracellular glutathione (GSH) levels are known to modulate NF-kappaB levels, we measured the levels of GSH. Mangiferin enhances glutathione level by almost 2-fold more than other antioxidants, and at the same time it decreases the levels of GSSG and increases the activity of catalase. Depletion of GSH by buthionine sulfoximine led to a significant reversal of mangiferin effect. Hence mangiferin with its ability to inhibit NF-kappaB and increase the intracellular GSH levels may prove to be a potent drug for anti-inflammatory and antioxidant therapy. Mangiferin-mediated down-regulation of NF-kappaB also potentiates chemotherapeutic agent-mediated cell death, suggesting a role in combination therapy for cancer.	Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India; Texas So Univ, Dept Biol, Houston, TX 77004 USA	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Texas Southern University	Manna, SK (corresponding author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.	manna@www.cdfd.org.in						ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Aucamp J, 1997, ANTICANCER RES, V17, P4381; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHENGUANG F, 2003, J BIOL CHEM, V278, P2072; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; Collins AR, 1999, BIOESSAYS, V21, P238, DOI 10.1002/(SICI)1521-1878(199903)21:3<238::AID-BIES8>3.0.CO;2-3; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Damianaki A, 2000, J CELL BIOCHEM, V78, P429, DOI 10.1002/1097-4644(20000901)78:3<429::AID-JCB8>3.0.CO;2-M; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Futakuchi M, 1998, EUR J CANCER PREV, V7, P153; Garcia D, 2002, INT IMMUNOPHARMACOL, V2, P797, DOI 10.1016/S1567-5769(02)00018-8; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Guha S, 1996, CHEMOTHERAPY, V42, P443, DOI 10.1159/000239478; Hutter D, 2000, J CELL PHYSIOL, V183, P45, DOI 10.1002/(SICI)1097-4652(200004)183:1<45::AID-JCP6>3.3.CO;2-G; Ichiki H, 1998, BIOL PHARM BULL, V21, P1389, DOI 10.1248/bpb.21.1389; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kumar A, 1999, METHOD ENZYMOL, V300, P339; LEVESQUE A, 1995, CYTOMETRY, V20, P181, DOI 10.1002/cyto.990200211; Li H, 1998, BIOL PHARM BULL, V21, P1322, DOI 10.1248/bpb.21.1322; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEYER A, 1994, EUR RESPIR J, V7, P431, DOI 10.1183/09031936.94.07030431; Miura T, 2001, PHYTOMEDICINE, V8, P85, DOI 10.1078/0944-7113-00009; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Moreira RRD, 2001, BIOL PHARM BULL, V24, P201, DOI 10.1248/bpb.24.201; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NUNN CJ, 1991, FOOD CHEM TOXICOL, V29, P73, DOI 10.1016/0278-6915(91)90070-N; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; Saccani A, 2000, P NATL ACAD SCI USA, V97, P2761, DOI 10.1073/pnas.97.6.2761; Sanchez GM, 2000, PHARMACOL RES, V42, P565, DOI 10.1006/phrs.2000.0727; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Shi MJ, 2004, AM J HYPERTENS, V17, P450, DOI 10.1016/j.amjhyper.2003.12.019; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; WATTENBERG LW, 1980, CANCER RES, V40, P2820; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yoshimi N, 2001, CANCER LETT, V163, P163, DOI 10.1016/S0304-3835(00)00678-9; Young IS, 2001, J CLIN PATHOL, V54, P176, DOI 10.1136/jcp.54.3.176; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	62	104	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33768	33781		10.1074/jbc.M403424200	http://dx.doi.org/10.1074/jbc.M403424200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161907	hybrid			2022-12-25	WOS:000223039700086
J	Toms, AV; Kinsland, C; McCloskey, DE; Pegg, AE; Ealick, SE				Toms, AV; Kinsland, C; McCloskey, DE; Pegg, AE; Ealick, SE			Evolutionary links as revealed by the structure of Thermotoga maritima S-adenosylmethionine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT HISTIDINE-DECARBOXYLASE; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; METHANOCOCCUS-JANNASCHII; PUTRESCINE STIMULATION; ESTER INTERMEDIATE; CRYSTAL-STRUCTURE; GENE DUPLICATION; PYRUVOYL ENZYMES; POLYAMINES	S-adenosylmethionine decarboxylase (AdoMetDC) is a critical regulatory enzyme of the polyamine biosynthetic pathway and belongs to a small class of pyruvoyl-dependent amino acid decarboxylases. Structural elucidation of the prokaryotic AdoMetDC is of substantial interest in order to determine the relationship between the eukaryotic and prokaryotic forms of the enzyme. Although both forms utilize pyruvoyl groups, there is no detectable sequence similarity except at the site of pyruvoyl group formation. The x-ray structure of the Thermatoga maritima AdoMetDC proenzyme reveals a dimeric protein fold that is remarkably similar to the eukaryotic AdoMetDC protomer, suggesting an evolutionary link between the two forms of the enzyme. Three key active site residues (Ser(55), His(68), and Cys(83)) involved in substrate binding, catalysis or proenzyme processing that were identified in the human and potato AdoMet-DCs are structurally conserved in the T. maritima AdoMetDC despite very limited primary sequence identity. The role of Ser(55), His(68), and Cys(83) in the self-processing reaction was investigated through site-directed mutagenesis. A homology model for the Escherichia coli AdoMetDC was generated based on the structures of the T. maritima and human AdoMetDCs.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Cornell University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ealick, SE (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	see3@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NCI NIH HHS [CA18138] Funding Source: Medline; NCRR NIH HHS [RR15301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Bennett EM, 2002, BIOCHEMISTRY-US, V41, P14509, DOI 10.1021/bi026710u; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Compaan DM, 2003, J EXP BIOL, V206, P1545, DOI 10.1242/jeb.00299; DIAZ E, 1991, BIOCHEMISTRY-US, V30, P4078, DOI 10.1021/bi00230a037; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; Ekstrom JL, 2001, BIOCHEMISTRY-US, V40, P9495, DOI 10.1021/bi010736o; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Franceschetti M, 2001, BIOCHEM J, V353, P403, DOI 10.1042/0264-6021:3530403; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HACKERT ML, 1997, COMPREHENSIVE BIOL C, P201; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Illingworth C, 2003, FEBS LETT, V549, P26, DOI 10.1016/S0014-5793(03)00756-7; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim AD, 2000, J BACTERIOL, V182, P6667, DOI 10.1128/JB.182.23.6667-6672.2000; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Li YF, 2001, P NATL ACAD SCI USA, V98, P10578, DOI 10.1073/pnas.181341198; Liu LJ, 2002, FEBS LETT, V528, P114, DOI 10.1016/S0014-5793(02)03264-7; MARKHAM GD, 1982, J BIOL CHEM, V257, P2063; MARTIRENOM MA, 2002, COMP PROTEIN STRUCTU; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; RECSEI PA, 1984, ANNU REV BIOCHEM, V53, P357, DOI 10.1146/annurev.bi.53.070184.002041; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schmitzberger F, 2003, EMBO J, V22, P6193, DOI 10.1093/emboj/cdg575; Sekowska A, 2000, MOL MICROBIOL, V36, P1135, DOI 10.1046/j.1365-2958.2000.01930.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tolbert WD, 2003, STRUCTURE, V11, P285, DOI 10.1016/S0969-2126(03)00026-1; Tolbert WD, 2003, BIOCHEMISTRY-US, V42, P2386, DOI 10.1021/bi0268854; Tolbert WD, 2001, BIOCHEMISTRY-US, V40, P9484, DOI 10.1021/bi010735w; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Xiong HS, 1999, J BIOL CHEM, V274, P35059, DOI 10.1074/jbc.274.49.35059; Xiong HS, 1997, J BIOL CHEM, V272, P28342, DOI 10.1074/jbc.272.45.28342; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	44	30	34	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33837	33846		10.1074/jbc.M403369200	http://dx.doi.org/10.1074/jbc.M403369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15150268	hybrid			2022-12-25	WOS:000223039700093
J	Zhai, L; Chaturvedi, D; Cumberledge, S				Zhai, L; Chaturvedi, D; Cumberledge, S			Drosophila Wnt-1 undergoes a hydrophobic modification and is targeted to lipid rafts, a process that requires porcupine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARITY GENE PORCUPINE; WINGLESS PROTEIN; CHOLESTEROL MODIFICATION; ENDOPLASMIC-RETICULUM; SONIC HEDGEHOG; TOUT-VELU; MEMBRANE; PALMITOYLATION; SECRETION; CELLS	Wnt signaling pathways regulate many developmental responses; however, little is known about how Wnt ligands function on a biochemical level. Recent studies have shown that Wnt-3a is palmitoylated before secretion. Here we report that Drosophila Wnt-1 ( Wingless) also undergoes a lipid modification. Lipidation occurs in the endoplasmic reticulum and is dependent on Porcupine, a putative O-acyltransferase. After modification, DWnt-1 partitions as a membrane-anchored protein and is sorted into lipid raft detergent-insoluble microdomains. Lipidation, raft targeting, and secretion can be blocked by the addition of 2-bromopalmitate, a competitive inhibitor of O-acyltransferase activity. Based on these results we propose a model whereby lipidation targets Wnt-1 to secretory vesicles that deliver the ligand to specialized microdomains at the cell surface where it can be packaged for secretion.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Cumberledge, S (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	susanc@biochem.umass.edu	vkg, testridreg/B-8565-2016	vkg, testridreg/0000-0002-1508-5647; g, vvk/0000-0003-1538-7589				Arias AM, 2003, NAT REV MOL CELL BIO, V4, P321, DOI 10.1038/nrm1078; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Caricasole A, 2002, GENE, V288, P147, DOI 10.1016/S0378-1119(02)00467-5; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; COLEMAN RA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P203, DOI 10.1016/0005-2760(92)90046-X; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gallet A, 2003, DEV CELL, V4, P191, DOI 10.1016/S1534-5807(03)00031-5; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Jeong J, 2002, J CLIN INVEST, V110, P591, DOI 10.1172/JCI200216506; JONES HE, 1992, LIPIDS, V27, P984, DOI 10.1007/BF02535576; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; Patterson SI, 2002, BIOL RES, V35, P139, DOI 10.4067/S0716-97602002000200005; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Tanaka K, 2003, CELL BIOL INT, V27, P549, DOI 10.1016/S1065-6995(03)00080-5; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Vilas GL, 2004, BIOCHEM J, V377, P121, DOI 10.1042/BJ20030951; Vincent JP, 2002, TRENDS CELL BIOL, V12, P57, DOI 10.1016/S0962-8924(01)02227-9; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; White T, 1998, ANAL BIOCHEM, V258, P109, DOI 10.1006/abio.1997.2545; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648	44	189	201	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33220	33227		10.1074/jbc.M403407200	http://dx.doi.org/10.1074/jbc.M403407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166250	hybrid			2022-12-25	WOS:000223039700027
J	Hemonnot, B; Cartier, C; Gay, B; Rebuffat, S; Bardy, M; Devaux, C; Boyer, V; Briant, L				Hemonnot, B; Cartier, C; Gay, B; Rebuffat, S; Bardy, M; Devaux, C; Boyer, V; Briant, L			The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6(gag) protein of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; GAG PROTEIN; MATRIX PROTEIN; NUCLEAR IMPORT; PARTICLE-SIZE; HUMAN HOMOLOG; POL PROTEINS; DOMAIN; INFECTIVITY	The host cell MAP kinase ERK-2 incorporated within human immunodeficiency virus type 1 particles plays a critical role in virus infectivity by phosphorylating viral proteins. Recently, a fraction of the virus incorporated late (L) domain-containing p6(gag) protein, which has an essential function in the release of viral particles from the cell surface, was reported to be phosphorylated by an unknown virus-associated cellular protein kinase (Muller, B., Patschinsky, T., and Krausslich, H. G. (2002) J. Virol. 76, 1015-1024). The present study demonstrates the contribution of the MAP kinase ERK-2 in p6(gag) phosphorylation. According to mutational analysis, a single ERK-2-phosphorylated threonine residue, belonging to a highly conserved phosphorylation MAP kinase consensus site, was identified at position 23 within p6(gag). Substitution by an alanine of the Thr(23) phosphorylable residue within the pNL4.3 molecular clone was found to decrease viral release from various cell types. As observed from electron microscopy experiments, most virions produced from this molecular clone remained incompletely separated from the host cell membrane with an immature morphology and displayed a reduced infectivity in single round infection experiments. Analysis of protein processing by Western blotting experiments revealed an incomplete Pr55(gag) maturation and a reduction in the virion-associated reverse transcriptase proteins was observed that was not related to differences in intracellular viral protein expression. Altogether, these data suggest that phosphorylation of p6(gag) protein by virus-associated ERK-2 is involved in the budding stage of HIV-1 life cycle.	Univ Montpellier I, Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CNRS,UMR 5121, F-34960 Montpellier 2, France; CHU La Tronche, INSERM EMI0108, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm)	Boyer, V (corresponding author), Univ Montpellier I, Inst Biol, Lab Infect Retrovirales & Signalisat Cellulaire, CNRS,UMR 5121, 4 Bd Henri IV,CS89508, F-34960 Montpellier 2, France.	laurence.briant@univ-montp1.fr	Briant, Laurence/AAB-9281-2021; Boyer, Veronique/E-6122-2017	Briant, Laurence/0000-0002-1995-3501; FAUVEL, Benedicte/0000-0003-1166-8391; Rebuffat, Sandra/0000-0002-1102-4935				Agostini I, 2000, EXP CELL RES, V259, P398, DOI 10.1006/excr.2000.4992; BRADAC J, 1984, VIROLOGY, V138, P260, DOI 10.1016/0042-6822(84)90350-7; Briant L, 1998, J IMMUNOL, V160, P1875; Briant L, 1996, J VIROL, V70, P5213, DOI 10.1128/JVI.70.8.5213-5220.1996; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; Cartier C, 2003, J BIOL CHEM, V278, P35211, DOI 10.1074/jbc.M301257200; Cartier C, 1997, J VIROL, V71, P4832, DOI 10.1128/JVI.71.6.4832-4837.1997; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHARRET R, 1967, J MICROSC-PARIS, V6, P1063; Cimarelli A, 1999, J VIROL, V73, P5388, DOI 10.1128/JVI.73.7.5388-5401.1999; CLINTON GM, 1979, VIROLOGY, V99, P84, DOI 10.1016/0042-6822(79)90039-4; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Dettenhofer M, 1999, J VIROL, V73, P4696, DOI 10.1128/JVI.73.6.4696-4704.1999; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FU XY, 1995, J GEN VIROL, V76, P3171, DOI 10.1099/0022-1317-76-12-3171; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Garnier L, 1999, J VIROL, V73, P2309, DOI 10.1128/JVI.73.3.2309-2320.1999; Garnier L, 1998, J VIROL, V72, P4667, DOI 10.1128/JVI.72.6.4667-4677.1998; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gupta K, 2000, J VIROL, V74, P11811, DOI 10.1128/JVI.74.24.11811-11824.2000; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; Hui EKW, 2002, CELL MOL LIFE SCI, V59, P920, DOI 10.1007/s00018-002-8479-6; Jacque JM, 1998, EMBO J, V17, P2607, DOI 10.1093/emboj/17.9.2607; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KUIKEN CL, 1999, HUMAN RETROVIRUSES A; Lama J, 1998, J VIROL, V72, P1671, DOI 10.1128/JVI.72.2.1671-1676.1998; Liu BD, 1999, J VIROL, V73, P2901, DOI 10.1128/JVI.73.4.2901-2908.1999; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; LUUKKONEN BGM, 1995, VIROLOGY, V206, P854, DOI 10.1006/viro.1995.1008; Martin-Serrano J, 2003, J VIROL, V77, P12373, DOI 10.1128/JVI.77.22.12373-12377.2003; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002; Ott DE, 1998, J VIROL, V72, P2962, DOI 10.1128/JVI.72.4.2962-2968.1998; Ott DE, 2002, REV MED VIROL, V12, P359, DOI 10.1002/rmv.367; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; Peytavi R, 1999, J BIOL CHEM, V274, P1635, DOI 10.1074/jbc.274.3.1635; Radding W, 2000, AIDS RES HUM RETROV, V16, P1519, DOI 10.1089/088922200750006047; Rey O, 1996, VIROLOGY, V220, P530, DOI 10.1006/viro.1996.0343; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; SEN A, 1977, CELL, V10, P489; SEN A, 1977, CELL, V10, P91, DOI 10.1016/0092-8674(77)90143-X; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tang Y, 1999, J VIROL, V73, P10508, DOI 10.1128/JVI.73.12.10508-10513.1999; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TRAUGER RJ, 1994, J INFECT DIS, V169, P1256, DOI 10.1093/infdis/169.6.1256; Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Wilk T, 1999, J VIROL, V73, P1931, DOI 10.1128/JVI.73.3.1931-1940.1999; Wilson SA, 1999, BIOCHEM J, V342, P97, DOI 10.1042/0264-6021:3420097; Yu XF, 1998, J VIROL, V72, P3412, DOI 10.1128/JVI.72.4.3412-3417.1998; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	64	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32426	32434		10.1074/jbc.M313137200	http://dx.doi.org/10.1074/jbc.M313137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155723	hybrid			2022-12-25	WOS:000222849700056
J	Tanaka, K; Russell, P				Tanaka, K; Russell, P			Cds1 phosphorylation by Rad3-Rad26 kinase is mediated by forkhead-associated domain interaction with Mrc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; LI-FRAUMENI-SYNDROME; FISSION YEAST; FHA DOMAIN; SCHIZOSACCHAROMYCES-POMBE; REPLICATION STRESS; S-PHASE; RECOMBINATIONAL REPAIR; PROTEIN-KINASE; IN-VITRO	The protein kinase Cds1 is an effector of the replication checkpoint in the fission yeast Schizosaccharomyces pombe. Cds1 is required to stabilize stalled replication forks, and it helps to prevent the onset of mitosis until the genome is fully replicated. Mrc1 (mediator of the replication checkpoint-1) and Rad3-Rad26 kinase are required for Cds1 activation, but exactly how Mrc1 mediates Cds1 activation is unknown. Here we show that Mrc1 is required for the initial threonine 11 phosphorylation of Cds1 by Rad3-Rad26. Mrc1 specifically interacts with the forkhead-associated (FHA) domain of Cds1 in yeast two-hybrid assays. Mutations in the FHA domain that abolish this interaction also eliminate Thr-11 phosphorylation of Cds1. Weak Thr-11 phosphorylation of a "kinase-dead" mutant of Cds1 is rescued by co-expression of wild type Cds1. The requirement for Mrc1 in the replication checkpoint can be partially eliminated by expression of a Rad26-Cds1 fusion protein. These findings suggest that recognition of Mrc1 by the FHA domain of Cds1 serves to recruit Cds1 to Rad3-Rad26. This interaction mediates the initial Thr-11 phosphorylation of Cds1 by Rad3-Rad26 with subsequent intermolecular phosphorylation events leading to full activation of Cds1.	Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, Matsue, Shimane 6908504, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Shimane University; Scripps Research Institute; Scripps Research Institute	Tanaka, K (corresponding author), Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, 1060 Nishikawatsu, Matsue, Shimane 6908504, Japan.	ktanaka@life.shimane-u.ac.jp	Tanaka, Katsunori/F-8086-2010	Tanaka, Katsunori/0000-0001-9692-0968	NIGMS NIH HHS [GM59447] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059447] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Bashkirov VI, 2003, MOL CELL BIOL, V23, P1441, DOI 10.1128/MCB.23.4.1441-1452.2003; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2003, MOL CELL BIOL, V23, P5939, DOI 10.1128/MCB.23.16.5939-5946.2003; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; KEENEY JB, 1994, GENETICS, V136, P849; KIM JS, 1993, PROTEIN SCI, V2, P348; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee SB, 2001, CANCER RES, V61, P8062; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 2000, J CELL SCI, V113, P3889; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tanaka K, 2001, MOL CELL BIOL, V21, P3398, DOI 10.1128/MCB.21.10.3398-3404.2001; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	50	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32079	32086		10.1074/jbc.M404834200	http://dx.doi.org/10.1074/jbc.M404834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173168	hybrid			2022-12-25	WOS:000222849700012
J	Bric, A; Radebaugh, CA; Paule, MR				Bric, A; Radebaugh, CA; Paule, MR			Photocross-linking of the RNA polymerase I preinitiation and immediate postinitiation complexes - Implications for promoter recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION-FACTOR; LARGE-SCALE PREPARATION; ACANTHAMOEBA-CASTELLANII; FACTOR TIF; STRUCTURAL BASIS; DNA; SUBUNIT; YEAST; BINDING; ELONGATION	The architecture of eukaryotic rRNA transcription complexes was analyzed, revealing facts significant to the RNA polymerase (pol) I initiation process. Functional initiation and elongation complexes were mapped by site-specific photocross-linking to template DNA. Polymerase I is recruited to the promoter via protein-protein interactions with DNA-bound transcription initiation factor-IB. The latter's TATA-binding protein (TBP) and TAFs photocross-link to the promoter from - 78 to + 10 relative to the tis ( + 1). Although TBP does not bind DNA using its TATA-binding saddle, it does photocross-link to a 22-bp sequence that does not resemble a TATA box. Only TAF(I)96 ( the mammalian TAF(I)68, yeast Rrn7p homolog) overlaps significantly with the DNA interaction cleft of pol I based on modeling to the pol II crystal structure. None of the pol I-specific subunits that are localized on the lips of the cleft (A49 and A34.5) or the pol I-specific stalk (A43 and A14) cross-link to DNA. Pol I does not extend significantly upstream of the promoter-proximal border of the factor complex ( - 11 to - 14), and similarly in the promoter proximal elongation complex, the enzyme does not contact DNA upstream of its normal exit from the cleft.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Paule, MR (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	mpaule@lamar.colostate.edu			NIGMS NIH HHS [GM22580] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Khouri AM, 2002, MOL CELL BIOL, V22, P750, DOI 10.1128/MCB.22.3.750-761.2002; ALKHOURI AM, 2002, IN PRESS MOL CELL BI, V22; Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; Bischler N, 2002, EMBO J, V21, P4136, DOI 10.1093/emboj/cdf392; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; Boukhgalter B, 2002, GENE, V291, P187, DOI 10.1016/S0378-1119(02)00597-8; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DALESSIO JM, 1979, J BIOL CHEM, V254, P4085; DALESSIO JM, 1979, J BIOL CHEM, V254, P1282; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Geiss GK, 1997, J BIOL CHEM, V272, P29243, DOI 10.1074/jbc.272.46.29243; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GONG XL, 1995, MOL CELL BIOL, V15, P4956; Kahl BF, 2000, J MOL BIOL, V299, P75, DOI 10.1006/jmbi.2000.3743; KAHL BF, 2001, DNA PROTEIN INTERACT, P63; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; Marilley M, 2002, MOL GENET GENOMICS, V267, P781, DOI 10.1007/s00438-002-0708-z; Milkereit P, 1997, BIOL CHEM, V378, P1433, DOI 10.1515/bchm.1997.378.12.1433; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; PAULE MR, 1991, MOL CELL BIOCHEM, V104, P119, DOI 10.1007/BF00229811; Perna Peter J., 1992, Gene Expression, V2, P71; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Radebaugh CA, 1998, J BIOL CHEM, V273, P27708, DOI 10.1074/jbc.273.42.27708; Radebaugh CA, 1997, J BIOL CHEM, V272, P3141, DOI 10.1074/jbc.272.6.3141; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SPINDLER SR, 1978, J BIOL CHEM, V253, P4669; SPINDLER SR, 1978, J BIOL CHEM, V253, P6242; Travers A, 2000, PRACT APPROACH SER, P229; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; Wooddell CI, 2000, BIOCHEMISTRY-US, V39, P13405, DOI 10.1021/bi0014249; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	47	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31259	31267		10.1074/jbc.M311828200	http://dx.doi.org/10.1074/jbc.M311828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15161919	hybrid			2022-12-25	WOS:000222726800045
J	Chen, C; Ko, Y; Delannoy, M; Ludtke, SJ; Chiu, W; Pedersen, PL				Chen, C; Ko, Y; Delannoy, M; Ludtke, SJ; Chiu, W; Pedersen, PL			Mitochondrial ATP synthasome - Three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for P-i and ADP/ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; ADENOSINE-TRIPHOSPHATASE; PROTEIN; RESOLUTION; INTERMEDIATE; F-1-ATPASE; MECHANISM	The terminal steps involved in making ATP in mitochondria require an ATP synthase (F0F1) comprised of two motors, a phosphate carrier (PIC), and an adenine nucleotide carrier (ANC). Under mild conditions, these entities sub-fractionate as an ATP synthase/PIC/ANC complex or "ATP synthasome" (Ko, Y. H., Delannoy, M, Hullihen, J., Chiu, W., and Pedersen, P. L. ( 2003) J. Biol. Chem. 278, 12305 - 12309). As a first step toward obtaining three-dimensional information about this large complex or "metabolon" and the locations of PIC and ANC therein, we dispersed ATP synthasomes into single complexes and visualized negatively stained images by electron microscopy ( EM) that showed clearly the classical headpiece, central stalk, and basepiece. Parallel immuno-EM studies revealed the presence of PIC and ANC located non-centrally in the basepiece, and other studies implicated an ATP synthase/PIC/ANC stoichiometry near 1: 1: 1. Single ATP synthasome images ( 7506) were boxed, and, using EMAN software, a three-dimensional model was obtained at a resolution of 23 Angstrom. Significantly, the basepiece is oblong and contains two domains, the larger of which connects to the central stalk, whereas the smaller appears as an extension. Docking studies with known structures together with the immuno-EM studies suggest that PIC or ANC may be located in the smaller domain, whereas the other transporter resides nearby in the larger domain. Collectively, these finding support a mechanism in which the entry of the substrates ADP and Pi into mitochondria, the synthesis of ATP on F-1, and the release and exit of ATP are very localized and highly coordinated events.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Baylor College of Medicine	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	ppederse@jhmi.edu	Ludtke, Steven/A-4478-2008	Ludtke, Steven/0000-0002-1903-1574	NCI NIH HHS [CA 10951] Funding Source: Medline; NCRR NIH HHS [P41RR02250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Belogrudov GI, 2002, J BIOL CHEM, V277, P6097, DOI 10.1074/jbc.M111256200; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BLOCK MR, 1982, BIOCHEM BIOPH RES CO, V109, P471, DOI 10.1016/0006-291X(82)91745-4; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HACKENBERG H, 1980, BIOCHEMISTRY-US, V19, P548, DOI 10.1021/bi00544a024; Hardy AW, 2003, J BIOENERG BIOMEMBR, V35, P389, DOI 10.1023/A:1027363012727; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; JACOBS EE, 1956, J BIOL CHEM, V223, P147; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Oster G, 1999, STRUCTURE, V7, pR67, DOI 10.1016/S0969-2126(99)80046-X; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P423, DOI 10.1023/A:1005652605340; Pedersen PL, 1999, J BIOENERG BIOMEMBR, V31, P291, DOI 10.1023/A:1005453700533; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	36	167	168	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31761	31768		10.1074/jbc.M401353200	http://dx.doi.org/10.1074/jbc.M401353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15166242	hybrid			2022-12-25	WOS:000222726800102
J	Yamasaki, M; Moriwaki, S; Miyake, O; Hashimoto, W; Murata, K; Mikami, B				Yamasaki, M; Moriwaki, S; Miyake, O; Hashimoto, W; Murata, K; Mikami, B			Structure and function of a hypothetical Pseudomonas aeruginosa protein PA1167 classified into family PL-7 - A novel alginate lyase with a beta-sandwich fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; CORYNEBACTERIUM SP; SEQUENCE-ANALYSIS; DIFFRACTION DATA; GENE; PURIFICATION; ACID	Structural and functional analyses of alginate lyases are important in the clarification of the biofilm-dependent ecosystem in Pseudomonas aeruginosa and in the development of therapeutic agents for bacterial disease. Most alginate lyases are classified into polysaccharide lyase (PL) family-5 and -7 based on their primary structures. Family PL-7 enzymes are still poorly characterized especially in structural properties. Among family PL-7, a gene coding for a hypothetical protein (PA1167) homologous to Sphingomonas alginate lyase A1-II was found to be present in the P. aeruginosa genome. PA1167 overexpressed in Escherichia coli cleaved glycosidic bonds in alginate and released unsaturated saccharides, indicating that PA1167 is an alginate lyase catalyzing a beta-elimination reaction. The enzyme acted preferably on heteropolymeric regions endolytically and worked most efficiently at pH 8.5 and 40 degreesC. The specific activity of PA1167, however, was much weaker than that of the known alginate lyase AlgL, suggesting that AlgL plays a main role in alginate depolymerization in P. aeruginosa. In addition to this specific activity, differences were found between PA1167 and AlgL in enzyme properties such as molecular mass, optimum pH, salt effect, and substrate specificity. The first crystal structure of the family PL-7 alginate lyase was determined at 2.0 Angstrom resolution. PA1167 was found to form a glove-like beta-sandwich composed of 15 beta-strands and 3 alpha-helices. The structural difference between the beta-sandwich PA1167 of family PL-7 and alpha/alpha-barrel AlgL of family PL-5 may be responsible for the enzyme characteristics. Crystal structures of polysaccharide lyases determined so far indicate that they can be assigned to three folding groups having parallel beta-helix, alpha/alpha-barrel, and alpha/alpha-barrel + antiparallel beta-sheet structures as basic frames. PA1167 is the fourth novel folding structure found among polysaccharide lyases.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Murata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan.	kmurata@kais.kyoto-u.ac.jp						Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; BARON JS, 1994, BIOGEOCHEMISTRY, V27, P61, DOI 10.1007/BF00002571; BAYER AS, 1991, INFECT IMMUN, V59, P302, DOI 10.1128/IAI.59.1.302-308.1991; BODEY GP, 1983, REV INFECT DIS, V5, P279; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; BOYD A, 1994, APPL ENVIRON MICROB, V60, P2355, DOI 10.1128/AEM.60.7.2355-2359.1994; BOYD A, 1993, GENE, V131, P1, DOI 10.1016/0378-1119(93)90662-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; CHITNIS CE, 1993, MOL MICROBIOL, V8, P583, DOI 10.1111/j.1365-2958.1993.tb01602.x; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; DUNNE WM, 1985, APPL ENVIRON MICROB, V50, P562, DOI 10.1128/AEM.50.3.562-567.1985; EFTEKHAR F, 1988, INFECT IMMUN, V56, P2788, DOI 10.1128/IAI.56.11.2788-2793.1988; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GACESA P, 1988, CARBOHYD POLYM, V8, P161, DOI 10.1016/0144-8617(88)90001-X; Hamelryck TW, 1999, J MOL BIOL, V286, P1161, DOI 10.1006/jmbi.1998.2534; Hardalo C, 1997, CRIT REV MICROBIOL, V23, P47, DOI 10.3109/10408419709115130; Hashimoto W, 2003, J BIOL CHEM, V278, P7663, DOI 10.1074/jbc.M208100200; Hashimoto W, 1998, J FERMENT BIOENG, V86, P236, DOI 10.1016/S0922-338X(98)80120-7; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Jenkins J, 2004, J BIOL CHEM, V279, P9139, DOI 10.1074/jbc.M311390200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULCZYCKI LL, 1978, JAMA-J AM MED ASSOC, V240, P30, DOI 10.1001/jama.240.1.30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; LINKER A, 1984, J BACTERIOL, V159, P958, DOI 10.1128/JB.159.3.958-964.1984; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MALISSARD M, 1993, FEMS MICROBIOL LETT, V110, P101, DOI 10.1016/0378-1097(93)90249-2; Matsubara Y, 1998, J PROTEIN CHEM, V17, P29, DOI 10.1023/A:1022534429792; Matsubara Y, 2000, J BIOSCI BIOENG, V89, P199, DOI 10.1016/S1389-1723(00)88738-1; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Monday SR, 1996, J BACTERIOL, V178, P625, DOI 10.1128/jb.178.3.625-632.1996; Onsoyen E, 1996, CARBOHYDR EUR, V46, P26; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rehm BHA, 1997, APPL MICROBIOL BIOT, V48, P281, DOI 10.1007/s002530051051; Sakakibara H, 2002, J PHARM SCI, V91, P1191, DOI 10.1002/jps.10110; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLER NL, 1993, J BACTERIOL, V175, P4780, DOI 10.1128/JB.175.15.4780-4789.1993; Schurks N, 2002, INT J BIOL MACROMOL, V30, P105, DOI 10.1016/S0141-8130(02)00002-8; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Sugimura I, 2000, MAR BIOTECHNOL, V2, P65; Tsai LC, 2003, J MOL BIOL, V330, P607, DOI 10.1016/S0022-2836(03)00630-2; WARREN L, 1960, NATURE, V186, P237, DOI 10.1038/186237a0; WEISSBACH A, 1959, J BIOL CHEM, V234, P705; Wong TY, 2000, ANNU REV MICROBIOL, V54, P289, DOI 10.1146/annurev.micro.54.1.289; Yamasaki M, 2003, ACTA CRYSTALLOGR D, V59, P1499, DOI 10.1107/S0907444903012836; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; Yoon HJ, 2000, PROTEIN EXPRES PURIF, V19, P84, DOI 10.1006/prep.2000.1226; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	61	102	108	3	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31863	31872		10.1074/jbc.M402466200	http://dx.doi.org/10.1074/jbc.M402466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15136569	hybrid			2022-12-25	WOS:000222726800113
J	Pischon, N; Darbois, LM; Palamakumbura, AH; Kessler, E; Trackman, PC				Pischon, N; Darbois, LM; Palamakumbura, AH; Kessler, E; Trackman, PC			Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; BONE MORPHOGENETIC PROTEIN-1; SMOOTH-MUSCLE CELLS; TERMINAL PROTEINASE; ENHANCER PROTEIN; CROSS-LINKS; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; FLUOROMETRIC ASSAY; FORMATION INVITRO	Tumor necrosis factor-alpha (TNF-alpha) inhibits osteoblast function in vitro by inhibiting collagen deposition. Studies generally support that TNF-alpha does not inhibit collagen biosynthesis by osteoblasts but that collagen deposition is in some way diminished. The study investigated TNF-alpha regulation of biosynthetic enzymes and proteins crucial for posttranslational extracellular collagen maturation in osteoblasts including procollagen C-proteinases, procollagen C-proteinase enhancer, and lysyl oxidase. The working hypothesis is that such regulation could inhibit collagen deposition by osteoblasts. We report that in phenotypically normal MC3T3-E1 osteoblasts, TNF-alpha decreases collagen deposition without decreasing collagen mRNA levels or procollagen protein synthesis. Analyses of the cell layers revealed that TNF-alpha diminished the levels of mature collagen cross-links, pyridinoline and deoxypyridinoline. Further analyses revealed that the mRNA expression for lysyl oxidase, the determining enzyme required for collagen cross-linking, is down-regulated by TNF-alpha in a concentration- and time-dependent manner by up to 50%. The decrease was accompanied by a significant reduction of lysyl oxidase protein levels and enzyme activity. By contrast, Northern and Western blotting studies revealed that procollagen C-proteinases bone morphogenic protein-1 and mammalians Tolloid and procollagen C-proteinase enhancer were expressed in MC3T3-E1 cells and not down-regulated. The data together demonstrate that TNF-alpha does not inhibit collagen synthesis but does inhibit the expression and activity of lysyl oxidase in osteoblasts, thereby contributing to perturbed collagen cross-linking and accumulation. These studies identify a novel mechanism in which proinflammatory cytokine modulation of an extracellular biosynthetic enzyme plays a determining role in the control of collagen accumulation by osteoblasts.	Boston Univ, Div Oral Biol, Goldman Sch Dent Med, Dept Oral Biol, Boston, MA 02118 USA; Tel Aviv Univ, Sackler Fac Med, Maurice & Gabriela Goldschleger Eye Res Inst, IL-52621 Tel Hashomer, Israel	Boston University; Tel Aviv University; Sackler Faculty of Medicine	Trackman, PC (corresponding author), Boston Univ, Div Oral Biol, Goldman Sch Dent Med, Dept Oral Biol, 700 Albany St,W-210, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NIDCR NIH HHS [DE14066, DE12209] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012209] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahsan T, 1999, J ORTHOPAED RES, V17, P850, DOI 10.1002/jor.1100170610; BAILEY AJ, 1993, CONNECT TISSUE RES, V29, P119, DOI 10.3109/03008209309014239; BELDEKAS JC, 1981, BIOCHEMISTRY-US, V20, P2162, DOI 10.1021/bi00511a014; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; Chou DHI, 1996, J IMMUNOL, V156, P4354; Delmas Pierre D., 1995, P319; DERENZIS FA, 1973, STAIN TECHNOL, V48, P135, DOI 10.3109/10520297309116602; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Geiger BJ, 1933, J NUTR, V6, P427, DOI 10.1093/jn/6.5.427; GERSTENFELD LC, 1993, J BONE MINER RES, V8, P1031; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Graves DT, 1999, CLIN INFECT DIS, V28, P482, DOI 10.1086/515178; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476; Hong HH, 1999, LAB INVEST, V79, P1655; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004; Kostenuik PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE1133; Lathyrism Selye H, 1957, REV CAN BIOL, V16, P3; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LORENZO JA, 1992, MATRIX, V12, P282, DOI 10.1016/S0934-8832(11)80080-6; Mizutani A, 2001, J BONE MINER RES, V16, P2043, DOI 10.1359/jbmr.2001.16.11.2043; MohamedAli H, 1996, CELL TISSUE RES, V284, P509, DOI 10.1007/s004410050613; Ogata I, 1997, HEPATOLOGY, V26, P611, DOI 10.1002/hep.510260312; Oxlund H, 1996, BONE, V19, P479, DOI 10.1016/S8756-3282(96)00283-9; OXLUND H, 1995, BONE, V17, pS365, DOI 10.1016/8756-3282(95)00328-B; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; PANAGAKOS FS, 1994, INFLAMMATION, V18, P267, DOI 10.1007/BF01534268; PANAGAKOS FS, 1994, INFLAMMATION, V18, P243, DOI 10.1007/BF01534267; Panagakos FS, 1996, MOL CELL BIOCHEM, V158, P81; PANAGAKOS FS, 1995, INFLAMMATION, V19, P423, DOI 10.1007/BF01534577; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Scott IC, 1999, GENOMICS, V55, P229, DOI 10.1006/geno.1998.5663; Seyedin SM, 1990, CURR OPIN CELL BIOL, V2, P914, DOI 10.1016/0955-0674(90)90092-S; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uchida M, 2000, J CELL PHYSIOL, V185, P207, DOI 10.1002/1097-4652(200011)185:2<207::AID-JCP5>3.0.CO;2-J; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VYTASEK R, 1982, ANAL BIOCHEM, V120, P243, DOI 10.1016/0003-2697(82)90342-6	60	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30060	30065		10.1074/jbc.M404208200	http://dx.doi.org/10.1074/jbc.M404208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138266	hybrid			2022-12-25	WOS:000222531900025
J	Wang, HM; Radjendirane, V; Wary, KK; Chakrabarty, S				Wang, HM; Radjendirane, V; Wary, KK; Chakrabarty, S			Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells	ONCOGENE			English	Article						TGFB; cell adhesion; colon cancer	C-ALPHA; CARCINOEMBRYONIC ANTIGEN; RECEPTOR EXPRESSION; CANCER CELLS; FIBRONECTIN; GROWTH-FACTOR-BETA-1; INDUCTION; DIFFERENTIATION; STIMULATION; REQUIREMENT	Transforming growth factor (TGF) beta is a potent regulator of cell-matrix and cell-cell adhesions (collectively termed cellular adhesions). Cellular adhesions play crucial roles in controlling the differentiation of epithelial cells and in maintaining the integrity of the epithelium. Loss of TGF beta-responsiveness is thought to be an important early initiating event in the malignant progression of epithelial cancer. In the TGFbeta-responsive human colon adenocarcinoma Moser cells, TGFbeta promotes cellular adhesions and suppresses their malignant phenotype. TGFbeta promotes cell-matrix adhesion by inducing the synthesis of extracellular matrix (ECM) adhesion molecules and the expression of integrin receptors for these molecules (termed ECM remodeling). TGFbeta promotes cell-cell adhesion through the induction of E-cadherin expression, an epithelial associated homotypic cell-cell adhesion molecule, which also functions as a tumor suppressor in colon cancer. How TGFbeta regulates E-cadherin expression is not known. In this study, we showed that the induction of E-cadherin by TGFbeta was mediated through the activation of focal adhesion kinase (FAK), a major signaling molecule in focal adhesion contacts and that the activation of FAK was due to ECM remodeling and increased cell-matrix interactions. Thus, TGFbeta regulates cell-cell adhesion through its ability to remodel the ECM and to activate FAK through ECM remodeling.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; Texas A&M Univ Syst, Inst Biossci & Technol, Hlth Sci Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Chakrabarty, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.	schakrab@mdanderson.org		Wary, Kishore/0000-0001-8851-8565	NATIONAL CANCER INSTITUTE [R01CA047775] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 47775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; BREEN E, 1995, ANN SURG ONCOL, V2, P378, DOI 10.1007/BF02306369; CHAKRABARTY S, 1989, CANCER RES, V49, P2112; Chakrabarty S, 1998, LAB INVEST, V78, P413; CHAKRABARTY S, 1995, J CELL PHYSIOL, V164, P148, DOI 10.1002/jcp.1041640119; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HUANG S, 1994, INT J CANCER, V57, P742, DOI 10.1002/ijc.2910570522; Ilyas M, 1999, P NATL ACAD SCI USA, V96, P3087, DOI 10.1073/pnas.96.6.3087; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Rajagopal S, 1997, J CELL PHYSIOL, V170, P138, DOI 10.1002/(SICI)1097-4652(199702)170:2<138::AID-JCP5>3.0.CO;2-P; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TANG DG, 1995, J CELL PHYSIOL, V165, P291, DOI 10.1002/jcp.1041650210; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Varallo VM, 2003, ONCOGENE, V22, P3680, DOI 10.1038/sj.onc.1206415; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	27	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5558	5561		10.1038/sj.onc.1207701	http://dx.doi.org/10.1038/sj.onc.1207701			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133493				2022-12-25	WOS:000222588400016
J	Kang, PJ; Lee, BY; Park, HO				Kang, PJ; Lee, BY; Park, HO			Specific residues of the GDP/GTP exchange factor Bud5p are involved in establishment of the cell type-specific budding pattern in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SELECTION; SACCHAROMYCES-CEREVISIAE; SPATIAL LANDMARK; GTPASE; PROTEINS; POLARITY; GENE; RAS; BUD1/RSR1; STRAINS	Cells of the budding yeast undergo oriented cell division by choosing a specific site for growth depending on their cell type. Haploid a and alpha cells bud in an axial pattern whereas diploid a/alpha cells bud in a bipolar pattern. The Ras-like GTPase Rsr1p/Bud1p, its GDP-GTP exchange factor Bud5p, and its GTPase- activating protein Bud2p are essential for selecting the proper site for polarized growth in all cell types. Here we showed that specific residues at the N terminus and the C terminus of Bud5p were important for bipolar budding, while some residues were involved in both axial and bipolar budding. These bipolar-specific mutations of BUD5 disrupted proper localization of Bud5p in diploid a/alpha cells without affecting Bud5p localization in haploid alpha cells. In contrast, Bud5p expressed in the bud5 mutants defective in both budding patterns failed to localize in all cell types. Thus, these results identify specific residues of Bud5p that are likely to be involved in direct interaction with spatial landmarks, which recruit Bud5p to the proper bud site. Finally, we found a new start codon of BUD5, which extends the open reading frame to 210 bp upstream of the previously estimated start site, thus encoding a polypeptide of 608 amino acid residues. Bud5p with these additional N-terminal residues interacted with Bud8p, a potential bipolar landmark, suggesting that the N-terminal region is necessary for recognition of the spatial cues.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	Ohio State University	Park, HO (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave, Columbus, OH 43210 USA.	park.294@osu.edu		Park, Hay-Oak/0000-0001-5782-2257	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056997] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056997-05, R01 GM 56997, R01 GM056997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Harkins HA, 2001, MOL BIOL CELL, V12, P2497, DOI 10.1091/mbc.12.8.2497; HICKS JB, 1977, GENETICS, V85, P373; Kang PJ, 2001, SCIENCE, V292, P1376, DOI 10.1126/science.1060360; Kozminski KG, 2003, MOL BIOL CELL, V14, P4958, DOI 10.1091/mbc.E03-06-0426; Marston AL, 2001, CURR BIOL, V11, P803, DOI 10.1016/S0960-9822(01)00230-5; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Schenkman LR, 2002, J CELL BIOL, V156, P829, DOI 10.1083/jcb.200107041; SIKORSKI RS, 1989, GENETICS, V122, P19; Taheri N, 2000, EMBO J, V19, P6686, DOI 10.1093/emboj/19.24.6686; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	22	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27980	27985		10.1074/jbc.C400175200	http://dx.doi.org/10.1074/jbc.C400175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15136576	hybrid			2022-12-25	WOS:000222265400020
J	Zhou, ZW; Yamamoto, Y; Sugai, F; Yoshida, K; Kishima, Y; Sumi, H; Nakamura, H; Sakoda, S				Zhou, ZW; Yamamoto, Y; Sugai, F; Yoshida, K; Kishima, Y; Sumi, H; Nakamura, H; Sakoda, S			Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; CHROMATIN PROTEIN; NEURITE OUTGROWTH; CELL-GROWTH; GENE FAMILY; SURVIVAL; BINDING; DNA; PROLIFERATION; AMPHOTERIN	Hepatoma-derived growth factor ( HDGF) is a heparin-binding proliferating factor originally isolated from conditioned medium of the hepatoma-derived cell line HuH-7. HDGF has greatest homology in an amino acid sequence with high mobility group 1 (HMG1), which has been characterized as a DNA-binding, inflammatory, and potent neurite outgrowth molecule. HDGF is reported to be widely expressed and act as a growth factor in many kinds of cells. However, it has not been investigated in the nervous system. Here, we show by Western blot analysis that HDGF is present in the mouse brain from the embryonic period until adulthood. In situ hybridization and immunohistochemical analyses revealed that HDGF was expressed mainly in neurons, and HDGF protein was localized to the nucleus. HDGF and high mobility group 1 were secreted under physiological conditions and released extracellularly in necrotic conditions. Furthermore, we showed that exogenously supplied HDGF had a neurotrophic effect and was able to partially prevent the cell death of neurons in which endogenous HDGF was suppressed. Therefore, we propose that HDGF is a novel type of neurotrophic factor, on account of its localization in the nucleus and its potential to function in an autocrine manner under both physiological and pathological conditions throughout life.	Osaka Univ, Dept Neurol, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Dept Mol Med, Grad Sch Med, Osaka 5650871, Japan; Hyogo Med Univ, Div Hepatobiliary & Pancreat Med, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan	Osaka University; Osaka University; Hyogo College of Medicine; University of Hyogo	Yamamoto, Y (corresponding author), Osaka Univ, Dept Neurol, Grad Sch Med, D4,2-2 Yamada Oka, Osaka 5650871, Japan.	yamamoto@neurol.med.osaka-u.ac.jp						Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Black IB, 1999, J NEUROBIOL, V41, P108, DOI 10.1002/(SICI)1097-4695(199910)41:1<108::AID-NEU14>3.0.CO;2-U; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687; deLapeyriere O, 1997, CURR OPIN GENET DEV, V7, P642, DOI 10.1016/S0959-437X(97)80012-3; Dietz F, 2002, BIOCHEM J, V366, P491, DOI 10.1042/BJ20011811; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Enomoto H, 2002, HEPATOLOGY, V36, P1519, DOI 10.1053/jhep.2002.36935; Everett AD, 2000, J CLIN INVEST, V105, P567, DOI 10.1172/JCI7497; Everett AD, 2001, J BIOL CHEM, V276, P37564, DOI 10.1074/jbc.M105109200; Everett AD, 2001, DEV DYNAM, V222, P450, DOI 10.1002/dvdy.1204; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; Giehl KM, 2001, REV NEUROSCIENCE, V12, P79; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 2002, CANCER RES, V62, P4805; Ikegame K, 1999, BIOCHEM BIOPH RES CO, V266, P81, DOI 10.1006/bbrc.1999.1733; Izumoto Y, 1997, BIOCHEM BIOPH RES CO, V238, P26, DOI 10.1006/bbrc.1997.7233; Jankowsky JL, 1999, MOL CELL NEUROSCI, V14, P273, DOI 10.1006/mcne.1999.0792; Kishima Y, 2002, HEPATO-GASTROENTEROL, V49, P1639; Kishima Y, 2002, J BIOL CHEM, V277, P10315, DOI 10.1074/jbc.M111122200; Kuroda T, 1999, BIOCHEM BIOPH RES CO, V262, P433, DOI 10.1006/bbrc.1999.1115; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; Oliver JA, 1998, J CLIN INVEST, V102, P1208, DOI 10.1172/JCI785; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; Passalacqua M, 1997, FEBS LETT, V400, P275, DOI 10.1016/S0014-5793(96)01402-0; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Siegel GJ, 2000, BRAIN RES REV, V33, P199, DOI 10.1016/S0165-0173(00)00030-8; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thoenen H, 2000, PROG BRAIN RES, V128, P183; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HC, 1999, SURGERY, V126, P389, DOI 10.1016/S0039-6060(99)70182-0; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yamamoto Y, 1997, DEVELOPMENT, V124, P2903	52	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	2004	279	26					27320	27326		10.1074/jbc.M308650200	http://dx.doi.org/10.1074/jbc.M308650200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	830KH	15140875	hybrid			2022-12-25	WOS:000222120400062
J	Chen, ZJJ; Vulevic, B; Ile, KE; Soulika, A; Davis, W; Reiner, PB; Connop, BP; Nathwan, P; Trojanowski, JQ; Tew, KD				Chen, ZJJ; Vulevic, B; Ile, KE; Soulika, A; Davis, W; Reiner, PB; Connop, BP; Nathwan, P; Trojanowski, JQ; Tew, KD			Association of ABCA2 expression with determinants of Alzheimer's disease	FASEB JOURNAL			English	Article						beta-amyloid; A beta precursor protein; AD	TRANSPORTER GENE; OXIDATIVE STRESS; PROTEIN; ESTRAMUSTINE; CASSETTE; CLONING; IDENTIFICATION; CELLS; BRAIN; NEURODEGENERATION	With the use of a novel method for detecting differential gene expression, alterations in functional gene clusters related to transport or oxidative stress response and beta-amyloid (Abeta) peptide metabolism were identified in a HEK293 cell line engineered to overexpress the human ATP binding cassette transporter ABCA2. These included fatty acid binding protein, phospholipid binding protein, phospholipid synthesis protein, transporter cofactors, seladin-1, Abeta precursor protein (APP), vimentin, and low-density lipoprotein receptor-related protein. ABCA2 was highly expressed in neuroblastoma cells and colocalized with Abeta and APP. Additionally, increased APP protein levels were detected within ABCA2/APP double-transfected cells, and increased Abeta was detected in the media of ABCA2-transfected cells relative to controls. The transporter was abundant in the temporal and frontal regions of both normal and Alzheimer's disease ( AD) brain but was detected at lower concentrations in the parietal, occipital, and cerebellar regions. The ABCA2 transfected cell line expressed resistance to a free radical initiator, confirming involvement in protection against reactive oxygen species and suggesting a further possible link to AD.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Act Pass Pharmaceut Inc, Vancouver, BC V5Z 4H5, Canada; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	Fox Chase Cancer Center; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Tew, KD (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29425 USA.	tewk@musc.edu			NCI NIH HHS [CA-06927, CA-83778, CA-10124] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083778, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; BUTTERFIELD DA, 1994, BIOCHEM BIOPH RES CO, V200, P710, DOI 10.1006/bbrc.1994.1508; Chen ZJJ, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.10.e46; Chen ZJJ, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-28; Choi J, 2003, BBA-MOL BASIS DIS, V1637, P135, DOI 10.1016/S0925-4439(02)00227-2; Connop BP, 1999, J NEUROCHEM, V72, P1457, DOI 10.1046/j.1471-4159.1999.721457.x; Dean M, 2001, J BIOENERG BIOMEMBR, V33, P475, DOI 10.1023/A:1012823120935; Dubin RL, 2001, BONE, V28, P617, DOI 10.1016/S8756-3282(01)00463-X; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; Greeve I, 2000, J NEUROSCI, V20, P7345; Gylys KH, 2003, J NEUROCHEM, V84, P1442, DOI 10.1046/j.1471-4159.2003.01643.x; Hu JY, 2003, J NEUROSCI, V23, P1804; HUDES GR, 1992, J CLIN ONCOL, V10, P1754, DOI 10.1200/JCO.1992.10.11.1754; Iivonen S, 2002, NEUROSCIENCE, V113, P301, DOI 10.1016/S0306-4522(02)00180-X; Ile KE, 2004, BBA-GENE STRUCT EXPR, V1678, P22, DOI 10.1016/j.bbaexp.2004.01.007; Jagust WJ, 1997, ANN NY ACAD SCI, V826, P254, DOI 10.1111/j.1749-6632.1997.tb48477.x; Kaminski WE, 2001, BIOCHEM BIOPH RES CO, V281, P249, DOI 10.1006/bbrc.2001.4305; Laing N, 1997, BIOCHEMISTRY-US, V36, P871, DOI 10.1021/bi961445w; Laing NM, 1998, CANCER RES, V58, P1332; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Ma SL, 2002, NEUROSCI LETT, V332, P216, DOI 10.1016/S0304-3940(02)00942-4; Mahapatra NR, 2003, J BIOL CHEM, V278, P19986, DOI 10.1074/jbc.M207983200; Mairhofer M, 2002, BLOOD, V100, P897, DOI 10.1182/blood.V100.3.897; Mills J, 1997, J NEUROSCI, V17, P9415; Perera HKI, 2003, MOL BIOL CELL, V14, P2946, DOI 10.1091/mbc.E02-11-0722; Petrella JR, 2003, RADIOLOGY, V226, P315, DOI 10.1148/radiol.2262011600; PUNZI JS, 1992, MOL PHARMACOL, V41, P569; Safieddine S, 2002, MOL CELL NEUROSCI, V20, P343, DOI 10.1006/mcne.2002.1120; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Schmidt ML, 2001, AM J PATHOL, V159, P937, DOI 10.1016/S0002-9440(10)61769-5; Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; STEARNS ME, 1985, P NATL ACAD SCI USA, V82, P8483, DOI 10.1073/pnas.82.24.8483; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; Vulevic B, 2001, CANCER RES, V61, P3339; Wang D, 2003, MOL PHARMACOL, V64, P905, DOI 10.1124/mol.64.4.905; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865; Zhou CJ, 2002, J COMP NEUROL, V451, P334, DOI 10.1002/cne.10354	40	52	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1129	+		10.1096/fj.03-1490fje	http://dx.doi.org/10.1096/fj.03-1490fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155565				2022-12-25	WOS:000221883200004
J	Jin, ZY; McDonald, ER; Dicker, DT; El-Deiry, WS				Jin, ZY; McDonald, ER; Dicker, DT; El-Deiry, WS			Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECOY RECEPTORS; MELANOMA-CELLS; KAPPA-B; FAMILY; DOMAIN; MEMBER; IDENTIFICATION; CLONING; METASTASIS; KILLER/DR5	Many tumor cell types are sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- induced apoptosis. Incubation of TRAIL-sensitive cells with TRAIL invariably leads to resistant survivors even when high doses of TRAIL are used. Because the emergence of resistance to apoptosis is a major concern in successful treatment of cancer, and TRAIL survivors may contribute to therapeutic failure, we investigated potential resistance mechanisms. We selected TRAIL-resistant SW480 human colon adenocarcinoma cells by repeatedly treating them with high and/or low doses of TRAIL. The resulting TRAIL-resistant clones were not cross-resistant to Fas or paclitaxel. Expression of modulators of apoptosis was not changed in the resistant cells, including TRAIL receptors, cFLIP, Bax, Bid, or IAP proteins. Surprisingly, we found that DISC formation was deficient in multiple selected TRAIL-resistant clones. DR4 was not recruited to the DISC upon TRAIL treatment, and caspase-8 was not activated at the DISC. Although total cellular DR4 mRNA and protein were virtually identical in TRAIL-sensitive parental and TRAIL-resistant clones, DR4 protein expression on the cell surface was essentially undetectable in the TRAIL-resistant clones. Moreover, exogenous DR4 and KILLER/DR5 were not properly transported to the cell surface in the TRAIL-resistant cells. Interestingly, TRAIL-resistant cells were resensitized to TRAIL by tunicamycin pretreatment, which increased cell surface expression of DR4 and KILLER/DR5. Our data suggest that tumor cells may become resistant to TRAIL through regulation of the death receptor cell surface transport and that resistance to TRAIL may be overcome by the glycosylation inhibitor/endoplasmic reticulum stress-inducing agent tunicamycin.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Abramson Canc Ctr, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst,Dept Med, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Gaeta ML, 2000, LAB INVEST, V80, P1185, DOI 10.1038/labinvest.3780126; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; Kim KH, 2000, CLIN CANCER RES, V6, P335; Lamothe B, 2002, J INTERF CYTOK RES, V22, P269, DOI 10.1089/107999002753536248; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; McDonald ER, 2001, J BIOL CHEM, V276, P14939, DOI 10.1074/jbc.M100399200; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang GQ, 2001, J BIOL CHEM, V276, P3610, DOI 10.1074/jbc.M006222200; WANG S, 2004, P NATL ACAD SCI USA, V100, P12095; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961	35	187	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35829	35839		10.1074/jbc.M405538200	http://dx.doi.org/10.1074/jbc.M405538200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15155747	hybrid			2022-12-25	WOS:000223303400084
J	Tzeng, YL; Datta, A; Ambrose, K; Lo, M; Davies, JK; Carlson, RW; Stephens, DS; Kahler, CM				Tzeng, YL; Datta, A; Ambrose, K; Lo, M; Davies, JK; Carlson, RW; Stephens, DS; Kahler, CM			The misR/misS two-component regulatory system influences inner core structure and immunotype of lipooligosaccharide in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; ENTERICA SEROVAR TYPHIMURIUM; LIPID-A; SALMONELLA-TYPHIMURIUM; POLYMYXIN-B; PSEUDOMONAS-AERUGINOSA; PHASE-VARIATION; SEROGROUP-B; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI	Lipooligosaccharide (LOS) of Neisseria meningitidis is the major inflammatory mediator that contributes to meningococcal pathogenesis. Variable attachments to the HepII residue of the LOS inner core together with the alpha-chain heterogeneity result in immunologically distinct LOS structures, which may be selected for during human infection. Lpt-3, a phosphoethanolamine ( PEA) transferase, and LgtG, a glucosyltransferase, mediate the substitution of PEA or glucose at the O-3 position of HepII in L3 or L2 LOS immunotypes, respectively. Inactivation of a two-component response regulator, encoded by NMB0595, in N. meningitidis strain NMB resulted in the loss of all PEA decorations on the LOS inner core expressed by the NMB0595 mutant. When compared with the parental strain NMB that predominantly expresses L2 immunotype LOS and other minor LOS structures, the NMB0595 mutant expresses a pure population of a novel LOS structure completely substituted at the HepII O-3 position with glucose, but lacking other PEA decorations on the inner core. Quantitative real time PCR experiments showed increased transcription of lgtG in the NMB0595 mutant, and no significant change in lpt-3 transcription. Inactivation of lgtG resulted in LOS inner cores without glucose, but these structures, even though the lpt-3 transcription was unaffected, also lacked the O-3-linked PEA. Consistently, a double mutation of lgtG and misR in strain NMB yielded a LOS structure without PEA or Glc substitution of HepII. These data indicated a new pathway for the regulation of LOS inner core structure in N. meningitidis through an environmental sensing two-component regulatory system, named misR( NMB0595)/misS(NMB0594) for regulator and sensor of the meningococcal inner core structure.	Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Decatur, GA 30033 USA; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Monash University; University System of Georgia; University of Georgia	Tzeng, YL (corresponding author), Woodruff Mem Bldg,Rm 2107,1639 Pierce Dr, Atlanta, GA 30322 USA.	ytzeng@emory.edu	Kahler, Charlene M/H-5159-2014; Stephens, David S/A-8788-2012	Kahler, Charlene M/0000-0003-4322-3055; DATTA, ANUP/0000-0002-3796-6891	NIAID NIH HHS [AI 33157] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banerjee A, 1998, P NATL ACAD SCI USA, V95, P10872, DOI 10.1073/pnas.95.18.10872; Bearson BL, 1998, J BACTERIOL, V180, P2409, DOI 10.1128/JB.180.9.2409-2417.1998; Berrington AW, 2002, FEMS IMMUNOL MED MIC, V34, P267, DOI 10.1016/S0928-8244(02)00369-3; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; BRANDTZAEG P, 1992, MICROB PATHOGENESIS, V13, P423, DOI 10.1016/0882-4010(92)90010-L; Cai SJ, 2002, J BIOL CHEM, V277, P24155, DOI 10.1074/jbc.M110715200; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Cox AD, 2003, J BACTERIOL, V185, P3270, DOI 10.1128/JB.185.11.3270-3277.2003; Cox AD, 2002, CARBOHYD RES, V337, P1435, DOI 10.1016/S0008-6215(02)00161-1; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; De Wulf P, 2000, MICROBIOL-UK, V146, P247, DOI 10.1099/00221287-146-2-247; DUNN KLR, 1995, MICROB PATHOGENESIS, V18, P81, DOI 10.1016/S0882-4010(95)90085-3; Egger LA, 1997, GENES CELLS, V2, P167, DOI 10.1046/j.1365-2443.1997.d01-311.x; Ernst RK, 2001, MICROBES INFECT, V3, P1327, DOI 10.1016/S1286-4579(01)01494-0; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Gidney MAJ, 2004, INFECT IMMUN, V72, P559, DOI 10.1128/IAI.72.1.559-569.2004; Gilbert M, 1996, J BIOL CHEM, V271, P28271, DOI 10.1074/jbc.271.45.28271; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1177/09680519010070011001; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Hitchen PG, 2002, MOL MICROBIOL, V44, P1637, DOI 10.1046/j.1365-2958.2002.02990.x; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Hyytiainen H, 2003, MOL MICROBIOL, V50, P795, DOI 10.1046/j.1365-2958.2003.03729.x; JANIK A, 1976, J CLIN MICROBIOL, V4, P71; Jennings MP, 1999, MICROBIOL-UK, V145, P3013, DOI 10.1099/00221287-145-11-3013; Johnson CR, 2001, MOL MICROBIOL, V39, P1345, DOI 10.1111/j.1365-2958.2001.02324.x; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; Kahler CM, 1998, INFECT IMMUN, V66, P5939, DOI 10.1128/IAI.66.12.5939-5947.1998; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Kahler CM, 1996, J BACTERIOL, V178, P1265, DOI 10.1128/jb.178.5.1265-1273.1996; Kogan G, 1997, CARBOHYD RES, V298, P191, DOI 10.1016/S0008-6215(96)00305-9; Macfarlane ELA, 2000, MICROBIOL-SGM, V146, P2543, DOI 10.1099/00221287-146-10-2543; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; MENARD R, 1993, J BACTERIOL, V175, P5899; MICHON F, 1990, J BIOL CHEM, V265, P7243; Monteiro MA, 2003, CARBOHYD RES, V338, P2905, DOI 10.1016/j.carres.2003.08.014; Moskowitz SM, 2004, J BACTERIOL, V186, P575, DOI 10.1128/JB.186.2.575-579.2004; NATH K, 1990, NUCLEIC ACIDS RES, V18, P6462, DOI 10.1093/nar/18.21.6462; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; Plested JS, 2003, J INFECT DIS, V187, P1223, DOI 10.1086/368360; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rahman MM, 1998, CARBOHYD RES, V307, P311; Rahman MM, 2001, GLYCOBIOLOGY, V11, P703, DOI 10.1093/glycob/11.8.703; Ram S, 2003, J BIOL CHEM, V278, P50853, DOI 10.1074/jbc.M308364200; Richardson AR, 2001, MOL MICROBIOL, V40, P645, DOI 10.1046/j.1365-2958.2001.02408.x; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Snyder LAS, 2001, J BACTERIOL, V183, P1233, DOI 10.1128/JB.183.4.1233-1241.2001; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tamayo R, 2002, INFECT IMMUN, V70, P6770, DOI 10.1128/IAI.70.12.6770-6778.2002; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Tzeng YL, 2002, J BIOL CHEM, V277, P24103, DOI 10.1074/jbc.M200931200; VANPUTTEN JPM, 1995, MOL MICROBIOL, V16, P847; Yethon JA, 2000, INFECT IMMUN, V68, P4485, DOI 10.1128/IAI.68.8.4485-4491.2000; Zhou DG, 1996, GENE, V171, P133, DOI 10.1016/0378-1119(96)00103-5	64	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35053	35062		10.1074/jbc.M401433200	http://dx.doi.org/10.1074/jbc.M401433200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173178	hybrid			2022-12-25	WOS:000223134800118
J	Perez-Marin, MC; Lopez-Rubio, JS; Murillo, FJ; Elias-Arnanz, M; Padmanabhan, S				Perez-Marin, MC; Lopez-Rubio, JS; Murillo, FJ; Elias-Arnanz, M; Padmanabhan, S			The N terminus of Myxococcus xanthus CarA repressor is an autonomously folding domain that mediates physical and functional interactions with both operator DNA and antirepressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED CAROTENOGENESIS; SIGMA-FACTOR CARQ; THERMODYNAMIC ANALYSIS; STRUCTURAL STABILITY; CAROTENOID SYNTHESIS; CRYSTAL-STRUCTURE; BINDING DOMAINS; RNA-POLYMERASE; TRANSCRIPTION; GENE	Expression of the Myxococcus xanthus carB operon, which encodes the majority of the enzymes involved in light-induced carotenogenesis, is down-regulated in the dark by the CarA repressor binding to its bipartite operator. CarS, produced on illumination, relieves repression of carB by physically interacting with CarA to dismantle CarA-DNA complexes. Here, we demonstrate that the N- and C-terminal portions of CarA are organized as distinct structural and functional domains. Specifically, we show that the 78 N- terminal residues of CarA, CarA( Nter), form a monomeric, highly helical, autonomously folding unit with significant structural stability. Significantly, CarA( Nter) houses both the operator and CarS binding specificity determinants of CarA. CarA( Nter) binds operator with a lower affinity than whole CarA, and the CarA( Nter)-CarS complex has a 1: 1 stoichiometry. In vitro, sufficiently high concentrations of CarA( Nter) block M. xanthus RNA polymerase-promoter binding, and this is relieved by CarS. In vivo, substitution of the gene carA by that for CarA( Nter) results in constitutive expression of carB just as in a carA-deleted background. However, re-engineering the latter strain to overexpress CarA( Nter) restores repression of carB. Thus, the 78-residue N- terminal portion of CarA is an autonomously folded, dual function domain that orchestrates specific DNA-protein and protein-protein interactions and, when overexpressed, can be functionally competent in vivo.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain	University of Murcia	Elias-Arnanz, M (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain.	melias@um.es; padhu@um.es	Padmanabhan, S./E-8943-2017; Elías-Arnanz, Montserrat/H-4707-2015; lopez-rubio, jose juan/A-4509-2014	Elías-Arnanz, Montserrat/0000-0003-1980-3092; Padmanabhan, S./0000-0002-8772-0152; lopez-rubio, jose juan/0000-0002-0555-1122				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; AVERY L, 1983, MOL GEN GENET, V191, P99, DOI 10.1007/BF00330896; BALSALOBRE JM, 1989, THESIS U MURCIA MURC; BOTELLA JA, 1995, EUR J BIOCHEM, V233, P238, DOI 10.1111/j.1432-1033.1995.238_1.x; BRETSCHER AP, 1978, J BACTERIOL, V133, P763, DOI 10.1128/JB.133.2.763-768.1978; Browning DF, 2003, MOL MICROBIOL, V48, P237, DOI 10.1046/j.1365-2958.2003.03431.x; Cayuela ML, 2003, J BACTERIOL, V185, P3527, DOI 10.1128/JB.185.12.3527-3537.2003; Cervantes M, 2002, J BACTERIOL, V184, P2215, DOI 10.1128/JB.184.8.2215-2224.2002; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; Cole J L, 1999, J Biomol Tech, V10, P163; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Felitsky DJ, 2003, BIOCHEMISTRY-US, V42, P2202, DOI 10.1021/bi0270992; Fontes M, 2003, MOL MICROBIOL, V47, P561, DOI 10.1046/j.1365-2958.2003.03319.x; FONTES M, 1993, EMBO J, V12, P1265, DOI 10.1002/j.1460-2075.1993.tb05771.x; Godsey MH, 2001, J BIOL CHEM, V276, P47178, DOI 10.1074/jbc.M105819200; Goodwin T.W, 1980, BIOCH CAROTENOIDS, V1; Gorham HC, 1996, MOL MICROBIOL, V19, P171, DOI 10.1046/j.1365-2958.1996.360888.x; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; Hodgson D, 1993, MYXOBACTERIA, VII, P157; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Julien B, 2000, P NATL ACAD SCI USA, V97, P9098, DOI 10.1073/pnas.97.16.9098; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lopez-Rubio JJ, 2004, J BIOL CHEM, V279, P28945, DOI 10.1074/jbc.M403459200; Lopez-Rubio JJ, 2002, J BIOL CHEM, V277, P7262, DOI 10.1074/jbc.M110351200; Martinez-Argudo I, 1998, MOL MICROBIOL, V30, P883, DOI 10.1046/j.1365-2958.1998.01129.x; MCGOWAN SJ, 1993, MOL MICROBIOL, V10, P713, DOI 10.1111/j.1365-2958.1993.tb00943.x; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; Moreno AJ, 2001, J BACTERIOL, V183, P557, DOI 10.1128/JB.183.2.557-569.2001; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NICOLAS FJ, 1994, GENE DEV, V8, P2375, DOI 10.1101/gad.8.19.2375; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PACE CN, 1990, PROTEIN STRUCTURE PR, P331; Padmanabhan S, 2001, J BIOL CHEM, V276, P41566, DOI 10.1074/jbc.M106352200; Padmanabhan S, 1999, BIOCHEMISTRY-US, V38, P15536, DOI 10.1021/bi991757+; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; Rau W., 1988, PLANT PIGMENTS, P231; Rohl CA, 1997, BIOCHEMISTRY-US, V36, P8435, DOI 10.1021/bi9706677; RUIZVAZQUEZ R, 1993, MOL MICROBIOL, V10, P25, DOI 10.1111/j.1365-2958.1993.tb00900.x; RUIZVAZQUEZ R, 1984, J BACTERIOL, V160, P818; Sambrook J., 2001, MOL CLONING LAB MANU, V3; SCHMID FX, 1990, PROTEIN STRUCTURE PR, P261; SPRATT BG, 1986, GENE, V41, P337, DOI 10.1016/0378-1119(86)90117-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Walkinshaw MD, 2002, MOL CELL, V9, P187, DOI 10.1016/S1097-2765(02)00435-5; ZHELEZNOVAHELDW.EE, 2001, NATURE, V409, P378	50	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33093	33103		10.1074/jbc.M405225200	http://dx.doi.org/10.1074/jbc.M405225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163666	hybrid			2022-12-25	WOS:000223039700011
J	Pesce, A; Nardini, M; Ascenzi, P; Geuens, E; Dewilde, S; Moens, L; Bolognesi, M; Riggs, AF; Hale, A; Deng, PC; Nienhaus, GU; Olson, JS; Nienhaus, K				Pesce, A; Nardini, M; Ascenzi, P; Geuens, E; Dewilde, S; Moens, L; Bolognesi, M; Riggs, AF; Hale, A; Deng, PC; Nienhaus, GU; Olson, JS; Nienhaus, K			Thr-E11 regulates O-2 affinity in Cerebratulus lacteus mini-hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DIOXYGENASE; SPERM-WHALE MYOGLOBIN; LIGAND-BINDING; STRUCTURAL DYNAMICS; HEME-PROTEINS; NONVERTEBRATE HEMOGLOBINS; CRYSTAL-STRUCTURE; DISTAL POCKET; OXYGEN; GLOBIN	The mini-hemoglobin from Cerebratulus lacteus (CerHb) belongs to a class of globins containing the polar Tyr-B10/Gln-E7 amino acid pair that normally causes low rates of O-2 dissociation and ultra-high O-2 affinity, which suggest O2 sensing or NO scavenging functions. CerHb, however, has high rates of O-2 dissociation (k(O2) = 200 - 600 s(-1)) and moderate O-2 affinity (K-O2 approximate to 1 muM(-1)) as a result of a third polar amino acid in its active site, Thr-E11. When Thr-E11 is replaced by Val, k(O2) decreases 1000-fold and K-O2 increases 130-fold at pH 7.0, 20 degreesC. The mutation also shifts the stretching frequencies of both heme-bound and photodissociated CO, indicating marked changes of the electrostatic field at the active site. The crystal structure of Thr-E11 --> Val CerHbO(2) at 1.70 Angstrom resolution is almost identical to that of the wildtype protein ( root mean square deviation of 0.12 Angstrom). The dramatic functional and spectral effects of the Thr-E11 --> Val mutation are due exclusively to changes in the hydrogen bonding network in the active site. Replacing Thr-E11 with Val "frees" the Tyr-B10 hydroxyl group to rotate toward and donate a strong hydrogen bond to the heme-bound ligand, causing a selective increase in O-2 affinity, a decrease of the rate coefficient for O-2 dissociation, a 40 cm(-1) decrease in nu(CO) of heme-bound CO, and an increase in ligand migration toward more remote intermediate sites.	Univ Ulm, Dept Biophys, D-89081 Ulm, Germany; Univ Genoa, Dept Phys, INFM, I-16146 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16146 Genoa, Italy; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Roma Tre, Interdept Lab Electron Microscopy, I-00146 Rome, Italy; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Natl Inst Canc Res, Struct Biol Unit, I-16132 Genoa, Italy; Univ Texas, Neurobiol Sect, Austin, TX 78712 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	Ulm University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; Roma Tre University; Roma Tre University; University of Antwerp; University of Genoa; IRCCS AOU San Martino IST; University of Texas System; University of Texas Austin; Rice University; Rice University; University of Illinois System; University of Illinois Urbana-Champaign	Nienhaus, K (corresponding author), Univ Ulm, Dept Biophys, Albert Einstein Allee 11, D-89081 Ulm, Germany.	Karin.Nienhaus@physik.uni-ulm.de	Pesce, Alessandra/A-3660-2015; Bolognesi, Martino/B-7924-2017; Nienhaus, Gerd Ulrich/G-8698-2012; Nardini, Marco/B-7842-2017	Bolognesi, Martino/0000-0002-9253-5170; Nienhaus, Gerd Ulrich/0000-0002-5027-3192; Nardini, Marco/0000-0002-3718-2165; Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERDING N, 1976, SCIENCE, V192, P1002, DOI 10.1126/science.1273579; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDZEN J, 1990, P NATL ACAD SCI USA, V87, P1, DOI 10.1073/pnas.87.1.1; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CHALAZON.N, 1966, CR SOC BIOL, V160, P1020; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; Das TK, 2004, J BIOL CHEM, V279, P10433, DOI 10.1074/jbc.M309590200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Franzen S, 2002, J AM CHEM SOC, V124, P13271, DOI 10.1021/ja017708d; Frey AD, 2003, FEMS MICROBIOL REV, V27, P525, DOI 10.1016/S0168-6445(03)00056-1; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Godecke A, 2003, J BIOL CHEM, V278, P21761, DOI 10.1074/jbc.M302573200; Goldberg DE, 1999, CHEM REV, V99, P3371, DOI 10.1021/cr970152l; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hernandez-Urzua E, 2003, J BIOL CHEM, V278, P34975, DOI 10.1074/jbc.M303629200; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kundu S, 2003, BIOPHYS J, V84, P3931, DOI 10.1016/S0006-3495(03)75121-2; Kundu S, 2003, PROTEINS, V50, P239, DOI 10.1002/prot.10277; Kundu S, 2002, PROTEINS, V46, P268, DOI 10.1002/prot.10048; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; LAMB DC, 2000, J PHYS ORG CHEM, V13, P1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NIENHAUS GU, 1994, BIOCHEMISTRY-US, V33, P13413, DOI 10.1021/bi00249a030; Nienhaus K, 2003, J BIOL CHEM, V278, P42532, DOI 10.1074/jbc.M306888200; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9647, DOI 10.1021/bi034788k; Nienhaus K, 2003, BIOCHEMISTRY-US, V42, P9633, DOI 10.1021/bi034787s; Olson J S, 1981, Methods Enzymol, V76, P631; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Pesce A, 2002, STRUCTURE, V10, P725, DOI 10.1016/S0969-2126(02)00763-3; Pesce A, 2001, J MOL BIOL, V309, P1153, DOI 10.1006/jmbi.2001.4731; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; Raushel FM, 2003, ACCOUNTS CHEM RES, V36, P539, DOI 10.1021/ar020047k; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro TG, 2001, ACCOUNTS CHEM RES, V34, P137, DOI 10.1021/ar000108j; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; YOUNG RD, 1984, J CHEM PHYS, V81, P3730, DOI 10.1063/1.448124; [No title captured]	81	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33662	33672		10.1074/jbc.M403597200	http://dx.doi.org/10.1074/jbc.M403597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161908	hybrid			2022-12-25	WOS:000223039700076
J	Zhang, ZX; Melia, TJ; He, F; Yuan, C; McGough, A; Schmid, MF; Wensel, TG				Zhang, ZX; Melia, TJ; He, F; Yuan, C; McGough, A; Schmid, MF; Wensel, TG			How a g protein binds a membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP PHOSPHODIESTERASE ACTIVATION; HELICAL IMAGE-RECONSTRUCTION; HETEROTRIMERIC G-PROTEIN; GAMMA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; BETA-GAMMA; ELECTRON CRYSTALLOGRAPHY; CRYOELECTRON MICROSCOPY; PHOSPHOLIPID-BILAYERS; ALPHA-SUBUNITS	Heterotrimeric G proteins interact with receptors and effectors at the membrane-cytoplasm interface. Structures of soluble forms have not revealed how they interact with membranes. We have used electron crystallography to determine the structure in ice of a helical array of the photoreceptor G protein, transducin, bound to the surface of a tubular lipid bilayer. The protein binds to the membrane with a very small area of contact, restricted to two points, between the surface of the protein and the surface of the lipids. Fitting the x-ray structure into the membrane-bound structure reveals one membrane contact near the lipidated Ggamma C terminus and Galpha N terminus, and another near the Galpha C terminus. The narrowness of the tethers to the lipid bilayer provides flexibility for the protein to adopt multiple orientations on the membrane, and leaves most of the G protein surface area available for protein-protein interactions.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Wensel, TG (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	twensel@bcm.tmc.edu		Wensel, Theodore/0000-0003-3518-9352; Schmid, Michael/0000-0003-1077-5750	NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02250] Funding Source: Medline; NEI NIH HHS [EY07981] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; AvilaSakar AJ, 1996, BIOPHYS J, V70, P57, DOI 10.1016/S0006-3495(96)79597-8; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brand SH, 1996, AM J PHYSIOL-CELL PH, V270, pC1362, DOI 10.1152/ajpcell.1996.270.5.C1362; Busconi L, 1997, BIOCHEM J, V323, P239, DOI 10.1042/bj3230239; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; DeRosier D, 1999, J MOL BIOL, V289, P159, DOI 10.1006/jmbi.1999.2677; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; Dietrich A, 1996, BIOCHEMISTRY-US, V35, P15174, DOI 10.1021/bi960305j; Diraviyam K, 2003, J MOL BIOL, V328, P721, DOI 10.1016/S0022-2836(03)00325-5; DOUGHERTY MT, 1998, MICROSC MICROANAL, V4, P452; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FUKADA Y, 1995, METHOD ENZYMOL, V250, P91; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; Fukami A, 1965, J Electron Microsc (Tokyo), V14, P112; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Hamm H E, 1990, Biochem Soc Symp, V56, P35; Hedin EMK, 2002, BIOCHEMISTRY-US, V41, P14185, DOI 10.1021/bi020158r; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; Matsuda T, 1998, BIOCHEMISTRY-US, V37, P9843, DOI 10.1021/bi973194c; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Melia TJ, 1999, J STRUCT BIOL, V128, P119, DOI 10.1006/jsbi.1999.4151; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; Rossmann MG, 2001, J STRUCT BIOL, V136, P190, DOI 10.1006/jsbi.2002.4435; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; STRYER L, 1983, METHOD ENZYMOL, V96, P617; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; VAILLANCOURT RR, 1990, P NATL ACAD SCI USA, V87, P3645, DOI 10.1073/pnas.87.10.3645; Valentine KG, 2003, BIOCHEMISTRY-US, V42, P6333, DOI 10.1021/bi0206816; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1989, BIOCHEM BIOPH RES CO, V159, P651, DOI 10.1016/0006-291X(89)90044-2; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wu XW, 2003, J STRUCT BIOL, V141, P63, DOI 10.1016/S1047-8477(02)00570-1; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	61	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33937	33945		10.1074/jbc.M403404200	http://dx.doi.org/10.1074/jbc.M403404200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173184	hybrid			2022-12-25	WOS:000223039700104
J	Berka, V; Wu, G; Yeh, HC; Palmer, G; Tsai, AL				Berka, V; Wu, G; Yeh, HC; Palmer, G; Tsai, AL			Three different oxygen-induced radical species in endothelial nitric-oxide synthase oxygenase domain under regulation by L-arginine and tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; SUPEROXIDE GENERATION; STRUCTURAL-CHARACTERIZATION; HYDROGEN-PEROXIDE; CYTOCHROME-C; HEME DOMAIN; EPR; REDUCTION; DYSFUNCTION; EXPRESSION	Endothelial nitric-oxide synthase ( eNOS) plays important roles in vascular physiology and homeostasis. Whether eNOS catalyzes nitric oxide biosynthesis or the synthesis of reactive oxygen species such as superoxide, hydrogen peroxide, and peroxynitrite is dictated by the bioavailability of tetrahydrobiopterin (BH4) and L-arginine during eNOS catalysis. The effect of BH4 and L-arginine on oxygen-induced radical intermediates has been investigated by single turnover rapid-freeze quench and EPR spectroscopy using the isolated eNOS oxygenase domain (eNOS(ox)). Three distinct radical intermediates corresponding to >50% of the heme were observed during the reaction between ferrous eNOS(ox) and oxygen. BH4-free eNOS(ox) produced the superoxide radical very efficiently in the absence of L-arginine. L-Arginine decreased the formation rate of superoxide by an order of magnitude but not its final level or EPR line shape. For BH4-containing eNOS(ox), only a stoichiometric amount of BH4 radical was produced in the presence of L-arginine, but in its absence a new radical was obtained. This new radical could be either a peroxyl radical of BH4 or an amino acid radical was in the vicinity of the heme. Formation of this new radical is very rapid, >150 s(-1), and it was subsequently converted to a BH4 radical. The trapping of the superoxide radical by cytochrome c in the reaction of BH4(-) eNOS(ox) exhibited a limiting rate of similar to15 s(-1), the time for the superoxide radical to leave the heme pocket and reach the protein surface; this reveals a general problem of the regular spin-trapping method in determining radical formation kinetics. Cytochrome c failed to trap the new radical species. Together with other EPR characteristics, our data strongly support the conclusion that this new radical is not a superoxide radical or a mixture of superoxide and biopterin radicals. Our study points out distinct roles of BH4 and L-arginine in regulating eNOS radical intermediates. BH4 prevented superoxide formation by chemical conversions of the Fe(II)O-2 intermediate, and L-arginine delayed superoxide formation by electronic interaction with the heme-bound oxygen.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77225 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77225 USA.	Ah-lim.Tsai@uth.tmc.edu			NIGMS NIH HHS [GM56818, GM55807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT JE, 1968, T FARADAY SOC, V64, P3200, DOI 10.1039/tf9686403200; Berka V, 2000, BIOCHEMISTRY-US, V39, P9373, DOI 10.1021/bi992769y; Berka V, 1998, BIOCHEMISTRY-US, V37, P6136, DOI 10.1021/bi980133l; Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; DeGray JA, 1997, J BIOL CHEM, V272, P2359; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; FELDMANN HJ, 1993, RADIOTHER ONCOL, V26, P38, DOI 10.1016/0167-8140(93)90024-3; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; Hiner ANP, 2001, EUR J BIOCHEM, V268, P3091, DOI 10.1046/j.1432-1327.2001.02208.x; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; JANZEN EG, 1984, METHOD ENZYMOL, V105, P188; KNOWLES PF, 1969, BIOCHEM J, V111, P53, DOI 10.1042/bj1110053; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; PALMER G, 1964, J BIOL CHEM, V239, P2657; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Reddy SG, 1998, BIOCHEMISTRY-US, V37, P558, DOI 10.1021/bi972086n; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Svistunenko DA, 2001, BBA-PROTEIN STRUCT M, V1546, P365, DOI 10.1016/S0167-4838(01)00157-1; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; Tsai AL, 1998, ANAL BIOCHEM, V264, P165, DOI 10.1006/abio.1998.2774; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vasquez-Vivar J, 2003, FREE RADICAL RES, V37, P121, DOI 10.1080/1071576021000040655; Vasquez-Vivar J, 2002, BIOCHEM J, V362, P733, DOI 10.1042/0264-6021:3620733; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; WANG JL, 1993, J BIOL CHEM, V268, P22255; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; YANEZ J, 1987, J PHYS CHEM-US, V91, P487, DOI 10.1021/j100286a044	46	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32243	32251		10.1074/jbc.M404044200	http://dx.doi.org/10.1074/jbc.M404044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166218	hybrid			2022-12-25	WOS:000222849700032
J	Kowanetz, K; Crosetto, N; Haglund, K; Schmidt, MHH; Heldin, CH; Dikic, I				Kowanetz, K; Crosetto, N; Haglund, K; Schmidt, MHH; Heldin, CH; Dikic, I			Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; UBA DOMAIN; UBIQUITIN; PROTEINS; COMPLEX; DEGRADATION; MONOUBIQUITYLATION; MONOUBIQUITINATION; IDENTIFICATION; PATHWAY	The ubiquitin (Ub) ligase Cbl plays a critical role in attenuation of receptor tyrosine kinase (RTK) signaling by inducing ubiquitination of RTKs and promoting their sorting for endosomal degradation. Herein, we describe the identification of two novel Cbl-interacting proteins, p70 and Clip4 ( recently assigned the names Sts-1 and Sts-2, respectively), that inhibit endocytosis of epidermal growth factor receptor ( EGFR) and platelet-derived growth factor receptor. Sts-1 and Sts-2 contain SH3 domains that interacted with Cbl, Ub-associated domains, which bound directly to mono-Ub or to the EGFR/Ub chimera as well as phosphoglycerate mutase domains that mediated oligomerization of Sts-1/2. Ligand-induced recruitment of Sts-1/Sts-2 into activated EGFR complexes led to inhibition of receptor internalization, reduction in the number of EGFR-containing endocytic vesicles, and subsequent block of receptor degradation followed by prolonged activation of mitogenic signaling pathways. On the other hand, interference with Sts-1/Sts-2 functions diminished ligand-induced receptor degradation, cell proliferation, and oncogenic transformation in cultured fibroblasts. We suggest that Sts-1 and Sts-2 represent a novel class of Ub-binding proteins that regulate RTK endocytosis and control growth factor-induced cellular functions.	Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Goethe University Frankfurt; Ludwig Institute for Cancer Research	Dikic, I (corresponding author), Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	ivan.dikic@biochem2.de	Schmidt, Mirko H. H./ABI-6650-2020; Dikic, Ivan/O-4650-2015; Haglund, Kaisa/B-3927-2017	Schmidt, Mirko H. H./0000-0001-7411-8835; Dikic, Ivan/0000-0001-8156-9511; Haglund, Kaisa/0000-0002-7946-3299				Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; BACHE KG, 2003, J BIOL CHEM, V27, P27; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Carpino N, 2002, MOL CELL BIOL, V22, P7491, DOI 10.1128/MCB.22.21.7491-7500.2002; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; FESHCHENKO EA, IN PRESS ONCOGENE; Gagny B, 2000, J CELL SCI, V113, P3309; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Jedrzejas MJ, 2000, PROG BIOPHYS MOL BIO, V73, P263, DOI 10.1016/S0079-6107(00)00007-9; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; SORKIN A, 1993, BIOESSAYS, V6, P375; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Soubeyran P, 2003, BIOCHEM J, V370, P29, DOI 10.1042/BJ20021539; Szymkiewicz I, 2004, FEBS LETT, V565, P33, DOI 10.1016/j.febslet.2004.03.100; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Usuba T, 2001, INT J CANCER, V94, P662, DOI 10.1002/ijc.1524; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wattenhofer M, 2001, HUM GENET, V108, P140, DOI 10.1007/s004390000453; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939	33	96	99	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32786	32795		10.1074/jbc.M403759200	http://dx.doi.org/10.1074/jbc.M403759200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159412	hybrid			2022-12-25	WOS:000222849700098
J	Maxwell, MJ; Yuan, YP; Anderson, KE; Hibbs, ML; Salem, HH; Jackson, SP				Maxwell, MJ; Yuan, YP; Anderson, KE; Hibbs, ML; Salem, HH; Jackson, SP			SHIP1 and Lyn kinase negatively regulate integrin alpha(IIb)beta(3) signaling in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; VON-WILLEBRAND-FACTOR; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE 3-KINASE; INTEGRIN ALPHA(IIB)BETA(3); TYROSINE PHOSPHORYLATION; GLYCOPROTEIN IB/V/IX; CALCIUM SIGNALS; STIMULATED PLATELETS	Integrin alpha(IIb)beta(3) plays a critical role in platelet function, promoting a broad range of functional responses including platelet adhesion, spreading, aggregation, clot retraction, and platelet procoagulant function. Signaling events operating downstream of this receptor (outside-in signaling) are important for these responses; however the mechanisms negatively regulating integrin alpha(IIb)beta(3) signaling remain ill-defined. We demonstrate here a major role for the Src homology 2 domain-containing inositol 5-phosphatase (SHIP1) and Src family kinase, Lyn, in this process. Our studies on murine SHIP1 knockout platelets have defined a major role for this enzyme in regulating integrin alpha(IIb)beta(3)-dependent phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) accumulation, necessary for a cytosolic calcium response and platelet spreading. SHIP1 phosphorylation and PtdIns( 3,4,5) P3 metabolism is partially regulated through Lyn kinase, resulting in an enhanced calcium flux and spreading response in Lyn-deficient mouse platelets. Analysis of platelet adhesion dynamics under physiological blood flow conditions revealed an important role for SHIP1 in regulating platelet adhesion on fibrinogen. Specifically, SHIP1-dependent PtdIns(3,4,5)P-3 metabolism down-regulates the stability of integrin alpha(IIb)beta(3)-fibrinogen adhesive bonds, leading to a decrease in the proportion of platelets forming shear-resistant adhesion contacts. These studies define a major role for SHIP1 and Lyn as negative regulators of integrin alpha(IIb)beta(3) adhesive and signaling function.	Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, Melbourne, Vic 3128, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia	Box Hill Hospital; Monash University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Jackson, SP (corresponding author), Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, Melbourne, Vic 3128, Australia.	Shaun.Jackson@med.monash.edu.au	Hibbs, Margaret L/D-7013-2011; Maxwell, Mhairi/G-5492-2011	Hibbs, Margaret L/0000-0002-3751-6751; Anderson, Karen/0000-0002-7394-6660; Jackson, Shaun/0000-0002-4750-1991				Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; Cicmil M, 2002, BLOOD, V99, P137, DOI 10.1182/blood.V99.1.137; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Giuriato S, 2000, BIOCHEM J, V348, P107, DOI 10.1042/0264-6021:3480107; Giuriato S, 2003, BIOCHEM J, V376, P199, DOI 10.1042/BJ20030581; Goncalves I, 2003, J BIOL CHEM, V278, P34812, DOI 10.1074/jbc.M306504200; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; JAKOBSEN E, 1974, THROMB RES, V4, P499, DOI 10.1016/0049-3848(74)90227-8; Jones KL, 2001, BLOOD, V98, P1456, DOI 10.1182/blood.V98.5.1456; Kottirsch G, 1997, BIOORG MED CHEM LETT, V7, P727, DOI 10.1016/S0960-894X(97)00095-4; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; Nakamura K, 2002, BLOOD, V100, P3374, DOI 10.1182/blood-2002-03-0787; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; NEWMAN PJ, 1997, J CLIN INVEST, V100, P25; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Phillips DR, 2001, THROMB HAEMOSTASIS, V86, P246; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saint-Dic D, 2001, J BIOL CHEM, V276, P21192, DOI 10.1074/jbc.M008336200; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varon D, 1998, BLOOD, V91, P500, DOI 10.1182/blood.V91.2.500.500_500_507; Watanabe N, 2003, BLOOD, V102, P541, DOI 10.1182/blood-2002-11-3327; Wonerow P, 2003, J BIOL CHEM, V278, P37520, DOI 10.1074/jbc.M305077200; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	63	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32196	32204		10.1074/jbc.M400746200	http://dx.doi.org/10.1074/jbc.M400746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166241	hybrid			2022-12-25	WOS:000222849700026
J	Strom, CS; Liu, XY; Jia, ZC				Strom, CS; Liu, XY; Jia, ZC			Antifreeze protein-induced morphological modification mechanisms linked to ice binding surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM DIHYDROGEN PHOSPHATE; GRAPH-THEORETIC CONSTRUCTION; WINTER FLOUNDER ANTIFREEZE; PERIODIC BOND CHAINS; X-RAY-DIFFRACTION; CRYSTAL MORPHOLOGY; SOLVENT INTERACTION; STRUCTURAL BASIS; NUCLEATION; GROWTH	The mechanisms by which the antifreeze protein (AFP) modifies the ice morphology are identified precisely as surface poisoning by the ice binding surface (IBS) of insect AFPs and as bridge-induced surface reconstruction by the IBS of fish AFPs and antifreeze glycoproteins. The primary surfaces of hexagonal ice have predetermined face indices. The "two-dimensional" insect type IBS has regularly spaced binding intervals in two directions. It causes surface poisoning by matching and reinforcing simultaneously intersecting strong bonding directions on the primary ice surfaces. The secondary ice surfaces have variable face indices. The "one-dimensional" and "irregular" IBS variants of fish AFPs and antifreeze glycoproteins are either linearly extended with regular ice binding intervals or have ice binding sites lacking spacing regularity. These variants can bridge transversely lattice periods or shorter oxygen-oxygen distances between parallel adjacent strong bonding directions that do not intersect. Thus, one-dimensional and irregular IBS variants induce supplementary bridges cross-wise on selected secondary surfaces by mimicking strong bonding directions that are not present in the ice structure. These proteins cause surfaces with variable face indices, which in the absence of the AFPs would not grow flat, to appear in the morphology. Whereas for the primary ice surfaces it is only the morphological importance that is determined by the experimental conditions, for the secondary ice surfaces it is the face indices themselves that become adjusted in the process of maximizing the AFP-substrate interaction through attainment of the best structural match. The growth morphology of the AFP-ice system is derived from various factors, including the face indices, surface molecular compositions, relative growth rates, and the mechanisms responsible for that morphology. The theoretical formulation agrees with experiments over a wide range and resolves these, to date, unexplained phenomena.	Natl Univ Singapore, Fac Sci, Dept Phys, Biophys & Micronanostruct Lab, Singapore 117542, Singapore; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	National University of Singapore; Queens University - Canada	Liu, XY (corresponding author), Natl Univ Singapore, Fac Sci, Dept Phys, Biophys & Micronanostruct Lab, 2 Sci Dr 3, Singapore 117542, Singapore.	phyliuxy@nus.edu.sg	Zhou, Weiqian/B-8991-2011; Li, Jingliang/A-6039-2011; Liu, XY/E-5090-2010	Li, Jingliang/0000-0003-0709-2246; Liu, XY/0000-0002-4747-1251; Liu, Xiang-Yang/0000-0002-5592-6885				Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2002, BBA-PROTEINS PROTEOM, V1601, P49, DOI 10.1016/S1570-9639(02)00431-4; Dalal P, 2001, PHYSCHEMCOMM, DOI 10.1039/b101331i; Dalal P, 2000, J CHEM INF COMP SCI, V40, P1276, DOI 10.1021/ci000449b; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; Du N, 2003, J BIOL CHEM, V278, P36000, DOI 10.1074/jbc.M305222200; Ewart KV, 1996, J BIOL CHEM, V271, P16627, DOI 10.1074/jbc.271.28.16627; Graether SP, 2000, NATURE, V406, P325, DOI 10.1038/35018610; Graham LA, 1997, NATURE, V388, P727, DOI 10.1038/41908; HARTMAN P, 1956, ACTA CRYSTALLOGR, V9, P569, DOI 10.1107/S0365110X56001583; HARTMAN P, 1958, ACTA CRYSTALLOGR, V11, P365, DOI 10.1107/S0365110X58000967; Haymet ADJ, 1998, FEBS LETT, V430, P301, DOI 10.1016/S0014-5793(98)00652-8; Haymet ADJ, 2001, FEBS LETT, V491, P285, DOI 10.1016/S0014-5793(01)02213-X; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; Knight CA, 2001, CRYST GROWTH DES, V1, P429, DOI 10.1021/cg015531t; KNIGHT CA, 1994, J CRYST GROWTH, V143, P301, DOI 10.1016/0022-0248(94)90071-X; Liu XY, 2004, J BIOL CHEM, V279, P6124, DOI 10.1074/jbc.M310487200; Miura K, 2001, J BIOL CHEM, V276, P1304, DOI 10.1074/jbc.M007902200; Mutaftschiev B., 1993, HDB CRYSTAL GROWTH, VI, P189; Ning D, 2002, APPL PHYS LETT, V81, P445, DOI 10.1063/1.1492849; Strom CS, 2000, J PHYS CHEM B, V104, P9638, DOI 10.1021/jp000883g; Strom CS, 2001, J CRYST GROWTH, V222, P298, DOI 10.1016/S0022-0248(00)00908-8; STROM CS, 1989, ACTA CRYSTALLOGR A, V45, P371, DOI 10.1107/S0108767389000395; STROM CS, 1980, Z KRISTALLOGR, V153, P99, DOI 10.1524/zkri.1980.0009; STROM CS, 1985, Z KRISTALLOGR, V172, P11, DOI 10.1524/zkri.1985.172.1-2.11; STROM CS, 1981, Z KRISTALLOGR, V154, P31, DOI 10.1524/zkri.1981.154.1-2.31; Strom CS, 1999, J PHYS CHEM B, V103, P11339, DOI 10.1021/jp992652j; STROM CS, 1999, MOL MODELING APPL CR, P228; VANDERVOORT E, 1991, J CRYST GROWTH, V112, P445, DOI 10.1016/0022-0248(91)90321-U; Wathen B, 2003, J AM CHEM SOC, V125, P729, DOI 10.1021/ja0267932; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; Wierzbicki A, 1997, J CHEM INF COMP SCI, V37, P1006, DOI 10.1021/ci9702353; Wilson PW, 2002, CRYOBIOLOGY, V44, P240, DOI 10.1016/S0011-2240(02)00028-7; WILSON PW, 1995, BIOPHYS J, V68, P2098, DOI 10.1016/S0006-3495(95)80389-9; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Zhang W, 1999, FEBS LETT, V455, P372, DOI 10.1016/S0014-5793(99)00906-0	39	21	24	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32407	32417		10.1074/jbc.M401712200	http://dx.doi.org/10.1074/jbc.M401712200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15140895	hybrid			2022-12-25	WOS:000222849700054
J	Tanaka, Y; Tsumoto, K; Yasutake, Y; Umetsu, M; Yao, M; Fukada, H; Tanaka, I; Kumagai, I				Tanaka, Y; Tsumoto, K; Yasutake, Y; Umetsu, M; Yao, M; Fukada, H; Tanaka, I; Kumagai, I			How oligomerization contributes to the thermostability of an Archaeon protein - Protein L-isoaspartyl-O-methyltransferase from Sulfolobus tokodaii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORIBOSYL ANTHRANILATE ISOMERASE; CRYSTAL-STRUCTURE; PYROCOCCUS-FURIOSUS; HYPERTHERMOPHILIC ARCHAEON; THERMAL-STABILITY; REPAIR METHYLTRANSFERASE; POSSIBLE DETERMINANTS; THERMOTOGA-MARITIMA; CITRATE SYNTHASE; DIMER INTERFACE	To study how oligomerization may contribute to the thermostability of archaeon proteins, we focused on a hexameric protein, protein L-isoaspartyl-O-methyltransferase from Sulfolobus tokodaii (StoPIMT). The crystal structure shows that StoPIMT has a distinctive hexameric structure composed of monomers consisting of two domains: an S-adenosylmethionine-dependent methyltransferase fold domain and a C-terminal alpha-helical domain. The hexameric structure includes three interfacial contact regions: major, minor, and coiled-coil. Several C-terminal deletion mutants were constructed and characterized. The hexameric structure and thermostability were retained when the C-terminal alpha-helical domain (Tyr(206)-Thr(231)) was deleted, suggesting that oligomerization via coiled-coil association using the C-terminal alpha-helical domains did not contribute critically to hexamerization or to the increased thermostability of the protein. Deletion of three additional residues located in the major contact region, Tyr(203)-Asp(204)-Asp(205), led to a significant decrease in hexamer stability and chemico/thermostability. Although replacement of Thr(146) and Asp(204), which form two hydrogen bonds in the interface in the major contact region, with Ala did not affect hexamer formation, these mutations led to a significant decrease in thermostability, suggesting that two residues in the major contact region make significant contributions to the increase in stability of the protein via hexamerization. These results suggest that cooperative hexamerization occurs via interactions of "hot spot" residues and that a couple of interfacial hot spot residues are responsible for enhancing thermostability via oligomerization.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Div Appl Biochem, Osaka 5998531, Japan	Tohoku University; Hokkaido University; Osaka Metropolitan University	Tsumoto, K (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	tsumoto@mail.tains.tohoku.ac.jp	yao, min/F-5287-2011; Yasutake, Yoshiaki/H-8079-2018	yao, min/0000-0003-1687-5904; Yasutake, Yoshiaki/0000-0002-4521-7516; Tanaka, Yoshikazu/0000-0002-7893-3236				Arndt KM, 2001, J MOL BIOL, V312, P221, DOI 10.1006/jmbi.2001.4915; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bennett EJ, 2003, BIOCHEMISTRY-US, V42, P12844, DOI 10.1021/bi034891+; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRITTON KL, 1995, EUR J BIOCHEM, V229, P688, DOI 10.1111/j.1432-1033.1995.tb20515.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; GEIGER T, 1987, J BIOL CHEM, V262, P785; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; Hart DJ, 2001, J MOL BIOL, V310, P563, DOI 10.1006/jmbi.2001.4724; Hatanaka H, 1997, J MOL BIOL, V268, P922, DOI 10.1006/jmbi.1997.1001; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; Li T, 2003, J MOL BIOL, V325, P1031, DOI 10.1016/S0022-2836(02)01285-8; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Loladze VV, 1999, BIOCHEMISTRY-US, V38, P16419, DOI 10.1021/bi992271w; Ogasahara K, 2003, J BIOL CHEM, V278, P8922, DOI 10.1074/jbc.M210893200; Ogasahara K, 2001, EUR J BIOCHEM, V268, P3233, DOI 10.1046/j.1432-1327.2001.02220.x; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; Ryttersgaard C, 2002, J BIOL CHEM, V277, P10642, DOI 10.1074/jbc.M200229200; Sanchez-Ruiz JM, 2001, TRENDS BIOTECHNOL, V19, P132, DOI 10.1016/S0167-7799(00)01548-1; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SCHUMANN J, 1993, PROTEIN SCI, V2, P1612, DOI 10.1002/pro.5560021007; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; Skinner MM, 2000, STRUCTURE, V8, P1189, DOI 10.1016/S0969-2126(00)00522-0; Smith CD, 2002, PROTEIN SCI, V11, P625, DOI 10.1110/ps.37802; SPASSOV VZ, 1995, PROTEIN SCI, V4, P1516, DOI 10.1002/pro.5560040809; Sterner R, 1996, PROTEIN SCI, V5, P2000, DOI 10.1002/pro.5560051006; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tahirov TH, 1998, J MOL BIOL, V284, P101, DOI 10.1006/jmbi.1998.2146; Tanaka Y, 2004, FEBS LETT, V556, P167, DOI 10.1016/S0014-5793(03)01402-9; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thapar N, 2002, J BIOL CHEM, V277, P1058, DOI 10.1074/jbc.M108261200; Thoma R, 2000, STRUCTURE, V8, P265, DOI 10.1016/S0969-2126(00)00106-4; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; Vogt G, 1997, FOLD DES, V2, pS40, DOI 10.1016/S1359-0278(97)00062-X; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433	58	66	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32957	32967		10.1074/jbc.M404405200	http://dx.doi.org/10.1074/jbc.M404405200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169774	hybrid			2022-12-25	WOS:000222849700116
J	Anest, V; Cogswell, PC; Baldwin, AS				Anest, V; Cogswell, PC; Baldwin, AS			I kappa B kinase alpha and p65/Re1A contribute to optimal epidermal growth factor-induced c-fos gene expression independent of I kappa B alpha degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HISTONE H3; IKK-ALPHA; TRANSCRIPTIONAL ACTIVATION; COVALENT MODIFICATIONS; PHOSPHORYLATION; ELK-1; PHOSPHOACETYLATION; CELL	Mitogenic activation of expression of immediate-early genes, such as c-fos, is controlled through signal-induced phosphorylation of constitutively bound transcription factors that is correlated with a nucleosomal response that involves inducible chromatin modifications, such as histone phosphorylation and acetylation. Here we have explored a potential role for the transcription factor NF-kappaB and its associated signaling components in mediating induction of c-fos gene expression downstream of epidermal growth factor (EGF)-dependent signaling. Here we show that EGF treatment of quiescent fibroblast does not induce the classical pathway of NF-kappaB activation through IkappaB kinase (IKK)-directed IkappaBalpha phosphorylation. Interestingly, efficient induction of c-fos transcription requires IKKalpha, one of the subunits of the IkappaB kinase complex. The NF-kappaB subunit, p65/RelA, is found constitutively associated with the c-fos promoter, and knock-out of this transcription factor significantly reduces c-fos gene expression. Importantly, EGF induces the recruitment of IKKalpha to the c-fos promoter to regulate promoter-specific histone H3 Ser(10) phosphorylation in a manner that is independent of p65/RelA. Collectively, our data demonstrate that IKKalpha and p65/RelA contribute significantly to EGF-induced c-fos gene expression in a manner independent of the classical, IkappaBalpha degradation, p65/RelA nuclear accumulation response pathway.	Univ N Carolina, Lineberger Comprehens Canc Ctr 22 000, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr 22 000, Curriculum Genet & Mol Biol, CB 7295, Chapel Hill, NC 27599 USA.	jhall@med.unc.edu			NATIONAL CANCER INSTITUTE [R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73756] Funding Source: Medline; NIAID NIH HHS [R01 AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Murai K, 2002, MOL CELL BIOL, V22, P7083, DOI 10.1128/MCB.22.20.7083-7092.2002; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamauchi T, 2002, MOL CANCER THER, V1, P287; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	34	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31183	31189		10.1074/jbc.M404380200	http://dx.doi.org/10.1074/jbc.M404380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155743	Green Published, hybrid			2022-12-25	WOS:000222726800036
J	Boehning, D; Sedaghat, L; Sedlak, TW; Snyder, SH				Boehning, D; Sedaghat, L; Sedlak, TW; Snyder, SH			Heme oxygenase-2 is activated by calcium-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; AKT-DEPENDENT PHOSPHORYLATION; NUCLEUS-TRACTUS-SOLITARII; CARBON-MONOXIDE; GLUTAMATE RECEPTORS; ENDOTHELIAL-CELLS; PENILE ERECTION; NEUROTRANSMISSION; ANTAGONISTS; ARTERIOLES	The heme oxygenase family of enzymes catalyzes the metabolism of heme to biliverdin, ferrous iron, and carbon monoxide (CO). At least two isoforms exist, heme oxygenase-1 (HO1) and heme oxygenase-2 (HO2), which are encoded by separate genes. HO2 is selectively enriched in neurons, and substantial evidence suggests that HO2-derived CO functions as a neurotransmitter/ neuromodulator. However, a molecular mechanism for the rapid activation of HO2 during neuronal activity has not been described. Through a yeast two-hybrid screen we identified calmodulin as a potential regulator of HO2 activity. Calmodulin binds with nanomolar affinity to HO2 in a calcium-dependent manner via a canonical 1 - 10 motif, resulting in a 3-fold increase in catalytic activity. Mutations within this motif block calmodulin binding and calcium-dependent stimulation of enzyme activity in vitro and in intact cells. The calcium mobilizing agents ionomycin and glutamate stimulate endogenous HO2 activity in primary cortical cultures, establishing in vivo relevance. Calcium-calmodulin provides a mechanism for rapid and transient activation of HO2 during neuronal activity.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St,813 WBSB, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu	Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NIDA NIH HHS [DA-000266, DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NINDS NIH HHS [NS-043850] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agullo L, 1997, EUR J PHARMACOL, V323, P119, DOI 10.1016/S0014-2999(97)00019-8; ASANO M, 1989, J PHARMACOL EXP THER, V251, P764; Baranano DE, 2000, J BIOL CHEM, V275, P15166, DOI 10.1074/jbc.275.20.15166; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fiumana E, 2003, AM J PHYSIOL-HEART C, V284, pH1073, DOI 10.1152/ajpheart.00881.2002; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hurt KJ, 2002, P NATL ACAD SCI USA, V99, P4061, DOI 10.1073/pnas.052712499; Leffler CW, 2003, AM J PHYSIOL-HEART C, V285, pH74, DOI 10.1152/ajpheart.01081.2002; LEINDERSZUFALL T, 1995, J NEUROPHYSIOL, V74, P1498, DOI 10.1152/jn.1995.74.4.1498; Li XQ, 2002, EUR J PHARMACOL, V450, P43, DOI 10.1016/S0014-2999(02)02051-4; Lin CH, 2004, J PHARMACOL EXP THER, V308, P1213, DOI 10.1124/jpet.103.060186; Lo WC, 2002, EUR J PHARMACOL, V454, P39, DOI 10.1016/S0014-2999(02)02480-9; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Parfenova H, 2003, J CEREBR BLOOD F MET, V23, P190, DOI 10.1097/01.WCB.000004823561824.C4; Robinson JS, 2002, AM J PHYSIOL-HEART C, V282, pH2371, DOI 10.1152/ajpheart.00911.2001; Sampaio-Maia B, 2001, CELL BIOL INT, V25, P245, DOI 10.1006/cbir.2000.0639; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; Watkins CC, 2004, P NATL ACAD SCI USA, V101, P2631, DOI 10.1073/pnas.0308695100; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Zufall F, 1997, J NEUROSCI, V17, P2703	30	69	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30927	30930		10.1074/jbc.C400222200	http://dx.doi.org/10.1074/jbc.C400222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15175337	hybrid			2022-12-25	WOS:000222726800004
J	Morgan, K; Obici, S; Rossetti, L				Morgan, K; Obici, S; Rossetti, L			Hypothalamic responses to long-chain fatty acids are nutritionally regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATASE GENE-EXPRESSION; FOOD-INTAKE; BODY-WEIGHT; INSULIN-RESISTANCE; DIETARY OBESITY; GLUCOSE-PRODUCTION; LEPTIN ACTION; RATS; INHIBITION; LIVER	Central administration of the long-chain fatty acid oleic acid inhibits food intake and glucose production in rats. Here we examined whether short term changes in nutrient availability can modulate these metabolic and behavioral effects of oleic acid. Rats were divided in three groups receiving a highly palatable energy-dense diet at increasing daily caloric levels ( below, similar, or above the average of rats fed standard chow). Following 3 days on the assigned diet regimen, rats were tested for acute biological responses to the infusion of oleic acid in the third cerebral ventricle. Three days of overfeeding virtually obliterated the metabolic and anorectic effects of the central administration of oleic acid. Furthermore, the infusion of oleic acid in the third cerebral ventricle failed to decrease the expression of neuropeptide Y in the hypothalamus and of glucose-6-phosphatase in the liver following short term overfeeding. The lack of hypothalamic responses to oleic acid following short term overfeeding is likely to contribute to the rapid onset of weight gain and hepatic insulin resistance in this animal model.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, R01DK045024, R37DK048321, R29DK045024, R01DK048321] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20541, DK 45024, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSMAN LM, 1981, AM J PHYSIOL, V241, pR316, DOI 10.1152/ajpregu.1981.241.5.R316; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; BERTHOUD HR, 1979, ENDOCRINOLOGY, V105, P146, DOI 10.1210/endo-105-1-146; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BRIEF DJ, 1984, BRAIN RES BULL, V12, P571, DOI 10.1016/0361-9230(84)90174-6; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; CLORE JN, 1995, J CLIN INVEST, V96, P1967, DOI 10.1172/JCI118243; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 2003, SCIENCE, V299, P856, DOI 10.1126/science.1079856; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GOTO M, 1971, P SOC EXP BIOL MED, V136, P1294; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HALL JE, 1995, HYPERTENSION, V25, P994, DOI 10.1161/01.HYP.25.5.994; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; INOUE S, 1977, ENDOCRINOLOGY, V100, P108, DOI 10.1210/endo-100-1-108; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Kopelman PG, 1998, LANCET, V352, P5; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MILLER JC, 1987, J NEUROCHEM, V49, P1507, DOI 10.1111/j.1471-4159.1987.tb01021.x; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; Obici S, 2003, NAT MED, V9, P756, DOI 10.1038/nm873; Obici S, 2002, DIABETES, V51, P271, DOI 10.2337/diabetes.51.2.271; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Pagliassotti MJ, 1997, ANN NY ACAD SCI, V827, P431, DOI 10.1111/j.1749-6632.1997.tb51853.x; PITHA J, 1994, J PHARM SCI, V83, P833, DOI 10.1002/jps.2600830615; Porte D, 1998, DIABETOLOGIA, V41, P863, DOI 10.1007/s001250051002; Qi KM, 2002, CURR OPIN CLIN NUTR, V5, P133, DOI 10.1097/00075197-200203000-00003; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rapoport SI, 2001, J MOL NEUROSCI, V16, P243, DOI 10.1385/JMN:16:2-3:243; Rapoport SI, 1996, LIPIDS, V31, pS97, DOI 10.1007/BF02637059; Ravussin E, 1999, INT J OBESITY, V23, P37, DOI 10.1038/sj.ijo.0800793; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; ROMSOS DR, 1978, P SOC EXP BIOL MED, V157, P528, DOI 10.3181/00379727-157-40090; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; SCHEMMEL R, 1970, J NUTR, V100, P1041; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SCLAFANI A, 1976, PHYSIOL BEHAV, V17, P461, DOI 10.1016/0031-9384(76)90109-8; SHIMAZU T, 1978, BRAIN RES, V144, P343, DOI 10.1016/0006-8993(78)90159-2; Shimazu T, 1996, NUTRITION, V12, P65; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; Wang Q, 1997, DIABETES, V46, P335, DOI 10.2337/diabetes.46.3.335; WEST DB, 1995, AM J PHYSIOL-REG I, V268, pR658, DOI 10.1152/ajpregu.1995.268.3.R658; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; Widdowson PS, 1997, DIABETES, V46, P1782, DOI 10.2337/diabetes.46.11.1782; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; YAKSH TL, 1991, LIFE SCI, V48, P623, DOI 10.1016/0024-3205(91)90537-L; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	71	152	157	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31139	31148		10.1074/jbc.M400458200	http://dx.doi.org/10.1074/jbc.M400458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155754	hybrid			2022-12-25	WOS:000222726800030
J	Thomas, D; Blakqori, G; Wagner, V; Banholzer, M; Kessler, N; Elliott, RM; Haller, O; Weber, F				Thomas, D; Blakqori, G; Wagner, V; Banholzer, M; Kessler, N; Elliott, RM; Haller, O; Weber, F			Inhibition of RNA polymerase II phosphorylation by a viral interferon antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN NSS; INFLUENZA-A VIRUS; C-TERMINAL DOMAIN; VESICULAR STOMATITIS-VIRUS; NF-KAPPA-B; GENE-EXPRESSION; TRANSCRIPTION FACTOR; BINDING-PROTEIN; MATRIX PROTEIN; MOSQUITO CELLS	Many viruses subvert the cellular interferon (IFN) system with so-called IFN antagonists. Bunyamwera virus (BUNV) belongs to the family Bunyaviridae and is transmitted by arthropods. We have recently identified the nonstructural protein NSs of BUNV as a virulence factor that inhibits IFN-beta gene expression in the mammalian host. Here, we demonstrate that NSs targets the RNA polymerase II ( RNAP II) complex. The C-terminal domain (CTD) of RNAP II consists of 52 repeats of the consensus sequence YSPTSPS. Phosphorylation at serine 5 is required for efficient initiation of transcription, and subsequent phosphorylation at serine 2 is required for mRNA elongation and 3'-end processing. In BUNV-infected mammalian cells, serine 5 phosphorylation occurred normally. Furthermore, RNAP II was able to bind to the IFN-beta gene promoter as revealed by chromatin immunoprecipitation analysis, indicating that the initiation of transcription was not disturbed by NSs. However, NSs prevented CTD phosphorylation at serine 2, suggesting a block in transition from initiation to elongation. Surprisingly, no interference with CTD phosphorylation was observed in insect cells. Our results indicate that BUNV uses an unconventional mechanism to block IFN synthesis in the mammalian host by directly dysregulating RNAP II. Moreover, by inducing a general transcriptional block, NSs may contribute to the lytic infection observed in mammalian cells as opposed to persistent infection in the insect host.	Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany; Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	University of Freiburg; University of Glasgow	Weber, F (corresponding author), Univ Freiburg, Inst Med Mikrobiol & Hyg, Abt Virol, D-79008 Freiburg, Germany.	fweber@UKL.uni-freiburg.de	Weber, Friedemann/AAB-3425-2019; Thomas-Rüddel, Daniel/B-4380-2013	Thomas-Rüddel, Daniel/0000-0001-9143-8566; Weber, Friedemann/0000-0001-9737-337X				Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; Bridgen A, 2001, P NATL ACAD SCI USA, V98, P664, DOI 10.1073/pnas.98.2.664; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; Colon-Ramos DA, 2003, MOL BIOL CELL, V14, P4162, DOI 10.1091/mbc.E03-03-0139; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; ELLIOTT RM, 1999, ENCY VIROLOGY, P212; Fong N, 2003, EMBO J, V22, P4274, DOI 10.1093/emboj/cdg396; FORTES P, 1994, EMBO J, V13, P704, DOI 10.1002/j.1460-2075.1994.tb06310.x; Gonzalez-Scarano F, 1996, VIROLOGY, P1473; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; HACKER D, 1989, J VIROL, V63, P5166, DOI 10.1128/JVI.63.12.5166-5174.1989; Han ZB, 2003, CURR BIOL, V13, P1921, DOI 10.1016/j.cub.2003.10.035; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P10096, DOI 10.1073/pnas.152327499; Kim MK, 1999, MOL CELL BIOL, V19, P6833; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Kohl A, 2003, J VIROL, V77, P7999, DOI 10.1128/JVI.77.14.7999-8008.2003; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KRUG RM, 1989, INFLUENZA VIRUSES, P89; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Le May N, 2004, CELL, V116, P541, DOI 10.1016/S0092-8674(04)00132-1; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; Ludwig S, 2002, J VIROL, V76, P11166, DOI 10.1128/JVI.76.21.11166-11171.2002; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; RAJU R, 1988, J VIROL, V62, P27, DOI 10.1128/JVI.62.1.27-32.1988; ROSSIER C, 1988, VIROLOGY, V165, P539, DOI 10.1016/0042-6822(88)90598-3; SCALLAN MF, 1992, J GEN VIROL, V73, P53, DOI 10.1099/0022-1317-73-1-53; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; WATRET GE, 1985, J GEN VIROL, V66, P473, DOI 10.1099/0022-1317-66-3-473; Weber F, 2003, J INTERF CYTOK RES, V23, P209, DOI 10.1089/107999003765027410; Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002; Weber F, 2002, VIRUS RES, V88, P129, DOI 10.1016/S0168-1702(02)00125-9; Weber F, 2001, VIROLOGY, V281, P67, DOI 10.1006/viro.2000.0774; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yuan H, 1998, VIROLOGY, V251, P383, DOI 10.1006/viro.1998.9413; Zhang F, 2003, GENE DEV, V17, P748, DOI 10.1101/gad.1068203	61	101	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31471	31477		10.1074/jbc.M400938200	http://dx.doi.org/10.1074/jbc.M400938200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150262	hybrid			2022-12-25	WOS:000222726800069
J	Palomba, L; Persichini, T; Mazzone, V; Colasanti, M; Cantoni, O				Palomba, L; Persichini, T; Mazzone, V; Colasanti, M; Cantoni, O			Inhibition of nitric-oxide synthase-I (NOS-I)-dependent nitric oxide production by lipopolysaccharide plus interferon-gamma is mediated by arachidonic acid - Effects on NF kappa B activation and late inducible NOS expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); CELL-LINE; PROTECTS; BINDING; PHOSPHORYLATION; PATHWAY	Previous results have indicated that lipopolysaccharide (LPS) plus interferon-gamma (IFNgamma) inhibits nitric-oxide synthase (NOS)-I activity in glial cells. We report here that arachidonic acid ( AA) plays a pivotal role in this response, which was consistently reproduced in different glial cell lines and in primary rat astrocytes. This notion was established using pharmacological inhibitors of phospholipase A(2) (PLA(2)), cytosolic PLA(2) (cPLA(2)) antisense oligonucleotides, and AA add-back experiments. This approach not only allowed the demonstration that AA promotes inhibition of NOS-I activity but also produced novel experimental evidence that LPS/IFNgamma itself is a potential stimulus for NOS-I. Indeed, LPS/IFNgamma fails to generate nitric oxide (NO) via NOS-I activation simply because it activates the AA-dependent signal that impedes NOS-I activity. Otherwise, LPS/IFNgamma promotes NO formation, sensitive to exogenous AA, in cells in which cPLA(2) is pharmacologically inhibited or genetically depleted. Because NO suppresses the NFkappaB-dependent NOS-II expression, inactivation of NOS-I by the LPS/IFNgamma-induced AA pathway provides optimal conditions for NFkappaB activation and subsequent NOS-II expression. Inhibition of cPLA(2) activity, while reducing the availability of AA, consistently inhibited NFkappaB activation and NOS-II mRNA induction and delayed NO formation. These responses were promptly re-established by addition of exogenous AA. Finally, we have demonstrated that the LPS/IFNgamma-dependent tyrosine phosphorylation of NOS-I and inhibition of its activity are mediated by endogenous AA.	Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy; Univ Urbino Carlo Bo, Ist Farmacol & Farmacognosia, I-61029 Urbino, Italy	Roma Tre University; University of Urbino	Colasanti, M (corresponding author), Univ Roma Tre, Dipartimento Biol, Viale Marconi 446, I-00146 Rome, Italy.	colasant@uniroma3.it	COLASANTI, MARCO/A-5616-2010	COLASANTI, MARCO/0000-0002-5752-4943; PERSICHINI, TIZIANA/0000-0001-8291-6706				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciani E, 2002, J BIOL CHEM, V277, P49896, DOI 10.1074/jbc.M206177200; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V246, P453, DOI 10.1006/bbrc.1998.8642; Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915; Colasanti M, 1997, J BIOL CHEM, V272, P7582, DOI 10.1074/jbc.272.12.7582; Colasanti M, 2000, BRAIN RES BULL, V52, P155, DOI 10.1016/S0361-9230(00)00262-8; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; DUGAN LL, 1995, J NEUROSCI, V15, P4545; GOLDRING CEP, 1995, BIOCHEM BIOPH RES CO, V209, P73, DOI 10.1006/bbrc.1995.1472; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MONCADA S, 1991, PHARMACOL REV, V43, P109; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Palomba L, 2004, FREE RADICAL BIO MED, V36, P319, DOI 10.1016/j.freeradbiomed.2003.10.026; Robb SJ, 2002, ANN NY ACAD SCI, V962, P93, DOI 10.1111/j.1749-6632.2002.tb04059.x; Rose K., 1992, METHODS TOXICOLOGY, V1, P46, DOI DOI 10.1371/J0URNAL.P0NE.0006591; Suzuki H, 2001, CIRCULATION, V103, pE81; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Visnjic D, 1997, BLOOD, V89, P81, DOI 10.1182/blood.V89.1.81.81_81_91; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	24	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29895	29901		10.1074/jbc.M312768200	http://dx.doi.org/10.1074/jbc.M312768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15148326	hybrid, Green Published			2022-12-25	WOS:000222531900005
J	Puig, S; Lau, M; Thiele, DJ				Puig, S; Lau, M; Thiele, DJ			Cti6 is an Rpd3-Sin3 histone deacetylase-associated protein required for growth under iron-limiting conditions in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; IN-VIVO; SCHIZOSACCHAROMYCES-POMBE; INTEGRAL COMPONENT; SIDEROPHORE UPTAKE; COPPER TRANSPORT; PHD DOMAIN; CELL-WALL; YEAST	Iron and copper are redox active metals essential for life. In the budding yeast Saccharomyces cerevisiae, expression of iron and copper genes involved in metal acquisition and utilization is tightly regulated at the transcriptional level. In addition iron and copper metabolism are inextricably linked because of the dependence on copper as a co-factor for iron uptake or mobilization. To further identify genes that function in iron and copper homeostasis, we screened for novel yeast mutants defective for iron limiting growth and thereby identified the CTI6 gene. Cti6 is a PHD finger-containing protein that has been shown to participate in the interaction of the Ssn6-Tup1 co-repressor with the Gcn5-containing SAGA chromatin-remodeling complex. In this report we show that CTI6 mRNA levels are increased under iron-limiting conditions, and that cti6 mutants display a growth defect under conditions of iron deprivation. Furthermore, we demonstrate that Cti6 is a nuclear protein that functionally associates with the Rpd3-Sin3 histone deacetylase complex involved in transcriptional repression. Cti6 demonstrates Rpd3-dependent transcriptional repression, and cti6 mutants exhibit an enhanced silencing of telomeric, rDNA and HMR loci, similar to mutants in genes encoding other Rpd3-Sin3-associated proteins. Microarray experiments with cti6 mutants grown under iron-limiting conditions show a down-regulation of telomeric genes and an up-regulation of Aft1 and Tup1 target genes involved in iron and oxygen regulation. Taken together, these data suggest a specific role for Cti6 in the regulation of gene expression under conditions of iron limitation.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA	University of Michigan System; University of Michigan; Duke University	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dennis.thiele@duke.edu	Puig, Sergi/E-4788-2010	Puig, Sergi/0000-0002-1856-490X	NIGMS NIH HHS [GM48140] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Abramova NE, 2001, GENETICS, V157, P1169; Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Dorland S, 2000, GENETICS, V154, P573; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Fragiadakis GS, 2004, EMBO J, V23, P333, DOI 10.1038/sj.emboj.7600043; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Georgatsou E, 1999, YEAST, V15, P573, DOI 10.1002/(SICI)1097-0061(199905)15:7<573::AID-YEA404>3.3.CO;2-Z; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 2002, YEAST, V19, P329, DOI 10.1002/yea.840; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Protchenko O, 2003, J BIOL CHEM, V278, P36582, DOI 10.1074/jbc.M306584200; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rachidi N, 2000, MOL MICROBIOL, V35, P1421, DOI 10.1046/j.1365-2958.2000.01807.x; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stubble J, 2003, CURR OPIN CHEM BIOL, V7, P183, DOI 10.1016/S1367-5931(03)00025-5; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wright R, 2003, YEAST, V20, P881, DOI 10.1002/yea.994; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1; Znaidi S, 2004, J BIOL CHEM, V279, P9462, DOI 10.1074/jbc.M312787200	61	33	34	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30298	30306		10.1074/jbc.M313463200	http://dx.doi.org/10.1074/jbc.M313463200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133041	hybrid			2022-12-25	WOS:000222531900055
J	Rouanet, C; Reverchon, S; Rodionov, DA; Nasser, W				Rouanet, C; Reverchon, S; Rodionov, DA; Nasser, W			Definition of a consensus DNA-binding site for PecS, a global regulator of virulence gene expression in Erwinia chrysanthemi and identification of new members of the PecS regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-ANTIBIOTIC-RESISTANCE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; PECTINOLYSIS GENES; PECTATE LYASES; BLUE PIGMENT; REPRESSOR; TRANSCRIPTION	In Erwinia chrysanthemi, production of pectic enzymes is modulated by a complex network involving several regulators. One of them, PecS, which belongs to the MarR family, also controls the synthesis of various other virulence factors, such as cellulases and indigoidine. Here, the PecS consensus-binding site is defined by combining a systematic evolution of ligands by an exponential enrichment approach and mutational analyses. The consensus consists of a 23-base pair palindromic-like sequence (C(-11)G(-10)A(-9)N(-8)W(-7)T(-6)C(-5)G(-4) T(-3)A(-2))T(-1)A(0)T(1)(T(2)A(3)C(4)G(5)A(6)N(7)N(8)N(9)C(10)G(11)). Mutational experiments revealed that (i) the palindromic organization is required for the binding of PecS, (ii) the very conserved part of the consensus (-6 to 6) allows for a specific interaction with PecS, but the presence of the relatively degenerated bases located apart significantly increases PecS affinity, (iii) the four bases G(-4), A(-2), T-2, and C-4 are required for efficient binding of PecS, and (iv) the presence of several binding sites on the same promoter increases the affinity of PecS. This consensus is detected in the regions involved in PecS binding on the previously characterized target genes. This variable consensus is in agreement with the observation that the members of the MarR family are able to bind various DNA targets as dimers by means of a winged helix DNA-binding motif. Binding of PecS on a promoter region containing the defined consensus results in a repression of gene transcription in vitro. Preliminary scanning of the E. chrysanthemi genome sequence with the consensus revealed the presence of strong PecS-binding sites in the intergenic region between fliE and fliFGHIJKLMNOPQR which encode proteins involved in the biogenesis of flagellum. Accordingly, PecS directly represses fliE expression. Thus, PecS seems to control the synthesis of virulence factors required for the key steps of plant infection.	Univ Lyon 1, Inst Natl Sci Appl, CNRS, Unite Mixte Rech 5122,Unite Microbiol & Genet, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Nasser, W (corresponding author), Univ Lyon 1, Inst Natl Sci Appl, CNRS, Unite Mixte Rech 5122,Unite Microbiol & Genet, F-69622 Villeurbanne, France.	William.nasser@insa-lyon.fr	NASSER, William/C-9611-2019; Sylvie, Reverchon/P-7932-2016; Rodionov, Dmitry/V-2688-2018	NASSER, William/0000-0001-9848-3597; Sylvie, Reverchon/0000-0002-0478-3474; Rouanet, Carine/0000-0001-9105-1855; Rodionov, Dmitry/0000-0002-0939-390X				Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; BAILEY TL, 1994, ISMB, V2, P28; BAUER DW, 1994, MOL PLANT MICROBE IN, V7, P573, DOI 10.1094/MPMI-7-0573; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Chesnokova O, 1997, MOL MICROBIOL, V23, P579, DOI 10.1046/j.1365-2958.1997.d01-1875.x; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Claret L, 2002, J MOL BIOL, V321, P185, DOI 10.1016/S0022-2836(02)00600-9; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; Condemine G, 1999, MOL PLANT MICROBE IN, V12, P45, DOI 10.1094/MPMI.1999.12.1.45; ELHASSOUNI ME, P NATL ACAD SCI US, V96, P887; Evans K, 1998, J BACTERIOL, V180, P5443, DOI 10.1128/JB.180.20.5443-5447.1998; EXPERT D, 1985, J BACTERIOL, V163, P221, DOI 10.1128/JB.163.1.221-227.1985; Hugouvieux-Cotte-Pattat N, 2002, J BACTERIOL, V184, P2664, DOI 10.1128/JB.184.10.2664-2673.2002; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; Josenhans C, 2002, INT J MED MICROBIOL, V291, P605, DOI 10.1078/1438-4221-00173; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; Lopez-Solanilla E, 1998, PLANT CELL, V10, P917, DOI 10.1105/tpc.10.6.917; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; Miller PF, 1996, MOL MICROBIOL, V21, P441, DOI 10.1111/j.1365-2958.1996.tb02553.x; Mironov A. A., 2000, Molekulyarnaya Biologiya (Moscow), V34, P253; MULHOLLAND V, 1993, MOL MICROBIOL, V9, P343, DOI 10.1111/j.1365-2958.1993.tb01695.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; NASSER W, 1994, J MOL BIOL, V236, P427, DOI 10.1006/jmbi.1994.1155; Nasser W, 2002, MOL MICROBIOL, V43, P733, DOI 10.1046/j.1365-2958.2002.02782.x; Nasser W, 1999, MOL MICROBIOL, V34, P641, DOI 10.1046/j.1365-2958.1999.01609.x; Nasser W, 1997, MOL MICROBIOL, V26, P1071, DOI 10.1046/j.1365-2958.1997.6472020.x; Nomura K, 1998, P NATL ACAD SCI USA, V95, P14034, DOI 10.1073/pnas.95.24.14034; Praillet T, 1997, MOL MICROBIOL, V24, P803, DOI 10.1046/j.1365-2958.1997.3901755.x; Praillet T, 1996, MOL MICROBIOL, V20, P391, DOI 10.1111/j.1365-2958.1996.tb02626.x; Revell PA, 2000, MOL MICROBIOL, V35, P677, DOI 10.1046/j.1365-2958.2000.01740.x; Reverchon S, 1997, J BACTERIOL, V179, P3500, DOI 10.1128/jb.179.11.3500-3508.1997; REVERCHON S, 1994, MOL MICROBIOL, V11, P1127, DOI 10.1111/j.1365-2958.1994.tb00389.x; Reverchon S, 1998, MOL MICROBIOL, V29, P1407, DOI 10.1046/j.1365-2958.1998.01023.x; Reverchon S, 2002, J BACTERIOL, V184, P654, DOI 10.1128/JB.184.3.654-665.2002; Rouanet C, 1999, J BACTERIOL, V181, P5948, DOI 10.1128/JB.181.19.5948-5957.1999; Santos R, 2001, MOL PLANT MICROBE IN, V14, P758, DOI 10.1094/MPMI.2001.14.6.758; Stapleton MR, 2002, J BIOL CHEM, V277, P17630, DOI 10.1074/jbc.M110178200; Surgey N, 1996, J BACTERIOL, V178, P1593, DOI 10.1128/jb.178.6.1593-1599.1996; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wu RY, 2003, J BIOL CHEM, V278, P20240, DOI 10.1074/jbc.M300292200	42	37	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30158	30167		10.1074/jbc.M403343200	http://dx.doi.org/10.1074/jbc.M403343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140891	hybrid			2022-12-25	WOS:000222531900037
J	Rasia, RM; Vila, AJ				Rasia, RM; Vila, AJ			Structural determinants of substrate binding to Bacillus cereus metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; BACTEROIDES-FRAGILIS; ACTIVE-SITE; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; COORDINATION GEOMETRY; ANGSTROM RESOLUTION; CARBOXYPEPTIDASE-A; POTENT INHIBITORS; D-CAPTOPRIL	Binding and hydrolysis of the beta-lactams cefotaxime, cephapirin, imipenem, and benzylpenicillin by the metallo-beta-lactamase from Bacillus cereus were studied by presteady state kinetic measurements. In all cases, the substrate was unmodified in the most populated reaction intermediate, and no chemically modified substrate species accumulated to a detectable amount. The cephalosporins tested showed similar formation rate constants for this intermediate, and they differed mostly in their decay rates. Formation of a non-productive enzyme . substrate complex was detected for imipenem. The substrate binding differences can be accounted for by considering the structural features of each substrate. The apoenzyme could not bind any of the substrates, but binding was restored when the apoenzyme was reconstituted with Zn(II), revealing that the metal ions are the main determinants of substrate binding. This evidence is in line with the lack of an optimized substrate recognition patch in B1 and B3 metallo-beta-lactamases that provides a broad substrate spectrum.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biofis, RA-2000 Rosario, Santa Fe, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Santa Fe, Argentina	National University of Rosario; National University of Rosario	Vila, AJ (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biofis, Suipacha 531,S2002LRK, RA-2000 Rosario, Santa Fe, Argentina.	vila@arnet.com.ar		Vila, Alejandro/0000-0002-7978-3233; Rasia, Rodolfo/0000-0003-3940-067X				AULD DS, 1972, BIOCHEMISTRY-US, V11, P4994, DOI 10.1021/bi00776a019; AULD DS, 1974, BIOCHEMISTRY-US, V13, P4355, DOI 10.1021/bi00718a018; BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P7208, DOI 10.1021/bi00370a066; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Bush K, 1999, CURR PHARM DESIGN, V5, P839; Carenbauer AL, 2002, BMC BIOCHEM, V3; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CHRISTIANSON DW, 1989, J BIOL CHEM, V264, P12849; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Cricco JA, 1999, CURR PHARM DESIGN, V5, P915; Dal Peraro M, 2004, PROTEINS, V54, P412, DOI 10.1002/prot.10554; DAVIES RB, 1975, BIOCHEM J, V145, P409, DOI 10.1042/bj1450409; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Diaz N, 2001, J AM CHEM SOC, V123, P9867, DOI 10.1021/ja0113246; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fast W, 2001, BIOCHEMISTRY-US, V40, P1640, DOI 10.1021/bi001860v; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; FELICI A, 1993, BIOCHEM J, V291, P151, DOI 10.1042/bj2910151; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Haruta S, 2001, FEMS MICROBIOL LETT, V197, P85, DOI 10.1111/j.1574-6968.2001.tb10587.x; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Kaminskaia NV, 2001, J AM CHEM SOC, V123, P6555, DOI 10.1021/ja002699e; Krum JG, 2002, BIOCHEMISTRY-US, V41, P5005, DOI 10.1021/bi0255221; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; McCall KA, 2000, ANAL BIOCHEM, V284, P307, DOI 10.1006/abio.2000.4706; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Moali C, 2003, CHEM BIOL, V10, P319, DOI 10.1016/S1074-5521(03)00070-X; Montoya-Pelaez PJ, 2002, INORG CHEM, V41, P309, DOI 10.1021/ic011005f; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Page M. I., 1992, CHEM BETA LACTAMS; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Prosperi-Meys C, 2002, CELL MOL LIFE SCI, V59, P2136, DOI 10.1007/s000180200013; Rasia RM, 2003, ARKIVOC, P507, DOI 10.3998/ark.5550190.0004.a47; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; SENY D, 2002, BIOCHEM J, V363, P687; Siemann S, 2002, BBA-GEN SUBJECTS, V1571, P190, DOI 10.1016/S0304-4165(02)00258-1; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; Suarez D, 2002, J COMPUT CHEM, V23, P1587, DOI 10.1002/jcc.10157; TANAKA M, 1968, INORG CHEM, V7, P573, DOI 10.1021/ic50061a038; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Varon-Castellanos R., 1995, COMPUTERIZED DERIVAT; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	60	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 18	2004	279	25					26046	26051		10.1074/jbc.M311373200	http://dx.doi.org/10.1074/jbc.M311373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	828VY	15140877	hybrid			2022-12-25	WOS:000222003000016
J	Suzuki, K; Murtuza, B; Beauchamp, JR; Smolenski, RT; Varela-Carver, A; Fukushima, S; Coppen, SR; Partridge, TA; Yacoub, MH				Suzuki, K; Murtuza, B; Beauchamp, JR; Smolenski, RT; Varela-Carver, A; Fukushima, S; Coppen, SR; Partridge, TA; Yacoub, MH			Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart	FASEB JOURNAL			English	Article						myeloperoxidase; Smcy gene; [C-14] thymidine	CELL TRANSPLANTATION; SKELETAL-MUSCLE; SURVIVAL; MYOCARDIUM; ANTIGEN; SYSTEM; MODEL	Survival and proliferation of skeletal myoblasts within the cardiac environment are crucial to the therapeutic efficacy of myoblast transplantation to the heart. We have analyzed the early dynamics of myoblasts implanted into the myocardium and investigated the mechanisms underlying graft attrition. At 10 min after implantation of [C-14] thymidine-labeled male myoblasts into female mice hearts, C-14 measurement showed that 39.2 +/- 3.0% of the grafted cells survived, and this steadily decreased to 16.0 +/- 1.7% by 24 h and to 7.4 +/- 0.9% by 72 h. PCR of male-specific Smcy gene calculated that the total ( surviving plus proliferated) number of donor-derived cells was 18.3 +/- 1.6 and 23.3 +/- 1.3% at 24 and 72 h, respectively, indicating that proliferation of the surviving cells began after 24 h. Acute inflammation became prominent by 24 h and was reduced by 72 h as indicated by myeloperoxidase activity and histological findings. Multiplex RT-PCR revealed corresponding changes in IL-1beta, TGF-beta, IL-6, and TNF-alpha expression. Treatment with CuZn-superoxide dismutase attenuated the initial rapid death and resulted in enhanced cell numbers afterward, giving a twofold increased total number at 72 h compared with the nontreatment. This effect was associated with reduced inflammatory response, suggesting a causative role for superoxide in the initial rapid graft death and subsequent inflammation. These data describe the early dynamics of myoblasts implanted into the myocardium and suggest that initial oxidative stress and following inflammatory response may be important mechanisms contributing to acute graft attrition, both of which could be potential therapeutic targets to improve the efficiency of cell transplantation to the heart.	Natl Heart & Lung Inst, Harefield Heart Sci Ctr, Cell & Gene Therapy Grp, Harefield UB9 6JH, Middx, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, MRC,Clin Sci Ctr,Muscle Cell Biol Grp, London SW7 2AZ, England	Imperial College London; Imperial College London	Suzuki, K (corresponding author), Natl Heart & Lung Inst, Harefield Heart Sci Ctr, Cell & Gene Therapy Grp, Harefield UB9 6JH, Middx, England.	k.suzuki@ic.ac.uk	Smolenski, Ryszard T/B-9713-2013	Beauchamp, Jonathan/0000-0003-2067-3088; Smolenski, Ryszard/0000-0002-0190-9414	Medical Research Council [G116/158] Funding Source: Medline; MRC [G116/158] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agulnik AI, 1999, MAMM GENOME, V10, P926, DOI 10.1007/s003359901116; Barbero A, 2001, J CELL PHYSIOL, V186, P183, DOI 10.1002/1097-4652(200102)186:2<183::AID-JCP1020>3.3.CO;2-H; Beauchamp JR, 1997, TRANSPLANTATION, V63, P1794, DOI 10.1097/00007890-199706270-00015; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; BURTON KP, 1985, AM J PHYSIOL, V248, pH637, DOI 10.1152/ajpheart.1985.248.5.H637; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Hodgetts SI, 2003, TRANSPLANTATION, V75, P863, DOI 10.1097/01.TP.0000053754.33317.4B; Ing DJ, 1999, CIRC RES, V84, P21; Leobon B, 2003, P NATL ACAD SCI USA, V100, P7808, DOI 10.1073/pnas.1232447100; Marelli D, 1992, Cell Transplant, V1, P383; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Merly F, 1998, TRANSPLANTATION, V65, P793, DOI 10.1097/00007890-199803270-00005; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Murtuza B, 2004, P NATL ACAD SCI USA, V101, P4216, DOI 10.1073/pnas.0306205101; Pouzet B, 2001, ANN THORAC SURG, V71, P844, DOI 10.1016/S0003-4975(00)01785-9; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; SCOTT DM, 1995, NATURE, V376, P695, DOI 10.1038/376695a0; Skuk D, 2002, CELL TRANSPLANT, V11, P671, DOI 10.3727/000000002783985378; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Suzuki K, 2000, CIRCULATION, V102, P359; Suzuki K, 2000, CIRCULATION, V102, P216; Suzuki K, 2002, TRANSPLANTATION, V73, P1398, DOI 10.1097/00007890-200205150-00007; Suzuki K, 2002, J THORAC CARDIOV SUR, V123, P984, DOI 10.1067/mtc.2002.121507; Suzuki K, 2001, CIRCULATION, V104, pI308; Suzuki K, 1999, ANN THORAC SURG, V68, P1266, DOI 10.1016/S0003-4975(99)00726-2; Suzuki K, 2001, CIRCULATION, V104, pI207; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929	31	136	143	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1153	+		10.1096/fj.03-1308fje	http://dx.doi.org/10.1096/fj.03-1308fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155562				2022-12-25	WOS:000221883200007
J	Sowa, H; Kaji, H; Hendy, GN; Canaff, L; Komori, T; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Hendy, GN; Canaff, L; Komori, T; Sugimoto, T; Chihara, K			Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; P300/CBP TRANSCRIPTIONAL COACTIVATORS; ALKALINE-PHOSPHATASE ACTIVITY; COLLAGEN GENE-EXPRESSION; TGF-BETA; CLEIDOCRANIAL DYSPLASIA; OSTEOCALCIN GENE; TYPE-1 GENE; CELL-LINE; PROTEIN	Menin, the product of the multiple endocrine neoplasia type 1 (MEN1) gene, is required for commitment of multipotential mesenchymal stem cells to the osteoblast lineage, however, it inhibits their later differentiation (Sowa, H., Kaji, H., Canaff, L., Hendy, G. N., Tsukamoto, T., Yamaguchi, T., Miyazono, K., Sugimoto, T., and Chihara, K. ( 2003) J. Biol. Chem. 278, 21058 - 21069). Here, we have examined the mechanism of action of menin in regulating osteoblast differentiation using the mouse bone marrow stromal ST2 and osteoblast MC3T3-E1 cell lines. In ST2 cells, reduced menin expression achieved by transfection of menin antisense DNA ( AS) antagonized bone morphogenetic protein (BMP)-2-induced alkaline phosphatase activity and osteocalcin and Runx2 mRNA expression. Menin was co-immunoprecipitated with Smad1/5 in ST2 and MC3T3-E1 cells, and inactivation of menin antagonized BMP-2-induced transcriptional activity of Smad1/5 in ST2 cells, but not MC3T3-E1 cells. Menin was co-immunoprecipitated with the key osteoblast regulator, Runx2, and AS antagonized Runx2 transcriptional activity and the ability of Runx2 to stimulate alkaline phosphatase activity only in ST2 cells but not in MC3T3-E1 cells. In the osteoblast MC3T3-E1 cells, transforming growth factor-beta and its signaling molecule, Smad3, negatively regulated Runx2 transcriptional activity. Menin and Smad3 were co-immunoprecipitated, and combined menin and Smad3 overexpression antagonized, whereas menin and the dominant-negative Smad3DeltaC together enhanced BMP-2-induced transcriptional activity of Smad1/5 and Runx2. Smad3 alone had no effect. Therefore, menin interacts physically and functionally with Runx2 in uncommitted mesenchymal stem cells, but not in well differentiated osteoblasts. In osteoblasts the interaction of menin and the transforming growth factor-beta/Smad3 pathway negatively regulates the BMP-2/Smad1/5- and Runx2-induced transcriptional activities leading to inhibition of late-tage differentiation.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol, Kobe, Hyogo 6500017, Japan; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada; Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka 565, Japan	Kobe University; McGill University; McGill University; McGill University; Osaka University	Sugimoto, T (corresponding author), Shimane Univ, Sch Med, Dept Endocrinol Metab & Hematol Oncol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	sugimoto@med.shimane-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.0.CO;2-U; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Karsenty G, 2000, NAT MED, V6, P970, DOI 10.1038/79655; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776-003-0702-2; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200; Sowa H, 2003, J BIOL CHEM, V278, P21058, DOI 10.1074/jbc.M302044200; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Sukhodolets KE, 2003, MOL CELL BIOL, V23, P493, DOI 10.1128/MCB.23.2.493-509.2003; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1990, J CELL SCI, P149; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F	56	114	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40267	40275		10.1074/jbc.M401312200	http://dx.doi.org/10.1074/jbc.M401312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15150273	hybrid			2022-12-25	WOS:000223916800006
J	Beringue, V; Vilette, D; Mallinson, G; Archer, F; Kaisar, M; Tayebi, M; Jackson, GS; Clarke, AR; Laude, H; Collinge, J; Hawke, S				Beringue, V; Vilette, D; Mallinson, G; Archer, F; Kaisar, M; Tayebi, M; Jackson, GS; Clarke, AR; Laude, H; Collinge, J; Hawke, S			PrPSc binding antibodies are potent inhibitors of prion replication in cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; SCRAPIE AGENT; MONOCLONAL-ANTIBODIES; PROTEIN; ACCUMULATION; PROPAGATION; RESISTANT; DISEASE; PRECURSOR; INFECTION	Conversion of the cellular alpha-helical prion protein (PrPC) into a disease-associated isoform (PrPSc) is central to the pathogenesis of prion diseases. Molecules targeting either normal or disease-associated isoforms may be of therapeutic interest, and the antibodies binding PrPC have been shown to inhibit prion accumulation in vitro. Here we investigate whether antibodies that additionally target disease-associated isoforms such as PrPSc inhibit prion replication in ovine PrP-inducible scrapie-infected Rov cells. We conclude from these experiments that antibodies exclusively binding PrPC were relatively inefficient inhibitors of ScRov cell PrPSc accumulation compared with antibodies that additionally targeted disease-associated PrP isoforms. Although the mechanism by which these monoclonal antibodies inhibit prion replication is unclear, some of the data suggest that antibodies might actively increase PrPSc turnmover. Thus antibodies that bind to both normal and disease-associated isoforms represent very promising anti-prion agents.	Univ London Imperial Coll Sci Technol & Med, Fac Med, CNS Infect & Immunol Grp, Dept Neurogenet, London W2 1PG, England; INRA, Unite Virol & Immunol Mol, F-78352 Jouy En Josas, France; Inst Neurol, MRC, Prion Unit, London WC1N 3BG, England; Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England	Imperial College London; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of London; University College London; University of London; University College London	Hawke, S (corresponding author), Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2006, Australia.	s.hawke@imperial.ac.uk	TAYEBI, MOURAD/F-7404-2010; Archer, Fabienne/E-9371-2010	Archer, Fabienne/0000-0002-8175-866X; Jackson, Graham/0000-0002-3125-2011; Kaisar, Maria/0000-0002-0712-9937; TAYEBI, MOURAD/0000-0001-8664-6918				Archer F, 2004, J VIROL, V78, P482, DOI 10.1128/JVI.78.1.482-490.2004; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; Beringue V, 2003, BRAIN, V126, P2065, DOI 10.1093/brain/awg205; Brown P, 2002, NEUROLOGY, V58, P1720, DOI 10.1212/WNL.58.12.1720; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Clarke AR, 2001, PHILOS T ROY SOC B, V356, P185, DOI 10.1098/rstb.2000.0764; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Ghani AC, 2000, NATURE, V406, P583, DOI 10.1038/35020688; Heppner FL, 2001, NAT MED, V7, P976, DOI 10.1038/nm0901-976; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Oesch B, 1991, Curr Top Microbiol Immunol, V172, P109; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Sabuncu E, 2003, J VIROL, V77, P2696, DOI 10.1128/JVI.77.4.2696-2700.2003; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998	32	51	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 17	2004	279	38					39671	39676		10.1074/jbc.M402270200	http://dx.doi.org/10.1074/jbc.M402270200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852YA	15133046	hybrid, Green Published			2022-12-25	WOS:000223791500058
J	Sun, Y; Li, TY; Chen, H; Zhang, K; Zheng, KY; Mu, Y; Yan, GL; Li, W; Shen, JC; Luo, GM				Sun, Y; Li, TY; Chen, H; Zhang, K; Zheng, KY; Mu, Y; Yan, GL; Li, W; Shen, JC; Luo, GM			Selenium-containing 15-mer peptides with high glutathione peroxidase-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODY; EBSELEN; GENERATION; ISCHEMIA; FAILURE	Glutathione peroxidase (GPX) is one of the most crucial antioxidant enzymes in a variety of organisms. Here we described a new strategy for generating a novel GPX mimic by combination of a phage-displayed random 15-mer peptide library followed by computer-aided rational design and chemical mutation. The novel GPX mimic is a homodimer consisting of a 15-mer selenopeptide with an appropriate catalytic center, a specific binding site for substrates, and high catalytic efficiency. Its steady state kinetics was also studied, and the values of k(cat)/K-mGSH and k(cat)/K-mH2O2 were found to be similar to that of native GPX and the highest among the existing GPX mimics. Moreover, the novel GPX mimic was confirmed to have a strong antioxidant ability to inhibit lipid peroxidation by measuring the content of malondialdehyde, cell viability, and lactate dehydrogenase activity. Importantly, the novel GPX mimic can penetrate into the cell membrane because of its small molecular size. These characteristics endue the novel mimic with potential perspective for pharmaceutical applications.	Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130023, Peoples R China; Jilin Univ, Minist Educ, Key Lab Supramol Struct & Mat, Changchun 130023, Peoples R China; Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China	Jilin University; Jilin University; Jilin University	Luo, GM (corresponding author), Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, 2519 Jiefang Rd, Changchun 130023, Peoples R China.	gmluo@mail.jlu.edu.cn		Sun, Ye/0000-0002-7674-9056				Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7; BELL IM, 1993, BIOCHEMISTRY-US, V32, P3754, DOI 10.1021/bi00065a030; Burke MP, 2002, MED SCI LAW, V42, P10, DOI 10.1177/002580240204200103; CHRISTOPHERSEN BO, 1968, BIOCHIM BIOPHYS ACTA, V164, P35, DOI 10.1016/0005-2760(68)90068-4; COTGREAVE IA, 1992, BIOCHEM PHARMACOL, V43, P793, DOI 10.1016/0006-2952(92)90245-E; Davis Randall L, 2002, Int J Exp Diabetes Res, V3, P185, DOI 10.1080/15604280214279; DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; DOWLING EJ, 1989, J LEUKOCYTE BIOL, V46, P336; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; Forgione MA, 2002, CIRCULATION, V106, P1154, DOI 10.1161/01.CIR.0000026820.87824.6A; HOSHIDA S, 1994, AM J PHYSIOL-HEART C, V267, pH2342, DOI 10.1152/ajpheart.1994.267.6.H2342; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; Lahiri D K, 1997, Ann N Y Acad Sci, V826, P416, DOI 10.1111/j.1749-6632.1997.tb48495.x; LITTLE C, 1968, BIOCHEM BIOPH RES CO, V31, P145, DOI 10.1016/0006-291X(68)90721-3; Liu JQ, 1998, BIOCHEM BIOPH RES CO, V247, P397, DOI 10.1006/bbrc.1998.8545; Liu JQ, 2000, BBA-PROTEIN STRUCT M, V1481, P222, DOI 10.1016/S0167-4838(00)00130-8; Liu JQ, 1999, CHEM COMMUN, P199, DOI 10.1039/a808347i; Liu JQ, 1999, MAT SCI ENG C-BIO S, V10, P131, DOI 10.1016/S0928-4931(99)00095-8; LUO GM, 1994, BIOCHEM BIOPH RES CO, V198, P1240, DOI 10.1006/bbrc.1994.1175; Madesh M, 1997, MOL CELL BIOCHEM, V167, P81, DOI 10.1023/A:1006871622049; MILLS GC, 1957, J BIOL CHEM, V229, P189; Ren XJ, 2001, ARCH BIOCHEM BIOPHYS, V387, P250, DOI 10.1006/abbi.2000.2238; Ren XJ, 2001, BIOCHEM J, V359, P369, DOI 10.1042/0264-6021:3590369; Romero FJ, 1998, ENVIRON HEALTH PERSP, V106, P1229, DOI 10.2307/3433990; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; SITU ZQ, 1996, CELL CULTURE, P90; Su D, 2001, ARCH BIOCHEM BIOPHYS, V395, P177, DOI 10.1006/abbi.2001.2551; Sun Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P90, DOI 10.1016/S0003-9861(03)00006-7; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; WU ZP, 1990, J AM CHEM SOC, V112, P5647, DOI 10.1021/ja00170a043; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12	36	43	43	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37235	37240		10.1074/jbc.M403032200	http://dx.doi.org/10.1074/jbc.M403032200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15148324	hybrid			2022-12-25	WOS:000223554600007
J	Cabedo, H; Carteron, C; Ferrer-Montiel, A				Cabedo, H; Carteron, C; Ferrer-Montiel, A			Oligomerization of the sensory and motor neuron-derived factor prevents protein O-glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CELL-SURFACE; RECEPTORS; NEUREGULINS; DIFFERENTIATION; HEREGULIN	The sensory and motor neuron-derived factor (SMDF) is a neuregulin that promotes Schwann cell proliferation and differentiation. Hence, understanding axon myelination is important to unveil the mechanisms involved in SMDF biogenesis, membrane delivery, and compartmentalization. SMDF is a type II membrane protein expressed as two distinct polypeptides of similar to40 and 83 kDa. Whether the 83-kDa polypeptide results from posttranslational modifications of the protein monomers or protein dimerization remains unknown. Here we have addressed this question and shown that the 83-kDa polypeptide is an O-glycosylated form of the protein. Deletion of the N-terminal domain fully abrogates the SMDF O-glycosylation, indicating that incorporation of O-glycans occurs in the intracellular domain of the protein. Notably, O-glycosylated forms are excluded from partitioning into lipid raft microdomains. In addition, we found that heterologously expressed SMDF monomers interact in intact living cells as evidenced from fluorescence resonance energy transfer of cyan fluorescent protein/ yellow fluorescent protein . SMDF fusion proteins. A stepwise deletion approach demonstrated that SMDF self-association is primarily determined by its transmembrane segment. Notably, biochemical analysis revealed that SMDF multimers are exclusively composed of the 40-kDa polypeptide. Collectively, these findings indicate that the 40-kDa form corresponds to unmodified SMDF, which may be present as multimers, whereas the 83-kDa polypeptide is a monomeric O-glycosylated form of the protein. Furthermore, our observations imply a role for oligomerization as a potential modulator of the distribution in membrane domains and O-glycosylation of the protein.	Univ Miguel Hernandez, Consejo Super Invest Cient, Inst Neurociencias, Alicante 03550, Spain; Univ Miguel Hernandez, Inst Biol Mol & Celular, Alicante 03202, Spain; Hosp St Joan Alacant, Unidad Invest, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad Miguel Hernandez de Elche	Cabedo, H (corresponding author), Univ Miguel Hernandez, Consejo Super Invest Cient, Inst Neurociencias, Alicante 03550, Spain.	hugo.cabedo@umh.es	Ferrer-Montiel, Antonio/C-3072-2015; Cabedo, Hugo/F-9404-2016	Ferrer-Montiel, Antonio/0000-0002-2973-6607; Cabedo, Hugo/0000-0002-1322-6290				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cabedo H, 2002, J BIOL CHEM, V277, P19905, DOI 10.1074/jbc.M201587200; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; El-Husseini AE, 2001, J BIOL CHEM, V276, P44984, DOI 10.1074/jbc.M103049200; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Jiang MS, 1997, J BIOL CHEM, V272, P2421; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Leimeroth R, 2002, DEV BIOL, V246, P245, DOI 10.1006/dbio.2002.0670; Longart M, 2002, REV NEUROLOGIA, V34, P91, DOI 10.33588/rn.3401.2001446; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Panchal RG, 2003, P NATL ACAD SCI USA, V100, P15936, DOI 10.1073/pnas.2533915100; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Van den Steen PE, 2000, TRENDS GLYCOSCI GLYC, V12, P35, DOI 10.4052/tigg.12.35; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	26	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33623	33629		10.1074/jbc.M401962200	http://dx.doi.org/10.1074/jbc.M401962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159404	hybrid			2022-12-25	WOS:000223039700071
J	Coronella-Wood, J; Terrand, J; Sun, HP; Chen, QM				Coronella-Wood, J; Terrand, J; Sun, HP; Chen, QM			c-Fos phosphorylation induced by H2O2 prevents proteasomal degradation of c-Fos in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; HYDROGEN-PEROXIDE GENERATION; CARDIAC MYOCYTE HYPERTROPHY; PROTEIN-KINASE-C; OXIDATIVE STRESS; SIGNALING PATHWAYS; HEART-FAILURE; TRANSCRIPTIONAL ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; OKADAIC ACID	Oxidants cause activation of the AP-1 transcription factor in cardiomyocytes. c-Fos, a component of the AP-1 transcription factor, is transiently induced by H2O2 and the induction is sensitive to the protein synthesis inhibitor cycloheximide. With high percentage gel electrophoresis, multiple c-Fos bands were resolved by Western blot analyses, indicating post-translational modification of newly synthesized c-Fos protein after H2O2 exposure. Treatment of immunoprecipitated c-Fos protein with the type 2 serine/threonine phosphatase A (PP2A) and immunoblotting of c-Fos protein with antibodies against phosphorylated serine or threonine demonstrated that c-Fos was phosphorylated at serine residues. A pharmacological inhibitor of JNKs inhibited the formation of multiple c-Fos bands without affecting c-fos transcription. The proteasomal inhibitor MG132 and Proteasome Inhibitor I extended the time course of c-Fos protein elevation. An increase in ubiquitin was detectable in c-Fos protein from H2O2-treated cells. Interestingly, treating the whole cell lysates with PP2A, but not calcineurin (i.e. PP2B), resulted in disappearance of c-Fos protein and MG132 was able to prevent this loss. H2O2 caused an elevation of PP2B and total phosphatase activity. The phosphatase inhibitor okadaic acid, but not PP2B inhibiter cypermethrin, extended the time course of c-Fos protein elevation after H2O2 exposure. These data suggest that JNK-mediated phosphorylation of newly synthesized c-Fos protects the protein from being degraded by the proteasome. PP2B independent dephosphorylation contributes to degradation of c-Fos protein during oxidative stress response of cardiomyocytes.	Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA	University of Arizona	Chen, QM (corresponding author), Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA.	qchen@email.arizona.edu	Sun, Haipeng/E-8854-2010	Terrand, jerome/0000-0002-8169-7713; Sun, Haipeng/0000-0003-2128-3209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL076530] Funding Source: Medline; NIEHS NIH HHS [R01 ES010826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acquaviva C, 2002, ANN NY ACAD SCI, V973, P426, DOI 10.1111/j.1749-6632.2002.tb04677.x; Acquaviva C, 2001, ONCOGENE, V20, P942, DOI 10.1038/sj.onc.1204155; AMSTAD P, 1990, B CANCER, V77, P501; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; Buetler TM, 2000, TRENDS PHARMACOL SCI, V21, P288, DOI 10.1016/S0165-6147(00)01508-X; Chen Q M, 2001, Cardiovasc Toxicol, V1, P267, DOI 10.1385/CT:1:4:267; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 2000, ARCH BIOCHEM BIOPHYS, V373, P242, DOI 10.1006/abbi.1999.1558; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; COPPER G, 1997, ANNU REV MED, V48, P13; CURRAN T, 1987, ONCOGENE, V2, P79; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dounay AB, 2002, CURR MED CHEM, V9, P1939, DOI 10.2174/0929867023368791; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Force T, 1999, GENE EXPRESSION, V7, P337; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FRANCIS GS, 1995, AM J CARDIOL, V75, pA11, DOI 10.1016/S0002-9149(99)80378-6; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Griendling KK, 2000, REGUL PEPTIDES, V91, P21, DOI 10.1016/S0167-0115(00)00136-1; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Homcy CJ, 1998, CIRCULATION, V97, P1890, DOI 10.1161/01.CIR.97.19.1890; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JarielEncontre I, 1997, MOL BIOL REP, V24, P51, DOI 10.1023/A:1006804723722; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Lijnen P, 1999, J MOL CELL CARDIOL, V31, P949, DOI 10.1006/jmcc.1999.0934; MARTIN B, 1985, J BIOL CHEM, V260, P4932; McCluskey A, 2002, J MED CHEM, V45, P1151, DOI 10.1021/jm010066k; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sawyer DB, 2000, CIRC RES, V86, P119, DOI 10.1161/01.RES.86.2.119; SHLAFER M, 1987, J MOL CELL CARDIOL, V19, P1195, DOI 10.1016/S0022-2828(87)80530-8; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SINGH N, 1995, MOL CELL BIOCHEM, V147, P77, DOI 10.1007/BF00944786; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Sugden PH, 2001, ANN MED, V33, P611; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Tu VC, 2002, J PHARMACOL EXP THER, V300, P1101, DOI 10.1124/jpet.300.3.1101; Tu Victoria C, 2003, Cardiovasc Toxicol, V3, P119, DOI 10.1385/CT:3:2:119; VANDEPLASSCHE G, 1989, J MOL CELL CARDIOL, V21, P383, DOI 10.1016/0022-2828(89)90649-4; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; ZHU H, 1997, MYOCARDIUM, P33	66	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33567	33574		10.1074/jbc.M404013200	http://dx.doi.org/10.1074/jbc.M404013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15136564	hybrid			2022-12-25	WOS:000223039700065
J	Duncan, RE; El-Sohemy, A; Archer, MC				Duncan, RE; El-Sohemy, A; Archer, MC			Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; COENZYME-A REDUCTASE; RAT MAMMARY TUMORIGENESIS; CHOLESTEROL-METABOLISM; DIETARY-CHOLESTEROL; STEROL SYNTHESIS; CORONARY EVENTS; MOUSE LUNG; STATIN USE; G1 ARREST	Malignant cells are known to have elevated rates of mevalonate synthesis because of increased levels and catalytic efficiency of 3-hydroxy-3-methylglutaryl-CoA reductase. Whether this increased mevalonate synthesis occurs as a consequence of increased requirements for a mevalonate-derived metabolite in response to rapid growth or whether mevalonate promotes the growth of tumor cells is unknown. To address this question, we administered mevalonate via miniosmotic pumps to nude mice inoculated with MDA-MB-435 human cancer cells. After 13 weeks of growth, tumors in mevalonate-treated mice were significantly larger than tumors in saline-treated, control mice (1.52 +/- 0.26 g versus 0.81 +/- 0.27 g respectively, p < 0.05). The cancer cells treated in culture with mevalonate also demonstrated increased proliferation rates associated with accelerated entry of cells into S phase. These cells had enhanced total and cyclin A-immunoprecipitable cyclin-dependent kinase-2 (CDK-2) activity, increased activating phosphorylation of CDK-2, and decreased inhibitory binding of CDK-2 to p21(Cip1). Our findings demonstrate that mevalonate promotes tumor growth and suggest that an increase in mevalonate synthesis in extrahepatic tissues following cholesterol-lowering therapy may explain the elevated risk of cancer shown in some studies.	Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	Archer, MC (corresponding author), Univ Toronto, Dept Nutr Sci, FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	m.archer@utoronto.ca	Duncan, Robin/AAH-7465-2021	El-Sohemy, Ahmed/0000-0002-8877-6414				Alonso DF, 1998, BREAST CANCER RES TR, V50, P83, DOI 10.1023/A:1006058409974; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Beck P, 2003, J CLIN EPIDEMIOL, V56, P280, DOI 10.1016/S0895-4356(02)00614-5; BENNIS F, 1993, INT J CANCER, V55, P640, DOI 10.1002/ijc.2910550421; BROWN MS, 1980, J LIPID RES, V21, P505; Calvert RJ, 2003, BIOCHEM PHARMACOL, V66, P393, DOI 10.1016/S0006-2952(03)00211-9; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Clutterbuck RD, 1998, BRIT J HAEMATOL, V102, P522, DOI 10.1046/j.1365-2141.1998.00783.x; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Connolly JM, 1997, NUTR CANCER, V29, P48, DOI 10.1080/01635589709514601; Connolly JM, 1996, NUTR CANCER, V25, P231, DOI 10.1080/01635589609514447; Coogan PF, 2002, EPIDEMIOLOGY, V13, P262, DOI 10.1097/00001648-200205000-00005; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; DUNCAN RE, 2004, IN PRESS J PHARM TOX; El-Sohemy A, 2000, CARCINOGENESIS, V21, P827, DOI 10.1093/carcin/21.4.827; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; ElSohemy A, 1996, NUTR CANCER, V25, P111, DOI 10.1080/01635589609514433; ElSohemy A, 1996, CARCINOGENESIS, V17, P159, DOI 10.1093/carcin/17.1.159; ENDO A, 1979, BIOCHIM BIOPHYS ACTA, V575, P266; Feleszko W, 1998, EUR J CANCER, V34, P406, DOI 10.1016/S0959-8049(97)10034-X; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; GEBHARDT A, 1995, J CANCER RES CLIN, V121, P343, DOI 10.1007/BF01225686; Ghosh PM, 1999, J CELL BIOCHEM, V74, P532; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4; HARPER JW, 1993, CELL, V75, P805; HARWOOD HJ, 1991, J LIPID RES, V32, P1237; Hawk MA, 1996, CANCER LETT, V109, P217, DOI 10.1016/S0304-3835(96)04465-5; KAWATA S, 1990, CANCER RES, V50, P3270; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kikuchi T, 1997, J NEURO-ONCOL, V34, P233, DOI 10.1023/A:1005753523949; KOGA T, 1990, BIOCHIM BIOPHYS ACTA, V1045, P115, DOI 10.1016/0005-2760(90)90139-O; Krause BR, 1998, ATHEROSCLEROSIS, V140, P15, DOI 10.1016/S0021-9150(98)00141-5; Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; Mater P, 1998, CANCER BIOTHER RADIO, V13, P387, DOI 10.1089/cbr.1998.13.387; MELHEM MF, 1987, BRIT J CANCER, V56, P45, DOI 10.1038/bjc.1987.150; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NARISAWA T, 1994, CARCINOGENESIS, V15, P2045, DOI 10.1093/carcin/15.9.2045; Narisawa T, 1996, JPN J CANCER RES, V87, P798, DOI 10.1111/j.1349-7006.1996.tb02103.x; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; PRICE JE, 1990, CANCER RES, V50, P717; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; RAO KN, 1988, J NATL CANCER I, V80, P1248, DOI 10.1093/jnci/80.15.1248; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reimann FM, 1996, ATHEROSCLEROSIS, V125, P63, DOI 10.1016/0021-9150(96)05848-0; ROSE DP, 1991, JNCI-J NATL CANCER I, V83, P1491, DOI 10.1093/jnci/83.20.1491; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; Seeger H, 2003, EXP CLIN ENDOCR DIAB, V111, P47, DOI 10.1055/s-2003-37501; SHAND JH, 1995, LIPIDS, V30, P917, DOI 10.1007/BF02537483; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE BG, 1989, J LIPID RES, V30, P1943; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; VANVLIET AK, 1995, BBA-LIPID LIPID MET, V1254, P105, DOI 10.1016/0005-2760(94)00176-Y; WEJDE J, 1992, ANTICANCER RES, V12, P317; YACHNIN S, 1982, ONCODEV BIOL MED, V3, P111	65	90	94	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33079	33084		10.1074/jbc.M400732200	http://dx.doi.org/10.1074/jbc.M400732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155733	hybrid			2022-12-25	WOS:000223039700009
J	Hu, YC; Yeh, SY; Yeh, SD; Sampson, ER; Huang, JT; Li, P; Hsu, CL; Ting, HJ; Lin, HK; Wang, L; Kim, E; Ni, J; Chang, CS				Hu, YC; Yeh, SY; Yeh, SD; Sampson, ER; Huang, JT; Li, P; Hsu, CL; Ting, HJ; Lin, HK; Wang, L; Kim, E; Ni, J; Chang, CS			Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-RECEPTOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONES; ESTROGEN-RECEPTOR; COMPLEMENTARY-DNA; AGONIST ACTIVITY	Androgen receptor (AR)-associated coregulator 70 (ARA70) was the first identified AR coregulator. However, its molecular mechanism and biological relevance to prostate cancer remain unclear. Here we show that ARA70 interacts with and promotes AR activity via the consensus FXXLF motif within the ARA70-N2 domain ( amino acids 176 - 401). However, it does not promote AR activity via the classic LXXLL motif located at amino acids 92 - 96, although this classic LXXLL motif is important for ARA70 to interact with other receptors, such as PPARgamma. The molecular mechanisms by which ARA70 enhances AR transactivation involve the increase of AR expression, protein stability, and nuclear translocation. Furthermore, ARA70 protein is more frequently detected in prostate cancer specimens (91.74%) than in benign tissues (64.64%, p < 0.0001). ARA70 expression is also increased in high-grade prostate cancer tissues as well as the hormone-refractory LNCaP xenografts and prostate cancer cell lines. Because ARA70 can promote the antiandrogen hydroxyflutamide (HF)-enhanced AR transactivation, the increased ARA70 expression in hormone-refractory prostate tumors may confer the development of HF withdrawal syndrome, commonly diagnosed in patients with the later stages of prostate cancer. Because ARA70-N2 containing the AR-interacting FXXLF motif without coactivation function can suppress HF-enhanced AR transactivation in the hormone-refractory LNCaP cells, using the ARA70-N2 inhibitory peptide at the hormone refractory stage to battle the HF withdrawal syndrome may become an alternative strategy to treat prostate cancer.	Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Taipei Med Univ, Dept Urol, Taipei 105, Taiwan	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Texas System; UTMD Anderson Cancer Center; Taipei Medical University	Chang, CS (corresponding author), Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020	Huang, Jiaoti/0000-0003-1195-1998; Chang, Chawnshang/0000-0001-8510-3516; Hu, Yueh-Chiang/0000-0002-7992-0525; Ting, Huei-Ju/0000-0003-3709-5755	NIDDK NIH HHS [DK067686, DK60905] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905, R01DK067686] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOULNIK I, 2000, KEYST S NUCL REC SUP; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gregory CW, 1998, CANCER RES, V58, P5718; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mitchell SH, 1999, CANCER RES, V59, P5892; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PAYNE AH, 1990, BIOL REPROD, V42, P399, DOI 10.1095/biolreprod42.3.399; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Rahman MM, 2003, J BIOL CHEM, V278, P19619, DOI 10.1074/jbc.M210941200; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Thin TH, 2002, J BIOL CHEM, V277, P36499, DOI 10.1074/jbc.M202824200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Truica CI, 2000, CANCER RES, V60, P4709; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	64	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33438	33446		10.1074/jbc.M401781200	http://dx.doi.org/10.1074/jbc.M401781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166229	hybrid			2022-12-25	WOS:000223039700052
J	Alonso, A; Narisawa, S; Bogetz, J; Tautz, L; Hadzic, R; Huynh, H; Williams, S; Gjorloff-Wingren, A; Bremer, MCD; Holsinger, LJ; Millan, JL; Mustelin, T				Alonso, A; Narisawa, S; Bogetz, J; Tautz, L; Hadzic, R; Huynh, H; Williams, S; Gjorloff-Wingren, A; Bremer, MCD; Holsinger, LJ; Millan, JL; Mustelin, T			VHY, a novel myristoylated testis-restricted dual specificity protein phosphatase related to VHX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHATASE; KINASE PHOSPHATASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; EYES ABSENT; IDENTIFICATION; MYRISTYLATION; LOCALIZATION	The human DUSP15 gene encodes an uncharacterized 235-amino acid member of the subfamily of small dual specificity protein phosphatases related to the Vaccinia virus VH1 phosphatase. Similar to VHR-related MKPX (VHX) (DUSP22), the predicted protein has an N-terminal myristoylation recognition sequence, and we show here that both are indeed modified by the attachment of a myristate to Gly-2. In recognition of this relatedness to VHX, we refer to the DUSP15-encoded protein as VH1-related member Y (VHY). We report that VHY is expressed at high levels in the testis and barely detectable levels in the brain, spinal cord, and thyroid. A VHY-specific antiserum detected a protein with an apparent molecular mass of 26 kDa, and histochemical analysis showed that VHY was readily detectable in pachytene spermatocytes (midstage of meiotic division I) and round spermatids and weakly in Leydig cells ( somatic cells outside of the seminiferous tubules). When expressed in 293T or NIH-3T3 cells, VHY was concentrated at the plasma membrane with some staining of vesicular structures in the Golgi region. Mutation of the myristoylation site Gly-2 abrogated membrane location. Finally, we demonstrate that VHY is an active phosphatase in vitro. We conclude that VHY is a new member of a subgroup of myristoylated VH1-like small dual specificity phosphatases.	Burnham Inst, Canc Res Ctr, Program Signal Transduct, La Jolla, CA 92037 USA; Burnham Inst, Canc Res Ctr, Program Stem Cell Biol, La Jolla, CA 92037 USA; Lund Univ, Dept Med Microbiol, SE-20502 Malmo, Sweden; SUGEN Inc, San Francisco, CA 94602 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Lund University; Pfizer	Mustelin, T (corresponding author), Burnham Inst, Canc Res Ctr, Program Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham.org	Millan, Jose Luis/B-6580-2008; Bogetz, Jori F./U-2258-2019; Alonso, Andrés/L-7523-2014; Tautz, Lutz/M-9989-2014	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840; Tautz, Lutz/0000-0002-4075-6238	NCI NIH HHS [CA96949] Funding Source: Medline; NIAID NIH HHS [AI48032, AI53585, AI55741, AI35603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048032, R01AI035603, R01AI053585, R01AI055741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Mustelin GS, 2002, FRONT BIOSCI, V7, P85; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nakamura K, 1999, BIOCHEM J, V344, P819, DOI 10.1042/0264-6021:3440819; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	47	22	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32586	32591		10.1074/jbc.M403442200	http://dx.doi.org/10.1074/jbc.M403442200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15138252	hybrid			2022-12-25	WOS:000222849700075
J	Dassa, B; Haviv, H; Amitai, G; Pietrokovski, S				Dassa, B; Haviv, H; Amitai, G; Pietrokovski, S			Protein splicing and auto-cleavage of bacterial intein-like domains lacking a C '-flanking nucleophilic residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOPROCESSING DOMAIN; HEDGEHOG; MECHANISM; EVOLUTION; PROTEASOME; GLUTAMINE; SEQUENCE; TERMINUS; ELEMENT; SYSTEM	Bacterial intein-like (BIL) domains are newly identified homologs of intein protein-splicing domains. The two known types of BIL domains together with inteins and hedgehog (Hog) auto-processing domains form the Hog/intein (HINT) superfamily. BIL domains are distinct from inteins and Hogs in sequence, phylogenetic distribution, and host protein type, but little is known about their biochemical activity. Here we experimentally study the auto-processing activity of four BIL domains. An A-type BIL domain from Clostridium thermocellum showed both protein-splicing and auto-cleavage activities. The splicing is notable, because this domain has a native Ala C'-flanking residue rather than a nucleophilic residue, which is absolutely necessary for intein protein splicing. B-type BIL domains from Rhodobacter sphaeroides and Rhodobacter capsulatus cleaved their N' or C' ends. We propose an alternative protein-splicing mechanism for the A-type BIL domains. After an initial N-S acyl shift, creating a thioester bond at the N' end of the domain, the C' end of the domain is cleaved by Asn cyclization. The resulting amino end of the C'-flank attacks the thioester bond next at the N' end of the domain. This aminolysis step splices the two flanks of the domain. The B-type BIL domain cleavage activity is explained in the context of the canonical intein protein-splicing mechanism. Our results suggest that the different HINT domains have related biochemical activities of proteolytic cleavages, ligation and splicing. Yet the predominant reactions diverged in each HINT type according to their specific biological roles. We suggest that the BIL domain cleavage and splicing reactions are mechanisms for post-translationally generating protein variability, particularly in extracellular bacterial proteins.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Pietrokovski, S (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	shmuel.pietrokovski@weizmann.ac.il		Pietrokovski, Shmuel/0000-0001-8573-5863				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amitai G, 2004, J BIOL CHEM, V279, P3121, DOI 10.1074/jbc.M311343200; Amitai G, 2003, MOL MICROBIOL, V47, P61, DOI 10.1046/j.1365-2958.2003.03283.x; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Burglin TR, 1996, CURR BIOL, V6, P1047, DOI 10.1016/S0960-9822(02)70659-3; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CLARKE ND, 1994, P NATL ACAD SCI USA, V91, P11084, DOI 10.1073/pnas.91.23.11084; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; DONG WY, 1998, J BACTERIOL, V180, P4102; Farazi TA, 2001, BIOCHEMISTRY-US, V40, P6335, DOI 10.1021/bi0101401; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HENIKOFF S, 1995, GENE, V163, P17; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; MEHLMAN T, 2002, P 50 C AM SOC MASS S; Mills KV, 2004, J BIOL CHEM, V279, P20685, DOI 10.1074/jbc.M400887200; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Perler FB, 2000, CURR OPIN BIOTECH, V11, P377, DOI 10.1016/S0958-1669(00)00113-0; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Pietrokovski S, 2001, TRENDS GENET, V17, P465, DOI 10.1016/S0168-9525(01)02365-4; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Romanelli A, 2004, P NATL ACAD SCI USA, V101, P6397, DOI 10.1073/pnas.0306616101; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Southworth MW, 2004, BIOCHEM SOC T, V32, P250, DOI 10.1042/BST0320250; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; Vigneron N, 2004, SCIENCE, V304, P587, DOI 10.1126/science.1095522; Wood DW, 1999, NAT BIOTECHNOL, V17, P889, DOI 10.1038/12879; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	37	20	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32001	32007		10.1074/jbc.M404562200	http://dx.doi.org/10.1074/jbc.M404562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15150275	hybrid			2022-12-25	WOS:000222849700003
J	Galgani, M; De Rosa, V; De Simone, S; Leonardi, A; D'Oro, U; Napolitani, G; Masci, AM; Zappacosta, S; Racioppi, L				Galgani, M; De Rosa, V; De Simone, S; Leonardi, A; D'Oro, U; Napolitani, G; Masci, AM; Zappacosta, S; Racioppi, L			Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REGULATES CYTOKINE PRODUCTION; NECROSIS-FACTOR-ALPHA; IN-VIVO; PROSTAGLANDIN E-2; C-JUN; ACTIVATION; MATURATION; INTERLEUKIN-12; RECEPTOR	Immature dendritic cells (iDCs) can be instructed to polarize the immune response toward a noninflammatory pathway by mediators that increase the intracellular concentration of cAMP. This phenomenon is associated with the ability of the cyclic nucleoside to inhibit the release of pro-inflammatory cytokines without affecting the differentiation process of the dendritic cells (DCs). Here we investigated the ability of cAMP to modulate the endotoxin signaling by exposing DCs to exogenous 8-bromium-cyclic AMP in the presence or absence of H89, a selective inhibitor of the protein kinase A, one of the major molecular targets of the cyclic nucleoside. cAMP affects the early lipopolysaccharide-induced signaling cascade dissociating the activation of NF-kappaB, p38, and ERK pathways from the stimulation of c-Src and Lyn kinases. This phenomenon was prevented by H89. The pharmacological block of Src-like tyrosine kinases induces comparable results confirming the involvement of this family of enzymes in the mechanism controlling the release of cytokines in human monocyte-derived iDCs. We propose that the cAMP-protein kinase A-dependent pathway regulates the functional plasticity of iDCs by gating the Toll-like receptor signaling at the level of Src-like kinases.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Endocrinol & Oncol Sperimentale, Naples, Italy; Chiron Vaccines, Siena, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Novartis	Racioppi, L (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, 5 Via S Pansini, I-80131 Naples, Italy.	racioppi@unina.it	leonardi, antonio/A-2887-2009; racioppi, luigi/AGB-8665-2022; racioppi, luigi/GNP-0349-2022; De Rosa, Veronica/K-6534-2016	leonardi, antonio/0000-0001-8636-9623; racioppi, luigi/0000-0002-9207-6752; De Rosa, Veronica/0000-0002-9477-0991; Galgani, Mario/0000-0001-8414-1676; Masci, Anna Maria/0000-0003-1940-6740				Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brocker T, 1997, J EXP MED, V185, P541, DOI 10.1084/jem.185.3.541; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; Delgado M, 2000, J IMMUNOL, V165, P3051, DOI 10.4049/jimmunol.165.6.3051; Finkelman FD, 1996, J IMMUNOL, V157, P1406; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1998, J IMMUNOL, V161, P2804; Kalinski P, 1997, J IMMUNOL, V159, P28; Kalinski P, 2001, BLOOD, V97, P3466, DOI 10.1182/blood.V97.11.3466; Kambayashi T, 2001, J LEUKOCYTE BIOL, V70, P903; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Mann J, 2002, J BIOL CHEM, V277, P17125, DOI 10.1074/jbc.M109250200; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakamura I, 2002, J IMMUNOL, V168, P5103, DOI 10.4049/jimmunol.168.10.5103; Napolitani G, 2003, EUR J IMMUNOL, V33, P2832, DOI 10.1002/eji.200324073; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schwartz JH, 2001, P NATL ACAD SCI USA, V98, P13482, DOI 10.1073/pnas.251533998; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Wilkin F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H; Wilkin F, 2001, J IMMUNOL, V166, P7172, DOI 10.4049/jimmunol.166.12.7172; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	46	42	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32507	32514		10.1074/jbc.M403355200	http://dx.doi.org/10.1074/jbc.M403355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166249	hybrid			2022-12-25	WOS:000222849700065
J	Izumi, M; Yatagai, F; Hanaoka, F				Izumi, M; Yatagai, F; Hanaoka, F			Localization of human Mcm10 is spatially and temporally regulated during the S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNA-REPLICATION; PROTEIN; COMPLEX; INITIATION; CHROMATIN; ORIGINS; PROTEOLYSIS; BINDING; CDC45; PHOSPHORYLATION	Mcm10 (Dna43) is an essential protein for the initiation of DNA replication in Saccharomyces cerevisiae. Recently, we identified a human Mcm10 homolog and found that it is regulated by proteolysis and phosphorylation in a cell cycle-dependent manner and that it binds chromatin exclusively during the S phase of the cell cycle. However, the precise roles that Mcm10 plays are still unknown. To study the localization dynamics of human Mcm10, we established HeLa cell lines expressing green fluorescent protein (GFP)-tagged Mcm10. From early to mid-S phase, GFP-Mcm10 appeared in discrete nuclear foci. In early S phase, several hundred foci appeared throughout the nucleus. In mid-S phase, the foci appeared at the nuclear periphery and nucleolar regions. In the late S and G(2) phases, GFP-Mcm10 was localized to nucleoli. Although the distributions of GFP-Mcm10 during the S phase resembled those of replication foci, GFP-Mcm10 foci did not colocalize with sites of DNA synthesis in most cases. Furthermore, the transition of GFP-Mcm10 distribution patterns preceded changes in replication foci patterns or proliferating cell nuclear antigen foci patterns by 30-60 min. These results suggest that human Mcm10 is temporarily recruited to the replication sites 30-60 min before they replicate and that it dissociates from chromatin after the activation of the prereplication complex.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; RIKEN, Cyclotron Ctr, Radioisotope Technol Div, Wako, Saitama 3510198, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; RIKEN; RIKEN; Japan Science & Technology Agency (JST)	Hanaoka, F (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	fhanaoka@fbs.osaka-u.ac.jp						Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Cook CR, 2003, J BIOL CHEM, V278, P36051, DOI 10.1074/jbc.M306049200; DEPAMPHILIS ML, 1999, CONCEPTS EUKARYOTIC; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Homesley L, 2000, GENE DEV, V14, P913; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, J CELL BIOCHEM, V76, P280, DOI 10.1002/(SICI)1097-4644(20000201)76:2<280::AID-JCB11>3.0.CO;2-0; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Izumi M, 2000, MOL BIOL CELL, V11, P4323, DOI 10.1091/mbc.11.12.4323; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	33	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32569	32577		10.1074/jbc.M314017200	http://dx.doi.org/10.1074/jbc.M314017200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15136575	hybrid			2022-12-25	WOS:000222849700073
J	Xu, MG; Zhao, MW; Wang, ED				Xu, MG; Zhao, MW; Wang, ED			Leucyl-tRNA synthetase from the hyperthermophilic bacterium Aquifex aeolicus recognizes minihelices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC-CODE; AMINO-ACID; ENZYMATIC AMINOACYLATION; NUCLEOTIDE DETERMINANTS; ACCEPTOR STEM; DISCRIMINATION; ISOLEUCINE; SUBSTRATE; LEUCINE	Aminoacylation of the minihelix mimicking the amino acid acceptor arm of tRNA has been demonstrated in more than 10 aminoacyl-tRNA synthetase systems. Although Escherichia coli or Homo sapiens cytoplasmic leucyl-tRNA synthetase (LeuRS) is unable to charge the cognate minihelix or microhelix, we show here that minihelix(Leu) is efficiently charged by Aquifex aeolicus synthetase, the only known heterodimeric LeuRS (alphabeta-LeuRS). Aminoacylation of minihelices is strongly dependent on the presence of the A73 identity nucleotide and greatly stimulated by destabilization of the first base pair as reported for the E. coli isoleucyl-tRNA synthetase and methionyl-tRNA synthetase systems. In the E. coli LeuRS system, the anticodon of tRNA(Leu) is not important for recognition by the synthetase. However, the addition of RNA helices that mimic the anticodon domain stimulates minihelix(Leu) charging by alphabeta-LeuRS, indicating possible domain-domain communication within alphabeta-LeuRS. The leucine-specific domain of alphabeta-LeuRS is responsible for minihelix recognition. To ensure accurate translation of the genetic code, LeuRS functions to hydrolyze misactivated amino acids (pretransfer editing) and misaminoacylated tRNA (post-transfer editing). In contrast to tRNA(Leu), minihelix(Leu) is unable to induce posttransfer editing even upon the addition of the anticodon domain of tRNA. Therefore, the context of tRNA is crucial for the editing of mischarged products. However, the minihelix(Leu) cannot be misaminoacylated, perhaps because of the tRNA-independent pretransfer editing activity of alphabeta-LeuRS.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Wang, ED (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	edwang@sibs.ac.cn						Alexander RW, 1998, P NATL ACAD SCI USA, V95, P12214, DOI 10.1073/pnas.95.21.12214; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; de Pouplana LR, 2000, CELL MOL LIFE SCI, V57, P865, DOI 10.1007/PL00000729; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DIETRICH A, 1990, NUCLEIC ACIDS RES, V18, P2589; Du X, 2003, NUCLEIC ACIDS RES, V31, P2865, DOI 10.1093/nar/gkg382; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Farrow MA, 1999, BIOCHEMISTRY-US, V38, P16898, DOI 10.1021/bi9920782; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; FRUGIER M, 1994, EMBO J, V13, P2218, DOI 10.1002/j.1460-2075.1994.tb06499.x; Fukai S, 2003, RNA, V9, P100, DOI 10.1261/rna.2760703; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Gouda M, 2002, FEBS LETT, V518, P139, DOI 10.1016/S0014-5793(02)02675-3; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; KHAN AS, 1988, SCIENCE, V241, P74, DOI 10.1126/science.2455342; Korencic D, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf104; Larkin DC, 2002, NUCLEIC ACIDS RES, V30, P2103, DOI 10.1093/nar/30.10.2103; Li Y, 1999, PROTEIN EXPRES PURIF, V16, P355, DOI 10.1006/prep.1999.1083; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; Metzger AU, 1997, NUCLEIC ACIDS RES, V25, P4551, DOI 10.1093/nar/25.22.4551; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nordin BE, 2003, BIOCHEMISTRY-US, V42, P12989, DOI 10.1021/bi035052q; Nordin BE, 2002, J BIOL CHEM, V277, P20510, DOI 10.1074/jbc.M202023200; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; NUREKI O, 1993, TRANSLATIONAL APPARATUS, P59; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RIBAS DPL, 2001, J BIOL CHEM, V276, P6881; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; Sankaranarayanan R, 2001, ACTA BIOCHIM POL, V48, P323; Schimmel P, 1996, P NATL ACAD SCI USA, V93, P4521, DOI 10.1073/pnas.93.10.4521; Shi PY, 1998, RNA, V4, P276; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Steer BA, 1999, J BIOL CHEM, V274, P35601, DOI 10.1074/jbc.274.50.35601; Tardif KD, 2002, NUCLEIC ACIDS RES, V30, P2538, DOI 10.1093/nar/30.11.2538; Tocchini-Valentini G, 2000, J MOL BIOL, V298, P779, DOI 10.1006/jmbi.2000.3694; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Xu MG, 2002, J BIOL CHEM, V277, P41590, DOI 10.1074/jbc.M205126200; Zhao MW, 2003, BIOCHEMISTRY-US, V42, P7694, DOI 10.1021/bi027394m	53	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32151	32158		10.1074/jbc.M403018200	http://dx.doi.org/10.1074/jbc.M403018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161932	hybrid			2022-12-25	WOS:000222849700021
J	Kalatskaya, I; Schussler, S; Blaukat, A; Muller-Esterl, W; Jochum, M; Proud, D; Faussner, A				Kalatskaya, I; Schussler, S; Blaukat, A; Muller-Esterl, W; Jochum, M; Proud, D; Faussner, A			Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B-2 bradykinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; HUMAN FIBROBLASTS; ACTIVATION; IDENTIFICATION; SEQUESTRATION; TRAFFICKING; PATHWAY; BINDING; STATE	Although the G protein-coupled receptors (GPCRs) share a similar seven-transmembrane domain structure, only a limited number of amino acid residues is conserved in their protein sequences. One of the most highly conserved sequences is the NPXXY motif located at the cytosolic end of the transmembrane region-7 of many GPCRs, particularly of those belonging to the family of the rhodopsin/beta-adrenergic-like receptors. Exchange of Tyr(305) in the corresponding NPLVY sequence of the bradykinin B-2 receptor (B2R) for Ala resulted in a mutant, termed Y305A, that internalized [H-3] bradykinin (BK) almost as rapidly as the wild-type (wt) B2R. However, receptor sequestration of the mutant after stimulation with BK was clearly reduced relative to the wt B2R. Confocal fluorescence microscopy revealed that, in contrast to the B2R-enhanced green fluorescent protein chimera, the Y305A-enhanced green fluorescent protein chimera was predominantly located intracellularly even in the absence of BK. Two-dimensional phosphopeptide analysis showed that the mutant Y305A constitutively exhibited a phosphorylation pattern similar to that of the BK-stimulated wt B2R. Ligand-independent Y305A internalization was demonstrated by the uptake of rhodamine-labeled antibodies directed to a tag sequence at the N terminus of the mutant receptor. Co-immunoprecipitation revealed that Y305A is precoupled to G(q/11) without activating the G protein because the basal accumulation rate of inositol phosphate was unchanged as compared with wt B2R. We conclude, therefore, that the Y305A mutation of B2R induces a receptor conformation which is prone to ligand-independent phosphorylation and internalization. The mutated receptor binds to, but does not activate, its cognate heterotrimeric G protein G(q/11), thereby limiting the extent of ligand-independent receptor internalization.	Univ Munich, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany; Heidelberg Univ, Inst Pharmakol, D-69120 Heidelberg, Germany; Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Munich; Ruprecht Karls University Heidelberg; Goethe University Frankfurt; University of Calgary	Faussner, A (corresponding author), Univ Munich, Klin Chem & Klin Biochem Abt, Nussbaumstr 20, D-80336 Munich, Germany.	alexander.faussner@med.uni-muenchen.de		Kalatskaya, Irina/0000-0002-1663-859X				Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Bouley R, 2003, AM J PHYSIOL-CELL PH, V285, pC750, DOI 10.1152/ajpcell.00477.2002; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; FAUSSNER A, 1991, J BIOL CHEM, V266, P9442; FAUSSNER A, 2003, AM J PHYSIOL, V284, pH1909; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gabilondo AM, 1996, EUR J PHARMACOL, V307, P243, DOI 10.1016/0014-2999(96)00247-6; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; Rosendorff A, 2000, MOL BRAIN RES, V84, P90, DOI 10.1016/S0169-328X(00)00227-8; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wang JF, 1997, MOL PHARMACOL, V52, P306, DOI 10.1124/mol.52.2.306	28	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31268	31276		10.1074/jbc.M401796200	http://dx.doi.org/10.1074/jbc.M401796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15161928	hybrid			2022-12-25	WOS:000222726800046
J	Wurzer, WJ; Ehrhardt, C; Pleschka, S; Berberich-Siebelt, F; Wolff, T; Walczak, H; Planz, O; Ludwig, S				Wurzer, WJ; Ehrhardt, C; Pleschka, S; Berberich-Siebelt, F; Wolff, T; Walczak, H; Planz, O; Ludwig, S			NF-kappa B-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; GENE-EXPRESSION REQUIRES; DOUBLE-STRANDED-RNA; NS1 PROTEIN; TRANSCRIPTION FACTORS; SIGNALING PATHWAY; FAS-LIGAND; CELL-DEATH; ENDOTHELIAL-CELLS; KINASE COMPLEX	Activation of the transcription factor NF-kappaB is a hallmark of infections by viral pathogens including influenza viruses. Because gene expression of many proinflammatory and antiviral cytokines is controlled by this factor, the concept emerged that NF-kappaB and its upstream regulator IkappaB kinase are essential components of the innate antiviral immune response to infectious pathogens. In contrast to this common view we report here that NF-kappaB activity promotes efficient influenza virus production. On a molecular level this is due to NF-kappaB-dependent viral induction of the proapoptotic factors tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and FasL, which enhance virus propagation in an autocrine and paracrine fashion. Thus, NF-kappaB acts both proapoptotically and provirally in the context of an influenza virus infection.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany; Univ Wurzburg, Inst Pathol, D-97078 Wurzburg, Germany; Robert Koch Inst, D-13353 Berlin, Germany; Deutsch Krebsforschungszentrum, Tumor Immunol Program, Div Apoptosis Regulat, D-69120 Heidelberg, Germany; Bundesforsch Anstalt Viruskrankheiten Tiere, D-72076 Tubingen, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg; Justus Liebig University Giessen; University of Wurzburg; Robert Koch Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Ludwig, S (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	Stephan.Ludwig@uni-duesseldorf.de	Pleschka, Stephan/HGU-9354-2022; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591; Ludwig, Stephan/0000-0003-4490-3052; Pleschka, Stephan/0000-0002-7372-7089				Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Delhase M, 1999, COLD SPRING HARB SYM, V64, P491, DOI 10.1101/sqb.1999.64.491; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; Fujimoto I, 1998, CELL DEATH DIFFER, V5, P426, DOI 10.1038/sj.cdd.4400362; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Geiss GK, 2002, P NATL ACAD SCI USA, V99, P10736, DOI 10.1073/pnas.112338099; Ghosh S, 1999, IMMUNOL RES, V19, P183, DOI 10.1007/BF02786486; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; HINSHAW VS, 1994, J VIROL, V68, P3667, DOI 10.1128/JVI.68.6.3667-3673.1994; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ludwig S, 1999, VIRAL IMMUNOL, V12, P175, DOI 10.1089/vim.1999.12.175; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2002, J VIROL, V76, P11166, DOI 10.1128/JVI.76.21.11166-11171.2002; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Majde JA, 2000, J INTERF CYTOK RES, V20, P259, DOI 10.1089/107999000312397; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsui K, 1998, J IMMUNOL, V161, P3469; Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; Sedger LM, 1999, J IMMUNOL, V163, P920; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; Washburn B, 2003, J IMMUNOL, V170, P1814, DOI 10.4049/jimmunol.170.4.1814; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002	60	187	205	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30931	30937		10.1074/jbc.M403258200	http://dx.doi.org/10.1074/jbc.M403258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143063	hybrid			2022-12-25	WOS:000222726800005
J	Gopalakrishnan, B; Wang, WM; Greenspan, DS				Gopalakrishnan, B; Wang, WM; Greenspan, DS			Biosynthetic processing of the pro-alpha 1(V)pro-alpha 2(V)pro-alpha 3(V) procollagen heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; EHLERS-DANLOS-SYNDROME; ALPHA-1(V)-ALPHA-2(V)-ALPHA-3(V) COLLAGEN MOLECULE; AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; V COLLAGEN; XI COLLAGEN; NH2-TERMINAL DOMAIN; FIBRILLAR COLLAGEN; SCHWANN-CELLS	Type V collagen is a quantitatively minor fibrillar collagen comprised of different chain compositions in different tissues. The most widely distributed form, an alpha1(V)(2)alpha2(V) heterotrimer, regulates the physical properties of type I/V heterotypic collagen fibrils via partially processed NH2-terminal globular sequences. A less characterized alpha1(V)alpha2(V)alpha3(V) heterotrimer has a much more limited distribution of expression and unknown function(s). We characterized the biosynthetic processing of pro-alpha1(V)(2)pro-alpha2(V) procollagen previously and showed it to differ in important ways from biosynthetic processing of the major fibrillar procollagens I-III. Here we have successfully produced recombinant pro-alpha1(V)pro-2(V)pro-alpha3(V) heterotrimers. We use these, and mouse embryo fibroblasts doubly homozygous null for the Bmp1 gene, which encodes the metalloproteinase bone morphogenetic protein-1 (BMP-1), and for a gene encoding the closely related metalloproteinase mammalian Tolloid-like 1, to characterize biosynthetic processing of pro-alpha1(V)pro-alpha2(V)pro-alpha3(V) heterotrimers, thus completing characterization of type V collagen biosynthetic processing. Whereas pro-alpha1(V) and pro-alpha2(V) processing in pro-alpha1(V)pro-alpha2(V)pro-alpha3(V) heterotrimers is similar to that which occurs in pro-alpha1(V)(2)pro-alpha2(V) heterotrimers, the processing of pro-alpha3(V) by BMP-1 occurs at an unexpected site within NH2-terminal globular sequences. We also demonstrate that, despite similarities in NH2-terminal domain structures, pro-alpha2(V) NH2-terminal globular sequences are not cleaved by ADAMTS-2, the metalloproteinase that cleaves the N-propeptides of the major fibrillar procollagen chains.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave,MSC 5675, Madison, WI 53706 USA.			Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [GM63471] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR047746, R01AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDIN MZ, 1982, BIOSCIENCE REP, V2, P493, DOI 10.1007/BF01115247; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROEK DL, 1985, J BIOL CHEM, V260, P555; BROWN RA, 1978, BIOCHEM BIOPH RES CO, V80, P866, DOI 10.1016/0006-291X(78)91324-4; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; Chernousov MA, 1999, J NEUROSCI RES, V56, P284, DOI 10.1002/(SICI)1097-4547(19990501)56:3<284::AID-JNR8>3.3.CO;2-H; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; GREENSPAN DS, 2005, IN PRESS TOP CURR CH; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KUHN K, 1987, STRUCTURE FUNCTION C, P1; KUMAMOTO CA, 1981, J BIOL CHEM, V256, P7053; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LEE ST, 1988, J BIOL CHEM, V263, P13414; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; Medeck RJ, 2003, BIOCHEM J, V376, P361, DOI 10.1042/BJ20030894; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432-1033.1994.00943.x; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; Pappano WN, 2003, MOL CELL BIOL, V23, P4428, DOI 10.1128/MCB.23.13.4428-4438.2003; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; RHODES RK, 1981, COLLAGEN REL RES, V1, P337; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SAGE H, 1979, BIOCHEMISTRY-US, V18, P3815, DOI 10.1021/bi00584a027; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VUORISTO MM, 1995, J BIOL CHEM, V270, P22873, DOI 10.1074/jbc.270.39.22873; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733; Wolfman NM, 2003, P NATL ACAD SCI USA, V100, P15842, DOI 10.1073/pnas.2534946100; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	69	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30904	30912		10.1074/jbc.M402252200	http://dx.doi.org/10.1074/jbc.M402252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136578	hybrid			2022-12-25	WOS:000222531900125
J	Gorr, TA; Tomita, T; Wappner, P; Bunn, HF				Gorr, TA; Tomita, T; Wappner, P; Bunn, HF			Regulation of Drosophila hypoxia-inducible factor (HIF) activity in SL2 cells - Identification of a hypoxia-induced variant isoform of the HIF alpha homolog gene similar	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BHLH-PAS PROTEIN; TUMOR-SUPPRESSOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; LOOP-HELIX PROTEIN; DNA METHYLATION; ERYTHROPOIETIN GENE; CNS MIDLINE; TRANSCRIPTIONAL REGULATION; DEGRADATION DOMAIN; FACTOR 1-ALPHA	Although hypoxia-inducible factor-alpha (HIFalpha) subunit-specific hydroxylation and proteolytic breakdown explain the binary switch between the presence (hypoxia) and absence (normoxia) of HIFs, little is known of the mechanisms that fine-tune HIF activity under constant, rather than changing, oxygen tensions. Here, we report that the Drosophila HIFalpha homolog, the basic helix-loop-helix/PAS protein Sima ((Sim) under bar il (a) under barr), in hypoxic cultures of SL2 cells is expressed in full-length (fl) and splice variant (sv) isoforms. The following evidence supports the role of flSima as functional HIFalpha and the role of SL2 HIF as a transcriptional activator or suppressor. The pO(2) dependence of Sima abundance matched that of HIF activity. HIF-dependent changes in candidate target gene expression were detected through variously effective stimuli: hypoxia (strong) > iron chelation, e. g. desferrioxamine (moderate) much greater than transition metals, e. g. cobalt similar or equal to normoxia (ineffective). Sima overexpression augmented hypoxic induction or suppression of different targets. In addition to the full-length exon 1-12 transcript yielding the 1510-amino acid HIFalpha homolog, the sima gene also expressed, specifically under hypoxia, an exon 1-7/12 splice variant, which translated into a 426-amino acid Sima truncation termed svSima. svSima contains basic helix-loop-helix and PAS sequences identical to those of flSima, but, because of deletion of exons 8-11, lacks the oxygen-dependent degradation domain and nuclear localization signals. Overexpressed svSima failed to transactivate reporter genes. However, it attenuated HIF (Sima.Tango)-stimulated reporter expression in a dose-dependent manner. Thus, svSima has the potential to regulate Drosophila HIF function under steady and hypoxic pO(2) by creating a cytosolic sink for the Sima partner protein Tango.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Consejo Nacl Invest Cient & Tecn, Inst Leloir, RA-1405 Buenos Aires, DF, Argentina	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires	Bunn, HF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, 221 Longwood Ave, Boston, MA 02115 USA.	hfbunn@rics.bwh.harvard.edu		Gorr, Thomas/0000-0002-6023-4234; Tomita, Takeshi/0000-0001-6815-2244; Wappner, Pablo/0000-0003-1517-0742	NIDDK NIH HHS [R01 DK41234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbuShumays RL, 1997, DEV GENET, V20, P11, DOI 10.1002/(SICI)1520-6408(1997)20:1<11::AID-DVG2>3.0.CO;2-C; Bacon NCM, 1998, BIOCHEM BIOPH RES CO, V249, P811, DOI 10.1006/bbrc.1998.9234; BELL J, 1988, MOL CELL BIOL, V8, P91, DOI 10.1128/MCB.8.1.91; Bruening W, 1999, CANCER RES, V59, P4973; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burmester T, 1999, MOL BIOL EVOL, V16, P1809, DOI 10.1093/oxfordjournals.molbev.a026093; CHADWICK LEIGH E., 1940, PHYSIOL ZOOL, V13, P398; CHUNG YT, 1990, MOL CELL BIOL, V10, P6172, DOI 10.1128/MCB.10.12.6172; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; CSIK L., 1939, ZEITSCHR VERGLEICH PHYSIOL, V27, P304; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DiGregorio PJ, 2001, J BIOL CHEM, V276, P1930, DOI 10.1074/jbc.M003911200; Douglas RM, 2001, AM J PHYSIOL-REG I, V280, pR1555, DOI 10.1152/ajpregu.2001.280.5.R1555; Ebert BL, 1999, BLOOD, V94, P1864; Emmons RB, 1999, DEVELOPMENT, V126, P3937; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gorr TA, 2004, J BIOL CHEM, V279, P36038, DOI 10.1074/jbc.M403981200; GORR TA, 2003, OXYGEN SENSING RESPO, P175; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grieshaber M K, 1994, Rev Physiol Biochem Pharmacol, V125, P43, DOI 10.1007/BFb0030909; GUANG LW, 1993, P NATL ACAD SCI USA, V90, P4304; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Haddad GG, 2000, J APPL PHYSIOL, V88, P1481, DOI 10.1152/jappl.2000.88.4.1481; Hankeln T, 2002, J BIOL CHEM, V277, P29012, DOI 10.1074/jbc.M204009200; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Jiang L, 2003, MOL CELL BIOL, V23, P5625, DOI 10.1128/MCB.23.16.5625-5637.2003; Keister M., 1974, P469; KLAGSBRUN M, 1976, CANCER RES, V36, P110; Krishnan SN, 1997, J INSECT PHYSIOL, V43, P203, DOI 10.1016/S0022-1910(96)00084-4; Kunert N, 2003, DEVELOPMENT, V130, P5083, DOI 10.1242/dev.00716; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Ledent V, 2001, GENOME RES, V11, P754, DOI 10.1101/gr.177001; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LOCKE M, 1958, Q J MICROSC SCI, V99, P373; LONG EO, 1980, J MOL BIOL, V138, P873, DOI 10.1016/0022-2836(80)90070-4; LOUDON C, 1988, J INSECT PHYSIOL, V34, P97, DOI 10.1016/0022-1910(88)90160-6; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Lyko F, 2001, TRENDS GENET, V17, P169, DOI 10.1016/S0168-9525(01)02234-X; Ma E, 1999, MOL BRAIN RES, V73, P11, DOI 10.1016/S0169-328X(99)00224-7; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mazure NM, 2002, CANCER RES, V62, P1158; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Ward MP, 1998, DEVELOPMENT, V125, P1599; Wegener G., 1988, OXYGEN SENSING TISSU, P13, DOI [10.1007/978-3-642-83444-8_2, DOI 10.1007/978-3-642-83444-8_2]; WEGENER G, 1993, SURVIVING HYPOXIA ME, P417; Wenger RH, 2000, J EXP BIOL, V203, P1253; WENGER RH, 1997, BIOL CHEM, V378, P1; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; WIGGLESWORTH VB, 1954, Q J MICROSC SCI, V95, P115; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	87	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36048	36058		10.1074/jbc.M405077200	http://dx.doi.org/10.1074/jbc.M405077200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169765	hybrid			2022-12-25	WOS:000223303400107
J	Golemi-Kotra, D; Meroueh, SO; Kim, C; Vakulenko, SB; Bulychev, A; Stemmler, AJ; Stemmler, TL; Mobashery, S				Golemi-Kotra, D; Meroueh, SO; Kim, C; Vakulenko, SB; Bulychev, A; Stemmler, AJ; Stemmler, TL; Mobashery, S			The importance of a critical protonation state and the fate of the catalytic steps in class A beta-lactamases and penicillin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ULTRAHIGH-RESOLUTION STRUCTURE; ESCHERICHIA-COLI; THERMODYNAMIC CONSEQUENCES; STAPHYLOCOCCUS-AUREUS; CHEMICAL-MODIFICATION; IMPROVED SENSITIVITY; SECONDARY STRUCTURE; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE	beta-Lactamases and penicillin-binding proteins are bacterial enzymes involved in antibiotic resistance to beta-lactam antibiotics and biosynthetic assembly of cell wall, respectively. Members of these large families of enzymes all experience acylation by their respective substrates at an active site serine as the first step in their catalytic activities. A Ser-X-X-Lys sequence motif is seen in all these proteins, and crystal structures demonstrate that the side-chain functions of the serine and lysine are in contact with one another. Three independent methods were used in this report to address the question of the protonation state of this important lysine (Lys-73) in the TEM-1 beta-lactamase from Escherichia coli. These techniques included perturbation of the pK(a) of Lys-73 by the study of the gamma-thialysine-73 variant and the attendant kinetic analyses, investigation of the protonation state by titration of specifically labeled proteins by nuclear magnetic resonance, and by computational treatment using the thermodynamic integration method. All three methods indicated that the pK(a) of Lys-73 of this enzyme is attenuated to 8.0 - 8.5. It is argued herein that the unique ground-state ion pair of Glu-166 and Lys-73 of class A beta-lactamases has actually raised the pK(a) of the active site lysine to 8.0 - 8.5 from that of the parental penicillin-binding protein. Whereas we cannot rule out that Glu-166 might activate the active site water, which in turn promotes Ser-70 for the acylation event, such as proposed earlier, we would like to propose as a plausible alternative for the acylation step the possibility that the ion pair would reconfigure to the protonated Glu-166 and unprotonated Lys-73. As such, unprotonated Lys-73 could promote serine for acylation, a process that should be shared among all active-site serine beta-lactamases and penicillin-binding proteins.	Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48202 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	Wayne State University; University of Notre Dame	Stemmler, TL (corresponding author), Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48202 USA.	tstemmle@med.wayne.edu; mobashery@nd.edu	/N-6611-2013	/0000-0003-1299-6987; Kim, Choon/0000-0003-0306-8935	NIAID NIH HHS [AI 33170, R01 AI033170] Funding Source: Medline; NIDDK NIH HHS [R01 DK068139] Funding Source: Medline; NIGMS NIH HHS [R01 GM061629, GM 61629] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061629] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC INC, 2000, FEL ND SPECTR PROC S; Atanasov BP, 2000, P NATL ACAD SCI USA, V97, P3160, DOI 10.1073/pnas.060027897; Bush K, 1998, ADV EXP MED BIOL, V456, P71; CASE DA, 2002, AMBER; Chen CC, 1996, BIOCHEMISTRY-US, V35, P12251, DOI 10.1021/bi961153v; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Damblon C, 1996, P NATL ACAD SCI USA, V93, P1747, DOI 10.1073/pnas.93.5.1747; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Gouda H, 2003, BIOPOLYMERS, V68, P16, DOI 10.1002/bip.10270; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; HERMANN P, 1968, H-S Z PHYSIOL CHEM, V349, P390, DOI 10.1515/bchm2.1968.349.1.390; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; Hopkins CE, 2002, PROTEIN SCI, V11, P1591, DOI 10.1110/ps.3900102; Ishiguro M, 1996, J MED CHEM, V39, P2207, DOI 10.1021/jm9506027; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KELLY JA, 1982, SCIENCE, V218, P479, DOI 10.1126/science.7123246; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; Kotra L P., 2002, BACTERIAL RESISTANCE, P123; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; Lamotte-Brasseur J, 1999, PROTEIN SCI, V8, P404; LAMOTTEBRASSEUR J, 1991, BIOCHEM J, V279, P213, DOI 10.1042/bj2790213; LEUNG YC, 1994, BIOCHEM J, V299, P671, DOI 10.1042/bj2990671; Lietz EJ, 2000, BIOCHEMISTRY-US, V39, P4971, DOI 10.1021/bi992681k; MADGWICK PJ, 1987, BIOCHEM J, V248, P657, DOI 10.1042/bj2480657; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Massova I, 2002, J COMPUT CHEM, V23, P1559, DOI 10.1002/jcc.10129; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Maveyraud L, 2002, J AM CHEM SOC, V124, P2461, DOI 10.1021/ja016736t; MERZ KM, 1991, J AM CHEM SOC, V113, P3572, DOI 10.1021/ja00009a053; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nukaga M, 2003, J MOL BIOL, V328, P289, DOI 10.1016/S0022-2836(03)00210-9; Paetzel M, 1997, J BIOL CHEM, V272, P9994; PLANAS A, 1991, BIOCHEMISTRY-US, V30, P8268, DOI 10.1021/bi00247a023; RAMESH V, 1994, EUR J BIOCHEM, V225, P601, DOI 10.1111/j.1432-1033.1994.00601.x; Rao BG, 1996, J COMPUT AID MOL DES, V10, P23, DOI 10.1007/BF00124462; Raquet X, 1997, BIOPHYS J, V73, P2416, DOI 10.1016/S0006-3495(97)78270-5; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SCHULTZ SC, 1987, PROTEINS, V2, P290, DOI 10.1002/prot.340020405; SMITH HB, 1988, J BIOL CHEM, V263, P4921; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Sun T, 2003, PROTEIN SCI, V12, P82, DOI 10.1110/ps.0224303; SWAREN P, 1995, STRUCTURE, V3, P603, DOI 10.1016/S0969-2126(01)00194-0; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; Vakulenko S, 2002, ANTIMICROB AGENTS CH, V46, P646, DOI 10.1128/AAC.46.3.646-653.2002; Vakulenko SB, 1998, ANTIMICROB AGENTS CH, V42, P1542, DOI 10.1128/AAC.42.7.1542; Vanhove M, 1997, BIOCHEM J, V321, P413, DOI 10.1042/bj3210413; YAMAZAKI T, 1991, BIOCHEMISTRY-US, V30, P6036, DOI 10.1021/bi00238a030	58	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34665	34673		10.1074/jbc.M313143200	http://dx.doi.org/10.1074/jbc.M313143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15152012	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000223134800071
J	Kennedy, MN; Mullen, GED; Leifer, CA; Lee, C; Mazzoni, A; Dileepan, KN; Segal, DM				Kennedy, MN; Mullen, GED; Leifer, CA; Lee, C; Mazzoni, A; Dileepan, KN; Segal, DM			A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LIPOPOLYSACCHARIDE; DENDRITIC CELLS; CUTTING EDGE; TLR4; ENDOTOXIN; CONFERS; MICE; RESPONSIVENESS; RECOGNITION; EXPRESSION	MD-2, a glycoprotein that is essential for the innate response to lipopolysaccharide (LPS), binds to both LPS and the extracellular domain of Toll-like receptor 4 (TLR4). Following synthesis, MD-2 is either secreted directly into the medium as a soluble, active protein, or binds directly to TLR4 in the endoplasmic reticulum before migrating to the cell surface. Here we investigate the function of the secreted form of MD-2. We show that secreted MD-2 irreversibly loses activity over a 24-h period at physiological temperature. LPS, but not lipid A, prevents this loss in activity by forming a stable complex with MD-2, in a CD14-dependent process. Once formed, the stable MD-2 . LPS complex activates TLR4 in the absence of CD14 or free LPS indicating that the activating ligand of TLR4 is the MD-2 . LPS complex. Finally we show that the MD-2 . LPS complex, but not LPS alone, induces epithelial cells, which express TLR4 but not MD-2, to secrete interleukin-6 and interleukin-8. We propose that the soluble MD-2 . LPS complex plays a crucial role in the LPS response by activating epithelial and other TLR4(+)/MD-2(-) cells in the inflammatory microenvironment.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66160 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Kansas; University of Kansas Medical Center	Segal, DM (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36, Bethesda, MD 20892 USA.	dave_segal@nih.gov			NATIONAL CANCER INSTITUTE [Z01BC009254, Z01BC009255, ZIABC009254, ZICBC009255] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Abreu MT, 2003, J ENDOTOXIN RES, V9, P322, DOI 10.1179/096805103225002593; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Talreja J, 2003, FASEB J, V17, pC57; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955	29	95	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34698	34704		10.1074/jbc.M405444200	http://dx.doi.org/10.1074/jbc.M405444200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175334	hybrid			2022-12-25	WOS:000223134800075
J	Hansson, K; Ma, XS; Eliasson, L; Czerwiec, E; Furie, B; Furie, BC; Rorsman, P; Stenflo, J				Hansson, K; Ma, XS; Eliasson, L; Czerwiec, E; Furie, B; Furie, BC; Rorsman, P; Stenflo, J			The first gamma-carboxyglutamic acid-containing contryphan - A selective L-type calcium ion channel blocker isolated from the venom of conus marmoreus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC-ACID; K-DEPENDENT CARBOXYLASE; VITAMIN-K; CONANTOKIN-G; GLUTAMYL CARBOXYLASE; CONTAINING CONOTOXIN; RECOGNITION SITE; CA2+ CHANNELS; AMINO-ACIDS; METAL-FREE	Contryphans constitute a group of conopeptides that are known to contain an unusual density of post-translational modifications including tryptophan bromination, amidation of the C-terminal residue, leucine, and tryptophan isomerization, and proline hydroxylation. Here we report the identification and characterization of a new member of this family, glacontryphan-M from the venom of Conus marmoreus. This is the first known example of a contryphan peptide carrying glutamyl residues that have been post-translationally carboxylated to gamma-carboxyglutamyl (Gla) residues. The amino acid sequence of glacontryphan-M was determined using automated Edman degradation and electrospray ionization mass spectrometry. The amino acid sequence of the peptide is: Asn-Gla-Ser-Gla-Cys-Pro-D-Trp-His-Pro-Trp-Cys. As with most other contryphans, glacontryphan-M is amidated at the C terminus and maintains the five-residue intercysteine loop. The occurrence of a D-tryptophan residue was confirmed by chemical synthesis and HPLC elution profiles. Using fluorescence spectroscopy we demonstrated that the Gla-containing peptide binds calcium with a K-D of 0.63 mM. Cloning of the full-length cDNA encoding glacontryphan-M revealed that the primary translation product carries an N-terminal signal/propeptide sequence that is homologous to earlier reported contryphan signal/propeptide sequences up to 10 amino acids preceding the toxin region. Electrophysiological experiments, carried out on mouse pancreatic B-cells, showed that glacontryphan-M blocks L-type voltage-gated calcium ion channel activity in a calcium-dependent manner. Glacontryphan-M is the first contryphan reported to modulate the activity of L-type calcium ion channels.	Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; Marine Biol Lab, Woods Hole, MA 02543 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis & Vasc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England	Lund University; Skane University Hospital; Lund University; Marine Biological Laboratory - Woods Hole; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; University of Oxford	Hansson, K (corresponding author), Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.	Karin.Hansson@klkemi.mas.lu.se	Rorsman, Patrik/A-4331-2016; Eliasson, Lena/E-9294-2012	Rorsman, Patrik/0000-0001-7578-0767; Eliasson, Lena/0000-0002-6467-5029				Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500; Begley GS, 2000, J BIOL CHEM, V275, P36245, DOI 10.1074/jbc.M003944200; Blandl T, 2000, FEBS LETT, V470, P139, DOI 10.1016/S0014-5793(00)01309-0; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; CAIRNS JR, 1991, ANAL BIOCHEM, V199, P93, DOI 10.1016/0003-2697(91)90274-W; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN Z, 1998, J BIOL CHEM, V26, P16248; Czerwiec E, 2002, EUR J BIOCHEM, V269, P6162, DOI 10.1046/j.1432-1033.2002.03335.x; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Fainzilber M, 1996, BIOCHEMISTRY-US, V35, P8748, DOI 10.1021/bi9602674; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; Fainzilber M, 1998, BIOCHEMISTRY-US, V37, P1470, DOI 10.1021/bi971571f; FERNLUND P, 1975, J BIOL CHEM, V250, P6125; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; Grant MA, 2004, J BIOL CHEM, V279, P32464, DOI 10.1074/jbc.M313826200; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HAUSCHKA PV, 1988, CURRENT ADV VITAMIN, P237; Jacobsen R, 1998, J PEPT RES, V51, P173; Jacobsen RB, 1999, J PEPT RES, V54, P93, DOI 10.1034/j.1399-3011.1999.00093.x; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Jimenez EC, 2001, TOXICON, V39, P803, DOI 10.1016/S0041-0101(00)00210-5; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; Kalume DE, 2000, J MASS SPECTROM, V35, P145, DOI 10.1002/(SICI)1096-9888(200002)35:2<145::AID-JMS922>3.0.CO;2-I; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; Massilia GR, 2003, BIOCHEM BIOPH RES CO, V303, P238, DOI 10.1016/S0006-291X(03)00331-0; Massilia GR, 2001, BIOCHEM BIOPH RES CO, V288, P908, DOI 10.1006/bbrc.2001.5833; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; Miles LA, 2002, J BIOL CHEM, V277, P43033, DOI 10.1074/jbc.M206690200; Nakamura T, 1996, PROTEIN SCI, V5, P524; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; TAO L, 2000, J BIOL CHEM, V275, P18291; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Zhou LM, 1996, J NEUROCHEM, V66, P620	58	61	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32453	32463		10.1074/jbc.M313825200	http://dx.doi.org/10.1074/jbc.M313825200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155730	hybrid, Green Published			2022-12-25	WOS:000222849700059
J	Isas, JM; Langen, R; Hubbell, WL; Haigler, HT				Isas, JM; Langen, R; Hubbell, WL; Haigler, HT			Structure and dynamics of a helical hairpin that mediates calcium-dependent membrane binding of annexin B12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; PHOSPHOLIPID-VESICLES; FLUIDITY GRADIENT; C2 DOMAIN; SPIN; BILAYERS; FLUORESCENCE; DIFFUSION; PROTEINS	A wealth of high-resolution structural data has accumulated for soluble annexins, but only limited information is available for the biologically important membrane-bound proteins. To investigate the structural and dynamic changes that occur upon membrane binding, we analyzed the electron paramagnetic resonance (EPR) mobility and accessibility parameters of a continuous 30-residue nitroxide scan encompassing helices D and E in repeat 2 of annexin B12 (residues 134-163) while the protein was bound to phospholipid vesicles in the presence of Ca2+. A comparison of these data to those from a previously published study of the protein in solution (Isas, J. M., Langen, R., Haigler, H. T., and Hubbell, W. L. (2002) Biochemistry 41, 1464-1473) showed that the overall backbone fold for the scanned region did not change upon membrane binding. However, side-chains in the loop between the D and E helices were highly dynamic in solution but became essentially frozen in the EPR time scale upon binding to membranes. Accessibility measurements clearly established that side-chains in this loop were exposed to the hydrophobic core of the bilayer and provide the first evidence that a D-E loop directly participates in the Ca2+-dependent binding of annexins to membranes. Other localized changes showed that the D-helix became much less dynamic after membrane binding and identified quaternary contact sites in the membrane-bound homo-trimer. Finally, immobilization of the D-E loop upon contact with phospholipid suggests that the bilayer, which is normally very mobile on the EPR time scale, is immobilized in the head-group region by the annexin B12. This suggests that annexin B12 alters membrane structure in a manner that may be biologically significant.	Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Irvine; University of Southern California; University of California System; University of California Los Angeles	Haigler, HT (corresponding author), Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.	langen@usc.edu; hhaigler@uci.edu	Haigler, Harry/C-3788-2011		NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063915, R01GM055651] Funding Source: NIH RePORTER; NEI NIH HHS [EY05216] Funding Source: Medline; NIGMS NIH HHS [GM55651, GM63915] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DEVAUX P, 1972, J AM CHEM SOC, V94, P4475, DOI 10.1021/ja00768a600; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GILMANSHIN R, 1994, BIOCHEMISTRY-US, V33, P8225, DOI 10.1021/bi00193a008; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Isas JM, 2003, J BIOL CHEM, V278, P30227, DOI 10.1074/jbc.M301228200; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Kaetzel MA, 2001, BIOCHEMISTRY-US, V40, P4192, DOI 10.1021/bi002507s; Kohout SC, 2003, BIOCHEMISTRY-US, V42, P1254, DOI 10.1021/bi026596f; Ladokhin AS, 2002, BIOCHEMISTRY-US, V41, P13617, DOI 10.1021/bi0264418; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Malmberg NJ, 2003, BIOCHEMISTRY-US, V42, P13227, DOI 10.1021/bi035119+; MCHAOURAB HS, 1996, BIOCHEMISTRY-US, V273, P810; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; Megli FM, 1998, BIOCHEMISTRY-US, V37, P10540, DOI 10.1021/bi9801255; Megli FM, 2000, BIOCHEMISTRY-US, V39, P5534, DOI 10.1021/bi992779z; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; Peng S, 2004, BIOPHYS J, V86, P145, DOI 10.1016/S0006-3495(04)74092-8; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Reviakine I, 2000, J STRUCT BIOL, V131, P234, DOI 10.1006/jsbi.2000.4286; Saurel O, 1998, BIOCHEMISTRY-US, V37, P1403, DOI 10.1021/bi971484n; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; Sopkova J, 1998, BIOCHEMISTRY-US, V37, P11962, DOI 10.1021/bi980773o; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281	33	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32492	32498		10.1074/jbc.M402568200	http://dx.doi.org/10.1074/jbc.M402568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15143059	hybrid			2022-12-25	WOS:000222849700063
J	McIntosh, DB; Clausen, JD; Woolley, DG; MacLennan, DH; Vilsen, B; Andersen, JP				McIntosh, DB; Clausen, JD; Woolley, DG; MacLennan, DH; Vilsen, B; Andersen, JP			Roles of conserved P domain residues and Mg2+ in ATP binding in the ground and Ca2+-activated states of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CONFORMATIONAL-CHANGES; PHOSPHORYLATION LOOP; CRYSTAL-STRUCTURE; MGATP BINDING; CALCIUM-PUMP; CA-2+-ATPASE; SITE; INTERMEDIATE; EFFICIENCY	Residues in conserved motifs (625)TGD, (676)FARXXPXXK, and (701)TGDGVND in domain P of sarcoplasmic reticulum Ca2+-ATPase, as well as in motifs (DPPR)-D-601 and (359)NQR(/K)MSV in the hinge segments connecting domains N and P, were examined by mutagenesis to assess their roles in nucleotide and Mg2+ binding and stabilization of the Ca2+-activated transition state for phosphoryl transfer. In the absence of Mg2+, mutations removing the charges of domain P residues Asp(627), Lys(684), Asp(703), and Asp(707) increased the affinity for ATP and 2', 3'-O-(2,4,6-trinitrophenyl)-8-azidoadenosine 5'-triphosphate. These mutations, as well as Gly(626)-->Ala, were inhibitory for ATP binding in the presence of Mg2+ and for tight binding of the beta, gamma-bidentate chromium(III) complex of ATP. The hinge mutations had pronounced, but variable, effects on ATP binding only in the presence of Mg2+. The data demonstrate an unfavorable electrostatic environment for binding of negatively charged nucleotide in domain P and show that Mg2+ is required to anchor the phosphoryl group of ATP at the phosphorylation site. Mutants Gly(626) --> Ala, Lys(684) --> Met, Asp(703) --> Ala/Ser/Cys, and mutants with alteration to Asp(707) exhibited very slow or negligible phosphorylation, making it possible to measure ATP binding in the pseudo-transition state attained in the presence of both Mg2+ and Ca2+. Under these conditions, ATP binding was almost completely blocked in Gly(626) --> Ala and occurred with 12- and 7-fold reduced affinities in Asp(703) --> Ala and Asp(707) --> Cys, respectively, relative to the situation in the presence of Mg2+ without Ca2+, whereas in Lys(684) --> Met and Asp(707) --> Ser/Asn the affinity was enhanced 14- and 3-5-fold, respectively. Hence, Gly(626) and Asp(703) seem particularly critical for mediating entry into the transition state for phosphoryl transfer upon Ca2+ binding at the transport sites.	Univ Cape Town, Fac Hlth Sci, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	University of Cape Town; University of Cape Town; University of Toronto; Aarhus University	McIntosh, DB (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa.	davidmci@chempath.uct.ac.za; jpa@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8	25	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32515	32523		10.1074/jbc.M403242200	http://dx.doi.org/10.1074/jbc.M403242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15133025	Green Published, hybrid			2022-12-25	WOS:000222849700066
J	Sobczak, I; Lolkema, JS				Sobczak, I; Lolkema, JS			Alternating access and a pore-loop structure in the Na+-citrate transporter CitS of Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; ESCHERICHIA-COLI; MUTAGENESIS REVEALS; MEMBRANE TOPOLOGY; CYTOPLASMIC LOOP; REENTRANT LOOP; MALATE MLEP; CARRIER; ACCESSIBILITY; INSERTION	CitS of Klebsiella pneumoniae is a secondary transporter that transports citrate in symport with 2 Na+ ions. Reaction of Cys-398 and Cys-414, which are located in a cytoplasmic loop of the protein that is believed to be involved in catalysis, with thiol reagents resulted in significant inhibition of uptake activity. The reactivity of the two residues was determined in single Cys mutants in different catalytic states of the transporter and from both sides of the membrane. The single Cys mutants were shown to have the same transport stoichiometry as wild type CitS, but the C398S mutation was responsible for a 10-fold loss of affinity for Na+. Both cysteine residues were accessible from the periplasmic as well as from the cytoplasmic side of the membrane by the membrane-impermeable thiol reagent [2-(trimethylammonium) ethyl] methanethiosulfonate bromide ( MTSET) suggesting that the residues are part of the translocation site. Binding of citrate to the outward facing binding site of the transporter resulted in partial protection against inactivation by N-ethylmaleimide, whereas binding to the inward facing binding site resulted in essentially complete protection. A 10-fold higher concentration of citrate was required at the cytoplasmic rather than at the periplasmic side of the membrane to promote protection. Only marginal effects of citrate binding were seen on reactivity with MTSET. Binding of Na+ at the periplasmic side of the transporter protected both Cys-398 and Cys-414 against reaction with the thiol reagents, whereas binding at the cytoplasmic side was less effective and discriminated between Cys-398 and Cys-414. A model is presented in which part of the cytoplasmic loop containing Cys-398 and Cys-414 folds back into the translocation pore as a pore-loop structure. The loop protrudes into the pore beyond the citrate-binding site that is situated at the membrane-ytoplasm interface.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Lolkema, JS (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	j.s.lolkema@biol.rug.nl						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Bandell M, 2000, BIOCHEMISTRY-US, V39, P13059, DOI 10.1021/bi0011882; Bandell M, 1997, J BIOL CHEM, V272, P18140, DOI 10.1074/jbc.272.29.18140; Bandell M, 2000, J BIOL CHEM, V275, P39130, DOI 10.1074/jbc.M005940200; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Ding PZ, 2004, BBA-BIOMEMBRANES, V1660, P106, DOI 10.1016/j.bbamem.2003.11.005; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Grunewald M, 2002, J BIOL CHEM, V277, P26074, DOI 10.1074/jbc.M202248200; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; Krom BP, 2003, BIOCHEMISTRY-US, V42, P467, DOI 10.1021/bi026874a; Lambert G, 2001, J GEN PHYSIOL, V117, P533, DOI 10.1085/jgp.117.6.533; LOLKEMA JS, 1994, EUR J BIOCHEM, V220, P469, DOI 10.1111/j.1432-1033.1994.tb18645.x; LOLKEMA JS, 1996, HDB BIOL PHYSICS, P229; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Pirch T, 2003, J BIOL CHEM, V278, P42942, DOI 10.1074/jbc.M308253200; POOLMAN B, 1991, J BACTERIOL, V173, P6030, DOI 10.1128/jb.173.19.6030-6037.1991; Pos KM, 1996, BIOCHEMISTRY-US, V35, P1018, DOI 10.1021/bi951609t; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Sobczak I, 2003, BIOCHEMISTRY-US, V42, P9789, DOI 10.1021/bi034683h; van Geest M, 2000, BBA-BIOMEMBRANES, V1466, P328, DOI 10.1016/S0005-2736(00)00185-1; van Geest M, 1999, J BIOL CHEM, V274, P29705, DOI 10.1074/jbc.274.42.29705; van Geest M, 1999, J BIOL CHEM, V274, P2816, DOI 10.1074/jbc.274.5.2816; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200	35	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31113	31120		10.1074/jbc.M404283200	http://dx.doi.org/10.1074/jbc.M404283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148311	hybrid, Green Published			2022-12-25	WOS:000222726800027
J	Colvin, RA; Campanella, GSV; Sun, JT; Luster, AD				Colvin, RA; Campanella, GSV; Sun, JT; Luster, AD			Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ALPHA CHEMOATTRACTANT; CHEMOKINE RECEPTOR CXCR3; HIGH-AFFINITY BINDING; IFN-GAMMA; BETA-ARRESTIN; T-CELLS; DIFFERENTIAL EXPRESSION; ACTIVATION; INTERNALIZATION; PROTEIN	The chemokine receptor CXCR3 is a G protein-coupled receptor found predominantly on T cells that is activated by three ligands as follows: CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (I-TAC). Previously, we have found that of the three ligands, CXCL11 is the most potent inducer of CXCR3 internalization and is the physiologic inducer of CXCR3 internalization after T cell contact with activated endothelial cells. We have therefore hypothesized that these three ligands transduce different signals to CXCR3. In light of this hypothesis, we sought to determine whether regions of CXCR3 are differentially required for CXCL9, CXCL10, and CXCL11 function. Here we identified two distinct domains that contributed to CXCR3 internalization. The carboxyl-terminal domain and beta-arrestin1 were predominantly required by CXCL9 and CXCL10, and the third intracellular loop was predominantly required by CXCL11. Chemotaxis and calcium mobilization induced by all three CXCR3 ligands were dependent on the CXCR3 carboxyl terminus and the DRY sequence in the third trans-membrane domain. Our findings demonstrate that distinct domains of CXCR3 mediate its functions and suggest that the differential requirement of these domains contributes to the complexity of the chemokine system.	Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St,Rm 8031, Charlestown, MA 02129 USA.	aluster@partners.org	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NCI NIH HHS [R01 CA69212] Funding Source: Medline; NIAID NIH HHS [K08 AI50147] Funding Source: Medline; NIDDK NIH HHS [P01 DK50305] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI050147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Amichay D, 1996, J IMMUNOL, V157, P4511; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Campanella GSV, 2003, J BIOL CHEM, V278, P17066, DOI 10.1074/jbc.M212077200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; El-Sawy T, 2002, CURR OPIN IMMUNOL, V14, P562, DOI 10.1016/S0952-7915(02)00382-5; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Feniger-Barish R, 1999, CYTOKINE, V11, P996, DOI 10.1006/cyto.1999.0510; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; Kobayashi H, 2002, TRANSPLANTATION, V74, P387, DOI 10.1097/00007890-200208150-00016; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Miura M, 2001, J IMMUNOL, V167, P3494, DOI 10.4049/jimmunol.167.6.3494; MORO O, 1993, J BIOL CHEM, V268, P6862; Murdoch C, 2000, BLOOD, V95, P3032; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Richardson RM, 2003, J IMMUNOL, V170, P2904, DOI 10.4049/jimmunol.170.6.2904; Roland J, 2003, BLOOD, V101, P399, DOI 10.1182/blood-2002-03-0978; Sauty A, 2001, J IMMUNOL, V167, P7084, DOI 10.4049/jimmunol.167.12.7084; Sun Y, 2002, J BIOL CHEM, V277, P49212, DOI 10.1074/jbc.M207294200; Vila-Coro AJ, 1999, J IMMUNOL, V163, P3037; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Xanthou G, 2003, EUR J IMMUNOL, V33, P2927, DOI 10.1002/eji.200324235; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205	52	186	197	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30219	30227		10.1074/jbc.M403595200	http://dx.doi.org/10.1074/jbc.M403595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150261	hybrid			2022-12-25	WOS:000222531900045
J	Calderwood, DA; Tai, V; Di Paolo, G; De Camilli, P; Ginsberg, MH				Calderwood, DA; Tai, V; Di Paolo, G; De Camilli, P; Ginsberg, MH			Competition for talin results in trans-dominant inhibition of integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL PHOSPHATE KINASE; BETA CYTOPLASMIC DOMAINS; FUNCTION-ASSOCIATED ANTIGEN-1; AMINO-ACID MOTIFS; TYROSINE PHOSPHORYLATION; LIGAND-BINDING; CELL-MIGRATION; GPIIB-IIIA; ADHESION; SUPPRESSION	The ability of integrin adhesion receptors to undergo rapid changes in affinity for their extracellular ligands ( integrin activation) is essential for the development and function of multicellular animals and is dependent on interactions between the integrin beta subunit-cytoplasmic tail and the cytoskeletal protein talin. Cross-talk among different integrins and between integrins and other receptors impacts many cellular processes including adhesion, spreading, migration, clot retraction, proliferation, and differentiation. One form of integrin cross-talk, transdominant inhibition of integrin activation, occurs when ligand binding to one integrin inhibits the activation of a second integrin. This may be relevant clinically in a number of settings such as during platelet adhesion, leukocyte trans-migration, and angiogenesis. Here we report that competition for talin underlies the trans-dominant inhibition of integrin activation. This conclusion is based on our observations that ( i) beta tails selectively defective in talin binding are unable to mediate trans-dominant inhibition, (ii) trans-dominant inhibition can be reversed by overexpression of integrin binding and activating fragments of talin, and (iii) expression of another non-integrin talin-binding protein, phosphatidylinositol phosphate kinase type Igamma-90, also inhibits integrin activation. Thus, the sequestration of talin by the suppressive species is both necessary and sufficient for trans-dominant inhibition of integrin activation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, New Haven, CT 06510 USA	Scripps Research Institute; Yale University; Howard Hughes Medical Institute; Yale University	Calderwood, DA (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	david.calderwood@yale.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NHLBI NIH HHS [HL31950] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NIGMS NIH HHS [GM68600] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Bodeau AL, 2001, J CELL SCI, V114, P2795; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fujimoto TT, 2003, BLOOD, V102, P4044, DOI 10.1182/blood-2003-06-1773; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Ginsberg MH, 2001, J BIOL CHEM, V276, P22514, DOI 10.1074/jbc.M101915200; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Keller RS, 2001, AM J PATHOL, V158, P1079, DOI 10.1016/S0002-9440(10)64055-2; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Ly DP, 2003, J BIOL CHEM, V278, P21878, DOI 10.1074/jbc.M212538200; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Mastrangelo AM, 1999, J CELL SCI, V112, P217; McDowall A, 2003, J CLIN INVEST, V111, P51, DOI 10.1172/JCI200314076; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PACIFICI R, 1994, J IMMUNOL, V153, P2222; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Rey-Ladino JA, 1998, J IMMUNOL, V160, P3494; Riederer MA, 2002, THROMB HAEMOSTASIS, V88, P858, DOI 10.1055/s-0037-1613314; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Rose DM, 2001, J IMMUNOL, V167, P2824, DOI 10.4049/jimmunol.167.5.2824; Schmeissner PJ, 2001, J IMMUNOL, V167, P3715, DOI 10.4049/jimmunol.167.7.3715; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shiraga M, 1999, J CELL BIOL, V147, P1419, DOI 10.1083/jcb.147.7.1419; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TAPLEY P, 1989, ONCOGENE, V4, P325; Valencik ML, 2002, J CARD FAIL, V8, P262, DOI 10.1054/jcaf.2002.127335; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	65	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28889	28895		10.1074/jbc.M402161200	http://dx.doi.org/10.1074/jbc.M402161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15143061	hybrid			2022-12-25	WOS:000222445300009
J	Kono, M; Mi, YD; Liu, YJ; Sasaki, T; Allende, ML; Wu, YP; Yamashita, T; Proia, RL				Kono, M; Mi, YD; Liu, YJ; Sasaki, T; Allende, ML; Wu, YP; Yamashita, T; Proia, RL			The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTOR; VASCULAR MATURATION; MOLECULAR-CLONING; MICE LACKING; FAMILY; S1P(1); LYSOPHOSPHOLIPIDS; DIFFERENTIATION; EXPRESSION	Sphingosine-1-phosphate (S1P) elicits diverse cellular responses through a family of G-protein-coupled receptors. We have shown previously that genetic disruption of the S1P(1) receptor, the most widely expressed of the family, results in embryonic lethality because of its key role within endothelial cells in regulating the coverage of blood vessels by vascular smooth muscle cells. To understand the physiologic functions of the two other widely expressed S1P receptors, we generated S1P(2) and S1P(3) null mice. Neither the S1P(2) null mice nor the S1P3 null mice exhibited significant embryonic lethality or obvious phenotypic abnormalities. To unmask possible overlapping or collaborative functions between the S1P(1), S1P(2), and S1P(3) receptors, we examined embryos with multiple S1P receptor mutations. We found that S1P(1) S1P(2) double null and S1P(1) S1P(2) S1P(3) triple null embryos displayed a substantially more severe vascular phenotype than did embryos with only S1P(1) deleted. We also found partial embryonic lethality and vascular abnormalities in S1P(2) S1P(3) double null embryos. Our results indicate that the S1P(1), S1P(2), and S1P(3) receptors have redundant or cooperative functions for the development of a stable and mature vascular system during embryonic development.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bldg 10,Rm 9N-314,10 Ctr Dr MSC 1821, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270; Kono, Mari/0000-0003-2447-4350	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chae SS, 2004, DEV BIOL, V268, P441, DOI 10.1016/j.ydbio.2004.01.001; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Li SJ, 2003, P NATL ACAD SCI USA, V100, P9366, DOI 10.1073/pnas.1233635100; Lindahl P, 1998, CURR OPIN LIPIDOL, V9, P407, DOI 10.1097/00041433-199810000-00004; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Liu YJ, 1999, J CLIN INVEST, V103, P497, DOI 10.1172/JCI5542; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McGiffert C, 2002, FEBS LETT, V531, P103, DOI 10.1016/S0014-5793(02)03404-X; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Niedernberg A, 2003, CELL SIGNAL, V15, P435, DOI 10.1016/S0898-6568(02)00119-5; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 2001, PROSTAG OTH LIPID M, V64, P107, DOI 10.1016/S0090-6980(01)00103-4; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	40	309	325	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29367	29373		10.1074/jbc.M403937200	http://dx.doi.org/10.1074/jbc.M403937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15138255	hybrid			2022-12-25	WOS:000222445300068
J	Rosado, JA; Lopez, JJ; Harper, AGS; Harper, MT; Redondo, PC; Pariente, JA; Sage, SO; Salido, GM				Rosado, JA; Lopez, JJ; Harper, AGS; Harper, MT; Redondo, PC; Pariente, JA; Sage, SO; Salido, GM			Two pathways for store-mediated calcium entry differentially dependent on the actin cytoskeleton in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA2+ ENTRY; FARNESYLCYSTEINE ANALOGS; CELLS; INHIBITION; THAPSIGARGIN; INVOLVEMENT; ACTIVATION; MAINTENANCE; GENERATION	A major pathway for stimulated Ca2+ entry in non-excitable cells is activated following depletion of intracellular Ca2+ stores. Secretion-like coupling between elements in the plasma membrane (PM) and Ca2+ stores has been proposed as the most likely mechanism to activate this store-mediated Ca2+ entry (SMCE) in several cell types. Here we identify two mechanisms for SMCE in human platelets activated by depletion of two independent Ca2+ pools, which are differentially modulated by the actin cytoskeleton. Ca2+ entry induced by depletion of a 2,5-di-(tert-butyl)-1,4-hydroquinone (TBHQ)sensitive pool is increased by disassembly of the actin cytoskeleton and that induced by a TBHQ-insensitive pool is reduced. Stabilization of the actin cytoskeleton prevented Ca2+ entry by both mechanisms. We propose that the membrane-associated actin network prevents constitutive Ca2+ entry via both pathways. Reorganization of the actin cytoskeleton permits the activation of Ca2+ entry via both mechanisms, but only SMCE activated by the TBHQ-insensitive pool requires new actin polymerization, which may support membrane trafficking toward the PM.	Univ Extremadura, Dept Physiol, Caceres 10071, Spain; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	Universidad de Extremadura; University of Cambridge	Rosado, JA (corresponding author), Univ Extremadura, Dept Physiol, Caceres 10071, Spain.	jarosado@unex.es	Liberal, Pedro C Redondo/F-4592-2016; Rosado, Juan A/H-3488-2015; Salido, Gines M/A-4292-2009; Lopez, Jose J/F-4602-2016; Harper, Matthew T/G-5630-2013; Harper, Alan/AFR-9139-2022	Liberal, Pedro C Redondo/0000-0002-2067-2627; Rosado, Juan A/0000-0002-9749-2325; Salido, Gines M/0000-0002-8687-2445; Lopez, Jose J/0000-0002-5234-1478; Harper, Matthew T/0000-0002-4740-637X; Harper, Alan/0000-0003-2413-4823; Sage, Stewart/0000-0001-8578-3558; PARIENTE, JOSE ANTONIO/0000-0002-9094-9943				BIRD GS, 1993, J BIOL CHEM, V268, P21486; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; Kovacs T, 1997, BRIT J HAEMATOL, V97, P192, DOI 10.1046/j.1365-2141.1997.9982639.x; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1991, J BIOL CHEM, V266, P14593; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Redondo PC, 2003, BIOCHEM J, V370, P255, DOI 10.1042/BJ20021505; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2004, J BIOL CHEM, V279, P1665, DOI 10.1074/jbc.M307963200; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Rosado JA, 2001, AM J PHYSIOL-CELL PH, V280, pC1636, DOI 10.1152/ajpcell.2001.280.6.C1636; Tiffert T, 1997, J PHYSIOL-LONDON, V500, P139, DOI 10.1113/jphysiol.1997.sp022005; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Xu YJ, 1996, MOL PHARMACOL, V50, P1495	22	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29231	29235		10.1074/jbc.M403509200	http://dx.doi.org/10.1074/jbc.M403509200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15136566	hybrid			2022-12-25	WOS:000222445300051
J	Weljie, AM; Vogel, HJ				Weljie, AM; Vogel, HJ			Unexpected structure of the Ca2+-regulatory region from soybean calcium-dependent protein kinase-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE DOMAIN; TROPONIN-C; NMR-SPECTROSCOPY; SKELETAL-MUSCLE; MACROMOLECULAR STRUCTURES; INTRAMOLECULAR BINDING; CONFORMATIONAL-CHANGES; ANGSTROM RESOLUTION; REGULATORY DOMAINS; CRYSTAL-STRUCTURE	Calcium-dependent protein kinases (CDPKs) are an extensive class of multidomain Ca2+-regulated enzymes from plants and protozoa. In vivo the so-called calmodulin-like domain (CLD) of CDPK binds intramolecularly to the junction domain (JD), which exhibits both kinase-inhibitory and CLD binding properties. Here we report the high resolution solution structure of the calcium-regulatory region from soybean CDPK-alpha determined in the presence of a peptide encompassing the JD. The structure of both lobes of CLD resembles that of related helix-loop-helix Ca2+-binding proteins. NMR chemical shift mapping studies demonstrate that the JD induces significant structural changes in isolated Ca2+-CLD, particularly the C-terminal domain, although a stable complex is not formed. A CLD solution structure calculated on the basis of NMR data and long range fluorescence resonance energy transfer distances reveals an activated state with both lobes positioned side by side, similar to calcineurin B rather than calmodulin, highlighting the possible pitfall of assigning function purely from sequence information.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca	Weljie, Aalim M/B-6203-2012; Weljie, Aalim/V-6952-2019	Weljie, Aalim/0000-0002-7145-4494				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; Christodoulou J, 2002, J BIOMOL NMR, V23, P249, DOI 10.1023/A:1019875822571; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demene H, 2002, J BIOMOL NMR, V22, P47, DOI 10.1023/A:1013821123201; Evans NH, 2001, CURR OPIN PLANT BIOL, V4, P415, DOI 10.1016/S1369-5266(00)00194-1; Fallon JL, 2003, STRUCTURE, V11, P1303, DOI 10.1016/j.str.2003.09.004; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARMON AC, 2001, NEW PHYTOL, V151, P175, DOI DOI 10.1046/j.1469-8137.2001.00171.x; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Hrabak EM, 2000, ADV BOT RES, V32, P185, DOI 10.1016/S0065-2296(00)32025-0; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kohno T, 1998, J BIOMOL NMR, V12, P109, DOI 10.1023/A:1008254603368; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JY, 1998, BIOCHEMISTRY-US, V37, P6801, DOI 10.1021/bi980062q; Lee SY, 2000, BIOCHEMISTRY-US, V39, P4225, DOI 10.1021/bi992697a; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Nagae M, 2003, J BIOL CHEM, V278, P42240, DOI 10.1074/jbc.M303630200; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Rudd JJ, 2001, NEW PHYTOL, V151, P7, DOI 10.1046/j.1469-8137.2001.00173.x; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; Vitart V, 2000, BIOCHEMISTRY-US, V39, P12102, DOI 10.1021/bi005113+; Weljie AM, 2003, J BIOL CHEM, V278, P43764, DOI 10.1074/jbc.M306799200; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; Wishart DS, 1998, BIOCHEM CELL BIOL, V76, P153, DOI 10.1139/bcb-76-2-3-153; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; Yoshino H, 1996, BIOCHEMISTRY-US, V35, P2388, DOI 10.1021/bi952121v; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhang XRS, 2001, J MOL EVOL, V53, P214, DOI 10.1007/s002390010211; ZHAO Y, 1994, BIOCHEMISTRY-US, V33, P3714, DOI 10.1021/bi00178a031; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	58	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35494	35502		10.1074/jbc.M311520200	http://dx.doi.org/10.1074/jbc.M311520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15155727	hybrid			2022-12-25	WOS:000223303400043
J	Brown, J; Theisler, C; Silberman, S; Magnuson, D; Gottardi-Littell, N; Lee, JM; Yager, D; Crowley, J; Sambamurti, K; Rahman, MM; Reiss, AB; Eckman, CB; Wolozin, B				Brown, J; Theisler, C; Silberman, S; Magnuson, D; Gottardi-Littell, N; Lee, JM; Yager, D; Crowley, J; Sambamurti, K; Rahman, MM; Reiss, AB; Eckman, CB; Wolozin, B			Differential expression of cholesterol hydroxylases in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; LIPID RAFTS; PLASMA 24S-HYDROXYCHOLESTEROL; NEUROFIBRILLARY TANGLES; URSODEOXYCHOLIC ACID; IN-VIVO; CELLS; BRAIN; NEURONS	Cholesterol is eliminated from neurons by oxidization, which generates oxysterols. Cholesterol oxidation is mediated by the enzymes cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27-hydroxylase (CYP27A1). Immunocytochemical studies show that CYP46A1 and CYP27A1 are expressed in neurons and some astrocytes in the normal brain, and CYP27A1 is present in oligodendrocytes. In Alzheimer's disease ( AD), CYP46A1 shows prominent expression in astrocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not apparent around amyloid plaques but increases in oligodendrocytes. Although previous studies have examined the effects of synthetic oxysterols on the processing of amyloid precursor protein (APP), the actions of the naturally occurring oxysterols have yet to be examined. To understand the role of cholesterol oxidation in AD, we compared the effects of 24(S)- and 27-hydroxycholesterol on the processing of APP and analyzed the cell-specific expression patterns of the two cholesterol hydroxylases in the human brain. Both oxysterols inhibited production of Abeta in neurons, but 24(S)-hydroxycholesterol was similar to1000-fold more potent than 27-hydroxycholesterol. The IC50 of 24( S)-hydroxycholesterol for inhibiting Abeta secretion was similar to1 nM. Both oxysterols induced ABCA1 expression with IC50 values similar to that for inhibition of Abeta secretion, suggesting the involvement of liver X receptor. Oxysterols also inhibited protein kinase C activity and APP secretion following stimulation of protein kinase C. The selective expression of CYP46A1 around neuritic plaques and the potent inhibition of APP processing in neurons by 24( S)- hydroxycholesterol suggests that CYP46A1 affects the pathophysiology of AD and provides insight into how polymorphisms in the CYP46A1 gene might influence the pathophysiology of this prevalent disease.	Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; Washington Univ, Dept Med, Mass Spectrometry Facil, St Louis, MO 63110 USA; Northwestern Univ, Med Ctr, Dept Pathol, Chicago, IL 60611 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Loyola University Chicago; Loyola University Chicago; Mayo Clinic; Washington University (WUSTL); Northwestern University; New York University; Medical University of South Carolina	Wolozin, B (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, 715 Albany St,L-603, Boston, MA 02118 USA.	bwolozin@bu.edu	Messier, Claude/A-2322-2008; Sambamurti, Kumar/A-1620-2012	Messier, Claude/0000-0002-4791-1763; Sambamurti, Kumar/0000-0001-9507-9214; Reiss, Allison B/0000-0002-4478-2441	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042192, R01NS041786, R01NS048554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017485] Funding Source: NIH RePORTER; NIA NIH HHS [AG/NS 17485-01A2] Funding Source: Medline; NINDS NIH HHS [NS 048554-01, NS 41786-01, NS 042192-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Bu BT, 2002, NEUROBIOL DIS, V11, P285, DOI 10.1006/nbdi.2002.0551; Burns M, 2003, J NEUROSCI, V23, P5645; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CALLAHAN LM, 1995, NEUROBIOL AGING, V16, P311, DOI 10.1016/0197-4580(95)00035-D; Chang JY, 1998, BRAIN RES BULL, V45, P615, DOI 10.1016/S0361-9230(97)00461-9; Chang JY, 1998, NEUROCHEM RES, V23, P7, DOI 10.1023/A:1022437000893; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fukumoto H, 2002, J BIOL CHEM, V277, P48508, DOI 10.1074/jbc.M209085200; Javitt NB, 2002, BIOCHEM BIOPH RES CO, V292, P1147, DOI 10.1006/bbrc.2001.2013; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109; Kolsch H, 2001, J NEURAL TRANSM, V108, P475, DOI 10.1007/s007020170068; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 2000, J LIPID RES, V41, P195; Marlow L, 2003, J MOL NEUROSCI, V20, P233, DOI 10.1385/JMN:20:3:233; Murthy S, 2002, J LIPID RES, V43, P1054, DOI 10.1194/jlr.M100358-JLR200; Palacino JJ, 2000, J BIOL CHEM, V275, P215, DOI 10.1074/jbc.275.1.215; Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Papassotiropoulos A, 2000, NEUROREPORT, V11, P1959, DOI 10.1097/00001756-200006260-00030; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sola S, 2003, J BIOL CHEM, V278, P48831, DOI 10.1074/jbc.M300468200; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tun H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/s12031-002-0007-5; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4	41	208	215	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34674	34681		10.1074/jbc.M402324200	http://dx.doi.org/10.1074/jbc.M402324200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15148325	hybrid			2022-12-25	WOS:000223134800072
J	Gaude, N; Tippmann, H; Flemetakis, E; Katinakis, P; Udvardi, M; Dormann, P				Gaude, N; Tippmann, H; Flemetakis, E; Katinakis, P; Udvardi, M; Dormann, P			The galactolipid digalactosyldiacylglycerol accumulates in the peribacteroid membrane of nitrogen-fixing nodules of soybean and Lotus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-COMPOSITION; SYMBIOTIC MEMBRANES; SYNTHASE GENES; LEGUME; EXPRESSION; BIOSYNTHESIS; PHOSPHORUS; NODULIN-26; DEFICIENT; JAPONICUS	The peribacteroid membrane (PBM) surrounding nitrogen fixing rhizobia in the nodules of legumes is crucial for the exchange of ammonium and nutrients between the bacteria and the host cell. Digalactosyldiacylglycerol (DGDG), a galactolipid abundant in chloroplasts, was detected in the PBM of soybean (Glycine max) and Lotus japonicus. Analyses of membrane marker proteins and of fatty acid composition confirmed that DGDG represents an authentic PBM lipid of plant origin and is not derived from the bacteria or from plastid contamination. In Arabidopsis, DGDG is known to accumulate in extraplastidic membranes during phosphate deprivation. However, the presence of DGDG in soybean PBM was not restricted to phosphate limiting conditions. Complementary DNA sequences corresponding to the two DGDG synthases, DGD1 and DGD2 from Arabidopsis, were isolated from soybean and Lotus. The two genes were expressed during later stages of nodule development in infected cells and in cortical tissue. Because nodule development depends on the presence of high amounts of phosphate in the growth medium, the accumulation of the non-phosphorus galactolipid DGDG in the PBM might be important to save phosphate for other essential processes, i.e. nucleic acid synthesis in bacteroids and host cells.	Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany; Agr Univ Athens, Dept Agr Biotechnol, Athens 11855, Greece	Max Planck Society; Agricultural University of Athens	Dormann, P (corresponding author), Max Planck Inst Mol Plant Physiol, Muhlenberg 1, D-14476 Golm, Germany.	Doermann@mpimp-golm.mpg.de	Udvardi, Michael/GPX-4653-2022	Udvardi, Michael/0000-0001-9850-0828; Flemetakis, Emmanouil/0000-0003-2530-9592				Andersson MX, 2003, FEBS LETT, V537, P128, DOI 10.1016/S0014-5793(03)00109-1; Awai K, 2001, P NATL ACAD SCI USA, V98, P10960, DOI 10.1073/pnas.181331498; Becher M, 2004, PLANT J, V37, P251, DOI 10.1046/j.1365-313X.2003.01959.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boumahdi M, 1999, J APPL MICROBIOL, V87, P611, DOI 10.1046/j.1365-2672.1999.00860.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brewin N J, 1993, Semin Cell Biol, V4, P149, DOI 10.1006/scel.1993.1018; Brewin N. J., 1990, The plant plasma membrane., P351; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; Day DA, 2001, AUST J PLANT PHYSIOL, V28, P667, DOI 10.1071/PP01028; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; Dormann P, 2002, TRENDS PLANT SCI, V7, P112, DOI 10.1016/S1360-1385(01)02216-6; Essigmann B, 1998, P NATL ACAD SCI USA, V95, P1950, DOI 10.1073/pnas.95.4.1950; Flemetakis E, 2003, BBA-GENE STRUCT EXPR, V1628, P186, DOI 10.1016/S0167-4781(03)00142-8; FORTIN MG, 1987, NUCLEIC ACIDS RES, V15, P813, DOI 10.1093/nar/15.2.813; GEIGER O, 1998, RHIZOBIACEAE MOL BIO, P56; HANDBERG K, 1992, PLANT J, V2, P487, DOI 10.1111/j.1365-313X.1992.00487.x; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hernandez LE, 1996, PHYTOCHEMISTRY, V42, P341, DOI 10.1016/0031-9422(96)00063-5; ISRAEL DW, 1987, PLANT PHYSIOL, V84, P835, DOI 10.1104/pp.84.3.835; Jiang QY, 1997, MOL PLANT MICROBE IN, V10, P59, DOI 10.1094/MPMI.1997.10.1.59; Jorasch P, 1998, MOL MICROBIOL, V29, P419, DOI 10.1046/j.1365-2958.1998.00930.x; Kelly AA, 2003, PLANT CELL, V15, P2694, DOI 10.1105/tpc.016675; Kelly AA, 2002, J BIOL CHEM, V277, P1166, DOI 10.1074/jbc.M110066200; Kelly AA, 2004, CURR OPIN PLANT BIOL, V7, P262, DOI 10.1016/j.pbi.2004.03.009; Leidi EO, 2000, NEW PHYTOL, V147, P337, DOI 10.1046/j.1469-8137.2000.00703.x; Lodwig EM, 2003, NATURE, V422, P722, DOI 10.1038/nature01527; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; Long SR, 2001, PLANT PHYSIOL, V125, P69, DOI 10.1104/pp.125.1.69; MIAO GH, 1993, PLANT CELL, V5, P781, DOI 10.1105/tpc.5.7.781; MILLER KJ, 1990, CURR MICROBIOL, V21, P205, DOI 10.1007/BF02092123; ORGAMBIDE GG, 1994, J BACTERIOL, V176, P4338, DOI 10.1128/jb.176.14.4338-4347.1994; Panter S, 2000, MOL PLANT MICROBE IN, V13, P325, DOI 10.1094/MPMI.2000.13.3.325; PAVKOVSKY R, 1988, PHYSIOL PLANTARUM, V72, P733; PRICE GD, 1987, J PLANT PHYSIOL, V130, P157, DOI 10.1016/S0176-1617(87)80219-5; RAE AL, 1992, PLANT J, V2, P385, DOI 10.1111/j.1365-313X.1992.00385.x; Reiter WD, 1997, PLANT J, V12, P335, DOI 10.1046/j.1365-313X.1997.12020335.x; SCHERES B, 1990, CELL, V60, P281, DOI 10.1016/0092-8674(90)90743-X; Schultze M, 1998, ANNU REV GENET, V32, P33, DOI 10.1146/annurev.genet.32.1.33; Stougaard J, 2000, PLANT PHYSIOL, V124, P531, DOI 10.1104/pp.124.2.531; SULLIVAN JT, 1995, P NATL ACAD SCI USA, V92, P8985, DOI 10.1073/pnas.92.19.8985; TAN Y, 1997, GLYCOBIOLOGY, V7, P935; Udvardi Michael K., 2001, Molecular Plant-Microbe Interactions, V14, P6, DOI 10.1094/MPMI.2001.14.1.6; Udvardi MK, 1997, ANNU REV PLANT PHYS, V48, P493, DOI 10.1146/annurev.arplant.48.1.493; Verma DPS, 1996, TRENDS MICROBIOL, V4, P364, DOI 10.1016/0966-842X(96)10053-6; VERMA DPS, 1992, PLANT CELL, V4, P373, DOI 10.1105/tpc.4.4.373; Weissenmayer B, 2000, MOL PLANT MICROBE IN, V13, P666, DOI 10.1094/MPMI.2000.13.6.666; Whitehead LF, 1997, PHYSIOL PLANTARUM, V100, P30, DOI 10.1034/j.1399-3054.1997.1000103.x; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002	51	69	76	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34624	34630		10.1074/jbc.M404098200	http://dx.doi.org/10.1074/jbc.M404098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15159398	hybrid			2022-12-25	WOS:000223134800067
J	Wang, XHL; Herzog, B; Waltner-Law, M; Hall, RK; Shiota, M; Granner, DK				Wang, XHL; Herzog, B; Waltner-Law, M; Hall, RK; Shiota, M; Granner, DK			The synergistic effect of dexamethasone and all-trans-retinoic acid on hepatic phosphoenolpyruvate carboxykinase gene expression involves the coactivator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; INSULIN-RESPONSE SEQUENCES; NUCLEAR HORMONE-RECEPTORS; RNA-POLYMERASE-II; ACCESSORY FACTORS; GLUCOCORTICOID RESPONSE; PEPCK GENE; COUP-TF; PROMOTER; TRANSCRIPTION	Activation of phosphoenolpyruvate carboxykinase ( PEPCK) gene transcription in response to all-transretinoic acid ( RA) or a glucocorticoid such as dexamethasone (Dex) requires a distinct arrangement of DNA-response elements and their cognate transcription activators on the gene promoter. Two of the accessory factor-binding elements involved in the Dex response (gAF1 and gAF3) coincide with the DNA-response elements involved in the RA response. We demonstrate here that the combination of Dex/RA has a synergistic effect on endogenous PEPCK gene expression in rat hepatocytes and H4IIE hepatoma cells. Reporter gene studies show that the gAF3 element and one of the two glucocorticoid receptor-binding elements (GR1) are most important for this effect. Chromatin immunoprecipitation assays revealed that when H4IIE cells were treated with Dex/RA, ligand-activated retinoic acid receptors ( retinoic acid receptor/ retinoid X receptor) and glucocorticoid receptors are recruited to this gene promoter, as are the transcription coregulators p300, CREB-binding protein, p/CIP, and SRC-1. Notably, the recruitment of p300 and RNA polymerase II to the PEPCK promoter is increased by the combined Dex/RA treatment compared with Dex or RA treatment alone. The functional importance of p300 in the Dex/RA response is illustrated by the observation that selective reduction of this coactivator, but not that of CREB-binding protein, abolishes the synergistic effect in H4IIE cells.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, P30DK020593, R01DK035107, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 20593, DK 35107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Herzog B, 2004, MOL ENDOCRINOL, V18, P807, DOI 10.1210/mg.2003-0384; Kung AL, 2000, GENE DEV, V14, P272; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; NAKASHATRI H, 1994, J BIOL CHEM, V269, P890; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Schweizer M, 2002, BIOCHEM SOC T, V30, P1070, DOI 10.1042/BST0301070; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Scribner KB, 2003, J NUTR, V133, P4112, DOI 10.1093/jn/133.12.4112; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; SUWANICHKUL A, 1994, J BIOL CHEM, V269, P30835; Ugai H, 1999, J MOL MED, V77, P481, DOI 10.1007/s001099900021; Vander Kooi BT, 2003, J BIOL CHEM, V278, P11782, DOI 10.1074/jbc.M212570200; Veitia RA, 2003, BIOL REV, V78, P149, DOI 10.1017/S1464793102006036; Waltner-Law M, 2003, J BIOL CHEM, V278, P10427, DOI 10.1074/jbc.M211846200; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074	37	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34191	34200		10.1074/jbc.M403455200	http://dx.doi.org/10.1074/jbc.M403455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15166231	hybrid			2022-12-25	WOS:000223134800017
J	Diederichs, S; Baumer, N; Ji, P; Metzelder, SK; Idos, GE; Cauvet, T; Wang, WB; Moller, M; Pierschalski, S; Gromoll, J; Schrader, MG; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C				Diederichs, S; Baumer, N; Ji, P; Metzelder, SK; Idos, GE; Cauvet, T; Wang, WB; Moller, M; Pierschalski, S; Gromoll, J; Schrader, MG; Koeffler, HP; Berdel, WE; Serve, H; Muller-Tidow, C			Identification of interaction partners and substrates of the cyclin A1-CDK2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACTIVATED C-KINASE; CELL-CYCLE; MAMMALIAN-CELLS; DNA-REPAIR; DEPENDENT KINASES; MESSENGER-RNA; GERM-CELLS; G-PROTEINS; BETA-SUBUNIT	The CDK2-associated cyclin A1 is essential for spermatogenesis and contributes to leukemogenesis. The detailed molecular functions of cyclin A1 remain unclear, since the molecular networks involving cyclin A1-CDK2 have not been elucidated. Here, we identified novel cyclin A1/CDK2 interaction partners in a yeast triple-hybrid approach. Several novel proteins (INCA1, KARCA1, and PROCA1) as well as the known proteins GPS2 (G-protein pathway suppressor 2), Ku70, receptor for activated protein kinase C1/guanine nucleotide-binding protein beta-2-like-1, and mRNA-binding motif protein 4 were identified as interaction partners. These proteins link the cyclin A1-CDK2 complex to diverse cellular processes such as DNA repair, signaling, and splicing. Interactions were confirmed by GST pull-down assays and co-immunoprecipitation. We cloned and characterized the most frequently isolated unknown gene, which we named INCA1 ( inhibitor of CDK interacting with cyclin A1). The nuclear INCA1 protein is evolutionarily conserved and lacks homology to any known gene. This novel protein and two other interacting partners served as substrates for the cyclin A1-CDK2 kinase complex. Cyclin A1 and all interaction partners were highly expressed in testis with varying degrees of tissue specificity. The highest expression levels were observed at different time points during testis maturation, whereas expression levels in germ cell cancers and infertile testes decreased. Taken together, we identified testicular interaction partners of the cyclin A1-CDK2 complex and studied their expression pattern in normal organs, testis development, and testicular malignancies. Thereby, we establish a new basis for future functional analyses of cyclin A1. We provide evidence that the cyclin A1-CDK2 complex plays a role in several signaling pathways important for cell cycle control and meiosis.	Univ Munster, Dept Med Hematol Oncol, D-48129 Munster, Germany; Univ Munster, Inst Reprod Med, D-48129 Munster, Germany; Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Hosp Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany	University of Munster; University of Munster; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Muller-Tidow, C (corresponding author), Univ Munster, Dept Med Hematol Oncol, Domagkstr 3, D-48129 Munster, Germany.	muellerc@uni-muenster.de	Gromoll, Joerg/AAB-2146-2019; Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018; Diederichs, Sven/J-6237-2012	Gromoll, Joerg/0000-0002-7788-8138; Müller-Tidow, Carsten/0000-0002-7166-5232; Diederichs, Sven/0000-0001-7901-4752				BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herrmann CH, 2001, J CELL SCI, V114, P1491; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Hsia KT, 2003, DEVELOPMENT, V130, P369, DOI 10.1242/dev.00221; Jackson FB, 1997, GENOMICS, V41, P444, DOI 10.1006/geno.1997.4704; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kishimoto T, 2003, CURR OPIN CELL BIOL, V15, P654, DOI 10.1016/j.ceb.2003.10.010; Lai MC, 2003, EMBO J, V22, P1359, DOI 10.1093/emboj/cdg126; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Muller-Tidow C, 2003, CANCER LETT, V190, P89, DOI 10.1016/S0304-3835(02)00582-7; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Peng YC, 2001, MOL CELL BIOL, V21, P5913, DOI 10.1128/MCB.21.17.5913-5924.2001; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schrader M, 2002, HUM REPROD, V17, P2338, DOI 10.1093/humrep/17.9.2338; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Sherr CJ, 2000, CANCER RES, V60, P3689; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Sweeney C, 1996, DEVELOPMENT, V122, P53; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Um JH, 2003, MECH AGEING DEV, V124, P967, DOI 10.1016/S0047-6374(03)00169-6; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	63	50	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33727	33741		10.1074/jbc.M401708200	http://dx.doi.org/10.1074/jbc.M401708200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159402	hybrid			2022-12-25	WOS:000223039700082
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			A mitochondrial-vacuolar signaling pathway in yeast that affects iron and copper metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; DEFICIENT STRAIN; CARRIER PROTEIN; FRATAXIN; HOMOLOG; GENE; ACCUMULATION; REGULON; CCC1	Mitochondria utilize iron, but the transporters that mediate mitochondrial iron uptake and efflux are largely unknown. Cells with a deletion in the vacuolar iron/manganese transporter Ccc1p are sensitive to high iron. Overexpression of MRS3 or MRS4 suppresses the high iron sensitivity of Deltaccc1 cells. MRS3 and MRS4 have recently been suggested to encode mitochondrial iron transporters. We demonstrate that deletion of MRS3 and MRS4 severely affects cellular and mitochondrial metal homeostasis, including a reduction in cytosolic and mitochondrial iron acquisition. We show that vacuolar iron transport is increased in Deltamrs3Deltamrs4 cells, resulting in decreased cytosolic iron and activation of the iron-sensing transcription factor Aft1p. Activation of Aft1p leads to increased expression of the high affinity iron transport system and increased iron uptake. Deletion of CCC1 in Deltamrs3Deltamrs4 cells restores cellular and mitochondrial iron homeostasis to near normal levels. Deltamrs3Deltamrs4 cells also show increased resistance to cobalt but decreased resistance to copper and cadmium. These phenotypes are also corrected by deletion of CCC1 in Deltamrs3Deltamrs4 cells. Decreased copper resistance in Deltamrs3Deltamrs4 cells results from activation of Aft1p by Ccc1p-mediated iron depletion, as deletion of CCC1 or AFT1 in Deltamrs3Deltamrs4 cells restores copper resistance. These results suggest that deletion of mitochondrial proteins can alter vacuolar metal homeostasis. The data also indicate that increased expression of the AFT1-regulated gene(s) can disrupt copper homeostasis.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu			NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380, R01DK030534] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 42014] Funding Source: Medline; NIDDK NIH HHS [R01-DK30534, R01-DK52380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chen OS, 2004, J BIOL CHEM, V279, P29513, DOI 10.1074/jbc.M403209200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P16922, DOI 10.1073/pnas.232392299; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Gross C, 2000, J BIOL CHEM, V275, P32310, DOI 10.1074/jbc.M005946200; Kaplan RS, 2001, J MEMBRANE BIOL, V179, P165, DOI 10.1007/s002320010046; Kumar A, 2002, METHOD ENZYMOL, V350, P219, DOI 10.1016/S0076-6879(02)50965-4; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Lesuisse E, 2004, BIOCHEM J, V378, P599, DOI 10.1042/BJ20031387; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; Moore DD, 1995, GLOB MOB SURV; Muhlenhoff U, 2003, J BIOL CHEM, V278, P40612, DOI 10.1074/jbc.M307847200; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Nyhus KJ, 2002, MED MYCOL, V40, P581, DOI 10.1080/mmy.40.6.581.591; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Stadler JA, 2002, J BIOL CHEM, V277, P39649, DOI 10.1074/jbc.M203924200; Vozza A, 2004, J BIOL CHEM, V279, P20850, DOI 10.1074/jbc.M313610200; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	29	86	88	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33653	33661		10.1074/jbc.M403146200	http://dx.doi.org/10.1074/jbc.M403146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161905	hybrid			2022-12-25	WOS:000223039700075
J	Lobo, IA; Mascia, MP; Trudell, JR; Harris, RA				Lobo, IA; Mascia, MP; Trudell, JR; Harris, RA			Channel gating of the glycine receptor changes accessibility to residues implicated in receptor potentiation by alcohols and anesthetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; TRYPTOPHAN SCANNING MUTAGENESIS; MEMBRANE-SPANNING SEGMENT; ACTIVATED CL-CURRENT; ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE DOMAIN; SECONDARY STRUCTURE; ION CHANNELS; M2-M3 LOOP; GABA(A)	The glycine receptor is a target for both alcohols and anesthetics, and certain amino acids in the alpha1 subunit transmembrane segments (TM) are critical for drug effects. Introducing larger amino acids at these positions increases the potency of glycine, suggesting that introducing larger residues, or drug molecules, into the drug-binding cavity facilitates channel opening. A possible mechanism for these actions is that the volume of the cavity expands and contracts during channel opening and closing. To investigate this hypothesis, mutations for amino acids in TM1 (I229C) and TM2 (G256C, T259C, V260C, M263C, T264C, S267C, S270C) and TM3 (A288C) were individually expressed in Xenopus laevis oocytes. The ability of sulfhydryl-specific alkyl methanethiosulfonate (MTS) compounds of different lengths to covalently react with introduced cysteines in both the closed and open states of the receptor was determined. S267C was accessible to short chain (C3 - C8) MTS in both open and closed states, but was only accessible to longer chain (C10 - C16) MTS compounds in the open state. Reaction with S267C was faster in the open state. I229C and A288C showed state-dependent reaction with MTS only in the presence of agonist. M263C and S270C were also accessible to MTS labeling. Mutated residues more intracellular than M263C did not react, indicating a floor of the cavity. These data demonstrate that the conformational changes accompanying channel gating increase accessibility to amino acids critical for drug action in TM1, TM2, and TM3, which may provide a mechanism by which alcohols and anesthetics can act on glycine ( and likely other) receptors.	Univ Texas, Waggoner Ctr Alcohol & Addict Res, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Neurobiol Sect, Austin, TX 78712 USA; Univ Cagliari, Dept Expt Biol, Inst Neurosci, CNR, I-09123 Cagliari, Italy; Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Consiglio Nazionale delle Ricerche (CNR); University of Cagliari; Stanford University	Lobo, IA (corresponding author), Univ Texas, Waggoner Ctr Alcohol & Addict Res, Inst Mol & Cellular Biol, Austin, TX 78712 USA.	dirgni@mail.utexas.edu			NIAAA NIH HHS [AA06399, AA13778, AA13378] Funding Source: Medline; NIGMS NIH HHS [GM47818] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013378, F31AA013778, R01AA006399, R37AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aguayo LG, 1996, J PHARMACOL EXP THER, V279, P1116; AGUAYO LG, 1994, J PHARMACOL EXP THER, V270, P61; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bali M, 2004, MOL PHARMACOL, V65, P68, DOI 10.1124/mol.65.1.68; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Bertaccini E, 2002, PROTEIN ENG, V15, P443, DOI 10.1093/protein/15.6.443; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; Colman A., 1984, TRANSCRIPTION TRANSL, P49; Eggers ED, 2000, J NEUROPHYSIOL, V84, P2409, DOI 10.1152/jn.2000.84.5.2409; ENGBLOM AC, 1991, J NEUROCHEM, V57, P384, DOI 10.1111/j.1471-4159.1991.tb03764.x; Findlay GS, 2002, J PHARMACOL EXP THER, V300, P526, DOI 10.1124/jpet.300.2.526; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Greenblatt Eric P., 1999, Anesthesiology (Hagerstown), V91, pA807; Guzman GR, 2003, BIOCHEMISTRY-US, V42, P12243, DOI 10.1021/bi034764d; Hara K, 2002, ANESTHESIOLOGY, V97, P1512, DOI 10.1097/00000542-200212000-00025; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; LANGOSCH D, 1995, HDB RECEPTORS CHANNE, P291; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LOBO IA, 2004, IN PRESS J NEUROCHEM; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Raines DE, 2001, ANESTHESIOLOGY, V95, P470, DOI 10.1097/00000542-200108000-00032; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; Sonner JM, 2003, ANESTH ANALG, V97, P718, DOI 10.1213/01.ANE.0000081063.76651.33; Spencer RH, 2002, ANNU REV BIOPH BIOM, V31, P207, DOI 10.1146/annurev.biophys.31.082901.134329; Tang P, 2002, BIOPHYS J, V83, P252, DOI 10.1016/S0006-3495(02)75166-7; TRUDELL JR, 2004, IN PRESS J MOL GRAPH; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Williams DB, 2000, MOL PHARMACOL, V58, P1129, DOI 10.1124/mol.58.5.1129; Williams DB, 1999, BIOPHYS J, V77, P2563, DOI 10.1016/S0006-3495(99)77091-8; Williams DB, 2002, J NEUROSCI, V22, P7417; Williams DB, 2001, NEUROPHARMACOLOGY, V41, P539, DOI 10.1016/S0028-3908(01)00099-5; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23; Ye JH, 2001, J PHARMACOL EXP THER, V296, P77; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zhang H, 1998, BIOCHEMISTRY-US, V37, P7952, DOI 10.1021/bi980143m	50	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33919	33927		10.1074/jbc.M313941200	http://dx.doi.org/10.1074/jbc.M313941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169788	hybrid			2022-12-25	WOS:000223039700102
J	Tomzig, A; Spassov, S; Friedrich, M; Naumann, D; Beekes, M				Tomzig, A; Spassov, S; Friedrich, M; Naumann, D; Beekes, M			Discriminating scrapie and bovine spongiform encephalopathy isolates by infrared spectroscopy of pathological prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; NATURAL SHEEP SCRAPIE; SECONDARY STRUCTURE; MOLECULAR ANALYSIS; STRAIN VARIATION; VARIANT CJD; BSE; PRPSC; MICE; CONFORMATIONS	For the surveillance of transmissible spongiform encephalopathies (TSEs) in animals and humans, the discrimination of different TSE strains causing scrapie, BSE, or Creutzfeldt-Jakob disease constitutes a substantial challenge. We addressed this problem by Fourier transform-infrared (FT-IR) spectroscopy of pathological prion protein PrP27-30. Different isolates of hamster-adapted scrapie (263K, 22A-H, and ME7-H) and BSE (BSE-H) were passaged in Syrian hamsters. Two of these agents, 22A-H and ME7-H, caused TSEs with indistinguishable clinical symptoms, neuropathological changes, and electrophoretic mobilities and glycosylation patterns of PrP27-30. However, FT-IR spectroscopy revealed that PrP27-30 of all four isolates featured different characteristics in the secondary structure, allowing a clear distinction between the passaged TSE agents. FT-IR analysis showed that phenotypic information is mirrored in beta-sheet and other secondary structure elements of PrP27-30, also in cases where immunobiochemical typing failed to detect structural differences. If the findings of this study hold true for nonexperimental TSEs in animals and humans, FT-IR characterization of PrP27-30 may provide a versatile tool for molecular strain typing without antibodies and without restrictions to specific TSEs or mammalian species.	Robert Koch Inst, D-13353 Berlin, Germany	Robert Koch Institute	Beekes, M (corresponding author), Robert Koch Inst, P26,Nordufer 20, D-13353 Berlin, Germany.	BeekesM@rki.de	Beekes, Michael/S-1975-2018; Spassov, Sashko/C-2105-2013	Beekes, Michael/0000-0002-6454-6657; Spassov, Sashko/0000-0002-3585-3682				BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; Baron TGM, 1999, J CLIN MICROBIOL, V37, P3701, DOI 10.1128/JCM.37.11.3701-3704.1999; Baron TGM, 2000, NEUROSCI LETT, V284, P175, DOI 10.1016/S0304-3940(00)01047-8; BEEKES M, 1995, J GEN VIROL, V76, P2567, DOI 10.1099/0022-1317-76-10-2567; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Biacabe AG, 2004, EMBO REP, V5, P110, DOI 10.1038/sj.embor.7400054; Bradshaw R., 2004, P 11 ACM C COMP COMM, P146, DOI DOI 10.1145/1030083.1030104; Bruce ME, 2003, BRIT MED BULL, V66, P99, DOI 10.1093/bmb/66.1.99; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Cousens SN, 1999, LANCET, V353, P18, DOI 10.1016/S0140-6736(98)08062-3; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; Diringer H, 1997, INTERVIROLOGY, V40, P238, DOI 10.1159/000150553; FABIAN H, 2000, ENCY ANAL CHEM, P5779; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hope J, 1999, J GEN VIROL, V80, P1, DOI 10.1099/0022-1317-80-1-1; JACKSON M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P231, DOI 10.1016/0167-4838(91)90563-F; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Kuczius T, 1999, MOL MED, V5, P406, DOI 10.1007/BF03402129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lezmi S, 2004, J VIROL, V78, P3654, DOI 10.1128/JVI.78.7.3654-3662.2004; Lucassen R, 2003, BIOCHEMISTRY-US, V42, P4127, DOI 10.1021/bi027218d; Madec JY, 1997, ARCH VIROL, V142, P1603, DOI 10.1007/s007050050183; McBride PA, 2001, J VIROL, V75, P9320, DOI 10.1128/JVI.75.19.9320-9327.2001; Notari S, 2004, J BIOL CHEM, V279, P16797, DOI 10.1074/jbc.M313220200; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schulz-Schaeffer WJ, 2000, AM J PATHOL, V156, P51, DOI 10.1016/S0002-9440(10)64705-0; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; Stack MJ, 2002, ACTA NEUROPATHOL, V104, P279, DOI 10.1007/s00401-002-0556-2; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Thuring CMA, 2004, J CLIN MICROBIOL, V42, P972, DOI 10.1128/JCM.42.3.972-980.2004; Yamada N, 1998, J AM CHEM SOC, V120, P12192, DOI 10.1021/ja981363q	48	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33847	33854		10.1074/jbc.M403730200	http://dx.doi.org/10.1074/jbc.M403730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155741	hybrid			2022-12-25	WOS:000223039700094
J	Wang, L; Kwak, JH; Kim, SI; He, YJ; Choi, ME				Wang, L; Kwak, JH; Kim, SI; He, YJ; Choi, ME			Transforming growth factor-beta 1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38 alpha and p38 delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; FACTOR VEGF; SIGNAL-TRANSDUCTION; FACTOR-BETA; P38 MAPK; MECHANICAL STRETCH; FACTOR EXPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; RECEPTORS	Transforming growth factor-beta1 (TGF-beta1) is a potent inducer of extracellular matrix synthesis leading to progressive glomerular fibrosis. The intracellular signaling mechanisms involved in this process remain incompletely understood. The p38 mitogen-activated protein kinase ( MAPK) is a major stress signal transducing pathway that is rapidly activated by TGF-beta1 in mesangial cells. We have previously demonstrated MKK3 as the immediate upstream MAPK kinase required for selective activation of p38 MAPK isoforms, p38alpha and p38delta, and stimulation of pro-alpha1( I) collagen by TGF-beta1 in murine mesangial cells. In this study, we further sought to determine MAPK kinase 3 ( MKK3)-dependent TGF-beta1 responses by gene expression profiling analysis utilizing mesangial cells isolated from Mkk3(-/-) mice compared with Mkk3(+/+) controls. Interestingly, vascular endothelial growth factor ( VEGF) was identified as a TGF-beta1-induced gene affected by deletion of Mkk3. VEGF is a well known endothelial mitogen, whose actions in nonendothelial cell types are still not well understood. We confirmed that TGF-beta1 increased VEGF mRNA and protein synthesis of VEGF(164) and VEGF(188) isoforms in wild-type mesangial cells. However, in the Mkk3(-/-) mesangial cells, both TGF-beta1-induced VEGF mRNA and VEGF(164) protein expression were inhibited, whereas TGF-beta1-induced VEGF(188) protein expression was unaffected. Furthermore, transfection of dominant negative mutants of p38alpha and p38delta resulted in marked inhibition of TGF-beta1-induced VEGF(164) expression but not VEGF(188), and treatment with recombinant mouse VEGF(164) increased collagen and fibronectin mRNA expression in mesangial cells. Taken together, our findings suggest a critical role for the MKK3-p38alpha and p38delta MAPK pathway in mediating VEGF(164) isoform-specific stimulation by TGF-beta1 in mesangial cells. Further, VEGF(164) stimulates collagen and fibronectin expression in mesangial cells and thus in turn enhances TGF-beta1-induced extracellular matrix and may play an important role in progressive glomerular fibrosis.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Choi, ME (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, E1158 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	choim@pitt.edu			NIDDK NIH HHS [R01 DK57661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ancelin M, 2002, P NATL ACAD SCI USA, V99, P6023, DOI 10.1073/pnas.082110999; Bailey E, 1999, J CLIN PATHOL, V52, P735, DOI 10.1136/jcp.52.10.735; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Benckert C, 2003, CANCER RES, V63, P1083; Bokemeyer D, 1998, KIDNEY INT, V54, pS189, DOI 10.1046/j.1523-1755.1998.06743.x; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cooper ME, 1999, DIABETES, V48, P2229, DOI 10.2337/diabetes.48.11.2229; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Dunlop ME, 2000, KIDNEY INT, V57, P464, DOI 10.1046/j.1523-1755.2000.t01-1-00866.x; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gruden G, 1997, P NATL ACAD SCI USA, V94, P12112, DOI 10.1073/pnas.94.22.12112; Gruden G, 1999, J AM SOC NEPHROL, V10, P730; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hovey RC, 2001, MOL ENDOCRINOL, V15, P819, DOI 10.1210/me.15.5.819; IIJIMA K, 1993, KIDNEY INT, V44, P959, DOI 10.1038/ki.1993.337; IRUELAARISPE L, 1995, AM J PATHOL, V147, P1715; Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Ju HS, 2002, J PHARMACOL EXP THER, V301, P15, DOI 10.1124/jpet.301.1.15; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim NH, 2000, J ENDOCRINOL, V165, P617, DOI 10.1677/joe.0.1650617; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuoka H, 2002, AM J PHYSIOL-LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ning W, 2002, AM J PHYSIOL-LUNG C, V283, pL1094, DOI 10.1152/ajplung.00151.2002; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Robinson CJ, 2001, J CELL SCI, V114, P853; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spector JA, 2001, AM J PHYSIOL-CELL PH, V280, pC72, DOI 10.1152/ajpcell.2001.280.1.C72; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Thomas S, 2000, J AM SOC NEPHROL, V11, P1236, DOI 10.1681/ASN.V1171236; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Wada T, 2000, J AM SOC NEPHROL, V11, P1534, DOI 10.1681/ASN.V1181534; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Yamamoto T, 2001, J CELL BIOCHEM, V82, P591, DOI 10.1002/jcb.1179; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	52	53	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33213	33219		10.1074/jbc.M403758200	http://dx.doi.org/10.1074/jbc.M403758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15143069	hybrid			2022-12-25	WOS:000223039700026
J	Chan, AYM; Soltys, CLM; Young, ME; Proud, CG; Dyck, JRB				Chan, AYM; Soltys, CLM; Young, ME; Proud, CG; Dyck, JRB			Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; LEFT-VENTRICULAR HYPERTROPHY; ELONGATION-FACTOR-2 KINASE; PHOSPHORYLATION SITE; MAMMALIAN TARGET; GAMMA(2) SUBUNIT; RAPAMYCIN; GROWTH; MTOR; AKT	A necessary mediator of cardiac myocyte enlargement is protein synthesis, which is controlled at the levels of both translation initiation and elongation. Eukaryotic elongation factor-2 (eEF2) mediates the translocation step of peptide-chain elongation and is inhibited through phosphorylation by eEF2 kinase. In addition, p70S6 kinase can regulate protein synthesis by phosphorylating eEF2 kinase or via phosphorylation of ribosomal protein S6. We have recently shown that eEF2 kinase is also controlled by phosphorylation by AMP-activated protein kinase ( AMPK), a key regulator of cellular energy homeostasis. Moreover, the mammalian target of rapamycin has also been shown to be inhibited, indirectly, by AMPK, thus leading to the inhibition of p70S6 kinase. Although AMPK activation has been shown to modulate protein synthesis, it is unknown whether AMPK could also be a regulator of cardiac hypertrophic growth. Therefore, we investigated the role of AMPK activation in regulating protein synthesis during both phenylephrine- and Akt-induced cardiac hypertrophy. Metformin and 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside were used to activate AMPK in neonatal rat cardiac myocytes. Activation of AMPK significantly decreased protein synthesis induced by phenylephrine treatment or by expression of constitutively active Akt. Activation of AMPK also resulted in decreased p70S6 kinase phosphorylation and increased phosphorylation of eEF2, suggesting that inhibition of protein synthesis involves the eEF2 kinase/eEF2 axis and/or the p70S6 kinase pathway. Together, our data suggest that the inhibition of protein synthesis by pharmacological activation of AMPK may be a key regulatory mechanism by which hypertrophic growth can be controlled.	Univ Alberta, Heritage Med Res Ctr 474, Fac Med, Dept Pediat,Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Fac Med, Dept Pharmacol, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Texas, Hlth Sci Ctr, Brown Fdn Inst Mol Med, Houston, TX 77030 USA; Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Alberta; University of Alberta; University of Texas System; University of Texas Health Science Center Houston; University of Dundee	Dyck, JRB (corresponding author), Univ Alberta, Heritage Med Res Ctr 474, Fac Med, Dept Pediat,Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada.	Jason.Dyck@UAlberta.ca		Proud, Christopher/0000-0003-0704-6442; Dyck, Jason/0000-0002-7045-2884				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLARD MF, 1991, AM J PHYSIOL, V267, pH742; Arad M, 2003, CIRCULATION, V107, P2850, DOI 10.1161/01.CIR.0000075270.13497.2B; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hannan RD, 2003, CLIN EXP PHARMACOL P, V30, P517, DOI 10.1046/j.1440-1681.2003.03873.x; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Krieg T, 2002, AM J PHYSIOL-HEART C, V283, pH2322, DOI 10.1152/ajpheart.00474.2002; Lehman John J, 2002, Heart Fail Rev, V7, P175; Lorell BH, 2000, CIRCULATION, V102, P470; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MULLANE K, 1993, CARDIOVASC RES, V27, P43, DOI 10.1093/cvr/27.1.43; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Proud CG, 2004, BIOCHEM BIOPH RES CO, V313, P429, DOI 10.1016/j.bbrc.2003.07.015; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; Richey PA, 1998, J SPORT SCI, V16, P129; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; Soltys CLM, 2002, AM J PHYSIOL-HEART C, V283, pH1056, DOI 10.1152/ajpheart.00275.2002; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Tian R, 2001, CIRCULATION, V104, P1664, DOI 10.1161/hc4001.097183; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Xia Y, 2003, J BIOL CHEM, V278, P13143, DOI 10.1074/jbc.M208500200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	59	267	286	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32771	32779		10.1074/jbc.M403528200	http://dx.doi.org/10.1074/jbc.M403528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159410	hybrid			2022-12-25	WOS:000222849700096
J	Kumar, DP; Tiwari, A; Bhat, R				Kumar, DP; Tiwari, A; Bhat, R			Effect of pH on the stability and structure of yeast hexokinase A - Acidic amino acid residues in the cleft region are critical for the opening and the closing of the structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSPHEROCYTIC HEMOLYTIC-ANEMIA; MOLTEN GLOBULE; FLUORESCENT-PROBE; SUBUNIT STRUCTURE; D-GLUCOSE; PROTEINS; MECHANISM; BINDING; SALT; DENATURATION	pH and salts have a marked effect on the stability, structure, and function of many globular proteins due to their ability to influence the electrostatic interactions. In this work, calorimetry, CD, and fluorescence studies have been carried out to understand the pH-dependent conformational changes of the two-domain protein yeast hexokinase A. In conjunction with the crystal structural data available, the present results have enabled the complete characterization and analysis of the pH-dependent conformational changes of the enzyme that have strong implications in understanding its structure-function relationship. The calorimetric profiles show a single thermal transition in the acidic pH range, whereas two independent transitions were observed in the alkaline pH range, suggesting the structural merger of the domains at the acidic pH. Comparison of the thermal transitions at pH 8.5 studied by different techniques suggests that the first transition corresponds to the smaller domain, and the second transition corresponds to the larger domain. The acid-denatured state of hexokinase A has high secondary structure content with little or no tertiary interactions and binds to the hydrophobic dye 8-anilinonaphthalene-1-sulfonic acid, suggesting that it is a molten globule-like state, whereas the alkali-denatured state is less structured than the acid-denatured state but more structured than the urea-denatured state, suggestive of a pre-molten globule-like state. Structural analysis using the published hexokinase B structure as well as the hexokinase A structure with the revised amino acid sequence in conjunction with the results obtained by us suggests that the ionization state of the acidic residues at the active site could regulate domain movements that are responsible for the opening and the closure of the cleft between the two domains and in turn affect the structure and function of the enzyme.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Bhat, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rajivbhat@mail.jnu.ac.in	Tiwari, Ashutosh/A-7458-2008	Tiwari, Ashutosh/0000-0001-7373-349X				ABE Y, 1995, J BIOCHEM-TOKYO, V118, P946, DOI 10.1093/jb/118.5.946; ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BARRIE SE, 1979, RES COMMUN CHEM PATH, V23, P375; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; Catanzano F, 1997, J BIOCHEM-TOKYO, V121, P568; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; FELDMAN I, 1978, BIOCHEMISTRY-US, V17, P1541, DOI 10.1021/bi00601a029; Filfil R, 2003, FEBS LETT, V554, P351, DOI 10.1016/S0014-5793(03)01187-6; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; Frommer WB, 2003, SCIENCE, V300, P261, DOI 10.1126/science.1084120; GarciaMoreno B, 1995, METHOD ENZYMOL, V259, P512; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GROUSELLE M, 1973, EUR J BIOCHEM, V39, P431, DOI 10.1111/j.1432-1033.1973.tb03141.x; KENAR KT, 1995, PROTEIN SCI, V4, P1934, DOI 10.1002/pro.5560040929; Kuser PR, 2000, J BIOL CHEM, V275, P20814, DOI 10.1074/jbc.M910412199; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MAGNANI M, 1985, BLOOD, V66, P690; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Neet KE, 2002, MOL CELL PROTEOMICS, V1, P415, DOI 10.1074/mcp.R200003-MCP200; OHNING GV, 1983, BIOCHEMISTRY-US, V22, P2986, DOI 10.1021/bi00281a031; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; PETERS BA, 1978, J BIOL CHEM, V253, P6826; Peters LL, 2001, BLOOD CELL MOL DIS, V27, P850, DOI 10.1006/bcmd.2001.0454; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Rami BR, 2002, BIOCHEMISTRY-US, V41, P1710, DOI 10.1021/bi0120300; RAND RP, 1993, BIOCHEMISTRY-US, V32, P5925, DOI 10.1021/bi00074a001; SCHMIDT JJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P458, DOI 10.1016/0003-9861(73)90537-7; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; SOLS A, 1958, BIOCHIM BIOPHYS ACTA, V30, P92; SORBI S, 1990, NEUROSCI LETT, V117, P165, DOI 10.1016/0304-3940(90)90138-Y; STEITZ TA, 1971, J MOL BIOL, V61, P695, DOI 10.1016/0022-2836(71)90073-8; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; VIOLA RE, 1978, BIOCHEMISTRY-US, V17, P4111, DOI 10.1021/bi00613a001; WOMACK FC, 1973, ARCH BIOCHEM BIOPHYS, V158, P451, DOI 10.1016/0003-9861(73)90536-5	42	29	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32093	32099		10.1074/jbc.M313449200	http://dx.doi.org/10.1074/jbc.M313449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145950	hybrid			2022-12-25	WOS:000222849700014
J	Page, MLD; Hamel, PP; Gabilly, ST; Zegzouti, H; Perea, JV; Alonso, JM; Ecker, JR; Theg, SM; Christensen, SK; Merchant, S				Page, MLD; Hamel, PP; Gabilly, ST; Zegzouti, H; Perea, JV; Alonso, JM; Ecker, JR; Theg, SM; Christensen, SK; Merchant, S			A homolog of prokaryotic thiol disulfide transporter CcdA is required for the assembly of the cytochrome b(6)f complex in Arabidopsis chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROME; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; ALKALINE-PHOSPHATASE; GENETIC-ANALYSIS; HEME ATTACHMENT; BIOGENESIS; PROTEIN; BIOSYNTHESIS; MEMBRANE	The c-type cytochromes are defined by the occurrence of heme covalently linked to the polypeptide via thioether bonds between heme and the cysteine sulfhydryls in the CXXCH motif of apocytochrome. Maintenance of apocytochrome sulfhydryls in a reduced state is a prerequisite for covalent ligation of heme to the CXXCH motif. In bacteria, a thiol disulfide transporter and a thioredoxin are two components in a thio-reduction pathway involved in c-type cytochrome assembly. We have identified in photosynthetic eukaryotes nucleus-encoded homologs of a prokaryotic thiol disulfide transporter, CcdA, which all display an N-terminal extension with respect to their bacterial counterparts. The extension of Arabidopsis CCDA functions as a targeting sequence, suggesting a plastid site of action for CCDA in eukaryotes. Using PhoA and LacZ as topological reporters, we established that Arabidopsis CCDA is a polytopic protein with within-membrane strictly conserved cysteine residues. Insertional mutants in the Arabidopsis CCDA gene were identified, and loss-of-function alleles were shown to impair photosynthesis because of a defect in cytochrome b(6)f accumulation, which we attribute to a block in the maturation of holocytochrome f, whose heme binding domain resides in the thylakoid lumen. We postulate that plastid cytochrome c maturation requires CCDA, thioredoxin HCF164, and other molecules in a membrane-associated trans-thylakoid thiol-reducing pathway.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA; Salk Inst Biol Studies, Genom Anal Lab, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Davis; Salk Institute	Merchant, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.	merchant@chem.ucla.edu	Ecker, Joseph R/B-9144-2008; Alonso, Jose M/K-6826-2014	Ecker, Joseph R/0000-0001-5799-5895; Alonso, Jose M/0000-0001-7087-1571; Zegzouti, Hicham/0000-0002-0989-6195	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064584] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48350, GM64584] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JWA, 2003, J BIOL CHEM, V278, P52075, DOI 10.1074/jbc.M307196200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Bardischewsky F, 2001, J BACTERIOL, V183, P257, DOI 10.1128/JB.183.1.257-263.2001; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Cocherel S, 1996, PLANT MOL BIOL, V30, P539, DOI 10.1007/BF00049330; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; Dreyfuss BW, 2003, J BIOL CHEM, V278, P2604, DOI 10.1074/jbc.M208652200; DREYFUSS BW, 1999, P 1 INT C PHOT, V4, P3139; Dubreucq B, 2000, PLANT J, V23, P643, DOI 10.1046/j.1365-313x.2000.00829.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; Erlendsson LS, 2002, J BACTERIOL, V184, P1423, DOI 10.1128/JB.184.5.1423-1429.2002; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Ferguson SJ, 2001, BIOCHEM SOC T, V29, P629, DOI 10.1042/0300-5127:0290629; GREVELDING C, 1993, PLANT MOL BIOL, V23, P847, DOI 10.1007/BF00021539; Gupta R, 2002, NATURE, V417, P567, DOI 10.1038/417567a; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hamel PP, 2003, J BIOL CHEM, V278, P2593, DOI 10.1074/jbc.M208651200; Hofmann NR, 2003, PLANT MOL BIOL, V53, P643, DOI 10.1023/B:PLAN.0000019065.31490.06; HOWE G, 1994, J BIOL CHEM, V269, P5824; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; Inoue K, 1997, J BIOL CHEM, V272, P31747, DOI 10.1074/jbc.272.50.31747; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Katzen F, 2003, P NATL ACAD SCI USA, V100, P10471, DOI 10.1073/pnas.1334136100; Kimball RA, 2003, J MOL MICROB BIOTECH, V5, P133, DOI 10.1159/000070263; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Kranz RG, 2002, RES MICROBIOL, V153, P1, DOI 10.1016/S0923-2508(01)01278-5; KRANZ RG, 1985, GENE, V40, P203, DOI 10.1016/0378-1119(85)90043-5; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; Lennartz K, 2001, PLANT CELL, V13, P2539, DOI 10.1105/tpc.13.11.2539; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Lukowitz W, 2000, PLANT PHYSIOL, V123, P795, DOI 10.1104/pp.123.3.795; Martienssen RA, 1998, P NATL ACAD SCI USA, V95, P2021, DOI 10.1073/pnas.95.5.2021; Methe BA, 2003, SCIENCE, V302, P1967, DOI 10.1126/science.1088727; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Monika EM, 1997, J MOL BIOL, V271, P679, DOI 10.1006/jmbi.1997.1227; Nakamoto SS, 2000, BIOCHIMIE, V82, P603, DOI 10.1016/S0300-9084(00)00605-2; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; NUNBERG JH, 1980, CELL, V19, P355, DOI 10.1016/0092-8674(80)90510-3; O'Brian MR, 2002, ADV MICROB PHYSIOL, V46, P257, DOI 10.1016/S0065-2911(02)46006-7; Ortenberg R, 2003, ANTIOXID REDOX SIGN, V5, P403, DOI 10.1089/152308603768295140; PAGE MD, 1989, MOL MICROBIOL, V3, P653, DOI 10.1111/j.1365-2958.1989.tb00213.x; Pollock MA, 1999, BIOTECHNIQUES, V26, P254, DOI 10.2144/99262bm16; Quinn JM, 1998, METHOD ENZYMOL, V297, P263; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SARSERO JP, 1995, J BACTERIOL, V177, P297, DOI 10.1128/jb.177.2.297-306.1995; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Tabata S, 2000, NATURE, V408, P823, DOI 10.1038/35048507; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Tissier C, 2002, EUR J BIOCHEM, V269, P3131, DOI 10.1046/j.1432-1033.2002.02943.x; Weigel M, 2003, TRENDS PLANT SCI, V8, P513, DOI 10.1016/j.tplants.2003.09.009; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1996, J BIOL CHEM, V271, P4632; Xie ZY, 1998, GENETICS, V148, P681	71	74	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32474	32482		10.1074/jbc.M404285200	http://dx.doi.org/10.1074/jbc.M404285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159384	hybrid			2022-12-25	WOS:000222849700061
J	Rosenkilde, MM; McLean, KA; Holst, PJ; Schwartz, TW				Rosenkilde, MM; McLean, KA; Holst, PJ; Schwartz, TW			The CXC chemokine receptor encoded by herpesvirus saimiri, ECRF3, shows ligand-regulated signaling through G(i), G(q), and G(12/13) proteins but constitutive signaling only through G(i) and G(12/13) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; GRANULOCYTE CHEMOTACTIC PROTEIN-2; COUPLED RECEPTOR; INVERSE AGONISTS; INTERFERON-GAMMA; IL-8 RECEPTORS; ACTIVATION; INTERLEUKIN-8; IDENTIFICATION	Open reading frame 74 (ORF74) of many gamma(2)-herpesviruses encodes a CXC chemokine receptor. The molecular pharmacological profile of ORF74 from herpesvirus saimiri, ECRF3, is characterized here and compared with that of the well known ORF74 from human herpesvirus 8 (HHV8). The ECRF3 receptor bound the so-called ELR (Glu-Leu-Arg) CXC chemokines I-125-CXCL1/GROalpha, I-125-CXCL6/GCP-2, and I-125-CXCL8/interleukin-8 with high affinity; but in contrast to ORF74 from HHV8, it did not bind the non-ELR CXC chemokine I-125-CXCL10/IP10. Interestingly, the B-max value for CXCL6/GCP-2 was 3-fold higher than the capacity for maximal binding of CXCL1/GROalpha to ECRF3 and 85-fold higher than that of CXCL8/interleukin-8, despite similar affinities. Like ORF74 from HHV8, ECRF3 activated a broad range of pathways (G(q), G(i), and G(12/13) as well as the cAMP response element-binding protein, NF-kappaB, NFAT, and serum response element transcription factors) in a ligand-regulated manner, with CXCL6/GCP-2 being the most potent and efficacious agonist. ECRF3 signaled constitutively through G(i) and G(12/13), but surprisingly not through G(q). At the level of transcription factor activation, the serum response element was activated constitutively by ECRF3, whereas cAMP response element-binding protein, NFAT, and NF-kappaB were only ligand-regulated. The maximal signaling capacities were similar for the two receptors; however, the ligand-regulated signaling was responsible for the major part of the total ECRF3 signaling and only for a minor part of the total HHV8 ORF74 signaling. The activation pattern of ECRF3 with constitutive activation of some ( but not all) of the employed pathways has not been seen before in endogenous or virus-encoded chemokine receptors. The results suggest that the unique ligand selectivity of ECRF3 among ORF74 receptors could reflect differences in the cellular tropism of the gamma(2)-herpesviruses.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	rosenkilde@molpharm.dk		Holst, Peter Johannes/0000-0002-1279-304X; Schwartz, Thue W./0000-0002-0261-6904; Rosenkilde, Mette Marie/0000-0001-9600-3254				Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alewijnse AE, 1998, J NEUROCHEM, V71, P799; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Casarosa P, 2003, J BIOL CHEM, V278, P50010, DOI 10.1074/jbc.M306530200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen G, 1999, J PHARMACOL TOX MET, V42, P199, DOI 10.1016/S1056-8719(00)00075-7; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Feniger-Barish R, 1999, CYTOKINE, V11, P996, DOI 10.1006/cyto.1999.0510; Feniger-Barish R, 2000, BLOOD, V95, P1551, DOI 10.1182/blood.V95.5.1551.005a36_1551_1559; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GAO JL, 1994, J BIOL CHEM, V269, P28539; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; Hill Stephen J., 2001, Current Opinion in Pharmacology, V1, P526, DOI 10.1016/S1471-4892(01)00091-1; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Liu Bo, 2003, V237, P145; Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Moorman NJ, 2003, VIROLOGY, V307, P179, DOI 10.1016/S0042-6822(02)00023-5; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Rabin RL, 1999, J IMMUNOL, V162, P3840; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; ROSENKILDE MM, 2004, HDB CELL SIGNALING; SCHWARTZ TW, 2003, TXB RECEPTOR PHARM, P81; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Sodhi A, 2000, CANCER RES, V60, P4873; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Verzijl D, 2004, J VIROL, V78, P3343, DOI 10.1128/JVI.78.7.3343-3351.2004; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Wolf M, 1998, EUR J IMMUNOL, V28, P164, DOI 10.1002/(SICI)1521-4141(199801)28:01<164::AID-IMMU164>3.0.CO;2-S; Wong SKF, 2003, NEUROSIGNALS, V12, P1, DOI 10.1159/000068914; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P1811; Wuyts A, 1998, EUR J BIOCHEM, V255, P67, DOI 10.1046/j.1432-1327.1998.2550067.x; Wuyts A, 2003, LAB INVEST, V83, P23, DOI 10.1097/01.LAB.0000048719.53282.00; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	68	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32524	32533		10.1074/jbc.M313392200	http://dx.doi.org/10.1074/jbc.M313392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155729	hybrid			2022-12-25	WOS:000222849700067
J	Toogood, HS; van Thiel, A; Basran, J; Sutcliffe, MJ; Scrutton, NS; Leys, D				Toogood, HS; van Thiel, A; Basran, J; Sutcliffe, MJ; Scrutton, NS; Leys, D			Extensive domain motion and electron transfer in the human electron transferring flavoprotein center dot medium chain acyl-CoA dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACID BETA-OXIDATION; MOLECULAR PATHOGENESIS; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURES; STRUCTURAL BASIS; CROSS-LINKING; DEFICIENCY; MUTATIONS; GENE	The crystal structure of the human electron transferring flavoprotein (ETF).medium chain acyl-CoA dehydrogenase ( MCAD) complex reveals a dual mode of protein-protein interaction, imparting both specificity and promiscuity in the interaction of ETF with a range of structurally distinct primary dehydrogenases. ETF partitions the functions of partner binding and electron transfer between (i) the recognition loop, which acts as a static anchor at the ETF.MCAD interface, and (ii) the highly mobile redox active FAD domain. Together, these enable the FAD domain of ETF to sample a range of conformations, some compatible with fast interprotein electron transfer. Disorders in amino acid or fatty acid catabolism can be attributed to mutations at the protein-protein interface. Crucially, complex formation triggers mobility of the FAD domain, an induced disorder that contrasts with general models of protein-protein interaction by induced fit mechanisms. The subsequent interfacial motion in the MCAD.ETF complex is the basis for the interaction of ETF with structurally diverse protein partners. Solution studies using ETF and MCAD with mutations at the protein-protein interface support this dynamic model and indicate ionic interactions between MCAD Glu(212) and ETF Argalpha(249) are likely to transiently stabilize productive conformations of the FAD domain leading to enhanced electron transfer rates between both partners.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Leys, D (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	dl37@le.ac.uk		Toogood, Helen/0000-0003-4797-0293; Sutcliffe, Mike/0000-0003-0414-1700				Bartlett K, 2004, EUR J BIOCHEM, V271, P462, DOI 10.1046/j.1432-1033.2003.03947.x; BECKMANN JD, 1983, J BIOL CHEM, V258, P7563; Busquets C, 2000, PEDIATR RES, V48, P315, DOI 10.1203/00006450-200009000-00009; Busquets C, 2000, MOL GENET METAB, V71, P535, DOI 10.1006/mgme.2000.3082; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; Chohan KK, 2001, J BIOL CHEM, V276, P34142, DOI 10.1074/jbc.M101341200; Collins ES, 2002, J MOL BIOL, V318, P787, DOI 10.1016/S0022-2836(02)00036-0; Corydon MJ, 2001, PEDIATR RES, V49, P18; Curcoy A, 2003, MOL GENET METAB, V78, P247, DOI 10.1016/S1096-7192(03)00024-6; DWYER TM, 1997, BIOCHIM BIOPHYS ACTA, V1433, P139; Feng CJ, 2002, BIOCHEMISTRY-US, V41, P5816, DOI 10.1021/bi016059f; FRERMAN FE, 1980, J BIOL CHEM, V255, P2199; Goodman SI, 2002, MOL GENET METAB, V77, P86, DOI 10.1016/S1096-7192(02)00138-5; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Gregersen N, 2004, EUR J BIOCHEM, V271, P470, DOI 10.1046/j.1432-1033.2003.03949.x; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Gutierrez A, 2002, BIOCHEMISTRY-US, V41, P4626, DOI 10.1021/bi0159433; Hoard-Fruchey HM, 2004, J BIOL CHEM, V279, P13786, DOI 10.1074/jbc.M313914200; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; Jacobs DM, 2003, J BIOL CHEM, V278, P26174, DOI 10.1074/jbc.M300796200; Kim JJP, 2004, EUR J BIOCHEM, V271, P483, DOI 10.1046/j.1432-1033.2003.03948.x; Kim JJP, 2002, CURR OPIN STRUC BIOL, V12, P721, DOI 10.1016/S0959-440X(02)00390-1; Knofel T, 2001, J MOL BIOL, V309, P255, DOI 10.1006/jmbi.2001.4657; Koeller DM, 2002, HUM MOL GENET, V11, P347, DOI 10.1093/hmg/11.4.347; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; Leys D, 2003, NAT STRUCT BIOL, V10, P219, DOI 10.1038/nsb894; Leys D, 2003, EMBO J, V22, P4038, DOI 10.1093/emboj/cdg395; Liu JF, 2002, J MOL BIOL, V322, P53, DOI 10.1016/S0022-2836(02)00736-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OKAMURAIKEDA K, 1985, J BIOL CHEM, V260, P1338; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; Parker AR, 2003, MOL CELL BIOCHEM, V254, P91, DOI 10.1023/A:1027349303797; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; Salazar D, 1997, J BIOL CHEM, V272, P26425, DOI 10.1074/jbc.272.42.26425; STEENKAMP DJ, 1988, BIOCHEM J, V255, P869, DOI 10.1042/bj2550869; STEENKAMP DJ, 1987, BIOCHEM J, V243, P519, DOI 10.1042/bj2430519; Takusa Y, 2002, MOL GENET METAB, V75, P227, DOI 10.1006/mgme.2002.3297; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	48	75	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32904	32912		10.1074/jbc.M404884200	http://dx.doi.org/10.1074/jbc.M404884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159392	hybrid			2022-12-25	WOS:000222849700110
J	Chen, XM; Splinter, PL; Tietz, PS; Huang, BQ; Billadeau, DD; LaRusso, NF				Chen, XM; Splinter, PL; Tietz, PS; Huang, BQ; Billadeau, DD; LaRusso, NF			Phosphatidylinositol 3-kinase and frabin mediate Cryptosporidium parvum cellular invasion via activation of Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; SMALL G-PROTEIN; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; MICROSPIKE FORMATION; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; BINDING; BILIARY; RAC	Cryptosporidium parvum invades target epithelia via a mechanism that involves host cell actin reorganization. We previously demonstrated that C. parvum activates the Cdc42/neural Wiskott-Aldrich syndrome protein network in host cells resulting in actin remodeling at the host cell-parasite interface, thus facilitating C. parvum cellular invasion. Here, we tested the role of phosphatidylinositol 3-kinase (PI3K) and frabin, a guanine nucleotide exchange factor specific for Cdc42 in the activation of Cdc42 during C. parvum infection of biliary epithelial cells. We found that C. parvum infection of cultured human biliary epithelial cells induced the accumulation of PI3K at the host cell-parasite interface and resulted in the activation of PI3K in infected cells. Frabin also was recruited to the host cell-parasite interface, a process inhibited by two PI3K inhibitors, wortmannin and LY294002. The cellular expression of either a dominant negative mutant of PI3K (PI3K-Deltap85) or functionally deficient mutants of frabin inhibited C. parvum-induced Cdc42 accumulation at the host cell-parasite interface. Moreover, LY294002 abolished C. parvum-induced Cdc42 activation in infected cells. Inhibition of PI3K by cellular overexpression of PI3K-Deltap85 or by wortmannin or LY294002, as well as inhibition of frabin by various functionally deficient mutants, decreased C. parvum-induced actin accumulation and inhibited C. parvum cellular invasion. In contrast, the overexpression of the p85 subunit of PI3K promoted C. parvum invasion. Our data suggest that an important component of the complex process of C. parvum invasion of target epithelia results from the ability of the organism to trigger host cell PI3K/frabin signaling to activate the Cdc42 pathway, resulting in host cell actin remodeling at the host cell-parasite interface.	Mayo Med Sch Clin & Fdn, Div Gastroenterol & Hepatol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Med Sch Clin & Fdn, Dept Immunol, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	LaRusso, NF (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.	larusso.nicholas@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024031, R37DK024031, R01DK057993] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK24031, DK57993] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen XM, 2000, GASTROENTEROLOGY, V118, P368, DOI 10.1016/S0016-5085(00)70219-8; Chen XM, 2004, INFECT IMMUN, V72, P3011, DOI 10.1128/IAI.72.5.3011-3021.2004; Chen XM, 2002, NEW ENGL J MED, V346, P1723, DOI 10.1056/NEJMra013170; Chen XM, 2003, GASTROENTEROLOGY, V125, P216, DOI 10.1016/S0016-5085(03)00662-0; Clark DP, 1999, CLIN MICROBIOL REV, V12, P554, DOI 10.1128/CMR.12.4.554; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Elliott DA, 2001, INFECT IMMUN, V69, P5940, DOI 10.1128/IAI.69.9.5940-5942.2001; Elliott DA, 2000, INFECT IMMUN, V68, P2315, DOI 10.1128/IAI.68.4.2315-2322.2000; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Forney JR, 1999, INFECT IMMUN, V67, P844, DOI 10.1128/IAI.67.2.844-852.1999; GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060, DOI 10.1152/ajpgi.1994.266.6.G1060; Gruenheid S, 2003, NATURE, V422, P775, DOI 10.1038/nature01603; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Ikeda W, 2001, ONCOGENE, V20, P3457, DOI 10.1038/sj.onc.1204463; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Jackson TR, 1996, J CELL SCI, V109, P289; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Martinez JJ, 2002, CELL MICROBIOL, V4, P19, DOI 10.1046/j.1462-5822.2002.00166.x; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tzipori S, 1998, ADV PARASIT, V40, P5, DOI 10.1016/S0065-308X(08)60116-5; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Wilkowsky SE, 2001, EXP CELL RES, V264, P211, DOI 10.1006/excr.2000.5123; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	39	46	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31671	31678		10.1074/jbc.M401592200	http://dx.doi.org/10.1074/jbc.M401592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133042	hybrid			2022-12-25	WOS:000222726800092
J	Cherukuri, A; Carter, RH; Brooks, S; Bornmann, W; Finn, R; Dowd, CS; Pierce, SK				Cherukuri, A; Carter, RH; Brooks, S; Bornmann, W; Finn, R; Dowd, CS; Pierce, SK			B cell signaling is regulated by induced palmitoylation of CD81	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; LIPID RAFTS; ANTIGEN RECEPTOR; SACCHAROMYCES-CEREVISIAE; ENRICHED MICRODOMAINS; MEMBRANE MICRODOMAIN; TETRASPANIN PROTEINS; CD19/CD21 COMPLEX; ANCHORED PROTEINS; FATTY-ACIDS	Signaling through the B cell antigen receptor (BCR) is amplified and prolonged by coligation of the BCR to the CD19/CD21/CD81 coreceptor complex. Coligation is induced during immune responses by the simultaneous binding of complement-tagged antigens to the complement receptor, CD21, and to the BCR. Enhanced signaling is due in part to the ability of the CD19/CD21/CD81 complex to stabilize the BCR in sphingolipid- and cholesterol-rich membrane microdomains termed lipid rafts. The tetraspanin CD81 is essential for the raft-stabilizing function of the coreceptor. Here we show that coligation of the BCR and the CD19/CD21/CD81 complex leads to selective, rapid, and reversible palmitoylation of CD81 and that palmitoylation is necessary for the raft stabilizing function of the CD19/CD21/CD81 complex. Inducible palmitoylation may represent a novel mechanism by which tetraspanins function to facilitate lipid raft-dependent receptor signaling.	NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Univ Alabama, Dept Med & Microbiol, Birmingham, AL 35294 USA; Mem Sloan Kettering Canc Ctr, Radiochem Core Facil, New York, NY 10021 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Alabama System; University of Alabama Birmingham; Memorial Sloan Kettering Cancer Center	Pierce, SK (corresponding author), NIAID, Immunogenet Lab, NIH, Twinbrook 2,12441 Parklawn Dr,Rm 200B,MSC 8180, Rockville, MD 20852 USA.	spierce@nih.gov						Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Berditchevski F, 2002, J BIOL CHEM, V277, P36991, DOI 10.1074/jbc.M205265200; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brooks SR, 2000, J IMMUNOL, V164, P3123, DOI 10.4049/jimmunol.164.6.3123; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Charrin S, 2002, FEBS LETT, V516, P139, DOI 10.1016/S0014-5793(02)02522-X; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cherukuri A, 2004, J IMMUNOL, V172, P370, DOI 10.4049/jimmunol.172.1.370; Cherukuri A, 2001, IMMUNITY, V14, P169; Clark KL, 2004, J BIOL CHEM, V279, P19401, DOI 10.1074/jbc.M312626200; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Gidwani A, 2001, BIOCHEMISTRY-US, V40, P12422, DOI 10.1021/bi010496c; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; KNAPP FF, 1984, J MED CHEM, V27, P94, DOI 10.1021/jm00367a021; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Maecker HT, 2000, HYBRIDOMA, V19, P15, DOI 10.1089/027245700315752; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; MASON DY, 1991, J IMMUNOL, V147, P2474; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Micchelli CA, 2002, DEVELOPMENT, V129, P843; Nakao F, 2002, CIRC RES, V91, P953, DOI 10.1161/01.RES.0000042702.04920.BF; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Weintraub BC, 2000, J EXP MED, V191, P1443, DOI 10.1084/jem.191.8.1443; Yang XW, 2002, MOL BIOL CELL, V13, P767, DOI 10.1091/mbc.01-05-0275; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	51	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31973	31982		10.1074/jbc.M404410200	http://dx.doi.org/10.1074/jbc.M404410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15161911	hybrid			2022-12-25	WOS:000222726800126
J	Gasol, E; Jimenez-Vidal, M; Chillaron, J; Zorzano, A; Palacin, M				Gasol, E; Jimenez-Vidal, M; Chillaron, J; Zorzano, A; Palacin, M			Membrane topology of system x(c)(-) light subunit reveals a re-entrant loop with substrate-restricted accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; HUMAN XCT; GLUTAMATE; CYSTINE; EXPRESSION; RESIDUES; CHANNEL; CLONING; IDENTIFICATION	Heteromeric amino acid transporters are composed of a heavy and a light subunit linked by a disulfide bridge. 4F2hc/xCT elicits sodium-independent exchange of anionic L-cysteine and L-glutamate (system x(c)(-)). Based on the accessibility of single cysteines to 3-(N-maleimidylpropionyl) biocytin, we propose a topological model for xCT of 12 transmembrane domains with the N and C termini located inside the cell. This location of N and C termini was confirmed by immunofluorescence. Studies of biotinylation and accessibility to sulfhydryl reagents revealed a re-entrant loop within intracellular loops 2 and 3. Residues His(110) and Thr(112), facing outside, are located at the apex of the re-entrant loop. Biotinylation of H110C was blocked by xCT substrates, by the nontransportable inhibitor (S)-4-carboxyphenylglycine, and by the impermeable reagent (2-sulfonatoethyl) methanethiosulfonate, which produced an inactivation of H110C that was protected by L-glutamate and L-cysteine with an IC50 similar to the K-m. Protection was temperature-independent. The data indicate that His110 may lie close to the substrate binding/permeation pathway of xCT. The membrane topology of xCT could serve as a model for other light subunits of heteromeric amino acid transporters.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Inst Recerca Oncol, Med & Mol Genet Ctr, E-08028 Barcelona, Spain	University of Barcelona	Palacin, M (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.	mpalacin@bio.ub.es	Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Chillaron, Josep/ABF-7663-2021	Chillaron, Josep/0000-0003-3068-7598; Palacin, Manuel/0000-0002-8670-293X				Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BANNAI S, 1989, J BIOL CHEM, V264, P18480; Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; Boado RJ, 2003, J NEUROCHEM, V84, P1322, DOI 10.1046/j.1471-4159.2003.01622.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Font M, 2001, HUM MOL GENET, V10, P305, DOI 10.1093/hmg/10.4.305; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Jimenez-Vidal M, 2004, J BIOL CHEM, V279, P11214, DOI 10.1074/jbc.M309866200; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Krom BP, 2003, BIOCHEMISTRY-US, V42, P467, DOI 10.1021/bi026874a; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Patel SA, 2004, NEUROPHARMACOLOGY, V46, P273, DOI 10.1016/j.neuropharm.2003.08.006; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; PIANI D, 1994, J IMMUNOL, V152, P3578; Pineda M, 2004, BIOCHEM J, V377, P665, DOI 10.1042/BJ20030956; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Shigekawa M, 2002, ANN NY ACAD SCI, V976, P19; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Wang HY, 2003, BIOCHEM BIOPH RES CO, V305, P611, DOI 10.1016/S0006-291X(03)00808-8	41	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31228	31236		10.1074/jbc.M402428200	http://dx.doi.org/10.1074/jbc.M402428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151999	hybrid			2022-12-25	WOS:000222726800042
J	Golabek, AA; Wujek, P; Walus, M; Bieler, S; Soto, C; Wisniewski, KE; Kida, E				Golabek, AA; Wujek, P; Walus, M; Bieler, S; Soto, C; Wisniewski, KE; Kida, E			Maturation of human tripeptidyl-peptidase I in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PEPSTATIN-INSENSITIVE PROTEINASE; HUMAN PROCATHEPSIN-B; LYSOSOMAL PH; GENE-PRODUCT; CELLS; ACIDIFICATION; PROPEPTIDE; ENZYMES; CLN2	Tripeptidyl-peptidase I (TPP I, CLN2 protein) is a lysosomal aminopeptidase that cleaves off tripeptides from the free N termini of oligopeptides and also shows minor endopeptidase activity. TPP I is synthesized as a preproenzyme. Its proenzyme autoactivates under acidic conditions in vitro, resulting in a rapid conversion into the mature form. In this study, we examined the process of maturation in vitro of recombinant latent human TPP I purified to homogeneity from secretions of Chinese hamster ovary cells overexpressing TPP I cDNA. Autoprocessing of TPP I proenzyme was carried out at a wide pH range, from similar to 2.0 to 6.0, albeit with different efficiencies depending on the pH and the type of buffer. However, the acquisition of enzymatic activity in the same buffer took place in a narrower pH "window," usually in the range of 3.6 - 4.2. N-terminal sequencing revealed that mature, inactive enzyme generated during autoactivation at higher pH contained N-terminal extensions ( starting at 6 and 14 amino acid residues upstream of the prosegment/mature enzyme junction), which could contribute to the lack of activity of TPP I generated in this manner. Autoprocessing was not associated with any major changes of the secondary structure of the proenzyme, as revealed by CD spectroscopy. Both the activation and proteolytic processing of the recombinant TPP I precursor were primarily concentration-independent. The addition of the mature enzyme did not accelerate the processing of the proenzyme. In addition, the maturation of the proenzyme was not affected by the presence of glycerol. Finally, the proenzyme with the active site mutated (S475L) was not processed in the presence of the wild-type enzyme. All of these findings indicate a primarily intramolecular (unimolecular) mechanism of TPP I activation and autoprocessing and suggest that in vivo mature enzyme does not significantly participate in its own generation from the precursor.	New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA; Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA	Institute for Basic Research in Developmental Disabilities; University of Texas System; University of Texas Medical Branch Galveston	Golabek, AA (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	a.golabek@att.net						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BUTOR C, 1995, J CELL SCI, V108, P2213; Chen CS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-21; Comellas-Bigler M, 2002, STRUCTURE, V10, P865, DOI 10.1016/S0969-2126(02)00772-4; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; Golabek AA, 2000, MOL GENET METAB, V70, P203, DOI 10.1006/mgme.2000.3006; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu ZX, 1996, J BIOL CHEM, V271, P3375; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Junaid MA, 2000, INT J BIOL MARKER, V15, P129, DOI 10.1177/172460080001500201; Khan AR, 1998, PROTEIN SCI, V7, P815; Kida E, 2001, ADV GENET, V45, P35, DOI 10.1016/S0065-2660(01)45003-6; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; Kurachi Y, 2001, ACTA NEUROPATHOL, V102, P20; Lamango NS, 1999, ARCH BIOCHEM BIOPHYS, V362, P275, DOI 10.1006/abbi.1998.1033; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Liu CG, 1998, GENOMICS, V50, P206, DOI 10.1006/geno.1998.5328; MACH L, 1994, J BIOL CHEM, V269, P13030; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MONTCOURRIER P, 1994, J CELL SCI, V107, P2381; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; TAKEDAEZAKI M, 1993, ARCH BIOCHEM BIOPHYS, V304, P352, DOI 10.1006/abbi.1993.1361; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; VANDYKE RW, 1992, BIOCHEM BIOPH RES CO, V184, P300, DOI 10.1016/0006-291X(92)91192-S; Vergne I, 1998, ANAL BIOCHEM, V255, P127, DOI 10.1006/abio.1997.2466; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Wisniewski K E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P73, DOI 10.1053/ejpn.2000.0439; Wisniewski KE, 2001, ADV GENET, V45, P1, DOI 10.1016/S0065-2660(01)45002-4; Wisniewski KE, 1999, MOL GENET METAB, V66, P248, DOI 10.1006/mgme.1999.2814; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	47	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31058	31067		10.1074/jbc.M400700200	http://dx.doi.org/10.1074/jbc.M400700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143070	hybrid			2022-12-25	WOS:000222726800020
J	Hua, W; Zhang, L; Liang, SP; Jones, RL; Lu, YT				Hua, W; Zhang, L; Liang, SP; Jones, RL; Lu, YT			A tobacco calcium/calmodulin-binding protein kinase functions as a negative regulator of flowering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN ISOFORMS; CALCIUM-CALMODULIN; FLORAL INITIATION; SENSITIVE METHOD; DNA METHYLATION; TARGET GENES; ARABIDOPSIS; PLANT; TIME; EXPRESSION	A tobacco calcium/calmodulin-binding protein kinase (NtCBK1) was isolated and identified. The predicted NtCBK1 protein has 599 amino acids, an N-terminal kinase domain, and shares high homology with other calmodulin (CaM)-related kinases. Whereas NtCBK1 phosphorylates itself and substrates such as histone IIIS and syntide-2 in the absence of CaM, its kinase activity can be stimulated by tobacco CaMs. However, unlike another tobacco protein kinase designated NtCBK2, NtCBK1 was not differentially regulated by the different CaM isoforms tested. The CaM-binding domain of NtCBK1 was located between amino acids 436 and 455, and this domain was shown to be necessary for CaM modulation of kinase activity. RNA in situ hybridization showed that NtCBK1 was highly regulated in the transition to flowering. Whereas NtCBK1 mRNA was accumulated in the shoot apical meristem during vegetative growth, its expression was dramatically decreased in the shoot apical meristem after floral determination, and in young flower primordia. The expression of NtCBK1 was up-regulated to high levels in floral organ primordia. Fluctuations in NtCBK1 expression were verified by analysis of tobacco plants expressing green fluorescent protein under the control of the NtCBK1 promoter, suggesting a role of NtCBK1 in the transition to flowering. This conclusion was confirmed by overexpressing NtCBK1 in transgenic tobacco plants, where maintenance of high levels of NtCBK1 in the shoot apical meristem delayed the switch to flowering and extended the vegetative phase of growth. Further work indicated that overexpression of NtCBK1 in transgenic tobacco did not affect the expression of NFL, a tobacco homologue of the LFY gene that controls meristem initiation and floral structure in tobacco. In addition, the promotion of tobacco flowering time by DNA demethylation cannot be blocked by the overexpression of NtCBK1.	Wuhan Univ, Coll Life Sci, Key Lab MOE Plant Dev Biol, Wuhan 430072, Peoples R China; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	Wuhan University; University of California System; University of California Berkeley	Lu, YT (corresponding author), Wuhan Univ, Coll Life Sci, Key Lab MOE Plant Dev Biol, Wuhan 430072, Peoples R China.	yingtlu@whu.edu.cn						Ahearn KP, 2001, PLANT CELL PHYSIOL, V42, P1130, DOI 10.1093/pcp/pce143; Aitken A, 2002, PROTEIN PROTOCOLS HD, P41; Amaya I, 1999, PLANT CELL, V11, P1405, DOI 10.1105/tpc.11.8.1405; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; Blazquez MA, 2000, NATURE, V404, P889, DOI 10.1038/35009125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Choi JY, 2002, J BIOL CHEM, V277, P21630, DOI 10.1074/jbc.M110803200; DREWS GN, 1995, FIXATION EMBEDDING I; Finnegan EJ, 1998, P NATL ACAD SCI USA, V95, P5824, DOI 10.1073/pnas.95.10.5824; Finnegan EJ, 2000, CURR OPIN GENET DEV, V10, P217, DOI 10.1016/S0959-437X(00)00061-7; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HEMPEL FD, 1995, PLANT J, V8, P725, DOI 10.1046/j.1365-313X.1995.08050725.x; Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297; Hua W, 2003, BIOCHEM J, V376, P291, DOI 10.1042/BJ20030736; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liang SP, 2001, SCI CHINA SER C, V44, P506, DOI 10.1007/BF02882393; LINDZEN E, 1995, PLANT MOL BIOL, V28, P785, DOI 10.1007/BF00042065; Liu BF, 2001, J CHROMATOGR A, V918, P401, DOI 10.1016/S0021-9673(01)00741-5; Liu ZH, 1998, PLANT MOL BIOL, V38, P889, DOI 10.1023/A:1006019001200; Lizal P, 2001, PHYSIOL PLANTARUM, V113, P121, DOI 10.1034/j.1399-3054.2001.1130116.x; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; Lu YT, 1996, PLANTA, V199, P18; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McDaniel CN, 1996, J EXP BOT, V47, P465, DOI 10.1093/jxb/47.4.465; MCDANIEL CN, 1989, AM J BOT, V76, P403, DOI 10.2307/2444610; Mouradov A, 2002, PLANT CELL, V14, pS111, DOI 10.1105/tpc.001362; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pandey S, 2001, J EXP BOT, V52, P691, DOI 10.1093/jexbot/52.357.691; Pnueli L, 2001, PLANT CELL, V13, P2687, DOI 10.1105/tpc.13.12.2687; Poovaiah BW, 1999, PLANTA, V209, P161, DOI 10.1007/s004250050618; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; Reddy VS, 1999, J BIOL CHEM, V274, P31727, DOI 10.1074/jbc.274.44.31727; Reddy VS, 2002, J BIOL CHEM, V277, P9840, DOI 10.1074/jbc.M111626200; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Schenk PW, 1999, BBA-MOL CELL RES, V1449, P1, DOI 10.1016/S0167-4889(98)00178-5; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; Simpson GG, 2002, SCIENCE, V296, P285, DOI 10.1126/science.296.5566.285; SINGER SR, 1987, P NATL ACAD SCI USA, V84, P2790, DOI 10.1073/pnas.84.9.2790; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Sugano S, 1999, P NATL ACAD SCI USA, V96, P12362, DOI 10.1073/pnas.96.22.12362; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Wang L, 2001, PLANTA, V213, P556, DOI 10.1007/s004250100540; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; Yamakawa H, 2001, EUR J BIOCHEM, V268, P3916, DOI 10.1046/j.1432-1327.2001.02301.x; Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077; Zhang L, 2003, TRENDS PLANT SCI, V8, P123, DOI 10.1016/S1360-1385(03)00013-X; Zhang L, 2002, BIOCHEM J, V368, P145, DOI 10.1042/BJ20020780	57	31	36	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31483	31494		10.1074/jbc.M402861200	http://dx.doi.org/10.1074/jbc.M402861200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138273	hybrid			2022-12-25	WOS:000222726800071
J	Jeon, HK; Jin, HS; Lee, DH; Choi, WS; Moon, CK; Oh, YJ; Lee, TH				Jeon, HK; Jin, HS; Lee, DH; Choi, WS; Moon, CK; Oh, YJ; Lee, TH			Proteome analysis associated with cadmium adaptation in U937 cells - Identification of calbindin-D-28k as a secondary cadmium-responsive protein that confers resistance to cadmium-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; EPITHELIAL-CELLS; OXIDANT RESISTANCE; BINDING PROTEIN; PC12 CELLS; EXPRESSION; DEATH; EXPOSURE; INHIBITION; ACTIVATION	Cadmium is a well known environmental toxicant and carcinogen. To identify proteins involved in cellular adaptive responses to cadmium, we established cadmium-adapted U937 cells that exhibit resistance to cadmium-induced apoptosis, and we performed comparative proteome analysis of these cells with parental cells that were either untreated or treated with cadmium. Newly identified proteins that were changed in expression level in both adapted cells and cadmium-treated parental cells included proteins implicated in cell proliferation and malignant transformation. Most interesting, a calcium-binding protein calbindin-D-28k was increased only in the adapted cells but not in cadmium-exposed parental cells. The level of calbindin-D-28k increased by the degree of cadmium adaptation and was stably maintained without selective pressure of cadmium. Cadmium-adapted U937 cells were resistant to the toxic effects of cytosolic calcium rise by cadmium treatment and by depletion of intracellular calcium stores, suggesting that enhanced calcium buffering by up-regulated calbindin-D-28k may be responsible for acquiring resistance to cadmium-induced apoptosis. We demonstrated that overexpression of calbindin-D-28k in MN9D neuronal cells resulted in reduced cadmium-induced apoptosis. Our study documents for the first time that cells respond to long term cadmium exposure by increasing calbindin-D-28k expression, thereby attenuating cadmium-induced apoptosis.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; Seoul Natl Univ, Coll Pharm, Seoul 110799, South Korea	Yonsei University; Yonsei University; Seoul National University (SNU)	Lee, TH (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	thlee@yonsei.ac.kr		jin, hyung-seung/0000-0002-3186-3488				Achanzar WE, 2002, PROSTATE, V52, P236, DOI 10.1002/pros.10106; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Beyersmann D, 1997, TOXICOL APPL PHARM, V144, P247, DOI 10.1006/taap.1997.8125; Castro CY, 2000, MODERN PATHOL, V13, P808, DOI 10.1038/modpathol.3880141; Choi WS, 2001, BIOCHEM BIOPH RES CO, V287, P656, DOI 10.1006/bbrc.2001.5649; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Eneman JD, 2000, TOXICOLOGY, V147, P215, DOI 10.1016/S0300-483X(00)00215-8; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; Habeebu SSM, 1998, TOXICOL APPL PHARM, V149, P203, DOI 10.1006/taap.1997.8334; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; HART BA, 1995, TOXICOLOGY, V98, P1, DOI 10.1016/0300-483X(94)02949-U; Hart BA, 1995, TOXICOL LETT, V81, P131, DOI 10.1016/0378-4274(95)03417-X; Hart BA, 1999, TOXICOLOGY, V133, P43, DOI 10.1016/S0300-483X(99)00013-X; INGERSOLL RJ, 1971, J BIOL CHEM, V246, P2808; Ishido Masami, 1995, Life Sciences, V56, P351; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Joseph P, 2001, TOXICOL SCI, V61, P295, DOI 10.1093/toxsci/61.2.295; Joseph P, 2002, CANCER RES, V62, P703; Joseph P, 2002, J BIOL CHEM, V277, P6131, DOI 10.1074/jbc.M109373200; Kanthasamy AG, 1995, TOXICOL LETT, V81, P151, DOI 10.1016/0378-4274(95)03425-0; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kim MS, 2000, TOXICOLOGY, V145, P27, DOI 10.1016/S0300-483X(99)00176-6; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; Lopez E, 2003, BRIT J PHARMACOL, V138, P901, DOI 10.1038/sj.bjp.0705111; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; McMahon A, 1998, MOL BRAIN RES, V54, P56, DOI 10.1016/S0169-328X(97)00305-7; Misra UK, 2003, CELL SIGNAL, V15, P1059, DOI 10.1016/S0898-6568(03)00117-7; Misra UK, 2002, CELL SIGNAL, V14, P327, DOI 10.1016/S0898-6568(01)00268-6; MORSELT AFW, 1991, TOXICOLOGY, V70, P1; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, P1; PETERS JM, 1995, TOXICOLOGY, V99, P11, DOI 10.1016/0300-483X(94)02989-8; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; Rabinovitch A, 2001, ENDOCRINOLOGY, V142, P3649, DOI 10.1210/en.142.8.3649; Rintoul GL, 2001, CELL CALCIUM, V29, P277, DOI 10.1054/ceca.2000.0190; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shen HM, 2001, TOXICOL APPL PHARM, V171, P12, DOI 10.1006/taap.2000.9092; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Wright JL, 2003, EUR RESPIR J, V22, P77, DOI 10.1183/09031936.03.00095703; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L	49	13	13	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31575	31583		10.1074/jbc.M400823200	http://dx.doi.org/10.1074/jbc.M400823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152011	hybrid			2022-12-25	WOS:000222726800080
J	Ohtaki, A; Mizuno, M; Tonozuka, T; Sakano, Y; Kamitori, S				Ohtaki, A; Mizuno, M; Tonozuka, T; Sakano, Y; Kamitori, S			Complex structures of Thermoactinomyces vulgaris R-47 alpha-amylase 2 with acarbose and cyclodextrins demonstrate the multiple substrate recognition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURES; ALPHA-AMYLASE; 3-DIMENSIONAL STRUCTURE; MALTOGENIC AMYLASE; CRYSTAL-STRUCTURE; KINETIC ANALYSES; BINDING; TVAII; ENZYME; CYCLOMALTODEXTRINASE	Thermoactinomyces vulgaris R-47 alpha-amylase 2 (TVAII) has the unique ability to hydrolyze cyclodextrins (CDs), with various sized cavities, as well as starch. To understand the relationship between structure and substrate specificity, x-ray structures of a TVAII-acarbose complex and inactive mutant TVAII (D325N/D421N)/alpha-, beta- and gamma-CDs complexes were determined at resolutions of 2.9, 2.9, 2.8, and 3.1 Angstrom, respectively. In all complexes, the interactions between ligands and enzymes at subsites - 1, - 2, and - 3 were almost the same, but striking differences in the catalytic site structure were found at subsites + 1 and + 2, where Trp(356) and Tyr(374) changed the conformation of the side chain depending on the structure and size of the ligands. Trp(356) and Tyr(374) are thought to be responsible for the multiple substrate-recognition mechanism of TVAII, providing the unique substrate specificity. In the beta-CD complex, the beta-CD maintains a regular conical structure, making it difficult for Glu(354) to protonate the O-4 atom at the hydrolyzing site as a previously proposed hydrolyzing mechanism of alpha-amylase. From the x-ray structures, it is suggested that the protonation of the O-4 atom is possibly carried out via a hydrogen atom of the inter-glucose hydrogen bond at the hydrolyzing site.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo 1838509, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology	Kamitori, S (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	kamitori@cc.tuat.ac.jp	Tonozuka, Takashi/D-2268-2013	Tonozuka, Takashi/0000-0002-5422-7548; Kamitori, Shigehiro/0000-0002-3950-3372				Abe A, 2004, J MOL BIOL, V335, P811, DOI 10.1016/j.jmb.2003.10.078; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Fritzsche HB, 2003, EUR J BIOCHEM, V270, P2332, DOI 10.1046/j.1432-1033.2003.03603.x; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hondoh H, 2003, J MOL BIOL, V326, P177, DOI 10.1016/S0022-2836(02)01402-X; Ichikawa K, 2000, BIOSCI BIOTECH BIOCH, V64, P2692, DOI 10.1271/bbb.64.2692; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Kamitori S, 2002, J MOL BIOL, V318, P443, DOI 10.1016/S0022-2836(02)00111-0; Kim JS, 1999, J BIOL CHEM, V274, P26279, DOI 10.1074/jbc.274.37.26279; Kondo S, 2001, J BIOCHEM, V129, P423, DOI 10.1093/oxfordjournals.jbchem.a002873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee HS, 2002, J BIOL CHEM, V277, P21891, DOI 10.1074/jbc.M201623200; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Machius M, 1996, J MOL BIOL, V260, P409, DOI 10.1006/jmbi.1996.0410; MANOR PC, 1974, J AM CHEM SOC, V96, P3630, DOI 10.1021/ja00818a042; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Ohtaki A, 2001, CARBOHYD RES, V334, P309, DOI 10.1016/S0008-6215(01)00190-2; Park KH, 2000, BBA-PROTEIN STRUCT M, V1478, P165, DOI 10.1016/S0167-4838(00)00041-8; Qian MX, 2001, BIOCHEMISTRY-US, V40, P7700, DOI 10.1021/bi0102050; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Ramasubbu N, 2003, J MOL BIOL, V325, P1061, DOI 10.1016/S0022-2836(02)01326-8; Schmidt AK, 1998, BIOCHEMISTRY-US, V37, P5909, DOI 10.1021/bi9729918; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; TONOZUKA T, 1993, BIOSCI BIOTECH BIOCH, V57, P395, DOI 10.1271/bbb.57.395; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235	35	23	24	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31033	31040		10.1074/jbc.M404311200	http://dx.doi.org/10.1074/jbc.M404311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138257	hybrid			2022-12-25	WOS:000222726800017
J	Rocheleau, JV; Head, WS; Piston, DW				Rocheleau, JV; Head, WS; Piston, DW			Quantitative NAD(P)H/flavoprotein autofluorescence imaging reveals metabolic mechanisms of pancreatic islet pyruvate response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED ANAPLEROSIS; STIMULATED INSULIN-SECRETION; RAT-LIVER MITOCHONDRIA; BETA-CELLS; FLUORESCENT FLAVOPROTEINS; METHYL PYRUVATE; MALONYL-COA; DEHYDROGENASE; SHUTTLE; NADH	Glucose-stimulated insulin secretion is a multistep process dependent on beta-cell metabolic flux. Our previous studies on intact pancreatic islets used two-photon NAD(P)H imaging as a quantitative measure of the combined redox signal from NADH and NADPH ( referred to as NAD( P) H). These studies showed that pyruvate, a non-secretagogue, enters beta-cells and causes a transient rise in NAD( P) H. To further characterize the metabolic fate of pyruvate, we have now developed one-photon flavoprotein microscopy as a simultaneous assay of lipoamide dehydrogenase (LipDH) autofluorescence. This flavoprotein is in direct equilibrium with mitochondrial NADH. Hence, a comparison of LipDH and NAD( P) H autofluorescence provides a method to distinguish the production of NADH, NADPH, or both. Using this method, the glucose dose response is consistent with an increase in both NADH and NADPH. In contrast, the transient rise in NAD( P) H observed with pyruvate stimulation is not accompanied by a significant change in LipDH, which indicates that pyruvate raises cellular NADPH without raising NADH. In comparison, methyl pyruvate stimulated a robust NADH and NADPH response. These data provide new evidence that exogenous pyruvate does not induce a significant rise in mitochondrial NADH. This inability likely results in its failure to produce the ATP necessary for stimulated secretion of insulin. Overall, these data are consistent with either a restricted pyruvate dehydrogenase-dependent metabolism or a buffering of the NADH response by other metabolic mechanisms.	Vanderbilt Univ, Nashville, TN 37232 USA	Vanderbilt University	Piston, DW (corresponding author), Vanderbilt Univ, 702 Light Hall, Nashville, TN 37232 USA.	David.Piston@vanderbilt.edu		Rocheleau, Jonathan/0000-0002-1760-2564	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK059737, R01DK053434] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59737, DK53434] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkhammar Per O. G., 1998, Methods in Cell Science, V19, P255, DOI 10.1023/A:1009712630494; Bennett BD, 1996, J BIOL CHEM, V271, P3647; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; CHANCE B, 1979, J BIOL CHEM, V254, P4764; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Dufer M, 2002, BIOCHEM J, V368, P817, DOI 10.1042/BJ20020657; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; HALL CL, 1975, J BIOL CHEM, V250, P3476; HASSINEN I, 1968, BIOCHEM BIOPH RES CO, V31, P895, DOI 10.1016/0006-291X(68)90536-6; Huang SH, 2002, BIOPHYS J, V82, P2811, DOI 10.1016/S0006-3495(02)75621-X; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; KUNZ WS, 1986, FEBS LETT, V195, P92, DOI 10.1016/0014-5793(86)80137-5; KUNZ WS, 1993, BIOCHEM MED METAB B, V50, P103, DOI 10.1006/bmmb.1993.1051; KUNZ WS, 1985, BIOCHIM BIOPHYS ACTA, V841, P237, DOI 10.1016/0304-4165(85)90064-9; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MacDonald MJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE302, DOI 10.1152/ajpendo.00041.2002; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MAEDAYORITA K, 1984, J BIOCHEM-TOKYO, V96, P683, DOI 10.1093/oxfordjournals.jbchem.a134886; Malaisse WJ, 1996, ARCH BIOCHEM BIOPHYS, V335, P229, DOI 10.1006/abbi.1996.0504; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PATEL MS, 1995, METHOD ENZYMOL, V252, P186; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; PEUHKURINEN KJ, 1983, BIOCHEM J, V210, P193, DOI 10.1042/bj2100193; Piston DW, 1999, METHOD CELL BIOL, V58, P31; Piston DW, 1999, METHOD ENZYMOL, V307, P351; Ramirez R, 1996, BBA-BIOENERGETICS, V1273, P263, DOI 10.1016/0005-2728(95)00156-5; Rocheleau JV, 2002, J BIOL CHEM, V277, P30914, DOI 10.1074/jbc.M202314200; SCHARP DW, 1973, TRANSPLANTATION, V16, P686, DOI 10.1097/00007890-197312000-00028; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; VOLTTI H, 1978, Journal of Bioenergetics and Biomembranes, V10, P45, DOI 10.1007/BF00743226; Wagnieres GA, 1998, PHOTOCHEM PHOTOBIOL, V68, P603; Zhang QH, 2002, SCIENCE, V295, P1895	38	159	161	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31780	31787		10.1074/jbc.M314005200	http://dx.doi.org/10.1074/jbc.M314005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148320	hybrid			2022-12-25	WOS:000222726800104
J	Singh, CR; He, H; Ii, M; Yamamoto, Y; Asano, K				Singh, CR; He, H; Ii, M; Yamamoto, Y; Asano, K			Efficient incorporation of eukaryotic initiation factor 1 into the multifactor complex is critical for formation of functional ribosomal preinitiation complexes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; YEAST; SUBUNITS; EIF5; RNA; BINDING; PROTEIN; RECOGNITION; ROLES	Eukaryotic initiation factor 1 (eIF1) is a low molecular weight factor critical for stringent AUG selection in eukaryotic translation. It is recruited to the 43 S complex in the multifactor complex (MFC) with eIF2, eIF3, and eIF5 via multiple interactions with the MFC constituents. Here we show that FLAG epitope tagging of eIF1 at either terminus abolishes its in vitro interactions with eIF5 and eIF2beta but not that with eIF3c. Nevertheless, both forms of FLAG-eIF1 fail to bind eIF3 and are incorporated into the 43 S complex inefficiently in vivo. C-terminal FLAG tagging of eIF1 is lethal; overexpression of C-terminal FLAG-eIF1 severely impedes 43 S complex formation and derepresses GCN4 translation due to limiting of eIF2 . GTP . Met-tRNA(i)(Met) ternary complex binding to the ribosome. Furthermore, N-terminal FLAG-eIF1 overexpression reduces eIF2 binding to the ribosome and moderately derepresses GCN4 translation. Our results provide the first in vivo evidence that eIF1 plays an important role in promoting 43 S complex formation as a core of factor interactions. We propose that the coordinated recruitment of eIF1 to the 40 S ribosome in the MFC is critical for the production of functional 40 S preinitiation complex.	Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Manhattan, KS 66506 USA	Kansas State University	Asano, K (corresponding author), Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Ackert Hall, Manhattan, KS 66506 USA.	kasano@ksu.edu			NCRR NIH HHS [1 P20 RR15563] Funding Source: Medline; NIGMS NIH HHS [R01GM64781] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064781] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 2002, METHOD ENZYMOL, V351, P221; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; HE H, 2003, THESIS KANSAS STATE; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Maag D, 2003, J MOL BIOL, V330, P917, DOI 10.1016/S0022-2836(03)00665-X; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; Pestova TV, 2002, GENE DEV, V16, P2906, DOI 10.1101/gad.1020902; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS A, 1980, FEBS LETT, V116, P67, DOI 10.1016/0014-5793(80)80530-8; Valasek L, 2003, GENE DEV, V17, P786, DOI 10.1101/gad.1065403; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; von der Haar T, 2002, MOL MICROBIOL, V46, P531, DOI 10.1046/j.1365-2958.2002.03172.x; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	31	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31910	31920		10.1074/jbc.M313940200	http://dx.doi.org/10.1074/jbc.M313940200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145951	hybrid			2022-12-25	WOS:000222726800118
J	Edinger, AL; Thompson, CB				Edinger, AL; Thompson, CB			An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival	ONCOGENE			English	Article						4F2hc; Akt; apoptosis; growth factor; mTOR	PROTEIN-KINASE B; FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR PROTEINS; COMPLEX GENE-PRODUCTS; RNA 5' CAP; MAMMALIAN TARGET; AMINO-ACID; SIGNALING PATHWAY; TOR PROTEINS; RAPAMYCIN	In yeast, TOR couples cellular growth and metabolism to the availability of extracellular nutrients. In contrast, mammalian TOR kinase activity has been reported to be regulated by growth factor stimulation via the PI3K/Akt pathway. Consistent with this, growth factor deprivation results in dephosphorylation of the mTOR target proteins p70S6k and 4EBP1 in the face of abundant extracellular nutrients. To determine whether the activation of mTOR was sufficient to support cell survival in the absence of other growth factor-mediated signal transduction, we evaluated the ability of a growth factor-independent mTOR mutant, DeltaTOR, to protect cells from growth factor deprivation. DeltaTOR- but not wild-type mTOR-expressing cells were protected from many of the sequelae of growth factor deprivation including amino-acid transporter degradation, reduction of the glycolytic rate, cellular atrophy, decreased mitochondrial membrane potential, and Bax activation. Furthermore, DeltaTOR expression increased growth factor-independent, nutrient-dependent cell survival and enhanced the ability of p53-/- MEFs to form colonies in soft agar. These results suggest that activating mutations of mTOR can contribute to apoptotic resistance and might contribute to cellular transformation.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu						Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hosoi H, 1999, CANCER RES, V59, P886; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	55	68	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5654	5663		10.1038/sj.onc.1207738	http://dx.doi.org/10.1038/sj.onc.1207738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15133498				2022-12-25	WOS:000222629500010
J	Wotton, SF; Blyth, K; Kilbey, A; Jenkins, A; Terry, A; Bernardin-Fried, F; Friedman, AD; Baxter, EW; Neil, JC; Cameron, ER				Wotton, SF; Blyth, K; Kilbey, A; Jenkins, A; Terry, A; Bernardin-Fried, F; Friedman, AD; Baxter, EW; Neil, JC; Cameron, ER			RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53	ONCOGENE			English	Article						RUNX1; oncogene; MEF; p53; TGF beta	ACUTE LYMPHOBLASTIC-LEUKEMIA; DOMAIN TRANSCRIPTION FACTOR; T(8/21) FUSION PROTEIN; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR BETA-1; T-CELL DEVELOPMENT; TGF-BETA; OSTEOBLAST DIFFERENTIATION; NEOPLASTIC TRANSFORMATION; NIH3T3 CELLS	The mammalian Runx gene family (Runx1-3) are transcription factors that play essential, lineage-specific roles in development. A growing body of evidence implicates these genes as mutational targets in cancer where, in different contexts, individual family members have been reported to act as tumour suppressors, dominant oncogenes or mediators of metastasis. We are exploring these paradoxical observations by ectopic expression of RUNX genes in primary murine embryonic fibroblasts where, in common with a number of other dominant oncogenes, RUNX1 induces senescence-like growth arrest in the presence of an intact p19(ARF)-p53 pathway. We now report that, in MEFs lacking functional p53, RUNX1 has apparently prooncogenic effects on cell growth that include cytoskeletal reorganization, reduced contact inhibition at confluence and accelerated tumour expansion in vivo. On the other hand, RUNX1 conferred no obvious growth advantage at low cell density and actually delayed entry of primary MEFs into S phase. We also found that ectopic RUNX1 interferes with the morphological and growth responses of p53-null MEFs to TGFbeta indicating that these effects are mediated by overlapping pathways. These observations help to elucidate the context-dependent consequences of loss and gain of Runx activity.	Univ Glasgow, Mol Oncol Lab, Inst Comparat Med, Fac Vet Med, Glasgow G61 1QH, Lanark, Scotland; Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Glasgow; Johns Hopkins University; Fred Hutchinson Cancer Center	Wotton, SF (corresponding author), Univ Glasgow, Mol Oncol Lab, Inst Comparat Med, Fac Vet Med, Bearsdon Rd, Glasgow G61 1QH, Lanark, Scotland.	S.Wotton@vet.gla.ac.uk		Blyth, Karen/0000-0002-9304-439X				Bae SC, 2001, J BONE JOINT SURG AM, V83A, pS48; Baxter EW, 2001, J VIROL, V75, P9790, DOI 10.1128/JVI.75.20.9790-9798.2001; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chow M, 2000, P NATL ACAD SCI USA, V97, P174, DOI 10.1073/pnas.97.1.174; Chow M, 2000, CANCER RES, V60, P6510; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Kurokawa M, 1996, ONCOGENE, V12, P883; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 1999, J CELL SCI, V112, P1169; Nelson PJ, 2002, KIDNEY INT S1, V61, P99, DOI DOI 10.1046/J.1523-1755.2002.0610S1099.X; Niini T, 2000, HAEMATOLOGICA, V85, P362; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sakamoto Y, 1999, CANCER LETT, V136, P159, DOI 10.1016/S0304-3835(98)00318-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sun LX, 2001, CANCER RES, V61, P4994; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wotton S, 2002, CANCER RES, V62, P7181; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	52	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2004	23	32					5476	5486		10.1038/sj.onc.1207729	http://dx.doi.org/10.1038/sj.onc.1207729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133495				2022-12-25	WOS:000222588400007
J	Macao, B; Olsson, M; Elias, P				Macao, B; Olsson, M; Elias, P			Functional properties of the herpes simplex virus type I origin-binding protein are controlled by precise interactions with the activated form of the origin of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; VIRAL ORIGIN; CRYSTAL-STRUCTURES; HELICASE; UL9; RECOMBINATION; DOMAIN; INITIATION; COMPLEXES; RESIDUES	The herpes simplex virus, type I origin-binding protein, OBP, is a superfamily II DNA helicase encoded by the UL9 gene. OBP binds in a sequence-specific and cooperative way to the viral origin of replication oriS. OBP may unwind partially and introduce a hairpin into the double-stranded origin of replication. The formation of the novel conformation referred to as oriS* also requires the single-stranded DNA-binding protein, ICP8, and ATP hydrolysis. OBP forms a stable complex with oriS*. The hairpin in oriS* provides a site for sequence-specific attachment, and a single-stranded region triggers ATP hydrolysis. Here we use Escherichia coli exonuclease I to map the binding of the C-terminal domain of OBP to the hairpin and the helicase domains to the single-stranded tail. The helicase domains cover a stretch of 23 nucleotides of single-stranded DNA. Using streptavidin-coated magnetic beads, we show that OBP may bind two copies of double-stranded DNA (one biotin-labeled and the other one radioactively labeled) but only one copy of oriS*. It is the length of the single-stranded tail that determines the stoichiometry of OBP.DNA complexes. OBP interacts with the bases of the single-stranded tail, and ATP hydrolysis is triggered by position-specific interactions between OBP and bases in the single-stranded tail of oriS*.	Univ Gothenburg, Dept Med Biochem, S-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, S-40530 Gothenburg, Sweden.	per.elias@medkem.gu.se						Aslani A, 2000, J BIOL CHEM, V275, P5880, DOI 10.1074/jbc.275.8.5880; Aslani A, 2002, J BIOL CHEM, V277, P41204, DOI 10.1074/jbc.M208270200; Aslani A, 2001, P NATL ACAD SCI USA, V98, P7194, DOI 10.1073/pnas.121177198; Boehmer PE, 2003, IUBMB LIFE, V55, P13, DOI 10.1080/1521654031000070645; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; ELIAS P, 1992, J BIOL CHEM, V267, P17424; ELIAS P, 1990, J BIOL CHEM, V265, P17167; Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GUSTAFSSON CM, 1994, P NATL ACAD SCI USA, V91, P4629, DOI 10.1073/pnas.91.11.4629; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; He XD, 2001, P NATL ACAD SCI USA, V98, P3024, DOI 10.1073/pnas.061028298; Jackson SA, 2003, P NATL ACAD SCI USA, V100, P7871, DOI 10.1073/pnas.1230643100; JACOB RJ, 1979, J VIROL, V29, P448, DOI 10.1128/JVI.29.2.448-457.1979; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Le Gac NT, 2002, J BIOL CHEM, V277, P5660, DOI 10.1074/jbc.M108316200; Lee SSK, 1999, J BIOL CHEM, V274, P18613, DOI 10.1074/jbc.274.26.18613; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Makhov AM, 2003, P NATL ACAD SCI USA, V100, P898, DOI 10.1073/pnas.0237171100; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Maluf NK, 2003, J MOL BIOL, V325, P913, DOI 10.1016/S0022-2836(02)01277-9; Marintcheva B, 2003, J VIROL, V77, P2477, DOI 10.1128/JVI.77.4.2477-2488.2003; Marintcheva B, 2001, J BIOL CHEM, V276, P6605, DOI 10.1074/jbc.M007743200; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; Nimonkar AV, 2003, P NATL ACAD SCI USA, V100, P10201, DOI 10.1073/pnas.1534569100; Reuven NB, 2003, J VIROL, V77, P7425, DOI 10.1128/JVI.77.13.7425-7433.2003; Silverman E, 2003, GENE, V312, P1, DOI 10.1016/S0378-1119(03)00626-7; Simonsson S, 1998, J BIOL CHEM, V273, P24633, DOI 10.1074/jbc.273.38.24633; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WELLER SK, 1985, MOL CELL BIOL, V5, P930, DOI 10.1128/MCB.5.5.930; Wilkinson DE, 2003, IUBMB LIFE, V55, P451, DOI 10.1080/15216540310001612237; Yao XD, 1997, J VIROL, V71, P6842, DOI 10.1128/JVI.71.9.6842-6849.1997; Yao XD, 2001, J BIOL CHEM, V276, P2905, DOI 10.1074/jbc.M005627200	42	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29211	29217		10.1074/jbc.M400371200	http://dx.doi.org/10.1074/jbc.M400371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133043	hybrid			2022-12-25	WOS:000222445300048
J	Fuchs, C; Heib, V; Kiger, L; Haberkamp, M; Roesner, A; Schmidt, M; Hamdane, D; Marden, MC; Hankeln, T; Burmester, T				Fuchs, C; Heib, V; Kiger, L; Haberkamp, M; Roesner, A; Schmidt, M; Hamdane, D; Marden, MC; Hankeln, T; Burmester, T			Zebrafish reveals different and conserved features of vertebrate neuroglobin gene structure, expression pattern, and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; HEXACOORDINATE HEMOGLOBIN; GLOBIN FAMILY; TELEOST FISH; DANIO-RERIO; PROTEIN; CYTOGLOBIN; BRAIN; GILLS	Neuroglobin has been identified as a respiratory protein that is primarily expressed in the mammalian nervous system. Here we present the first detailed analysis of neuroglobin from a non-mammalian vertebrate, the zebrafish Danio rerio. The zebrafish neuroglobin gene reveals a mammalian-type exon-intron pattern in the coding region (B12.2, E11.0, and G7.0), plus an additional 5'-non-coding exon. Similar to the mammalian neuroglobin, the zebrafish protein displays a hexacoordinate deoxybinding scheme. Flash photolysis kinetics show the competitive binding on the millisecond timescale of external ligands and the distal histidine, resulting in an oxygen affinity of 1 torr. Western blotting, immune staining, and mRNA in situ hybridization demonstrate neuroglobin expression in the fish central nervous system and the retina but also in the gills. Neurons containing neuroglobin have a widespread distribution in the brain but are also present in the olfactory system. In the fish retina, neuroglobin is mainly present in the inner segments of the photoreceptor cells. In the gills, the chloride cells were identified to express neuroglobin. Neuroglobin appears to be associated with mitochondria-rich cell types and thus oxygen consumption rates, suggesting a myoglobin-like function of this protein in facilitated oxygen diffusion.	Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany; INSERM, U473, F-94276 Le Kremlin Bicetre, France	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Institut National de la Sante et de la Recherche Medicale (Inserm)	Burmester, T (corresponding author), Univ Mainz, Inst Zool, Saarstr 21, D-55099 Mainz, Germany.	burmeste@uni-mainz.de	Marden, Michael C/G-3139-2012; Burmester, Thorsten/I-7225-2013; Kiger, Laurent/Q-1686-2018; Marden, Michael/AAA-5923-2020	Marden, Michael C/0000-0002-5254-6385; Burmester, Thorsten/0000-0002-5772-7863; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Benton M.J., 1990, VERTEBRATE PALEONTOL; BLANCHETOT A, 1986, EUR J BIOCHEM, V159, P469, DOI 10.1111/j.1432-1033.1986.tb09909.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; BURMESTER T, 2004, IN PRESS NEWS PHYSL; BURNSIDE B, 1978, J CELL BIOL, V78, P227, DOI 10.1083/jcb.78.1.227; Claiborne JB, 2002, J EXP ZOOL, V293, P302, DOI 10.1002/jez.10125; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; Douglas RH, 1998, VISION RES, V38, P2697, DOI 10.1016/S0042-6989(98)00021-2; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; JOHANSEN K, 1981, RESP PHYSIOL, V44, P277, DOI 10.1016/0034-5687(81)90023-2; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Kundu S, 2003, TRENDS PLANT SCI, V8, P387, DOI 10.1016/S1360-1385(03)00163-8; LAUFS T, 2004, IN PRESS NEUROSCI LE; LYNDON AR, 1994, J FISH BIOL, V44, P707, DOI 10.1111/j.1095-8649.1994.tb01246.x; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Marshall WS, 2002, J EXP ZOOL, V293, P264, DOI 10.1002/jez.10127; Merx Marc W., 2001, FASEB Journal, V15, P1077; Nakatani K, 2004, LAB INVEST, V84, P91, DOI 10.1038/labinvest.3700013; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Perry SF, 1997, ANNU REV PHYSIOL, V59, P325, DOI 10.1146/annurev.physiol.59.1.325; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Rombough P, 2002, J EXP BIOL, V205, P1787; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schmidt M, 2004, J BIOL CHEM, V279, P8063, DOI 10.1074/jbc.M310540200; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Wenger RH, 1997, BIOL CHEM, V378, P609; Wittbrodt J, 2002, NAT REV GENET, V3, P53, DOI 10.1038/nrg704; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; WITTENBERG JB, 1975, COMP BIOCHEM PHYS A, V51, P425, DOI 10.1016/0300-9629(75)90390-4; Wullimann MF, 1996, NEUROANATOMY ZEBRAFI, DOI 10.1007/978-3-0348-8979-7_6; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; WYSTUB S, 2004, IN PRESS CYTOGENET G; [No title captured]	53	66	71	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24116	24122		10.1074/jbc.M402011200	http://dx.doi.org/10.1074/jbc.M402011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140880	hybrid			2022-12-25	WOS:000221702500034
J	Chen, XD; Fisher, LW; Robey, PG; Young, MF				Chen, XD; Fisher, LW; Robey, PG; Young, MF			The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation	FASEB JOURNAL			English	Article						microenvironment; osteoblastic progenitors	BONE MORPHOGENETIC PROTEIN-4; GROWTH-FACTOR-BETA; EXTRACELLULAR-MATRIX; TARGETED DISRUPTION; STROMAL CELLS; DECORIN; EXPRESSION; CBFA1; GENE; ABNORMALITIES	Biglycan (bgn) is a small leucine-rich proteoglycan enriched in extracellular matrices of skeletal tissues. Bgn-deficient mice develop age-related osteopenia with a phenotype that resembles osteoporosis and premature arthritis. In the present study, we have examined the differentiation of bgn-deficient osteoblasts from neonatal murine calvariae and found that the absence of bgn caused less BMP-4 binding, which reduced the sensitivity of osteoblasts to BMP-4 stimulation. The loss of sensitivity resulted in a reduction of Cbfa1 expression, which ultimately led to a defect in the differentiation of osteoblasts. However, the response of bgn-deficient osteoblasts to BMP-4 was completely rescued by reintroduction of biglycan by viral transfection. We propose that biglycan modulates BMP-4-induced signaling to control osteoblast differentiation.	Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Chen, XD (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Bldg 30,Room 225,9000 Rockville Pike,MSC 4320, Bethesda, MD 20892 USA.	xchen@dir.nidr.nih.gov	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Young, Marian F/0000-0003-0929-8854; Chen, Xiao-Dong/0000-0003-1602-806X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000074, ZIADE000380, ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379, Z01DE000074, Z01DE000380] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Andrades JA, 2001, PROTOPLASMA, V218, P95, DOI 10.1007/BF01288365; BAB I, 1988, BONE MINER, V4, P373; BANERJEE U, 1997, LOOP TR RESTRUCT COM, V3, P1; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331; Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362; Cohn D H, 2001, Novartis Found Symp, V232, P195; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HORTON WA, 1987, PEDIATR RES, V22, P324, DOI 10.1203/00006450-198709000-00017; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; James IE, 1996, J BONE MINER RES, V11, P1453; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KRESSE H, 1994, EUR J CLIN CHEM CLIN, V32, P259; Larrain J, 2000, DEVELOPMENT, V127, P821; LIU F, 1995, MOL CELL BIOL, V15, P3479; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; Natsume T, 1997, J BIOL CHEM, V272, P11535; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; Silver FH, 2001, CRIT REV BIOMED ENG, V29, P373, DOI 10.1615/CritRevBiomedEng.v29.i4.10; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; Stordeur P, 2002, J IMMUNOL METHODS, V259, P55, DOI 10.1016/S0022-1759(01)00489-6; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	39	170	185	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2004	18	9					948	958		10.1096/fj.03-0899com	http://dx.doi.org/10.1096/fj.03-0899com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	833HJ	15173106				2022-12-25	WOS:000222327500012
J	Shi, H; Wang, HZ; Yang, BF; Xu, DH; Wang, ZG				Shi, H; Wang, HZ; Yang, BF; Xu, DH; Wang, ZG			The M-3 receptor-mediated K+ current (I-KM3), a G(q) protein-coupled K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; FUNCTIONAL M-3-MUSCARINIC RECEPTORS; ATRIAL-FIBRILLATION; HUMAN HEART; MULTIPLE SUBTYPES; PHOSPHOLIPASE-C; MOLECULAR-BASIS; CA2+ RELEASE; ACTIVATION; EXPRESSION	Stimulation of muscarinic acetylcholine receptors ( mAChRs) can activate an inward rectifier K+ current ( I-KACh), which is mediated by the M-2 subtype of mAChR in cardiac myocytes. Recently, a novel delayed rectifier-like K+ current mediated by activation of the cardiac M-3 receptors ( designated I-KM3) was identified, which is distinct from I-KACh and other known K+ currents. While I-KACh is known to be a G(i) protein- gated K+ channel, the signal transduction mechanisms for I-KM3 activation remained unexplored. We studied I-KM3 with whole- cell patch clamp and macropatch clamp techniques. Whole cell I-KM3 activated by choline persisted with minimal rundown over 2 h in presence of internal GTP. When GTP was replaced by guanyl-5'-yl thiophosphate, I-KM3 demonstrated rapid and extensive rundown. While I-KACh ( induced by ACh) was markedly reduced in cells pretreated with pertussis toxin, I-KM3 was unaltered. Intracellular application of antibodies targeting alpha-subunit of G(i/o) protein suppressed I-KACh without affecting I-KM3. Antibodies targeting the N and the C terminus, respectively, of G(q) protein alpha-subunit substantially depressed I-KM3 but failed to alter I-KACh. The antibody against beta-subunits of G proteins inhibited both I-KACh and I-KM3. I-KM3 activated by choline in the cell- attached mode of macropatches persisted in the cell- free configuration. Application of purified G(q) protein alpha-subunit or betagamma-subunit of G proteins or guanosine 5'-O-( thiotriphosphate) to the internal solution activated I-KM3- like currents in inside- out patches. Our findings revealed a novel aspect of receptor- channel signal transduction mechanisms, and I-KM3 represents the first G(q) protein- coupled K+ channel. We propose that the G protein- coupled K+ channel family could be divided into two subfamilies: G(i) protein- coupled K+ channel subfamily and G(q) protein-coupled K+ channel subfamily.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Harbin Med Univ, Heilongjiang 150086, Peoples R China; Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510275, Guangdong, Peoples R China	Universite de Montreal; Universite de Montreal; Harbin Medical University; Sun Yat Sen University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.	wangz@icm.umontreal.ca	Wang, Zhiguo/GRS-4339-2022; wang, zhiguo/AAN-4182-2021	Wang, Zhiguo/0000-0002-0811-2045; 				Bian JS, 2001, CIRC RES, V89, P1168, DOI 10.1161/hh2401.101375; BIRNBAUMER L, 1989, RECENT PROG HORM RES, V45, P121; BLUML K, 1994, J BIOL CHEM, V269, P11537; Brundel BJJM, 2001, CIRCULATION, V103, P684; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Dobrev D, 2002, CARDIOVASC RES, V54, P397, DOI 10.1016/S0008-6363(01)00555-7; Dobrev D, 2001, CIRCULATION, V104, P2551, DOI 10.1161/hc4601.099466; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; Hellgren I, 2000, CELL MOL LIFE SCI, V57, P175, DOI 10.1007/s000180050507; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Morel JL, 1997, BRIT J PHARMACOL, V121, P451, DOI 10.1038/sj.bjp.0701157; Oberhauser V, 2001, CIRCULATION, V103, P1638, DOI 10.1161/01.CIR.103.12.1638; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Ponicke K, 2003, BRIT J PHARMACOL, V138, P156, DOI 10.1038/sj.bjp.0704997; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Schotten U, 2001, CIRCULATION, V103, P691; Shi H, 2004, CELL PHYSIOL BIOCHEM, V14, P31, DOI 10.1159/000076924; Shi H, 1999, J MEMBRANE BIOL, V169, P55, DOI 10.1007/PL00005901; Shi H, 2003, CELL PHYSIOL BIOCHEM, V13, P59, DOI 10.1159/000070250; Shi H, 1999, MOL PHARMACOL, V55, P497; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; Wang HZ, 2001, MOL PHARMACOL, V59, P1029, DOI 10.1124/mol.59.5.1029; Wang HZ, 1999, BRIT J PHARMACOL, V126, P1725, DOI 10.1038/sj.bjp.0702486; Wang JX, 2004, BRIT J PHARMACOL, V141, P586, DOI 10.1038/sj.bjp.0705646; Wang YX, 1997, AM J PHYSIOL-CELL PH, V273, pC500, DOI 10.1152/ajpcell.1997.273.2.C500; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Willmy-Matthes P, 2003, N-S ARCH PHARMACOL, V368, P316, DOI 10.1007/s00210-003-0796-2; Yamada M, 1998, PHARMACOL REV, V50, P723; Yue LX, 1999, J PHYSIOL-LONDON, V516, P385, DOI 10.1111/j.1469-7793.1999.0385v.x	34	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					21774	21778		10.1074/jbc.C400100200	http://dx.doi.org/10.1074/jbc.C400100200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15140874	hybrid			2022-12-25	WOS:000221417100013
J	Podsiadlo, P; Komiyama, T; Fuller, RS; Blum, O				Podsiadlo, P; Komiyama, T; Fuller, RS; Blum, O			Furin inhibition by compounds of copper and zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; KEX2 PROTEASE; PROTEINASE-K; COMPLEXES; SPECIFICITY; EMBRYOGENESIS; PARAMETERS; PATHWAY; MERCURY	Furin, a human subtilisin-related proprotein convertase (SPC), is emerging as an important pharmaceutical target because it processes vital proteins of many aggressive pathogens. Furin inhibitors reported as yet are peptide derivatives and proteins, with the exception of andrographolides, which are natural compounds. Here we report that the small and highly stable compounds M(chelate)Cl-2 (M is copper or zinc) inhibit furin and Kex2, with Cu(TTP)Cl-2 and Zn(TTP)Cl-2 as the most efficient inhibitors. (TTP is 4'-[p-tolyl]-2,2':6',2'-terpyridine.) Inhibition is irreversible, competitive with substrate, and affected by substituents on the chelate. The free chelates are not inhibitors. Solvated Zn2+ is less potent than its complexes. This is true also for copper and Kex2. However, solvated Cu2+ (k(on) of 25,000 +/- 2,500 s(-1)) is more potent than Cu(TTP)Cl-2 (k(on) = 140 +/- 13 s(-1)) and allows recovery of furin activity prior to a second inhibition phase. A mechanism that involves coordination to the catalytic histidine is proposed for all inhibitors. Target specificity is indicated by the fact that these metal chelate inhibitors are much less potent toward Kex2, the yeast homologue of furin. For example, kon with Zn(TTP)Cl-2 is 120 +/- 20 s(-1) for furin, but only 1.2 +/- 0.1 s(-1) for Kex2.	Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Technion Israel Institute of Technology	Blum, O (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.	oferblum@tx.technion.ac.il			NIGMS NIH HHS [GM 39667] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambundo EA, 1999, INORG CHEM, V38, P4233, DOI 10.1021/ic990334t; Basak A, 1999, BIOCHEM J, V338, P107, DOI 10.1042/0264-6021:3380107; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; Brinkerhoff CJ, 2002, CHEMBIOCHEM, V3, P1141, DOI 10.1002/1439-7633(20021104)3:11<1141::AID-CBIC1141>3.0.CO;2-7; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; CONSTABLE EC, 1990, INORG CHIM ACTA, V178, P47, DOI 10.1016/S0020-1693(00)88132-3; CORNILSEN BC, 1974, J INORG NUCL CHEM, V36, P2467, DOI 10.1016/0022-1902(74)80455-0; FUGERE M, CURR PHARM DES, V8, P125; HARRIS CM, 1970, AUST J CHEM, V23, P673, DOI 10.1071/CH9700673; Hathaway B.J., 1987, COMPREHENSIVE COORDI, P533; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hill MG, 1996, INORG CHEM, V35, P4585, DOI 10.1021/ic960137j; Hitomi Y, 2001, J AM CHEM SOC, V123, P8614, DOI 10.1021/ja016146v; Holyoak T, 2003, BIOCHEMISTRY-US, V42, P6709, DOI 10.1021/bi034434t; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; KEIM W, 1994, BIOINORGANIC CHEM IN, P20; KEIM W, 1994, BIOINORGANIC CHEM IN, P6; Komiyama T, 2003, P NATL ACAD SCI USA, V100, P8205, DOI 10.1073/pnas.1032865100; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; KUNJAPPU JT, 1991, J PHOTOCH PHOTOBIO A, V56, P365, DOI 10.1016/1010-6030(91)80036-H; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P21; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MULLER A, 1993, J BIOL CHEM, V268, P26150; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Ohta T, 2000, INORG CHEM, V39, P4358, DOI 10.1021/ic000018a; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Saxena AK, 1996, PROTEINS, V25, P195, DOI 10.1002/(SICI)1097-0134(199606)25:2<195::AID-PROT5>3.0.CO;2-H; SCHMIDT KH, 1975, INORG CHEM, V14, P2183, DOI 10.1021/ic50151a031; Steiner D. F., 2002, ENZYMES, V22, P163; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	36	31	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36219	36227		10.1074/jbc.M400338200	http://dx.doi.org/10.1074/jbc.M400338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15140896	hybrid			2022-12-25	WOS:000223453600009
J	Lee, SP; So, CH; Rashid, AJ; Varghese, G; Cheng, R; Lanca, AJ; O'Dowd, BF; George, SR				Lee, SP; So, CH; Rashid, AJ; Varghese, G; Cheng, R; Lanca, AJ; O'Dowd, BF; George, SR			Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-OPIOID RECEPTORS; LOCOMOTOR-ACTIVITY; RAT; STIMULATION; EXPRESSION; GENE; D-2; HOMODIMERIZATION; MODULATION; STRIATUM	Although dopamine D1 and D2 receptors belong to distinct subfamilies of dopamine receptors, several lines of evidence indicate that they are functionally linked. However, a mechanism for this linkage has not been elucidated. In this study, we demonstrate that agonist stimulation of co-expressed D1 and D2 receptors resulted in an increase of intracellular calcium levels via a signaling pathway not activated by either receptor alone or when only one of the co-expressed receptors was activated by a selective agonist. Calcium signaling by D1-D2 receptor co-activation was abolished following treatment with a phospholipase C inhibitor but not with pertussis toxin or inhibitors of protein kinase A or protein kinase C, indicating coupling to the G(q) pathway. We also show, by co-immunoprecipitation from rat brain and from cells co-expressing the receptors, that D1 and D2 receptors are part of the same heteromeric protein complex and, by immunohistochemistry, that these receptors are co-expressed and co-localized within neurons of human and rat brain. This demonstration that D1 and D2 receptors have a novel cellular function when co-activated in the same cell represents a significant step toward elucidating the mechanism of the functional link observed between these two receptors in brain.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	George, SR (corresponding author), Univ Toronto, Dept Pharmacol, Rm 4358,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	s.george@utoronto.ca	George, Susan/W-7494-2019; George, Susan R/P-9669-2018					Aizman O, 2000, NAT NEUROSCI, V3, P226, DOI 10.1038/72929; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; Charles AC, 2003, MOL PHARMACOL, V63, P89, DOI 10.1124/mol.63.1.89; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DREHER JK, 1989, BRAIN RES, V487, P267, DOI 10.1016/0006-8993(89)90831-7; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Gerfen CR, 1995, J NEUROSCI, V15, P8167; Kita K, 1999, EUR NEUROPSYCHOPHARM, V9, P1, DOI 10.1016/S0924-977X(97)00098-9; LaHoste GJ, 2000, J NEUROSCI, V20, P6666, DOI 10.1523/JNEUROSCI.20-17-06666.2000; LANCA AJ, 1994, NEUROSCIENCE, V58, P359, DOI 10.1016/0306-4522(94)90043-4; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lidow MS, 2003, BRAIN RES REV, V43, P70, DOI 10.1016/S0165-0173(03)00203-0; LIN CW, 1995, MOL PHARMACOL, V47, P131; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MEADORWOODRUFF JH, 1991, NEUROPSYCHOPHARMACOL, V5, P231; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Neumeyer JL, 2003, EUR J PHARMACOL, V474, P137, DOI 10.1016/S0014-2999(03)02008-9; Pacheco MA, 1997, J NEUROCHEM, V69, P639; PEDERSEN UB, 1994, EUR J PHARM-MOLEC PH, V267, P85, DOI 10.1016/0922-4106(94)90228-3; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schachter JB, 1997, NEUROPHARMACOLOGY, V36, P1181, DOI 10.1016/S0028-3908(97)00138-X; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Svenningsson P, 2000, NEUROSCIENCE, V98, P749, DOI 10.1016/S0306-4522(00)00155-X; UNDIE AS, 1990, J PHARMACOL EXP THER, V253, P987; Yu PY, 1996, J BIOL CHEM, V271, P19503, DOI 10.1074/jbc.271.32.19503; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000	39	352	362	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35671	35678		10.1074/jbc.M401923200	http://dx.doi.org/10.1074/jbc.M401923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15159403	hybrid			2022-12-25	WOS:000223303400064
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - I. The glycosylated end of human alpha-subunit loop 2 is threaded through a beta-subunit hole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; STIMULATING-HORMONE; DISULFIDE BONDS; PROTEIN; RECEPTOR; BINDING; CHORIOGONADOTROPIN; FOLLITROPIN; LUTROPIN; SECRETION	Glycoprotein hormone heterodimers are stabilized by their unusual structures in which a glycosylated loop of the alpha-subunit straddles a hole in the beta-subunit. This hole is formed when a cysteine at the end of a beta-subunit strand known as the "seatbelt" becomes "latched" by a disulfide to a cysteine in the beta-subunit core. The heterodimer is stabilized in part by the difficulty of threading the glycosylated end of the alpha-subunit loop 2 through this hole, a phenomenon required for subunit dissociation. Subunit combination in vitro, which occurs by the reverse process, can be accelerated by removing the alpha-subunit oligosaccharide. In cells, heterodimer assembly was thought to occur primarily by a mechanism in which the seatbelt is wrapped around the alpha-subunit after the subunits dock. Here we show that this "wrap-around" process can be used to assemble disulfide crosslinked human choriogonadotropin analogs that contain an additional alpha-subunit cysteine, but only if the normal beta-subunit latch site has been removed. Normally, the seatbelt is latched before the subunits dock and assembly is completed when the glycosylated end of alpha-subunit loop 2 is threaded beneath the seatbelt. The unexpected finding that most assembly of human choriogonadotropin, human follitropin, and human thyrotropin heterodimers occurs in this fashion, indicates that threading may be an important phenomenon during protein folding and macromolecule assembly in the endoplasmic reticulum. We suggest that the unusual structures of the glycoprotein hormones makes them useful for identifying factors that influence this process in living cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R01HD038547, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD14907, HD38547] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard MP, 2004, ANAL BIOCHEM, V327, P278, DOI 10.1016/j.ab.2003.12.029; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN C, 1987, BIOTECHNIQUES, V6, P632; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lorenz IC, 2002, J VIROL, V76, P5480, DOI 10.1128/JVI.76.11.5480-5491.2002; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; Moyle WR, 1998, CHEM BIOL, V5, P241, DOI 10.1016/S1074-5521(98)90617-2; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35458, DOI 10.1074/jbc.M403055200; Xing YN, 2003, BIOCHEM BIOPH RES CO, V303, P201, DOI 10.1016/S0006-291X(03)00322-X; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	26	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35426	35436		10.1074/jbc.M403052200	http://dx.doi.org/10.1074/jbc.M403052200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15161918	hybrid			2022-12-25	WOS:000223303400036
J	Hellwig, N; Plant, TD; Janson, W; Schafer, M; Schultz, GN; Schaefer, M				Hellwig, N; Plant, TD; Janson, W; Schafer, M; Schultz, GN; Schaefer, M			TRPV1 acts as proton channel to induce acidification in nociceptive neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; PROTEIN-KINASE-C; CAPSAICIN RECEPTOR; INTRACELLULAR PH; ION CHANNELS; VANILLOID RECEPTOR-1; HIPPOCAMPAL-NEURONS; CALCIUM CURRENT; CELLS; VR1	The low extracellular pH of inflamed or ischemic tissues enhances painful sensations by sensitizing and activating the vanilloid receptor 1 (TRPV1). We report here that activation of TRPV1 results in a marked intracellular acidification in nociceptive dorsal root ganglion neurons and in a heterologous expression system. A characterization of the underlying mechanisms revealed a Ca2+-dependent intracellular acidification operating at neutral pH and an additional as yet unrecognized direct proton conductance through the poorly selective TRPV1 pore operating in acidic extracellular media. Large organic cations permeate through the activated TRPV1 pore even in the presence of physiological concentrations of Na+, Mg2+, and Ca2+. The wide pore and the unexpectedly high proton permeability of TRPV1 point to a proton hopping permeation mechanism along the water-filled channel pore. In acidic media, the high relative proton permeability through TRPV1 defines a novel proton entry mechanism in nociceptive neurons.	Charite Univ Med Berlin, Dept Pharmacol, D-14195 Berlin, Germany; Charite Univ Med Berlin, Dept Anaesthesiol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schaefer, M (corresponding author), Charite Univ Med Berlin, Dept Pharmacol, Campus Benjamin Franklin,Thielallee 67-73, D-14195 Berlin, Germany.	schae@zedat.fu-berlin.de	Schäfer, Michael/AAB-1395-2020	Schaefer, Michael/0000-0002-1581-706X				Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DeCoursey TE, 2003, NATURE, V422, P531, DOI 10.1038/nature01523; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; DeCoursey TE, 1997, J GEN PHYSIOL, V109, P415, DOI 10.1085/jgp.109.4.415; Dedov VN, 2001, NEUROSCIENCE, V103, P219, DOI 10.1016/S0306-4522(00)00540-6; DIXON DB, 1993, NEURON, V11, P267, DOI 10.1016/0896-6273(93)90183-R; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; HARTLEY Z, 1993, J NEUROSCI, V13, P4690; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; IRWIN RP, 1994, J NEUROSCI, V14, P1352, DOI 10.1523/JNEUROSCI.14-03-01352.1994; JANCSO G, 1990, NEUROSCIENCE, V39, P501, DOI 10.1016/0306-4522(90)90286-D; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kiss L, 1999, J NEUROPHYSIOL, V81, P1839, DOI 10.1152/jn.1999.81.4.1839; Kuzhikandathil EV, 2001, J NEUROSCI, V21, P8697, DOI 10.1523/JNEUROSCI.21-22-08697.2001; Lenz JC, 2002, J CELL BIOL, V159, P291, DOI 10.1083/jcb.200203048; Liu M, 2003, J BIOL CHEM, V278, P5462, DOI 10.1074/jbc.M209111200; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Meyer TM, 2000, NEUROREPORT, V11, P33, DOI 10.1097/00001756-200001170-00007; Meyers JR, 2003, J NEUROSCI, V23, P4054; MIRONOV SL, 1991, PFLUG ARCH EUR J PHY, V419, P138, DOI 10.1007/BF00372999; Olah Z, 2001, J BIOL CHEM, V276, P31163, DOI 10.1074/jbc.M101607200; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Paalasmaa P, 1996, J NEUROPHYSIOL, V75, P2354, DOI 10.1152/jn.1996.75.6.2354; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; TORNQUIST K, 1992, ENDOCRINOLOGY, V130, P717, DOI 10.1210/en.130.2.717; Trapp S, 1996, NEUROREPORT, V7, P2000, DOI 10.1097/00001756-199608120-00029; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Vulcu SD, 2004, NEUROSCIENCE, V125, P861, DOI 10.1016/j.neuroscience.2004.02.032; WANG GJ, 1994, J NEUROPHYSIOL, V72, P2563, DOI 10.1152/jn.1994.72.6.2563; WERTH JL, 1994, J NEUROSCI, V14, P348; WU ML, 1999, AM J PHYSIOL, V277, P717; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	50	118	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34553	34561		10.1074/jbc.M402966200	http://dx.doi.org/10.1074/jbc.M402966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173182	hybrid			2022-12-25	WOS:000223134800059
J	Reinhart, GJ; Xie, Q; Liu, XJ; Zhu, YF; Fan, J; Chen, C; Struthers, RS				Reinhart, GJ; Xie, Q; Liu, XJ; Zhu, YF; Fan, J; Chen, C; Struthers, RS			Species selectivity of nonpeptide antagonists of the gonadotropin-releasing hormone receptor is determined by residues in extracellular loops II and III and the amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GNRH RECEPTOR; MOLECULAR-MECHANISMS; BINDING; POTENT; ACTIVATION; AGONIST; DESIGN; SITE; IDENTIFICATION; SENSITIVITY	Efforts to develop orally available gonadotropin-releasing hormone (GnRH) receptor antagonists have led to the discovery of several classes of potent nonpeptide antagonists. Here we investigated molecular interactions of three classes of nonpeptide antagonists with human, rat, and macaque GnRH receptors. Although all are high affinity ligands of the human receptor (K-i < 5 nM), these compounds show reduced affinity for the macaque receptor and bind only weakly (K-i > 1 muM) to the rat receptor. To identify residues responsible for this selectivity, a series of chimeric receptors and mutant receptors was constructed and evaluated for nonpeptide binding. Surprisingly, 4 key residues located in the amino terminus (Met-24) and extracellular loops II (Ser-203, Gln-208) and III (Leu-300) of the GnRH receptor appear to be primarily responsible for species-selective binding. Comparisons of reciprocal mutations suggest that these may not be direct contacts but rather may be involved in organizing extracellular portions of the receptor. These data are novel because most previous reports of residues involved in binding of nonpeptide ligands to peptide-activated G protein-coupled receptors, including the GnRH receptor as well as mono-amine receptors, have identified binding sites in the transmembrane regions.	Neuroendocrine Biosci Inc, Dept Endocrinol, San Diego, CA 92121 USA; Neuroendocrine Biosci Inc, Dept Peptide Chem, San Diego, CA 92121 USA; Neuroendocrine Biosci Inc, Dept Med Chem, San Diego, CA 92121 USA; Neuroendocrine Biosci Inc, Dept Mol Biol, San Diego, CA 92121 USA	Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences; Neurocrine Biosciences	Struthers, RS (corresponding author), Neuroendocrine Biosci Inc, Dept Endocrinol, 10555 Sci Ctr Dr, San Diego, CA 92121 USA.	sstruthers@neurocrine.com			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD038625, R44HD038625] Funding Source: NIH RePORTER; NICHD NIH HHS [1R43 HD 38625-01, 2R44 HD 38625-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Assefa D, 1999, MOL CELL ENDOCRINOL, V156, P179, DOI 10.1016/S0303-7207(99)00123-9; BURGUS R, 1972, P NATL ACAD SCI USA, V69, P278, DOI 10.1073/pnas.69.1.278; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cho NB, 1998, J MED CHEM, V41, P4190, DOI 10.1021/jm9803673; Cui JS, 2000, MOL ENDOCRINOL, V14, P671, DOI 10.1210/me.14.5.671; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; Escrieut C, 2002, J BIOL CHEM, V277, P7546, DOI 10.1074/jbc.M108563200; Feighner SD, 1998, MOL ENDOCRINOL, V12, P137, DOI 10.1210/mend.12.1.0051; Fromme BJ, 2001, MOL PHARMACOL, V60, P1280, DOI 10.1124/mol.60.6.1280; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gross TD, 2002, BIOORG MED CHEM LETT, V12, P2185, DOI 10.1016/S0960-894X(02)00371-2; Guo ZQ, 2003, BIOORG MED CHEM LETT, V13, P3311, DOI 10.1016/S0960-894X(03)00620-6; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; Hunyady L, 1998, MOL PHARMACOL, V54, P427, DOI 10.1124/mol.54.2.427; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Labbe-Jullie C, 1998, J BIOL CHEM, V273, P16351, DOI 10.1074/jbc.273.26.16351; LIMONTA P, 1985, CONTRACEPTION, V32, P75, DOI 10.1016/0010-7824(85)90117-9; LUNENFELD B, 1999, GNRH ANALOGUES STATE; MATSUO H, 1971, BIOCHEM BIOPH RES CO, V43, P1334, DOI 10.1016/S0006-291X(71)80019-0; Millar RP, 2000, BRIT MED BULL, V56, P761, DOI 10.1258/0007142001903346; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Renzetti AR, 1999, J PHARMACOL EXP THER, V290, P487; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; THAU RB, 1985, J STEROID BIOCHEM, V23, P811, DOI 10.1016/S0022-4731(85)80020-0; Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195; Tokita K, 2001, J BIOL CHEM, V276, P495, DOI 10.1074/jbc.M006059200; Wilcoxen KM, 2002, BIOORG MED CHEM LETT, V12, P2179, DOI 10.1016/S0960-894X(02)00370-0; Zhu YF, 2002, BIOORG MED CHEM LETT, V12, P399, DOI 10.1016/S0960-894X(01)00779-X; Zhu YF, 2003, J MED CHEM, V46, P1769, DOI 10.1021/jm0205402	30	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34115	34122		10.1074/jbc.M404474200	http://dx.doi.org/10.1074/jbc.M404474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15155770	hybrid			2022-12-25	WOS:000223134800008
J	Chung, J; Yoon, SO; Lipscomb, EA; Mercurio, AM				Chung, J; Yoon, SO; Lipscomb, EA; Mercurio, AM			The met receptor and alpha(6)beta(4) integrin can function independently to promote carcinoma invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; ALPHA-6-BETA-4 INTEGRIN; CHEMOTACTIC MIGRATION; CELL MIGRATION; BETA 4; GROWTH; HEMIDESMOSOMES; ACTIVATION; ADHESION; METASTASIS	It has been proposed that a constitutive, physical association of the Met receptor and the alpha(6)beta(4) integrin exists on the surface of invasive carcinoma cells and that hepatocyte growth factor (HGF)-mediated invasion is dependent on alpha(6)beta(4) (Trusolino, L., Bertotti, A., and Comoglio, P. M. (2001) Cell 107, 643-654). The potential significance of these results prompted us to re-examine this hypothesis. Using three different carcinoma cell lines that express both Met and alpha(6)beta(4), we were unable to detect the constitutive association of these receptors by co-immunoprecipitation. Moreover, carcinoma cells that lacked expression of alpha(6)beta(4) exhibited Met-dependent invasion toward HGF, and increasing Met expression by viral infection of these cells enhanced invasion without inducing alpha(6)beta(4) expression. Although expression of alpha(6)beta(4) in such cells enhanced their invasion to HGF, it also enhanced their ability to invade toward other chemoattractants such as lysophosphatidic acid, and this latter invasion was not inhibited by a function-blocking Met antibody. Finally, depletion of beta(4) by RNA interference in invasive carcinoma cells that express both receptors reduced the ability of these cells to invade toward HGF by similar to25%, but it did not abrogate their invasion. These data argue that the invasive function of Met can be independent of alpha(6)beta(4) and that alpha(6)beta(4) has a generic influence on the invasion of carcinoma cells that is not specific to Met.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mercurio, AM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Res N,330 Brookline Ave, Boston, MA 02215 USA.	amercuri@caregroup.harvard.edu			NCI NIH HHS [CA80789, R01 CA080789] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080789] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Ke S, 2003, CANCER RES, V63, P7870; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Mercurio A M, 2001, Surg Oncol Clin N Am, V10, P313; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Mercurio AM, 2001, J MAMMARY GLAND BIOL, V6, P299, DOI 10.1023/A:1011323608064; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Tantivejkul K, 2003, ANTICANCER RES, V23, P3681; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366	28	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32287	32293		10.1074/jbc.M403809200	http://dx.doi.org/10.1074/jbc.M403809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161909	hybrid			2022-12-25	WOS:000222849700038
J	Jensik, PJ; Huggenvik, JI; Collard, MW				Jensik, PJ; Huggenvik, JI; Collard, MW			Identification of a nuclear export signal and protein interaction domains in deformed epidermal autoregulatory factor-1 (DEAF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID MODULATORY ELEMENT; SAND DOMAIN; LIM DOMAIN; GENE; SEQUENCE; BINDING; LMO4; TRANSCRIPTION; REPRESSION; DROSOPHILA	Deformed epidermal autoregulatory factor-1 (DEAF-1) is a DNA-binding protein required for embryonic development and linked to clinical depression and suicidal behavior in humans. Although primarily nuclear, cytoplasmic localization of DEAF-1 has been observed, and this suggests the presence of a nuclear export signal (NES). Using a series of fluorescent fusion proteins, an NES with a novel spacing of leucines (LXLX6LLX5LX2L) was identified near the COOH-terminal MYND domain at amino acids 454-476. The NES was leptomycin B-sensitive and mutation of the leucine residues decreased or eliminated nuclear export activity. In vitro pull downs and an in vivo fluorescent protein interaction assay identified a DEAF-1/DEAF-1 protein interaction domain within the NES region. DNA binding had been previously mapped to a positively charged surface patch in the novel DNA binding fold called the "SAND" domain. A second protein-protein interaction domain was identified at amino acids 243-306 that contains the DNA-binding SAND domain and also an adjacent zinc binding motif and a monopartite nuclear localization signal (NLS). Deletion of these adjacent sequences or mutation of the conserved cysteines or histidine in the zinc binding motif not only inhibits protein interaction but also eliminates DNA binding, demonstrating that DEAF-1 protein-protein interaction is required for DNA recognition. The identification of an NES and NLS provides a basis for the control of DEAF-1 subcellular localization and function, whereas the requirement of protein-protein interaction by the SAND domain appears to be unique among this class of transcription factors.	So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Collard, MW (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.	mcollard@siumed.edu			NCI NIH HHS [CA89438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chen HH, 2002, DEVELOPMENT, V129, P4879; Chen J, 2002, J BIOL CHEM, V277, P22053, DOI 10.1074/jbc.M202311200; Comerford KM, 2003, P NATL ACAD SCI USA, V100, P986, DOI 10.1073/pnas.0337412100; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Jensik P, 2002, J COMP PHYSIOL B, V172, P569, DOI 10.1007/s00360-002-0285-9; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Lemonde S, 2003, J NEUROSCI, V23, P8788; Lo Surdo P, 2003, MOL ENDOCRINOL, V17, P1283, DOI 10.1210/me.2002-0409; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Luque CM, 2003, J BIOL CHEM, V278, P2686, DOI 10.1074/jbc.M201521200; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Manne U, 2001, CLIN CANCER RES, V7, P3495; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; Veraksa A, 2002, GENESIS, V33, P67, DOI 10.1002/gene.10090; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756	38	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32692	32699		10.1074/jbc.M400946200	http://dx.doi.org/10.1074/jbc.M400946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161925	hybrid			2022-12-25	WOS:000222849700088
J	Lee, HT; Lee, JG; Na, M; Kay, EDP				Lee, HT; Lee, JG; Na, M; Kay, EDP			FGF-2 induced by interleukin-1 beta through the action of phosphatidylinositol 3-kinase mediates endothelial mesenchymal transformation in corneal endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; RETROCORNEAL FIBROUS MEMBRANE; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; COLLAGEN-SYNTHESIS; EPITHELIAL-CELLS; POLYMORPHONUCLEAR LEUKOCYTES; INFLAMMATORY CYTOKINES; EXTRACELLULAR-MATRIX; SIGNALING PATHWAYS	Our previous work demonstrated that both polymorphonuclear leukocytes (PMNs) and protein fractions released from PMNs induced de novo synthesis of fibroblast growth factor 2 (FGF-2), which in turn becomes the direct mediator of endothelial mesenchymal transformation observed in corneal endothelial cells (CECs). To identify the protein factor, we used ProteinChip Array technology. Protein fractions obtained from the conditioned medium released by PMNs were resolved by two-dimensional electrophoresis with immobilized pH gradient strips. Most of the protein spots, with molecular masses of 17 kDa, were sequentially subjected to in-gel trypsin digestion and mass spectrometry. The 17-kDa peptide band was identified as interleukin-1beta (IL-1beta). Biological activities of IL-1beta were further determined; IL-1beta altered the shape of CECs from polygonal to fibroblastic morphologies in a time- and dose-dependent manner, whereas neutralizing IL-1beta antibody, neutralizing antibody to FGF-2, and LY294002 blocked the action of IL-1beta. IL-1beta greatly increased the levels of FGF-2 mRNA in a time- and dose-dependent manner; IL-1beta stimulated expression of all isoforms of FGF-2. IL-1beta initially induced nuclear accumulation of FGF-2 and facilitated translocation of FGF-2 to plasma membrane and extracellular matrix. IL-1beta activated phosphatidylinositol (PI) 3-kinase, the enzyme activity of which was greatly stimulated after a 5-min exposure to IL-1beta. This early and rapid activation of PI 3-kinase greatly enhanced FGF-2 production in CECs; pretreatment with LY294002 hampered the induction activity of IL-1beta. These observations suggest that IL-1beta takes part in endothelial to mesenchymal transformation of CECs through its inductive potential on FGF-2 via the action of PI 3-kinase.	Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA	Doheny Eye Institute; University of Southern California; University of Southern California	Kay, EDP (corresponding author), Univ So Calif, Keck Sch Med, Doheny Eye Inst, 1450 San Pablo St,DVRC 203, Los Angeles, CA 90033 USA.	ekay@usc.edu	谭, 德华 德/D-1910-2009		NEI NIH HHS [EY06431, EY03040] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006431, P30EY003040] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Arndt PG, 2004, J BIOL CHEM, V279, P10883, DOI 10.1074/jbc.M309901200; BROWN SI, 1966, ARCH OPHTHALMOL-CHIC, V75, P518; Caputo E, 2003, ANAL BIOCHEM, V321, P116, DOI 10.1016/S0003-2697(03)00361-0; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Cronauer MV, 1999, AM J PATHOL, V155, P1977, DOI 10.1016/S0002-9440(10)65516-2; Cubitt CL, 2001, INVEST OPHTH VIS SCI, V42, P701; Daniels JT, 2000, INVEST OPHTH VIS SCI, V41, P3754; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1991, BLOOD, V77, P1627; Faris M, 1998, AIDS, V12, P19, DOI 10.1097/00002030-199801000-00003; Gu X, 1998, INVEST OPHTH VIS SCI, V39, P2252; Gu X, 1996, INVEST OPHTH VIS SCI, V37, P2326; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Kay E P, 1998, Mol Vis, V4, P22; KAY EDP, 1994, INVEST OPHTH VIS SCI, V35, P2427; KAY EP, 1982, J BIOL CHEM, V257, P7116; KAY EP, 1984, INVEST OPHTH VIS SCI, V25, P502; KAY EP, 1993, INVEST OPHTH VIS SCI, V34, P663; KAY EP, 1982, INVEST OPHTH VIS SCI, V22, P200; KAY EP, 1985, J BIOL CHEM, V260, P5139; Ko MHK, 2002, MOL VIS, V8, P1; Leak LV, 2004, PROTEOMICS, V4, P753, DOI 10.1002/pmic.200300573; Lee HT, 2003, MOL VIS, V9, P624; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P1521, DOI 10.1167/iovs.02-0637; Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200; Leung EW, 2000, MOL VIS, V6, P15; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; McDermott AM, 2003, INVEST OPHTH VIS SCI, V44, P1859, DOI 10.1167/iovs.02-0787; Merchant M, 2000, ELECTROPHORESIS, V21, P1164, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.0.CO;2-0; MICHELS RG, 1972, INVEST OPHTH VISUAL, V11, P822; Mohri M, 2002, INVEST OPHTH VIS SCI, V43, P3190; Moore JE, 2002, INVEST OPHTH VIS SCI, V43, P2905; Narita Y, 2002, CANCER RES, V62, P6764; Neumann D, 2002, EUR J IMMUNOL, V32, P3689, DOI 10.1002/1521-4141(200212)32:12<3689::AID-IMMU3689>3.0.CO;2-X; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; PSHENICHKIN SP, 1994, J NEUROCHEM, V63, P419; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Sobue T, 2001, BIOCHEM BIOPH RES CO, V286, P33, DOI 10.1006/bbrc.2001.5343; TAMURA M, 1993, J BIOL CHEM, V268, P8140; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Yano K, 2001, J BONE MINER METAB, V19, P365, DOI 10.1007/s007740170006; Yoshida S, 2003, LAB INVEST, V83, P927, DOI 10.1097/01.LAB.0000075642.11787.83; Zhang JF, 2002, FEBS LETT, V521, P180, DOI 10.1016/S0014-5793(02)02872-7	54	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32325	32332		10.1074/jbc.M405208200	http://dx.doi.org/10.1074/jbc.M405208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173165	hybrid			2022-12-25	WOS:000222849700043
J	Misiaszek, R; Crean, C; Joffe, A; Geacintov, NE; Shafirovich, V				Misiaszek, R; Crean, C; Joffe, A; Geacintov, NE; Shafirovich, V			Oxidative DNA damage associated with combination of guanine and superoxide radicals and repair mechanisms via radical trapping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-ELECTRON OXIDATION; DOUBLE-STRANDED DNA; AQUEOUS-SOLUTION; MAJOR PRODUCT; PHOTOSENSITIZED OXIDATION; TRANSFORMATION REACTIONS; REDUCTION POTENTIALS; HYDANTOIN PRODUCTS; NITROGEN-DIOXIDE; REACTIVE OXYGEN	In living tissues under inflammatory conditions, superoxide radicals (O-2(-.).) are generated and are known to cause oxidative DNA damage. However, the mechanisms of action are poorly understood. It is shown here that the combination of O-2(-.) with guanine neutral radicals, G(-H)(.) in single- or double-stranded oligodeoxyribonucleotides (rate constant of 4.7 +/- 1.0 x 10(8) M-1 s(-1) in both cases), culminates in the formation of oxidatively modified guanine bases (major product, imidazolone; minor product, 8-oxo-7,8-dihydroguanine). The G(-H)(.) and O-2(-.) radicals were generated by intense 308 nm excimer laser pulses resulting in the one-electron oxidation and deprotonation of guanine in the 5'-d(CC[2AP]-TCGCTACC) strands and the trapping of the ejected electrons by molecular oxygen (Shafirovich, V., Dourandin, A., Huang, W., Luneva, N. P., and Geacintov, N. E. (2000) Phys. Chem. Chem. Phys. 2, 4399-4408). The addition of Cu,Zn-superoxide dismutase, known to react rapidly with superoxide, dramatically enhances the lifetimes of guanine radicals from 4 to 7 ms to 0.2-0.6 s in the presence of 5 muM superoxide dismutase. Oxygen-18 isotope labeling experiments reveal two pathways of 8-oxo-7,8-dihydroguanine formation including either addition of O-2(-.) to the C-8 position of G(-H)(.) (in the presence of oxygen), or the hydration of G(-H)(.) (in the absence of oxygen). The formation of the guanine lesions via combination of guanine and superoxide radicals is greatly reduced in the presence of typical antioxidants such as trolox and catechol that rapidly regenerate guanine by the reductive "repair" of G(-H)(.) radicals. The mechanistic aspects of the radical reactions that either regenerate undamaged guanine in DNA or lead to oxidatively modified guanine bases are discussed.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Radiat & Solid State Lab, New York, NY 10003 USA	New York University; New York University	Shafirovich, V (corresponding author), NYU, Dept Chem, 31 Washington Pl, New York, NY 10003 USA.	vs5@nyu.edu	Crean, Conor/A-6609-2010		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011589] Funding Source: NIH RePORTER; NIEHS NIH HHS [5R01ES11589] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adam W, 2002, ORG LETT, V4, P537, DOI 10.1021/ol017138m; ALSHEIKHLY M, 1994, RADIAT PHYS CHEM, V44, P297, DOI 10.1016/0969-806X(94)90007-8; BERGER M, 1990, J LIQ CHROMATOGR, V13, P929, DOI 10.1080/01483919008049222; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BIELSKI BHJ, 1978, PHOTOCHEM PHOTOBIOL, V28, P645, DOI 10.1111/j.1751-1097.1978.tb06986.x; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Cadet J, 2002, BIOL CHEM, V383, P933, DOI 10.1515/BC.2002.100; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; Candeias LP, 2000, CHEM-EUR J, V6, P475, DOI 10.1002/(SICI)1521-3765(20000204)6:3<475::AID-CHEM475>3.0.CO;2-E; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Douki T, 1999, INT J RADIAT BIOL, V75, P571; Duarte V, 2000, J AM CHEM SOC, V122, P12622, DOI 10.1021/ja002218r; Flyunt R, 2003, J PHYS CHEM B, V107, P7242, DOI 10.1021/jp022455b; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gasparutto D, 1998, J AM CHEM SOC, V120, P10283, DOI 10.1021/ja980674y; Grisham MB, 2000, ALIMENT PHARM THERAP, V14, P3, DOI 10.1046/j.1365-2036.2000.014s1003.x; Halliwell B, 1999, MUTAT RES-GEN TOX EN, V443, P37, DOI 10.1016/S1383-5742(99)00009-5; HILDENBRAND K, 1990, FREE RADICAL RES COM, V11, P195, DOI 10.3109/10715769009088916; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; ITO K, 1993, J BIOL CHEM, V268, P13221; Joffe A, 2003, CHEM RES TOXICOL, V16, P1528, DOI 10.1021/tx034142t; Joffe A, 2003, CHEM RES TOXICOL, V16, P966, DOI 10.1021/tx025578w; JONSSON M, 1993, J PHYS CHEM-US, V97, P8229, DOI 10.1021/j100133a018; JOVANOVIC SV, 1989, BIOCHIM BIOPHYS ACTA, V1008, P39, DOI 10.1016/0167-4781(89)90167-X; Kang P, 2002, J AM CHEM SOC, V124, P4865, DOI 10.1021/ja012038x; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; KLUG D, 1972, J BIOL CHEM, V247, P4839; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Luo WC, 2001, ORG LETT, V3, P2801, DOI 10.1021/ol0161763; Luo WC, 2001, CHEM RES TOXICOL, V14, P927, DOI 10.1021/tx010072j; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; Martinez GR, 2002, BIOL CHEM, V383, P607, DOI 10.1515/BC.2002.063; Mestre B, 1998, CR ACAD SCI II C, V1, P725, DOI 10.1016/S1387-1609(99)80030-9; Niles JC, 2001, ORG LETT, V3, P963, DOI 10.1021/ol006993n; RAOUL S, 1996, J CHEM SOC P2, V2, P371; Ravanat JL, 2000, ARCH BIOCHEM BIOPHYS, V374, P118, DOI 10.1006/abbi.1999.1610; Ravanat JL, 2003, J AM CHEM SOC, V125, P2030, DOI 10.1021/ja028608q; RAVANAT JL, 1992, PHOTOCHEM PHOTOBIOL, V55, P809, DOI 10.1111/j.1751-1097.1992.tb08528.x; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; Seguy C, 2001, CHEM COMMUN, P2116, DOI 10.1039/b106799k; Shafirovich V, 2001, J BIOL CHEM, V276, P24621, DOI 10.1074/jbc.M101131200; Shafirovich V, 2000, PHYS CHEM CHEM PHYS, V2, P4399, DOI 10.1039/b004896h; Shafirovich V, 1999, J PHYS CHEM B, V103, P10924, DOI 10.1021/jp992002f; Shafirovich V, 2002, CHEM RES TOXICOL, V15, P591, DOI 10.1021/tx015593l; Shafirovich V, 2001, J PHYS CHEM B, V105, P8431, DOI 10.1021/jp0044734; Shafirovich V, 2001, CHEM RES TOXICOL, V14, P233, DOI 10.1021/tx000204t; Simic M. G., 1986, MECH DNA DAMAGE REPA, V38, P39; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; Steenken S, 1997, BIOL CHEM, V378, P1293; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; STEENKEN S, 1982, J PHYS CHEM-US, V86, P3661, DOI 10.1021/j100215a033; Valentine JS, 1999, ADV EXP MED BIOL, V448, P193; VONSONNTAG C, 1994, INT J RADIAT BIOL, V66, P485, DOI 10.1080/09553009414551501; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843	58	172	172	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32106	32115		10.1074/jbc.M313904200	http://dx.doi.org/10.1074/jbc.M313904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15152004	hybrid			2022-12-25	WOS:000222849700016
J	Xia, H; Nho, RS; Kahm, J; Kleidon, J; Henke, CA				Xia, H; Nho, RS; Kahm, J; Kleidon, J; Henke, CA			Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta(1) integrin viability signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; TYROSINE KINASES; CELL-SURVIVAL; ENDOTHELIAL-CELLS; SHEAR-STRESS; APOPTOSIS; INTEGRIN; PHOSPHORYLATION; 3-KINASE; PP125(FAK)	The beta(1) integrin, functioning as a mechanoreceptor, senses a mechanical stimulus generated during collagen matrix contraction and down-regulates the phosphatidylinositol 3-kinase (PI3K)/Akt survival signal triggering apoptosis. The identities of integrin-associated signal molecules in the focal adhesion complex that are responsible for propagating beta1 integrin viability signals in response to collagen matrix contraction are not known. Here we show that in response to collagen contraction focal adhesion kinase (FAK) is dephosphorylated. In contrast, enforced activation of beta(1) integrin by anti-beta(1) integrin antibody, which protects fibroblasts from apoptosis, preserves FAK phosphorylation. We demonstrate that ligation of beta(1) integrin by type I collagen or by enforced activation of beta(1) integrin by antibody promotes phosphorylation of FAK, p85 subunit of PI3K, and serine 473 of Akt. Wortmannin inhibited Akt but not FAK phosphorylation in response to enforced activation of beta(1) integrin by antibody. Blocking FAK by pharmacologic inhibition or by dominant negative FAK attenuated phosphorylation of p85 subunit of PI3K and Akt. Dominant negative FAK augmented fibroblast apoptosis during collagen contraction, and this was associated with diminished Akt activity. Constitutively active FAK augmented levels of p85 subunit of PI3K and Akt phosphorylation, and fibroblasts were protected from apoptosis. Our data identify a novel role for FAK, functioning upstream of PI3K/Akt, in transducing a beta(1) integrin viability signal in collagen matrices.	Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Henke, CA (corresponding author), Univ Minnesota, Dept Med, 420 Delaware St SE,Box 276, Minneapolis, MN 55455 USA.	henke002@umn.edu						Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; Crouch DH, 1996, ONCOGENE, V12, P2689; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mortier E, 2001, CELL SIGNAL, V13, P901, DOI 10.1016/S0898-6568(01)00226-1; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yamada KM, 2001, J CELL SCI, V114, P2375	37	273	280	4	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					33024	33034		10.1074/jbc.M313265200	http://dx.doi.org/10.1074/jbc.M313265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166238	hybrid			2022-12-25	WOS:000222849700122
J	Arimura, A; van Peer, M; Schroder, AJ; Rothman, PB				Arimura, A; van Peer, M; Schroder, AJ; Rothman, PB			The transcriptional co-activator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; CREB-BINDING PROTEIN; KAPPA-B; TRANSACTIVATION DOMAIN; LXXLL MOTIF; IL-4; CBP; IGE; INTERLEUKIN-4; COMPLEX	Transcriptional activation by signal transducer and activator of transcription 6 (STAT6) has been shown to require the direct interaction not only with co-activators such as p300 and cAMP-responsive element-binding protein-binding protein (CBP) but also with nuclear coactivator 1, a member of the p160/steroid receptor coactivator family. Among the p160/steroid receptor coactivators, only p/CIP ( nuclear co-activator 3) has been shown to be up-regulated by interleukin (IL)-4 in B cells through a STAT-6-dependent mechanism using Gene-hip analysis. In this study, we have investigated the function of p/CIP in the transcriptional activation by STAT6. We found that p/CIP indirectly interacted with STAT6 via p300, and overexpression of the CBP-interacting domain of p/CIP (p/CIP947-1084) prevented the interaction of p/CIP with STAT6 by blocking the binding of p/CIP to p300. Whereas expression of p/CIP947-1084 resulted in a marked reduction of STAT6-mediated transactivation, overexpression of wild type p/CIP resulted in significant enhancement of it. In addition, p/CIP947-1084 markedly reduced CD23 expression on B cells stimulated with IL-4, whereas overexpression of wild type p/CIP enhanced it. Chromatin immunoprecipitations demonstrate that IL-4 increases the interaction of p/CIP with the murine immunoglobulin heavy chain germ line epsilon promoter in B cells. These results suggest that p/CIP positively regulates STAT6 transcriptional activation through formation of a STAT6, p300/ CBP, and p/CIP complex.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Rothman, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 630 W 168 St,Box 91, New York, NY 10032 USA.	pbr3@columbia.edu		Schroder, Andreas/0000-0002-3568-1358				Andrews RP, 2002, J BIOL CHEM, V277, P36563, DOI 10.1074/jbc.M200986200; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Curiel RE, 1997, EUR J IMMUNOL, V27, P1982, DOI 10.1002/eji.1830270823; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deVries JE, 1995, CURR OPIN IMMUNOL, V7, P771, DOI 10.1016/0952-7915(95)80046-8; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; HUUSKONEN J, 2004, ARTERIOSCLER THROMB, P703; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Litterst CM, 2002, J BIOL CHEM, V277, P36052, DOI 10.1074/jbc.M203556200; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Messner B, 1997, J IMMUNOL, V159, P3330; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; Schroder AJ, 2002, J IMMUNOL, V168, P996, DOI 10.4049/jimmunol.168.3.996; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tinnell SB, 1998, INT IMMUNOL, V10, P1529, DOI 10.1093/intimm/10.10.1529; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yasuda J, 2004, CANCER SCI, V95, P52, DOI 10.1111/j.1349-7006.2004.tb03170.x; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	52	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31105	31112		10.1074/jbc.M404428200	http://dx.doi.org/10.1074/jbc.M404428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145939	hybrid			2022-12-25	WOS:000222726800026
J	Beard, WA; Shock, DD; Wilson, SH				Beard, WA; Shock, DD; Wilson, SH			Influence of DNA structure on DNA polymerase beta active site function - Extension of mutagenic DNA intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; REVERSE-TRANSCRIPTASE; NUCLEOTIDE INCORPORATION; CATALYTIC EFFICIENCY; DYNAMICS SIMULATIONS; REPLICATION FIDELITY; MISMATCH EXTENSION; CRYSTAL-STRUCTURES; TERNARY COMPLEXES; BINDING	In the ternary substrate complex of DNA polymerase (pol) beta, the nascent base pair (templating and incoming nucleotides) is sandwiched between the duplex DNA terminus and polymerase. To probe molecular interactions in the dNTP-binding pocket, we analyzed the kinetic behavior of wild-type pol beta on modified DNA substrates that alter the structure of the DNA terminus and represent mutagenic intermediates. The DNA substrates were modified to 1) alter the sequence of the duplex terminus ( matched and mismatched), 2) introduce abasic sites near the nascent base pair, and 3) insert extra bases in the primer or template strands to mimic frameshift intermediates. The results indicate that the nucleotide insertion efficiency (k(cat)/K-m, dGTP-dC) is highly dependent on the sequence identity of the matched (i.e. Watson-Crick base pair) DNA terminus (template/primer, G/C similar to A/T > T/A similar to C/G). Mismatches at the primer terminus strongly diminish correct nucleotide insertion efficiency but do not affect DNA binding affinity. Transition intermediates are generally extended more easily than transversions. Most mismatched primer termini decrease the rate of insertion and binding affinity of the incoming nucleotide. In contrast, the loss of catalytic efficiency with homopurine mismatches at the duplex DNA terminus is entirely due to the inability to insert the incoming nucleotide, since K-d(dGTP) is not affected. Abasic sites and extra nucleotides in and around the duplex terminus decrease catalytic efficiency and are more detrimental to the nascent base pair binding pocket when situated in the primer strand than the equivalent position in the template strand.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; Beard WA, 1995, METHOD ENZYMOL, V262, P98; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BEARD WA, 1995, HIV PRACTICAL APPROA, V2, P15; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P7321, DOI 10.1021/bi9803372; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson SJ, 2004, CELL, V116, P803, DOI 10.1016/S0092-8674(04)00252-1; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kraynov VS, 1997, BIOCHEM J, V323, P103, DOI 10.1042/bj3230103; Kraynov VS, 2000, BIOCHEMISTRY-US, V39, P16008, DOI 10.1021/bi0008480; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kuzmic P, 2003, ANAL BIOCHEM, V319, P272, DOI 10.1016/S0003-2697(03)00248-3; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Osheroff WP, 2000, J BIOL CHEM, V275, P28033; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Shah AM, 2003, BIOCHEMISTRY-US, V42, P10709, DOI 10.1021/bi034885d; Skandalis A, 2001, NUCLEIC ACIDS RES, V29, P2418, DOI 10.1093/nar/29.11.2418; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Vaisman A, 2001, J BIOL CHEM, V276, P18999, DOI 10.1074/jbc.M007805200; Washington MT, 2001, J BIOL CHEM, V276, P2263, DOI 10.1074/jbc.M009049200; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Yang LJ, 2002, J MOL BIOL, V321, P459, DOI 10.1016/S0022-2836(02)00617-4; Yang LJ, 2004, BIOPHYS J, V86, P3392, DOI 10.1529/biophysj.103.036012	46	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31921	31929		10.1074/jbc.M404016200	http://dx.doi.org/10.1074/jbc.M404016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145936	hybrid			2022-12-25	WOS:000222726800119
J	Jokinen, J; Dadu, E; Nykvist, P; Kapyla, J; White, DJ; Ivaska, J; Vehvilainen, P; Reunanen, H; Larjava, H; Hakkinen, L; Heino, J				Jokinen, J; Dadu, E; Nykvist, P; Kapyla, J; White, DJ; Ivaska, J; Vehvilainen, P; Reunanen, H; Larjava, H; Hakkinen, L; Heino, J			Integrin-mediated cell adhesion to type I collagen fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL COLLAGEN; BINDING-SITE; ALPHA-1-BETA-1 INTEGRIN; CRYSTAL-STRUCTURE; GEL CONTRACTION; LIGAND-BINDING; A-DOMAIN; ALPHA-2-BETA-1; ALPHA(2)BETA(1); EXPRESSION	In the integrin family, the collagen receptors form a structurally and functionally distinct subgroup. Two members of this subgroup, alpha(1)beta(1) and alpha(2)beta(1) integrins, are known to bind to monomeric form of type I collagen. However, in tissues type I collagen monomers are organized into large fibrils immediately after they are released from cells. Here, we studied collagen fibril recognition by integrins. By an immunoelectron microscopy method we showed that integrin alpha(2)I domain is able to bind to classical D-banded type I collagen fibrils. However, according to the solid phase binding assay, the collagen fibril formation appeared to reduce integrin alpha(1)I and alpha(2)I domain avidity to collagen and to lower the number of putative alphaI domain binding sites on it. Respectively, cellular alpha(1)beta(1) integrin was able to mediate cell spreading significantly better on monomeric than on fibrillar type I collagen matrix, whereas alpha(2)beta(1) integrin appeared still to facilitate both cell spreading on fibrillar type I collagen matrix and also the contraction of fibrillar type I collagen gel. Additionally, alpha(2)beta(1) integrin promoted the integrin-mediated formation of long cellular projections typically induced by fibrillar collagen. Thus, these findings suggest that alpha(2)beta(1) integrin is a functional cellular receptor for type I collagen fibrils, whereas alpha(1)beta(1) integrin may only effectively bind type I collagen monomers. Furthermore, when the effect of soluble alphaI domains on type I collagen fibril formation was tested in vitro, the observations suggest that integrin type collagen receptors might guide or even promote pericellular collagen fibrillogenesis.	Univ Turku, Dept Biochem & Food Chem, FI-20014 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FI-40014 Jyvaskyla, Finland; Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ Turku, Ctr Biotechnol, VTT Med Biotechnol, FI-20520 Turku, Finland	University of Turku; University of Jyvaskyla; University of British Columbia; University of Turku; VTT Technical Research Center Finland	Jokinen, J (corresponding author), Univ Turku, Dept Biochem & Food Chem, FI-20014 Turku, Finland.	jyrki.heino@utu.fi	Larjava, Hannu/GRO-4325-2022; white, daniel J/G-1159-2012; Hakkinen, Lari/B-2228-2016	white, daniel J/0000-0003-4233-0166; Dadu, Elina/0000-0001-5200-8256; Kapyla, Jarmo/0000-0003-3036-713X; Ruuhilehto, Elina/0000-0003-1450-1175; Ivaska, Johanna/0000-0002-6295-6556				BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Cooke ME, 2000, J CELL SCI, V113, P2375; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002-9440(10)61124-8; Emsley J, 2004, J MOL BIOL, V335, P1019, DOI 10.1016/j.jmb.2003.11.030; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Gardner H, 1999, J CELL SCI, V112, P263; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Grundstrom G, 2003, EXP CELL RES, V291, P463, DOI 10.1016/j.yexcr.2003.07.010; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Kadler KE, 1996, BIOCHEM J, V316, P1; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Kuznetsova N, 1999, J BIOL CHEM, V274, P36083, DOI 10.1074/jbc.274.51.36083; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Pozzi M, 1998, J CELL BIOL, V142, P587; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Racine-Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RIIKONEN T, 1995, J BIOL CHEM, V270, P376, DOI 10.1074/jbc.270.1.376; Sato K, 2003, CELL STRUCT FUNCT, V28, P229, DOI 10.1247/csf.28.229; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; WOOD GC, 1960, BIOCHEM J, V75, P605, DOI 10.1042/bj0750605; WOOD GC, 1960, BIOCHEM J, V75, P598, DOI 10.1042/bj0750598; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	54	266	289	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31956	31963		10.1074/jbc.M401409200	http://dx.doi.org/10.1074/jbc.M401409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145957	hybrid			2022-12-25	WOS:000222726800124
J	Leonard, PM; Grogan, G				Leonard, PM; Grogan, G			Structure of 6-oxo camphor hydrolase H122A mutant bound to its natural product, (2S,4S)-alpha-campholinic acid - Mutant structure suggests an atypical mode of transition state binding for a crotonase homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRO-CLAISEN REACTION; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ENZYME; COENZYME; DESYMMETRIZATION; SUPERFAMILY; REFINEMENT; MOLSCRIPT; PROGRAM	The crotonase homolog, 6-oxo camphor hydrolase (OCH), catalyzes the desymmetrization of bicyclic beta-diketones to optically active keto acids via an enzymatic retro-Claisen reaction, resulting in the cleavage of a carbon-carbon bond. We have previously reported the structure of OCH (Whittingham, J. L., Turkenburg, J. P., Verma, C. S., Walsh, M. A., and Grogan, G. ( 2003) J. Biol. Chem. 278, 1744 - 1750), which suggested the involvement of five residues, His-45, His-122, His-145, Asp-154, and Glu-244, in catalysis. Here we report mutation studies on OCH that reveal that H145A and D154N mutants of OCH have greatly reduced values of k(cat)/K-m derived from a very large increase in K-m for the native substrate, 6-oxo camphor. In addition, H122A has a greatly reduced value of k(cat), and its K-m is five times that of the wildtype. The location of the active site is confirmed by the 1.9-Angstrom structure of the H122A mutant of OCH complexed with the minor diastereoisomer of (2S, 4S)-alpha-campholinic acid, the natural product of the enzyme. This shows the pendant acetate of the product hydrogen bonded to a His-145/Asp-154 dyad and the endocyclic carbonyl of the cyclopentane ring hydrogen bonded to Trp-40. The results are suggestive of a base-catalyzed mechanism of C-C bond cleavage and provide clues to the origin of prochiral selectivity by the enzyme and to the recruitment of the crotonase fold for alternate modes of transition state stabilization to those described for other crotonase superfamily members.	Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England	University of York - UK	Grogan, G (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	gg12@york.ac.uk		Leonard, Philip/0000-0002-2988-5557				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; CHAPMAN PJ, 1966, J AM CHEM SOC, V88, P618, DOI 10.1021/ja00955a049; Eberhard ED, 2002, BIOCHEMISTRY-US, V41, P8978; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Grogan G, 2002, J MOL CATAL B-ENZYM, V19, P73, DOI 10.1016/S1381-1177(02)00153-4; Grogan G, 2001, ANGEW CHEM INT EDIT, V40, P1111, DOI 10.1002/1521-3773(20010316)40:6<1111::AID-ANIE11110>3.0.CO;2-2; Grogan G, 2001, J BIOL CHEM, V276, P12565, DOI 10.1074/jbc.M011538200; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier DA, 1998, J BACTERIOL, V180, P2330, DOI 10.1128/JB.180.9.2330-2336.1998; Schoffers E, 1996, TETRAHEDRON, V52, P3769, DOI 10.1016/S0040-4020(95)01021-1; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; Shimao M, 2000, MICROBIOL-UK, V146, P649, DOI 10.1099/00221287-146-3-649; Straganz G, 2002, BIOCHEM BIOPH RES CO, V297, P232, DOI 10.1016/S0006-291X(02)02182-4; Truglio JJ, 2003, J BIOL CHEM, V278, P42352, DOI 10.1074/jbc.M307399200; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200	30	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31312	31317		10.1074/jbc.M403514200	http://dx.doi.org/10.1074/jbc.M403514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138275	hybrid			2022-12-25	WOS:000222726800051
J	Ooshio, T; Irie, K; Morimoto, K; Fukuhara, A; Imai, T; Takai, Y				Ooshio, T; Irie, K; Morimoto, K; Fukuhara, A; Imai, T; Takai, Y			Involvement of LMO7 in the association of two cell-cell adhesion molecules, nectin and E-cadherin, through afadin and alpha-actinin in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENS JUNCTIONS; BINDING PROTEIN; TIGHT JUNCTIONS; INTERCELLULAR-JUNCTIONS; DIFFERENTIAL BEHAVIOR; CANDIDATE GENES; ROLES; POLARITY; DOMAIN; MUSCLE	Nectins are Ca2+-independent immunoglobulin-like cell-cell adhesion molecules that are involved in formation of cadherin-based adherens junctions (AJs). The nectin-based cell-cell adhesion induces activation of Cdc42 and Rac small G proteins, which eventually enhances the formation of AJs through reorganization of the actin cytoskeleton. Although evidence has accumulated that nectins recruit cadherins to the nectin-based cell-cell adhesion sites through their cytoplasm-associated proteins, afadin and catenins, it is not fully understood how nectins are physically associated with cadherins. Here we identified a rat counterpart of the human LIM domain only 7 (LMO7) as an afadin- and alpha-actinin-binding protein. Rat LMO7 has two splice variants, LMO7a and LMO7b, consisting of 1,729 and 1,395 amino acids, respectively. LMO7 has calponin homology, PDZ, and LIM domains. Western blotting revealed that LMO7 was expressed ubiquitously in various rat tissues. Immunofluorescence and immunoelectron microscopy revealed that LMO7 localized at cell-cell AJs, where afadin localized, in epithelial cells of rat gallbladder. In addition, LMO7 localized at the cytoplasmic faces of apical membranes in the same epithelial cells. We furthermore revealed that LMO7 bound alpha-actinin, an actin filament-bundling protein, which bound to alpha-catenin. Immunoprecipitation analysis revealed that LMO7 was associated with both the nectin-afadin and E-cadherin-catenin systems. LMO7 was assembled at the cell-cell adhesion sites after both the nectin-afadin and E-cadherin-catenin systems had been assembled. These results indicate that LMO7 is an afadin- and alpha-actinin-binding protein that connects the nectin-afadin and E-cadherin-catenin systems through alpha-actinin.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan	Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778; Ooshio, Takako/0000-0001-6508-8152				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; James P, 1996, GENETICS, V144, P1425; Kaiser C., 1994, METHODS YEAST GENETI; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Kurihara LJ, 2002, GENOMICS, V79, P154, DOI 10.1006/geno.2002.6692; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Putilina T, 1998, BIOCHEM BIOPH RES CO, V252, P433, DOI 10.1006/bbrc.1998.9656; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Semenova E, 2003, HUM MOL GENET, V12, P1301, DOI 10.1093/hmg/ddg140; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CURR OPIN NEUROBIOL, V13, P520, DOI 10.1016/j.conb.2003.09.003; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	43	110	114	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31365	31373		10.1074/jbc.M401957200	http://dx.doi.org/10.1074/jbc.M401957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140894	hybrid			2022-12-25	WOS:000222726800057
J	Morand, S; Agnandji, D; Noel-Hudson, MS; Nicolas, V; Buisson, S; Macon-Lemaitre, L; Gnidehou, S; Kaniewski, J; Ohayon, R; Virion, A; Dupuy, C				Morand, S; Agnandji, D; Noel-Hudson, MS; Nicolas, V; Buisson, S; Macon-Lemaitre, L; Gnidehou, S; Kaniewski, J; Ohayon, R; Virion, A; Dupuy, C			Targeting of the dual oxidase 2 N-terminal region to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; NADPH OXIDASE; H2O2 GENERATOR; INTRACELLULAR TRAFFICKING; CONGENITAL GOITER; PROTEINS; THYROGLOBULIN; EXPRESSION; HEME; THYROPEROXIDASE	Dual oxidase 2 (Duox2) is a cell surface glycoprotein that probably provides thyroperoxidase with the H2O2 required to catalyze thyroid hormone synthesis. No functional H2O2-generating system has yet been obtained after transfecting Duox2 into non-thyroid cell lines, because it is retained in the endoplasmic reticulum ( ER). We investigated the level of maturation of various Duox2 truncated proteins in an attempt to identify the region of Duox2 responsible for its remaining in the ER. Duox2-Q686X mutant, corresponding to the N-terminal ectodomain including the first putative transmembrane domain, was expressed in different cell lines. Carbohydrate content analysis revealed that complex type-specific Golgi apparatus (GA) oligosaccharides were present on pig Duox2-Q686X, whereas human truncated Duox2 carried only high mannose-type sugar chains characteristic of the ER. Further characterization using surface biotinylation and flow cytometry assays indicated that pig Duox2-Q686X was present at the plasma membrane, whereas human Duox2-Q686X remained inside the cell. The replacement of the last 90 residues of the human Duox2-Q686X with the pig equivalent region allowed the chimerical peptide to reach the Golgi apparatus. Pig mutants containing the complete first intracellular loop with or without the second transmembrane domain accumulated in the ER. These findings show that 1) the human Duox2-Q686X region encompassing residues 596-685 prevents mutant exportation from the ER and 2) there is a pig Duox2 retention domain in the first intracellular loop. In addition, missense mutations of four cysteines (Cys-351, -370, -568, or -582) completely inhibited the emergence of pig Duox2-Q686X from the ER compartment, indicating their importance in Duox2 maturation.	Univ Paris 11, Fac Pharm, INSERM, U468, F-92296 Chatenay Malabry, France; Univ Paris 11, Fac Pharm, Imagerie Cellulaire IFR75 ISIT, F-92296 Chatenay Malabry, France; Univ Paris 11, Fac Pharm, Equipe Accueil 3545, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Morand, S (corresponding author), Univ Paris 11, Fac Pharm, INSERM, U468, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	stanislas.morand@cep.u-psud.fr						Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; De Deken X, 2002, EXP CELL RES, V273, P187, DOI 10.1006/excr.2001.5444; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DEME D, 1994, BIOCHEM J, V301, P75, DOI 10.1042/bj3010075; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; EKHOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141, DOI 10.1016/0303-7207(81)90056-3; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; Gorin Y, 1997, BIOCHEM J, V321, P383, DOI 10.1042/bj3210383; Hishinuma A, 1999, J CLIN ENDOCR METAB, V84, P1438, DOI 10.1210/jc.84.4.1438; Kim PS, 1998, P NATL ACAD SCI USA, V95, P9909, DOI 10.1073/pnas.95.17.9909; KLUG J, 1991, NUCLEIC ACIDS RES, V19, P2793, DOI 10.1093/nar/19.10.2793; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Morand S, 2003, ENDOCRINOLOGY, V144, P1241, DOI 10.1210/en.2002-220981; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; NAKAMURA Y, 1990, J ENDOCRINOL, V26, P283; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Taurog AM, 2000, WERNER INGBARS THYRO, P61; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288	29	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30244	30251		10.1074/jbc.M405406200	http://dx.doi.org/10.1074/jbc.M405406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150274	hybrid			2022-12-25	WOS:000222531900048
J	Rave-Harel, N; Givens, ML; Nelson, SB; Duong, HA; Coss, D; Clark, ME; Hall, SB; Kamps, MP; Mellon, PL				Rave-Harel, N; Givens, ML; Nelson, SB; Duong, HA; Coss, D; Clark, ME; Hall, SB; Kamps, MP; Mellon, PL			TALE homeodomain proteins regulate gonadotropin-releasing hormone gene expression independently and via interactions with Oct-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC ENHANCER; GLUCOCORTICOID RESPONSE ELEMENT; BINDING TRANSCRIPTION FACTORS; GNRH GENE; PROTOONCOGENE PBX1; OLFACTORY PLACODE; PROMOTER ACTIVITY; MESSENGER-RNA; SUBUNIT GENE; IN-VIVO	Gonadotropin-releasing hormone ( GnRH) is the central regulator of reproductive function. Expression of the GnRH gene is confined to a rare population of neurons scattered throughout the hypothalamus. Restricted expression of the rat GnRH gene is driven by a multicomponent enhancer and an evolutionarily conserved promoter. Oct-1, a ubiquitous POU homeodomain transcription factor, was identified as an essential factor regulating GnRH transcription in the GT1-7 hypothalamic neuronal cell line. In this study, we conducted a two-hybrid interaction screen in yeast using a GT1-7 cDNA library to search for specific Oct-1 cofactors. Using this approach, we isolated Pbx1b, a TALE homeodomain transcription factor that specifically associates with Oct-1. We show that heterodimers containing Pbx/Prep1 or Pbx/Meis1 TALE homeodomain proteins bind to four functional elements within the GnRH regulatory region, each in close proximity to an Oct-1-binding site. Cotransfection experiments indicate that TALE proteins are essential for GnRH promoter activity in the GT1-7 cells. Moreover, Pbx1 and Oct-1, as well as Prep1 and Oct-1, form functional complexes that enhance GnRH gene expression. Finally, Pbx1 is expressed in GnRH neurons in embryonic as well as mature mice, suggesting that the associations between TALE homeodomain proteins and Oct-1 regulate neuron-specific expression of the GnRH gene in vivo.	Univ Calif San Diego, Dept Reprod Med, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Mellon, PL (corresponding author), Univ Calif San Diego, Dept Reprod Med, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pmellon@ucsd.edu		Coss, Djurdjica/0000-0003-0692-1612	NIA NIH HHS [T32 AG00216] Funding Source: Medline; NICHD NIH HHS [P50 HD012303, F32 HD041301, R01 HD072754, F32 HD041301-01, F32 HD41301, F32 HD041301-02] Funding Source: Medline; NIDA NIH HHS [DA07315] Funding Source: Medline; NIDDK NIH HHS [R01 DK44838, R01 DK044838, R01 DK044838-17A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P50HD012303, R01HD072754] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD041301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000216] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bailey JS, 2004, MOL ENDOCRINOL, V18, P1158, DOI 10.1210/me.2003-0442; Belsham DD, 2000, MOL ENDOCRINOL, V14, P212, DOI 10.1210/me.14.2.212; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Carrier JS, 2000, BIOCHEM BIOPH RES CO, V272, P616, DOI 10.1006/bbrc.2000.2795; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; CLARK ME, 1995, MOL CELL BIOL, V15, P6169; Coss D, 2004, J BIOL CHEM, V279, P152, DOI 10.1074/jbc.M304697200; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; Di Rocco G, 2001, J BIOL CHEM, V276, P20506, DOI 10.1074/jbc.M011175200; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Herzig S, 2000, J BIOL CHEM, V275, P27989; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; Kelley CG, 2002, MOL ENDOCRINOL, V16, P2413, DOI 10.1210/me.2002-0189; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Lawson MA, 1996, MOL CELL BIOL, V16, P3596; Lawson MA, 1998, MOL ENDOCRINOL, V12, P364, DOI 10.1210/me.12.3.364; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mayer CM, 2003, BIOCHEM BIOPH RES CO, V307, P847, DOI 10.1016/S0006-291X(03)01289-0; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Palazzolo M, 2000, EUR J BIOCHEM, V267, P5427, DOI 10.1046/j.1432-1327.2000.01604.x; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schnabel CA, 2003, DEV BIOL, V254, P262, DOI 10.1016/S0012-1606(02)00038-6; Schnabel CA, 2001, MECH DEVELOP, V100, P131, DOI 10.1016/S0925-4773(00)00516-5; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; SCHWANZELFUKUDA M, 1992, ENDOCR REV, V13, P623, DOI 10.1210/er.13.4.623; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; Selleri L, 2001, DEVELOPMENT, V128, P3543; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; Subramaniam N, 2003, BIOCHEM J, V370, P1087, DOI 10.1042/BJ20020471; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Turgeon D, 2000, J MOL BIOL, V295, P489, DOI 10.1006/jmbi.1999.3374; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WHYTE DB, 1995, MOL ENDOCRINOL, V9, P467, DOI 10.1210/me.9.4.467; Wierman ME, 1997, MOL CELL BIOL, V17, P1652, DOI 10.1128/MCB.17.3.1652; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Wolfe A, 2002, MOL ENDOCRINOL, V16, P435, DOI 10.1210/me.16.3.435; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132	61	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30287	30297		10.1074/jbc.M402960200	http://dx.doi.org/10.1074/jbc.M402960200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138251	Green Accepted, hybrid			2022-12-25	WOS:000222531900054
J	Du, XO; Zhang, HL; Lopes, C; Mirshahi, T; Rohacs, T; Logothetis, DE				Du, XO; Zhang, HL; Lopes, C; Mirshahi, T; Rohacs, T; Logothetis, DE			Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of Kir channels by diverse modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECTIFIER K+ CHANNELS; RECTIFYING POTASSIUM CHANNEL; XENOPUS-OOCYTES; ATP CHANNELS; PHOSPHOLIPASE-C; ACETYLCHOLINE-RECEPTOR; DIRECT ACTIVATION; INTRACELLULAR PH; ROMK1 CHANNEL	The activity of specific inwardly rectifying potassium (Kir) channels is regulated by any of a number of different modulators, such as protein kinase C, G(q)-coupled receptor stimulation, pH, intracellular Mg2+ or the betagamma-subunits of G proteins. Phosphatidylinositol 4,5-bisphosphate (PIP2) is an essential factor for maintenance of the activity of all Kir channels. Here, we demonstrate that the strength of channel-PIP2 interactions determines the sensitivity of Kir channels to regulation by the various modulators. Furthermore, our results suggest that differences among Kir channels in their specific regulation by a given modulator may reflect differences in their apparent affinity of interactions with PIP2.	Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China; NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Hebei Medical University; Icahn School of Medicine at Mount Sinai; New York University	Logothetis, DE (corresponding author), Hebei Med Univ, Dept Pharmacol, Shijiazhuang, Peoples R China.	diomedes.logothetis@mssm.edu			NHLBI NIH HHS [HL59949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BENNDORF K, 1990, PFLUGERS ARCH, V416, P207; Brown AM, 1997, TRENDS CARDIOVAS MED, V7, P118, DOI 10.1016/S1050-1738(97)00002-9; Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Chuang HH, 1997, CELL, V89, P1121, DOI 10.1016/S0092-8674(00)80299-8; Collins A, 2002, J BIOL CHEM, V277, P35815, DOI 10.1074/jbc.M206032200; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Haruna T, 2002, CIRC RES, V91, P232, DOI 10.1161/01.RES.0000029971.60214.49; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hibino H, 1997, J NEUROSCI, V17, P4711; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ishii M, 1997, J NEUROSCI, V17, P7725; Karle CA, 2002, CIRCULATION, V106, P1493, DOI 10.1161/01.CIR.0000029747.53262.5C; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; MADUH EU, 1990, TOXICOL APPL PHARM, V106, P201, DOI 10.1016/0041-008X(90)90240-U; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; OKITANI N, 2002, AM J PHYSIOL, V282, pH757; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Ruppersberg JP, 2000, PFLUG ARCH EUR J PHY, V441, P1, DOI 10.1007/s004240000380; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Thorneloe KS, 2002, J PHYSIOL-LONDON, V541, P65, DOI 10.1113/jphysiol.2002.018101; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhang LY, 2004, J BIOL CHEM, V279, P7037, DOI 10.1074/jbc.M307323200; Zhu GY, 1999, J BIOL CHEM, V274, P11643, DOI 10.1074/jbc.274.17.11643	52	147	157	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37271	37281		10.1074/jbc.M403413200	http://dx.doi.org/10.1074/jbc.M403413200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15155739	hybrid			2022-12-25	WOS:000223554600011
J	Gorr, TA; Cahn, JD; Yamagata, H; Bunn, HF				Gorr, TA; Cahn, JD; Yamagata, H; Bunn, HF			Hypoxia-induced synthesis of hemoglobin in the crustacean Daphnia magna is hypoxia-inducible factor-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; RECEPTOR NUCLEAR TRANSLOCATOR; BHLH-PAS PROTEIN; DROSOPHILA-MELANOGASTER; WATER-FLEA; FACTOR-I; TRANSCRIPTIONAL REGULATION; RESPONSE ELEMENTS; DNA-BINDING; LACTATE-DEHYDROGENASE	Of the four known globin genes that exist in the freshwater crustacean Daphnia magna, several are individually induced by hypoxia, lending pale normoxic animals a visible red color when challenged by oxygen deprivation. The promoter regions of the Daphnia globin genes each contain numerous hypoxia response elements (HREs) as potential binding sites for hypoxia-inducible factors (HIFs). Daphnia HIF, bound to human HRE sequences, was detected in extracts from hypoxic (red), but not normoxic (pale), animals. Taking advantage of the phylogenetically conserved HIF/HRE recognition, we employed heterologous transfections of HIF-expressing human and Drosophila cells to model HIF signaling in Daphnia. These experiments revealed that three functional HREs within the promoter of the D. magna globin-2 gene cooperate for maximal hypoxic induction of a downstream luciferase reporter gene. Two of these three cis-elements, at promoter positions -258 and -107, are able to specifically bind human, Drosophila, or Daphnia HIF complexes in vitro. The same two sites are also necessary for maximal induction of reporter transcription under low oxygen tension in the presence of either endogenous human or overexpressed Drosophila HIF proteins. The third motif of the globin-2 gene promoter, a CACGTG palindrome at position -146, functions as a docking site for an unknown constitutive transcription factor. In human cells, this -146 complex interferes with HIF occupancy at the adjacent -107 HRE and thus controls the extent of HIF-mediated hypoxic activation of the downstream target.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, Boston, MA 02115 USA; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Environm Sci, Lab Environm & Mol Biol, Tokyo 1920392, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tokyo University of Pharmacy & Life Sciences	Bunn, HF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Hematol, 221 Longwood Ave, Boston, MA 02115 USA.	hfbunn@rics.bwh.harvard.edu		Gorr, Thomas/0000-0002-6023-4234	NIDDK NIH HHS [R01 DK041234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECHER B, 2002, THESIS U MUNSTER MUN; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BROOKS JL, 1957, MEM CONN ACAD ARTS S, V13, P30; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CHANDLER ANN, 1954, PROC ZOOL SOC LONDON, V124, P625; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Dewilde S, 1999, MOL BIOL EVOL, V16, P1208, DOI 10.1093/oxfordjournals.molbev.a026211; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ebert BL, 1999, BLOOD, V94, P1864; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FOX HM, 1948, PROC R SOC SER B-BIO, V135, P195, DOI 10.1098/rspb.1948.0006; FOX HM, 1950, NATURE, V166, P609, DOI 10.1038/166609a0; FOX HM, 1949, NATURE, V164, P59, DOI 10.1038/164059a0; FOX HM, 1953, PROC R SOC SER B-BIO, V141, P179, DOI 10.1098/rspb.1953.0034; FOX HM, 1949, PROC R SOC SER B-BIO, V136, P388, DOI 10.1098/rspb.1949.0032; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUANG LW, 1993, P NATL ACAD SCI USA, V90, P4304; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hebert PDN, 1999, J MOL EVOL, V49, P769, DOI 10.1007/PL00006599; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; ILAN E, 1982, BIOCHEM J, V207, P297, DOI 10.1042/bj2070297; Jelkmann W, 1996, ANN ANAT, V178, P391, DOI 10.1016/S0940-9602(96)80124-5; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kato K, 2001, GENE, V273, P41, DOI 10.1016/S0378-1119(01)00569-8; Kimura S, 1999, J BIOL CHEM, V274, P10649, DOI 10.1074/jbc.274.15.10649; KOBAYASHI M, 1988, PHYSIOL ZOOL, V61, P415, DOI 10.1086/physzool.61.5.30161263; KOBAYASHI M, 1994, COMP BIOCHEM PHYS A, V107, P127; KOBAYASHI M, 1990, COMP BIOCHEM PHYS A, V97, P513; KOBAYASHI M, 1982, COMP BIOCHEM PHYS A, V72, P247, DOI 10.1016/0300-9629(82)90040-8; KOBAYASHI M, 1981, COMP BIOCHEM PHYS A, V69, P679; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Ledent V, 2001, GENOME RES, V11, P754, DOI 10.1101/gr.177001; Ma E, 1999, MOL BRAIN RES, V73, P11, DOI 10.1016/S0169-328X(99)00224-7; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mazure NM, 2002, CANCER RES, V62, P1158; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; PENNAK RW, 1989, FRESH WATER INVERTEB, P386; Peters R.H., 1987, Memorie dell'Istituto Italiano di Idrobiologia Dott Marco de Marchi, V45, P193; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Pirow R, 2001, J EXP BIOL, V204, P3425; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; REMANE A, 1980, SYSTEMATISCHE ZOOLOG, P260; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; SWAMMERDAM J, 1758, BOOK NATURE HIST INS, P39; Swanson HI, 1999, NUCLEIC ACIDS RES, V27, P3205, DOI 10.1093/nar/27.15.3205; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Tokishita S, 1997, GENE, V189, P73, DOI 10.1016/S0378-1119(96)00836-0; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WENGER RH, 1997, BIOL CHEM, V378, P1; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Zeis B, 2003, BIOL CHEM, V384, P1133, DOI 10.1515/BC.2003.126; Zeis B, 2003, COMP BIOCHEM PHYS B, V134, P243, DOI 10.1016/S1096-4959(02)00253-1	69	86	93	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					36038	36047		10.1074/jbc.M403981200	http://dx.doi.org/10.1074/jbc.M403981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169764	hybrid			2022-12-25	WOS:000223303400106
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - III. The seatbelt and its latch site determine the assembly pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HUMAN CHORIOGONADOTROPIN; SALMON GONADOTROPINS; STIMULATING-HORMONE; BIOLOGICAL-ACTIVITY; BETA-SUBUNIT; GTH-II; PROTEIN; FOLLITROPIN; LUTROPIN	Vertebrate glycoprotein hormone heterodimers are stabilized by a strand of their beta-subunits known as the "seatbelt" that is wrapped around loop 2 of their alpha-subunits (alpha2). The cysteine that terminates the seatbelt is "latched" by a disulfide to a cysteine in beta-subunit loop 1 (beta1) of all vertebrate hormones except some teleost follitropins (teFSH), wherein it is latched to a cysteine in the beta-subunit NH2 terminus. As reported here, teFSH analogs of human choriogonadotropin (hCG) are assembled by a pathway in which the subunits dock before the seatbelt is latched; assembly is completed by wrapping the seatbelt around loop alpha2 and latching it to the NH2 terminus. This differs from hCG assembly, which occurs by threading the glycosylated end of loop alpha2 beneath the latched seatbelt through a hole in the beta-subunit. The seatbelt is the part of the beta-subunit that has the greatest influence on biological function. Changes in its sequence during the divergence of lutropins, follitropins, and thyrotropins and the speciation of teleost fish may have impeded heterodimer assembly by a threading mechanism, as observed when the hCG seatbelt was replaced with its salmon FSH counterpart. Whereas wrapping is less efficient than threading, it may have facilitated natural experimentation with the composition of the seatbelt during the co-evolution of glycoprotein hormones and their receptors. Migration of the seatbelt latch site to the NH2-terminal end of the beta-subunit would have facilitated teFSH assembly by a wraparound mechanism and may have contributed also to its ability to distinguish lutropin and follitropin receptors.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038547, R01HD014907, R37HD014907] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALOJ SM, 1973, ARCH BIOCHEM BIOPHYS, V159, P497, DOI 10.1016/0003-9861(73)90480-3; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; Campbell RK, 1997, NAT BIOTECHNOL, V15, P439, DOI 10.1038/nbt0597-439; CHEN F, 1991, J BIOL CHEM, V266, P6904; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; GarciaHernandez MP, 1997, GEN COMP ENDOCR, V106, P389, DOI 10.1006/gcen.1997.6887; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SLAUGHTER S, 1995, MOL CELL ENDOCRINOL, V112, P21, DOI 10.1016/0303-7207(95)03579-V; SWANSON P, 1991, BIOL REPROD, V44, P29, DOI 10.1095/biolreprod44.1.29; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; YAN LG, 1992, BIOL REPROD, V47, P418, DOI 10.1095/biolreprod47.3.418	20	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35449	35457		10.1074/jbc.M403054200	http://dx.doi.org/10.1074/jbc.M403054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15161904	hybrid			2022-12-25	WOS:000223303400038
J	Prince, WS; McCormick, LM; Wendt, DJ; Fitzpatrick, PA; Schwartz, KL; Aguilera, AI; Koppaka, V; Christianson, TM; Vellard, MC; Pavloff, N; Lemontt, JF; Qin, MM; Starr, CM; Bu, GJ; Zankel, TC				Prince, WS; McCormick, LM; Wendt, DJ; Fitzpatrick, PA; Schwartz, KL; Aguilera, AI; Koppaka, V; Christianson, TM; Vellard, MC; Pavloff, N; Lemontt, JF; Qin, MM; Starr, CM; Bu, GJ; Zankel, TC			Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSISTED CARBOHYDRATE ELECTROPHORESIS; HEPARAN-SULFATE PROTEOGLYCANS; ENZYME REPLACEMENT THERAPY; CULTURED HUMAN-FIBROBLASTS; COMPLEMENT-TYPE REPEATS; HAMSTER OVARY CELLS; LDL RECEPTOR; PLASMINOGEN-ACTIVATOR; LIGAND-BINDING; BETA-GLUCURONIDASE	Enzyme replacement therapy for lysosomal storage disorders depends on efficient uptake of recombinant enzyme into the tissues of patients. This uptake is mediated by oligosaccharide receptors including the cation-independent mannose 6-phosphate receptor and the mannose receptor. We have sought to exploit alternative receptor systems that are independent of glycosylation but allow for efficient delivery to the lysosome. Fusions of the human lysosomal enzymes alpha-L-iduronidase or acid alpha-glucosidase with the receptor-associated protein were efficiently endocytosed by lysosomal storage disorder patient fibroblasts, rat C6 glioma cells, mouse C2C12 myoblasts, and recombinant Chinese hamster ovary cells expressing individual members of the low-density lipoprotein receptor family. Uptake of the fusions exceeded that of phosphorylated enzyme in all cases, often by an order of magnitude or greater. Uptake was specifically mediated by members of the low-density lipoprotein receptor protein family and was followed by delivery of the fusions to the lysosome. The advantages of the lipoprotein receptor system over oligosaccharide receptor systems include more efficient cellular delivery and the potential for transcytosis of ligands across tight endothelia, including the blood-brain barrier.	BioMarin Pharmaceut Inc, Novato, CA 94949 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Physiol, St Louis, MO 63110 USA	BioMarin Pharmaceutical Inc.; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Zankel, TC (corresponding author), BioMarin Pharmaceut Inc, Novato, CA 94949 USA.	tzankel@bmrn.com						Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; Argraves WS, 2001, FRONT BIOSCI, V6, pD406, DOI 10.2741/Argraves; BARTON RW, 1971, J BIOL CHEM, V246, P7773; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Bu GJ, 2001, INT REV CYTOL, V209, P79; BU GJ, 1993, J BIOL CHEM, V268, P13002; Chun JT, 1999, EXP NEUROL, V157, P194, DOI 10.1006/exnr.1999.7052; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Fuller M, 1995, EUR J BIOCHEM, V234, P903, DOI 10.1111/j.1432-1033.1995.903_a.x; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; Green I, 2003, TRENDS PHARMACOL SCI, V24, P213, DOI 10.1016/S0165-6147(03)00076-2; Hague C, 1998, ELECTROPHORESIS, V19, P2612, DOI 10.1002/elps.1150191508; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; Kakkis ED, 2002, EXPERT OPIN INV DRUG, V11, P675, DOI 10.1517/13543784.11.5.675; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; Kakkis ED, 2001, MOL GENET METAB, V72, P199, DOI 10.1006/mgme.2000.3140; LeBowitz JH, 2004, P NATL ACAD SCI USA, V101, P3083, DOI 10.1073/pnas.0308728100; Li YH, 2002, BIOCHEMISTRY-US, V41, P4921, DOI 10.1021/bi011894i; Li YH, 2001, MOL NEUROBIOL, V23, P53; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Marino M, 2000, J BIOL CHEM, V275, P7125, DOI 10.1074/jbc.275.10.7125; Marino M, 2001, J AM SOC NEPHROL, V12, P637, DOI 10.1681/ASN.V124637; Marzolo MP, 2003, TRAFFIC, V4, P273, DOI 10.1034/j.1600-0854.2003.00081.x; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; MURRAY GJ, 1987, METHOD ENZYMOL, V149, P25; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; NARITA M, 1995, J CLIN INVEST, V96, P1164, DOI 10.1172/JCI118105; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Obunike JC, 2001, J BIOL CHEM, V276, P8934, DOI 10.1074/jbc.M008813200; PAN W, 2004, IN PRESS J CELL SCI; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; Sands MS, 2001, J BIOL CHEM, V276, P43160, DOI 10.1074/jbc.M107778200; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; Starr CM, 1996, J CHROMATOGR A, V720, P295, DOI 10.1016/0021-9673(95)00749-0; TROUSSARD AA, 1995, J BIOL CHEM, V270, P17068, DOI 10.1074/jbc.270.29.17068; Van Hove JLK, 1997, BIOCHEM MOL BIOL INT, V43, P613; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Yang HW, 1998, PEDIATR RES, V43, P374, DOI 10.1203/00006450-199803000-00011; Zhao KW, 1997, J BIOL CHEM, V272, P22758, DOI 10.1074/jbc.272.36.22758; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	53	37	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35037	35046		10.1074/jbc.M402630200	http://dx.doi.org/10.1074/jbc.M402630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15170390	hybrid			2022-12-25	WOS:000223134800116
J	Balasubramanyam, K; Altaf, M; Varier, RA; Swaminathan, V; Ravindran, A; Sadhale, PP; Kundu, TK				Balasubramanyam, K; Altaf, M; Varier, RA; Swaminathan, V; Ravindran, A; Sadhale, PP; Kundu, TK			Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; ACTIVATION; P300; PCAF; DEACETYLASES; CBP/P300; MUSCLE; CANCER; ROLES; CELLS	Histone acetylation is a diagnostic feature of transcriptionally active genes. The proper recruitment and function of histone acetyltransferases (HATs) and deacetylases (HDACs) are key regulatory steps for gene expression and cell cycle. Functional defects of either of these enzymes may lead to several diseases, including cancer. HATs and HDACs thus are potential therapeutic targets. Here we report that garcinol, a polyisoprenylated benzophenone derivative from Garcinia indica fruit rind, is a potent inhibitor of histone acetyltransferases p300 (IC50 approximate to 7 muM) and PCAF (IC50 approximate to5 muM) both in vitro and in vivo. The kinetic analysis shows that it is a mixed type of inhibitor with an increased affinity for PCAF compared with p300. HAT activity-dependent chromatin transcription was strongly inhibited by garcinol, whereas transcription from DNA template was not affected. Furthermore, it was found to be a potent inducer of apoptosis, and it alters ( predominantly downregulates) the global gene expression in HeLa cells.	Jawaharlal Nehru Ctr Adv Sci Res, Transcript & Dis Lab, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Kundu, TK (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Transcript & Dis Lab, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India.	tapas@jncasr.ac.in	Sadhale, PArag/A-7799-2009	Kundu, Tapas/0000-0001-7790-214X; Varier, Radhika/0000-0003-1302-3159; Venkatesh, Swaminathan/0000-0001-9837-1501; Ravindran, Aarti/0000-0001-7558-4627				An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Cebrat M, 2003, BIOORGAN MED CHEM, V11, P3307, DOI 10.1016/S0968-0896(03)00265-7; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CULLIS PM, 1982, J BIOL CHEM, V257, P2165; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ito C, 2003, J NAT PROD, V66, P206, DOI 10.1021/np020372g; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; Kagoshima M, 2003, BIOCHEM SOC T, V31, P60, DOI 10.1042/bst0310060; Kalkhoven E, 2003, HUM MOL GENET, V12, P441, DOI 10.1093/hmg/ddg039; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Matsumoto K, 2003, BIOL PHARM BULL, V26, P569, DOI 10.1248/bpb.26.569; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pan MH, 2001, J AGR FOOD CHEM, V49, P1464, DOI 10.1021/jf001129v; Pillai B, 2001, CURR SCI INDIA, V81, P574; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; PRES V, 2002, EMBO J, V21, P6811; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; RYAN CA, 2001, CURRENT PROTOCOLS MO; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SPACER TE, 1997, NATURE, V389, P194; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Wolffe A, 1998, CHROMATIN - STRUCTURE AND FUNCTION, 3RD EDITION, P1, DOI 10.1016/B978-012761914-9/50003-9; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Yamaguchi F, 2000, J AGR FOOD CHEM, V48, P2320, DOI 10.1021/jf990908c; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	46	415	437	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33716	33726		10.1074/jbc.M402839200	http://dx.doi.org/10.1074/jbc.M402839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155757	hybrid			2022-12-25	WOS:000223039700081
J	Choudhury, AD; XuO, H; Baer, R				Choudhury, AD; XuO, H; Baer, R			Ubiquitination and proteasomal degradation the BRCA1 tumor suppressor is regulated during cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; DIRECTED DNA-REPAIR; BREAST-CANCER; POLYUBIQUITIN CHAINS; HOMOLOGOUS RECOMBINATION; SUBCELLULAR-LOCALIZATION; BRCA1/BARD1 HETERODIMER; NUCLEAR PHOSPHOPROTEIN; GENETIC INSTABILITY; LIGASE ACTIVITY	The BRCA1 tumor suppressor and the BARD1 protein form a stable heterodimeric complex that can catalyze the formation of polyubiquitin chains. Expression of BRCA1 fluctuates in a cell cycle-dependent manner, such that low steady-state levels of BRCA1 gene products are found in resting cells and early G(1) cycling cells and high levels in S and G(2) phase cells. Although transcriptional activation of the BRCA1 gene can account for induction of BRCA1 expression at the G(1)/S transition, the mechanisms by which BRCA1 is down-regulated during cell cycle progression have not been addressed. Here we show that the steady-state levels of BRCA1 protein remain elevated throughout mitosis but begin to decline at the M/G(1) transition. This decline in BRCA1 levels coincides with the appearance of proteasome-sensitive ubiquitin conjugates of BRCA1 at the onset of G(1). Formation of these conjugates occurs throughout G(1) and S, but not in cells arrested in prometaphase by nocodazole. The proteasome-sensitive ubiquitin conjugates of BRCA1 appear to be distinct from BRCA1 autoubiquitination products and are probably catalyzed by the action of other cellular E3 ligases. Interestingly, co-expression of BARD1 inhibits the formation of these conjugates, suggesting that BARD1 serves to stabilize BRCA1 expression in part by reducing proteasome-sensitive ubiquitination of BRCA1 polypeptides. In summary, these data indicate that the cell cycle-dependent pattern of BRCA1 expression is determined in part by ubiquitin-dependent proteasomal degradation.	Columbia Univ, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA	Columbia University	Baer, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.	rb670@columbia.edu		Choudhury, Atish/0000-0001-9344-6631	NATIONAL CANCER INSTITUTE [P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [CA97403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chen YM, 1996, CANCER RES, V56, P3168; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Le Page F, 2000, CANCER RES, V60, P5548; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Moynahan ME, 2001, CANCER RES, V61, P4842; Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	56	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33909	33918		10.1074/jbc.M403646200	http://dx.doi.org/10.1074/jbc.M403646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166217	hybrid			2022-12-25	WOS:000223039700101
J	Degot, S; Le Hir, H; Alpy, F; Kedinger, V; Stoll, I; Wendling, C; Seraphin, B; Rio, MC; Tomasetto, C				Degot, S; Le Hir, H; Alpy, F; Kedinger, V; Stoll, I; Wendling, C; Seraphin, B; Rio, MC; Tomasetto, C			Association of the breast cancer protein MLN51 with the Exon junction complex via its speckle localizer and RNA binding module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MAMMALIAN-CELLS; NUCLEAR EXPORT; DEPENDENT MANNER; GENE-EXPRESSION; DROSOPHILA; COMPONENT; DOMAINS; IDENTIFICATION; RECEPTOR	MLN51 is a nucleocytoplasmic shuttling protein that is overexpressed in breast cancer. The function of MLN51 in mammals remains elusive. Its fly homolog, named barentsz, as well as the proteins mago nashi and tsunagi have been shown to be required for proper oskar mRNA localization to the posterior pole of the oocyte. Magoh and Y14, the human homologs of mago nashi and tsunagi, are core components of the exon junction complex (EJC). The EJC is assembled on spliced mRNAs and plays important roles in post-splicing events including mRNA export, nonsense-mediated mRNA decay, and translation. In the present study, we show that human MLN51 is an RNA-binding protein present in ribonucleoprotein complexes. By co-immunoprecipitation assays, endogenous MLN51 protein is found to be associated with EJC components, including Magoh, Y14, and NFX1/TAP, and subcellular localization studies indicate that MLN51 transiently co-localizes with Magoh in nuclear speckles. Moreover, we demonstrate that MLN51 specifically associates with spliced mRNAs in co-precipitation experiments, both in the nucleus and in the cytoplasm, at the position where the EJC is deposited. Most interesting, we have identified a region within MLN51 sufficient to bind RNA, to interact with Magoh and spliced mRNA, and to address the protein to nuclear speckles. This conserved region of MLN51 was therefore named SELOR for speckle localizer and RNA binding module. Altogether our data demonstrate that MLN51 associates with EJC in the nucleus and remains stably associated with mRNA in the cytoplasm, suggesting that its overexpression might alter mRNA metabolism in cancer.	Univ Strasbourg 1, CNRS,UPR 6520, INSERM,U596, Dept Pathol Mol,Inst Genet & Biol Mol & Cellulair, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; CNRS, UPR 2167, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Tomasetto, C (corresponding author), IGBMC, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	cat@igbmc.u-strasbg.fr	Alpy, Fabien/H-8941-2016; Tomasetto, Catherine Laure/J-2783-2014; Alpy, Fabien/ABD-5893-2020	Alpy, Fabien/0000-0002-0526-0720; Tomasetto, Catherine Laure/0000-0002-1811-5848; Alpy, Fabien/0000-0002-0526-0720; Seraphin, Bertrand/0000-0002-5168-1921; Le Hir, Herve/0000-0001-7964-9221				Allain FHT, 2000, J MOL BIOL, V303, P227, DOI 10.1006/jmbi.2000.4118; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; Bieche I, 1996, CANCER RES, V56, P3886; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Corbin F, 1997, HUM MOL GENET, V6, P1465, DOI 10.1093/hmg/6.9.1465; Degot S, 2002, ONCOGENE, V21, P4422, DOI 10.1038/sj.onc.1205611; Degot Sebastien, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P365; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hyman E, 2002, CANCER RES, V62, P6240; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; LINDBERG U, 1974, J MOL BIOL, V86, P451, DOI 10.1016/0022-2836(74)90030-8; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Macchi P, 2003, J NEUROSCI, V23, P5778; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; Martin SG, 2003, DEVELOPMENT, V130, P4201, DOI 10.1242/dev.00630; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Plewniak F, 2003, NUCLEIC ACIDS RES, V31, P3829, DOI 10.1093/nar/gkg518; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Severt WL, 1999, J CELL SCI, V112, P3691; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; van Eeden FJM, 2001, J CELL BIOL, V154, P511, DOI 10.1083/jcb.200105056; Wagner S, 2003, P NATL ACAD SCI USA, V100, P3269, DOI 10.1073/pnas.0438055100; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Yoon DW, 1997, IMMUNITY, V6, P571, DOI 10.1016/S1074-7613(00)80345-3; Zhao XF, 1998, GENOMICS, V47, P319, DOI 10.1006/geno.1997.5126; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	57	87	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33702	33715		10.1074/jbc.M402754200	http://dx.doi.org/10.1074/jbc.M402754200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166247	hybrid			2022-12-25	WOS:000223039700080
J	Kamei, D; Yamakawa, K; Takegoshi, Y; Mikami-Nakanishi, M; Nakatani, Y; Oh-ishi, S; Yasui, H; Azuma, Y; Hirasawa, N; Ohuchi, K; Kawaguchi, H; Ishikawa, Y; Ishii, T; Uematsu, S; Akira, S; Murakami, M; Kudo, I				Kamei, D; Yamakawa, K; Takegoshi, Y; Mikami-Nakanishi, M; Nakatani, Y; Oh-ishi, S; Yasui, H; Azuma, Y; Hirasawa, N; Ohuchi, K; Kawaguchi, H; Ishikawa, Y; Ishii, T; Uematsu, S; Akira, S; Murakami, M; Kudo, I			Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; E-2 SYNTHASE; OSTEOCLAST DIFFERENTIATION; HISTIDINE DECARBOXYLASE; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; PROSTANOID RECEPTORS; GRANULATION-TISSUE; DUCTUS-ARTERIOSUS; FACTOR EXPRESSION	We examined the in vivo role of membrane-bound prostaglandin E synthase (mPGES)-1, a terminal enzyme in the PGE(2)-biosynthetic pathway, using mPGES-1 knockout (KO) mice. Comparison of PGES activity in the membrane fraction of tissues from mPGES-1 KO and wild-type (WT) mice indicated that mPGES-1 accounted for the majority of lipopolysaccharide (LPS)-inducible PGES in WT mice. LPS-stimulated production of PGE(2), but not other PGs, was impaired markedly in mPGES-1-null macrophages, although a low level of cyclooxygenase-2-dependent PGE(2) production still remained. Pain nociception, as assessed by the acetic acid writhing response, was reduced significantly in KO mice relative to WT mice. This phenotype was particularly evident when these mice were primed with LPS, where the stretching behavior and the peritoneal PGE(2) level of KO mice were far less than those of WT mice. Formation of inflammatory granulation tissue and attendant angiogenesis in the dorsum induced by subcutaneous implantation of a cotton thread were reduced significantly in KO mice compared with WT mice. Moreover, collagen antibody-induced arthritis, a model for human rheumatoid arthritis, was milder in KO mice than in WT mice. Collectively, our present results provide unequivocal evidence that mPGES-1 contributes to the formation of PGE(2) involved in pain hypersensitivity and inflammation.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Univ Tokyo, Fac Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138655, Japan; Teijin Pharma Ltd, Inst Biomed Biochem, Pharmaceut Discovery Res Labs, Hino, Tokyo 1918512, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pathophysiol Biochem, Aoba Ku, Sendai, Miyagi 9808578, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	Showa University; University of Tokyo; Teijin Pharma Limited; Tohoku University; Osaka University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kudo@pharm.showa-u.ac.jp	Akira, Shizuo/C-3134-2009	Hirasawa, Noriyasu/0000-0002-8062-4838				Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Azuma Y, 1998, J PHARMACOL EXP THER, V286, P128; Ballou LR, 2000, P NATL ACAD SCI USA, V97, P10272, DOI 10.1073/pnas.180319297; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Bensen W, 2002, RHEUMATOLOGY, V41, P1008, DOI 10.1093/rheumatology/41.9.1008; Besse A, 1999, BBA-MOL CELL RES, V1450, P444, DOI 10.1016/S0167-4889(99)00048-8; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; Bonner JC, 2002, AM J PATHOL, V161, P459, DOI 10.1016/S0002-9440(10)64202-2; Chikazu D, 2001, J BONE MINER RES, V16, P2074, DOI 10.1359/jbmr.2001.16.11.2074; Claveau D, 2003, J IMMUNOL, V170, P4738, DOI 10.4049/jimmunol.170.9.4738; Desplat V, 2000, EXP HEMATOL, V28, P741, DOI 10.1016/S0301-472X(00)00180-6; Engblom D, 2003, NAT NEUROSCI, V6, P1137, DOI 10.1038/nn1137; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; Ghosh AK, 2002, J EXP MED, V195, P973, DOI 10.1084/jem.20011782; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; Guan YF, 2001, AM J PHYSIOL-RENAL, V281, pF1173, DOI 10.1152/ajprenal.0116.2001; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hegen M, 2003, J EXP MED, V197, P1297, DOI 10.1084/jem.20030016; Hizaki H, 1999, P NATL ACAD SCI USA, V96, P10501, DOI 10.1073/pnas.96.18.10501; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Lader CS, 1998, ENDOCRINOLOGY, V139, P3157, DOI 10.1210/en.139.7.3157; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Lorenz M, 1999, EXP HEMATOL, V27, P1494, DOI 10.1016/S0301-472X(99)00087-9; Manabe N, 1999, RHEUMATOLOGY, V38, P714, DOI 10.1093/rheumatology/38.8.714; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Matsumoto AK, 2002, J RHEUMATOL, V29, P1623; Matsumoto H, 1998, EUR J PHARMACOL, V352, P47, DOI 10.1016/S0014-2999(98)00340-9; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; MEHINDATE K, 1995, J IMMUNOL, V155, P3570; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Murakami M, 2002, PROSTAG OTH LIPID M, V68-9, P383, DOI 10.1016/S0090-6980(02)00043-6; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Nakashima K, 2003, BBA-MOL CELL BIOL L, V1633, P96, DOI 10.1016/S1388-1981(03)00092-1; Naraba H, 1998, J IMMUNOL, V160, P2974; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Norwood VF, 2000, KIDNEY INT, V58, P2291, DOI 10.1046/j.1523-1755.2000.00413.x; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172/JCI6400; Saegusa M, 2003, J CELL PHYSIOL, V197, P348, DOI 10.1002/jcp.10356; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Schuligoi R, 2003, NEUROSCIENCE, V116, P1043, DOI 10.1016/S0306-4522(02)00783-2; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soruri A, 2003, J IMMUNOL, V171, P2631, DOI 10.4049/jimmunol.171.5.2631; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Stock JL, 2001, J CLIN INVEST, V107, P325, DOI 10.1172/JCI6749; Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Takeda H, 2003, CANCER RES, V63, P4872; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2003, BIOCHEM BIOPH RES CO, V303, P1018, DOI 10.1016/S0006-291X(03)00470-4; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; TERATO K, 1992, J IMMUNOL, V148, P2103; Terato K, 1995, AUTOIMMUNITY, V22, P137, DOI 10.3109/08916939508995311; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; Trebino CE, 2003, P NATL ACAD SCI USA, V100, P9044, DOI 10.1073/pnas.1332766100; Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; WOOLEY PH, 1981, J EXP MED, V154, P688, DOI 10.1084/jem.154.3.688; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001	75	256	266	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33684	33695		10.1074/jbc.M400199200	http://dx.doi.org/10.1074/jbc.M400199200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15140897	hybrid			2022-12-25	WOS:000223039700078
J	Foley, JD; Rosenbaum, H; Griep, AE				Foley, JD; Rosenbaum, H; Griep, AE			Temporal regulation of VEID-7-amino-4-trifluoromethylcoumarin cleavage activity and caspase-6 correlates with organelle loss during lens development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; TERMINAL DIFFERENTIATION; DNA FRAGMENTATION; CYSTEINE PROTEASE; EPITHELIAL-CELLS; CYCLE REGULATION; APOPTOSIS; INHIBITION; ACTIVATION; DEGRADATION	Lens fiber cell differentiation involves extensive reconstruction of the cell's architecture, including the degradation and elimination of all membrane-bound organelles via a process that has been likened to apoptosis. Using caspase reporter assays under conditions in which nonspecific cleavage of the reporter peptides by the proteasome has been inhibited, we investigated whether any specific caspase activities are temporally correlated with this process of organelle loss. Extracts from neonatal mouse lenses contained strong VEID-7-amino-4-trifluoromethylcoumarin (AFC) and minor IETD-AFC and LEVD-AFC cleavage activities, but no DEVD-AFC cleavage activity. Further testing suggested that the VEID-AFC and IETD-AFC cleavage activities were likely due to the same enzyme. In lens extracts from rat embryos, VEID-AFC cleavage activity increased during the period when organelles are eliminated, between embryonic days 15.5 and 18.5, whereas procaspase-6 protein levels decreased, suggesting that this enzyme is responsible for VEID-AFC cleavage. By contrast, in extracts from alphaAE7 transgenic mouse lenses in which apoptosis was induced, strong DEVD-AFC cleavage activity and activated caspase-3 protein were detected. Thus, within the same tissue, different caspase activities can predominate depending on the context, normal differentiation versus apoptosis. These results highlight the difference between normal fiber cell differentiation and apoptosis and the capacity of the lens to differentially regulate these two processes.	Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Griep, AE (corresponding author), Univ Wisconsin, Sch Med, Dept Anat, 1300 Univ Ave, Madison, WI 53706 USA.	aegriep@wisc.edu	Griep, Anne/ABA-9636-2020		NEI NIH HHS [EY09091] Funding Source: Medline; NICHD NIH HHS [HD1007477] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009091] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andersson M, 2000, INVEST OPHTH VIS SCI, V41, P2623; Andersson M, 1998, EXP EYE RES, V67, P231, DOI 10.1006/exer.1998.0519; APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Bassnett S, 1999, J CELL SCI, V112, P2155; Bassnett S, 2002, EXP EYE RES, V74, P1, DOI 10.1006/exer.2001.1111; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fenteany G, 1996, CHEM BIOL, V3, P905, DOI 10.1016/S1074-5521(96)90179-9; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; GRIEP A E, 1990, New Biologist, V2, P727; He HY, 1998, DEV DYNAM, V211, P26, DOI 10.1002/(SICI)1097-0177(199801)211:1<26::AID-AJA3>3.0.CO;2-9; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jordan JF, 2001, GRAEF ARCH CLIN EXP, V239, P613, DOI 10.1007/s004170100332; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kobayashi T, 1996, J BIOCHEM, V120, P699; Kuszak JR, 1995, INT REV CYTOL, V163, P305, DOI 10.1016/S0074-7696(08)62213-5; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V45, P271; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Morioka K, 1998, EXP CELL RES, V240, P206, DOI 10.1006/excr.1997.3927; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishi O, 2001, CURR EYE RES, V23, P192, DOI 10.1076/ceyr.23.3.192.5462; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; *PROM CORP, 2003, TECHN B PROM CORP, V248; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shang F, 1999, EXP EYE RES, V68, P179, DOI 10.1006/exer.1998.0576; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Stolen CM, 1997, DEVELOPMENT, V124, P4009; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tamada Y, 2000, BIOCHEM BIOPH RES CO, V275, P300, DOI 10.1006/bbrc.2000.3298; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WAGNER BJ, 1986, EXP EYE RES, V43, P1141, DOI 10.1016/0014-4835(86)90091-6; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Yao K, 2003, CHINESE MED J-PEKING, V116, P1034; Yoshizawa K, 2000, TOXICOL PATHOL, V28, P555, DOI 10.1177/019262330002800408; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122	60	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32142	32150		10.1074/jbc.M313683200	http://dx.doi.org/10.1074/jbc.M313683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161922	hybrid			2022-12-25	WOS:000222849700020
J	Hirose, M; Kitano, J; Nakajima, Y; Moriyoshi, K; Yanagi, S; Yamamura, H; Muto, T; Jingami, H; Nakanishi, S				Hirose, M; Kitano, J; Nakajima, Y; Moriyoshi, K; Yanagi, S; Yamamura, H; Muto, T; Jingami, H; Nakanishi, S			Phosphorylation and recruitment of Syk by immunoreceptor tyrosine-based activation motif-based phosphorylation of tamalin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; TRANSDUCING ADAPTER MOLECULE; CELL SIGNAL-TRANSDUCTION; ANTIGEN-RECEPTOR; PHOSPHOLIPASE-C; B-CELLS; PROTEIN; KINASES; DOMAIN; ITAM	Tamalin is a scaffold protein that forms a multiple protein assembly including metabotropic glutamate receptors (mGluRs) and several postsynaptic and protein-trafficking scaffold proteins in distinct mode of protein-protein association. In the present investigation, we report that tamalin possesses a typical immunoreceptor tyrosine-based activation motif (ITAM), which enables Syk kinase to be recruited and phosphorylated by the Src family kinases. Coimmunoprecipitation analysis of rat brain membrane fractions showed that tamalin is present in a multimolecular protein assembly comprising not only mGluR1 but also c-Src, Fyn, and a protein phosphatase, SHP-2. The protein association of both tamalin and c-Src, as determined by truncation analysis of mGluR1 in COS-7 cells, occurred at the carboxyl-terminal tail of mGluR1. Mutation analysis of tyrosine with phenylalanine in COS-7 cells revealed that paired tyrosines at the ITAM sequence of tamalin are phosphorylated preferentially by c-Src and Fyn, and this phosphorylation can recruit Syk kinase and enables it to be phosphorylated by the Src family kinases. The phosphorylated tyrosines at the ITAM sequence of tamalin were highly susceptible to dephosphorylation by protein-tyrosine phosphatases in COS-7 cells. Importantly, tamalin was endogenously phosphorylated and associated with Syk in retinoic acid-treated P19 embryonal carcinoma cells that undergo neuron-like differentiation. The present investigation demonstrates that tamalin is a novel signaling molecule that possesses a PDZ domain and a PDZ binding motif and mediates Syk signaling in an ITAM-based fashion.	Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto 6068501, Japan; Kobe Univ, Grad Sch Med, Dept Genome Sci, Chuo Ku, Kobe, Hyogo 6500017, Japan; Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan	Kyoto University; Kyoto University; Kobe University	Nakanishi, S (corresponding author), Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	snakanis@phy.med.kyoto-u.ac.jp						BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Heidinger V, 2002, J NEUROSCI, V22, P5452; Heuss C, 1999, NAT NEUROSCI, V2, P1070, DOI 10.1038/15996; Husi H, 2001, TRENDS NEUROSCI, V24, P259, DOI 10.1016/S0166-2236(00)01792-6; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; Kitano J, 2003, J BIOL CHEM, V278, P14762, DOI 10.1074/jbc.M300184200; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Miah SMS, 2004, MOL CELL BIOL, V24, P71, DOI 10.1128/MCB.24.1.71-83.2004; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsujimura T, 2001, FEBS LETT, V489, P129, DOI 10.1016/S0014-5793(01)02097-X; Urzainqui A, 2002, IMMUNITY, V17, P401, DOI 10.1016/S1074-7613(02)00420-X; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	41	27	27	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32308	32315		10.1074/jbc.M400547200	http://dx.doi.org/10.1074/jbc.M400547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173175	hybrid			2022-12-25	WOS:000222849700041
J	Peng, Y; Kang, Q; Luo, Q; Jiang, W; Si, WK; Liu, BA; Luu, HH; Park, JK; Li, XM; Luo, J; Montag, AG; Haydon, RC; He, TC				Peng, Y; Kang, Q; Luo, Q; Jiang, W; Si, WK; Liu, BA; Luu, HH; Park, JK; Li, XM; Luo, J; Montag, AG; Haydon, RC; He, TC			Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ID PROTEINS; GENE; REGULATORS; INDUCTION; RECEPTORS; IDENTIFICATION; EXPRESSION; SYSTEM; CANCER	Bone morphogenetic proteins (BMPs) belong to the TGF-beta superfamily and play an important role in development and in many cellular processes. We have found that BMP-2, BMP-6, and BMP-9 induce the most potent osteogenic differentiation of mesenchymal stem cells. Expression profiling analysis has revealed that the Inhibitors of DNA binding/differentiation (Id)-1, Id-2, and Id-3 are among the most significantly up-regulated genes upon BMP-2, BMP-6, or BMP-9 stimulation. Here, we sought to determine the functional role of these Id proteins in BMP-induced osteoblast differentiation. We demonstrated that the expression of Id-1, Id-2, and Id-3 genes was significantly induced at the early stage of BMP-9 stimulation and returned to basal levels at 3 days after stimulation. RNA interference-mediated knockdown of Id expression significantly diminished the BMP-9-induced osteogenic differentiation of mesenchymal progenitor cells. Surprisingly, a constitutive overexpression of these Id genes also inhibited osteoblast differentiation initiated by BMP-9. Furthermore, we demonstrated that BMP-9-regulated Id expression is Smad4-dependent. Overexpression of the three Id genes was shown to promote cell proliferation that was coupled with an inhibition of osteogenic differentiation. Thus, our findings suggest that the Id helix-loop-helix proteins may play an important role in promoting the proliferation of early osteoblast progenitor cells and that Id expression must be down-regulated during the terminal differentiation of committed osteoblasts, suggesting that a balanced regulation of Id expression may be critical to BMP-induced osteoblast lineage-specific differentiation of mesenchymal stem cells.	Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Funct Genom Facil, Chicago, IL 60637 USA; Chongqing Univ Med Sci, Childrens Hosp, Chongqing 400016, Peoples R China; Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Surg, Seoul 130709, South Korea	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago; Chongqing Medical University; Catholic University of Korea	He, TC (corresponding author), Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.	tche@surgery.bsd.uchicago.edu	Liu, Bernard/A-3687-2012; Liu, Bernard Arthur/AAR-4915-2021	Liu, Bernard/0000-0003-3060-3120; Liu, Bernard Arthur/0000-0003-3060-3120	NCCIH NIH HHS [F05 AT002014-01] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [F05AT002014] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Chen C, 2003, NAT BIOTECHNOL, V21, P294, DOI 10.1038/nbt795; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helm GA, 2000, J NEUROSURG, V92, P191, DOI 10.3171/spi.2000.92.2.0191; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; KANG Q, 2004, IN PRESS GENE THER; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kingsley D M, 2001, Novartis Found Symp, V232, P213; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lopez-Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Norton JD, 2000, J CELL SCI, V113, P3897; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744; Ploemacher RE, 1999, LEUKEMIA, V13, P428, DOI 10.1038/sj.leu.2401363; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Rosen V, 1996, ANN NY ACAD SCI, V785, P59, DOI 10.1111/j.1749-6632.1996.tb56244.x; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; URIST MR, 1987, CLIN ORTHOP RELAT R, P295; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600-0722.1998.tb02170.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	45	179	192	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32941	32949		10.1074/jbc.M403344200	http://dx.doi.org/10.1074/jbc.M403344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161906	hybrid			2022-12-25	WOS:000222849700114
J	Sanz-Rodriguez, F; Guerrero-Esteo, M; Botella, LM; Banville, D; Vary, CPH; Bernabeu, C				Sanz-Rodriguez, F; Guerrero-Esteo, M; Botella, LM; Banville, D; Vary, CPH; Bernabeu, C			Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; ZYXIN-RELATED PROTEIN; HUMAN ENDOTHELIAL-CELLS; NUCLEAR EXPORT SIGNAL; SMOOTH-MUSCLE-CELLS; MOLECULAR CHARACTERIZATION; STIMULATED PHOSPHOPROTEIN; LISTERIA-MONOCYTOGENES; CELLULAR-RESPONSES	Endoglin is a component of the transforming growth factor-beta receptor complex abundantly expressed at the surface of endothelial cells and plays an important role in cardiovascular development and vascular remodeling. By using the cytoplasmic domain of endoglin as a bait for screening protein interactors, we have identified ZRP-1 (zyxin-related protein 1), a 476-amino acid member that belongs to a family of LIM containing proteins that includes zyxin and lipoma-preferred partner. The endoglin interacting region was mapped within the three double zinc finger LIM domains of the ZRP-1 C terminus. Analysis of the subcellular distribution of ZRP-1 demonstrated that in the absence of endoglin, ZRP-1 mainly localizes to focal adhesion sites, whereas in the presence of endoglin ZRP-1 is found along actin stress fibers. Because the LIM family of proteins has been shown to associate with the actin cytoskeleton, we investigated the possibility of a regulatory role for endoglin with regard to this structure. Expression of endoglin resulted in a dramatic reorganization of the actin cytoskeleton. In the absence of endoglin, F-actin was localized to dense aggregates of bundles, whereas in the presence of endoglin, expressed in endothelial cells, F-actin was in stress fibers and colocalized with ZRP-1. Furthermore, small interfering RNA-mediated suppression of endoglin or ZRP-1, or clustering of endoglin in endothelial cells, led to mislocalization of F-actin fibers. These results suggest a regulatory role for endoglin, via its interaction with ZRP-1, in the actin cytoskeletal organization.	CSIC, Ctr Invest Biol, Madrid 28040, Spain; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); National Research Council Canada; Maine Medical Center	Sanz-Rodriguez, F (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maetzu 9, Madrid 28040, Spain.	francisco.sanz@uam.es	Bernabeu, Carmelo/L-3226-2014; Botella, Luisa M/L-1392-2014; Bernabeu, Carmelo/P-4662-2019; Sanz-Rodriguez, Francisco/AAK-8388-2020	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR15555] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2000, ATHEROSCLEROSIS, V153, P323, DOI 10.1016/S0021-9150(00)00422-6; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Golsteyn RM, 1997, J CELL SCI, V110, P1893; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Holt MR, 1998, INT J BIOCHEM CELL B, V30, P307, DOI 10.1016/S1357-2725(97)00101-5; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; MA K, 2000, ARTERIOSCLER THROMB, V20, P2546; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; Munster AK, 2002, J BIOL CHEM, V277, P19688, DOI 10.1074/jbc.M201093200; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Price CJ, 2000, ARTERIOSCL THROM VAS, V20, P2051, DOI 10.1161/01.ATV.20.9.2051; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; van der Gaag EJ, 2002, J INVEST DERMATOL, V118, P246, DOI 10.1046/j.0022-202x.2001.01657.x; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; Wang Y, 1999, GENE, V234, P403, DOI 10.1016/S0378-1119(99)00168-7; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; Wang Y, 2003, BBA-MOL CELL RES, V1593, P115, DOI 10.1016/S0167-4889(02)00349-X; Williams G, 1998, INDEX CENSORSHIP, V27, P186, DOI 10.1080/03064229808536405; Xu J, 2003, J BIOL CHEM, V278, P38104; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Yi JS, 2002, J BIOL CHEM, V277, P9580, DOI 10.1074/jbc.M106922200; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Zhao MK, 1999, GENE EXPRESSION, V8, P207; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	60	111	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32858	32868		10.1074/jbc.M400843200	http://dx.doi.org/10.1074/jbc.M400843200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148318	Green Published, hybrid			2022-12-25	WOS:000222849700106
J	Almaguer, C; Cheng, W; Nolder, C; Patton-Vogt, J				Almaguer, C; Cheng, W; Nolder, C; Patton-Vogt, J			Glycerophosphoinositol, a novel phosphate source whose transport is regulated by multiple factors in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; FUNCTIONAL-CHARACTERIZATION; YEAST; GENE; INOSITOL; PERMEASE; PHOSPHATIDYLINOSITOL; ACCUMULATION; DEGRADATION; STARVATION	Git1p mediates the transport of the phospholipid metabolite, glycerophosphoinositol, into Saccharomyces cerevisiae. We report that phosphate limitation and inositol limitation affect GIT1 expression and Git1p transport activity via distinct mechanisms that involve multiple transcription factors. GIT1 transcript levels and Git1p activity are greater in cells starved for phosphate, with or without inositol limitation, than in cells only limited for inositol. Furthermore, the kinetics of GIT1 transcript accumulation and Git1p activity upon transfer of cells to phosphate starvation media are different from those obtained upon transfer of cells to inositol-free media. Pho2p and Pho4p are required for GIT1 expression and for Git1p transport activity under all growth conditions tested. In contrast, Ino2p and Ino4p are required for full GIT1 expression when inositol is limiting, with or without phosphate limitation, but not when only phosphate is limiting. Greatly reduced transport activity was detected in ino2Delta and ino4Delta cells under all growth conditions. A 300-base pair region of the GIT1 promoter containing potential Pho4p binding sites was shown to be required for full GIT1 expression. Git1p appears to act as a H+-symporter, and neither inositol nor phosphate effectively compete with glycerophosphoinositol for transport by Git1p. Glycerophosphoinositol was shown previously to support the growth of an inositol auxotroph. Remarkably, we now report that glycerophosphoinositol can act as the sole source of phosphate for the cell, providing functional relevance for the regulation of Git1p transport activity by phosphate.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	Duquesne University	Patton-Vogt, J (corresponding author), Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.	pattonvogt@duq.edu			NIGMS NIH HHS [GM59817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059817] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almaguer C, 2003, EUKARYOT CELL, V2, P729, DOI 10.1128/EC.2.4.729-736.2003; AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Boer VM, 2003, J BIOL CHEM, V278, P3265, DOI 10.1074/jbc.M209759200; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graves JA, 2000, GENETICS, V154, P1485; Hama H, 2000, METHODS, V20, P465, DOI 10.1006/meth.2000.0959; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Naumov GI, 1998, CAN J MICROBIOL, V44, P1045, DOI 10.1139/cjm-44-11-1045; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; Patton-Vogt JL, 1998, GENETICS, V149, P1707; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Persson BL, 2003, CURR GENET, V43, P225, DOI 10.1007/s00294-003-0400-9; Pinson B, 1996, EUR J BIOCHEM, V239, P439, DOI 10.1111/j.1432-1033.1996.0439u.x; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P1499, DOI 10.1093/nar/28.7.1499; Robinson KA, 2000, NUCLEIC ACIDS RES, V28, P4460, DOI 10.1093/nar/28.22.4460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wykoff DD, 2001, GENETICS, V159, P1491	28	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31937	31942		10.1074/jbc.M403648200	http://dx.doi.org/10.1074/jbc.M403648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145930	hybrid			2022-12-25	WOS:000222726800121
J	Bzymek, KP; Holz, RC				Bzymek, KP; Holz, RC			The catalytic role of glutamate 151 in the leucine aminopeptidase from Aeromonas proteolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED-ACIDIC DIPEPTIDASE; CRYSTAL-STRUCTURE; ZINC; INHIBITION; BINDING; BRAIN; NAALADASE; MECHANISM; ANALOG; INVOLVEMENT	Glutamate 151 has been proposed to act as the general acid/base during the peptide hydrolysis reaction catalyzed by the co-catalytic metallohydrolase from Aeromonas proteolytica (AAP). However, to date, no direct evidence has been reported for the role of Glu-151 during catalytic turnover by AAP. In order to elucidate the catalytic role of Glu-151, altered AAP enzymes have been prepared in which Glu-151 has been substituted with a glutamine, an alanine, and an aspartate. The Michaelis constant ( Km) does not change upon substitution to aspartate or glutamine, but the rate of the reaction changes drastically in the following order: glutamate (100% activity), aspartate (0.05%), glutamine (0.004%), and alanine (0%). Examination of the pH dependence of the kinetic constants k(cat) and K-m revealed a change in the pK(a) of a group that ionizes at pH 4.8 in recombinant leucine aminopeptidase (rAAP) to 4.2 for E151D-AAP. The remaining pK(a) values at 5.2, 7.5, and 9.9 do not change. Proton inventory studies indicate that one proton is transferred in the rate-limiting step of the reaction at pH 10.50 for both rAAP and E151D-AAP, but at pH 6.50 two protons and general solvation effects are responsible for the observed effects in the reaction catalyzed by rAAP and E151D-AAP, respectively. Based on these data, Glu-151 is intrinsically involved in the peptide hydrolysis reaction catalyzed by AAP and can be assigned the role of a general acid and base.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Holz, RC (corresponding author), Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA.	rholz@cc.usu.edu						Albery W. J., 1975, PROTON TRANSFER REAC, P263; BAKER JO, 1983, BIOCHEMISTRY-US, V22, P5322, DOI 10.1021/bi00292a011; BAKER JO, 1985, BIOCHEM BIOPH RES CO, V130, P1154, DOI 10.1016/0006-291X(85)91736-X; Barinka C, 2002, J NEUROCHEM, V80, P477, DOI 10.1046/j.0022-3042.2001.00715.x; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Bennett B, 1997, BIOCHEMISTRY-US, V36, P9837, DOI 10.1021/bi970735p; Bennett B, 1997, J AM CHEM SOC, V119, P1923, DOI 10.1021/ja963021v; Bienvenue DL, 2002, BIOCHEMISTRY-US, V41, P3712, DOI 10.1021/bi011752o; Bienvenue DL, 2002, J BIOL INORG CHEM, V7, P129, DOI 10.1007/s007750100280; BOYEN A, 1992, GENE, V116, P1, DOI 10.1016/0378-1119(92)90621-U; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; D'souza VM, 2000, BIOCHEMISTRY-US, V39, P3817, DOI 10.1021/bi9925827; De Paola CC, 1999, BIOCHEMISTRY-US, V38, P9048, DOI 10.1021/bi9900572; Desmarais WT, 2002, STRUCTURE, V10, P1063, DOI 10.1016/S0969-2126(02)00810-9; DIXON M, 1979, ENZYMES, P140; ELROD JP, 1980, J AM CHEM SOC, V102, P3917, DOI 10.1021/ja00531a039; Elstner M, 2003, J COMPUT CHEM, V24, P565, DOI 10.1002/jcc.10201; Holz RC, 2002, COORDIN CHEM REV, V232, P5, DOI 10.1016/S0010-8545(01)00470-2; Holz RC, 2003, CURR OPIN CHEM BIOL, V7, P197, DOI 10.1016/S1367-5931(03)00033-4; Holz RC, 1998, J AM CHEM SOC, V120, P6329, DOI 10.1021/ja971589d; Huntington KM, 1999, BIOCHEMISTRY-US, V38, P15587, DOI 10.1021/bi991283e; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; MAKINEN KK, 1982, EUR J BIOCHEM, V128, P257; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Prescott J M, 1976, Methods Enzymol, V45, P530; PRESCOTT JM, 1983, BIOCHEM BIOPH RES CO, V114, P646, DOI 10.1016/0006-291X(83)90829-X; PRESCOTT JM, 1985, BIOCHEMISTRY-US, V24, P5350, DOI 10.1021/bi00341a012; PRESCOTT JM, 1971, J BIOL CHEM, V246, P1756; Pulido-Cejudo G, 1997, ANTIVIR RES, V36, P167, DOI 10.1016/S0166-3542(97)00052-1; Remaut H, 2001, NAT STRUCT BIOL, V8, P674, DOI 10.1038/90380; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; SEGEL IH, 1975, ENZYME KINETICS BEHA, P847; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Slusher BS, 2001, SYNAPSE, V41, P22, DOI 10.1002/syn.1056; Stamper C, 2001, BIOCHEMISTRY-US, V40, P7035, DOI 10.1021/bi0100891; Thomas AG, 1999, BRAIN RES, V843, P48, DOI 10.1016/S0006-8993(99)01879-X; Tiffany CW, 1999, PROSTATE, V39, P28; Ustynyuk L, 1999, BIOCHEMISTRY-US, V38, P11433, DOI 10.1021/bi991090r; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; Velasco AM, 2002, J MOL EVOL, V55, P445, DOI 10.1007/s00239-002-2340-2; VENKATASUBBAN KS, 1984, CRC CR REV BIOCH MOL, V17, P1, DOI 10.3109/10409238409110268; WINZOR DJ, 1995, QUANTITATIVE CHARACT; Witkin JM, 2002, NEUROPHARMACOLOGY, V43, P348, DOI 10.1016/S0028-3908(02)00124-7; Zhang ZZ, 2000, BIOCHEM J, V350, P671, DOI 10.1042/0264-6021:3500671	50	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31018	31025		10.1074/jbc.M404035200	http://dx.doi.org/10.1074/jbc.M404035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138277	hybrid, Green Published			2022-12-25	WOS:000222726800015
J	Inesi, G; Ma, HL; Lewis, D; Xu, C				Inesi, G; Ma, HL; Lewis, D; Xu, C			Ca2+ occlusion and gating function of Glu(309) in the ADP-fluoroaluminate analog of the Ca2+-ATPase phosphoenzyme intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; ATPASE; BINDING; PHOSPHORYLATION; DISSOCIATION; ACTIVATION; MECHANISM; SITES	In the absence of ATP the sarcoplasmic reticulum ATPase (SERCA) binds two Ca2+ with high affinity. The two bound Ca2+ rapidly undergo reverse dissociation upon addition of EGTA, but can be distinguished by isotopic exchange indicating fast exchange at a superficial site ( site II), and retardation of exchange at a deeper site ( site I) by occupancy of site II. Site II mutations that allow high affinity binding to site I, but only low affinity binding to site II, show that retardation of isotopic exchange requires higher Ca2+ concentrations with the N796A mutant, and is not observed with the E309Q mutant even at millimolar Ca2+. Fluoroaluminate forms a complex at the catalytic site yielding stable analogs of the phosphoenzyme intermediate, with properties similar to E2-P or E1-P.Ca2. Mutational analysis indicates that Asp(351), Lys(352), Thr(353), Asp(703), Asn(706), Asp(707), Thr(625), and Lys(684) participate in stabilization of fluoroaluminate and Mg2+ at the phosphorylation site. In the presence of fluoroaluminate and Ca2+, ADP ( or AMP-PCP) favors formation of a stable ADP . E1- P . Ca-2 analog. This produces strong occlusion of Ca2+ bound to both sites ( I and II), whereby dissociation occurs very slowly even following addition of EGTA. Occlusion by fluoraluminate and ADP is not observed with the E309Q mutant, suggesting a gating function of Glu(309) at the mouth of a binding cavity with a single path of entry. This phenomenon corresponds to the earliest step of the catalytic cycle following utilization of ATP. Experiments on limited proteolysis reveal that a long range conformational change, involving displacement of headpiece domains and transmembrane helices, plays a mechanistic role.	Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Inesi, G (corresponding author), Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA.	ginesi@umaryland.edu			NHLBI NIH HHS [R01 HL69830] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069830] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen JP, 1998, ACTA PHYSIOL SCAND, V163, P45; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Chen BW, 2004, BIOCHEMISTRY-US, V43, P4366, DOI 10.1021/bi0356350; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2004, P NATL ACAD SCI USA, V101, P2776, DOI 10.1073/pnas.0400122101; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Gadsby DC, 2004, NATURE, V427, P795, DOI 10.1038/427795a; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; INESI G, 1987, J BIOL CHEM, V262, P16338; Inesi G, 2002, BIOPHYS J, V83, P2327, DOI 10.1016/S0006-3495(02)75247-8; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TOYOSHIMA C, 2004, IN PRESS NATURE; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	34	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31629	31637		10.1074/jbc.M403211200	http://dx.doi.org/10.1074/jbc.M403211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150270	hybrid			2022-12-25	WOS:000222726800087
J	Ling, KKY; Siow, NL; Choi, RCY; Ting, AKL; Kong, LW; Tsim, KWK				Ling, KKY; Siow, NL; Choi, RCY; Ting, AKL; Kong, LW; Tsim, KWK			ATP potentiates agrin-induced AChR aggregation in cultured myotubes - Activation of RhoA in P2Y1 nucleotide receptor signaling at vertebrate neuromuscular junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTORS; EXPRESSION; MUSCLE; P2Y(1); MUSK; CALCIUM; KINASE; RAPSYN; ROLES; NERVE	At vertebrate neuromuscular junctions, ATP is known to stabilize acetylcholine in the synaptic vesicles and to be co-released with it. We have shown previously that a nucleotide receptor, P2Y(1) receptor, is localized at the nmjs, and we propose that this mediates a trophic role for synaptic ATP there. In cultured myotubes, the activation of P2Y(1) receptors modulated agrin-induced acetylcholine receptor ( AChR) aggregation in a potentiation manner. This potentiation effect in agrin-induced AChR aggregation was reduced by antagonizing the P2Y(1) receptors. The guanosine triphosphatase RhoA was shown to be responsible for this P2Y(1)-potentiated effect. The localization of RhoA in rat and chicken skeletal muscles was restricted at the neuromuscular junctions. Application of P2Y(1) agonists in cultured myotubes induced RhoA activation, which showed an additive effect with agrin-induced RhoA activation. Over-expression of dominant-negative mutant of RhoA in cultured myotubes diminished the agrin-induced AChR aggregation, as well as the potentiation effect of P2Y(1)-specific agonist. Application of UTP in the cultures also triggered similar responses as did 2-methylthioadenosine 5'diphosphate, suggesting the involvement of other subtypes of P2Y receptors. These results demonstrate that RhoA could serve as a downstream mediator of signaling mediated by P2Y(1) receptor and agrin, which therefore synergizes the effects of the two neuron-derived trophic factors in modulating the formation and/or maintenance of post-synaptic apparatus at the neuromuscular junctions.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Cleary Water Bay Rd, Hong Kong, Hong Kong, Peoples R China.	botsim@ust.hk		Tsim, Karl/0000-0003-4808-1674				Borges LS, 2002, J NEUROBIOL, V50, P69, DOI 10.1002/neu.10020; Burgess RW, 1999, NEURON, V23, P33, DOI 10.1016/S0896-6273(00)80751-5; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheung KK, 2003, DEV DYNAM, V228, P254, DOI 10.1002/dvdy.10378; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 2003, J NEUROSCI, V23, P4445; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DESCHENES MR, 1993, J NEUROCYTOL, V22, P603, DOI 10.1007/BF01181487; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fu WM, 1997, EUR J NEUROSCI, V9, P676, DOI 10.1111/j.1460-9568.1997.tb01416.x; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; GLANTZ SA, 1988, PRIMER BIOSTATISTICS; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Jones MA, 2004, MOL CELL NEUROSCI, V25, P195, DOI 10.1016/j.mcn.2003.10.013; Jones MA, 2000, MOL CELL NEUROSCI, V16, P649, DOI 10.1006/mcne.2000.0901; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; Luo Z, 2003, NEURON, V40, P703, DOI 10.1016/S0896-6273(03)00695-0; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; Megeath LJ, 2003, NEUROSCIENCE, V122, P659, DOI 10.1016/S0306-4522(03)00602-X; Megeath LJ, 1998, J NEUROSCI, V18, P672; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Moore D, 2000, J COMP NEUROL, V421, P374, DOI 10.1002/(SICI)1096-9861(20000605)421:3<374::AID-CNE6>3.0.CO;2-Z; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; OMalley JP, 1997, J CELL BIOL, V138, P159, DOI 10.1083/jcb.138.1.159; Pun S, 1997, MOL CELL NEUROSCI, V10, P87, DOI 10.1006/mcne.1997.0637; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Silinsky EM, 1996, J PHYSIOL-LONDON, V492, P815, DOI 10.1113/jphysiol.1996.sp021348; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; Smith CL, 2001, J NEUROSCI, V21, P3151, DOI 10.1523/JNEUROSCI.21-09-03151.2001; Strochlic L, 2001, J CELL BIOL, V153, P1127, DOI 10.1083/jcb.153.5.1127; Tsim KWK, 2003, J NEUROCYTOL, V32, P603, DOI 10.1023/B:NEUR.0000020613.25367.78; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WALLACE BG, 1986, J CELL BIOL, V102, P783, DOI 10.1083/jcb.102.3.783; Watty A, 2000, P NATL ACAD SCI USA, V97, P4585, DOI 10.1073/pnas.080061997; Webb TE, 1996, MOL PHARMACOL, V50, P258; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Weston C, 2003, J BIOL CHEM, V278, P6450, DOI 10.1074/jbc.M210249200	47	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31081	31088		10.1074/jbc.M403316200	http://dx.doi.org/10.1074/jbc.M403316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145960	hybrid			2022-12-25	WOS:000222726800023
J	El Ghachi, M; Bouhss, A; Blanot, D; Mengin-Lecreulx, D				El Ghachi, M; Bouhss, A; Blanot, D; Mengin-Lecreulx, D			The bacA gene of Escherichia coli encodes an undecaprenyl pyrophosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CELL-WALLS; C55-ISOPRENOID ALCOHOL PHOSPHOKINASE; BACITRACIN ABC TRANSPORTER; STAPHYLOCOCCUS-AUREUS; PEPTIDOGLYCAN SYNTHESIS; BACILLUS-LICHENIFORMIS; DIPHOSPHATE SYNTHASE; RESISTANCE; MEMBRANE; PURIFICATION	The bacA gene, the overexpression of which results in bacitracin resistance, was inactivated and shown to be non-essential for growth of Escherichia coli. It was proposed earlier that the bacA gene product may confer resistance to the antibiotic by phosphorylation of undecaprenol (Cain, B. D., Norton, P. J., Eubanks, W., Nick, H. S., and Allen, C. M. (1983) J. Bacteriol. 175, 3784-3789). In the present work, this extremely hydrophobic membrane protein was overproduced and purified to near homogeneity. The analysis of its catalytic properties clearly demonstrated that the purified BacA protein exhibited undecaprenyl pyrophosphate phosphatase activity but not undecaprenol phosphokinase activity. This finding was perfectly consistent with the mechanism of action of bacitracin that consists in the sequestration of undecaprenyl pyrophosphate, the BacA enzyme substrate. The level of undecaprenyl pyrophosphate phosphatase was increased by 280-fold in cells carrying bacA on a multicopy expression plasmid. It was decreased by similar to75% but was not completely abolished in a bacA disruption mutant, suggesting that BacA is the main E. coli undecaprenyl pyrophosphate phosphatase but that other protein(s) exhibiting such an activity should exist to account for the residual activity and viability of the mutant strain. This is the first gene encoding undecaprenyl pyrophosphate phosphatase identified to date. Considering its newly identified function, we propose to rename the bacA gene uppP.	Univ Paris 11, Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim & Biophys Mol & Cellulaire, CNRS,UMR 8619, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, Lab Enveloppes Bacteriennes & Antibiot, Inst Biochim & Biophys Mol & Cellulaire, CNRS,UMR 8619, Batiment 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275				ALLEN CM, 1985, METHOD ENZYMOL, V110, P281; ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Bouhss A, 1999, MOL MICROBIOL, V34, P576, DOI 10.1046/j.1365-2958.1999.01623.x; BOUHSS A, 2004, IN PRESS J BIOL CHEM, V279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; CAIN BD, 1993, J BACTERIOL, V175, P3784, DOI 10.1128/JB.175.12.3784-3789.1993; Cao M, 2002, J BACTERIOL, V184, P6123, DOI 10.1128/JB.184.22.6123-6129.2002; Chalker AF, 2000, MICROBIOL-SGM, V146, P1547, DOI 10.1099/00221287-146-7-1547; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; FIEDLER W, 1988, J BIOL CHEM, V263, P14684; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GOLDMAN R, 1972, J BIOL CHEM, V247, P5116; Gruber G, 2002, BIOCHEM BIOPH RES CO, V298, P383, DOI 10.1016/S0006-291X(02)02468-3; Harel YM, 1999, J BACTERIOL, V181, P6176, DOI 10.1128/JB.181.19.6176-6178.1999; HIGASHI Y, 1970, J BIOL CHEM, V245, P3697; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; KALIN JR, 1979, BIOCHIM BIOPHYS ACTA, V574, P112, DOI 10.1016/0005-2760(79)90090-0; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; PODLESEK Z, 1995, MOL MICROBIOL, V16, P969, DOI 10.1111/j.1365-2958.1995.tb02322.x; Podlesek Z, 2000, FEMS MICROBIOL LETT, V188, P103, DOI 10.1111/j.1574-6968.2000.tb09176.x; POLLOCK TJ, 1994, J BACTERIOL, V176, P6229, DOI 10.1128/jb.176.20.6229-6237.1994; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rick P, 1996, ESCHERICHIA COLI SAL, P104; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERMA.H, 1971, P NATL ACAD SCI USA, V68, P2441, DOI 10.1073/pnas.68.10.2441; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORM DR, 1973, J BIOL CHEM, V248, P3940; TOSCANO WA, 1987, ANTIBIOTIC INHIBITOR, P101; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; WILLOUGHBY E, 1972, J BIOL CHEM, V247, P5113; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	142	147	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30106	30113		10.1074/jbc.M401701200	http://dx.doi.org/10.1074/jbc.M401701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138271	hybrid			2022-12-25	WOS:000222531900031
J	Viard, T; Cossard, R; Duguet, M; de la Tour, CB				Viard, T; Cossard, R; Duguet, M; de la Tour, CB			Thermotoga maritima-Escherichia coli chimeric topoisomerases - Answers about involvement of the carboxyl-terminal domain in DNA topoisomerase I-mediated catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE GYRASE; MECHANISM; CLEAVAGE; TEMPERATURE; BACTERIAL; FRAGMENT; CLONING; COMPLEX	Bacterial topoisomerases I are generally composed of two domains as follows: a core domain, which contains all the conserved motifs involved in the trans-esterification reactions, and a carboxyl-terminal domain, highly variable in size and sequence. In the present work, we have addressed the question of the respective roles of the two domains in the different steps of the topoisomerization cycle. For this purpose, we prepared various recombinant topoisomerases from two model enzymes: topoisomerase I from the hyperthermophilic bacterium Thermotoga maritima and topoisomerase I from Escherichia coli. We compared the properties of the two core domains to that of the topoisomerases formed by combining the core domain of one enzyme to the carboxyl-terminal domain of the other. We found that, contrary to E. coli (Lima, C. D., Wang, J. C., and Mondragon, A. (1993) J. Mol. Biol. 232, 1213-1216), the core domain from T. maritima (TmTop65) is able to sustain by itself a complete topoisomerization cycle, although with low efficiency. Fusion of TmTop65 to the entire carboxyl-terminal domain from E. coli considerably increases binding efficiency, thermal stability, and DNA relaxation activity. Moreover, the chimera predominantly acquires the cleavage specificity of E. coli full-length topoisomerase. For the chimera obtained by fusion of the T. maritima carboxyl-terminal domain to the core EcTop67, very low DNA relaxation activity and binding are recovered, but formation of a covalent DNA adduct is impaired. Taken together, our results show that the presence and the nature of the carboxyl-terminal domain of bacterial topoisomerases I strongly determine their DNA binding efficiency and cleavage specificity but is not strictly required for strand passage.	Univ Paris 11, Ctr Orsay, CNRS,UMR 8621, Inst Genet & Microbiol,Lab Enzymol Acides Nucl, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	de la Tour, CB (corresponding author), Univ Paris 11, Ctr Orsay, CNRS,UMR 8621, Inst Genet & Microbiol,Lab Enzymol Acides Nucl, Batiment 400, F-91405 Orsay, France.	bouthier@igmors.u-psud.fr						Ahumada A, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-13; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; DEAN FB, 1985, J BIOL CHEM, V260, P4984; Dekker NH, 2003, J MOL BIOL, V329, P271, DOI 10.1016/S0022-2836(03)00320-6; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; delaTour CB, 1995, BBA-GENE STRUCT EXPR, V1264, P279, DOI 10.1016/0167-4781(96)83596-2; Grishin NV, 2000, J MOL BIOL, V299, P1165, DOI 10.1006/jmbi.2000.3841; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Jaxel C, 1999, EUR J BIOCHEM, V260, P103, DOI 10.1046/j.1432-1327.1999.00128.x; Kaltoum H, 1997, SYST APPL MICROBIOL, V20, P505, DOI 10.1016/S0723-2020(97)80019-7; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; Li ZY, 2001, MOL CELL, V7, P301, DOI 10.1016/S1097-2765(01)00178-2; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIMA CD, 1993, J MOL BIOL, V232, P1213, DOI 10.1006/jmbi.1993.1474; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; Perry K, 2003, STRUCTURE, V11, P1349, DOI 10.1016/j.str.2003.09.013; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Serre MC, 2003, PROG NUCLEIC ACID RE, V74, P37, DOI 10.1016/S0079-6603(03)01010-9; Tse-Dinh YC, 1998, BBA-GENE STRUCT EXPR, V1400, P19, DOI 10.1016/S0167-4781(98)00125-0; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; Viard T, 2001, J BIOL CHEM, V276, P46495, DOI 10.1074/jbc.M107714200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Zhang HL, 1996, J BIOL CHEM, V271, P9039, DOI 10.1074/jbc.271.15.9039; ZHU CX, 1995, J MOL BIOL, V250, P609, DOI 10.1006/jmbi.1995.0402; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	27	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30073	30080		10.1074/jbc.M309692200	http://dx.doi.org/10.1074/jbc.M309692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140883	hybrid			2022-12-25	WOS:000222531900027
J	Meissner, B; Boll, M; Daniel, H; Baumeister, R				Meissner, B; Boll, M; Daniel, H; Baumeister, R			Deletion of the intestinal peptide transporter affects insulin and TOR signaling in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; DIETARY RESTRICTION; OXIDATIVE STRESS; KINASE; DROSOPHILA; RECEPTOR; GENE; PHOSPHORYLATION; THERMOTOLERANCE; METABOLISM	The mammalian intestinal peptide transporter PEPT1 mediates the uptake of di- and tripeptides from the gut lumen into intestinal epithelial cells and acts in parallel with amino acid transporters. Here we address the importance of the PEPT1 orthologue PEP-2 for the assimilation of dietary protein and for overall protein nutrition in Caenorhabditis elegans. pep-2 is expressed specifically along the apical membrane of the intestinal cells, and in pep-2 deletion mutant animals, uptake of intact peptides from the gut lumen is abolished. The consequences are a severely retarded development, reduced progeny and body size, and increased stress tolerance. We show here that pep-2 cross-talks with both the C. elegans target of rapamycin (TOR) and the DAF2/insulin-signaling pathways. The pep-2 mutant enhances the developmental and longevity phenotypes of daf-2, resulting, among other effects, in a pronounced increase in adult life span. Moreover, all aspects of a weak let-363/TOR RNA interference phenotype are intensified by pep-2 deletion, indicating that pep-2 function upstream of TOR-mediated nutrient sensing. Our findings provide evidence for a predominant role of the intestinal peptide transporter for the delivery of bulk quantities of amino acids for growth and development, which consequently affects signaling pathways that regulate metabolism and aging.	Univ Freiburg, Bio3, D-79104 Freiburg, Germany; Univ Munich, Adolph Butenandt Inst Mol Neurogenet, D-80336 Munich, Germany; Tech Univ Munich, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	University of Freiburg; University of Munich; Technical University of Munich	Baumeister, R (corresponding author), Univ Freiburg, Bio3, Schaenzlestr 1, D-79104 Freiburg, Germany.	baumeister@celegans.de	Daniel, Hannelore/B-8982-2009					Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; AVERY L, 1997, FEEDING DEFECATION C, V2; BAI JPF, 1992, PHARM RES-DORDR, V9, P969, DOI 10.1023/A:1015885823793; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Doring F, 2002, J MEMBRANE BIOL, V186, P55, DOI 10.1007/s00232-001-0135-9; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; GANAPATHY ME, 1995, J BIOL CHEM, V270, P25672, DOI 10.1074/jbc.270.43.25672; Gems D, 2001, CURR OPIN GENET DEV, V11, P287, DOI 10.1016/S0959-437X(00)00192-1; Gems D, 1998, GENETICS, V150, P129; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; Groneberg DA, 2001, AM J PHYSIOL-GASTR L, V281, pG697, DOI 10.1152/ajpgi.2001.281.3.G697; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nehrke K, 2003, J BIOL CHEM, V278, P44657, DOI 10.1074/jbc.M307351200; RAIZEN DM, 1995, GENETICS, V141, P1365; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Rubio-Aliaga I, 2000, BIOCHEM BIOPH RES CO, V276, P734, DOI 10.1006/bbrc.2000.3546; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Takenaka A, 2000, J NUTR, V130, P2910, DOI 10.1093/jn/130.12.2910; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; WONG A, 1995, GENETICS, V139, P1247; Yasuda K, 1999, J GERONTOL A-BIOL, V54, pB47, DOI 10.1093/gerona/54.2.B47; YOUNGMAN LD, 1992, P NATL ACAD SCI USA, V89, P9112, DOI 10.1073/pnas.89.19.9112; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	48	139	147	2	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36739	36745		10.1074/jbc.M403415200	http://dx.doi.org/10.1074/jbc.M403415200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15155758	hybrid			2022-12-25	WOS:000223453600074
J	Briancon, N; Bailly, A; Clotman, F; Jacquemin, P; Lemaigre, FP; Weiss, MC				Briancon, N; Bailly, A; Clotman, F; Jacquemin, P; Lemaigre, FP; Weiss, MC			Expression of the alpha 7 isoform of hepatocyte nuclear factor (HNF) 4 is activated by HNF6/OC-2 and HNF1 and repressed by HNF4 alpha 1 in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTION FACTORS; PHENYLALANINE-HYDROXYLASE GENE; FACTOR 4-ALPHA; VISCERAL ENDODERM; ONECUT CLASS; DNA-BINDING; HOMEODOMAIN PROTEINS; MAMMALIAN MEMBER; MOUSE EMBRYO; CELL	The hepatocyte nuclear factor (HNF) 4alpha gene possesses two promoters, proximal P1 and distal P2, whose use results in HNF4alpha1 and HNF4alpha7 transcripts, respectively. Both isoforms are expressed in the embryonic liver, whereas HNF4alpha1 is almost exclusively in the adult liver. A 516-bp fragment, encompassing a DNase I-hypersensitive site associated with P2 activity that is still retained in adult liver, contains functional HNF1 and HNF6 binding sites and confers full promoter activity in transient transfections. We demonstrate a critical role of the Onecut factors in P2 regulation using site-directed mutagenesis and embryos doubly deficient for HNF6 and OC-2 that show reduced hepatic HNF4alpha7 transcript levels. Transient transgenesis showed that a 4-kb promoter region is sufficient to drive expression of a reporter gene in the stomach, intestine, and pancreas, but not the liver, for which additional activating sequences may be required. Quantitative PCR analysis revealed that throughout liver development HNF4alpha7 transcripts are lower than those of HNF4alpha1. HNF4alpha1 represses P2 activity in transfection assays and as deduced from an increase in P2-derived transcript levels in recombinant mice in which HNF4alpha1 has been deleted and replaced by HNF4alpha7. We conclude that although HNF6/OC-2 and perhaps HNF1 activate the P2 promoter in the embryo, increasing HNF4alpha1 expression throughout development causes a switch to essentially exclusive P1 promoter activity in the adult liver.	Inst Pasteur, Dept Dev Biol, CNRS,URA 2578, Unite Genet Differenciat, F-75724 Paris 15, France; Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Univ Catholique Louvain, B-1200 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite Catholique Louvain	Weiss, MC (corresponding author), Inst Pasteur, Dept Dev Biol, CNRS,URA 2578, Unite Genet Differenciat, 25 Rue Dr Roux, F-75724 Paris 15, France.	mweiss@pasteur.fr	Jacquemin, Patrick/ABA-7932-2021	Lemaigre, Frederic/0000-0002-3609-434X	NIDDK NIH HHS [1 U01 DK63588-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063588] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ANGRAND PO, 1990, CELL GROWTH DIFFER, V1, P519; [Anonymous], 2001, NUCL RECEPTORS GENET; Bailly A, 1998, J CELL SCI, V111, P2411; Bailly A, 2001, NUCLEIC ACIDS RES, V29, P3495, DOI 10.1093/nar/29.17.3495; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; COON HG, 1969, P NATL ACAD SCI USA, V62, P852, DOI 10.1073/pnas.62.3.852; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Duncan SA, 2003, MECH DEVELOP, V120, P19, DOI 10.1016/S0925-4773(02)00328-3; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Duncan SA, 1997, DEVELOPMENT, V124, P279; Eeckhoute J, 2004, NUCLEIC ACIDS RES, V32, P2586, DOI 10.1093/nar/gkh581; Eeckhoute J, 2003, ENDOCRINOLOGY, V144, P1686, DOI 10.1210/en.2002-0024; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Faust DM, 1996, MOL CELL BIOL, V16, P3125; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREENGARD O, 1972, J CELL BIOL, V52, P261, DOI 10.1083/jcb.52.2.261; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hansen SK, 2002, J CLIN INVEST, V110, P827, DOI 10.1172/JCI200215085; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 2003, GENE EXPR PATTERNS, V3, P639, DOI 10.1016/S1567-133X(03)00110-8; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Jiang GQ, 1997, J BIOL CHEM, V272, P1218, DOI 10.1074/jbc.272.2.1218; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lehto M, 1999, DIABETES, V48, P423, DOI 10.2337/diabetes.48.2.423; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Li JX, 2000, GENE DEV, V14, P464; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Maestro MA, 2003, HUM MOL GENET, V12, P3307, DOI 10.1093/hmg/ddg355; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Nakhei H, 1998, NUCLEIC ACIDS RES, V26, P497, DOI 10.1093/nar/26.2.497; NICOLAS JF, 1976, CANCER RES, V36, P4224; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; Parrado A, 2001, NUCLEIC ACIDS RES, V29, P4901, DOI 10.1093/nar/29.24.4901; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Pontoglio M, 1997, MOL CELL BIOL, V17, P4948, DOI 10.1128/MCB.17.9.4948; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; SZPIRER C, 1975, DIFFERENTIATION, V4, P85, DOI 10.1111/j.1432-0436.1975.tb01446.x; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Torres-Padilla ME, 2002, J BIOL CHEM, V277, P44677, DOI 10.1074/jbc.M207545200; Torres-Padilla ME, 2001, MECH DEVELOP, V109, P183, DOI 10.1016/S0925-4773(01)00521-4; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO, V1, P5; Vanhorenbeeck V, 2002, BIOCHEM BIOPH RES CO, V292, P848, DOI 10.1006/bbrc.2002.6760; Watt AJ, 2003, HEPATOLOGY, V37, P1249, DOI 10.1053/jhep.2003.50273; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Zhang SSM, 2002, MOL NEUROBIOL, V26, P137, DOI 10.1385/MN:26:2-3:137; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	85	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33398	33408		10.1074/jbc.M405312200	http://dx.doi.org/10.1074/jbc.M405312200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159395	hybrid			2022-12-25	WOS:000223039700047
J	Kim, H; Li, Q; Hempstead, BL; Madri, JA				Kim, H; Li, Q; Hempstead, BL; Madri, JA			Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; RAT-BRAIN; EXPRESSION; RECEPTORS; SURVIVAL; ANGIOGENESIS; VEGF; PHOSPHORYLATION; INVOLVEMENT; NEURONS	Brain-derived neurotrophic factor (BDNF) is expressed by endothelial cells. We investigated the characteristics of BDNF expression by brain-derived endothelial cells and tested the hypothesis that BDNF serves paracrine and autocrine functions affecting the vasculature of the central nervous system. In addition to expressing TrkB and p75(NTR) and BDNF under normoxic conditions, these cells increased their expression of BDNF under hypoxia. While the expression of TrkB is unaffected by hypoxia, TrkB exhibits a base-line phosphorylation under normoxic conditions and an increased phosphorylation when BDNF is added. TrkB phosphorylation is decreased when endogenous BDNF is sequestered by soluble TrkB. Exogenous BDNF elicits robust angiogenesis and survival in three-dimensional cultures of these endothelial cells, while sequestration of endogenous BDNF caused significant apoptosis. The effects of BDNF engagement of TrkB appears to be mediated via the phosphatidylinositol ( PI) 3-kinase-Akt pathway. Modulation of BDNF levels directly correlate with Akt phosphorylation and inhibitors of PI 3-kinase abrogate the BDNF responses. BDNF-mediated effects on endothelial cell survival/apoptosis correlated directly with activation of caspase 3. These endothelial cells also express p75(NTR) and respond to its preferred ligand, pro-nerve growth factor (pro-NGF), by undergoing apoptosis. These data support a role for neurotrophins signaling in the dynamic maintenance/differentiation of central nervous system endothelia.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Yale University; Cornell University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	drhkim@kosin.ac.kr; joseph.madri@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058130, P01HL059312, P50HL059312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035476] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59312, HL-58130] Funding Source: Medline; NIDDK NIH HHS [P01-DK-55389] Funding Source: Medline; NINDS NIH HHS [P01-NS-035476] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Chow J, 2001, DEV BRAIN RES, V130, P123, DOI 10.1016/S0165-3806(01)00220-6; Curristin SM, 2002, P NATL ACAD SCI USA, V99, P15729, DOI 10.1073/pnas.232568799; DONOVAN MJ, 1995, AM J PATHOL, V147, P309; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hiltunen JO, 1996, CIRC RES, V79, P930, DOI 10.1161/01.RES.79.5.930; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Ilan N, 1998, J CELL SCI, V111, P3621; Ilan N, 2003, LAB INVEST, V83, P1105, DOI 10.1097/01.LAB.0000083531.84403.8B; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; KOLBECK R, 1994, EUR J BIOCHEM, V225, P995, DOI 10.1111/j.1432-1033.1994.0995b.x; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Ment LR, 1997, IN VITRO CELL DEV-AN, V33, P684; Ment LR, 1997, DEV BRAIN RES, V100, P52, DOI 10.1016/S0165-3806(97)00012-6; Miyata K, 2001, NEUROSCIENCE, V105, P571, DOI 10.1016/S0306-4522(01)00225-1; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Ricci A, 2000, J VASC RES, V37, P355, DOI 10.1159/000025751; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Ruprecht K, 2002, NEUROSCI LETT, V330, P175, DOI 10.1016/S0304-3940(02)00778-4; Saarelainen T, 2000, MOL CELL NEUROSCI, V16, P87, DOI 10.1006/mcne.2000.0863; SCARISBRICK IA, 1993, J NEUROSCI, V13, P875; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Sobue G, 1998, NEUROCHEM RES, V23, P821, DOI 10.1023/A:1022434209787; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Stanzani L, 2001, CEREBROVASC DIS, V12, P240, DOI 10.1159/000047710; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; Wang SY, 2000, AM J PATHOL, V157, P1247, DOI 10.1016/S0002-9440(10)64640-8; Yanamoto H, 2000, BRAIN RES, V877, P331, DOI 10.1016/S0006-8993(00)02718-9; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	53	161	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33538	33546		10.1074/jbc.M404115200	http://dx.doi.org/10.1074/jbc.M404115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169782	hybrid			2022-12-25	WOS:000223039700062
J	Koike, M; Kose, S; Furuta, M; Taniguchi, N; Yokoya, F; Yoneda, Y; Imamoto, N				Koike, M; Kose, S; Furuta, M; Taniguchi, N; Yokoya, F; Yoneda, Y; Imamoto, N			beta-catenin shows an overlapping sequence requirement but distinct molecular interactions for its bidirectional passage through nuclear pores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAN-INDEPENDENT MANNER; IMPORTIN-BETA; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; RNA EXPORT; TARGETING COMPLEX; GTP HYDROLYSIS; LIVING CELLS; DROSOPHILA; MECHANISM	beta-Catenin is an example of a typical molecule that can be translocated bidirectionally through nuclear pore complexes (NPCs) on its own in a facilitated manner. In this work the nuclear import and export of beta-catenin were examined to compare the sequence requirement of this molecule and to determine whether molecular interactions required for its bidirectional NPC passage are distinct or not. Deletion analysis of beta-catenin revealed that armadillo repeats 10-12 and the C terminus comprise the minimum region necessary for nuclear migration activity. Further dissection of this fragment showed that the C terminus tail plays an essential role in nuclear migration. The region of beta-catenin required for export substantially overlapped the region required for import. Therefore, the NPC translocation of beta-catenin is apparently reversible, which is consistent with findings reported previously. However, different translocating molecules blocked nuclear import and export of beta-catenin differentially. The data herein indicate that beta-catenin shows an overlapping sequence requirement for its import and export but that bidirectional movement through the NPC proceeds through distinct molecular interactions.	RIKEN, Discovery Res Inst, Cellular Dynam Lab, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Osaka 5650871, Japan	RIKEN; Osaka University	Imamoto, N (corresponding author), RIKEN, Discovery Res Inst, Cellular Dynam Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	nimamoto@riken.jp	Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Hurt E, 2000, J BIOL CHEM, V275, P8361, DOI 10.1074/jbc.275.12.8361; Imamoto N, 2000, CELL STRUCT FUNCT, V25, P207, DOI 10.1247/csf.25.207; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kose S, 1999, J BIOL CHEM, V274, P3946, DOI 10.1074/jbc.274.7.3946; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lee SJ, 2000, J MOL BIOL, V302, P251, DOI 10.1006/jmbi.2000.4055; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Neufeld KL, 2000, EMBO REP, V1, P519; Polakis P, 2000, GENE DEV, V14, P1837; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schwoebel ED, 1998, J BIOL CHEM, V273, P35170, DOI 10.1074/jbc.273.52.35170; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Tago K, 2000, GENE DEV, V14, P1741; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	51	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34038	34047		10.1074/jbc.M405821200	http://dx.doi.org/10.1074/jbc.M405821200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173161	hybrid			2022-12-25	WOS:000223039700116
J	Lee, TH; Shank, J; Cusson, N; Kelliher, MA				Lee, TH; Shank, J; Cusson, N; Kelliher, MA			The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced I kappa B kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TNF RECEPTOR; CELL-DEATH; RECRUITMENT; COMPLEX; DOMAIN; IKK; SIGNAL; ENZYME; CYLD	The death domain kinase Rip1 is recruited to the tumor necrosis factor receptor type 1 and mediates the IkappaB kinase and p38 MAP kinase pathways. In response to tumor necrosis factor-alpha (TNF-alpha), we find Rip1 phosphorylated and ubiquitinated, suggesting that Rip1 phosphorylation may stimulate its ubiquitination. To address the contribution of the kinase activity of Rip1 to its ubiquitination and to TNF-alpha signaling, we introduced wild type Rip1 and a kinase-inactive form of Rip1, Rip1D138N, into rip1-/- murine embryonic fibroblast cells by retroviral infection. TNF-alpha-induced ubiquitination of Rip1 is observed in Rip1D138N cells, supporting the argument that Rip1 autophosphorylation is not required for Rip1 ubiquitination. TNF-alpha-induced Ikk and p38 MAP kinase activation is normal, and the Rip1D138N cells are resistant to TNF-alpha-induced cell death, indicating that the kinase activity of Rip1 is not required to mediate its antiapoptotic functions. In the absence of Traf2, TNF-alpha-induced ubiquitination of Rip1 is impaired, suggesting that Traf2 may be the E3 ubiquitin ligase responsible for the TNF-alpha-dependent, ubiquitination of Rip1. Finally, recruitment of the ubiquitinated Tak1 complex is dependent on the presence of Rip1, suggesting that Rip1 ubiquitination rather than its phosphorylation is critical in signaling.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Lazare Res Bldg, Worcester, MA 01605 USA.	Michelle.Kelliher@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061298] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061298, GM61298] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; MEYLAN E, 2004, NAT IMMUNOL; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	25	201	212	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33185	33191		10.1074/jbc.M404206200	http://dx.doi.org/10.1074/jbc.M404206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175328	hybrid			2022-12-25	WOS:000223039700022
J	Ralston, KJ; Hird, SL; Zhang, XH; Scott, JL; Jin, BQ; Thorne, RF; Brendt, MC; Boyd, AW; Burns, GF				Ralston, KJ; Hird, SL; Zhang, XH; Scott, JL; Jin, BQ; Thorne, RF; Brendt, MC; Boyd, AW; Burns, GF			The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-SUPPRESSOR; INTERCELLULAR-ADHESION MOLECULE-3; GTPASE-ACTIVATING PROTEIN; IMMUNOLOGICAL SYNAPSE; HUMAN HOMOLOG; STRUCTURAL BASIS; LIPID RAFTS; FUNCTIONAL ASSOCIATION; RAP1-INDUCED ADHESION; POTASSIUM CHANNELS	Clustering of the T cell integrin, LFA-1, at specialized regions of intercellular contact initiates integrin-mediated adhesion and downstream signaling, events that are necessary for a successful immunological response. But how clustering is achieved and sustained is not known. Here we establish that an LFA-1-associated molecule, PTA-1, is localized to membrane rafts and binds the carboxyl-terminal domain of isoforms of the actin-binding protein 4.1G. Protein 4.1 is known to associate with the membrane-associated guanylate kinase homologue, human discs large. We show that the carboxyl-terminal peptide of PTA-1 also can bind human discs large and that the presence or absence of this peptide greatly influences binding between PTA-1 and different isoforms of 4.1G. T cell stimulation with phorbol ester or PTA-1 cross-linking induces PTA-1 and 4.1G to associate tightly with the cytoskeleton, and the PTA-1 from such activated cells now can bind to the amino-terminal region of 4.1G. We propose that these dynamic associations provide the structural basis for a regulated molecular adhesive complex that serves to cluster and transport LFA-1 and associated molecules.	Univ Newcastle, Sch Biomed Sci, Canc Res Unit, Callaghan, NSW 2308, Australia; 4th Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Royal Brisbane Hosp PO, Queensland Inst Med Res, Div Canc & Cell Biol, Brisbane, Qld 4029, Australia	University of Newcastle; Air Force Military Medical University; Monash University; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Burns, GF (corresponding author), Univ Newcastle, Sch Biomed Sci, Canc Res Unit, Univ Dr, Callaghan, NSW 2308, Australia.	Gordon.Burns@newcastle.edu.au	Boyd, Andrew/G-2083-2010	Thorne, Rick/0000-0001-7882-7081				Adey NB, 2000, CANCER RES, V60, P35; Alonso MA, 2001, J CELL SCI, V114, P3957; ANDERSON RA, 1988, J CELL BIOCHEM, V37, P269, DOI 10.1002/jcb.240370303; Asaba N, 2003, J BIOL CHEM, V278, P8395, DOI 10.1074/jbc.M210362200; Baldari Cosima T., 2000, EMBO (European Molecular Biology Organization) Journal, V19, P4857, DOI 10.1093/emboj/19.18.4857; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURNS GF, 1985, J EXP MED, V161, P1063, DOI 10.1084/jem.161.5.1063; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; CHEN LK, 1986, EUR J IMMUNOL, V16, P767, DOI 10.1002/eji.1830160709; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; Delon J, 2000, CURR BIOL, V10, pR923, DOI 10.1016/S0960-9822(00)00870-8; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Galjart N, 2003, CURR OPIN CELL BIOL, V15, P48, DOI 10.1016/S0955-0674(02)00007-8; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Jia W, 2000, HYBRIDOMA, V19, P489, DOI 10.1089/027245700750053986; JIN B, 1989, IMMUNOLOGY, V66, P570; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Leclerc E, 1998, EUR J BIOCHEM, V258, P567, DOI 10.1046/j.1432-1327.1998.2580567.x; Leitinger B, 2002, J CELL SCI, V115, P963; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Liddington RC, 2000, EXP CELL RES, V261, P37, DOI 10.1006/excr.2000.5058; Lu CF, 1997, J IMMUNOL, V159, P268; Lu DC, 2004, BIOCHEM J, V377, P51, DOI 10.1042/BJ20030952; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Marwali MR, 2003, BLOOD, V102, P215, DOI 10.1182/blood-2002-10-3195; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Miceli MC, 2001, SEMIN IMMUNOL, V13, P115, DOI 10.1006/smim.2000.0303; Montoya MC, 2002, NAT IMMUNOL, V3, P159, DOI 10.1038/ni753; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Panyi G, 2003, P NATL ACAD SCI USA, V100, P2592, DOI 10.1073/pnas.0438057100; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Porter JC, 2002, J IMMUNOL, V168, P6330, DOI 10.4049/jimmunol.168.12.6330; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Roy BC, 2002, GENES CELLS, V7, P607; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Shaw AS, 2001, IMMUNITY, V15, P683, DOI 10.1016/S1074-7613(01)00237-0; Sherrington PD, 1997, J BIOL CHEM, V272, P21735, DOI 10.1074/jbc.272.35.21735; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya A, 1998, J IMMUNOL, V161, P1671; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tohyama Y, 2003, MOL BIOL CELL, V14, P2570, DOI 10.1091/mbc.E02-09-0615; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	84	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33816	33828		10.1074/jbc.M401040200	http://dx.doi.org/10.1074/jbc.M401040200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15138281	hybrid			2022-12-25	WOS:000223039700091
J	Ricci, G; Turella, P; De Maria, F; Antonini, G; Nardocci, L; Board, PG; Parker, MW; Carbonelli, MG; Federici, G; Caccuri, AM				Ricci, G; Turella, P; De Maria, F; Antonini, G; Nardocci, L; Board, PG; Parker, MW; Carbonelli, MG; Federici, G; Caccuri, AM			Binding and kinetic mechanisms of the zeta class glutathione transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICHLOROACETIC ACID; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; MIXED DISULFIDE; ACTIVE-SITE; P1-1; POLYMORPHISM; THIOREDOXIN; CATALYSIS; ENZYME	The Zeta class of glutathione transferases (GSTs) has only recently been discovered and hence has been poorly characterized. Here we investigate the substrate binding and kinetic mechanisms of the human Zeta class GSTZ1c-1c by means of pre-steady state and steady-state experiments and site-directed mutagenesis. Binding of GSH occurs at a very low rate compared with that observed for the more recently evolved GSTs ( Alpha, Mu, and Pi classes). Moreover, the single step binding mechanism observed in this enzyme is reminiscent of that found for the Theta class enzyme, whereas the Alpha, Mu, and Pi classes have adopted a multistep binding mechanism. Replacement of Cys(16) with Ala increases the rate of GSH release from the active site causing a 10-fold decrease of affinity toward GSH. Cys(16) also plays a crucial role in co-substrate binding; the mutant enzyme is unable to bind the carcinogenic substrate dichloroacetic acid in the absence of GSH. However, both substrate binding and GSH activation are not rate-limiting in catalysis. A peculiarity of the hGSTZ1c-1c is the half-site activation of bound GSH. This suggests a primitive monomer-monomer interaction that, in the recently diverged GSTP1-1, gives rise to a sophisticated cooperative mechanism that preserves the catalytic efficiency of this GST under stress conditions.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Rome, Dept Biol, I-00146 Rome, Italy; Australian Natl Univ, John Curtin Sch Med Res, Mol Genet Grp, Canberra, ACT 2601, Australia; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Azienda Osp San Camillo Forlanini, I-00149 Rome, Italy; Childrens Hosp IRCCS, I-00165 Rome, Italy	University of Rome Tor Vergata; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research; Azienda Ospedaliera San Camillo-Forlanini	Caccuri, AM (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Viale Ric Sci, I-00133 Rome, Italy.	caccuri@uniroma2.it	CACCURI, ANNA MARIA/AFU-2643-2022; Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846; Antonini, Giovanni/0000-0002-2115-8961				Anandarajah K, 2000, BIOCHEMISTRY-US, V39, P5303, DOI 10.1021/bi9923813; Anderson WB, 2002, CHEM RES TOXICOL, V15, P1387, DOI 10.1021/tx025553x; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Blackburn AC, 2000, PHARMACOGENETICS, V10, P49, DOI 10.1097/00008571-200002000-00007; Blackburn AC, 2001, PHARMACOGENETICS, V11, P671, DOI 10.1097/00008571-200111000-00005; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOARD PG, 2003, BIOCHEM J, V374, P737; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 2002, BIOCHEMISTRY-US, V41, P4686, DOI 10.1021/bi0158425; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Lantum HBM, 2002, CHEM RES TOXICOL, V15, P957, DOI 10.1021/tx010095y; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 2003, BIOCHEM J, V376, P71, DOI 10.1042/BJ20030860; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Segel, 1975, ENZYME KINETICS BEHA, P274; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Tong Z, 1998, BIOCHEM J, V331, P371, DOI 10.1042/bj3310371; Tzeng HF, 2000, CHEM RES TOXICOL, V13, P231, DOI 10.1021/tx990175q	26	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33336	33342		10.1074/jbc.M404631200	http://dx.doi.org/10.1074/jbc.M404631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173170	hybrid			2022-12-25	WOS:000223039700040
J	Stanhope-Baker, P; Kessler, PM; Li, WL; Agarwal, ML; Williams, BRG				Stanhope-Baker, P; Kessler, PM; Li, WL; Agarwal, ML; Williams, BRG			The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR EPITHELIAL-CELL; P53-STABILIZING COMPOUND; FUNCTIONAL INTERACTION; ACTIN CYTOSKELETON; LIVING CELLS; WT1 GENE; PROTEIN; CP-31398; IDENTIFICATION; APOPTOSIS	Wilms tumors are a heterogeneous class of tumors in which Wilms tumor suppressor-1 (WT1) and the p53 tumor suppressor may be variously inactivated by mutation, reduced in expression, or even overexpressed in the wild-type state. The downstream transcriptional targets of WT1 and p53 that are critical for mediating their roles in Wilms tumorigenesis are not well defined. The WiT49 cell line is characteristic of anaplastic Wilms tumors that are refractory to treatment and expresses wild-type WT1 and mutant p53. We have used the small molecule compound CP- 31398 ( Pfizer) to restore wildtype p53 function to the codon 248 mutant p53 present in WiT49 cells. In these cells, CP- 31398 activated transcription of p53-regulated promoters and enhanced UV light-induced apoptosis without altering the overall p53 protein level. These phenotypes were accompanied by restored binding of the p53 protein to promoter sequences in vivo. Gene expression profiling of CP-31398-treated WiT49 cells revealed subsets of putative p53 target genes that were up- or down-regulated. A preferred target of p53-mediated repression in this system is the podocalyxin (PODXL) gene. PODXL is also transcriptionally regulated by WT1 and has roles in cell adhesion and anti-adhesion. Our results show that PODXL is a bona fide target of p53-mediated transcriptional repression while being positively regulated by WT1. We propose that inappropriate expression of PODXL due to changes in WT1 and/or p53 activity may contribute to Wilms tumorigenesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Genet, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40,9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621; BONADIO JF, 1985, J CLIN ONCOL, V3, P513, DOI 10.1200/JCO.1985.3.4.513; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Doyonnas R, 2001, J EXP MED, V194, P13, DOI 10.1084/jem.194.1.13; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELBAHTIMI R, 1996, MODERN PATHOL, V9, P233; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; HARTLEY AL, 1993, CANCER GENET CYTOGEN, V67, P133, DOI 10.1016/0165-4608(93)90166-J; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; Kershaw DB, 1997, J BIOL CHEM, V272, P15708, DOI 10.1074/jbc.272.25.15708; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Loeb DM, 2002, INT J HEMATOL, V76, P117, DOI 10.1007/BF02982573; Luu Y, 2002, J INVEST DERMATOL, V119, P1207, DOI 10.1046/j.1523-1747.2002.19517.x; Luu Y, 2003, ANTICANCER RES, V23, P99; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Orlando RA, 2001, J AM SOC NEPHROL, V12, P1589, DOI 10.1681/ASN.V1281589; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; Schopperle WM, 2003, BIOCHEM BIOPH RES CO, V300, P285; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Teruyama K, 2001, FEBS LETT, V504, P1, DOI 10.1016/S0014-5793(01)02724-7; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang WH, 2001, J BIOL CHEM, V276, P16810, DOI 10.1074/jbc.M009687200; Yaoita E, 2001, CELL TISSUE RES, V304, P339; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	46	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33575	33585		10.1074/jbc.M404787200	http://dx.doi.org/10.1074/jbc.M404787200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155752	hybrid			2022-12-25	WOS:000223039700066
J	Banno, T; Gazel, A; Blumenberg, M				Banno, T; Gazel, A; Blumenberg, M			Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MATRIX METALLOPROTEINASES; ADHESION MOLECULES; INDUCED APOPTOSIS; EXPRESSION; RECEPTOR; IDENTIFICATION; LOCALIZATION; LIPOXYGENASE; MODULATION	Identification of tumor necrosis factor-alpha (TNFalpha) as the key agent in inflammatory disorders, e. g. rheumatoid arthritis, Crohn's disease, and psoriasis, led to TNFalpha-targeting therapies, which, although avoiding many of the side-effects of previous drugs, nonetheless causes other side-effects, including secondary infections and cancer. By controlling gene expression, TNFalpha orchestrates the cutaneous responses to environmental damage and inflammation. To define TNFalpha action in epidermis, we compared the transcriptional profiles of normal human keratinocytes untreated and treated with TNFalpha for 1, 4, 24, and 48 h by using oligonucleotide microarrays. We found that TNFalpha regulates not only immune and inflammatory responses but also tissue remodeling, cell motility, cell cycle, and apoptosis. Specifically, TNFalpha regulates innate immunity and inflammation by inducing a characteristic large set of chemokines, including newly identified TNFalpha targets, that attract neutrophils, macrophages, and skin-specific memory T-cells. This implicates TNFalpha in the pathogenesis of psoriasis, fixed drug eruption, atopic and allergic contact dermatitis. TNFalpha promotes tissue repair by inducing basement membrane components and collagen-degrading proteases. Unexpectedly, TNFalpha induces actin cytoskeleton regulators and integrins, enhancing keratinocyte motility and attachment, effects not previously associated with TNFalpha. Also unanticipated was the influence of TNFalpha upon keratinocyte cell fate by regulating cell-cycle and apoptosis-associated genes. Therefore, TNFalpha initiates not only the initiation of inflammation and responses to injury, but also the subsequent epidermal repair. The results provide new insights into the harmful and beneficial TNFalpha effects and define the mechanisms and genes that achieve these outcomes, both of which are important for TNFalpha-targeted therapies.	NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA; Univ Tsukuba, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	New York University; New York University; New York University; University of Tsukuba; University of Tsukuba	Blumenberg, M (corresponding author), NYU, Sch Med, Dept Dermatol, 550 1st Ave, New York, NY 10016 USA.	blumem01@med.nyu.edu		Blumenberg, Miroslav/0000-0002-8672-7774	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041850] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41850] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Banno T, 2003, ANTIVIR THER, V8, P541; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635; Becke FM, 2001, EUR CYTOKINE NETW, V12, P45; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; FOGH K, 1987, ARCH DERMATOL RES, V279, P504, DOI 10.1007/BF00413280; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; GRIFFITHS CEM, 1991, BRIT J DERMATOL, V124, P519, DOI 10.1111/j.1365-2133.1991.tb04943.x; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Komine M, 2000, J BIOL CHEM, V275, P32077, DOI 10.1074/jbc.M001253200; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Kondo T, 1996, INT J LEGAL MED, V108, P231, DOI 10.1007/BF01369816; KONO T, 1990, Journal of Dermatology (Tokyo), V17, P409; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mahlknecht U, 2002, BIOCHEM BIOPH RES CO, V293, P182, DOI 10.1016/S0006-291X(02)00193-6; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McDermott MF, 2001, CELL MOL BIOL, V47, P619; McNamara RK, 2002, DEV NEUROSCI-BASEL, V24, P485, DOI 10.1159/000069359; Moses MA, 1996, J CELL BIOCHEM, V60, P379, DOI 10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.0.CO;2-T; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Muller I, 2003, FASEB J, V17, P476, DOI 10.1096/fj.02-0574fje; Murakami T, 2000, J Atheroscler Thromb, V7, P39; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nahar IK, 2003, ANN PHARMACOTHER, V37, P1256, DOI 10.1345/aph.1C039; Neely AN, 1999, WOUND REPAIR REGEN, V7, P166, DOI 10.1046/j.1524-475X.1999.00166.x; Palecek SP, 1998, J CELL SCI, V111, P929; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PILLAI S, 1989, J CLIN INVEST, V83, P816, DOI 10.1172/JCI113963; Quensel C, 2002, J CELL BIOCHEM, V85, P403, DOI 10.1002/jcb.10143; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Romer J, 1996, NAT MED, V2, P725, DOI 10.1038/nm0796-725a; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sallenave JM, 2003, INFECT IMMUN, V71, P3766, DOI 10.1128/IAI.71.7.3766-3774.2003; SALO T, 1994, LAB INVEST, V70, P176; Schilham MW, 1998, SEMIN IMMUNOL, V10, P127, DOI 10.1006/smim.1998.0114; Shakhov AN, 2000, J LEUKOCYTE BIOL, V68, P151; SHAM RL, 1993, BLOOD, V82, P2546; Shiohara T, 2002, CURR OPIN ALLERGY CL, V2, P317, DOI 10.1097/00130832-200208000-00005; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TERAKI Y, 1994, AM J PATHOL, V145, P550; Urieli-Shoval S, 2002, BLOOD, V99, P1224, DOI 10.1182/blood.V99.4.1224; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; WAKEFIELD PE, 1991, J AM ACAD DERMATOL, V24, P675, DOI 10.1016/0190-9622(91)70102-8; Wolf R, 2002, CLIN DERMATOL, V20, P522, DOI 10.1016/S0738-081X(02)00273-0; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	66	235	244	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32633	32642		10.1074/jbc.M400642200	http://dx.doi.org/10.1074/jbc.M400642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145954	hybrid			2022-12-25	WOS:000222849700081
J	Michel, G; Pojasek, K; Li, YG; Sulea, T; Linhardt, RJ; Raman, R; Prabhakar, V; Sasisekharan, R; Cygler, M				Michel, G; Pojasek, K; Li, YG; Sulea, T; Linhardt, RJ; Raman, R; Prabhakar, V; Sasisekharan, R; Cygler, M			The structure of chondroitin B lyase complexed with glycosaminoglycan oligosaccharides unravels a calcium-dependent catalytic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRANOSE RING FLEXIBILITY; CRYSTAL-STRUCTURE; PECTATE LYASE; FLAVOBACTERIUM-HEPARINUM; DERMATAN SULFATE; AC LYASE; IOTA-CARRAGEENAN; BINDING SITES; ACTIVE-SITE; BETA-HELIX	Chondroitinase B from Pedobacter heparinus is the only known enzyme strictly specific for dermatan sulfate and is a widely used enzymatic tool for the structural characterization of glycosaminoglycans. This beta-helical polysaccharide lyase belongs to family PL-6 and cleaves the beta(1,4) linkage of dermatan sulfate in a random manner, yielding 4,5-unsaturated dermatan sulfate disaccharides as the product. The previously reported structure of its complex with a dermatan sulfate disaccharide product identified the -1 and -2 subsites of the catalytic groove. We present here the structure of chondroitinase B complexed with several dermatan sulfate and chondroitin sulfate oligosaccharides. In particular, the soaking of chondroitinase B crystals with a dermatan sulfate hexasaccharide results in a complex with two dermatan sulfate disaccharide reaction products, enabling the identification of the +2 and +1 subsites. Unexpectedly, this structure revealed the presence of a calcium ion coordinated by sequence-conserved acidic residues and by the carboxyl group of the L-iduronic acid at the +1 subsite. Kinetic and site-directed mutagenesis experiments have subsequently demonstrated that chondroitinase B absolutely requires calcium for its activity, indicating that the protein-Ca2+-oligosaccharide complex is functionally relevant. Modeling of an intact tetrasaccharide in the active site of chondroitinase B provided a better understanding of substrate specificity and the role of Ca2+ in enzymatic activity. Given these results, we propose that the Ca2+ ion neutralizes the carboxyl moiety of the L-iduronic acid at the cleavage site, whereas the conserved residues Lys-250 and Arg-271 act as Bronsted base and acid, respectively, in the lytic degradation of dermatan sulfate by chondroitinase B.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada; MIT, Biol Engn Div, Cambridge, MA 02139 USA; Rensselaer Polytech Inst, Dept Chem & Biol Chem, Troy, NY 12180 USA	National Research Council Canada; Massachusetts Institute of Technology (MIT); Rensselaer Polytechnic Institute	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	MICHEL, Gurvan/B-3490-2008	MICHEL, Gurvan/0000-0002-3009-6205	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052622, R01HL062244] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060, R01GM057073, R37GM057073] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL052622-07, R01 HL062244, HL62244, R01 HL052622-08, R01 HL062244-05A1, R01 HL062244-06, HL52622, R01 HL052622] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060, R01 GM038060-16A2, R01 GM038060-17, R01 GM057073, R37 GM057073, GM38060, GM57073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar JAK, 2003, BIOTECHNOL APPL BIOC, V37, P115, DOI 10.1042/BA20020089; Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson V. E., 1998, COMPREHENSIVE BIOL C; ARNOTT S, 1974, J MOL BIOL, V90, P253, DOI 10.1016/0022-2836(74)90371-4; Berces A, 2001, TETRAHEDRON, V57, P477, DOI 10.1016/S0040-4020(00)01019-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Coutinho PM, 1999, ROY SOC CH, P3; Das SK, 2001, CHEM-EUR J, V7, P4821; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, J AM CHEM SOC, V120, P2099, DOI 10.1021/ja972185o; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; GU KN, 1995, BIOCHEM J, V312, P569, DOI 10.1042/bj3120569; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Herron SR, 2003, J BIOL CHEM, V278, P12271, DOI 10.1074/jbc.M209306200; HOPWOOD JJ, 1981, CARBOHYD RES, V91, P165, DOI 10.1016/S0008-6215(00)86029-2; Howard MB, 2003, J BACTERIOL, V185, P3352, DOI 10.1128/JB.185.11.3352-3360.2003; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Janaswamy S, 2002, CARBOHYD RES, V337, P523, DOI 10.1016/S0008-6215(02)00017-4; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kuwaba K, 2002, J DERMATOL SCI, V29, P185, DOI 10.1016/S0923-1811(02)00023-3; Larsson AM, 2003, STRUCTURE, V11, P1111, DOI 10.1016/S0969-2126(03)00147-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li YG, 1999, ACTA CRYSTALLOGR D, V55, P1055, DOI 10.1107/S0907444999002097; Liu DF, 1999, J BIOL CHEM, V274, P4089, DOI 10.1074/jbc.274.7.4089; Lunin VV, 2004, J MOL BIOL, V337, P367, DOI 10.1016/j.jmb.2003.12.071; Manning G.S., 1974, LIMITING LAWS EQUILI, P9, DOI 10.1007/978-94-010-2185-2_2; Michel G, 2003, J MOL BIOL, V334, P421, DOI 10.1016/j.jmb.2003.09.056; Michel G, 2001, J BIOL CHEM, V276, P40202, DOI 10.1074/jbc.M100670200; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; MICHELACCI YM, 1974, BIOCHEM BIOPH RES CO, V56, P973, DOI 10.1016/S0006-291X(74)80284-6; MITRA AK, 1983, J MOL BIOL, V169, P873, DOI 10.1016/S0022-2836(83)80141-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pojasek K, 2002, J BIOL CHEM, V277, P31179, DOI 10.1074/jbc.M201552200; Pojasek K, 2001, BIOCHEM BIOPH RES CO, V286, P343, DOI 10.1006/bbrc.2001.5380; Rye CS, 2002, J ORG CHEM, V67, P4505, DOI 10.1021/jo020089m; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Scott JE, 2001, PATHOL BIOL, V49, P284, DOI 10.1016/S0369-8114(01)00152-3; Shimizu T, 2002, BIOCHEMISTRY-US, V41, P6651, DOI 10.1021/bi025541a; Shriver Z, 1999, J BIOL CHEM, V274, P4082, DOI 10.1074/jbc.274.7.4082; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Steyn PL, 1998, INT J SYST BACTERIOL, V48, P165, DOI 10.1099/00207713-48-1-165; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Tkalec AL, 2000, APPL ENVIRON MICROB, V66, P29, DOI 10.1128/AEM.66.1.29-35.2000; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; VENKATARAMAN G, 1994, P NATL ACAD SCI USA, V91, P6171, DOI 10.1073/pnas.91.13.6171; VYAS NK, 1991, J BIOL CHEM, V266, P5226; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; WOODS RJ, 1995, J PHYS CHEM-US, V99, P3832, DOI 10.1021/j100011a061; Yang HO, 2000, GLYCOBIOLOGY, V10, P1033, DOI 10.1093/glycob/10.10.1033; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	68	77	81	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32882	32896		10.1074/jbc.M403421200	http://dx.doi.org/10.1074/jbc.M403421200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155751	Green Accepted, hybrid			2022-12-25	WOS:000222849700108
J	Park, SJ; Ciccone, SLM; Beck, BD; Hwang, B; Freie, B; Clapp, DW; Lee, SH				Park, SJ; Ciccone, SLM; Beck, BD; Hwang, B; Freie, B; Clapp, DW; Lee, SH			Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; REDOX REGULATION; YEAST 2-HYBRID; CELL-CYCLE; DAMAGE; COMPLEX; REPAIR; FAA; FANCG/XRCC9; PROTECTION	Fanconi anemia (FANC) is a heterogeneous genetic disorder characterized by a hypersensitivity to DNA-damaging agents, chromosomal instability, and defective DNA repair. Eight FANC genes have been identified so far, and five of them (FANCA, -C, -E, -F, and -G) assemble in a multinuclear complex and function at least in part in a complex to activate FANCD2 by monoubiquitination. Here we show that FANCA and FANCG are redox-sensitive proteins that are multimerized and/or form a nuclear complex in response to oxidative stress/damage. Both FANCA and FANCG proteins exist as monomers under non-oxidizing conditions, whereas they become multimers following H2O2 treatment. Treatment of cells with oxidizing agent not only triggers the multimeric complex of FANCA and FANCG in vivo but also induces the interaction between FANCA and FANCG. N-Ethylmaleimide treatment abolishes multimerization and interaction of FANCA and FANCG in vitro. Taken together, our results lead us to conclude that FANCA and FANCG uniquely respond to oxidative damage by forming complex(es) via intermolecular disulfide linkage(s), which may be crucial in forming such complexes and in determining their function.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Lee, SH (corresponding author), Indiana Univ, Canc Res Inst, 1044 W Walnut St,Rm 153, Indianapolis, IN 46202 USA.	slee@iupui.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM020167] Funding Source: NIH RePORTER; NCI NIH HHS [CA92111] Funding Source: Medline; NIGMS NIH HHS [F32 GM20167-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Fortini P, 2003, MUTAT RES-FUND MOL M, V531, P127, DOI 10.1016/j.mrfmmm.2003.07.004; Futaki M, 2002, CARCINOGENESIS, V23, P67, DOI 10.1093/carcin/23.1.67; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Gordon SM, 2003, BLOOD, V102, P136, DOI 10.1182/blood-2002-11-3517; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huber PAJ, 2000, BIOCHEM BIOPH RES CO, V268, P73, DOI 10.1006/bbrc.1999.2055; Hussain S, 2003, HUM MOL GENET, V12, P2503, DOI 10.1093/hmg/ddg266; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kelley MR, 2001, MUTAT RES-DNA REPAIR, V485, P107, DOI 10.1016/S0921-8777(00)00067-7; Kruyt FAE, 1999, J BIOL CHEM, V274, P34212, DOI 10.1074/jbc.274.48.34212; Kruyt FAE, 1998, BLOOD, V92, P2229, DOI 10.1182/blood.V92.7.2229.2229_2229_2236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Naf D, 1998, MOL CELL BIOL, V18, P5952; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; OKUNO H, 1993, ONCOGENE, V8, P695; Opstelten DJE, 1998, J VIROL, V72, P6537, DOI 10.1128/JVI.72.8.6537-6545.1998; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Reuter T, 2000, BLOOD, V95, P719, DOI 10.1182/blood.V95.2.719; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; You JS, 2003, J BIOL CHEM, V278, P7476, DOI 10.1074/jbc.M210603200; Zunino A, 2001, MUTAGENESIS, V16, P283, DOI 10.1093/mutage/16.3.283	42	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30053	30059		10.1074/jbc.M403527200	http://dx.doi.org/10.1074/jbc.M403527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138265	hybrid			2022-12-25	WOS:000222531900024
J	Harvey, BP; Banga, SS; Ozer, HL				Harvey, BP; Banga, SS; Ozer, HL			Regulation of the multifunctional Ca2+/calmodulin-dependent protein kinase II by the PP2C phosphatase PPM1F in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; EXTRACELLULAR CALCIUM; PYRAMIDAL NEURONS; OKADAIC-ACID; 2A ACTIVITY; 3Y1 CELLS; CALMODULIN; AUTOPHOSPHORYLATION; ACTIVATION; GROWTH	The regulation of the multifunctional calcium/calmodulin dependent protein kinase II (CaMKII) by serine/threonine protein phosphatases has been extensively studied in neuronal cells; however, this regulation has not been investigated previously in fibroblasts. We cloned a cDNA from SV40-transformed human fibroblasts that shares 80% homology to a rat calcium/calmodulin-dependent protein kinase phosphatase that encodes a PPM1F protein. By using extracts from transfected cells, PPM1F, but not a mutant (R326A) in the conserved catalytic domain, was found to dephosphorylate in vitro a peptide corresponding to the autoinhibitory region of CaMKII. Further analyses demonstrated that PPM1F specifically dephosphorylates the phospho-Thr-286 in autophosphorylated CaMKII substrate and thus deactivates the CaMKII in vitro. Coimmunoprecipitation of CaMKII with PPM1F indicates that the two proteins can interact intracellularly. Binding of PPM1F to CaMKII involves multiple regions and is not dependent on intact phosphatase activity. Furthermore, overexpression of PPM1F in fibroblasts caused a reduction in the CaMKII-specific phosphorylation of the known substrate vimentin(Ser-82) following induction of the endogenous CaM kinase. These results identify PPM1F as a CaM kinase phosphatase within fibroblasts, although it may have additional functions intracellularly since it has been presented elsewhere as POPX2 and hFEM-2. We conclude that PPM1F, possibly together with the other previously described protein phosphatases PP1 and PP2A, can regulate the activity of CaMKII. Moreover, because PPM1F dephosphorylates the critical autophosphorylation site of CaMKII, we propose that this phosphatase plays a key role in the regulation of the kinase intracellularly.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07101 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ozer, HL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave,MSB,Rm C-671, Newark, NJ 07101 USA.	ozerhl@umdnj.edu			NCI NIH HHS [T32 CA09665] Funding Source: Medline; NIA NIH HHS [AG04821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aplin AE, 1999, J CELL SCI, V112, P695; Bennecib M, 2001, FEBS LETT, V490, P15, DOI 10.1016/S0014-5793(01)02127-5; BOYNTON AL, 1977, J CELL PHYSIOL, V92, P241, DOI 10.1002/jcp.1040920212; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; Cai XA, 2002, J BIOL CHEM, V277, P36553, DOI 10.1074/jbc.M203752200; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DERMODY JJ, 1986, MOL CELL BIOL, V6, P4594, DOI 10.1128/MCB.6.12.4594; Dhavan R, 2002, J NEUROSCI, V22, P7879; DURKIN JP, 1981, BIOCHEM BIOPH RES CO, V103, P233, DOI 10.1016/0006-291X(81)91684-3; Easom RA, 1998, BIOCHEM J, V329, P283; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Famulski KS, 1999, FEBS LETT, V453, P183, DOI 10.1016/S0014-5793(99)00664-X; Fladmark KE, 2002, J BIOL CHEM, V277, P2804, DOI 10.1074/jbc.M109049200; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; Goto H, 2002, GENES CELLS, V7, P91, DOI 10.1046/j.1356-9597.2001.00504.x; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; He H, 2001, J BIOL CHEM, V276, P26741, DOI 10.1074/jbc.C100229200; Hwang J, 1996, BIOCHEM BIOPH RES CO, V225, P520, DOI 10.1006/bbrc.1996.1205; Ishida A, 1998, BIOCHEM BIOPH RES CO, V253, P159, DOI 10.1006/bbrc.1998.9771; Ishida A, 2002, ARCH BIOCHEM BIOPHYS, V408, P229, DOI 10.1016/S0003-9861(02)00592-1; Ishida A, 1998, J BIOL CHEM, V273, P1904, DOI 10.1074/jbc.273.4.1904; JHA KK, 1978, J CELL PHYSIOL, V97, P147, DOI 10.1002/jcp.1040970203; Kameshita I, 1997, ANAL BIOCHEM, V245, P149, DOI 10.1006/abio.1996.9945; Kitani A, 1998, J IMMUNOL, V161, P4931; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; KLUG M, 1991, CELL BIOL INT REP, V15, P907, DOI 10.1016/0309-1651(91)90141-5; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; LOU LL, 1989, J NEUROSCI, V9, P2020; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Menegon A, 2002, J NEUROSCI, V22, P7016; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mishra-Gorur K, 2002, AM J PATHOL, V161, P1893, DOI 10.1016/S0002-9440(10)64465-3; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; Nomura K, 2003, J NEUROSCI RES, V72, P198, DOI 10.1002/jnr.10563; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Ofek P, 2003, J BIOL CHEM, V278, P14299, DOI 10.1074/jbc.M211699200; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; OHTA Y, 1988, J BIOL CHEM, V263, P11540; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; Pardinas J, 1997, J CELL PHYSIOL, V171, P325, DOI 10.1002/(SICI)1097-4652(199706)171:3<325::AID-JCP11>3.0.CO;2-9; Scholz WK, 1998, J NEUROCHEM, V71, P580; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Strack S, 1997, J NEUROCHEM, V68, P2119; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; TERASAWA M, 1991, J BIOCHEM-TOKYO, V110, P417, DOI 10.1093/oxfordjournals.jbchem.a123596; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Wang N, 2002, J MUSCLE RES CELL M, V23, P535, DOI 10.1023/A:1023470709071; YATSUNAMI J, 1991, BIOCHEM BIOPH RES CO, V177, P1165, DOI 10.1016/0006-291X(91)90662-Q; Yoshimura Y, 1999, FEBS LETT, V446, P239, DOI 10.1016/S0014-5793(99)00226-4; Zhang S, 2003, CIRCULATION, V107, P1539, DOI 10.1161/01.CIR.0000056766.45109.C1; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200	64	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24889	24898		10.1074/jbc.M400656200	http://dx.doi.org/10.1074/jbc.M400656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140879	hybrid			2022-12-25	WOS:000221702500121
J	Jang, HD; Yoon, K; Shin, YJ; Kim, J; Lee, SY				Jang, HD; Yoon, K; Shin, YJ; Kim, J; Lee, SY			PIAS3 suppresses NF-kappa B-mediated transcription by interacting with the p65/RelA subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INHIBITOR; STAT3 INHIBITOR; GENE ACTIVATION; BINDING; PHOSPHORYLATION; REQUIRES; CANCER; DOMAIN; ASSOCIATION; CONJUGATION	Nuclear factor-kappaB (NF-kappaB) is a transcription factor critical for key cellular processes, including immune response, apoptosis, and cell cycle progression. A yeast two-hybrid screening, using the Rel homology domain (RHD) of the p65 subunit (RelA) of NF-kappaB as bait, led to the isolation of PIAS3, previously identified as a specific inhibitor of STAT3. We show that PIAS3 can directly associate with p65 using an in vitro pull-down and in vivo coimmunoprecipitation assays. When overexpressed, PIAS3 inhibits NF-kappaB-dependent transcription induced by treatment with tumor necrosis factor alpha (TNF-alpha) or interleukin-1beta or by overexpression of TNF family receptors such as RANK, TNFR1, and CD30 or signal transducers of TNF receptor-associated factors (TRAFs), including TRAF2, TRAF5, and TRAF6. Down-regulation of PIAS3 by RNA interference reverses its effect on TNF-alpha-mediated NF-kappaB activation. We found that an N-terminal region of PIAS3 is necessary for both the interaction with p65 and the transcriptional suppression activity. In addition, we found that an LXXLL coregulator signature motif located within the N-terminal region of PIAS3 is the minimal requirement for the interaction with p65. Furthermore, we demonstrate that PIAS3 interferes with p65 binding to the CBP coactivator, thereby resulting in a decreased NF-kappaB-dependent transcription. Taken together, these data suggest that PIAS3 may function in vivo as a modulator in suppressing the transcriptional activity of p65.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University	Lee, SY (corresponding author), Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.	leesy@ewha.ac.kr						Alen P, 1999, MOL CELL BIOL, V19, P6085; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bours V, 2000, TOXICOLOGY, V153, P27, DOI 10.1016/S0300-483X(00)00302-4; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung YM, 2001, BIOCHEM BIOPH RES CO, V284, P15, DOI 10.1006/bbrc.2001.4936; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Foo SY, 1999, TRENDS GENET, V15, P229; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Jimenez-Lara AM, 2002, FEBS LETT, V526, P142, DOI 10.1016/S0014-5793(02)03154-X; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; SCHDEV S, 2001, GENE DEV, V15, P3088; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	45	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24873	24880		10.1074/jbc.M313018200	http://dx.doi.org/10.1074/jbc.M313018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140884	hybrid			2022-12-25	WOS:000221702500119
J	Sitko, JC; Guevara, CI; Cacalano, NA				Sitko, JC; Guevara, CI; Cacalano, NA			Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHYSIOLOGICAL NEGATIVE REGULATOR; STIMULATING FACTOR-RECEPTOR; ALDRICH SYNDROME PROTEIN; SRC HOMOLOGY-3 DOMAIN; EXCHANGE FACTOR C3G; SH3 DOMAIN; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; CONSTITUTIVE EXPRESSION	Suppressors of cytokine signaling ( SOCS) are negative feedback inhibitors of cytokine and growth factor signal transduction. Although the affect of SOCS proteins on the Jak-STAT pathway has been well characterized, their role in the regulation of other signaling modules is not well understood. In the present study, we demonstrate that SOCS3 physically interacts with the SH2/SH3-containing adapter proteins Nck and Crk-L, which are known to couple activated receptors to multiple downstream signaling pathways and the actin cytoskeleton. Our data show that the SOCS3/Nck and SOCS3/Crk-L interactions depend on tyrosine phosphorylation of SOCS3 Tyr(221) within the conserved SOCS box motif and intact SH2 domains of Nck and Crk-L. Furthermore, SOCS3 Tyr(221) forms a YXXP motif, which is a consensus binding site for the Nck and Crk-L SH2 domains. Expression of SOCS3 in NIH3T3 cells induces constitutive recruitment of a Nck-GFP fusion protein to the plasma membrane and constitutive tyrosine phosphorylation of endogenous Nck. Our findings suggest that SOCS3 regulates multiple cytokine and growth factor-activated signaling pathways by acting as a recruitment factor for adapter proteins.	Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Radiat Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cacalano, NA (corresponding author), Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci, Dept Radiat Oncol, Rm B3-133, Los Angeles, CA 90095 USA.	ncacalano@mednet.ucla.edu						Abramson J, 2003, EUR J IMMUNOL, V33, P85, DOI 10.1002/immu.200390011; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aoki S, 2004, ANTI-CANCER DRUG, V15, P363, DOI 10.1097/00001813-200404000-00009; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Kimura A, 2004, J BIOL CHEM, V279, P6905, DOI 10.1074/jbc.C300496200; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liu E, 2003, EMBO J, V22, P5036, DOI 10.1093/emboj/cdg503; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Martelli MP, 2001, J BIOL CHEM, V276, P45654, DOI 10.1074/jbc.M105777200; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; NICHOLS GL, 1994, BLOOD, V84, P2912; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Pramatarova A, 2003, MOL CELL BIOL, V23, P7210, DOI 10.1128/MCB.23.20.7210-7221.2003; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Ronn SG, 2002, MOL ENDOCRINOL, V16, P2124, DOI 10.1210/me.2002-0082; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 1996, ONCOGENE, V12, P839; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takahashi Y, 2003, EMBO J, V22, P372, DOI 10.1093/emboj/cdg057; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; TENHOEVE J, 1994, BLOOD, V84, P1731; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; van Dijk TB, 2000, BLOOD, V96, P3406; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V310, P1188, DOI 10.1016/j.bbrc.2003.09.140; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	96	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37662	37669		10.1074/jbc.M404007200	http://dx.doi.org/10.1074/jbc.M404007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15173187	hybrid			2022-12-25	WOS:000223554600057
J	Fedoroff, OY; Townson, SA; Golovanov, AP; Baron, M; Avis, JM				Fedoroff, OY; Townson, SA; Golovanov, AP; Baron, M; Avis, JM			The structure and dynamics of tandem WW domains in a negative regulator of notch signaling, suppressor of deltex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAINS; PROTEIN; RECOGNITION; COMPLEX; KINASE; NEDD4; GENE; IDENTIFICATION; SPECIFICITY; RELAXATION	WW domains mediate protein recognition, usually though binding to proline-rich sequences. In many proteins, WW domains occur in tandem arrays. Whether or how individual domains within such arrays cooperate to recognize biological partners is, as yet, poorly characterized. An important question is whether functional diversity of different WW domain proteins is reflected in the structural organization and ligand interaction mechanisms of their multiple domains. We have determined the solution structure and dynamics of a pair of WW domains (WW3-4) from a Drosophila Nedd4 family protein called Suppressor of deltex (Su(dx)), a regulator of Notch receptor signaling. We find that the binding of a type 1 PPPY ligand to WW3 stabilizes the structure with effects propagating to the WW4 domain, a domain that is not active for ligand binding. Both WW domains adopt the characteristic triple-stranded beta-sheet structure, and significantly, this is the first example of a WW domain structure to include a domain ( WW4) lacking the second conserved Trp ( replaced by Phe). The domains are connected by a flexible linker, which allows a hingelike motion of domains that may be important for the recognition of functionally relevant targets. Our results contrast markedly with those of the only previously determined three-dimensional structure of tandem WW domains, that of the rigidly oriented WW domain pair from the RNA-splicing factor Prp40. Our data illustrate that arrays of WW domains can exhibit a variety of higher order structures and ligand interaction mechanisms.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Victoria Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester	Avis, JM (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	J.Avis@umist.ac.uk	Fedorov, Oleg Y./B-6412-2014; Golovanov, Alexander P./ABN-0572-2022	Fedorov, Oleg Y./0000-0001-9004-1815; Golovanov, Alexander P./0000-0002-8592-3984				Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bayer E, 2003, J BIOL CHEM, V278, P26183, DOI 10.1074/jbc.M300721200; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Braddock DT, 2001, J AM CHEM SOC, V123, P8634, DOI 10.1021/ja016234f; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; BUSSEAU I, 1994, GENETICS, V136, P585; Carper WR, 1997, J PHYS CHEM A, V101, P3246, DOI 10.1021/jp963338h; Cornell M, 1999, GENETICS, V152, P567; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Fostier M, 1998, GENETICS, V150, P1477; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hu H, 2004, PROTEOMICS, V4, P643, DOI 10.1002/pmic.200300632; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; KESSLER H, 1988, ANGEW CHEM INT EDIT, V27, P490, DOI 10.1002/anie.198804901; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Mazaleyrat SL, 2003, DEV BIOL, V255, P363, DOI 10.1016/S0012-1606(02)00086-6; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PENG JW, 1994, METHOD ENZYMOL, V239, P563; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; Wintjens R, 2001, J BIOL CHEM, V276, P25150, DOI 10.1074/jbc.M010327200; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	55	30	33	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34991	35000		10.1074/jbc.M404987200	http://dx.doi.org/10.1074/jbc.M404987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173166	hybrid			2022-12-25	WOS:000223134800111
J	Qi, C; Kashireddy, P; Zhu, YWT; Rao, SM; Zhu, YJ				Qi, C; Kashireddy, P; Zhu, YWT; Rao, SM; Zhu, YJ			Null mutation of peroxisome proliferator-activated receptor-interacting protein in mammary glands causes defective mammopoiesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; PROGESTERONE-RECEPTOR; COACTIVATOR PRIP; BINDING PROTEIN; ESTROGEN; GENE; DIFFERENTIATION; EXPRESSION; MICE; TUMORIGENESIS	To investigate the role of nuclear receptor coactivator peroxisome proliferator-activated receptor-interacting protein ( PRIP) in mammary gland development, we generated a conditional null mutation of PRIP in mammary glands. In PRIP-deficient mammary glands, the elongation of ducts during puberty was not affected, but the numbers of ductal branches were decreased, a condition that persisted long after puberty, indicating that the potential of ductal branching was impaired. During pregnancy, PRIP-deficient mammary glands exhibited decreased alveolar density. The lactating PRIP-deficient glands contained scant lobuloalveoli with many adipocytes, whereas the wild type glands were composed of virtually no adipocytes but mostly lobuloalveoli. As a result, PRIP mammary-deficient glands could not produce enough milk to nurse all the pups during lactation. The ductal branching of mammary glands in response to estrogen treatment was attenuated in PRIP mutant glands. Whereas the proliferation index was similar between wild type and PRIP-deficient glands, increased apoptosis was observed in PRIP-deficient glands. PRIP-deficient glands expressed increased amphiregulin, transforming growth factor-alpha, and betacellulin mRNA as compared with wild type glands. The differentiated function of PRIP-deficient mammary epithelial cells was largely intact, as evidenced by the expression of abundant beta-casein, whey acidic protein (WAP), and WDNM1 mRNA. We conclude that PRIP is important for normal mammary gland development.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Zhu, YJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E chicago Ave, Chicago, IL 60611 USA.	y-zhu2@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA088898, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84472, CA 88898] Funding Source: Medline; NIEHS NIH HHS [K08 ES 00356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Brisken C, 2000, GENE DEV, V14, P650; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Charpentier AH, 2000, CANCER RES, V60, P5977; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gallahan D, 1996, CANCER RES, V56, P1775; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Kester HA, 1997, J BIOL CHEM, V272, P16637, DOI 10.1074/jbc.272.26.16637; Ko L, 2003, J BIOL CHEM, V278, P11471, DOI 10.1074/jbc.M209723200; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Medina D, 2001, CANCER LETT, V169, P1, DOI 10.1016/S0304-3835(01)00507-9; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Murphy LC, 2002, BIOMED PHARMACOTHER, V56, P65, DOI 10.1016/S0753-3322(01)00157-3; Nass SJ, 1999, HEMATOL ONCOL CLIN N, V13, P311, DOI 10.1016/S0889-8588(05)70058-7; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; YANG J, 1980, P NATL ACAD SCI-BIOL, V77, P2088, DOI 10.1073/pnas.77.4.2088; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	40	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33696	33701		10.1074/jbc.M401266200	http://dx.doi.org/10.1074/jbc.M401266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161927	hybrid			2022-12-25	WOS:000223039700079
J	Swingle, MR; Honkanen, RE; Ciszak, EM				Swingle, MR; Honkanen, RE; Ciszak, EM			Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; TRANSITION-STATE; CALCINEURIN; SUBUNIT; IDENTIFICATION; PHOSPHORYL; ISOTOPE; PP5	Serine/threonine protein phosphatase-5 (PP5) affects many signaling networks that regulate cell growth and cellular responses to stress. Here we report the crystal structure of the PP5 catalytic domain (PP5c) at a resolution of 1.6 Angstrom. From this structure we propose a mechanism for PP5-mediated hydrolysis of phosphoprotein substrates, which requires the precise positioning of two metal ions within a conserved Asp(271)-M-1: M-2-W-1-His(427)-His(304)-Asp(274) catalytic motif (where M-1 and M-2 are metals and W-1 is a water molecule). The structure of PP5c provides a structural basis for explaining the exceptional catalytic proficiency of protein phosphatases, which are among the most powerful known catalysts. Resolution of the entire C terminus revealed a novel subdomain, and the structure of the PP5c should also aid development of type-specific inhibitors.	NASA, George C Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA; Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; Univ Alabama, Struct Biol Lab, Huntsville, AL 35812 USA	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; University of South Alabama; University of Alabama System; University of Alabama Huntsville	Ciszak, EM (corresponding author), NASA, George C Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA.	ewa.m.ciszak@nasa.gov			NCI NIH HHS [CA 60750, R01 CA060750] Funding Source: Medline; NHLBI NIH HHS [HL 59154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060750, R29CA060750] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baes C.R., 1976, HYDROLYSIS CATIONS, P219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bertini I., 1994, BIOINORG CHEM, P37; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Hengge AC, 2002, ACCOUNTS CHEM RES, V35, P105, DOI 10.1021/ar000143q; Hengge AC, 2001, FEBS LETT, V501, P99, DOI 10.1016/S0014-5793(01)02638-2; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P10185, DOI 10.1021/bi9706374; Hoff RH, 1999, J AM CHEM SOC, V121, P6382, DOI 10.1021/ja990667p; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Jackson MD, 2001, CHEM REV, V101, P2313, DOI 10.1021/cr000247e; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; KING MM, 1984, J BIOL CHEM, V259, P8847; Kita A, 2002, STRUCTURE, V10, P715, DOI 10.1016/S0969-2126(02)00764-5; Lad C, 2003, P NATL ACAD SCI USA, V100, P5607, DOI 10.1073/pnas.0631607100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MARTIN BL, 1986, J BIOL CHEM, V261, P4545; Maynes JT, 2001, J BIOL CHEM, V276, P44078, DOI 10.1074/jbc.M107656200; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; RAJCA A, 1987, J AM CHEM SOC, V109, P4189, DOI 10.1021/ja00248a011; Reiter TA, 2002, BIOCHEMISTRY-US, V41, P15404, DOI 10.1021/bi026317o; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Rusnak F, 1996, J BIOL INORG CHEM, V1, P388, DOI 10.1007/s007750050070; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Smoukov SK, 2002, J AM CHEM SOC, V124, P2595, DOI 10.1021/ja003169l; Ullrich V, 2003, TOXICOL LETT, V139, P107, DOI 10.1016/S0378-4274(02)00424-1; Urban G, 2003, J BIOL CHEM, V278, P9747, DOI 10.1074/jbc.M210993200; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Voegtli WC, 2000, BIOCHEMISTRY-US, V39, P15365, DOI 10.1021/bi0021030; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WYNNE CJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P133, DOI 10.1006/abbi.1995.1275; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yu L, 1997, BIOCHEMISTRY-US, V36, P10727, DOI 10.1021/bi970519g; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; Zhang LF, 1997, BIOCHEMISTRY-US, V36, P8209, DOI 10.1021/bi9704865; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	70	88	90	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33992	33999		10.1074/jbc.M402855200	http://dx.doi.org/10.1074/jbc.M402855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155720	hybrid			2022-12-25	WOS:000223039700110
J	Cordeiro, Y; Kraineva, J; Ravindra, R; Lima, LMTR; Gomes, MPB; Foguel, D; Winter, R; Silva, JL				Cordeiro, Y; Kraineva, J; Ravindra, R; Lima, LMTR; Gomes, MPB; Foguel, D; Winter, R; Silva, JL			Hydration and packing effects on prion folding and beta-sheet conversion - High pressure spectroscopy and pressure perturbation calorimetry studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL TRANSITIONS; SECONDARY STRUCTURE; SCRAPIE PRION; HYDROSTATIC-PRESSURE; ALPHA-HELICES; NMR STRUCTURE; PROTEIN; AGGREGATION; STABILITY; FTIR	The main hypothesis for prion diseases proposes that the cellular protein (PrPC) can be altered into a misfolded, beta-sheet-rich isoform (PrPSc), which undergoes aggregation and triggers the onset of transmissible spongiform encephalopathies. Here, we compare the stability against pressure and the thermomechanical properties of the alpha-helical and beta-sheet conformations of recombinant murine prion protein, designated as alpha-rPrP and beta-rPrP, respectively. High temperature induces aggregates and a large gain in intermolecular antiparallel beta-sheet (beta-rPrP), a conformation that shares structural similarity with PrPSc.alpha-rPrP is highly stable, and only pressures above 5 kilobars (1 kilobar = 100 MegaPascals) cause reversible denaturation, a process that leads to a random and turn-rich conformation with concomitant loss of alpha-helix, as measured by Fourier transform infrared spectroscopy. In contrast, aggregates of beta-rPrP are very sensitive to pressure, undergoing transition into a dissociated species that differs from the denatured form derived from alpha-rPrP. The higher susceptibility to pressure of beta-rPrP can be explained by its less hydrated structure. Pressure perturbation calorimetry supports the view that the accessible surface area of alpha-rPrP is much higher than that of alpha-rPrP, which explains the lower degree of hydration of alpha-rPrP. Our findings shed new light on the mechanism of prion conversion and show how water plays a prominent role. Our results allow us to propose a volume and free energy diagram of the different species involved in the conversion and aggregation. The existence of different folded conformations as well as different denatured states of PrP may explain the elusive character of its conversion into a pathogenic form.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; Univ Dortmund, Dept Chem, D-44227 Dortmund, Germany; Univ Fed Rio de Janeiro, Fac Farm, Dept Medicamentos, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Dortmund University of Technology; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Ctr Nacl Ressonancia Magnet Nucl Macromol, Av Bauhinia 400,Bloco E S10, BR-21941590 Rio De Janeiro, Brazil.	Jerson@bioqmed.ufrj.br	Cordeiro, Yraima/J-7619-2012; Lima, Luis Mauricio/AAL-2098-2021; SILVA, JERSON Lima/GRF-1442-2022; Silva, Jerson/J-8984-2014; Gomes, Mariana/A-6618-2013	Cordeiro, Yraima/0000-0003-4278-212X; SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441; Winter, Roland/0000-0002-3512-6928; Foguel, Debora/0000-0001-7312-7115; TR Lima, Luis Mauricio/0000-0001-6020-0504				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Apetri AC, 2003, J BIOL CHEM, V278, P22187, DOI 10.1074/jbc.M302130200; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Brown P, 2003, P NATL ACAD SCI USA, V100, P6093, DOI 10.1073/pnas.1031826100; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 2003, NATURE, V425, P673, DOI 10.1038/425673a; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Dzwolak W, 2003, BIOCHEMISTRY-US, V42, P11347, DOI 10.1021/bi034879h; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; Herberhold H, 2003, J MOL BIOL, V330, P1153, DOI 10.1016/S0022-2836(03)00657-0; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Inouye H, 1998, J STRUCT BIOL, V122, P247, DOI 10.1006/jsbi.1998.3998; Ishimaru D, 2003, BIOCHEMISTRY-US, V42, P9022, DOI 10.1021/bi034218k; ISMAIL AA, 1992, BIOCHIM BIOPHYS ACTA, V1121, P183, DOI 10.1016/0167-4838(92)90353-F; Jamin N, 2002, FEBS LETT, V529, P256, DOI 10.1016/S0014-5793(02)03353-7; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kuwata K, 2002, BIOCHEMISTRY-US, V41, P12277, DOI 10.1021/bi026129y; Lin LN, 2002, ANAL BIOCHEM, V302, P144, DOI 10.1006/abio.2001.5524; Martins SM, 2003, J BIOL CHEM, V278, P50449, DOI 10.1074/jbc.M307354200; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nandi PK, 2002, J MOL BIOL, V322, P153, DOI 10.1016/S0022-2836(02)00750-7; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Panick G, 1999, BIOCHEMISTRY-US, V38, P6512, DOI 10.1021/bi982825f; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ravindra R, 2003, CHEMPHYSCHEM, V4, P359, DOI 10.1002/cphc.200390062; Rezaei H, 2002, J MOL BIOL, V322, P799, DOI 10.1016/S0022-2836(02)00856-2; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3; WONG PTT, 1985, APPL SPECTROSC, V39, P733, DOI 10.1366/0003702854250176; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	51	99	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32354	32359		10.1074/jbc.M404295200	http://dx.doi.org/10.1074/jbc.M404295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173173	hybrid			2022-12-25	WOS:000222849700047
J	Petrakis, TG; Wittschieben, BO; Svejstrup, JQ				Petrakis, TG; Wittschieben, BO; Svejstrup, JQ			Molecular architecture, structure-function relationship, and importance of the Elp3 subunit for the RNA binding of holo-elongator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II HOLOENZYME; SACCHAROMYCES-CEREVISIAE ELONGATOR; KLUYVEROMYCES-LACTIS ZYMOCIN; IN-VIVO; HISTONE ACETYLTRANSFERASE; COMPLEX; PROTEIN; YEAST; ACETYLATION; GENES	The molecular architecture of six-subunit yeast holo-Elongator complex was investigated by the use of immunoprecipitation, two-hybrid interaction mapping, and in vitro studies of binary interactions between individual subunits. Surprisingly, Elp2 is dispensable for the integrity of the holo-Elongator complex, and a purified five-subunit elp2Delta Elongator complex retains histone acetyltransferase activity in vitro. These results indicate that the WD40 repeats in Elp2 are required neither for subunit-subunit interactions within Elongator nor for Elongator interaction with histones during catalysis. Elp2 and Elp4 were largely dispensable for the association of Elongator with nascent RNA transcript in vivo. In contrast, Elongator-RNA interaction requires the Elp3 protein. Together, these data shed light on the structure-function relationship of the Elongator complex.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147				Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Fichtner L, 2003, MOL MICROBIOL, V49, P1297, DOI 10.1046/j.1365-2958.2003.03632.x; Fichtner L, 2002, MOL MICROBIOL, V45, P817, DOI 10.1046/j.1365-2958.2002.03055.x; Fichtner L, 2002, MOL MICROBIOL, V43, P783, DOI 10.1046/j.1365-2958.2002.02794.x; Formosa T, 2002, GENETICS, V162, P1557; Frohloff F, 2003, J BIOL CHEM, V278, P956, DOI 10.1074/jbc.M210060200; Frohloff F, 2001, EMBO J, V20, P1993, DOI 10.1093/emboj/20.8.1993; Gilbert C, 2004, MOL CELL, V14, P457, DOI 10.1016/S1097-2765(04)00239-4; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Li Y, 2001, J BIOL CHEM, V276, P29628, DOI 10.1074/jbc.C100274200; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Van Mullem V, 2002, J BIOL CHEM, V277, P10220, DOI 10.1074/jbc.M107207200; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Winkler GS, 2002, P NATL ACAD SCI USA, V99, P3517, DOI 10.1073/pnas.022042899; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X	23	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32087	32092		10.1074/jbc.M403361200	http://dx.doi.org/10.1074/jbc.M403361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15138274	hybrid			2022-12-25	WOS:000222849700013
J	Golestaneh, N; Fan, JG; Fariss, RN; Lo, WK; Zelenka, PS; Chepelinsky, AB				Golestaneh, N; Fan, JG; Fariss, RN; Lo, WK; Zelenka, PS; Chepelinsky, AB			Lens major intrinsic Protein (MIP)/aquaporin expression in rat lens epithelia explants requires fibroblast growth factor-induced ERK and JNK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER CELL-DIFFERENTIATION; CATARACTOUS HUMAN LENSES; TRANSGENIC MICE; OCULAR LENS; MOUSE LENS; MIP; PROLIFERATION; GENE; AQUAPORIN-0; DISRUPTION	Lens major intrinsic protein (MIP), exclusive to the vertebrate lens, otherwise known as MIP26 and Aquaporin 0, is abundantly expressed as a lens fiber membrane protein. Although relatively less efficient compared with other aquaporins, MIP is suggested to function as a water channel, as an adhesion molecule, and is required for lens transparency. Because MIP is specifically expressed in lens fiber cells, we investigated in this study the activation of Mip expression after triggering differentiation of rat lens epithelia explants by fibroblast growth factor (FGF)-2. Here, we show that Mip expression in the lens cells is regulated by FGF-2. Using Real time PCR we demonstrate that endogenous Mip levels in the explants were up-regulated upon FGF-2 stimulation, in a concentration-dependent manner. Up-regulation of Mip at the transcriptional level was simultaneous with the activation of the FGF downstream signaling components, ERK1/2 and JNK. Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants. This inhibition pattern was recapitulated in reporter assays for transfection of the rat lens epithelia explants, driven by the Mip promoter ( -1648/ +44). Our studies show that ERK1/2 and JNK signaling pathways are required for Mip expression in lens epithelia explants induced to differentiate by FGF-2.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Morehouse Sch Med, Dept Anat & Neurobiol, Atlanta, GA 30310 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Morehouse School of Medicine	Chepelinsky, AB (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 7 Mem Dr,MSC 0704 Bldg 7,Rm 105, Bethesda, MD 20892 USA.		Fariss, Robert/ABI-1771-2020	Fariss, Robert/0000-0003-3227-7170	NATIONAL EYE INSTITUTE [Z01EY000238, ZIAEY000238, Z01EY000253] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Belecky-Adams TL, 2002, DEVELOPMENT, V129, P3795; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Boyle DL, 1999, EXP EYE RES, V68, P41, DOI 10.1006/exer.1998.0579; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; Chamberlain CG, 1989, GROWTH FACTORS, V1, P125, DOI 10.3109/08977198909029122; Chepelinsky AB, 2003, J EXP ZOOL PART A, V300A, P41, DOI 10.1002/jez.a.10307; Chow RL, 1995, DEVELOPMENT, V121, P4383; DePianto DJ, 2003, MOL VIS, V9, P288; Dunia I, 1998, J CELL SCI, V111, P2109; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; Faber SC, 2002, DEVELOPMENT, V129, P3727; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; Francis P, 2000, HUM MOL GENET, V9, P2329, DOI 10.1093/oxfordjournals.hmg.a018925; Gong XH, 2001, INVEST OPHTH VIS SCI, V42, P539; Grey AC, 2003, EXP EYE RES, V77, P567, DOI 10.1016/S0014-4835(03)00192-1; Klok EJ, 1998, EXP EYE RES, V67, P425, DOI 10.1006/exer.1998.0534; Kok A, 2002, GROWTH FACTORS, V20, P27, DOI 10.1080/08977190290022202; Lang RA, 1999, INVEST OPHTH VIS SCI, V40, P3075; Le ACN, 2001, DEV BIOL, V233, P394, DOI 10.1006/dbio.2001.0194; Leenders WPJ, 1997, MECH DEVELOP, V67, P193, DOI 10.1016/S0925-4773(97)00121-4; Lovicu FJ, 2001, DEVELOPMENT, V128, P5075; Lovicu FJ, 1998, DEVELOPMENT, V125, P3365; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MICHEA LF, 1995, EXP EYE RES, V61, P293, DOI 10.1016/S0014-4835(05)80124-1; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Ohtaka-Maruyama C, 1998, DEV BIOL, V202, P125, DOI 10.1006/dbio.1998.8997; Okamura T, 2003, GENOMICS, V81, P361, DOI 10.1016/S0888-7543(03)00029-6; Potts JD, 1998, DEV BIOL, V204, P277, DOI 10.1006/dbio.1998.9077; Robinson ML, 1995, DEVELOPMENT, V121, P3959; Robinson ML, 1998, DEV BIOL, V198, P13, DOI 10.1016/S0012-1606(98)80026-2; Saika S, 2001, EXP EYE RES, V72, P679, DOI 10.1006/exer.2001.1002; SAX CM, 1995, EXP EYE RES, V61, P125, DOI 10.1016/S0014-4835(95)80066-2; Seth RK, 2001, INVEST OPHTH VIS SCI, V42, P3239; Shiels A, 2000, FASEB J, V14, P2207, DOI 10.1096/fj.99-1071com; Shiels A, 2001, PHYSIOL GENOMICS, V7, P179, DOI 10.1152/physiolgenomics.00078.2001; Sidjanin DJ, 2001, GENOMICS, V74, P313, DOI 10.1006/geno.2001.6509; STEVEN ZD, 2002, EXP EYE RES, V75, P177; Stolen CM, 1997, DEVELOPMENT, V124, P4009; Stolen CM, 2000, DEV BIOL, V217, P205, DOI 10.1006/dbio.1999.9557; Tan FG, 2004, INVEST OPHTH VIS SCI, V45, P863, DOI 10.1167/iovs.03-0708; Varadaraj K, 1999, J MEMBRANE BIOL, V170, P191, DOI 10.1007/s002329900549; Verkman AS, 2003, EXP EYE RES, V76, P137, DOI 10.1016/S0014-4835(02)00303-2; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; Yu XS, 2004, J CELL SCI, V117, P871, DOI 10.1242/jcs.00945; Zatechka DS, 2002, EXP EYE RES, V74, P703, DOI 10.1006/exer.2002.1168	49	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31813	31822		10.1074/jbc.M403473200	http://dx.doi.org/10.1074/jbc.M403473200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145928	hybrid			2022-12-25	WOS:000222726800108
J	Johnson, E; Theisen, CS; Johnson, KR; Wheelock, MJ				Johnson, E; Theisen, CS; Johnson, KR; Wheelock, MJ			R-cadherin influences cell motility via Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CADHERIN; P120 CATENIN; VE-CADHERIN; ACTIN CYTOSKELETON; CONTACT FORMATION; CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL EXPRESSION; ENDOTHELIAL-CELLS; CARCINOMA-CELLS	Classical cadherins are the transmembrane proteins of the adherens junction and mediate cell-cell adhesion via homotypic interactions in the extracellular space. In addition, they mediate connections to the cytoskeleton by means of their association with catenins. Decreased cadherin-mediated adhesion has been implicated as an important component of tumorigenesis. Cadherin switching is central to the epithelial to mesenchymal transitions that drive normal developmental processes. Cadherin switching has also been implicated in tumorigenesis, particularly in metastasis. Recently, cadherins have been shown to be engaged in cellular activities other than adhesion, including motility, invasion, and signaling. In this study, we show that inappropriate expression of R-cadherin in tumor cells results in decreased expression of endogenous cadherins ( cadherin switching) and sustained signaling through Rho GTPases. In addition, we show that R-cadherin induces cell motility when expressed in epithelial cells and that this increased motility is dependent upon Rho GTPase activity.	Univ Nebraska, Med Ctr 987696, Dept Oral Biol, Coll Dent, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr 987696, Dept Oral Biol, Coll Dent, 600 S 42nd St, Omaha, NE 68198 USA.	mwheelock@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051188] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR018759] Funding Source: Medline; NIDCR NIH HHS [R01-DE12308] Funding Source: Medline; NIGMS NIH HHS [R01-GM51188] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Giroldi Laurence A., 2000, Morphologie, V84, P31; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Grignani F, 1998, CANCER RES, V58, P14; Grosheva I, 2001, J CELL SCI, V114, P695; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; INUZUKA H, 1991, DEVELOPMENT, V113, P959; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Jaggi M, 2002, CELL COMMUN ADHES, V9, P103, DOI 10.1080/15419060214150; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; MATSUNAMI H, 1993, J CELL SCI, V106, P401; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieman MT, 1999, J CELL SCI, V112, P1621; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pishvaian MJ, 1999, CANCER RES, V59, P947; Redfield A, 1997, J CELL BIOL, V138, P1323, DOI 10.1083/jcb.138.6.1323; REDIES C, 1993, J COMP NEUROL, V333, P398, DOI 10.1002/cne.903330307; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomita K, 2000, CANCER RES, V60, P3650; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wong AST, 1999, INT J CANCER, V81, P180; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	55	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31041	31049		10.1074/jbc.M400024200	http://dx.doi.org/10.1074/jbc.M400024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143071	hybrid			2022-12-25	WOS:000222726800018
J	Lin, HH; Chang, GW; Davies, JQ; Stacey, M; Harris, J; Gordon, S				Lin, HH; Chang, GW; Davies, JQ; Stacey, M; Harris, J; Gordon, S			Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LATROTOXIN CIRL; 3-DIMENSIONAL STRUCTURE; EGF-TM7 FAMILY; AUTOPROTEOLYSIS; DOMAIN; 7-TRANSMEMBRANE; ACTIVATION; THREONINE; REQUIRES; FURIN	Post-translational cleavage at the G protein-coupled receptor proteolytic site (GPS) has been demonstrated in many class B2 G protein-coupled receptors as well as other cell surface proteins such as polycystin-1. However, the mechanism of the GPS proteolysis has never been elucidated. Here we have characterized the cleavage of the human EMR2 receptor and identified the molecular mechanism of the proteolytic process at the GPS. Proteolysis at the highly conserved His-Leu down arrow Ser(518) cleavage site can occur inside the endoplasmic reticulum compartment, resulting in two protein subunits that associate noncovalently as a heterodimer. Site-directed mutagenesis of the P+1 cleavage site (Ser(518)) shows an absolute requirement of a Ser, Thr, or Cys residue for efficient proteolysis. Substitution of the P-2 His residue to other amino acids produces slow processing precursor proteins, which spontaneously hydrolyze in a defined cell-free system. Further biochemical characterization indicates that the GPS proteolysis is mediated by an autocatalytic intramolecular reaction similar to that employed by the N-terminal nucleophile hydrolases, which are known to activate themselves by self-catalyzed cis-proteolysis. We propose here that the autoproteolytic cleavage of EMR2 represents a paradigm for the other GPS motif-containing proteins and suggest that these GPS proteins belong to a cell surface receptor subfamily of N-terminal nucleophile hydrolases.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Lin, HH (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	hsi-hsien.lin@path.ox.ac.uk	LIN, Hsi-Hsien/N-1488-2015	Harris, James/0000-0002-5634-9637				Abe J, 2002, J BIOL CHEM, V277, P23391, DOI 10.1074/jbc.M110877200; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Aronson NN, 1999, BBA-MOL BASIS DIS, V1455, P139, DOI 10.1016/S0925-4439(99)00076-9; Boker C, 1997, J CELL SCI, V110, P1023; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chang GW, 2003, FEBS LETT, V547, P145, DOI 10.1016/S0014-5793(03)00695-1; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; Gray JX, 1996, J IMMUNOL, V157, P5438; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Harmar AJ, 2001, GENOME BIOL, V2; Hauri HP, 2000, J CELL SCI, V113, P587; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Kwakkenbos MJ, 2002, J LEUKOCYTE BIOL, V71, P854; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Obermann H, 2003, MOL REPROD DEV, V64, P13, DOI 10.1002/mrd.10220; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Qian F, 2002, P NATL ACAD SCI USA, V99, P16981, DOI 10.1073/pnas.252484899; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shao Y, 1997, CHEM BIOL, V4, P187, DOI 10.1016/S1074-5521(97)90287-8; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Suzuki H, 2002, J BIOL CHEM, V277, P43536, DOI 10.1074/jbc.M207680200; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Tikkanen R, 1996, EMBO J, V15, P2954, DOI 10.1002/j.1460-2075.1996.tb00658.x; TRIMMER JS, 1986, P NATL ACAD SCI USA, V83, P9055, DOI 10.1073/pnas.83.23.9055; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Wang YM, 2003, J BIOL CHEM, V278, P3210, DOI 10.1074/jbc.M210431200; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	61	153	155	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31823	31832		10.1074/jbc.M402974200	http://dx.doi.org/10.1074/jbc.M402974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150276	hybrid			2022-12-25	WOS:000222726800109
J	Schultz, A; Ling, M; Larsson, C				Schultz, A; Ling, M; Larsson, C			Identification of an amino acid residue in the protein kinase CC1b domain crucial for its localization to the Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHORBOL ESTER RECEPTORS; C-DELTA; REGULATORY DOMAIN; NEURITE OUTGROWTH; CATALYTIC DOMAIN; BINDING-SITES; C1B DOMAIN; APOPTOSIS; COMPLEX	Protein kinase C (PKC) isoforms have been reported to be targeted to the Golgi complex via their C1 domains. We have shown recently that the regulatory domain of PKCtheta induces apoptosis in neuroblastoma cells and that this effect is correlated to Golgi localization via the C1b domain. This study was designed to identify specific residues in the C1 domains that mediate Golgi localization. We demonstrate that the isolated C1b domains from PKCalpha, -delta, -epsilon, -eta, and -theta are targeted to the Golgi complex, whereas the corresponding C1a domains localize throughout the cell. Sequence alignment showed that amino acid residues corresponding to Glu-246 and Met-267 in PKCtheta are conserved among C1b but absent from C1a domains. Mutation of Met-267, but not of Glu-246, to glycine abolished the Golgi localization of the isolated C1b domain and the regulatory domain of PKCtheta. The mutated PKCtheta regulatory domain constructs lacking Golgi localization were unable to induce apoptosis, suggesting a direct correlation between Golgi localization and apoptotic activity of PKCtheta regulatory domain. Mutation of analogous residues in the C1b domain of PKCepsilon abrogated its Golgi localization, demonstrating that this effect is not restricted to one PKC isoform. The abolished Golgi localization did not affect neurite induction by PKCepsilon. However, the PKCepsilon mutant did not relocate to the Golgi network in response to ceramide and ceramide did not suppress the neurite-inducing capacity of the protein. Thus, the specific mutations in the C1b domain influence both the localization and function of full-length PKCepsilon.	Lund Univ, Dept Lab Med, S-20502 Malmo, Sweden	Lund University	Larsson, C (corresponding author), UMAS, Entrance 78,3rd Floor, S-20502 Malmo, Sweden.	christer.larsson@molmed.mas.lu.se						AKITA Y, 1994, J BIOL CHEM, V269, P4653; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; CARRASCO S, 2004, MOL BIOL CELL; Chen D, 2004, J BIOL CHEM, V279, P4829, DOI 10.1074/jbc.M311196200; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DE MR, 1997, SCIENCE, V277, P1652; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; HUBBARD SR, 1991, SCIENCE, V254, P1776; Hurley JH, 1997, PROTEIN SCI, V6, P477; Imam A, 2001, FASEB J, V15, P28; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Maceyka M, 1997, J CELL BIOL, V139, P1411, DOI 10.1083/jcb.139.6.1411; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schultz A, 2004, J NEUROCHEM, V89, P1427, DOI 10.1111/j.1471-4159.2004.02431.x; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Wang QMJ, 2001, J BIOL CHEM, V276, P19580, DOI 10.1074/jbc.M010089200; Wang SM, 1996, J MED CHEM, V39, P2541, DOI 10.1021/jm950403n; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	42	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31750	31760		10.1074/jbc.M313017200	http://dx.doi.org/10.1074/jbc.M313017200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145947	hybrid			2022-12-25	WOS:000222726800101
J	Tombline, G; Bartholomew, LA; Urbatsch, IL; Senior, AE				Tombline, G; Bartholomew, LA; Urbatsch, IL; Senior, AE			Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; ADENOSINE-TRIPHOSPHATASE; CONSERVED WALKER; SER RESIDUES; MOTOR DOMAIN; SITES; CYCLE; TRANSPORTER; MECHANISM; HYDROLYSIS	Combined mutation of "catalytic carboxylates" in both nucleotide binding domains (NBDs) of P-glycoprotein generates a conformation capable of tight binding of 8-azido-ADP ( Sauna, Z. E., Muller, M., Peng, X. H., and Ambudkar, S. V. ( 2002) Biochemistry 41, 13989 - 14000). Here we characterized this conformation using pure mouse MDR3 P-glycoprotein and natural MgATP and MgADP. Mutants E552A/E1197A, E552Q/E1197Q, E552D/ E1197D, and E552K/E1197K had low but real ATPase activity in the order Ala > Gln > Asp > Lys, emphasizing the requirement for Glu stereochemistry. Mutant E552A/ E1197A bound MgATP and MgADP ( 1 mol/mol) with K-d 9.2 and 92 muM, showed strong temperature sensitivity of MgATP binding and equal dissociation rates for MgATP and MgADP. With MgATP as the added ligand, 80% of bound nucleotide was in the form of ATP. None of these parameters was vanadate-sensitive. The other mutants showed lower stoichiometry of MgATP and MgADP binding, in the order Ala > Gln > Asp > Lys. We conclude that the E552A/ E1197A mutation arrests the enzyme in a conformation, likely a stabilized NBD dimer, which occludes nucleotide, shows preferential binding of ATP, does not progress to a normal vanadate-sensitive transition state, but hydrolyzes ATP and releases ADP slowly. Impairment of turnover is primarily due to inability to form the normal transition state rather than to slow ADP release. The Gln, Asp, and Lys mutants are less effective at stabilizing the occluded nucleotide, putative dimeric NBD, conformation. We envisage that in wild-type the occluded nucleotide conformation occurs transiently after MgATP binds to both NBDs with associated dimerization, and before progression to the transition state.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09363] Funding Source: Medline; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503	38	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31212	31220		10.1074/jbc.M404689200	http://dx.doi.org/10.1074/jbc.M404689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159388	hybrid			2022-12-25	WOS:000222726800040
J	Webb, GC; Dey, A; Wang, J; Stein, J; Milewski, M; Steiner, DF				Webb, GC; Dey, A; Wang, J; Stein, J; Milewski, M; Steiner, DF			Altered proglucagon processing in an alpha-cell line derived from prohormone convertase 2 null mouse islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC2; GLUCAGON; EXPRESSION; PEPTIDE; FURIN; IDENTIFICATION; BIOSYNTHESIS; INSULIN; PROTEIN; GENE	The endoproteolytic processing of proproteins in the secretory pathway depends on the expression of selected members of a family of subtilisin-like endoproteases known as the prohormone convertases (PCs). The main PC family members expressed in mammalian neuroendocrine cells are PC2 and PC1/3. The differential processing of proglucagon in pancreatic alpha-cells and intestinal L cells leads to production of distinct hormonal products with opposing physiological effects from the same precursor. Here we describe the establishment and characterization of a novel alpha-cell line (alphaTC-DeltaPC2) derived from PC2 homozygous null animals. The alphaTC-DeltaPC2 cells are shown to be similar to the well characterized alphaTC1-6 cell line in both morphology and overall gene expression. However, the absence of PC2 activity in alphaTC-DeltaPC2 leads to a complete block in the production of mature glucagon. Surprisingly, alphaTC-DeltaPC2 cells are able to efficiently cleave the interdomain site in proglucagon (KR 70 - 71). Further analysis reveals that alphaTC-DeltaPC2 cells, unlike alphaTC1-6 cells, express low levels of PC1/3 that lead to the generation of glicentin as well as low amounts of oxyntomodulin, GLP-1, truncated GLP-1, and N-terminally extended GLP-2. We conclude that alphaTC-DeltaPC2 cells provide additional evidence for PC2 as the major convertase in alpha-cells leading to mature glucagon production and provide a robust model for further analysis of the mechanisms of proprotein processing by the prohormone convertases.	Univ Chicago, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Comm Human Nutr & Nutr Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Steiner, DF (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Biochem & Mol Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dfsteine@midway.uchicago.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R37DK013914, R01DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-13914, DK-20595] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; Cain BM, 2001, PEPTIDES, V22, P1271, DOI 10.1016/S0196-9781(01)00451-X; Cameron A., 2001, ENZYMES, V22, P291; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Dey A, 2004, ENDOCRINOLOGY, V145, P1961, DOI 10.1210/en.2003-1472; Dey A, 2003, J BIOL CHEM, V278, P15007, DOI 10.1074/jbc.M212128200; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Fortenberry Y, 1999, J NEUROCHEM, V73, P994, DOI 10.1046/j.1471-4159.1999.0730994.x; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Furuta M, 2001, J BIOL CHEM, V276, P27197, DOI 10.1074/jbc.M103362200; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Lee YC, 1999, MOL CELL ENDOCRINOL, V155, P27, DOI 10.1016/S0303-7207(99)00119-7; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nie Y, 2000, J CLIN INVEST, V105, P955, DOI 10.1172/JCI7456; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Rouille Y, 1997, FEBS LETT, V413, P119, DOI 10.1016/S0014-5793(97)00892-2; Rouille Y, 1997, J BIOL CHEM, V272, P32810, DOI 10.1074/jbc.272.52.32810; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STEINER DF, 1974, FED PROC, V33, P2105; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ugleholdt R, 2004, ENDOCRINOLOGY, V145, P1349, DOI 10.1210/en.2003-0801; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; Vincent M, 2003, ENDOCRINOLOGY, V144, P4061, DOI 10.1210/en.2003-0088; Wang J, 2003, P NATL ACAD SCI USA, V100, P12660, DOI 10.1073/pnas.1735286100; Webb GC, 2002, DIABETES, V51, P398, DOI 10.2337/diabetes.51.2.398; Webb GC, 2001, DIABETES, V50, pS135, DOI 10.2337/diabetes.50.2007.S135; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Wilson ME, 2002, MECH DEVELOP, V115, P171, DOI 10.1016/S0925-4773(02)00118-1; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	50	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31068	31075		10.1074/jbc.M404110200	http://dx.doi.org/10.1074/jbc.M404110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143067	hybrid			2022-12-25	WOS:000222726800021
J	Xu, XF; Tan, YW; Lam, L; Hackett, J; Zhang, MJ; Mok, YK				Xu, XF; Tan, YW; Lam, L; Hackett, J; Zhang, MJ; Mok, YK			NMR structure of a Type IVb pilin from Salmonella typhi and its assembly into pilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROTOXIGENIC ESCHERICHIA-COLI; TORSION ANGLE DYNAMICS; R64 THIN-PILUS; PSEUDOMONAS-AERUGINOSA; RECEPTOR-BINDING; X-RAY; PAK; PROTEINS; SEQUENCE; PROGRAM	The structure of the N-terminal-truncated Type IVb structural pilin (t-PilS) from Salmonella typhi was determined by NMR. Although topologically similar to the recently determined x-ray structure of pilin from Vibrio cholerae toxin-coregulated pilus, the only Type IVb pilin with known structure, t-PilS contains many distinct structural features. The protein contains an extra pair of beta-strands in the N-terminal alphabeta loop that align with the major beta-strands to form a continuous 7-stranded antiparallel beta-sheet. The C-terminal disulfide-bonded region of t-PilS is only half the length of that of toxin-coregulated pilus pilin. A model of S. typhi pilus has been proposed and mutagenesis studies suggested that residues on both the alphabeta loop and the C-terminal disulfide-bonded region of PilS might be involved in binding specificity of the pilus. This model structure reveals an exposed surface between adjacent subunits of PilS that could be a potential binding site for the cystic fibrosis transmembrane conductance regulator.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	National University of Singapore; Hong Kong University of Science & Technology	Mok, YK (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbsmokh@nus.edu.sg	Mok, Yu Keung/H-8019-2012; Xu, Xingfu/A-1359-2015	Mok, Yu Keung/0000-0002-2829-4878; Xu, Xingfu/0000-0001-6231-269X; Zhang, Mingjie/0000-0001-9404-0190				Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114; Campbell AP, 1995, BIOCHEMISTRY-US, V34, P16255, DOI 10.1021/bi00050a005; CAmpbell AP, 1997, BIOCHEMISTRY-US, V36, P12791, DOI 10.1021/bi9709304; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Craig L, 2003, MOL CELL, V11, P1139, DOI 10.1016/S1097-2765(03)00170-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Giron JA, 1997, GENE, V192, P39, DOI 10.1016/S0378-1119(97)00039-5; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hahn HP, 1997, GENE, V192, P99, DOI 10.1016/S0378-1119(97)00116-9; Hazes B, 2000, J MOL BIOL, V299, P1005, DOI 10.1006/jmbi.2000.3801; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Keizer DW, 2001, J BIOL CHEM, V276, P24186, DOI 10.1074/jbc.M100659200; Kim SR, 1997, J BACTERIOL, V179, P3594, DOI 10.1128/jb.179.11.3594-3603.1997; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Manning PA, 1997, GENE, V192, P63, DOI 10.1016/S0378-1119(97)00036-X; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Sakai D, 2002, J BACTERIOL, V184, P444, DOI 10.1128/JB.184.2.444-451.2002; Sakellaris H, 1999, P NATL ACAD SCI USA, V96, P12828, DOI 10.1073/pnas.96.22.12828; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsui ISM, 2003, INFECT IMMUN, V71, P6049, DOI 10.1128/IAI.71.10.6049-6050.2003; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Zaidi TS, 1999, INFECT IMMUN, V67, P1481, DOI 10.1128/IAI.67.3.1481-1492.1999; Zhang XL, 2000, INFECT IMMUN, V68, P3067, DOI 10.1128/IAI.68.6.3067-3073.2000; Zhang XL, 1997, GENE, V202, P139, DOI 10.1016/S0378-1119(97)00466-6	37	26	27	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31599	31605		10.1074/jbc.M404727200	http://dx.doi.org/10.1074/jbc.M404727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159389	hybrid			2022-12-25	WOS:000222726800083
J	Drummer, HE; Poumbourios, P				Drummer, HE; Poumbourios, P			Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK-BORNE ENCEPHALITIS; ENVELOPE PROTEIN-E; SCAVENGER RECEPTOR; CELL ENTRY; FUSION; BINDING; CD81; COMPLEXES; LOCALIZATION; CONFORMATION	The E1 and E2 glycoproteins of hepatitis C virus form a noncovalently associated heterodimer that mediates viral entry. Glycoprotein E2 comprises a receptor-binding domain (residues 384-661) that is connected to the transmembrane domain (residues 716-746) via a highly conserved sequence containing a hydrophobic heptad repeat (residues 675-699). Alanine- and proline-scanning mutagenesis of the E2 heptad repeat revealed that Leu(675), Ser(678), Leu(689), and Leu(692) are important for E1E2 heterodimerization. Furthermore, Pro and Ala substitution of all but one heptad repeat residue (Ser(678)) blocked the entry of E1E2-HIV-1 pseudotypes into Huh7 cells, irrespective of an effect on heterodimerization. Two conserved prolines (Pro(676) and Pro(683)), occupying consecutive b positions of the heptad, were not required for E1E2 heterodimerization; however, Pro(683) was critical for viral entry. Thus, disruption of the predicted alpha-helical structure by proline at position 683 is important for E2 function. The inability of mutants to mediate viral entry was not explained by a loss of receptor binding function, because all mutants were able to interact with a recombinant form of the CD81 large extracellular loop. Chimeras formed between the E1 and E2 ectodomains and the transmembrane domains of flavivirus prM and E glycoproteins, respectively, were able to heterodimerize, although with lower efficiency in comparison with wild type E1E2. The heptad repeat of E2 therefore requires the native transmembrane domain for full heterodimerization and viral entry function. Our data indicate that the membrane-proximal heptad repeat of E2 is functionally homologous to the stem of flavivirus E glycoproteins. We propose that E2 has mechanistic features in common with class II fusion proteins.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Drummer, HE (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	heidid@ariel.its.unimelb.edu.au		Drummer, Heidi/0000-0002-0042-6277				Allison SL, 1999, J VIROL, V73, P5605, DOI 10.1128/JVI.73.7.5605-5612.1999; Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Cocquerel L, 2000, J VIROL, V74, P3623, DOI 10.1128/JVI.74.8.3623-3633.2000; Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Drummer HE, 2002, J VIROL, V76, P11143, DOI 10.1128/JVI.76.21.11143-11147.2002; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Ferlenghi I, 2001, MOL CELL, V7, P593, DOI 10.1016/S1097-2765(01)00206-4; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Lorenz IC, 2002, J VIROL, V76, P5480, DOI 10.1128/JVI.76.11.5480-5491.2002; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Molenkamp R, 2003, J VIROL, V77, P1644, DOI 10.1128/JVI.77.2.1644-1648.2003; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004	30	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30066	30072		10.1074/jbc.M405098200	http://dx.doi.org/10.1074/jbc.M405098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136562	hybrid			2022-12-25	WOS:000222531900026
J	Knowles, LM; Axelrod, F; Browne, CD; Smith, JW				Knowles, LM; Axelrod, F; Browne, CD; Smith, JW			A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; SERINE HYDROLASE ACTIVITIES; DEPENDENT KINASE; PROTEIN PALMITOYLATION; ANTITUMOR-ACTIVITY; CERULENIN ANALOGS; COMPLEX PROTEOMES; INHIBITOR P27; EXPRESSION; FAS	In eukaryotes, fatty acid synthase (FAS) is the enzyme responsible for synthesis of palmitate, the precursor of long-chain nonessential fatty acids. FAS is up-regulated in a wide range of cancers and has been suggested as a relevant drug target. Here, two independent approaches are taken toward knocking down FAS and then probing its connection to tumor cell proliferation. In one approach, Orlistat, a drug approved for treating obesity, is used as a potent inhibitor of the thioesterase function of FAS. In a separate strategy, the expression of FAS is suppressed by targeted knock-down with small interfering RNA. In both circumstances, the ablation of FAS activity causes a dramatic down-regulation of Skp2, a component of the E3 ubiquitin ligase that controls the turnover of p27(Kip1). These effects ultimately tie into the retinoblastoma protein pathway and lead to a cell-cycle arrest at the G(1)/S boundary. Altogether, the findings of the study reveal unappreciated links between fatty acid synthase and ubiquitin-dependent proteolysis of cell-cycle regulatory proteins.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jsmith@burnham.org		Knowles, Lynn/0000-0002-6250-9289	NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA6982713, CA69306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Alo PL, 2001, AM J CLIN PATHOL, V116, P129; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chirala SS, 2001, P NATL ACAD SCI USA, V98, P3104, DOI 10.1073/pnas.051635998; De Vos ML, 2001, BIOCHEM PHARMACOL, V62, P985, DOI 10.1016/S0006-2952(01)00739-0; Furuya Y, 1997, ANTICANCER RES, V17, P4589; HADVARY P, 1991, J BIOL CHEM, V266, P2021; Harvey S, 2001, PHYSIOL GENOMICS, V5, P129, DOI 10.1152/physiolgenomics.2001.5.3.129; HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309; Heiligtag SJ, 2002, CELL DEATH DIFFER, V9, P1017, DOI 10.1038/sj.cdd.4401055; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.can-03-3645; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lawrence DS, 1999, J MED CHEM, V42, P4932, DOI 10.1021/jm980591s; Li JN, 2001, CANCER RES, V61, P1493; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Rank KB, 2000, BIOCHEM BIOPH RES CO, V271, P469, DOI 10.1006/bbrc.2000.2648; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; Wang Y, 2001, CANCER LETT, V167, P99, DOI 10.1016/S0304-3835(01)00464-5; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040; Yang G, 2002, CLIN CANCER RES, V8, P3419	38	109	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30540	30545		10.1074/jbc.M405061200	http://dx.doi.org/10.1074/jbc.M405061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138278	hybrid			2022-12-25	WOS:000222531900083
J	Cetin, S; Ford, HR; Sysko, LR; Agarwal, C; Wang, J; Neal, MD; Baty, C; Apodaca, G; Hackam, DJ				Cetin, S; Ford, HR; Sysko, LR; Agarwal, C; Wang, J; Neal, MD; Baty, C; Apodaca, G; Hackam, DJ			Endotoxin inhibits intestinal epithelial restitution through activation of Rho-GTPase and increased focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; NECROTIZING ENTEROCOLITIS; ENTEROCYTE PROLIFERATION; BINDING PROTEIN; GROWTH-FACTOR; KAPPA-B; LIPOPOLYSACCHARIDE; MD-2	Diseases of gut inflammation such as neonatal necrotizing enterocolitis (NEC) result after an injury to the mucosal lining of the intestine, leading to translocation of bacteria and endotoxin ( lipopolysaccharide). Intestinal mucosal defects are repaired by the process of intestinal restitution, during which enterocytes migrate from healthy areas to sites of injury. In an animal model of NEC, we determined that intestinal restitution was significantly impaired compared with control animals. We therefore sought to determine the mechanisms governing enterocyte migration under basal conditions and after an endotoxin challenge. Here we show that the cytoskeletal reorganization and stress fiber formation required for migration in IEC-6 enterocytes requires RhoA. Enterocytes were found to express the endotoxin receptor Toll-like receptor 4, which served to bind and internalize lipopolysaccharide. Strikingly, endotoxin treatment significantly inhibited intestinal restitution, as measured by impaired IEC-6 cell migration across a scraped wound. Lipopolysaccharide was found to increase RhoA activity in a phosphatidylinositol 3-kinase-dependent manner, leading to an increase in phosphorylation of focal adhesion kinase and an enhanced number of focal adhesions. Importantly, endotoxin caused a progressive, RhoA-dependent increase in cell matrix tension/contractility, which correlated with the observed impairment in enterocyte migration. We therefore conclude that endotoxin inhibits enterocyte migration through a RhoA-dependent increase in focal adhesions and enhanced cell adhesiveness, which may participate in the impaired restitution observed in experimental NEC.	Childrens Hosp Pittsburgh, Div Pediat Surg, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hackam, DJ (corresponding author), Childrens Hosp Pittsburgh, Div Pediat Surg, Dept Surg, Rm 4A-486 DeSoto Wing,3705 5th Ave, Pittsburgh, PA 15213 USA.	david.hackam@chp.edu	Neal, Matthew/GMW-5601-2022	Neal, Matthew/0000-0001-8931-6236; Hackam, David/0000-0001-5195-8807	NIAID NIH HHS [R01 AI-49473-01, R01-AI-14032-20] Funding Source: Medline; NIDDK NIH HHS [R01 DK51970-06] Funding Source: Medline; NIGMS NIH HHS [K08 GM65583-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014032, R01AI049473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051970] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Amer MD, 2004, BIOL NEONATE, V85, P159, DOI 10.1159/000075306; Atabai K, 2002, AM J PHYSIOL-LUNG C, V283, pL163, DOI 10.1152/ajplung.00396.2001; Basson MD, 2001, LIFE SCI, V69, P3005, DOI 10.1016/S0024-3205(01)01408-4; Berseth CL, 2003, PEDIATRICS, V111, P529, DOI 10.1542/peds.111.3.529; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Bury RG, 2001, COCHRANE DB SYST REV, V2001, pCD000405, DOI DOI 10.1002/14651858.CD000405; Campbell BH, 2003, J BIOMECH, V36, P137, DOI 10.1016/S0021-9290(02)00325-1; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; de Plaen IG, 2002, IMMUNOLOGY, V106, P577, DOI 10.1046/j.1365-2567.2002.01453.x; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; Duffy LC, 2001, ADV EXP MED BIOL, V501, P519; Ewer AK, 2004, GUT, V53, P207, DOI 10.1136/gut.2003.024521; Forsythe RM, 2002, SHOCK, V17, P180, DOI 10.1097/00024382-200203000-00004; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; Guthrie Scott O, 2003, J Perinatol, V23, P278, DOI 10.1038/sj.jp.7210892; Hackam D. J., 2002, SURG INFECT LARCHMT, V3, P23, DOI DOI 10.1089/10962960260496316; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halpern MD, 2003, AM J PHYSIOL-GASTR L, V284, pG695, DOI 10.1152/ajpgi.00353.2002; Han XN, 2004, SHOCK, V21, P261, DOI 10.1097/01.shk.0000112346.38599.10; Hirabayashi T, 2000, EUR J BIOCHEM, V267, P2525, DOI 10.1046/j.1432-1327.2000.01258.x; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Houle VM, 2000, PEDIATR RES, V48, P497, DOI 10.1203/00006450-200010000-00013; Kafetzis DA, 2003, CURR OPIN INFECT DIS, V16, P349, DOI 10.1097/00001432-200308000-00007; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Lavelle J, 2002, AM J PHYSIOL-RENAL, V283, pF242, DOI 10.1152/ajprenal.00307.2001; Le Roy D, 2001, J IMMUNOL, V167, P2759, DOI 10.4049/jimmunol.167.5.2759; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Longo WE, 1998, MEDIAT INFLAMM, V7, P85, DOI 10.1080/09629359891225; Mammen JMV, 2003, CRIT CARE MED, V31, pS532, DOI 10.1097/01.CCM.0000081429.89277.AF; Medvedev AE, 2003, J ENDOTOXIN RES, V9, P60, DOI 10.1179/096805103125001360; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; Mishima S, 1997, ARCH SURG-CHICAGO, V132, P1190; Nadler EP, 2000, J SURG RES, V92, P71, DOI 10.1006/jsre.2000.5877; Nieuwenhuijzen GAP, 1996, J ANAT, V189, P537; Noerr Barbara, 2003, Adv Neonatal Care, V3, P107; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; Potoka DA, 2003, AM J PHYSIOL-GASTR L, V285, pG861, DOI 10.1152/ajpgi.00412.2002; Potoka DA, 2002, WORLD J SURG, V26, P806, DOI 10.1007/s00268-002-4056-2; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang Q, 1998, J SURG RES, V76, P27, DOI 10.1006/jsre.1998.5288	62	107	114	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24592	24600		10.1074/jbc.M313620200	http://dx.doi.org/10.1074/jbc.M313620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15169791	hybrid			2022-12-25	WOS:000221702500089
J	Price, LS; Hajdo-Milasinovic, A; Zhao, J; Zwartkruis, FJT; Collard, JG; Bos, JL				Price, LS; Hajdo-Milasinovic, A; Zhao, J; Zwartkruis, FJT; Collard, JG; Bos, JL			Rap1 regulates E-cadherin-mediated cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; DOWN-REGULATION; SMALL GTPASE; CYCLIC-AMP; MDCK CELLS; RHO FAMILY; ACTIVATION; RAS; PROTEIN; EXPRESSION	The small GTPase Rap is best characterized as a critical regulator of integrin-mediated cell adhesion, although its mechanism of action is not understood. Rap also influences the properties of other cell-surface receptors and biological processes, although whether these are a consequence of effects on integrins is not clear. We show here that Rap also plays an important role in the regulation of cadherin-mediated cell-cell adhesion in epithelial cells. Expression of constitutively active Rap1A restored cadherin-mediated cell-cell contacts in mesenchymal Ras-transformed Madin-Darby canine kidney cells, resulting in reversion to an epithelial phenotype. Activation of endogenous Rap via the Rap exchange factor Epac1 also antagonized hepatocyte growth factor-induced disruption of adherens junctions. Inhibition of Rap signaling resulted in disruption of epithelial cell-cell contacts. Rap activity was required for adhesion of cells to recombinant E-cadherin extracellular domains, i.e. in the absence of integrin-mediated adhesion. These findings suggest that Rap signaling positively contributes to cadherin-mediated adhesion and that this occurs independently of effects on integrin-mediated adhesion. Our results imply that Rap may function in a broader manner to regulate the function of cell-surface adhesion receptors.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute	Price, LS (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Stratenum Bldg,Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	l.s.price@med.uu.nl						Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 2003, BIOCHEM SOC T, V31, P83, DOI 10.1042/bst0310083; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLARK P, 1994, J CELL SCI, V107, P1265; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Noe V, 1999, BIOCHEM SOC SYMP, V65, P43; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	47	170	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35127	35132		10.1074/jbc.M404917200	http://dx.doi.org/10.1074/jbc.M404917200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166221	hybrid			2022-12-25	WOS:000223303400002
J	Nielsen, FS; Sauer, J; Backlund, J; Voldborg, B; Gregorius, K; Mouritsen, S; Bratt, T				Nielsen, FS; Sauer, J; Backlund, J; Voldborg, B; Gregorius, K; Mouritsen, S; Bratt, T			Insertion of foreign T cell epitopes in human tumor necrosis factor alpha with minimal effect on protein structure and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; BINDING; SPECIFICITY; RECOGNITION; RECEPTORS; BLOCKING; ANTIBODY; THERAPY	To create a human therapeutic vaccine able to circumvent self-tolerance against tumor necrosis factor (TNF) alpha, foreign T helper epitopes were inserted into human TNFalpha, with minimal effect on the native three-dimensional structure. TNFalpha variants were screened for solubility, structural stability, biological activity, and after immunization, for eliciting inhibitory antibodies. The longest and most flexible loop in TNFalpha, also designated loop 3, is the only region that is not involved in intra- or intermolecular interactions and therefore constitute an attractive insertion site. However, the extension of the flexible loop by epitope insertions destabilized the TNFalpha molecule. Therefore, two cysteines were introduced to form a stabilizing disulfide bond between loops 2 and 3. In a second design approach, three TNFalpha monomers were linked by two T cell epitopes and expressed as a single chain TNFalpha trimer. TNFalpha variants that were expressed as soluble proteins also had a conserved tertiary structure, as determined by circular dichroism. The biological activity of the TNFalpha variants was of the same magnitude as human TNFalpha in cellular assays. Introduction of three separate single-point mutations (D143N, A145R, or Y87S) diminished the cytotoxicity of the mutated variants 50 - 800-fold compared with native TNFalpha. Antisera from mice immunized with the different TNFalpha variants were able to cross-react with native human TNFalpha and to inhibit TNFalpha signaling via the TNF receptors in vitro, suggesting that the structural binding epitopes of native human TNFalpha and thus the native conformation were conserved in the constructed vaccine candidates.	Pharmexa AS, DK-2970 Horsholm, Denmark; ALK Abello AS, DK-2970 Horsholm, Denmark; PreciSense AS, DK-2970 Horsholm, Denmark	ALK-Abello AS	Nielsen, FS (corresponding author), Pharmexa AS, Kogle Alle 6, DK-2970 Horsholm, Denmark.	fn@pharmexa.com		Voldborg, Bjorn Gunnar/0000-0002-7005-1642				*ABB LAB, 2003, 03A64063161 ABB LAB; ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; ASHER A, 1987, J IMMUNOL, V138, P963; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; CORTI A, 1992, MOL IMMUNOL, V29, P471, DOI 10.1016/0161-5890(92)90004-H; Dalum I, 1999, NAT BIOTECHNOL, V17, P666, DOI 10.1038/10878; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Girolomoni Giampiero, 2002, Curr Opin Investig Drugs, V3, P1590; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Lochs H, 1999, Z GASTROENTEROL, V37, P509; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Machold KP, 2003, EXPERT OPIN BIOL TH, V3, P351, DOI 10.1517/14712598.3.2.351; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MEAGER A, 1991, J IMMUNOL METHODS, V144, P141, DOI 10.1016/0022-1759(91)90239-C; Narhi LO, 1996, BIOCHEMISTRY-US, V35, P11447, DOI 10.1021/bi952766v; NARHI LO, 1987, BIOCHEM BIOPH RES CO, V147, P740, DOI 10.1016/0006-291X(87)90992-2; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PAQUET A, 1994, J CHROMATOGR A, V667, P125, DOI 10.1016/0021-9673(94)89060-9; Saks S, 1992, Immunol Ser, V56, P567; SMITH RA, 1987, J BIOL CHEM, V262, P6951; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; YANG SC, 1991, CANCER RES, V51, P3669; Yung R L, 2001, Curr Opin Investig Drugs, V2, P216; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	30	9	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33593	33600		10.1074/jbc.M403072200	http://dx.doi.org/10.1074/jbc.M403072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173183	hybrid			2022-12-25	WOS:000223039700068
J	Aoki, M; Yamashita, T; Tohyama, M				Aoki, M; Yamashita, T; Tohyama, M			EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAP1; MORPHOLOGY; ADHESION; RHO	Ephrins are cell surface-associated ligands for Eph receptor tyrosine kinases and are implicated in repulsive axon guidance and cell migration. EphA2, 3, and 4 receptors and one of their cognate ligands, ephrin-A2, are expressed by cells in the subventricular zone and ganglionic eminence of the embryonic day 14.5 telencephalon and by neural precursor cells in vitro. Activation of EphA receptors in dissociated neural precursor cells in vitro facilitates the commitment to neuronal fates. The majority of ephrin-A1-induced neurons is immunoreactive for tyrosine hydroxylase. Blocking the signal by the extracellular domain of EphA in forebrain slices results in a decrease in neurogenesis. Extracellular signal-regulated kinase is activated by the ligand binding to EphA receptors and is involved in the neurogenesis through EphA receptors. Rap1, but not Ras, is activated in response to ephrin-A1. Our results identify EphA receptors as positive regulators of the mitogen-activated protein kinase pathway that exerts neurogenesis of neural precursor cells from the developing central nervous system.	Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, Chiba 2608670, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan	Chiba University; Osaka University	Yamashita, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Neurobiol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	t-yamashita@faculty.chiba-u.jp		Yamashita, Toshihide/0000-0003-4559-7018				Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rajan P, 1998, J NEUROSCI, V18, P3620; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	23	66	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32643	32650		10.1074/jbc.M313247200	http://dx.doi.org/10.1074/jbc.M313247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145949	hybrid			2022-12-25	WOS:000222849700082
J	Jepson, BJN; Anderson, LJ; Rubio, LM; Taylor, CJ; Butler, CS; Flores, E; Herrero, A; Butt, JN; Richardson, DJ				Jepson, BJN; Anderson, LJ; Rubio, LM; Taylor, CJ; Butler, CS; Flores, E; Herrero, A; Butt, JN; Richardson, DJ			Tuning a nitrate reductase for function - The first spectropotentiometric characterization of a bacterial assimilatory nitrate reductase reveals novel redox properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SYNECHOCOCCUS SP PCC-7942; PROTEIN FILM VOLTAMMETRY; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; THIOSPHAERA-PANTOTROPHA; AZOTOBACTER-VINELANDII; NITRITE REDUCTASES; ELECTRON-TRANSFER; FERREDOXIN	Bacterial cytoplasmic assimilatory nitrate reductases are the least well characterized of all of the subgroups of nitrate reductases. In the present study the ferredoxin-dependent nitrate reductase NarB of the cyanobacterium Synechococcus sp. PCC 7942 was analyzed by spectropotentiometry and protein film voltammetry. Metal and acid-labile sulfide analysis revealed nearest integer values of 4: 4: 1 (iron/sulfur/molybdenum)/molecule of NarB. Analysis of dithionite-reduced enzyme by low temperature EPR revealed at 10 K the presence of a signal that is characteristic of a [4Fe-4S](1+) cluster. EPR-monitored potentiometric titration of NarB revealed that this cluster titrated as an n = 1 Nernstian component with a midpoint redox potential (E-m) of -190 mV. EPR spectra collected at 60 K revealed a Mo(V) signal termed "very high g" with g(av) = 2.0047 in air-oxidized enzyme that accounted for only 10-20% of the total molybdenum. This signal disappeared upon reduction with dithionite, and a new "high g" species (g(av) = 1.9897) was observed. In potentiometric titrations the high g Mo( V) signal developed over the potential range of -100 to -350 mV (E-m Mo6+/5+ = -150 mV), and when fully developed, it accounted for 1 mol of Mo(V)/mol of enzyme. Protein film voltammetry of NarB revealed that activity is turned on at potentials below -200 mV, where the cofactors are predominantly [4Fe-4S](1+) and Mo5+. The data suggests that during the catalytic cycle nitrate will bind to the Mo5+ state of NarB in which the enzyme is minimally two-electron-reduced. Comparison of the spectral properties of NarB with those of the membrane-bound and periplasmic respiratory nitrate reductases reveals that it is closely related to the periplasmic enzyme, but the potential of the molybdenum center of NarB is tuned to operate at lower potentials, consistent with the coupling of NarB to low potential ferredoxins in the cell cytoplasm.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ E Anglia, Sch Chem Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ Sevilla, CSIC, Inst Bioquim Vegetale & Fotosintesis, E-41092 Seville, Spain; Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of East Anglia; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Newcastle University - UK	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	d.richardson@uea.ac.uk	Flores, Enrique/L-2007-2014; Flores, Enrique/M-8407-2019; Butt, Julea/E-2133-2011; Richardson, David J/E-2275-2011; Rubio, Luis M./B-5827-2009; Herrero, Antonia/B-7246-2015	Flores, Enrique/0000-0001-7605-7343; Flores, Enrique/0000-0001-7605-7343; Butt, Julea/0000-0002-9624-5226; Rubio, Luis M./0000-0003-1596-2475; Herrero, Antonia/0000-0003-1071-6590				Anderson LJ, 2001, BIOCHEMISTRY-US, V40, P11294, DOI 10.1021/bi002706b; Arnoux P, 2003, NAT STRUCT BIOL, V10, P928, DOI 10.1038/nsb994; BENNETT B, 1994, EUR J BIOCHEM, V226, P789, DOI 10.1111/j.1432-1033.1994.00789.x; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BOTTIN H, 1992, BIOCHIM BIOPHYS ACTA, V1101, P48, DOI 10.1016/0167-4838(92)90465-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON J, 1994, FEBS LETT, V345, P76, DOI 10.1016/0014-5793(94)00445-5; Butler CS, 2002, BIOCHEM J, V363, P817, DOI 10.1042/0264-6021:3630817; Butler CS, 1999, BIOCHEMISTRY-US, V38, P9000, DOI 10.1021/bi990402n; Butt JN, 2002, BIOELECTROCHEMISTRY, V56, P17, DOI 10.1016/S1567-5394(02)00049-X; CRASKE A, 1986, EUR J BIOCHEM, V158, P429, DOI 10.1111/j.1432-1033.1986.tb09771.x; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; EADY RR, 1987, BIOCHEM J, V244, P197, DOI 10.1042/bj2440197; Ellington MJK, 2002, J BACTERIOL, V184, P4767, DOI 10.1128/JB.184.17.4767-4774.2002; Elliott SJ, 2004, BIOCHEMISTRY-US, V43, P799, DOI 10.1021/bi035869j; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Flores E., 1994, MOL BIOL CYANOBACTER, VVol 1, P487; Frangioni B, 2004, J AM CHEM SOC, V126, P1328, DOI 10.1021/ja0384072; GANGESWARAN R, 1993, BIOCHEM J, V289, P335, DOI 10.1042/bj2890335; Gangeswaran R, 1996, BIOCHEM J, V317, P103, DOI 10.1042/bj3170103; Hirasawa M, 2004, BBA-BIOENERGETICS, V1608, P155, DOI 10.1016/j.bbabio.2003.11.006; Jormakka M, 2004, STRUCTURE, V12, P95, DOI 10.1016/j.str.2003.11.020; LARA C, 1987, J BACTERIOL, V169, P4376, DOI 10.1128/jb.169.9.4376-4378.1987; LIN JT, 1993, J BACTERIOL, V175, P2370, DOI 10.1128/JB.175.8.2370-2378.1993; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; LUQUE I, 1994, BBA-BIOENERGETICS, V1184, P296, DOI 10.1016/0005-2728(94)90236-4; Magalon A, 1998, BIOCHEMISTRY-US, V37, P7363, DOI 10.1021/bi972858f; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MIKAMI B, 1984, BIOCHIM BIOPHYS ACTA, V791, P294, DOI 10.1016/0167-4838(84)90340-6; OGAWA KI, 1995, J BACTERIOL, V177, P1409, DOI 10.1128/jb.177.5.1409-1413.1995; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; Rasmussen T, 2000, BIOCHEMISTRY-US, V39, P12753, DOI 10.1021/bi001811i; Richardson DJ, 2001, CELL MOL LIFE SCI, V58, P165, DOI 10.1007/PL00000845; Rubio LM, 1998, J BACTERIOL, V180, P1200, DOI 10.1128/JB.180.5.1200-1206.1998; Rubio LM, 1999, FEBS LETT, V462, P358, DOI 10.1016/S0014-5793(99)01556-2; Rubio LM, 1996, PLANT MOL BIOL, V30, P845, DOI 10.1007/BF00019017; Rubio LM, 2002, PHOTOSYNTH RES, V72, P13, DOI 10.1023/A:1016078700839	39	67	70	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32212	32218		10.1074/jbc.M402669200	http://dx.doi.org/10.1074/jbc.M402669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166246	hybrid			2022-12-25	WOS:000222849700028
J	Schelling, P; Claus, MT; Johner, R; Marquez, VE; Schulz, GE; Scapozza, L				Schelling, P; Claus, MT; Johner, R; Marquez, VE; Schulz, GE; Scapozza, L			Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; QUANTITATIVE-DETERMINATION; BIOLOGICAL-ACTIVITY; BRAIN-TUMORS; ACTIVE-SITE; THERAPY; GANCICLOVIR; NUCLEOSIDE; SUICIDE; ACYCLOVIR	Two analogs of the natural nucleoside dT featuring a pseudosugar with fixed conformation in place of the deoxyribosyl residue ( carbathymidine analogs) were biochemically and structurally characterized for their acceptance by both human cytosolic thymidine kinase isoenzyme 1 (hTK1) and herpes simplex virus type 1 thymidine kinase (HSV1 TK) and subsequently tested in cell proliferation assays. 3'-exo-Methanocarbathymidine ((South)-methanocarbathymidine (S)-MCT), which is a substrate for HSV1 TK, specifically inhibited growth of HSV1 TK-transduced human osteosarcoma cells with an IC50 value in the range of 15 muM without significant toxicity toward both hTK1-negative (TK-) and non-transduced cells. 2'-exo-Methanocarbathymidine ((North)-methanocarbathymidine (N)-MCT), which is a weak substrate for hTK1 and a substantial one for HSV1 TK, induced a specific growth inhibition in HSV1 TK-transfected cells comparable to that of (S)-MCT and ganciclovir. A growth inhibition activity was also observed with (N)-MCT and ganciclovir in non-transduced cells in a cell line-dependent manner, whereas TK- cells were not affected. The presented 1.95-Angstrom crystal structure of the complex (S)-MCT.HSV1 TK explains both the more favorable binding affinity and catalytic turnover of (S)-MCT for HSV1 TK over the North analog. Additionally the plasticity of the active site of the enzyme is addressed by comparing the binding of (North)- and (South)- carbathymidine analogs. The presented study of these two potent candidate prodrugs for HSV1 TK gene-directed enzyme prodrug therapy suggests that (S)-MCT may be even safer to use than its North counterpart ( N)-MCT.	ETH, Inst Pharmaceut Sci, CH-8057 Zurich, Switzerland; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; NCI, Med Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Freiburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Scapozza, L (corresponding author), ETH, Inst Pharmaceut Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	Leonardo.Scapozza@pharma.ethz.ch	Marquez, Victor/AAP-3549-2021	Scapozza, Leonardo/0000-0003-1079-648X	NATIONAL CANCER INSTITUTE [Z01BC006174, ZIABC006174] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGBARIA R, 1994, MOL PHARMACOL, V45, P777; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bennett MS, 1999, FEBS LETT, V443, P121, DOI 10.1016/S0014-5793(98)01619-6; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Block A, 1997, PANCREAS, V15, P25, DOI 10.1097/00006676-199707000-00004; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; CHEN MS, 1978, J BIOL CHEM, V253, P1325; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; Degreve B, 2001, MOL PHARMACOL, V59, P285, DOI 10.1124/mol.59.2.285; Drake RR, 1999, J BIOL CHEM, V274, P37186, DOI 10.1074/jbc.274.52.37186; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; Drobyski WR, 2003, J IMMUNOL, V170, P3046, DOI 10.4049/jimmunol.170.6.3046; Fillat C., 2003, Current Gene Therapy, V3, P13, DOI 10.2174/1566523033347426; Gerber S, 1996, BIOCHEM BIOPH RES CO, V225, P263, DOI 10.1006/bbrc.1996.1164; Haynes P, 1996, MUTAT RES-GENET TOX, V369, P65, DOI 10.1016/S0165-1218(96)90049-X; Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Iwayama S, 1998, ANTIMICROB AGENTS CH, V42, P1666, DOI 10.1128/AAC.42.7.1666; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOST LM, 1992, J IMMUNOL METHODS, V147, P153, DOI 10.1016/S0022-1759(12)80003-2; Kohn DB, 2003, MOL THER, V8, P180, DOI 10.1016/S1525-0016(03)00212-0; Kokoris MS, 2000, ANTICANCER RES, V20, P959; Kokoris MS, 1999, GENE THER, V6, P1415, DOI 10.1038/sj.gt.3300966; Kussmann-Gerber S, 1999, NUCLEOS NUCLEOT, V18, P311, DOI 10.1080/15257779908043078; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marquez VE, 2004, J AM CHEM SOC, V126, P543, DOI 10.1021/ja037929e; Marquez VE, 1998, J AM CHEM SOC, V120, P2780, DOI 10.1021/ja973535+; Marquez VE, 1999, NUCLEOS NUCLEOT, V18, P521, DOI 10.1080/15257779908041487; Marquez VE, 1996, J MED CHEM, V39, P3739, DOI 10.1021/jm960306+; MORGAN SJ, 1994, KULTUR TIERISCHER ZE, P63; Mu L, 2000, BIOCHEMISTRY-US, V39, P11205, DOI 10.1021/bi001090n; Noy R, 2002, MOL CANCER THER, V1, P585; Ono N, 1998, ANTIMICROB AGENTS CH, V42, P2095, DOI 10.1128/AAC.42.8.2095; Perozzo R, 2000, J BIOL CHEM, V275, P16139, DOI 10.1074/jbc.M000509200; Pilger BD, 1999, J BIOL CHEM, V274, P31967, DOI 10.1074/jbc.274.45.31967; Prota A, 2000, BIOCHEMISTRY-US, V39, P9597, DOI 10.1021/bi000668q; PROTA A, 1999, STRUCTURE ELUCIDATIO, P61; Qasim W, 2002, GENE THER, V9, P824, DOI 10.1038/sj.gt.3301690; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Russ P, 2003, J MED CHEM, V46, P5045, DOI 10.1021/jm030241s; Saenger W., 1984, PRINCIPLES NUCL ACID, P51; Schelling P, 2001, ANAL BIOCHEM, V295, P82, DOI 10.1006/abio.2001.5191; Sekiyama T, 1998, J MED CHEM, V41, P1284, DOI 10.1021/jm9705869; Siddiqui MA, 1996, NUCLEOS NUCLEOT, V15, P235, DOI 10.1080/07328319608002382; Stockhammer G, 1997, J MOL MED, V75, P300, DOI 10.1007/s001090050116; Sulpizi M, 2001, J BIOL CHEM, V276, P21692, DOI 10.1074/jbc.M010223200; Terazaki Y, 2003, HEPATOLOGY, V37, P155, DOI 10.1053/jhep.2003.50018; Thust R, 1996, ANTIVIR RES, V31, P105, DOI 10.1016/0166-3542(96)00961-8; Thust R, 2000, CANCER GENE THER, V7, P107, DOI 10.1038/sj.cgt.7700106; Tiberghien P, 2001, BLOOD, V97, P63, DOI 10.1182/blood.V97.1.63; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; Yazawa K, 2002, WORLD J SURG, V26, P783, DOI 10.1007/s00268-002-4053-5	59	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32832	32838		10.1074/jbc.M313343200	http://dx.doi.org/10.1074/jbc.M313343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15163659	hybrid			2022-12-25	WOS:000222849700103
J	Schulz, JM; Watson, AL; Sanders, R; Ross, KL; Thoden, JB; Holden, HM; Fridovich-Keil, JL				Schulz, JM; Watson, AL; Sanders, R; Ross, KL; Thoden, JB; Holden, HM; Fridovich-Keil, JL			Determinants of function and substrate specificity in human UDP-galactose 4 '-epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; N-ACETYLGLUCOSAMINE 4-EPIMERASE; ESCHERICHIA-COLI; ACTIVE-SITE; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; HUMAN UDP-GALACTOSE-4-EPIMERASE; GALE GENE; GLUCOSE; YEAST; IDENTIFICATION	UDP-galactose 4'-epimerase (GALE) interconverts UDP-galactose and UDP-glucose in the final step of the Leloir pathway. Unlike the Escherichia coli enzyme, human GALE (hGALE) also efficiently interconverts a larger pair of substrates: UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine. The basis of this differential substrate specificity has remained obscure. Recently, however, x-ray crystallographic data have both predicted essential active site residues and suggested that differential active site cleft volume may be a key factor in determining GALE substrate selectivity. We report here a direct test of this hypothesis. In brief, we have created four substituted alleles: S132A, Y157F, S132A/Y157F, and C307Y-hGALE. While the first three substitutions were predicted to disrupt catalytic activity, the fourth was predicted to reduce active site cleft volume, thereby limiting entry or rotation of the larger but not the smaller substrate. All four alleles were expressed in a null-background strain of Saccharomyces cerevisiae and characterized in terms of activity with regard to both UDP-galactose and UDP-N-acetylgalactosamine. The S132A/Y157F and C307Y-hGALE proteins were also overexpressed in Pichia pastoris and purified for analysis. In all forms tested, the Y157F, S132A, and Y157F/S132A-hGALE proteins each demonstrated a complete loss of activity with respect to both substrates. In contrast, the C307Y-hGALE demonstrated normal activity with respect to UDP-galactose but complete loss of activity with respect to UDP-N-acetylgalactosamine. Together, these results serve to validate the wild-type hGALE crystal structure and fully support the hypothesis that residue 307 acts as a gatekeeper mediating substrate access to the hGALE active site.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Emory University; Emory University; Emory University; University of Wisconsin System; University of Wisconsin Madison	Fridovich-Keil, JL (corresponding author), Emory Univ, Sch Med, Dept Human Genet, Rm 325-2 Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	jfridov@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46403] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bengoechea JA, 2002, J BACTERIOL, V184, P4277, DOI 10.1128/JB.184.15.4277-4287.2002; BUBECK P, 1993, NUCLEIC ACIDS RES, V21, P3601, DOI 10.1093/nar/21.15.3601; Christacos NC, 2000, MOL GENET METAB, V70, P272, DOI 10.1006/mgme.2000.3019; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; Dormann P, 1998, PLANT J, V13, P641, DOI 10.1046/j.1365-313X.1998.00067.x; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; Fry BN, 2000, INFECT IMMUN, V68, P2594, DOI 10.1128/IAI.68.5.2594-2601.2000; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Holden HM, 2003, J BIOL CHEM, V278, P43885, DOI 10.1074/jbc.R300025200; Holton J. B., 2000, METABOLIC MOL BASES, P1553; Ishiyama N, 2004, J BIOL CHEM, V279, P22635, DOI 10.1074/jbc.M401642200; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; Maceratesi P, 1998, MOL GENET METAB, V63, P26, DOI 10.1006/mgme.1997.2645; Maceratesi Patrizia, 1996, American Journal of Human Genetics, V59, pA204; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; METZGER M, 1994, J BACTERIOL, V176, P450, DOI 10.1128/JB.176.2.450-459.1994; PILLER F, 1983, J BIOL CHEM, V258, P774; Potter MD, 1996, INFECT IMMUN, V64, P855, DOI 10.1128/IAI.64.3.855-860.1996; Quimby BB, 1996, J BIOL CHEM, V271, P26835, DOI 10.1074/jbc.271.43.26835; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; Roper JR, 2003, MOL BIOCHEM PARASIT, V132, P47, DOI 10.1016/j.molbiopara.2003.07.002; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Smits HP, 1998, ANAL BIOCHEM, V261, P36, DOI 10.1006/abio.1998.2714; Soldo B, 2003, GENE, V319, P65, DOI 10.1016/S0378-1119(03)00793-5; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P10685, DOI 10.1021/bi9704313; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 2002, J BIOL CHEM, V277, P27528, DOI 10.1074/jbc.M204413200; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; Wang L, 2002, J BACTERIOL, V184, P2620, DOI 10.1128/JB.184.10.2620-2625.2002; WILSON DB, 1969, J BIOL CHEM, V244, P2132; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263; Xu DQ, 2003, J BACTERIOL, V185, P5419, DOI 10.1128/JB.185.18.5419-5430.2003; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	45	52	53	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32796	32803		10.1074/jbc.M405005200	http://dx.doi.org/10.1074/jbc.M405005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175331	hybrid			2022-12-25	WOS:000222849700099
J	Yamada, S; Busse, M; Ueno, M; Kelly, OG; Skarnes, WC; Sugahara, K; Kusche-Gullberg, M				Yamada, S; Busse, M; Ueno, M; Kelly, OG; Skarnes, WC; Sugahara, K; Kusche-Gullberg, M			Embryonic fibroblasts with a gene trap mutation in Ext1 produce short heparan sulfate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY MULTIPLE EXOSTOSES; TUMOR SUPPRESSORS EXT1; GLUCURONYL C5-EPIMERASE; FUNCTIONAL-ANALYSIS; NEONATAL LETHALITY; GOLGI-APPARATUS; TOUT-VELU; BIOSYNTHESIS; FAMILY; PROTEOGLYCANS	Mutational defects in either EXT1 or EXT2 genes cause multiple exostoses, an autosomal hereditary human disorder. The EXT1 and EXT2 genes encode glycosyltransferases that play an essential role in heparan sulfate chain elongation. In this study, we have analyzed heparan sulfate synthesized by primary fibroblast cell cultures established from mice with a gene trap mutation in Ext1. The gene trap mutation results in embryonic lethality, and homozygous mice die around embryonic day 14. Metabolic labeling and immunohistochemistry revealed that Ext1 mutant fibroblasts still produced small amounts of heparan sulfate. The domain structure of the mutant heparan sulfate was conserved, and the disaccharide composition was similar to that of wild type heparan sulfate. However, a dramatic difference was seen in the polysaccharide chain length. The average molecular sizes of the heparan sulfate chains from wild type and Ext1 mutant embryonic fibroblasts were estimated to be around 70 and 20 kDa, respectively. These data suggest that not only the sulfation pattern but also the length of the heparan sulfate chains is a critical determinant of normal mouse development.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Uppsala University; Kobe Pharmaceutical University; University of California System; University of California Berkeley	Kusche-Gullberg, M (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Marion.Kusche@imbim.uu.se	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; COOK A, 1993, AM J HUM GENET, V53, P71; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Hagner-McWhirter A, 2000, GLYCOBIOLOGY, V10, P159, DOI 10.1093/glycob/10.2.159; Han C, 2004, DEVELOPMENT, V131, P1563, DOI 10.1242/dev.01051; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kishibe J, 2000, J BIOL CHEM, V275, P15321, DOI 10.1074/jbc.275.20.15321; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V268, P860, DOI 10.1006/bbrc.2000.2219; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; KURE S, 1986, J IMMUNOL, V137, P3900; LEMERRER M, 1994, HUM MOL GENET, V3, P717, DOI 10.1093/hmg/3.5.717; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin X, 1998, BIOCHEM BIOPH RES CO, V248, P738, DOI 10.1006/bbrc.1998.9050; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOLOMON L, 1963, J BONE JOINT SURG BR, V45, P292, DOI 10.1302/0301-620X.45B2.292; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Takei Y, 2004, DEVELOPMENT, V131, P73, DOI 10.1242/dev.00913; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wei G, 2000, J BIOL CHEM, V275, P27733; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	47	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32134	32141		10.1074/jbc.M312624200	http://dx.doi.org/10.1074/jbc.M312624200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161920	hybrid			2022-12-25	WOS:000222849700019
J	Karbat, I; Frolow, F; Froy, O; Gilles, N; Cohen, L; Turkov, M; Gordon, D; Gurevitz, M				Karbat, I; Frolow, F; Froy, O; Gilles, N; Cohen, L; Turkov, M; Gordon, D; Gurevitz, M			Molecular basis of the high insecticidal potency of scorpion alpha-toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; LEIURUS-QUINQUESTRIATUS-HEBRAEUS; ANDROCTONUS-AUSTRALIS HECTOR; CIS PEPTIDE-BONDS; RECEPTOR-SITE; NA+-CHANNELS; RAT-BRAIN; DIFFERENTIALLY INTERACT; BINDING; NEUROTOXIN	Scorpion alpha-toxins are similar in their mode of action and three-dimensional structure but differ considerably in affinity for various voltage-gated sodium channels (NaChs). To clarify the molecular basis of the high potency of the alpha-toxin LqhalphaIT ( from Leiurus quinquestriatus hebraeus) for insect NaChs, we identified by mutagenesis the key residues important for activity. We have found that the functional surface is composed of two distinct domains: a conserved "Core-domain" formed by residues of the loops connecting the secondary structure elements of the molecule core and a variable "NC-domain" formed by a five-residue turn ( residues 8 - 12) and a C-terminal segment ( residues 56 - 64). We further analyzed the role of these domains in toxin activity on insects by their stepwise construction onto the scaffold of the anti-mammalian alpha-toxin, Aah2 ( from Androctonus australis hector). The chimera harboring both domains, Aah2(LqhalphaIT(face)), was as active to insects as LqhalphaIT. Structure determination of Aah2(LqhalphaIT(face)) by x-ray crystallography revealed that the NC-domain deviates from that of Aah2 and forms an extended protrusion off the molecule core as appears in LqhalphaIT. Notably, such a protrusion is observed in all alpha-toxins active on insects. Altogether, the division of the functional surface into two domains and the unique configuration of the NC-domain illuminate the molecular basis of alpha-toxin specificity for insects and suggest a putative binding mechanism to insect NaChs.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; CEA, CE Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Tel Aviv University; Tel Aviv University; Hebrew University of Jerusalem; CEA; UDICE-French Research Universities; Universite Paris Saclay	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il; mamgur@post.tau.ac.il	Frolow, Felix/A-1760-2013; Froy, Oren/C-3550-2009					Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1999, EUR J NEUROSCI, V11, P975, DOI 10.1046/j.1460-9568.1999.00505.x; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chen HJ, 2002, EUR J NEUROSCI, V16, P767, DOI 10.1046/j.1460-9568.2002.02142.x; Chen HJ, 2000, PFLUG ARCH EUR J PHY, V439, P423, DOI 10.1007/s004240050959; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; DARBON H, 1983, INT J PEPT PROT RES, V22, P179; ELAYEB M, 1986, BIOCHEMISTRY-US, V25, P6671, DOI 10.1021/bi00369a052; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; Gilles N, 2002, EUR J BIOCHEM, V269, P1500, DOI 10.1046/j.1432-1033.2002.02799.x; Gilles N, 2001, BIOCHEMISTRY-US, V40, P14576, DOI 10.1021/bi010973r; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gilles N, 2000, EUR J NEUROSCI, V12, P2823, DOI 10.1046/j.1460-9568.2000.00168.x; Gilles N, 1999, J NEUROSCI, V19, P8730, DOI 10.1523/JNEUROSCI.19-20-08730.1999; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; Gordon D, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P215; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; GUREVITZ M, 1991, TOXICON, V29, P1270, DOI 10.1016/0041-0101(91)90200-B; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; He XL, 2000, ACTA CRYSTALLOGR D, V56, P25, DOI 10.1107/S0907444999014614; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Karbat I, 2004, FASEB J, V18, P683, DOI 10.1096/fj.03-0733com; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Little MJ, 1998, J BIOL CHEM, V273, P27076, DOI 10.1074/jbc.273.42.27076; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Menez A, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P175; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; Sautiere P, 1998, TOXICON, V36, P1141, DOI 10.1016/S0041-0101(98)00080-4; Smith GD, 1997, ACTA CRYSTALLOGR D, V53, P551, DOI 10.1107/S0907444997005386; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wang CG, 2003, BIOCHEMISTRY-US, V42, P4699, DOI 10.1021/bi0270438; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	56	85	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31679	31686		10.1074/jbc.M402048200	http://dx.doi.org/10.1074/jbc.M402048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133045	hybrid			2022-12-25	WOS:000222726800093
J	Lu, R; Niida, H; Nakanishi, M				Lu, R; Niida, H; Nakanishi, M			Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; NIM1/CDR1 MITOTIC INDUCER; FISSION YEAST; MAP KINASE; S-PHASE; WEE1; CHK1; P53; PATHWAY	Checkpoint activation by DNA damage during G(2) prevents activation of cyclin B/Cdc2 complexes, and as a consequence, mitotic entry is blocked. Although initiation and maintenance of G2 arrest are known to be regulated by at least two distinct signaling pathways, including those of p38MAPK and ataxia-telangiectasiamutated (ATM)- and Rad3-related (ATR)-Chk1 in higher eukaryotes, the actual number of signaling pathways involved in this regulation is still elusive. In the present study, we identified human SAD1 (hsSAD1) by searching a sequence data base. The predicted hsSAD1 protein comprises 778 amino acids and shares significant homology with the fission yeast Cdr2, a mitosis-regulatory kinase, and Caenorhabditis elegans SAD1, a neuronal cell polarity regulator. HsSAD1 transcript was expressed ubiquitously with the highest levels of expression in brain and testis. HsSAD1 specifically phosphorylated Wee1A, Cdc25-C, and - B on Ser-642, Ser-216, and Ser-361 in vitro, respectively. Overexpression of hsSAD1 resulted in an increased phosphorylation of Cdc25C on Ser-216 in vivo. DNA damage induced by UV or methyl methane sulfonate but not by IR enhanced endogenous hsSAD1 kinase activity in a caffeine-sensitive manner and caused translocation of its protein from cytoplasm to nucleus. Overexpression of wild-type hsSAD1 induced G(2)/M arrest in HeLa S2 cells. Furthermore, UV-induced G(2)/M arrest was partially abrogated by the reduced expression of hsSAD1 using small interfering RNA. These results suggest that hsSAD1 acts as checkpoint kinase upon DNA damage induced by UV or methyl methane sulfonate. The identification of this new kinase suggests the existence of an alternative checkpoint pathway other than those of ATR-Chk1 and p38MAPK.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Nakanishi, M (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem & Cell Biol, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	mkt-naka@med.nagoya-cu.ac.jp						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Carr AM, 1997, CURR OPIN GENET DEV, V7, P93, DOI 10.1016/S0959-437X(97)80115-3; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Crump JG, 2001, NEURON, V29, P115, DOI 10.1016/S0896-6273(01)00184-2; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu QH, 2000, GENE DEV, V14, P1448; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Prives C, 1999, J PATHOL, V187, P112; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 2001, MOL CELL BIOL, V21, P1499, DOI 10.1128/MCB.21.5.1499-1508.2001; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang SW, 1999, J CELL SCI, V112, P927; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	47	43	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31164	31170		10.1074/jbc.M404728200	http://dx.doi.org/10.1074/jbc.M404728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150265	hybrid			2022-12-25	WOS:000222726800033
J	Jones, AL; Hulett, MD; Parish, CR				Jones, AL; Hulett, MD; Parish, CR			Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IGG; ANTITHROMBIN; SERUM; MODULATION; INHIBITOR; MECHANISM; SEQUENCE; PROLINE; PROTEIN; GLYCOSAMINOGLYCANS	Histidine-rich glycoprotein (HRG) is an alpha(2)-glycoprotein found in mammalian plasma at high concentrations (similar to150 mug/ml) and is distinguished by its high content of histidine and proline. Structurally, HRG is a modular protein consisting of an N-terminal cystatin-like domain (N1N2), a central histidine-rich region (HRR) flanked by proline-rich sequences, and a C-terminal domain. HRG binds to cell surfaces and numerous ligands such as plasminogen, fibrinogen, thrombospondin, C1q, heparin, and IgG, suggesting that it may act as an adaptor protein either by targeting ligands to cell surfaces or by cross-linking soluble ligands. Despite the suggested functional importance of HRG, the cell-binding characteristics of the molecule are poorly defined. In this study, HRG was shown to bind to most cell lines in a Zn2+-dependent manner, but failed to interact with the Chinese hamster ovary cell line pgsA-745, which lacks cell-surface glycosaminoglycans (GAGs). Subsequent treatment of GAG-positive Chinese hamster ovary cells with mammalian heparanase or bacterial heparinase III, but not chondroitinase ABC, abolished HRG binding. Furthermore, blocking studies with various GAG species indicated that only heparin was a potent inhibitor of HRG binding. These data suggest that heparan sulfate is the predominate cell-surface ligand for HRG and that mammalian heparanase is a potential regulator of HRG binding. Using recombinant forms of full-length HRG and the N-terminal N1N2 domain, it was shown that the N1N2 domain bound specifically to immobilized heparin and cell-surface heparan sulfate. In contrast, synthetic peptides corresponding to the Zn2+-binding HRR of HRG did not interact with cells. Furthermore, the binding of full-length HRG, but not the N1N2 domain, was greatly potentiated by physiological concentrations of Zn2+. Based on these data, we propose that the N1N2 domain binds to cell-surface heparan sulfate and that the interaction of Zn2+ with the HRR can indirectly enhance cell-surface binding.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, GPO Box 4, Canberra, ACT 2601, Australia.	christopher.parish@anu.edu.au	Hulett, Mark D/C-4160-2012	Parish, Christopher/0000-0001-7740-0430; Hulett, Mark/0000-0003-2072-5968				AKTULGA A, 1974, RECENT ADV BASIC RES, P185; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BURCH MK, 1987, BIOCHEMISTRY-US, V26, P7477, DOI 10.1021/bi00397a042; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG NS, 1992, IMMUNOLOGY, V77, P532; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 2002, J IMMUNOL, V169, P4745, DOI 10.4049/jimmunol.169.9.4745; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; GUTHANS SL, 1982, ARCH BIOCHEM BIOPHYS, V218, P320, DOI 10.1016/0003-9861(82)90350-2; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; ICHINOSE A, 1984, THROMB RES, V33, P401, DOI 10.1016/0049-3848(84)90079-3; KAZAMA Y, 1992, THROMB HAEMOSTASIS, V67, P50; KOIDE T, 1987, FEBS LETT, V216, P17, DOI 10.1016/0014-5793(87)80748-2; KOIDE T, 1986, FEBS LETT, V194, P242, DOI 10.1016/0014-5793(86)80092-8; KOIDE T, 1982, FEBS LETT, V141, P222, DOI 10.1016/0014-5793(82)80052-5; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; KOIDE T, 1985, J BIOCHEM-TOKYO, V98, P1191, DOI 10.1093/oxfordjournals.jbchem.a135385; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; MORGAN WT, 1978, BIOCHIM BIOPHYS ACTA, V535, P319, DOI 10.1016/0005-2795(78)90098-3; MORGAN WT, 1981, BIOCHEMISTRY-US, V20, P1054, DOI 10.1021/bi00508a002; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Olsen HM, 1996, IMMUNOLOGY, V88, P198, DOI 10.1111/j.1365-2567.1996.tb00005.x; Olsson AK, 2004, CANCER RES, V64, P599, DOI 10.1158/0008-5472.CAN-03-1941; PARISH CR, 1984, J CELL SCI, V67, P145; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; SAIGO K, 1989, J BIOL CHEM, V264, P8249; Schedin-Weiss S, 2002, BIOCHEMISTRY-US, V41, P12369, DOI 10.1021/bi020406j; Simantov R, 2001, J CLIN INVEST, V107, P45, DOI 10.1172/JCI9061	38	58	64	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30114	30122		10.1074/jbc.M401996200	http://dx.doi.org/10.1074/jbc.M401996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138272	hybrid			2022-12-25	WOS:000222531900032
J	Paetzel, M; Goodall, JJ; Kania, M; Dalbey, RE; Page, MGP				Paetzel, M; Goodall, JJ; Kania, M; Dalbey, RE; Page, MGP			Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; CATALYTICALLY ACTIVE FORM; STREPTOMYCES SP TU-6075; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ARYLOMYCIN-A; PROTEIN; PROGRAM; SERINE; MECHANISM	We report here the crystallographic and biophysical analysis of a soluble, catalytically active fragment of the Escherichia coli type I signal peptidase (SPase Delta2-75) in complex with arylomycin A(2). The 2.5-Angstrom resolution structure revealed that the inhibitor is positioned with its COOH-terminal carboxylate oxygen (O45) within hydrogen bonding distance of all the functional groups in the catalytic center of the enzyme (Ser(90) O-gamma, Lys(145) N-zeta, and Ser(88) O-gamma) and that it makes beta-sheet type interactions with the beta-strands that line each side of the binding site. Ligand binding studies, calorimetry, fluorescence spectroscopy, and stopped-flow kinetics were also used to analyze the binding mode of this unique non-covalently bound inhibitor. The crystal structure was solved in the space group P4(3)2(1)2. A detailed comparison is made to the previously published acyl-enzyme inhibitor complex structure (space group: P2(1)2(1)2) and the apo-enzyme structure (space group: P4(1)2(1)2). Together this work provides insights into the binding of pre-protein substrates to signal peptidase and will prove helpful in the development of novel antibiotics.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Basilea Pharmaceut Ltd, CH-4058 Basel, Switzerland; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA	Simon Fraser University; Basilea Pharmaceutica Ltd.; University System of Ohio; Ohio State University	Paetzel, M (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, S Sci Bldg,8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	mpaetzel@sfu.ca		Paetzel, Mark/0000-0002-7408-5487				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARKOCYGALLAGHER GA, 1992, J BIOL CHEM, V267, P1231; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; Black MT, 1998, CURR PHARM DESIGN, V4, P133; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruton G, 2003, EUR J MED CHEM, V38, P351, DOI 10.1016/S0223-5234(03)00040-0; Bullock TL, 1996, J MOL BIOL, V255, P714, DOI 10.1006/jmbi.1996.0058; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; Carlos J. L., 2001, ENZYMES, V22, P27; Carlos JL, 2000, BIOCHEMISTRY-US, V39, P7276, DOI 10.1021/bi000301l; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; Davies JS, 2003, J PEPT SCI, V9, P471, DOI 10.1002/psc.491; Holtzel A, 2002, J ANTIBIOT, V55, P571; Hubbard BK, 2000, CHEM BIOL, V7, P931, DOI 10.1016/S1074-5521(00)00043-0; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanwar R, 2000, BIOCHEMISTRY-US, V39, P14976, DOI 10.1021/bi0008579; KIM YT, 1995, EUR J BIOCHEM, V234, P358, DOI 10.1111/j.1432-1033.1995.358_c.x; KIM YT, 1995, J BIOCHEM-TOKYO, V117, P535, DOI 10.1093/oxfordjournals.jbchem.a124741; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO D, 1994, BIOCHEMISTRY-US, V33, P8347, DOI 10.1021/bi00193a023; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Kurz M, 1996, BIOCHEMISTRY-US, V35, P12570, DOI 10.1021/bi961017q; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Paetzel M, 1999, PROTEIN SCI, V8, P2533; Paetzel M, 1997, J BIOL CHEM, V272, P9994; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PAETZEL M, 1995, PROTEINS, V23, P122, DOI 10.1002/prot.340230115; Paetzel M, 2000, PHARMACOL THERAPEUT, V87, P27, DOI 10.1016/S0163-7258(00)00064-4; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; Schimana J, 2002, J ANTIBIOT, V55, P565, DOI 10.7164/antibiotics.55.565; SUNG M, 1992, J BIOL CHEM, V267, P13154; TSCHANTZ WR, 1995, BIOCHEMISTRY-US, V34, P3935, DOI 10.1021/bi00012a010; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; WICKNER W, 1987, J BACTERIOL, V169, P3821, DOI 10.1128/jb.169.8.3821-3822.1987; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593; [No title captured]	58	76	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30781	30790		10.1074/jbc.M401686200	http://dx.doi.org/10.1074/jbc.M401686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136583	Green Submitted, hybrid			2022-12-25	WOS:000222531900109
J	Tanaka, T; Fukui, T; Fujiwara, S; Atomi, H; Imanaka, T				Tanaka, T; Fukui, T; Fujiwara, S; Atomi, H; Imanaka, T			Concerted action of diacetylchitobiose deacetylase and exo-beta-D-glucosaminidase in a novel chitinolytic pathway in the hyperthermophilic archaeon Thermococcus kodakaraensis KOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PIG-L; CHITINASE; CLONING; N,N'-DIACETYLCHITOBIOSE; DISACCHARIDE	The hyperthermophilic archaeon Thermococcus kodakaraensis KOD1 possesses chitinase (Tk-ChiA) and exo-beta-D-glucosaminidase (Tk-GlmA) for chitin degradation; the former produces diacetylchitobiose (GlcNAc(2)) from chitin, and the latter hydrolyzes chitobiose (GlcN(2)) to glucosamine ( GlcN). To identify the enzyme that physiologically links these two activities, here we focused on the deacetylase that provides the substrate for Tk-GlmA from GlcNAc2. The deacetylase could be detected in and partially purified from T. kodakaraensis cells, and the corresponding gene (Tk-dac) was identified on the genome. The deduced amino acid sequence was classified into the LmbE protein family including N-acetylglucosaminylphosphatidylinositol de-N-acetylases and 1-D-myo-inosityl-2-acetamido-2-deoxy-alpha-D-glucopyranoside deacetylase. Recombinant Tk-Dac showed deacetylase activity toward N-acetylchitooligosaccharides (GlcNAc(2-5)), and the deacetylation site was revealed to be specific at the nonreducing GlcNAc residue. The enzyme also deacetylated GlcNAc monomer. In T. kodakaraensis cells, the transcription of Tk-dac, Tk-glmA, Tk-chiA, and the clustered genes were induced by GlcNAc(2), suggesting the function of this gene cluster in chitin catabolism in vivo. These results have revealed a unique chitin catabolic pathway in T. kodakaraensis, in which GlcNAc(2) produced from chitin is degraded by the concerted action of Tk-Dac and Tk-GlmA. That is, GlcNAc(2) is site-specifically deacetylated to GlcN-GlcNAc by Tk-Dac and then hydrolyzed to GlcN and GlcNAc by Tk-GlmA followed by a second deacetylation step of the remaining GlcNAc by Tk-Dac to form GlcN. This is the first elucidation of an archaeal chitin catabolic pathway and defines a novel mechanism for dimer processing using a combination of deacetylation and cleavage, distinct from any previously known pathway.	Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Nishikyo Ku, Kyoto 6158510, Japan; Kwansei Gakuin Univ, Dept Biosci, Nanobiotechnol Res Ctr, Sch Sci & Technol, Sanda 6691337, Japan	Kyoto University; Kwansei Gakuin University	Imanaka, T (corresponding author), Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Nishikyo Ku, Kyoto 6158510, Japan.	imanaka@sbchem.kyoto-u.ac.jp	Fujiwara, Shinsuke/CAE-9955-2022; Tanaka, Takeshi/C-2921-2012; Fukui, Toshiaki/S-6882-2019; 福居, 俊昭/K-5056-2012	Tanaka, Takeshi/0000-0001-7547-7928; Fukui, Toshiaki/0000-0003-4557-6284; 福居, 俊昭/0000-0003-4557-6284; Atomi, Haruyuki/0000-0001-9687-6426				Andronopoulou E, 2003, EXTREMOPHILES, V7, P43, DOI 10.1007/s00792-002-0294-3; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Ezaki S, 1999, J BIOSCI BIOENG, V88, P130, DOI 10.1016/S1389-1723(99)80190-X; Gao J, 2003, APPL ENVIRON MICROB, V69, P3119, DOI 10.1128/AEM.69.6.3119-3128.2003; Gooday Graham W., 1994, P279; Handa N, 2003, PROTEIN SCI, V12, P1621, DOI 10.1110/gad.03104003; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; Keyhani NO, 2000, J BIOL CHEM, V275, P33084, DOI 10.1074/jbc.M001043200; Keyhani NO, 1997, P NATL ACAD SCI USA, V94, P14367, DOI 10.1073/pnas.94.26.14367; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; Sambrook J, 2001, MOL CLONING LAB MANU; Tanaka T, 1999, APPL ENVIRON MICROB, V65, P5338; Tanaka T, 2003, J BACTERIOL, V185, P5175, DOI 10.1128/JB.185.17.5175-5181.2003; Tanaka T, 2001, J BIOL CHEM, V276, P35629, DOI 10.1074/jbc.M105919200; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tsigos I, 2000, TRENDS BIOTECHNOL, V18, P305, DOI 10.1016/S0167-7799(00)01462-1; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185	20	68	75	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30021	30027		10.1074/jbc.M314187200	http://dx.doi.org/10.1074/jbc.M314187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136574	hybrid			2022-12-25	WOS:000222531900020
J	Terrones, O; Antonsson, B; Yamaguchi, H; Wang, HG; Liu, JH; Lee, RM; Herrmann, A; Basanez, G				Terrones, O; Antonsson, B; Yamaguchi, H; Wang, HG; Liu, JH; Lee, RM; Herrmann, A; Basanez, G			Lipidic pore formation by the concerted action of proapoptotic BAX and tBID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; CONFORMATIONAL-CHANGE; MITOCHONDRIAL-MEMBRANES; PROTEIN; CELL; APOPTOSIS; BH3; OLIGOMERIZATION; ACTIVATION	BCL-2 homology 3 (BH3)-only proteins of the BCL-2 family such as tBID and BIMEL assist BAX-type proteins to breach the permeability barrier of the outer mitochondrial membrane, thereby allowing cytoplasmic release of cytochrome c and other active inducers of cell death normally confined to the mitochondrial intermembrane space. However, the exact mechanism by which tBID and BIMEL aid BAX and its close homologues in this mitochondrial protein release remains enigmatic. Here, using pure lipid vesicles, we provide evidence that tBID acts in concert with BAX to 1) form large membrane openings through both BH3-dependent and BH3-independent mechanisms, 2) cause lipid trans-bilayer movement concomitant with membrane permeabilization, and 3) disrupt the lipid bilayer structure of the membrane by promoting positive monolayer curvature stress. None of these effects were observed with BAX when BIMEL was substituted for tBID. Based on these data, we propose a novel model in which tBID assists BAX not only via protein-protein but also via protein-lipid interactions to form lipidic pore-type nonbilayer structures in the outer mitochondrial membrane through which intermembrane prodeath molecules exit mitochondria during apoptosis.	Univ Basque Country, Euskal Herriko Unibertsitatea, Ctr Mixto, CSIC,Unidad Biofis, E-48080 Bilbao, Spain; Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Humboldt Univ, Inst Biol Mol Biophys, D-10115 Berlin, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; Merck & Company; Serono International S.A.; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Humboldt University of Berlin	Basanez, G (corresponding author), Univ Basque Country, Euskal Herriko Unibertsitatea, Ctr Mixto, CSIC,Unidad Biofis, POB 644, E-48080 Bilbao, Spain.	gbzbaasg@lg.ehu.es	Basanez, Gorka/L-9509-2014; Terrones, Oihana/AAA-8903-2019; Wang, Hong-Gang/A-3018-2015; Terrones, Oihana/I-4023-2015	Basanez, Gorka/0000-0002-7475-7861; Wang, Hong-Gang/0000-0003-0551-0571; Terrones, Oihana/0000-0001-7421-6486				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 2002, FEBS LETT, V532, P115, DOI 10.1016/S0014-5793(02)03651-7; Basanez G, 2002, CELL MOL LIFE SCI, V59, P1478, DOI 10.1007/s00018-002-8523-6; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; CULLIS PR, 1999, MEMBRANE FUSION, P35; DEJONG D, 1994, CANCER RES, V54, P256; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; Epand RF, 2003, BIOCHEMISTRY-US, V42, P14576, DOI 10.1021/bi035348w; Epand RF, 2004, BIOCHEM J, V377, P509, DOI 10.1042/BJ20030938; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Festjens N, 2003, ACTA HAEMATOL-BASEL, V111, P7, DOI 10.1159/000074483; Fuller N, 2001, BIOPHYS J, V81, P243, DOI 10.1016/S0006-3495(01)75695-0; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; Iverson SL, 2004, J BIOL CHEM, V279, P1100, DOI 10.1074/jbc.M305020200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; LIU J, 2004, IN PRESS APOPTOSIS; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Malisan F, 2003, CURR MED CHEM, V10, P1573, DOI 10.2174/0929867033457188; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Menestrina G, 2001, TOXICON, V39, P1661, DOI 10.1016/S0041-0101(01)00153-2; Montessuit S, 1999, PROTEIN EXPRES PURIF, V15, P202, DOI 10.1006/prep.1998.1010; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Muller P, 2000, CHEM PHYS LIPIDS, V106, P89, DOI 10.1016/S0009-3084(00)00134-1; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Polster BM, 2003, J NEUROSCI, V23, P2735; Polster BM, 2001, J BIOL CHEM, V276, P37887; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; SHEAU YH, 1998, MOL ENDOCRINOL, V12, P1432; SORICE M, 2004, IN PRESS CELL DEATH; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Szule JA, 2002, BIOPHYS J, V83, P977, DOI 10.1016/S0006-3495(02)75223-5; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; WANG K, 1999, GENE DEV, V15, P2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhai DY, 2001, EUR J BIOCHEM, V268, P48, DOI 10.1046/j.1432-1327.2001.01841.x; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	78	194	198	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30081	30091		10.1074/jbc.M313420200	http://dx.doi.org/10.1074/jbc.M313420200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138279	hybrid			2022-12-25	WOS:000222531900028
J	Vougier, S; Mary, J; Dautin, N; Vinh, J; Friguet, B; Ladant, D				Vougier, S; Mary, J; Dautin, N; Vinh, J; Friguet, B; Ladant, D			Essential role of methionine residues in calmodulin binding to Bordetella pertussis adenylate cyclase, as probed by selective oxidation and repair by the peptide methionine sulfoxide reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA-ATPASE; OXIDIZED CALMODULIN; CALCIUM SENSOR; EXPRESSION; ACTIVATION; PROTEINS; CLONING; TOXIN; MUTAGENESIS; ABILITY	Bordetella pertussis, the causative agent of whooping cough, secretes among other virulence factors an adenylate cyclase (AC) toxin that is able to enter into eukaryotic cells where it is activated upon binding to endogenous calmodulin (CaM) and synthesizes supraphysiological cAMP levels. In vivo, the AC toxin, through its specific interaction with the CD11b/CD18 integrin, primarily targets phagocytic cells such as neutrophils and macrophages. Because neutrophil priming and activation result in the production of reactive oxygen species that may cause intracellular oxidation, we have examined the biological consequences of the oxidation of CaM methionines upon its interaction with AC. We show here that the interaction of CaM with AC is dependent on the reduced state of methionines, because oxidation of all methionine residues of CaM dramatically decreases its affinity for AC. Peptide methionine sulfoxide reductases A (MsrA) and B (MsrB) were able to partially reduce the oxidized CaM, and these partially "repaired" forms could interact with AC nearly as efficiently as the native protein. We further showed that the CaM.AC complex is resistant to oxidation with tert-butylhydroperoxide, and we identified methionine residues 109, 124, and 145 as critical for binding to AC. The resistance of the AC.CaM complex to oxidation and the ability of AC to be efficiently activated by partially oxidized CaM molecules should allow the toxin to exert its cytotoxic effects on activated neutrophils and contribute to the host colonization.	Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, F-75005 Paris, France; Inst Pasteur, Dept Biol Struct & Chim, CNRS, URA 2185,Unite Biochim Interact Macromol, F-75015 Paris, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, UMR 7637, Lab Neurobiol & Divers Cellulaire, F-75005 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Friguet, B (corresponding author), Univ Paris 07, Lab Biol & Biochim Cellulaire Vieillissement, EA 3106, IFR 117, 2 Pl Jussieu, F-75005 Paris, France.	bfriguet@paris7.jussieu.fr; ladant@pasteur.fr	Mary, Jean/H-2344-2011; Vinh, Joelle/K-1347-2015	Mary, Jean/0000-0002-2438-8383; Vinh, Joelle/0000-0001-7184-2668; Friguet, Bertrand/0000-0001-8085-1961; LADANT, Daniel/0000-0003-1955-548X				Balog EM, 2003, J BIOL CHEM, V278, P15615, DOI 10.1074/jbc.M209180200; Bartlett RK, 2003, BIOCHEMISTRY-US, V42, P3231, DOI 10.1021/bi026956z; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Jung S, 2002, FEBS LETT, V527, P91, DOI 10.1016/S0014-5793(02)03171-X; Keck RG, 1996, ANAL BIOCHEM, V236, P56, DOI 10.1006/abio.1996.0131; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1992, J BIOL CHEM, V267, P2244; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3; Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; Montgomery HJ, 2003, BIOCHEMISTRY-US, V42, P7759, DOI 10.1021/bi027097h; Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shen YQ, 2002, EMBO J, V21, P6721, DOI 10.1093/emboj/cdf681; Sun HY, 1999, BIOCHEMISTRY-US, V38, P105, DOI 10.1021/bi981295k; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664; WOLFF J, 1986, BIOCHEMISTRY-US, V25, P7950, DOI 10.1021/bi00372a025; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841; Yin D, 2000, CHEM RES TOXICOL, V13, P103, DOI 10.1021/tx990142a	36	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30210	30218		10.1074/jbc.M400604200	http://dx.doi.org/10.1074/jbc.M400604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15148319	hybrid			2022-12-25	WOS:000222531900044
J	Li, XF; Song, S; Liu, Y; Ko, SH; Kao, HY				Li, XF; Song, S; Liu, Y; Ko, SH; Kao, HY			Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; PROLYL ISOMERASE PIN1; MUSCLE DIFFERENTIATION; BETA-CATENIN; 14-3-3 PROTEINS; HDAC4 DEACETYLASE; NUCLEAR EXPORT; RECEPTOR-ALPHA; P53; UBIQUITINATION	Class II histone deacetylases (HDACs) play a role in myogenesis and inhibit transcriptional activation by myocyte enhancer factors 2. A distinct feature of class II HDACs is their ability to shuttle between the nucleus and the cytoplasm in a cell type- and signal-dependent manner. We demonstrate here that treatment with the 26 S proteosome inhibitors, MG132 and ALLN, leads to detection of ubiquitinated HDAC7 and causes accumulation of cytoplasmic HDAC7. We also show that treatment with calyculin A, a protein phosphatase inhibitor, leads to a marked increase of HDAC7 but not HDAC5. The increase in HDAC7 is accompanied by enhanced interaction between 14-3-3 proteins and HDAC7. HDAC7 mutations that prevent the interaction with 14-3-3 proteins also block calyculin A-mediated stabilization. Expression of constitutively active calcium/calmodulin-dependent kinase I stabilizes HDAC7 and causes an increased association between HDAC7 and 14-3-3. Together, our results suggest that calcium/calmodulin-dependent kinase I-mediated phosphorylation of HDAC7 acts, in part, to promote association of HDAC7 with 14-3-3 and stabilizes HDAC7.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Kao, HY (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk43@po.cwru.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062985] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 62985] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajiro Kozo, 2002, Tanpakushitsu Kakusan Koso, V47, P753; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Huang EY, 2000, GENE DEV, V14, P45; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2000, GENE DEV, V14, P55; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Maki CG, 1996, CANCER RES, V56, P2649; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Osburn DL, 2001, MOL CELL BIOL, V21, P4909, DOI 10.1128/MCB.21.15.4909-4918.2001; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Willems AR, 1999, PHILOS T ROY SOC B, V354, P1533, DOI 10.1098/rstb.1999.0497; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	60	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34201	34208		10.1074/jbc.M405179200	http://dx.doi.org/10.1074/jbc.M405179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15166223	hybrid			2022-12-25	WOS:000223134800018
J	Hao, JJ; Carey, GB; Zhan, X				Hao, JJ; Carey, GB; Zhan, X			Syk-mediated tyrosine phosphorylation is required for the association of hematopoietic lineage cell-specific protein 1 with lipid rafts and B cell antigen receptor signalosome complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED MEMBRANE DOMAINS; HS1 PROTEIN; SEQUENTIAL PHOSPHORYLATION; ACTIN CYTOSKELETON; SRC; SUBSTRATE; DYNAMICS; KINASES; PATCHES; EDGE	Hematopoietic lineage cell-specific protein 1 (HS1) is an F-actin- and actin-related proteins 2 and 3 (Arp2/3)binding protein that undergoes a rapid tyrosine phosphorylation upon B cell antigen receptor (BCR) activation. Density gradient centrifugation of Triton X-100 lysates from B lymphocytes demonstrated that HS1 was translocated in response to BCR cross-linking into lipid raft microdomain along with Arp2/3 complex and Wiskott-Aldrich syndrome protein. HS1-green fluorescent protein was localized in membrane patches enriched with GM1 gangliosides and BCR in the cells treated with anti-IgM antibody. Colocalization of HS1-green fluorescent protein with BCR was also correlated with tyrosine phosphorylation of HS1. Interestingly a murine HS1 mutant at the tyrosine residues Tyr(388) and Tyr(405) targeted by Syk failed to respond to BCR cross-linking for either translocation into lipid rafts or colocalization with BCR within cells. Furthermore HS1 was unable to translocate into lipid rafts in a chicken B cell line deficient in Syk. Reintroducing a Syk construct into the Syk knock-out cells recovered effectively both tyrosine phosphorylation and translocation of HS1 into lipid rafts. In contrast, translocation of HS1 into rafts was normal in a Lyn knock-out B cell line, and an HS1 mutant at the tyrosine residue Tyr(222) targeted by Lyn maintained the ability to partition into rafts upon BCR cross-linking. These data indicate that Syk plays an important role in the translocation of HS1 into lipid rafts and may be responsible for actin assembly recruitment to rafts and subsequent antigen presentations.	Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; Amer Red Cross, Holland Lab, Dept Immunol, Rockville, MD 20855 USA	American Red Cross; American Red Cross	Zhan, X (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Pathol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	szhan001@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA091984] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 91984-02] Funding Source: Medline; NHLBI NIH HHS [R01-HL 50753-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown BK, 2001, TRAFFIC, V2, P414, DOI 10.1034/j.1600-0854.2001.002006414.x; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Gupta N, 2003, MOL BIOL CELL, V14, P432, DOI 10.1091/mbc.02-05-0078; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Ingley E, 2000, J BIOL CHEM, V275, P7887, DOI 10.1074/jbc.275.11.7887; Jordan S, 2003, J IMMUNOL, V171, P78, DOI 10.4049/jimmunol.171.1.78; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; Kurosaki T, 1998, INT J MOL MED, V1, P515; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Rodgers W, 2001, EXP CELL RES, V267, P173, DOI 10.1006/excr.2001.5253; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Saeki K, 2003, EMBO J, V22, P3015, DOI 10.1093/emboj/cdg293; Sawabe T, 2003, GENES IMMUN, V4, P122, DOI 10.1038/sj.gene.6363932; Shrivastava P, 2004, BLOOD, V103, P1425, DOI 10.1182/blood-2003-03-0716; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Stoddart A, 2002, IMMUNITY, V17, P451, DOI 10.1016/S1074-7613(02)00416-8; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631	39	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33413	33420		10.1074/jbc.M313564200	http://dx.doi.org/10.1074/jbc.M313564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166239	hybrid			2022-12-25	WOS:000223039700049
J	Sweeney, G; Garg, RR; Ceddia, RB; Li, DL; Ishiki, M; Somwar, R; Foster, LJ; Neilsen, PO; Prestwich, GD; Rudich, A; Klip, A				Sweeney, G; Garg, RR; Ceddia, RB; Li, DL; Ishiki, M; Somwar, R; Foster, LJ; Neilsen, PO; Prestwich, GD; Rudich, A; Klip, A			Intracellular delivery of phosphatidylinositol (3,4,5)-trisphosphate causes incorporation of glucose transporter 4 into the plasma membrane of muscle and fat cells without increasing glucose uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; AKT/PROTEIN KINASE-B; AMINO-ACID-TRANSPORT; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; INSULIN-RESISTANCE; L6 MYOBLASTS; SUBCELLULAR-DISTRIBUTION; SIGNALING MECHANISMS	Insulin stimulates glucose uptake into muscle and fat cells by translocating glucose transporter 4 (GLUT4) to the cell surface, with input from phosphatidylinositol ( PI) 3-kinase and its downstream effector Akt/protein kinase B. Whether PI3,4,5-trisphosphate (PI(3,4,5)P-3) suffices to produce GLUT4 translocation is unknown. We used two strategies to deliver PI(3,4,5)P-3 intracellularly and two insulin-sensitive cell lines to examine Akt activation and GLUT4 translocation. In 3T3-L1 adipocytes, the acetoxymethyl ester of PI(3,4,5)P-3 caused GLUT4 migration to the cell periphery and increased the amount of plasma membrane-associated phospho-Akt and GLUT4. Intracellular delivery of PI(3,4,5)P-3 using polyamine carriers also induced translocation of myc-tagged GLUT4 to the surface of intact L6 myoblasts, demonstrating membrane insertion of the transporter. GLUT4 translocation caused by carrier-delivered PI(3,4,5)P-3 was not reproduced by carrier-PI 4,5-bisphosphate or carrier alone. Like insulin, carrier-mediated delivery of PI( 3,4,5) P3 elicited redistribution of perinuclear GLUT4 and Akt phosphorylation at the cell periphery. In contrast to its effect on GLUT4 mobilization, delivered PI(3,4,5) P3 did not increase 2-deoxyglucose uptake in either L6GLUT4myc myoblasts or 3T3-L1 adipocytes. The ability of exogenously delivered PI(3,4,5)P-3 to augment plasma membrane GLUT4 content without increasing glucose uptake suggests that input at the level of PI 3-kinase suffices for GLUT4 translocation but is insufficient to stimulate glucose transport.	Hosp Sick Children, Programme Cell Biol, Toronto, ON M5G 1X8, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Echelon Biosci, Salt Lake City, UT 84108 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); York University - Canada; Utah System of Higher Education; University of Utah	Klip, A (corresponding author), Hosp Sick Children, Programme Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.ca		Rudich, Assaf/0000-0002-1366-1444	NIGMS NIH HHS [GM62734-03] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM062734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; EVANS JL, 1995, CELL SIGNAL, V7, P365, DOI 10.1016/0898-6568(95)00007-C; Fletcher LM, 1999, BIOCHEM SOC T, V27, P677, DOI 10.1042/bst0270677; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hou JCQ, 2003, MOL BIOL CELL, V14, P3578, DOI 10.1091/mbc.E03-02-0012; Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jebailey L, 2004, MOL ENDOCRINOL, V18, P359, DOI 10.1210/me.2003-0294; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Khayat ZA, 2000, J CELL SCI, V113, P279; KLIP A, 2001, HDB PHYSL 7, V2, P451; KONRAD D, 2004, KEYST M DIAB MELL MO, P123; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; Mosser VA, 2001, BIOCHEM BIOPH RES CO, V288, P1011, DOI 10.1006/bbrc.2001.5876; Mueckler M, 2001, J CLIN INVEST, V107, P1211, DOI 10.1172/JCI13020; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Niu WY, 2003, J BIOL CHEM, V278, P17953, DOI 10.1074/jbc.M211136200; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Patel N, 2003, MOL CELL BIOL, V23, P4611, DOI 10.1128/MCB.23.13.4611-4626.2003; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; Rudich A, 2003, ACTA PHYSIOL SCAND, V178, P297, DOI 10.1046/j.1365-201X.2003.01163.x; Rudich A, 2003, DIABETOLOGIA, V46, P649, DOI 10.1007/s00125-003-1080-1; SARGEANT R, 1993, J ENDOCRINOL INVEST, V16, P147, DOI 10.1007/BF03347669; Sasaoka T, 2004, J BIOL CHEM, V279, P14835, DOI 10.1074/jbc.M311534200; Sasaoka T, 2001, DIABETOLOGIA, V44, P1258, DOI 10.1007/s001250100645; Shisheva A, 2003, DIABETOLOGIA, V46, pA213; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tengholm A, 2002, CURR BIOL, V12, P1871, DOI 10.1016/S0960-9822(02)01223-X; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; YANG J, 1992, J BIOL CHEM, V267, P10393	65	55	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32233	32242		10.1074/jbc.M402897200	http://dx.doi.org/10.1074/jbc.M402897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166230	hybrid			2022-12-25	WOS:000222849700031
J	Thomas, LR; Henson, A; Reed, JC; Salsbury, FR; Thorburn, A				Thomas, LR; Henson, A; Reed, JC; Salsbury, FR; Thorburn, A			Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX; CELL-DEATH; TRAIL RECEPTORS; CASPASE-8; PROTEIN; RECRUITMENT; ACTIVATION; FADD/MORT1; INDUCTION; INSIGHTS	Members of the tumor necrosis factor superfamily of receptors induce apoptosis by recruiting adaptor molecules through death domain interactions. The central adaptor molecule for these receptors is the death domain-containing protein Fas-associated death domain ( FADD). FADD binds a death domain on a receptor or additional adaptor and recruits caspases to the activated receptor. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signals apoptosis through two receptors, DR4 and DR5. Although there is much interest in TRAIL, the mechanism by which FADD is recruited to the TRAIL receptors is not clear. Using a reverse two-hybrid system we previously identified mutations in the death effector domain of FADD that prevented binding to Fas/CD95. Here we show that these mutations also prevent binding to DR5. FADD-deficient Jurkat cells stably expressing these FADD mutations did not transduce TRAIL or Fas/CD95 signaling. Second site compensating mutations that restore binding to and signaling through Fas/CD95 and DR5 were also in the death effector domain. We conclude that in contrast to current models where the death domain of FADD functions independently of the death effector domain, the death effector domain of FADD comes into direct contact with both TRAIL and Fas/CD95 receptors.	Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA; Burnham Inst, La Jolla, CA 92037 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Sanford Burnham Prebys Medical Discovery Institute; Wake Forest University	Thorburn, A (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	athorbur@wfubmc.edu	Salsbury, FR/A-5923-2008	Salsbury, FR/0000-0002-2699-829X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee MS, 2002, J CHEM PHYS, V116, P10606, DOI 10.1063/1.1480013; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Peter ME, 2000, CELL DEATH DIFFER, V7, P759, DOI 10.1038/sj.cdd.4400735; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	33	69	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32780	32785		10.1074/jbc.M401680200	http://dx.doi.org/10.1074/jbc.M401680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173180	hybrid			2022-12-25	WOS:000222849700097
J	Trausch-Azar, JS; Lingbeck, J; Ciechanover, A; Schwartz, AL				Trausch-Azar, JS; Lingbeck, J; Ciechanover, A; Schwartz, AL			Ubiquitin-proteasome-mediated degradation of Id1 is modulated by MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; LOOP-HELIX PROTEINS; TRANSCRIPTION FACTORS; NUCLEAR; REGULATORS; PATHWAY; BINDING; SYSTEM; PROTEOLYSIS; TRANSPORT	Degradation of many short-lived cellular proteins such as the transcription factor MyoD occurs via the ubiquitin-proteasome pathway. MyoD, similar to many rapidly degraded regulatory factors, interacts with several high affinity binding partners, including members of the Id ( inhibitors of DNA binding) family. Following transfection to HeLa cells, Id1 is localized to the nucleus and rapidly (t(1/2) similar to 1 h) degraded via the ubiquitin-proteasome system. Mutagenesis of lysine residues within the putative nuclear localization region (amino acids 68-82) directs Id1(NLS) to the cytoplasm yet confers an increased rate of degradation (t(1/2) similar to 0.5 h). Id1 in which all lysine residues were mutagenized to alanine (lysineless Id1) was also rapidly degraded (t(1/2) similar to 0.6 h). Addition of a Myc(6) tag to the N terminus of lysine-less Id1 markedly stabilized Id1 (t(1/2) > 10 h) and suggests degradation via the N terminus-dependent pathway. Co-transfection of MyoD with Id1 or Id1(NLS) increases Id1 or Id1(NLS) within the nucleus and markedly reduces the rate of Id1 or Id1(NLS) degradation. These results thus demonstrate that in vivo MyoD modulates the rate of Id1 degradation and suggest a dynamic interplay of these factors.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat & Mol Biol & Phar, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Immink RGH, 2002, P NATL ACAD SCI USA, V99, P2416, DOI 10.1073/pnas.042677699; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Paulmurugan R, 2002, P NATL ACAD SCI USA, V99, P15608, DOI 10.1073/pnas.242594299; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; RODRIGUEZ MS, 1999, J BIOL CHEM, V274, P9017; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	46	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32614	32619		10.1074/jbc.M403794200	http://dx.doi.org/10.1074/jbc.M403794200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15163661	hybrid			2022-12-25	WOS:000222849700078
J	Wright, TG; Tsai, J; Jia, ZC; Elliott, BE				Wright, TG; Tsai, J; Jia, ZC; Elliott, BE			Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor met and blockade of HGF/Met function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET; EPITHELIAL-CELLS; TYROSINE KINASE; BREAST-CANCER; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; NK1 FRAGMENT; EXPRESSION; ANTAGONIST	Overexpression of hepatocyte growth factor (HGF) and its receptor Met often occurs in carcinoma cells, leading to establishment of an HGF/Met autocrine loop. Therefore, disruption of the HGF/Met autocrine loop may lead to down-regulation of tumorigenesis. To study the HGF/Met interaction, we have developed a cell-free system to detect HGF binding to a Met fusion protein, Met-IgG, using a modified enzyme-linked immunosorbent assay methodology. Since we previously showed that HGF can be purified by copper(II) affinity chromatography, we further explored the effect of copper( II) on the HGF/Met interaction. The divalent metal cations copper( II) and zinc( II) significantly inhibited HGF binding to immobilized Met-IgG with IC50 values of 230-270 muM, respectively, whereas manganese(II) and magnesium (II) were less inhibitory with 20-60-fold higher IC50 values. Incubation of 1 mM copper( II) with HGF resulted in nondenaturing and denaturing gel-mobility shifts, indicating that copper(II) binds directly to HGF. This interaction occurs at the N terminus of HGF, as incubation of 1 mM copper( II) with both HGF and the HGF derivative NK1 yielded similar results on SDS-PAGE. HGF-induced activation of Met and cell scattering were inhibited upon addition of HGF in the presence of 1 mM and 500 muM copper(II), respectively. Chemical protonation with diethyl pyrocarbonate of HGF histidine residues impeded the ability of 500 muM copper(II) to inhibit the binding of HGF to immobilized Met-IgG. Based on the NK1 domain structure, we propose that copper( II) may interact with HGF via the histidine residues in either N-terminal or kringle domains. The inhibition of HGF/Met interaction and subsequent downstream cellular functions may be through direct interference by copper(II), such as a change in charge or an induced local conformational change. This putative copper( II) binding domain may be the basis for developing potential inhibitors of HGF/Met binding and downstream functions and could lead to novel strategies for anti-cancer treatment.	Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Elliott, BE (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.	elliottb@post.queensu.ca						ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ALITALO K, 1982, ADV CANCER RES, V37, P111, DOI 10.1016/S0065-230X(08)60883-0; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; Gherardi E, 1997, CIBA F SYMP, V212, P84; Gherardi E, 1993, EXS, V65, P31; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hill BC, 2003, ARCH BIOCHEM BIOPHYS, V412, P186, DOI 10.1016/S0003-9861(03)00032-8; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuba K, 2000, BIOCHEM BIOPH RES CO, V279, P846, DOI 10.1006/bbrc.2000.4034; LEE HS, 1995, BIOCHEM BIOPH RES CO, V210, P1017, DOI 10.1006/bbrc.1995.1758; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARS WM, 1993, AM J PATHOL, V143, P949; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MIZUNO K, 1994, BIOCHEM BIOPH RES CO, V198, P1161, DOI 10.1006/bbrc.1994.1164; Mizushima H, 1996, J BIOCHEM-TOKYO, V120, P1196; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; Parr C, 2000, INT J CANCER, V85, P563, DOI 10.1002/(SICI)1097-0215(20000215)85:4<563::AID-IJC19>3.0.CO;2-D; Parr C, 2001, BIOCHEM BIOPH RES CO, V285, P1330, DOI 10.1006/bbrc.2001.5307; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rahimi N, 1996, PROTEIN EXPRES PURIF, V7, P329, DOI 10.1006/prep.1996.0047; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; Toi M, 1998, CLIN CANCER RES, V4, P659; Tsai YH, 2002, J CHROMATOGR B, V766, P133, DOI 10.1016/S0378-4347(01)00459-5; Tuck AB, 1996, AM J PATHOL, V148, P225; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Woodbury RL, 2002, J PROTEOME RES, V1, P233, DOI 10.1021/pr025506q; Yao Y, 1996, AM J PATHOL, V149, P1707; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641	51	5	7	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32499	32506		10.1074/jbc.M405043200	http://dx.doi.org/10.1074/jbc.M405043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161915	hybrid			2022-12-25	WOS:000222849700064
J	Bucciantini, M; Calloni, G; Chiti, F; Formigli, L; Nosi, D; Dobson, CM; Stefani, M				Bucciantini, M; Calloni, G; Chiti, F; Formigli, L; Nosi, D; Dobson, CM; Stefani, M			Prefibrillar amyloid protein aggregates share common features of cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; CELL-DEATH; MISFOLDING DISEASES; PARKINSONS-DISEASE; PRION PROTEIN; A-BETA; MECHANISM; TOXICITY	The intracellular free Ca2+ concentration and redox status of murine fibroblasts exposed to prefibrillar aggregates of the HypF N-terminal domain have been investigated in vitro and in vivo using a range of fluorescent probes. Aggregate entrance into the cytoplasm is followed by an early rise of reactive oxygen species and free Ca2+ levels and eventually by cell death. Such changes correlate directly with the viability of the cells and are not observed when cell are cultured in the presence of reducing agents or in Ca2+-free media. In addition, moderate cell stress following exposure to the aggregates was found to be fully reversible. The results show that the cytotoxicity of prefibrillar aggregates of HypF-N, a protein not associated with clinical disease, has the same fundamental origin as that produced by similar types of aggregates of proteins linked with specific amyloidoses. These findings suggest that misfolded proteinaceous aggregates stimulate generic cellular responses as a result of the exposure of regions of the structure ( such as hydrophobic residues and the polypeptide main chain) that are buried in the normally folded proteins. They also support the idea that a higher number of degenerative pathologies than previously known might be considered as protein deposition diseases.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Univ Florence, Ctr Excellence Mol & Clin Studies Chron Inflammat, I-50134 Florence, Italy; Univ Florence, Dept Anat Histol & Forens Med, I-50134 Florence, Italy	University of Cambridge; University of Florence; University of Florence; University of Florence	Stefani, M (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	stefani@scibio.unifi.it		bucciantini, monica/0000-0002-5243-9301; STEFANI, MASSIMO/0000-0002-4490-1922; Calloni, Giulia/0000-0002-7216-929X				Abe K, 1996, J NEUROCHEM, V67, P2074; Andersson K, 2002, BIOCHEM BIOPH RES CO, V294, P309, DOI 10.1016/S0006-291X(02)00465-5; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Gillmore JD, 2001, LANCET, V358, P24, DOI 10.1016/S0140-6736(00)05252-1; Gillmore JD, 1997, BRIT J HAEMATOL, V99, P245, DOI 10.1046/j.1365-2141.1997.303194.x; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Hirakura Y, 2001, AMYLOID, V8, P94, DOI 10.3109/13506120109007350; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; KANSKI J, 2001, BIOCHIM BIOPHYS ACTA, V1586, P190; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Keller JN, 2000, NEUROSCIENCE, V98, P149, DOI 10.1016/S0306-4522(00)00067-1; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; Kranenburg O, 2003, FEBS LETT, V539, P149, DOI 10.1016/S0014-5793(03)00218-7; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Mattson MP, 2002, NEUROMOL MED, V2, P215, DOI 10.1385/NMM:2:2:215; Mattson MP, 1999, METHOD ENZYMOL, V309, P733; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PACIFICI M, 1988, J BIOL CHEM, V263, P2483; Relini A, 2004, J MOL BIOL, V338, P943, DOI 10.1016/j.jmb.2004.03.054; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sousa MM, 2001, AM J PATHOL, V159, P1993; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Svanborg C, 2003, ADV CANCER RES, V88, P1; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Turmaine M, 2000, P NATL ACAD SCI USA, V97, P8093, DOI 10.1073/pnas.110078997; Tweten RK, 2001, CURR TOP MICROBIOL, V257, P15; Velez-Pardo C, 2001, J ALZHEIMERS DIS, V3, P409, DOI 10.3233/JAD-2001-3408; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang LM, 2002, P NATL ACAD SCI USA, V99, P15947, DOI 10.1073/pnas.252508399; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; Weatherall DJ, 1995, OXFORD TXB MED, V2, P1512; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905	58	313	323	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31374	31382		10.1074/jbc.M400348200	http://dx.doi.org/10.1074/jbc.M400348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133040	hybrid			2022-12-25	WOS:000222726800058
J	Kaniuk, NA; Vinogradov, E; Li, JJ; Monteiro, MA; Whitfield, C				Kaniuk, NA; Vinogradov, E; Li, JJ; Monteiro, MA; Whitfield, C			Chromosomal and plasmid-encoded enzymes are required for assembly of the R3-type core oligosaccharide in the lipopolysaccharide of Escherichia coli O157 : H7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-SPECIFIC POLYSACCHARIDE; COMPLETE GENOME SEQUENCE; LARGE VIRULENCE PLASMID; COMPLETE DNA-SEQUENCE; RFB GENE-CLUSTER; D-GALACTAN-I; SALMONELLA-ENTERICA; STRUCTURAL-ANALYSIS; OUTER-MEMBRANE; SHIGELLA-FLEXNERI	The type R3 core oligosaccharide predominates in the lipopolysaccharides from enterohemorrhagic Escherichia coli isolates including O157: H7. The R3 core biosynthesis (waa) genetic locus contains two genes, waaD and waaJ, that are predicted to encode glycosyltransferases involved in completion of the outer core. Through determination of the structures of the lipopolysaccharide core in precise mutants and biochemical analyses of enzyme activities, WaaJ was shown to be a UDP-glucose:( galactosyl) lipopolysaccharide alpha-1,2-glucosyltransferase, and WaaD was shown to be a UDP-glucose:( glucosyl) lipopolysaccharide alpha- 1,2-glucosyltransferase. The residue added by WaaJ was identified as the ligation site for O polysaccharide, and this was confirmed by determination of the structure of the linkage region in serotype O157 lipopolysaccharide. The initial O157 repeat unit begins with an N-acetylgalactosamine residue in a beta-anomeric configuration, whereas the biological repeat unit for O157 contains alpha-linked N-acetylgalactosamine residues. With the characterization of WaaJ and WaaD, the activities of all of the enzymes encoded by the R3 waa locus are either known or predicted from homology data with a high level of confidence. However, when core oligosaccharide structure is considered, the origin of an additional alpha-1,3-linked N-acetylglucosamine residue in the outer core is unknown. The gene responsible for a nonstoichiometric alpha-1,7-linked N-acetylglucosamine substituent in the heptose ( inner core) region was identified on the large virulence plasmids of E. coli O157 and Shigella flexneri serotype 2a. This is the first plasmid-encoded core oligosaccharide biosynthesis enzyme reported in E. coli.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of Guelph; National Research Council Canada	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca		Vinogradov, Evgeny/0000-0002-5364-1376				Amor K, 2000, INFECT IMMUN, V68, P1116, DOI 10.1128/IAI.68.3.1116-1124.2000; Amor PA, 1997, MOL MICROBIOL, V26, P145, DOI 10.1046/j.1365-2958.1997.5631930.x; APPELMELK B, 1987, MICROB PATHOGENESIS, V2, P391, DOI 10.1016/0882-4010(87)90080-5; APPELMELK BJ, 1994, MICROBIOL-UK, V140, P1119, DOI 10.1099/13500872-140-5-1119; APPELMELK BJ, 1988, J MED MICROBIOL, V26, P107, DOI 10.1099/00222615-26-2-107; APPELMELK BJ, 1993, J GEN MICROBIOL, V139, P2641, DOI 10.1099/00221287-139-11-2641; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BINOTTO J, 1991, CAN J MICROBIOL, V37, P474, DOI 10.1139/m91-078; Buchrieser C, 2000, MOL MICROBIOL, V38, P760, DOI 10.1046/j.1365-2958.2000.02179.x; Burland V, 1998, NUCLEIC ACIDS RES, V26, P4196, DOI 10.1093/nar/26.18.4196; Chart H, 2002, J MED MICROBIOL, V51, P1050, DOI 10.1099/0022-1317-51-12-1050; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Currie CG, 1999, FEMS IMMUNOL MED MIC, V24, P57, DOI 10.1016/S0928-8244(99)00007-3; Currie CG, 2001, J MED MICROBIOL, V50, P345, DOI 10.1099/0022-1317-50-4-345; Czeczulin JR, 1999, INFECT IMMUN, V67, P2692, DOI 10.1128/IAI.67.6.2692-2699.1999; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; DASGUPTA T, 1994, INFECT IMMUN, V62, P809, DOI 10.1128/IAI.62.3.809-817.1994; DIPADOVA FE, 1993, INFECT IMMUN, V61, P3863, DOI 10.1128/IAI.61.9.3863-3872.1993; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; Frirdich E, 2003, J BACTERIOL, V185, P1659, DOI 10.1128/JB.185.5.1659-1671.2003; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GAMIAN A, 1992, CARBOHYD RES, V236, P195, DOI 10.1016/0008-6215(92)85016-S; GIBB AP, 1992, J INFECT DIS, V166, P1051, DOI 10.1093/infdis/166.5.1051; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; Heinrichs DE, 1998, J BIOL CHEM, V273, P8849, DOI 10.1074/jbc.273.15.8849; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; HOLST O, 1992, BACTERIAL ENDOTOXIC, P136; Hull S., 1997, P145; Inagaki M, 2003, FEMS MICROBIOL LETT, V226, P221, DOI 10.1016/S0378-1097(03)00601-3; Jin Q, 2002, NUCLEIC ACIDS RES, V30, P4432, DOI 10.1093/nar/gkf566; Joiner K A, 1985, Curr Top Microbiol Immunol, V121, P99; KADAM SK, 1985, J BACTERIOL, V161, P277, DOI 10.1128/JB.161.1.277-284.1985; Kaniuk NA, 2002, MOL MICROBIOL, V46, P1305, DOI 10.1046/j.1365-2958.2002.03243.x; Kim SH, 2004, INFECT IMMUN, V72, P1174, DOI 10.1128/IAI.72.2.1174-1180.2004; KJAER M, 1994, METHODS ENZYMOL, V239, P288; MACLACHLAN PR, 1991, J BACTERIOL, V173, P7151, DOI 10.1128/jb.173.22.7151-7163.1991; Makino K, 1998, DNA Res, V5, P1, DOI 10.1093/dnares/5.1.1; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; MENG AM, 1994, BIOTECHNIQUES, V17, P72; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Muller-Loennies S, 2003, J BIOL CHEM, V278, P25618, DOI 10.1074/jbc.M302904200; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P5982, DOI 10.1046/j.1432-1033.2002.03322.x; NAKATA N, 1992, MOL MICROBIOL, V6, P2387, DOI 10.1111/j.1365-2958.1992.tb01413.x; Olsthoorn MA, 2000, EUR J BIOCHEM, V267, P2014, DOI 10.1046/j.1432-1327.2000.01205.x; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; PERRY MB, 1986, BIOCHEM CELL BIOL, V64, P21, DOI 10.1139/o86-004; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT G, 1970, EUR J BIOCHEM, V14, P357, DOI 10.1111/j.1432-1033.1970.tb00297.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; Shibayama K, 1998, J BACTERIOL, V180, P5313, DOI 10.1128/JB.180.20.5313-5318.1998; Thibault P, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P439; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Venkatesan MM, 2001, INFECT IMMUN, V69, P3271, DOI 10.1128/IAI.69.5.3271-3285.2001; Vinogradov E, 2002, CARBOHYD RES, V337, P1285, DOI 10.1016/S0008-6215(02)00160-X; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; Wei J, 2003, INFECT IMMUN, V71, P2775, DOI 10.1128/IAI.71.5.2775-2786.2003; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; XIANG SH, 1994, J BACTERIOL, V176, P4357, DOI 10.1128/jb.176.14.4357-4365.1994; Yethon JA, 2000, J BACTERIOL, V182, P5620, DOI 10.1128/JB.182.19.5620-5623.2000; Yethon JA, 1998, J BIOL CHEM, V273, P26310, DOI 10.1074/jbc.273.41.26310; Yethon JA, 2001, J BIOL CHEM, V276, P5498, DOI 10.1074/jbc.M008255200; Yoon JW, 2004, MOL MICROBIOL, V51, P419, DOI 10.1046/j.1365-2958.2003.03827.x; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	78	28	29	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31237	31250		10.1074/jbc.M401879200	http://dx.doi.org/10.1074/jbc.M401879200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155763	hybrid			2022-12-25	WOS:000222726800043
J	Hu, Y; Riesland, L; Paterson, AJ; Kudlow, JE				Hu, Y; Riesland, L; Paterson, AJ; Kudlow, JE			Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase increases the enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; O-GLCNAC TRANSFERASE; BETA-CELL; GLUCOSAMINE-6-PHOSPHATE SYNTHASE; HEXOSAMINE BIOSYNTHESIS; N-ACETYLGLUCOSAMINE; INSULIN-RESISTANCE; GLUCOSE; APOPTOSIS; GLUTAMINE	A protein encoded by a new gene with approximately 75% homology to glutamine-fructose-6-phosphate amidotransferase (GFAT) was termed GFAT2 on the basis of this similarity. The mouse GFAT2 cDNA was cloned, and the protein was expressed with either an N-terminal glutathione S-transferase or His tag. The purified protein expressed in mammalian cells had GFAT activity. The K-m values for the two substrates of reaction, fructose 6-phosphate and glutamine, were determined to be 0.8 mM for fructose 6-phosphate and 1.2 mM for glutamine, which are within the ranges determined for GFAT1. The protein sequence around the serine 202 of GFAT2 was conserved to the serine 205 of GFAT1, whereas the serine at 235 in GFAT1 was not present in GFAT2. Previously we showed that phosphorylation of serine 205 in GFAT1 by the catalytic subunit of cAMP-dependent protein kinase (PKA) inhibits its activity. Like GFAT1, GFAT2 was phosphorylated by PKA, but GFAT2 activity increased approximately 2.2-fold by this modification. When serine 202 of GFAT2 was mutated to an alanine, the enzyme not only became resistant to phosphorylation, but also the increase in activity in response to PKA also was blocked. These results indicated that the phosphorylation of serine 202 was necessary and sufficient for these alterations by PKA. GFAT2 was modestly inhibited (15%) by UDP-GlcNAc but not through detectable O-glycosylation. GFAT2 is, therefore, an isoenzyme of GFAT1, but its regulation by cAMP is the opposite, allowing differential regulation of the hexosamine pathway in specialized tissues.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.	kudlow@uab.edu						AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Broschat KO, 2002, J BIOL CHEM, V277, P14764, DOI 10.1074/jbc.M201056200; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; Chang Q, 2000, J BIOL CHEM, V275, P21981, DOI 10.1074/jbc.M001049200; Drucker DJ, 2003, ENDOCRINOLOGY, V144, P5145, DOI 10.1210/en.2003-1147; Graack HR, 2001, BIOCHEM J, V360, P401, DOI 10.1042/0264-6021:3600401; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han I, 2000, BIOCHEM J, V350, P109, DOI 10.1042/0264-6021:3500109; Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103; Li YZ, 2003, J BIOL CHEM, V278, P471, DOI 10.1074/jbc.M209423200; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Liu K, 2004, J NEUROCHEM, V89, P1044, DOI 10.1111/j.1471-4159.2004.02389.x; Liu K, 2002, MOL CELL ENDOCRINOL, V194, P135, DOI 10.1016/S0303-7207(02)00155-7; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; Milewski S, 1999, J BIOL CHEM, V274, P4000, DOI 10.1074/jbc.274.7.4000; Milewski S, 2002, BBA-PROTEIN STRUCT M, V1597, P173, DOI 10.1016/S0167-4838(02)00318-7; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Oki T, 1999, GENOMICS, V57, P227, DOI 10.1006/geno.1999.5785; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhou JX, 1998, DIABETES, V47, P1836, DOI 10.2337/diabetes.47.12.1836	31	59	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29988	29993		10.1074/jbc.M401547200	http://dx.doi.org/10.1074/jbc.M401547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133036	hybrid			2022-12-25	WOS:000222531900016
J	Malliri, A; van Es, S; Huveneers, S; Collard, JG				Malliri, A; van Es, S; Huveneers, S; Collard, JG			The Rac exchange factor Tiam1 is required for the establishment and maintenance of cadherin-based adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; EPITHELIAL-CELLS; SMALL GTPASES; NEGATIVE MODULATION; TUMOR PROGRESSION; ADENOVIRUS-5 E1A; DROSOPHILA CTBP; RHO ACTIVITY; MDCK CELLS; C-TERMINUS	Rho family proteins are essential for the formation of adherens junctions, which are required for the maintenance of epithelial integrity. Activated Rac and the Rac exchange factor Tiam1 have been shown to promote the formation of adherens junctions and the accompanying induction of an epithelioid phenotype in a number of cell lines. Here we show that Madin-Darby canine kidney II cells in which Tiam1 was down-regulated using short interfering RNA disassembled their cadherin-based adhesions and acquired a flattened, migratory, and mesenchymal morphology. In addition, the expression of E1A in mesenchymal V12Ras-transformed Madin-Darby canine kidney II cells led simultaneously to the up-regulation of the Tiam1 protein, the activation of Rac, the formation of cadherin-based adhesions, and reversion to an epithelial phenotype. This finding suggests that E1A induces an epithelial morphology through the up-regulation of Tiam1 and, thereby, the activation of Rac and the formation of cadherin-based adhesions. Indeed, we found that E1A is able to induce an epithelial-like morphology accompanied by the formation of cadherin-based adhesions only in wild-type but not in Tiam1-deficient primary mouse embryonic fibroblasts. These studies indicate that the Rac activator Tiam1 is essential for the formation as well as the maintenance of cadherin-based adhesions.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.collard@nki.nl		Huveneers, Stephan/0000-0002-1091-475X; Malliri, Angeliki/0000-0001-6848-090X				BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Drews R, 1998, MUTAT RES-FUND MOL M, V421, P9, DOI 10.1016/S0027-5107(98)00149-3; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; HABETS GGM, 1995, CYTOGENET CELL GENET, V70, P48, DOI 10.1159/000133989; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Mymryk JS, 1996, ONCOGENE, V13, P1581; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	35	104	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30092	30098		10.1074/jbc.M401192200	http://dx.doi.org/10.1074/jbc.M401192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138270	hybrid			2022-12-25	WOS:000222531900029
J	Sanokawa-Akakura, R; Dai, HC; Akakura, S; Weinstein, D; Fajardo, JE; Lang, SE; Wadsworth, S; Siekierka, J; Birge, RB				Sanokawa-Akakura, R; Dai, HC; Akakura, S; Weinstein, D; Fajardo, JE; Lang, SE; Wadsworth, S; Siekierka, J; Birge, RB			A novel role for the immunophilin FKBP52 in copper transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; PROGESTERONE-RECEPTOR; ISOMERASE ACTIVITY; TERMINAL DOMAIN; PROTEIN; FK506; EXPRESSION; GENE; REGENERATION; HOMEOSTASIS	FK506-binding protein 52 (FKBP52) is an immunophilin that possesses peptidylprolyl cis/trans-isomerase (PPIase) activity and is a component of a subclass of steroid hormone receptor complexes. Several recent studies indicate that immunophilins can regulate neuronal survival and nerve regeneration although the molecular mechanisms are poorly understood. To investigate the function of FKBP52 in the nervous system, we employed a yeast two-hybrid strategy using the PPIase domain ( domain I) as bait to screen a neonatal rat dorsal root ganglia cDNA expression library. We identified an interaction between FKBP52 domain I and Atox1, a copper-binding metallochaperone. Atox1 interacts with Menkes disease protein and Wilson disease protein (WD) and functions in copper efflux. The interaction between FKBP52 and Atox1 was observed in both glutathione S-transferase pull-down experiments and when proteins were ectopically expressed in human embryonic kidney (HEK) 293T cells and was sensitive to FK506. Interestingly, the FKBP52/Atox1 interaction was enhanced when HEK 293T cells were cultured in copper-supplemented medium and decreased in the presence of the copper chelator, bathocuproine disulfate, suggesting that the interaction is regulated in part by intracellular copper. Overexpression of FKBP52 increased rapid copper efflux in Cu-64-loaded cells, as did the overexpression of WD transporter. Taken together, our present findings suggest that FKBP52 is a component of the copper efflux machinery, and in so, may also promote neuroprotection from copper toxicity.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; GliaMed Inc, New York, NY 10032 USA; Rockefeller Univ, New York, NY 10021 USA; Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ 08869 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rockefeller University; Johnson & Johnson; Johnson & Johnson USA	Birge, RB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu			NCI NIH HHS [R24 CA 86307] Funding Source: Medline; NIGMS NIH HHS [GM 55760] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Birge RB, 2004, NEUROSCIENCE, V124, P351, DOI 10.1016/j.neuroscience.2003.10.013; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Goel M, 2001, J BIOL CHEM, V276, P38762, DOI 10.1074/jbc.M104125200; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; GOLD BG, 1994, NEUROSCI LETT, V176, P123, DOI 10.1016/0304-3940(94)90886-9; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; Hamza I, 2003, P NATL ACAD SCI USA, V100, P1215, DOI 10.1073/pnas.0336230100; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Li PY, 2003, ACTA CRYSTALLOGR D, V59, P16, DOI 10.1107/S0907444902017523; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Marks PW, 1998, J CELL SCI, V111, P2129; Muller T, 1999, Eur J Med Res, V4, P293; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Qing KY, 2001, J VIROL, V75, P8968, DOI 10.1128/JVI.75.19.8968-8976.2001; Railson JE, 2001, J MOL CELL CARDIOL, V33, P1209, DOI 10.1006/jmcc.2001.1384; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SMITH DF, 1993, J BIOL CHEM, V268, P18365; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; Tapiero H, 2003, BIOMED PHARMACOTHER, V57, P386, DOI 10.1016/S0753-3322(03)00012-X; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; Udina E, 2003, EXP NEUROL, V183, P220, DOI 10.1016/S0014-4886(03)00173-0; Wu BL, 2003, ACTA CRYSTALLOGR D, V59, P2269, DOI 10.1107/S090744490301970X	32	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					27845	27848		10.1074/jbc.C400118200	http://dx.doi.org/10.1074/jbc.C400118200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15133031	hybrid			2022-12-25	WOS:000222265400004
J	Campbell, SE; Tandon, NN; Woldegiorgis, G; Luiken, JJFP; Glatz, JFC; Bonen, A				Campbell, SE; Tandon, NN; Woldegiorgis, G; Luiken, JJFP; Glatz, JFC; Bonen, A			A novel function for fatty acid translocase (FAT)/CD36 - Involvement in long chain fatty acid transfer into the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MITOCHONDRIA; CONTRACTILE ACTIVITY; MALONYL-COA; CELL-FREE; CPT-I; OXIDATION; PROTEIN; INTERMYOFIBRILLAR; TRANSPORT; RAT	Fatty acid translocase (FAT)/CD36 is a long chain fatty acid transporter present at the plasma membrane, as well as in intracellular pools of skeletal muscle. In this study, we assessed the unexpected presence of FAT/CD36 in both subsarcolemmal and intermyofibril fractions of highly purified mitochondria. Functional assessments demonstrated that the mitochondria could bind C-14-labeled palmitate, but could only oxidize it in the presence of carnitine. However, the addition of sulfo-N-succinimidyl oleate, a known inhibitor of FAT/CD36, resulted in an 87 and 85% reduction of palmitate oxidation in subsarcolemmal and intermyofibril fractions, respectively. Further studies revealed that maximal carnitine palmitoyltransferase I (CPTI) activity in vitro was inhibited by succinimidyl oleate (42 and 48% reduction). Interestingly, CPTI immunoprecipitated with FAT/CD36, indicating a physical pairing. Tissue differences in mitochondrial FAT/CD36 protein follow the same pattern as the capacity for fatty acid oxidation (heart >> red muscle > white muscle). Additionally, chronic stimulation of hindlimb muscles (7 days) increased FAT/CD36 expression and also resulted in a concomitant increase in mitochondrial FAT/CD36 content (46 and 47% increase). Interestingly, with acute electrical stimulation of hindlimb muscles (30 min), FAT/CD36 expression was not altered, but there was an increase in the mitochondrial content of FAT/CD36 compared with the non-stimulated control limb (35 and 37% increase). Together, these data suggest a role for FAT/CD36 in mitochondrial long chain fatty acid uptake and demonstrate system flexibility to match FAT/CD36 mitochondrial content with an increased capacity for fatty acid oxidation, possibly involving translocation of FAT/CD36 to the mitochondria.	Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada; Otsuka Amer Pharmaceut Inc, Thrombosis & Vasc Biol Lab, Rockville, MD 20850 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Maastricht Univ, Dept Mol Genet, NL-6200 MD Maastricht, Netherlands	University of Guelph; Maastricht University	Bonen, A (corresponding author), Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada.	abonen@uoguelph.ca						Bezaire V, 2004, AM J PHYSIOL-ENDOC M, V286, pE85, DOI 10.1152/ajpendo.00237.2003; BONAS B, 2003, AM J PHYSIOL, V285, pE481; Bonen A, 2000, J BIOL CHEM, V275, P14501, DOI 10.1074/jbc.275.19.14501; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Chilibeck PD, 2002, INT J SPORTS MED, V23, P33, DOI 10.1055/s-2002-19269; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; Connor MK, 2000, J APPL PHYSIOL, V88, P1601, DOI 10.1152/jappl.2000.88.5.1601; Coort SLM, 2002, MOL CELL BIOCHEM, V239, P213, DOI 10.1023/A:1020539932353; Coyle EF, 1997, AM J PHYSIOL-ENDOC M, V273, pE268, DOI 10.1152/ajpendo.1997.273.2.E268; Dean D, 2000, DIABETES, V49, P1295, DOI 10.2337/diabetes.49.8.1295; Eaton S, 2001, BIOCHEM BIOPH RES CO, V285, P537, DOI 10.1006/bbrc.2001.5201; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Febbraio M, 2002, MOL CELL BIOCHEM, V239, P193, DOI 10.1023/A:1020515210972; Glatz JFC, 2002, CURR OPIN CLIN NUTR, V5, P365, DOI 10.1097/00075197-200207000-00003; GLATZ JFC, 1984, BIOCHIM BIOPHYS ACTA, V794, P454, DOI 10.1016/0005-2760(84)90012-2; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hoppel C, 2001, ARCH BIOCHEM BIOPHYS, V392, P321, DOI 10.1006/abbi.2001.2463; Jimenez M, 2002, EUR J BIOCHEM, V269, P2878, DOI 10.1046/j.1432-1033.2002.02953.x; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Luiken JJFP, 1999, LIPIDS, V34, pS169, DOI 10.1007/BF02562278; Luiken JJFP, 2002, AM J PHYSIOL-ENDOC M, V282, pE491, DOI 10.1152/ajpendo.00419.2001; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; Odland LM, 1996, AM J PHYSIOL-ENDOC M, V270, pE541, DOI 10.1152/ajpendo.1996.270.3.E541; Odland LM, 1998, AM J PHYSIOL-REG I, V274, pR894, DOI 10.1152/ajpregu.1998.274.4.R894; Schleiff E, 1999, J CELL BIOL, V145, P973, DOI 10.1083/jcb.145.5.973; Sidossis LS, 1996, AM J PHYSIOL-ENDOC M, V270, pE733, DOI 10.1152/ajpendo.1996.270.4.E733; Spriet LL, 2002, MED SCI SPORT EXER, V34, P1477, DOI 10.1097/00005768-200209000-00013; Starritt EC, 2000, AM J PHYSIOL-ENDOC M, V278, pE462, DOI 10.1152/ajpendo.2000.278.3.E462; Takahashi M, 1996, J BIOL CHEM, V271, P27285, DOI 10.1074/jbc.271.44.27285; TANAKA T, 1995, J MOL CELL CARDIOL, V27, P1613, DOI 10.1016/S0022-2828(95)90557-X; VEERKAMP JH, 1983, BIOCHIM BIOPHYS ACTA, V753, P399, DOI 10.1016/0005-2760(83)90064-4; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	38	202	212	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36235	36241		10.1074/jbc.M400566200	http://dx.doi.org/10.1074/jbc.M400566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15161924	hybrid			2022-12-25	WOS:000223453600011
J	Yoo, YG; Lee, MO				Yoo, YG; Lee, MO			Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UP-REGULATION; TRANSACTIVATOR PROTEIN; NUCLEAR-FACTOR; T-LYMPHOCYTES; ACTIVATION; PROMOTER; CELLS; MECHANISM; APOPTOSIS; SITES	FasL expressed in tumor cells plays an important role in the escape from immune surveillance by inducing apoptosis in T-cells bearing Fas. Since the Fas/FasL signaling pathway requires transcriptional induction of the FasL gene, elucidation of the precise mechanisms underlying regulation of FasL gene expression may provide useful molecular insights on tumor progression. We and others (Shin, E. C., Shin, J. S., Park, J. H., Kim, H., and Kim, S. J. (1999) Int. J. Cancer 82, 587-591; Lee, M. O., Kang, H. J., Cho, H., Shin, E. C., Park, J. H., and Kim, S. J. (2001) Biochem. Biophys. Res. Commun. 288, 1162-1168) have previously reported that hepatitis B virus X protein (HBx) plays a role in the induction of FasL expression in hepatitis B virus-associated hepatoma. In the present study, we analyzed the potential cis- and trans-acting factors that regulate FasL promoter. We found that HBx induced activity of the reporter containing FasL promoter through binding site for Egr but not through NFAT or SP-1, which are known as strong activators of the FasL promoter in T-cells. Transient expression of antisense Egr-2 and antisense Egr-3 abolished expression of FasL, which further confirmed the role of Egr in the HBx-mediated FasL expression. Also we observed that HBx increased the transcriptional activity of Egr-2 and Egr-3 by enhancing expression as well as the transactivation function of these proteins. HBx interacted with Egr-2 and Egr-3 in vivo and enhanced binding of Egr to the co-activator, cAMP-response element-binding protein-binding protein, which may explain the molecular mechanism by which HBx induced the transactivation function of Egr. Finally, we found that the carboxyl terminus of HBx was necessary and sufficient for FasL induction as well as activation of Egr. Taken together, our results show a novel mechanism by which HBx induces FasL gene expression that is mediated by enhancing transcriptional activity of Egr-2 and Egr-3.	Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea	Sejong University	Lee, MO (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, Seoul 143747, South Korea.	molee@sejong.ac.kr						Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Carretero M, 2002, VIROLOGY, V299, P288, DOI 10.1006/viro.2002.1526; Chan HM, 2001, J CELL SCI, V114, P2363; Chiou SH, 2001, J IMMUNOL, V167, P4098, DOI 10.4049/jimmunol.167.7.4098; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; Gottlob K, 1998, CANCER RES, V58, P3566; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; Kong HJ, 2003, HEPATOLOGY, V38, P1258, DOI 10.1053/jhep.2003.50451; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lee MO, 2002, J HEPATOL, V37, P380, DOI 10.1016/S0168-8278(02)00181-2; Lee MO, 2002, EUR J BIOCHEM, V269, P1162, DOI 10.1046/j.1432-1033.2002.02748.x; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Mages HW, 1998, MOL CELL BIOL, V18, P7157, DOI 10.1128/MCB.18.12.7157; Matsui K, 1998, J IMMUNOL, V161, P3469; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; O'Connell J, 1998, J PATHOL, V186, P240; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Ruggieri A, 2003, VIRUS RES, V97, P103, DOI 10.1016/j.virusres.2003.08.004; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shin EC, 1999, INT J CANCER, V82, P587, DOI 10.1002/(SICI)1097-0215(19990812)82:4<587::AID-IJC19>3.0.CO;2-9; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Yang YL, 2002, J BIOL CHEM, V277, P19482, DOI 10.1074/jbc.M201687200; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896; Zauli G, 1999, BLOOD, V93, P1000, DOI 10.1182/blood.V93.3.1000.403a12_1000_1010	50	41	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36242	36249		10.1074/jbc.M401290200	http://dx.doi.org/10.1074/jbc.M401290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15173177	hybrid, Green Submitted			2022-12-25	WOS:000223453600012
J	Deng, L; Markova, SV; Vysotski, ES; Liu, ZJ; Lee, J; Rose, J; Wang, BC				Deng, L; Markova, SV; Vysotski, ES; Liu, ZJ; Lee, J; Rose, J; Wang, BC			Crystal structure of a Ca2+-discharged photoprotein - Implications for mechanisms of the calcium trigger and bioluminescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIOLET BIOLUMINESCENCE; W92F OBELIN; AEQUORIN; LIGHT; SEQUENCE; LUMINESCENCE; EVOLUTION; EMISSION; PROTEINS; CLONING	Ca2+-regulated photoproteins are members of the EF-hand calcium-binding protein family. The addition of Ca2+ produces a blue bioluminescence by triggering a decarboxylation reaction of protein-bound hydroperoxycoelenterazine to form the product, coelenteramide, in an excited state. Based on the spatial structures of aequorin and several obelins, we have postulated mechanisms for the Ca2+ trigger and for generation of the different excited states that are the origin of the different colors of bioluminescence. Here we report the crystal structure of the Ca2+-discharged photoprotein obelin at 1.96-Angstrom resolution. The results lend support to the proposed mechanisms and provide new structural insight into details of these processes. Global conformational changes caused by Ca2+ association are typical of the class of calcium signal modulators within the EF-hand protein superfamily. Accommodation of the Ca2+ ions into the loops of the EF-hands is seen to propagate into the active site of the protein now occupied by the coelenteramide where there is a significant repositioning and flipping of the His-175 imidazole ring as crucially required in the trigger hypothesis. Also the H-bonding between His-22 and the coelenterazine found in the active photoprotein is preserved at the equivalent position of coelenteramide, confirming the proposed rapid excited state proton transfer that would lead to the excited state of the phenolate ion pair, which is responsible for the blue emission of bioluminescence.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Russian Acad Sci, Inst Biophys, Siberian Branch, Krasnoyarsk 660036, Russia	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Russian Academy of Sciences; Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Sciences; Biophysics Institute, Siberian Branch, Russian Academy of Sciences	Lee, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	jlee@uga.edu	Liu, Zhi-Jie/A-3946-2012; Deng, Lu/AAE-1635-2021; Vysotski, Eugene/I-1761-2013; Markova, Svetlana V./AAT-7574-2020	Liu, Zhi-Jie/0000-0001-7279-2893; Vysotski, Eugene/0000-0002-5884-3081; Markova, Svetlana V./0000-0001-5702-1193				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BREHM P, 1989, NEURON, V3, P191, DOI 10.1016/0896-6273(89)90032-9; CHARBONNEAU H, 1985, BIOCHEMISTRY-US, V24, P6762, DOI 10.1021/bi00345a006; Deng L, 2004, ACTA CRYSTALLOGR D, V60, P512, DOI 10.1107/S090744490302852X; Deng L, 2001, FEBS LETT, V506, P281, DOI 10.1016/S0014-5793(01)02937-4; Head JF, 2000, NATURE, V405, P372, DOI 10.1038/35012659; ILLARIONOV BA, 1995, GENE, V153, P273, DOI 10.1016/0378-1119(94)00797-V; Imai Y, 2001, J PHOTOCH PHOTOBIO A, V146, P95, DOI 10.1016/S1010-6030(01)00554-8; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; Jeffery G.A., 1997, INTRO HYDROGEN BONDI; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J., 2001, BIOLUMINESCENCE CHEM, P99; Liu ZJ, 2003, BIOCHEM BIOPH RES CO, V311, P433, DOI 10.1016/j.bbrc.2003.09.231; Liu ZJ, 2000, PROTEIN SCI, V9, P2085, DOI 10.1110/ps.9.11.2085; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Malikova NP, 2003, FEBS LETT, V554, P184, DOI 10.1016/S0014-5793(03)01166-9; Markova SV, 2002, BIOCHEMISTRY-US, V41, P2227, DOI 10.1021/bi0117910; MCCAPRA F, 1967, CHEM COMMUN, P1011, DOI 10.1039/c19670001011; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; Morin J.G., 1974, pUnpaginated; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; OHMIYA Y, 1993, FEBS LETT, V320, P267, DOI 10.1016/0014-5793(93)80600-Y; Ohmiya Y, 1996, CHEM BIOL, V3, P337, DOI 10.1016/S1074-5521(96)90116-7; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405; Shimomura O, 2000, LUMINESCENCE, V15, P51, DOI 10.1002/(SICI)1522-7243(200001/02)15:1<51::AID-BIO555>3.0.CO;2-J; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Vysotski ES, 2003, BIOCHEMISTRY-US, V42, P6013, DOI 10.1021/bi027258h	31	49	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33647	33652		10.1074/jbc.M402427200	http://dx.doi.org/10.1074/jbc.M402427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155735	hybrid			2022-12-25	WOS:000223039700074
J	Grant, MA; Hansson, K; Furie, BC; Furie, B; Stenflo, J; Rigby, AC				Grant, MA; Hansson, K; Furie, BC; Furie, B; Stenflo, J; Rigby, AC			The metal-free and calcium-bound structures of a gamma-carboxyglutamic acid-containing contryphan from Conus marmoreus, glacontryphan-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; NMR CHEMICAL-SHIFTS; BLOOD-COAGULATION; CONANTOKIN-T; FACTOR-IX; PROTEIN-STRUCTURE; MEMBRANE-BINDING; MOLECULAR-BASIS; D-TRYPTOPHAN; AMINO-ACIDS	Glacontryphan-M, a novel calcium-dependent inhibitor of L-type voltage-gated Ca2+ channels expressed in mouse pancreatic beta-cells, was recently isolated from the venom of the cone snail Conus marmoreus (Hansson, K., Ma, X., Eliasson, L., Czerwiec, E., Furie, B., Furie, B. C., Rorsman, P., and Stenflo, J. ( 2004) J. Biol. Chem. 278, 32453-32463). The conserved disulfide-bonded loop of the contryphan family of conotoxins including a D-Trp is present; however, unique to glacontryphan-M is a histidine within the intercysteine-loop and two gamma-carboxy-glutamic acid (Gla) residues, formed by post-translational modification of glutamic acid. The two calcium-binding Gla residues are located in a four residue N-terminal extension of this contryphan. To better understand the structural and functional significance of these residues, we have determined the structure of glacontryphan-M using two-dimensional H-1 NMR spectroscopy in the absence and presence of calcium. Comparisons of the glacontryphan-M structures reveal that calcium binding induces structural perturbations within the Gla-containing N terminus and the Cys(11)-Cys(5)-Pro(6) region of the intercysteine loop. The backbone of N-terminal residues perturbed by calcium, Gla(2) and Ser(3), moves away from the His(8) and Trp(10) aromatic rings and the alignment of the D-Trp(7) and His(8) aromatic rings with respect to the Trp(10) rings is altered. The blockage of L-type voltage-gated Ca2+ channel currents by glacontryphan-M requires calcium binding to N-terminal Gla residues, where presumably histidine and tryptophan may be accessible for interaction with the channel. The backbone Calpha conformation of the intercysteine loop of calcium-bound glacontryphan-M superimposes on known structures of contryphan-R and Vn (0.83 and 0.66 Angstrom, respectively). Taken together these data identify that glacontryphan-M possesses the canonical contryphan intercysteine loop structure, yet possesses critical determinants necessary for a calcium-induced functionally required conformation.	Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Lund Univ, Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Marine Biol Lab, Woods Hole, MA 02543 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Lund University; Skane University Hospital; Marine Biological Laboratory - Woods Hole	Rigby, AC (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Hemostasis Thrombosis & Vasc Biol, 330 Brookline Ave, Boston, MA 02215 USA.	arigby@bidmc.harvard.edu						BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Blandl T, 1999, J PEPT RES, V53, P453, DOI 10.1034/j.1399-3011.1999.00042.x; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; Espiritu DJD, 2001, TOXICON, V39, P1899, DOI 10.1016/S0041-0101(01)00175-1; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAACK JA, 1990, J BIOL CHEM, V265, P6025; Hansson K, 2004, J BIOL CHEM, V279, P32453, DOI 10.1074/jbc.M313825200; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; Huang MD, 2004, J BIOL CHEM, V279, P14338, DOI 10.1074/jbc.M314011200; Huang MD, 2003, NAT STRUCT BIOL, V10, P751, DOI 10.1038/nsb971; Jacobsen RB, 1999, J PEPT RES, V54, P93, DOI 10.1034/j.1399-3011.1999.00093.x; Jimenez EC, 1997, BIOCHEMISTRY-US, V36, P989, DOI 10.1021/bi962840p; Jimenez EC, 1996, J BIOL CHEM, V271, P28002, DOI 10.1074/jbc.271.45.28002; Jimenez EC, 2001, TOXICON, V39, P803, DOI 10.1016/S0041-0101(00)00210-5; Kreil G, 1997, ANNU REV BIOCHEM, V66, P337, DOI 10.1146/annurev.biochem.66.1.337; Massilia GR, 2003, BIOCHEM BIOPH RES CO, V303, P238, DOI 10.1016/S0006-291X(03)00331-0; Massilia GR, 2001, BIOCHEM BIOPH RES CO, V288, P908, DOI 10.1006/bbrc.2001.5833; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; Nakamura T, 1996, PROTEIN SCI, V5, P524; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAIN R, 1996, PROTOCOLS PROTEIN SC; Pallaghy PK, 1999, BIOCHEMISTRY-US, V38, P11553, DOI 10.1021/bi990685j; Pallaghy PK, 2000, BIOPOLYMERS, V54, P173, DOI 10.1002/1097-0282(200009)54:3<173::AID-BIP30>3.3.CO;2-1; Pallaghy PK, 2000, BIOCHEMISTRY-US, V39, P12845, DOI 10.1021/bi0010930; PASTORE A, 1990, J MAGN RESON, V90, P165, DOI 10.1016/0022-2364(90)90375-J; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARZ R, 1978, BIOPOLYMERS, V17, P2133, DOI 10.1002/bip.1978.360170908; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; STENFLO J, 2001, MOL BASIS BLOOD DIS, P579; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Woody RW, 1996, CIRCULAR DICHROISM C, P109; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130	39	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32464	32473		10.1074/jbc.M313826200	http://dx.doi.org/10.1074/jbc.M313826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155731	Green Published, hybrid			2022-12-25	WOS:000222849700060
J	Lundequist, A; Tchougounova, E; Abrink, M; Pejler, G				Lundequist, A; Tchougounova, E; Abrink, M; Pejler, G			Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN; TISSUE; GENERATION; EXPRESSION; ENZYME; MICE	The octapeptide angiotensin II (Ang II) exerts a wide range of effects on the cardiovascular system but has also been implicated in the regulation of cell proliferation, fibrosis, and apoptosis. Ang II is formed by cleavage of Ang I by angiotensin-converting enzyme, but there is also evidence for non-angiotensin-converting enzyme-dependent conversion of Ang I to Ang II. Here we address the role of mast cell proteases in Ang II production by using two different mouse strains lacking mast cell heparin or mouse mast cell protease 4 (mMCP-4), the chymase that may be the functional homologue to human chymase. Ang I was added to ex vivo cultures of peritoneal cells, and the generation of Ang II and other metabolites was analyzed. Activation of mast cells resulted in marked increases in both the formation and subsequent degradation of Ang II, and both of these processes were strongly reduced in heparin-deficient peritoneal cells. In the mMCP-4(-/-) cell cultures no reduction in the rate of Ang II generation was seen, but the formation of Ang-(5-10) was completely abrogated. Addition of a carboxypeptidase A (CPA) inhibitor to wild type cells caused complete inhibition of the formation of Ang-(1-9) and Ang-(1-7) but did not inhibit Ang II formation. However, when the CPA inhibitor was added to them MCP-4(-/-) cultures, essentially complete inhibition of Ang II formation was obtained. Taken together, the results of this study indicate that mast cell chymase and CPA have key roles in both the generation and degradation of Ang II.	Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biosci, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Pejler, G (corresponding author), Swedish Univ Agr Sci, Biomed Ctr, Dept Mol Biosci, Box 575, S-75123 Uppsala, Sweden.	Gunnar.Pejler@bmc.uu.se	Åbrink, Magnus/AAK-8346-2020	Abrink, Magnus/0000-0002-1335-3927				Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Caughey GH, 2002, MOL IMMUNOL, V38, P1353, DOI 10.1016/S0161-5890(02)00087-1; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; Dell'Italia LJ, 2002, CURR OPIN CARDIOL, V17, P374, DOI 10.1097/00001573-200207000-00009; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Kim S, 2000, PHARMACOL REV, V52, P11; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Ruiz-Ortega M, 2001, HYPERTENSION, V38, P1382, DOI 10.1161/hy1201.100589; Saito K, 2003, BIOCHEM BIOPH RES CO, V302, P773, DOI 10.1016/S0006-291X(03)00263-8; Santos RAS, 2000, REGUL PEPTIDES, V91, P45, DOI 10.1016/S0167-0115(00)00138-5; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SNYDER RA, 1986, BIOCHIM BIOPHYS ACTA, V871, P1, DOI 10.1016/0167-4838(86)90125-1; Tchougounova E, 2003, J EXP MED, V198, P423, DOI 10.1084/jem.20030671; Tchougounova E, 2001, FASEB J, V15, P2763, DOI 10.1096/fj.01-0486fje; Wei CC, 2002, AM J PHYSIOL-HEART C, V282, pH2254, DOI 10.1152/ajpheart.00191.2001	19	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32339	32344		10.1074/jbc.M405576200	http://dx.doi.org/10.1074/jbc.M405576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173164	hybrid			2022-12-25	WOS:000222849700045
J	Meek, SEM; Lane, WS; Piwnica-Worms, H				Meek, SEM; Lane, WS; Piwnica-Worms, H			Comprehensive proteomic analysis of interphase and mitotic 14-3-3-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC25C; DNA-DAMAGE; NUCLEAR EXPORT; BINDING; CHECKPOINT; KINASE; PHOSPHORYLATION; LOCALIZATION; ASSOCIATION; TSC2	14-3-3 proteins regulate the cell division cycle and play a pivotal role in blocking cell cycle advancement after activation of the DNA replication and DNA damage checkpoints. Here we describe a global proteomics analysis to identify proteins that bind to 14-3-3s during interphase and mitosis. 14-3-3-binding proteins were purified from extracts of interphase and mitotic HeLa cells using specific peptide elution from 14-3-3zeta affinity columns. Proteins that specifically bound and eluted from the affinity columns were identified by microcapillary high pressure liquid chromatography tandem mass spectrometry analysis. Several known and novel 14-3-3-interacting proteins were identified in this screen. Identified proteins are involved in cell cycle regulation, signaling, metabolism, protein synthesis, nucleic acid binding, chromatin structure, protein folding, proteolysis, nucleolar function, and nuclear transport as well as several other cellular processes. In some cases 14-3-3 binding was cell cycle-dependent, whereas in other cases the binding was shown to be cell cycle-independent. This study adds to the growing list of human 14-3-3-binding proteins and implicates a role for 14-3-3 proteins in a plethora of essential biological processes.	Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Washington University (WUSTL); Washington University (WUSTL)	Piwnica-Worms, H (corresponding author), Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.	hpiwnica@cellbiology.wustl.edu	Piwnica-Worms, Helen/C-5214-2012					AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Catalano CM, 2004, ELECTROPHORESIS, V25, P519, DOI 10.1002/elps.200305711; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cohen D, 2003, METHODS, V30, P269, DOI 10.1016/S1046-2023(03)00033-1; Cotelle V, 2000, EMBO J, V19, P2869, DOI 10.1093/emboj/19.12.2869; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Itagaki C, 1999, BIOCHEMISTRY-US, V38, P15673, DOI 10.1021/bi9914255; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; KASTAN MB, 1991, CANCER RES, V51, P6304; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu HT, 1999, CANCER LETT, V144, P45, DOI 10.1016/S0304-3835(99)00184-6; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Moorhead G, 1999, PLANT J, V18, P1, DOI 10.1046/j.1365-313X.1999.00417.x; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Siles-Lucas MD, 2003, TRENDS PARASITOL, V19, P575, DOI 10.1016/j.pt.2003.10.003; Stavridi ES, 2001, CANCER RES, V61, P7030; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Hemert MJ, 2004, J CELL SCI, V117, P1411, DOI 10.1242/jcs.00990; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	51	168	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32046	32054		10.1074/jbc.M403044200	http://dx.doi.org/10.1074/jbc.M403044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161933	hybrid			2022-12-25	WOS:000222849700008
J	Gauthier, BR; Brun, T; Sarret, EJ; Ishihara, H; Schaad, O; Descombes, P; Wollheim, CB				Gauthier, BR; Brun, T; Sarret, EJ; Ishihara, H; Schaad, O; Descombes, P; Wollheim, CB			Oligonucleotide microarray analysis reveals PDX1 as an essential regulator of mitochondrial metabolism in rat islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; STIMULATED INSULIN-SECRETION; TYPE-2 DIABETES-MELLITUS; FACTOR-I GENE; TRANSCRIPTION FACTOR; PROMOTER FACTOR-1; UBIQUINONE OXIDOREDUCTASE; TRANSGENIC MICE; COMPLEX-I; EXPRESSION	Mutations in the transcription factor IPF1/PDX1 have been associated with type 2 diabetes. To elucidate beta-cell dysfunction, PDX1 was suppressed by transduction of rat islets with an adenoviral construct encoding a dominant negative form of PDX1. After 2 days, there was a marked inhibition of insulin secretion in response to glucose, leucine, and arginine. Increasing cAMP levels with forskolin and isobutylmethylxanthine restored glucose-stimulated insulin secretion, indicating normal capacity for exocytosis. To identify molecular targets implicated in the altered metabolism secretion coupling, DNA microarray analysis was performed on PDX1-deficient and control islets. Of the 2640 detected transcripts, 70 were up-regulated and 56 were down-regulated. Transcripts were subdivided into 12 clusters; the most prevalent were associated with metabolism. Quantitative reverse transcriptase-CR confirmed increases in succinate dehydrogenase and ATP synthase mRNAs as well as pyruvate carboxylase and the transcript for the malate shuttle. In parallel there was a 50% reduction in mRNA levels for the mitochondrially encoded nd1 gene, a subunit of the NADH dehydrogenase comprising complex I of the mitochondrial respiratory chain. As a consequence, total cellular ATP concentration was drastically decreased by 75%, and glucose failed to augment cytosolic ATP, explaining the blunted glucose-stimulated insulin secretion. Rotenone, an inhibitor of complex I, mimicked this effect. Surprisingly, TFAM, a nuclear-encoded transcription factor important for sustaining expression of mitochondrial genes, was down-regulated in islets expressing DN79PDX1. In conclusion, loss of PDX1 function alters expression of mitochondrially encoded genes through regulation of TFAM leading to impaired insulin secretion.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; Univ Geneva, Natl Ctr Competence Res Frontiers Genet, CH-1211 Geneva 4, Switzerland; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet, Sendai, Miyagi 980, Japan	University of Geneva; University of Geneva; Tohoku University	Gauthier, BR (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	benoit.gauthier@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; BRUN, Thierry/0000-0002-1659-4283				Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; BROWN MD, 1992, GENETICS, V130, P163; Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Collins CL, 1998, BIOTECHNIQUES, V24, P803, DOI 10.2144/98245st04; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Forman HJ, 2003, BIOFACTORS, V17, P1, DOI 10.1002/biof.5520170101; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2002, MOL ENDOCRINOL, V16, P170, DOI 10.1210/me.16.1.170; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Hart AW, 2000, NATURE, V408, P864, DOI 10.1038/35048589; Hattori Y, 2003, DIABETES CARE, V26, P952, DOI 10.2337/diacare.26.3.952; Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lottmann H, 2001, J MOL MED-JMM, V79, P321, DOI 10.1007/s001090100229; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Odawara M, 1999, J MED GENET, V36, P934; Offield MF, 1996, DEVELOPMENT, V122, P983; OHTA M, 1990, J BIOL CHEM, V265, P17525; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schwitzgebel VM, 2003, J CLIN ENDOCR METAB, V88, P4398, DOI 10.1210/jc.2003-030046; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Smith PA, 1997, J PHYSIOL-LONDON, V499, P625, DOI 10.1113/jphysiol.1997.sp021955; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Thomas MK, 2001, J CLIN INVEST, V108, P319, DOI 10.1172/JCI200112029; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044	54	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31121	31130		10.1074/jbc.M405030200	http://dx.doi.org/10.1074/jbc.M405030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151993	hybrid			2022-12-25	WOS:000222726800028
J	Heiz, M; Grunberg, J; Schubiger, PA; Novak-Hofer, I				Heiz, M; Grunberg, J; Schubiger, PA; Novak-Hofer, I			Hepatocyte growth factor-induced ectodomain shedding of cell adhesion molecule L1 - Role of the L1 cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CARCINOMA CELLS; PROSTATE-CANCER; ANKYRIN-BINDING; FACTOR RECEPTOR; EXPRESSION; TYROSINE; SERUM; PHOSPHORYLATION; NEUROBLASTOMA; KINASE	The L1 cell adhesion molecule and its soluble form are tumor-associated proteins and potential markers for tumor staging as well as targets for therapeutic intervention. Soluble L1 is produced by metalloprotease-mediated ectodomain shedding of L1. We investigated effects of hepatocyte growth factor (HGF), a growth factor shown to increase invasiveness of renal carcinoma cells, on ectodomain shedding of L1 from these cells. All of the tested L1-positive renal carcinoma cell lines released a 180-kDa form of L1 into the medium. In the presence of serum, addition of HGF led to a dose-dependent increase in L1 shedding with a maximum reached at 5 ng/ml. In contrast, L1 shedding was inhibited by glial cell line-derived neurotrophic factor ( GDNF). The tyrosine kinase inhibitor Genistein reduced basal and HGF-stimulated L1 shedding, indicating that protein phosphorylation is involved. To investigate the role of the L1 intracellular domain, two mutants of the L1 cytoplasmic part were constructed. L1trun lacking the complete intracellular domain showed enhanced basal shedding. In a L1YH mutant, containing the mutation tyrosine 1229 to histidine that deletes the ankyrin binding motif of L1, basal shedding was reduced. Disruption of actin assembly by cytochalasin D also reduced shedding of L1. These results indicate that the cytoplasmic domain regulates basal shedding of L1, and association with the cytoskeleton through the L1 ankyrin binding site is involved. HGF stimulated L1 shedding in both mutants, indicating that receptor-mediated phosphorylation in the L1 cytoplasmic domain is not required for HGF-stimulated shedding.	Paul Scherrer Inst, ETH, PSI,USZ, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland	ETH Zurich; Paul Scherrer Institute	Novak-Hofer, I (corresponding author), Paul Scherrer Inst, ETH, PSI,USZ, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland.	ilse.novak@psi.ch						AMSTUTZ H, 1993, INT J CANCER, V53, P147, DOI 10.1002/ijc.2910530127; Beer S, 1999, J CELL SCI, V112, P2667; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; Davies G, 2001, CLIN CANCER RES, V7, P3289; Davies J, 2001, J ANAT, V198, P257, DOI 10.1046/j.1469-7580.2000.19830257.x; Debiec H, 1998, J CELL BIOL, V143, P2067, DOI 10.1083/jcb.143.7.2067; Debiec H, 2002, NEPHROL DIAL TRANSPL, V17, P42, DOI 10.1093/ndt/17.suppl_9.42; Dihne M, 2003, J NEUROSCI, V23, P6638; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; El-Ghoneimi A, 2002, J UROLOGY, V168, P2624, DOI 10.1016/S0022-5347(05)64231-0; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Gil OD, 2003, J CELL BIOL, V162, P719, DOI 10.1083/jcb.200211011; Grunberg J, 2003, BIOTECHNIQUES, V34, P968, DOI 10.2144/03345st02; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hoefnagel CA, 2001, EUR J NUCL MED, V28, P359, DOI 10.1007/s002590000454; Holzer G, 2003, MED PEDIATR ONCOL, V40, P64, DOI 10.1002/mpo.10058; Horie S, 1999, J UROLOGY, V161, P990, DOI 10.1016/S0022-5347(01)61834-2; Islam R, 2004, MOL BIOL CELL, V15, P2003, DOI 10.1091/mbc.e03-05-0333; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; LEDERMANN JA, 1994, INT J CANCER, P49; Lee DCW, 2002, ONCOGENE, V21, P5582, DOI 10.1038/sj.onc.1205741; Lynch DF, 1997, PROSTATE, V32, P214, DOI 10.1002/(SICI)1097-0045(19970801)32:3<214::AID-PROS8>3.0.CO;2-K; McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078-0432.CCR-0846-3; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meli ML, 1999, INT J CANCER, V83, P401, DOI 10.1002/(SICI)1097-0215(19991029)83:3<401::AID-IJC17>3.0.CO;2-A; Miyata Y, 2003, BIOCHEM BIOPH RES CO, V302, P892, DOI 10.1016/S0006-291X(03)00281-X; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nakamura T, 2001, ONCOGENE, V20, P7610, DOI 10.1038/sj.onc.1204975; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Needham LK, 2001, J NEUROSCI, V21, P1490, DOI 10.1523/JNEUROSCI.21-05-01490.2001; Oh RR, 2002, APMIS, V110, P229, DOI 10.1034/j.1600-0463.2002.100305.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RICHTERLANDSBERG C, 1984, J NEUROCHEM, V43, P841, DOI 10.1111/j.1471-4159.1984.tb12807.x; Roselli M, 2003, ONCOLOGY-BASEL, V65, P132, DOI 10.1159/000072338; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Sambrook J, 2001, MOL CLONING LAB MANU; Sandler B, 1999, ANTICANCER RES, V19, P4229; Tuvia S, 1997, P NATL ACAD SCI USA, V94, P12957, DOI 10.1073/pnas.94.24.12957; Yokota A, 1999, HEMATOL ONCOL, V17, P161, DOI 10.1002/(SICI)1099-1069(199912)17:4<161::AID-HON646>3.0.CO;2-Y	43	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31149	31156		10.1074/jbc.M403587200	http://dx.doi.org/10.1074/jbc.M403587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151998	Green Published, hybrid			2022-12-25	WOS:000222726800031
J	Iacovoni, JS; Cohen, SB; Berg, T; Vogt, PK				Iacovoni, JS; Cohen, SB; Berg, T; Vogt, PK			v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype	ONCOGENE			English	Article						Jun; AP-1; target genes; coordinate expression; reversion; oncogenic transformation; DNA microarray	C-JUN; ONCOGENE JUN; IN-VIVO; PROTEIN; CELLS; AP-1; GENE; SRC; FIBROBLASTS; SEQUENCE	Targets of the oncogenic transcription factor v-Jun in the murine cell line C3H 10T1/2 cells have been identified using DNA microarrays. Two targets, Akap12 and Marcks, are downregulated in transformed cells and are known tumor suppressor genes. Overexpression of either Akap12 or Marcks in v-Jun-transformed cells reverses the transformed phenotype and leads to the re-expression of the other tumor suppressor gene, suggesting that these two genes cooperate in the establishment of the nontransformed state. Reverted cells continue to express v-Jun at high levels and also re-express c-Jun, which is normally repressed by v-Jun. A panel of six cell lines has been generated to evaluate the expression levels of other v-Jun targets in 10T1/2 cells. With these cells, we find that the upregulated target Sprr1a has an expression pattern that correlates with the transformed phenotype.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, Dept Prot Sci, La Jolla, CA 92121 USA; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Scripps Research Institute; Novartis; Max Planck Society	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Berg, Thorsten/A-1306-2012; Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA79616, CA78045, CA78230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079616, P01CA078045, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Iacovoni JS, 2003, BIOINFORMATICS, V19, P2316, DOI 10.1093/bioinformatics/btg304; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; Kilbey A, 1996, ONCOGENE, V12, P2409; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13	24	9	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5703	5706		10.1038/sj.onc.1207737	http://dx.doi.org/10.1038/sj.onc.1207737			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15133497				2022-12-25	WOS:000222629500017
J	Billecke, SS; Draganov, DI; Morishima, Y; Murphy, PJM; Dunbar, AY; Pratt, WB; Osawa, Y				Billecke, SS; Draganov, DI; Morishima, Y; Murphy, PJM; Dunbar, AY; Pratt, WB; Osawa, Y			The role of hsp90 in heme-dependent activation of apo-neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; HSP90/HSP70-BASED CHAPERONE MACHINERY; RAT GLUCOCORTICOID RECEPTORS; 7-AMINO ACID SEQUENCE; STEROID-BINDING; LIGAND-BINDING; CONFORMATIONAL-CHANGES; MOLECULAR CHAPERONE; AMINO-TERMINUS; PROTEIN	Like other nitric-oxide synthase (NOS) enzymes, neuronal NOS (nNOS) turnover and activity are regulated by the ubiquitous protein chaperone hsp90. We have shown previously that nNOS expressed in Sf9 cells where endogenous heme levels are low is activated from the apo- to the holo-enzyme by addition of exogenous heme to the culture medium, and this activation is inhibited by radicicol, a specific inhibitor of hsp90 (Billecke, S. S., Bender, A. T., Kanelakis, K. C., Murphy, P. J. M., Lowe, E. R., Kamada, Y., Pratt, W. B., and Osawa, Y. (2002) J. Biol. Chem. 278, 15465-15468). In this work, we examine heme binding by apo-nNOS to form the active enzyme in a cell-free system. We show that cytosol from Sf9 cells facilitates heme-dependent apo- nNOS activation by promoting functional heme insertion into the enzyme. Sf9 cytosol also converts the glucocorticoid receptor (GR) to a state where the hydrophobic ligand binding cleft is open to access by steroid. Both cell-free heme activation of purified nNOS and activation of steroid binding activity of the immunopurified GR are inhibited by radicicol treatment of Sf9 cells prior to cytosol preparation, and addition of purified hsp90 to cytosol partially overcomes this inhibition. Although there is an hsp90-dependent machinery in Sf9 cytosol that facilitates heme binding by apo- nNOS, it is clearly different from the machinery that facilitates steroid binding by the GR. hsp90 regulation of apo- nNOS heme activation is very dynamic and requires higher concentrations of radicicol for its inhibition, whereas GR steroid binding is determined by assembly of stable GR.hsp90 heterocomplexes that are formed by a purified five-chaperone machinery that does not activate apo- nNOS.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	osawa@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hemmens B, 1998, BIOCHEM J, V332, P337, DOI 10.1042/bj3320337; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; Kanelakis KC, 2003, METHOD ENZYMOL, V364, P159; Kanelakis KC, 2002, J BIOL CHEM, V277, P33698, DOI 10.1074/jbc.M204164200; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Ou JS, 2004, AM J PHYSIOL-HEART C, V286, pH561, DOI 10.1152/ajpheart.00736.2003; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	42	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30252	30258		10.1074/jbc.M403864200	http://dx.doi.org/10.1074/jbc.M403864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15155759	hybrid			2022-12-25	WOS:000222531900049
J	Fulton, D; Babbitt, R; Zoelllner, S; Fontana, J; Acevedo, L; McCabe, TJ; Iwakiri, Y; Sessa, WC				Fulton, D; Babbitt, R; Zoelllner, S; Fontana, J; Acevedo, L; McCabe, TJ; Iwakiri, Y; Sessa, WC			Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT ENOS ACTIVATION; PROTEIN INTERACTIONS; ESTROGEN-RECEPTOR; S-NITROSYLATION; GROWTH-FACTOR; PHOSPHORYLATION; PALMITOYLATION; DOMAIN; CELLS; LOCALIZATION	The heterogeneous localization of endothelial nitric-oxide synthase (eNOS) on the Golgi complex versus the plasma membrane has made it difficult to dissect the regulation of each pool of enzyme. Here, we generated fusion proteins that specifically target the plasma membrane or cytoplasmic aspects of the Golgi complex and have assessed eNOS activation. Plasma membrane-targeted eNOS constructs were constitutively active, phosphorylated, and responsive to transmembrane calcium fluxes, yet were insensitive to further activation by Akt-mediated phosphorylation. In contrast, cis-Golgi complex-targeted eNOS behaved similarly to wild-type eNOS and was less sensitive to calcium-dependent activation and highly responsive to Akt-dependent phosphorylation compared with plasma membrane versions. In plasma membrane- and Golgi complex-targeted constructs, Ser(1179) is critical for NO production. This study provides clear evidence for functional roles of plasma membrane- and Golgi complex-localized eNOS and supports the concept that proteins thought to be regulated and to function exclusively in the plasma membrane of cells can indeed signal and be regulated in internal Golgi membranes.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	Yale University; Yale University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave, New Haven, CT 06536 USA.	william.sessa@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061371, R37HL061371, R01HL074279, R01HL064793, R01HL057665] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64793, HL61371, HL074279-01, R01 HL57665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andries LJ, 1998, CIRC RES, V82, P195; Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; Bauersachs J, 1997, HYPERTENSION, V30, P1598, DOI 10.1161/01.HYP.30.6.1598; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; Boo YC, 2003, FREE RADICAL BIO MED, V35, P729, DOI 10.1016/S0891-5849(03)00397-6; Brown DL, 2001, TRAFFIC, V2, P336, DOI 10.1034/j.1600-0854.2001.002005336.x; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193; Govers R, 2002, J HISTOCHEM CYTOCHEM, V50, P779, DOI 10.1177/002215540205000604; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jobin CM, 2003, BIOCHEMISTRY-US, V42, P11716, DOI 10.1021/bi035066w; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Kone BC, 2003, AM J PHYSIOL-RENAL, V285, pF178, DOI 10.1152/ajprenal.00048.2003; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Matsushita K, 2003, CELL, V115, P139, DOI 10.1016/S0092-8674(03)00803-1; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; OBRIEN AJ, 1995, HISTOCHEM CELL BIOL, V103, P221, DOI 10.1007/BF01454027; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SINGER HA, 1982, HYPERTENSION, V4, P19, DOI 10.1161/01.HYP.4.3_Pt_2.19; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; STANBOLI A, 1994, NEUROSCI LETT, V171, P209, DOI 10.1016/0304-3940(94)90641-6; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; van Haperen R, 2003, AM J PATHOL, V163, P1677, DOI 10.1016/S0002-9440(10)63524-9; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	65	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30349	30357		10.1074/jbc.M402155200	http://dx.doi.org/10.1074/jbc.M402155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136572	hybrid			2022-12-25	WOS:000222531900060
J	Lusetti, SL; Voloshin, ON; Inman, RB; Camerini-Otero, RD; Cox, MM				Lusetti, SL; Voloshin, ON; Inman, RB; Camerini-Otero, RD; Cox, MM			The DinI protein stabilizes RecA protein filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-RECA; SINGLE-STRANDED-DNA; NUCLEOSIDE TRIPHOSPHATE; COPROTEASE ACTIVITIES; STABLE COMPLEXES; BINDING-PROTEIN; IN-VITRO; EXCHANGE; LEXA; INHIBITION	When DinI is present at concentrations that are stoichiometric with those of RecA or somewhat greater, DinI has a substantial stabilizing effect on RecA filaments bound to DNA. Exchange of RecA between free and bound forms was almost entirely suppressed, and highly stable filaments were documented with several different experimental methods. DinI-mediated stabilization did not affect RecA-mediated ATP hydrolysis and LexA co-protease activities. Initiation of DNA strand exchange was affected in a DNA structure-dependent manner, whereas ongoing strand exchange was not affected. Destabilization of RecA filaments occurred as reported in earlier work but only when DinI protein was present at very high concentrations, generally super-stoichiometric, relative to the RecA protein concentration. DinI did not facilitate RecA filament formation but stabilized the filaments only after they were formed. The interaction between the RecA protein and DinI was modulated by the C terminus of RecA. We discuss these results in the context of a new hypothesis for the role of DinI in the regulation of recombination and the SOS response.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NIGMS NIH HHS [GM52725] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; Haruta N, 2003, J BIOL CHEM, V278, P52710, DOI 10.1074/jbc.M308563200; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; LEWIS LK, 1994, J MOL BIOL, V241, P507, DOI 10.1006/jmbi.1994.1528; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; Mustard JA, 2000, J BACTERIOL, V182, P1659, DOI 10.1128/JB.182.6.1659-1670.2000; REGISTER JC, 1986, P NATL ACAD SCI USA, V83, P624, DOI 10.1073/pnas.83.3.624; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Walker GC, 2000, BACTERIAL STRESS RESPONSES, P131; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; WILLIAMS JGK, 1981, J BIOL CHEM, V256, P7573; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yasuda T, 1996, J BACTERIOL, V178, P3854, DOI 10.1128/jb.178.13.3854-3859.1996; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256	41	74	78	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30037	30046		10.1074/jbc.M403064200	http://dx.doi.org/10.1074/jbc.M403064200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138263	hybrid			2022-12-25	WOS:000222531900022
J	Shintani, T; Klionsky, DJ				Shintani, T; Klionsky, DJ			Cargo proteins facilitate the formation of transport vesicles in the cytoplasm to vacuole targeting pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-AUTOPHAGOSOMAL STRUCTURE; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; AMINOPEPTIDASE-I; YEAST; REQUIRES; COMPLEX; COMPONENTS; INDUCTION; MECHANISM	Selective incorporation of cargo proteins into the forming vesicle is an important aspect of protein targeting via vesicular trafficking. Based on the current paradigm of cargo selection in vesicular transport, proteins to be sorted to other organelles are condensed at the vesicle budding site in the donor organelle, a process that is mediated by the interaction between cargo and coat proteins, which constitute part of the vesicle forming machinery. The cytoplasm to vacuole targeting (Cvt) pathway is an unconventional vesicular trafficking pathway in yeast, which is topologically and mechanistically related to autophagy. Aminopeptidase I (Ape1) is the major cargo protein of the Cvt pathway. Unlike the situation in conventional vesicular transport, precursor Ape1, along with its receptor Atg19/Cvt19, is packed into a huge complex, termed a Cvt complex, independent of the vesicle formation machinery. The Cvt complex is subsequently incorporated into the forming Cvt vesicle. The deletion of APE1 or ATG19 compromised the organization of the pre-autophagosomal structure ( PAS), a site that is thought to play a critical role in Cvt vesicle/autophagosome formation. The proper organization of the PAS also required Atg11/Cvt9, a protein that localizes the cargo complex at the PAS. Accordingly, the deletion of APE1, ATG19, or ATG11 affected the formation of Cvt vesicles. These observations suggest a unique concept; in the case of the Cvt pathway, the cargo proteins facilitate receptor recruitment and vesicle formation rather than the situation with most vesicular transport, in which the forming vesicle concentrates the cargo proteins.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Klionsky, DJ (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave,Rm 6036, Ann Arbor, MI 48109 USA.	klionsky@umich.edu	SHINTANI, Takahiro/ABE-1267-2020	Shintani, Takahiro/0000-0001-6630-5892	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053396, GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; Hamasaki M, 2003, CELL STRUCT FUNCT, V28, P49; Hettema EH, 2003, EMBO J, V22, P548, DOI 10.1093/emboj/cdg062; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Nice DC, 2002, J BIOL CHEM, V277, P30198, DOI 10.1074/jbc.M204736200; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Reggiori F, 2004, DEV CELL, V6, P79, DOI 10.1016/S1534-5807(03)00402-7; Reggiori F, 2004, MOL BIOL CELL, V15, P2189, DOI 10.1091/mbc.E03-07-0479; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200	34	288	299	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29889	29894		10.1074/jbc.M404399200	http://dx.doi.org/10.1074/jbc.M404399200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138258	hybrid, Green Accepted			2022-12-25	WOS:000222531900004
J	Zhu, QS; Qian, B; Levy, D				Zhu, QS; Qian, B; Levy, D			CCAAT/enhancer-binding protein alpha (C/EBP alpha) activates transcription of the human microsomal epoxide hydrolase gene (EPHX1) through the interaction with DNA-bound NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID TRANSPORT; NUCLEAR-FACTOR-Y; C-MYC; HISTONE ACETYLTRANSFERASE; TOPOLOGICAL ORIENTATIONS; FUNCTIONAL EXPRESSION; MOLECULAR-BIOLOGY; BETA-RECEPTOR; CCAAT BOXES; RAT-LIVER	Microsomal epoxide hydrolase (mEH) plays a central role in xenobiotic metabolism as well as mediating the sodium-dependent uptake of bile acids into the liver, where these compounds regulate numerous biological processes such as cholesterol metabolism and hepatocyte signaling pathways. Little is known, however, about the factors that control the constitutive and inducible expression of the mEH gene (EPHX1) that is altered during development and in response to numerous xenobiotics. In previous studies we have established that GATA-4 binding to the EPHX1 core promoter is critical for EPHX1 expression. The -80/+25 bp core promoter also contained a reversed CCAAT box (-5/-1 bp), integrity of which was required for maximal basal EPHX1 transcription in HepG2 cells. Transient transfection of CCAAT/enhancer-binding protein alpha (C/EBPalpha) substantially stimulated EPHX1 promoter activity. Electrophoretic mobility shift assays, however, revealed that nuclear factor Y (NF-Y), but not C/EBPalpha, directly bound to this site although increased expression of NF-Y had no effect on EPHX1 promoter activity. These results suggested that C/EBPalpha activated EPHX1 expression through its interaction with NF-Y bound to the CCAAT box. The existence of a C/EBPalpha[NF-Y] complex was supported by electrophoretic mobility shift assays using antibodies against NF-Y and C/EBPalpha as well as by the ability of a dominant-negative NF-Y expression vector to inhibit promoter activity. The interaction between these transcription factors was established by co-immunoprecipitation analysis and glutathione S-transferase pull-down assays, whereas the association of the two factors and the interaction of NF-Y with the CCAAT box in vivo was confirmed by chromatin immunoprecipitation assays. C/EBPalpha-dependent EPHX1 activation was also supported by reconstitution studies in HeLa cells that lack this protein. These results establish that EPHX1 expression is regulated by C/EBPalpha interacting with DNA-bound NF-Y.	Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Levy, D (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, 2011 Zonal Ave, Los Angeles, CA 90033 USA.	dlevy@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 25836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVES C, 1993, J BIOL CHEM, V268, P20148; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; Cortessis V, 2001, CANCER RES, V61, P2381; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dinic S, 2000, CELL BIOL INT, V24, P691, DOI 10.1006/cbir.2000.0531; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; HASSETT C, 1994, GENOMICS, V23, P433, DOI 10.1006/geno.1994.1520; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Izumi H, 2001, J CELL SCI, V114, P1533; Jackson SM, 1998, J LIPID RES, V39, P767; Jacobs SBR, 2003, MOL ENDOCRINOL, V17, P1470, DOI 10.1210/me.2002-0286; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KIM SG, 1992, MOL PHARMACOL, V42, P273; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liang FQ, 2001, J BIOL CHEM, V276, P1516, DOI 10.1074/jbc.M006350200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; OMIECINSKI CJ, 1994, J PHARMACOL EXP THER, V269, P417; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; ROSSI AM, 1987, MUTAT RES, V182, P75, DOI 10.1016/0165-1161(87)90056-2; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Taira T, 1999, J BIOL CHEM, V274, P24270, DOI 10.1074/jbc.274.34.24270; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Tomizawa M, 1998, BIOCHEM BIOPH RES CO, V249, P1, DOI 10.1006/bbrc.1998.8999; Ueda A, 1998, J BIOL CHEM, V273, P19339, DOI 10.1074/jbc.273.30.19339; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; VONDIPPE P, 1983, J BIOL CHEM, V258, P8890; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; VONDIPPE P, 1990, J BIOL CHEM, V265, P5942; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251; Zhu QS, 1999, J BIOL CHEM, V274, P27898, DOI 10.1074/jbc.274.39.27898; Zhu QS, 2004, BBA-GENE STRUCT EXPR, V1676, P251, DOI 10.1016/j.bbaexp.2004.01.002; Zhu QS, 2003, BBA-MOL BASIS DIS, V1638, P208, DOI 10.1016/S0925-4439(03)00085-1	49	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29902	29910		10.1074/jbc.M400438200	http://dx.doi.org/10.1074/jbc.M400438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150264	hybrid			2022-12-25	WOS:000222531900006
J	Vorberg, I; Raines, A; Priola, SA				Vorberg, I; Raines, A; Priola, SA			Acute formation of protease-resistant prion protein does not always lead to persistent scrapie infection in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; CELL-FREE FORMATION; NEUROBLASTOMA-CELLS; STRAIN VARIATION; AGENT PROTEIN; MICE; PRP; PROPAGATION; BSE; CONFORMATIONS	Transmissible spongiform encephalopathies are accompanied by the accumulation of a pathologic isoform of a host-encoded protein, termed prion protein (PrP). Despite the widespread distribution of the cellular isoform of PrP (protease-sensitive PrP; PrP-sen), the disease-associated isoform (protease-resistant PrP; PrP-res) appears to be primarily restricted to cells of the nervous and lymphoreticular systems. In order to study why scrapie infection appears to be restricted to certain cells, we followed acute and persistent PrP-res formation upon exposure of cells to different scrapie agents. We found that, independent of the cell type and scrapie strain, initial PrP-res formation occurred rapidly in cells. However, sustained generation of PrP-res and persistent infection did not necessarily follow acute PrP-res formation. Persistent PrP-res formation and scrapie infection was restricted to one cell line inoculated with the mouse scrapie strain 22L. In contrast to cells that did not become scrapie-infected, the level of PrP-res in the 22L-infected cells rapidly increased in the absence of a concomitant increase in the number of PrP-resproducing cells. Furthermore, the protein banding pattern of PrP-res in these cells changed over time as the cells became chronically infected. Thus, our results suggest that the events leading to the initial formation of PrP-res may differ from those required for sustained PrP-res formation and infection. This may, at least in part, explain the observation that not all PrP-sen-expressing cells appear to support transmissible spongiform encephalopathy agent replication.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	spriola@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; BENDHEIM PE, 1988, J INFECT DIS, V158, P1198, DOI 10.1093/infdis/158.6.1198; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; Bruce Moira E., 1996, P223; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; DICKINSON AG, 1972, NATURE-NEW BIOL, V237, P244, DOI 10.1038/newbio237244a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gonzalez L, 2003, J GEN VIROL, V84, P1339, DOI 10.1099/vir.0.18800-0; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Kanu N, 2002, CURR BIOL, V12, P523, DOI 10.1016/S0960-9822(02)00722-4; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 2000, J GEN VIROL, V81, P2555, DOI 10.1099/0022-1317-81-10-2555; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Mulcahy ER, 2004, J BIOL CHEM, V279, P1643, DOI 10.1074/jbc.M307844200; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Pammer J, 1999, LANCET, V354, P1702, DOI 10.1016/S0140-6736(99)02800-7; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; RUBENSTEIN R, 1992, J GEN VIROL, V73, P3027, DOI 10.1099/0022-1317-73-11-3027; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schatzl HM, 1997, J VIROL, V71, P8821; SKLAVIADIS T, 1993, P NATL ACAD SCI USA, V90, P5713, DOI 10.1073/pnas.90.12.5713; Soto C, 2002, TRENDS NEUROSCI, V25, P390, DOI 10.1016/S0166-2236(02)02195-1; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vorberg I, 2004, J INFECT DIS, V189, P431, DOI 10.1086/381166; Vorberg I, 2002, J BIOL CHEM, V277, P36775, DOI 10.1074/jbc.M206865200; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377	44	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29218	29225		10.1074/jbc.M402576200	http://dx.doi.org/10.1074/jbc.M402576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133048	hybrid			2022-12-25	WOS:000222445300049
J	Kimura, Y; Kimura, H				Kimura, Y; Kimura, H			Hydrogen sulfide protects neurons from oxidative stress	FASEB JOURNAL			English	Article						glutamate toxicity; oxytosis; cystine transport; glutathione; neuroprotection	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; GLUTAMATE TOXICITY; CELL-LINE; BRAIN-TISSUE; RAT-KIDNEY; GLUTATHIONE; CYSTINE; METABOLISM; NEUROTOXICITY	Hydrogen sulfide (H2S), which is a well-known toxic gas, is found in relatively high concentrations in the brain. Although a neuromodulatory role of H2S has been demonstrated, little is known of its other biological functions. Here we show that H2S protects primary cultures of neurons from death in a well-studied model of oxidative stress caused by glutamate, a process called oxidative glutamate toxicity - or oxytosis. We found that H2S increases the glutathione levels, which normally decrease during the cell death cascade, by enhancing the activity of gamma-glutamylcysteine synthetase and up-regulating cystine transport. Cystine ( cysteine) is the rate-limiting substrate of glutathione synthesis. These observations reveal that H2S protects neurons from oxytosis by increasing the production of the antioxidant glutathione.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan	National Center for Neurology & Psychiatry - Japan	Kimura, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; 				ABE K, 1990, JPN J PHARMACOL, V53, P221, DOI 10.1254/jjp.53.221; Abe K, 1996, J NEUROSCI, V16, P1066; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bannai S., 1989, GLUTATHIONE CENTENNI, P407; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P369; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; Devai I, 2002, ENVIRON TECHNOL, V23, P319, DOI 10.1080/09593332508618412; EKLOW L, 1981, FEBS LETT, V127, P125, DOI 10.1016/0014-5793(81)80357-2; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; Herschbach C, 2000, PLANT PHYSIOL, V124, P461, DOI 10.1104/pp.124.1.461; Kwak WJ, 2003, FEMS MICROBIOL LETT, V219, P99, DOI 10.1016/S0378-1097(02)01198-9; Maher P, 1996, J NEUROSCI, V16, P6394; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nagai Y, 2004, FASEB J, V18, P557, DOI 10.1096/fj.03-1052fje; Noctor G, 1996, PLANT PHYSIOL, V112, P1071, DOI 10.1104/pp.112.3.1071; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010; REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pa.32.040192.000545; Sagara Y, 1998, J NEUROSCI, V18, P6662; SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Sunda W, 2002, NATURE, V418, P317, DOI 10.1038/nature00851; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; VORNOV JJ, 1991, J NEUROCHEM, V56, P996, DOI 10.1111/j.1471-4159.1991.tb02020.x; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; YAN N, 1990, J BIOL CHEM, V265, P1588; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	38	672	766	3	76	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1165	+		10.1096/fj.04-1815fje	http://dx.doi.org/10.1096/fj.04-1815fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155563				2022-12-25	WOS:000221883200006
J	Dettwiler, S; Aringhieri, C; Cardinale, S; Keller, W; Barabino, SML				Dettwiler, S; Aringhieri, C; Cardinale, S; Keller, W; Barabino, SML			Distinct sequence motifs within the 68-kDa subunit of cleavage factor I-m mediate RNA binding, protein-protein interactions, and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLYADENYLATION SPECIFICITY FACTOR; VERTEBRATE POLY(A) POLYMERASE; SR PROTEINS; SPLICING FACTOR; SUBNUCLEAR LOCALIZATION; MOLECULAR-CLONING; CARBOXYL-TERMINUS; 3'-END CLEAVAGE; NUCLEAR EXPORT	Cleavage factor I-m (CF I-m) is required for the first step in pre-mRNA 3'-end processing and can be reconstituted in vitro from its heterologously expressed 25- and 68-kDa subunits. The binding of CF I-m to the pre-mRNA is one of the earliest steps in the assembly of the cleavage and polyadenylation machinery and facilitates the recruitment of other processing factors. We identified regions in the subunits of CF I-m involved in RNA binding, protein-protein interactions, and subcellular localization. CF I(m)68 has a modular domain organization consisting of an N-terminal RNA recognition motif and a C-terminal alternating charge domain. However, the RNA recognition motif of CF I(m)68 on its own is not sufficient to bind RNA but is necessary for association with the 25-kDa subunit. RNA binding appears to require a CF I(m)68/25 heterodimer. Whereas multiple protein interactions with other 3'-end-processing factors are detected with CF I(m)25, CF I(m)68 interacts with SRp20, 9G8, and hTra2beta, members of the SR family of splicing factors, via its C-terminal alternating charge domain. This domain is also required for targeting CF I(m)68 to the nucleus. However, CF I(m)68 does not concentrate in splicing speckles but in foci that partially colocalize with paraspeckles, a subnuclear component in which other proteins involved in transcriptional control and RNA processing have been found.	Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; Univ Basel, Bioctr, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Milano-Bicocca; University of Basel	Barabino, SML (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	silvia.barabino@unimib.it	Barabino, Silvia/AAC-4674-2021	Cardinale, Stefano/0000-0003-4357-9246	Telethon [GP0020Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Awasthi S, 2003, RNA, V9, P1400, DOI 10.1261/rna.5104603; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Dichtl B, 2001, EMBO J, V20, P3197, DOI 10.1093/emboj/20.12.3197; Emili A, 2002, RNA, V8, P1102, DOI 10.1017/S1355838202025037; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; Kim H, 2001, BIOCHEM BIOPH RES CO, V289, P513, DOI 10.1006/bbrc.2001.5992; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Lamond AI, 2003, NAT REV MOL CELL BIO, V4, P605, DOI 10.1038/nrm1172; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Lutz CS, 1998, RNA, V4, P1493, DOI 10.1017/S1355838298981183; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; Millevoi S, 2002, EMBO REP, V3, P869, DOI 10.1093/embo-reports/kvf173; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rosonina E, 2003, J BIOL CHEM, V278, P43034, DOI 10.1074/jbc.M307289200; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Schul W, 1998, EXP CELL RES, V238, P1, DOI 10.1006/excr.1997.3808; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Vagner S, 2000, GENE DEV, V14, P403; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zhou ZL, 2002, P NATL ACAD SCI USA, V99, P12203, DOI 10.1073/pnas.182427099	61	112	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35788	35797		10.1074/jbc.M403927200	http://dx.doi.org/10.1074/jbc.M403927200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169763	Green Accepted, hybrid			2022-12-25	WOS:000223303400079
J	Lu, ZM; Hu, XH; Li, Y; Zheng, L; Zhou, Y; Jiang, HD; Ning, T; Basang, Z; Zhang, CF; Ke, Y				Lu, ZM; Hu, XH; Li, Y; Zheng, L; Zhou, Y; Jiang, HD; Ning, T; Basang, Z; Zhang, CF; Ke, Y			Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR; GENE-PRODUCTS; CELL-GROWTH; HUMAN KERATINOCYTES; PROTEINS TARGET; TSC2; RHEB; HAMARTIN; COMPLEX	Tuberous sclerosis complex (TSC) is a genetic disorder caused by mutations in either TSC1 or TSC2 tumor suppressor gene. TSC1 and TSC2 products, Harmatin and Tuberin, form the functional complex to serve as the negative regulator for insulin-induced phosphorylation of S6 kinase and elF4E-binding protein 1. High-risk human papillomavirus (HPV) infection is the necessary cause for cervical cancer. E6 oncoprotein encoded by HPV plays a pivotal role in carcinogenesis by interference with the host intracellular protein functions. In this study, we show that HPV16 E6 interacts with tumor suppressor gene TSC2 product, Tuberin, and results in the phosphorylation of S6 kinase and S6 even in the absence of insulin. The overexpression of Tuberin overcomes the effect of E6 on S6 kinase phosphorylation. Binding with HPV16 E6 causes the proteasome-mediated degradation of Tuberin. A DILG motif and an ELVG motif located in the carboxyl-terminal of Tuberin are required for E6 binding. In addition, the Tuberin interaction region in E6 has been mapped in the amino-terminal portion of HPV16 E6, which is different from the binding domain with p53. These results provide a possible link between E6-induced oncogenesis and the insulin-stimulated cell proliferation signaling pathway.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Genet, Beijing 100034, Peoples R China	Peking University	Ke, Y (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Genet, 1 Da Hong Luo Chang St,West Dist, Beijing 100034, Peoples R China.	keyang@mx.cei.gov.cn						Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; DENG GR, 1989, CANCER RES, V47, P3195; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Filippova M, 2002, J BIOL CHEM, V277, P21730, DOI 10.1074/jbc.M200113200; Gao QS, 1999, MOL CELL BIOL, V19, P733; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengstschlager M, 2001, MUTAT RES-REV MUTAT, V488, P233, DOI 10.1016/S1383-5742(01)00058-8; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liu Y, 1999, J VIROL, V73, P7297, DOI 10.1128/JVI.73.9.7297-7307.1999; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NELLIST M, 1993, CELL, V75, P1305; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomas M, 1996, ONCOGENE, V13, P471; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	59	85	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35664	35670		10.1074/jbc.M403385200	http://dx.doi.org/10.1074/jbc.M403385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15175323	hybrid			2022-12-25	WOS:000223303400063
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - IV. Probable mechanism of subunit docking and completion of assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; BETA-SUBUNIT; BIOLOGICAL-ACTIVITY; DISULFIDE BONDS; PROTEIN; COMBINATION; ANALOGS	The unique structures of human choriogonadotropin (hCG) and related glycoprotein hormones make them well suited for studies of protein folding in the endoplasmic reticulum. hCG is stabilized by a strand of its beta-subunit that has been likened to a "seatbelt" because it surrounds alpha-subunit loop 2 and its end is "latched" by an intrasubunit disulfide bond to the beta-subunit core. As shown here, assembly begins when parts of the NH2 terminus, cysteine knot, and loops 1 and 3 of the alpha-subunit dock reversibly with parts of the NH2 terminus, cystine knot, and loop 2 of the hCG beta-subunit. Whereas the seatbelt can contribute to the stability of the docked subunit complex, it interferes with docking and/or destabilizes the docked complex when it is unlatched. This explains why most hCG is assembled by threading the glycosylated end of alpha-subunit loop 2 beneath the latched seatbelt rather than by wrapping the unlatched seatbelt around this loop. hCG assembly appears to be limited by the need to disrupt the disulfide that stabilizes the small seatbelt loop prior to threading. We postulate that assembly depends on a "zipper- like" sequential formation of intersubunit and intrasubunit hydrogen bonds between backbone atoms of several residues in the beta-subunit cystine knot, alpha-subunit loop 2, and the small seatbelt loop. The resulting intersubunit beta-sheet enhances the stability of the seatbelt loop disulfide, which shortens the seatbelt and secures the heterodimer. Formation of this disulfide also explains the ability of the seatbelt loop to facilitate latching during assembly by the wraparound pathway.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038547, R01HD014907, R37HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALOJ SM, 1973, ARCH BIOCHEM BIOPHYS, V159, P497, DOI 10.1016/0003-9861(73)90480-3; CHEN F, 1991, J BIOL CHEM, V266, P6904; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lin W, 1999, MOL CELL ENDOCRINOL, V152, P91, DOI 10.1016/S0303-7207(99)00056-8; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SLAUGHTER S, 1995, MOL CELL ENDOCRINOL, V112, P21, DOI 10.1016/0303-7207(95)03579-V; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35449, DOI 10.1074/jbc.M403054200; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	18	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35458	35468		10.1074/jbc.M403055200	http://dx.doi.org/10.1074/jbc.M403055200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166248	hybrid			2022-12-25	WOS:000223303400039
J	Apuzzo, S; Abdelhakim, A; Fortin, AS; Gros, P				Apuzzo, S; Abdelhakim, A; Fortin, AS; Gros, P			Cross-talk between the paired domain and the homeodomain of Pax3 - DNA binding by each domain causes a structural change in the other domain, supporting interdependence for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; INDUCED CONFORMATIONAL-CHANGES; SPLOTCH MUTANT MOUSE; NUCLEOTIDE-BINDING; P-GLYCOPROTEIN; WAARDENBURG-SYNDROME; CRYSTAL-STRUCTURE; TERMINAL SUBDOMAIN; ESCHERICHIA-COLI; PBX HOMEODOMAIN	The Pax3 protein has two DNA binding domains, a Paired domain (PD) and a paired-type Homeo domain (HD). Although the PD and HD can bind to cognate DNA sequences when expressed individually, genetic and biochemical data indicate that the two domains are functionally interdependent in intact Pax3. The mechanistic basis of this functional interdependence is unknown and was studied by protease sensitivity. Pax3 was modified by the creation of Factor Xa cleavage sites at discrete locations in the PD, the HD, and in the linker segment joining the PD and the HD (Xa172, Xa189, and Xa216) in individual Pax3 mutants. The effect of Factor Xa insertions on protein stability and on DNA binding by the PD and the HD was measured using specific target site sequences. Independent insertions at position 100 in the linker separating the first from the second helix-turn-helix motif of the PD and at position 216 immediately upstream of the HD were found to be readily accessible to Factor Xa cleavage. The effect of DNA binding by the PD or the HD on accessibility of Factor Xa sites inserted in the same or in the other domain was monitored and quantitated for multiple mutants bearing different numbers of Xa sites at each position. In general, DNA binding reduced accessibility of all sites, suggesting a more compact and less solvent-exposed structure of DNA-bound versus DNA-free Pax3. Results of dose response and time course experiments were consistent and showed that DNA binding by the PD not only caused a local structural change in the PD but also caused a conformational change in the HD (P3OPT binding to Xa216 mutants); similarly, DNA binding by the HD also caused a conformational change in the PD (P2 binding to Xa100 mutants). These results provide a structural basis for the functional interdependence of the two DNA binding domains of Pax3.	McGill Univ, Dept Biochem, Quebec City, PQ H1E 1S9, Canada; McGill Univ, McGill Canc Ctr, Quebec City, PQ H1E 1S9, Canada	McGill University; McGill University	Gros, P (corresponding author), McGill Univ, Dept Biochem, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	sapuzz@po-box.mcgill.ca; philippe.gros@mcgill.ca						Apuzzo S, 2002, BIOCHEMISTRY-US, V41, P12076, DOI 10.1021/bi0260583; AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALDWIN CT, 1995, AM J MED GENET, V58, P115, DOI 10.1002/ajmg.1320580205; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Beechey CV, 1986, MOUSE NEWS LETT, V75, P28; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; BOBER E, 1994, DEVELOPMENT, V120, P603; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fortin AS, 1998, NUCLEIC ACIDS RES, V26, P4574, DOI 10.1093/nar/26.20.4574; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; FRANZ T, 1989, ANAT EMBRYOL, V180, P457, DOI 10.1007/BF00305120; FRANZ T, 1990, ACTA ANAT, V138, P246; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HE MG, 1993, J PROTEIN CHEM, V12, P1, DOI 10.1007/BF01024906; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Jabet C, 1999, J MOL BIOL, V291, P521, DOI 10.1006/jmbi.1999.2983; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Jun S, 1996, DEVELOPMENT, V122, P2639; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; MENEZES ME, 1990, P NATL ACAD SCI USA, V87, P1638, DOI 10.1073/pnas.87.5.1638; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; QIAN YQ, 1994, P NATL ACAD SCI USA, V91, P4091, DOI 10.1073/pnas.91.9.4091; Rothman A, 1997, BIOCHEMISTRY-US, V36, P14572, DOI 10.1021/bi971800y; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Sprules T, 2000, BIOCHEMISTRY-US, V39, P9943, DOI 10.1021/bi0001067; Sprules T, 2003, J BIOL CHEM, V278, P1053, DOI 10.1074/jbc.M207504200; Stout JG, 1998, BIOCHEMISTRY-US, V37, P14860, DOI 10.1021/bi9812930; STUART ET, 1994, ANNU REV GENET, V28, P219, DOI 10.1146/annurev.ge.28.120194.001251; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Torres M, 1995, DEVELOPMENT, V121, P4057; TREISMAN J, 1989, CELL, V59, P553; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; Vogan KJ, 1997, J BIOL CHEM, V272, P28289, DOI 10.1074/jbc.272.45.28289; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P20126; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	69	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33601	33612		10.1074/jbc.M402949200	http://dx.doi.org/10.1074/jbc.M402949200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15148315	hybrid			2022-12-25	WOS:000223039700069
J	Marchetti, L; Klein, M; Schlett, K; Pfizenmaier, K; Eisel, ULM				Marchetti, L; Klein, M; Schlett, K; Pfizenmaier, K; Eisel, ULM			Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation - Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; ZETA-PKC; EXPRESSION; SURVIVAL; SUBUNIT; AKT; PATHOGENESIS; INHIBITORS; APOPTOSIS	We have previously shown that two tumor necrosis factor (TNF) receptors (TNFR) exhibit antagonistic functions during neurodegenerative processes in vivo with TNFR1 aggravating and TNFR2 reducing neuronal cell loss, respectively. To elucidate the neuroprotective signaling pathways of TNFR2, we investigated glutamate-induced excitotoxicity in primary cortical neurons. TNF-expressing neurons from TNF-transgenic mice were found to be strongly protected from glutamate-induced apoptosis. Neurons from wild type and TNFR1(-/-) mice prestimulated with TNF or agonistic TNFR2-specific antibodies were also resistant to excitotoxicity, whereas TNFR2(-/-) neurons died upon glutamate and/or TNF exposures. Both protein kinase B/Akt and nuclear factor-kappaB (NF-kappaB) activation were apparent upon TNF treatment. Both TNFR1 and TNFR2 induced the NF-kappaB pathway, yet with distinguishable kinetics and upstream activating components, TNFR1 only induced transient NF-kappaB activation, whereas TNFR2 facilitated long term phosphatidylinositol 3-kinase-dependent NF-kappaB activation strictly. Glutamate-induced triggering of the ionotropic N-methyl-D-aspartate receptor was required for the enhanced and persistent phosphatidylinositol 3-kinase-dependent NF-kappaB activation by TNFR2, indicating a positive cooperation of TNF and neurotransmitter-induced signal pathways. TNFR2-induced persistent NF-kappaB activity was essential for neuronal survival. Thus, the duration of NF-kappaB activation is a critical determinant for sensitivity toward excitotoxic stress and is dependent on a differential upstream signal pathway usage of the two TNFRs.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Xantos Biomed AG, D-82152 Martinsried, Germany; Eotvos Lorand Univ, Dept Physiol & Neurobiol, H-1117 Budapest, Hungary; Univ Groningen, Dept Mol Neurobiol, NL-9750 AA Haren, Netherlands	University of Stuttgart; Eotvos Lorand University; University of Groningen	Pfizenmaier, K (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	klaus.pfizenmaier@izi.uni-stuttgart.de	Schlett, Katalin/AAF-1952-2020	Schlett, Katalin/0000-0001-9265-4236; Eisel, Ulrich/0000-0003-4178-0384				Akassoglou K, 1997, J IMMUNOL, V158, P438; Akassoglou K, 1998, AM J PATHOL, V153, P801, DOI 10.1016/S0002-9440(10)65622-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; Eisel ULM, 2002, CURR TOP MICROBIOL, V265, P49; ESKANDARI MK, 1990, IMMUNOL INVEST, V19, P69, DOI 10.3109/08820139009042026; Fleischmann R, 2002, DRUG SAFETY, V25, P173, DOI 10.2165/00002018-200225030-00004; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GREEN S, 1982, J NATL CANCER I, V68, P997; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Kassiotis G, 1999, EUR J IMMUNOL, V29, P912, DOI 10.1002/(SICI)1521-4141(199903)29:03<912::AID-IMMU912>3.0.CO;2-G; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Klein M, 1998, GENE, V208, P259, DOI 10.1016/S0378-1119(98)00005-5; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller C, 2002, IMMUNOLOGY, V105, P1, DOI 10.1046/j.1365-2567.2002.01329.x; Ozes ON, 1999, NATURE, V401, P82; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Petegnief V, 2001, NEUROSCIENCE, V104, P223, DOI 10.1016/S0306-4522(01)00046-X; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Sandra F, 2002, CELL SIGNAL, V14, P771, DOI 10.1016/S0898-6568(02)00025-6; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Tacchini-Cottier F, 1998, J IMMUNOL, V160, P6182; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002	54	330	347	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32869	32881		10.1074/jbc.M311766200	http://dx.doi.org/10.1074/jbc.M311766200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155767	Green Published, hybrid			2022-12-25	WOS:000222849700107
J	Moore, VD; Payne, RM				Moore, VD; Payne, RM			Transactivator of transcription fusion protein transduction causes membrane inversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; CELL-PENETRATING PEPTIDES; INTRACELLULAR DELIVERY; IN-VIVO; ANTENNAPEDIA HOMEODOMAIN; PLASMA-MEMBRANE; MAMMALIAN-CELLS; ANNEXIN-V; 3RD HELIX; INTERNALIZATION	The transactivator of transcription ( TAT) protein transduction domain is an 11-amino acid positively charged peptide that has been shown to pull diverse molecules across cell membranes in vitro and in vivo. Fusion proteins constructed with TAT rapidly enter and exit cells and have been shown to cross intracellular membranes as well. Electrostatic interactions between TAT and the cell membrane have been implicated as a part of the mechanism of transduction. Here, we report that TAT transduction causes membrane phospholipid rearrangement as evidenced by detection of phosphatidylserine on the outer surface of the cell membrane. Furthermore, these rearrangements can be blocked by positively charged polylysine, further implicating electrostatic interactions as a part of the mechanism. Neither apoptosis nor necrosis is induced in these cells after exposure to TAT. We conclude that the process of TAT.GFP transduction causes phosphatidylserine to translocate from the inner to the outer leaflet of the plasma membrane. These results provide insight into the mechanism of TAT protein transduction domain transduction.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Div Mol Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Div Cardiol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Payne, RM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Div Mol Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mpayne@wfubmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055765, R01DK067763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK67763, DK55765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Del Gaizo V, 2003, MOL GENET METAB, V80, P170, DOI 10.1016/j.ymgme.2003.08.017; Del Gaizo V, 2003, MOL THER, V7, P720, DOI 10.1016/S1525-0016(03)00130-8; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Levchenko TS, 2003, METHOD ENZYMOL, V372, P339; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; van Heerde WL, 2000, CARDIOVASC RES, V45, P549, DOI 10.1016/S0008-6363(99)00396-X; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	32	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32541	32544		10.1074/jbc.M405930200	http://dx.doi.org/10.1074/jbc.M405930200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169776	hybrid			2022-12-25	WOS:000222849700069
J	Sorger, D; Athenstaedt, K; Hrastnik, C; Daum, G				Sorger, D; Athenstaedt, K; Hrastnik, C; Daum, G			A yeast strain lacking lipid particles bears a defect in ergosterol formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SQUALENE EPOXIDASE; CHOLESTEROL ACYLTRANSFERASE; FUNCTIONAL EXPRESSION; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; BIOSYNTHESIS	Lipid particles of the yeast Saccharomyces cerevisiae are storage compartments for triacylglycerols (TAG) and steryl esters (STE). Four gene products, namely the TAG synthases Dga1p and Lro1p, and the STE synthases Are1p and Are2p contribute to storage lipid synthesis. A yeast strain lacking the four respective genes is devoid of lipid particles thus providing a valuable tool to study the physiological role of storage lipids and lipid particles. Using a dga1lro1are1are2 quadruple mutant transformed with plasmids bearing inducible DGA1, LRO1, or ARE2 we demonstrate that TAG synthesis contributes more efficiently to lipid particle proliferation than synthesis of STE. Moreover, we show that proteins typically located to lipid particles in wild type such as Erg1p, Erg6p, Erg7p, and Ayr1p are refined to microsomal fractions of the dga1lro1are1are2 quadruple mutant. This result confirms the close relationship between lipid particles and endoplasmic reticulum. Most interestingly, the amount of the squalene epoxidase Erg1p, which is dually located in lipid particles and endoplasmic reticulum of wild type, is decreased in the quadruple mutant, whereas amounts of other lipid particle proteins tested were not reduced. This decrease is not caused by downregulation of ERG1 transcription but by the low stability of Erg1p in the quadruple mutant. Because a similar effect was also observed in are1are2 mutants this finding can be mainly attributed to the lack of STE. The quadruple mutant, however, was more sensitive to terbinafine, an inhibitor of Erg1p, than the are1are2 strain suggesting that the presence of TAG and/or intact lipid particles has an additional protective effect. In a strain lacking the two STE synthases, Are1p and Are2p, incorporation of ergosterol into the plasma membrane was reduced, although the total cellular amount of free ergosterol was higher in the mutant than in wild type. Thus, an esterification/deacylation mechanism appears to contribute to the supply of ergosterol to the plasma membrane.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, G (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at		Athenstaedt, Karin/0000-0001-7198-3989				Athenstaedt K, 1997, J BACTERIOL, V179, P7611, DOI 10.1128/jb.179.24.7611-7616.1997; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Daum G, 1999, YEAST, V15, P601, DOI 10.1002/(SICI)1097-0061(199905)15:7<601::AID-YEA390>3.0.CO;2-N; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; Lacey DJ, 1999, PLANT J, V17, P397, DOI 10.1046/j.1365-313X.1999.00387.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; LEBER R, 1995, BBA-BIOMEMBRANES, V1234, P119, DOI 10.1016/0005-2736(94)00270-Y; Leber R, 2001, EUR J BIOCHEM, V268, P914, DOI 10.1046/j.1432-1327.2001.01940.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MBAYA B, 1989, LIPIDS, V24, P1020, DOI 10.1007/BF02544072; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Quail M A, 1996, Methods Mol Biol, V53, P123; Routaboul JM, 1999, PLANT PHYSIOL BIOCH, V37, P831, DOI 10.1016/S0981-9428(99)00115-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Shibata N, 2001, P NATL ACAD SCI USA, V98, P2244, DOI 10.1073/pnas.041620398; SIBORSKI RS, 1989, GENETICS, V122, P19; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; Zou JT, 1999, PLANT J, V19, P645, DOI 10.1046/j.1365-313x.1999.00555.x; Zweytick D, 2000, EUR J BIOCHEM, V267, P1075, DOI 10.1046/j.1432-1327.2000.01103.x; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	42	93	96	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31190	31196		10.1074/jbc.M403251200	http://dx.doi.org/10.1074/jbc.M403251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155725	hybrid			2022-12-25	WOS:000222726800037
J	Kathuria, H; Cao, YX; Ramirez, MI; Williams, MC				Kathuria, H; Cao, YX; Ramirez, MI; Williams, MC			Transcription of the caveolin-1 gene is differentially regulated in lung type I epithelial and endothelial cell lines - A role for ETS proteins in epithelial cell expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROGRESSION; MESSENGER-RNA; PROMOTER; IDENTIFICATION; ACTIVATION; BINDING; TRAFFICKING; ASSOCIATION; SEQUENCES; REPRESSOR	In the lung, caveolin-1 is expressed in both type I alveolar epithelial and endothelial cells where it is hypothesized to modulate molecular signaling activities and progression of tumorigenesis. Developmentally, caveolin-1alpha is expressed in fetal lung endothelial, but not epithelial, cells; in adult lung, both cell types express caveolin-1alpha. To test the hypothesis that caveolin-1 transcription is differentially regulated in type I and endothelial cells, we characterized the proximal promoter of the mouse caveolin-1 gene in lung cell lines to identify factors that control its cell-specific expression. We show that caveolin-1 expression is regulated by an Ets cis-element in a lung epithelial cell line, but not a lung endothelial cell line, and that three ETS family members, ETS-1, PEA3, and ERM, recognize and bind the Ets site in the epithelial cell line. Based on these findings, we have identified the Ets cis-element as a region that accounts for differential transcriptional regulation of caveolin-1 in lung epithelial and endothelial cells.	Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Anat, Boston, MA 02118 USA	Boston University; Boston University	Kathuria, H (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 80 E Concord St, Boston, MA 02118 USA.	hasmeena.kathuria@bmc.org	Kathuria, Hasmeena/I-4169-2019	Kathuria, Hasmeena/0000-0002-9062-409X; Cao, Yu-Xia/0000-0001-7396-9988; Ramirez, Maria Isabel/0000-0001-6294-4419	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073605] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073605] Funding Source: Medline; PHS HHS [47049] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akeson AL, 2000, DEV DYNAM, V217, P11, DOI 10.1002/(SICI)1097-0177(200001)217:1<11::AID-DVDY2>3.0.CO;2-L; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Bonner AE, 2004, ONCOGENE, V23, P1166, DOI 10.1038/sj.onc.1207234; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Cao YX, 2003, J CELL BIOCHEM, V89, P887, DOI 10.1002/jcb.10555; CAO YX, 2001, AM J RESP CRIT CARE, V163, P575; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Chen YH, 2003, J BIOL CHEM, V278, P39572, DOI 10.1074/jbc.M308179200; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DING W, 2003, GENE, V332, P175; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; Fuchs S, 2003, CELL TISSUE RES, V311, P31, DOI 10.1007/s00441-002-0653-5; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Horiuchi S, 2003, J PATHOL, V200, P568, DOI 10.1002/path.1387; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; Lu Z, 2003, BIOCHEM BIOPH RES CO, V303, P190, DOI 10.1016/S0006-291X(03)00314-0; Maier H, 2003, MOL CELL BIOL, V23, P1946, DOI 10.1128/MCB.23.6.1946-1960.2003; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Martin CSS, 2004, J VIROL, V78, P2310, DOI 10.1128/JVI.78.5.2310-2318.2004; Marx J, 2001, SCIENCE, V294, P1862, DOI 10.1126/science.294.5548.1862; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Park DS, 2003, BIOCHEMISTRY-US, V42, P15124, DOI 10.1021/bi0356348; Parton RG, 2001, SCIENCE, V293, P2404, DOI 10.1126/science.1065677; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Perez A, 2003, J BIOL CHEM, V278, P36942, DOI 10.1074/jbc.M300264200; Peters PJ, 2003, J CELL BIOL, V162, P703, DOI 10.1083/jcb.200304140; Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Ramirez MI, 2002, J HISTOCHEM CYTOCHEM, V50, P33, DOI 10.1177/002215540205000104; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Takanami I, 2001, TUMOR BIOL, V22, P205, DOI 10.1159/000050617; TAKEFUMI S, 2003, CANCER, V97, P1225; Tsokos GC, 2003, ANN NY ACAD SCI, V987, P240, DOI 10.1111/j.1749-6632.2003.tb06054.x; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	56	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30028	30036		10.1074/jbc.M402236200	http://dx.doi.org/10.1074/jbc.M402236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138262	hybrid			2022-12-25	WOS:000222531900021
J	Reid, J; Svejstrup, JQ				Reid, J; Svejstrup, JQ			DNA damage-induced Def1-RNA polymerase II interaction and Def1 requirement for polymerase ubiquitylation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; NUCLEOTIDE EXCISION-REPAIR; LARGE SUBUNIT; SACCHAROMYCES-CEREVISIAE; DHFR GENE; DEGRADATION; COMPLEXES; REMOVAL; YEAST; CELLS	UV-induced DNA damage results in ubiquitylation and degradation of RNA polymerase II (RNAPII). In yeast, this requires the DEF1 gene, the product of which forms a complex with the transcription-coupling repair factor, Rad26. However, whether Def1 is directly involved in RNAPII ubiquitylation has remained unclear. Here we report the establishment of a reconstituted system for studying UV-induced RNAPII ubiquitylation, which mimics the known requirements for this process in vitro. Using this system, we show that Def1 is indeed directly required for RNAPII ubiquitylation. Moreover, Def1 interacts with RNAPII in a damage-dependent manner. These results support a model in which Def1 interacts with RNAPII in response to DNA damage, recruiting the ubiquitylation machinery to enable its modification and subsequent degradation.	Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Clare Hall Labs, Canc Res UK, London Res Inst, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Svejstrup, Jesper/0000-0003-4964-6147				Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kong SE, 2002, DNA REPAIR, V1, P731, DOI 10.1016/S1568-7864(02)00080-0; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Wang GL, 1999, MOL CELL BIOL, V19, P342; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a	21	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29875	29878		10.1074/jbc.C400185200	http://dx.doi.org/10.1074/jbc.C400185200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15166235	hybrid			2022-12-25	WOS:000222531900002
J	Srivastava, KK; Batra, S; Sassano, A; Li, YZ; Majchrzak, B; Kiyokawa, H; Altman, A; Fish, EN; Platanias, LC				Srivastava, KK; Batra, S; Sassano, A; Li, YZ; Majchrzak, B; Kiyokawa, H; Altman, A; Fish, EN; Platanias, LC			Engagement of protein kinase C-theta in interferon signaling in T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TYROSINE PHOSPHORYLATION; STAT1 SERINE PHOSPHORYLATION; VAV PROTOONCOGENE PRODUCT; JUN NH2-TERMINAL KINASE; P70 S6 KINASE; I INTERFERONS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; MAP KINASE; IFN-GAMMA	Protein kinase C-theta (PKC-theta) plays important roles in the activation and survival of lymphocytes and is the predominant PKC isoform expressed in T-cells. Interferons regulate T-cell function and activation, but the precise signaling mechanisms by which they mediate such effects have not been elucidated. We determined whether PKC-theta is engaged in interferon (INF) signaling in T-cells. Both Type I (alpha, beta) and Type II (gamma) IFNs induced phosphorylation of PKC-theta in human T-cell lines and primary human T-lymphocytes. Such phosphorylation of PKC-theta resulted in activation of its kinase domain, suggesting that this kinase plays a functional role in interferon signaling. Consistent with this, inhibition of PKC-theta protein expression using small interfering RNAs (siRNA) abrogated IFN-alpha- and IFN-gamma-dependent gene transcription via GAS elements. Similarly, blocking of PKC-theta kinase activity by overexpression of a dominant-negative PKC-theta mutant also blocked GAS-driven transcription, further demonstrating a requirement for PKC-theta in IFN-dependent transcriptional activation. The effects of PKC-theta on IFN-dependent gene transcription were not mediated by regulation of the IFN-activated STAT pathway, as siRNA-mediated PKC-theta knockdown had no effects on STAT1 phosphorylation and binding of STAT1-containing complexes to SIE/GAS elements. On the other hand, siRNA-mediated PKC-theta inhibition blocked phosphorylation/activation of MKK4, suggesting that interferon-dependent PKC-theta activation regulates downstream engagement of MAP kinase pathways. Altogether, these findings demonstrate that PKC-theta is an interferon-inducible kinase and strongly suggest that it plays an important role in the generation of interferon-responses in T-cells.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; Univ Toronto, Div Cell & Mol Biol, Toronto Res Inst, Univ Network, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; La Jolla Institute for Immunology; University of Toronto; University of Toronto	Platanias, LC (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, 710 N Fairbanks Ave,Olson Pavil 8250, Chicago, IL 60611 USA.	1-platanias@northwestern.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [CA94079, CA77816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077816, R01CA094079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Altman A, 2002, J BIOCHEM, V132, P841, DOI 10.1093/oxfordjournals.jbchem.a003295; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; Avraham A, 1998, EUR J IMMUNOL, V28, P2320, DOI 10.1002/(SICI)1521-4141(199808)28:08<2320::AID-IMMU2320>3.0.CO;2-K; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Langer J, 1996, BIOTHERAPY, V8, P163, DOI 10.1007/BF01877201; Lekmine F, 2004, EXP CELL RES, V295, P173, DOI 10.1016/j.yexcr.2003.12.021; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Micouin A, 2000, ONCOGENE, V19, P387, DOI 10.1038/sj.onc.1203314; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Parmar Simrit, 2003, Current Opinion in Oncology, V15, P431, DOI 10.1097/00001622-200311000-00005; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka S, 2000, BIOPOLYMERS, V55, P254, DOI 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Platanias LC, 2003, PHARMACOL THERAPEUT, V98, P129, DOI 10.1016/S0163-7258(03)00016-0; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Schnaper HW, 2000, PEDIATR NEPHROL, V14, P254, DOI 10.1007/s004670050050; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; Verma A, 2002, J IMMUNOL, V168, P5984, DOI 10.4049/jimmunol.168.12.5984; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; WEN Z, 1995, CELL, V28, P241; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; Yu F, 1997, EXP CELL RES, V234, P240, DOI 10.1006/excr.1997.3621; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	64	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29911	29920		10.1074/jbc.M401997200	http://dx.doi.org/10.1074/jbc.M401997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150272	hybrid			2022-12-25	WOS:000222531900007
J	Thomae, TL; Glover, E; Bradfield, CA				Thomae, TL; Glover, E; Bradfield, CA			A maternal Ahr null genotype sensitizes embryos to chemical teratogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; EPITHELIAL-CELL DIFFERENTIATION; PATENT DUCTUS-VENOSUS; CLEFT-PALATE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN TCDD; DEVELOPMENTAL TOXICITY; EXTRACELLULAR-MATRIX; NUCLEAR TRANSLOCATOR; AROMATIC-HYDROCARBON; DEFICIENT MICE	The aryl hydrocarbon receptor (encoded by the Ahr locus) is a ligand-activated transcription factor that mediates the toxicology and teratology of 2,3,7,8-tetrachlorodibenzo-p-dioxin ( dioxin). In an effort to understand the role of the maternal compartment in dioxin teratology, we designed a breeding strategy that allowed us to compare the teratogenic response in embryos from Ahr(-/-) (null) and Ahr(+/+) (wild-type) dams. Using this strategy, we demonstrate that embryos from the Ahr(-/-) dams are 5-fold more sensitive to dioxin-induced cleft palate and hydronephrosis as compared with embryos from an Ahr(+/+) dam. Moreover, this increased teratogenic sensitivity extends beyond dioxin, because embryos from Ahr(-/-) dams exhibited a 9-fold increase in their sensitivity to the fetotoxic effects of the glucocorticoid, dexamethasone. In searching for an explanation for this increased sensitivity, we found that more dioxin and dexamethasone reached the embryos from Ahr(-/-) dams as compared with embryos from Ahr(+/+) dams. We propose that increased deposition of teratogens/fetotoxicants to the embryonic compartment is the result of porto-systemic shunting and/or blocked P4501A induction in Ahr(+/+) dams. In addition to demonstrating the importance of maternal AHR in teratogenesis, these data may have implications that reach beyond the mechanism of action of dioxin. In this regard, the Ahr(-/-) mouse may provide a system that allows pharmacological agents and toxicants to be more easily studied in a model where first pass clearance is a significant obstacle.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	Bradfield@oncology.wisc.edu			NIEHS NIH HHS [R01 ES006883] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006883] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1987, TERATOLOGY, V35, P329, DOI 10.1002/tera.1420350307; ABBOTT BD, 1989, TOXICOL APPL PHARM, V100, P119, DOI 10.1016/0041-008X(89)90096-3; ABBOTT BD, 1987, TERATOLOGY, V35, P335, DOI 10.1002/tera.1420350308; Abbott BD, 1996, TOXICOL APPL PHARM, V141, P256; ABBOTT BD, 1989, TOXICOL APPL PHARM, V99, P276, DOI 10.1016/0041-008X(89)90010-0; Andreola F, 1997, CANCER RES, V57, P2835; BEER AE, 1986, MEAD JOHNSON S PERIN, V24, P20; BENESOVA O, 1989, NEUROPHARMACOLOGY, V28, P89, DOI 10.1016/0028-3908(89)90073-7; BIRNBAUM LS, 1985, TOXICOL APPL PHARM, V77, P292, DOI 10.1016/0041-008X(85)90329-1; Bittencourt M A, 2000, Braz Dent J, V11, P117; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P682; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Burczynski ME, 2000, CANCER RES, V60, P908; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; CHAN WK, 1994, J BIOL CHEM, V269, P26464; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; Cummings AM, 1996, TOXICOL APPL PHARM, V138, P131, DOI 10.1006/taap.1996.0106; Dao D, 1998, HUM MOL GENET, V7, P597, DOI 10.1093/hmg/7.4.597; DEWAAL EJ, 1992, TOXICOL APPL PHARM, V115, P80, DOI 10.1016/0041-008X(92)90370-8; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; EMA M, 1994, J BIOL CHEM, V269, P27337; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; EPA, 2002, TEST METH EV SOL WAS, P1; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOLDMAN AS, 1978, NATURE, V272, P464, DOI 10.1038/272464a0; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; Hansen DK, 1999, TOXICOL SCI, V48, P230, DOI 10.1093/toxsci/48.2.230; Jacob S, 1999, GUT, V45, P442, DOI 10.1136/gut.45.3.442; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Knutson J. C., 1981, TOXICITY HALOGENATED, P187; KRAUTH J, 1983, J NEUROSCI METH, V9, P269, DOI 10.1016/0165-0270(83)90058-4; Kulkarni AP, 2001, CURR PHARM DESIGN, V7, P833, DOI 10.2174/1381612013397735; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Luch A, 1998, CHEM RES TOXICOL, V11, P686, DOI 10.1021/tx970236p; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Montenegro MA, 1998, J CRAN GENET DEV BIO, V18, P100; MOSIER HD, 1981, TERATOLOGY, V23, P15, DOI 10.1002/tera.1420230105; NATSUME N, 1986, INT J ORAL MAX SURG, V15, P752, DOI 10.1016/S0300-9785(86)80117-X; NAU H, 1981, TOXICOLOGY, V20, P299, DOI 10.1016/0300-483X(81)90037-8; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; Pisano MM, 2000, METH MOL B, V137, P267; POLAND A, 1989, MOL PHARMACOL, V36, P121; POLAND A, 1989, MOL PHARMACOL, V36, P113; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND AP, 1974, J BIOL CHEM, V249, P5599; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; SAUERBIER I, 1986, DRUG CHEM TOXICOL, V9, P25, DOI 10.3109/01480548609042827; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Taya Y, 1999, DEVELOPMENT, V126, P3869; Uchino T, 1996, GASTROENTEROLOGY, V110, P1964, DOI 10.1053/gast.1996.v110.pm8964424; WEBER H, 1985, TOXICOL LETT, V26, P159, DOI 10.1016/0378-4274(85)90161-4; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574	60	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30189	30194		10.1074/jbc.M403690200	http://dx.doi.org/10.1074/jbc.M403690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145931	hybrid			2022-12-25	WOS:000222531900041
J	Wu, CA; Tsujita, M; Hayashi, M; Yokoyama, S				Wu, CA; Tsujita, M; Hayashi, M; Yokoyama, S			Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; TANGIER-DISEASE; CELLULAR CHOLESTEROL; EXTRACELLULAR DOMAIN; PEST SEQUENCE; APOA-I; EFFLUX; MUTATIONS; ATHEROSCLEROSIS; PHOSPHORYLATION	Probucol has been shown to inhibit the release of cellular lipid by helical apolipoprotein and thereby to reduce plasma high density lipoprotein. We attempted to explore the underlying mechanism for this effect in human fibroblast WI-38. Probucol inhibited the apoA-I-mediated cellular lipid release and binding of apoA-I to the cells in a dose-dependent manner. It did not influence cellular uptake of low density lipoprotein, transport of cholesterol to the cell surface whether de novo synthesized or delivered as low density lipoprotein, and overall cellular content of cholesterol, although biosynthesis of lipids from acetate was somewhat increased. Probucol did not affect the mRNA level of ABCA1, and ABCA1 was recovered along with marker proteins for plasma membrane regardless of the presence of probucol. However, the protein level of ABCA1 increased, and the rate of its decay in the presence of cycloheximide was slower in the probucol-treated cells. ABCA1 in the probucol-treated cells was resistant to digestion by calpain but not by trypsin. We concluded that probucol inactivates ABCA1 in the plasma membrane with respect to its function in mediating binding of and lipid release by apolipoprotein and with respect to proteolytic degradation by calpain.	Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.	syokoyam@med.nagoya-cu.ac.jp		TSUJITA, MAKI/0000-0003-1108-621X				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2004, J BIOL CHEM, V279, P6217, DOI 10.1074/jbc.C300553200; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Costet P, 2000, J BIOL CHEM, V275, P28240; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GOTOH N, 1992, BIOCHIM BIOPHYS ACTA, V1128, P147, DOI 10.1016/0005-2760(92)90300-K; HARA H, 1991, J BIOL CHEM, V266, P3080; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; KUZUYA M, 1993, FREE RADICAL BIO MED, V14, P67, DOI 10.1016/0891-5849(93)90510-2; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; NISHIKAWA O, 1986, J BIOCHEM, V99, P295, DOI 10.1093/oxfordjournals.jbchem.a135473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PORN MI, 1993, J LIPID RES, V34, P1385; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SATONIN DK, 1986, J CHROMATOGR, V380, P401, DOI 10.1016/S0378-4347(00)83670-1; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; STANBRIDGE E, 1969, EXP CELL RES, V57, P397, DOI 10.1016/0014-4827(69)90166-9; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; YAMAMOTO A, 1986, AM J CARDIOL, V57, pH29, DOI 10.1016/0002-9149(86)90434-0; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811; YOKOYAMA S, 1988, ATHEROSCLEROSIS, V70, P179, DOI 10.1016/0021-9150(88)90114-1; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	48	81	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30168	30174		10.1074/jbc.M403765200	http://dx.doi.org/10.1074/jbc.M403765200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140889	hybrid			2022-12-25	WOS:000222531900038
J	Kolli, S; Zito, CI; Mossink, MH; Wiemer, EAC; Bennett, AM				Kolli, S; Zito, CI; Mossink, MH; Wiemer, EAC; Bennett, AM			The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-RELATED PROTEIN; KSR-1 GENE ENCODES; DRUG-RESISTANCE; FACTOR RECEPTOR; RIBONUCLEOPROTEIN-PARTICLES; PHOSPHOTYROSINE PHOSPHATASE; CELL-ADHESION; BREAST-CANCER; C-ELEGANS; ACTIVATION	The catalytic activity of the Src homology 2 (SH2) domain-containing tyrosine phosphatase, SHP-2, is required for virtually all of its signaling effects. Elucidating the molecular mechanisms of SHP-2 signaling, therefore, rests upon the identification of its target substrates. In this report, we have used SHP-2 substrate-trapping mutants to identify the major vault protein (MVP) as a putative SHP-2 substrate. MVP is the predominant component of vaults that are cytoplasmic ribonucleoprotein complexes of unknown function. We show that MVP is dephosphorylated by SHP-2 in vitro and it forms an enzyme-substrate complex with SHP-2 in vivo. In response to epidermal growth factor (EGF), SHP-2 associates via its SH2 domains with tyrosyl-phosphorylated MVP. MVP also interacts with the activated form of the extracellular-regulated kinases (Erks) in response to EGF and a constitutive complex between tyrosyl-phosphorylated MVP, SHP-2, and the Erks was detected in MCF-7 breast cancer cells. Using MVP-deficient fibroblasts, we demonstrate that MVP cooperates with Ras for optimal EGF-induced Elk-1 activation and is required for cell survival. We propose that MVP functions as a novel scaffold protein for both SHP-2 and Erk. The regulation of MVP tyrosyl phosphorylation by SHP-2 may play an important role in cell survival signaling.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Erasmus Med Ctr, Dept Med Oncol, NL-3000 DR Rotterdam, Netherlands	Yale University; Erasmus University Rotterdam; Erasmus MC	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, SHM-B 226D,333 Cedar St, New Haven, CT 06520 USA.	anton.bennett@yale.edu		Bennett, Anton/0000-0001-5187-7599; Wiemer, Erik/0000-0002-0673-7236	NATIONAL CANCER INSTITUTE [T32CA009085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046504] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09085] Funding Source: Medline; NIAMS NIH HHS [R01-AR46504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams A, 2000, J BIOL CHEM, V275, P27414; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHUGANI DC, 1993, J CELL SCI, V106, P23; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1611; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Herrmann C, 1996, J BIOL CHEM, V271, P13908, DOI 10.1074/jbc.271.23.13908; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Linn SC, 1997, INT J CANCER, V71, P787, DOI 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Morrison DK, 2001, J CELL SCI, V114, P1609; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Mossink MH, 2002, CANCER RES, V62, P7298; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pohl G, 1999, ANTICANCER RES, V19, P5051; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Suprenant KA, 2002, BIOCHEMISTRY-US, V41, P14447, DOI 10.1021/bi026747e; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; van Zon A, 2001, J BIOL CHEM, V276, P37715, DOI 10.1074/jbc.M106055200; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	59	107	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29374	29385		10.1074/jbc.M313955200	http://dx.doi.org/10.1074/jbc.M313955200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133037	hybrid			2022-12-25	WOS:000222445300069
J	Jensen, PE; Haldrup, A; Zhang, SP; Scheller, HV				Jensen, PE; Haldrup, A; Zhang, SP; Scheller, HV			The PSI-O subunit of plant photosystem I is involved in balancing the excitation pressure between the two photosystems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; STATE TRANSITIONS; H SUBUNIT; PROMOTER; TRANSFORMATION; IDENTIFICATION; PROTEINS; BINDING; GENES; DNA	PSI-O is a subunit of photosystem I in eukaryotes. The function of PSI-O was characterized in Arabidopsis plants using RNA interference. Several transformants with the psaO-RNAi construct were generated, and a high proportion of the plants contained only very little or virtually no residual PSI-O. Plants lacking PSI-O have a 50% reduction in state transitions indicating a role for PSI-O in the balancing of excitation energy between the two photosystems. PSI-H and -L have been shown previously to be involved in state transitions, and immunoblot analysis revealed that plants devoid of PSI-L or -H also have 80-90% reduction in the abundance of PSI-O. In contrast, down-regulation of PSI-O has no negative effect on the content of PSI-H and -L. The interaction between PSI-O and the PSI-L was confirmed by chemical cross-linking. A model of PSI is proposed in which PSI-L as the most ancient subunit is closest to the reaction center, and PSI-O is positioned close to PSI-L on the PSI-H/-L/-I side of the PSI complex. PSI-H, -L, -O, and possibly -I are all involved in forming a domain in PSI that is involved in the interaction with light-harvesting complex II.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Jensen, PE (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	peje@kvl.dk	Scheller, Henrik/AAH-4770-2020; Scheller, Henrik V/A-8106-2008; Jensen, Poul Erik/A-4862-2014	Scheller, Henrik/0000-0002-6702-3560; Scheller, Henrik V/0000-0002-6702-3560; Jensen, Poul Erik/0000-0001-6524-7723; Haldrup, Anna/0000-0002-2348-7072				Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; Asamizu E, 2000, DNA RES, V7, P175, DOI 10.1093/dnares/7.3.175; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Ganeteg U, 2001, PLANT PHYSIOL, V127, P150, DOI 10.1104/pp.127.1.150; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Haldrup A, 1999, PLANT J, V17, P689, DOI 10.1046/j.1365-313X.1999.00419.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2002, J BIOL CHEM, V277, P2798, DOI 10.1074/jbc.M110448200; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KAY R, 1987, SCIENCE, V236, P1299, DOI 10.1126/science.236.4806.1299; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Lunde C, 2003, PLANT CELL PHYSIOL, V44, P44, DOI 10.1093/pcp/pcg012; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1999, J BIOL CHEM, V274, P10784, DOI 10.1074/jbc.274.16.10784; ODELL JT, 1985, NATURE, V313, P810, DOI 10.1038/313810a0; SANDER L, 1995, PLANT MOL BIOL, V27, P165, DOI 10.1007/BF00019188; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; SHEN WJ, 1989, NUCLEIC ACIDS RES, V17, P8385, DOI 10.1093/nar/17.20.8385; Varotto C, 2002, PLANT PHYSIOL, V129, P616, DOI 10.1104/pp.002089; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525; Zhang SP, 2004, J BIOL CHEM, V279, P3180, DOI 10.1074/jbc.M311640200	32	66	78	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24212	24217		10.1074/jbc.M403147200	http://dx.doi.org/10.1074/jbc.M403147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15169790	hybrid			2022-12-25	WOS:000221702500045
J	Edwards, KM; Munger, K				Edwards, KM; Munger, K			Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli	ONCOGENE			English	Article						apoptosis; DnaJ; tumor suppressor; mitochondria	CYTOCHROME-C RELEASE; HUMAN DNAJ PROTEIN; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE; MOLECULAR CHAPERONES; OXIDATIVE STRESS; BAX; DROSOPHILA; GENE; EXPRESSION	The human homologue of the Drosophila tumor suppressor lethal ( 2) tumorous imaginal discs ( l( 2) tid) gene, hTID1, encodes two proteins derived from alternate mRNA splicing. The splice variants TidL and TidS were previously reported from protein overexpression and dominant-negative mutant protein studies to exhibit opposing biological activities in response to exogenous cytotoxic stimuli. TidL was found to promote apoptosis while TidS suppressed it. To elucidate the physiological function of hTID1, we depleted hTID1 proteins using the technique of RNA interference (RNAi). Here, we show that cells essentially lacking expression of hTID1 proteins are protected from cell death in response to multiple stimuli, including cisplatin, tumor necrosis factor alpha/ cycloheximide and mitomycin C. We also generated stable cell populations depleted of hTID1 proteins by RNAi using DNA vectors. In addition to apoptosis resistance, stable hTID1 knockdown cells exhibited an enhanced ability for anchorage-independent growth, as measured by an increase in soft-agar colony formation. These results suggest that hTID1 functions as an important cell death regulator and raise the interesting possibility that hTID1 could exert tumor suppressor activity.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, NRB 0958,77 Ave Louis Pasteur, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA081135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81135] Funding Source: Medline; NHLBI NIH HHS [HL56949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Benedict CA, 2003, CURR OPIN IMMUNOL, V15, P59, DOI 10.1016/S0952-7915(02)00018-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Canamasas I, 2003, J BIOL CHEM, V278, P30952, DOI 10.1074/jbc.M304225200; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gajkowska B, 2001, CELL BIOL INT, V25, P725, DOI 10.1006/cbir.2001.0768; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maroto R, 1997, J NEUROCHEM, V69, P514; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	50	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8419	8431		10.1038/sj.onc.1207732	http://dx.doi.org/10.1038/sj.onc.1207732			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15156195				2022-12-25	WOS:000224870700002
J	Toledo, MS; Suzuki, E; Handa, K; Hakomori, S				Toledo, MS; Suzuki, E; Handa, K; Hakomori, S			Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE-MEDIATED MODULATION; DENSITY-DEPENDENT REGULATION; METASTASIS SUPPRESSOR GENE; PROTEIN-TYROSINE KINASE; CAVEOLAE-LIKE DOMAINS; MELANOMA B16 CELLS; SIGNAL-TRANSDUCTION; BETA-CATENIN; GM3 GANGLIOSIDE; DOWN-REGULATION	Cell growth control mechanisms were studied based on organization of components in glycosphingolipid-enriched microdomain ( GEM) in WI38 cells versus their oncogenic transformant VA13 cells. Levels of fibroblast growth factor receptor ( FGFR) and cSrc were 4 times and 2 - 3 times higher, respectively, in VA13 than in WI38 GEM, whereas the level of tetraspanin CD9/CD81 was 3 - 5 times higher in WI38 than in VA13 GEM. Csk, the physiological inhibitor of cSrc, was present in WI38 but not in VA13 GEM. Functional association of GEM components in control of cell growth in WI38 is indicated by several lines of evidence. (i) Confluent, growth-inhibited WI38 showed a lower degree of FGF-induced MAPK activation than actively growing cells in sparse culture. (ii) The level of inactive cSrc ( with Tyr-527 phosphate) was higher in confluent cells than in actively growing cells. Both processes i and ii were inhibited by GM3 since they were enhanced by GM3 depletion with D-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4). (iii) The high level of inactive cSrc associated with growth-inhibited cells was caused by coexisting Csk in WI38 GEM. (iv) Interaction of GM3 with FGFR was demonstrated by binding of GM3 to FGFR in the GEM fraction, as probed with GM3-coated beads, and by confocal microscopy. In contrast to WI38, both cSrc and MAPK in VA13 were strongly activated regardless of FGF stimulation or GM3 depletion by P4. Continuous, constitutive activation of both cSrc and MAPK was due to ( i) a much higher level of cSrc and FGFR in VA13 than in WI38 GEM, ( ii) their close association/ interaction in VA13 GEM as indicated by clear coimmunoprecipitation between cSrc and FGFR, and ( iii) the absence of Csk in VA13 GEM, making GEM incapable of inhibiting cSrc activation.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu	de Toledo, Marcos Sergio/M-7185-2019; Suzuki, Erika/B-3456-2008; Toledo, Marcos S/B-6243-2008	de Toledo, Marcos Sergio/0000-0002-6605-0874; Suzuki, Erika/0000-0002-4010-8716; 	NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 80054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERCROMBIE M, 1953, EXP CELL RES, V5, P111, DOI 10.1016/0014-4827(53)90098-6; ABERCROMBIE M, 1962, CANCER RES, V22, P525; Anderson RGW, 2003, TRENDS CELL BIOL, V13, P534, DOI 10.1016/j.tcb.2003.08.007; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bagnato C, 2003, J BIOL CHEM, V278, P52203, DOI 10.1074/jbc.M305760200; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; Gospodarowicz D, 1979, Recent Prog Horm Res, V35, P375; GRANZER E, 1964, H-S Z PHYSIOL CHEM, V337, P52, DOI 10.1515/bchm2.1964.337.1.52; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HAKOMORI SI, 1970, P NATL ACAD SCI USA, V67, P1741, DOI 10.1073/pnas.67.4.1741; Handa K, 2001, BIOCHEM BIOPH RES CO, V285, P788, DOI 10.1006/bbrc.2001.5225; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HOLLEY RW, 1977, P NATL ACAD SCI USA, V74, P5046, DOI 10.1073/pnas.74.11.5046; HOLLEY RW, 1972, P NATL ACAD SCI USA, V69, P2840, DOI 10.1073/pnas.69.10.2840; Hollmann CA, 2001, ONCOGENE, V20, P7645, DOI 10.1038/sj.onc.1204980; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; SAKIYAMA H, 1972, P NATL ACAD SCI USA, V69, P872, DOI 10.1073/pnas.69.4.872; Satoh M, 2001, INT J ONCOL, V19, P723; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sekimoto H, 2003, ENDOCRINOLOGY, V144, P2546, DOI 10.1210/en.2003-0187; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Sorice M, 1997, J LIPID RES, V38, P969; Trembacz H, 2002, CELL MOL BIOL LETT, V7, P1047; Vukelic Z, 2001, GLYCOCONJUGATE J, V18, P429, DOI 10.1023/A:1016066816457; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; Zhang LF, 2002, CARCINOGENESIS, V23, P1251, DOI 10.1093/carcin/23.7.1251	63	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34655	34664		10.1074/jbc.M403857200	http://dx.doi.org/10.1074/jbc.M403857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15143068	hybrid			2022-12-25	WOS:000223134800070
J	Park, SY; Avraham, HK; Avraham, S				Park, SY; Avraham, HK; Avraham, S			RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; CELL-ADHESION; PYK2; PHOSPHORYLATION; FAK; MEGAKARYOCYTES; BRAIN	The related adhesion focal tyrosine kinase ( RAFTK), also known as Pyk2, undergoes autophosphorylation upon its stimulation. This leads to cascades of intracellular signaling that result in the regulation of various cellular activities. However, the molecular mechanism of RAFTK autophosphorylation is not yet known. Using various RAFTK constructs fused with two different tags, we found that the autophosphorylation of RAFTK was mediated by a trans-acting mechanism, not a cis-acting mechanism. In addition, overexpression of kinase-mutated RAFTK inhibited wild type RAFTK autophosphorylation in a dose-dependent manner by a trans-acting interaction. Trans-acting autophosphorylation was also observed between endogenous and exogenous RAFTK upon potassium depolarization of neuroendocrine PC12 cells. Using immunoprecipitation and affinity chromatography, we detected RAFTK self-association that was not affected by deletion of a single region or domain of RAFTK. Furthermore, RAFTK autophosphorylation occurred only at site Tyr(402) in a Src kinase activity-independent manner. However, Src significantly enhanced RAFTK-mediated paxillin phosphorylation, suggesting a key role for Src in RAFTK activation and phosphorylation of downstream substrates. Our results indicate that the activation of RAFTK occurs in several steps. First, upon stimulus, RAFTK trans-autophosphorylates Tyr(402). Second, phosphorylated Tyr(402) recruits and activates Src kinase that in turn phosphorylates RAFTK and enhances its kinase activity. Lastly, the enhanced RAFTK activity induces the activation of downstream signaling molecules. Taken together, these studies provide insights into the molecular mechanism of RAFTK autophosphorylation and the specific role of Src in the regulation of RAFTK activation.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640; Park, Shin-Young/0000-0001-6385-4132	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER; NCI NIH HHS [CA97153] Funding Source: Medline; NIAMS NIH HHS [K18 PAR-02-069] Funding Source: Medline; NINDS NIH HHS [NS39558] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Benzing T, 2001, P NATL ACAD SCI USA, V98, P9784, DOI 10.1073/pnas.171269898; Bongiorno-Borbone L, 2002, J NEUROCHEM, V81, P1212, DOI 10.1046/j.1471-4159.2002.00906.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Katagiri T, 2000, J BIOL CHEM, V275, P19645, DOI 10.1074/jbc.M909828199; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	22	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33315	33322		10.1074/jbc.M313527200	http://dx.doi.org/10.1074/jbc.M313527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166227	hybrid			2022-12-25	WOS:000223039700038
J	Schweinitz, A; Steinmetzer, T; Banke, IJ; Arlt, MJE; Sturzebecher, A; Schuster, O; Geissler, A; Giersiefen, H; Zeslawska, E; Jacob, U; Kruger, A; Sturzebecher, J				Schweinitz, A; Steinmetzer, T; Banke, IJ; Arlt, MJE; Sturzebecher, A; Schuster, O; Geissler, A; Giersiefen, H; Zeslawska, E; Jacob, U; Kruger, A; Sturzebecher, J			Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITORS; SMALL-MOLECULE INHIBITORS; THROMBIN INHIBITORS; TUMOR INVASION; GROWTH-FACTOR; CANCER-CELLS; METASTASIS; RECEPTOR; BINDING; SYSTEM	The serine protease urokinase-type plasminogen activator (uPA) interacts with a specific receptor ( uPAR) on the surface of various cell types, including tumor cells, and plays a crucial role in pericellular proteolysis. High levels of uPA and uPAR often correlate with poor prognosis of cancer patients. Therefore, the specific inhibition of uPA with small molecule active-site inhibitors is one strategy to decrease the invasive and metastatic activity of tumor cells. We have developed a series of highly potent and selective uPA inhibitors with a C-terminal 4-amidinobenzylamide residue. Optimization was directed toward reducing the fast elimination from circulation that was observed with initial analogues. The x-ray structures of three inhibitor/uPA complexes have been solved and were used to improve the inhibition efficacy. One of the most potent and selective derivatives, benzylsulfonyl-D-Ser-Ser- 4-amidinobenzylamide ( inhibitor 26), inhibits uPA with a K-i of 20 nM. This inhibitor was used in a fibrosarcoma model in nude mice using lacZ-tagged human HT1080 cells, to prevent experimental lung metastasis formation. Compared with control (100%), an inhibitor dose of 2 x 1.5 mg/kg/day reduced the number of experimental metastases to 4.6 +/- 1%. Under these conditions inhibitor 26 also significantly prolonged survival. All mice from the control group died within 43 days after tumor cell inoculation, whereas 50% of mice from the inhibitor-treated group survived more than 117 days. This study demonstrates that the specific inhibition of uPA by these inhibitors may be a useful strategy for the treatment of cancer to prevent metastasis.	Curacyte Chem GmbH, D-07745 Jena, Germany; Tech Univ Munich, Inst Expt Onkol & Therapieforsch, D-81675 Munich, Germany; Curacyte AG, D-80339 Munich, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Univ Jena Klinikum, Zentrum Vaskulare Biol & Med, D-99089 Erfurt, Germany	Technical University of Munich; Max Planck Society; Friedrich Schiller University of Jena	Steinmetzer, T (corresponding author), Curacyte Chem GmbH, Winzerlaer Str 2, D-07745 Jena, Germany.	torsten.steinmetzer@curacyte.com		Zeslawska, Ewa/0000-0003-1946-9370				Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; ARNOLD RT, 1948, J AM CHEM SOC, V70, P2590, DOI 10.1021/ja01187a088; Banke IJ, 2003, BIOL CHEM, V384, P1515, DOI 10.1515/BC.2003.168; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Dullweber F, 2001, J MOL BIOL, V313, P593, DOI 10.1006/jmbi.2001.5062; Edwards DR, 1996, EXP GERONTOL, V31, P207, DOI 10.1016/0531-5565(95)02010-1; Eriksson H, 1999, THROMB HAEMOSTASIS, V81, P358; Eriksson UG, 2003, DRUG METAB DISPOS, V31, P294, DOI 10.1124/dmd.31.3.294; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Gustafsson D, 1998, THROMB HAEMOSTASIS, V79, P110; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Harbeck Nadia, 2002, Clin Breast Cancer, V3, P196, DOI 10.3816/CBC.2002.n.023; Hauptmann J, 2002, PHARM RES-DORDR, V19, P1027, DOI 10.1023/A:1016426724831; Jankun J, 2001, INT J MOL MED, V8, P365; Judkins BD, 1996, SYNTHETIC COMMUN, V26, P4351, DOI 10.1080/00397919608003838; KAISER B, 1987, PHARMAZIE, V42, P119; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; Klinghofer V, 2001, BIOCHEMISTRY-US, V40, P9125, DOI 10.1021/bi010186u; Kruger A, 1998, CANCER METAST REV, V17, P285, DOI 10.1023/A:1006066706040; Kunzel S, 2002, BIOORG MED CHEM LETT, V12, P645, DOI 10.1016/S0960-894X(01)00815-0; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Mammoto T, 2002, CANCER LETT, V184, P165, DOI 10.1016/S0304-3835(02)00210-0; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Ossowski L, 1996, BRAZ J MED BIOL RES, V29, P1099; Pallottini V, 2002, IUBMB LIFE, V54, P301, DOI 10.1080/15216540215672; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Praus M, 2002, INT J CANCER, V102, P584, DOI 10.1002/ijc.10767; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Renwinkel JBM, 1999, CURR PHARM DESIGN, V5, P1043; Reuning U, 2003, BIOL CHEM, V384, P1119, DOI 10.1515/BC.2003.125; Reuning U, 1998, INT J ONCOL, V13, P893; Rockway TW, 2003, EXPERT OPIN THER PAT, V13, P773, DOI 10.1517/eotp.13.6.773.23017; Rockway TW, 2002, CURR PHARM DESIGN, V8, P2541, DOI 10.2174/1381612023392676; ROWLAND M, 1995, CLIN PHARMACOKINET, P315; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmitt M, 2000, FIBRINOLYSIS PROTEOL, V14, P114, DOI 10.1054/fipr.2000.0079; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Sier CFM, 1998, CANCER RES, V58, P1843; Steinmetzer T, 2001, EXPERT OPIN INV DRUG, V10, P845, DOI 10.1517/13543784.10.5.845; Steinmetzer T, 2003, IDRUGS, V6, P138; Sturzebecher J, 1999, BIOORG MED CHEM LETT, V9, P3147, DOI 10.1016/S0960-894X(99)00541-7; Sturzebecher J, 1997, J MED CHEM, V40, P3091, DOI 10.1021/jm960668h; Tucker TJ, 1997, J MED CHEM, V40, P830, DOI 10.1021/jm960762y; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Zeslawska E, 2000, J MOL BIOL, V301, P465, DOI 10.1006/jmbi.2000.3966; Zeslawska E, 2003, J MOL BIOL, V328, P109, DOI 10.1016/S0022-2836(03)00267-5; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	55	119	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33613	33622		10.1074/jbc.M314151200	http://dx.doi.org/10.1074/jbc.M314151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15150279	hybrid			2022-12-25	WOS:000223039700070
J	Kao, MC; Di Bernardo, S; Perego, M; Nakamaru-Ogiso, E; Matsuno-Yagi, A; Yagi, T				Kao, MC; Di Bernardo, S; Perego, M; Nakamaru-Ogiso, E; Matsuno-Yagi, A; Yagi, T			Functional roles of four conserved charged residues in the membrane domain subunit NuoA of the proton-translocating NADH-quinone oxidoreductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; RHODOBACTER-CAPSULATUS; MISSENSE MUTATION; RESPIRATORY-CHAIN; PROTEIN-STRUCTURE; READING FRAME; NDH-1; STOICHIOMETRY	The H+(Na+)-translocating NADH-quinone (Q) oxidoreductase (NDH-1) of Escherichia coli is composed of 13 different subunits (NuoA-N). Subunit NuoA (ND3, Nqo7) is one of the seven membrane domain subunits that are considered to be involved in H+(Na+) translocation. We demonstrated that in the Paracoccus denitrificans NDH-1 subunit, Nqo7 ( ND3) directly interacts with peripheral subunits Nqo6 (PSST) and Nqo4 ( 49 kDa) by using cross-linkers (Di Bernardo, S., and Yagi, T. (2001) FEBS Lett. 508, 385-388 and Kao, M.-C., Matsuno-Yagi, A., and Yagi, T. ( 2004) Biochemistry 43, 3750-3755). To investigate the structural and functional roles of conserved charged amino acid residues, a nuoA knock-out mutant and site-specific mutants K46A, E51A, D79N, D79A, E81Q, E81A, and D79N/E81Q were constructed by utilizing chromosomal DNA manipulation. In terms of immunochemical and NADH dehydrogenase activity-staining analyses, all site-specific mutants are similar to the wild type, suggesting that those NuoA site-specific mutations do not significantly affect the assembly of peripheral subunits in situ. In addition, site-specific mutants showed similar deamino-NADH-K3Fe(CN)(6) reductase activity to the wild type. The K46A mutation scarcely inhibited deamino-NADH-Q reductase activity. In contrast, E51A, D79A, D79N, E81A, and E81Q mutation partially suppressed deamino-NADH-Q reductase activity to 30, 90, 40, 40, and 50%, respectively. The double mutant D79N/E81Q almost completely lost the energy-transducing NDH-1 activities but did not display any loss of deamino-NADH-K3Fe(CN)(6) reductase activity. The possible functional roles of residues Asp-79 and Glu-81 were discussed.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Matsuno-Yagi, A (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	yagi@scripps.edu; yagi2@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055594, R01GM033712] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM33712, R01GM55594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amarneh B, 2003, BIOCHEMISTRY-US, V42, P4800, DOI 10.1021/bi0340346; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Carelli V, 1999, ANN NEUROL, V45, P320, DOI 10.1002/1531-8249(199903)45:3<320::AID-ANA7>3.0.CO;2-L; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chevallet M, 1997, EUR J BIOCHEM, V250, P451, DOI 10.1111/j.1432-1033.1997.0451a.x; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; Clapham DE, 1998, NAT STRUCT BIOL, V5, P342, DOI 10.1038/nsb0598-342; Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Di Bernardo S, 2000, BIOCHEMISTRY-US, V39, P9411; Di Bernardo S, 2001, FEBS LETT, V508, P385, DOI 10.1016/S0014-5793(01)03111-8; Falk-Krzesinski HJ, 1998, J BACTERIOL, V180, P1174, DOI 10.1128/JB.180.5.1174-1184.1998; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Flemming D, 2003, J BIOL CHEM, V278, P47602, DOI 10.1074/jbc.M308967200; Flemming D, 2003, J BIOL CHEM, V278, P3055, DOI 10.1074/jbc.M208849200; Friedrich T, 1998, BBA-BIOENERGETICS, V1365, P215, DOI 10.1016/S0005-2728(98)00070-X; Galkin AS, 1999, FEBS LETT, V451, P157, DOI 10.1016/S0014-5793(99)00575-X; Garofano A, 2003, J BIOL CHEM, V278, P42435, DOI 10.1074/jbc.M305819200; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Greenamyre JT, 2001, IUBMB LIFE, V52, P135, DOI 10.1080/15216540152845939; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; HASSINEN IE, 1993, BIOCHIM BIOPHYS ACTA, V1144, P107, DOI 10.1016/0005-2728(93)90164-B; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kao MC, 2004, BIOCHEMISTRY-US, V43, P3750, DOI 10.1021/bi049927s; Kao MC, 2003, BIOCHEMISTRY-US, V42, P4534, DOI 10.1021/bi034166z; Kao MC, 2002, BIOCHEMISTRY-US, V41, P4377, DOI 10.1021/bi025525d; Kervinen M, 2004, BIOCHEMISTRY-US, V43, P773, DOI 10.1021/bi0355903; Kurki S, 2000, BIOCHEMISTRY-US, V39, P13496, DOI 10.1021/bi001134s; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Lunardi J, 1998, BBA-MOL BASIS DIS, V1407, P114, DOI 10.1016/S0925-4439(98)00036-2; Majander A, 1996, EUR J BIOCHEM, V239, P201, DOI 10.1111/j.1432-1033.1996.0201u.x; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787; MURPHY E, 1985, EMBO J, V4, P3357, DOI 10.1002/j.1460-2075.1985.tb04089.x; Nakamaru-Ogiso E, 2003, FEBS LETT, V549, P43, DOI 10.1016/S0014-5793(03)00766-X; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; Satoh T, 1996, BBA-BIOENERGETICS, V1273, P21, DOI 10.1016/0005-2728(95)00131-X; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; Steuber J, 2003, J BIOL CHEM, V278, P26817, DOI 10.1074/jbc.M301682200; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; YAGI T, 1987, BIOCHEMISTRY-US, V26, P2822, DOI 10.1021/bi00384a025; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; YAGI T, 2004, RESP ARCHAEA BACTERI, P15; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; Yano T, 1999, J BIOL CHEM, V274, P28606, DOI 10.1074/jbc.274.40.28606; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; ZHANG Y, 1994, J BIOL CHEM, V269, P5473	55	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32360	32366		10.1074/jbc.M403885200	http://dx.doi.org/10.1074/jbc.M403885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175326	hybrid			2022-12-25	WOS:000222849700048
J	Lanciault, C; Champoux, JJ				Lanciault, C; Champoux, JJ			Single unpaired nucleotides facilitate HIV-1 reverse transcriptase displacement synthesis through duplex RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; IN-VITRO ANALYSIS; DNA-SYNTHESIS; NUCLEOCAPSID PROTEIN; SECONDARY STRUCTURE; STRAND TRANSFER; POLYPURINE TRACT; AVIAN RETROVIRUS; TYPE-1	During reverse transcription of viral RNA, HIV-1 reverse transcriptase (RT) encounters RNA stem-loop structures that require displacement synthesis activity in which RT disrupts the RNA helix to access the template strand. A primer extension assay was developed to assess HIV-1 RT RNA displacement synthesis activity in vitro. Initial results revealed that HIV-1 RT performs only limited amounts of RNA displacement through long stretches of RNA duplex, with the majority of synthesis stalling at sequence-dependent pause positions. DNA displacement synthesis through the same sequence, however, proceeded rapidly to the end of the template. The RNA folding algorithm mfold indicated that the presence of an unpaired nucleotide, or "bulge," along the RNA duplex would promote helix melting ahead of the DNA primer terminus to create a small gap of nondisplacement synthesis. Primer extension assays using substrates possessing single-nucleotide bulges in the nontemplate strand near pause sites resulted in diminished pausing at positions within the predicted melted region. Surprisingly, the bulges also reduced pausing distal to the bulge at positions that are expected to remain base-paired. Further analysis revealed that stalling during RNA displacement synthesis results from the displaced RNA re-annealing to the template strand thus forcing the primer terminus to become unpaired and, therefore, not extendable. Introduction of a bulge facilitates displacement synthesis through distal regions by increasing RT processivity in the vicinity of a bulge and reducing the impact of branch migration on primer extension.	Univ Washington, Dept Microbiol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Dept Microbiol, Sch Med, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMACKER M, 1995, J VIROL, V69, P6273, DOI 10.1128/JVI.69.10.6273-6279.1995; Amacker M, 1997, AIDS, V11, P534; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Bibillo A, 2002, J BIOL CHEM, V277, P34836, DOI 10.1074/jbc.M204345200; BOONE LR, 1981, J VIROL, V37, P117, DOI 10.1128/JVI.37.1.117-126.1981; BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; COFFIN JM, 1997, RETROVIRUSES, P121; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Fisher TS, 2003, J MOL BIOL, V325, P443, DOI 10.1016/S0022-2836(02)01225-1; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; Fuentes GM, 1996, J BIOL CHEM, V271, P29605, DOI 10.1074/jbc.271.47.29605; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; Hameau L, 2001, J VIROL, V75, P3301, DOI 10.1128/JVI.75.7.3301-3313.2001; HILLEBRAND GG, 1985, J BIOL CHEM, V260, P3116; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KUNG HJ, 1981, J VIROL, V37, P127, DOI 10.1128/JVI.37.1.127-138.1981; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; MCDONALD WF, 1994, J BIOL CHEM, V269, P31190; MOK M, 1987, J BIOL CHEM, V262, P2304; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; Pop MP, 1996, BIOCHEMISTRY-US, V35, P5054, DOI 10.1021/bi9530292; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; Tasara T, 1999, BIOCHEMISTRY-US, V38, P1633, DOI 10.1021/bi9821162; TAYLOR JM, 1983, J VIROL, V48, P654, DOI 10.1128/JVI.48.3.654-659.1983; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; Whiting SH, 1998, J MOL BIOL, V278, P559, DOI 10.1006/jmbi.1998.1720; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Xiong Y, 2000, RNA, V6, P1316, DOI 10.1017/S135583820000090X; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	44	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32252	32261		10.1074/jbc.M404117200	http://dx.doi.org/10.1074/jbc.M404117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169769	hybrid			2022-12-25	WOS:000222849700033
J	Li, J; Wynn, RM; Machius, M; Chuang, JL; Karthikeyan, S; Tomchick, DR; Chuang, DT				Li, J; Wynn, RM; Machius, M; Chuang, JL; Karthikeyan, S; Tomchick, DR; Chuang, DT			Cross-talk between thiamin diphosphate binding and phosphorylation loop conformation in human branched-chain alpha-keto acid decarboxylase/dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; ACTIVE-SITE; KINASE; RAT; RECONSTITUTION; EXPRESSION	The decarboxylase/dehydrogenase (E1b) component of the 4-megadalton human branched-chain alpha-keto acid dehydrogenase (BCKD) metabolic machine is a thiamin diphosphate (ThDP)-dependent enzyme with a heterotetrameric cofactor-binding fold. The E1b component catalyzes the decarboxylation of alpha-keto acids and the subsequent reductive acylation of the lipoic acid-bearing domain (LBD) from the 24-meric transacylase (E2b) core. In the present study, we show that the binding of cofactor ThDP to the E1b active site induces a disorder-to-order transition of the conserved phosphorylation loop carrying the two phosphorylation sites Ser(292)-alpha and Ser(302)-alpha, as deduced from the 1.80-1.85 Angstrom apoE1b and holoE1b structures. The induced loop conformation is essential for the recognition of lipoylated LBD to initiate E1b-catalyzed reductive acylation. Alterations of invariant Arg(287)-alpha, Asp(295)-alpha, Tyr(300)-alpha, and Arg(301)-alpha that form a hydrogen-bonding network in the phosphorylation loop result in the disordering of the loop conformation as elucidated by limited proteolysis, accompanied by the impaired binding and diminished reductive acylation of lipoylated LBD. In contrast, k(cat) values for E1b-catalyzed decarboxylation of the alpha-keto acid are higher in these E1b mutants than in wild-type E1b, with higher K-m values for the substrate in the mutants. ThDP binding that orders the loop prevents phosphorylation of E1b by the BCKD kinase and averts the inactivation of wild-type E1b, but not the above mutants, by this covalent modification. Our results establish that the cross-talk between the bound ThDP and the phosphorylation loop conformation serves as a feed-forward switch for multiple reaction steps in the BCKD metabolic machine.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.chuang@utsouthwestern.edu	Tomchick, Diana/HGV-2018-2022; Karthikeyan, Subramanian/F-8808-2010	Wynn, Richard/0000-0002-1879-2136; Tomchick, Diana/0000-0002-7529-4643	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062306, R56DK062306, R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758, DK-62306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BETTENDORFF L, 1994, BBA-MOL CELL RES, V1222, P1, DOI 10.1016/0167-4889(94)90018-3; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; CHUANG DT, 2001, ENCY MOL MED, V5, P393; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Chuang JL, 2002, J BIOL CHEM, V277, P36905, DOI 10.1074/jbc.C200430200; Chuang JL, 2004, J BIOL CHEM, V279, P17792, DOI 10.1074/jbc.M313879200; Ciszak EM, 2003, J BIOL CHEM, V278, P21240, DOI 10.1074/jbc.M300339200; COOK KG, 1985, BIOCHEM J, V225, P731, DOI 10.1042/bj2250731; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fries M, 2003, EUR J BIOCHEM, V270, P861, DOI 10.1046/j.1432-1033.2003.03444.x; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; Iakoucheva LM, 2004, NUCLEIC ACIDS RES, V32, P1037, DOI 10.1093/nar/gkh253; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan F, 2003, NAT PROD REP, V20, P184, DOI 10.1039/b111348h; Karthikeyan S, 2003, BIOCHEMISTRY-US, V42, P12532, DOI 10.1021/bi035450t; LAKOWICZ JR, 1983, BIOCHEMISTRY-US, V22, P1741, DOI 10.1021/bi00277a001; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MULLINAX TR, 1985, ARCH BIOCHEM BIOPHYS, V243, P655, DOI 10.1016/0003-9861(85)90543-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nemeria N, 2001, J BIOL CHEM, V276, P45969, DOI 10.1074/jbc.M104116200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAXTON R, 1982, J BIOL CHEM, V257, P4433; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SCHELLENBERGER V, 1991, EUR J BIOCHEM, V199, P623, DOI 10.1111/j.1432-1033.1991.tb16163.x; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; Song QL, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-8; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 2003, J BIOL CHEM, V278, P43402, DOI 10.1074/jbc.M306204200	39	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32968	32978		10.1074/jbc.M403611200	http://dx.doi.org/10.1074/jbc.M403611200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166214	hybrid			2022-12-25	WOS:000222849700117
J	Merkel, AB; Major, LL; Errey, JC; Burkart, MD; Field, RA; Walsh, CT; Naismith, JN				Merkel, AB; Major, LL; Errey, JC; Burkart, MD; Field, RA; Walsh, CT; Naismith, JN			The position of a key tyrosine in dTDP-4-Keto-6-deoxy-D-glucose-5-epimerase (EvaD) alters the substrate profile for this RmlC-like enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPEPTIDE ANTIBIOTICS; VANCOMYCIN-GROUP; STAPHYLOCOCCUS-AUREUS; BIOSYNTHETIC PATHWAYS; L-EPIVANCOSAMINE; MODE; DTDP; DIMERIZATION; 3,5-EPIMERASE; RESISTANCE	Vancomycin, the last line of defense antibiotic, depends upon the attachment of the carbohydrate vancosamine to an aglycone skeleton for antibacterial activity. Vancomycin is a naturally occurring secondary metabolite that can be produced by bacterial fermentation. To combat emerging resistance, it has been proposed to genetically engineer bacteria to produce analogues of vancomycin. This requires a detailed understanding of the biochemical steps in the synthesis of vancomycin. Here we report the 1.4 Angstrom structure and biochemical characterization of EvaD, an RmlC-like protein that is required for the C-5' epimerization during synthesis of dTDP-epivancosamine. EvaD, although clearly belonging to the RmlC class of enzymes, displays very low activity in the archetypal RmlC reaction ( double epimerization of dTDP-6-deoxy-4-keto-D-glucose at C-3' and C-5'). The high resolution structure of EvaD compared with the structures of authentic RmlC enzymes indicates that a subtle change in the enzyme active site repositions a key catalytic Tyr residue. A mutant designed to re-establish the normal position of the Tyr increases the RmlC-like activity of EvaD.	Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ E Anglia, Sch Chem Sci & Pharm, Ctr Carbohydrate Chem, Norwich NR4 7TJ, Norfolk, England; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of St Andrews; University of East Anglia; Harvard University; Harvard Medical School	Naismith, JN (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	naismith@st-and.ac.uk	Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Major, Louise/0000-0001-5287-4488; Field, Rob/0000-0001-8574-0275	Biotechnology and Biological Sciences Research Council [BBS/E/J/000C0618] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Albermann C, 2003, ORG LETT, V5, P933, DOI 10.1021/ol0341086; Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNA JCJ, 1984, ANNU REV MICROBIOL, V38, P339, DOI 10.1146/annurev.mi.38.100184.002011; Blankenfeldt W, 2002, STRUCTURE, V10, P773, DOI 10.1016/S0969-2126(02)00770-0; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Christendat D, 2000, J BIOL CHEM, V275, P24608, DOI 10.1074/jbc.C000238200; Dong CJ, 2003, STRUCTURE, V11, P715, DOI 10.1016/S0969-2126(03)00098-4; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; FOLDES M, 1983, J ANTIMICROB CHEMOTH, V11, P21, DOI 10.1093/jac/11.1.21; Gaisser S, 2002, CHEM COMMUN, P618, DOI 10.1039/b200536k; Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; Giraud MF, 2000, NAT STRUCT BIOL, V7, P398; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; Hubbard BK, 2003, ANGEW CHEM INT EDIT, V42, P730, DOI 10.1002/anie.200390202; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirkpatrick PN, 2000, CHEM COMMUN, P1565, DOI 10.1039/b004463f; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P548; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1992, CRYSTALLOGRAPHY, V26, P1; MACKAY JP, 1994, J AM CHEM SOC, V116, P4573, DOI 10.1021/ja00090a005; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; McAtee JJ, 2002, BIOORG MED CHEM LETT, V12, P1319, DOI 10.1016/S0960-894X(02)00130-0; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Merkel AB, 2002, ACTA CRYSTALLOGR D, V58, P1226, DOI 10.1107/S0907444902007382; Meyers CLF, 2003, BIOCHEMISTRY-US, V42, P4179, DOI 10.1021/bi0340088; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P240, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<240::AID-ANIE240>3.0.CO;2-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pootoolal J, 2002, ANNU REV PHARMACOL, V42, P381, DOI 10.1146/annurev.pharmtox.42.091601.142813; Rodriguez L, 2002, CHEM BIOL, V9, P721, DOI 10.1016/S1074-5521(02)00154-0; Sharman GJ, 1997, CHEM COMMUN, P723, DOI 10.1039/a608477j; Trefzer A, 2002, J AM CHEM SOC, V124, P6056, DOI 10.1021/ja017385l; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WATANAKUNAKORN C, 1984, J ANTIMICROB CHEMOTH, V14, P7, DOI 10.1093/jac/14.suppl_D.7	39	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32684	32691		10.1074/jbc.M404091200	http://dx.doi.org/10.1074/jbc.M404091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159413	hybrid			2022-12-25	WOS:000222849700087
J	Palaniyar, N; Nadesalingam, J; Clark, H; Shih, MJ; Dodds, AW; Reid, KBM				Palaniyar, N; Nadesalingam, J; Clark, H; Shih, MJ; Dodds, AW; Reid, KBM			Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-DNA; BRONCHOALVEOLAR LAVAGE; CYSTIC-FIBROSIS; IN-VITRO; ASPERGILLUS-FUMIGATUS; CRYSTAL-STRUCTURE; APOPTOTIC CELLS; CPG MOTIFS; CLEARANCE; C1Q	Collectins are a family of innate immune proteins that contain fibrillar collagen-like regions and globular carbohydrate recognition domains (CRDs). The CRDs of these proteins recognize various microbial surface-specific carbohydrate patterns, particularly hexoses. We hypothesized that collectins, such as pulmonary surfactant proteins (SPs) SP-A and SP-D and serum protein mannose-binding lectin, could recognize nucleic acids, pentose-based anionic phosphate polymers. Here we show that collectins bind DNA from a variety of origins, including bacteria, mice, and synthetic oligonucleotides. Pentoses, such as arabinose, ribose, and deoxyribose, inhibit the interaction between SP-D and mannan, one of the well-studied hexose ligands for SP-D, and biologically relevant D-forms of the pentoses are better competitors than the L-forms. In addition, DNA and RNA polymer-related compounds, such as nucleotide diphosphates and triphosphates, also inhibit the carbohydrate binding ability of SP-D, or similar to60 kDa trimeric recombinant fragments of SP-D that are composed of the alpha-helical coiled-coil neck region and three CRDs (SP-D(n/CRD)) or SP-D(n/CRD) with eight GXY repeats (SPD(GXY)(8)(n/CRD)). Direct binding and competition studies suggest that collectins bind nucleic acid via their CRDs as well as by their collagen-like regions, and that SP-D binds DNA more effectively than do SP-A and mannose-binding lectin at physiological salt conditions. Furthermore, the SP-D(GXY)(8)(n/CRD) fragments co-localize with DNA, and the protein competes the interaction between propidium iodide, a DNA-binding dye, and apoptotic cells. In conclusion, we show that collectins are a new class of proteins that bind free DNA and the DNA present on apoptotic cells by both their globular CRDs and collagen-like regions. Collectins may therefore play an important role in decreasing the inflammation caused by DNA in lungs and other tissues.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Hosp Sick Children, Res Inst, Lung Biol Res Program, Toronto, ON M5G 1X8, Canada	University of Oxford; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Palaniyar, N (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	Nades@bioch.ox.ac.uk		Dodds, Alister William/0000-0003-3396-1257; Clark, Howard/0000-0001-7354-2028; Palaniyar, Nades/0000-0002-2170-8548				Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Clark H, 2002, J IMMUNOL, V169, P2892, DOI 10.4049/jimmunol.169.6.2892; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; Hawgood S, 2001, ANNU REV PHYSIOL, V63, P495, DOI 10.1146/annurev.physiol.63.1.495; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; Holmskov UL, 2000, APMIS, V108, P7; JIANG HX, 1992, J BIOL CHEM, V267, P25597; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; Liacos C, 2001, CRIT CARE MED, V29, P2310, DOI 10.1097/00003246-200112000-00013; Lu J, 1993, Behring Inst Mitt, P6; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; McLachlan G, 2000, GENE THER, V7, P384, DOI 10.1038/sj.gt.3301097; Nadesalingam J, 2003, J BIOL CHEM, V278, P25678, DOI 10.1074/jbc.M210186200; Noah TL, 2003, AM J RESP CRIT CARE, V168, P685, DOI 10.1164/rccm.200301-005OC; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Palaniyar N, 1999, J MOL BIOL, V287, P9, DOI 10.1006/jmbi.1999.2586; Palaniyar N, 1998, J STRUCT BIOL, V122, P297, DOI 10.1006/jsbi.1998.4004; Palaniyar N, 1998, BIOCHEM BIOPH RES CO, V250, P131, DOI 10.1006/bbrc.1998.9284; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P471, DOI 10.1196/annals.1299.085; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P467, DOI 10.1196/annals.1299.084; Palaniyar N, 2002, IMMUNOBIOLOGY, V205, P575, DOI 10.1078/0171-2985-00156; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; PERSSON A, 1990, J BIOL CHEM, V265, P5755; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; REID KBM, 1982, METHOD ENZYMOL, V82, P319; Ruiz FE, 2001, HUM GENE THER, V12, P751, DOI 10.1089/104303401750148667; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Strong P, 1998, J IMMUNOL METHODS, V220, P139, DOI 10.1016/S0022-1759(98)00160-4; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Tseng M, 1999, J BIOL CHEM, V274, P21637, DOI 10.1074/jbc.274.31.21637; van de Wetering JK, 2001, J INFECT DIS, V184, P1143, DOI 10.1086/323746; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Whitchurch CB, 2002, SCIENCE, V295, P1487, DOI 10.1126/science.295.5559.1487	48	129	141	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32728	32736		10.1074/jbc.M403763200	http://dx.doi.org/10.1074/jbc.M403763200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145932	hybrid			2022-12-25	WOS:000222849700092
J	Valentijn, AJ; Gilmore, AP				Valentijn, AJ; Gilmore, AP			Translocation of full-length bid to mitochondria during anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; FOCAL ADHESION KINASE; PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; CASPASE ACTIVATION; SUBCELLULAR-LOCALIZATION; CONFORMATIONAL-CHANGE; BCL-2 FAMILY; BAX; SURVIVAL	Epithelial cells require adhesion to the extracellular matrix for survival, and in the absence of adhesion they undergo apoptosis (anoikis). This is distinct from apoptosis induced by extracellular death ligands, such as tumor necrosis factor, which result in direct activation of caspase 8. Bid is a member of the BH3-only subfamily of the Bcl-2 proteins and is important for most cell types to apoptose in response to Fas and tumor necrosis factor receptor activation. Caspase 8 cleaves full-length Bid, resulting in truncated p15 tBid. p15 tBid is potently apoptotic and activates the multidomain Bcl-2 protein, Bax, resulting in release of cytochrome c from mitochondria. We have previously shown that Bax rapidly translocates from the cytosol to mitochondria following loss of adhesion and that this is required for anoikis. We have now examined the role of Bid in anoikis. Bid translocates to mitochondria with identical kinetics as Bax. Although Bid is required for anoikis, it does not require proteolytic cleavage by caspase 8. Furthermore, it does not require Bid to interact directly with other Bcl-2 family proteins, such as Bax. Our data indicate that Bid is important for regulating apoptosis via the intrinsic pathway and has implications for how Bid may fulfill that role.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Gilmore, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, A-3034 Smith Bldg, Manchester M13 9PT, Lancs, England.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bouillet P, 2002, J CELL SCI, V115, P1567; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Ilic D, 1998, J CELL BIOL, V143, P547; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	54	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32848	32857		10.1074/jbc.M313375200	http://dx.doi.org/10.1074/jbc.M313375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148322	hybrid			2022-12-25	WOS:000222849700105
J	Yin, P; Xu, QJ; Duan, CM				Yin, P; Xu, QJ; Duan, CM			Paradoxical actions of endogenous and exogenous insulin-like growth factor-binding protein-5 revealed by RNA interference analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SMOOTH-MUSCLE-CELLS; HORMONE-RELATED PROTEIN; FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; INCREASED EXPRESSION; PROSTATE REGRESSION; MOLECULAR-CLONING; INDUCED APOPTOSIS; EPITHELIAL-CELLS	Insulin-like growth factor-binding protein-5 (IGFBP5) is abundantly expressed in bone cells. To determine the physiological role(s) of endogenous IGFBP-5 in regulating bone cell growth, differentiation, and survival, we used short double-stranded RNA ( siRNA) to trigger RNA interference of IGFBP-5 in human osteosarcoma cells. The IGFBP-5 siRNA, targeting against a sequence unique to the IGFBP-5 middle domain, efficiently reduced IGFBP-5 mRNA and protein levels. The IGFBP-5 siRNA did not change the levels of IGFBP-4, a structurally related protein, or glyceraldehyde-3-phosphate dehydrogenase, a housekeeping gene. Knock-down of IGFBP-5 resulted in a significant increase in the number of transferase-mediated dUTP nick end labeling-positive cells and a decrease in a bone differentiation parameter (alkaline phosphatase activity) but had little effect on basal or insulin-like growth factor I-induced proliferation. Overexpression of a siRNA-resistant IGFBP-5 mutant in the IGFBP-5 knock-down cells restored the levels of survival to the control level; overexpression of IGFBP-4 or wild type IGFBP-5 had no such effect. Paradoxically, the addition of exogenous IGFBP5 not only failed to rescue IGFBP-5 knock-down-induced apoptosis, it caused a further increase in apoptosis. Furthermore, the addition of exogenous IGFBP-5 alone increased apoptosis. This pro-apoptotic action of exogenous IGFBP-5 was abolished when IGF-I was added in excess, suggesting that exogenous IGFBP-5 increases apoptosis by binding to and inhibiting the activities of insulin-like growth factors. These results indicate that endogenous and exogenous IGFBP-5 exhibits opposing biological actions on cell survival and underscore the necessity and utility of studying IGFBP functions through loss-of-function approaches.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu	Xu, Qijin/B-2680-2009	Xu, Qijin/0000-0003-0521-9039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL60679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Andress DL, 2001, AM J PHYSIOL-ENDOC M, V281, pE283, DOI 10.1152/ajpendo.2001.281.2.E283; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; Cobb LJ, 2004, J CELL SCI, V117, P1737, DOI 10.1242/jcs.01028; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; Devlin RD, 2002, ENDOCRINOLOGY, V143, P3955, DOI 10.1210/en.2002-220129; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Flint DJ, 1997, J MAMMARY GLAND BIOL, V2, P41, DOI 10.1023/A:1026321529451; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; JAMES PL, 1993, J BIOL CHEM, V268, P22305; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; Marshman E, 2003, J CELL SCI, V116, P675, DOI 10.1242/jcs.00263; Massfelder T, 2001, FASEB J, V15, P707, DOI 10.1096/fj.00-0053com; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; McCaig C, 2002, J CELL BIOCHEM, V84, P784, DOI 10.1002/jcb.10093; Meadows KA, 2000, J CELL PHYSIOL, V183, P330, DOI 10.1002/(SICI)1097-4652(200006)183:3<330::AID-JCP5>3.0.CO;2-N; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nickerson T, 1999, UROLOGY, V54, P1120, DOI 10.1016/S0090-4295(99)00421-5; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Nickerson T, 1999, J ENDOCRINOL, V160, P223, DOI 10.1677/joe.0.1600223; OKAZAKI R, 1995, J BONE MINER RES, V10, P788; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; Perks CM, 1999, J CELL BIOCHEM, V75, P652, DOI 10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0; Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schmid C., 1995, Progress in Growth Factor Research, V6, P167, DOI 10.1016/0955-2235(95)00037-2; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; Shimizu M, 2003, GEN COMP ENDOCR, V132, P103, DOI 10.1016/S0016-6480(03)00052-2; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 2000, ADV EXP MED BIOL, V480, P45; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Xu QJ, 2004, CIRC RES, V94, pE46, DOI 10.1161/01.RES.0000124761.62846.DF; Xu QJ, 2004, J BIOL CHEM, V279, P4269, DOI 10.1074/jbc.M311586200	49	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32660	32666		10.1074/jbc.M401378200	http://dx.doi.org/10.1074/jbc.M401378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155755	hybrid			2022-12-25	WOS:000222849700084
J	Anderson, KA; Noeldner, PK; Reece, K; Wadzinski, BE; Means, AR				Anderson, KA; Noeldner, PK; Reece, K; Wadzinski, BE; Means, AR			Regulation and function of the calcium/calmodulin-dependent protein kinase IV/protein serine/threonine phosphatase 2A signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; MOLECULAR-CLONING; ACTIVATION; CALMODULIN; IV; CALCIUM; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION; EXPRESSION	Calcium/calmodulin-dependent protein kinase IV (CaMKIV) is a member of the broad substrate specificity class of Ca2+/calmodulin (CaM)-dependent protein kinases and functions as a potent stimulator of Ca2+-dependent gene expression. Activation of CaMKIV is a transient, tightly regulated event requiring both Ca2+/ CaM binding and phosphorylation of the kinase on T200 by an upstream CaMK kinase ( CaMKK). Previously, CaMKIV was shown to stably associate with protein serine/ threonine phosphatase 2A (PP2A), which was proposed to play a role in negatively regulating the kinase. Here we report that the Ca2+/CaM binding-autoinhibitory domain of CaMKIV is required for association of the kinase with PP2A and that binding of PP2A and Ca2+/ CaM appears to be mutually exclusive. We demonstrate that inhibition of the CaMKIV/PP2A association in cells results in enhanced CaMKIV-mediated gene transcription that is independent of Ca2+/CaM. The enhanced transcriptional activity correlates with the elevated level of phospho-T200 that accumulates when CaMKIV is prevented from interacting with PP2A. Collectively, these data suggest a molecular basis for the sequential activation and inactivation of CaMKIV. First, in response to an increase in intracellular Ca2+, CaMKIV binds Ca2+/CaM and becomes phosphorylated on T200 by CaMKK. These events result in the generation of autonomous activity required for CaMKIV-mediated transcriptional regulation. The CaMKIV-associated PP2A then dephosphorylates CaMKIV T200, thereby terminating autonomous activity and CaMKIV-mediated gene transcription.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Duke University; Vanderbilt University	Means, AR (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	means001@mc.duke.edu			NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM-51366, GM-33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366, R01GM033976] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23-29.2002; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Anderson KA, 1998, BIOMETALS, V11, P331, DOI 10.1023/A:1009276932076; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Boudreau RTM, 2002, J BIOL CHEM, V277, P5322, DOI 10.1074/jbc.M108623200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Heist EK, 1998, CELL CALCIUM, V23, P103; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Pawson T, 2000, GENE DEV, V14, P1027; Raman V, 2001, J IMMUNOL, V167, P6270, DOI 10.4049/jimmunol.167.11.6270; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wu JY, 2001, MOL CELL BIOL, V21, P6066, DOI 10.1128/MCB.21.17.6066-6070.2001; Yokoyama N, 2003, ARCH BIOCHEM BIOPHYS, V417, P87, DOI 10.1016/S0003-9861(03)00333-3	40	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31708	31716		10.1074/jbc.M404523200	http://dx.doi.org/10.1074/jbc.M404523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143065	hybrid			2022-12-25	WOS:000222726800096
J	Itoh, T; Akao, S; Hashimoto, W; Mikami, B; Murata, K				Itoh, T; Akao, S; Hashimoto, W; Mikami, B; Murata, K			Crystal structure of unsaturated glucuronyl hydrolase, responsible for the degradation of glycosaminoglycan, from Bacillus sp GL1 at 1.8 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN AC LYASE; POLYSACCHARIDE DEPOLYMERIZATION; HYALURONATE LYASE; MICROBIAL SYSTEM; DIFFRACTION DATA; ENZYMATIC ROUTE; COMPLEX; FAMILY; GLUCOAMYLASE; MECHANISM	Unsaturated glucuronyl hydrolase (UGL) is a novel glycosaminoglycan hydrolase that releases unsaturated D-glucuronic acid from oligosaccharides produced by polysaccharide lyases. The x-ray crystallographic structure of UGL from Bacillus sp. GL1 was first determined by multiple isomorphous replacement (mir) and refined at 1.8 Angstrom resolution with a final R-factor of 16.8% for 25 to 1.8 Angstrom resolution data. The refined UGL structure consists of 377 amino acid residues and 478 water molecules, four glycine molecules, two dithiothreitol (DTT) molecules, and one 2-methyl-2,4-pentanediol (MPD) molecule. UGL includes an alpha(6)/alpha(6)-barrel, whose structure is found in the six-hairpin enzyme superfamily of an alpha/alpha-toroidal fold. One side of the UGL alpha(6)/ alpha(6)-barrel structure consists of long loops containing three short beta-sheets and contributes to the formation of a deep pocket. One glycine molecule and two DTT molecules surrounded by highly conserved amino acid residues in UGLs were found in the pocket, suggesting that catalytic and substrate-binding sites are located in this pocket. The overall UGL structure, with the exception of some loops, very much resembled that of the Bacillus subtilis hypothetical protein Yter, whose function is unknown and which exhibits little amino acid sequence identity with UGL. In the active pocket, residues possibly involved in substrate recognition and catalysis by UGL are conserved in UGLs and Yter. The most likely candidate catalytic residues for glycosyl hydrolysis are Asp(88) and Asp(149). This was supported by site-directed mutagenesis studies in Asp(88) and Asp(149).	Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Mikami, B (corresponding author), Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Kyoto 6110011, Japan.	mikami@kais.kyoto-u.ac.jp						Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Aleshin AE, 1996, BIOCHEMISTRY-US, V35, P8319, DOI 10.1021/bi960321g; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Egloff MP, 2001, STRUCTURE, V9, P689, DOI 10.1016/S0969-2126(01)00626-8; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Guerin DMA, 2002, J MOL BIOL, V316, P1061, DOI 10.1006/jmbi.2001.5404; Hashimoto W, 1997, ARCH BIOCHEM BIOPHYS, V339, P17, DOI 10.1006/abbi.1996.9851; Hashimoto W, 2003, J BIOL CHEM, V278, P7663, DOI 10.1074/jbc.M208100200; Hashimoto W, 1999, ARCH BIOCHEM BIOPHYS, V368, P367, DOI 10.1006/abbi.1999.1305; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Itoh T, 2000, J MOL BIOL, V303, P733, DOI 10.1006/jmbi.2000.4188; JANSSON PE, 1983, CARBOHYD RES, V124, P135, DOI 10.1016/0008-6215(83)88361-X; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINKER A, 1955, J BIOL CHEM, V213, P237; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mori S, 2003, PROTEIN EXPRES PURIF, V29, P77, DOI 10.1016/S1046-5928(03)00019-6; Mori S, 2003, ACTA CRYSTALLOGR D, V59, P946, DOI 10.1107/S0907444903005912; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nankai H, 1999, APPL ENVIRON MICROB, V65, P2520; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parsiegla G, 2000, BIOCHEMISTRY-US, V39, P11238, DOI 10.1021/bi001139p; Parsiegla G, 2002, BIOCHEMISTRY-US, V41, P11134, DOI 10.1021/bi025816m; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Sakon J, 1997, NAT STRUCT BIOL, V4, P810, DOI 10.1038/nsb1097-810; Sawitzky D, 1996, MED MICROBIOL IMMUN, V184, P155, DOI 10.1007/BF02456129; SCOTT JE, 1995, J ANAT, V187, P259; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; Van Petegem F, 2003, J BIOL CHEM, V278, P7531, DOI 10.1074/jbc.M206862200; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883	53	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31804	31812		10.1074/jbc.M403288200	http://dx.doi.org/10.1074/jbc.M403288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148314	hybrid			2022-12-25	WOS:000222726800107
J	Kato, T; Sakamoto, E; Kutsuna, H; Kimura-Eto, A; Hato, F; Kitagawa, S				Kato, T; Sakamoto, E; Kutsuna, H; Kimura-Eto, A; Hato, F; Kitagawa, S			Proteolytic conversion of STAT3 alpha to STAT3 gamma in human neutrophils - Role of granule-derived serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MYELOID-LEUKEMIA BLASTS; SIGNAL TRANSDUCER; G-CSF; GRANULOCYTIC DIFFERENTIATION; POLYMORPHONUCLEAR LEUKOCYTES; TRANSCRIPTION PROTEINS; HUMAN MONOCYTES; STAT3; ALPHA	Four isoforms (alpha, beta, gamma, and delta) have been identified for signal transducer and activator of transcription 3 (STAT3). It has been reported that STAT3gamma, which is derived from STAT3alpha by limited proteolysis during granulocytic differentiation, is a major STAT3 isoform expressed in human neutrophils. We confirmed that STAT3gamma was a major STAT3 isoform detected in human neutrophil lysates prepared with the conventional lysis buffer. The enzymes capable of converting STAT3alpha to STAT3gamma in vitro were localized in neutrophil granule fraction and were released into the medium upon ionomycin stimulation. The enzyme activity was strongly inhibited by phenylmethylsulfonyl fluoride, CuSO4, and ONO-5046 ( a specific inhibitor of neutrophil elastase), but not by aprotinin, leupeptin, benzamidine, and EDTA. STAT3gamma was effectively generated in vitro from STAT3alpha by limited proteolysis with human neutrophil elastase or proteinase 3 but not cathepsin G. The converting activity in neutrophil lysates was reduced by immunodepletion of elastase but not proteinase 3. Unexpectedly, STAT3gamma was undetected in the lysates of neutrophil-derived cytoplasts, which lack granules, and the cytosol fraction prepared by nitrogen cavitation. The STAT3 isoform detected in these preparations was primarily STAT3alpha. STAT3gamma was also undetected in the lysates of PMSF-pretreated neutrophils and was markedly decreased in the lysates of ionomycin-pretreated neutrophils. These findings indicate that, in contrast to the previous reports, STAT3alpha, but not STAT3gamma, is primarily expressed in human neutrophils, and STAT3gamma is rapidly generated from STAT3alpha by limited proteolysis with granule-derived serine proteases during preparation of neutrophil lysates with the conventional lysis buffer.	Osaka City Univ, Sch Med, Dept Physiol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Sch Med, Dept Dermatol, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University	Kitagawa, S (corresponding author), Osaka City Univ, Sch Med, Dept Physiol, Abeno Ku, Asahi Machi, Osaka 5458585, Japan.	kitagawas@med.osaka-cu.ac.jp						Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BRITZ ML, 1981, AUST J EXP BIOL MED, V59, P63, DOI 10.1038/icb.1981.3; Chakraborty A, 1998, J LEUKOCYTE BIOL, V64, P675, DOI 10.1002/jlb.64.5.675; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Hevehan DL, 2002, BLOOD, V99, P1627, DOI 10.1182/blood.V99.5.1627; KAWABATA K, 1991, BIOCHEM BIOPH RES CO, V177, P814, DOI 10.1016/0006-291X(91)91862-7; Kjeldsen L, 1999, J IMMUNOL METHODS, V232, P131, DOI 10.1016/S0022-1759(99)00171-4; Lane AA, 2003, CELL, V115, P305, DOI 10.1016/S0092-8674(03)00852-3; Lee CK, 2002, IMMUNITY, V17, P63, DOI 10.1016/S1074-7613(02)00336-9; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; Nishiki S, 2004, AM J PHYSIOL-CELL PH, V286, pC1302, DOI 10.1152/ajpcell.00387.2003; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; Sakamoto C, 2003, INT J HEMATOL, V77, P60, DOI 10.1007/BF02982604; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Suzuki K, 1999, BLOOD, V93, P341, DOI 10.1182/blood.V93.1.341.401k09_341_349; Suzuki K, 2001, J IMMUNOL, V166, P1185, DOI 10.4049/jimmunol.166.2.1185; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Xia Z, 2001, CANCER RES, V61, P1747; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; YUO A, 1992, BLOOD, V79, P1553	24	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31076	31080		10.1074/jbc.M400637200	http://dx.doi.org/10.1074/jbc.M400637200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145953	hybrid			2022-12-25	WOS:000222726800022
J	Lefevre, G; Glotin, AL; Calipel, A; Mouriaux, F; Tran, T; Kherrouche, Z; Maurage, CA; Auclair, C; Mascarelli, F				Lefevre, G; Glotin, AL; Calipel, A; Mouriaux, F; Tran, T; Kherrouche, Z; Maurage, CA; Auclair, C; Mascarelli, F			Roles of stem cell factor/c-kit and effects of Glivec (R)/STI571 in human uveal melanoma cell tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE INHIBITOR; OF-FUNCTION MUTATIONS; C-KIT; LUNG-CANCER; BRAF GENE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; AUTOCRINE GROWTH; PROTEIN-KINASES	The B-Raf(V599E)-mediated constitutive activation of ERK1/2 is involved in establishing the transformed phenotype of some uveal melanoma cells (Calipel, A., Lefevre, G., Pouponnot, C., Mouriaux, F., Eychene, A., and Mascarelli, F. (2003) J. Biol. Chem. 278, 42409 42418). We have shown that stem cell factor (SCF) is involved in the proliferation of normal uveal melanocytes and that c-Kit is expressed in 75% of primary uveal melanomas. This suggests that the acquisition of autonomous growth during melanoma progression may involve the SCF/c-Kit axis. We used six human uveal melanoma tumor-derived cell lines and normal uveal melanocytes to characterize the SCF/c-Kit system and to assess its specific role in transformation. We investigated the possible roles of activating mutations in c-KIT, the overexpression of this gene, and ligand-dependent c-Kit overactivation in uveal melanoma cell tumorigenesis. Four cell lines (92.1, SP6.5, Mel270, and TP31) expressed both SCF and c-Kit, and none harbored the c-KIT mutations in exons 9, 11, 13, and 17 that have been shown to induce SCF-independent c-Kit activation. Melanoma cell proliferation was strongly inhibited by small interfering RNA-mediated depletion of c-Kit in these cells, despite the presence of B-V599E-Raf in SP6.5 and TP31 cells. We characterized the signaling pathways involved in SCF/c-Kit-mediated cell growth and survival in normal and tumoral melanocytes and found that constitutive ERK1/2 activation played a key role in both the SCF/c-Kit autocrine loop and the gain of function of (EB)-E-V599-Raf for melanoma cell proliferation and transformation. We also provide the first evidence that Glivec(R)/STI571, a c-Kit tyrosine kinase inhibitor, could be used to treat uveal melanomas.	INSERM, U598, Inst Biomed Cordeliers, F-75006 Paris, France; CHU Caen, Serv Ophtalmol, F-14000 Caen, France; AB Sci, F-75008 Paris, France; CNRS, Inst Biol, F-59000 Lille, France; Fac Med, Serv Anat Pathol, F-59000 Lille, France; Fac Med, Serv Commun Morphol Cellulaire, F-59000 Lille, France; CNRS, ENS, UMR 8113, F-94235 Cachan, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay	Mascarelli, F (corresponding author), INSERM, U598, Inst Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	KHERROUCHE, Zoulika/L-6549-2019; Mascarelli, Frederic/L-8916-2018; KHERROUCHE, Zoulika/HHN-0213-2022; Mouriaux, Frederic/T-1440-2019					Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brose MS, 2002, CANCER RES, V62, P6997; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Chui X, 1996, BRIT J CANCER, V73, P1233, DOI 10.1038/bjc.1996.236; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Fabbro D, 2002, CURR OPIN DRUG DISC, V5, P701; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fiorentini G, 2003, ANN ONCOL, V14, P805, DOI 10.1093/annonc/mdg192; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JOURIAUX F, 2003, MELANOMA RES, V13, P161; Kishore K, 1996, AM J OPHTHALMOL, V121, P561, DOI 10.1016/S0002-9394(14)75431-5; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Krystal GW, 1996, CANCER RES, V56, P370; Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MATSUDA R, 1993, AM J PATHOL, V142, P339; McGary EC, 2002, CLIN CANCER RES, V8, P3584; Merbs SL, 1999, INVEST OPHTH VIS SCI, V40, P779; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mouriaux F, 2001, EXP EYE RES, V73, P151, DOI 10.1006/exer.2001.1017; Pache M, 2003, VIRCHOWS ARCH, V443, P741, DOI 10.1007/s00428-003-0883-2; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singh AD, 1996, SEMIN ONCOL, V23, P768; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wardelmann E, 2002, MODERN PATHOL, V15, P125, DOI 10.1038/modpathol.3880504; Weber A, 2003, LAB INVEST, V83, P1771, DOI 10.1097/01.LAB.0000101732.89463.29; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	56	71	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31769	31779		10.1074/jbc.M403907200	http://dx.doi.org/10.1074/jbc.M403907200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145934	hybrid			2022-12-25	WOS:000222726800103
J	Banno, F; Kaminaka, K; Soejima, K; Kokame, K; Miyata, T				Banno, F; Kaminaka, K; Soejima, K; Kokame, K; Miyata, T			Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; VONWILLEBRAND-FACTOR MULTIMERS; MUTATIONS; CLEAVAGE; FAMILY; DOMAIN; PURIFICATION; PROTEOLYSIS; EXPRESSION; INSERTION	Human ADAMTS13 was recently identified as a gene encoding von Willebrand factor-cleaving protease, hADAMTS13. Both congenital and acquired defects in this enzyme can cause thrombotic thrombocytopenic purpura. hADAMTS13 consists of 1,427 amino acid residues and is composed of multiple structural domains including thrombospondin type 1 motifs and CUB domains. To analyze the functional roles of these domains in vivo, we determined the cDNA sequence of the mouse ortholog, mADAMTS13. Unexpectedly, two forms of the mouse Adamts13 gene were isolated that differed in the insertion of an intracisternal A particle (IAP) retrotransposon including a premature stop codon. The IAP insertion was found in BALB/c, C3H/He, C57BL/6, and DBA/2 strains but not in the 129/Sv strain. The outbred ICR strain had either the IAP-free or IAP-inserted allele or both. IAP-free Adamts13 encoded mADAMTS13L, a protein of 1,426 amino acid residues with the same domain organization as hADAMTS13. In contrast, IAP-inserted Adamts13 encoded a C-terminally truncated enzyme, mADAMTS13S, that is comprised of only 1,037 amino acid residues and lacking the C-terminal two thrombospondin type 1 motifs and two CUB domains. Strain specificity was also confirmed by reverse transcription-PCR and Northern blot analyses. Both recombinant mADAMTS13L and mADAMTS13S exhibited von Willebrand factor cleaving activities in vitro. The natural variation in mouse ADAMTS13 should allow for the determination of hitherto unknown functions of its C-terminal domains in vivo.	Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Chemoserotherapeut Res Inst, Res Dept 1, Kumamoto 8691298, Japan	National Cerebral & Cardiovascular Center - Japan	Miyata, T (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Osaka 5658565, Japan.	miyata@ri.ncvc.go.jp		Kokame, Koichi/0000-0002-9654-6299				Antoine G, 2003, BRIT J HAEMATOL, V120, P821, DOI 10.1046/j.1365-2141.2003.04183.x; BERNARDO A, 2003, J THROMB HAEMOST, V1, pA405; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Dupressoir A, 1999, J BIOL CHEM, V274, P31068, DOI 10.1074/jbc.274.43.31068; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; Fujikawa K, 2001, BLOOD, V98, P1662, DOI 10.1182/blood.V98.6.1662; Furlan M, 1996, ANN HEMATOL, V72, P341, DOI 10.1007/s002770050184; Furlan M, 1996, BLOOD, V87, P4223, DOI 10.1182/blood.V87.10.4223.bloodjournal87104223; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Gwynn B, 1998, MOL CELL BIOL, V18, P6474, DOI 10.1128/MCB.18.11.6474; Johnson KR, 1999, HUM MOL GENET, V8, P645, DOI 10.1093/hmg/8.4.645; KALAFATIS M, 1987, BLOOD, V70, P1577; KESHET E, 1991, ADV CANCER RES, V56, P215; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kokame K, 2004, BLOOD, V103, P607, DOI 10.1182/blood-2003-08-2861; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LAMB BT, 1992, MOL CELL BIOL, V12, P4824, DOI 10.1128/MCB.12.11.4824; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Matsumoto M, 2004, BLOOD, V103, P1305, DOI 10.1182/blood-2003-06-1796; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; Moschcowitz E., 1924, P NY PATHOL SOC, V24, P21; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pimanda JE, 2004, BLOOD, V103, P627, DOI 10.1182/blood-2003-04-1346; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Schneppenheim R, 2003, BLOOD, V101, P1845, DOI 10.1182/blood-2002-08-2399; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Tsai HM, 1996, BLOOD, V87, P4235, DOI 10.1182/blood.V87.10.4235.bloodjournal87104235; Vasicek TJ, 1997, GENETICS, V147, P777; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	33	52	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30896	30903		10.1074/jbc.M314184200	http://dx.doi.org/10.1074/jbc.M314184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136581	hybrid			2022-12-25	WOS:000222531900124
J	Murphy, PJM; Galigniana, MD; Morishima, Y; Harrell, JM; Kwok, RPS; Ljungman, M; Pratt, WB				Murphy, PJM; Galigniana, MD; Morishima, Y; Harrell, JM; Kwok, RPS; Ljungman, M; Pratt, WB			Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLPROLYL ISOMERASE DOMAIN; HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; INDUCED APOPTOSIS; HSP90-BINDING IMMUNOPHILINS; DYNEIN INTERACTION; MOVEMENT; MUTANT; DEATH; MICE	Pifithrin-alpha (PFTalpha) was originally thought to be a specific inhibitor of signaling by the tumor suppressor protein p53. However, the laboratory that discovered pifithrin recently reported that the compound also inhibits heat shock and glucocorticoid receptor (GR) signaling, and they suggested that PFTalpha targets a factor common to all three signal transduction pathways, such as the hsp90/hsp70-based chaperone machinery (Komarova, E. A., Neznanov, N., Komarov, P. G., Chernov, M. V., Wang, K., and Gudkov, A. V. ( 2003) J. Biol. Chem. 278, 15465-15468). Because it is important for the mechanistic study of this machinery to identify unique inhibitors of chaperone action, we have examined the effect of PFTalpha on transcriptional activation, the hsp90 heterocomplex assembly, and hsp90-dependent nuclear translocation for both p53 and the GR. At concentrations where PFTalpha blocks p53-mediated induction of p21/Waf-1 in human embryonic kidney cells, we observed no inhibition of GR-mediated induction of a chloramphenicol acetyl transferase reporter in LMCAT cells. PFTalpha did, however, cause a left shift in the dexamethasone dose response curve by increasing intracellular dexamethasone concentration, apparently by competing for dexamethasone efflux from the cell. The assembly of p53 or GR heterocomplexes with hsp90 and immunophilins was not affected by PFTalpha either in vivo or in vitro and did not affect the nuclear translocation of either transcription factor. Thus, we conclude that PFTalpha does not inhibit GR-mediated induction or the function of the chaperone machinery, and, as originally thought, it may specifically inhibit p53 signaling by acting at a stage after p53 translocation to the nucleus.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem & Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	pjmurphy@umich.edu		GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA082376, R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, CA82376] Funding Source: Medline; NIDDK NIH HHS [P60DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2002, BIOCHEMISTRY-US, V41, P13602, DOI 10.1021/bi020399z; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GANNON JV, 1991, NATURE, V349, P802; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu XW, 2004, AM J PHYSIOL-HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; Merchant AK, 1996, ONCOGENE, V13, P2631; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; NING YM, 1993, J BIOL CHEM, V268, P6073; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Schafer T, 2003, FASEB J, V17, P660, DOI 10.1096/fj.02-0774com; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhang M, 2003, NEUROSCIENCE, V120, P191, DOI 10.1016/S0306-4522(03)00286-0	34	95	98	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30195	30201		10.1074/jbc.M403539200	http://dx.doi.org/10.1074/jbc.M403539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145929	Green Published, hybrid			2022-12-25	WOS:000222531900042
J	Pudi, R; Srinivasan, P; Das, S				Pudi, R; Srinivasan, P; Das, S			La protein binding at the GCAC site near the initiator AUG facilitates the ribosomal assembly on the hepatitis C virus RNA to influence internal ribosome entry site-mediated translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-INDEPENDENT TRANSLATION; 5' NONTRANSLATED REGIONS; STEM-LOOP; POLYMERASE-III; SS-B; AUTOANTIGEN; POLIOVIRUS; ELEMENT; GENOME; CODON	Human La autoantigen has been shown to influence internal initiation of translation of hepatitis C virus (HCV) RNA. Previously, we have demonstrated that, among the three RRMs of La protein, the RRM2 interacts with HCV internal ribosome entry site (IRES) around the GCAC motif near the initiator AUG present in the stem region of stem-loop IV (SL IV) (Pudi, R., Abhiman, S., Srinivasan, N., and Das S. (2003) J. Biol. Chem. 278, 12231-12240). Here, we have demonstrated that the mutations in the GCAC motif, which altered the binding to RRM2, had drastic effect on HCV IRES-mediated translation, both in vitro and in vivo. The results indicated that the primary sequence of the stem region of SL IV plays an important role in mediating internal initiation. Furthermore, we have shown that the mutations also altered the ability to bind to ribosomal protein S5 (p25), through which 40 S ribosomal subunit is known to contact the HCV IRES RNA. Interestingly, binding of La protein to SL IV region induced significant changes in the circular dichroism spectra of the HCV RNA indicating conformational alterations that might assist correct positioning of the initiation complex. Finally, the ribosome assembly analysis using sucrose gradient centrifugation implied that the mutations within SL IV of HCV IRES impair the formation of functional ribosomal complexes. These observations strongly support the hypothesis that La protein binding near the initiator AUG facilitates the interactions with ribosomal protein S5 and 48 S ribosomal assembly and influences the formation of functional initiation complex on the HCV IRES RNA to mediate efficient internal initiation of translation.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Sir CV Raman Ave, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in		Limgala, Renuka/0000-0001-6957-6284				ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; Das S, 1998, J VIROL, V72, P5638, DOI 10.1128/JVI.72.7.5638-5647.1998; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Fouraux MA, 2002, RNA, V8, P1428, DOI 10.1017/S1355838202021076; Fukushi S, 1997, J VIROL, V71, P1662, DOI 10.1128/JVI.71.2.1662-1666.1997; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; Fukushi S, 2001, J BIOL CHEM, V276, P20824, DOI 10.1074/jbc.C100206200; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HARDIN CC, 1993, BIOCHEMISTRY-US, V32, P5870, DOI 10.1021/bi00073a021; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Honda M, 1996, RNA, V2, P955; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Izumi RE, 2004, J VIROL, V78, P3763, DOI 10.1128/JVI.78.7.3763-3776.2004; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Lemon SM, 1997, SEMIN VIROL, V8, P274, DOI 10.1006/smvy.1997.0129; Lu HH, 1996, P NATL ACAD SCI USA, V93, P1412, DOI 10.1073/pnas.93.4.1412; McKnight KL, 2003, VIROLOGY, V317, P345, DOI 10.1016/j.virol.2003.08.033; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Pestova TV, 1999, VIROLOGY, V258, P249, DOI 10.1006/viro.1999.9741; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Ray PS, 2004, NUCLEIC ACIDS RES, V32, P1678, DOI 10.1093/nar/gkh328; Ray PS, 2002, NUCLEIC ACIDS RES, V30, P4500, DOI 10.1093/nar/gkf583; Reynolds JE, 1996, RNA, V2, P867; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; YOO CJ, 1994, MOL CELL BIOL, V14, P5412, DOI 10.1128/MCB.14.8.5412	41	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29879	29888		10.1074/jbc.M403417200	http://dx.doi.org/10.1074/jbc.M403417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138264	hybrid			2022-12-25	WOS:000222531900003
J	Fukuda, M; Itoh, T				Fukuda, M; Itoh, T			Slac2-a/melanophilin contains multiple PEST-like sequences that are highly sensitive to proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLP HOMOLOGY DOMAIN; MYOSIN-VA; GRISCELLI-SYNDROME; MELANOSOME TRANSPORT; BINDING DOMAIN; C2 DOMAINS; SYNAPTOTAGMIN FAMILY; CRITICAL DETERMINANT; MISSENSE MUTATIONS; RAB EFFECTOR	The synaptotagmin-like protein homologue lacking C2 domains-a (Slac2-a)/melanophilin was recently identified as the "missing link" between the small GTPase Rab27A and the actin-based motor protein myosin Va. Although formation of a tripartite protein complex by three molecules had been shown to be required for proper melanosome distribution in melanocytes (Kuroda, T. S., Ariga, H., and Fukuda, M. ( 2003) Mol. Cell. Biol. 23, 5245-5255), the regulatory mechanisms of the complex (i.e. assembly and disassembly of the complex) had never been elucidated. In this study, we discovered that Slac2-a and a closely related isoform, Slac2-c/MyRIP, contain multiple PEST-like sequences ( potential signals for rapid protein degradation) in the myosin Va- and actin-binding domains at the C terminus. We found that the C-terminal domain of Slac2-a is highly sensitive to low concentrations of proteases, such as trypsin and calpain, in vitro, whereas the N-terminal Rab27A-binding domain is highly resistant to these proteases. We further found that endogenous calpains selectively cleave Slac2-a, but not Rab27A or myosin Va, in melanocytes. A mutant Slac2-a lacking one of the PEST-like sequences located at the interface between the myosin Va- and actin-binding domains (DeltaPEST; amino acids 399-405) is more stable than the wild-type protein, both in vitro and in melanocytes. Expression of the mutant Slac2-a-DeltaPEST with an N-terminal green fluorescence protein tag often induced perinuclear aggregation of melanosomes (similar to40% of the transfected cells) compared with the wild-type Slac2-a. Our findings suggest that protein degradation of Slac2-a is an essential process for proper melanosome distribution in melanocytes.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bizario JCD, 2002, CELL MOTIL CYTOSKEL, V51, P57, DOI 10.1102/cmc.10010; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2003, J BIOL CHEM, V278, P15373, DOI 10.1074/jbc.M212341200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2004, J CELL SCI, V117, P583, DOI 10.1242/jcs.00891; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, J BIOL CHEM, V276, P41112, DOI 10.1074/jbc.M106209200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Huang JD, 1998, GENETICS, V148, P1963; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Imai A, 2004, J CELL SCI, V117, P1945, DOI 10.1242/jcs.01048; Ishikawa K, 2003, J CELL BIOL, V160, P887, DOI 10.1083/jcb.200210139; Jimbow K, 2000, PIGM CELL RES, V13, P222, DOI 10.1034/j.1600-0749.2000.130403.x; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Kuroda TS, 2003, MOL CELL BIOL, V23, P5245, DOI 10.1128/MCB.23.15.5245-5255.2003; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Nagashima K, 2002, FEBS LETT, V517, P233, DOI 10.1016/S0014-5793(02)02634-0; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHOLLMEYER JE, 1986, EXP CELL RES, V163, P413, DOI 10.1016/0014-4827(86)90072-8; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tang FS, 2003, NATURE, V422, P87, DOI 10.1038/nature01453; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	53	48	50	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 21	2004	279	21					22314	22321		10.1074/jbc.401791200	http://dx.doi.org/10.1074/jbc.401791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	820VH	15145961	Bronze			2022-12-25	WOS:000221417100079
J	Pop, M; Aktories, K; Schmidt, G				Pop, M; Aktories, K; Schmidt, G			Isotype-specific degradation of Rac activated by the cytotoxic necrotizing factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO GTPASES; PROTEIN; COMPLEX; CDC42; TOXIN; CELLS; TRANSFORMATION; LOCALIZATION; DEAMIDATION; POLYAMINES	The cytotoxic necrotizing factor 1 (CNF1) from Escherichia coli activates members of the Rho family by deamidation of glutamine 61/63. Because this amino acid is crucial for GTP hydrolysis, deamidation of glutamine 61/63 results in constitutively active Rho proteins. Recently, it was shown that the level of CNF1-activated Rac is rapidly diminished in CNF1-treated cells by proteolytic degradation. Here, we studied the requirements for CNF1-induced Rac degradation. By overexpressing His-tagged activated Rac mutants we show that constitutive activation is necessary for degradation of Rac. However, permanent activation is not sufficient for degradation, because Rac that is constitutively activated by transamidation at glutamine 61 by the Bordetella dermonecrotic toxin is not degraded. Overexpression of His-tagged Rac mutants deficient in interaction with GTPase-activating protein (Rac(N92D) and Rac(Y64H)) and guanosine nucleotide dissociation inhibitor (Rac(H103E)) were degraded after activation by CNF1, whereas Rac(Y40C), which is not able to interact with CRIB domain effectors or plenty of SH3, was not degraded. Isoprenylation and the presence of a putative mitotic destruction box are essential for CNF-induced degradation. In contrast to Rac1, Rac2, and Rac3 were not degraded following constitutive activation by CNF1. Using site-directed mutagenesis, we defined the polybasic region and amino acids 90, 107, 147, and 151 as responsible for isotype-specific degradation.	Univ Freiburg, Inst Expt, D-79104 Freiburg, Germany; Univ Freiburg, Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Schmidt, G (corresponding author), Univ Freiburg, Inst Expt, Albert Str 25, D-79104 Freiburg, Germany.	Gudula.Schmidt@uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lerm M, 2000, FEMS MICROBIOL LETT, V188, P1; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Masuda M, 2000, EMBO J, V19, P521, DOI 10.1093/emboj/19.4.521; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Schmidt G, 1999, J BIOL CHEM, V274, P31875, DOI 10.1074/jbc.274.45.31875; Schmidt G, 2001, INFECT IMMUN, V69, P7663, DOI 10.1128/IAI.69.12.7663-7670.2001; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021	28	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35840	35848		10.1074/jbc.M404346200	http://dx.doi.org/10.1074/jbc.M404346200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15143066	hybrid			2022-12-25	WOS:000223303400085
J	Rozan, L; Krysan, DJ; Rockwell, NC; Fuller, RS				Rozan, L; Krysan, DJ; Rockwell, NC; Fuller, RS			Plasticity of extended subsites facilitates divergent substrate recognition by Kex2 and furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROHORMONE-PROCESSING ENZYME; SUBTILISIN BPN'; CRYSTAL-STRUCTURE; PROTEASE KEX2; SPECIFICITY; ENDOPROTEASE; INHIBITOR; YEAST; CLEAVAGE	Yeast Kex2 and human furin are subtilisin-related proprotein convertases that function in the late secretory pathway and exhibit similar though distinguishable patterns of substrate recognition. Although both enzymes prefer Arg at P-1 and basic residues at P-2, the two differ in recognition of P-4 and P-6 residues. To probe P-4 and P-6 recognition by Kex2p, furin-like substitutions were made in the putative S-4 and S-6 subsites of Kex2. T252D and Q283E mutations were introduced to increase the preference for Arg at P-4 and P-6, respectively. Glu(255) was replaced with Ile to limit recognition of P-4 Arg. The effects of putative S-4 and S-6 mutations were determined by examining the cleavage by purified mutant enzymes of a series of fluorogenic substrates with systematic changes in P-4 and/or P-6. Whereas wild type Kex2 exhibited little preference for Arg at P-6, the T252D mutant and T252D/Q283E double mutant exhibited clear interactions with P-6 Arg. Moreover, the T252D and T252D/Q283E substitutions altered the influence of the P-6 residue on P-4 recognition. We infer that cross-talk between S-4 and S-6, not seen in furin, allows wild type and mutant forms of Kex2 to adapt their subsites for altered modes of recognition. This apparent plasticity may allow the subsites to rearrange their local environment to interact with different substrates in a productive manner. E255I-Kex2 exhibited significantly decreased recognition of P-4 Arg in a tetrapeptide substrate with Lys at P-1, although the general pattern of selectivity for aliphatic residues at P-4 remained unchanged.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, CS Mott Childrens Hosp, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fuller, RS (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	bfuller@umich.edu		Krysan, Damian/0000-0001-6330-3365	NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039697, R55GM039697] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA46592] Funding Source: Medline; NIGMS NIH HHS [GM 39697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; BALLINGER MD, 1995, BIOCHEMISTRY-US, V34, P13312, DOI 10.1021/bi00041a006; Ballinger MD, 1996, BIOCHEMISTRY-US, V35, P13579, DOI 10.1021/bi961543h; BECH LM, 1993, BIOCHEMISTRY-US, V32, P2845, DOI 10.1021/bi00062a016; BECH LM, 1992, EUR J BIOCHEM, V209, P869, DOI 10.1111/j.1432-1033.1992.tb17359.x; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; BEVAN A, 1997, THESIS STANFORD U; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; Constam DB, 2000, DEVELOPMENT, V127, P245; Constam DB, 2000, GENE DEV, V14, P1146; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holyoak T, 2004, BIOCHEMISTRY-US, V43, P2412, DOI 10.1021/bi035849h; Holyoak T, 2003, BIOCHEMISTRY-US, V42, P6709, DOI 10.1021/bi034434t; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Legendre D, 2000, J MOL BIOL, V296, P87, DOI 10.1006/jmbi.1999.3437; MCPHALEN CA, 1985, P NATL ACAD SCI USA, V82, P7242, DOI 10.1073/pnas.82.21.7242; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; RHEINNECKER M, 1993, BIOCHEMISTRY-US, V32, P1199, DOI 10.1021/bi00056a001; RHEINNECKER M, 1994, BIOCHEMISTRY-US, V33, P221, DOI 10.1021/bi00167a029; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Rockwell NC, 2001, J BIOL CHEM, V276, P38394, DOI 10.1074/jbc.M105782200; Rockwell NC, 2001, BIOCHEMISTRY-US, V40, P3657, DOI 10.1021/bi0020877; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIZEN RJ, 1994, EUR J BIOCHEM, V222, P255; SEIZEN RJ, 1997, PROTEIN SCI, V6, P501; Siekhaus DE, 1999, J NEUROSCI, V19, P6942, DOI 10.1523/JNEUROSCI.19-16-06942.1999; SORENSON SB, 1993, BIOCHEMISTRY-US, V32, P8894; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; Thacker C, 2000, BIOESSAYS, V22, P545, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;545::AID-BIES7&gt;3.0.CO;2-F	48	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35656	35663		10.1074/jbc.M405362200	http://dx.doi.org/10.1074/jbc.M405362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15159396	hybrid			2022-12-25	WOS:000223303400062
J	Uchimura, K; Kadomatsu, K; El-Fasakhany, FM; Singer, MS; Izawa, M; Kannagi, R; Takeda, N; Rosen, SD; Muramatsu, T				Uchimura, K; Kadomatsu, K; El-Fasakhany, FM; Singer, MS; Izawa, M; Kannagi, R; Takeda, N; Rosen, SD; Muramatsu, T			N-acetylglucosamine 6-O-sulfotransferase-1 regulates expression of L-selectin ligands and lymphocyte homing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-ENDOTHELIAL VENULES; SIALYL-LEWIS-X; HEV-RESTRICTED SULFOTRANSFERASE; MOLECULAR-CLONING; CHONDROITIN 6-SULFOTRANSFERASE; P-SELECTIN; O-GLYCANS; NODES; BIOSYNTHESIS; SULFATION	Lymphocyte homing is initiated by the binding of L-selectin on lymphocytes to its ligands on high endothelial venules (HEV). Sialyl 6-sulfo Lewis X is a major capping group of L-selectin ligands. N-Acetylglucosamine ( GlcNAc) 6-sulfation is essential for the ligand activity, and is catalyzed by GlcNAc 6-O-sulfotransferases (GlcNAc6STs) of which GlcNAc6ST-1 and GlcNAc6ST-2 are expressed in HEV. Here, we report that mice deficient in GlcNAc6ST-1 were impaired in the elaboration of sialyl 6-sulfo Lewis X in HEV and that an epitope of L-selectin ligands recognized by the MECA-79 antibody was greatly reduced or abolished in the abluminal aspect of HEV. Lymphocyte homing to peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches was significantly reduced in GlcNAc6ST-1 null mice. These results demonstrate that GlcNAc6ST-1 is involved in lymphocyte homing in vivo, and indicate that GlcNAc6ST-1 and -2 play complementary roles. The importance of GlcNAc6ST-1 is particularly highlighted by its involvement in lymphocyte homing to Peyer's patches where GlcNAc6ST-2 expression is undetectable.	Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Calif San Francisco, Program Immunol, Dept Anat, San Francisco, CA 94143 USA; Aichi Canc Ctr, Res Inst, Program Mol Pathol, Nagoya, Aichi 4648681, Japan; Kumamoto Univ, Ctr Anim Resources & Dev, Kumamoto 8600811, Japan	Nagoya University; University of California System; University of California San Francisco; Aichi Cancer Center; Kumamoto University	Muramatsu, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tmurama@med.nagoya-u.ac.jp	Uchimura, Kenji/C-9635-2014; Kadomatsu, Kenji/G-8083-2012; Uchimura, Kenji/AFV-1802-2022; Kannagi, Reiji/Q-6459-2018; ELFASAKHANY, Fathy/ABD-2927-2021	Uchimura, Kenji/0000-0003-3009-248X; Uchimura, Kenji/0000-0003-3009-248X; Kannagi, Reiji/0000-0003-4202-2921; Rosen, Steven/0000-0002-6245-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM057411] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57411, R37 GM 23547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Bistrup A, 2004, AM J PATHOL, V164, P1635, DOI 10.1016/S0002-9440(10)63722-4; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Bruehl RE, 2000, J BIOL CHEM, V275, P32642, DOI 10.1074/jbc.M001703200; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; de Graffenried CL, 2003, J BIOL CHEM, V278, P40282, DOI 10.1074/jbc.M304928200; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drayton DL, 2003, J EXP MED, V197, P1153, DOI 10.1084/jem.20021761; Fukuda M, 2001, J BIOL CHEM, V276, P47747, DOI 10.1074/jbc.R100049200; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hickey MJ, 2000, J IMMUNOL, V165, P7164, DOI 10.4049/jimmunol.165.12.7164; Hiraoka N, 2004, J BIOL CHEM, V279, P3058, DOI 10.1074/jbc.M311150200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; Izawa M, 2000, CANCER RES, V60, P1410; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Lee JK, 2003, GLYCOBIOLOGY, V13, P245, DOI 10.1093/glycob/cwg018; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Ogawa D, 2004, J BIOL CHEM, V279, P2085, DOI 10.1074/jbc.M305809200; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; ROSEN SD, 1989, J IMMUNOL, V142, P1895; Satomaa T, 2002, BLOOD, V99, P2609, DOI 10.1182/blood.V99.7.2609; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Uchimura K, 1998, GLYCOBIOLOGY, V8, P489, DOI 10.1093/glycob/8.5.489; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; van Zante A, 2003, J EXP MED, V198, P1289, DOI 10.1084/jem.20030057; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	48	64	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35001	35008		10.1074/jbc.M404456200	http://dx.doi.org/10.1074/jbc.M404456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175329	hybrid			2022-12-25	WOS:000223134800112
J	Weber, ANR; Morse, MA; Gay, NJ				Weber, ANR; Morse, MA; Gay, NJ			Four N-linked glycosylation sites in human Toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; GLYCOPROTEIN IB-ALPHA; DROSOPHILA TOLL; CRYSTAL-STRUCTURE; SOLUBLE FORMS; PROTEIN; RECOGNITION; DOMAIN; FAMILY; MD-2	Most higher organisms have a system of innate immune defense that is mediated by a group of evolutionarily related, germ line-encoded receptors, so-called Toll-like receptors. In mammals Toll-like receptors signal in response to pathogen-associated microbial structures. For example, Toll-like receptor 2 appears to mediate responses to bacterial peptidoglycan and acylated lipoproteins and Toll-like receptor 4 to bacterial lipopolysaccharide. However, the structural principles that underlie recognition of these structures are poorly understood. Toll-like receptors have leucine-rich repeats in their extracellular domains and are thus believed to adopt solenoid structures, similar to that found in platelet glycoprotein Ib. Additionally, all Toll-like receptors contain N-linked glycosylation consensus sites, and Toll-like receptor 4 requires glycosylation for function. Toll-like receptor glycosylation is also likely to influence receptor surface representation, trafficking, and pattern recognition. Using circular dichroism spectroscopy, we show here that purified human Toll-like receptor 2 and 4 proteins have secondary structure contents similar to glycoprotein Ib. We have also analyzed where consensus glycosylation sites are located in the extracellular domains of other human Toll-like receptors. We found that there are significant differences in the location and degree of conservation between sites in different Toll-like receptors. Using site-directed mutagenesis, we have found that in Toll-like receptor 2 extracellular domain all four predicted glycosylation sites are substituted, although one site is inefficiently core-glycosylated and its removal drastically affects secretion. The remaining Toll-like receptor 2 glycosylation sites also contribute to efficient protein secretion, albeit to a lesser degree.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; GlaxoSmithKline Med Res Ctr, RA Pharmacol, RI CEDD, Stevenage SG1 2NY, Herts, England	University of Cambridge; GlaxoSmithKline	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk		Weber, Alexander/0000-0002-8627-7056				Assil IQ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1015, DOI 10.1152/ajpendo.2001.281.5.E1015; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DUBE S, 1988, J BIOL CHEM, V263, P17516; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; HICKMAN S, 1978, J IMMUNOL, V121, P990; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; LeBouder E, 2003, J IMMUNOL, V171, P6680, DOI 10.4049/jimmunol.171.12.6680; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; RECNY MA, 1992, J BIOL CHEM, V267, P22428; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; Taylor WR, 1997, J MOL BIOL, V269, P902, DOI 10.1006/jmbi.1997.1008; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Wojczyk BS, 1998, GLYCOBIOLOGY, V8, P121, DOI 10.1093/glycob/8.2.121	30	98	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34589	34594		10.1074/jbc.M403830200	http://dx.doi.org/10.1074/jbc.M403830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173186	hybrid			2022-12-25	WOS:000223134800063
J	Ammanamanchi, S; Brattain, MG				Ammanamanchi, S; Brattain, MG			Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; I RECEPTOR; REDUCED EXPRESSION; SP3; PROMOTER; CARCINOMA; GENE; ACETYLTRANSFERASE; ACTIVATION; P300	The loss of transforming growth factor-beta (TGF-beta) response due to the dysregulation of TGF-beta receptors type I (RI) and type II (RII) is well known for its contribution to oncogenesis. Estrogen receptor-expressing breast cancer cells are refractory to TGF-beta-mediated growth control because of the reduced expression of TGF-beta receptors. Although RII is required for the binding of TGF-beta to RI, RI is responsible for directly transducing TGF-beta signals through the Smad protein family. Treatment of estrogen receptor-expressing MCF-7L and ZR75 breast cancer cells with the histone deacetylase ( HDAC) inhibitor suberoylanilide hydroxamic acid ( SAHA) led to a dramatic induction of RI. Accumulation of acetylated histones H3 and H4 was observed in the SAHA-treated cells. Chromatin immunoprecipitation analysis followed by PCR with RI promoter-specific primers indicated an accumulation of acetylated histones in chromatin associated with the RI gene, suggesting that histone deacetylation was involved in the transcriptional inactivation of RI. SAHA treatment stimulated RI promoter activity through the inhibition of Sp1/Sp3-associated HDAC activity. Histone acetyltransferase p300 stimulated RI promoter activity, thus further confirming the involvement of HDAC activity in the transcriptional repression of RI. Significantly, SAHA-mediated RI regeneration restored the TGF-beta response in breast cancer cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Ammanamanchi, S (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	sudhakar.ammanamanchi@roswellpark.org; michael.brattain@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA072001, R37CA038173, R01CA038173] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72001, CA 38173, CA 16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Chen T, 2001, CANCER RES, V61, P4679; Chen TP, 1998, CANCER RES, V58, P4805; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929; Kaklamani VG, 2003, J CLIN ONCOL, V21, P3236, DOI 10.1200/JCO.2003.11.524; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Knobloch TJ, 2001, MUTAT RES-FUND MOL M, V479, P131, DOI 10.1016/S0027-5107(01)00157-9; Lee BI, 2001, CANCER RES, V61, P931; Marks PA, 2001, CLIN CANCER RES, V7, P759; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Pinto M, 2003, J PATHOL, V200, P32, DOI 10.1002/path.1327; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Tokunaga H, 1999, CLIN CANCER RES, V5, P2520; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Zhang HT, 2003, LUNG CANCER-J IASLC, V40, P281, DOI 10.1016/S0169-5002(03)00121-1	27	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32620	32625		10.1074/jbc.M402691200	http://dx.doi.org/10.1074/jbc.M402691200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155736	hybrid			2022-12-25	WOS:000222849700079
J	Pangas, SA; Jorgez, CJ; Matzuk, MM				Pangas, SA; Jorgez, CJ; Matzuk, MM			Growth differentiation factor 9 regulates expression of the bone morphogenetic protein antagonist gremlin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; GRANULOSA-CELLS; OSTEOGENIC PROTEIN-1; FOLLISTATIN; OOCYTE; RECEPTOR; NOGGIN; OVULATION; DEFECTS; INDUCE	Growth differentiation factor 9 (GDF9) is an oocyte-expressed member of the transforming growth factor beta (TGF-beta) superfamily and is required for normal ovarian follicle development and female fertility. GDF9 acts as a paracrine factor and affects granulosa cell physiology. Only a few genes regulated by GDF9 are known. Our microarray analysis has identified gremlin as one of the genes up-regulated by GDF9 in cultures of granulosa cells. Gremlin is a known member of the DAN family of bone morphogenetic protein (BMP) antagonists, but its expression and function in the ovary are unknown. We have investigated the regulation of gremlin in mouse granulosa cells by GDF9 as well as other members of the TGF-beta superfamily. GDF9 and BMP4 induce gremlin, but TGF-beta does not. In addition, in cultures of granulosa cells, gremlin negatively regulates BMP4 signaling but not GDF9 activity. The expression of gremlin in the ovary was also examined by in situ hybridization. A distinct change in gremlin mRNA compartmentalization occurs during follicle development and ovulation, indicating a highly regulated expression pattern during folliculogenesis. We propose that gremlin modulates the cross-talk between GDF9 and BMP signaling that is necessary during follicle development because both ligands use components of the same signaling pathway.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu	xu, huanfang/I-4315-2012	Pangas, Stephanie/0000-0001-5748-5844				Albrecht U, 1997, MOL CELLULAR METHODS, P23; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0; Durlinger ALL, 2002, REPRODUCTION, V124, P601, DOI 10.1530/reprod/124.5.601; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1035, DOI 10.1210/me.13.6.1035; Elvin JA, 1999, MOL ENDOCRINOL, V13, P1018, DOI 10.1210/me.13.6.1018; Elvin JA, 2000, P NATL ACAD SCI USA, V97, P10288, DOI 10.1073/pnas.180295197; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Erickson Gregory F, 2003, Reprod Biol Endocrinol, V1, P9, DOI 10.1186/1477-7827-1-9; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Fulop C, 1997, ARCH BIOCHEM BIOPHYS, V337, P261, DOI 10.1006/abbi.1996.9793; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; GHIGLIERI C, 1995, HUM REPROD, V10, P2115, DOI 10.1093/oxfordjournals.humrep.a136245; Groppe J, 2003, J BONE JOINT SURG AM, V85A, P52, DOI 10.2106/00004623-200300003-00010; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Jorgez CJ, 2004, MOL ENDOCRINOL, V18, P953, DOI 10.1210/me.2003-0301; Joyce IM, 2001, ENDOCRINOLOGY, V142, P3187, DOI 10.1210/en.142.7.3187; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lee WS, 2001, BIOL REPROD, V65, P994, DOI 10.1095/biolreprod65.4.994; MICHEL U, 1992, J MOL ENDOCRINOL, V9, P147, DOI 10.1677/jme.0.0090147; Moore RK, 2003, J BIOL CHEM, V278, P304, DOI 10.1074/jbc.M207362200; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nilsson EE, 2003, BIOL REPROD, V69, P1265, DOI 10.1095/biolreprod.103.018671; Otsuka F, 2001, BIOCHEM BIOPH RES CO, V289, P961, DOI 10.1006/bbrc.2001.6103; Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Shi W, 2001, AM J PHYSIOL-LUNG C, V280, pL1030, DOI 10.1152/ajplung.2001.280.5.L1030; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimasaki S, 1999, P NATL ACAD SCI USA, V96, P7282, DOI 10.1073/pnas.96.13.7282; Shimasaki S, 2004, ENDOCR REV, V25, P72, DOI 10.1210/er.2003-0007; TANO M, 1995, MOL CELL ENDOCRINOL, V109, P167, DOI 10.1016/0303-7207(95)03499-W; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Varani S, 2002, MOL ENDOCRINOL, V16, P1154, DOI 10.1210/me.16.6.1154; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Vitt UA, 2002, BIOL REPROD, V67, P473, DOI 10.1095/biolreprod67.2.473; Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600-0722.1998.tb02170.x; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhuo LS, 2001, CELL STRUCT FUNCT, V26, P189, DOI 10.1247/csf.26.189; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	51	91	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32281	32286		10.1074/jbc.M403212200	http://dx.doi.org/10.1074/jbc.M403212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15133038	hybrid			2022-12-25	WOS:000222849700037
J	Samuel, VT; Liu, ZX; Qu, XQ; Elder, BD; Bilz, S; Befroy, D; Romanelli, AJ; Shulman, GI				Samuel, VT; Liu, ZX; Qu, XQ; Elder, BD; Bilz, S; Befroy, D; Romanelli, AJ; Shulman, GI			Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1; GLUCOSE-PRODUCTION; GLYCOGEN-SYNTHASE; KAPPA-B; ACTIVATION; MUSCLE; ACID; ASSOCIATION	Short term high fat feeding in rats results specifically in hepatic fat accumulation and provides a model of non-alcoholic fatty liver disease in which to study the mechanism of hepatic insulin resistance. Short term fat feeding (FF) caused a similar to3-fold increase in liver triglyceride and total fatty acyl-CoA content without any significant increase in visceral or skeletal muscle fat content. Suppression of endogenous glucose production (EGP) by insulin was diminished in the FF group, despite normal basal EGP and insulin-stimulated peripheral glucose disposal. Hepatic insulin resistance could be attributed to impaired insulin-stimulated IRS-1 and IRS-2 tyrosine phosphorylation. These changes were associated with activation of PKC-epsilon and JNK1. Ultimately, hepatic fat accumulation decreased insulin activation of glycogen synthase and increased gluconeogenesis. Treatment of the FF group with low dose 2,4-dinitrophenol to increase energy expenditure abrogated the development of fatty liver, hepatic insulin resistance, activation of PKC-epsilon and JNK1, and defects in insulin signaling. In conclusion, these data support the hypothesis hepatic steatosis leads to hepatic insulin resistance by stimulating gluconeogenesis and activating PKC-epsilon and JNK1, which may interfere with tyrosine phosphorylation of IRS-1 and IRS-2 and impair the ability of insulin to activate glycogen synthase.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Univ Technol Sydney, Dept Hlth Sci, Sydney, NSW 2007, Australia	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Technology Sydney	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, S269 CAB 300 Cedar St, New Haven, CT 06510 USA.	gerald.shulman@yale.edu	Shulman, Gerald I./P-7176-2019; Adiels, Martin/C-9278-2011	Shulman, Gerald I./0000-0003-1529-5668; Bilz, Stefan/0000-0002-7716-2791	NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR017404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NCRR NIH HHS [K23 RR-17404] Funding Source: Medline; NIDDK NIH HHS [R01 DK-40936, R01 DK040936, P30 DK-45735] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; CHIASSON JL, 1976, DIABETES, V25, P283, DOI 10.2337/diabetes.25.4.283; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hundal RS, 2000, DIABETES, V49, P2063, DOI 10.2337/diabetes.49.12.2063; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Jiang GQ, 2004, BIOCHEM J, V377, P339, DOI 10.1042/BJ20031207; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Koizumi M, 2001, J Toxicol Sci, V26, P299, DOI 10.2131/jts.26.299; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; Krappmann D, 2001, MOL CELL BIOL, V21, P6640, DOI 10.1128/MCB.21.19.6640-6650.2001; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE281, DOI 10.1152/ajpendo.00332.2002; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; McCullough AJ, 2002, J CLIN GASTROENTEROL, V34, P255, DOI 10.1097/00004836-200203000-00013; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; Previs SF, 1999, AM J PHYSIOL-ENDOC M, V277, pE154, DOI 10.1152/ajpendo.1999.277.1.E154; Qu X, 1999, J ENDOCRINOL, V162, P207, DOI 10.1677/joe.0.1620207; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; SALORANTA C, 1993, AM J PHYSIOL, V264, pE599, DOI 10.1152/ajpendo.1993.264.4.E599; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Sanyal Arun J, 2002, Gastroenterology, V123, P1705, DOI 10.1053/gast.2002.36572; Wang JL, 2001, DIABETES, V50, P2786, DOI 10.2337/diabetes.50.12.2786; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	31	964	1034	1	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32345	32353		10.1074/jbc.M313478200	http://dx.doi.org/10.1074/jbc.M313478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166226	hybrid			2022-12-25	WOS:000222849700046
J	Tikhonova, EB; Zgurskaya, HI				Tikhonova, EB; Zgurskaya, HI			AcrA, AcrB, and TolC of Escherichia coli form a stable intermembrane multidrug efflux complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION PROTEIN; OUTER-MEMBRANE; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; ANTIBIOTIC-RESISTANCE; CRYSTAL-STRUCTURE; CHANNEL-TUNNEL; PUMP; EXPORT; SYSTEM	Many transporters of Gram-negative bacteria involved in the extracellular secretion of proteins and the efflux of toxic molecules operate by forming intermembrane complexes. These complexes are proposed to span both inner and outer membranes and create a bridge across the periplasm. In this study, we analyzed interactions between the inner and outer membrane components of the tri-partite multidrug efflux pump AcrAB-TolC from Escherichia coli. We found that, once assembled, the intermembrane AcrAB-TolC complex is stable during the separation of the inner and outer membranes and subsequent purification. All three components of the complex co-purify when the affinity tag is attached to either of the proteins suggesting bi-partite interactions between AcrA, AcrB, and TolC. We show that antibiotics, the substrates of AcrAB-TolC, stabilize interactions within the complex. However, the formation of the AcrAB-TolC complex does not require an input of energy.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Zgurskaya, HI (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval,Rm 208, Norman, OK 73019 USA.	elenaz@ou.edu	Tikhonova, Elena/P-2515-2015	Tikhonova, Elena/0000-0002-7892-9173; Zgurskaya, Helen/0000-0001-8929-4727	NIAID NIH HHS [1-R01-AI052293-01A1, R01 AI052293] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052293] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen C, 2001, CURR OPIN CELL BIOL, V13, P412, DOI 10.1016/S0955-0674(00)00229-5; Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; Balakrishnan L, 2001, J MOL BIOL, V313, P501, DOI 10.1006/jmbi.2001.5038; Borges-Walmsley MI, 2003, J BIOL CHEM, V278, P12903, DOI 10.1074/jbc.M209457200; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Chen JC, 2002, J BACTERIOL, V184, P695, DOI 10.1128/JB.184.3.695-705.2002; Elkins CA, 2002, J BACTERIOL, V184, P6490, DOI 10.1128/JB.184.23.6490-6499.2002; Fasman G. D., 1975, HDB BIOCH MOL BIOL; Fralick JA, 1996, J BACTERIOL, V178, P5803, DOI 10.1128/jb.178.19.5803-5805.1996; German GJ, 2001, J MOL BIOL, V308, P579, DOI 10.1006/jmbi.2001.4578; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; Ip H, 2003, J BIOL CHEM, V278, P50474, DOI 10.1074/jbc.M305152200; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; Jones HE, 2003, BBA-BIOMEMBRANES, V1612, P90, DOI 10.1016/S0005-2736(03)00082-8; Koch AL, 1998, CRIT REV MICROBIOL, V24, P23, DOI 10.1080/10408419891294172; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 1997, MOL MICROBIOL, V23, P617, DOI 10.1046/j.1365-2958.1997.d01-1880.x; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Lomovskaya O, 1999, ANTIMICROB AGENTS CH, V43, P1340, DOI 10.1128/AAC.43.6.1340; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Maseda H, 2002, MOL MICROBIOL, V46, P677, DOI 10.1046/j.1365-2958.2002.03197.x; Matsuo E, 2003, MOL GENET GENOMICS, V268, P808, DOI 10.1007/s00438-003-0803-9; Miyamae S, 2001, ANTIMICROB AGENTS CH, V45, P3341, DOI 10.1128/AAC.45.12.3341-3346.2001; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Possot OM, 1997, MOL MICROBIOL, V24, P457, DOI 10.1046/j.1365-2958.1997.3451726.x; SCHULEIN R, 1994, MOL GEN GENET, V245, P203; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Tikhonova EB, 2002, J BACTERIOL, V184, P6499, DOI 10.1128/JB.184.23.6499-6507.2002; YAMANE K, 1987, J BIOL CHEM, V262, P2358; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; Zgurskaya HI, 2002, INT J MED MICROBIOL, V292, P95, DOI 10.1078/1438-4221-00195; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	39	197	203	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32116	32124		10.1074/jbc.M402230200	http://dx.doi.org/10.1074/jbc.M402230200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155734	hybrid			2022-12-25	WOS:000222849700017
J	Torizawa, T; Ueda, T; Kuramitsu, S; Hitomi, K; Todo, T; Iwai, S; Morikawa, K; Shimada, I				Torizawa, T; Ueda, T; Kuramitsu, S; Hitomi, K; Todo, T; Iwai, S; Morikawa, K; Shimada, I			Investigation of the cyclobutane pyrimidine dimer (CPD) photolyase DNA recognition mechanism by NMR analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; EXCISION-REPAIR; ANACYSTIS-NIDULANS; STRUCTURAL BASIS; 2ND CHROMOPHORE; BASE-EXCISION; ENZYME; BINDING; SUBSTRATE	The cyclobutane pyrimidine dimer (CPD) is one of the major forms of DNA damage caused by irradiation with ultraviolet (UV) light. CPD photolyases recognize and repair UV-damaged DNA. The DNA recognition mechanism of the CPD photolyase has remained obscure because of a lack of structural information about DNA-CPD photolyase complexes. In order to elucidate the CPD photolyase DNA binding mode, we performed NMR analyses of the DNA-CPD photolyase complex. Based upon results from P-31 NMR measurements, in combination with site-directed mutagenesis, we have demonstrated the orientation of CPD-containing single-stranded DNA (ssDNA) on the CPD photolyase. In addition, chemical shift perturbation analyses, using stable isotope-labeled DNA, revealed that the CPD is buried in a cavity within CPD photolyase. Finally, NMR analyses of a double-stranded DNA (dsDNA)-CPD photolyase complex indicated that the CPD is flipped out of the dsDNA by the enzyme, to gain access to the active site.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; JBIC, JBIRC, Chuo Ku, Tokyo 1040032, Japan; Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan; Natl Inst Adv Ind Sci & Technol, BIRC, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Osaka University; Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp						BAER ME, 1993, J BIOL CHEM, V268, P16717; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; Friedberg EC, 1995, DNA REPAIR MUTAGENES, P91; HEELIS PF, 1992, INT J RADIAT BIOL, V62, P137, DOI 10.1080/09553009214551941; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1985, BIOCHEMISTRY-US, V24, P1856, DOI 10.1021/bi00329a008; Kato R, 1997, J BACTERIOL, V179, P6499, DOI 10.1128/jb.179.20.6499-6503.1997; KAY LE, 1990, J AM CHEM SOC, V112, P888, DOI 10.1021/ja00158a070; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, BIOCHEMISTRY-US, V31, P11244, DOI 10.1021/bi00160a040; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; MAHER VM, 1982, P NATL ACAD SCI-BIOL, V79, P2613, DOI 10.1073/pnas.79.8.2613; MARINO JP, 1994, J AM CHEM SOC, V116, P6472, DOI 10.1021/ja00093a073; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SANCAR A, 1984, J MOL BIOL, V172, P223, DOI 10.1016/S0022-2836(84)80040-6; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SKLENAR V, 1993, J BIOMOL NMR, V3, P721, DOI 10.1007/BF00198375; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Smith DE, 1997, J BIOMOL NMR, V10, P245, DOI 10.1023/A:1018358602001; SUZUKI F, 1981, CANCER RES, V41, P4916; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Torizawa T, 1998, FEBS LETT, V429, P157, DOI 10.1016/S0014-5793(98)00582-1; Torizawa T, 2000, NUCLEIC ACIDS RES, V28, P944, DOI 10.1093/nar/28.4.944; Vande Berg BJ, 1998, J BIOL CHEM, V273, P20276, DOI 10.1074/jbc.273.32.20276; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6	39	36	39	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32950	32956		10.1074/jbc.M404536200	http://dx.doi.org/10.1074/jbc.M404536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169780	hybrid			2022-12-25	WOS:000222849700115
J	Wallace, MA; Liou, LL; Martins, J; Clement, MHS; Bailey, S; Longo, VD; Valentine, JS; Gralla, EB				Wallace, MA; Liou, LL; Martins, J; Clement, MHS; Bailey, S; Longo, VD; Valentine, JS; Gralla, EB			Superoxide inhibits 4Fe-4S cluster enzymes involved in amino acid biosynthesis - Cross-compartment protection by CuZn-superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; LYSINE BIOSYNTHESIS; INTERMEMBRANE SPACE; SULFITE REDUCTASE; YEAST-CELLS; IRON; MITOCHONDRIA; PROTEINS; SENSITIVITY	Among the phenotypes of Saccharomyces cerevisiae mutants lacking CuZn-superoxide dismutase (Sod1p) is an aerobic lysine auxotrophy; in the current work we show an additional leaky auxotrophy for leucine. The lysine and leucine biosynthetic pathways each contain a 4Fe-4S cluster enzyme homologous to aconitase and likely to be superoxide-sensitive, homoaconitase (Lys4p) and isopropylmalate dehydratase (Leu1p), respectively. We present evidence that direct aerobic inactivation of these enzymes in sod1Delta yeast results in the auxotrophies. Located in the cytosol and intermembrane space of the mitochondria, Sod1p likely provides direct protection of the cytosolic enzyme Leu1p. Surprisingly, Lys4p does not share a compartment with Sod1p but is located in the mitochondrial matrix. The activity of a second matrix protein, the tricarboxylic acid cycle enzyme aconitase, was similarly lowered in sod1Delta mutants. We measured only slight changes in total mitochondrial iron and found no detectable difference in mitochondrial "free" (EPR-detectable) iron making it unlikely that a gross defect in mitochondrial iron metabolism is the cause of the decreased enzyme activities. Thus, we conclude that when Sod1p is absent a lysine auxotrophy is induced because Lys4p is inactivated in the matrix by superoxide that originates in the intermembrane space and diffuses across the inner membrane.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Gralla, EB (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	egralla@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X	NIDDK NIH HHS [DK46828] Funding Source: Medline; NIGMS NIH HHS [GM08496] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, pCH10; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BILINSKI T, 1985, ACTA MICROBIOL POL, V34, P15; BOWLER C, 1991, EMBO J, V10, P1723, DOI 10.1002/j.1460-2075.1991.tb07696.x; Broquist HP., 1971, METHODS ENZYMOL, V17B, P112; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12101, DOI 10.1021/bi971065q; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Davis CA, 2004, J BIOL CHEM, V279, P12769, DOI 10.1074/jbc.M310623200; De Freitas JM, 2000, J BIOL CHEM, V275, P11645, DOI 10.1074/jbc.275.16.11645; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRALLA EB, 1997, COLD SPRING HARBOR M, V34, P495; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HASSAN HM, 1982, CAN J PHYSIOL PHARM, V60, P1367, DOI 10.1139/y82-204; Hearn AS, 2004, J BIOL CHEM, V279, P5861, DOI 10.1074/jbc.M311310200; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hsu JL, 1996, J BIOL CHEM, V271, P17687, DOI 10.1074/jbc.271.30.17687; Irvin SD, 1998, J MOL EVOL, V46, P401, DOI 10.1007/PL00006319; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Liu SS, 1999, J BIOENERG BIOMEMBR, V31, P367; LIU XF, 1992, J BIOL CHEM, V267, P18298; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; NAKATANI Y, 1972, ANAL BIOCHEM, V49, P225, DOI 10.1016/0003-2697(72)90261-8; NICHOLLS DG, 2002, BIOENERGETICS, V3, P65; RASMUSSEN H, 1965, P NATL ACAD SCI USA, V53, P1069, DOI 10.1073/pnas.53.5.1069; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Srinivasan C, 2002, METHOD ENZYMOL, V349, P173, DOI 10.1016/S0076-6879(02)49333-0; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; STRASSMAN M, 1966, J BIOL CHEM, V241, P5401; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WANG L, 1989, CURR GENET, V16, P7, DOI 10.1007/BF00411077; Wei JPJ, 2001, J BIOL CHEM, V276, P44798, DOI 10.1074/jbc.M104708200; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; YOSHIMOTO A, 1968, BIOCHIM BIOPHYS ACTA, V153, P555, DOI 10.1016/0005-2728(68)90185-0	61	82	84	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32055	32062		10.1074/jbc.M403590200	http://dx.doi.org/10.1074/jbc.M403590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166213	hybrid			2022-12-25	WOS:000222849700009
J	Zou, H; Lee, J; Kilani, AF; Kim, K; Trang, P; Kim, J; Liu, FY				Zou, H; Lee, J; Kilani, AF; Kim, K; Trang, P; Kim, J; Liu, FY			Engineered RNase P ribozymes increase their cleavage activities and efficacies in inhibiting viral gene expression in cells by enhancing the rate of cleavage and binding of the target mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL GUIDE SEQUENCES; RIBONUCLEASE-P; ESCHERICHIA-COLI; SUBSTRATE-BINDING; HAIRPIN RIBOZYME; THERAPEUTIC AGENTS; CATALYTIC SUBUNIT; PROTEIN COFACTOR; ENZYME; REPLICATION	Engineered RNase P ribozymes are promising gene-targeting agents that can be used in both basic research and clinical applications. We have previously selected ribozyme variants for their activity in cleaving an mRNA substrate from a pool of ribozymes containing randomized sequences. In this study, one of the variants was used to target the mRNA encoding thymidine kinase (TK) of herpes simplex virus 1 (HSV-1). The variant exhibited enhanced cleavage and substrate binding and was at least 30 times more efficient in cleaving TK mRNA in vitro than the ribozyme derived from the wild type sequence. Our results provide the first direct evidence to suggest that a point mutation at nucleotide 95 of RNase P catalytic RNA from Escherichia coli (G(95)-->U-95) increases the rate of cleavage, whereas another mutation at nucleotide 200 (A(200)-->C-200) enhances substrate binding of the ribozyme. A reduction of about 99% in TK expression was observed in cells expressing the variant, whereas a 70% reduction was found in cells expressing the ribozyme derived from the wild type sequence. Thus, the RNase P ribozyme variant is highly effective in inhibiting HSV-1 gene expression. Our study demonstrates that ribozyme variants increase their cleavage activity and efficacy in blocking gene expression in cells through enhanced substrate binding and rate of cleavage. These results also provide insights into the mechanism of how RNase P ribozymes efficiently cleave an mRNA substrate and, furthermore, facilitate the development of highly active RNase P ribozymes for gene-targeting applications.	Univ Calif Berkeley, Sch Publ Hlth, Program Comparat Biochem, Program Infect Dis & Immun, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Program Comparat Biochem, Program Infect Dis & Immun, 140 Warren Hall, Berkeley, CA 94720 USA.	liu_fy@uclink4.berkeley.edu		Lee, Jarone/0000-0002-4532-8523				Altman S., 1999, RNA WORLD, P351; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; Bertrand E, 1997, RNA, V3, P75; Chen JL, 1998, EMBO J, V17, P1515, DOI 10.1093/emboj/17.5.1515; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; Donahue CP, 1997, RNA, V3, P961; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANK DN, 1994, BIOCHEMISTRY-US, V33, P10800, DOI 10.1021/bi00201a030; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Gopalan V, 2002, J BIOL CHEM, V277, P6759, DOI 10.1074/jbc.R100067200; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Haas ES, 1998, NUCLEIC ACIDS RES, V26, P4093, DOI 10.1093/nar/26.18.4093; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; Hsu AW, 2000, NUCLEIC ACIDS RES, V28, P3105, DOI 10.1093/nar/28.16.3105; Kawa D, 1998, RNA, V4, P1397, DOI 10.1017/S1355838298980918; Kilani AF, 1999, RNA, V5, P1235, DOI 10.1017/S1355838299990672; Kilani AF, 2000, J BIOL CHEM, V275, P10611, DOI 10.1074/jbc.275.14.10611; Kim JJ, 1997, RNA, V3, P613; Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; Loria A, 1999, BIOCHEMISTRY-US, V38, P8612, DOI 10.1021/bi990691f; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Plehn-Dujowich D, 1998, P NATL ACAD SCI USA, V95, P7327, DOI 10.1073/pnas.95.13.7327; Pulitz JZ, 1999, J VIROL, V73, P5381, DOI 10.1128/JVI.73.7.5381-5387.1999; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; Scherer LJ, 2003, NAT BIOTECHNOL, V21, P1457, DOI 10.1038/nbt915; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; Trang P, 1999, NUCLEIC ACIDS RES, V27, P4590, DOI 10.1093/nar/27.23.4590; Trang P, 2000, P NATL ACAD SCI USA, V97, P5812, DOI 10.1073/pnas.100101797; Trang P, 2000, J MOL BIOL, V301, P817, DOI 10.1006/jmbi.2000.4022; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZAUG AJ, 1995, RNA, V1, P363	46	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32063	32070		10.1074/jbc.M403059200	http://dx.doi.org/10.1074/jbc.M403059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169770	hybrid			2022-12-25	WOS:000222849700010
J	Macchi, P; Brownawell, AM; Grunewald, B; DesGroseillers, L; Macara, IG; Kiebler, MA				Macchi, P; Brownawell, AM; Grunewald, B; DesGroseillers, L; Macara, IG; Kiebler, MA			The brain-specific double-stranded RNA-binding protein Staufen2 - Nucleolar accumulation and isoform-specific exportin-5-dependent export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES NUCLEAR EXPORT; SOMATODENDRITIC DOMAIN; MAMMALIAN STAUFEN; TRANSPORT; LOCALIZATION; RECOGNITION; TRANSLATION; NEURONS; SIGNAL	The mammalian double-stranded RNA-binding proteins Staufen (Stau1 and Stau2) are involved in RNA localization in polarized neurons. In contrast to the more ubiquitously expressed Stau1, Stau2 is mainly expressed in the nervous system. In Drosophila, the third double-stranded RNA-binding domain (RBD3) of Staufen is essential for RNA interaction. When conserved amino acids within the RBD3 of Stau2 were mutated to render Stau2 defective for RNA binding, the mutant Stau2 proteins accumulate predominantly in the nucleolus. This is in contrast to wild type Stau2 that mostly localizes in the cytosol. The nuclear import is dependent on a nuclear localization signal in close proximity to the RBD3. The nuclear export of Stau2 is not dependent on CRM1 but rather on Exportin-5. We show that Exportin-5 interacts with the RBD3 of wild type Stau2 in an RNA-dependent manner in vitro but not with mutant Stau2. When Exportin-5 is down-regulated by RNA interference, only the largest isoform of Stau2 (Stau2(62)) preferentially accumulates in the nucleolus. It is tempting to speculate that Stau2(62) binds RNA in the nucleus and assembles into ribonucleoparticles, which are then exported via the Exportin-5 pathway to their final destination.	Max Planck Inst Dev Biol, D-72076 Tubingen, Germany; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Max Planck Society; University of Virginia; Universite de Montreal	Kiebler, MA (corresponding author), Max Planck Inst Dev Biol, Spemannstr 35, D-72076 Tubingen, Germany.	michael.kiebler@tuebingen.mpg.de		Kiebler, Michael/0000-0002-8850-6297				Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Bohnsack MT, 2002, EMBO J, V21, P6205, DOI 10.1093/emboj/cdf613; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002; Duchaine TF, 2002, J CELL SCI, V115, P3285; GOETZE B, 2004, IN PRESS J NEUROBIOL; GOETZE B, 2003, SCI STKE; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Politz JC, 2002, J CELL BIOL, V159, P411, DOI 10.1083/jcb.200208037; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; Strehblow A, 2002, MOL BIOL CELL, V13, P3822, DOI 10.1091/mbc.E02-03-0161; Tamanini F, 1999, HUM MOL GENET, V8, P863, DOI 10.1093/hmg/8.5.863; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803	22	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31440	31444		10.1074/jbc.C400226200	http://dx.doi.org/10.1074/jbc.C400226200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15166236	hybrid			2022-12-25	WOS:000222726800065
J	Mochizuki, T; Miyazaki, H; Hara, T; Furuya, T; Imamura, T; Watabe, T; Miyazono, K				Mochizuki, T; Miyazaki, H; Hara, T; Furuya, T; Imamura, T; Watabe, T; Miyazono, K			Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-beta superfamily signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN; SPEMANNS ORGANIZER; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; XENOPUS-EMBRYOS; CELL-MEMBRANE; PROMOTER; RECEPTOR; TRANSCRIPTION; DEGRADATION	Signals by cytokines of the transforming growth factor-beta( TGF-beta) superfamily are negatively regulated by inhibitory Smads ( I-Smads). Smad7 inhibits signaling by both TGF-beta and bone morphogenetic proteins (BMPs), whereas Smad6 inhibits TGF-beta signals less effectively. I-Smads have amino-terminal N domains and carboxyl-terminal Mad homology 2 (MH2) domains. The N domains are essential for specific inhibition of TGF-beta signaling by Smad7, whereas the MH2 domains of I-Smads are involved in the inhibition of TGF-beta superfamily signals through interaction with type I receptors. Here, we have identified four basic amino acid residues (Lys-312, Lys-316, Lys-401, and Arg-409) in the basic surface of the Smad7 MH2 domain that play important roles in interaction with type I receptors. Mutations of the four basic amino acid residues to acidic residues (K312E, K316E, K401E, and R409E) abolished the interaction of Smad7 with TGF-beta type I receptors, inhibition of Smad2 phosphorylation and transcriptional responses induced by TGF-beta, and induction of target genes of endogenous activin/Nodal signals in Xenopus early embryos. The K401E and R409E mutants of Smad7 were also unable to interact with BMP type I receptors ( BMPR-I), repress the Smad5 phosphorylation and transcription induced by BMP, and effectively inhibit endogenous BMP signals in Xenopus early embryos. However, the K312E and K316E mutants were able to interact with BMPR-I and retained the ability to inhibit BMP signaling. Thus, the MH2 domain of Smad7 plays important roles in specific inhibition of TGF-beta superfamily signals through differential interaction with type I receptors.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo 1130033, Japan; PharmaDesign Inc, Tokyo 1040032, Japan	Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	miyazono-ind@umin.ac.jp						Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Casellas R, 1998, DEV BIOL, V198, P1; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mochizuki T, 2000, DEV BIOL, V224, P470, DOI 10.1006/dbio.2000.9778; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nakayama T, 2001, MECH DEVELOP, V100, P251, DOI 10.1016/S0925-4773(00)00533-5; Osada SI, 2003, DEVELOPMENT, V130, P1783, DOI 10.1242/dev.00401; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200	38	51	58	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31568	31574		10.1074/jbc.M313977200	http://dx.doi.org/10.1074/jbc.M313977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148321	hybrid			2022-12-25	WOS:000222726800079
J	Niu, SL; Mitchell, DC; Lim, SY; Wen, ZM; Kim, HY; Salem, N; Litman, BJ				Niu, SL; Mitchell, DC; Lim, SY; Wen, ZM; Kim, HY; Salem, N; Litman, BJ			Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; TERM INFANTS; METARHODOPSIN-II; VISUAL-ACUITY; DISK MEMBRANES; BRAIN; PHOSPHOLIPIDS; ACTIVATION; RATS	The fatty acid ( FA) docosahexaenoic acid ( DHA, 22: 6n-3) is highly enriched in membrane phospholipids of the central nervous system and retina. Loss of DHA because of n-3 FA deficiency leads to suboptimal function in learning, memory, olfactory-based discrimination, spatial learning, and visual acuity. G protein-coupled receptor (GPCR) signal transduction is a common signaling motif in these neuronal pathways. Here we investigated the effect of n-3 FA deficiency on GPCR signaling in retinal rod outer segment (ROS) membranes isolated from rats raised on n-3-adequate or -deficient diets. ROS membranes of second generation n-3 FA-deficient rats had similar to 80% less DHA than n-3-adequate rats. DHA was replaced by docosapentaenoic acid ( 22: 5n-6), an n-6 FA. This replacement correlated with desensitization of visual signaling in n-3 FA-deficient ROS, as evidenced by reduced rhodopsin activation, rhodopsin-ransducin (G(t)) coupling, cGMP phosphodiesterase activity, and slower formation of metarhodopsin II (MII) and the MII-G(t) complex relative to n-3 FA-adequate ROS. ROS membranes from n-3 FA-deficient rats exhibited a higher degree of phospholipid acyl chain order relative to n-3 FA-adequate rats. These findings reported here provide an explanation for the reduced amplitude and delayed response of the electroretinogram a-wave observed in n-3 FA deficiency in rodents and nonhuman primates. Because members of the GPCR family are widespread in signaling pathways in the nervous system, the effect of reduced GPCR signaling due to the loss of membrane DHA may serve as an explanation for the suboptimal neural signaling observed in n-3 FA deficiency.	NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), NIAAA, Lab Membrane Biochem & Biophys, Rockville, MD 20852 USA.	litman@helix.nih.gov		Lim, Sun Young/0000-0002-8091-3496	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000080, Z01AA000080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGOSTONI C, 1995, PEDIATR RES, V38, P262, DOI 10.1203/00006450-199508000-00021; BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2365; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; BIRCH EE, 1992, INVEST OPHTH VIS SCI, V33, P3242; BOURRE JM, 1989, J NUTR, V119, P1880, DOI 10.1093/jn/119.12.1880; Carlson SE, 1996, PEDIATR RES, V39, P882, DOI 10.1203/00006450-199605000-00024; Catalan J, 2002, BEHAV NEUROSCI, V116, P1022, DOI 10.1037//0735-7044.116.6.1022; Champoux M, 2002, PEDIATR RES, V51, P273, DOI 10.1203/00006450-200203000-00003; CONNOR WE, 1988, BIOL MEMBRANES ABERR, P275; Eldho NV, 2003, J AM CHEM SOC, V125, P6409, DOI 10.1021/ja029029o; Frances H, 1996, EUR J PHARMACOL, V298, P217, DOI 10.1016/0014-2999(95)00825-X; GALLI C, 1971, BIOCHIM BIOPHYS ACTA, V248, P449, DOI 10.1016/0005-2760(71)90233-5; Greiner RS, 2001, PHYSIOL BEHAV, V72, P379, DOI 10.1016/S0031-9384(00)00437-6; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Jeffrey BG, 2002, LIPIDS, V37, P839, DOI 10.1007/s11745-002-0969-0; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KIM HY, 1994, ANAL CHEM, V66, P3977, DOI 10.1021/ac00094a020; Koenig BW, 1997, BIOPHYS J, V73, P1954, DOI 10.1016/S0006-3495(97)78226-2; LAMPTEY MS, 1976, J NUTR, V106, P86, DOI 10.1093/jn/106.1.86; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; MAKRIDES M, 1993, PEDIATR RES, V33, P425; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; MILLER JL, 1987, BIOCHIM BIOPHYS ACTA, V898, P81, DOI 10.1016/0005-2736(87)90111-8; MILLS DE, 1988, NUTR RES, V8, P273, DOI 10.1016/S0271-5317(88)80045-9; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; Niu SL, 2002, J BIOL CHEM, V277, P20139, DOI 10.1074/jbc.M200594200; ORGANISCIAK DT, 1982, EXP EYE RES, V34, P401, DOI 10.1016/0014-4835(82)90086-0; Pawlosky RJ, 1997, AM J CLIN NUTR, V65, P465, DOI 10.1093/ajcn/65.2.465; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; SALEM N, 1989, CURRENT TOPICS NUTRI, V22, P109; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; Wainwright P E, 1998, Nutr Neurosci, V1, P281, DOI 10.1080/1028415X.1998.11747238; Weisinger HS, 2002, LIPIDS, V37, P759, DOI 10.1007/s11745-002-0958-3; Weisinger HS, 1996, ANN NUTR METAB, V40, P91, DOI 10.1159/000177900; Werkman SH, 1996, LIPIDS, V31, P91, DOI 10.1007/BF02522417; WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197; YAMAMOTO N, 1991, J GERONTOL, V46, P17; YEE R, 1978, J BIOL CHEM, V253, P8902	44	190	197	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31098	31104		10.1074/jbc.M404376200	http://dx.doi.org/10.1074/jbc.M404376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145938	hybrid			2022-12-25	WOS:000222726800025
J	Yeh, M; Gharavi, NM; Choi, J; Hsieh, X; Reed, E; Mouillesseaux, KP; Cole, AL; Reddy, ST; Berliner, JA				Yeh, M; Gharavi, NM; Choi, J; Hsieh, X; Reed, E; Mouillesseaux, KP; Cole, AL; Reddy, ST; Berliner, JA			Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers and activators of transcription (STAT)3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; MONOCYTE CHEMOTACTIC PROTEIN-1; LOW-DENSITY-LIPOPROTEIN; ENDOTHELIAL-CELLS; OXIDATION-PRODUCTS; TYROSINE KINASE; GENE-EXPRESSION; V-SRC; STAT3	Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (Ox-PAPC) and its component phospholipids 1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-phosphorylcholine (PEIPC) and 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine induce endothelial cells to synthesize chemotactic factors, such as interleukin 8 (IL-8). We have shown recently that Ox-PAPC-mediated induction of IL-8 transcription is independent of NF-kappaB activation, a major transcription factor utilized by cytokines and lipopolysaccharide for the induction of IL-8 transcription. In this study, we provide evidence for the role of c-src in Ox-PAPC and, specifically, PEIPC-mediated IL-8 induction. Ox-PAPC and its component phospholipids induced a rapid and transient phosphorylation of c-src Tyr(418), a hallmark of c-src activation, in human aortic endothelial cells ( HAEC). Ox-PAPC-mediated IL-8 protein synthesis in HAEC was inhibited by Src family kinase inhibitors, PP1 and PP2, but not by an inactive analog, PP3. Transient expression of plasmids containing C-terminal Src kinase or kinase-deficient dominant-negative c-src resulted in a 72 and 50% reduction in Ox-PAPC- induced IL-8 promoter activation in human microvascular endothelial cells, respectively. In contrast, overexpression of v-src kinase resulted in a 4-fold increase in IL-8 promoter activation, without inducing NF-kappaB promoter activation. Furthermore, treatment of HAEC with Ox-PAPC and its component PEIPC induced the activation of STAT3 by phosphorylating Tyr(705), a feature of STAT3 activation. STAT3 is a known downstream effector of c-src. Ox-PAPC- induced activation of STAT3 resulted in the translocation of STAT3 from the cytoplasm of HAEC into their nuclear compartment. Transient expression of a dominant-negative STAT3beta construct in HMEC strongly inhibited IL-8 induction by Ox-PAPC. Taken together, these data demonstrate the role of the c-src kinase/STAT3 pathway in Ox-PAPC- mediated IL-8 expression in endothelial cells.	Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Berliner, JA (corresponding author), 13-239 CHS Pathol,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.	myeh@mednet.ucla.edu	Gharavi, Nima/AAN-7890-2020					Berliner JA, 2001, TRENDS CARDIOVAS MED, V11, P142, DOI 10.1016/S1050-1738(01)00098-6; Blaber R, 2003, J AM SOC NEPHROL, V14, P116, DOI 10.1097/01.ASN.0000040595.35207.62; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Cole AL, 2003, ARTERIOSCL THROM VAS, V23, P1384, DOI 10.1161/01.ATV.0000081215.45714.71; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EICHER DM, 1994, J IMMUNOL, V152, P2710; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Fujimoto J, 2003, J BIOMED SCI, V10, P320, DOI 10.1159/000070097; Funakoshi-Tago M, 2003, EUR J BIOCHEM, V270, P1257, DOI 10.1046/j.1432-1033.2003.03487.x; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Lee H, 2000, CIRC RES, V87, P516; Liu R, 2001, J LEUKOCYTE BIOL, V70, P961; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masamune A, 2002, J PHARMACOL EXP THER, V302, P36, DOI 10.1124/jpet.302.1.36; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Myers SJ, 1999, ATHEROSCLEROSIS, V143, P389, DOI 10.1016/S0021-9150(98)00331-1; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; SCHMID P, 1993, ARCH DERMATOL RES, V285, P334, DOI 10.1007/BF00371833; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Shih PT, 1999, J CLIN INVEST, V103, P613, DOI 10.1172/JCI5710; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; Velichko S, 2002, J BIOL CHEM, V277, P35635, DOI 10.1074/jbc.M204578200; Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE; Walton KA, 2003, J BIOL CHEM, V278, P29661, DOI 10.1074/jbc.M300738200; Walton KA, 2003, ARTERIOSCL THROM VAS, V23, P1197, DOI 10.1161/01.ATV.0000079340.80744.B8; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Yeh M, 2001, ARTERIOSCL THROM VAS, V21, P1585, DOI 10.1161/hq1001.097027; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	45	105	107	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30175	30181		10.1074/jbc.M312198200	http://dx.doi.org/10.1074/jbc.M312198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15143062	hybrid			2022-12-25	WOS:000222531900039
J	Meertens, L; Pise-Masison, C; Quere, N; Brady, J; Gessain, A; Mahieux, R				Meertens, L; Pise-Masison, C; Quere, N; Brady, J; Gessain, A; Mahieux, R			Utilization of the CBP but not the p300 co-activator by human T-lymphotropic virus type-2 Tax for p53 inhibition	ONCOGENE			English	Article						HTLV; tax; p53; CBP/p300; NF-kappa B	CELL LEUKEMIA-VIRUS; NF-KAPPA-B; CREB BINDING-PROTEIN; WILD-TYPE P53; II HTLV-II; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION FUNCTION; FUNCTIONAL IMPAIRMENT; ABERRANT EXPRESSION; DOMAIN	We previously reported, both in transfected cells and in human T-cell leukemia virus type-2 subtype B infected cells, that the viral transactivator Tax-2B protein could inhibit p53 functions. We have now investigated the mechanism through which Tax-2B represses p53 using GFPTax-2B fusion proteins. We present evidence that Tax-2B inhibition of p53 function is not linked to CREB/ ATF activation, but is uniquely correlated with the interaction of CREB binding protein (CBP), but not p300, with the C-terminus of Tax-2B. Wild type, but not a Tax-2B-M47 mutant, inhibits p53 function in adherent cells. We demonstrate that both Tax-2B and Tax-2B-M47 can bind p300, while Tax-2B-M47 is impaired for CBP binding. Importantly, transfection of increasing amounts of CBP but not p300 or p300/CBP-associated factor (P/CAF) could rescue p53 transcriptional activity in the presence of Tax-2B in nonlymphocytic cells. In lymphoid cells, Tax-2B mediated inhibition of p53 is correlated with the NF-kappaB pathway activation and could be prevented by the overexpression of an IkappaBalpha mutant. Given the similarities between the functional domains of CBP and p300, these results are intriguing and suggest that Tax-2B must bind the CR2 domain of CBP, but not that of p300 in order to repress p53.	Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; NCI, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mahieux, R (corresponding author), Inst Pasteur, Unite Edpidemiol & Physiopathol Virus Oncogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	rmahieux@pasteur.fr	Meertens, Laurent/E-8043-2017	Meertens, Laurent/0000-0003-2811-3675; mahieux, renaud/0000-0002-5129-6804				ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Casoli C, 2004, BLOOD, V103, P995, DOI 10.1182/blood-2003-07-2503; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Eiraku N, 1996, J VIROL, V70, P1481, DOI 10.1128/JVI.70.3.1481-1492.1996; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fouchard N, 1995, LEUKEMIA, V9, P2087; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; GESSAIN A, 1985, LANCET, V2, P407; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson JM, 2001, INT J EXP PATHOL, V82, P135, DOI 10.1046/j.1365-2613.2001.00191.x; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Lewis MJ, 2002, VIROLOGY, V295, P182, DOI 10.1006/viro.2002.1357; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Murphy EL, 1997, NEUROLOGY, V48, P315, DOI 10.1212/WNL.48.2.315; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REID RL, 1993, ONCOGENE, V8, P3029; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Ross TM, 1997, J VIROL, V71, P8912, DOI 10.1128/JVI.71.11.8912-8917.1997; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; SHAH NP, 1986, MOL CELL BIOL, V6, P3626, DOI 10.1128/MCB.6.11.3626; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Takemoto S, 2000, BLOOD, V95, P3939; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9	57	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5447	5458		10.1038/sj.onc.1207719	http://dx.doi.org/10.1038/sj.onc.1207719			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15156194				2022-12-25	WOS:000222588400004
J	Wang, Q; Liu, M; Kozasa, T; Rothstein, JD; Sternweis, PC; Neubig, RR				Wang, Q; Liu, M; Kozasa, T; Rothstein, JD; Sternweis, PC; Neubig, RR			Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; G(12) FAMILY; KINASE; LARG; PHOSPHORYLATION; IDENTIFICATION; G-ALPHA(13); EXPRESSION	Thrombin and lysophosphatidic acid (LPA) receptors play important roles in vascular biology, development, and cancer. These receptors activate rho via G(12/13) family heterotrimeric G proteins, which are known to directly activate three distinct rho guanine nucleotide exchange factors ( rhoGEFs) that contain a regulator of G protein signaling (RGS) domain (RGS-rhoGEFs). However, it is not known which, if any, of these RGS-rhoGEFs ( LARG (leukemia-associated rhoGEF), p115rhoGEF, or PDZrhoGEF) plays a role in G protein-coupled receptor-stimulated rho signaling. Using oligonucleotide small interfering RNAs that suppress specific RGS-rhoGEF expression, we show that thrombin receptor stimulation of rho is primarily mediated by LARG in HEK293T and PC-3 prostate cancer cell lines. In contrast, the LPA-stimulated rho response in PC-3 cells is dependent on PDZrhoGEF expression. Suppression of p115rhoGEF had no effect. Thus different rhoGEFs ( LARG and PDZrhoGEF) mediate downstream rho signaling by the thrombin and LPA receptors.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Neubig, RR (corresponding author), Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.	rneubig@umich.edu	rothstein, jeffrey d/C-9470-2013	Neubig, Richard/0000-0003-0501-0008	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, R01GM061454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM39561, GM61454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; Cooper CR, 2003, CANCER-AM CANCER SOC, V97, P739, DOI 10.1002/cncr.11181; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hollenberg MD, 1997, CAN J PHYSIOL PHARM, V75, P832, DOI 10.1139/cjpp-75-7-832; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Liu J, 2003, UROL RES, V31, P163, DOI 10.1007/s00240-003-0309-2; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; WANG Q, 2004, IN PRESS METHODS ENZ, V389; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200	29	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					28831	28834		10.1074/jbc.C400105200	http://dx.doi.org/10.1074/jbc.C400105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15143072	hybrid			2022-12-25	WOS:000222445300002
J	Ivey, RA; Zhang, YM; Virga, KG; Hevener, K; Lee, RE; Rock, CO; Jackowski, S; Park, HW				Ivey, RA; Zhang, YM; Virga, KG; Hevener, K; Lee, RE; Rock, CO; Jackowski, S; Park, HW			The structure of the pantothenate kinase center dot ADP center dot pantothenate ternary complex reveals the relationship between the binding sites for substrate, allosteric regulator, and antimetabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A; ESCHERICHIA-COLI; ACUTE ENCEPHALOPATHY; CALCIUM HOPANTENATE; CRYSTAL-STRUCTURE; GENE; CLONING; ADENYLYLTRANSFERASE; IDENTIFICATION; MECHANISMS	Pantothenate kinase catalyzes the first step in the biosynthesis of coenzyme A, the major acyl group carrier in biology. In bacteria, regulation of pantothenate kinase activity is a major factor in controlling intracellular coenzyme A levels, and pantothenate analogs are growth-inhibiting antimetabolites. We have extended the structural information on Escherichia coli pantothenate kinase by determining the structure of the enzyme.ADP. pantothenate ternary complex. Pantothenate binding induces a significant conformational change in amino acids 243-263, which form a "lid" that folds over the open pantothenate binding groove. The positioning of the substrates suggests the reaction proceeds by a concerted mechanism that involves a dissociative transition state, although the negative charge neutralization of the gamma-phosphate by Arg-243, Lys-101, and Mg2+ coupled with hydrogen bonding of the C1 of pantothenate to Asp-127 suggests different interpretations of the phosphoryl transfer mechanism of pantothenate kinase. N-alkylpantothenamides are substrates for pantothenate kinase. Modeling these antimetabolites into the pantothenate active site predicts that they bind in the same orientation as pantothenate with their alkyl chains interacting with the hydrophobic dome over the pantothenate pocket, which is also accessed by the beta-mercaptoethylamine moiety of the allosteric regulator, coenzyme A. These structural/biochemical studies illustrate the intimate relationship between the substrate, allosteric regulator, and antimetabolite binding sites on pantothenate kinase and provide a framework for studies of its catalysis and feedback regulation.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Biosci, Memphis, TN 38163 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Park, HW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	hee-won.park@stjude.org	Lee, Richard/AAX-3996-2021; Hevener, Kirk/AAC-4828-2020; Lee, Richard/J-4997-2013; Jackowski, Suzanne/N-8168-2018	Lee, Richard/0000-0002-2397-0443; Hevener, Kirk/0000-0002-5584-3625; Lee, Richard/0000-0002-2397-0443; Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496, R01GM062896] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIGMS NIH HHS [GM 62896, GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Begley TP, 2001, VITAM HORM, V61, P157; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN ID, 1985, ACTA CRYSTALLOGR B, V41, P244, DOI 10.1107/S0108768185002063; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Cleland WW, 1995, FASEB J, V9, P1585, DOI 10.1096/fasebj.9.15.8529838; CLIFTON G, 1970, ARCH BIOCHEM BIOPHYS, V137, P523, DOI 10.1016/0003-9861(70)90470-4; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Madhusudan, 2002, NAT STRUCT BIOL, V9, P273, DOI 10.1038/nsb780; MATSUMOTO M, 1991, J CHROMATOGR-BIOMED, V562, P139, DOI 10.1016/0378-4347(91)80572-T; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Mishra PK, 2000, CHEM REV, V100, P3283, DOI 10.1021/cr990010m; NODA S, 1991, LIVER, V11, P134; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1960, NATURE CHEM BOND, V3rd; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SASAKI T, 1991, BRAIN DEV-JPN, V13, P52, DOI 10.1016/S0387-7604(12)80298-1; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Strauss E, 2002, J BIOL CHEM, V277, P48205, DOI 10.1074/jbc.M204560200; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; VALLARI DS, 1985, J BACTERIOL, V162, P1156, DOI 10.1128/JB.162.3.1156-1161.1985; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; Yun M, 2000, J BIOL CHEM, V275, P28093	33	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35622	35629		10.1074/jbc.M403152200	http://dx.doi.org/10.1074/jbc.M403152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15136582	hybrid			2022-12-25	WOS:000223303400058
J	Miki, T; Okada, N; Danbara, H				Miki, T; Okada, N; Danbara, H			Two periplasmic disulfide oxidoreductases, DsbA and SrgA, target outer membrane protein SpiA, a component of the Salmonella pathogenicity island 2 type III secretion system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOND FORMATION; VIRULENCE PLASMID; SHIGELLA-FLEXNERI; IN-VIVO; TYPHIMURIUM; IDENTIFICATION; PATHWAY; INVASION; GENES	The formation of disulfide is essential for the folding, activity, and stability of many proteins secreted by Gram-negative bacteria. The disulfide oxidoreductase, DsbA, introduces disulfide bonds into proteins exported from the cytoplasm to periplasm. In pathogenic bacteria, DsbA is required to process virulence determinants for their folding and assembly. In this study, we examined the role of the Dsb enzymes in Salmonella pathogenesis, and we demonstrated that DsbA, but not DsbC, is required for the full expression of virulence in a mouse infection model of Salmonella enterica serovar Typhimurium. Salmonella strains carrying a dsbA mutation showed reduced function mediated by type III secretion systems (TTSSs) encoded on Salmonella pathogenicity islands 1 and 2 (SPI-1 and SPI-2). To obtain a more detailed understanding of the contribution of DsbA to both SPI-1 and SPI-2 TTSS function, we identified a protein component of the SPI- 2 TTSS apparatus affected by DsbA. Although we found no substrate protein for DsbA in the SPI- 1 TTSS apparatus, we identified SpiA (SsaC), an outer membrane protein of SPI- 2 TTSS, as a DsbA substrate. Site-directed mutagenesis of the two cysteine residues present in the SpiA protein resulted in the loss of SPI- 2 function in vitro and in vivo. Furthermore, we provided evidence that a second disulfide oxidoreductase, SrgA, also oxidizes SpiA. Analysis of in vivo mixed infections demonstrated that a Salmonella dsbA srgA double mutant strain was more attenuated than either single mutant, suggesting that DsbA acts in concert with SrgA in vivo.	Kitasato Univ, Sch Pharmaceut Sci, Dept Microbiol, Minato Ku, Tokyo 1088641, Japan	Kitasato University	Okada, N (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Dept Microbiol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	okadan@pharm.kitasato-u.ac.jp						Agudo D, 2004, PROTEOMICS, V4, P355, DOI 10.1002/pmic.200300554; ALTMEYER RM, 1993, MOL MICROBIOL, V7, P89, DOI 10.1111/j.1365-2958.1993.tb01100.x; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bajaj V, 1995, MOL MICROBIOL, V18, P715, DOI 10.1111/j.1365-2958.1995.mmi_18040715.x; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Beuzon CR, 2001, MICROBES INFECT, V3, P1345, DOI 10.1016/S1286-4579(01)01496-4; Bouwman CW, 2003, J BACTERIOL, V185, P991, DOI 10.1128/JB.185.3.991-1000.2003; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; Crago AM, 1998, MOL MICROBIOL, V30, P47, DOI 10.1046/j.1365-2958.1998.01036.x; Daefler S, 1998, MOL MICROBIOL, V28, P1367, DOI 10.1046/j.1365-2958.1998.00908.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DELEPELAIRE P, 1990, J BIOL CHEM, V265, P17118; Ellermeier CD, 2004, J BACTERIOL, V186, P68, DOI 10.1128/JB.186.1.68-79.2004; Freeman JA, 2003, INFECT IMMUN, V71, P418, DOI 10.1128/IAI.71.1.418-427.2003; GALAN JE, 1992, J BACTERIOL, V174, P4338; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Gotoh H, 2003, MICROB PATHOGENESIS, V34, P227, DOI 10.1016/S0882-4010(03)00034-2; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Ha UH, 2003, INFECT IMMUN, V71, P1590, DOI 10.1128/IAI.71.3.1590-1595.2003; Henderson IR, 2001, INFECT IMMUN, V69, P1231, DOI 10.1128/IAI.69.3.1231-1243.2001; Henderson IR, 2000, TRENDS MICROBIOL, V8, P529, DOI 10.1016/S0966-842X(00)01853-9; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jackson MW, 1999, J BACTERIOL, V181, P5126, DOI 10.1128/JB.181.16.5126-5130.1999; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KANIGA K, 1995, J BACTERIOL, V177, P3965, DOI 10.1128/jb.177.14.3965-3971.1995; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Komoriya K, 1999, MOL MICROBIOL, V34, P767, DOI 10.1046/j.1365-2958.1999.01639.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 2001, CURR OPIN STRUC BIOL, V11, P403, DOI 10.1016/S0959-440X(00)00224-4; LEONG JM, 1993, J BIOL CHEM, V268, P20524; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; MENARD R, 1993, J BACTERIOL, V175, P5899; Miller JH., 1992, SHORT COURSE BACTERI, P72; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; MORONA R, 1995, J BACTERIOL, V177, P1059, DOI 10.1128/jb.177.4.1059-1068.1995; Nikolaus T, 2001, J BACTERIOL, V183, P6036, DOI 10.1128/JB.183.20.6036-6045.2001; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; OKAMOTO K, 1995, J BACTERIOL, V177, P4579, DOI 10.1128/jb.177.16.4579-4586.1995; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rappl C, 2003, FEMS MICROBIOL LETT, V226, P363, DOI 10.1016/S0378-1097(03)00638-4; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; RodriguezPena JM, 1997, MICROBIOL-UK, V143, P1405, DOI 10.1099/00221287-143-4-1405; Ruiz-Albert J, 2002, MOL MICROBIOL, V44, P645, DOI 10.1046/j.1365-2958.2002.02912.x; Sandkvist M, 2001, MOL MICROBIOL, V40, P271, DOI 10.1046/j.1365-2958.2001.02403.x; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Stafford SJ, 1999, FEMS MICROBIOL LETT, V174, P179, DOI 10.1111/j.1574-6968.1999.tb13566.x; STERNBERG NL, 1991, METHOD ENZYMOL, V204, P18; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Turcot I, 2001, CAN J MICROBIOL, V47, P711, DOI 10.1139/cjm-47-8-711; WATARAI M, 1995, P NATL ACAD SCI USA, V92, P4927, DOI 10.1073/pnas.92.11.4927; YAMANAKA H, 1994, J BACTERIOL, V176, P2906, DOI 10.1128/JB.176.10.2906-2913.1994; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x; Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x	72	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34631	34642		10.1074/jbc.M402760200	http://dx.doi.org/10.1074/jbc.M402760200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15169785	hybrid			2022-12-25	WOS:000223134800068
J	Milovic, S; Steinecker-Frohnwieser, B; Schreibmayer, W; Weigl, LG				Milovic, S; Steinecker-Frohnwieser, B; Schreibmayer, W; Weigl, LG			The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-BETA-GAMMA; GENERAL-ANESTHETICS; ADENYLATE-CYCLASE; POTASSIUM CHANNEL; GIRK2 SUBUNITS; BINDING; ANALGESIA; SITES; INHIBITION; MODULATION	G protein-activated K+ channels (GIRKs or Kir3.x) are targets for the volatile anesthetic, halothane. When coexpressed with the m(2) acetylcholine (ACh) receptor in Xenopus oocytes, agonist-activated GIRK1(F137S)- and GIRK2-mediated currents are inhibited by halothane, whereas in the absence of ACh, high concentrations of halothane induce GIRK1F137S- mediated currents. To elucidate the molecular mechanism of halothane action on GIRK currents of different subunit compositions, we constructed deletion mutants of GIRK1(F137S) (GIRK1(Delta363*)) and GIRK2 (GIRK2(Delta356)) lacking the C-terminal ends, as well as chimeric GIRK channels. Mutated GIRK channels showed normal currents when activated by ACh but exhibited different pharmacological properties toward halothane. GIRK2(Delta356) showed no sensitivity against the inhibitory action of halothane but was activated by halothane in the absence of an agonist. GIRK1(Delta363*) was activated by halothane more efficiently. Currents mediated by chimeric channels were inhibited by anesthetic concentrations that were at least 30-fold lower than those necessary to decrease GIRK2 wild type currents. Glutathione S-transferase pulldown experiments did not show displacement of bound Gbetagamma by halothane, indicating that halothane does not interfere with Gbetagamma binding. Single channel experiments revealed an influence of halothane on the gating of the channels: The agonist-induced currents of GIRK1 and GIRK2, carried mainly by brief openings, were inhibited, whereas higher concentrations of the anesthetic promoted long openings of GIRK1 channels. Because the C terminus is crucial for these effects, an interaction of halothane with the channel seems to be involved in the mechanism of current modulation.	Med Univ Vienna, Dept Anesthesia & Intens Care Med B, A-1090 Vienna, Austria; Med Univ Graz, Inst Med Phys & Biophys, A-8010 Graz, Austria	Medical University of Vienna; Medical University of Graz	Weigl, LG (corresponding author), Med Univ Vienna, Dept Anesthesia & Intens Care Med B, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	lukas.weigl@univie.ac.at		Weigl, Lukas/0000-0002-9359-536X; Steinecker-Frohnwieser, Bibiane/0000-0001-6852-4466; Schreibmayer, Wolfgang/0000-0002-4631-7922				Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Blednow YA, 2003, P NATL ACAD SCI USA, V100, P277, DOI 10.1073/pnas.012682399; BOHM M, 1994, MOL PHARMACOL, V45, P380; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Ikeda K, 2002, NEUROSCI RES, V44, P121, DOI 10.1016/S0168-0102(02)00094-9; Ivanina T, 2003, J BIOL CHEM, V278, P29174, DOI 10.1074/jbc.M304518200; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; KIRSCH GE, 1989, AM J PHYSIOL, V257, pH334, DOI 10.1152/ajpheart.1989.257.1.H334; KRESS HG, 1998, RECENT ADV ANESTHESI, V20, P1; KREYSZIG E, 1979, STAT METHODEN IHRE A, P191; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luchian T, 1997, J PHYSIOL-LONDON, V505, P13, DOI 10.1111/j.1469-7793.1997.013bc.x; Marker CL, 2004, J NEUROSCI, V24, P2806, DOI 10.1523/JNEUROSCI.5251-03.2004; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Mitrovic I, 2003, P NATL ACAD SCI USA, V100, P271, DOI 10.1073/pnas.0136822100; NARAYANAN TK, 1988, BIOCHEM PHARMACOL, V37, P1219, DOI 10.1016/0006-2952(88)90774-5; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Pentyala SN, 1999, EUR J PHARMACOL, V384, P213, DOI 10.1016/S0014-2999(99)00625-1; Rebecchi MJ, 2002, BRIT J ANAESTH, V89, P62, DOI 10.1093/bja/aef160; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sambrook J., 2001, MOL CLONING LAB MANU; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Spauschus A, 1996, J NEUROSCI, V16, P930; Weigl LG, 2001, MOL PHARMACOL, V60, P282, DOI 10.1124/mol.60.2.282; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; Yamakura T, 2001, ANESTHESIOLOGY, V95, P144, DOI 10.1097/00000542-200107000-00025	38	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34240	34249		10.1074/jbc.M403448200	http://dx.doi.org/10.1074/jbc.M403448200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175324	hybrid			2022-12-25	WOS:000223134800022
J	Nguyen, TLA; Calomme, C; Wijmeersch, G; Nizet, S; Veithen, E; Portetelle, D; de Launoit, Y; Burny, A; Van Lint, C				Nguyen, TLA; Calomme, C; Wijmeersch, G; Nizet, S; Veithen, E; Portetelle, D; de Launoit, Y; Burny, A; Van Lint, C			Deacetylase inhibitors and the viral transactivator Tax(BLV) synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element and cAMP-responsive element-binding protein-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; TRANSCRIPTIONAL COACTIVATORS P300; INTERFERON REGULATORY FACTOR-2; I TAX PROTEIN; NF-KAPPA-B; DNA-BINDING; HISTONE ACETYLATION; HIV-1 TAT; FACTOR CREB; T-CELLS	Efficient bovine leukemia virus (BLV) transcription requires the virus-encoded transactivator Tax(BLV), which acts through three Tax(BLV)-responsive elements located in the 5' long terminal repeat. It has been proposed that the binding of the CRE-binding protein (CREB) and the activating transcription factor (ATF) to the three imperfect cAMP-responsive elements (CREs) located in each Tax(BLV)-responsive element mediates Tax(BLV) transactivation. Here we demonstrated that deacetylase inhibitors (HDACis) synergistically enhanced the transcriptional activation of the BLV promoter by Tax(BLV) in a CRE-dependent manner. Tax(BLV) was acetylated in vivo at its N-alpha terminus but not at internal lysine residues. Rather, HDACi potentiation of Tax(BLV) transactivation was mediated by an HDACi indirect action that requires new protein synthesis. Mechanistically, using a dominant-negative form of CREB, we showed that Tax(BLV) and HDACi synergistically activated BLV gene expression via a CREB-dependent mechanism. Moreover, electrophoretic mobility shift assay and Western blot experiments revealed that HDACi increased the in vitro DNA binding activity of CREB/ ATF but did not alter CREB/ ATF intranuclear presence. Remarkably, chromatin immunoprecipitation assays demonstrated that HDACi treatment increased the level of CREB bound to the BLV promoter in vivo. Our results together suggest that an increase in CREB/ ATF occupancy of the viral CREs in response to HDACi potentiates Tax(BLV) transactivation of the BLV promoter.	Free Univ Brussels, Inst Biol & Med Mol, Serv Chim Biol, Mol Virol Lab, B-6041 Gosselies, Belgium; Fac Univ Sci Agron Gembloux, Dept Biol Mol, B-5030 Gembloux, Belgium; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium; Univ Lille 1, Inst Pasteur Lille, Inst Biol Lille, CNRS,UMR 8117, F-59021 Lille, France	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Van Lint, C (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Serv Chim Biol, Mol Virol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	cvlint@ulb.ac.be						Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; ADAM E, 1994, J VIROL, V68, P5845, DOI 10.1128/JVI.68.9.5845-5853.1994; Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bondzio A, 2001, BIOL CHEM, V382, P407, DOI 10.1515/BC.2001.050; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Calomme C, 2002, J BIOL CHEM, V277, P8775, DOI 10.1074/jbc.M107441200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chan HM, 2001, J CELL SCI, V114, P2363; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; Dormeyer W, 2003, ANAL BIOANAL CHEM, V376, P994, DOI 10.1007/s00216-003-2058-z; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Eklund EA, 1999, J IMMUNOL, V163, P6095; Gachon F, 2002, VIROLOGY, V299, P271, DOI 10.1006/viro.2002.1501; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Goren I, 2001, J MOL BIOL, V313, P695, DOI 10.1006/jmbi.2001.5064; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kawasaki H, 2000, Nucleic Acids Symp Ser, P259; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kino T, 1999, J STEROID BIOCHEM, V70, P15, DOI 10.1016/S0960-0760(99)00100-4; KISSTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3677, DOI 10.1093/nar/21.16.3677; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Merezak C, 2002, J VIROL, V76, P5034, DOI 10.1128/JVI.76.10.5034-5042.2002; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Quivy V, 2002, J VIROL, V76, P11091, DOI 10.1128/JVI.76.21.11091-11103.2002; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Van den Broeke A, 1999, J VIROL, V73, P1054, DOI 10.1128/JVI.73.2.1054-1065.1999; Van Lint C, 2000, Adv Pharmacol, V48, P121; VanLint C, 1996, GENE EXPRESSION, V5, P245; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VANLINT C, 1994, J VIROL, V68, P2632, DOI 10.1128/JVI.68.4.2632-2648.1994; Wallberg AE, 2000, BIOCHEM SOC T, V28, P410, DOI 10.1042/0300-5127:0280410; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WILLEMS L, 1992, J VIROL, V66, P766, DOI 10.1128/JVI.66.2.766-772.1992; Willems L, 1987, Haematol Blood Transfus, V31, P482; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xiao JQ, 1998, J VIROL, V72, P5994, DOI 10.1128/JVI.72.7.5994-6003.1998; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	78	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35025	35036		10.1074/jbc.M404081200	http://dx.doi.org/10.1074/jbc.M404081200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15163662	hybrid			2022-12-25	WOS:000223134800115
J	Vaquero, EC; Edderkaoui, M; Pandol, SJ; Gukovsky, I; Gukovskaya, AS				Vaquero, EC; Edderkaoui, M; Pandol, SJ; Gukovsky, I; Gukovskaya, AS			Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; NADPH OXIDASE; HYDROGEN-PEROXIDE; SUPEROXIDE ANION; REGULATES GROWTH; MITOCHONDRIAL; ACTIVATION; DEATH	One reason why pancreatic cancer is so aggressive and unresponsive to treatments is its resistance to apoptosis. We report here that reactive oxygen species (ROS) are a prosurvival, antiapoptotic factor in pancreatic cancer cells. Human pancreatic adenocarcinoma MIA PaCa-2 and PANC-1 cells generated ROS, which was stimulated by growth factors ( serum, insulin-like growth factor I, or fibroblast growth factor-2). Growth factors also stimulated membrane NAD(P) H oxidase activity in these cells. Both intracellular ROS and NAD( P) H oxidase activity were inhibited by antioxidants tiron and N-acetylcysteine and the inhibitor of flavoprotein-dependent oxidases, diphenylene iodonium, but not by inhibitors of various other ROS-generating enzymes. Using Rho(0) cells deficient in mitochondrial DNA, we showed that a nonmitochondrial NAD( P) H oxidase is a major source of growth factor-induced ROS in pancreatic cancer cells. Among proteins that have been implicated in NAD( P) H oxidase activity, MIA PaCa-2 and PANC-1 cells do not express the phagocytic gp91(phox) subunit but express several nonphagocytic oxidase (NOX) isoforms. Transfection with Nox4 antisense oligonucleotide inhibited NAD( P) H oxidase activity and ROS production in MIA PaCa-2 and PANC-1 cells. Inhibiting ROS with the antioxidants, Nox4 antisense, or MnSOD overexpression all stimulated apoptosis in pancreatic cancer cells as measured by internucleosomal DNA fragmentation, phosphatidylserine externalization, cytochrome c release, and effector caspase activation. The results show that growth factor-induced ROS produced by NAD( P) H oxidase ( probably Nox4) protect pancreatic cancer cells from apoptosis. This mechanism may play an important role in pancreatic cancer resistance to treatment and thus represent a novel therapeutic target.	Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, W Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Gukovskaya, AS (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, W Los Angeles Healthcare Ctr, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	agukovsk@ucla.edu		Gukovskaya, Anna/0000-0003-3737-5335; Edderkaoui, Mouad/0000-0002-2549-8242; Vaquero, Eva C./0000-0003-0098-5295	NIDDK NIH HHS [DK 59936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cullen JJ, 2003, CANCER RES, V63, P1297; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Green DR, 2003, MOL CELL, V11, P551, DOI 10.1016/S1097-2765(03)00107-2; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Hail N, 2001, CANCER RES, V61, P6698; Janiszewski M, 2002, FREE RADICAL BIO MED, V32, P446, DOI 10.1016/S0891-5849(01)00828-0; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; King M P, 1996, Methods Enzymol, V264, P339, DOI 10.1016/S0076-6879(96)64032-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304-3940(02)01385-X; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RAND MJ, 1993, CLIN EXP PHARMACOL P, V20, P141, DOI 10.1111/j.1440-1681.1993.tb01661.x; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Sakamoto T, 1996, BIOCHEM BIOPH RES CO, V220, P643, DOI 10.1006/bbrc.1996.0457; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sorescu D, 2001, FREE RADICAL BIO MED, V30, P603, DOI 10.1016/S0891-5849(00)00507-4; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Taanman JW, 1997, J BIOENERG BIOMEMBR, V29, P151, DOI 10.1023/A:1022638013825; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tong WG, 2002, MOL CANCER THER, V1, P929; Vaquero EC, 2003, GASTROENTEROLOGY, V125, P1188, DOI 10.1016/S0016-5085(03)01203-4; Wanebo HJ, 1996, CANCER-AM CANCER SOC, V78, P580; Wedgwood S, 2003, AM J PHYSIOL-LUNG C, V285, pL305, DOI 10.1152/ajplung.00382.2002; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; YAGI T, 1990, ARCH BIOCHEM BIOPHYS, V281, P305, DOI 10.1016/0003-9861(90)90448-8; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC	57	287	306	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34643	34654		10.1074/jbc.M400078200	http://dx.doi.org/10.1074/jbc.M400078200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15155719	hybrid			2022-12-25	WOS:000223134800069
J	Wagner, KW; Engels, IH; Deveraux, QL				Wagner, KW; Engels, IH; Deveraux, QL			Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH; MITOCHONDRIA; ACTIVATION; APO2L/TRAIL; MECHANISMS; PROTEINS; RELEASE; MODEL; BAX	In many mammalian cell types, engagement of the TRAIL/Apo2L death receptors DR4 and DR5 alters mitochondrial physiology, thereby promoting the release of pro-apoptotic proteins normally contained within this organelle. A contemporary view of this process is that in so-called type II cells death receptor-activated caspase-8 cleaves the Bcl-2 family member Bid, which generates a truncated Bid fragment that collaborates with Bax, another Bcl-2 relative, to promote the release of mitochondrial factors necessary for activation of executioner caspases and apoptosis. Here we show that in some type II cells caspase-2 is necessary for optimal TRAIL-mediated cleavage of Bid. Down-regulation of caspase-2 using RNA interference significantly inhibited TRAIL-induced apoptosis. Analysis of the TRAIL proteolytic cascade following gene silencing of specific pathway components revealed that caspase-2 is necessary for efficient cleavage of Bid; however, caspase-2 proteolytic processing, which occurs downstream of Bax, is not necessary for its role in Bid cleavage.	Novartis Res Fdn, Genom Inst, Dept Canc Biol, San Diego, CA 92121 USA	Novartis	Deveraux, QL (corresponding author), GNF, Dept Canc Biol, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	deveraux@gnf.org						Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 2003, SEMIN CANCER BIOL, V13, P293, DOI 10.1016/S1044-579X(03)00043-9; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roucou Xavier, 2001, Cardiology Clinics, V19, P45, DOI 10.1016/S0733-8651(05)70194-6; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Wagner KW, 2003, CANCER BIOL THER, V2, P534, DOI 10.4161/cbt.2.5.453; Wang XD, 2001, GENE DEV, V15, P2922; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	30	97	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					35047	35052		10.1074/jbc.M400708200	http://dx.doi.org/10.1074/jbc.M400708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15173176	hybrid			2022-12-25	WOS:000223134800117
J	Oliveira, JS; Redaelli, E; Zaharenko, AJ; Cassulini, RR; Konno, K; Pimenta, DC; Freitas, JC; Clare, JJ; Wanke, E				Oliveira, JS; Redaelli, E; Zaharenko, AJ; Cassulini, RR; Konno, K; Pimenta, DC; Freitas, JC; Clare, JJ; Wanke, E			Binding specificity of sea anemone toxins to Na(v)1.1-1.6 sodium channels - Unexpected contributions from differences in the IV/S3-S4 outer loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE ANTHOPLEURIN-B; HUMAN BRAIN; PHARMACOLOGICAL PROPERTIES; FUNCTIONAL-ANALYSIS; SCORPION TOXINS; CELL-LINE; RESIDUES; SUBUNIT; CLONING; NEURONS	Sea anemones are an important source of various biologically active peptides, and it is known that ATX-II from Anemonia sulcata slows sodium current inactivation. Using six different sodium channel genes ( from Na(v)1.1 to Na(v)1.6), we investigated the differential selectivity of the toxins AFT-II ( purified from Anthopleura fuscoviridis) and Bc-III ( purified from Bunodosoma caissarum) and compared their effects with those recorded in the presence of ATX-II. Interestingly, ATX-II and AFT-II differ by only one amino acid (L36A) and Bc-III has 70% similarity. The three toxins induced a low voltage-activated persistent component primarily in the Na(v)1.3 and Na(v)1.6 channels. An analysis showed that the 18 dose-response curves only partially fit the hypothesized binding of Lys-37 ( sea anemone toxin Anthopleurin B) to the Asp ( or Glu) residue of the extracellular IV/S3-S4 loop in cardiac ( or nervous) Na+ channels, thus suggesting the substantial contribution of some nearby amino acids that are different in the various channels. As these channels are atypically expressed in mammalian tissues, the data not only suggest that the toxicity is highly dependent on the channel type but also that these toxins and their various physiological effects should be considered prototype models for the design of new and specific pharmacological tools.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Sao Paulo, Dept Fisiol, Inst Biosci, BR-05508900 Sao Paulo, Brazil; Inst Butantan, Ctr Toxinol Aplicada, CAT CEPID FAPESP, BR-05503900 Sao Paulo, Brazil; GlaxoSmithKline, Med Res Ctr, Gene Express & Prot Biochem, Stevenage SG1 2NY, Herts, England	University of Milano-Bicocca; Universidade de Sao Paulo; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Instituto Butantan; GlaxoSmithKline	Wanke, E (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	enzo.wanke@unimib.it	Stolarz-de-Oliveira, Joacir/AAG-4165-2020; Zaharenko, André/A-4946-2010; Pimenta, Daniel C/B-4361-2008	Stolarz-de-Oliveira, Joacir/0000-0002-0764-017X; Zaharenko, André/0000-0003-0374-1608; Pimenta, Daniel C/0000-0003-2406-0860; Konno, Katsuhiro/0000-0002-1949-1845				Benzinger GR, 1998, J BIOL CHEM, V273, P80, DOI 10.1074/jbc.273.1.80; BERESS L, 1975, FEBS LETT, V50, P311, DOI 10.1016/0014-5793(75)80517-5; Bosmans F, 2002, FEBS LETT, V532, P131, DOI 10.1016/S0014-5793(02)03653-0; Brand S, 2000, EUR J NEUROSCI, V12, P2387, DOI 10.1046/j.1460-9568.2000.00136.x; Burbidge SA, 2002, MOL BRAIN RES, V103, P80, DOI 10.1016/S0169-328X(02)00188-2; CATTERAL WA, 2002, IUPHAR COMPENDIUM VO; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Chahine M, 1996, J MEMBRANE BIOL, V152, P39, DOI 10.1007/s002329900083; Chen HJ, 2002, EUR J NEUROSCI, V16, P767, DOI 10.1046/j.1460-9568.2002.02142.x; Chen YH, 2000, EUR J NEUROSCI, V12, P4281, DOI 10.1111/j.1460-9568.2000.01336.x; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; Goudet C, 2001, BRIT J PHARMACOL, V134, P1195, DOI 10.1038/sj.bjp.0704361; ISOM LI, 1995, J BIOL CHEM, V17, P3306; Khera PK, 1996, BIOCHEMISTRY-US, V35, P3503, DOI 10.1021/bi9528457; Lanio ME, 2001, TOXICON, V39, P187, DOI 10.1016/S0041-0101(00)00106-9; LORET EP, 1994, J BIOL CHEM, V269, P16785; MALPEZZI ELA, 1993, TOXICON, V31, P853, DOI 10.1016/0041-0101(93)90220-D; Mantegazza M, 1998, J PHYSIOL-LONDON, V507, P105, DOI 10.1111/j.1469-7793.1998.105bu.x; MEIER J, 1986, TOXICON, V24, P395, DOI 10.1016/0041-0101(86)90199-6; Moran O, 2000, FEBS LETT, V473, P132, DOI 10.1016/S0014-5793(00)01518-0; Mouhat S, 2004, BIOCHEM J, V378, P717, DOI 10.1042/BJ20031860; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROMEY G, 1980, J PHARMACOL EXP THER, V213, P607; Salceda E, 2002, J PHARMACOL EXP THER, V303, P1067, DOI 10.1124/jpet.102.038570; SUNAHARA S, 1987, TOXICON, V25, P211, DOI 10.1016/0041-0101(87)90243-1; WIDMER H, 1989, PROTEINS, V6, P357, DOI 10.1002/prot.340060403; Xie XM, 2001, PFLUG ARCH EUR J PHY, V441, P425, DOI 10.1007/s004240000448	29	89	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33323	33335		10.1074/jbc.M404344200	http://dx.doi.org/10.1074/jbc.M404344200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169781	hybrid			2022-12-25	WOS:000223039700039
J	Salahpour, A; Angers, S; Mercier, JF; Lagace, M; Marullo, S; Bouvier, M				Salahpour, A; Angers, S; Mercier, JF; Lagace, M; Marullo, S; Bouvier, M			Homodimerization of the beta 2-adrenergic receptor as a prerequisite for cell surface targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; OPIOID RECEPTORS; GABA(B) RECEPTOR; POTASSIUM CHANNELS; LIVING CELLS; DIMERIZATION; OLIGOMERIZATION; TRAFFICKING; HETERODIMERIZATION; EXPRESSION	Although homodimerization has been demonstrated for a large number of G protein-coupled receptors (GPCRs), no general role has been attributed to this process. Because it is known that oligomerization plays a key role in the quality control and endoplasmic reticulum ( ER) export of many proteins, we sought to determine if homodimerization could play such a role in GPCR biogenesis. Using the beta2-adrenergic receptor (beta2AR) as a model, cell fractionation studies revealed that receptor homodimerization is an event occurring as early as the ER. Supporting the hypothesis that receptor homodimerization is involved in ER processing, beta2AR mutants lacking an ER-export motif or harboring a heterologous ER-retention signal dimerized with the wild-type receptor and inhibited its trafficking to the cell surface. Finally, in addition to inhibiting receptor dimerization, disruption of the putative dimerization motif, (276)GXXXGXXXL(284), prevented normal trafficking of the receptor to the plasma membrane. Taken together, these data indicate that beta2AR homodimerization plays an important role in ER export and cell surface targeting.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Univ Paris 05, CNRS, Dept Cell Biol, Inst Cochin,INSERM, F-75014 Paris, France	Universite de Montreal; Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bouvier, M (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	michel.bouvier@umontreal.ca	Bouvier, Michel/H-2758-2014; Marullo, Stefano/C-6142-2008; Angers, Stephane/E-1432-2014	Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973; Angers, Stephane/0000-0001-7241-9044				AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Chapple JP, 2003, J BIOL CHEM, V278, P19087, DOI 10.1074/jbc.M212349200; Chelli M, 2001, J BIOL CHEM, V276, P46975, DOI 10.1074/jbc.M106432200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Hague C, 2004, J BIOL CHEM, V279, P15541, DOI 10.1074/jbc.M314014200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yuan HB, 2003, CURR BIOL, V13, P638, DOI 10.1016/S0960-9822(03)00208-2	51	250	252	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33390	33397		10.1074/jbc.M403363200	http://dx.doi.org/10.1074/jbc.M403363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155738	hybrid			2022-12-25	WOS:000223039700046
J	Jekabsons, MB; Nicholls, DG				Jekabsons, MB; Nicholls, DG			In situ respiration and bioenergetic status of mitochondria in primary cerebellar granule neuronal cultures exposed continuously to glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HIPPOCAMPAL-NEURONS; PLASMA-MEMBRANE DEPOLARIZATION; NITRIC-OXIDE; NMDA-RECEPTOR; CALCIUM HOMEOSTASIS; BRAIN NEURONS; PROTON LEAK; CELL-DEATH; NEUROTOXICITY; EXCITOTOXICITY	Mitochondria play a central role in neuronal death during pathological exposure to glutamate (excitotoxicity). To investigate the detailed bioenergetics of the in situ mitochondria, a method is described to monitor continuously the respiration of primary cerebellar granule neuron cultures while simultaneously imaging cytoplasmic Ca2+ and mitochondrial membrane potential. Coverslip-attached cells were perfused in an imaging chamber with upstream and downstream flow-through oxygen electrodes. The bioenergetic consequences of chronic glutamate exposure were investigated, including ATP supply and demand, proton leak, and mitochondrial respiratory capacity during chronic glutamate exposure. In 25 mM K+ medium supplemented with 10% dialyzed serum, cells utilized 54% of their respiratory capacity in the absence of receptor activation (37% for ATP generation, 12% to drive the mitochondrial proton leak, and the residual 5% was nonmitochondrial). Glutamate initially increased mitochondrial respiration from 51 to 68% of capacity, followed by a slow decline. It was estimated that 85% of this increased respiration was because of increased ATP demand, whereas 15% was attributable to a transient mitochondrial proton leak. N-Methyl-D-aspartate receptor activation was only responsible for 62% of the increased respiration. When adjusted for cell death over 3 h of glutamate exposure, respiration of the viable cells remained near basal and protonophore stimulated respiration to the same extent as control cells. Pyruvate-supplemented media protected cells from glutamate excitotoxicity, although this was associated with mitochondrial dysfunction. We conclude that excitotoxicity under these conditions is not because of an ATP deficit or uncoupling. Furthermore, mitochondria maintain the same respiratory capacity as in control cells.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Nicholls, DG (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dnicholls@buckinstitute.org	NICHOLLS, DAVID G/K-4300-2012		NATIONAL INSTITUTE ON AGING [R01AG021440] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG21440] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Almeida A, 1998, BRAIN RES, V790, P209, DOI 10.1016/S0006-8993(98)00064-X; Atlante A, 1996, NEUROREPORT, V7, P2519, DOI 10.1097/00001756-199611040-00023; Atlante A, 1999, J NEUROCHEM, V73, P237, DOI 10.1046/j.1471-4159.1999.0730237.x; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bal-Price A, 2002, J NEUROCHEM, V80, P73, DOI 10.1046/j.0022-3042.2001.00675.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Castilho RF, 1998, J NEUROSCI, V18, P10277; COURTNEY MJ, 1990, J NEUROSCI, V10, P3873, DOI 10.1523/JNEUROSCI.10-12-03873.1990; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; Desagher S, 1997, J NEUROSCI, V17, P9060; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; EIMERL S, 1995, J NEUROCHEM, V65, P739; EIMERL S, 1994, J NEUROCHEM, V62, P1223; GALLO V, 1987, J NEUROSCI, V7, P2203; GARTHWAITE G, 1986, NEUROSCI LETT, V66, P193, DOI 10.1016/0304-3940(86)90189-8; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HERTZ L, 1988, NEUROCHEM RES, V13, P605, DOI 10.1007/BF00973275; HERTZ L, 1992, CAN J PHYSIOL PHARM, V70, P145; Izumi Y, 1997, J NEUROSCI, V17, P9448; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NICHOLLS DG, 1980, BIOCHEM J, V186, P833, DOI 10.1042/bj1860833; NICHOLLS DG, 2002, BIOENERGETICS, P57; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PLATT B, 1995, NEUROPHARMACOLOGY, V34, P1339, DOI 10.1016/0028-3908(95)00123-N; POCOCK JM, 1993, NEUROPHARMACOLOGY, V32, P1185, DOI 10.1016/0028-3908(93)90012-R; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Ruiz F, 1998, NEUROREPORT, V9, P1277; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; Ward MW, 2000, J NEUROSCI, V20, P7208; White RJ, 1996, J NEUROSCI, V16, P5688	44	109	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32989	33000		10.1074/jbc.M401540200	http://dx.doi.org/10.1074/jbc.M401540200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166243	hybrid			2022-12-25	WOS:000222849700119
J	Malik, P; Blackbourn, DJ; Clements, JB				Malik, P; Blackbourn, DJ; Clements, JB			The evolutionarily conserved Kaposi's sarcoma-associated herpesvirus ORF57 protein interacts with REF protein and acts as an RNA export factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CONSTITUTIVE TRANSPORT ELEMENT; NUCLEAR-PORE COMPLEX; VIRAL MESSENGER-RNA; READING FRAME 57; SIMPLEX-VIRUS; GENE-EXPRESSION; REGULATORY PROTEIN; SM PROTEIN; POSTTRANSCRIPTIONAL ACTIVATOR	ORF57 (MTA) one of the earliest Kaposi's sarcoma-associated herpesvirus (KSHV) regulatory proteins to be expressed is essential for virus lytic replication. A counterpart is present in every herpesvirus sequenced, indicating the importance of this signature viral protein and those examined act post-transcriptionally, affecting RNA splicing and transport. In KSHV-infected cells, ORF57 protein was present in a complex with REF (Aly) and TAP (NXF1), factors involved in cellular mRNA export. The ORF57 N-terminal region interacts with REF, whereas both N- and C-terminal domains of REF interact with ORF57. The ORF57-REF interaction was direct, whereas TAP appeared to be recruited via REF. In somatic cells, ectopically expressed ORF57 protein was shown to function as a CRM1-independent nuclear mRNA export factor, promoting export of mRNAs that are poor substrates for splicing. The gamma-herpesvirus ORF57 protein, and its alpha-1 herpesvirus ICP27 counterpart both export RNA through pathways involving REF and TAP proteins, although divergence of these herpesvirus subfamilies occurred some 180-210 million years ago. The TAP-mediated cellular mRNA export pathway is CRM1-independent. However, human immunodeficiency virus type 1 Rev protein-mediated RNA export, which is CRM1-dependent, was considerably inhibited by ORF57, suggesting that Rev and ORF57 compete for a common export component. These data strengthen arguments that TAP and CRM1 pathways converge in accessing similar components of the nuclear pore complex. We propose that ORF57-mediated RNA export may use different export factors to accommodate the KSHV-infected host cell environments, for example, in B-cells or endothelial cells and during the different phases of lytic virus replication.	Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	University of Glasgow	Clements, JB (corresponding author), Univ Glasgow, Inst Virol, Church St, Glasgow G11 5JR, Lanark, Scotland.	b.clements@vir.gla.ac.uk	Malik, Poonam/A-1756-2008	Malik, Poonam/0000-0002-1733-722X; Blackbourn, David/0000-0002-6703-4497				Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bello LJ, 1999, J GEN VIROL, V80, P3207, DOI 10.1099/0022-1317-80-12-3207; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Boshoff C, 2001, PHILOS T R SOC B, V356, P517, DOI 10.1098/rstb.2000.0778; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boyer JL, 2002, J VIROL, V76, P9420, DOI 10.1128/JVI.76.18.9420-9433.2002; Boyle SM, 1999, J VIROL, V73, P6872, DOI 10.1128/JVI.73.8.6872-6881.1999; Braun IC, 2002, MOL CELL BIOL, V22, P5405, DOI 10.1128/MCB.22.15.5405-5418.2002; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Bryant HE, 2001, J VIROL, V75, P4376, DOI 10.1128/JVI.75.9.4376-4385.2001; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen IHB, 2002, J VIROL, V76, P12877, DOI 10.1128/JVI.76.24.12877-12889.2002; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7; Cullen BR, 1998, VIROLOGY, V249, P203, DOI 10.1006/viro.1998.9331; Cunningham C, 2003, J GEN VIROL, V84, P1471, DOI 10.1099/vir.0.19015-0; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Gupta AK, 2000, J VIROL, V74, P1038, DOI 10.1128/JVI.74.2.1038-1044.2000; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; HARDWICKE MA, 1994, J VIROL, V68, P4797, DOI 10.1128/JVI.68.8.4797-4810.1994; Herold A, 2001, RNA, V7, P1768; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; Jean S, 2001, VIROLOGY, V283, P273, DOI 10.1006/viro.2001.0902; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lengyel J, 2002, J VIROL, V76, P11866, DOI 10.1128/JVI.76.23.11866-11879.2002; LIEBERMAN PM, 1986, J VIROL, V60, P140, DOI 10.1128/JVI.60.1.140-148.1986; Longman D, 2003, RNA, V9, P881, DOI 10.1261/rna.5420503; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCDONALD D, 1992, J VIROL, V66, P7232, DOI 10.1128/JVI.66.12.7232-7238.1992; MCGEOCH DJ, 1995, J MOL BIOL, V247, P443, DOI 10.1006/jmbi.1995.0152; MCLAUCHLAN J, 1992, J VIROL, V66, P6939, DOI 10.1128/JVI.66.12.6939-6945.1992; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Otero GC, 1998, J VIROL, V72, P7593, DOI 10.1128/JVI.72.9.7593-7597.1998; Paulose-Murphy M, 2001, J VIROL, V75, P4843, DOI 10.1128/JVI.75.10.4843-4853.2001; Portman DS, 1997, RNA, V3, P527; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; Sarid R, 1999, ADV VIRUS RES, V52, P139, DOI 10.1016/S0065-3527(08)60299-7; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Sokolowski M, 2003, J BIOL CHEM, V278, P33540, DOI 10.1074/jbc.M302063200; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan W, 2000, RNA, V6, P1762, DOI 10.1017/S1355838200000832; Virbasius CMA, 1999, MOL CELL, V4, P219, DOI 10.1016/S1097-2765(00)80369-X; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Whitehouse A, 1998, J VIROL, V72, P857, DOI 10.1128/JVI.72.1.857-861.1998; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Zheng ZM, 2003, REV MED VIROL, V13, P173, DOI 10.1002/rmv.387; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	81	90	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					33001	33011		10.1074/jbc.M313008200	http://dx.doi.org/10.1074/jbc.M313008200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155762	hybrid			2022-12-25	WOS:000222849700120
J	McMahon, M; Thomas, N; Itoh, K; Yamamoto, M; Hayes, JD				McMahon, M; Thomas, N; Itoh, K; Yamamoto, M; Hayes, JD			Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; PROTEASOMAL DEGRADATION; CHEMOPREVENTIVE AGENTS; ENDOPLASMIC-RETICULUM; INDUCIBLE EXPRESSION; TUMOR SUPPRESSORS; GOLGI-APPARATUS; GENE-EXPRESSION; UBIQUITIN	The Nrf2 transcription factor is more rapidly turned over in cells grown under homeostatic conditions than in those experiencing oxidative stress. The variable turnover of Nrf2 is accomplished through the use of at least two degrons and its redox-sensitive interaction with the Kelch-repeat protein Keap1. In homeostatic COS1 cells, the Neh2 degron confers on Nrf2 a half-life of less than 10 min. Analyses of deletion mutants of a Gal4(HA) mNeh2 fusion protein and full-length mNrf2 indicate that full redox-sensitive Neh2 destabilizing activity depends upon two separate sequences within this N-terminal domain. The DIDLID element ( amino acids 17 - 32) is indispensable for Neh2 activity and appears necessary to recruit a ubiquitin ligase to the fusion protein. A second motif within Neh2, the ETGE tetrapeptide ( amino acids 79 - 82), allows the redox-sensitive recruitment of Nrf2 to Keap1. This interaction, which occurs only in homeostatic cells, enhances the capacity of the Neh2 degron to direct degradation by functioning downstream of ubiquitination mediated by the DIDLID element. By contrast with the situation under homeostatic conditions, the Neh2 degron is neither necessary nor sufficient to account for the characteristic half-life of Nrf2 in oxidatively stressed cells. Instead, the previously uncharacterized, redox-insensitive Neh6 degron ( amino acids 329 - 379) is essential to ensure that the transcription factor is still appropriately turned over in stressed cells, albeit with an increased half-life of 40 min. A model can now be proposed to explain how the turnover of this protein adapts in response to alterations in cellular redox state.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	University of Dundee; University of Tsukuba; University of Tsukuba	McMahon, M (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	m.j.m.mcmahon@dundee.ac.uk	Yamamoto, Masayuki/A-4873-2010; McMahon, Michael J/A-1702-2008; Itoh, Ken/B-9506-2013; McMahon, Michael J/F-7070-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Itoh, Ken/0000-0002-5518-0729; McMahon, Michael J/0000-0001-8615-9351; Hayes, John/0000-0002-2927-5548				AN JH, 2003, EMBO J, V17, P1882; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Boevink P, 1998, PLANT J, V15, P441, DOI 10.1046/j.1365-313X.1998.00208.x; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CULLINAN SB, 2003, MOL CELL BIOL, V101, P2040; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jager S, 2001, EMBO J, V20, P4423, DOI 10.1093/emboj/20.16.4423; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Krzywda S, 2004, J BIOL CHEM, V279, P1541, DOI 10.1074/jbc.M310265200; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Rezvani K, 2003, BIOCHEM SOC T, V31, P470, DOI 10.1042/BST0310470; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shimada O, 2003, CELL STRUCT FUNCT, V28, P155; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Walker AK, 2000, J BIOL CHEM, V275, P22166, DOI 10.1074/jbc.M001746200; Wollert T, 2002, J CELL BIOL, V159, P571, DOI 10.1083/jcb.200204065; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003	53	292	324	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31556	31567		10.1074/jbc.M403061200	http://dx.doi.org/10.1074/jbc.M403061200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143058	hybrid			2022-12-25	WOS:000222726800078
J	Rajagopalan, L; Rajarathnam, K				Rajagopalan, L; Rajarathnam, K			Ligand selectivity and affinity of chemokine receptor CXCR1 - Role of N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-STIMULATING ACTIVITY; INTERLEUKIN-8 RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; AMINO-TERMINUS; A RECEPTOR; BINDING; RESIDUES; H-1-NMR; ANALOGS	Glu-Leu-Arg ("ELR") CXC chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA) recruit neutrophils by binding and activating two receptors, CXCR1 and CXCR2. CXCR1 is specific, binding only IL-8 with nanomolar affinity, whereas CXCR2 is promiscuous, binding all ELRCXC chemokines with high affinity. Receptor signaling consists of two events: interactions between the ligand N-terminal loop (N-loop) and receptor N-terminal domain (N-domain) residues ( site I), and between the ligand N-terminal ELR and the receptor juxtamembrane domain (J-domain) residues (site II). It is not known how these interactions mediate ligand affinity and selectivity, and whether binding at one site influences binding and function at the other. Sequence analysis and structure-function studies have suggested that the receptor N-domain plays an important role in ligand selectivity. Here, we report ligand-binding properties and structural characteristics of the CXCR1 N-domain in solution and in detergent micelles that mimic the native membrane environment. We find that IL-8 binds the N-domain with significantly higher affinity in micelles than in solution (similar to1 muM versus similar to20 muM) and that MGSA does not bind the N-domain in solution but does in micelles with appreciable affinity (similar to3 muM). We find that the N-domain is structured in micelles and that the entire N-domain interacts with the micelle in an extended fashion. We conclude that the micellar environment constrains the N-domain, and this conformational restraint influences its ligand-binding properties. Most importantly, our data suggest that for both ligands, site I interaction provides similar affinity and that differential coupling between site I and II interactions is responsible for the observed differences in affinity.	Univ Texas, Dept Human Biol Chem & Genet, Med Branch, Galveston, TX 77555 USA; Univ Texas, Sealy Ctr Struct Biol, Med Branch, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Rajarathnam, K (corresponding author), Univ Texas, Dept Human Biol Chem & Genet, Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	krrajara@utmb.edu						Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Attwood MR, 1996, BIOORG MED CHEM LETT, V6, P1869, DOI 10.1016/0960-894X(96)00331-9; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Baly DL, 1998, J IMMUNOL, V161, P4944; Catusse J, 2003, BIOCHEM PHARMACOL, V65, P813, DOI 10.1016/S0006-2952(02)01619-2; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Garavito RM, 2001, J BIOL CHEM, V276, P32403, DOI 10.1074/jbc.R100031200; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Katancik JA, 2000, CYTOKINE, V12, P1480, DOI 10.1006/cyto.2000.0742; KIM KS, 1994, J BIOL CHEM, V269, P32909; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MOSER B, 1993, J BIOL CHEM, V268, P7125; Murphy PM, 2000, PHARMACOL REV, V52, P145; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; Rajarathnam K, 1999, BIOCHEMISTRY-US, V38, P7653, DOI 10.1021/bi990033v; Rajarathnam K, 1996, FEBS LETT, V399, P43, DOI 10.1016/S0014-5793(96)01277-X; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032; Rajarathnam K, 2002, CURR PHARM DESIGN, V8, P2159, DOI 10.2174/1381612023393233; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Suetomi K, 1999, J BIOL CHEM, V274, P11768, DOI 10.1074/jbc.274.17.11768; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; Vinogradova O, 1998, J BIOMOL NMR, V11, P381, DOI 10.1023/A:1008289624496; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202	49	92	94	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30000	30008		10.1074/jbc.M313883200	http://dx.doi.org/10.1074/jbc.M313883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133028	hybrid			2022-12-25	WOS:000222531900018
J	Wang, Q; Hurd, TW; Margolis, B				Wang, Q; Hurd, TW; Margolis, B			Tight junction protein Par6 interacts with an evolutionarily conserved region in the amino terminus of PALS1/Stardust	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASYMMETRIC CELL-DIVISION; DISCS LOST; PDZ DOMAIN; KINASE-C; DROSOPHILA STARDUST; EPITHELIAL POLARITY; COMPLEX; CRUMBS; CDC42; NEUROBLASTS	Tight junctions are the structures in mammalian epithelial cells that separate the apical and basolateral membranes and may also be important in the establishment of cell polarity. Two evolutionarily conserved multiprotein complexes, Crumbs-PALS1 (Stardust)-PATJ and Cdc42-Par6-Par3-atypical protein kinase C, have been implicated in the assembly of tight junctions and in polarization of Drosophila melanogaster epithelia. These two complexes have been linked physically and functionally by an interaction between PALS1 and Par6. Here we identify an evolutionarily conserved region in the amino terminus of PALS1 as the Par6 binding site and identify valine and aspartic acid residues in this region as essential for interacting with the PDZ domain of Par6. We have also characterized, in more detail, the amino terminus of Drosophila Stardust and demonstrate that the interaction mechanism between Stardust and Drosophila Par6 is evolutionarily conserved. Par6 interferes with PATJ in binding PALS1, and these two interactions do not appear to function synergistically. Taken together, these results define the molecular mechanisms linking two conserved polarity complexes.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu			NIDDK NIH HHS [DK-58208] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058208] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KNUST E, SCIENCE, V298, P1955; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Nam SC, 2003, DEVELOPMENT, V130, P4363, DOI 10.1242/dev.00648; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Peterson FC, 2004, MOL CELL, V13, P665, DOI 10.1016/S1097-2765(04)00086-3; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Pielage J, 2003, DEV CELL, V5, P841, DOI 10.1016/S1534-5807(03)00358-7; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; ROB MH, 2003, AM J PHYSIOL, V285, pF377; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.E03-08-0620; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	30	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30715	30721		10.1074/jbc.M401930200	http://dx.doi.org/10.1074/jbc.M401930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140881	hybrid			2022-12-25	WOS:000222531900102
J	Sumigama, S; Ito, T; Kajiyama, H; Shibata, K; Tamakoshi, K; Kikkawa, F; Williams, T; Tainsky, MA; Nomura, S; Mizutani, S				Sumigama, S; Ito, T; Kajiyama, H; Shibata, K; Tamakoshi, K; Kikkawa, F; Williams, T; Tainsky, MA; Nomura, S; Mizutani, S			Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2 alpha	ONCOGENE			English	Article						tumorigenicity; erbB2; Akt; ERK; E-cadherin; matrix metalloproteinase; peritoneal dissemination	TRANSCRIPTION FACTOR AP-2; HUMAN BREAST-CANCER; SIGNALING PATHWAYS; PROSTATE-CANCER; DOWN-REGULATION; UP-REGULATION; TUMOR-GROWTH; DNA-BINDING; EXPRESSION; GENE	A previous report demonstrated that AP-2alpha favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2alpha in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2alpha in SKOV3 human ovarian cancer cells, which originally possess little AP-2alpha. AP-2alpha overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2alpha-overexpressing cells survived longer than those with neotransfected cells. The present data represent the first direct evidence that AP-2alpha plays a tumor suppressive role in ovarian cancer.	Nagoya Grad Univ, Dept Obstet & Gynecol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Grad Univ, Dept Publ Hlth, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Denver, CO 80262 USA; Wayne State Univ, Program Mol Biol & Genet, Karmanos Canc Inst, Detroit, MI 48201 USA	Nagoya University; Nagoya University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Barbara Ann Karmanos Cancer Institute; Wayne State University	Ito, T (corresponding author), Nagoya Grad Univ, Dept Obstet & Gynecol, Sch Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.	itoto@med.nagoya-u.ac.jp	KIKKAWA, Fumitaka/I-7341-2014; Kotani, Tomomi/I-7360-2014; Sumigama, Seiji/AAR-9926-2020	Sumigama, Seiji/0000-0001-6913-3731; Kotani, Tomomi/0000-0002-3082-6116; Tainsky, Michael/0000-0002-0261-831X				Agus DB, 2000, SEMIN ONCOL, V27, P53; Anttila MA, 2000, BRIT J CANCER, V82, P1974; Auman HJ, 2002, DEVELOPMENT, V129, P2733; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CLIBY W, 1993, CANCER RES, V53, P2393; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; Davidson B, 2001, ANAL CELL PATHOL, V23, P107, DOI 10.1155/2001/418547; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ENOMOTO T, 1990, CANCER RES, V50, P6139; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; Hayakawa A, 1999, CANCER LETT, V140, P113, DOI 10.1016/S0304-3835(99)00062-2; Ho AT, 2001, J BIOL CHEM, V276, P40215, DOI 10.1074/jbc.M101647200; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Kajiyama H, 2002, CANCER RES, V62, P2753; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIKKAWA F, 1993, ANTICANCER RES, V13, P891; Kikkawa F, 2000, GYNECOL OBSTET INVES, V50, P269, DOI 10.1159/000010330; Klapper LN, 2000, ADV CANCER RES, V77, P25; Levkowitz G, 1996, ONCOGENE, V12, P1117; Luo J, 1999, CANCER RES, V59, P3552; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; MIZUNO K, 1992, ANTICANCER RES, V12, P21; MIZUTANI S, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P769; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Qvist H, 1998, BIOL CHEM, V379, P75; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; SLAMON DJ, 1987, NEW ENGL J MED, V317, P955, DOI 10.1056/NEJM198710083171509; Turner BC, 1998, CANCER RES, V58, P5466; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Vernimmen D, 2003, BRIT J CANCER, V89, P899, DOI 10.1038/sj.bjc.6601200; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; Williams TM, 1999, J MOL DIAGN, V1, P5; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2002, BREAST CANCER RES TR, V71, P47, DOI 10.1023/A:1013378113916	49	23	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5496	5504		10.1038/sj.onc.1207723	http://dx.doi.org/10.1038/sj.onc.1207723			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15146170				2022-12-25	WOS:000222588400009
J	Wei, M; Tai, GH; Gao, YG; Li, N; Huang, BQ; Zhou, YF; Hao, S; Zeng, XL				Wei, M; Tai, GH; Gao, YG; Li, N; Huang, BQ; Zhou, YF; Hao, S; Zeng, XL			Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELLS; CARBOHYDRATE INTERACTIONS; ENDOTHELIAL-CELLS; SULFATE; METASTASIS; LIGANDS; PROTEOGLYCANS; AGGREGATION; DESULFATION; EXPRESSION	Accumulating evidence indicates that the formation of tumor cell platelet emboli complexes in the blood stream is a very important step during metastases and that the anti-metastasis effects of heparin are partially due to a blockade of P-selectin on platelets. In this study, heparin and chemically modified heparins were tested as inhibitors of three human colon carcinoma cell lines (COLO320, LS174T, and CW-2) binding to P-selectin, adhering to CHO cells expressing a transfected human P-selectin cDNA, and adhering to surface-anchored platelets expressing P-selectin under static and flow conditions. The aim was to screen for heparin derivatives with high anti-adhesion activity but negligible anticoagulant activity. In this study, four modified heparins with high anti-adhesion activity were identified including RO-heparin, CR-heparin, 2/3ODS-heparin, and N/2/3DS-heparin. NMR analysis proved the reliability of structure of the four modified heparins. Our findings suggested that the 6-O-sulfate group of glucosamine units in heparin is critical for the inhibition of P-selectin-mediated tumor cell adhesion. Heparan sulfate-like proteoglycans on these tumor cell surfaces are implicated in adhesion of the tumor cells to P-selectin. Some chemically modified heparins with low anticoagulant activities, such as 2/3ODS-heparin, may have potential value as therapeutic agents that block P-selectin-mediated cell adhesion and prevent tumor metastasis.	NE Normal Univ, Sch Life Sci, Inst Cytol & Genet, Changchun 130024, Jilin, Peoples R China	Northeast Normal University - China	Zeng, XL (corresponding author), NE Normal Univ, Sch Life Sci, Inst Cytol & Genet, Changchun 130024, Jilin, Peoples R China.	zengx1779@nenu.edu.cn						Aigner S, 1998, FASEB J, V12, P1241, DOI 10.1096/fasebj.12.12.1241; Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; BAI XM, 1994, J HISTOCHEM CYTOCHEM, V42, P1043, DOI 10.1177/42.8.8027524; Baumann H, 1998, CARBOHYD RES, V308, P381, DOI 10.1016/S0008-6215(98)00097-4; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; BUTTRUM SM, 1993, BLOOD, V82, P1165; CASU B, 1986, ARZNEIMITTEL-FORSCH, V36-1, P637; Dardik R, 1997, INT J CANCER, V70, P201, DOI 10.1002/(SICI)1097-0215(19970117)70:2<201::AID-IJC11>3.0.CO;2-L; Dardik R, 1998, BRIT J CANCER, V77, P2069, DOI 10.1038/bjc.1998.349; Fryer A, 1997, J PHARMACOL EXP THER, V282, P208; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Goetz DJ, 1996, AM J PATHOL, V149, P1661; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; Konstantopoulos K, 1998, CIRCULATION, V98, P873, DOI 10.1161/01.CIR.98.9.873; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Ma YQ, 2000, J IMMUNOL, V165, P558, DOI 10.4049/jimmunol.165.1.558; MANNORI G, CANC RES, V55, P4425; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NIERODZIK MLR, 1992, CANCER RES, V52, P3267; Nieswandt B, 1999, CANCER RES, V59, P1295; OLEKSOWICZ L, 1995, THROMB RES, V79, P261, DOI 10.1016/0049-3848(95)00113-6; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Pottratz ST, 1996, AM J PHYSIOL-LUNG C, V271, pL918, DOI 10.1152/ajplung.1996.271.6.L918; Rabenstein DL, 2002, NAT PROD REP, V19, P312, DOI 10.1039/b100916h; Salmivirta M, 1998, GLYCOBIOLOGY, V8, P1029, DOI 10.1093/glycob/8.10.1029; Sobel M, 2001, J VASC SURG, V33, P587, DOI 10.1067/mva.2001.112696; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; Varki NM, 2002, SEMIN THROMB HEMOST, V28, P53, DOI 10.1055/s-2002-20564; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Wei M, 2003, PROG BIOCHEM BIOPHYS, V30, P185; WESSEL HP, 1990, CARBOHYD RES, V204, P131, DOI 10.1016/0008-6215(90)84028-S	44	63	70	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29202	29210		10.1074/jbc.M312951200	http://dx.doi.org/10.1074/jbc.M312951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133030	hybrid			2022-12-25	WOS:000222445300047
J	Yang, YP; Zhang, ZJ; Mukherjee, AB; Linnoila, RI				Yang, YP; Zhang, ZJ; Mukherjee, AB; Linnoila, RI			Increased susceptibility of mice lacking Clara cell 10-kDa protein to lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a potent carcinogen in cigarette smoke	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; BLASTOCYST DEVELOPMENT; TRANSFORMED PHENOTYPE; UTEROGLOBIN GENE; EXPRESSION; TUMORS; CC10; ADENOCARCINOMA; OVEREXPRESSION; POLYMORPHISM	Ninety percent of all human lung cancers are related to cigarette smoking. Both tobacco smoke and lung tumorigenesis are associated with drastically reduced levels of Clara cell 10-kDa protein (CC10), a multifunctional secreted protein, naturally produced by the airway epithelia of virtually all mammals. We previously reported that the expression of CC10 is markedly reduced in animals exposed to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNK, a potent carcinogen in tobacco smoke. Furthermore, it has been reported that CC10 expression, induced in certain tumor cells, reverses the transformed phenotype. We demonstrate here that NNK exposure of CC10-knock-out (CC10-KO) mice causes a significantly higher incidence of airway epithelial hyperplasia and lung adenomas compared with wild type (WT) littermates (30% CC10-KO versus 5% WT, p = 0.041). We also found that compared with NNK-treated WT mice, CC10-KO mice manifest increased frequency of K-ras mutation, elevated level of Fas ligand (FasL) expression, and increased MAPK/Erk phosphorylation, all of which are considered predisposing events in NNK-induced lung tumorigenesis. We propose that CC10 has a protective role against NNK-induced lung tumorigenesis mediated via down-regulation of the above-mentioned predisposing events.	NCI, Cell & Canc Biol Branch, Ctr Canc Res, NIH, Rockville, MD 20850 USA; NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yang, YP (corresponding author), NCI, MCGP, POB B,Bldg 560,Rm 32-12, Frederick, MD 21702 USA.	yongpiny@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000910] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000910] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC000167, ZIASC000167] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BELINSKY SA, 1989, CANCER RES, V49, P5305; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BROERS JLV, 1992, LAB INVEST, V66, P337; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; DEVEREUX TR, 1993, MOL CARCINOGEN, V8, P177, DOI 10.1002/mc.2940080308; Gochuico BR, 1998, AM J PHYSIOL-LUNG C, V274, pL444, DOI 10.1152/ajplung.1998.274.3.L444; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646, DOI 10.1164/ajrccm.159.2.9806064; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1998, J BIOL CHEM, V273, P22819, DOI 10.1074/jbc.273.35.22819; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; LEYTON J, 1994, CANCER RES, V54, P3696; Linnoila RI, 2000, ANN NY ACAD SCI, V923, P249; LINNOILA RI, 1992, AM J CLIN PATHOL, V97, P233, DOI 10.1093/ajcp/97.2.233; Magdaleno SM, 1997, CELL GROWTH DIFFER, V8, P145; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; MATZINGER SA, 1995, CARCINOGENESIS, V16, P2487, DOI 10.1093/carcin/16.10.2487; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; MUKHERJEE AB, 2000, ANN NY ACAD SCI, V923, P348; Peri A, 2000, INT J CANCER, V88, P525, DOI 10.1002/1097-0215(20001115)88:4<525::AID-IJC3>3.0.CO;2-Z; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Singh G, 2000, ANN NY ACAD SCI, V923, P43; Stripp BR, 1996, AM J PHYSIOL-LUNG C, V271, pL656, DOI 10.1152/ajplung.1996.271.4.L656; Szabo E, 1998, CELL GROWTH DIFFER, V9, P475; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408; Zhang ZJ, 1999, P NATL ACAD SCI USA, V96, P3963, DOI 10.1073/pnas.96.7.3963; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	36	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29336	29340		10.1074/jbc.C400162200	http://dx.doi.org/10.1074/jbc.C400162200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15148323	hybrid			2022-12-25	WOS:000222445300064
J	Kurtev, V; Margueron, R; Kroboth, K; Ogris, E; Cavailles, V; Seiser, C				Kurtev, V; Margueron, R; Kroboth, K; Ogris, E; Cavailles, V; Seiser, C			Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I TRANSCRIPTION; COUP-TF; N-COR; NUCLEAR RECEPTORS; OXYTOCIN GENE; PROTEIN; COMPLEX; PROMOTER; FAMILY; COREPRESSOR	Histone acetyltransferases and deacetylases are recruited by transcription factors and adapter proteins to regulate specific subsets of target genes. We were interested in identifying interaction partners of histone deacetylase 1 (HDAC1) that might be involved in conferring target or substrate specificity. Using the yeast two-hybrid system, we isolated the repressor of estrogen receptor activity ( REA) as a novel HDAC1-associated protein. We demonstrated the in vivo interaction of REA with HDAC1 and characterized the respective domains required for their interaction in vitro. In addition, we found that REA also associates with the class II histone deacetylase HDAC5. In luciferase reporter assays, REA decreased transcription, and this repression was sensitive to the deacetylase inhibitor trichostatin A. Finally, we showed that REA specifically interacts with the chicken ovalbumin upstream binding transcription factors and II. The nuclear receptor chicken ovalbumin upstream binding transcription factor I was found to cooperate with REA and histone deacetylases in the repression of target genes. We, therefore, propose a novel function for REA as a mediator of transcriptional repression by nuclear hormone receptors via recruitment of histone deacetylases.	Med Univ Vienna, Vienna Bioctr, Inst Med Biochem, MAx F Perutz Labs, A-1030 Vienna, Austria; INSERM, U540, F-34090 Montpellier, France	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Seiser, C (corresponding author), Med Univ Vienna, Vienna Bioctr, Inst Med Biochem, MAx F Perutz Labs, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	christian.seiser@univie.ac.at	Cavailles, Vincent/Y-5379-2019; Margueron, Raphael F/B-9996-2015; cavailles, vincent/C-6277-2017	Cavailles, Vincent/0000-0002-7160-3074; Margueron, Raphael F/0000-0002-9093-7977; Ogris, Egon/0000-0001-5950-9264; Seiser, Christian/0000-0002-7046-9352				ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; Chu K, 1997, J MOL ENDOCRINOL, V19, P163, DOI 10.1677/jme.0.0190163; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hou SH, 2002, J VIROL, V76, P3212, DOI 10.1128/JVI.76.7.3212-3220.2002; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kurihara I, 2002, ENDOCR RES, V28, P581, DOI 10.1081/ERC-120016845; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mellgren G, 2003, MOL CELL ENDOCRINOL, V203, P91, DOI 10.1016/S0303-7207(03)00097-2; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Pereira FA, 2000, CELL MOL LIFE SCI, V57, P1388, DOI 10.1007/PL00000624; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Schuettengruber B, 2003, MOL CELL BIOL, V23, P6993, DOI 10.1128/MCB.23.19.6993-7004.2003; SEISER C, 1993, J BIOL CHEM, V268, P13074; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Wei LN, 2001, J BIOL CHEM, V276, P16107, DOI 10.1074/jbc.M010185200; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	68	77	85	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24834	24843		10.1074/jbc.M312300200	http://dx.doi.org/10.1074/jbc.M312300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140878	hybrid			2022-12-25	WOS:000221702500114
J	Ingram, JL; Rice, AB; Geisenhoffer, K; Madtes, DK; Bonner, JC				Ingram, JL; Rice, AB; Geisenhoffer, K; Madtes, DK; Bonner, JC			IL-13 and IL-1 beta promote lung fibroblast growth through coordinated up-regulation of PDGF-AA and PDGF-R alpha	FASEB JOURNAL			English	Article						stromal cells; cytokines; cytokine receptors; cellular proliferation; lung	SMOOTH-MUSCLE-CELLS; RECEPTOR-ALPHA; TRANSFORMING GROWTH-FACTOR-BETA-1; AIRWAYS HYPERREACTIVITY; PULMONARY-FIBROSIS; IN-VITRO; INTERLEUKIN-13; PROLIFERATION; MYOFIBROBLASTS; EXPRESSION	Peribronchiolar fibrosis is a prominent feature of airway remodeling in asthma and involves fibroblast growth and collagen deposition. Interleukin-13 (IL-13), a T-helper 2 cytokine, is a key mediator of airway remodeling in asthma, yet the mechanism through which IL-13 promotes fibroblast growth has not been investigated. In this study, we show that IL-13 stimulates the mitogenesis of mouse, rat, and human lung fibroblasts through release of a soluble mitogen that we identified as PDGF-AA. The IL-13-induced growth of human lung fibroblasts was attenuated by an anti-PDGF-AA neutralizing antibody, and IL-13 stimulated human lung fibroblasts to secrete PDGF-AA. Fibroblasts derived from mouse embryos possessing the lethal Patch mutation, which lack the PDGF-Ralpha, showed no mitogenic response to IL-13. However, Patch cells did exhibit IL-13-induced STAT-6 phosphorylation. Stable transfection of the PDGF-Ralpha into Patch cells restored the growth response to PDGF-AA and IL-13. Through the use of lung fibroblasts from STAT-6-deficient mice, we showed that IL-13-induced PDGF-AA release is STAT-6 dependent, but PDGF-AA-induced growth is STAT-6 independent. Finally, we showed that IL-1beta enhanced IL-13-induced mitogenesis of rat lung fibroblasts through up-regulation of the PDGF-Ralpha. Our findings indicate that IL-13 acts in synergy with IL-1beta to stimulate growth by coordinately up-regulating PDGF-AA and the PDGF-Ralpha, respectively.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Fred Hutchinson Cancer Center	Bonner, JC (corresponding author), CIIT Ctr Hlth Res, POB 12137, Res Triangle Pk, NC 27709 USA.	jbonner@ciit.org						Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; BATTEGAY EJ, 1995, J IMMUNOL, V154, P6040; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; BONNER JC, 1991, AM J RESP CELL MOL, V5, P539, DOI 10.1165/ajrcmb/5.6.539; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72, DOI 10.1152/ajplung.1998.274.1.L72; BONNER JC, 1995, AM J RESP CELL MOL, V13, P496, DOI 10.1165/ajrcmb.13.4.7546780; Booth BW, 2001, AM J RESP CELL MOL, V25, P739, DOI 10.1165/ajrcmb.25.6.4659; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Coin PG, 1996, J IMMUNOL, V156, P4797; Doucet C, 2000, ONCOGENE, V19, P5898, DOI 10.1038/sj.onc.1203933; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Gabay C, 1999, BLOOD, V93, P1299, DOI 10.1182/blood.V93.4.1299.404k26_1299_1307; Greenfeder S, 2001, RESP RES, V2, P71, DOI 10.1186/rr41; Hancock A, 1998, AM J RESP CELL MOL, V18, P60, DOI 10.1165/ajrcmb.18.1.2627; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LASKY JA, 1995, AM J RESP CELL MOL, V12, P162, DOI 10.1165/ajrcmb.12.2.7865215; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; Lindroos PM, 1998, J IMMUNOL, V161, P3464; LINDROOS PM, 1995, AM J RESP CELL MOL, V13, P455, DOI 10.1165/ajrcmb.13.4.7546776; Madtes DK, 1999, AM J RESP CELL MOL, V20, P924, DOI 10.1165/ajrcmb.20.5.3526; Mattes J, 2001, J IMMUNOL, V167, P1683, DOI 10.4049/jimmunol.167.3.1683; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; SEIFERT RA, 1994, J BIOL CHEM, V269, P13951; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Wang YZ, 2000, J BIOL CHEM, V275, P22550, DOI 10.1074/jbc.M909785199; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WIN KM, 1993, HEPATOLOGY, V18, P137, DOI 10.1002/hep.1840180121; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	39	66	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1132	+		10.1096/fj.03-1492fje	http://dx.doi.org/10.1096/fj.03-1492fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155567				2022-12-25	WOS:000221883200002
J	Marchini, A; Marttila, T; Winter, A; Caldeira, S; Malanchi, I; Blaschke, RJ; Hacker, B; Rao, E; Karperien, M; Wit, JM; Richter, W; Tommasino, M; Rappold, GA				Marchini, A; Marttila, T; Winter, A; Caldeira, S; Malanchi, I; Blaschke, RJ; Hacker, B; Rao, E; Karperien, M; Wit, JM; Richter, W; Tommasino, M; Rappold, GA			The short stature homeodomain protein SHOX induces cellular growth arrest and apoptosis and is expressed in human growth plate chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE SHOX; CASEIN KINASE-II; TURNER-SYNDROME; LERI-WEILL; DOMAIN GENE; MUTATIONS; HORMONE; CELLS; DYSCHONDROSTEOSIS; CHONDRODYSPLASIA	Mutations in the homeobox gene SHOX cause growth retardation and the skeletal abnormalities associated with Leri-Weill, Langer, and Turner syndromes. Little is known about the mechanism underlying these SHOX-related inherited disorders of bone formation. Here we demonstrate that SHOX expression in osteogenic stable cell lines, primary oral fibroblasts, and primary chondrocytes leads to cell cycle arrest and apoptosis. These events are associated with alterations in the expression of several cellular genes, including pRB, p53, and the cyclin kinase inhibitors p21(Cip1) and p27(Kip1). A SHOX mutant, such as seen in Leri-Weill syndrome patients, does not display these activities of the wild type protein. We have also shown that endogenous SHOX is mainly expressed in hypertrophic/apoptotic chondrocytes of the growth plate, strongly suggesting that the protein plays a direct role in regulating the differentiation of these cells. This study provides the first insight into the biological function of SHOX as regulator of cellular proliferation and viability and relates these cellular events to the phenotypic consequences of SHOX deficiency.	Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany; Univ Heidelberg, Orthopaed Hosp, D-69118 Heidelberg, Germany; Univ Lisbon, Inst Mol Med, P-1649028 Lisbon, Portugal; WHO, Int Agcy Res Canc, Unit Infect & Canc, F-69372 Lyon 08, France; Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Universidade de Lisboa; World Health Organization; International Agency for Research on Cancer (IARC); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rappold, GA (corresponding author), Univ Heidelberg, Inst Human Genet, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	gudrun_rappold@med.uni-heidelberg.de	Richter, Wiltrud/V-3217-2017; Marchini, Antonio/ABD-3328-2020; Caldeira, Sandra/Y-3652-2019; Marchini, Antonio/AAG-7151-2019; Karperien, Marcel/R-3270-2018	Richter, Wiltrud/0000-0003-4694-2768; Caldeira, Sandra/0000-0002-6057-5979; Karperien, Marcel/0000-0003-0751-0604; Marchini, Antonio/0000-0003-3157-4552				BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; Ballock RT, 2000, ENDOCRINOLOGY, V141, P4552, DOI 10.1210/en.141.12.4552; Belin V, 1998, NAT GENET, V19, P67, DOI 10.1038/ng0198-67; Blaschke RJ, 2000, TRENDS ENDOCRIN MET, V11, P227, DOI 10.1016/S1043-2760(00)00262-9; Boncinelli E, 1997, CURR OPIN GENET DEV, V7, P331, DOI 10.1016/S0959-437X(97)80146-3; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Brunelli S, 1996, NAT GENET, V12, P94, DOI 10.1038/ng0196-94; Caldeira S, 2003, J VIROL, V77, P2195, DOI 10.1128/JVI.77.3.2195-2206.2003; CASCIOLAROSEN L, 1996, J EXP MED, V183, P1947; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Clement-Jones M, 2000, HUM MOL GENET, V9, P695, DOI 10.1093/hmg/9.5.695; DEAR TN, 1995, DEVELOPMENT, V121, P2909; Ellison JW, 1997, HUM MOL GENET, V6, P1341, DOI 10.1093/hmg/6.8.1341; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Quaggin SE, 1997, J CLIN INVEST, V99, P718, DOI 10.1172/JCI119216; Rao E, 1997, NAT GENET, V16, P54, DOI 10.1038/ng0597-54; Rao E, 2001, HUM MOL GENET, V10, P3083, DOI 10.1093/hmg/10.26.3083; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Semina EV, 1998, NAT GENET, V19, P167, DOI 10.1038/527; Shears DJ, 1998, NAT GENET, V19, P70, DOI 10.1038/ng0198-70; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Stewart MC, 1997, CALCIFIED TISSUE INT, V61, P199, DOI 10.1007/s002239900323; Van Der Eerden BCJ, 2000, J BONE MINER RES, V15, P1045, DOI 10.1359/jbmr.2000.15.6.1045; Weir EC, 1996, P NATL ACAD SCI USA, V93, P10240, DOI 10.1073/pnas.93.19.10240; Winter A, 2003, ARTHRITIS RHEUM-US, V48, P418, DOI 10.1002/art.10767	38	79	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					37103	37114		10.1074/jbc.M307006200	http://dx.doi.org/10.1074/jbc.M307006200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15145945	hybrid			2022-12-25	WOS:000223453600114
J	Feng, JH; Tamaskovic, R; Yang, ZZ; Brazil, DP; Merlo, A; Hess, D; Hemmings, BA				Feng, JH; Tamaskovic, R; Yang, ZZ; Brazil, DP; Merlo, A; Hess, D; Hemmings, BA			Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TUMOR-SUPPRESSOR; HEMATOPOIETIC-CELLS; P53 ACTIVATION; PATHWAY; AKT; DEGRADATION; APOPTOSIS; SURVIVAL; GROWTH	The tumor suppressor p53 is commonly inhibited under conditions in which the phosphatidylinositide 3'-OH kinase/protein kinase B (PKB) Akt pathway is activated. Intracellular levels of p53 are controlled by the E3 ubiquitin ligase Mdm2. Here we show that PKB inhibits Mdm2 self-ubiquitination via phosphorylation of Mdm2 on Ser(166) and Ser(188). Stimulation of human embryonic kidney 293 cells with insulin-like growth factor-1 increased Mdm2 phosphorylation on Ser(166) and Ser(188) in a phosphatidylinositide 3'-OH kinase-dependent manner, and the treatment of both human embryonic kidney 293 and COS-1 cells with phosphatidylinositide 3'-OH kinase inhibitor LY-294002 led to proteasome-mediated Mdm2 degradation. Introduction of a constitutively active form of PKB together with Mdm2 into cells induced phosphorylation of Mdm2 at Ser(166) and Ser(188) and stabilized Mdm2 protein. Moreover, mouse embryonic fibroblasts lacking PKBalpha displayed reduced Mdm2 protein levels with a concomitant increase of p53 and p21(Cip1), resulting in strongly elevated apoptosis after UV irradiation. In addition, activation of PKB correlated with Mdm2 phosphorylation and stability in a variety of human tumor cells. These findings suggest that PKB plays a critical role in controlling of the Mdm2.p53 signaling pathway by regulating Mdm2 stability.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Univ Basel, Dept Clin & Biol Sci, Mol Neurooncol Lab, CH-4031 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Basel	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch		Brazil, Derek/0000-0003-1375-1076				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Goetz AW, 2001, CANCER RES, V61, P7635; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HJERRILD M, 1999, BIOCHEM J, V15, P347; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hong M, 1999, CANCER RES, V59, P2847; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Moll UM, 2003, MOL CANCER RES, V1, P1001; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Pan Y, 1999, CANCER RES, V59, P2064; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Zeng SX, 2003, J BIOL CHEM, V278, P7453, DOI 10.1074/jbc.M209030200; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	61	217	223	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35510	35517		10.1074/jbc.M404936200	http://dx.doi.org/10.1074/jbc.M404936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169778	hybrid			2022-12-25	WOS:000223303400045
J	Giese, KC; Vierling, E				Giese, KC; Vierling, E			Mutants in a small heat shock protein that affect the oligomeric state - Analysis and allele-specific suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; CHAPERONE-LIKE ACTIVITY; GENETIC INTERACTION; ESCHERICHIA-COLI; IN-VITRO; BINDING; TEMPERATURE; PHOSPHORYLATION; MECHANISM; SUBSTRATE	Oligomerization is an essential property of small heat shock proteins (sHSPs) that appears to regulate their chaperone activity. We have examined the role of conserved hydrophobic residues that are postulated to stabilize sHSP oligomers. We identified a mutation of Synechocystis Hsp16.6 that impairs function in vivo and in vitro. The V143A mutation is in the C-terminal extension, a region predicted to form an oligomeric interaction with a hydrophobic region that includes the site of a previously characterized mutation, L66A. Both mutants were dimeric, but V143A had a stronger oligomerization defect than L66A. However, V143A protected a model substrate better than L66A. This suggests that although the two regions both play a role in oligomerization, they are not equivalent. Nevertheless, the addition of either dimeric sHSP enhanced the in vitro chaperone activity of wild type Hsp16.6, consistent with models that the sHSP dimers initiate interactions with substrates. Suppressor analysis of V143A identified mutations in the N terminus that restored activity by restabilizing the oligomer. These mutants were allele-specific and unable to suppress L66A, although they suppressed a dimeric C-terminal truncation of Hsp16.6. Conversely, suppressors of L66A were unable to suppress either V143A or the truncation, although they, like suppressors of V143A, stabilize the Hsp16.6 oligomer. We interpret these data as evidence that the mutations V143A and L66A stabilize two different dimeric structures and as further support that sHSP dimers are active species.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@email.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NIGMS NIH HHS [R01 GM42762] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Kelley PB, 2003, MOL CELL BIOCHEM, V252, P273, DOI 10.1023/A:1025568417000; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 2003, P NATL ACAD SCI USA, V100, P8151, DOI 10.1073/pnas.1032940100; Laksanalamai P, 2003, EXTREMOPHILES, V7, P79, DOI 10.1007/s00792-002-0298-z; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; Studer S, 2002, EUR J BIOCHEM, V269, P3578, DOI 10.1046/j.1432-1033.2002.03049.x; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	38	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32674	32683		10.1074/jbc.M404455200	http://dx.doi.org/10.1074/jbc.M404455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15152007	hybrid			2022-12-25	WOS:000222849700086
J	Jones, CE; Abdelraheim, SR; Brown, DR; Viles, JH				Jones, CE; Abdelraheim, SR; Brown, DR; Viles, JH			Preferential Cu2+ coordination by His(96) and His(111) induces beta-sheet formation in the unstructured amyloidogenic region of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-BINDING; STRUCTURAL IMPLICATIONS; CIRCULAR-DICHROISM; REPEAT REGION; METAL-BINDING; AMINO-ACIDS; RECOMBINANT; SCRAPIE; DOMAIN; SITES	The prion protein (PrP) is a Cu2+ binding cell surface glycoprotein that can misfold into a beta-sheet-rich conformation to cause prion diseases. The majority of copper binding studies have concentrated on the octarepeat region of PrP. However, using a range of spectroscopic techniques, we show that copper binds preferentially to an unstructured region of PrP between residues 90 and 115, outside of the octarepeat domain. Comparison of recombinant PrP with PrP-(91-115) indicates that this prion fragment is a good model for Cu2+ binding to the full-length protein. In contrast to previous reports we show that Cu2+ binds to this region of PrP with a nano-molar dissociation constant. NMR and EPR spectroscopy indicate a square-planar or square-pyramidal Cu2+ coordination utilizing histidine residues. Studies with PrP analogues show that the high affinity site requires both His(96) and His(111) as Cu2+ ligands, rather than a complex centered on His(96) as has been previously suggested. Our circular dichroism studies indicate a loss of irregular structure on copper coordination with an increase in beta-sheet conformation. It has been shown that this unstructured region, between residues 90 and 120, is vital for prion propagation and different strains of prion disease have been linked with copper binding. The role of Cu2+ in prion misfolding and disease must now be re-evaluated in the light of these findings.	Univ London, Queen Mary, Sch Biol Sci, London E1 4NS, England; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of London; Queen Mary University London; University of Bath	Viles, JH (corresponding author), Univ London, Queen Mary, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	j.viles@qmul.ac.uk	Brown, David/A-4083-2008; Jones, Christopher/C-5725-2014					Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Belosi B, 2004, CHEMBIOCHEM, V5, P349, DOI 10.1002/cbic.200300786; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 2001, BRAIN RES BULL, V55, P165, DOI 10.1016/S0361-9230(01)00453-1; Brown DR, 2004, J INORG BIOCHEM, V98, P133, DOI 10.1016/j.jinorgbio.2003.09.006; BRYCE GF, 1966, J BIOL CHEM, V241, P1439; Burns CS, 2002, BIOCHEMISTRY-US, V41, P3991, DOI 10.1021/bi011922x; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; Cui T, 2003, EUR J BIOCHEM, V270, P3368, DOI 10.1046/j.1432-1033.2003.03717.x; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; Florio T, 2003, J NEUROCHEM, V85, P62, DOI 10.1046/j.1471-4159.2003.01664.x; Garnett AP, 2003, J BIOL CHEM, V278, P6795, DOI 10.1074/jbc.M209280200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hasnain SS, 2001, J MOL BIOL, V311, P467, DOI 10.1006/jmbi.2001.4795; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; LAU SJ, 1971, J BIOL CHEM, V246, P5938; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LENTNER C, 1984, GEIGY SCI TABLES, V3; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Millhauser GL, 2004, ACCOUNTS CHEM RES, V37, P79, DOI 10.1021/ar0301678; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Orfei M, 2003, J INORG BIOCHEM, V97, P299, DOI 10.1016/S0162-0134(03)00283-6; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Rachidi W, 2003, J BIOL CHEM, V278, P14595, DOI 10.1074/jbc.C300092200; Rachidi W, 2003, J BIOL CHEM, V278, P9064, DOI 10.1074/jbc.M211830200; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SHIRAISHI N, 2000, BIOCH BIOPHYS RES CO, V267; SIGEL H, 1982, CHEM REV, V82, P385, DOI 10.1021/cr00050a003; Sigurdsson EM, 2003, J BIOL CHEM, V278, P46199, DOI 10.1074/jbc.C300303200; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Thackray AM, 2002, BIOCHEM J, V362, P253, DOI 10.1042/0264-6021:3620253; TSANGARIS JM, 1970, J AM CHEM SOC, V92, P4255, DOI 10.1021/ja00717a020; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; Vassallo N, 2003, J NEUROCHEM, V86, P538, DOI 10.1046/j.1471-4159.2003.01882.x; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2000, BIOCHEM BIOPH RES CO, V275, P249, DOI 10.1006/bbrc.2000.3158; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	68	217	220	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32018	32027		10.1074/jbc.M403467200	http://dx.doi.org/10.1074/jbc.M403467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145944	hybrid			2022-12-25	WOS:000222849700005
J	Song, WZ; Liu, ZQ; Tan, JG; Nomura, Y; Dong, K				Song, WZ; Liu, ZQ; Tan, JG; Nomura, Y; Dong, K			RNA editing generates tissue-specific sodium channels with distinct gating properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KNOCKDOWN-RESISTANCE; FUNCTIONAL-ANALYSIS; RECEPTOR CHANNELS; MEMBRANE-PROTEIN; IONIC CURRENTS; MESSENGER-RNAS; DROSOPHILA; BRAIN; GENE; MODULATION	Sodium channels play an essential role in generating the action potential in eukaryotic cells, and their transcripts, especially those in insects, undergo extensive A-to-I RNA editing. The functional consequences of RNA editing of sodium channel transcripts, however, have yet to be determined. We characterized 20 splice variants of the German cockroach sodium channel gene BgNa(v). Functional analysis revealed that these variants exhibited a broad range of voltage-dependent activation and inactivation. Further analysis of two variants, BgNan(v)1-1 and BgNa(v)1-2, which activate at more depolarizing membrane potentials than other variants, showed that RNA editing events were responsible for variant-specific gating properties. Two U-to-C editing sites identified in BgNa(v)1-1 resulted in a Leu to Pro change in segment 1 of domain III (IIIS1) and a Val to Ala change in IVS4. The Leu to Pro change shifted both the voltage dependence of activation and steady-state inactivation in the depolarizing direction. Two A-to-I editing events in BgNa(v)1-2 resulted in a Lys to Arg change in IS2 and an Ile to Met change in IVS3. The Lys to Arg change shifted the voltage dependence of activation in the depolarizing direction. Moreover, these RNA editing events occurred in a tissue-specific and development-specific manner. Our findings provide direct evidence that RNA editing is an important mechanism generating tissue-/cell type-specific functional variants of sodium channels.	Michigan State Univ, Dept Entomol, Ctr Integrated Plant Syst 106, E Lansing, MI 48824 USA; Michigan State Univ, Neurosci Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Dong, K (corresponding author), Michigan State Univ, Dept Entomol, Ctr Integrated Plant Syst 106, E Lansing, MI 48824 USA.	dongk@msu.edu			NIGMS NIH HHS [R01 GM057440, R01 GM057440-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bass BL, 2001, RNA EDITING; Bell W. J., 1981, LAB COCKROACH; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; BYERLY L, 1988, J NEUROSCI, V8, P4379; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Catterall WA, 2003, PHARMACOL REV, V55, P575, DOI 10.1124/pr.55.4.7; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.physiol.58.1.349; Dib-Hajj S, 2002, TRENDS NEUROSCI, V25, P253, DOI 10.1016/S0166-2236(02)02150-1; Dietrich PS, 1998, J NEUROCHEM, V70, P2262; Dong K, 1997, INSECT BIOCHEM MOLEC, V27, P93, DOI 10.1016/S0965-1748(96)00082-3; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Grauso M, 2002, GENETICS, V160, P1519; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; Hanrahan CJ, 2000, GENETICS, V155, P1149; Lee Si Hyeock, 2002, Invertebrate Neuroscience, V4, P125, DOI 10.1007/s10158-001-0014-1; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; NAGALLA SR, 1994, MOL ENDOCRINOL, V8, P943, DOI 10.1210/me.8.8.943; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ODOWD DK, 1995, J NEUROSCI, V15, P4005; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; Patton DE, 1997, NEURON, V19, P711, DOI 10.1016/S0896-6273(00)80383-9; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; Rosenthal JJC, 2002, NEURON, V34, P743, DOI 10.1016/S0896-6273(02)00701-8; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; Seeburg PH, 2000, NEURON, V25, P261, DOI 10.1016/S0896-6273(00)80891-0; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Seeburg PH, 2002, NEURON, V35, P17, DOI 10.1016/S0896-6273(02)00760-2; Semenov EP, 1999, J NEUROCHEM, V72, P66, DOI 10.1046/j.1471-4159.1999.0720066.x; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Smith L A, 1998, J Neurogenet, V12, P227; Smith RD, 1996, J NEUROSCI, V16, P1965; Smith RD, 1997, J NEUROSCI, V17, P6086; Smith RD, 2000, AM J PHYSIOL-CELL PH, V278, pC638, DOI 10.1152/ajpcell.2000.278.4.C638; Smith TJ, 1997, INSECT BIOCHEM MOLEC, V27, P807, DOI 10.1016/S0965-1748(97)00065-9; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Tan J, 2002, INSECT BIOCHEM MOLEC, V32, P445, DOI 10.1016/S0965-1748(01)00122-9; Tan JG, 2002, J NEUROSCI, V22, P5300; THACKERAY JR, 1995, GENETICS, V141, P203; THACKERAY JR, 1994, J NEUROSCI, V14, P2569; Villegas J, 2002, NUCLEIC ACIDS RES, V30, P1895, DOI 10.1093/nar/30.9.1895; Warmke JW, 1997, J GEN PHYSIOL, V110, P119, DOI 10.1085/jgp.110.2.119; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207	49	82	90	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32554	32561		10.1074/jbc.M402392200	http://dx.doi.org/10.1074/jbc.M402392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15136570	hybrid, Green Accepted			2022-12-25	WOS:000222849700071
J	Armesilla, AL; Williams, JC; Buch, MH; Pickard, A; Emerson, M; Cartwright, EJ; Oceandy, D; Vos, MD; Gillies, S; Clark, GJ; Neyses, L				Armesilla, AL; Williams, JC; Buch, MH; Pickard, A; Emerson, M; Cartwright, EJ; Oceandy, D; Vos, MD; Gillies, S; Clark, GJ; Neyses, L			Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ION MOTIVE ATPASES; CALCIUM-PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; KINASE FAMILY; CA-2+ PUMP; ISOFORM 4B; PROTEIN; IDENTIFICATION	Plasma membrane calmodulin-dependent calcium ATPases (PMCAs) are enzymatic systems implicated in the extrusion of calcium from the cell. We and others have previously identified molecular interactions between the cytoplasmic COOH-terminal end of PMCA and PDZ domain-containing proteins. These interactions suggested a new role for PMCA as a modulator of signal transduction pathways. The existence of other intracellular regions in the PMCA molecule prompted us to investigate the possible participation of other domains in interactions with different partner proteins. A two-hybrid screen of a human fetal heart cDNA library, using the region 652 - 840 of human PMCA4b ( located in the catalytic, second intracellular loop) as bait, revealed a novel interaction between PMCA4b and the tumor suppressor RASSF1, a Ras effector protein involved in H-Ras-mediated apoptosis. Immunofluorescence co-localization, immunoprecipitation, and glutathione S-transferase pull-down experiments performed in mammalian cells provided further confirmation of the physical interaction between the two proteins. The interaction domain has been narrowed down to region 74 - 123 of RASSF1C ( 144 - 193 in RASSF1A) and 652 - 748 of human PMCA4b. The functionality of this interaction was demonstrated by the inhibition of the epidermal growth factor-dependent activation of the Erk pathway when PMCA4b and RASSF1 were co-expressed. This inhibition was abolished by blocking PMCA/ RASSSF1 association with an excess of a green fluorescent protein fusion protein containing the region 50 - 123 of RASSF1C. This work describes a novel protein-protein interaction involving a domain of PMCA other than the COOH terminus. It suggests a function for PMCA4b as an organizer of macromolecular protein complexes, where PMCA4b could recruit diverse proteins through interaction with different domains. Furthermore, the functional association with RASSF1 indicates a role for PMCA4b in the modulation of Ras-mediated signaling.	Univ Manchester, Div Cardiol, Manchester M13 9PT, Lancs, England; NCI, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA	University of Manchester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neyses, L (corresponding author), Univ Manchester, Div Cardiol, Rm 1-302,Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	ludwig.neyses@cmmc.nhs.uk	Oceandy, Delvac/G-9911-2015; Neyses, Ludwig/AGY-7446-2022	Oceandy, Delvac/0000-0002-6242-6491; Armesilla, Angel/0000-0003-3546-5580; pickard, adam/0000-0001-9757-143X; Cartwright, Elizabeth/0000-0002-6836-7795	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010279, Z01SC010359] Funding Source: NIH RePORTER; Medical Research Council [G0200020] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Brown BJ, 1996, BBA-BIOMEMBRANES, V1283, P10, DOI 10.1016/0005-2736(96)00108-3; Chami M, 2003, J BIOL CHEM, V278, P31745, DOI 10.1074/jbc.M304202200; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Goellner GM, 2003, ANN NY ACAD SCI, V986, P461, DOI 10.1111/j.1749-6632.2003.tb07230.x; GREEB J, 1989, J BIOL CHEM, V264, P18569; Hammes A, 1998, CIRC RES, V83, P877; HEIM R, 1992, J BIOL CHEM, V267, P24476; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; JAMES P, 1988, J BIOL CHEM, V263, P2905; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Ko YG, 1999, J IMMUNOL, V162, P7217; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Oxhorn BC, 2003, CELL SIGNAL, V15, P489, DOI 10.1016/S0898-6568(02)00149-3; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRIOR IA, 2003, BIOCHEMIST, V25, P22; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasamura S, 2002, JPN J PHARMACOL, V90, P164, DOI 10.1254/jjp.90.164; Schuh K, 2003, J BIOL CHEM, V278, P9778, DOI 10.1074/jbc.M212507200; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Sugden PH, 2000, TRENDS CARDIOVAS MED, V10, P1, DOI 10.1016/S1050-1738(00)00038-4; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Zabe M, 2001, J BIOL CHEM, V276, P14704, DOI 10.1074/jbc.M009850200	46	91	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31318	31328		10.1074/jbc.M307557200	http://dx.doi.org/10.1074/jbc.M307557200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145946	hybrid, Green Published			2022-12-25	WOS:000222726800052
J	Mattera, R; Puertollano, R; Smith, WJ; Bonifacino, JS				Mattera, R; Puertollano, R; Smith, WJ; Bonifacino, JS			The trihelical bundle subdomain of the GGA proteins interacts with multiple partners through overlapping but distinct sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; AMINO-TERMINAL DOMAIN; TRANS-GOLGI NETWORK; EAR HOMOLOGY DOMAIN; GAMMA-ADAPTIN; UBIQUITIN-BINDING; VHS DOMAINS; GAT DOMAIN; MEMBRANE-FUSION; CLATHRIN	The Golgi-localized, gamma-adaptin ear-containing, ARF-binding (GGA) proteins are monomeric clathrin adaptors that mediate the sorting of cargo at the trans-Golgi network and endosomes. The GGAs contain four different domains named Vps27, Hrs, Stam (VHS); GGAs and TOM1 (GAT); hinge; and gamma-adaptin ear (GAE). The VHS domain recognizes transmembrane cargo, whereas the hinge and GAE regions bind clathrin and accessory proteins, respectively. The GAT domain is a polyfunctional module that interacts with various partners including the small GTPase ARF, the endosomal fusion regulator Rabaptin-5, ubiquitin, and the product of the tumor susceptibility gene 101 (TSG101). Previous x-ray crystallographic analyses showed that the GAT region is composed of two subdomains, an N-terminal helix-loop-helix containing the ARF binding site, and a C-terminal triple alpha-helical (trihelical) bundle. In this study, we define the Rabaptin-5 binding site on the GGA1-GAT domain and its relationship to the binding sites for ubiquitin and TSG101. Our observations show that Rabaptin-5, ubiquitin, and TSG101 bind to overlapping but distinct binding sites on the trihelical bundle. The different GAT binding partners engage in both competitive and cooperative interactions that may be important for the function of the GGAs in protein sorting.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 2002, MOL BIOL CELL, V13, P3078, DOI 10.1091/mbc.E02-02-0078; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P8018, DOI 10.1074/jbc.M311873200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Seet LF, 2004, J BIOL CHEM, V279, P4670, DOI 10.1074/jbc.M311228200; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Yamakami M, 2003, J BIOL CHEM, V278, P52865, DOI 10.1074/jbc.M306740200; Zhai P, 2003, BIOCHEMISTRY-US, V42, P13901, DOI 10.1021/bi035392b; Zhu GY, 2003, BIOCHEMISTRY-US, V42, P6392, DOI 10.1021/bi034334n; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	45	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31409	31418		10.1074/jbc.M402183200	http://dx.doi.org/10.1074/jbc.M402183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143060	hybrid			2022-12-25	WOS:000222726800062
J	Seshasayee, D; Wang, H; Lee, WP; Gribling, P; Ross, J; Van Bruggen, N; Carano, R; Grewal, IS				Seshasayee, D; Wang, H; Lee, WP; Gribling, P; Ross, J; Van Bruggen, N; Carano, R; Grewal, IS			A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; TNF FAMILY-MEMBER; T-CELLS; FACTOR RECEPTOR; LYMPHOCYTE DEVELOPMENT; HUMORAL HYPERCALCEMIA; MONOCLONAL-ANTIBODIES; CD40; CYTOKINE	Osteoprotegerin Ligand (OPGL) is a member of the tumor necrosis factor ligand superfamily and has been shown to be involved in interactions between T cells and dendritic cells. Its role in monocyte effector function, however, has not been defined. In the present study a role for OPGL in activating monocytes/macrophages has been characterized. OPGL was found to up-regulate receptor activator of NF-kappaB (RANK) receptor expression on monocytes, regulate their effector function by inducing cytokine and chemokine secretion, activate antigen presentation through up-regulation of co-stimulatory molecule expression, and promote survival. This activation is mediated through the MAPK pathway as evidenced by activation of p38 and p42/44 MAPK and upregulation of BCL-XL protein levels. A physiological role for OPGL in monocyte activation and effector function was tested in a model of lipopolysaccharide-induced endotoxic shock. Administration of receptor activator of NF-kappaB (RANK)-Fc to block OPGL activity in vivo was able to protect mice from death induced by sepsis, indicating a hitherto undescribed role for OPGL in monocyte function and in mediating inflammatory response. This was further tested in an animal model of inflammation-mediated arthritis. Treatment with RANK-Fc significantly ameliorated disease development and attenuated bone destruction. Thus, our study strongly suggests that administration of receptor fusion proteins to specifically block OPGL activity in vivo may result in blocking development of monocyte/macrophage-mediated diseases.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Grewal, IS (corresponding author), Genentech Inc, Dept Immunol, 1 DNA Way,MS 34, San Francisco, CA 94080 USA.	iqbal@gene.com		Grewal, Iqbal S/0000-0002-4775-055X				Akatsu T, 1998, BONE, V23, P495, DOI 10.1016/S8756-3282(98)00141-0; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Capparelli C, 2000, CANCER RES, V60, P783; Clark LB, 1996, ADV IMMUNOL, V63, P43; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Genant HK, 1998, ARTHRITIS RHEUM, V41, P1583, DOI 10.1002/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Josien R, 1999, J IMMUNOL, V162, P2562; KIENER PA, 1995, J IMMUNOL, V155, P4917; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440-1711.1999.00815.x; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malik N, 1996, J IMMUNOL, V156, P3952; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Ravirajan C T, 1999, Int Rev Immunol, V18, P563, DOI 10.3109/08830189909088499; Ross FP, 2000, J CLIN INVEST, V105, P555, DOI 10.1172/JCI9557; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; Stout RD, 1996, J IMMUNOL, V156, P8; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; Suttles J, 1996, J LEUKOCYTE BIOL, V60, P651, DOI 10.1002/jlb.60.5.651; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; TERATO K, 1992, J IMMUNOL, V148, P2103; Terato K, 1995, AUTOIMMUNITY, V22, P137, DOI 10.3109/08916939508995311; TIAN LC, 1995, EUR J IMMUNOL, V25, P306, DOI 10.1002/eji.1830250152; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	39	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30202	30209		10.1074/jbc.M403968200	http://dx.doi.org/10.1074/jbc.M403968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145935	hybrid			2022-12-25	WOS:000222531900043
J	Jin, YH; Jeon, EJ; Li, QL; Lee, YH; Choi, JK; Kim, WJ; Lee, KY; Bae, SC				Jin, YH; Jeon, EJ; Li, QL; Lee, YH; Choi, JK; Kim, WJ; Lee, KY; Bae, SC			Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; CORE-BINDING FACTOR; T-CELL-RECEPTOR; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL COOPERATION; HISTONE DEACETYLASE-6; DNA-BINDING; AML1	The Runt domain transcription factors (RUNXs) play essential roles in normal development and neoplasias. Genetic analyses of animals and humans have revealed the involvement of RUNX1 in hematopoiesis and leukemia, RUNX2 in osteogenesis and cleidocranial dysplasia, and RUNX3 in the development of T-cells and dorsal root ganglion neurons and in the genesis of gastric cancer. Here we report that RUNX3 is a target of the acetyltransferase activity of p300. The p300-dependent acetylation of three lysine residues protects RUNX3 from ubiquitin ligase Smurf-mediated degradation. The extent of the acetylation is up-regulated by the transforming growth factor-beta signaling pathway and down-regulated by histone deacetylase activities. Our findings demonstrate that the level of RUNX3 protein is controlled by the competitive acetylation and deacetylation of the three lysine residues, revealing a new mechanism for the posttranslational regulation of RUNX3 expression.	Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Sch Med, Dept Urol, Cheongju 361763, South Korea; Chungbuk Natl Univ, Inst Tumor Res, Cheongju 361763, South Korea	Chungbuk National University; Chungbuk National University; Chungbuk National University	Lee, KY (corresponding author), Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	ginsenoside@runx3.co.kr; scbae@med.chungbuk.ac.kr	Li, Qinglin/K-2570-2015; jin, yun/GQZ-6618-2022; 高, 雨莉/HGU-8187-2022	Li, Qinglin/0000-0002-4125-1944; 				Bae SC, 1999, HISTOL HISTOPATHOL, V14, P1213, DOI 10.14670/HH-14.1213; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	38	172	178	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29409	29417		10.1074/jbc.M313120200	http://dx.doi.org/10.1074/jbc.M313120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15138260	hybrid			2022-12-25	WOS:000222445300073
J	Kepley, CL; Taghavi, S; Mackay, G; Zhu, DC; Morel, PA; Zhang, K; Ryan, JJ; Satin, LS; Zhang, M; Pandolfi, PP; Saxon, A				Kepley, CL; Taghavi, S; Mackay, G; Zhu, DC; Morel, PA; Zhang, K; Ryan, JJ; Satin, LS; Zhang, M; Pandolfi, PP; Saxon, A			Co-aggregation of Fc gamma RII with Fc epsilon RI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATION; TYROSINE PHOSPHORYLATION; PROTEIN P62(DOK); SHIP BINDS; B-CELLS; DOMAIN; IGE; EXPRESSION	Signaling through the high affinity IgE receptor FcepsilonRI on human basophils and rodent mast cells is decreased by co-aggregating these receptors to the low affinity IgG receptor FcgammaRII. We used a recently described fusion protein, GE2, which is composed of key portions of the human gamma1 and the human epsilon heavy chains, to dissect the mechanisms that lead to human mast cell and basophil inhibition through co-aggregation of FcgammaRII and FcepsilonRI. Unstimulated human mast cells derived from umbilical cord blood express the immunoreceptor tyrosine-based inhibitory motif-containing receptor FcgammaRII but not FcgammaRI or FcgammaRIII. Interaction of the mast cells with GE2 alone did not cause degranulation. Co-aggregating FcepsilonRI and FcgammaRII with GE2 1) significantly inhibited IgE-mediated histamine release, cytokine production, and Ca2+ mobilization, 2) reduced the antigen-induced morphological changes associated with mast cell degranulation, 3) reduced the tyrosine phosphorylation of several cellular substrates, and 4) increased the tyrosine phosphorylation of the adapter protein downstream of kinase 1 (p62(dok); Dok), growth factor receptor-bound protein 2 (Grb2), and SH2 domain containing inositol 5-phosphatase (SHIP). Tyrosine phosphorylation of Dok was associated with increased binding to Grb2. Surprisingly, in non-stimulated cells, there were complexes of phosphorylated SHIP-Grb2-Dok that were lost upon IgE receptor activation but retained under conditions of Fcepsilon-Fcgamma co-aggregation. Finally, studies using mast cells from Dok-1 knock-out mice showed that IgE alone triggers degranulation supporting an inhibitory role for Dok degranulation. Our results demonstrate how human FcepsilonRI-mediated responses can be inhibited by co-aggregation with FcgammaRIIB and implicate Dok, SHIP, and Grb2 as key intermediates in regulating antigen-induced mediator release.	Virginia Commonwealth Univ Hlth Syst, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ Hlth Syst, Dept Biol, Richmond, VA 23298 USA; Virginia Commonwealth Univ Hlth Syst, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Univ So Calif, Dept Med, Los Angeles, CA 90033 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Melbourne; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Memorial Sloan Kettering Cancer Center; University of Southern California	Kepley, CL (corresponding author), Virginia Commonwealth Univ Hlth Syst, Dept Internal Med, Div Rheumatol Allergy & Immunol, POB 263,MCV Stn, Richmond, VA 23298 USA.	clkepley@mail1.vcu.edu	Morel, Penelope Anne/AAI-6239-2020	Morel, Penelope Anne/0000-0002-1743-3676; Mackay, Graham/0000-0002-9083-1304; Taghavi, Sharven/0000-0001-6289-2129	FOGARTY INTERNATIONAL CENTER [R03TW000440] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042204, R01AI015251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00440] Funding Source: Medline; NHLBI NIH HHS [P50 HL56384] Funding Source: Medline; NIAID NIH HHS [R01-AI15251, R01 AI42204] Funding Source: Medline; NIGMS NIH HHS [R01 GM49814] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2002, IMMUNOL LETT, V82, P23, DOI 10.1016/S0165-2478(02)00013-5; Anderson CC, 1998, CRIT REV IMMUNOL, V18, P525, DOI 10.1615/CritRevImmunol.v18.i6.30; BENJAMIN CW, 1994, J BIOL CHEM, V269, P31346; BUDDE P, 1994, J BIOL CHEM, V269, P30636; Chacko GW, 1996, J IMMUNOL, V157, P2234; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Dustin LB, 1999, J IMMUNOL, V162, P2717; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V100, P219, DOI 10.1159/000236415; EGUCHI M, 1991, ELECTRON MICROSC REV, V4, P293, DOI 10.1016/0892-0354(91)90007-Y; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; FURITSU T, 1989, P NATL ACAD SCI USA, V86, P10039, DOI 10.1073/pnas.86.24.10039; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GHOSH J, 1995, MECH AGEING DEV, V80, P171, DOI 10.1016/0047-6374(94)01568-7; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; Kepley CL, 1998, J ALLERGY CLIN IMMUN, V102, P304, DOI 10.1016/S0091-6749(98)70100-9; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2003, CLIN IMMUNOL, V108, P89, DOI 10.1016/S1521-6616(03)00155-4; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; Lesourne R, 2001, J BIOL CHEM, V276, P6327, DOI 10.1074/jbc.M006537200; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Lyden TW, 2001, J IMMUNOL, V166, P3882, DOI 10.4049/jimmunol.166.6.3882; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; Malbec O, 1998, J IMMUNOL, V160, P1647; Matricardi PM, 2001, CURR OPIN ALLERGY CL, V1, P413, DOI 10.1097/00130832-200110000-00006; Metes D, 1998, BLOOD, V91, P2369, DOI 10.1182/blood.V91.7.2369.2369_2369_2380; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Ott VL, 2002, J IMMUNOL, V168, P4430, DOI 10.4049/jimmunol.168.9.4430; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Platts-Mills TAE, 2002, CLIN EXP ALLERGY, V32, P335, DOI 10.1046/j.1365-2222.2002.01352.x; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; RISKE F, 1991, J BIOL CHEM, V266, P11245; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; ROSENFELD SI, 1987, J IMMUNOL, V138, P2869; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Suzuki H, 1997, J IMMUNOL, V159, P5881; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Tkaczyk C, 2001, CLIN IMMUNOL, V99, P198, DOI 10.1006/clim.2001.4992; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; Yamada T, 2003, J BIOL CHEM, V278, P32818, DOI 10.1074/jbc.M304590200; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Yamanashi Y, 2000, GENE DEV, V14, P11; ZHANG K, 2004, IN PRESS J ALLERGY C; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	64	96	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35139	35149		10.1074/jbc.M404318200	http://dx.doi.org/10.1074/jbc.M404318200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15151996	hybrid			2022-12-25	WOS:000223303400004
J	Sandberg, EM; Sayeski, PP				Sandberg, EM; Sayeski, PP			Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ANGIOTENSIN-II; STAT PATHWAY; ACTIVATION; MECHANISMS; EXPRESSION; BAX	In vascular smooth muscle cells, Jak2 tyrosine kinase becomes activated in response to oxidative stress in the form of hydrogen peroxide. Although it has been postulated that hydrogen peroxide-induced Jak2 activation promotes cell survival, this has never been tested. We therefore examined the role that Jak2 plays in vascular smooth muscle cell apoptosis following hydrogen peroxide treatment. Here, we report that Jak2 tyrosine kinase activation by hydrogen peroxide is required for apoptosis of vascular smooth muscle cells. Upon treatment of primary rat aortic smooth muscle cells with hydrogen peroxide, we observed laddering of genomic DNA and nuclear condensation, both hallmarks of apoptotic cells. However, apoptosis was prevented by either the expression of a dominant negative Jak2 protein or by the Jak2 pharmacological inhibitor AG490. Moreover, expression of the proapoptotic Bax protein was induced following hydrogen peroxide treatment. Again, expression of a dominant negative Jak2 protein or treatment of cells with AG490 prevented this Bax induction. Following Bax induction by hydrogen peroxide, mitochondrial membrane integrity was compromised, and caspase-9 became activated. In contrast, in cells expressing a Jak2 dominant negative we observed that mitochondrial membrane integrity was preserved, and no caspase-9 activation occurred. These data demonstrate that the activation of Jak2 tyrosine kinase by hydrogen peroxide is essential for apoptosis of vascular smooth muscle cells. Furthermore, this report identifies Jak2 as a potential therapeutic target in vascular diseases in which vascular smooth muscle cell apoptosis contributes to pathological progression.	Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Sayeski, PP (corresponding author), Univ Florida, Coll Med, Dept Physiol & Funct Genom, POB 100274, Gainesville, FL 32610 USA.	Psayeski@phys.med.ufl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060471] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 67277] Funding Source: Medline; NIDDK NIH HHS [K01 DK 60471] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDBERG EM, 2004, J BIOL CHEM, V279, P1956; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; El-Adawi H, 2003, CARDIOVASC RES, V57, P129, DOI 10.1016/S0008-6363(02)00614-4; Frank GD, 2003, MOL CELL BIOL, V23, P1581, DOI 10.1128/MCB.23.5.1581-1589.2003; GENG YJ, 1995, AM J PATHOL, V147, P251; Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Li JF, 2003, BRAIN RES BULL, V62, P101, DOI 10.1016/j.brainresbull.2003.08.011; Li PF, 1997, CIRCULATION, V96, P3602; Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; Naderi J, 2003, APOPTOSIS, V8, P91, DOI 10.1023/A:1021657220843; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Sarosi LAG, 2003, BIOCHEM BIOPH RES CO, V312, P355, DOI 10.1016/j.bbrc.2003.10.133; Sayeski PP, 1999, J BIOL CHEM, V274, P33131, DOI 10.1074/jbc.274.46.33131; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Sotnikova R, 1998, GEN PHARMACOL, V31, P115, DOI 10.1016/S0306-3623(97)00392-3; Yamakawa H, 2000, NEUROL RES, V22, P556	26	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34547	34552		10.1074/jbc.M405045200	http://dx.doi.org/10.1074/jbc.M405045200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15159394	hybrid			2022-12-25	WOS:000223134800058
J	Kanki, H; Kupershmidt, S; Yang, T; Wells, S; Roden, DM				Kanki, H; Kupershmidt, S; Yang, T; Wells, S; Roden, DM			A structural requirement for processing the cardiac K+ channel KCNQ1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; DEFECTIVE PROTEIN TRAFFICKING; POTASSIUM CHANNEL; GABA(B) RECEPTOR; COILED-COILS; GENOMIC ORGANIZATION; MUTATIONAL ANALYSIS; DRUG BLOCK; I-KS; LOCALIZATION	Normal membrane protein function requires trafficking from the endoplasmic reticulum. Here, we studied processing of the KCNQ1 channel mutated in LQT1, the commonest form of the long QT syndrome. Serial C terminus truncations identified a small region ( amino acids (aa) 610-620) required for normal cell surface expression. Non-trafficked truncations assembled as tetramers but were nevertheless retained in the endoplasmic reticulum. Further mutagenesis did not identify specific residues mediating channel processing; cell surface expression was preserved with the mutation of known trafficking motifs in the channel and with alanine scanning across aa 610-620. Structural prediction algorithms place aa 610-620 at the C-terminal end of an alpha-helix (aa 586-618) that includes a leucine zipper and is part of a coiled coil. Mutants disrupting the leucine zipper but preserving the predicted coiled coil reached the cell surface, whereas those disrupting the coil did not. These data suggest that specific protein-protein interactions are required for normal channel processing. Further biochemical studies ruled out three candidate proteins, namely KCNE1, yotiao, and KCNQ1 itself, as effectors of this coiled coil-mediated trafficking. Four LQT1 mutations within this helix generated little or no current and were not expressed on the cell surface, whereas LQT1 mutations in adjacent residues, which produce a milder clinical phenotype, generate only slightly reduced current and are expressed on the cell surface. These data suggest that mutations within this domain cause human disease by interfering with normal channel processing. More generally, we have identified a domain whose structural integrity is required for normal surface expression of the KCNQ1 channel.	Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Roden, DM (corresponding author), Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Dept Med, 532C Med Res Bldg 1, Nashville, TN 37232 USA.	dan.roden@vanderbilt.edu	Kupershmidt, Sabina/AAO-5464-2021; Roden, Dan/ABD-5412-2021	Kupershmidt, Sabina/0000-0002-8119-2723; 	NCI NIH HHS [CA68485] Funding Source: Medline; NHLBI NIH HHS [HL46681, HL49989] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL049989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baroudi G, 2002, CIRC RES, V90, pE11, DOI 10.1161/hh0102.102977; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Chouabe C, 2000, CARDIOVASC RES, V45, P971, DOI 10.1016/S0008-6363(99)00411-3; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Fothergill-Gilmore Linda A., 1993, P467, DOI 10.1007/978-1-59259-438-2_13; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Grunewald S, 2002, MOL PHARMACOL, V61, P1070, DOI 10.1124/mol.61.5.1070; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; Itoh T, 1998, HUM GENET, V103, P290, DOI 10.1007/s004390050819; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lam BCH, 2001, PLANT CELL, V13, P2499, DOI 10.1105/tpc.13.11.2499; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Monera OD, 1996, J BIOL CHEM, V271, P3995; MYSZKA DG, 1994, BIOCHEMISTRY-US, V33, P2363, DOI 10.1021/bi00175a003; Neyroud N, 1999, CIRC RES, V84, P290, DOI 10.1161/01.RES.84.3.290; Nilsson I, 1998, J MOL BIOL, V284, P1165, DOI 10.1006/jmbi.1998.2217; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Pagano A, 2001, J NEUROSCI, V21, P1189; Piippo K, 2001, J AM COLL CARDIOL, V37, P562, DOI 10.1016/S0735-1097(00)01124-4; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; Raiborg C, 2001, J CELL SCI, V114, P2255; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; Seaman MNJ, 2002, MOL BIOL CELL, V13, P2826, DOI 10.1091/mbc.02-05-0064; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Yamashita F, 2001, J MOL CELL CARDIOL, V33, P197, DOI 10.1006/jmcc.2000.1300; Yang P, 2002, CIRCULATION, V105, P1943, DOI 10.1161/01.CIR.0000014448.19052.4C; Yang T, 2003, CIRCULATION, V108, P132, DOI 10.1161/01.CIR.0000082708.86266.B8; Yang T, 2001, J CARDIOVASC PHARM, V38, P737, DOI 10.1097/00005344-200111000-00010; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	46	65	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33976	33983		10.1074/jbc.M404539200	http://dx.doi.org/10.1074/jbc.M404539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15140888	hybrid			2022-12-25	WOS:000223039700108
J	Kedjouar, B; de Medina, P; Oulad-Abdelghani, M; Payre, B; Silvente-Poirot, S; Favre, G; Faye, JC; Poirot, M				Kedjouar, B; de Medina, P; Oulad-Abdelghani, M; Payre, B; Silvente-Poirot, S; Favre, G; Faye, JC; Poirot, M			Molecular characterization of the microsomal tamoxifen binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIONAL-CANCER-INSTITUTE; HIGH-AFFINITY BINDING; PROTEIN-KINASE-C; ESTROGEN-RECEPTOR; BREAST-CANCER; RAT-LIVER; CHOLESTEROL-BIOSYNTHESIS; STRUCTURAL REQUIREMENTS; EPOXIDE HYDROLASE; MASS-SPECTROMETRY	Tamoxifen is a selective estrogen receptor modulator widely used for the prophylactic treatment of breast cancer. In addition to the estrogen receptor ( ER), tamoxifen binds with high affinity to the microsomal antiestrogen binding site (AEBS), which is involved in ER-independent effects of tamoxifen. In the present study, we investigate the modulation of the biosynthesis of cholesterol in tumor cell lines by AEBS ligands. As a consequence of the treatment with the antitumoral drugs tamoxifen or PBPE, a selective AEBS ligand, we show that tumor cells produced a significant concentration- and time-dependent accumulation of cholesterol precursors. Sterols have been purified by HPLC and gas chromatography, and their chemical structures determined by mass spectrometric analysis. The major metabolites identified were 5 alpha-cholest-8-en-3beta-ol for tamoxifen treatment and 5alpha-cholest-8-en-3beta-ol and cholesta-5,7-dien-3beta-ol, for PBPE treatment, suggesting that these AEBS ligands affect at least two enzymatic steps: the 3beta-hydroxysterol-Delta(8)-Delta(7)-isomerase and the 3beta-hydroxysterol-Delta(7)-reductase. Steroidal antiestrogens such as ICI 182,780 and RU 58,668 did not affect these enzymatic steps, because they do not bind to the AEBS. Transient co-expression of human 3beta-hydroxysterol-Delta(8)-Delta(7)- isomerase and 3beta-hydroxysterol-Delta(7)-reductase and immunoprecipitation experiments showed that both enzymes were required to reconstitute the AEBS in mammalian cells. Altogether, these data provide strong evidence that the AEBS is a hetero-oligomeric complex including 3beta-hydroxysterol-Delta(8)-Delta(7)-isomerase and the 3beta-hydroxysterol-Delta(7)-reductase as subunits that are necessary and sufficient for tamoxifen binding in mammary cells. Furthermore, because selective AEBS ligands are antitumoral compounds, these data suggest a link between cholesterol metabolism at a post-lanosterol step and tumor growth control. These data afford both the identification of the AEBS and give new insight into a novel molecular mechanism of action for drugs of clinical value.	INSERM, U563, CPTP,Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Poirot, M (corresponding author), INSERM, U563, CPTP,Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, 20-24 Rue Pont Saint Pierre, F-31052 Toulouse, France.	poirot@icr.fnclcc.fr	Poirot, Marc/K-3551-2012; Poirot, Sandrine/D-5448-2017; Poirot, Marc/C-7613-2009; abdelghani, mustapha oulad/A-5986-2017; FAVRE, Gilles/K-9189-2014; de Medina, Philippe/X-1358-2019	Poirot, Marc/0000-0002-5711-6624; Poirot, Marc/0000-0002-5711-6624; abdelghani, mustapha oulad/0000-0002-8381-4397; FAVRE, Gilles/0000-0002-2344-1883; Silvente-Poirot, Sandrine/0000-0003-2245-9069; de Medina, Philippe/0000-0002-9618-3133				BECKER A, 1994, ARTERIOSCLER THROMB, V14, P1346, DOI 10.1161/01.ATV.14.8.1346; Bencze W L, 1969, Prog Drug Res, V13, P217; Bitsch F, 2003, ANAL BIOCHEM, V323, P139, DOI 10.1016/j.ab.2003.08.029; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDES LJ, 1988, CANCER RES, V48, P3954; BRANDES LJ, 1984, BIOCHEM BIOPH RES CO, V124, P244, DOI 10.1016/0006-291X(84)90943-4; BRANDES LJ, 1995, J CLIN ONCOL, V13, P1398, DOI 10.1200/JCO.1995.13.6.1398; CHAILLEUX C, 1994, J RECEPTOR RES, V14, P23, DOI 10.3109/10799899409066994; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cho SY, 1998, MOL CELLS, V8, P233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Medina P, 2004, J PHARMACOL EXP THER, V308, P1165, DOI 10.1124/jpet.103.060426; Delarue F, 1999, BIOCHEM PHARMACOL, V57, P657, DOI 10.1016/S0006-2952(98)00347-5; FARGIN A, 1988, CHEM-BIOL INTERACT, V66, P101, DOI 10.1016/0009-2797(88)90044-0; Ferlini C, 1999, BRIT J CANCER, V79, P257, DOI 10.1038/sj.bjc.6690042; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Gerst N, 1997, J LIPID RES, V38, P1685; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HWANG PLH, 1989, J LIPID RES, V30, P239; HWANG PLH, 1990, BIOCHIM BIOPHYS ACTA, V1033, P154, DOI 10.1016/0304-4165(90)90006-I; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Jetten AM, 2002, CELL DEATH DIFFER, V9, P1167, DOI 10.1038/sj.cdd.4401085; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; JOZAN S, 1982, BIOCHEM BIOPH RES CO, V107, P1566, DOI 10.1016/S0006-291X(82)80178-2; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kedjouar B, 1999, BIOCHEM PHARMACOL, V58, P1927, DOI 10.1016/S0006-2952(99)00285-3; Khoo K, 1999, J CLIN ONCOL, V17, P3431, DOI 10.1200/JCO.1999.17.11.3431; LaBella FS, 2000, J CELL BIOCHEM, V76, P686, DOI 10.1002/(SICI)1097-4644(20000315)76:4<686::AID-JCB16>3.3.CO;2-M; LI L, 1991, BIOCHIM BIOPHYS ACTA, V1082, P177, DOI 10.1016/0005-2760(91)90192-K; Mesange F, 1998, BIOCHEM J, V334, P107, DOI 10.1042/bj3340107; Mesange F, 2002, BIOCONJUGATE CHEM, V13, P766, DOI 10.1021/bc015588t; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; Moebius FF, 1998, MOL PHARMACOL, V54, P591, DOI 10.1124/mol.54.3.591; PAIK YK, 1986, J BIOL CHEM, V261, P6470; Paul R, 1998, J PHARMACOL EXP THER, V285, P1296; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; POIROT M, 1990, J BIOL CHEM, V265, P17039; Poirot M, 2000, BIOORGAN MED CHEM, V8, P2007, DOI 10.1016/S0968-0896(00)00119-X; POIROT M, 1990, BIOCHEM PHARMACOL, V40, P425, DOI 10.1016/0006-2952(90)90539-W; POPJAK G, 1989, J BIOL CHEM, V264, P6230; Porter FD, 2002, J CLIN INVEST, V110, P715, DOI 10.1172/JCI200216386; Reyno L, 2004, J CLIN ONCOL, V22, P269, DOI 10.1200/JCO.2003.04.075; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SHEEN YY, 1985, ENDOCRINOLOGY, V117, P561, DOI 10.1210/endo-117-2-561; Shefer S, 1998, J LIPID RES, V39, P2471; SHEFER S, 1995, J CLIN INVEST, V96, P1779, DOI 10.1172/JCI118223; Smith LL, 1996, LIPIDS, V31, P453, DOI 10.1007/BF02522641; SMITH LL, 1987, CHEM PHYS LIPIDS, V44, P87, DOI 10.1016/0009-3084(87)90046-6; SUTHERLAND RL, 1980, NATURE, V288, P273, DOI 10.1038/288273a0; TANG BL, 1989, BIOCHIM BIOPHYS ACTA, V1014, P162, DOI 10.1016/0167-4889(89)90029-3; VANDENKOEDIJK CDMA, 1992, BIOCHEM PHARMACOL, V43, P2511, DOI 10.1016/0006-2952(92)90138-9; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; Wassif CA, 2003, STEROIDS, V68, P497, DOI 10.1016/S0039-128X(03)00090-4; WATTS CKW, 1987, MOL PHARMACOL, V31, P541; WATTS CKW, 1984, J BIOL CHEM, V259, P4223; WAYS P, 1964, J LIPID RES, V5, P318; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200	61	72	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34048	34061		10.1074/jbc.M405230200	http://dx.doi.org/10.1074/jbc.M405230200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175332	hybrid			2022-12-25	WOS:000223039700117
J	Nogami, K; Freas, J; Manithody, C; Wakabayashi, H; Rezaie, AR; Fay, PJ				Nogami, K; Freas, J; Manithody, C; Wakabayashi, H; Rezaie, AR; Fay, PJ			Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN HIRUDIN COMPLEX; LENGTH CROSS-LINKING; LIGHT-CHAIN; HEAVY-CHAIN; HEPARIN-BINDING; A2 SUBUNITS; FACTOR-IXA; CLEAVAGE; RESIDUES; ACTIVATION	The 337 - 372 sequence of the factor VIIIa A1 subunit contains interactive sites for both zymogen factor X and the active enzyme, factor Xa. Solid phase binding studies indicated that factor Xa possessed a > 20-fold higher affinity for the isolated A1 subunit of factor VIIIa compared with factor X. Heparin completely inhibited zero-length cross-linking of the 337 - 372 peptide to factor Xa but not to factor X. In the presence of calcium, factor Xa showed greater affinity for heparin than factor X. Studies using factor Xa mutants in which heparin-binding exosite residues were individually replaced by Ala showed that the R240A mutant was defective in recognition of the Lys(36) cleavage site, generating the A1(37-372) intermediate with similar to 20% the catalytic efficiency of wild type. This defect likely resulted from an similar to 4-fold increase in K-m for the A1 substrate because k(cat) values for the wild type and mutant were equivalent. Cleavage of the A1-A2 domain junction by factor Xa R240A was not blocked by the 337 - 372 peptide. Studies using mutant factor VIII where clustered acidic residues in the 337 372 segment were replaced by Ala showed that a factor VIIIa D361A/D362A/D363A mutant possessed a similar to 1.6-fold increase in Km for factor X compared with wild type. However, similar Km values were observed for recombinant factor X and R240A substrates. These results indicate that the binding regions of factor X and factor Xa for A1 domain overlap and that both utilize acidic residues 361 - 363. Furthermore, factor Xa but not factor X interacts with high affinity at this site via residues contained within the heparin-binding exosite of the proteinase.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of Rochester; University of Rochester; Saint Louis University	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL038199, R01HL076213, R01HL062565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62565, HL 68571, HL 38199, HL 76213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; BETZ A, 1991, BIOCHEMISTRY-US, V30, P9848, DOI 10.1021/bi00105a006; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 2004, J BIOL CHEM, V279, P15763, DOI 10.1074/jbc.M400568200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; Nogami K, 2003, J BIOL CHEM, V278, P16502, DOI 10.1074/jbc.M213044200; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	32	28	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33104	33113		10.1074/jbc.M405537200	http://dx.doi.org/10.1074/jbc.M405537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15166225	hybrid			2022-12-25	WOS:000223039700012
J	Warmka, JK; Mauro, LJ; Wattenberg, EV				Warmka, JK; Mauro, LJ; Wattenberg, EV			Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE; CONSTITUTIVE ACTIVATION; TYROSINE PHOSPHATASES; AP-1 TRANSACTIVATION; SKIN CARCINOGENESIS; TERMINAL KINASE; GENE-EXPRESSION	We have capitalized on the unique properties of the skin tumor promoter palytoxin, which does not activate protein kinase C, to investigate alternative mechanisms by which major signaling molecules can be modulated during carcinogenesis. We report here that palytoxin activates extracellular signal-regulated kinase (ERK) through a novel mechanism that involves inactivation of an ERK phosphatase in keratinocytes derived from initiated mouse skin ( 308 cells). Use of U0126 revealed that palytoxin requires the ERK kinase MEK to stimulate ERK activity, although palytoxin did not activate MEK. We found that 308 keratinocytes highly express mitogen-activated protein kinase phosphatase-3 (MKP-3), which selectively inactivates ERK. Palytoxin induced the loss of MKP-3 in a manner that corresponded to increased ERK phosphorylation. Complementary studies showed that sustained expression of exogenous MKP-3 inhibited palytoxin-stimulated ERK activation. As is characteristic of initiated keratinocytes, 308 cells express activated H-Ras. To investigate whether expression of oncogenic Ras is key to palytoxin-stimulated ERK activation, we determined how palytoxin affected ERK and MKP-3 in MCF10A human breast epithelial cells and in H-ras MCF10A cells, which stably express activated H-Ras. Palytoxin did not affect ERK activity in MCF10A cells, which had no detectable MKP-3. Like 308 cells, H-ras MCF10A cells highly express MKP-3. Strikingly, palytoxin stimulated ERK activity and induced a corresponding loss of MKP-3 in H-ras MCF10A cells. These studies indicate that in initiated cells palytoxin unleashes ERK activity by down-regulating MKP-3, an ERK inhibitor, and further suggest that MKP-3 may be a vulnerable target in cells that express oncogenic Ras.	Univ Minnesota, Div Environm Hlth Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Anim Sci Physiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Wattenberg, EV (corresponding author), Univ Minnesota, Div Environm Hlth Sci, Mayo Mail Code 807,420 Delaware St SE, Minneapolis, MN 55455 USA.	watte004@umn.edu						Albanell J, 2001, CANCER RES, V61, P6500; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Dowd S, 1998, J CELL SCI, V111, P3389; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FUJIKI H, 1986, CARCINOGENESIS, V7, P707, DOI 10.1093/carcin/7.5.707; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kuroki DW, 1997, J BIOL CHEM, V272, P23905, DOI 10.1074/jbc.272.38.23905; Kuroki DW, 1996, CANCER RES, V56, P637; Li SN, 1998, TOXICOL APPL PHARM, V151, P377, DOI 10.1006/taap.1998.8471; Li SN, 1999, TOXICOL APPL PHARM, V160, P109, DOI 10.1006/taap.1999.8754; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MOORE RE, 1981, J AM CHEM SOC, V103, P2491, DOI 10.1021/ja00399a093; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PITOT HC, 1995, PROG CLIN  BIOL, V391, P21; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; STRICKLAND JE, 1988, CANCER RES, V48, P165; Thilly WG, 2003, NAT GENET, V34, P255, DOI 10.1038/ng1205; Warmka JK, 2002, TOXICOL APPL PHARM, V185, P8, DOI 10.1006/taap.2002.9519; WATTENBERG EV, 1989, J BIOL CHEM, V264, P213; WATTENBERG EV, 1987, CANCER RES, V47, P4618; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zeliadt NA, 2004, BIOCHEM BIOPH RES CO, V317, P570, DOI 10.1016/j.bbrc.2004.03.081; Zhan XL, 2001, CHEM REV, V101, P2477, DOI 10.1021/cr000245u; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	54	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33085	33092		10.1074/jbc.M403120200	http://dx.doi.org/10.1074/jbc.M403120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159408	hybrid			2022-12-25	WOS:000223039700010
J	Ortiz, DF; Moseley, J; Calderon, G; Swift, AL; Li, SH; Arias, IM				Ortiz, DF; Moseley, J; Calderon, G; Swift, AL; Li, SH; Arias, IM			Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MULTIDRUG-RESISTANCE PROTEIN-2; RAT-LIVER; CANALICULAR MEMBRANE; PLASMA-MEMBRANE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INTRAHEPATIC CHOLESTASIS; FUNCTIONAL EXPRESSION; ABC TRANSPORTERS; P-GLYCOPROTEINS	ATP-binding cassette (ABC)-type proteins are essential for bile formation in vertebrate liver. BSEP, MDR1, MDR2, and MRP2 ABC transporters are targeted to the apical (canalicular) membrane of hepatocytes where they execute ATP-dependent transport of bile acids, drugs, amphipathic cations, phospholipids, and conjugated organic anions, respectively. Changes in activity and abundance of transporters in the canalicular membrane regulate bile flow; however, little is known regarding cellular proteins that bind ABC transporters and regulate their trafficking. A yeast two-hybrid screen identified HAX-1 as a binding partner for BSEP, MDR1, and MDR2. The interactions were validated biochemically by glutathione S-transferase pull-down and co-immunoprecipitation assays. BSEP and HAX-1 were over-represented in rat liver subcellular fractions enriched for canalicular membrane vesicles, microsomes, and clathrin-coated vesicles. HAX-1 was bound to BSEP, MDR1, and MDR2 in canalicular membrane vesicles and co-localized with BSEP and MDR1 in the apical membrane of Madin-Darby canine kidney (MDCK) cells. RNA interference of HAX-1 increased BSEP levels in the apical membrane of MDCK cells by 71%. Pulse-chase studies indicated that HAX-1 depletion did not affect BSEP translation, post-translational modification, delivery to the plasma membrane, or half-life. HAX-1 depletion resulted in an increased peak of metabolically labeled apical membrane BSEP at 4 h and enhanced retention at 6 and 9 h. HAX-1 also interacts with cortactin. Expression of dominant negative cortactin increased steady state levels of BSEP 2-fold in the apical membrane of MDCK cells, as did expression of dominant negative EPS15. These findings suggest that HAX-1 and cortactin participate in BSEP internalization from the apical membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Ortiz, DF (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	daniel.ortiz@tuffs.edu			NIDDK NIH HHS [T32DK07542, R01 DK060719, R01DK35652, P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542, R01DK060719, P30DK034928, R01DK035652] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANIENTO F, 1993, J BIOL CHEM, V268, P10463; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Bond TD, 1998, J PHYSIOL-LONDON, V508, P333, DOI 10.1111/j.1469-7793.1998.333bq.x; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Buchler M, 1996, J BIOL CHEM, V271, P15091; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Cao H, 2001, HEPATOLOGY, V34, p450A; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; Dixon PH, 2000, HUM MOL GENET, V9, P1209, DOI 10.1093/hmg/9.8.1209; Dombrowski F, 2000, BIOCHEM J, V348, P183, DOI 10.1042/0264-6021:3480183; Dufva M, 2001, J GEN VIROL, V82, P1581, DOI 10.1099/0022-1317-82-7-1581; Fischer T, 1999, P NATL ACAD SCI USA, V96, P6722, DOI 10.1073/pnas.96.12.6722; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; Juvvadi SR, 1997, BIOCHEM BIOPH RES CO, V230, P442, DOI 10.1006/bbrc.1996.5932; Kawaguchi Y, 2000, J VIROL, V74, P10104, DOI 10.1128/JVI.74.21.10104-10111.2000; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kocher O, 1999, LAB INVEST, V79, P1161; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; LIN SH, 1989, J BIOL CHEM, V264, P14403; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Matsuda G, 2003, MICROBIOL IMMUNOL, V47, P91, DOI 10.1111/j.1348-0421.2003.tb02790.x; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Nies AT, 1996, J LIPID RES, V37, P1125; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; RUETZ S, 1994, J BIOL CHEM, V269, P12277; Sai Y, 1999, J CELL SCI, V112, P4535; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Suzuki Y, 1997, J IMMUNOL, V158, P2736; Szabo K, 1997, J BIOL CHEM, V272, P23165, DOI 10.1074/jbc.272.37.23165; VREE JMD, 1998, P NATL ACAD SCI USA, V95, P282; Wang L, 2002, J CLIN INVEST, V110, P965, DOI 10.1172/JCI200215968; Yin HL, 2001, CYTOKINE, V15, P122, DOI 10.1006/cyto.2001.0891	53	89	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32761	32770		10.1074/jbc.M404337200	http://dx.doi.org/10.1074/jbc.M404337200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159385	hybrid			2022-12-25	WOS:000222849700095
J	Sandoval, R; Xue, JP; Pilkinton, M; Salvi, D; Kiyokawa, H; Colamonici, OR				Sandoval, R; Xue, JP; Pilkinton, M; Salvi, D; Kiyokawa, H; Colamonici, OR			Different requirements for the cytostatic and apoptotic effects of type I Interferons - Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; INDEPENDENT RESPONSES; INK4A LOCUS; ALPHA; CANCER; EXPRESSION; GROWTH; CYCLE; P14(ARF); PROTEIN	The regulation of cell growth is one of the most important effects of type I interferons (IFNs). This response may involve a cytostatic effect or the induction of apoptosis depending on the cell context. Often the growth-inhibitory response of type I IFNs is studied in tumor cell lines carrying mutations of tumor suppressor genes, and therefore, the growth-inhibitory effect can be influenced by inactivation of these important regulators of cell proliferation. In this report, we explored the role of the ARF-p53 pathway in the growth-inhibitory effect of type I IFNs. We found that p53 is only induced in cells that express p14(ARF) (p19(ARF) in mouse cells). Surprisingly, mouse embryonal fibroblasts that are null for p19(ARF) or P53, even after transformation with oncogenic RAS, respond as well as wild type to the growth-inhibitory effect of type I IFNs. Similarly, human ARF(-/-) U2OS and P53(-/-) SAOS-2 cells show a significant decrease in cell proliferation. However, only SAOS-2 or U2OS reconstituted with inducible p14(ARF) undergo apoptosis in response to IFNbeta treatment, and this effect was not inhibited by expression of dominant negative p53. These data suggest that (i) at least in specific cell types, the induction of apoptosis by type I IFNs requires an ARF pathway that is p53-independent and (ii) the cytostatic and pro-apoptotic effects of type I IFNs employ different pathways.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colamonici, OR (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave,Rm E403, Chicago, IL 60612 USA.	ocolamon@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NCI NIH HHS [CA55079] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Erickson S, 1999, CELL GROWTH DIFFER, V10, P575; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JEWELL AP, 1994, BRIT J HAEMATOL, V88, P268, DOI 10.1111/j.1365-2141.1994.tb05017.x; Kamijo T, 1999, CANCER RES, V59, P2217; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Matsuoka M, 1998, ONCOGENE, V16, P2075, DOI 10.1038/sj.onc.1201745; MILNER AE, 1995, INT J CANCER, V61, P348, DOI 10.1002/ijc.2910610313; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Munro J, 1999, CANCER RES, V59, P2516; Nakamura M, 2001, CANCER RES, V61, P6335; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Prejean C, 2000, SEMIN CANCER BIOL, V10, P83, DOI 10.1006/scbi.2000.0311; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; RODRIGUEZVILLANUEVA J, 1995, INT J CANCER, V61, P110, DOI 10.1002/ijc.2910610119; ROOS G, 1984, CANCER RES, V44, P2358; Rubinstein M, 1998, CYTOKINE GROWTH F R, V9, P175; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TIEFERBRUN N, 1996, MOL CELL BIOL, V7, P3934; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yano H, 1999, HEPATOLOGY, V29, P1708, DOI 10.1002/hep.510290624; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	53	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32275	32280		10.1074/jbc.M313830200	http://dx.doi.org/10.1074/jbc.M313830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169789	hybrid			2022-12-25	WOS:000222849700036
J	Zhong, Q; Gohil, VM; Ma, LN; Greenberg, ML				Zhong, Q; Gohil, VM; Ma, LN; Greenberg, ML			Absence of cardiolipin results in temperature sensitivity, respiratory defects, and mitochondrial DNA instability independent of pet56	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BARTH-SYNDROME; YEAST MITOCHONDRIA; SYNTHASE; MUTANT; GENE; EXPRESSION; GROWTH; ABNORMALITIES; STABILITY	Cardiolipin ( CL) is a dimeric phospholipid localized primarily in the mitochondrial membrane. Previous studies have shown that yeast cells containing a disruption of CRD1, the structural gene encoding CL synthase, exhibit temperature-sensitive colony formation and multiple mitochondrial defects. A recent report (Zhang, M., Su, X., Mileykovskaya, E., Amoscato, A. A., and Dowhan, W. ( 2003) J. Biol. Chem. 278, 35204-35210) suggested that defects associated with CL deficiency may result from the reduced expression of PET56 in crd1Delta mutant backgrounds and should be reevaluated. In the current study, we present evidence that CL deficiency leads to mitochondrial DNA instability, loss of viability, and defects in oxidative phosphorylation at elevated temperatures. The observed mutant phenotypes are characteristic of crd1Delta mutant cells of both PET56 and pet56 backgrounds and are complemented by an episomal copy of CRD1 but not by expression of the PET56 gene. Phosphatidylglycerol is elevated in crd1Delta mutant cells when grown in the presence of fermentable and non-fermentable carbon sources, although the extent of the increase is higher in nonfermentable medium. An increase in the ratio of phosphatidylethanolamine to phosphatidylcholine was also apparent in the mutant. These findings demonstrate that CRD1, independent of PET56, is required for optimal mitochondrial function and for an essential cellular function at elevated temperatures.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 GullenM all, Detroit, MI 48202 USA.	mlgreen@sun.science.wayne.edu	zhong, quan/AAE-8893-2021	Gohil, Vishal/0000-0002-9920-2563; Zhong, Quan/0000-0003-2910-5597	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson MS, 1996, J BIOL CHEM, V271, P26596, DOI 10.1074/jbc.271.43.26596; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Barth PG, 1996, J INHERIT METAB DIS, V19, P157, DOI 10.1007/BF01799418; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Chen R, 2002, MOL GENET METAB, V77, P319, DOI 10.1016/S1096-7192(02)00195-6; COLLART MA, 1994, CURRENT PROTOCOLS MO; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; Gu ZM, 2004, MOL MICROBIOL, V51, P149, DOI 10.1046/j.1365-2958.2003.03802.x; JAKOVCIC S, 1971, J CELL BIOL, V48, P490, DOI 10.1083/jcb.48.3.490; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; LERAY C, 1987, J CHROMATOGR-BIOMED, V420, P411, DOI 10.1016/0378-4347(87)80198-6; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Rieger KJ, 1997, YEAST, V13, P1547, DOI 10.1002/(SICI)1097-0061(199712)13:16<1547::AID-YEA230>3.3.CO;2-P; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SIKORSKI RS, 1989, GENETICS, V122, P19; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; Storey MK, 2001, BBA-MOL CELL BIOL L, V1532, P234, DOI 10.1016/S1388-1981(01)00129-9; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Zhang M, 2003, J BIOL CHEM, V278, P35204, DOI 10.1074/jbc.M306729200	31	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32294	32300		10.1074/jbc.M403275200	http://dx.doi.org/10.1074/jbc.M403275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169766	hybrid			2022-12-25	WOS:000222849700039
J	Abdulhussein, R; McFadden, C; Fuentes-Prior, P; Vogel, WF				Abdulhussein, R; McFadden, C; Fuentes-Prior, P; Vogel, WF			Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VIIIC2 DOMAIN; COAGULATION-FACTOR-V; MEMBRANE-BINDING; C2 DOMAIN; IDENTIFICATION; EXPRESSION; PROTEIN; RETINOSCHISIS; C2-DOMAIN; MUTATIONS	Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are tyrosine kinase receptors activated by triple-helical collagens. Aberrant expression and signaling of these receptors have been implicated in several human diseases linked to accelerated matrix degradation and remodeling including tumor invasion, atherosclerosis and liver fibrosis. The objective of this study is to characterize the collagen-binding sites in the discoidin domains of DDR1 and DDR2 at a molecular level. We expressed glutathione S-transferase fusion proteins containing the discoidin and extracellular domains of DDR1 and DDR2 in insect cells and subjected them to a solid-phase collagen-binding assay. We found high affinity binding of the DDR extracellular domains to immobilized type I collagen and confirmed the discoidin-collagen interaction with an enzyme-linked immunosorbent assay-based read-out. Furthermore, we created a three-dimensional model of the DDR1 discoidin domain based on the related domains of blood coagulation factors V and VIII. This model predicts the presence of four neighboring, surface-exposed loops that are topologically equivalent to a major phospholipid-binding site in factors V and VIII. To test the involvement of these loops in collagen binding, we mutated individual amino acid residues to alanine or deleted short sequence stretches within these loops. We found that several residues within loop 1 (Ser-52-Thr-57) and loop 3 (Arg-105-Lys-112) as well as Ser-175 in loop 4 are critically involved in collagen binding. Our structure-function analysis of the DDR discoidin domains provides new insights into this non-integrin-mediated collagen-signaling mechanism and may ultimately lead to the design of small molecule inhibitors that interfere with aberrant DDR function.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Max Planck Inst Biochem, D-82152 Martinsried, Germany; CSIC, Inst Catala Ciencies Cardiovasc, Cardiovasc Res Ctr, Barcelona 08025, Spain	University of Toronto; Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC)	Vogel, WF (corresponding author), 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	w.vogel@utoronto.ca		Fuentes-Prior, Pablo/0000-0002-6618-3204				ALVES F, 1995, ONCOGENE, V10, P609; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Curat CA, 2001, J BIOL CHEM, V276, P45952, DOI 10.1074/jbc.M104360200; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Fraternali F, 2003, FEBS LETT, V544, P21, DOI 10.1016/S0014-5793(03)00433-2; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; Grayson C, 2000, HUM MOL GENET, V9, P1873, DOI 10.1093/hmg/9.12.1873; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; KANE WH, 1988, BLOOD, V71, P539; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Leitinger B, 2003, J BIOL CHEM, V278, P16761, DOI 10.1074/jbc.M301370200; Lewis DA, 2003, BLOOD COAGUL FIBRIN, V14, P361, DOI 10.1097/00001721-200306000-00007; Liu ML, 2000, BLOOD, V96, P979, DOI 10.1182/blood.V96.3.979.015k42a_979_987; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; Mooy CM, 2002, ARCH OPHTHALMOL-CHIC, V120, P979; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, EUR J DERMATOL, V11, P506; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028	35	51	56	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31462	31470		10.1074/jbc.M400651200	http://dx.doi.org/10.1074/jbc.M400651200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15136580	hybrid			2022-12-25	WOS:000222726800068
J	Cao, JS; Liu, YF; Lockwood, J; Burn, P; Shi, YG				Cao, JS; Liu, YF; Lockwood, J; Burn, P; Shi, YG			A novel cardiolipin-remodeling pathway revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA : lysocardiolipin acyltransferase (ALCAT1) in mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; MAMMALIAN-CELLS; MONOLYSOCARDIOLIPIN ACYLTRANSFERASE; SPECIES PATTERN; CYTOCHROME-C; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPIDS; APOPTOSIS; LIPIDS; HEART	Cardiolipin is a major membrane polyglycerophospholipid that is required for the reconstituted activity of a number of key mitochondrial enzymes involved in energy metabolism. Cardiolipin is subjected to remodeling subsequent to its de novo biosynthesis to attain appropriate acyl composition for its biological functions. Yet, the enzyme(s) involved in the remodeling process have not been identified. We report here the identification and characterization of a murine gene that encodes an acyl-CoA: lysocardiolipin acyltransferase 1 (ALCAT1). Expression of the ALCAT1 cDNA in either insect or mammalian cells led to a significant increase in acyl-CoA: monolysocardiolipin acyltransferase and acyl-CoA: dilysocardiolipin acyltransferase activities that exhibited a dependence upon ALCAT1 enzyme levels. The recombinant ALCAT1 enzyme recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors. In contrast, no significant increases in acyltransferase activities by the recombinant ALCAT1 were detected against either glycerol-3-phosphate or a variety of other lysophospholipids as substrates, including lysophosphatidylcholine, lysophosphatidylethanolamine, and lysophosphatidylserine. Immunocytohistochemical analysis showed that the ALCAT1 enzyme is localized in the endoplasmic reticulum, which is supported by a significant ALCAT activity in isolated liver and heart microsomes. Northern blot analysis indicates that the mouse ALCAT1 is widely distributed, with the highest expression in heart and liver. In support of a role for ALCAT1 in maintaining heart function, the ALCAT1 gene is conserved among different species of vertebrates, but not in non-atrium organisms. ALCAT1 represents the first identified cardiolipin-remodeling enzyme from any living organism; its identification implies a novel role for the endoplasmic reticulum in cardiolipin metabolism.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, DC 0545, Indianapolis, IN 46285 USA.	shi_yuguang@lilly.com						Berger A, 1993, Adv Food Nutr Res, V37, P259, DOI 10.1016/S1043-4526(08)60118-7; Cao JS, 2004, J BIOL CHEM, V279, P18878, DOI 10.1074/jbc.M313272200; CAO SG, 1995, BBA-LIPID LIPID MET, V1256, P97, DOI 10.1016/0005-2760(95)00002-T; Daum G, 1997, PROG LIPID RES, V36, P103, DOI 10.1016/S0163-7827(97)00006-4; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EICHBERG J, 1974, J BIOL CHEM, V249, P3423; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; HALLMAN M, 1980, PEDIATR RES, V14, P1250, DOI 10.1203/00006450-198011000-00020; HARDING PGR, 1983, BIOCHIM BIOPHYS ACTA, V750, P373, DOI 10.1016/0005-2760(83)90042-5; Hatch GM, 1998, INT J MOL MED, V1, P33; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOF H, 1970, LIPIDS, V5, P485, DOI 10.1007/BF02531312; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; LANDS WEM, 1965, J BIOL CHEM, V240, P1905; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Ma BJ, 1999, J LIPID RES, V40, P1837; MAVIS RD, 1981, BIOCHIM BIOPHYS ACTA, V664, P409, DOI 10.1016/0005-2760(81)90063-1; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; MCMURRAY WC, 1986, BIOCHEM CELL BIOL, V64, P1115, DOI 10.1139/o86-147; Mutter T, 2000, BIOCHEM J, V346, P403, DOI 10.1042/0264-6021:3460403; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1986, BIOCHEM J, V240, P247, DOI 10.1042/bj2400247; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SCHLAME M, 1994, J AM COLL CARDIOL, V42, P1994; Taylor WA, 2003, J BIOL CHEM, V278, P12716, DOI 10.1074/jbc.M210329200; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; Valianpour F, 2002, J PEDIATR-US, V141, P729, DOI 10.1067/mpd.2002.129174; VANCE JE, 1985, BIOCH LIPIDS MEMBRAN; VOELKER DR, 1990, EXPERIENTIA, V46, P569, DOI 10.1007/BF01939695; Xu Y, 2003, J BIOL CHEM, V278, P51380, DOI 10.1074/jbc.M307382200; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003	40	167	182	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31727	31734		10.1074/jbc.M402930200	http://dx.doi.org/10.1074/jbc.M402930200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152008	hybrid			2022-12-25	WOS:000222726800098
J	Daubenspeck, JM; Zeng, HD; Chen, P; Dong, SL; Steichen, CT; Krishna, NR; Pritchard, DG; Turnbough, CL				Daubenspeck, JM; Zeng, HD; Chen, P; Dong, SL; Steichen, CT; Krishna, NR; Pritchard, DG; Turnbough, CL			Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE LIGANDS; GENE-EXPRESSION; SPORES; PROTEINS; CEREUS; SUBTILIS; IDENTIFICATION; BACTERIAL; HYDRAZINOLYSIS; TRANSCRIPTION	Spores of Bacillus anthracis, the causative agent of anthrax, are enclosed by a prominent loose fitting layer called the exosporium. The exosporium consists of a basal layer and an external hairlike nap. The filaments of the nap are composed of a highly immunogenic glycoprotein called BclA, which has a long, central collagen-like region with multiple XXG repeats. Most of the triplet repeats are PTG, and nearly all of the triplet repeats contain a threonine residue, providing multiple potential sites for O-glycosylation. In this study, we demonstrated that two O-linked oligosaccharides, a 715-Da tetrasaccharide and a 324-Da disaccharide, are released from spore- and exosporium-associated BclA by hydrazinolysis. Each oligosaccharide is probably attached to BclA through a GalNAc linker, which was lost during oligosaccharide release. We found that multiple copies of the tetrasaccharide are linked to the collagen-like region of BclA, whereas the disaccharide may be attached outside of this region. Using NMR, mass spectrometry, and other analytical techniques, we determined that the structure of the tetrasaccharide is 2-O-methyl-4-(3-hydroxy-3-methylbutamido)-4,6- dideoxy-beta-D-glucopyranosyl-(1-->3)-alpha-L-rhamnopyranosyl( 1-->3)-alpha-L-rhamnopyranosyl-(1-->2)-L- rhamnopyranose. The previously undescribed nonreducing terminal sugar ( i.e. 2-O-methyl-4-(3-hydroxy- 3-methylbutamido)-4,6-dideoxy-D-glucose) was given the trivial name anthrose. Anthrose was not found in spores of either Bacillus cereus or Bacillus thuringiensis, two species that are the most phylogenetically similar to B. anthracis. Thus, anthrose may be useful for species-specific detection of B. anthracis spores or as a new target for therapeutic intervention.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Turnbough, CL (corresponding author), Univ Alabama, Dept Microbiol, BBRB 409,1530 3rd Ave S, Birmingham, AL 35294 USA.	ChuckT@uab.edu			NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050566] Funding Source: NIH RePORTER; NCI NIH HHS [CA13148] Funding Source: Medline; NIAID NIH HHS [AI50566] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEAMAN TC, 1971, J BACTERIOL, V107, P320, DOI 10.1128/JB.107.1.320-324.1971; BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; DAI ZH, 1995, MOL MICROBIOL, V16, P1171, DOI 10.1111/j.1365-2958.1995.tb02340.x; DISCHE Z, 1948, J BIOL CHEM, V175, P595; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; Fox A, 2003, J MICROBIOL METH, V54, P143, DOI 10.1016/S0167-7012(03)00095-2; FOX A, 1993, J CLIN MICROBIOL, V31, P887, DOI 10.1128/JCM.31.4.887-894.1993; GERHARDT P, 1964, J BACTERIOL, V88, P1774, DOI 10.1128/JB.88.6.1774-1789.1964; GERHARDT P, 1967, FED PROC, V26, P1504; HACHISUKA Y, 1966, J BACTERIOL, V91, P2382, DOI 10.1128/JB.91.6.2382-2384.1966; Henriques AO, 2000, METHODS, V20, P95, DOI 10.1006/meth.1999.0909; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KASAI R, 1979, TETRAHEDRON, V35, P1427, DOI 10.1016/0040-4020(79)85038-3; Knurr J, 2003, APPL ENVIRON MICROB, V69, P6841, DOI 10.1128/AEM.69.11.6841-6847.2003; KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/jb.176.3.586-595.1994; KRAMER MJ, 1968, CAN J MICROBIOL, V14, P1297, DOI 10.1139/m68-217; Lai EM, 2003, J BACTERIOL, V185, P1443, DOI 10.1128/JB.185.4.1443-1454.2003; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; Liu HB, 2004, J BACTERIOL, V186, P164, DOI 10.1128/JB.186.1.164-178.2004; MATZ LL, 1970, J BACTERIOL, V101, P196, DOI 10.1128/JB.101.1.196-201.1970; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; Moens S, 1997, ARCH MICROBIOL, V168, P169, DOI 10.1007/s002030050484; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Nicholson WL., 1990, MOL BIOL METHODS BAC, P391, DOI DOI 10.1111/J.1751-1097.1991.TB02087.X; Paidhungat M., 2002, BACILLUS SUBTILIS IT, P537, DOI DOI 10.1128/9781555817992.CH37; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; PATEL TP, 1994, METHOD ENZYMOL, V230, P57; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Priest Fergus G., 1993, P3; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; Saile E, 2002, J BACTERIOL, V184, P370, DOI 10.1128/JB.184.2.370-380.2002; Schmidt MA, 2003, TRENDS MICROBIOL, V11, P554, DOI 10.1016/j.tim.2003.10.004; Steichen C, 2003, J BACTERIOL, V185, P1903, DOI 10.1128/JB.185.6.1903-1910.2003; Suzen S, 1999, J PEPT SCI, V5, P283, DOI 10.1002/(SICI)1099-1387(199906)5:6<283::AID-PSC198>3.0.CO;2-O; Sylvestre P, 2003, J BACTERIOL, V185, P1555, DOI 10.1128/JB.185.5.1555-1563.2003; Sylvestre P, 2002, MOL MICROBIOL, V45, P169, DOI 10.1046/j.1365-2958.2000.03000.x; Todd SJ, 2003, J BACTERIOL, V185, P3373, DOI 10.1128/JB.185.11.3373-3378.2003; Webb GF, 2003, P NATL ACAD SCI USA, V100, P4355, DOI 10.1073/pnas.0830963100; Williams DD, 2004, J BACTERIOL, V186, P566, DOI 10.1128/JB.186.2.566-569.2004; Williams DD, 2003, APPL ENVIRON MICROB, V69, P6288, DOI 10.1128/AEM.69.10.6288-6293.2003	44	165	176	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30945	30953		10.1074/jbc.M401613200	http://dx.doi.org/10.1074/jbc.M401613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152001	hybrid			2022-12-25	WOS:000222726800007
J	Ives, JH; Fung, S; Tiwari, P; Payne, HL; Thompson, CL				Ives, JH; Fung, S; Tiwari, P; Payne, HL; Thompson, CL			Microtubule-associated protein light chain 2 is a stargazin-AMPA receptor complex-interacting protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; MUTANT MOUSE STARGAZER; CHANNEL GAMMA-SUBUNIT; POSTSYNAPTIC DENSITY; REGULATORY PROTEINS; NEUROTROPHIC FACTOR; GABA(A) RECEPTORS; BETA-3 SUBUNITS; CA2+ CHANNEL; RAT-BRAIN	The ataxic mutant mouse stargazer is a null mutant for stargazin, a protein involved in the regulation of cell surface trafficking and synaptic targeting of AMPA receptors. The extreme C terminus of stargazin ( sequence, - TTPV), confers high affinity for PDZ domain-containing proteins e.g. PSD-95. Interaction with PDZ proteins enables stargazin to fulfill its role as an AMPA receptor synaptic targeting molecule but is not essential for its ability to influence AMPA receptor trafficking to the neuronal cell surface. Using the yeast-two hybrid approach we screened for proteins that interact with the intracellular C-terminal tail of stargazin. Positive interactors included PDZ domain-containing proteins e.g. SAP97, SAP102, and PIST. Interestingly, light chain 2 of microtubule-associated protein 1 (LC2), which does not contain a PDZ domain, was also a strong interactor. This was shown to be a direct interaction that occurred upstream of the - TTPV sequence of stargazin. Immunoprecipitations of Triton X-100 soluble cerebellar extracts revealed that LC2 is pulled down not only by anti-stargazin antibodies but also anti-GluR2 antibodies suggesting that stargazin and AMPA receptor subunits associate with LC2. Immunopurified full-length, native stargazin was shown to co-associate not only with GluR2 in vivo but also with full-length, native LC2. Indeed, LC2 co-associates with stargazin when part of a tripartite complex comprising LC2-stargazin-GluR2. Since this complex was extracted using Triton X-100 and was devoid of PSD95, SAP97, and actin we postulate that LC2 is involved in trafficking of AMPA receptors in cerebellar neurons before they are anchored at the synapse.	Univ Durham, Sci Res Labs, Sch Biol & Biomed Sci, Durham DH1 3LE, England	Durham University	Thompson, CL (corresponding author), Univ Durham, Sci Res Labs, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	C.L.Thompson@durham.ac.uk						Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Brenman JE, 1998, J NEUROSCI, V18, P8805; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen L, 1999, P NATL ACAD SCI USA, V96, P12132, DOI 10.1073/pnas.96.21.12132; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Dakoji S, 2003, NEUROPHARMACOLOGY, V45, P849, DOI 10.1016/S0028-3908(03)00267-3; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Ikeda A, 2002, NAT GENET, V30, P401, DOI 10.1038/ng838; Ives JH, 2000, EUR J NEUROSCI, V12, P45; Ives JH, 2002, J NEUROCHEM, V80, P317, DOI 10.1046/j.0022-3042.2001.00700.x; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; LANGKOPF A, 1992, J BIOL CHEM, V267, P16561; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mei X, 2000, BRAIN RES BULL, V53, P801, DOI 10.1016/S0361-9230(00)00416-0; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Noiges R, 2002, J NEUROSCI, V22, P2106, DOI 10.1523/JNEUROSCI.22-06-02106.2002; QIAO X, 1998, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Rousset M, 2001, J PHYSIOL-LONDON, V532, P583, DOI 10.1111/j.1469-7793.2001.0583e.x; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sharp AH, 2001, NEUROSCIENCE, V105, P599, DOI 10.1016/S0306-4522(01)00220-2; Thompson CL, 1998, MOL BRAIN RES, V60, P282, DOI 10.1016/S0169-328X(98)00205-8; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636	40	29	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31002	31009		10.1074/jbc.M402214200	http://dx.doi.org/10.1074/jbc.M402214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15136571	hybrid			2022-12-25	WOS:000222726800013
J	Schwamborn, JC; Fiore, R; Bagnard, D; Kappler, J; Kaltschmidt, C; Puschel, AW				Schwamborn, JC; Fiore, R; Bagnard, D; Kappler, J; Kaltschmidt, C; Puschel, AW			Semaphorin 3A stimulates neurite extension and regulates gene expression in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX REGULATION; GROWTH; APOPTOSIS; DIFFERENTIATION; ACTIVATION; REPULSION; RESPONSES; OXIDANTS; PATHWAY; GTPASES	The secreted semaphorin 3A (Sema3A) is a member of a large family of proteins that act as guidance signals for axons and dendrites. While the receptors and signaling pathways that mediate the repulsive effects of semaphorins are beginning to be understood in some detail, the mechanisms that are responsible for the ability of Sema3A to stimulate the extension of dendrites remain to be elucidated. Here we show that PC12 cells, a model widely used to study neuronal differentiation, can be used to dissect this pathway. Sema3A is as effective as nerve growth factor in stimulating the extension of neurites from PC12 cells. We show that Sema3A is able to regulate gene expression and identify mitochondria as a novel target of Sema3A signaling. Pharmacological block of mitochondrial reactive oxygen species production abolishes the extension of neurites in response to Sema3A. These results show that the characterization of transcripts that are regulated by axon guidance signals may help to identify novel components of their signaling pathways.	Univ Munster, Inst Allgemeine Zool & Genet, D-48149 Munster, Germany; Univ Witten Herdecke, Inst Neurobiochem, D-58448 Witten, Germany; Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany; Ctr Neurochim, INSERM, U Physiopathol Syst Nerveux 575, Grp Physiol Mol Regenerat Nerveuse, F-67084 Strasbourg, France	University of Munster; Witten Herdecke University; University of Bonn; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Puschel, AW (corresponding author), Univ Munster, Inst Allgemeine Zool & Genet, Schlosspl 5, D-48149 Munster, Germany.	apuschel@uni-muenster.de	Schwamborn, Jens C/F-9395-2011; Bagnard, Dominique/I-6535-2013	Schwamborn, Jens C/0000-0003-4496-0559; Bagnard, Dominique/0000-0002-5261-902X				Atwal JK, 2003, J NEUROSCI, V23, P7602; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagnard D, 2004, MOL CELL NEUROSCI, V25, P722, DOI 10.1016/j.mcn.2003.12.007; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Campbell DS, 2003, NEURON, V37, P939, DOI 10.1016/S0896-6273(03)00158-2; Chiarugi P, 2003, TRENDS BIOCHEM SCI, V28, P509, DOI 10.1016/S0968-0004(03)00174-9; Fenstermaker V, 2004, J NEUROBIOL, V58, P403, DOI 10.1002/neu.10304; Fiore R, 2003, FRONT BIOSCI-LANDMRK, V8, pS484, DOI 10.2741/1080; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411; Franken S, 2003, J BIOL CHEM, V278, P3241, DOI 10.1074/jbc.M210181200; Fujioka S, 2003, BIOCHEM BIOPH RES CO, V301, P304, DOI 10.1016/S0006-291X(02)03023-1; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; Ming GL, 2002, NATURE, V417, P411, DOI 10.1038/nature745; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Schwamborn J, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-46; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002	31	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30923	30926		10.1074/jbc.C400082200	http://dx.doi.org/10.1074/jbc.C400082200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155748	hybrid			2022-12-25	WOS:000222726800003
J	Bertoli, G; Simmen, T; Anelli, T; Molteni, SN; Fesce, R; Sitia, R				Bertoli, G; Simmen, T; Anelli, T; Molteni, SN; Fesce, R; Sitia, R			Two conserved cysteine triads in human Ero1 alpha cooperate for efficient disulfide bond formation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ERO1P; ISOMERASE; GENE; ERO1-L-ALPHA; COMPLEXES; YEAST; ERP44; MOTIF; ER	Human Ero1alpha is an endoplasmic reticulum (ER)-resident protein responsible for protein disulfide isomerase (PDI) oxidation. To clarify the molecular mechanisms underlying its function, we generated a panel of cysteine replacement mutants and analyzed their capability of: 1) complementing a temperature-sensitive yeast Ero1 mutant, 2) favoring oxidative folding in mammalian cells, 3) forming mixed disulfides with PDI and ERp44, and 4) adopting characteristic redox-dependent conformations. Our results reveal that two essential cysteine triads (Cys(85)-Cys(94)-Cys(99) and Cys(391)-Cys(394)-Cys(397)) cooperate in electron transfer, with Cys(94) likely forming mixed disulfides with PDI. Dominant negative phenotypes arise when critical residues within the triads are mutated (Cys(394), Cys(397), and to a lesser extent Cys(99)). Replacing the first cysteine in either triad (Cys(85) or Cys(391)) generates mutants with weaker activity. In addition, mutating either Cys(85) or Cys(391), but not Cys(397), reverts the dominant negative phenotype of the C394A mutant. These findings suggest that interactions between the two triads, dependent on Cys(85) and Cys(391), are important for Ero1alpha function, possibly stabilizing a platform for efficient PDI oxidation.	Univ Vita Salute San Raffaele, I-20132 Milan, Italy; San Raffaele Sci Inst, Dept Biol & Technol, Milan, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Sitia, R (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.	r.sitia@hsr.it	Bertoli, Gloria/J-6559-2016; fesce, riccardo/A-6317-2008; Sitia, Roberto/AAB-5005-2019; Anelli, Tiziana/AAN-3717-2020	Bertoli, Gloria/0000-0002-5901-4269; Sitia, Roberto/0000-0001-7086-4152; Anelli, Tiziana/0000-0002-9159-9164; fesce, riccardo/0000-0001-9473-896X	Telethon [GP0117Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Anelli T, 2003, EMBO J, V22, P5015, DOI 10.1093/emboj/cdg491; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; CLACKSON T, 1989, NUCLEIC ACIDS RES, V17, P10163, DOI 10.1093/nar/17.24.10163; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Frand AR, 2000, MOL BIOL CELL, V11, P2833, DOI 10.1091/mbc.11.9.2833; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pagani M, 2001, FEBS LETT, V508, P117, DOI 10.1016/S0014-5793(01)03034-4; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Woycechowsky KJ, 2003, BIOCHEMISTRY-US, V42, P5387, DOI 10.1021/bi026993q	24	46	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30047	30052		10.1074/jbc.M403192200	http://dx.doi.org/10.1074/jbc.M403192200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136577	hybrid			2022-12-25	WOS:000222531900023
J	Nishitani, H; Lygerou, Z; Nishimoto, T				Nishitani, H; Lygerou, Z; Nishimoto, T			Proteolysis of DNA replication licensing factor Cdt1 in S-phase is performed independently of Geminin through its N-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ORIGIN RECOGNITION COMPLEX; CELL-CYCLE; BUDDING YEAST; FISSION YEAST; CDK PHOSPHORYLATION; MCM PROTEINS; CHROMATIN ASSOCIATION; MEDIATED PROTEOLYSIS; HELICASE ACTIVITY	Licensing of replication origins is carefully regulated in a cell cycle to maintain genome integrity. Using an in vivo ubiquitination assay and temperature-sensitive cell lines we demonstrate that Cdt1 in mammalian cells is degraded through ubiquitin-dependent proteolysis in S-phase. siRNA experiments for Geminin indicate that Cdt1 is degraded in the absence of Geminin. The N terminus of Cdt1 is required for its nuclear localization, associates with cyclin A, but is dispensable for the association of Cdt1 with Geminin in cells. This region is responsible for proteolysis of Cdt1 in S-phase. On the other hand, the N terminus-truncated Cdt1 is stable in S-phase, and associates with the licensing inhibitor, Geminin. High level expression of this form of Cdt1 brings about cells having higher DNA content. Proteasome inhibitors stabilize Cdt1 in S-phase, and the protein is detected in the nucleus in a complex with Geminin. This form of Cdt1 associates with chromatin as tightly as that of G1-cells, when no Geminin is detected. Our data show that proteolysis and Geminin binding independently inactivate Cdt1 after the onset of S-phase to prevent re-replication.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Univ Patras, Sch Med, Lab Gen Biol, Patras 26500, Greece	Kyushu University; University of Patras	Nishitani, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	hideon@molbiol.med.kyushu-u.ac.jp		Nishitani, Hideo/0000-0001-5907-9380				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Coverley D, 2000, J CELL SCI, V113, P1929; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; FUJITA M, 1999, FRONT BIOSCI, V4, P816; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Homesley L, 2000, GENE DEV, V14, P913; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jares P, 2000, GENE DEV, V14, P1528; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1992, BIOCHEM BIOPH RES CO, V184, P1015, DOI 10.1016/0006-291X(92)90692-E; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Zhang YX, 2002, CELL, V109, P849, DOI 10.1016/S0092-8674(02)00805-X; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	63	93	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30807	30816		10.1074/jbc.M312644200	http://dx.doi.org/10.1074/jbc.M312644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138268	hybrid			2022-12-25	WOS:000222531900112
J	Zhang, L; Keane, MP; Zhu, LX; Sharma, S; Rozengurt, E; Strieter, RM; Dubinett, SM; Huang, M				Zhang, L; Keane, MP; Zhu, LX; Sharma, S; Rozengurt, E; Strieter, RM; Dubinett, SM; Huang, M			Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; PATHWAY; SMAD3; CELLS; CD40; IL-2	Transforming growth factor-beta (TGF-beta) is a potent fibrogenic factor responsible for promoting synthesis of extracellular matrix. Interleukin-7 (IL-7) inhibits TGF-beta signaling by up-regulating Smad7, a major inhibitor of the Smad family. In a variety of cells, TGF-beta-mediated activation of target genes requires active protein kinase C-delta (PKC-delta) in addition to Smads (1). We determined the role of PKC-delta in the regulation of pulmonary fibroblast collagen synthesis in response to TGF-beta and IL-7 stimulation. Here we show that TGF-beta and IL-7 have opposing effects on PKC-delta; TGF-beta stimulates, while IL-7 inhibits, PKC-delta activity. IL-7 inhibits TGF-beta-induced PKC-delta phosphorylation at Ser-645 and Thr-505. Inhibition of PKC-delta with specific small inhibitory RNA restores TGF-beta-mediated induction of Smad7 and in parallel significantly reduces TGF-beta-mediated collagen synthesis. Thus, PKC-delta may play a critical role in the pathogenesis of pulmonary fibrosis and may serve as a molecular target for therapeutic intervention to suppress fibrosis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Huang, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.	minhuang@mednet.ucla.edu			NCI NIH HHS [P50 CA 90388, R01 CA 085686] Funding Source: Medline; NHLBI NIH HHS [P50 HL 67665, P01 HL 03906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388, R01CA085686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067665] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bloor CA, 2001, AM J RESP CRIT CARE, V164, P265, DOI 10.1164/ajrccm.164.2.2003114; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; HUANG M, 1990, ARCH BIOCHEM BIOPHYS, V277, P296, DOI 10.1016/0003-9861(90)90582-J; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; Kaufman J, 2004, J IMMUNOL, V172, P1862, DOI 10.4049/jimmunol.172.3.1862; Keane MP, 1997, J IMMUNOL, V159, P1437; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kucich U, 2002, AM J RESP CELL MOL, V26, P183, DOI 10.1165/ajrcmb.26.2.4666; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI WQ, 1994, J BIOL CHEM, V269, P2349; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sheppard D, 2001, J CLIN INVEST, V107, P1501, DOI 10.1172/JCI13318; Xiao H, 2002, J BIOL CHEM, V277, P8091, DOI 10.1074/jbc.M106650200; Zhao Y, 2002, BIOCHEM BIOPH RES CO, V294, P319, DOI 10.1016/S0006-291X(02)00471-0	21	49	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28315	28319		10.1074/jbc.C400115200	http://dx.doi.org/10.1074/jbc.C400115200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15133032	hybrid			2022-12-25	WOS:000222265400063
J	Mitchell, SM; Lee, E; Garcia, ML; Stephan, MM				Mitchell, SM; Lee, E; Garcia, ML; Stephan, MM			Structure and function of extracellular loop 4 of the serotonin transporter as revealed by cysteine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE TRANSPORTER; MEGAPRIMER METHOD; MONOAMINE TRANSPORTERS; TRANSMEMBRANE DOMAIN; EXPRESSION SYSTEM; ESCHERICHIA-COLI; PROLINE RESIDUES; LACTOSE PERMEASE; BINDING; ACID	Residues 386-423 of the rat brain serotonin transporter (SERT) are predicted to form a hydrophilic loop connecting transmembrane spans 7 and 8 (extracellular loop 4 or EL4). EL4 has been hypothesized to play a role in conformational changes associated with substrate translocation. To more fully investigate EL4 structure and function, we performed cysteine-scanning mutagenesis and methanethiosulfonate (MTS) accessibility studies on these 38 residues. Four EL4 mutants (M386C, R390C, G402C, and L405C) showed very low transport activities, low cell surface expression, and strong inhibition by MTS reagents, indicating high structural and functional importance. Twelve mutants were sensitive to very low MTS concentrations, indicating positions highly exposed to the aqueous environment. Eleven mutants were MTS-insensitive, indicating positions that were either buried in EL4 structure or functionally unimportant. The patterns of sensitivity to mutation and MTS reagents were used to produce a structural model of EL4. Positions 386-399 and 409-421 are proposed to form alpha-helices, connected by nine consecutive MTS-sensitive positions, within which four positions, 402-405, may form a turn or hinge. The presence of serotonin changed the MTS accessibility of cysteines at nine positions, while cocaine, a non-transportable blocker, did not affect accessibility. Serotonin-induced accessibility changes required both Na+ and Cl-, indicating that they were associated with active substrate translocation. With the exception of a single mutant, F407C, neither mutation to cysteine nor treatment with MTS reagents affected SERT affinities for serotonin or the cocaine analog beta-CIT. These studies support the role of EL4 in conformational changes occurring during translocation and show that it does not play a direct role in serotonin binding.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Stephan, MM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.	megan.stephan@yale.edu			NIDA NIH HHS [DA12408, DA12586] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012586, P01DA012408] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BARIK S, 1991, BIOTECHNIQUES, V10, P489; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chou KC, 2000, ANAL BIOCHEM, V286, P1, DOI 10.1006/abio.2000.4757; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LANGER SZ, 1988, PROG NEURO-PSYCHOPH, V12, P193, DOI 10.1016/0278-5846(88)90037-1; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; MEINILD AK, 2003, ANN M SOC NEUR NEW O; Norregaard L, 2003, J BIOL CHEM, V278, P30587, DOI 10.1074/jbc.M303854200; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Penado KMY, 1998, J BIOL CHEM, V273, P28098, DOI 10.1074/jbc.273.43.28098; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; Saier MH, 1999, J CELL BIOCHEM, P84; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; TATE CG, 1994, J BIOL CHEM, V269, P26303; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2003, BIOCHEMISTRY-US, V42, P6784, DOI 10.1021/bi0273415; WALL SC, 1993, MOL PHARMACOL, V43, P264; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; Yan BX, 1997, J BIOL CHEM, V272, P3190, DOI 10.1074/jbc.272.6.3190; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200	40	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24089	24099		10.1074/jbc.M311173200	http://dx.doi.org/10.1074/jbc.M311173200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15140876	hybrid			2022-12-25	WOS:000221702500031
J	van Wijnen, AJ; Stein, GS; Gergen, JP; Groner, Y; Hiebert, SW; Ito, Y; Liu, P; Neil, JC; Ohki, M; Speck, N				van Wijnen, AJ; Stein, GS; Gergen, JP; Groner, Y; Hiebert, SW; Ito, Y; Liu, P; Neil, JC; Ohki, M; Speck, N			Nomenclature for Runt-related (RUNX) proteins	ONCOGENE			English	Article									Inst Mol & Cell Biol, Mol & Cell Biol & Oncol Res Inst, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Ito, Y (corresponding author), Inst Mol & Cell Biol, Mol & Cell Biol & Oncol Res Inst, 30 Med Dr, Singapore 117609, Singapore.	itoy@imcb.nus.edu.sg	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))			0	91	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4209	4210		10.1038/sj.onc.1207758	http://dx.doi.org/10.1038/sj.onc.1207758			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156174				2022-12-25	WOS:000221586000003
J	Fiedler, M; Muller-Holzner, E; Viertler, HP; Widschwendter, A; Laich, A; Pfister, G; Spoden, GA; Jansen-Durr, P; Zwerschke, W				Fiedler, M; Muller-Holzner, E; Viertler, HP; Widschwendter, A; Laich, A; Pfister, G; Spoden, GA; Jansen-Durr, P; Zwerschke, W			High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies	FASEB JOURNAL			English	Article						cervical cancer; retinoblastoma protein; SIL; anti-HPV 16 E7 antibodies	HUMAN-PAPILLOMAVIRUS TYPE-16; RISK HUMAN-PAPILLOMAVIRUS; RETINOBLASTOMA GENE-PRODUCT; MONKEY COS-1 CELLS; CARCINOMA CELLS; TRANSFORMING ACTIVITY; PEPTIDE APTAMERS; BINDING-PROTEIN; GROWTH ARREST; CANCER-CELLS	High-risk human papillomaviruses (HPVs) are major etiological agents of cervical cancer. Despite excellent epidemiological evidence for a direct role of HPV-16 in cervical carcinogenesis, molecular pathways underlying carcinogenesis in vivo remain obscure. The E7 gene is required for immortalization and maintenance of the transformed phenotype in vitro; however, little is known about its role for tumorigenesis in vivo. The E7 gene codes for an unstable protein the abundance of which in cervical biopsies is unknown. We show here that E7 protein levels strongly increase during cervical carcinogenesis, underlining its fundamental role in cervical cancer. The E7 protein was found predominantly in the nucleus and to a minor extent in the cytoplasm in the cervical cancer cell line Ca Ski in vitro and in invasive cervical carcinoma in situ, suggesting that nuclear resident E7 plays a major role in cervical carcinogenesis in humans. The retinoblastoma protein (pRb) is a major E7-target in vitro. We show here that pRb expression is initially upregulated in LSIL and disappears in later stages concomitant with increased E7 levels, suggesting that E7-driven degradation of pRb is involved in cervical tumorigenesis in humans.	Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria	University of Innsbruck; Austrian Academy of Sciences; University of Innsbruck	Zwerschke, W (corresponding author), Univ Innsbruck, Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	werner.zwerschke@uklibk.ac.at	Fiedler, Marc/ABD-5356-2021; Jansen-Dürr, Pidder/ABG-2466-2020	Fiedler, Marc/0000-0003-4269-7873; Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953; Pfister, Gerald/0000-0003-4928-6612				Angeline M, 2003, VIROLOGY, V317, P13, DOI 10.1016/j.virol.2003.08.024; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Boyer SN, 1996, CANCER RES, V56, P4620; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1992, INT J CANCER, V51, P831; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FUJIKAWA K, 1994, VIROLOGY, V204, P789, DOI 10.1006/viro.1994.1594; Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harlow E., 1999, USING ANTIBODIES LAB; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HOWLEY PM, 2001, FIELDS VIROLOGY, V2; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KANDA T, 1991, VIROLOGY, V182, P723, DOI 10.1016/0042-6822(91)90613-G; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; Kehmeier E, 2002, VIROLOGY, V299, P72, DOI 10.1006/viro.2002.1502; KOSS LG, 1987, CANCER-AM CANCER SOC, V60, P1942, DOI 10.1002/1097-0142(19901015)60:8+<1942::AID-CNCR2820601504>3.0.CO;2-V; Kristensen GB, 1999, GYNECOL ONCOL, V74, P245, DOI 10.1006/gyno.1999.5420; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Munoz N, 2000, J CLIN VIROL, V19, P1, DOI 10.1016/S1386-6532(00)00125-6; Nauenburg S, 2001, FASEB J, V15, P592; Nobbenhuis MAE, 2001, LANCET, V358, P1782, DOI 10.1016/S0140-6736(01)06809-X; OLTERSDORF T, 1987, J GEN VIROL, V68, P2933, DOI 10.1099/0022-1317-68-11-2933; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rey O, 2000, VIROLOGY, V268, P372, DOI 10.1006/viro.1999.0175; Salcedo M, 2002, INT J EXP PATHOL, V83, P275, DOI 10.1046/j.1365-2613.2002.00198.x; Sano T, 1998, PATHOL INT, V48, P580, DOI 10.1111/j.1440-1827.1998.tb03954.x; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Stanley MA, 2001, J REPROD IMMUNOL, V52, P45, DOI 10.1016/S0165-0378(01)00113-9; STEGNER HE, 1986, INT J GYNECOL PATHOL, V5, P23, DOI 10.1097/00004347-198603000-00003; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Wheatley SP, 1998, METHOD CELL BIOL, V57, P313; WILCZYNSKI SP, 1988, HUM PATHOL, V19, P697, DOI 10.1016/S0046-8177(88)80176-X; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	64	46	60	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2004	18	7					1120	+		10.1096/fj.03-1332fje	http://dx.doi.org/10.1096/fj.03-1332fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155561				2022-12-25	WOS:000221883200008
J	Rosen, ML; Edman, M; Sjostrom, M; Wieslander, A				Rosen, ML; Edman, M; Sjostrom, M; Wieslander, A			Recognition of fold and sugar linkage for glycosyltransferases by multivariate sequence analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPORT VECTOR MACHINES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BLOOD-GROUP; GLYCOSIDE HYDROLASES; CATALYTIC DOMAIN; PROTEIN; COMPLEX; BIOSYNTHESIS; PREDICTION	Glycosyltransferases (GTs) are among the largest groups of enzymes found and are usually classified on the basis of sequence comparisons into many families of varying similarity (CAZy systematics). Only two different Rossman-like folds have been detected (GT-A and GT-B) within the small number of established crystal structures. A third uncharacterized fold has been indicated with transmembrane organization (GT-C). We here use a method based on multivariate data analyses (MVDAs) of property patterns in amino acid sequences and can with high accuracy recognize the correct fold in a large data set of GTs. Likewise, a retaining or inverting enzymatic mechanism for attachment of the donor sugar could be properly revealed in the GT-A and GT-B fold group sequences by such analyses. Sequence alignments could be correlated to important variables in MVDA, and the separating amino acid positions could be mapped over the active sites. These seem to be localized to similar positions in space for the alpha/beta/alpha binding motifs in the GT-B fold group structures. Analogous, active-site sequence positions were found for the GT-A fold group. Multivariate property patterns could also easily group most GTs annotated in the genomes of Escherichia coli and Synechocystis to proper fold or organization group, according to bench-marking comparisons at the MetaServer. We conclude that the sequence property patterns revealed by the multivariate analyses seem more conserved than amino acid types for these GT groups, and these patterns are also conserved in the structures. Such patterns may also potentially define substrate preferences.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Umea Univ, Chemometr Res Grp, Dept Chem, SE-90187 Umea, Sweden	Stockholm University; Umea University	Wieslander, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	ake@dbb.su.se						Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boix E, 2001, J BIOL CHEM, V276, P48608, DOI 10.1074/jbc.M108828200; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Branden C., 1999, INTRO PROTEIN STRUCT; Breton C, 2001, BIOCHIMIE, V83, P713, DOI 10.1016/S0300-9084(01)01298-6; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Cai YD, 2003, PEPTIDES, V24, P159, DOI 10.1016/S0196-9781(02)00289-9; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chou KC, 2002, J BIOL CHEM, V277, P45765, DOI 10.1074/jbc.M204161200; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Edman M, 1999, PROTEINS, V35, P195, DOI 10.1002/(SICI)1097-0134(19990501)35:2<195::AID-PROT6>3.3.CO;2-G; Edman M, 2003, J BIOL CHEM, V278, P8420, DOI 10.1074/jbc.M211492200; Eriksson L, MULTI MEGAVARIATE DA; Franco OL, 2003, GLYCOBIOLOGY, V13, P707, DOI 10.1093/glycob/cwg098; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GEBLER J, 1992, J BIOL CHEM, V267, P12559; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Heissigerova H, 2003, GLYCOBIOLOGY, V13, P377, DOI 10.1093/glycob/cwg042; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; HORNE DS, 1988, BIOPOLYMERS, V27, P451, DOI 10.1002/bip.360270308; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Kikuchi N, 2003, BIOCHEM BIOPH RES CO, V310, P574, DOI 10.1016/j.bbrc.2003.09.031; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; Mulichak AM, 2003, P NATL ACAD SCI USA, V100, P9238, DOI 10.1073/pnas.1233577100; Mulichak AM, 2001, STRUCTURE, V9, P547, DOI 10.1016/S0969-2126(01)00616-5; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Rackovsky S, 1998, P NATL ACAD SCI USA, V95, P8580, DOI 10.1073/pnas.95.15.8580; SJOSTROM M, 1995, CHEMOMETR INTELL LAB, V29, P295, DOI 10.1016/0169-7439(95)00059-1; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Wimmerova M, 2003, BIOCHIMIE, V85, P691, DOI 10.1016/S0300-9084(03)00120-2; Wold S, 1998, ACTA CHEM SCAND, V52, P517, DOI 10.3891/acta.chem.scand.52-0517; WOLD S, 1993, ANAL CHIM ACTA, V277, P239, DOI 10.1016/0003-2670(93)80437-P; Wold S., 2002, ENCY COMPUTATIONAL C, P79, DOI [10.1002/0470845015, 10.1002/0470845015.cpa012, DOI 10.1002/0470845015.CPA012]	47	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38683	38692		10.1074/jbc.M402925200	http://dx.doi.org/10.1074/jbc.M402925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15148316	hybrid			2022-12-25	WOS:000223684100077
J	Chaudhry, HW; Dashoush, NH; Tang, HY; Zhang, L; Wang, XY; Wu, EX; Wolgemuth, DJ				Chaudhry, HW; Dashoush, NH; Tang, HY; Zhang, L; Wang, XY; Wu, EX; Wolgemuth, DJ			Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-SYNTHESIS; GROWTH-FACTORS; CARDIAC MYOCYTES; ADULT MYOCARDIUM; EXPRESSION; OVEREXPRESSION; DIFFERENTIATION; PROTOONCOGENES; LOCALIZATION	Cell cycle withdrawal limits proliferation of adult mammalian cardiomyocytes. Therefore, the concept of stimulating myocyte mitotic divisions has dramatic implications for cardiomyocyte regeneration and hence, cardiovascular disease. Previous reports describing manipulation of cell cycle proteins have not shown induction of cardiomyocyte mitosis after birth. We now report that cyclin A2, normally silenced in the postnatal heart, induces cardiac enlargement because of cardiomyocyte hyperplasia when constitutively expressed from embryonic day 8 into adulthood. Cardiomyocyte hyperplasia during adulthood was coupled with an increase in cardiomyoctye mitosis, noted in transgenic hearts at all time points examined, particularly during postnatal development. Several stages of mitosis were observed within cardiomyocytes and correlated with the nuclear localization of cyclin A2. Magnetic resonance analysis confirmed cardiac enlargement. These results reveal a previously unrecognized critical role for cyclin A2 in mediating cardiomyocyte mitosis, a role that may significantly impact upon clinical treatment of damaged myocardium.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Chaudhry, HW (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 622 W 168th St, New York, NY 10032 USA.	hwc7@columbia.edu	Wu, Ed/C-1579-2009	Wu, Ed/0000-0001-5581-1546	NHLBI NIH HHS [K08 HL067048] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; BASI G, 1995, MOL CELL BIOL, V15, P2028; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BEINLICH CJ, 1993, MOL CELL BIOCHEM, V119, P3, DOI 10.1007/BF00926846; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Bianchi C, 2001, CIRCULATION, V104, pI319; Brooks G, 1998, CARDIOVASC RES, V39, P301, DOI 10.1016/S0008-6363(98)00125-4; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2261, DOI 10.1006/jmcc.1997.0471; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; JACKSON T, 1990, MOL CELL BIOL, V10, P3709, DOI 10.1128/MCB.10.7.3709; Kajstura J, 2000, AM J PATHOL, V156, P813, DOI 10.1016/S0002-9440(10)64949-8; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Leri A, 2000, J MOL CELL CARDIOL, V32, P385, DOI 10.1006/jmcc.1999.1084; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liao HS, 2001, CIRC RES, V88, P443; MENDEZ J, 1960, METABOLISM, V9, P184; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Poolman RA, 1998, INT J CARDIOL, V67, P133, DOI 10.1016/S0167-5273(98)00320-9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Rumyantsev PP., 1991, GROWTH HYPERPLASIA C; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; Slawson SE, 1998, MAGN RESON MED, V39, P980, DOI 10.1002/mrm.1910390616; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1997, J CLIN INVEST, V99, P2644, DOI 10.1172/JCI119453; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Tang HY, 2000, ANN NY ACAD SCI, V904, P32; Wei L, 2002, DEVELOPMENT, V129, P1705; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wiesmann F, 2000, AM J PHYSIOL-HEART C, V278, pH652, DOI 10.1152/ajpheart.2000.278.2.H652; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	43	143	150	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35858	35866		10.1074/jbc.M404975200	http://dx.doi.org/10.1074/jbc.M404975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15159393	hybrid			2022-12-25	WOS:000223303400087
J	Song, MY; Kim, HJ; Kim, EY; Shin, MS; Lee, HC; Hong, YJ; Rhee, JH; Yoon, H; Ryu, S; Lim, S; Choy, HE				Song, MY; Kim, HJ; Kim, EY; Shin, MS; Lee, HC; Hong, YJ; Rhee, JH; Yoon, H; Ryu, S; Lim, S; Choy, HE			ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTERICA SEROVAR TYPHIMURIUM; RIBONUCLEIC ACID SYNTHESIS; ARAC/XYLS FAMILY-MEMBERS; ALTERNATIVE SIGMA-FACTOR; ESCHERICHIA-COLI; INVASION GENES; GUANOSINE TETRAPHOSPHATE; HISTIDINE OPERON; HILA EXPRESSION; III SECRETION	We have examined expression of the genes on Salmonella pathogenicity island 1 (SPI1) during growth under the physiologically well defined standard growth condition of Luria-Bertani medium with aeration. We found that the central regulator hilA and the genes under its control are expressed at the onset of stationary phase. Interestingly, the two-component regulatory genes hilC/ hilD, sirA/barA, and ompR, which are known to modulate expression from the hilA promoter (hilAp) under so-called "inducing conditions" (Luria-Bertani medium containing 0.3 M NaCl without aeration), acted under standard conditions at the stationary phase induction level. The induction of hilAp depended not on RpoS, the stationary phase sigma factor, but on the stringent signal molecule ppGpp. In the ppGpp null mutant background, hilAp showed absolutely no activity. The stationary phase induction of hilAp required spoT but not relA. Consistent with this requirement, hilAp was also induced by carbon source deprivation, which is known to transiently elevate ppGpp mediated by spoT function. The observation that amino acid starvation elicited by the addition of serine hydroxamate did not induce hilAp in a RelA(+) SpoT(+) strain suggested that, in addition to ppGpp, some other alteration accompanying entry into the stationary phase might be necessary for induction. It is speculated that during the course of infection Salmonella encounters various stressful environments that are sensed and translated to the intracellular signal, ppGpp, which allows expression of Salmonella virulence genes, including SPI1 genes.	Chonnam Natl Univ, Coll Med, Genome Res Ctr Enteropathogen Bacteria, Kwangju 501746, South Korea; Chonnam Natl Univ, Coll Med, Res Inst Vibrio Infect, Kwangju 501746, South Korea; Chonnam Natl Univ, Coll Med, Dept Microbiol, Kwangju 501746, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Sch Agr Biotechnol, Dept Food Sci & Technol, Seoul 151742, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Seoul National University (SNU)	Choy, HE (corresponding author), Chonnam Natl Univ, Coll Med, Genome Res Ctr Enteropathogen Bacteria, Kwangju 501746, South Korea.	hyonchoy@chonnam.ac.kr		Shin, Minsang/0000-0001-8679-446X				Akbar S, 2003, MOL MICROBIOL, V47, P715, DOI 10.1046/j.1365-2958.2003.03322.x; Altier C, 2000, MOL MICROBIOL, V35, P635, DOI 10.1046/j.1365-2958.2000.01734.x; Altier C, 2000, INFECT IMMUN, V68, P6790, DOI 10.1128/IAI.68.12.6790-6797.2000; Bajaj V, 1996, MOL MICROBIOL, V22, P703, DOI 10.1046/j.1365-2958.1996.d01-1718.x; Bang IS, 2000, J BACTERIOL, V182, P2245, DOI 10.1128/JB.182.8.2245-2252.2000; Bang IS, 2002, MOL MICROBIOL, V44, P1235, DOI 10.1046/j.1365-2958.2002.02937.x; CARTER PB, 1974, J EXP MED, V139, P1189, DOI 10.1084/jem.139.5.1189; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1968, J MOL BIOL, V34, P317, DOI 10.1016/0022-2836(68)90256-8; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; DaCosta XJ, 1997, J BACTERIOL, V179, P5211, DOI 10.1128/jb.179.16.5211-5217.1997; Darwin KH, 1999, J BACTERIOL, V181, P4949; Darwin KH, 2000, MOL MICROBIOL, V35, P949, DOI 10.1046/j.1365-2958.2000.01772.x; Darwin KH, 2001, EMBO J, V20, P1850, DOI 10.1093/emboj/20.8.1850; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davis R., 1980, ADV BACTERIAL GENETI; DEBOER HA, 1976, BIOCHIM BIOPHYS ACTA, V432, P361, DOI 10.1016/0005-2787(76)90146-5; Eichelberg K, 1999, MOL MICROBIOL, V33, P139, DOI 10.1046/j.1365-2958.1999.01458.x; Fahlen TF, 2001, J BACTERIOL, V183, P6620, DOI 10.1128/JB.183.22.6620-6629.2001; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FRIESEN JD, 1975, J BIOL CHEM, V250, P304; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; HANSEN MT, 1975, J BACTERIOL, V122, P585, DOI 10.1128/JB.122.2.585-591.1975; HARSHMAN RB, 1971, BIOCHEMISTRY-US, V10, P3980, DOI 10.1021/bi00797a027; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; Heyde M, 2000, J BACTERIOL, V182, P198, DOI 10.1128/JB.182.1.198-202.2000; HOHMANN AW, 1978, INFECT IMMUN, V22, P763, DOI 10.1128/IAI.22.3.763-770.1978; Hong KH, 1998, J BACTERIOL, V180, P1793, DOI 10.1128/JB.180.7.1793-1802.1998; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Humphreys S, 1999, INFECT IMMUN, V67, P1560; ISHIGURO EE, 1979, CAN J MICROBIOL, V25, P1206, DOI 10.1139/m79-188; Johnston C, 1996, MOL MICROBIOL, V22, P715, DOI 10.1046/j.1365-2958.1996.d01-1719.x; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAGOSKY PA, 1980, J BACTERIOL, V144, P499, DOI 10.1128/JB.144.2.499-508.1980; Lawhon SD, 2003, MOL MICROBIOL, V48, P1633, DOI 10.1046/j.1365-2958.2003.03535.x; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; Lindgren SW, 1996, P NATL ACAD SCI USA, V93, P4197, DOI 10.1073/pnas.93.9.4197; Lucas RL, 2000, MOL MICROBIOL, V36, P1024, DOI 10.1046/j.1365-2958.2000.01961.x; Lucas RL, 2001, J BACTERIOL, V183, P2733, DOI 10.1128/JB.183.9.2733-2745.2001; Lundberg U, 1999, J BACTERIOL, V181, P3433, DOI 10.1128/JB.181.11.3433-3437.1999; Magnusson LU, 2003, J BIOL CHEM, V278, P968, DOI 10.1074/jbc.M209881200; Marcus SL, 2000, MICROBES INFECT, V2, P145, DOI 10.1016/S1286-4579(00)00273-2; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; Murray KD, 1996, J MOL BIOL, V259, P41; Murray RA, 2000, INFECT IMMUN, V68, P5050, DOI 10.1128/IAI.68.9.5050-5055.2000; Olekhnovich IN, 2002, J BACTERIOL, V184, P4148, DOI 10.1128/JB.184.15.4148-4160.2002; PRATT LA, 1995, MOL MICROBIOL, V17, P565, DOI 10.1111/j.1365-2958.1995.mmi_17030565.x; PUTNAM SL, 1975, ANAL BIOCHEM, V63, P350, DOI 10.1016/0003-2697(75)90357-7; Rakeman JL, 1999, J BACTERIOL, V181, P3096, DOI 10.1128/JB.181.10.3096-3104.1999; RYALS J, 1982, J BACTERIOL, V151, P1425, DOI 10.1128/JB.151.3.1425-1432.1982; SANDS MK, 1952, J BACTERIOL, V63, P505, DOI 10.1128/JB.63.4.505-511.1952; Schechter LM, 1999, MOL MICROBIOL, V32, P629, DOI 10.1046/j.1365-2958.1999.01381.x; Schechter LM, 2003, INFECT IMMUN, V71, P5432, DOI 10.1128/IAI.71.9.5432-5435.2003; Schechter LM, 2001, MOL MICROBIOL, V40, P1289, DOI 10.1046/j.1365-2958.2001.02462.x; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; Shin D, 2001, J BIOL CHEM, V276, P25871, DOI 10.1074/jbc.M101757200; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Tedin K, 2001, J BACTERIOL, V183, P6184, DOI 10.1128/JB.183.21.6184-6196.2001; Testerman TL, 2002, MOL MICROBIOL, V43, P771, DOI 10.1046/j.1365-2958.2002.02787.x; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; Wilson RL, 2001, MOL MICROBIOL, V39, P79, DOI 10.1046/j.1365-2958.2001.02192.x; XIAO H, 1991, J BIOL CHEM, V266, P5980	68	108	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34183	34190		10.1074/jbc.M313491200	http://dx.doi.org/10.1074/jbc.M313491200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15161921	hybrid			2022-12-25	WOS:000223134800016
J	Cen, S; Guo, F; Niu, MJ; Saadatmand, J; Deflassieux, J; Kleiman, L				Cen, S; Guo, F; Niu, MJ; Saadatmand, J; Deflassieux, J; Kleiman, L			The interaction between HIV-1 Gag and APOBEC3G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIF PROTEIN BINDS; SOR GENE-PRODUCT; TYPE-1 VIF; CYTIDINE DEAMINASE; HTLV-III/LAV; ANTIVIRAL ACTIVITY; ENZYME APOBEC3G; EDITING ENZYME; RNA-BINDING	APOBEC3G, a member of an RNA/DNA cytidine deaminase superfamily, has been identified as a cellular inhibitor of HIV-1 infectivity, possibly through the dC to dU deamination of the first minus strand cDNA synthesized during reverse transcription. Virions incorporate APOBEC3G during viral assembly in non-permissive cells, and this incorporation is inhibited by the viral protein Vif. The mechanism of APOBEC3G incorporation into HIV-1 is examined in this report. In the absence of Vif, cytoplasmic APOBEC3G becomes membrane-bound in cells expressing HIV-1 Gag, and its incorporation into Gag viral-like particles (VLPs) is proportional to the amount of APOBEC3G expressed in the cell. The expression of Vif, or mutant Gag unable to bind to membrane, prevents the APOBEC3G association with membrane. HIV-1 Gag alone among viral proteins is sufficient for packaging of APOBEC3G into Gag VLPs, and this incorporation requires the presence of Gag nucleocapsid. The presence of amino acids 104 - 156 in APOBEC3G, located in the linker region between two zinc coordination motifs, is also required for its incorporation into Gag VLPs. Evidence against an RNA bridge facilitating the Gag/APOBEC3G interaction includes data indicating that 1) the incorporation of APOBEC3G occurs independently of viral genomic RNA, 2) a Gag/APOBEC3G complex is immunoprecipitated from cell lysate after RNase treatment, and 3) the zinc coordination motif, rather than the regions flanking this motif, have been implicated in RNA binding in another family member, APOBEC1.	Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Cen, S (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	shan.cen@staff.mcgill.ca; Lawrence.Kleiman@mcgill.ca		Guo, Fei/0000-0003-3500-1006				Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Cen S, 2004, J VIROL, V78, P1042, DOI 10.1128/JVI.78.2.1042-1049.2004; Chatterji U, 2000, J VIROL, V74, P2533, DOI 10.1128/JVI.74.6.2533-2540.2000; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; Halwani R, 2003, J VIROL, V77, P3973, DOI 10.1128/JVI.77.7.3973-3984.2003; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KAN NC, 1986, SCIENCE, V231, P1553, DOI 10.1126/science.3006245; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Khorchid A, 2002, J VIROL, V76, P4131, DOI 10.1128/JVI.76.8.4131-4137.2002; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LEE TH, 1986, SCIENCE, V231, P1546, DOI 10.1126/science.3006243; Liu BD, 2004, J VIROL, V78, P2072, DOI 10.1128/JVI.78.4.2072-2081.2004; LIU HM, 1995, J VIROL, V69, P7630, DOI 10.1128/JVI.69.12.7630-7638.1995; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1999, J VIROL, V73, P2667, DOI 10.1128/JVI.73.4.2667-2674.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; Sova P, 2001, J VIROL, V75, P5504, DOI 10.1128/JVI.75.12.5504-5517.2001; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	53	214	222	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33177	33184		10.1074/jbc.M402062200	http://dx.doi.org/10.1074/jbc.M402062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159405	hybrid			2022-12-25	WOS:000223039700021
J	Mercuri, PS; Garcia-Saez, I; De Vriendt, K; Thamm, I; Devreese, B; Van Beeumen, J; Dideberg, O; Rossolini, GM; Frere, JM; Galleni, M				Mercuri, PS; Garcia-Saez, I; De Vriendt, K; Thamm, I; Devreese, B; Van Beeumen, J; Dideberg, O; Rossolini, GM; Frere, JM; Galleni, M			Probing the specificity of the subclass B3FEZ-1 metallo-beta-lactamase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; FLUORIBACTER-GORMANII; AEROMONAS-HYDROPHILA; BACTEROIDES-FRAGILIS; ACTIVE-SITE; BINDING; L1; INHIBITOR	The subclass B3 FEZ-1 beta-lactamase produced by Fluoribacter ( Legionella) gormanii is a Zn(II)-containing enzyme that hydrolyzes the beta-lactam bond in penicillins, cephalosporins, and carbapenems. FEZ-1 has been extensively studied using kinetic, computational modeling and x-ray crystallography. In an effort to probe residues potentially involved in substrate binding and zinc binding, five site-directed mutants of FEZ-1 (H121A, Y156A, S221A, N225A, and Y228A) were prepared and characterized using metal analyses and steady state kinetics. The activity of H121A is dependent on zinc ion concentration. The H121A monozinc form is less active than the dizinc form, which exhibits an activity similar to that of the wild type enzyme. Tyr(156) is not essential for binding and hydrolysis of the substrate. Substitution of residues Ser(221) and Asn(225) modifies the substrate profile by selectively decreasing the activity against carbapenems. The Y228A mutant is inhibited by the product formed upon hydrolysis of cephalosporins. A covalent bond between the side chain of Cys(200) and the hydrolyzed cephalosporins leads to the formation of an inactive and stable complex.	Univ Liege, Ctr Ingn Prot, B-4000 Liege, Belgium; UJF, CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, F-38027 Grenoble, France; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium; Univ Siena, Sez Microbiol, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Liege; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Ghent University; University of Siena	Galleni, M (corresponding author), Univ Liege, Ctr Ingn Prot, B6 Sart Tilman, B-4000 Liege, Belgium.	mgalleni@ulg.ac.be	Devreese, Bart/K-2841-2019; Devreese, Bart/B-2011-2009	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581; ROSSOLINI, Gian Maria/0000-0002-9386-0434				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P3028, DOI 10.1128/AAC.44.11.3028-3034.2000; Boschi L, 2000, ANTIMICROB AGENTS CH, V44, P1538, DOI 10.1128/AAC.44.6.1538-1543.2000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Carenbauer AL, 2002, BMC BIOCHEM, V3; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; de Seny D, 2002, BIOCHEM J, V363, P687, DOI 10.1042/0264-6021:3630687; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DEMEESTER F, 1987, BIOCHEM PHARMACOL, V36, P2393, DOI 10.1016/0006-2952(87)90609-5; Docquier JD, 2002, ANTIMICROB AGENTS CH, V46, P1823, DOI 10.1128/AAC.46.6.1823-1830.2002; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; FELICI A, 1995, ANTIMICROB AGENTS CH, V39, P192, DOI 10.1128/AAC.39.1.192; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; Mercuri PS, 2002, MICROB DRUG RESIST, V8, P193, DOI 10.1089/107662902760326904; Mercuri PS, 2001, ANTIMICROB AGENTS CH, V45, P1254, DOI 10.1128/AAC.45.4.1254-1262.2001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rossolini GM, 2001, ANTIMICROB AGENTS CH, V45, P837, DOI 10.1128/AAC.45.3.837-844.2001; SAMBROOOK J, 1989, MOL CLONING LAB MANU; Schnaible V, 2002, ANAL CHEM, V74, P4980, DOI 10.1021/ac025807j; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Simm AM, 2002, J BIOL CHEM, V277, P24744, DOI 10.1074/jbc.M201524200; Simm AM, 2001, FEBS LETT, V509, P350, DOI 10.1016/S0014-5793(01)03152-0; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; TOWNS ML, 1994, CLIN INFECT DIS, V18, P265, DOI 10.1093/clinids/18.2.265; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Zervosen A, 2001, EUR J BIOCHEM, V268, P3840, DOI 10.1046/j.1432-1327.2001.02298.x	36	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33630	33638		10.1074/jbc.M403671200	http://dx.doi.org/10.1074/jbc.M403671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159411	hybrid			2022-12-25	WOS:000223039700072
J	Zhang, LL; Shimizu, S; Sakamaki, K; Yonehara, S; Tsujimoto, Y				Zhang, LL; Shimizu, S; Sakamaki, K; Yonehara, S; Tsujimoto, Y			A caspase-8-independent signaling pathway activated by fas ligation leads to exposure of the Bak N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MITOCHONDRIAL DYSFUNCTION; CELL-DEATH; CONFORMATIONAL-CHANGE; KINASE ACTIVATION; APOPTOSIS; BCL-2; PROTEIN; MEMBRANE; OLIGOMERIZATION	Bak is a pro-apoptotic member of the Bcl-2 family that is activated by apoptotic stimulation: its activation is characterized by conformational changes such as exposure of the N terminus and oligomerization. In death receptor-mediated apoptosis, the activation of Bak depends on activation of caspase-8. However, we found that exposure of the N terminus of Bak ( but not oligomerization) can occur in the absence of active caspase-8. Although exposure of the N terminus of Bak without oligomerization is not sufficient to release cytochrome c from the mitochondria and commit cells to apoptosis, this change sensitizes the mitochondria to apoptotic signals ( including Bid) and thus sensitizes cells to apoptotic death. Fas-induced, caspase-8-independent exposure of the N terminus of Bak is blocked by staurosporine, a pan protein kinase inhibitor. These results suggest that Fas stimulation not only activates caspase-8, but also a distinct signaling pathway involving protein kinase(s) to induce exposure of the N terminus of Bak.	Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Solut Oriented Res Sci & Technol, Suita, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University; Kyoto University	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis, Genet Mol Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp		Sakamaki, Kazuhiro/0000-0002-7072-9628				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lambert C, 2003, APOPTOSIS, V8, P551, DOI 10.1023/A:1026113222478; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nomura M, 1999, CANCER RES, V59, P5542; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shinohara H, 2000, CANCER RES, V60, P1766; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	40	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33865	33874		10.1074/jbc.M403499200	http://dx.doi.org/10.1074/jbc.M403499200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159409	hybrid			2022-12-25	WOS:000223039700096
J	Hashimoto, G; Shimoda, M; Okada, Y				Hashimoto, G; Shimoda, M; Okada, Y			ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; SYNOVIAL-FLUID; ACTIVATION; CLEAVAGE; EXPRESSION; BINDING; FAMILY; IDENTIFICATION	ADAMTS4 (aggrecanase-1), a secreted enzyme belonging to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) gene family, is considered to play a key role in the degradation of cartilage proteoglycan (aggrecan) in osteoarthritis and rheumatoid arthritis. To clone molecules that bind to ADAMTS4, we screened a human chondrocyte cDNA library by the yeast two-hybrid system using the ADAMTS4 spacer domain as bait and obtained cDNA clones derived from fibronectin. Interaction between ADAMTS4 and fibronectin was demonstrated by chemical cross-linking. A yeast two-hybrid assay and solid-phase binding assay using wild-type fibronectin and ADAMTS4 and their mutants demonstrated that the C-terminal domain of fibronectin is capable of binding to the C-terminal spacer domain of ADAMTS4. Wild-type ADAMTS4 was co-localized with fibronectin as determined by confocal microscopy on the cell surface of stable 293T transfectants expressing ADAMTS4, although ADAMTS4 deletion mutants, including DeltaSp (DeltaArg(693)-Lys(837), lacking the spacer domain), showed negligible localization. The aggrecanase activity of wild-type ADAMTS4 was dose-dependently inhibited by fibronectin (IC50 = 110 nM), whereas no inhibition was observed with DeltaSp. The C-terminal 40-kDa fibronectin fragment also inhibited the activity of wild-type ADAMTS4 (IC50 = 170 nM). These data demonstrate for the first time that the aggrecanase activity of ADAMTS4 is inhibited by fibronectin through interaction with their C-terminal domains and suggest that this extracellular regulation mechanism of ADAMTS4 activity may be important for the degradation of aggrecan in arthritic cartilage.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan	Keio University	Okada, Y (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	okada@sc.itc.keio.ac.jp	Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; CARNEMOLLA B, 1984, ARTHRITIS RHEUM, V27, P913, DOI 10.1002/art.1780270811; *CLONT, 2001, YEAST PROT HDB; Cucuianu M, 1996, BLOOD COAGUL FIBRIN, V7, P779, DOI 10.1097/00001721-199611000-00006; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hashimoto G, 2001, FEBS LETT, V494, P192, DOI 10.1016/S0014-5793(01)02323-7; Imai K, 1997, AM J PATHOL, V151, P245; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Martin JA, 2002, OSTEOARTHR CARTILAGE, V10, P556, DOI 10.1053/joca.2002.0791; Nakada M, 2001, CANCER RES, V61, P8896; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; SCOTT DL, 1981, ANN RHEUM DIS, V40, P142, DOI 10.1136/ard.40.2.142; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Yamanaka H, 2000, LAB INVEST, V80, P677, DOI 10.1038/labinvest.3780071; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Yasuda T, 2003, ARTHRITIS RHEUM, V48, P1271, DOI 10.1002/art.10951; Zamir E, 2001, J CELL SCI, V114, P3583	36	61	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32483	32491		10.1074/jbc.M314216200	http://dx.doi.org/10.1074/jbc.M314216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161923	hybrid			2022-12-25	WOS:000222849700062
J	Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y				Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y			Nucleolar Nek11 is a novel target of Nek2A in G(1)/S-arrested cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDC14A PHOSPHATASE; NIMA-FAMILY KINASE; PROTEIN-KINASE; DNA-REPLICATION; CHROMOSOME SEGREGATION; CENTROSOME STRUCTURE; ZYGOTIC CENTROSOME; CYCLE PROGRESSION; XENOPUS-LAEVIS; CHECKPOINT	We previously reported that Nek11, a member of the NIMA (never-in-mitosis A) family of kinases, is activated in G(1)/S-arrested cells. We provide herein several lines of evidence for a novel interaction between Nek11 and Nek2A. Both Nek11 and Nek2A, but not Nek2B, were detected at nucleoli, and the Nek2A-specific C-terminal end (amino acids 399-445) was responsible for nucleolar localization. Endogenous Nek11 coimmunoprecipitated with endogenous Nek2A, and non-catalytic regions of each kinase were involved in the complex formation. Nek11L interacted with phosphorylated Nek2A but barely with the kinase-inactive Nek2A (K37R) mutant. In addition, both Nek2A autophosphorylation activity and the Nek11L-Nek2A complex formation increased in G(1)/S-arrested cells. These results indicate that autophosphorylation of Nek2A could stimulate its interaction with Nek11L at the nucleolus. Moreover, Nek2 directly phosphorylated Nek11 in the C-terminal noncatalytic region and elevated Nek11 kinase activity. The non-catalytic region of Nek11 showed autoinhibitory activity through intramolecular interaction with its N-terminal catalytic domain. Nek2 dissociated this autoinhibitory interaction. Altogether, our studies demonstrate a unique mechanism of Nek11 activation by Nek(2)A in G(1)/S-arrested cells and suggest a novel possibility for nucleolar function of the NIMA family.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Uehara, Y (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	yuehara@nih.go.jp						Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Belham C, 2003, J BIOL CHEM, V278, P34897, DOI 10.1074/jbc.M303663200; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2000, J CELL SCI, V113, P1973; Graf R, 2002, J CELL SCI, V115, P1919; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Hanrahan J, 2003, MOL CELL, V12, P663, DOI 10.1016/j.molcel.2003.08.006; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kallstrom G, 2003, MOL CELL BIOL, V23, P4344, DOI 10.1128/MCB.23.12.4344-4355.2003; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Mahjoub MR, 2002, J CELL SCI, V115, P1759; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meraldi P, 2001, J CELL SCI, V114, P3749; Noguchi K, 2002, J BIOL CHEM, V277, P39655, DOI 10.1074/jbc.M204599200; O'Connell MJ, 2003, TRENDS CELL BIOL, V13, P221, DOI 10.1016/S0962-8924(03)00056-4; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Park JH, 2001, J CELL SCI, V114, P173; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Shimada K, 2002, GENE DEV, V16, P3236, DOI 10.1101/gad.239802; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Stegmeier F, 2004, CURR BIOL, V14, P467, DOI 10.1016/j.cub.2004.03.009; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Twomey C, 2004, DEV BIOL, V265, P384, DOI 10.1016/j.ydbio.2003.10.001; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Uto K, 1999, DEV BIOL, V208, P456, DOI 10.1006/dbio.1999.9231; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816	40	31	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32716	32727		10.1074/jbc.M404104200	http://dx.doi.org/10.1074/jbc.M404104200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161910	hybrid			2022-12-25	WOS:000222849700091
J	Shen, RK; Olcott, MC; Kim, J; Rajagopal, I; Mathews, CK				Shen, RK; Olcott, MC; Kim, J; Rajagopal, I; Mathews, CK			Escherichia coli nucleoside diphosphate kinase interactions with T4 phage proteins of deoxyribonucleotide synthesis and possible regulatory functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INFECTED BACTERIA; DNA-REPAIR NUCLEASE; PYRUVATE-KINASE; DEOXYCYTIDYLATE HYDROXYMETHYLASE; NUCLEOTIDE POOLS; AMBER MUTANTS; T4; BACTERIOPHAGE-T4; ENZYMOLOGY; COMPLEX	In both prokaryotic and eukaryotic organisms, nucleoside diphosphate kinase is a multifunctional protein, with well defined functions in ribo- and deoxyribonucleoside triphosphate biosynthesis and more recently described functions in genetic and metabolic regulation, signal transduction, and DNA repair. This paper concerns two unusual properties of nucleoside diphosphate (NDP) kinase from Escherichia coli: 1) its ability to interact specifically with enzymes encoded by the virulent bacteriophage T4 and 2) its roles in regulating metabolism of the host cell. By means of optical biosensor analysis, fluorescence spectroscopy, immunoprecipitation, and glutathione S-transferase pull-down assays, we have shown that E. coli NDP kinase interacts directly with T4 thymidylate synthase, aerobic ribonucleotide reductase, dCTPase-dUTPase, gene 32 single-strand DNA-binding protein, and deoxycytidylate hydroxymethylase. The interactions with ribonucleotide reductase and with gp32 are enhanced by nucleoside triphosphates, suggesting that the integrity of the T4 dNTP synthetase complex in vivo is influenced by the composition of the nucleotide pool. The other investigations in this work stem from the unexpected finding that E. coli NDP kinase is dispensable for successful T4 phage infection, and they deal with two observations suggesting that the NDP kinase protein plays a genetic role in regulating metabolism of the host cell: 1) the elevation of CTP synthetase activity in an ndk mutant, in which the structural gene for NDP kinase is disrupted, and 2) the apparent ability of NDP kinase to suppress anaerobic growth in a pyruvate kinase-negative E. coli mutant. Our data indicate that the regulatory roles are metabolic, not genetic, in nature.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.	mathewsc@onid.orst.edu			NIEHS NIH HHS [ES 00040] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALLEN JR, 1983, J BIOL CHEM, V258, P5746; ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; BELLO LJ, 1963, BIOCHIM BIOPHYS ACTA, V72, P647; BELLO LJ, 1963, J BIOL CHEM, V238, P1777; Bennett SE, 2004, P NATL ACAD SCI USA, V101, P6391, DOI 10.1073/pnas.0401031101; Bernard MA, 2000, J BIOENERG BIOMEMBR, V32, P259, DOI 10.1023/A:1005537013120; DUCKWORTH DH, 1967, J BIOL CHEM, V242, P2877; Ellis RJ, 2003, NATURE, V425, P27, DOI 10.1038/425027a; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; FLANEGAN JB, 1977, J BIOL CHEM, V252, P3019; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANSON E, 1994, J BIOL CHEM, V269, P30999; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Levit MN, 2002, J BIOL CHEM, V277, P5163, DOI 10.1074/jbc.M111170200; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATHEWS CK, 1966, BIOCHEMISTRY-US, V4, P2092; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Postel EH, 1999, J BIOL CHEM, V274, P22821, DOI 10.1074/jbc.274.32.22821; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; REDDY GPV, 1977, P NATL ACAD SCI USA, V74, P3152, DOI 10.1073/pnas.74.8.3152; REDDY GPV, 1978, J BIOL CHEM, V253, P3461; SAEKI T, 1974, J BIOCHEM-TOKYO, V76, P631, DOI 10.1093/oxfordjournals.jbchem.a130607; SAEKI T, 1975, J ANTIBIOT, V28, P974, DOI 10.7164/antibiotics.28.974; Srere P, 1987, ANNU REV BIOCHEM, V56, P21; WHEELER L, 1992, J BIOL CHEM, V267, P7664; Wheeler LJ, 1996, J BIOL CHEM, V271, P11156, DOI 10.1074/jbc.271.19.11156; YOUNG JP, 1992, J BIOL CHEM, V267, P10786; Zhang XL, 1996, J BACTERIOL, V178, P4115, DOI 10.1128/jb.178.14.4115-4121.1996	35	13	13	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32225	32232		10.1074/jbc.M402750200	http://dx.doi.org/10.1074/jbc.M402750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169771	hybrid			2022-12-25	WOS:000222849700030
J	Vollbrandt, T; Tiedemann, K; El-Hallous, E; Lin, GQ; Brinckmann, J; John, H; Batge, B; Notbohm, H; Reinhardt, DP				Vollbrandt, T; Tiedemann, K; El-Hallous, E; Lin, GQ; Brinckmann, J; John, H; Batge, B; Notbohm, H; Reinhardt, DP			Consequences of cysteine mutations in calcium-binding epidermal growth factor modules of fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; FBN1 MUTATIONS; MATRIX METALLOPROTEINASES; GENE; EXPRESSION; PATHOGENESIS; ORGANIZATION; PROTEOLYSIS; SECRETION	Mutations in fibrillin-1 lead to Marfan syndrome and some related genetic disorders. Many of the more than 600 mutations currently known in fibrillin-1 eliminate or introduce cysteine residues in epidermal growth factor-like modules. Here we report structural and functional consequences of three selected cysteine mutations (R627C, C750G, and C926R) in fibrillin-1. The mutations have been analyzed by means of recombinant polypeptides produced in mammalian expression systems. The mRNA levels for the mutation constructs were similar to wild-type levels. All three mutated polypeptides were secreted by embryonic kidney cells ( 293) into the culture medium. Purification was readily feasible for mutants R627C and C750G, but not for C926R, which restricted the availability of this mutant polypeptide to selected analyses. The overall folds of the mutant polypeptides were indistinguishable from the wild-type as judged by the ultrastructural shape, CD analysis, and reactivity with a specific antibody sensitive for intact disulfide bonds. Subtle structural changes caused by R627C and C750G, however, were monitored by proteolysis and heat denaturation experiments. These changes occurred in the vicinity of the mutations either as short range effects (R627C) or both short and long range effects (C750G). Enhanced proteolytic susceptibility was observed for R627C and C750G to a variety of proteases. These results expand and further strengthen the concept that proteolytic degradation of mutated fibrillin-1 might be an important potential mechanism in the pathogenesis of Marfan syndrome and other disorders caused by mutations in fibrillin-1.	Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; IPF PharmaCeut GmbH, D-30625 Hannover, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	University of Lubeck	Reinhardt, DP (corresponding author), Med Univ Lubeck, Dept Med Mol Biol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	reinhardt@molbio.uni-luebeck.de	Tiedemann, one/A-9739-2016; Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872; El-Hallous, Ehab/0000-0003-0189-3720				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Booms P, 1999, CLIN GENET, V55, P110, DOI 10.1034/j.1399-0004.1999.550207.x; Booms P, 2000, HUM GENET, V107, P216, DOI 10.1007/s004390000368; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Halliday D, 1999, HUM GENET, V105, P587, DOI 10.1007/s004390051150; HAYWARD C, 1994, HUM MOL GENET, V3, P373, DOI 10.1093/hmg/3.2.373; HEWETT D, 1994, AM J HUM GENET, V55, P447; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; Montgomery RA, 1998, AM J HUM GENET, V63, P1703, DOI 10.1086/302144; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Robinson PN, 2001, CELL MOL LIFE SCI, V58, P1698, DOI 10.1007/PL00000807; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Schrijver I, 1999, AM J HUM GENET, V65, P1007, DOI 10.1086/302582; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	41	48	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32924	32931		10.1074/jbc.M405239200	http://dx.doi.org/10.1074/jbc.M405239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161917	Green Published, hybrid			2022-12-25	WOS:000222849700112
J	Moraczewska, J; Gruszczynska-Biegala, J; Redowicz, MJ; Khaitlina, SY; Strzelecka-Golaszewska, H				Moraczewska, J; Gruszczynska-Biegala, J; Redowicz, MJ; Khaitlina, SY; Strzelecka-Golaszewska, H			The DNase-I binding loop of actin may play a role in the regulation of actin-myosin interaction by tropomyosin/troponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-CLEAVED ACTIN; THIN FILAMENT REGULATION; RAY FIBER DIFFRACTION; F-ACTIN; TROPONIN-TROPOMYOSIN; COOPERATIVE BINDING; SUBDOMAIN 2; ALPHA-TROPOMYOSIN; ENERGY-TRANSFER; CROSS-LINKING	Various lines of evidence suggest that communication between tropomyosin and myosin in the regulation of vertebrate-striated muscle contraction involves yet unknown changes in actin conformation. Possible participation of loop 38 - 52 in this communication has recently been questioned based on unimpaired Ca2+ regulation of myosin interaction, in the presence of the tropomyosin-troponin complex, with actin cleaved by subtilisin between Met(47) and Gly(48). We have compared the effects of actin cleavage by subtilisin and by protease ECP32, between Gly(42) and Val(43), on its interaction with myosin S1 in the presence and absence of tropomyosin or tropomyosin-troponin. Both individual modifications reduced activation of S1 ATPase by actin to a similar extent. The effect of ECP cleavage, but not of subtilisin cleavage, was partially reversed by stabilization of interprotomer contacts with phalloidin, indicating different pathways of signal transmission from the N- and C-terminal parts of loop 38 - 52 to myosin binding sites. ECP cleavage diminished the affinity to tropomyosin and reduced its inhibition of acto-S1 ATPase at low S1 concentrations, but increased the tropomyosin-mediated cooperative enhancement of the ATPase by S1 binding to actin. These effects were reversed by phalloidin. Subtilisin-cleaved actin more closely resembled unmodified actin than the ECP-modified actin. Limited proteolysis of the modified and unmodified F-actins revealed an allosteric effect of ECP cleavage on the conformation of the actin subdomain 4 region that is presumably involved in tropomyosin binding. Our results point to a possible role of the N- terminal part of loop 38 - 52 of actin in communication between tropomyosin and myosin through changes in actin structure.	M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland; Kazimierz Wielki Univ Bydgoszcz, Inst Biol & Environm Protect, PL-85064 Bydgoszcz, Poland; Russian Acad Sci, Inst Cytol, Dept Cell Culture, St Petersburg 194064, Russia	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Kazimierz Wielki University; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Strzelecka-Golaszewska, H (corresponding author), M Nencki Inst Expt Biol, Dept Muscle Biochem, 3 Pasteur St, PL-02093 Warsaw, Poland.	hannas@nencki.gov.pl	Moraczewska, Joanna/AAL-7738-2021; Gruszczynska-Biegala, Joanna/U-4945-2019; Redowicz, Maria Jolanta/R-4083-2016; Redowicz, Maria Jolanta/AAM-8020-2020	Gruszczynska-Biegala, Joanna/0000-0003-3541-2550; Redowicz, Maria Jolanta/0000-0001-5834-471X; Moraczewska, Joanna/0000-0003-4518-3843				BRADFORD M, 1976, ANAL BIOCHEM, V64, P215; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Chalovich JM, 2002, BIOPHYS J, V82, P1679, DOI 10.1016/S0006-3495(02)75519-7; Chen YD, 2001, BIOPHYS J, V80, P2338, DOI 10.1016/S0006-3495(01)76204-2; Craig R, 2001, J MOL BIOL, V311, P1027, DOI 10.1006/jmbi.2001.4897; CROSBIE RH, 1994, BIOPHYS J, V67, P1957, DOI 10.1016/S0006-3495(94)80678-2; DABROWSKA R, 1983, J MUSCLE RES CELL M, V4, P143, DOI 10.1007/BF00712027; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; EGELMAN EH, 1995, CURR OPIN STRUC BIOL, V5, P172, DOI 10.1016/0959-440X(95)80072-7; ELSALEH SC, 1984, J BIOL CHEM, V259, P1014; Fiske CH, 1925, J BIOL CHEM, V66, P375; Geeves MA, 2002, BIOPHYS J, V82, P1677, DOI 10.1016/S0006-3495(02)75518-5; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; Gerson JH, 2001, J BIOL CHEM, V276, P18442, DOI 10.1074/jbc.M011070200; Graceffa P, 2003, J BIOL CHEM, V278, P34172, DOI 10.1074/jbc.M303689200; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLMES KC, 1995, BIOPHYS J, V68, pS2; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; Khaitlina S, 2003, BIOPHYS J, V84, p480A; KHAITLINA SY, 1993, EUR J BIOCHEM, V218, P911, DOI 10.1111/j.1432-1033.1993.tb18447.x; KHAITLINA SY, 1991, FEBS LETT, V279, P49, DOI 10.1016/0014-5793(91)80247-Z; Khaitlina SY, 2002, BIOPHYS J, V82, P321, DOI 10.1016/S0006-3495(02)75397-6; Kim E, 1996, BIOPHYS J, V70, P1439, DOI 10.1016/S0006-3495(96)79703-5; Kim E, 1998, BIOCHEMISTRY-US, V37, P17801, DOI 10.1021/bi981286b; Kim E, 2000, BIOPHYS CHEM, V86, P191, DOI 10.1016/S0301-4622(00)00143-5; Kim E, 2000, J MOL BIOL, V299, P421, DOI 10.1006/jmbi.2000.3727; Kim E, 1996, BIOPHYS J, V71, P1914, DOI 10.1016/S0006-3495(96)79390-6; Kim E, 2002, BIOCHEMISTRY-US, V41, P86, DOI 10.1021/bi0113824; Korman VL, 2000, J BIOL CHEM, V275, P22470, DOI 10.1074/jbc.M002939200; Kuznetsova I, 1996, FEBS LETT, V383, P105, DOI 10.1016/0014-5793(96)00238-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MAK AS, 1983, J BIOL CHEM, V258, P4330; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MILLER CJ, 1995, BIOPHYS J, V68, pS50; Moraczewska J, 2000, BIOCHEMISTRY-US, V39, P6891, DOI 10.1021/bi000242b; Moraczewska J, 2003, BIOPHYS J, V84, p246A; Pavlov D, 2003, J BIOL CHEM, V278, P5517, DOI 10.1074/jbc.M210889200; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; RAYMENT I, 1993, SCIENCE, V261, P1; Resetar AM, 2002, BIOPHYS J, V83, P1039, DOI 10.1016/S0006-3495(02)75229-6; Rommelaere H, 2003, STRUCTURE, V11, P1279, DOI 10.1016/j.str.2003.09.002; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; Saeki K, 1996, BIOCHEMISTRY-US, V35, P14465, DOI 10.1021/bi961292c; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Smith DA, 2003, BIOPHYS J, V84, P3155, DOI 10.1016/S0006-3495(03)70040-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; Strand J, 2001, J BIOL CHEM, V276, P34832, DOI 10.1074/jbc.M104750200; STRZELECKAGOLASZEWSKA H, 1995, BIOCHEM J, V307, P527, DOI 10.1042/bj3070527; StrzeleckaGolaszewska H, 1996, BIOCHEM J, V316, P713, DOI 10.1042/bj3160713; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; Tobacman LS, 2000, J BIOL CHEM, V275, P27587; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; VAHDAT A, 1995, FEBS LETT, V365, P149, DOI 10.1016/0014-5793(95)00446-G; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YANG YZ, 1979, J BIOL CHEM, V254, P7137	72	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31197	31204		10.1074/jbc.M400794200	http://dx.doi.org/10.1074/jbc.M400794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159400	hybrid			2022-12-25	WOS:000222726800038
J	Zhang, YM; Rock, CO				Zhang, YM; Rock, CO			Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; TEA CAMELLIA-SINENSIS; ESCHERICHIA-COLI; GREEN TEA; THIOLACTOMYCIN RESISTANCE; NATURAL INHIBITOR; ACTIVE-SITE; BIOSYNTHESIS; TRICLOSAN; CATECHINS	Epigallocatechin gallate ( EGCG) is the major component of green tea extracts and possesses antibacterial, antiviral, and antitumor activity. Our study focused on validating the inhibition of the bacterial type II fatty acid synthesis system as a mechanism for the antibacterial effects of EGCG and related plant polyphenols. EGCG and the related tea catechins potently inhibited both the FabG and FabI reductase steps in the fatty acid elongation cycle with IC50 values between 5 and 15 muM. The presence of the galloyl moiety was essential for activity, and EGCG was a competitive inhibitor of FabI and a mixed type inhibitor of FabG demonstrating that EGCG interfered with cofactor binding in both enzymes. EGCG inhibited acetate incorporation into fatty acids in vivo, although it was much less potent than thiolactomycin, a validated fatty acid synthesis inhibitor, and overexpression of FabG, FabI, or both did not confer resistance. A panel of other plant polyphenols was screened for FabG/FabI inhibition and antibacterial activity. Most of these inhibited both reductase steps, possessed antibacterial activity, and inhibited cellular fatty acid synthesis. The ability of the plant secondary metabolites to interfere with the activity of multiple NAD(P)dependent cellular processes must be taken into account when assessing the specificity of their effects.	St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org			NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhami VM, 2003, J NUTR, V133, p2417S, DOI 10.1093/jn/133.7.2417S; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Berger F, 2004, TRENDS BIOCHEM SCI, V29, P111, DOI 10.1016/j.tibs.2004.01.007; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Brusselmans K, 2003, INT J CANCER, V106, P856, DOI 10.1002/ijc.11317; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P95; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; De Smet PAGM, 2002, NEW ENGL J MED, V347, P2046, DOI 10.1056/NEJMra020398; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; HAMILTONMILLER JMT, 1995, ANTIMICROB AGENTS CH, V39, P2375, DOI 10.1128/AAC.39.11.2375; HAYASHI T, 1984, J ANTIBIOT, V37, P1456, DOI 10.7164/antibiotics.37.1456; Heath Richard J, 2004, Curr Opin Investig Drugs, V5, P146; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jackowski S, 2002, ANTIMICROB AGENTS CH, V46, P1246, DOI 10.1128/AAC.46.5.1246-1252.2002; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Laakso JA, 2003, J NAT PROD, V66, P1041, DOI 10.1021/np030046g; Lai CY, 2004, J BACTERIOL, V186, P1869, DOI 10.1128/JB.186.6.1869-1878.2004; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Li BH, 2004, J BIOCHEM, V135, P85, DOI 10.1093/jb/mvh010; Li XC, 2002, J NAT PROD, V65, P1909, DOI 10.1021/np020289t; Mabe K, 1999, ANTIMICROB AGENTS CH, V43, P1788, DOI 10.1128/AAC.43.7.1788; Marrakchi H, 2003, BIOCHEM J, V370, P1055, DOI 10.1042/BJ20021699; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Price AC, 2004, STRUCTURE, V12, P417, DOI 10.1016/j.str.2004.02.008; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Rausher MD, 2001, NATURE, V411, P857, DOI 10.1038/35081193; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; Sivaraman S, 2003, BIOCHEMISTRY-US, V42, P4406, DOI 10.1021/bi0300229; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Tegos G, 2002, ANTIMICROB AGENTS CH, V46, P3133, DOI 10.1128/AAC.46.10.3133-3141.2002; Tian WX, 2004, LIFE SCI, V74, P2389, DOI 10.1016/j.lfs.2003.09.064; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Verhoef J, 2003, ADV EXP MED BIOL, V531, P301; Wang X, 2003, BIOCHEM PHARMACOL, V66, P2039, DOI 10.1016/S0006-2952(03)00585-9; Wang X, 2001, BIOCHEM BIOPH RES CO, V288, P1200, DOI 10.1006/bbrc.2001.5923; Wright HT, 2004, STRUCTURE, V12, P358, DOI 10.1016/j.str.2004.02.027; Yam TS, 1997, FEMS MICROBIOL LETT, V152, P169, DOI 10.1016/S0378-1097(97)00197-3; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yee YK, 2000, ALIMENT PHARM THER, V14, P635, DOI 10.1046/j.1365-2036.2000.00747.x; Yeh CW, 2003, PHARMACOGENOMICS J, V3, P267, DOI 10.1038/sj.tpj.6500192; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	59	158	169	4	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30994	31001		10.1074/jbc.M403697200	http://dx.doi.org/10.1074/jbc.M403697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133034	hybrid			2022-12-25	WOS:000222726800012
J	Zheng, WJ; Wang, HY; Xue, LX; Zhang, ZY; Tong, TJ				Zheng, WJ; Wang, HY; Xue, LX; Zhang, ZY; Tong, TJ			Regulation of cellular senescence and p16(INK4a) expression by Id1 and E47 proteins in human diploid fibroblast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; GROWTH-FACTOR; NEGATIVE REGULATOR; G(1) PROGRESSION; DIFFERENTIATION; TRANSCRIPTION; DISTINCT; E2A; EXTRAMACROCHAETAE	Id1, a member of Id family of helix-loop-helix transcriptional regulatory proteins, is implicated in cellular senescence by repressing p16(INK4a) expression, but the mechanisms and cellular effects in human diploid fibroblasts remain unknown. Here we analyzed the patterns of p16(INK4a) and Id1 expression during the lifespan of 2BS cells and presented the inverse correlation between these two proteins. Immunoprecipitation assays demonstrated the presence of endogenous interaction of Id1 and E47 proteins that was strong in young 2BS cells and weakened during replicative senescence and, thereby, influenced the transcription activation of p16(INK4a) by E47. Furthermore, we found that E47 protein could bind to the E-box-containing region in p16(INK4a) promoter in senescent cells by chromatin immunoprecipitation analyses, suggesting that E47 is indeed ultimately involved in the regulation of p16(INK4a) transcription in vivo. Silencing Id1 expression in young cells by RNA interference induced an increased p16(INK4a) level and premature cellular senescence, whereas silencing E47 expression inhibited the expression of p16(INK4a) and delayed the onset of senescent phenotype. The present study demonstrated not only the capacity of Id1 to regulate p16(INK4a) gene expression by E47, but also the phenotypic consequence of the regulation on cellular senescence, moreover, raised the possibility of Id1-specific gene silencing for human cancer therapy.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Capital Univ Med Sci, Beijing Chao Yang Hosp, Beijing 100020, Peoples R China	Peking University; Capital Medical University	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xueyuan Rd, Beijing 100083, Peoples R China.	ttj@bjmu.edu.cn						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Barndt RJ, 1999, COLD SPRING HARB SYM, V64, P45, DOI 10.1101/sqb.1999.64.45; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DEED RW, 1993, ONCOGENE, V8, P599; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1994, J BIOL CHEM, V269, P2139; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LEJOSSIC C, 1994, CANCER RES, V54, P6065; LI JH, 1995, MECH AGEING DEV, V80, P25, DOI 10.1016/0047-6374(94)01557-3; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, CANCER RES, V60, P1376; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Spector D.I., 1998, CELL LAB MANUAL, V1; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Wadhwa R, 2000, Prog Mol Subcell Biol, V24, P191; Wang W, 2001, J BIOL CHEM, V276, P48655, DOI 10.1074/jbc.M108278200; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	48	68	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31524	31532		10.1074/jbc.M400365200	http://dx.doi.org/10.1074/jbc.M400365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138269	hybrid			2022-12-25	WOS:000222726800075
J	Kutney, SN; Hong, R; Macfarlan, T; Chakravarti, D				Kutney, SN; Hong, R; Macfarlan, T; Chakravarti, D			A signaling role of histone-binding proteins and INHAT subunits pp32 and Set/TAF-I alpha in integrating chromatin hypoacetylation and transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; LYSINE 9; H3; ACETYLATION; METHYLATION; COMPLEX; YEAST; HETEROCHROMATIN; BROMODOMAIN; DEACETYLASE	Various post-translational modifications of histones significantly influence gene transcription. Although un- or hypoacetylated histones are tightly linked to transcriptional repression, the mechanisms and identities of chromatin signal transducer proteins integrating histone hypoacetylation into repression in humans have remained largely unknown. Here we show that the mammalian histone-binding proteins and inhibitor of acetyltransferases (INHAT) complex subunits, Set/template-activating factor-Ibeta (TAF-Ibeta) and pp32, specifically bind to unacetylated, hypoacetylated, and repressively marked histones but not to hyperacetylated histones. Additionally, Set/TAF-Ibeta and pp32 associate with histone deacetylases in vitro and in vivo and repress transcription from a chromatin-integrated template in vivo. Finally, Set/TAF-Ibeta and pp32 associate with an endogenous estrogen receptor-regulated gene, EB1, in the hypoacetylated transcriptionally inactive state but not with the hyperacetylated transcriptionally active form. Together, these data define a novel in vivo mechanistic role for the mammalian Set/TAF-Ibeta and pp32 proteins as transducers of chromatin signaling by integrating chromatin hypoacetylation and transcriptional repression.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Chakravarti, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	debu@pharm.med.upenn.edu	Macfarlan, Todd/S-3750-2017	Macfarlan, Todd/0000-0003-2495-9809; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065148, R01DK057079, R56DK065148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57079, DK65148, R01 DK057079, R01 DK065148] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM-007229] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 2004, AM J PATHOL, V164, P273, DOI 10.1016/S0002-9440(10)63117-3; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Dey A, 2000, MOL CELL BIOL, V20, P6537, DOI 10.1128/MCB.20.17.6537-6549.2000; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Hong R, 2003, J BIOL CHEM, V278, P44505, DOI 10.1074/jbc.M303138200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okuwaki M, 1998, J BIOL CHEM, V273, P34511, DOI 10.1074/jbc.273.51.34511; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	39	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30850	30855		10.1074/jbc.M404969200	http://dx.doi.org/10.1074/jbc.M404969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136563	hybrid			2022-12-25	WOS:000222531900118
J	Barlic, A; Gutierrez-Aguirre, I; Caaveiro, JMM; Cruz, A; Ruiz-Arguello, MB; Perez-Gil, J; Gonzalez-Manas, JM				Barlic, A; Gutierrez-Aguirre, I; Caaveiro, JMM; Cruz, A; Ruiz-Arguello, MB; Perez-Gil, J; Gonzalez-Manas, JM			Lipid phase coexistence favors membrane insertion of equinatoxin-II, a pore-forming toxin from Actinia equina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMONE STICHODACTYLA-HELIANTHUS; ATOMIC-FORCE MICROSCOPY; SEA-ANEMONE; MODEL MEMBRANES; PHOSPHOLIPASE-C; CONDENSED COMPLEXES; CELL-MEMBRANES; STICHOLYSIN-II; BIOLOGICAL-MEMBRANES; ANCHORED PROTEINS	Equinatoxin-II is a eukaryotic pore-forming toxin belonging to the family of actinoporins. Its interaction with model membranes is largely modulated by the presence of sphingomyelin. We have used large unilamellar vesicles and lipid monolayers to gain further information about this interaction. The coexistence of gel and liquid-crystal lipid phases in sphingomyelin/phosphatidylcholine mixtures and the coexistence of liquid-ordered and liquid-disordered lipid phases in phosphatidylcholine/cholesterol or sphingomyelin/phosphatidylcholine/cholesterol mixtures favor membrane insertion of equinatoxin-II. Phosphatidylcholine vesicles are not permeabilized by equinatoxin-II. However, the localized accumulation of phospholipase C-generated diacylglycerol creates conditions for toxin activity. By using epifluorescence microscopy of transferred monolayers, it seems that lipid packing defects arising at the interfaces between coexisting lipid phases may function as preferential binding sites for the toxin. The possible implications of such a mechanism in the assembly of a toroidal pore are discussed.	Univ Pais Vasco Euskal herriko Unibertsitatea, CSIC, Unidad Biofis, Bilbao 48080, Spain; Univ Pais Vasco Euskal herriko Unibertsitatea, Dept Bioquim & Biol Mol, Bilbao 48080, Spain; Univ Complutense, Fac Biol, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Complutense University of Madrid	Gonzalez-Manas, JM (corresponding author), Univ Pais Vasco Euskal herriko Unibertsitatea, CSIC, Unidad Biofis, Apdo 644, Bilbao 48080, Spain.	gbpgomaj@lg.ehu.es	Perez-Gil, Jesus/H-3102-2019; Cruz, Antonio/H-2881-2015; Caaveiro, Jose/J-2790-2013	Perez-Gil, Jesus/0000-0003-3587-7147; Cruz, Antonio/0000-0002-0465-4111; Caaveiro, Jose/0000-0001-5568-2369; Gutierrez Aguirre, Ion/0000-0002-8348-8616; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982; Barlic, Ariana/0000-0003-4822-142X				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; Anderluh G, 2003, J BIOL CHEM, V278, P45216, DOI 10.1074/jbc.M305916200; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Basanez G, 1996, BIOCHEMISTRY-US, V35, P15183, DOI 10.1021/bi9616561; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; BERNHEIMER AW, 1976, P NATL ACAD SCI USA, V73, P467, DOI 10.1073/pnas.73.2.467; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Cruz A, 2004, BIOPHYS J, V86, P308, DOI 10.1016/S0006-3495(04)74106-5; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Fivaz M, 2000, PROTOPLASMA, V212, P8, DOI 10.1007/BF01279342; Giocondi MC, 2001, ULTRAMICROSCOPY, V86, P151, DOI 10.1016/S0304-3991(00)00086-3; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; HAMILTON JA, 1991, BIOCHEMISTRY-US, V30, P2894, DOI 10.1021/bi00225a024; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Honger T, 1996, BIOCHEMISTRY-US, V35, P9003, DOI 10.1021/bi960866a; HOUSLAY MD, 1982, DYNAMICS BIOL MEMBRA, P41; IPSEN JH, 1987, BIOCHIM BIOPHYS ACTA, V905, P162; IPSEN JH, 1989, BIOPHYS J, V56, P661, DOI 10.1016/S0006-3495(89)82713-4; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Mancheno JM, 2003, STRUCTURE, V11, P1319, DOI 10.1016/j.str.2003.09.019; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McConnell HM, 2003, BBA-BIOMEMBRANES, V1610, P159, DOI 10.1016/S0005-2736(03)00015-4; McConnell HM, 2003, ANNU REV BIOPH BIOM, V32, P469, DOI 10.1146/annurev.biophys.32.110601.141704; Netz RR, 1996, J PHYS II, V6, P1023, DOI 10.1051/jp2:1996114; Nielsen LK, 1999, BBA-BIOMEMBRANES, V1420, P266, DOI 10.1016/S0005-2736(99)00103-0; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; NORTON RS, 1992, TOXICON, V30, P13, DOI 10.1016/0041-0101(92)90497-S; PAPAHADJOPOULOS D, 1972, BIOCHIM BIOPHYS ACTA, V266, P561, DOI 10.1016/0005-2736(72)90354-9; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; Radhakrishnan A, 1999, BIOPHYS J, V77, P1507, DOI 10.1016/S0006-3495(99)76998-5; Radhakrishnan A, 2001, BBA-BIOMEMBRANES, V1511, P1, DOI 10.1016/S0005-2736(01)00274-7; RECKTENWALD DJ, 1981, BIOCHEMISTRY-US, V20, P4505, DOI 10.1021/bi00518a042; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Ruiz-Arguello MB, 1998, BIOCHEMISTRY-US, V37, P11621, DOI 10.1021/bi980615x; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; Ruiz-Arguello MB, 2002, CHEM PHYS LIPIDS, V114, P11, DOI 10.1016/S0009-3084(01)00195-5; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; Schief WR, 2000, PHYS REV E, V62, P6831, DOI 10.1103/PhysRevE.62.6831; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHIPLEY GG, 1974, J LIPID RES, V15, P126; Silvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; THEWALT JL, 1992, BIOPHYS J, V63, P1176, DOI 10.1016/S0006-3495(92)81681-8; TURK T, 1986, PERIOD BIOL, V88, P216; UNTRACHT SH, 1977, J BIOL CHEM, V252, P4449; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Veiga MP, 2001, BIOCHEMISTRY-US, V40, P2614, DOI 10.1021/bi0019803; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X; ZOREC R, 1990, J MEMBRANE BIOL, V118, P243, DOI 10.1007/BF01868608	77	109	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34209	34216		10.1074/jbc.M313817200	http://dx.doi.org/10.1074/jbc.M313817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175339	hybrid			2022-12-25	WOS:000223134800019
J	Beekman, JM; Bakema, JE; van der Linden, J; Tops, B; Hinten, M; van Vugt, M; van de Winkel, JGJ; Leusen, JHW				Beekman, JM; Bakema, JE; van der Linden, J; Tops, B; Hinten, M; van Vugt, M; van de Winkel, JGJ; Leusen, JHW			Modulation of Fc gamma RI (CD64) ligand binding by blocking peptides of periplakin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE EXPRESSION; CYTOPLASMIC DOMAIN; TRANSGENIC MICE; PLAKIN FAMILY; IGE RECEPTOR; CLASS-I; CHAIN; ASSOCIATION; AFFINITY; CELLS	FcgammaRI requires both the intracellular domain of the alpha-chain and associated leukocyte Fc receptor (FcR) gamma-chains for its biological function. We recently found the C terminus of periplakin to selectively interact with the cytoplasmic domain of the FcgammaRI alpha-chain. It thereby enhances the capacity of FcgammaRI to bind, internalize, and present antigens on MHC class II. Here, we characterized the domains involved in FcgammaRI-periplakin interaction using truncated and alanine-substituted FcgammaRI mutants and randomly mutagenized periplakin. This allowed us to design TAT peptides that selectively interfered with endogenous FcgammaRI-periplakin interactions. The addition of these peptides to FcgammaRI-expressing cells modulated FcgammaRI ligand binding, as assessed by erythrocyte-antibody-rosetting. These data support a dominant-negative role of C-terminal periplakin for FcgammaRI biological activity and implicate periplakin as a novel regulator of FcgammaRI in immune cells.	Univ Med Ctr Utrecht, Dept Immunol, Immunotherapy Lab, NL-3584 EA Utrecht, Netherlands; Medarex Europe, NL-3584 EA Utrecht, Netherlands; Genmab, NL-3584 CM Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Genmab	Leusen, JHW (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, Immunotherapy Lab, Lundlaan 6,KC-02-085-2, NL-3584 EA Utrecht, Netherlands.	J.H.W.leusen@lab.azu.nl	Beekman, Jeffrey M/I-7781-2014; , Jeanette/AAG-3736-2019; Leusen, Jeanette/I-9010-2014; Tops, Bastiaan/L-4697-2015	Beekman, Jeffrey M/0000-0003-4886-3756; Tops, Bastiaan/0000-0002-1699-8210; Leusen, Jeanette/0000-0003-4982-6914				Aho S, 1998, GENOMICS, V48, P242, DOI 10.1006/geno.1997.5188; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOOT JHA, 1989, J IMMUNOL, V142, P1217; Bracke M, 2001, BLOOD, V97, P3478, DOI 10.1182/blood.V97.11.3478; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAVIS W, 1995, EMBO J, V14, P432, DOI 10.1002/j.1460-2075.1995.tb07019.x; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Edberg JC, 2002, J BIOL CHEM, V277, P41287, DOI 10.1074/jbc.M207835200; Edberg JC, 1999, J BIOL CHEM, V274, P30328, DOI 10.1074/jbc.274.42.30328; ERNST LK, 1992, J BIOL CHEM, V267, P15692; Ernst LK, 1998, MOL IMMUNOL, V35, P943, DOI 10.1016/S0161-5890(98)00079-0; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Feng GJ, 2003, J BIOL CHEM, V278, P33400, DOI 10.1074/jbc.M305866200; Gavin AL, 2000, IMMUNOGENETICS, V51, P206, DOI 10.1007/s002510050033; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; GRAZIANO RF, 1995, J IMMUNOL, V155, P4996; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; INDIK ZK, 1994, EXP HEMATOL, V22, P599; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8; Leung CL, 2001, J CELL SCI, V114, P3409; MASUDA M, 1993, J IMMUNOL, V151, P7188; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; MORTON HC, 1995, J BIOL CHEM, V270, P29781; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PORGES AJ, 1992, J CLIN INVEST, V90, P2102, DOI 10.1172/JCI116094; RA C, 1989, J BIOL CHEM, V264, P15323; Radsak M, 2000, IMMUNOLOGY, V101, P521, DOI 10.1046/j.1365-2567.2000.00140.x; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Thepen T, 2000, NAT BIOTECHNOL, V18, P48, DOI 10.1038/71908; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; van Roon JAG, 2003, ARTHRITIS RHEUM-US, V48, P1229, DOI 10.1002/art.10940; van Spriel AB, 2001, J IMMUNOL, V166, P7019, DOI 10.4049/jimmunol.166.12.7019; van Vugt MJ, 1999, BLOOD, V94, P808, DOI 10.1182/blood.V94.2.808.414k31_808_817; van Vugt MJ, 1999, EUR J IMMUNOL, V29, P143; Van Vugt MJ, 1998, CLIN EXP IMMUNOL, V113, P415; VANDEWINKEL JGJ, 1996, MOL BIOL INTELLIGENC; vanVugt MJ, 1996, BLOOD, V87, P3593, DOI 10.1182/blood.V87.9.3593.bloodjournal8793593; Wallace PK, 2001, J IMMUNOL METHODS, V248, P183, DOI 10.1016/S0022-1759(00)00351-3	50	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33875	33881		10.1074/jbc.M401018200	http://dx.doi.org/10.1074/jbc.M401018200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161926	hybrid			2022-12-25	WOS:000223039700097
J	Olson, LJ; Dahms, NM; Kim, JJP				Olson, LJ; Dahms, NM; Kim, JJP			The N-terminal carbohydrate recognition site of the cation-independent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; LYSOSOMAL-ENZYMES; BINDING-SITES; RESIDUES; LOCALIZATION; CLONING; TWISTS	The 300-kDa cation-independent mannose 6-phosphate receptor (CI-MPR) plays a critical role in the trafficking of newly synthesized mannose 6-phosphate-containing acid hydrolases to the lysosome. The receptor contains two high affinity carbohydrate recognition sites within its 15-domain extracytoplasmic region, with essential residues for carbohydrate recognition located in domain 3 and domain 9. Previous studies have shown that these two sites are distinct with respect to carbohydrate specificity. In addition, expression of truncated forms of the CI-MPR demonstrated that domain 9 can be expressed as an isolated domain, retaining high affinity (K-d similar to 1 nM) carbohydrate binding, whereas expression of domain 3 alone resulted in a protein capable of only low affinity binding (K-d similar to 1 muM) toward a lysosomal enzyme. In the current report the crystal structure of the N-terminal 432 residues of the CI-MPR, encompassing domains 1-3, was solved in the presence of bound mannose 6-phosphate. The structure reveals the unique architecture of this carbohydrate binding pocket and provides insight into the ability of this site to recognize a variety of mannose-containing sugars.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NIDDK NIH HHS [DK42667] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042667, R29DK042667, R56DK042667] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brown J, 2002, EMBO J, V21, P1054, DOI 10.1093/emboj/21.5.1054; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hancock MK, 2002, J BIOL CHEM, V277, P11255, DOI 10.1074/jbc.M109855200; HASILIK A, 1980, J BIOL CHEM, V255, P4946; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson LJ, 2002, J BIOL CHEM, V277, P10156, DOI 10.1074/jbc.M112230200; Olson LJ, 1999, J BIOL CHEM, V274, P29889, DOI 10.1074/jbc.274.42.29889; Olson LJ, 1999, J BIOL CHEM, V274, P36905, DOI 10.1074/jbc.274.52.36905; Olson LJ, 2004, EMBO J, V23, P2019, DOI 10.1038/sj.emboj.7600215; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; Roberts DL, 1998, CELL, V93, P639, DOI 10.1016/S0092-8674(00)81192-7; ROUSSEL A, 2002, TURBOFRODO MANUAL; Saris JJ, 2001, AM J PHYSIOL-HEART C, V280, pH1706, DOI 10.1152/ajpheart.2001.280.4.H1706; Sohar I, 1998, BIOCHEM J, V330, P903, DOI 10.1042/bj3300903; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; WENDLAND M, 1991, J BIOL CHEM, V266, P2917; WESTLUND B, 1991, J BIOL CHEM, V266, P23233	32	44	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34000	34009		10.1074/jbc.M404588200	http://dx.doi.org/10.1074/jbc.M404588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15169779	hybrid			2022-12-25	WOS:000223039700111
J	Chigaev, A; Zwartz, GJ; Buranda, T; Edwards, BS; Prossnitz, ER; Sklar, LA				Chigaev, A; Zwartz, GJ; Buranda, T; Edwards, BS; Prossnitz, ER; Sklar, LA			Conformational regulation of alpha(4)beta(1)-integrin affinity by reducing agents - "Inside-out" signaling is independent of and additive to reduction-regulated integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; T-CELL MIGRATION; CYTOPLASMIC DOMAIN; BETA(3) INTEGRINS; RECEPTOR SUBTYPES; ADHESION; BINDING; PHOSPHORYLATION; EXPRESSION; DISRUPTION	The alpha(4)beta(1)-integrin (very late antigen-4 (VLA-4), CD49d/CD29) is an adhesion receptor involved in the interaction of lymphocytes, dendritic cells, and stem cells with the extracellular matrix and endothelial cells. This and other integrins have the ability to regulate their affinity for ligands through a process termed "inside-out" signaling that affects cell adhesion avidity. Several mechanisms are known to regulate integrin affinity and conformation: conformational changes induced by separation of the C-terminal tails, divalent ions, and reducing agents. Recently, we described a fluorescent LDV-containing small molecule that was used to monitor VLA-4 affinity changes in live cells (Chigaev, A., Blenc, A. M., Braaten, J. V., Kumaraswamy, N., Kepley, C. L., Andrews, R. P., Oliver, J. M., Edwards, B. S., Prossnitz, E. R., Larson, R. S., and Sklar, L. A. (2001) J. Biol. Chem. 276, 48670-48678). Using the same molecule, we also developed a fluorescence resonance energy transfer-based assay to probe the "switchblade-like" opening of VLA-4 upon activation. Here, we investigated the effect of reducing agents on the affinity and conformational state of the VLA-4 integrin simultaneously with cell activation initiated by inside-out signaling through G protein-coupled receptors or Mn2+ in live cells in real time. We found that reducing agents ( dithiothreitol and 2,3-dimercapto-1-propanesulfonic acid) induced multiple states of high affinity of VLA-4, where the affinity change was accompanied by an extension of the integrin molecule. Bacitracin, an inhibitor of the reductive function of the plasma membrane, diminished the effect of dithiothreitol, but had no effect on inside-out signaling. Based on this result and differences in the kinetics of integrin activation, we conclude that conformational activation of VLA-4 by inside-out signaling is independent of and additive to reduction-regulated integrin activation.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Ctr Canc, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Los Alamos Natl Lab, Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Sklar, LA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008; Chigaev, Alexandre/A-3103-2010	Prossnitz, Eric/0000-0001-9190-8302; Chigaev, Alexandre/0000-0002-7726-638X	NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002022] Funding Source: NIH RePORTER; NCI NIH HHS [1R24 CA88339] Funding Source: Medline; NHLBI NIH HHS [P50 HL56384] Funding Source: Medline; NIBIB NIH HHS [1R01EB02022] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; Brower DL, 1997, P NATL ACAD SCI USA, V94, P9182, DOI 10.1073/pnas.94.17.9182; Butta N, 2003, BLOOD, V102, P2491, DOI 10.1182/blood-2003-01-0213; Chen C, 1999, J IMMUNOL, V162, P1084; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen P, 2001, J BIOL CHEM, V276, P38628, DOI 10.1074/jbc.M105737200; Chigaev A, 2003, BIOPHYS J, V85, P3951, DOI 10.1016/S0006-3495(03)74809-7; Chigaev A, 2003, J BIOL CHEM, V278, P38174, DOI 10.1074/jbc.M210472200; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165-2478(03)00108-1; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Edwards BS, 1998, J LEUKOCYTE BIOL, V63, P190, DOI 10.1002/jlb.63.2.190; EDWARDS BS, 1995, BLOOD, V86, P2288, DOI 10.1182/blood.V86.6.2288.bloodjournal8662288; Essex DW, 2001, BIOCHEMISTRY-US, V40, P6070, DOI 10.1021/bi002454e; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Han JW, 2003, J BIOL CHEM, V278, P34845, DOI 10.1074/jbc.M304691200; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lahav J, 2000, FEBS LETT, V475, P89, DOI 10.1016/S0014-5793(00)01630-6; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; Lahav J, 2002, BLOOD, V100, P2472, DOI 10.1182/blood-2001-12-0339; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; PEERSCHKE EI, 1995, THROMB HAEMOSTASIS, V73, P862; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Zwartz G, 2004, BIOPHYS J, V86, P1243, DOI 10.1016/S0006-3495(04)74198-3	51	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32435	32443		10.1074/jbc.M404387200	http://dx.doi.org/10.1074/jbc.M404387200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166232	hybrid			2022-12-25	WOS:000222849700057
J	Cicchillo, RM; Baker, MA; Schnitzer, EJ; Newman, EB; Krebs, C; Booker, SJ				Cicchillo, RM; Baker, MA; Schnitzer, EJ; Newman, EB; Krebs, C; Booker, SJ			Escherichia coli L-serine deaminase requires a [4Fe-4S] cluster in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYASE ACTIVATING ENZYME; IRON-SULFUR PROTEINS; DOUBLE-RESONANCE CHARACTERIZATION; FORMATE-LYASE; PEPTOSTREPTOCOCCUS-ASACCHAROLYTICUS; <4FE-4S>+ CLUSTER; THREONINE DEHYDRATASE; S-ADENOSYLMETHIONINE; INHIBITOR BINDING; ACONITASE	L-Serine deaminases catalyze the deamination of L-serine, producing pyruvate and ammonia. Two families of these proteins have been described and are delineated by the cofactor that each employs in catalysis. These are the pyridoxal 5'-phosphate-dependent deaminases and the deaminases that are activated in vitro by iron and dithiothreitol. In contrast to the enzymes that employ pyridoxal 5'-phosphate, detailed physical and mechanistic characterization of the iron-dependent deaminases is limited, primarily because of their extreme instability. We report here the characterization of L-serine deaminase from Escherichia coli, which is the product of the sdaA gene. When purified anaerobically, the isolated protein contains 1.86 +/- 0.46 eq of iron and 0.670 +/- 0.019 eq of sulfide per polypeptide and displays a UV-visible spectrum that is consistent with a [4Fe-4S] cluster. Reconstitution of the protein with iron and sulfide generates considerably more of the cluster, and treatment of the reconstituted protein with dithionite gives rise to an axial EPR spectrum, displaying g\\ = 2.03 and g(perpendicular to) = 1.93. Mossbauer spectra of the Fe-57-reconstituted protein reveal that the majority of the iron is in the form of [4Fe-4S](2+) clusters, as evidenced by the typical Mossbauer parameters-isomer shift, delta = 0.47 mm/s, quadrupole splitting of DeltaE(Q) = 1.14 mm/s, and a diamagnetic (S = 0) ground state. Treatment of the dithionite-reduced protein with L-serine results in a slight broadening of the feature at g = 2.03 in the EPR spectrum of the protein, and a dramatic loss in signal intensity, suggesting that the amino acid interacts directly with the cluster.	Penn State Univ, Dept Biochem & Mol Biol, S Frear Lab 306, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Concordia University - Canada	Booker, SJ (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, S Frear Lab 306, University Pk, PA 16802 USA.	ckrebs@psu.edu; sjb14@psu.edu	Krebs, Carsten/D-4773-2009	Krebs, Carsten/0000-0002-3302-7053	NIGMS NIH HHS [GM-63847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Beinert H, 1978, Methods Enzymol, V54, P435; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EA, 1990, J GEN MICROBIOL, V136, P1017, DOI 10.1099/00221287-136-6-1017; CARTER JE, 1972, J BACTERIOL, V109, P757, DOI 10.1128/JB.109.2.757-763.1972; Chen DW, 2003, J AM CHEM SOC, V125, P11788, DOI 10.1021/ja036120z; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Davis L, 1972, ENZYMES, P33; DOWHAN W, 1970, J BIOL CHEM, V245, P4629; DOWHAN W, 1970, J BIOL CHEM, V245, P4618; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRABOWSKI R, 1991, EUR J BIOCHEM, V199, P89, DOI 10.1111/j.1432-1033.1991.tb16095.x; GRABOWSKI R, 1993, TRENDS BIOCHEM SCI, V18, P297, DOI 10.1016/0968-0004(93)90040-T; Hesslinger C, 1998, MOL MICROBIOL, V27, P477, DOI 10.1046/j.1365-2958.1998.00696.x; Hofmeister AEM, 1997, J BACTERIOL, V179, P4937, DOI 10.1128/jb.179.15.4937-4941.1997; HOFMEISTER AEM, 1993, EUR J BIOCHEM, V215, P341, DOI 10.1111/j.1432-1033.1993.tb18040.x; HOFMEISTER AEM, 1994, FEBS LETT, V351, P416, DOI 10.1016/0014-5793(94)00901-5; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENT TA, 1985, J BIOL CHEM, V260, P6871; Krebs C, 2002, J AM CHEM SOC, V124, P912, DOI 10.1021/ja017562i; Krebs C, 2000, J AM CHEM SOC, V122, P12497, DOI 10.1021/ja003335p; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MEISTER A, 1950, J BIOL CHEM, V184, P117; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; MUDD SH, 1965, BIOCHEM BIOPH RES CO, V19, P665; NEWMAN EB, 1990, BIOCHEM CELL BIOL, V68, P723, DOI 10.1139/o90-104; NEWMAN EB, 1985, J BACTERIOL, V162, P1270, DOI 10.1128/JB.162.3.1270-1275.1985; NEWMAN EB, 1980, CAN J BIOCHEM CELL B, V58, P1292, DOI 10.1139/o80-173; OGAWA H, 1989, J BIOL CHEM, V264, P15818; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; Rao PV, 2004, CHEM REV, V104, P527, DOI 10.1021/cr020615+; SHAO ZQ, 1993, EUR J BIOCHEM, V212, P777, DOI 10.1111/j.1432-1033.1993.tb17718.x; SU HS, 1989, J BACTERIOL, V171, P5095, DOI 10.1128/jb.171.9.5095-5102.1989; SU HS, 1993, EUR J BIOCHEM, V211, P521, DOI 10.1111/j.1432-1033.1993.tb17578.x; TELSER J, 1986, J BIOL CHEM, V261, P4840; UMBARGER HE, 1973, ADV ENZYMOL RAMB, V37, P349; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10533, DOI 10.1021/bi00498a016; YANOFSKY C, 1972, ENZYMES, V7, P1; Zinecker H, 1998, J BASIC MICROB, V38, P147, DOI 10.1002/(SICI)1521-4028(199805)38:2<147::AID-JOBM147>3.0.CO;2-M	47	35	37	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32418	32425		10.1074/jbc.M404381200	http://dx.doi.org/10.1074/jbc.M404381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155761	hybrid			2022-12-25	WOS:000222849700055
J	Dumoutier, L; Tounsi, A; Michiels, T; Sommereyns, C; Kotenko, SV; Renauld, JC				Dumoutier, L; Tounsi, A; Michiels, T; Sommereyns, C; Kotenko, SV; Renauld, JC			Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1 - Similarities with type I interferon signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT2; ACTIVATION; TRANSDUCER; EXPRESSION; DISTINCT; DOCKING; DOMAIN; IDENTIFICATION; RECRUITMENT; CLONING	Interferon (IFN)-lambda1, -lambda2, and -lambda3 are the latest members of the class II cytokine family and were shown to have antiviral activity. Their receptor is composed of two chains, interleukin-28R/likely interleukin or cytokine or receptor 2 (IL-28R/LICR2) and IL-10Rbeta, and mediates the tyrosine phosphorylation of STAT1, STAT2, STAT3, and STAT5. Here, we show that activation of this receptor by IFN-lambda1 can also inhibit cell proliferation and induce STAT4 phosphorylation, further extending functional similarities with type I IFNs. We used IL-28R/LICR2-mutated receptors to identify the tyrosines required for STAT activation, as well as antiproliferative and antiviral activities. We found that IFN-lambda1-induced STAT2 tyrosine phosphorylation is mediated through tyrosines 343 and 517 of the receptor, which showed some similarities with tyrosines from type I IFN receptors involved in STAT2 activation. These two tyrosines were also responsible for antiviral and antiproliferative activities of IFN-lambda1. By contrast, STAT4 phosphorylation ( and to some extent STAT3 activation) was independent from IL-28R/LICR2 tyrosine residues. Taken together, these observations extend the functional similarities between IFN-lambdas and type I IFNs and shed some new light on the mechanisms of activation of STAT2 and STAT4 by these cytokines.	Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium; Univ Louvain, Expt Med Unit, B-1200 Brussels, Belgium; Univ Louvain, Christian de Duce Inst Cellular Pathol, MIPA VIRO Unit, B-1200 Brussels, Belgium; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Rutgers State University New Brunswick; Rutgers State University Medical Center	Renauld, JC (corresponding author), Univ Louvain, Ludwig Inst Canc Res, Brussels Branch, Ave Hippocrate 74, B-1200 Brussels, Belgium.	renauld@licr.ucl.ac.be	Michiels, Thomas/ABE-3203-2021; Renauld, Jean-Christophe/B-7268-2012	Michiels, Thomas/0000-0001-9615-8053; Dumoutier, Laure/0000-0002-6645-684X; Renauld, Jean-Christophe/0000-0003-1736-2131	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051139] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI051139, R01 AI51139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clifford JL, 2003, MOL CANCER THER, V2, P453; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Decker T, 2002, J CLIN INVEST, V109, P1271, DOI 10.1172/JCI200215770; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; DUKE GM, 1989, J VIROL, V63, P1822, DOI 10.1128/JVI.63.4.1822-1826.1989; Dumoutier L, 2003, BIOCHEM J, V370, P391, DOI 10.1042/BJ20021935; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Krishnan K, 1998, J BIOL CHEM, V273, P19495, DOI 10.1074/jbc.273.31.19495; Langer JA, 2004, CYTOKINE GROWTH F R, V15, P33, DOI 10.1016/j.cytogfr.2003.10.001; Lejeune D, 2002, J BIOL CHEM, V277, P33676, DOI 10.1074/jbc.M204204200; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Sheikh F, 2004, J IMMUNOL, V172, P2006, DOI 10.4049/jimmunol.172.4.2006; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; van Pesch V, 2003, J BIOL CHEM, V278, P46321, DOI 10.1074/jbc.M302554200; VANPESCH V, 2004, IN PRESS J VIROL; Wagner TC, 2002, J BIOL CHEM, V277, P1493, DOI 10.1074/jbc.M108928200; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x	29	256	303	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32269	32274		10.1074/jbc.M404789200	http://dx.doi.org/10.1074/jbc.M404789200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166220	hybrid			2022-12-25	WOS:000222849700035
J	Molteni, SN; Fassio, A; Ciriolo, MR; Filomeni, G; Pasqualetto, E; Fagioli, C; Sitia, R				Molteni, SN; Fassio, A; Ciriolo, MR; Filomeni, G; Pasqualetto, E; Fagioli, C; Sitia, R			Glutathione limits Ero1-dependent oxidation in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; QUALITY-CONTROL; BOND FORMATION; MOLECULAR CHAPERONES; THIOREDOXIN FAMILY; CHOLERA-TOXIN; REDOX STATE; DEGRADATION; MEMBRANE; THIOLS	Many proteins of the secretory pathway contain disulfide bonds that are essential for structure and function. In the endoplasmic reticulum (ER), Ero1alpha and Ero1beta oxidize protein disulfide isomerase (PDI), which in turn transfers oxidative equivalents to newly synthesized cargo proteins. However, oxidation must be limited, as some reduced PDI is necessary for disulfide isomerization and ER-associated degradation. Here we show that in semipermeable cells, PDI is more oxidized, disulfide bonds are formed faster, and high molecular mass covalent protein aggregates accumulate in the absence of cytosol. Addition of reduced glutathione (GSH) reduces PDI and restores normal disulfide formation rates. A higher GSH concentration is needed to balance oxidative folding in semipermeable cells overexpressing Ero1alpha, indicating that cytosolic GSH and lumenal Ero1alpha play antagonistic roles in controlling the ER redox. Moreover, the overexpression of Ero1alpha significantly increases the GSH content in HeLa cells. Our data demonstrate tight connections between ER and cytosol to guarantee redox exchange across compartments: a reducing cytosol is important to ensure disulfide isomerization in secretory proteins.	Univ Vita Salute San Raffaele, I-20132 Milan, Italy; San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy	Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Rome Tor Vergata	Sitia, R (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.	r.sitia@hsr.it	Sitia, Roberto/AAB-5005-2019; fassio, anna/K-4482-2014; Fagioli, Claudio/AAN-4147-2020; Ciriolo, Maria Rosa/K-6572-2016	Sitia, Roberto/0000-0001-7086-4152; fassio, anna/0000-0002-8801-038X; Fagioli, Claudio/0000-0001-9889-4695; Filomeni, Giuseppe/0000-0002-2719-1412; Ciriolo, Maria Rosa/0000-0002-7863-9029; Pasqualetto, Elena/0000-0003-2130-1577	Telethon [GP0117Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fagioli C, 2001, J BIOL CHEM, V276, P40962, DOI 10.1074/jbc.M107456200; FAHEY RC, 1977, J MOL EVOL, V10, P155, DOI 10.1007/BF01751808; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jansens A, 2002, SCIENCE, V298, P2401, DOI 10.1126/science.1078376; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pagani M, 2001, FEBS LETT, V508, P117, DOI 10.1016/S0014-5793(01)03034-4; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Yoneda T, 2002, GENE DEV, V16, P1307, DOI 10.1101/gad.1000902	39	115	125	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32667	32673		10.1074/jbc.M404992200	http://dx.doi.org/10.1074/jbc.M404992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161913	Green Published, hybrid			2022-12-25	WOS:000222849700085
J	Sekiya, F; Poulin, B; Kim, YJ; Rhee, SG				Sekiya, F; Poulin, B; Kim, YJ; Rhee, SG			Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1 - Tyrosine 783 phosphorylation is not sufficient for lipase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; CELL ANTIGEN RECEPTOR; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR; ARACHIDONIC-ACID; GENETIC-EVIDENCE; SH2 DOMAINS; C-GAMMA-1	Phospholipase C-gamma1 (PLC-gamma1) is phosphorylated on three tyrosine residues: Tyr-771, Tyr-783, and Tyr-1253. With the use of antibodies specific for each of these phosphorylation sites, we have now determined the kinetics and magnitude of phosphorylation at each site. Phosphorylation of Tyr-783, which is essential for lipase activation, was observed in all stimulated cell types examined. The extent of phosphorylation of Tyr-1253 was similar to50 to 70% of that of Tyr-783 in cells stimulated with platelet-derived growth factor ( PDGF) or epidermal growth factor (EGF), but Tyr-1253 phosphorylation was not detected in B or T cell lines stimulated through Band T-cell antigen receptors, respectively. Tyr-771 was phosphorylated only at a low level in all cells studied. In cells stimulated with PDGF, phosphorylation and dephosphorylation of Tyr-783 and of Tyr-1253 occurred with similar kinetics; the receptor kinase appeared to phosphorylate both sites, albeit with Tyr-783 favored over Tyr-1253, before the bound PLC-gamma1 was released, and phosphorylation at the two sites occurred independently. PDGF and EGF induced similar levels of phosphorylation of Tyr-783 and of Tyr-1253 in a cell line that expressed receptors for both growth factors. However, only PDGF, not EGF, elicited substantial PLC activity, suggesting that Tyr-783 phosphorylation was not sufficient for enzyme activation. Finally, concurrent production of phosphatidylinositol 3,4,5-trisphosphate was found to contribute to the activation of phosphorylated PLC-gamma1.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University; Ewha Womans University	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.	sgrhee@nih.gov						Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; CUNNINGHAM TW, 1989, J BIOL CHEM, V264, P15351; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; LAROSE L, 1993, ONCOGENE, V8, P2493; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Pawson T, 2000, GENE DEV, V14, P1027; Poulin B, 2000, J BIOL CHEM, V275, P6411, DOI 10.1074/jbc.275.9.6411; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Singh SM, 2003, PROTEIN SCI, V12, P1934, DOI 10.1110/ps.0358803; Smith AJ, 2001, J BIOL CHEM, V276, P17213, DOI 10.1074/jbc.M100417200; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUH PG, 1988, J BIOL CHEM, V263, P14497; Sung JY, 2001, J NEUROCHEM, V78, P1044, DOI 10.1046/j.1471-4159.2001.00491.x; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tvorogov D, 2002, EXP CELL RES, V277, P86, DOI 10.1006/excr.2002.5545; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL M, 1988, J BIOL CHEM, V263, P7581; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Zhang L, 1998, Methods Mol Biol, V105, P47; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	53	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32181	32190		10.1074/jbc.M405116200	http://dx.doi.org/10.1074/jbc.M405116200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161916	hybrid			2022-12-25	WOS:000222849700024
J	Desaint, S; Luriau, S; Aude, JC; Rousselet, G; Toledano, MB				Desaint, S; Luriau, S; Aude, JC; Rousselet, G; Toledano, MB			Mammalian antioxidant Defenses are not inducible by H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; HYDROGEN-PEROXIDE; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; MICROARRAY ANALYSIS; CELLULAR-RESPONSE; REDOX REGULATION; P53; GROWTH; CELLS	As an approach to understanding how mammals regulate H2O2 intracellular concentration to prevent its toxicity, we analyzed the genome-wide mRNA profile changes of human cells after treatment with a non-toxic H2O2 concentration. We identified a large and essentially late H2O2 response of induced and repressed genes that unexpectedly comprise few or no antioxidants but mostly apoptosis and cell cycle control activities. The requirement of the p53 regulator for regulating about a third of this H2O2 stimulon and the lack of an associated enhancement of total cellular H2O2 scavenging activity further suggest that H2O2 elicits a stress antiproliferative/ repair response that does not increase antioxidant defenses. We conclude that mammalian antioxidant defenses are constitutive, a finding that contrasts with the oxidant-inducibility of such defenses in microorganisms. This finding might be important in understanding the role of H2O2 as a key signaling molecule in mammals.	CEA Saclay, Lab Stress Oxydants & Canc, Serv Biol Mol Syst, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, Lab Physiogenom, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Toledano, MB (corresponding author), CEA Saclay, Lab Stress Oxydants & Canc, Serv Biol Mol Syst, F-91191 Gif Sur Yvette, France.	toledano@jonas.saclay.cea.fr	Rousselet, Germain/E-3525-2018; AUDE, Jean-Christophe/C-7111-2011	Rousselet, Germain/0000-0002-1710-1639; AUDE, Jean-Christophe/0000-0002-1755-7417				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chuang YYE, 2002, CANCER RES, V62, P6246; De Nigris F, 2001, ANTIOXID REDOX SIGN, V3, P1119, DOI 10.1089/152308601317203620; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jurado J, 2003, J BIOL CHEM, V278, P45546, DOI 10.1074/jbc.M307866200; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; Nakamura Y, 2003, BIOCHEMISTRY-US, V42, P4300, DOI 10.1021/bi0340090; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Schonhoff CM, 2002, BIOCHEMISTRY-US, V41, P13570, DOI 10.1021/bi026262q; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Toledano MB, 2003, TOP CURR GENET, V1, P241; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	37	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31157	31163		10.1074/jbc.M401888200	http://dx.doi.org/10.1074/jbc.M401888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155764	hybrid			2022-12-25	WOS:000222726800032
J	Fabbro, M; Savage, K; Hobson, K; Deans, AJ; Powell, SN; McArthur, GA; Khanna, KK				Fabbro, M; Savage, K; Hobson, K; Deans, AJ; Powell, SN; McArthur, GA; Khanna, KK			BRCA1-BARD1 complexes are required for p53(Ser-15) phosphorylation and a G(1)/S arrest following ionizing radiation-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; TELANGIECTASIA-MUTATED ATM; S-PHASE CHECKPOINT; HISTONE H2AX; CELL-CYCLE; DEPENDENT PHOSPHORYLATION; BRCA1; CHK1; KINASE; CANCER	BRCA1 is a major player in the DNA damage response. This is evident from its loss, which causes cells to become sensitive to a wide variety of DNA damaging agents. The major BRCA1 binding partner, BARD1, is also implicated in the DNA damage response, and recent reports indicate that BRCA1 and BARD1 co-operate in this pathway. In this report, we utilized small interfering RNA to deplete BRCA1 and BARD1 to demonstrate that the BRCA1-BARD1 complex is required for ATM/ ATR (ataxia-telangiectasia-mutated/ATM and Rad3-related)mediated phosphorylation of p53(Ser-15) following IR- and UV radiation-induced DNA damage. In contrast, phosphorylation of a number of other ATM/ ATR targets including H2AX, Chk2, Chk1, and c-jun does not depend on the presence of BRCA1-BARD1 complexes. Moreover, prior ATM/ ATR-dependent phosphorylation of BRCA1 at Ser-1423 or Ser-1524 regulates the ability of ATM/ ATR to phosphorylate p53(Ser-15) efficiently. Phosphorylation of p53(Ser-15) is necessary for an IR-induced G(1)/S arrest via transcriptional induction of the cyclin-dependent kinase inhibitor p21. Consistent with these data, repressing p53(Ser-15) phosphorylation by BRCA1-BARD1 depletion compromises p21 induction and the G(1)/S checkpoint arrest in response to IR but not UV radiation. These findings suggest that BRCA1-BARD1 complexes act as an adaptor to mediate ATM/ ATR-directed phosphorylation of p53, influencing G(1)/S cell cycle progression after DNA damage.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Sch Med, Cent Clin Div, Brisbane, Qld 4072, Australia; Peter MacCallum Canc Inst, Oncol Mol Lab, Melbourne 3002, Australia; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Peter Maccallum Cancer Center; Harvard University; Massachusetts General Hospital	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Hobson, Keith/Q-9306-2019; Deans, Andrew/U-3515-2019; Deans, Andrew J/E-5817-2011; Khanna, Kum Kum/I-1747-2013	Deans, Andrew/0000-0002-5271-4422; Deans, Andrew J/0000-0002-5271-4422; Savage, Kienan/0000-0002-4898-899X; Khanna, Kum Kum/0000-0001-8650-5381				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Lee JH, 2003, MOL CANCER RES, V1, P674; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu QH, 2000, GENE DEV, V14, P1448; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Okubo E, 2003, J VIROL, V77, P1257, DOI 10.1128/JVI.77.2.1257-1267.2003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang Y, 2000, GENE DEV, V14, P927; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	62	116	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31251	31258		10.1074/jbc.M405372200	http://dx.doi.org/10.1074/jbc.M405372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159397	hybrid			2022-12-25	WOS:000222726800044
J	Gourbal, B; Sonuc, N; Bhattacharjee, H; Legare, D; Sundar, S; Ouellette, M; Rosen, BP; Mukhopadhyay, R				Gourbal, B; Sonuc, N; Bhattacharjee, H; Legare, D; Sundar, S; Ouellette, M; Rosen, BP; Mukhopadhyay, R			Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPLIFIED H-CIRCLE; MOLECULAR CHARACTERIZATION; SODIUM STIBOGLUCONATE; PENTAVALENT ANTIMONY; GENE AMPLIFICATION; TARENTOLAE; ARSENITE; AMASTIGOTES; ACCUMULATION; PURIFICATION	Leishmaniasis is a protozoan parasitic disease that affects 12 million people worldwide. The first line choice for the treatment of this disease is antimonial drugs. In the endemic regions, resistance to this class of drugs is a major impediment to treatment. Microbes often become resistant to drugs by mutation or down-regulation of uptake systems, but the uptake system for the antimonial drugs in Leishmania is unknown. In other organisms, aquaglyceroporins have been shown to facilitate uptake of trivalent metalloids. In this study, we report the identification and characterization of aquaglyceroporins from Leishmania major (LmAQP1) and Leishmania tarentolae (LtAQP1), respectively. These Leishmania proteins have the conserved signature motifs of aquaglyceroporins. Transfection of LmAQP1 into three species of Leishmania, L. tarentolae, Leishmania infantum, and L. major, produced hypersensitivity to both As(III) and Sb(III) in all three strains. Increased production of LmAQP1 was detected by immunoblotting. Drug-resistant parasites with various mutations leading to resistance mechanisms became hypersensitive to both metalloids after expression of LmAQP1. Increased rates of uptake of As( III) or Sb( III) correlated with metalloid sensitivity of the wild type and drug-resistant transfectants. Transfection of LmAQP1 in a Pentostam-resistant field isolate also sensitized the parasite in the macrophage-associated amastigote form. One allele of LmAQP1 was disrupted in L. major, and the resulting cells became 10-fold more resistant to Sb( III). This is the first report of the uptake of a metalloid drug by an aquaglyceroporin in Leishmania, suggesting a strategy to reverse resistance in the field.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Laval, Dept Microbiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Univ Munich, Klinikum Grosshadern, Dept Med 2, D-81377 Munich, Germany; Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India	Wayne State University; Laval University; Laval University; University of Munich; Banaras Hindu University (BHU)	Mukhopadhyay, R (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	rmukhopa@med.wayne.edu	Ouellette, Marc/K-8694-2017; GOURBAL, Benjamin E.F./B-3743-2010	Ouellette, Marc/0000-0002-6743-9646; GOURBAL, Benjamin E.F./0000-0003-2097-2563; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM2216-08] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brochu C, 2003, ANTIMICROB AGENTS CH, V47, P3073, DOI 10.1128/AAC.47.10.3073-3079.2003; Choi Christine M, 2002, Am J Clin Dermatol, V3, P91, DOI 10.2165/00128071-200203020-00003; CROFT SL, 1981, COMP BIOCHEM PHYS C, V68, P95, DOI 10.1016/0306-4492(81)90043-5; SILVA Eduardo Sérgio da, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P145, DOI 10.1590/S0036-46652002000300006; DENTON H, 2004, IN PRESS BIOCH J; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; Ferreira CD, 2003, BIOMETALS, V16, P441, DOI 10.1023/A:1022823605068; Guerin PJ, 2002, LANCET INFECT DIS, V2, P564, DOI 10.1016/S1473-3099(02)00372-9; Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; Haimeur A, 1998, ANTIMICROB AGENTS CH, V42, P1689, DOI 10.1128/AAC.42.7.1689; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; Liu ZJ, 2004, J BIOL CHEM, V279, P17312, DOI 10.1074/jbc.M314006200; Liu ZJ, 2002, P NATL ACAD SCI USA, V99, P6053, DOI 10.1073/pnas.092131899; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; Ouellette M, 1998, DRUG RESIST UPDATE, V1, P43, DOI 10.1016/S1368-7646(98)80213-6; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; Ramirez-Solis A, 2004, INORG CHEM, V43, P2954, DOI 10.1021/ic0351592; ROBERTS WL, 1995, ANTIMICROB AGENTS CH, V39, P1234, DOI 10.1128/AAC.39.6.1234; ROBERTS WL, 1993, ANTIMICROB AGENTS CH, V37, P1842, DOI 10.1128/AAC.37.9.1842; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders OI, 1997, J BACTERIOL, V179, P3365, DOI 10.1128/jb.179.10.3365-3367.1997; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; Shaked-Mishan P, 2001, J BIOL CHEM, V276, P3971, DOI 10.1074/jbc.M005423200; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Tsukaguchi H, 1999, AM J PHYSIOL-RENAL, V277, pF685, DOI 10.1152/ajprenal.1999.277.5.F685; WHITE TC, 1988, J BIOL CHEM, V263, P16977; Wysocki R, 2001, MOL MICROBIOL, V40, P1391, DOI 10.1046/j.1365-2958.2001.02485.x	37	195	202	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31010	31017		10.1074/jbc.M403959200	http://dx.doi.org/10.1074/jbc.M403959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138256	hybrid			2022-12-25	WOS:000222726800014
J	Morikawa, Y; Goto, T; Momose, F				Morikawa, Y; Goto, T; Momose, F			Human immunodeficiency virus type 1 Gag assembly through assembly intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA-VIRUS; CRYSTAL-STRUCTURE; CAPSID PROTEIN; DELETION MUTANTS; ESCHERICHIA-COLI; PARTICLES; MYRISTOYLATION; PRECURSOR; HIV; IDENTIFICATION	Human immunodeficiency virus Gag protein self-assembles into spherical particles, and recent reports suggest the formation of assembly intermediates during the process. To understand the nature of such assembly intermediates along with the mechanism of Gag assembly, we employed expression in Escherichia coli and an in vitro assembly reaction. When E. coli expression was performed at 37 degreesC, Gag predominantly assembled to a high order of multimer, apparently equivalent to the virus-like particles obtained following Gag expression in eukaryotic cells, through the formation of low orders of multimer characterized with a discreet sedimentation value of 60 S. Electron microscopy confirmed the presence of spherical particles in the E. coli cells. In contrast, expression at 30 degreesC resulted in the production of only the 60 S form of Gag multimer, and crescent-shaped structures or small patches with double electrondense layers were accumulated, but no complete particles. In vitro assembly reactions using purified Gag protein, when performed at 37 degreesC, also produced the high order of Gag multimers with some 60 S multimers, whereas the 30 degreesC reaction produced only the 60 S multimers. However, when the 60 S multimers were crosslinked so as not to allow conformational changes, in vitro assembly reactions at 37 degreesC did not produce any higher order of multimers. ATP depletion did not halt Gag assembly in the E. coli cells, and the addition of GroEL-GroES to in vitro reactions did not facilitate Gag assembly, indicating that conformational changes rather than protein refolding by chaperonins, induced at 37 degreesC, were solely responsible for the Gag assembly observed here. We suggest that Gag assembles to a capsid through the formation of the 60 S multimer, possibly a key intermediate of the assembly process, accompanied with conformational changes in Gag.	Kitasato Univ, Kitasato Inst Life Sci, Minato Ku, Tokyo 1088641, Japan; Kyoto Univ, Coll Med Technol, Sakyo Ku, Kyoto 6068507, Japan	Kitasato University; Kyoto University	Morikawa, Y (corresponding author), Kitasato Univ, Kitasato Inst Life Sci, Minato Ku, Shirokane 5-9-1, Tokyo 1088641, Japan.	morikawa@lisci.kitasato-u.ac.jp						Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; Campbell S, 1999, J VIROL, V73, P2270, DOI 10.1128/JVI.73.3.2270-2279.1999; Campbell S, 1997, J VIROL, V71, P4425, DOI 10.1128/JVI.71.6.4425-4435.1997; CARRIERE C, 1995, J VIROL, V69, P2366; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715; Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; Gross I, 1998, J VIROL, V72, P4798, DOI 10.1128/JVI.72.6.4798-4810.1998; Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099; Hong S, 2001, J VIROL, V75, P2526, DOI 10.1128/JVI.75.6.2526-2534.2001; HOSHIKAWA N, 1991, J GEN VIROL, V72, P2509, DOI 10.1099/0022-1317-72-10-2509; Kihara A, 1998, J BIOL CHEM, V273, P29770, DOI 10.1074/jbc.273.45.29770; KLIKOVA M, 1995, J VIROL, V69, P1093, DOI 10.1128/JVI.69.2.1093-1098.1995; Lee YM, 1999, J VIROL, V73, P5654, DOI 10.1128/JVI.73.7.5654-5662.1999; Lee YM, 1998, VIROLOGY, V243, P78, DOI 10.1006/viro.1998.9064; Lingappa JR, 1997, J CELL BIOL, V136, P567, DOI 10.1083/jcb.136.3.567; Ma YM, 2004, J VIROL, V78, P52, DOI 10.1128/JVI.78.1.52-60.2004; Ma YM, 2002, J VIROL, V76, P5452, DOI 10.1128/JVI.76.11.5452-5462.2002; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morikawa Y, 1999, J BIOL CHEM, V274, P27997, DOI 10.1074/jbc.274.39.27997; Morikawa Y, 2000, J VIROL, V74, P16, DOI 10.1128/JVI.74.1.16-23.2000; Morikawa Y, 2001, VIROLOGY, V283, P343, DOI 10.1006/viro.2001.0886; Nermut MV, 2003, VIROLOGY, V305, P219, DOI 10.1006/viro.2002.1692; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; PARENT LJ, 1995, J VIROL, V69, P5455, DOI 10.1128/JVI.69.9.5455-5460.1995; Perrin-Tricaud C, 1999, VIROLOGY, V255, P20, DOI 10.1006/viro.1998.9573; RAO ZH, 1995, NATURE, V378, P743, DOI 10.1038/378743a0; REICIN AS, 1995, J VIROL, V69, P642, DOI 10.1128/JVI.69.2.642-650.1995; ROSE JR, 1995, J VIROL, V69, P2751; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; STEWART L, 1990, J VIROL, V64, P5076, DOI 10.1128/JVI.64.10.5076-5092.1990; Tritel M, 2000, J VIROL, V74, P5845, DOI 10.1128/JVI.74.13.5845-5855.2000; Tritel M, 2001, J VIROL, V75, P5473, DOI 10.1128/JVI.75.12.5473-5481.2001; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Wang JJ, 2001, APPL IMMUNOHISTO M M, V9, P371, DOI 10.1097/00022744-200112000-00014; Weldon RA, 1998, J VIROL, V72, P3098, DOI 10.1128/JVI.72.4.3098-3106.1998; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	48	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31964	31972		10.1074/jbc.M313432200	http://dx.doi.org/10.1074/jbc.M313432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152006	hybrid			2022-12-25	WOS:000222726800125
J	Abecassis, L; Rogier, E; Vazquez, A; Atfi, A; Bourgeade, MF				Abecassis, L; Rogier, E; Vazquez, A; Atfi, A; Bourgeade, MF			Evidence for a role of MSK1 in transforming growth factor-beta-mediated responses through p38 alpha and Smad signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TGF-BETA; FUNCTIONAL-CHARACTERIZATION; C-JUN; TRANSCRIPTION; MAPK; TRANSDUCTION; EXPRESSION; PROMOTER; ISOFORMS	Smad proteins are central mediators of the transforming growth factor-beta (TGF-beta) superfamily signaling. The mitogen-activated protein kinase (MAPK) p38 is also one of the downstream targets required for TGF-beta-mediated responses. Although the interplay between the p38 and Smad signaling pathways might allow cells to display diverse patterns of responses to TGF-beta, the mechanism of this cross-talk is not well established. We report here that inhibition of the p38alpha isoform suppressed the ability of Smad3 to mediate TGF-beta-induced transcriptional responses. The inhibition of p38 activity blocked TGF-beta-mediated phosphorylation of the MSK1 kinase, a substrate of p38 that plays an important role in the remodeling of chromatin. Moreover, we observed that expression of dominant-interfering mutants of MSK1 blocked the binding of Smad3 to the coactivator p300 in response to TGF-beta signaling. These data reveal a new mechanism whereby the Smad signaling pathway and the p38 cascade are integrated in the nucleus to activate gene expression.	Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, France; Hop St Antoine, INSERM, U482, F-75771 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bourgeade, MF (corresponding author), Hop Paul Brousse, INSERM, U542, Batiment Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	bourgeade@vjf.inserm.fr						Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Hale KK, 1999, J IMMUNOL, V162, P4246; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Markou T, 2002, BIOCHEM J, V365, P757, DOI 10.1042/BJ20011828; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Yue JB, 2000, METH MOL B, V142, P125	20	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30474	30479		10.1074/jbc.M403294200	http://dx.doi.org/10.1074/jbc.M403294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133024	hybrid			2022-12-25	WOS:000222531900075
J	Chiang, CS; Stacey, G; Tsay, YF				Chiang, CS; Stacey, G; Tsay, YF			Mechanisms and functional properties of two peptide transporters, AtPTR2 and fPTR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED OLIGOPEPTIDE TRANSPORTER; NITRATE TRANSPORTER; PEPTIDE/HISTIDINE TRANSPORTER; TISSUE DISTRIBUTION; EXPRESSION CLONING; LACTOCOCCUS-LACTIS; MOLECULAR-CLONING; ESCHERICHIA-COLI; ARABIDOPSIS; GENE	The Arabidopsis AtPTR2 and fungal fPTR2 genes, which encode H+/dipeptide cotransporters, belong to two different subgroups of the peptide transporter (PTR) (NRT1) family. In this study, the kinetics, substrate specificity, stoichiometry, and voltage dependence of these two transporters expressed in Xenopus oocytes were investigated using the two-microelectrode voltage-clamp method. The results showed that: 1) although AtPTR2 belongs to the same PTR family subgroup as certain H+/nitrate cotransporters, neither AtPTR2 nor fPTR2 exhibited any nitrate transporting activity; 2) AtPTR2 and fPTR2 transported a wide spectrum of dipeptides with apparent affinity constants in the range of 30 muM to 3 mM, the affinity being dependent on the side chain structure of both the N- and C-terminal amino acids; 3) larger maximal currents (I-max) were evoked by positively charged dipeptides in AtPTR2- or fPTR2-injected oocytes; 4) a major difference between AtPTR2 and fPTR2 was that, whereas fPTR2 exhibited low Ala-Asp(-) transporting activity, AtPTR2 transported Ala-Asp(-) as efficiently as some of the positively charged dipeptides; 5) kinetic analysis suggested that both fPTR2 and AtPTR2 transported by a random binding, simultaneous transport mechanism. The results also showed that AtPTR2 and fPTR2 were quite distinct from PepT1 and PepT2, two well characterized animal PTR transporters in terms of order of binding of substrate and proton(s), pH sensitivity, and voltage dependence.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Univ Missouri, Dept Microbiol & Plant Pathol, Columbia, MO 65211 USA	Academia Sinica - Taiwan; University of Missouri System; University of Missouri Columbia	Tsay, YF (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	yftsay@gate.sinica.edu.tw	Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687				Amasheh S, 1997, J MEMBRANE BIOL, V155, P247, DOI 10.1007/s002329900177; Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BASRAI MA, 1995, MICROBIOL-UK, V141, P1147, DOI 10.1099/13500872-141-5-1147; Boll M, 1996, P NATL ACAD SCI USA, V93, P284, DOI 10.1073/pnas.93.1.284; CAO YW, 1992, PLANT CELL, V4, P961, DOI 10.1105/tpc.4.8.961; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; DANIEL H, 1992, J BIOL CHEM, V267, P9565; Fang G, 2000, J BACTERIOL, V182, P2530, DOI 10.1128/JB.182.9.2530-2535.2000; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FROMMER WB, 1994, FEBS LETT, V347, P185, DOI 10.1016/0014-5793(94)00533-8; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Herrera-Ruiz D, 2003, J PHARM SCI-US, V92, P691, DOI 10.1002/jps.10303; Huang NC, 1996, PLANT CELL, V8, P2183, DOI 10.1105/tpc.8.12.2183; Huang NC, 1999, PLANT CELL, V11, P1381, DOI 10.1105/tpc.11.8.1381; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Lin CM, 2000, PLANT PHYSIOL, V122, P379, DOI 10.1104/pp.122.2.379; LIU W, 1995, BBA-BIOMEMBRANES, V1235, P461, DOI 10.1016/0005-2736(95)80036-F; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Miyamoto K, 1996, BBA-GENE STRUCT EXPR, V1305, P34, DOI 10.1016/0167-4781(95)00208-1; MULDIN I, 1995, PLANT PHYSIOL, V108, P1341; Nakajima H, 1997, APPL ENVIRON MICROB, V63, P2213, DOI 10.1128/AEM.63.6.2213-2217.1997; PAULSEN IT, 1994, TRENDS BIOCHEM SCI, V19, P404, DOI 10.1016/0968-0004(94)90087-6; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Roche JP, 1998, J NEUROSCI, V18, P4883; Roman G, 1998, AM J PHYSIOL-CELL PH, V275, pC857, DOI 10.1152/ajpcell.1998.275.3.C857; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Saito H, 1996, BBA-BIOMEMBRANES, V1280, P173, DOI 10.1016/0005-2736(96)00024-7; Saito H, 1995, J PHARMACOL EXP THER, V275, P1631; Sakata K, 2001, BIOCHEM J, V356, P53, DOI 10.1042/0264-6021:3560053; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Song W, 1996, PLANT PHYSIOL, V110, P171, DOI 10.1104/pp.110.1.171; Stacey G, 2002, TRENDS PLANT SCI, V7, P257, DOI 10.1016/S1360-1385(02)02249-5; STEINER HY, 1994, PLANT CELL, V6, P1289, DOI 10.1105/tpc.6.9.1289; Steiner HY, 2000, PLANT CELL, V12, P2295; Szczyglowski K, 1997, PLANT PHYSIOL, V114, P1335, DOI 10.1104/pp.114.4.1335; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; West CE, 1998, PLANT J, V15, P221, DOI 10.1046/j.1365-313X.1998.00199.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yamashita T, 1997, J BIOL CHEM, V272, P10205; Zhou JJ, 1998, J BIOL CHEM, V273, P12017, DOI 10.1074/jbc.273.20.12017	43	69	72	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30150	30157		10.1074/jbc.M405192200	http://dx.doi.org/10.1074/jbc.M405192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138259	hybrid			2022-12-25	WOS:000222531900036
J	Kato, M; Ito, T; Wagner, G; Ellenberger, T				Kato, M; Ito, T; Wagner, G; Ellenberger, T			A molecular handoff between bacteriophage T7 DNA primase and T7 DNA polymerase initiates DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENE 2.5 PROTEIN; CARBOXYL-TERMINAL DOMAIN; RNA PRIMER SYNTHESIS; BINDING-PROTEIN; TEMPLATE RECOGNITION; CRYSTAL-STRUCTURE; HELICASE-PRIMASE; DEOXYRIBONUCLEIC-ACID; ANGSTROM RESOLUTION	The T7 DNA primase synthesizes tetraribonucleotides that prime DNA synthesis by T7 DNA polymerase but only on the condition that the primase stabilizes the primed DNA template in the polymerase active site. We used NMR experiments and alanine scanning mutagenesis to identify residues in the zinc binding domain of T7 primase that engage the primed DNA template to initiate DNA synthesis by T7 DNA polymerase. These residues cover one face of the zinc binding domain and include a number of aromatic amino acids that are conserved in bacteriophage primases. The phage T7 single-stranded DNA-binding protein gp2.5 specifically interfered with the utilization of tetraribonucleotide primers by interacting with T7 DNA polymerase and preventing a productive interaction with the primed template. We propose that the opposing effects of gp2.5 and T7 primase on the initiation of DNA synthesis reflect a sequence of mutually exclusive interactions that occur during the recycling of the polymerase on the lagging strand of the replication fork.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu	Ito, Takuhiro/N-6893-2015	Ito, Takuhiro/0000-0003-3704-5205	NIGMS NIH HHS [GM55390, P01 GM047467, GM47467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055390, P01GM047467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 2001, ANNU REV BIOCHEM, V70, P39, DOI 10.1146/annurev.biochem.70.1.39; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; Higgins D G, 1994, Methods Mol Biol, V25, P307; HILL J, 1979, ANN BOT-LONDON, V43, P449, DOI 10.1093/oxfordjournals.aob.a085655; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Hyland EM, 2003, J BIOL CHEM, V278, P7247, DOI 10.1074/jbc.M210605200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Kato M, 2001, J BIOL CHEM, V276, P21809, DOI 10.1074/jbc.M101470200; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kornberg A., 1992, DNA REPLICATION; Kusakabe T, 1999, P NATL ACAD SCI USA, V96, P4295, DOI 10.1073/pnas.96.8.4295; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lee SJ, 2001, J BIOL CHEM, V276, P49419, DOI 10.1074/jbc.M108443200; Lee SJ, 2002, P NATL ACAD SCI USA, V99, P12703, DOI 10.1073/pnas.202471499; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; ROWEN L, 1978, J BIOL CHEM, V253, P770; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHERZINGER E, 1975, MOL GEN GENET, V141, P233, DOI 10.1007/BF00341802; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STUDIER FW, 1982, COLD SPRING HARB SYM, V47, P999, DOI 10.1101/SQB.1983.047.01.114; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	58	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30554	30562		10.1074/jbc.M403485200	http://dx.doi.org/10.1074/jbc.M403485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133047	hybrid			2022-12-25	WOS:000222531900085
J	Morel, N; Simon, S; Frobert, Y; Volland, H; Mourton-Gilles, C; Negro, A; Sorgato, MC; Creminon, C; Grassi, J				Morel, N; Simon, S; Frobert, Y; Volland, H; Mourton-Gilles, C; Negro, A; Sorgato, MC; Creminon, C; Grassi, J			Selective and efficient immunoprecipitation of the disease-associated form of the prion protein can be mediated by nonspecific interactions between monoclonal antibodies and scrapie-associated fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNIZATION; IMMUNOASSAY; CONVERSION; MOLECULES; HAPTENS; PLASMA; PRPSC	Transmissible spongiform encephalopathies are characterized by the accumulation in brain tissues of an abnormal isoform of the prion protein named PrPsc, which is the only direct marker known for transmissible spongiform encephalopathies. Here we show that PrPsc can be specifically immunoprecipitated by using several monoclonal antibodies (mAbs) of various specificities independently of the properties of their binding site (paratope). These results strongly suggest that a significant proportion of mAbs can interact with PrPsc aggregates through nonspecific paratope-independent interactions allowing selective immunoprecipitation of PrPsc when these mAbs are immobilized on a polydisperse solid phase like microbeads.	CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France; Fac Pharm Montpellier, CNRS, UMR 5160, F-34093 Montpellier 5, France; Univ Padua, CRIBI, I-35100 Padua, Italy; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Padua; University of Padua	Grassi, J (corresponding author), CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France.	jacques.grassi@cea.fr	Morel, Nathalie/O-9012-2016; Simon, Stephanie/E-4289-2012	Simon, Stephanie/0000-0002-6071-8255; NEGRO, ALESSANDRO/0000-0003-3142-7632	Telethon [E.0945] Funding Source: Medline	Telethon(Fondazione Telethon)		Andreoletti O, 2000, J GEN VIROL, V81, P3115, DOI 10.1099/0022-1317-81-12-3115; Ben-Zaken O, 2003, J BIOL CHEM, V278, P40041, DOI 10.1074/jbc.M301152200; Bieschke J, 2000, P NATL ACAD SCI USA, V97, P5468, DOI 10.1073/pnas.97.10.5468; BON S, 1987, J NEUROCHEM, V49, P1720, DOI 10.1111/j.1471-4159.1987.tb02429.x; CURIN S, 2004, J BIOL CHEM, V279, P3694; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Grassi J, 1996, CLIN CHEM, V42, P1532; Grassi J, 2000, Arch Virol Suppl, P197; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Krasemann S, 1996, J IMMUNOL METHODS, V199, P109, DOI 10.1016/S0022-1759(96)00165-2; Krasemann S, 1999, J BIOTECHNOL, V73, P119, DOI 10.1016/S0168-1656(99)00115-7; Meggio F, 2000, BIOCHEM J, V352, P191, DOI 10.1042/0264-6021:3520191; Molina F, 1996, PEPTIDE RES, V9, P151; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; PRADELLES P, 1994, ANAL CHEM, V66, P16, DOI 10.1021/ac00073a005; PRADELLES P, 1990, BIOCHEM BIOPH RES CO, V170, P986, DOI 10.1016/0006-291X(90)90489-A; Schonberger O, 2003, BIOCHEM BIOPH RES CO, V312, P473, DOI 10.1016/j.bbrc.2003.10.150; Volland H, 1999, J IMMUNOL METHODS, V228, P37, DOI 10.1016/S0022-1759(99)00097-6; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	23	49	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30143	30149		10.1074/jbc.M403896200	http://dx.doi.org/10.1074/jbc.M403896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140886	hybrid			2022-12-25	WOS:000222531900035
J	Fera, E; O'Neil, C; Lee, W; Li, SH; Pickering, JG				Fera, E; O'Neil, C; Lee, W; Li, SH; Pickering, JG			Fibroblast growth factor-2 and remodeled type I collagen control membrane protrusion in human vascular smooth muscle cells - Biphasic activation of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(2)BETA(1) INTEGRIN; RHO GTPASES; MIGRATION; EXPRESSION; MATRIX; CLEAVAGE; PROLIFERATION; CYTOSKELETON; ADHESION; RELEASE	Plasma membrane protrusion is fundamental to cell motility, but its regulation by the extracellular environment is not well elucidated. We have quantified lamellipodial protrusion dynamics in human vascular smooth muscle cells exposed to fibroblast growth factor 2 (FGF-2) and type I collagen, two distinct ligands presented to vascular cells during arterial remodeling. Video microscopy revealed that FGF-2 stimulated a modest increase in lamellipodial protrusion rate that peaked within 15 min. This response was associated with immediate but transient activation of Rac1 and was inhibited in cells infected with retrovirus containing cDNA encoding dominant-negative Rac1. A 1-h exposure to FGF-2 also set up a second phase of more striking lamellipodial protrusion evident at 24-36 h. This delayed response was most pronounced when cells were on type 1 collagen and was associated with FGF-2-induced expression of collagenase-1 that localized to the edge of protruding lamellipodia. Moreover, late membrane protrusion was inhibited when cells were on collagenase-resistant type I collagen, implicating degraded collagen as a mediator. For cells on collagen, the immediate activation of Rac1 by FGF-2 was followed by a sustained wave of Rac1 activation that was inhibited when cleavage of the collagen triple helix was prevented and also by blockade of alpha(v)beta(3) integrin. We conclude that lamellipodial protrusion in smooth muscle cells can be regulated by waves of Rac1 activation, corresponding to the sequential presentation of FGF-2 and remodeled collagen. The findings thus reveal a previously unrecognized level of coordination among extracellular input that enables cells to maintain protrusive activity over prolonged periods.	Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Med Cardiol, London, ON N6A 5A5, Canada; Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Biochem, London, ON N6A 5A5, Canada; Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Med Biophys, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Pickering, JG (corresponding author), Univ Western Ontario, Robarts Res Inst, Vasc Biol Grp, London Hlth Sci Ctr,Dept Med Cardiol, 339 Windermere Rd, London, ON N6A 5A5, Canada.	gpickering@robarts.ca	Pickering, J. Geoffrey/G-3341-2011	Pickering, J. Geoffrey/0000-0001-6474-3274				Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BILATO C, 1995, J CLIN INVEST, V96, P1905, DOI 10.1172/JCI118236; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; JACKSON CL, 1993, AM J PATHOL, V143, P1024; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Li SH, 2000, J BIOL CHEM, V275, P35384, DOI 10.1074/jbc.M005139200; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Messent AJ, 1998, J CELL SCI, V111, P1127; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pickering JG, 1997, ARTERIOSCL THROM VAS, V17, P475, DOI 10.1161/01.ATV.17.3.475; PICKERING JG, 1993, J CLIN INVEST, V91, P724, DOI 10.1172/JCI116254; Pickering JG, 2000, AM J PATHOL, V156, P453, DOI 10.1016/S0002-9440(10)64750-5; Pickering JG, 1997, CIRC RES, V80, P627, DOI 10.1161/01.RES.80.5.627; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Rocnik EF, 2002, J BIOL CHEM, V277, P38571, DOI 10.1074/jbc.M206689200; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	38	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35573	35582		10.1074/jbc.M400711200	http://dx.doi.org/10.1074/jbc.M400711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15166228	hybrid			2022-12-25	WOS:000223303400053
J	Munro, P; Flatau, G; Doye, A; Boyer, L; Oregioni, O; Mege, JL; Landraud, L; Lemichez, E				Munro, P; Flatau, G; Doye, A; Boyer, L; Oregioni, O; Mege, JL; Landraud, L; Lemichez, E			Activation and proteasomal degradation of rho GTPases by cytotoxic necrotizing factor-1 elicit a controlled inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE-SYSTEM; CHEMOKINES; HOST; INFECTION; BINDING; CELLS; RAC	The CNF1 toxin is produced by uropathogenic and meningitis-causing Escherichia coli. CNF1 penetrates autonomously into cells and confers phagocytic properties to epithelial and endothelial cells. CNF1 acts at the molecular level by constitutively activating Rho GTPases attenuated by their cellular ubiquitin-mediated proteasomal degradation. Here we report the relationship between the ubiquitin-mediated proteasomal degradation of activated Rho and the endothelial cell response to the toxin. The type of cellular response to CNF1 intoxication, first screened by DNA microarray analysis, revealed the launching of a program oriented toward an inflammatory response. Parallel to Rho protein activation by CNF1, we also established the kinetics of production of monocyte chemotactic protein-1 (MCP1), interleukin-8 (IL-8), IL-6, monocyte inflammatory protein-3alpha(MIP-3alpha) and E-selectin. Both the mutation of the catalytic domain of the toxin (CNF1-C866S) and the inhibition of Rho proteins abrogate the CNF1-induced production of the immunomodulators MIP-3alpha, MCP-1, and IL-8. These immunomodulators are also produced upon activation of Cdc42 and Rac preferentially. Our results indicate that, in addition to pathogen molecular pattern recognition by host-receptors, a direct activation of Rho proteins by the CNF1 virulence factor efficiently triggers a cellular reaction of host alert. Consistently, we assume that the CNF1-induced ubiquitin-mediated proteasomal degradation of activated Rho proteins may limit the amplitude of the host cell immune responses.	Fac Med Nice, INSERM, U627, F-06107 Nice 2, France; Univ Mediterranee, Fac Med, Unite Rickettsies, CNRS,UMR 6020, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Lemichez, E (corresponding author), Fac Med Nice, INSERM, U627, 28 Ave Valombrose, F-06107 Nice 2, France.	lemichez@unice.fr	MEGE, JEAN-LOUIS/O-6063-2016; Munro, Patrick/A-6579-2009; BOYER, Laurent/AAH-4543-2021; Landraud, Luce/HGB-1249-2022; Lemichez, Emmanuel/G-3559-2013; Boyer, laurent/F-8921-2015	Munro, Patrick/0000-0003-4283-4671; BOYER, Laurent/0000-0002-1375-1706; Landraud, Luce/0000-0001-8486-1403; Lemichez, Emmanuel/0000-0001-9080-7761; Boyer, laurent/0000-0002-1375-1706				Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Barbieri JT, 2002, ANNU REV CELL DEV BI, V18, P315, DOI 10.1146/annurev.cellbio.18.012502.134748; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boquet P, 2003, TRENDS CELL BIOL, V13, P238, DOI 10.1016/S0962-8924(03)00037-0; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Hubbell E, 2002, BIOINFORMATICS, V18, P1585, DOI 10.1093/bioinformatics/18.12.1585; Janeway CA, 2001, P NATL ACAD SCI USA, V98, P7461, DOI 10.1073/pnas.131202998; Khan NA, 2002, J BIOL CHEM, V277, P15607, DOI 10.1074/jbc.M112224200; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Kubori T, 2003, CELL, V115, P333, DOI 10.1016/S0092-8674(03)00849-3; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lerm M, 1999, J BIOL CHEM, V274, P28999, DOI 10.1074/jbc.274.41.28999; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mysorekar IU, 2002, J BIOL CHEM, V277, P7412, DOI 10.1074/jbc.M110560200; Pedron T, 2003, J BIOL CHEM, V278, P33878, DOI 10.1074/jbc.M303749200; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Shapiro SD, 2003, NATURE, V421, P223, DOI 10.1038/421223a; Szyperski T, 1998, P NATL ACAD SCI USA, V95, P2262, DOI 10.1073/pnas.95.5.2262; VANNHIEU GT, 2000, CELL MICROBIOL, V2, P187, DOI DOI 10.1046/J.1462-5822.2000.00046.X; WAKAI Y, 2001, PHYSIOL REV, V81, P153; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang YX, 2000, J BIOL CHEM, V275, P4687, DOI 10.1074/jbc.275.7.4687; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024	37	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35849	35857		10.1074/jbc.M401580200	http://dx.doi.org/10.1074/jbc.M401580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15152002	hybrid			2022-12-25	WOS:000223303400086
J	Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR				Xing, YN; Myers, RV; Cao, DH; Lin, W; Jiang, M; Bernard, MP; Moyle, WR			Glycoprotein hormone assembly in the endoplasmic reticulum - II. Multiple roles of a redox sensitive beta-subunit disulfide switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ALPHA-SUBUNIT; STIMULATING-HORMONE; PROTEIN; RECEPTOR; CHORIOGONADOTROPIN; FOLLITROPIN; LUTROPIN; BINDING; CONFORMATION	All three human glycoprotein hormone heterodimers are assembled in the endoplasmic reticulum by threading the glycosylated end of alpha-subunit loop two (alpha2) beneath a disulfide "latched" strand of the beta-subunit known as the "seatbelt." This remarkable event occurs efficiently even though the seatbelt effectively blocks the reverse process, thereby stabilizing each heterodimer. Studies described here show that assembly is facilitated by the formation, disruption, and reformation of a loop within the seatbelt that is stabilized by the most easily reduced disulfide in the free beta-subunit. We refer to this disulfide as the "tensor" because it shortens the seatbelt, thereby securing the heterodimer. Formation of the tensor disulfide appears to precede and facilitate seatbelt latching in most human choriogonadotropin beta-subunit molecules. Subsequent disruption of the tensor disulfide elongates the seatbelt, thereby increasing the space beneath the seatbelt and the beta-subunit core. This permits the formation of hydrogen bonds between backbone atoms of the beta-subunit cystine knot and the tensor loop with backbone atoms in loop alpha2, a process that causes the glycosylated end of loop alpha2 to be threaded between the seatbelt and the beta-subunit core. Contacts between the tensor loop and loop alpha2 promote reformation of the tensor disulfide, which explains why it is more stable in the heterodimer than in the uncombined beta-subunit. These findings unravel the puzzling nature of how a threading mechanism can be used in the endoplasmic reticulum to assemble glycoprotein hormones that have essential roles in vertebrate reproduction and thyroid function.	Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Rutgers Med Sch, Dept Obstet & Gynecol, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R37HD014907, R01HD038547] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DeBeer T, 1996, EUR J BIOCHEM, V241, P229; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; HUTH JR, 1993, J BIOL CHEM, V268, P16472; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Lin W, 1999, MOL CELL ENDOCRINOL, V152, P91, DOI 10.1016/S0303-7207(99)00056-8; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; STRICKLAND TW, 1982, J BIOL CHEM, V257, P2954; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P35449, DOI 10.1074/jbc.M403054200; Xing YN, 2004, J BIOL CHEM, V279, P35458, DOI 10.1074/jbc.M403055200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2003, BIOCHEM BIOPH RES CO, V303, P201, DOI 10.1016/S0006-291X(03)00322-X; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; Xing YN, 2001, PROTEIN SCI, V10, P226, DOI 10.1110/ps.25901	24	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35437	35448		10.1074/jbc.M403053200	http://dx.doi.org/10.1074/jbc.M403053200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15161903	hybrid			2022-12-25	WOS:000223303400037
J	Mould, J; Yasuda, T; Schroeder, CI; Beedle, AM; Doering, CJ; Zamponi, GW; Adams, DJ; Lewis, RJ				Mould, J; Yasuda, T; Schroeder, CI; Beedle, AM; Doering, CJ; Zamponi, GW; Adams, DJ; Lewis, RJ			The alpha(2)delta auxiliary subunit reduces affinity of omega-conotoxins for recombinant N-type (Ca(v)2.2) calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLION; CA2+ CHANNEL; RAT-BRAIN; NEUROPATHIC PAIN; BETA-SUBUNITS; XENOPUS OOCYTES; TRANSMITTER RELEASE; GENE-EXPRESSION; IDENTIFICATION; ALPHA(1B)	The omega-conotoxins from fish-hunting cone snails are potent inhibitors of voltage-gated calcium channels. The omega-conotoxins MVIIA and CVID are selective N-type calcium channel inhibitors with potential in the treatment of chronic pain. The beta and alpha(2)delta-1 auxiliary subunits influence the expression and characteristics of the alpha(1B) subunit of N-type channels and are differentially regulated in disease states, including pain. In this study, we examined the influence of these auxiliary subunits on the ability of the omega-conotoxins GVIA, MVIIA, CVID and analogues to inhibit peripheral and central forms of the rat N-type channels. Although the beta3 subunit had little influence on the on- and off-rates of omega-conotoxins, coexpression of alpha(2)delta with alpha(1B) significantly reduced on- rates and equilibrium inhibition at both the central and peripheral isoforms of the N-type channels. The alpha(2)delta also enhanced the selectivity of MVIIA, but not CVID, for the central isoform. Similar but less pronounced trends were also observed for N-type channels expressed in human embryonic kidney cells. The influence of alpha(2)delta was not affected by oocyte deglycosylation. The extent of recovery from the omega-conotoxin block was least for GVIA, intermediate for MVIIA, and almost complete for CVID. Application of a hyperpolarizing holding potential ( - 120 mV) did not significantly enhance the extent of CVID recovery. Interestingly, [R10K] MVIIA and [O10K] GVIA had greater recovery from the block, whereas [K10R] CVID had reduced recovery from the block, indicating that position 10 had an important influence on the extent of omega-conotoxin reversibility. Recovery from CVID block was reduced in the presence of alpha(2)delta in human embryonic kidney cells and in oocytes expressing alpha(1B-b). These results may have implications for the antinociceptive properties of omega-conotoxins, given that the alpha(2)delta subunit is up-regulated in certain pain states.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Queensland; University of Queensland; University of Calgary	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard J/E-8674-2013; Beedle, Aaron/AAI-7014-2020; Adams, David John/K-3578-2019; Lewis, Richard/T-8763-2019; Schroeder, Cristina I./K-2042-2014; Beedle, Aaron M/K-1902-2015	Lewis, Richard J/0000-0003-3470-923X; Adams, David John/0000-0002-7030-2288; Lewis, Richard/0000-0003-3470-923X; Schroeder, Cristina I./0000-0002-6737-6374; Beedle, Aaron M/0000-0002-1019-3235; Zamponi, Gerald W./0000-0002-0644-9066				Abe M, 2002, SPINE, V27, P1517, DOI 10.1097/00007632-200207150-00007; Adams DJ, 2003, J BIOL CHEM, V278, P4057, DOI 10.1074/jbc.M209969200; ADAMS ME, 1993, BIOCHEMISTRY-US, V32, P12566, DOI 10.1021/bi00210a003; Atanassoff PG, 2000, REGION ANESTH PAIN M, V25, P274, DOI 10.1016/S1098-7339(00)90010-5; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; COUSINS MJ, 2003, P 10 WORLD C PAIN PR, pA615; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DUNLAP K, 1994, SCIENCE, V266, P828, DOI 10.1126/science.7973643; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Felix R, 1997, J NEUROSCI, V17, P6884; Feng ZP, 2003, J BIOL CHEM, V278, P20171, DOI 10.1074/jbc.M300581200; Feng ZP, 2001, J BIOL CHEM, V276, P15728, DOI 10.1074/jbc.M100406200; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P2403, DOI 10.1517/13543784.9.10.2403; Jones LP, 1998, J GEN PHYSIOL, V112, P125, DOI 10.1085/jgp.112.2.125; Kaneko S, 2002, J NEUROSCI, V22, P82, DOI 10.1523/JNEUROSCI.22-01-00082.2002; Kim DS, 2001, MOL BRAIN RES, V96, P151, DOI 10.1016/S0169-328X(01)00285-6; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; Levin T, 2002, PSYCHOSOMATICS, V43, P63, DOI 10.1176/appi.psy.43.1.63; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; Lin ZX, 1999, J NEUROSCI, V19, P5322; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Ludwig A, 1997, J NEUROSCI, V17, P1339; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; Meadows HJ, 1999, ANN NY ACAD SCI, V868, P224, DOI 10.1111/j.1749-6632.1999.tb11291.x; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Newton RA, 2001, MOL BRAIN RES, V95, P1, DOI 10.1016/S0169-328X(01)00188-7; Nielsen KJ, 1999, J MOL BIOL, V289, P1405, DOI 10.1006/jmbi.1999.2817; Nielsen KJ, 1999, BIOCHEMISTRY-US, V38, P6741, DOI 10.1021/bi982980u; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Qin N, 1998, AM J PHYSIOL-CELL PH, V274, pC1324, DOI 10.1152/ajpcell.1998.274.5.C1324; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Scott DA, 2002, EUR J PHARMACOL, V451, P279, DOI 10.1016/S0014-2999(02)02247-1; Smith MT, 2002, PAIN, V96, P119, DOI 10.1016/S0304-3959(01)00436-5; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; Stocker JW, 1997, J NEUROSCI, V17, P3002; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; Wakamori M, 1999, J PHYSIOL-LONDON, V517, P659, DOI 10.1111/j.1469-7793.1999.0659s.x; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; Wu LG, 1999, J NEUROSCI, V19, P726; Xiao HS, 2002, P NATL ACAD SCI USA, V99, P8360, DOI 10.1073/pnas.122231899; YAMADA K, 1994, NEUROPHARMACOLOGY, V33, P251, DOI 10.1016/0028-3908(94)90016-7; Yasuda T, 2004, J GEN PHYSIOL, V123, P401, DOI 10.1085/jgp.200308967	53	64	71	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34705	34714		10.1074/jbc.M310848200	http://dx.doi.org/10.1074/jbc.M310848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15166237	hybrid			2022-12-25	WOS:000223134800076
J	Aoki, K; Uchiyama, R; Yamauchi, S; Katayama, T; Itonori, S; Sugita, M; Hada, N; Yamada-Hada, J; Takeda, T; Kumagai, H; Yamamoto, K				Aoki, K; Uchiyama, R; Yamauchi, S; Katayama, T; Itonori, S; Sugita, M; Hada, N; Yamada-Hada, J; Takeda, T; Kumagai, H; Yamamoto, K			Newly discovered neutral glycosphingolipids in Aureobasidin A-resistant Zygomycetes - Identification of a novel family of gala-series glycolipids with core Gal alpha 1-6Gal beta 1-6Gal beta sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID BIOSYNTHESIS; TRANSPLANT RECIPIENT; OLIGOSACCHARIDES; MUCORMYCOSIS; INHIBITION; SUGAR; CELLS; FUNGI	We found for the first time that Zygomycetes species showed resistance to Aureobasidin A, an antifungal agent. A novel family of neutral glycosphingolipids (GSLs) was found in these fungi and isolated from Mucor hiemalis, which is a typical Zygomycetes species. Their structures were completely determined by compositional sugar, fatty acid, and sphingoid analyses, methylation analysis, matrix-assisted laser desorption ionization time-of-flight/mass spectrometry, and H-1 NMR spectroscopy. They were as follows: Galbeta1-6Galbeta1-1Cer (CDS), Galalpha1-6Galbeta1-6Galbeta1-1Cer (CTS), Galalpha1-6Galalpha1-6Galbeta1-6Galbeta1-1Cer (CTeS), and Galalpha1-6Galalpha1-6Galalpha1-6Galbeta1-6Galbeta1-1Cer (CPS). The ceramide moieties of these GSLs consist of 24: 0, 25: 0, and 26: 0 2-hydroxy acids as major fatty acids and 4-hydroxyoctadecasphinganine ( phytosphingosine) as the sole sphingoid. However, the glycosylinositolphosphoceramide families that are the major GSLs components in fungi were not detected in Zygomycetes at all. This seems to be the reason that Aureobasidin A is not effective for Zygomycetes as an antifungal agent. Our results indicate that the biosynthetic pathway for GSLs in Zygomycetes is significantly different from those in other fungi and suggest that any inhibitor of this pathway may be effective for mucormycosis, which is a serious pathogenic disease for humans.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; Shiga Univ Med Sci, Fac Liberal Arts & Educ, Shiga 5200862, Japan; Kyoritsu Univ Pharm, Minato Ku, Tokyo 1058512, Japan	Kyoto University; Shiga University of Medical Science	Aoki, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Oiwake Cho, Kyoto 6068502, Japan.	kaoki@lif.kyoto-u.ac.jp	Aoki, Kazuhiro/H-8283-2014	Katayama, Takane/0000-0003-4009-7874; Aoki, Kazuhiro/0000-0003-0029-4291				Aoki K, 2004, BIOCHEM J, V378, P461, DOI 10.1042/BJ20031307; CARAVEO J, 1977, AM J MED, V62, P404, DOI 10.1016/0002-9343(77)90838-5; Cheng JJ, 2001, MOL CELL BIOL, V21, P6198, DOI 10.1128/MCB.21.18.6198-6209.2001; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dai YQ, 1997, CARBOHYD RES, V304, P1, DOI 10.1016/S0008-6215(97)00195-X; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Fischl AS, 2000, METHOD ENZYMOL, V311, P123; FLORENCE P, 1996, INFECT IMMUN, V64, P3682; FUJINO Y, 1977, BIOCHIM BIOPHYS ACTA, V486, P161; Heidler SA, 2000, BBA-MOL BASIS DIS, V1500, P147, DOI 10.1016/S0925-4439(99)00097-6; IKAI K, 1991, J ANTIBIOT, V44, P925, DOI 10.7164/antibiotics.44.925; Itonori S, 2004, J LIPID RES, V45, P574, DOI 10.1194/jlr.D300030-JLR200; KADOWAKI S, 1990, AGR BIOL CHEM TOKYO, V54, P97, DOI 10.1080/00021369.1990.10869923; KADOWAKI S, 1989, AGR BIOL CHEM TOKYO, V53, P111, DOI 10.1080/00021369.1989.10869270; Kremery V, 1996, SUPPORT CARE CANCER, V4, P39, DOI 10.1007/BF01769874; LESTER RL, 1993, ADV LIPID RES, V26, P253; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NOZIA N, 1996, CHEM PHARM BULL, V44, P895; Oliver MR, 1996, CLIN INFECT DIS, V22, P521, DOI 10.1093/clinids/22.3.521; PERSAT F, 1992, J BIOL CHEM, V267, P8764; Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000; Rother RP, 1996, CELL, V86, P185, DOI 10.1016/S0092-8674(00)80090-2; SUGITA M, 1997, JPN OIL CHEM SOC, V46, P755; TAKESAKO K, 1993, J ANTIBIOT, V46, P1414, DOI 10.7164/antibiotics.46.1414; Tobon AM, 2003, CLIN INFECT DIS, V36, P1488, DOI 10.1086/375075; WANG E, 1991, J BIOL CHEM, V266, P14486; WEITZMAN I, 1993, J CLIN MICROBIOL, V31, P2523, DOI 10.1128/JCM.31.9.2523-2525.1993; YAWEI NI, 2000, CLIN DIAGN LAB IMMUN, V7, P490; Zabel D D, 1997, Del Med J, V69, P459; Zhong WY, 2000, ANTIMICROB AGENTS CH, V44, P651, DOI 10.1128/AAC.44.3.651-653.2000	31	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32028	32034		10.1074/jbc.M312918200	http://dx.doi.org/10.1074/jbc.M312918200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155728	hybrid			2022-12-25	WOS:000222849700006
J	Anneren, C; Cowan, CA; Melton, DA				Anneren, C; Cowan, CA; Melton, DA			The Src family of tyrosine kinases is important for embryonic stem cell self-renewal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; SIGNAL-TRANSDUCTION; ACTIVATION; EXPRESSION; DIFFERENTIATION; PLURIPOTENCY; MAINTENANCE; MAINTAIN; RECEPTOR; STAT3	cYes, a member of the Src family of non-receptor tyrosine kinases, is highly expressed in mouse and human embryonic stem (ES) cells. We demonstrate that cYes kinase activity is regulated by leukemia inhibitory factor (LIF) and serum and is down-regulated when cells differentiate. Moreover, selective chemical inhibition of Src family kinases decreases growth and expression of stem cell genes that mark the undifferentiated state, including Oct3/4, alkaline phosphatase, fibroblast growth factor 4, and Nanog. A synergistic effect on differentiation is observed when ES cells are cultured with an Src family inhibitor and low levels of retinoic acid. Src family kinase inhibition does not interfere with LIF-induced JAK/STAT3 (Janus-associated tyrosine kinases/ signal transducer and activator of transcription 3) or p42/p44 MAPK (mitogen-activated protein kinase) phosphorylation. Together the results suggest that the activation of the Src family is important for maintaining mouse and human ES in an undifferentiated state and may represent a third, independent pathway, downstream of LIF in mouse ES cells.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute	Melton, DA (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	dmelton@mcb.harvard.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Anneren, Cecilia/0000-0003-3600-6650				Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BOULTER CA, 1991, DEVELOPMENT, V111, P357; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rose-John S, 2002, TRENDS BIOTECHNOL, V20, P417, DOI 10.1016/S0167-7799(02)02056-5; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Shen MM, 1997, DEVELOPMENT, V124, P429; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Summy JM, 2003, FRONT BIOSCI-LANDMRK, V8, pS185, DOI 10.2741/1011; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	40	118	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31590	31598		10.1074/jbc.M403547200	http://dx.doi.org/10.1074/jbc.M403547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15148312	hybrid			2022-12-25	WOS:000222726800082
J	Kasrayan, A; Birgander, PL; Pappalardo, L; Regnstrom, K; Westman, M; Slaby, A; Gordon, E; Sjoberg, BM				Kasrayan, A; Birgander, PL; Pappalardo, L; Regnstrom, K; Westman, M; Slaby, A; Gordon, E; Sjoberg, BM			Enhancement by effectors and substrate nucleotides of R1-R2 interactions in Escherichia coli class Ia ribonucleotide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; SITE-DIRECTED MUTAGENESIS; DIPHOSPHATE REDUCTASE; ALLOSTERIC REGULATION; SUBUNIT INTERACTION; ELECTRON-TRANSFER; PROTEIN R1; THIOREDOXIN REDUCTASE; COMPREHENSIVE MODEL	Ribonucleotide reductases are a family of essential enzymes that catalyze the reduction of ribonucleotides to their corresponding deoxyribonucleotides and provide cells with precursors for DNA synthesis. The different classes of ribonucleotide reductase are distinguished based on quaternary structures and enzyme activation mechanisms, but the components harboring the active site region in each class are evolutionarily related. With a few exceptions, ribonucleotide reductases are allosterically regulated by nucleoside triphosphates (ATP and dNTPs). We have used the surface plasmon resonance technique to study how allosteric effects govern the strength of quaternary interactions in the class Ia ribonucleotide reductase from Escherichia coli, which like all class I enzymes has a tetrameric alpha(2)beta(2) structure. The alpha(2) component called R1 harbors the active site and two types of binding sites for allosteric effector nucleotides, whereas the beta(2) component called R2 harbors the tyrosyl radical necessary for catalysis. Our results show that only the known allosteric effector nucleotides, but not non-interacting nucleotides, promote a specific interaction between R1 and R2. Interestingly, the presence of substrate together with allosteric effector nucleotide strengthens the complex 2 - 3 times with a similar free energy change as the mutual allosteric effects of substrate and effector nucleotide binding to protein R1 in solution experiments. The dual allosteric effects of dATP as positive allosteric effector at low concentrations and as negative allosteric effector at high concentrations coincided with an almost 100-fold stronger R1-R2 interaction. Based on the experimental setup, we propose that the inhibition of enzyme activity in the E. coli class Ia enzyme occurs in a tight 1: 1 complex of R1 and R2. Most intriguingly, we also discovered that thioredoxin, one of the physiological reductants of ribonucleotide reductases, enhances the R1-R2 interaction 4-fold.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden	Stockholm University	Sjoberg, BM (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.	britt-marie.sjoberg@molbio.su.se	Pappalardo, Lucia/ABA-9311-2020	Pappalardo, Lucia/0000-0002-4491-2082; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Berardi MJ, 1999, J MOL BIOL, V292, P151, DOI 10.1006/jmbi.1999.3067; Birgander PL, 2004, J BIOL CHEM, V279, P14496, DOI 10.1074/jbc.M310142200; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Ekberg M, 1998, J BIOL CHEM, V273, P21003, DOI 10.1074/jbc.273.33.21003; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Erickson HK, 2001, BIOCHEMISTRY-US, V40, P9631, DOI 10.1021/bi010651n; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; HANSON E, 1994, J BIOL CHEM, V269, P30999; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Larsson A, 1996, EUR J BIOCHEM, V237, P58, DOI 10.1111/j.1432-1033.1996.0058n.x; LARSSON A, 1966, J BIOL CHEM, V241, P2540; LUNN CA, 1984, J BIOL CHEM, V259, P469; LYCKSELL PO, 1995, FEBS LETT, V368, P441, DOI 10.1016/0014-5793(95)00706-F; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; RUSSEL M, 1985, J BACTERIOL, V163, P238, DOI 10.1128/JB.163.1.238-242.1985; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; SJOBERG BM, 2001, ENCY LIFE SCI; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1973, J BIOL CHEM, V248, P4591; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0	44	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31050	31057		10.1074/jbc.M400693200	http://dx.doi.org/10.1074/jbc.M400693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145955	hybrid			2022-12-25	WOS:000222726800019
J	Okochi, M; Nomura, T; Zako, T; Arakawa, T; Iizuka, R; Ueda, H; Funatsu, T; Leroux, M; Yohda, M				Okochi, M; Nomura, T; Zako, T; Arakawa, T; Iizuka, R; Ueda, H; Funatsu, T; Leroux, M; Yohda, M			Kinetics and binding sites for interaction of the prefoldin with a group II chaperonin - Contiguous non-native substrate and chaperonin binding sites in the archaeal prefoldin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCOCCUS STRAIN KS-1; EUKARYOTIC PREFOLDIN; CYTOSOLIC CHAPERONIN; UNFOLDED PROTEINS; THERMOSOME; POLYPEPTIDE; COMPLEXES; SUBUNITS; TUBULIN; CAVITY	Prefoldin is a jellyfish-shaped hexameric co-chaperone of the group II chaperonins. It captures a protein folding intermediate and transfers it to a group II chaperonin for completion of folding. The manner in which prefoldin interacts with its substrates and cooperates with the chaperonin is poorly understood. In this study, we have examined the interaction between a prefoldin and a chaperonin from hyperthermophilic archaea by immunoprecipitation, single molecule observation, and surface plasmon resonance. We demonstrate that Pyrococcus prefoldin interacts most tightly with its cognate chaperonin, and vice versa, suggesting species specificity in the interaction. Using truncation mutants, we uncovered by kinetic analyses that this interaction is multivalent in nature, consistent with multiple binding sites between the two chaperones. We present evidence that both N- and C-terminal regions of the prefoldin beta subunit are important for molecular chaperone activity and for the interaction with a chaperonin. Our data are consistent with substrate and chaperonin binding sites on prefoldin that are different but in close proximity, which suggests a possible handover mechanism of prefoldin substrates to the chaperonin.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; Waseda Univ, Sch Sci & Engn, Dept Phys, Tokyo 1698555, Japan; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Tokyo University of Agriculture & Technology; University of Tokyo; Waseda University; Simon Fraser University	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Ueda, Hiroshi/A-3515-2011; Yohda, Masafumi/A-5149-2013; Funatsu, Takashi/Q-1404-2015; Arakawa, Takatoshi/K-9739-2013; Zako, Tamotsu/C-3004-2012	Ueda, Hiroshi/0000-0001-8849-4217; Yohda, Masafumi/0000-0001-8307-9671; Funatsu, Takashi/0000-0002-9656-8308; Arakawa, Takatoshi/0000-0001-6496-5440; Iizuka, Ryo/0000-0002-9328-5628				Archibald JM, 1999, CURR BIOL, V9, P1053, DOI 10.1016/S0960-9822(99)80457-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; Fenton WA, 1997, PROTEIN SCI, V6, P743; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Iizuka R, 2003, J BIOL CHEM, V278, P44959, DOI 10.1074/jbc.M305484200; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Leroux MR, 1999, EMBO J, V18, P6730, DOI 10.1093/emboj/18.23.6730; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Okochi M, 2002, BIOCHEM BIOPH RES CO, V291, P769, DOI 10.1006/bbrc.2002.6523; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Shomura Y, 2004, J MOL BIOL, V335, P1265, DOI 10.1016/j.jmb.2003.11.028; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Simons CT, 2004, J BIOL CHEM, V279, P4196, DOI 10.1074/jbc.M306053200; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Yoshida T, 2001, MOL MICROBIOL, V39, P1406, DOI 10.1046/j.1365-2958.2001.02334.x	32	51	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31788	31795		10.1074/jbc.M402889200	http://dx.doi.org/10.1074/jbc.M402889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145959	hybrid			2022-12-25	WOS:000222726800105
J	Velarde, JJ; Nataro, JP				Velarde, JJ; Nataro, JP			Hydrophobic residues of the autotransporter EspP linker domain are important for outer membrane translocation of its passenger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXTRACELLULAR TRANSPORT; SERINE-PROTEASE; SECRETION; PROTEINS; SURFACE; BRKA; DETERMINANTS; SEQUENCE; RELEASE	The autotransporter family of proteins is an important class of Gram-negative secreted virulence factors. Their secretion mechanism comprises entry to the periplasm via the Sec apparatus, followed by formation of an outer membrane beta barrel, which allows the N-terminal passenger domain to pass to the extracellular space. Several groups have identified a region immediately upstream of the beta domain that is important for outer membrane translocation, the so-called linker region. Here we characterize this region in EspP, a prototype of the serine protease autotransporters of enterobacteriaceae. We hypothesized that the folding of this region would be important in the outer membrane translocation process. We tested this hypothesis using a mutagenesis approach in conjunction with a series of nested deletions and found that in the absence of a complete passenger, mutations to the C-terminal helix, but not the upstream linker, significantly decrease secretion efficiency. However, in the presence of the passenger mutations to the amino-terminal region of the linker decrease secretion efficiency. Moreover, amino acids of hydrophobic character play a crucial role in linker function, suggesting the existence of a hydrophobic core or hydrophobic interaction necessary for outer membrane translocation of autotransporter proteins.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Nataro, JP (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, 685 W Baltimore St,HSF 441, Baltimore, MD 21201 USA.	jnataro@medicine.umaryland.edu			NIAID NIH HHS [AI-43615, F31-AI50249] Funding Source: Medline; NIGMS NIH HHS [R25-GM55036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI050249, R56AI043615, R01AI043615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Brandon LD, 2003, MOL MICROBIOL, V50, P45, DOI 10.1046/j.1365-2958.2003.03674.x; Brandon LD, 2001, J BACTERIOL, V183, P951, DOI 10.1128/JB.183.3.951-958.2001; Brunder W, 1997, MOL MICROBIOL, V24, P767, DOI 10.1046/j.1365-2958.1997.3871751.x; DIEDRICH DL, 1977, J BACTERIOL, V131, P598, DOI 10.1128/JB.131.2.598-607.1977; Djafari S, 1997, MOL MICROBIOL, V25, P771, DOI 10.1046/j.1365-2958.1997.5141874.x; Dutta PR, 2003, J BIOL CHEM, V278, P39912, DOI 10.1074/jbc.M303595200; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; ELISH ME, 1988, J GEN MICROBIOL, V134, P1355; FUKUDA I, 1995, J BACTERIOL, V177, P1719, DOI 10.1128/jb.177.7.1719-1726.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW E, 1999, USING ANTIBODIES LAB, P269; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; Hendrixson DR, 1997, MOL MICROBIOL, V26, P505, DOI 10.1046/j.1365-2958.1997.5921965.x; Jose J, 1996, GENE, V178, P107, DOI 10.1016/0378-1119(96)00343-5; JOSE J, 1995, MOL MICROBIOL, V18, P378, DOI 10.1111/j.1365-2958.1995.mmi_18020378.x; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; Konieczny MPJ, 2001, ANTON LEEUW INT J G, V80, P19, DOI 10.1023/A:1012084325728; Loveless BJ, 1997, MOL MEMBR BIOL, V14, P113, DOI 10.3109/09687689709048171; MARSHAK DR, 1996, STRATEGIES PROTEIN P, P373; Maurer J, 1997, J BACTERIOL, V179, P794, DOI 10.1128/jb.179.3.794-804.1997; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P10; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Oliver DC, 2003, J BACTERIOL, V185, P489, DOI 10.1128/JB.185.2.489-495.2003; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; Purdy GE, 2002, INFECT IMMUN, V70, P6355, DOI 10.1128/IAI.70.11.6355-6364.2002; Roggenkamp A, 2003, J BACTERIOL, V185, P3735, DOI 10.1128/JB.185.13.3735-3744.2003; Sambrook J, 2001, MOL CLONING LAB MANU; Shannon JL, 1999, J BACTERIOL, V181, P5838, DOI 10.1128/JB.181.18.5838-5842.1999; Sheikh J, 2001, MOL MICROBIOL, V41, P983, DOI 10.1046/j.1365-2958.2001.02512.x; Surana NK, 2004, J BIOL CHEM, V279, P14679, DOI 10.1074/jbc.M311496200; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; Tao Bernard Y., 1994, P69; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Veiga E, 1999, MOL MICROBIOL, V33, P1232, DOI 10.1046/j.1365-2958.1999.01571.x; Veiga E, 2004, MOL MICROBIOL, V52, P1069, DOI 10.1111/j.1365-2958.2004.04014.x; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; [No title captured]	47	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31495	31504		10.1074/jbc.M404424200	http://dx.doi.org/10.1074/jbc.M404424200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15151995	hybrid			2022-12-25	WOS:000222726800072
J	Crambert, G; Li, CM; Swee, LK; Geering, K				Crambert, G; Li, CM; Swee, LK; Geering, K			FXYD7, mapping of functional sites involved in endoplasmic reticulum export, association with and regulation of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; GAMMA-SUBUNIT; SECRETORY PATHWAY; PROTGF-ALPHA; BETA-SUBUNIT; TRANSPORT; PROTEIN; MEMBRANE; ISOZYMES; LOCALIZATION	The brain-specific FXYD7 is a member of the recently defined FXYD family that associates with the alpha1-beta1 Na,K-ATPase isozyme and induces an about 2-fold decrease in its apparent K+ affinity. By using the Xenopus oocyte as an expression system, we have investigated the role of conserved and FXYD7-specific amino acids in the cellular routing of FXYD7 and in its association with and regulation of Na,K-ATPase. In contrast to FXYD2 and FXYD4, the studies on FXYD7 show that the conserved FXYD motif in the extracytoplasmic domain is not involved in the efficient association of FXYD7 with Na,K-ATPase. On the other hand, the conserved Gly(40) and Gly(29), located on the same face of the transmembrane helix, were found to be implicated both in the association with and the regulation of Na,K-ATPase. Mutational analysis of FXYD7-specific regions revealed the presence of an ER export signal at the end of the cytoplasmic tail. Deletion of a C-terminal valine residue in FXYD7 significantly delayed and decreased its O-glycosylation processing and retarded the rate of its cell surface expression. This result indicates that the C-terminal valine residue is involved in the rapid and selective ER export of FXYD7, which could explain the observed post-translational association of FXYD7 with Na,K-ATPase. In conclusion, our study on FXYD7 provides new information on structural determinants of general importance for FXYD protein action. Moreover, FXYD7 is identified as a new member of proteins with a regulated ER export, which suggests that, among FXYD proteins, FXYD7 has a particular regulatory function in brain.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	kaethi.geering@ipharm.unil.ch		Crambert, Gilles/0000-0001-7065-9124				Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cordat E, 2003, TRAFFIC, V4, P642, DOI 10.1034/j.1600-0854.2003.00123.x; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE, V166, pRE1; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; Iodice L, 2001, J BIOL CHEM, V276, P28920, DOI 10.1074/jbc.M103558200; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nourry Claire, 2003, Sci STKE, V2003, pRE7; Nufer O, 2002, J CELL SCI, V115, P619; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Urena JM, 1999, J CELL SCI, V112, P773; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	34	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30888	30895		10.1074/jbc.M313494200	http://dx.doi.org/10.1074/jbc.M313494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133029	hybrid			2022-12-25	WOS:000222531900123
J	Yamaguchi, T; Omatsu, N; Matsushita, S; Osumi, T				Yamaguchi, T; Omatsu, N; Matsushita, S; Osumi, T			CGI-58 interacts with perilipin and is localized to lipid droplets - Possible involvement of CGI-58 mislocalization in Chanarin-Dorfman syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; HORMONE-SENSITIVE LIPASE; GENE; EXPRESSION; IDENTIFICATION; LIPOLYSIS; STORAGE; CELLS; OBESITY; TISSUE	Lipid droplets (LDs) are a class of ubiquitous cellular organelles that are involved in lipid storage and metabolism. Although the mechanisms of the biogenesis of LDs are still unclear, a set of proteins called the PAT domain family have been characterized as factors associating with LDs. Perilipin, a member of this family, is expressed exclusively in the adipose tissue and regulates the breakdown of triacylglycerol in LDs via its phosphorylation. In this study, we used a yeast two-hybrid system to examine the potential function of perilipin. We found direct interaction between perilipin and CGI-58, a deficiency of which correlated with the pathogenesis of Chanarin-Dorfman syndrome (CDS). Endogenous CGI-58 was distributed predominantly on the surface of LDs in differentiated 3T3-L1 cells, and its expression increased during adipocyte differentiation. Overexpressed CGI-58 tagged with GFP gathered at the surface of LDs and colocalized with perilipin. This interaction seems physiologically important because CGI-58 mutants carrying an amino acid substitution identical to that found in CDS lost the ability to be recruited to LDs. These mutations significantly weakened the binding of CGI-58 with perilipin, indicating that the loss of this interaction is involved in the etiology of CDS. Furthermore, we identified CGI-58 as a binding partner of ADRP, another PAT domain protein expressed ubiquitously, by yeast two-hybrid assay. GFP-CGI-58 expressed in non-differentiated 3T3-L1 or CHO-K1 cells was colocalized with ADRP, and the CGI-58 mutants were not recruited to LDs carrying ADRP, indicating that CGI-58 may also cooperate with ADRP.	Univ Hyogo, Grad Sch Life Sci, Himeji Inst Technol, Kamigori, Hyogo 6781297, Japan	University of Hyogo	Osumi, T (corresponding author), Univ Hyogo, Grad Sch Life Sci, Himeji Inst Technol, 3-2-1 Koto, Kamigori, Hyogo 6781297, Japan.	osumi@sci.u-hyogo.ac.jp						Akiyama M, 2003, J INVEST DERMATOL, V121, P1029, DOI 10.1046/j.1523-1747.2003.12520.x; Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; Corsini E, 2003, J INVEST DERMATOL, V121, P337, DOI 10.1046/j.1523-1747.2003.12371.x; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Krise JP, 2000, J BIOL CHEM, V275, P25188, DOI 10.1074/jbc.M001138200; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nagai S, 2004, ENDOCRINOLOGY, V145, P2346, DOI 10.1210/en.2003-1180; Nakamura N, 2003, BIOCHEM BIOPH RES CO, V306, P333, DOI 10.1016/S0006-291X(03)00979-3; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Osada S, 1997, GENES CELLS, V2, P315, DOI 10.1046/j.1365-2443.1997.1220319.x; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rosenbaum SE, 1998, MOL ENDOCRINOL, V12, P1150, DOI 10.1210/me.12.8.1150; ROZENSZAJN L, 1966, BLOOD-J HEMATOL, V28, P258, DOI 10.1182/blood.V28.2.258.258; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Shimizu M, 2004, MOL CELL BIOL, V24, P1313, DOI 10.1128/MCB.24.3.1313-1323.2004; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Targett-Adams P, 2003, J BIOL CHEM, V278, P15998, DOI 10.1074/jbc.M211289200; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Tominaga S, 2002, J BIOCHEM, V132, P881, DOI 10.1093/oxfordjournals.jbchem.a003301; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Yamasaki M, 1999, J BIOL CHEM, V274, P35293, DOI 10.1074/jbc.274.50.35293; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200	49	199	204	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30490	30497		10.1074/jbc.M403920200	http://dx.doi.org/10.1074/jbc.M403920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136565	hybrid			2022-12-25	WOS:000222531900077
J	Ramirez-Montagut, T; Blachere, NE; Sviderskaya, EV; Bennett, DC; Rettig, WJ; Garin-Chesa, P; Houghton, AN				Ramirez-Montagut, T; Blachere, NE; Sviderskaya, EV; Bennett, DC; Rettig, WJ; Garin-Chesa, P; Houghton, AN			FAP alpha, a surface peptidase expressed during wound healing, is a tumor suppressor	ONCOGENE			English	Article						peptidase; wound healing; fibroblast activation protein alpha; melanoma; tumor suppressor	FIBROBLAST ACTIVATION PROTEIN; REACTIVE STROMAL FIBROBLASTS; SERINE-PROTEASE; EPITHELIAL CANCERS; MOLECULAR-CLONING; HUMAN MELANOCYTES; MELANOMA; CELLS; DIFFERENTIATION; GROWTH	Fibroblast activation protein-alpha (FAP) is a cell surface serine protease expressed at sites of tissue remodeling in embryonic development. FAP is not expressed by mature somatic tissues except activated melanocytes and fibroblasts in wound healing or tumor stroma. FAP expression is specifically silenced in proliferating melanocytic cells during malignant transformation. To study the role of FAP as a tumor suppressor, the gene for mouse fap was cloned and mutated at the catalytic domain (FAP serine mutant, FSM). We found that expression of FAP or FSM at physiologic levels in mouse melanoma cells abrogated tumorigenicity. Remarkably, the mutant form FSM lacking specific serine protease activity was a more potent tumor suppressor. Tumor rejection was not due to adaptive immune responses because RAG1-/- mice challenged with melanoma cells expressing either FAP or FSM were not tumorigenic. In in vitro assays, FAP or FSM expression restored contact inhibition, led to cell cycle arrest at G0/G1 phase, and increased susceptibility to stress-induced apoptosis. Cell death in FAP + or FSM + melanoma cells was readily triggered by depletion of survival factors from the media, leading to subsequent activation of caspases via the intrinsic pathway. These results show that expression of FAP is a tumor suppressor that abrogates tumorigenicity through regulation of cell growth and survival.	Cornell Univ, Mem Sloan Kettering Canc Ctr, Swim Amer Lab, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; St George Hosp, Sch Med, London SW17 0RE, England; Boehringer Ingelheim Austria GmbH, Div Res & Dev, Vienna, Austria; Univ Vienna, Dept Clin Pathol, Gen Hosp, Vienna, Austria	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Rockefeller University; Howard Hughes Medical Institute; St Georges University London; Boehringer Ingelheim; University of Vienna	Houghton, AN (corresponding author), Cornell Univ, Mem Sloan Kettering Canc Ctr, Swim Amer Lab, 1275 York Ave, New York, NY 10021 USA.	a-houghton@ski.mskcc.org	Bennett, Dorothy C/C-2418-2008; Sviderskaya, Elena V/D-2419-2009	Bennett, Dorothy C/0000-0002-3639-7527; 				BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERKELHAMMER J, 1982, CANCER RES, V42, P3157; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; Cheng JD, 2002, CANCER RES, V62, P4767; DESMOULIERE A, 1995, CELL BIOL INT, V19, P471, DOI 10.1006/cbir.1995.1090; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; HEARING VJ, 1985, INT J CANCER, V35, P403, DOI 10.1002/ijc.2910350317; HEARING VJ, 1988, INT J CANCER, V41, P275, DOI 10.1002/ijc.2910410219; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1987, J EXP MED, V165, P812, DOI 10.1084/jem.165.3.812; Huber MA, 2003, J INVEST DERMATOL, V120, P182, DOI 10.1046/j.1523-1747.2003.12035.x; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; Niedermeyer J, 2001, INT J DEV BIOL, V45, P445; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; RETTIG WJ, 1993, CANCER RES, V53, P3327; RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; SVIDERSKAYA EV, 1995, DEVELOPMENT, V121, P1547; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311	23	88	101	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5435	5446		10.1038/sj.onc.1207730	http://dx.doi.org/10.1038/sj.onc.1207730			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133496				2022-12-25	WOS:000222588400003
J	Poso, D; Clarke, AR; Burston, SG				Poso, D; Clarke, AR; Burston, SG			Identification of a major inter-ring coupling step in the GroEL reaction cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ALLOSTERIC TRANSITIONS; INDUCED CONFORMATIONAL-CHANGES; KINETIC-ANALYSIS; CHAPERONIN GROEL; THERMOANAEROBACTER-BROCKII; CRYSTAL-STRUCTURE; FOLDING REACTION; ATPASE CYCLE; HEAT-SHOCK; BINDING	It has been shown previously that the double-ring structure of GroEL can be converted to a single-ring species by site-directed amino acid replacements at the ring interface and that the resultant molecule retains many of the crucial chaperonin properties; it is structurally stable, hydrolytically active, and can bind both the co-chaperonin, GroES, and unfolded substrate proteins. By comparing the behavior of the double- and single-ring structures in response to nucleotide binding and hydrolysis, we elucidate steps in the ATP-driven reaction cycle at which there is conformational coupling between the rings. Remarkably, the parting of the rings has little effect either on the thermodynamic properties of ATP binding or on the ATP-induced conformational changes prior to hydrolysis. However, there is a marked effect on the rate-limiting process in the steady-state cycle; a step that is coincident with bond cleavage in ATP. The effect of the ring-ring interaction is to increase its activation enthalpy from 42.0 to 94.2 kJ/mol. These results show that the major conformational coupling step, where structural rearrangements in one ring are propagated to the other, is the slowest process the ATPase cycle of GroEL.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Poso, D (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	d.poso@bristol.ac.uk; s.g.burston@bristol.ac.uk		Burston, Steven/0000-0003-1848-1853				Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; Amir A, 2004, J MOL BIOL, V338, P979, DOI 10.1016/j.jmb.2004.02.076; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Carrascosa JL, 2001, MICRON, V32, P43, DOI 10.1016/S0968-4328(00)00027-5; Case A, 2003, BIOCHEMISTRY-US, V42, P3335, DOI 10.1021/bi020668l; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Cornish-Bowden A, 2002, J BIOSCIENCES, V27, P121, DOI 10.1007/BF02703768; Ellis R J, 1990, Semin Cell Biol, V1, P1; FINZI A, 1992, J APPL RABBIT RES, V15, P745; Franzetti B, 2001, J BIOL CHEM, V276, P29906, DOI 10.1074/jbc.M102098200; Galan A, 1999, EUR J BIOCHEM, V259, P347, DOI 10.1046/j.1432-1327.1999.00045.x; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; Gibbons DL, 1996, J BIOL CHEM, V271, P31989, DOI 10.1074/jbc.271.50.31989; Grallert N, 2000, J BIOL CHEM, V275, P20424, DOI 10.1074/jbc.M002243200; Horovitz A, 2001, J STRUCT BIOL, V135, P104, DOI 10.1006/jsbi.2001.4377; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KOHL B, 1987, BIOPHYS J, V52, P271, DOI 10.1016/S0006-3495(87)83214-9; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; Llorca O, 1998, J BIOL CHEM, V273, P32587, DOI 10.1074/jbc.273.49.32587; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Poso D, 2004, J MOL BIOL, V338, P969, DOI 10.1016/j.jmb.2004.03.010; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SITHERLAND GB, 1958, J APPL PHYSIOL, V12, P367; Sot B, 2002, J BIOL CHEM, V277, P34024, DOI 10.1074/jbc.M205733200; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; Sun Z, 2003, J MOL BIOL, V332, P715, DOI 10.1016/S0022-2836(03)00830-1; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TRUSCOTT KN, 1994, EUR J BIOCHEM, V222, P277, DOI 10.1111/j.1432-1033.1994.tb18866.x; Walter S, 2002, CELL MOL LIFE SCI, V59, P1589, DOI 10.1007/PL00012485; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Weissman JS, 2001, MOL CELL, V8, P730, DOI 10.1016/S1097-2765(01)00359-8; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	45	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					38111	38117		10.1074/jbc.M401730200	http://dx.doi.org/10.1074/jbc.M401730200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15169772	hybrid			2022-12-25	WOS:000223684100008
J	Kulanthaivel, P; Kreuzman, AJ; Strege, MA; Belvo, MD; Smitka, TA; Clemens, M; Swartling, JR; Minton, KL; Zheng, F; Angleton, EL; Mullen, D; Jungheim, LN; Klimkowski, VJ; Nicas, TI; Thompson, RC; Peng, SB				Kulanthaivel, P; Kreuzman, AJ; Strege, MA; Belvo, MD; Smitka, TA; Clemens, M; Swartling, JR; Minton, KL; Zheng, F; Angleton, EL; Mullen, D; Jungheim, LN; Klimkowski, VJ; Nicas, TI; Thompson, RC; Peng, SB			Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENTIAL ACTIVE-SITE; COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; BETA-LACTAMS; MECHANISM; SERINE; EXPRESSION; MEMBRANE; IDENTIFICATION; VANCOMYCIN	Signal peptidase (SPase) I is responsible for the cleavage of signal peptides of many secreted proteins in bacteria. Because of its unique physiological and biochemical properties, it serves as a potential target for development of novel antibacterial agents. In this study, we report the production, isolation, and structure determination of a family of structurally related novel lipoglycopeptides from a Streptomyces sp. as inhibitors of SPase I. Detailed spectroscopic analyses, including MS and NMR, revealed that these lipoglycopeptides share a common 14-membered cyclic peptide core, an acyclic tripeptide chain, and a deoxy-alpha-mannose sugar, but differ in the degree of oxidation of the N-methylphenylglycine residue and the length and branching of the fatty acyl chain. Biochemical analysis demonstrated that these peptides are potent and competitive inhibitors of SPase I with K-i 50 to 158 nM. In addition, they showed modest antibacterial activity against a panel of pathogenic Gram-positive and Gram-negative bacteria with minimal inhibitory concentration of 8-64 muM against Streptococcus pneumonniae and 4-8 muM against Escherichia coli. Notably, they mechanistically blocked the protein secretion in whole cells as demonstrated by inhibiting beta-lactamase release from Staphylococcus aureus. Taken together, the present discovery of a family of novel lipoglycopeptides as potent inhibitors of bacterial SPase I may lead to the development of a novel class of broad-spectrum antibiotics.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Peng, SB (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.	Peng_Sheng-Bin@Lilly.com						Allen NE, 2003, FEMS MICROBIOL REV, V26, P511, DOI 10.1111/j.1574-6976.2003.tb00628.x; Allsop A, 1996, J ANTIBIOT, V49, P921, DOI 10.7164/antibiotics.49.921; ALLSOP AE, 1995, BIOORG MED CHEM LETT, V5, P443, DOI 10.1016/0960-894X(95)00052-U; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; Boger DL, 2001, MED RES REV, V21, P356, DOI 10.1002/med.1014; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; HIKAIDO H, 1996, J BACTERIOL, V178, P5853; Holtzel A, 2002, J ANTIBIOT, V55, P571; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; Irvine G B, 1994, Methods Mol Biol, V32, P257; KUO D, 1994, BIOCHEMISTRY-US, V33, P8347, DOI 10.1021/bi00193a023; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Laganas V, 2003, ANTIMICROB AGENTS CH, V47, P2682, DOI 10.1128/AAC.47.8.2682-2684.2003; LEE JI, 1992, J BIOL CHEM, V267, P938; MOORE KE, 1987, J BIOL CHEM, V262, P8806; National Committee for Clinical Laboratory Standards, 1990, M7A2 NAT COMM CLIN L; NORMARK S, 1969, J BACTERIOL, V97, P1334, DOI 10.1128/JB.97.3.1334-1342.1969; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Peng SB, 2001, ANAL BIOCHEM, V293, P88, DOI 10.1006/abio.2001.5102; Peng SB, 2001, J BACTERIOL, V183, P621, DOI 10.1128/JB.183.2.621-627.2001; SCHAEFLER S, 1981, J CLIN MICROBIOL, V13, P754, DOI 10.1128/JCM.13.4.754-759.1981; Schmid D. G., 2001, PEPTIDES WAVE FUTURE, P768; SMITH MD, 1979, J BACTERIOL, V137, P735, DOI 10.1128/JB.137.2.735-739.1979; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG M, 1992, J BIOL CHEM, V267, P13154; Tally FP, 2000, J ANTIMICROB CHEMOTH, V46, P523, DOI 10.1093/jac/46.4.523; Taylor P, 1999, J BIOL CHEM, V274, P24901, DOI 10.1074/jbc.274.35.24901; Tew DG, 1998, BIOCHEMISTRY-US, V37, P10087, DOI 10.1021/bi9801412; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; Tsubery H, 2000, J MED CHEM, V43, P3085, DOI 10.1021/jm0000057; VALKENBURG CV, 1999, J BIOL CHEM, V274, P11519; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1988, MOL GEN GENET, V214, P55; Wilmouth RC, 1999, BIOCHEMISTRY-US, V38, P7989, DOI 10.1021/bi990098y; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; Zahn JA, 2001, APPL ENVIRON MICROB, V67, P377, DOI 10.1128/AEM.67.1.377-386.2001	47	81	84	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36250	36258		10.1074/jbc.M405884200	http://dx.doi.org/10.1074/jbc.M405884200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15173160	hybrid			2022-12-25	WOS:000223453600013
J	Auguin, D; Barthe, P; Royer, C; Stern, MH; Noguchi, M; Arold, ST; Roumestand, C				Auguin, D; Barthe, P; Royer, C; Stern, MH; Noguchi, M; Arold, ST; Roumestand, C			Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; NMR-SPECTROSCOPY; PROLYMPHOCYTIC LEUKEMIA; SIGNAL-TRANSDUCTION; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; ONCOGENE PRODUCT; BETA-GAMMA; C-AKT	Chromosomal translocations leading to overexpression of p14(TCL1) and its homologue p13(MTCP1) are hallmarks of several human T-cell malignancies (1). p14(TCL1)/p13(MTCP1) co-activate protein kinase B (PKB, also named Akt) by binding to its pleckstrin homology (PH) domain, suggesting that p14(TCL1)/p13(MTCP1) induce T-cell leukemia by promoting anti-apoptotic signals via PKB (2,3). Here we combined fluorescence anisotropy, NMR, and small angle x-ray-scattering measurements to determine the affinities, molecular interfaces, and low resolution structure of the complex formed between PKBbeta-PH and p14(TCL1)/p13(MTCP1). We show that p14(TCL1)/p13(MTCP1) target PKB-PH at a site that has not yet been observed in PH-protein interactions. Located opposite the phospholipid binding pocket and distal from known protein-protein interaction sites on PH domains, the binding of dimeric TCL1 proteins to this site would allow the cross-linking of two PKB molecules at the cellular membrane in a preactivated conformation without disrupting certain PH-ligand interactions. Thus this interaction could serve to strengthen membrane association, promote trans-phosphorylation, hinder deactivation of PKB, and involve PKB in a multi-protein complex, explaining the array of known effects of TCL1. The binding sites on both proteins present attractive drug targets against leukemia caused by TCL1 proteins.	UM1, Fac Pharm, Ctr Biochim Struct, CNRS,UMR 5048,INSERM,UMR 554, F-34093 Montpellier 5, France; Inst Curie, Sect Rech, INSERM, U509, F-75248 Paris 5, France; Hokkaido Univ, Inst Med Genet, Div Canc Biol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Hokkaido University	Arold, ST (corresponding author), UM1, Fac Pharm, Ctr Biochim Struct, CNRS,UMR 5048,INSERM,UMR 554, BP14491,15 Ave Charles Flahault, F-34093 Montpellier 5, France.	stef@cbs.cnrs.fr; roume@cbs.cnrs.fr	Arold, Stefan/T-2612-2019; Stern, Marc-Henri/A-2728-2011; Auguin, Daniel/Y-2074-2019; Royer, Catherine A/E-5266-2016	Stern, Marc-Henri/0000-0002-8100-2272; Auguin, Daniel/0000-0003-4713-9096; Royer, Catherine A/0000-0002-2670-3391; Arold, Stefan T/0000-0001-5278-0668; Barthe, Philippe/0000-0003-4282-6604; ROUMESTAND, Christian/0000-0002-4082-3293				Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Auguin D, 2004, CR CHIM, V7, P265, DOI 10.1016/j.crci.2003.10.017; Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2; Auguin D, 2003, J BIOMOL NMR, V27, P287, DOI 10.1023/A:1025490109384; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; FU TB, 1994, CANCER RES, V54, P6297; Fu ZQ, 1998, P NATL ACAD SCI USA, V95, P3413, DOI 10.1073/pnas.95.7.3413; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; Guignard L, 2000, J BIOMOL NMR, V17, P215, DOI 10.1023/A:1008386110930; Hoh F, 1998, STRUCTURE, V6, P147, DOI 10.1016/S0969-2126(98)00017-3; Howard MJ, 2000, J MOL BIOL, V295, P1023, DOI 10.1006/jmbi.1999.3391; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MARKUS MA, 1994, PROTEIN SCI, V3, P70; Matsuo H, 1999, J AM CHEM SOC, V121, P9903, DOI 10.1021/ja991881g; McAlister MSB, 1996, BIOCHEMISTRY-US, V35, P5982, DOI 10.1021/bi952756u; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Pekarsky Y, 2001, ONCOGENE, V20, P5638, DOI 10.1038/sj.onc.1204596; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; ROGERS MT, 1962, J PHYS CHEM-US, V66, P540, DOI 10.1021/j100809a043; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; SKLENAR V, 1995, J MAGN RESON SER A, V114, P132, DOI 10.1006/jmra.1995.1119; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; STERN MH, 1993, ONCOGENE, V8, P2475; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; VANNULAND NAJ, 1993, FEBS LETT, V315, P11, DOI 10.1016/0014-5793(93)81122-G; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Wang LC, 2001, P NATL ACAD SCI USA, V98, P7684, DOI 10.1073/pnas.121069998; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang YS, 1998, J BIOMOL NMR, V11, P337, DOI 10.1023/A:1008279616063; ZUIDERWEG ERP, 1981, EUR J BIOCHEM, V118, P95, DOI 10.1111/j.1432-1033.1981.tb05490.x; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	64	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35890	35902		10.1074/jbc.M400364200	http://dx.doi.org/10.1074/jbc.M400364200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15169787	hybrid			2022-12-25	WOS:000223303400090
J	Moon, SK; Kim, HM; Lee, YC; Kim, CH				Moon, SK; Kim, HM; Lee, YC; Kim, CH			Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNALING TRANSDUCTION PATHWAY; MONOCLONAL-ANTIBODY; MALIGNANT-MELANOMA; MOLECULAR-CLONING; GANGLIOSIDES GM1; KINASE-ACTIVITY; GROWTH; PROLIFERATION; ATHEROSCLEROSIS	Sialic acid-containing glycosphingolipids (gangliosides) have been implicated in the regulation of various biological phenomena such as atherosclerosis. Recent report suggests that exogenously supplied disialoganglioside (GD3) serves a dual role in vascular smooth muscle cells (VSMC) proliferation and apoptosis. However, the role of the GD3 synthase gene in VSMC responses has not yet been elucidated. To determine whether a ganglioside is able to modulate VSMC growth, the effect of overexpression of the GD3 synthase gene on DNA synthesis was examined. The results show that the overexpression of this gene has a potent inhibitory effect on DNA synthesis and ERK phosphorylation in cultured VSMC in the presence of PDGF. The suppression of the GD3 synthase gene was correlated with the down-regulation of cyclinE/CDK2, the up-regulation of the CDK inhibitor p21 and blocking of the p27 inhibition, whereas up-regulation of p53 as the result of GD3 synthase gene expression was not observed. Consistently, blockade of GD3 function with anti-GD3 antibody reversed VSMC proliferation and cell cycle proteins. The expression of the GD3 synthase gene also led to the inhibition of TNF-alpha-induced matrix metalloproteinase-9 (MMP-9) expression in VSMC as determined by zymography and immunoblot. Furthermore, GD3 synthase gene expression strongly decreased MMP-9 promoter activity in response to TNF-alpha. This inhibition was characterized by the downregulation of MMP-9, which was transcriptionally regulated at NF-kappaB and activation protein-1 (AP-1) sites in the MMP-9 promoter. Finally, the overexpression of MMP-9 in GD3 synthase transfectant cells rescued VSMC proliferation. However, MMP-2 overexpression was not affected by cell proliferation. These findings suggest that the GD3 synthase gene represents a physiological modulator of VSMC responses that may contribute to plaque instability in atherosclerosis.	Dongguk Univ, Coll Oriental Med, Minist Sci & Technol, NRL Glycobiol, Kyungju 780714, Kyungbuk, South Korea; Dongguk Univ, Coll Oriental Med, Dept Biochem & Mol Biol, Kyungju 780714, Kyungbuk, South Korea; Dong A Univ, Fac Biotechnol, Pusan 604714, South Korea	Dongguk University; Dongguk University; Dong A University	Kim, CH (corresponding author), Dongguk Univ, Coll Oriental Med, Minist Sci & Technol, NRL Glycobiol, Sukjang Dong 707, Kyungju 780714, Kyungbuk, South Korea.	chkimbio@dongguk.ac.kr		Kim, Cheorl-Ho/0000-0002-6323-0714				Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; CHANG HR, 1992, CANCER, V70, P633, DOI 10.1002/1097-0142(19920801)70:3<633::AID-CNCR2820700315>3.0.CO;2-F; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cho A, 2002, CIRC RES, V91, P845, DOI 10.1161/01.RES.0000040420.17366.2E; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; Galis ZS, 2002, CIRC RES, V91, P852, DOI 10.1161/01.RES.0000041036.86977.14; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAMILTON WB, 1993, INT J CANCER, V53, P566, DOI 10.1002/ijc.2910530407; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Kim KW, 2001, GENE, V273, P163, DOI 10.1016/S0378-1119(01)00595-9; Kim SW, 2002, BBA-GENE STRUCT EXPR, V1578, P84, DOI 10.1016/S0167-4781(02)00505-5; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; Kim YJ, 1997, BIOCHEM BIOPH RES CO, V235, P327, DOI 10.1006/bbrc.1997.6725; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maria R.D., 1997, SCIENCE, V277, P1652; Moon SK, 2003, BIOCHEM BIOPH RES CO, V301, P1069, DOI 10.1016/S0006-291X(03)00091-3; Moon SK, 2004, J CELL PHYSIOL, V198, P417, DOI 10.1002/jcp.10435; Moon SK, 2003, FEBS LETT, V552, P130, DOI 10.1016/S0014-5793(03)00935-9; Moon SK, 2001, AM J PHYSIOL-HEART C, V280, pH2779, DOI 10.1152/ajpheart.2001.280.6.H2779; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; Nakamura K, 1999, CANCER RES, V59, P5323; Newby AC, 2000, J PATHOL, V190, P300, DOI 10.1002/(SICI)1096-9896(200002)190:3<300::AID-PATH596>3.0.CO;2-I; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachinidis A, 1996, EUR J CELL BIOL, V71, P79; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHINOURA N, 1992, NEUROSURGERY, V31, P541, DOI 10.1227/00006123-199209000-00017; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUCHIDA T, 1987, J NATL CANCER I, V78, P45, DOI 10.1093/jnci/78.1.45; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang SL, 1997, INT J CANCER, V73, P50, DOI 10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.3.CO;2-O	50	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33063	33070		10.1074/jbc.M313462200	http://dx.doi.org/10.1074/jbc.M313462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175338	hybrid			2022-12-25	WOS:000223039700007
J	Vertegaal, ACO; Ogg, SC; Jaffray, E; Rodriguez, MS; Hay, RT; Andersen, JS; Mann, M; Lamond, AI				Vertegaal, ACO; Ogg, SC; Jaffray, E; Rodriguez, MS; Hay, RT; Andersen, JS; Mann, M; Lamond, AI			A proteomic study of SUMO-2 target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; CONJUGATING ENZYME; SUBSTRATE RECOGNITION; E3 LIGASE; NUCLEAR; RANGAP1; SENTRIN; IDENTIFICATION; COMPLEX	The SUMO family in vertebrates includes at least three distinct proteins ( SUMO-1, -2, and -3) that are added as post-translational modifications to target proteins. A considerable number of SUMO-1 target proteins have been identified, but little is known about SUMO-2. A stable HeLa cell line expressing His(6)-tagged SUMO-2 was established and used to label and purify novel endogenous SUMO-2 target proteins. Tagged forms of SUMO-2 were functional and localized predominantly in the nucleus. His(6)-tagged SUMO-2 conjugates were affinity-purified from nuclear fractions and identified by mass spectrometry. Eight novel potential SUMO-2 target proteins were identified by at least two peptides. Three of these proteins, SART1, heterogeneous nuclear ribonucleoprotein (RNP) M, and the U5 small nuclear RNP 200-kDa helicase, play a role in RNA metabolism. SART1 and heterogeneous nuclear RNP M were both shown to be genuine SUMO targets, confirming the validity of the approach.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark	University of Dundee; University of St Andrews; University of Southern Denmark	Lamond, AI (corresponding author), Univ Dundee, Wellcome Trust Bioctr, MSI WTB Complex, Dundee DD1 5EH, Scotland.	a.i.lamond@dundee.ac.uk	Andersen, Jens S/L-2100-2015; Hay, Ronald/S-3233-2019; Vertegaal, Alfred CO/Y-3875-2018; Hay, Ronald T/F-9338-2011; Vertegaal, Alfred/ABG-8141-2021; Mann, Matthias/A-3454-2013	Andersen, Jens S/0000-0002-6091-140X; Hay, Ronald/0000-0001-7113-9024; Vertegaal, Alfred CO/0000-0002-7989-0493; Hay, Ronald T/0000-0001-7113-9024; Vertegaal, Alfred/0000-0002-7989-0493; Mann, Matthias/0000-0003-1292-4799; Lamond, Angus/0000-0001-6204-6045; Ogg, Stephen/0000-0003-4157-1654	MRC [G0301131] Funding Source: UKRI; Medical Research Council [G0301131] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Boddy MN, 1996, ONCOGENE, V13, P971; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Jones D, 2002, GENOME BIOL, V3; Joseph J, 2002, J CELL BIOL, V156, P595, DOI 10.1083/jcb.200110109; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P3168, DOI 10.1021/bi026861x; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Trinkle-Mulcahy L, 2003, MOL BIOL CELL, V14, P107, DOI 10.1091/mbc.E02-07-0376; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	72	172	188	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33791	33798		10.1074/jbc.M404201200	http://dx.doi.org/10.1074/jbc.M404201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175327	hybrid			2022-12-25	WOS:000223039700088
J	Angata, K; Long, JM; Bukalo, O; Lee, W; Dityatev, A; Wynshaw-Boris, A; Schachner, M; Fukuda, M; Marth, JD				Angata, K; Long, JM; Bukalo, O; Lee, W; Dityatev, A; Wynshaw-Boris, A; Schachner, M; Fukuda, M; Marth, JD			Sialyltransferase ST8Sia-II assembles a subset of polysialic acid that directs hippocampal axonal targeting and promotes fear behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CENTRAL-NERVOUS-SYSTEM; LONG-TERM POTENTIATION; MOSSY FIBER SYNAPSES; SYNAPTIC PLASTICITY; MICE DEFICIENT; PSA-NCAM; GENOMIC STRUCTURE; OLFACTORY-BULB; DENTATE GYRUS	Polysialic acid (PSA) is a post-translational protein modification that is widely expressed among neural cell types during development. Found predominantly on the neural cell adhesion molecule ( NCAM), PSA becomes restricted to regions of neurogenesis and neuroplasticity in the adult. In the mammalian genome, two polysialyltransferases termed ST8Sia-II and ST8Sia-IV have been hypothesized to be responsible for the production of PSA in vivo. Approaches to discover PSA function have involved the application of endoneuraminidase-N to remove PSA and genetic manipulations in the mouse to deplete either NCAM or ST8Sia-IV. Here we report the production and characterization of mice deficient in the ST8Sia-II polysialyltransferase. We observed alterations in brain PSA expression unlike those observed in mice lacking ST8Sia-IV. This included a PSA deficit in regions of neurogenesis but without changes in the frequency of mitotic neural progenitor cells. In further contrast with ST8Sia-IV deficiency, loss of ST8Sia-II did not impair hippocampal synaptic plasticity but instead resulted in the misguidance of infrapyramidal mossy fibers and the formation of ectopic synapses in the hippocampus. Consistent with studies of animal models bearing these morphological changes, ST8Sia-II-deficient mice exhibited higher exploratory drive and reduced behavioral responses to Pavlovian fear conditioning. PSA produced by the ST8Sia-II polysialyltransferase modifies memory and behavior processes that are distinct from the neural roles reported for ST8Sia-IV. This genetic partitioning of PSA formation engenders discrete neurological processes and reveals that this post-translational modification forms the predominant basis for the multiple functions attributed to the NCAM glycoprotein.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA.	minoru@burnham-inst.org; jmarth@ucsd.edu	Angata, Kiyohiko/M-2749-2018; Dityatev, Alexander/A-4034-2008	Angata, Kiyohiko/0000-0001-5561-1368; Dityatev, Alexander/0000-0002-0472-0553	NCI NIH HHS [CA33895] Funding Source: Medline; NHLBI NIH HHS [P01-HL57345] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline; NIGMS NIH HHS [GM62116] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMASSARITEULE M, 1991, BRAIN RES, V551, P104, DOI 10.1016/0006-8993(91)90919-M; Anagnostaras SG, 2001, HIPPOCAMPUS, V11, P8; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; Bagri A, 2003, CELL, V113, P285, DOI 10.1016/S0092-8674(03)00267-8; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; CLAIBORNE BJ, 1993, HIPPOCAMPUS, V3, P115, DOI 10.1002/hipo.450030202; Corbo JC, 2002, J NEUROSCI, V22, P7548; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 1998, P NATL ACAD SCI USA, V95, P13242, DOI 10.1073/pnas.95.22.13242; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; Cremer H, 1997, MOL CELL NEUROSCI, V8, P323, DOI 10.1006/mcne.1996.0588; Crusio WE, 2001, BEHAV BRAIN RES, V125, P127, DOI 10.1016/S0166-4328(01)00280-7; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Eckhardt M, 1998, GLYCOBIOLOGY, V8, P1165, DOI 10.1093/glycob/8.12.1165; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; Evers MR, 2002, J NEUROSCI, V22, P7177; Fanselow MS, 1999, NEURON, V23, P229, DOI 10.1016/S0896-6273(00)80775-8; Franklin K. B. J., 1996, MOUSE BRAIN STEREOTA; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; GAARSKJAER FB, 1986, BRAIN RES REV, V11, P335, DOI 10.1016/0165-0173(86)90004-4; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; Henze DA, 2000, NEUROSCIENCE, V98, P407, DOI 10.1016/S0306-4522(00)00146-9; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kurosawa N, 1997, J NEUROCHEM, V69, P494; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Maccaferri G, 1998, SCIENCE, V279, P1368, DOI 10.1126/science.279.5355.1368; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; Marx M, 2001, DEVELOPMENT, V128, P4949; McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5; Montag-Sallaz M, 2002, MOL CELL BIOL, V22, P7967, DOI 10.1128/MCB.22.22.7967-7981.2002; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nacher J, 2002, NEUROSCIENCE, V113, P479, DOI 10.1016/S0306-4522(02)00219-1; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Prior H, 1997, BEHAV BRAIN RES, V87, P183, DOI 10.1016/S0166-4328(97)02282-1; Rodriguez JJ, 1998, EUR J NEUROSCI, V10, P2994, DOI 10.1046/j.1460-9568.1998.00316.x; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Sandi C, 2003, BIOL PSYCHIAT, V54, P599, DOI 10.1016/S0006-3223(03)00182-3; Sandi C, 2001, NEUROSCIENCE, V102, P329, DOI 10.1016/S0306-4522(00)00484-X; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1998, J NEUROSCI, V18, P3757; SERESS L, 1993, J COMP NEUROL, V337, P208, DOI 10.1002/cne.903370204; Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3; Stork O, 2000, EUR J NEUROSCI, V12, P3291, DOI 10.1046/j.1460-9568.2000.00197.x; Takashima S, 1998, J BIOL CHEM, V273, P7675, DOI 10.1074/jbc.273.13.7675; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VANDAAL JHHM, 1991, BEHAV BRAIN RES, V43, P57, DOI 10.1016/S0166-4328(05)80052-X; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167	66	150	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32603	32613		10.1074/jbc.M403429200	http://dx.doi.org/10.1074/jbc.M403429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15140899	hybrid			2022-12-25	WOS:000222849700077
J	Lenoir, G; Picard, M; Moller, JV; le Maire, M; Champeil, P; Falson, P				Lenoir, G; Picard, M; Moller, JV; le Maire, M; Champeil, P; Falson, P			Involvement of the L6-7 loop in SERCA1a Ca2+-ATPase activation by Ca2+ (or Sr2+) and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE SEGMENTS 6; P-TYPE ATPASES; CALCIUM-PUMP; ADENOSINE-TRIPHOSPHATASE; INORGANIC-PHOSPHATE; CYTOPLASMIC LOOP; KINETIC CHARACTERIZATION; GLYCOGEN-PHOSPHORYLASE	Wild-type (WT) and the double mutant D813A, D818A (ADA) of the L6-7 loop of SERCA1a were expressed in yeast, purified, and reconstituted into lipids. This allowed us to functionally study these ATPases by both kinetic and spectroscopic means, and to solve previous discrepancies in the published literature about both experimental facts and interpretation concerning the role of this loop in P-type ATPases. We show that in a solubilized state, the ADA mutant experiences a dramatic decrease of its calcium-dependent ATPase activity. On the contrary, reconstituted in a lipid environment, it displays an almost unaltered maximal calcium-dependent ATPase activity at high ( millimolar) ATP, with an apparent affinity for Ca2+ altered only moderately (3-fold). In the absence of ATP, the true affinity of ADA for Ca2+ is, however, more significantly reduced (20-30-fold) compared with WT, as judged from intrinsic (Trp) or extrinsic ( fluorescence isothiocyanate) fluorescence experiments. At low ATP, transient kinetics experiments reveal an overshoot in the ADA phosphorylation level primarily arising from the slowing down of the transition between the nonphosphorylated "E2" and "Ca(2)E1" forms of ADA. At high ATP, this slowing down is only partially compensated for, as ADA turnover remains more sensitive to orthovanadate than WT turnover. ADA ATPase also proved to have a reduced affinity for ATP in studies performed under equilibrium conditions in the absence of Ca2+, highlighting the long range interactions between L6-7 and the nucleotide-binding site. We propose that these mutations in L6-7 could affect protonation-dependent winding and unwinding events in the nearby M6 transmembrane segment.	CEA Saclay, Dept Biol Joliot Curie, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, Sect Biophys Fonct Membranaires, F-91191 Gif Sur Yvette, France; Univ Paris 11, Lab Rech Associe 17V, Orsay, France; Univ Paris 11, Inst Federat Rech 46, Orsay, France; Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University	Falson, P (corresponding author), CEA Saclay, Dept Biol Joliot Curie, CNRS, URA 2096, F-91191 Gif Sur Yvette, France.	pierre.falson@cea.fr	Picard, Martin/A-3236-2016; Lenoir, Guillaume/I-4002-2019	Picard, Martin/0000-0002-6518-8900; Lenoir, Guillaume/0000-0002-8759-5179; Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2003, ANN NY ACAD SCI, V986, P72, DOI 10.1111/j.1749-6632.2003.tb07141.x; ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1983, EUR J BIOCHEM, V134, P205, DOI 10.1111/j.1432-1033.1983.tb07552.x; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CARVALHO CAM, 1976, EXPERIENTIA, V32, P428, DOI 10.1007/BF01920776; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P., 1996, BIOMEMBR, V5, P43; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Costa V, 2003, PROTEINS, V50, P104, DOI 10.1002/prot.10219; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DEFORESTA B, 1992, EUR J BIOCHEM, V209, P1023, DOI 10.1111/j.1432-1033.1992.tb17378.x; DEFORESTA B, 1994, EUR J BIOCHEM, V223, P359; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1976, J BIOL CHEM, V251, P2055; DRUECKES P, 1995, ANAL BIOCHEM, V230, P173, DOI 10.1006/abio.1995.1453; Duchesne L, 2003, EUR J BIOCHEM, V270, P422, DOI 10.1046/j.1432-1033.2003.03389.x; DUPONT Y, 1988, METHOD ENZYMOL, V157, P206; DUX L, 1987, J BIOL CHEM, V262, P6439; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; Falson P, 2003, ANN NY ACAD SCI, V986, P312, DOI 10.1111/j.1749-6632.2003.tb07198.x; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Inesi G, 2002, BIOPHYS J, V83, P2327, DOI 10.1016/S0006-3495(02)75247-8; INESI G, 1980, J BIOL CHEM, V255, P3025; KARLISH SJD, 1979, NATURE, V282, P333, DOI 10.1038/282333a0; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenoir G, 2002, BBA-BIOMEMBRANES, V1560, P67, DOI 10.1016/S0005-2736(01)00458-8; Lenoir G, 2004, J BIOL CHEM, V279, P9156, DOI 10.1074/jbc.M311411200; Lenoir G, 2003, ANN NY ACAD SCI, V986, P333, DOI 10.1111/j.1749-6632.2003.tb07206.x; LUND S, 1989, J BIOL CHEM, V264, P4907; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; Martonosi AN, 2003, ACTA BIOCHIM POL, V50, P337; MEIS LD, 1971, J BIOL CHEM, V246, P4759; Menguy T, 2002, J BIOL CHEM, V277, P13016, DOI 10.1074/jbc.M108899200; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Menguy T, 1998, ANAL BIOCHEM, V264, P141, DOI 10.1006/abio.1998.2854; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Miras R, 2001, PROTEIN EXPRES PURIF, V22, P299, DOI 10.1006/prep.2001.1436; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLNAR E, 1988, ACTA BIOCHIM BIOPHYS, V23, P63; NAKAMURA Y, 1984, J BIOL CHEM, V259, P8183; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; ORLOWSKI S, 1993, FEBS LETT, V328, P296, DOI 10.1016/0014-5793(93)80947-S; ORTIZ A, 1984, BIOCHEM J, V221, P213, DOI 10.1042/bj2210213; PICK U, 1982, J BIOL CHEM, V257, P6111; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Scarborough GA, 2002, J BIOENERG BIOMEMBR, V34, P235, DOI 10.1023/A:1020211016696; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, INT CONGR SER, V1207, P405; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VIJAYA S, 1984, J INORG BIOCHEM, V20, P247, DOI 10.1016/0162-0134(84)85022-9; VYSKOCIL F, 1980, NATURE, V286, P516, DOI 10.1038/286516a0; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WEBER K, 1969, J BIOL CHEM, V244, P4406; Xu G, 2003, ANN NY ACAD SCI, V986, P96, DOI 10.1111/j.1749-6632.2003.tb07144.x; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	84	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32125	32133		10.1074/jbc.M402934200	http://dx.doi.org/10.1074/jbc.M402934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155750	Green Submitted, hybrid			2022-12-25	WOS:000222849700018
J	Leslie, EM; Haimeur, A; Waalkes, MP				Leslie, EM; Haimeur, A; Waalkes, MP			Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1) - Evidence that a tri-glutathione conjugate is required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; S-TRANSFERASE-PI; ORGANIC ANION TRANSPORT; CHARGED AMINO-ACIDS; SUBSTRATE-SPECIFICITY; MEMBRANE-VESICLES; TUMOR-CELLS; PHARMACOKINETIC MODEL; VINCRISTINE TRANSPORT; MONOCLONAL-ANTIBODIES	Inorganic arsenic is an established human carcinogen, but its metabolism is incompletely defined. The ATP binding cassette protein, multidrug resistance protein (MRP1/ABCC1), transports conjugated organic anions (e.g. leukotriene C-4) and also co-transports certain unmodified xenobiotics ( e. g. vincristine) with glutathione (GSH). MRP1 also confers resistance to arsenic in association with GSH; however, the mechanism and the species of arsenic transported are unknown. Using membrane vesicles prepared from the MRP1-overexpressing lung cancer cell line, H69AR, we found that MRP1 transports arsenite (As-III) only in the presence of GSH but does not transport arsenate (As-V) ( with or without GSH). The non-reducing GSH analogs L-gamma-glutamyl-L-alpha-aminobutyryl glycine and S-methyl GSH did not support AsIII transport, indicating that the free thiol group of GSH is required. GSH-dependent transport of As-III was 2-fold higher at pH 6.5-7 than at a more basic pH, consistent with the formation and transport of the acid-stable arsenic triglutathione (As(GS)(3)). Immunoblot analysis of H69AR vesicles revealed the unexpected membrane association of GSH S-transferase P1-1 (GSTP1-1). Membrane vesicles from an MRP1-transfected HeLa cell line lacking membrane-associated GSTP1-1 did not transport AsIII even in the presence of GSH but did transport synthetic As(GS)(3). The addition of exogenous GSTP1-1 to HeLa-MRP1 vesicles resulted in GSH-dependent AsIII transport. The apparent K-m of As(GS)(3) for MRP1 was 0.32 muM, suggesting a remarkably high relative affinity. As(GS)(3) transport by MRP1 was osmotically sensitive and was inhibited by several conjugated organic anions ( MRP1 substrates) as well as the metalloid antimonite (K-i 2.8 muM). As(GS) 3 transport experiments using MRP1 mutants with substrate specificities differing from wild-type MRP1 suggested a commonality in the substrate binding pockets of As(GS)(3) and leukotriene C-4. Finally, human MRP2 also transported As(GS)(3). In conclusion, MRP1 transports inorganic arsenic as a tri-GSH conjugate, and GSTP1-1 may have a synergistic role in this process.	NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI,NIH, Res Triangle Pk, NC 27709 USA; Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); Queens University - Canada	Waalkes, MP (corresponding author), NIEHS, Inorgan Carcinogenesis Sect, Comparat Carcinogenesis Lab, NCI,NIH, POB 12233,Mail Drop F0-09,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	waalkes@niehs.nih.gov		Leslie, Elaine/0000-0003-1825-348X	NATIONAL CANCER INSTITUTE [ZIABC005488, Z01BC005488] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; AliOsman F, 1997, J BIOL CHEM, V272, P10004; Aposhian HV, 2003, TOXICOL APPL PHARM, V193, P1, DOI 10.1016/S0041-008X(03)00324-7; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; Depeille P, 2004, MOL PHARMACOL, V65, P897, DOI 10.1124/mol.65.4.897; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, J BIOL CHEM, V269, P25442; Flens MJ, 1996, AM J PATHOL, V148, P1237; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; Gomez-Caminero A. P., 2001, ENV HLTH CRITERIA, V224; Gregus Z, 2002, TOXICOL SCI, V70, P13, DOI 10.1093/toxsci/70.1.13; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; GYURASICS A, 1991, BIOCHEM PHARMACOL, V42, P465, DOI 10.1016/0006-2952(91)90306-P; Haimeur A, 2004, MOL PHARMACOL, V65, P1375, DOI 10.1124/mol.65.6.1375; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Hemachand T, 2002, J CELL SCI, V115, P2053; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Kala SV, 2004, CHEM RES TOXICOL, V17, P243, DOI 10.1021/tx0342060; Kala SV, 2000, J BIOL CHEM, V275, P33404, DOI 10.1074/jbc.M007030200; Kumana CR, 2002, EUR J CLIN PHARMACOL, V58, P521, DOI 10.1007/s00228-002-0514-x; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Leslie EM, 2003, J PHARMACOL EXP THER, V304, P643, DOI 10.1124/jpet.102.044073; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; LO JF, 1992, BIOCHEM J, V288, P977, DOI 10.1042/bj2880977; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Lorico A, 2002, BIOCHEM BIOPH RES CO, V291, P617, DOI 10.1006/bbrc.2002.6489; Lorico A, 1997, CANCER RES, V57, P5238; Mann S, 1996, TOXICOL APPL PHARM, V140, P471, DOI 10.1006/taap.1996.0244; Mann S, 1996, TOXICOL APPL PHARM, V137, P8, DOI 10.1006/taap.1996.0052; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Marnell LL, 2003, CHEM RES TOXICOL, V16, P1507, DOI 10.1021/tx034149a; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; Nemeti B, 2003, TOXICOL SCI, V74, P22, DOI 10.1093/toxsci/kfg116; O'Brien ML, 1999, J PHARMACOL EXP THER, V291, P1348; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Radabaugh TR, 2002, CHEM RES TOXICOL, V15, P692, DOI 10.1021/tx0101853; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Salerno M, 2002, J BIOENERG BIOMEMBR, V34, P135, DOI 10.1023/A:1015180026665; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; Smitherman PK, 2004, J PHARMACOL EXP THER, V308, P260, DOI 10.1124/jpet.103.057729; STYBLO M, 1995, BIOCHEM PHARMACOL, V49, P971, DOI 10.1016/0006-2952(95)00008-N; Vernhet L, 1999, FEBS LETT, V443, P321, DOI 10.1016/S0014-5793(98)01716-5; Vernhet L, 2000, TOXICOLOGY, V142, P127; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886	67	196	209	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32700	32708		10.1074/jbc.M404912200	http://dx.doi.org/10.1074/jbc.M404912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161912	hybrid			2022-12-25	WOS:000222849700089
J	Rao, KVR; Norenberg, MD				Rao, KVR; Norenberg, MD			Manganese induces the mitochondrial permeability transition in cultured astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; RAT-BRAIN; CALCIUM-TRANSPORT; INDUCED APOPTOSIS; CELL-DEATH; PORE; NEUROTOXICITY; TOXICITY; MODULATION; INHIBITION	Manganese is known to cause central nervous system injury leading to parkinsonism and to contribute to the pathogenesis of hepatic encephalopathy. Although mechanisms of manganese neurotoxicity are not completely understood, chronic exposure of various cell types to manganese has shown oxidative stress and mitochondrial energy failure, factors that are often implicated in the induction of the mitochondrial permeability transition (MPT). In this study, we examined whether exposure of cultured neurons and astrocytes to manganese induces the MPT. Cells were treated with manganese acetate (10-100 muM), and the MPT was assessed by changes in the mitochondrial membrane potential and in mitochondrial calcein fluorescence. In astrocytes, manganese caused a dissipation of the mitochondrial membrane potential and decreased the mitochondrial calcein fluorescence in a concentration- and time-dependent manner. These changes were completely blocked by pretreatment with cyclosporin A, consistent with induction of the MPT. On the other hand, similarly treated cultured cortical neurons had a delayed or reduced MPT as compared with astrocytes. The manganese-induced MPT in astrocytes was blocked by pretreatment with antioxidants, suggesting the potential involvement of oxidative stress in this process. Induction of the MPT by manganese and associated mitochondrial dysfunction in astrocytes may represent key mechanisms in manganese neurotoxicity.	Vet Affairs Med Ctr, Miami, FL 33125 USA; Univ Miami, Sch Med, Dept Pathol, Miami, FL 33125 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33125 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Miami	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu			NIDDK NIH HHS [DK063311] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLSHIRE A, 1985, BIOCHIM BIOPHYS ACTA, V807, P202, DOI 10.1016/0005-2728(85)90123-9; ASCHNER M, 1992, J NEUROCHEM, V58, P730, DOI 10.1111/j.1471-4159.1992.tb09778.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BLOKHUIS GG, 1970, FEBS LETT, V11, P197, DOI 10.1016/0014-5793(70)80527-0; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; Chen CJ, 2002, EXP NEUROL, V175, P216, DOI 10.1006/exnr.2002.7894; Chen JY, 2001, TOXICOL APPL PHARM, V175, P160, DOI 10.1006/taap.2001.9245; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; DESOLE MS, 1995, NEUROSCI LETT, V192, P73, DOI 10.1016/0304-3940(95)11613-2; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gavin CE, 1999, NEUROTOXICOLOGY, V20, P445; GAVIN CE, 1992, TOXICOL APPL PHARM, V115, P1, DOI 10.1016/0041-008X(92)90360-5; GAVIN CE, 1990, BIOCHEM J, V266, P329, DOI 10.1042/bj2660329; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HaMai D, 2001, FREE RADICAL BIO MED, V31, P763, DOI 10.1016/S0891-5849(01)00639-6; Hazell AS, 1997, NEUROCHEM RES, V22, P1443, DOI 10.1023/A:1021994126329; HERTZ L, 1989, NEUROCHEM RES, V14, P755, DOI 10.1007/BF00964954; Higuchi H, 2001, HEPATOLOGY, V34, P320, DOI 10.1053/jhep.2001.26380; Jou MJ, 2002, J BIOMED SCI, V9, P507; Kaiser J, 2003, SCIENCE, V300, P927, DOI 10.1126/science.300.5621.927; Kaiser J, 2003, SCIENCE, V300, P926, DOI 10.1126/science.300.5621.926; Kerr PM, 1999, AM J PHYSIOL-HEART C, V276, pH496, DOI 10.1152/ajpheart.1999.276.2.H496; KREIGER D, 1995, LANCET, V346, P270; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Norenberg MD, 2003, ENCEPHALOPATHY AND NITROGEN METABOLISM IN LIVER FAILURE, P267; Olanow CW, 1996, NEUROLOGY, V46, P492, DOI 10.1212/WNL.46.2.492; Pal PK, 1999, NEUROTOXICOLOGY, V20, P227; PENTSCHEW A, 1963, J NEUROPATH EXP NEUR, V22, P488, DOI 10.1097/00005072-196307000-00010; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; POMIERLAYRARGUES G, 1995, LANCET, V345, P735, DOI 10.1016/S0140-6736(95)90909-5; Rao KVR, 2003, NEUROCHEM INT, V43, P517, DOI 10.1016/S0197-0186(03)00042-1; Rao KVR, 2003, METAB BRAIN DIS, V18, P113, DOI 10.1023/A:1023858902184; Reichert SA, 2001, J NEUROSCI, V21, P6608, DOI 10.1523/JNEUROSCI.21-17-06608.2001; Roth JA, 2002, J NEUROSCI RES, V68, P76, DOI 10.1002/jnr.10207; Spranger M, 1998, EXP NEUROL, V149, P277, DOI 10.1006/exnr.1997.6666; SUAREZ N, 1993, J NEUROCHEM, V61, P127, DOI 10.1111/j.1471-4159.1993.tb03546.x; Suleiman MS, 2001, PHARMACOL THERAPEUT, V89, P29, DOI 10.1016/S0163-7258(00)00102-9; SUN AY, 1993, ANN NY ACAD SCI, V679, P358; Takeda A, 2003, BRAIN RES REV, V41, P79, DOI 10.1016/S0165-0173(02)00234-5; THOLEY G, 1987, NEUROCHEM RES, V12, P45; Verity MA, 1999, NEUROTOXICOLOGY, V20, P489; WEDLER FC, 1989, NEUROCHEM RES, V14, P1129, DOI 10.1007/BF00965619; WEDLER FC, 1986, MANGANESE METABOLISM, P221; Zhang SR, 2004, TOXICOL IN VITRO, V18, P71, DOI 10.1016/j.tiv.2003.09.002; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	88	88	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32333	32338		10.1074/jbc.M402096200	http://dx.doi.org/10.1074/jbc.M402096200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173181	hybrid			2022-12-25	WOS:000222849700044
J	Russo, GL; Tosto, M; Mupo, A; Castellano, I; Cuomo, A; Tosti, E				Russo, GL; Tosto, M; Mupo, A; Castellano, I; Cuomo, A; Tosti, E			Biochemical and functional characterization of protein kinase CK2 in ascidian Ciona intestinalis oocytes at fertilization - Cloning and sequence analysis of cDNA for alpha and beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION; CALCIUM OSCILLATIONS; PHOSPHORYLATION SITE; METAPHASE ARREST; P34(CDC2); CKII; IDENTIFICATION; PURIFICATION; EXPRESSION; MEIOSIS	The ubiquitous and pleiotropic dual specificity protein kinase CK2 has been studied and characterized in many organisms, from yeast to mammals. Generally, the enzyme is composed of two catalytic (alpha and/or alpha') and two regulatory (beta) subunits, forming a differently assembled tetramer. Although prone to controversial interpretation, the function of CK2 has been associated with fundamental biological processes such as signal transduction, cell cycle progression, cell growth, apoptosis, and transcription. Less known is the role of CK2 during meiosis and the early phase of embryogenesis. In this work, we studied CK2 activity during oocyte activation, a process occurring at the end of oocyte maturation and triggered by fertilization. In ascidian Ciona intestinalis, an organism whose complete genome has been published recently, CK2 was constitutively active in unfertilized and fertilized oocytes. The enzymatic activity oscillated through meiosis showing three major peaks: soon after fertilization ( metaphase I exit), before metaphase II, and at the exit from metaphase II. Biochemical analysis of CK2 subunit composition in activated oocytes indicated that CK2-alpha was catalytically active as a monomer, independently from its regulatory subunit beta; however, CK2-beta was only detectable in unfertilized oocytes where it was associated with a bona fide identified ascidian mitogen-activated protein kinase. After fertilization, CK2-beta was undetectable, suggesting its rapid degradation. Protein sequence analysis of CK2-alpha and -beta cDNA indicated a high identity compared with vertebrate homologs. In addition, the absence of putative phosphorylation sites for Cdc2 kinase on both alpha and beta subunits suggested an important role for CK2 in regulating meiotic cell cycle in C. intestinalis oocytes.	CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy; Staz Zool Anton Dohrn, I-80121 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); Stazione Zoologica Anton Dohrn di Napoli	Russo, GL (corresponding author), CNR, Ist Sci Alimentaz, Via Roma 52 A-C, I-83100 Avellino, Italy.	glrusso@szn.it	RUSSO, GIAN LUIGI/GQB-0962-2022; Castellano, Immacolata/AAD-5523-2019	Castellano, Immacolata/0000-0002-4274-6738; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Mupo, Annalisa/0000-0002-2771-0462				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BELLE R, 1990, International Journal of Developmental Biology, V34, P111; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Donella-Deana A, 2001, BIOCHEM J, V357, P563, DOI 10.1042/0264-6021:3570563; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Gotz C, 1996, ONCOGENE, V13, P391; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; Hutson SF, 2003, DEV GENES EVOL, V213, P1, DOI 10.1007/s00427-002-0286-4; KANDROR KV, 1989, EUR J BIOCHEM, V180, P441, DOI 10.1111/j.1432-1033.1989.tb14666.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 2001, MOL CELL BIOCHEM, V227, P153, DOI 10.1023/A:1013108822847; LEIVA L, 1987, BIOCHEM INT, V14, P707; Levasseur M, 2000, DEVELOPMENT, V127, P631; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LONGO FJ, 1983, MOLLUSCA, V3, P49; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MARSHAK DR, 1994, CELL MOL BIOL RES, V40, P513; McDougall A, 1998, DEVELOPMENT, V125, P4451; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nixon VL, 2000, BIOL CELL, V92, P187, DOI 10.1016/S0248-4900(00)01068-6; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OSBORNE HB, 1989, BIOCHEM BIOPH RES CO, V158, P520, DOI 10.1016/S0006-291X(89)80080-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Russo GL, 1997, BIOCHEM BIOPH RES CO, V233, P673, DOI 10.1006/bbrc.1997.6515; Russo GL, 2000, BIOCHEM J, V351, P143, DOI 10.1042/0264-6021:3510143; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Russo GL, 2001, MOL CELL BIOCHEM, V227, P113, DOI 10.1023/A:1013189629207; Russo GL, 1996, DEVELOPMENT, V122, P1995; Russo GL, 1998, SEMIN CELL DEV BIOL, V9, P559, DOI 10.1006/scdb.1998.0250; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; Sambrook J, 2001, MOL CLONING LAB MANU; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SARDET C, 1989, DEVELOPMENT, V105, P237; Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Satoh N, 2003, NAT REV GENET, V4, P285, DOI 10.1038/nrg1042; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Tosti E, 2004, HUM REPROD UPDATE, V10, P53, DOI 10.1093/humupd/dmh006; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; WILHELM V, 1995, EUR J BIOCHEM, V232, P671, DOI 10.1111/j.1432-1033.1995.tb20859.x; XU Z, 1993, DEV GENET, V14, P424, DOI 10.1002/dvg.1020140604; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; Zhang CJ, 2002, ONCOGENE, V21, P3754, DOI 10.1038/sj.onc.1205467	73	12	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					33012	33023		10.1074/jbc.M401085200	http://dx.doi.org/10.1074/jbc.M401085200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159401	hybrid			2022-12-25	WOS:000222849700121
J	Frick, C; Atanasov, AG; Arnold, P; Ozols, J; Odermatt, A				Frick, C; Atanasov, AG; Arnold, P; Ozols, J; Odermatt, A			Appropriate function of 11 beta-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum lumen is dependent on its N-terminal region sharing similar topological determinants with 50-kDa esterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; ARYLACETAMIDE DEACETYLASE; CHOLESTEROL-METABOLISM; REDUCTASE-ACTIVITY; ER MEMBRANES; HUMAN LIVER; ENZYME; CELLS; MACROPHAGES; OXYSTEROLS	By interconverting glucocorticoids, 11beta-hydroxysteroid dehydrogenase type 1 ( 11beta-HSD1) exerts an important pre-receptor function and is currently considered a promising therapeutic target. In addition, 11beta-HSD1 plays a potential role in 7-ketocholesterol metabolism. Here we investigated the role of the N-terminal region on enzymatic activity and addressed the relevance of 11beta-HSD1 orientation into the endoplasmic reticulum ( ER) lumen. Previous studies revealed that the luminal orientation of 11beta-HSD1 and 50-kDa esterase/ arylacetamide deacetylase (E3) is determined by their highly similar N-terminal transmembrane domains. Substitution of Lys(5) by Ser in 11beta-HSD1, but not of the analogous Lys(4) by Ile in E3, led to an inverted topology in the ER membrane, indicating the existence of a second topological determinant. Here we identified Glu(25)/Glu(26) in 11beta-HSD1 and Asp(25) in E3 as the second determinant for luminal orientation. Our results suggest that the exact location of specific residues rather than net charge distribution on either side of the helix is critical for membrane topology. Analysis of charged residues in the N-terminal domain revealed an essential role of Lys(35)/Lys(36) and Glu(25)/Glu(26) on enzymatic activity, suggesting that these residues are responsible for the observed stabilizing effect of the N-terminal membrane anchor on the catalytic domain of 11beta-HSD1. Moreover, activity measurements in intact cells expressing wildtype 11beta-HSD1, facing the ER lumen, or mutant K5S/ K6S, facing the cytoplasm, revealed that the luminal orientation is essential for efficient oxidation of cortisol. Furthermore, we demonstrate that 11beta-HSD1, but not mutant K5S/ K6S with cytoplasmic orientation, catalyzes the oxoreduction of 7-ketocholesterol. 11beta-HSD1 and E3 constructs with cytosolic orientation of their catalytic moiety should prove useful in future studies addressing the physiological function of these proteins.	Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Bern; University of Connecticut	Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.	alex.odermatt@dkf1.unibe.ch	Atanasov, Atanas G./C-5535-2013	Atanasov, Atanas G./0000-0003-2545-0967; Odermatt, Alex/0000-0002-6820-2712				Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Arnold P, 2003, MOL CELL ENDOCRINOL, V201, P177, DOI 10.1016/S0303-7207(02)00304-0; BANBEGYI G, 2004, J BIOL CHEM, V279, P27017; Bannenberg G, 2003, CHEM-BIOL INTERACT, V143, P449, DOI 10.1016/S0009-2797(02)00183-7; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; Blum A, 2000, BIOCHEM BIOPH RES CO, V276, P428, DOI 10.1006/bbrc.2000.3491; Blum A, 2003, CHEM-BIOL INTERACT, V143, P469, DOI 10.1016/S0009-2797(02)00224-7; Blum A, 2003, BIOCHEMISTRY-US, V42, P4108, DOI 10.1021/bi027425d; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; CHARUK JHM, 1994, AM J PHYSIOL, V266, pF66, DOI 10.1152/ajprenal.1994.266.1.F66; Chrousos GP, 2004, P NATL ACAD SCI USA, V101, P6329, DOI 10.1073/pnas.0401671101; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Gao HB, 1996, ENDOCRINOLOGY, V137, P1714, DOI 10.1210/en.137.5.1714; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Maser E, 2003, CHEM-BIOL INTERACT, V143, P435, DOI 10.1016/S0009-2797(02)00180-1; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Robinzon B, 2003, ARCH BIOCHEM BIOPHYS, V412, P251, DOI 10.1016/S0003-9861(03)00056-0; SampathKumar R, 1997, J STEROID BIOCHEM, V62, P195, DOI 10.1016/S0960-0760(97)00027-7; Sandeep TC, 2004, P NATL ACAD SCI USA, V101, P6734, DOI 10.1073/pnas.0306996101; Schmitz G, 2001, NEUROCHEM RES, V26, P1045, DOI 10.1023/A:1012357106398; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; Schweizer RAS, 2004, J BIOL CHEM, V279, P18415, DOI 10.1074/jbc.M313615200; Schweizer RAS, 2003, MOL CELL ENDOCRINOL, V212, P41, DOI 10.1016/j.mce.2003.09.027; Stewart PM, 1999, VITAM HORM, V57, P249; Thieringer R, 2001, J IMMUNOL, V167, P30, DOI 10.4049/jimmunol.167.1.30; Trickett JI, 2001, J BIOL CHEM, V276, P39522, DOI 10.1074/jbc.M101764200; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wsol V, 2003, CHEM-BIOL INTERACT, V143, P459, DOI 10.1016/S0009-2797(02)00221-1	45	45	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31131	31138		10.1074/jbc.M313666200	http://dx.doi.org/10.1074/jbc.M313666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152005	hybrid			2022-12-25	WOS:000222726800029
J	Hirano, Y; Yoshinaga, S; Ogura, K; Yokochi, M; Noda, Y; Sumimoto, H; Inagaki, F				Hirano, Y; Yoshinaga, S; Ogura, K; Yokochi, M; Noda, Y; Sumimoto, H; Inagaki, F			Solution structure of atypical protein kinase CPB1 domain and its mode of interaction with ZIP/p62 and MEK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; EPITHELIAL TIGHT JUNCTION; NERVE GROWTH-FACTOR; CELL-POLARITY; NADPH OXIDASE; PB1 DOMAIN; PC MOTIF; MOLECULAR-CLONING; C ZETA; COMPLEX	Atypical protein kinase C ( aPKC) has been implicated in several signaling pathways such as cell polarity, cell survival, and cell differentiation. In contrast to other PKCs, aPKC is unique in having the PB1 ( Phox and Bem 1) domain in the N terminus. The aPKC PB1 domain binds with ZIP/p62, Par6, or MEK5 through a PB1-PB1 domain interaction that controls the localization of aPKC. Here, we determined the three-dimensional structure of the PB1 domain of PKCiota by NMR and found that the PB1 domain adopts a ubiquitin fold. The OPCA (OPR, PC, and AID) motif inserted into the ubiquitin fold was presented as a betabetaalpha fold in which the side chains of conserved Asp residues were oriented to the same direction to form an acidic surface. This structural feature suggested that the acidic surface of the PKCiota PB1 domain interacted with the basic surface of the target PB1 domains, and this was confirmed in the case of the PKCiota-ZIP/p62 complex by mutational analysis. Interestingly, in the PKCiota PB1 domain a conserved lysine residue was located on the side opposite to the OPCA motif-presenting surface, suggesting dual roles for the PKCiota PB1 domain in that it could interact with either the conserved lysine residue or the acidic residues on the OPCA motif of the target PB1 domains.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Kita Ku, N-12 W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp		Hirano, Yoshinori/0000-0001-9888-1616				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Coligan J.E., 1997, CURRENT PROTOCOLS PR; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; OLEJNICZAK ET, 1992, J BIOMOL NMR, V2, P655, DOI 10.1007/BF02192854; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Roehrl MHA, 2003, J BIOMOL NMR, V26, P373, DOI 10.1023/A:1024047110957; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yoshinaga S, 2003, EMBO J, V22, P4888, DOI 10.1093/emboj/cdg475	51	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31883	31890		10.1074/jbc.M403092200	http://dx.doi.org/10.1074/jbc.M403092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143057	hybrid			2022-12-25	WOS:000222726800115
J	Tamura, Y; Osuga, J; Adachi, H; Tozawa, R; Takanezawa, Y; Ohashi, K; Yahagi, N; Sekiya, M; Okazaki, H; Tomita, S; Iizuka, Y; Koizumi, H; Inaba, T; Yagyu, H; Kamada, N; Suzuki, H; Shimano, H; Kadowaki, T; Tsujimoto, M; Arai, H; Yamada, N; Ishibashi, S				Tamura, Y; Osuga, J; Adachi, H; Tozawa, R; Takanezawa, Y; Ohashi, K; Yahagi, N; Sekiya, M; Okazaki, H; Tomita, S; Iizuka, Y; Koizumi, H; Inaba, T; Yagyu, H; Kamada, N; Suzuki, H; Shimano, H; Kadowaki, T; Tsujimoto, M; Arai, H; Yamada, N; Ishibashi, S			Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-A; ATHEROSCLEROTIC LESIONS; BACTERIA-BINDING; MICE LACKING; ENDOTOXIN; CLONING; HYPERCHOLESTEROLEMIA; INFLAMMATION; RECOGNITION; INFECTION	Scavenger receptor expressed by endothelial cells I (SREC-I) is a novel endocytic receptor for acetylated low density lipoprotein (LDL). Here we show that SREC-I is expressed in a wide variety of tissues, including macrophages and aortas. Lipopolysaccharide (LPS) robustly stimulated the expression of SREC-I in macrophages. In an initial attempt to clarify the role of SREC-I in the uptake of modified lipoproteins as well as in the development of atherosclerosis, we generated mice with a targeted disruption of the SREC-I gene by homologous recombination in embryonic stem cells. To exclude the overwhelming effect of the type A scavenger receptor (SR-A) on the uptake of Ac-LDL, we further generated mice lacking both SR-A and SREC-I (SR-A(-/-); SREC-I-/-) by cross-breeding and compared the uptake and degradation of Ac-LDL in the isolated macrophages. The contribution of SR-A and SREC-I to the overall degradation of Ac-LDL was 85 and 5%, respectively, in a non-stimulated condition. LPS increased the uptake and degradation of Ac-LDL by 1.8-fold. In this condition, the contribution of SR-A and SREC-I to the overall degradation of Ac-LDL was 90 and 6%, respectively. LPS increased the absolute contribution of SR-A and SREC-I by 1.9- and 2.3-fold, respectively. On the other hand, LPS decreased the absolute contribution of other pathways by 31%. Consistently, LPS did not increase the expression of other members of the scavenger receptor family such as CD36. In conclusion, SREC-I serves as a major endocytic receptor for Ac-LDL in LPS-stimulated macrophages lacking SR-A, suggesting that it has a key role in the development of atherosclerosis in concert with SR-A.	Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; Chugai Res Inst Med Sci Inc, Shizuoka 4128513, Japan; Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Unit Funct Genom, Obihiro, Hokkaido 0808555, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; RIKEN; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; Obihiro University of Agriculture & Veterinary Medicine; University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	ishibash@jichi.ac.jp	Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Takanezawa, Yasukazu/0000-0002-9220-5825				ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 2002, J BIOL CHEM, V277, P24014, DOI 10.1074/jbc.M201854200; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Babaev VR, 2000, ARTERIOSCL THROM VAS, V20, P2593, DOI 10.1161/01.ATV.20.12.2593; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Becker AE, 2001, ANNU REV MED, V52, P289, DOI 10.1146/annurev.med.52.1.289; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; de Winther MPJ, 2000, INT J TISSUE REACT, V22, P85; de Winther MPJ, 1999, ATHEROSCLEROSIS, V144, P315, DOI 10.1016/S0021-9150(98)00332-3; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fitzgerald ML, 2000, J IMMUNOL, V164, P2692, DOI 10.4049/jimmunol.164.5.2692; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FUNK JL, 1993, ATHEROSCLEROSIS, V98, P67, DOI 10.1016/0021-9150(93)90224-I; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ishiguro T, 2001, AM J PATHOL, V158, P179, DOI 10.1016/S0002-9440(10)63956-9; Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200; Kamada N, 2001, J Atheroscler Thromb, V8, P1; Khovidhunkit W, 2001, J LIPID RES, V42, P1636; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lehr HA, 2001, CIRCULATION, V104, P914, DOI 10.1161/hc3401.093153; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; LYNN WA, 1995, CLIN INFECT DIS, V20, P143, DOI 10.1093/clinids/20.1.143; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Perrey S, 2001, ATHEROSCLEROSIS, V154, P51, DOI 10.1016/S0021-9150(00)00457-3; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Sakaguchi H, 1998, LAB INVEST, V78, P423; Sambrook J, 2001, MOL CLONING LAB MANU; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; Vink A, 2002, CIRCULATION, V106, P1985, DOI 10.1161/01.CIR.0000032146.75113.EE; Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	55	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30938	30944		10.1074/jbc.M313088200	http://dx.doi.org/10.1074/jbc.M313088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145948	Green Published, hybrid			2022-12-25	WOS:000222726800006
J	Trinidad, JC; Cohen, JB				Trinidad, JC; Cohen, JB			Neuregulin inhibits acetylcholine receptor aggregation in myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMUSCULAR-JUNCTION; TYROSINE-PHOSPHATASE; SYNAPSE ELIMINATION; GENE-EXPRESSION; PROTEIN-KINASE; NERVOUS-SYSTEM; MUSCLE-FIBERS; IN-VIVO; ARIA; ACTIVATION	The high local concentration of acetylcholine receptors (AChRs) at the vertebrate neuromuscular junction results from their aggregation by the agrin/MuSK signaling pathway and their synthetic up-regulation by the neuregulin/ErbB pathway. Here, we show a novel role for the neuregulin/ErbB pathway, the inhibition of AChR aggregation on the muscle surface. Treatment of C2C12 myotubes with the neuregulin epidermal growth factor domain decreased the number of both spontaneous and agrin-induced AChR clusters, in part by increasing the rate of cluster disassembly. Upon cluster disassembly, AChRs were internalized into caveolae ( as identified by caveolin-3). Time-lapse microscopy revealed that individual AChR clusters fragmented into puncta, and application of neuregulin accelerated the rate at which AChR clusters decreased in area without affecting the density of AChRs remaining in individual clusters ( as measured by the fluorescence intensity/unit area). We propose that this novel action of neuregulin regulates synaptic competition at the developing neuromuscular junction.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu	Trinidad, Jonathan/GWR-2077-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18458] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; Astrow SH, 1996, J NEUROSCI, V16, P5130; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; Bezakova G, 2001, P NATL ACAD SCI USA, V98, P9924, DOI 10.1073/pnas.171539698; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; Culican SM, 1998, J NEUROSCI, V18, P4953; Dai ZS, 1998, J CELL BIOL, V141, P1613, DOI 10.1083/jcb.141.7.1613; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Finn AJ, 2003, NAT NEUROSCI, V6, P717, DOI 10.1038/nn1071; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; Gonzalez M, 1999, NEURON, V24, P567, DOI 10.1016/S0896-6273(00)81113-7; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kim S, 2000, J NEUROBIOL, V42, P22, DOI 10.1002/(SICI)1097-4695(200001)42:1<22::AID-NEU3>3.0.CO;2-#; KO PK, 1977, SCIENCE, V196, P540, DOI 10.1126/science.850796; Li QF, 2001, J BIOL CHEM, V276, P38068; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; Meyer D, 1997, DEVELOPMENT, V124, P3575; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; MOSS BL, 1987, J NEUROBIOL, V18, P101, DOI 10.1002/neu.480180108; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; RICH M, 1989, NEURON, V3, P677, DOI 10.1016/0896-6273(89)90236-5; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267; Walsh MK, 2003, NEURON, V37, P67, DOI 10.1016/S0896-6273(02)01142-X; Wells DG, 1999, P NATL ACAD SCI USA, V96, P1112, DOI 10.1073/pnas.96.3.1112; Werle MJ, 1996, J NEUROBIOL, V30, P293, DOI 10.1002/(SICI)1097-4695(199606)30:2<293::AID-NEU10>3.0.CO;2-L; Weston C, 2003, J BIOL CHEM, V278, P6450, DOI 10.1074/jbc.M210249200; Willmann R, 2002, CELL MOL LIFE SCI, V59, P1296, DOI 10.1007/s00018-002-8509-4; Yang JF, 1997, FEBS LETT, V403, P163, DOI 10.1016/S0014-5793(97)00044-6; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2	46	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31622	31628		10.1074/jbc.M400044200	http://dx.doi.org/10.1074/jbc.M400044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155732	hybrid			2022-12-25	WOS:000222726800086
J	Aubol, BE; Ungs, L; Lukasiewicz, R; Ghosh, G; Adams, JA				Aubol, BE; Ungs, L; Lukasiewicz, R; Ghosh, G; Adams, JA			Chemical clamping allows for efficient phosphorylation of the RNA carrier protein Npl3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SRC KINASE; SUBSTRATE-SPECIFICITY; CONFORMATIONAL-CHANGES; KINETIC MECHANISM; STRUCTURAL BASIS; SPLICING FACTORS; DOCKING SITE; C-JUN; INSIGHTS; SKY1P	Protein kinases phosphorylate the appropriate protein substrate by recognizing residues both proximal and distal to the site of phosphorylation. Although these distal contacts may provide excellent binding affinities (low K-m values) through stabilization of the enzyme-substrate complex, these contacts could reduce catalytic turnover (decrease k(cat)) through slow phosphoprotein release. To investigate how protein kinases can overcome this problem and maintain both high substrate affinities and high turnover rates, the phosphorylation of the yeast RNA transport protein Npl3 by its natural protein kinase, Sky1p, was evaluated. Sky1p bound and phosphorylated Npl3 with a K-m that was 2 orders of magnitude lower than a short peptide mimic representing the phosphorylation site and only proximal determinants. Surprisingly, this extraordinary difference is not the result of high affinity Npl3 binding. Rather, Npl3 achieves a low K-m through a rapid and favorable phosphoryl transfer step. This step serves as a chemical clamp that locks the protein substrate in the active site without unduly stabilizing the product phosphoprotein and slowing its release. The chemical clamping mechanism offers an efficient means whereby a protein kinase can simultaneously achieve both high turnover and good substrate binding properties.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Adams, JA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	joeadams@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067969] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 67969, GM 07752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Aubol BE, 2003, BIOCHEMISTRY-US, V42, P12813, DOI 10.1021/bi035200c; Aubol BE, 2002, BIOCHEMISTRY-US, V41, P10002, DOI 10.1021/bi020233y; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Cohen P, 2001, EUR J BIOCHEM, V268, P5001, DOI 10.1046/j.0014-2956.2001.02473.x; COLE PA, 1994, J BIOL CHEM, V269, P30880; Fabbro D, 2002, PHARMACOL THERAPEUT, V93, P79, DOI 10.1016/S0163-7258(02)00179-1; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant BD, 1996, BIOCHEMISTRY-US, V35, P2022, DOI 10.1021/bi952144+; Hawkins J, 2000, ARCH BIOCHEM BIOPHYS, V382, P310, DOI 10.1006/abbi.2000.2005; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jan AY, 2000, BIOCHEMISTRY-US, V39, P9786, DOI 10.1021/bi9924922; Johnson KA, 1998, CURR OPIN BIOTECH, V9, P87, DOI 10.1016/S0958-1669(98)80089-X; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSSON MSA, 1992, CRIT REV ORAL BIOL M, V3, P61, DOI 10.1177/10454411920030010601; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Nolen B, 2001, NAT STRUCT BIOL, V8, P176, DOI 10.1038/84178; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Shaffer J, 1999, BIOCHEMISTRY-US, V38, P12072, DOI 10.1021/bi991109q; Shaffer J, 2001, BIOCHEMISTRY-US, V40, P11149, DOI 10.1021/bi011029y; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; Waas WF, 2003, BIOCHEMISTRY-US, V42, P12273, DOI 10.1021/bi0348617; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zhou J, 1997, BIOCHEMISTRY-US, V36, P15733, DOI 10.1021/bi971438n; Zhou J, 1997, BIOCHEMISTRY-US, V36, P2977, DOI 10.1021/bi9619132	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30182	30188		10.1074/jbc.M402797200	http://dx.doi.org/10.1074/jbc.M402797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15145958	hybrid			2022-12-25	WOS:000222531900040
J	Vanden Abeele, F; Lemonnier, L; Thebault, S; Lepage, G; Parys, JB; Shuba, Y; Skryma, R; Prevarskaya, N				Vanden Abeele, F; Lemonnier, L; Thebault, S; Lepage, G; Parys, JB; Shuba, Y; Skryma, R; Prevarskaya, N			Two types of store-operated Ca2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; INTRACELLULAR CA2+; CATION CHANNELS; XENOPUS OOCYTES; MAST-CELLS; DIFFUSIBLE MESSENGER; PHOSPHOLIPASE A(2); SIGNALING COMPLEX	The one or more coupling mechanisms of store-operated channels (SOCs) to endoplasmic reticulum ( ER) Ca2+ store depletion as well as the molecular identity of SOCs per se still remain a mystery. Here, we demonstrate the co-existence of two populations of molecular distinct endogenous SOCs in LNCaP prostate cancer epithelial cells, which are preferentially activated by either active inositol 1,4,5-trisphosphate (IP3)-mediated or passive thapsigargin-facilitated store depletion and have different ER store content sensitivity. The first population, called SOCCC (for "conformational coupling"), is characterized by preferential IP3 receptor-dependent mode of activation, as judged from sensitivity to cytoskeleton modifications, and dominant contribution of transient receptor potential (TRP) TRPC1 within it. The second one, called SOCCIF (for "calcium influx factor"), depends on Ca2+-independent phospholipase A(2) for activation with probable CIF involvement and is mostly represented by TRPC4. The previously identified SOC constituent in LNCaP cells, TRPV6, seems to play equal role in both SOC populations. These results provide new insight into the nature of SOCs and their representation in the single cell type as well as permit reconciliation of current SOC activation hypotheses.	Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM, EMI 0228, F-59655 Villeneuve Dascq, France; Catholic Univ Louvain, Fysiol Lab, B-3000 Louvain, Belgium; Natl Acad Sci Ukraine, Bogomoletz Inst Physiol, UA-01024 Kiev 24, Ukraine	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite Catholique Louvain; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology	Prevarskaya, N (corresponding author), Univ Sci & Technol Lille, Lab Physiol Cellulaire, INSERM, EMI 0228, Bat SN3, F-59655 Villeneuve Dascq, France.	natacha.prevarskaya@univ-lille1.f	Shuba, Yaroslav/AAT-6758-2021; Lemonnier, Loic/L-7289-2018; Vanden Abeele, Fabien/O-6012-2017; Thébault, Stéphanie/AAD-8350-2019	Lemonnier, Loic/0000-0001-6200-5382; Thebault, Stephanie/0000-0003-3233-282X; Prevarskaya, natacha/0000-0003-0316-197X; Parys, Jan/0000-0002-3591-4967; Vanden Abeele, Fabien/0000-0001-7111-7220				Bakowski D, 2003, J PHYSIOL-LONDON, V553, P387, DOI 10.1113/jphysiol.2003.055335; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bodding M, 2003, J BIOL CHEM, V278, P50872, DOI 10.1074/jbc.M308800200; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gregory RB, 1999, BIOCHEM J, V341, P401, DOI 10.1042/0264-6021:3410401; Gusev K, 2003, J GEN PHYSIOL, V122, P81, DOI 10.1085/jgp.200308815; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Itagaki K, 2004, J IMMUNOL, V172, P601, DOI 10.4049/jimmunol.172.1.601; Kahr H, 2004, J PHYSIOL-LONDON, V557, P121, DOI 10.1113/jphysiol.2004.062653; Kinoshita M, 2000, CELL CALCIUM, V28, P151, DOI 10.1054/ceca.2000.0143; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Peng JB, 2003, J PHYSIOL-LONDON, V551, P729, DOI 10.1113/jphysiol.2003.043349; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2003, CELL CALCIUM, V34, P339, DOI 10.1016/S0143-4160(03)00143-X; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; van Rossum DB, 2004, P NATL ACAD SCI USA, V101, P2323, DOI 10.1073/pnas.0308565100; Vanden Abeele F, 2003, CELL CALCIUM, V33, P357, DOI 10.1016/S0143-4160(03)00049-6; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanlingen S, 2000, BIOCHEM J, V346, P275, DOI 10.1042/0264-6021:3460275; Vanlingen S, 1997, CELL CALCIUM, V22, P475, DOI 10.1016/S0143-4160(97)90075-0; Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1; Vazquez G, 2003, J BIOL CHEM, V278, P21649, DOI 10.1074/jbc.M302162200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	70	86	89	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30326	30337		10.1074/jbc.M400106200	http://dx.doi.org/10.1074/jbc.M400106200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138280	hybrid			2022-12-25	WOS:000222531900058
J	Rahn, JJ; Shen, Q; Mah, BK; Hugh, JC				Rahn, JJ; Shen, Q; Mah, BK; Hugh, JC			MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; PROTEIN-KINASE-C; BETA-CATENIN; TYROSINE PHOSPHORYLATION; BREAST-CANCER; CYTOPLASMIC DOMAIN; CELL-ADHESION; SRC	The MUC1 mucin is normally restricted to the apical surface of breast epithelial cells. In tumors, it is frequently overexpressed and underglycosylated. The MUC1 peptide core mediates firm adhesion of tumor cells to adjacent cells via binding to intercellular adhesion molecule-1 (ICAM-1). There is increasing evidence that MUC1 is involved in signaling, with current reports focusing on phosphorylation of the MUC1 cytoplasmic tail after indirect or artificial modes of stimulation. ICAM-1 is the only known direct ligand of the MUC1 extracellular domain. The data presented herein show that MUC1 expressed on the surface of breast cancer cell lines or transfected 293T cells can initiate a calcium-based oscillatory signal on contact with ICAM-1-transfected NIH 3T3 cells, and we present a novel method of quantifying and comparing calcium oscillations. The MUC1-induced signal appears to be distinct from those previously described, and may involve a Src family kinase, phosphoinositol 3-kinase, phospholipase C, and lipid rafts, but not mitogen-activated protein kinase. As calcium signaling has been associated with cytoskeletal change and motility, it is possible that the functions of MUC1 include heterotypic cell-cell adhesion followed by a calcium-based promigratory signal within tumor cells, thus facilitating metastasis.	Univ Alberta, Cross Canc Inst, Dept Lab Med & Pathol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Hugh, JC (corresponding author), Univ Alberta, Cross Canc Inst, Dept Lab Med & Pathol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	judith.hugh@cancerboard.ab.ca						Bodin S, 2003, THROMB HAEMOSTASIS, V89, P318, DOI 10.1055/s-0037-1613449; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; HORNE G, 1999, THESIS U ALBERTA EDM; Hur EM, 2004, J BIOL CHEM, V279, P5852, DOI 10.1074/jbc.M311687200; Kam JL, 1998, CANCER RES, V58, P5577; Kiely JM, 2003, J IMMUNOL, V171, P3216, DOI 10.4049/jimmunol.171.6.3216; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Meerzaman D, 2000, AM J PHYSIOL-LUNG C, V278, pL625, DOI 10.1152/ajplung.2000.278.3.L625; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Oosawa Y, 1997, CELL BIOCHEM FUNCT, V15, P113, DOI 10.1002/(SICI)1099-0844(19970601)15:2<113::AID-CBF730>3.3.CO;2-O; Ozdener F, 2002, MOL PHARMACOL, V62, P672, DOI 10.1124/mol.62.3.672; PANDEY P, 1995, CANCER RES, V55, P4000; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Quin RJ, 2000, INT J CANCER, V87, P499, DOI 10.1002/1097-0215(20000815)87:4<499::AID-IJC6>3.0.CO;2-9; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ranta-Knuuttila T, 2002, DIGEST DIS SCI, V47, P1008, DOI 10.1023/A:1015025704589; Regimbald LH, 1996, CANCER RES, V56, P4244; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	30	65	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29386	29390		10.1074/jbc.C400010200	http://dx.doi.org/10.1074/jbc.C400010200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15169768	hybrid			2022-12-25	WOS:000222445300070
J	Schmitt, JM; Wayman, GA; Nozaki, N; Soderling, TR				Schmitt, JM; Wayman, GA; Nozaki, N; Soderling, TR			Calcium activation of ERK mediated by calmodulin kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; SYNAPTIC PLASTICITY; GENE-EXPRESSION; NG108-15 CELLS; NEURONAL DIFFERENTIATION; CREB PHOSPHORYLATION; SIGNAL-TRANSDUCTION; NEUROBLASTOMA-CELLS; NMDA RECEPTOR	Elevated intracellular Ca2+ triggers numerous signaling pathways including protein kinases such as the calmodulin-dependent kinases (CaMKs) and the extracellular signal-regulated kinases (ERKs). In the present study we examined Ca2+-dependent" cross-talk" between these two protein kinase families. Using a combination of pharmacological inhibitors and dominant-negative kinases (dnKinase), we identified a requirement for CaMKK acting through CaMKI in the stimulation of ERKs upon depolarization of the neuroblastoma cell line, NG108. Depolarization stimulated prolonged ERK and JNK activation that was blocked by the CaMKK inhibitor, STO-609; this inhibition of ERK activation by STO-609 was rescued by expression of a STO-609-insensitive mutant of CaMKK. However, activation of ERK by epidermal growth factor or carbachol were not suppressed by inhibition of CaMKK, indicating specificity for this "cross-talk." To identify the downstream target of CaMKK that mediated ERK activation upon depolarization, dnKinases were expressed. The dnCaMKI completely suppressed ERK2 activation whereas dnAKT/PKB or nuclear-targeted dnCaMKIV, other substrates for CaMKK, were not inhibitory. ERK activation upon depolarization or transfection with constitutively active (ca) CaMKI was blocked by dnRas. Additionally, depolarization of NG108 cells promoted neurite outgrowth, and this effect was blocked by inhibition of either CaMKK (STO-609) or ERK (UO126). Co-transfection with caCaMKK plus caCaMKI also stimulated neurite outgrowth that was blocked by inhibition of ERK (UO126). These data are the first to suggest that ERK activation and neurite outgrowth in response to depolarization are mediated by CaMKK activation of CaMKI.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA; Kanagawa Dent Coll, Yokosuka, Kanagawa, Japan	Oregon Health & Science University; Oregon Health & Science University; Kanagawa Dental College	Soderling, TR (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Mailcode L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	soderlit@ohsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK44239, DK007680, T32 DK007680] Funding Source: Medline; NIGMS NIH HHS [R01 GM 41292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Adams JP, 2000, ACTA NEUROBIOL EXP, V60, P377; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chang BH, 1998, P NATL ACAD SCI USA, V95, P10890, DOI 10.1073/pnas.95.18.10890; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Fan GH, 1997, NEUROPHARMACOLOGY, V36, P1763, DOI 10.1016/S0028-3908(97)00164-0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; Gendron L, 1999, MOL ENDOCRINOL, V13, P1615, DOI 10.1210/me.13.9.1615; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hashii M, 2000, BIOCHEM J, V345, P207, DOI 10.1042/0264-6021:3450207; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Illario M, 2003, J BIOL CHEM, V278, P45101, DOI 10.1074/jbc.M305355200; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Komiyama NH, 2002, J NEUROSCI, V22, P9721; Kozireski-Chuback D, 1999, J NEUROSCI RES, V57, P541, DOI 10.1002/(SICI)1097-4547(19990815)57:4<541::AID-JNR14>3.0.CO;2-X; Kutcher LW, 2003, AM J PHYSIOL-CELL PH, V284, pC1334, DOI 10.1152/ajpcell.00510.2002; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; Markus A, 2002, NEURON, V35, P65, DOI 10.1016/S0896-6273(02)00752-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NORONHABLOB L, 1988, J NEUROCHEM, V50, P1381, DOI 10.1111/j.1471-4159.1988.tb03020.x; OH JS, 2004, J BIOL CHEM; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QIN H, 2003, J BIOL CHEM; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Takeuchi Y, 2003, J NEUROCHEM, V85, P729, DOI 10.1046/j.1471-4159.2003.01711.x; Tokumitsu H, 2003, J BIOL CHEM, V278, P10908, DOI 10.1074/jbc.M213183200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Tomizawa K, 2003, NAT NEUROSCI, V6, P384, DOI 10.1038/nn1023; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Uezu A, 2002, J NEUROCHEM, V82, P585, DOI 10.1046/j.1471-4159.2002.00984.x; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vaudry D, 2002, ANN NY ACAD SCI, V971, P491, DOI 10.1111/j.1749-6632.2002.tb04513.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Whitmarsh AJ, 2001, NAT NEUROSCI, V4, P963, DOI 10.1038/nn1001-963; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Wu G, 1998, J NEUROCYTOL, V27, P1, DOI 10.1023/A:1006910001869; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xiao JN, 2003, J NEUROCHEM, V86, P1516, DOI 10.1046/j.1471-4159.2003.01961.x; Xie X, 2002, J NEUROCHEM, V81, P1185, DOI 10.1046/j.1471-4159.2002.00917.x; Yamauchi T, 1998, BRAIN RES PROTOC, V2, P250, DOI 10.1016/S1385-299X(98)00002-6; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	77	124	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24064	24072		10.1074/jbc.M401501200	http://dx.doi.org/10.1074/jbc.M401501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15150258	hybrid, Green Submitted			2022-12-25	WOS:000221702500028
J	Ferrandi, M; Molinari, I; Barassi, P; Minotti, E; Bianchi, G; Ferrari, P				Ferrandi, M; Molinari, I; Barassi, P; Minotti, E; Bianchi, G; Ferrari, P			Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+/K+-ATPASE; ESSENTIAL-HYPERTENSION; NA,K-ATPASE; PLASMA; CELLS; RAT; GLYCOSIDES; INHIBITOR; MECHANISM; PROTEIN	In addition to inhibition of the Na-K ATPase, ouabain activates a signal transduction function, triggering growth and proliferation of cultured cells even at nanomolar concentrations. An isomer of ouabain ( EO) circulates in mammalians at subnanomolar concentrations, and increased levels are associated with cardiac hypertrophy and hypertension. We present here a study of cardiac and renal hypertrophy induced by ouabain infused into rats for prolonged periods and relate this effect to the recently described ouabain-induced activation of the Src-EGFr-ERK signaling pathway. Ouabain infusion into rats ( 15 mu\g/kg/day for 18 weeks) doubled plasma ouabain levels from 0.3 to 0.7 nM and increased blood pressure by 20 mm Hg ( p < 0.001), cardiac left ventricle ( + 11%, p < 0.05), and kidney weight ( + 9%, p < 0.01). These effects in vivo are associated with a significant enrichment of alpha 1, beta 1, gamma a Na-K ATPase subunits together with Src and EGFr in isolated renal caveolae membranes and activation of ERK1/2. In caveolae, direct Na-K ATPase/Src interactions can be demonstrated by co-immunoprecipitation. The interaction is amplified by ouabain, at a high affinity binding site, detectable in caveolae but not in total rat renal membranes. The high affinity site for ouabain is associated with Src-dependent tyrosine phosphorylation of rat alpha 1 Na-K ATPase. The antihypertensive compound, PST 2238, antagonized all ouabain-induced effects at 10 mu g/kg/day in vivo or 10(-10) 10(-8) M in vitro. These findings provide a molecular mechanism for the in vivo pro-hypertrophic and hypertensinogenic activity of ouabain, or by analogy those of EO in humans. They also explain the pharmacological basis for PST 2238 treatment.	Prassis Sigma Tau Res Inst, I-20019 Milan, Italy; Vita & Salute Univ, Div Nephrol Dialysis & Hypertens, Hosp San Raffaele, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ferrandi, M (corresponding author), Prassis Sigma Tau Res Inst, Via Forlanini, I-20019 Milan, Italy.	mara.ferrandi@prassis.it		Bianchi, Giuseppe/0000-0002-8365-3618; BARASSI, PAOLO/0000-0002-8086-2342				Bagrov AY, 1996, AM J HYPERTENS, V9, P982, DOI 10.1016/0895-7061(96)00148-3; BAKER PF, 1970, NATURE, V226, P521, DOI 10.1038/226521a0; Balzan S, 2001, EUR J HEART FAIL, V3, P165, DOI 10.1016/S1388-9842(00)00132-X; Blaustein MP, 1998, CLIN EXP HYPERTENS, V20, P691, DOI 10.3109/10641969809053247; Bozulic LD, 2004, AM J PHYSIOL-CELL PH, V286, pC90, DOI 10.1152/ajpcell.00174.2003; Breton S, 1998, J HISTOCHEM CYTOCHEM, V46, P205, DOI 10.1177/002215549804600209; Dmitrieva RI, 2003, J BIOL CHEM, V278, P28160, DOI 10.1074/jbc.M303768200; FERRAILLE E, 1995, EUR J PHYSL, V430, P205; Ferrandi M, 1996, HYPERTENSION, V28, P1018, DOI 10.1161/01.HYP.28.6.1018; Ferrandi M, 1997, HYPERTENSION, V30, P886, DOI 10.1161/01.HYP.30.4.886; Ferrari P, 1998, J PHARMACOL EXP THER, V285, P83; Gerbi A, 1999, J MEMBRANE BIOL, V168, P19, DOI 10.1007/s002329900494; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; HAMLYN JM, 1982, NATURE, V300, P650, DOI 10.1038/300650a0; JORGENSEN PL, 1986, KIDNEY INT, V29, P10, DOI 10.1038/ki.1986.3; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; Lucking K, 1996, AM J PHYSIOL-RENAL, V271, pF253, DOI 10.1152/ajprenal.1996.271.2.F253; Manunta P, 1999, HYPERTENSION, V34, P450, DOI 10.1161/01.HYP.34.3.450; MANUNTA P, 1994, J HYPERTENS, V12, P549; Manunta P, 2001, HYPERTENSION, V38, P198, DOI 10.1161/01.HYP.38.2.198; Miyakawa-Naito A, 2003, J BIOL CHEM, V278, P50355, DOI 10.1074/jbc.M305378200; Pierdomenico SD, 2001, AM J HYPERTENS, V14, P44, DOI 10.1016/S0895-7061(00)01225-5; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Quadri L, 1997, J MED CHEM, V40, P1561, DOI 10.1021/jm970162e; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Schoner W, 2002, EUR J BIOCHEM, V269, P2440, DOI 10.1046/j.1432-1033.2002.02911.x; SHAUL P, 1998, AM J PHYSIOL, V276, pL843; Shelly DA, 2004, AM J PHYSIOL-CELL PH, V286, pC813, DOI 10.1152/ajpcell.00389.2003; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Wu BJ, 2001, J EXP BIOL, V204, P4271; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x	36	114	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33306	33314		10.1074/jbc.M402187200	http://dx.doi.org/10.1074/jbc.M402187200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15161929	hybrid			2022-12-25	WOS:000223039700037
J	Maertens, G; Cherepanov, P; Debyser, Z; Engelborghs, Y; Engelman, A				Maertens, G; Cherepanov, P; Debyser, Z; Engelborghs, Y; Engelman, A			Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PREINTEGRATION COMPLEXES; CENTRAL DNA FLAP; LARGE-T-ANTIGEN; VIRAL MATRIX PROTEIN; STRESS-RELATED GENES; NONDIVIDING CELLS; IMPORTIN-BETA; SUBCELLULAR-LOCALIZATION; LENTIVIRAL VECTOR	Human lens epithelium-derived growth factor ( LEDGF)/p75 protein forms a specific nuclear complex with human immunodeficiency virus type 1 (HIV-1) integrase and is essential for nuclear localization and chromosomal association of the viral protein. We now studied nuclear import of LEDGF/p75 in live and semipermeabilized cells. We show that nuclear import of LEDGF/p75 is GTP-, Ran-, importin-alpha/beta-, and energy-dependent and that the protein competes with the canonical SV40 large T antigen nuclear localization signal (NLS) for nuclear import receptors. We identified the NLS of LEDGF/p75 through deletion analysis and site-directed mutagenesis. The LEDGF/p75 NLS, (148)GRKR-KAEKQ(156), belongs to the canonical SV40-like family. Fusion of this short peptide to the amino terminus of Escherichia coli beta-galactosidase rendered the fusion protein nuclear, confirming that the LEDGF/p75 NLS is transferable. Moreover, a single amino acid change in the NLS was sufficient to exclude the mutant LEDGF/ p75 protein from the nucleus and abolish nuclear import of HIV-1 integrase.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Katholieke Univ Leuven, KULAK, B-3000 Louvain, Belgium	Harvard University; Dana-Farber Cancer Institute; KU Leuven; Harvard University; Harvard Medical School; KU Leuven; KU Leuven	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.	Alan_Engelman@dfci.harvard.edu	Cherepanov, Peter P/F-6859-2010; Maertens, Goedele/D-8628-2015	Cherepanov, Peter P/0000-0002-0634-538X; Maertens, Goedele/0000-0002-1963-8026	NIAID NIH HHS [AI52014] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052014] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Depienne C, 2000, EXP CELL RES, V260, P387, DOI 10.1006/excr.2000.5016; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Devroe E, 2003, J CELL SCI, V116, P4401, DOI 10.1242/jcs.00747; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; Dvorin JD, 2002, J VIROL, V76, P12087, DOI 10.1128/JVI.76.23.12087-12096.2002; Fassati A, 2003, EMBO J, V22, P3675, DOI 10.1093/emboj/cdg357; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GULIZIA J, 1994, J VIROL, V68, P2021, DOI 10.1128/JVI.68.3.2021-2025.1994; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Huber J, 2002, J CELL BIOL, V156, P467, DOI 10.1083/jcb.200108114; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kukolj G, 1997, J VIROL, V71, P843, DOI 10.1128/JVI.71.1.843-847.1997; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Limon A, 2002, J VIROL, V76, P12078, DOI 10.1128/JVI.76.23.12078-12086.2002; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; MAHALINGAM S, 1995, VIROLOGY, V212, P331, DOI 10.1006/viro.1995.1490; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Reil H, 1998, EMBO J, V17, P2699, DOI 10.1093/emboj/17.9.2699; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WOLFF B, 1988, EXP CELL RES, V178, P318, DOI 10.1016/0014-4827(88)90402-8; Woodward CL, 2003, J VIROL, V77, P4516, DOI 10.1128/JVI.77.8.4516-4527.2003; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	74	82	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33421	33429		10.1074/jbc.M404700200	http://dx.doi.org/10.1074/jbc.M404700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163664	hybrid, Green Published			2022-12-25	WOS:000223039700050
J	Miller, SLH; Malotky, E; O'Bryan, JP				Miller, SLH; Malotky, E; O'Bryan, JP			Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASOME; DEUBIQUITINATING ENZYME; MULTIUBIQUITIN CHAINS; PROTEIN-DEGRADATION; FAT FACETS; IN-VIVO; DOMAIN; HRS; RECEPTOR; SUBUNIT	The ubiquitin-interacting motif (UIM) is a short peptide motif with the dual function of binding ubiquitin and promoting ubiquitylation. This motif is conserved throughout eukaryotes and is present in numerous proteins involved in a wide variety of cellular processes including endocytosis, protein trafficking, and signal transduction. We previously reported that the UIMs of epsin were both necessary and sufficient for its ubiquitylation. In this study, we found that many, but not all, UIM-containing proteins were ubiquitylated. When expressed as chimeric fusion proteins, most UIMs promoted ubiquitylation of the chimera. In contrast to previous studies, we found that UIMs do not exclusively promote monoubiquitylation but rather a mixture of mono-, multi-, and polyubiquitylation. However, UIM-dependent polyubiquitylation does not lead to degradation of the modified protein. UIMs also bind polyubiquitin chains of varying lengths and to different degrees, and this activity is required for UIM-dependent ubiquitylation. Mutational analysis of the UIM revealed specific amino acids that are important for both polyubiquitin binding and ubiquitin conjugation. Finally we provide evidence that UIM-dependent ubiquitylation inhibits the interaction of UIM-containing proteins with other ubiquitylated cellular proteins. Our results suggest a new model for the ubiquitylation of UIM-containing proteins.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Dept Biomed Engn, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Bldg Rm 101-F336,MD F3-06,POB 12233, Res Triangle Pk, NC 27709 USA.	obryan@niehs.nih.gov	Scappini, Erica/C-7684-2019	Scappini, Erica/0000-0002-9100-0027; O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; Chen H, 2003, P NATL ACAD SCI USA, V100, P14908, DOI 10.1073/pnas.2136625100; Chen X, 2002, GENE DEV, V16, P289, DOI 10.1101/gad.961502; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Valero R, 1999, GENOMICS, V62, P395, DOI 10.1006/geno.1999.6025; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	42	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33528	33537		10.1074/jbc.M313097200	http://dx.doi.org/10.1074/jbc.M313097200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155768	Green Published, hybrid			2022-12-25	WOS:000223039700061
J	Sinclair, JF; O'Brien, AD				Sinclair, JF; O'Brien, AD			Intimin types alpha, beta, and gamma bind to nucleolin with equivalent affinity but lower avidity than to the translocated intimin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; MURINE COLONIC HYPERPLASIA; CITROBACTER-FREUNDII BIOTYPE; ACTIVATED PROTEIN-KINASES; SITE-DIRECTED MUTAGENESIS; TISSUE-CULTURE CELLS; NF-KAPPA-B; EAE GENE; INFLAMMATORY RESPONSE; ENTEROCYTE EFFACEMENT	The outer membrane adhesins of enteropathogenic Escherichia coli, Citrobacter rodentium, and enterohemorrhagic E. coli (EHEC) O157: H7 that mediate attach and efface intestinal lesions are classified as intimin alpha, beta, and gamma, respectively. Each of these intimin types binds to its cognate, bacterially encoded receptor ( called Tir for translocated intimin receptor) to promote tight adherence of the organism to the host-cell plasma membrane. We previously reported that gamma intimin of EHEC O157: H7 also bound to a eucaryotic receptor that we determined was nucleolin. The objective of this study was to investigate in vitro and in vivo the interactions of intimins alpha, beta, and gamma with nucleolin in the presence of Tir from EHEC O157: H7. Protein binding experiments demonstrated that intimin of types alpha, beta, and gamma bound nucleolin with similar affinity. Moreover, all three intimin types co-localized with regions of nucleolin expressed on the surface of HEp-2 cells. When intimin alpha, beta, or gamma bound to Tir in vitro, the intimin interaction with nucleolin was blocked. Both Tir and nucleolin accumulated beneath intimin-presenting bacteria that had attached to the surface of HEp-2 cells. Taken together, these findings suggest that nucleolin is involved in bacterial adherence promoted by all intimin types and that Tir and nucleolin compete for intimin during adherence.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	O'Brien, AD (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aobrien@usuhs.mil		O'Brien, Alison/0000-0002-1315-3204	NIAID NIH HHS [AI20148-21] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020148, R22AI020148, R01AI020148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTHOLD SW, 1976, LAB ANIM SCI, V26, P889; Batchelor M, 2000, EMBO J, V19, P2452, DOI 10.1093/emboj/19.11.2452; Berin MC, 2002, CELL MICROBIOL, V4, P635, DOI 10.1046/j.1462-5822.2002.00218.x; Celli J, 2000, CELL MICROBIOL, V2, P1, DOI 10.1046/j.1462-5822.2000.00033.x; Czerucka D, 2001, INFECT IMMUN, V69, P1298, DOI 10.1128/IAI.69.3.1298-1305.2001; Dahan S, 2002, INFECT IMMUN, V70, P2304, DOI 10.1128/IAI.70.5.2304-2310.2002; De Grado M, 2001, INFECT IMMUN, V69, P6217, DOI 10.1128/IAI.69.10.6217-6224.2001; Deng WY, 2003, MOL MICROBIOL, V48, P95, DOI 10.1046/j.1365-2958.2003.03429.x; Deng WY, 2001, INFECT IMMUN, V69, P6323, DOI 10.1128/IAI.69.10.6323-6335.2001; DeVinney R, 1999, INFECT IMMUN, V67, P2389, DOI 10.1128/IAI.67.5.2389-2398.1999; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1418, DOI 10.1172/JCI116718; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Fitzhenry RJ, 2002, GUT, V50, P180, DOI 10.1136/gut.50.2.180; Frankel G, 1998, MOL MICROBIOL, V29, P559, DOI 10.1046/j.1365-2958.1998.00950.x; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Hartland EL, 2000, INFECT IMMUN, V68, P4637, DOI 10.1128/IAI.68.8.4637-4646.2000; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; Higgins LM, 1999, SCIENCE, V285, P588, DOI 10.1126/science.285.5427.588; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1991, INFECT IMMUN, V59, P4302, DOI 10.1128/IAI.59.12.4302-4309.1991; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; KNUTTON S, 1989, INFECT IMMUN, V57, P1290, DOI 10.1128/IAI.57.4.1290-1298.1989; LEVINE MM, 1978, LANCET, V1, P1119; Liu H, 1999, MOL MICROBIOL, V34, P67, DOI 10.1046/j.1365-2958.1999.01574.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; McGraw EA, 1999, MOL BIOL EVOL, V16, P12, DOI 10.1093/oxfordjournals.molbev.a026032; MCKEE ML, 1995, INFECT IMMUN, V63, P3739, DOI 10.1128/IAI.63.9.3739-3744.1995; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; Phillips AD, 2000, MICROBIOL-SGM, V146, P1333, DOI 10.1099/00221287-146-6-1333; Phillips AD, 2000, J INFECT DIS, V181, P1496, DOI 10.1086/315404; Ramachandran V, 2003, J CLIN MICROBIOL, V41, P5022, DOI 10.1128/JCM.41.11.5022-5032.2003; Reece S, 2002, MICROBES INFECT, V4, P1389, DOI 10.1016/S1286-4579(02)00021-7; Reece S, 2001, MOL MICROBIOL, V40, P86, DOI 10.1046/j.1365-2958.2001.02371.x; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Savkovic SD, 2003, AM J PHYSIOL-CELL PH, V285, pC512, DOI 10.1152/ajpcell.00444.2002; Savkovic SD, 2001, AM J PHYSIOL-GASTR L, V281, pG890, DOI 10.1152/ajpgi.2001.281.4.G890; SCHAUER DB, 1993, INFECT IMMUN, V61, P2486, DOI 10.1128/IAI.61.6.2486-2492.1993; SCHAUER DB, 1993, INFECT IMMUN, V61, P4654, DOI 10.1128/IAI.61.11.4654-4661.1993; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; Sinclair JF, 2002, J BIOL CHEM, V277, P2876, DOI 10.1074/jbc.M110230200; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Tarr CL, 2002, J BACTERIOL, V184, P479, DOI 10.1128/JB.184.2.479-487.2002; Torres AG, 2003, INFECT IMMUN, V71, P4985, DOI 10.1128/IAI.71.9.4985-4995.2003; TZIPORI S, 1995, INFECT IMMUN, V63, P3621, DOI 10.1128/IAI.63.9.3621-3627.1995; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	57	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33751	33758		10.1074/jbc.M401616200	http://dx.doi.org/10.1074/jbc.M401616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173179	hybrid			2022-12-25	WOS:000223039700084
J	Verma, S; Shewan, AM; Scott, JA; Helwani, FM; den Elzen, NR; Miki, H; Takenawa, T; Yap, AS				Verma, S; Shewan, AM; Scott, JA; Helwani, FM; den Elzen, NR; Miki, H; Takenawa, T; Yap, AS			Arp2/3 activity is necessary for efficient formation of E-cadherin adhesive contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN NUCLEATION; BINDING-ACTIVITY; PLASMA-MEMBRANE; COMPLEX; DYNAMICS; POLYMERIZATION; MORPHOGENESIS; MECHANISMS	Classical cadherin adhesion molecules are fundamental determinants of cell-cell recognition that function in cooperation with the actin cytoskeleton. Productive cadherin-based cell recognition is characterized by a distinct morphological process of contact zone extension, where limited initial points of adhesion are progressively expanded into broad zones of contact. We recently demonstrated that E-cadherin ligation recruits the Arp2/3 actin nucleator complex to the plasma membrane in regions where cell contacts are undergoing protrusion and extension. This suggested that Arp2/3 might generate the protrusive forces necessary for cell surfaces to extend upon one another during contact assembly. We tested this hypothesis in mammalian cells by exogenously expressing the CA region of N-WASP. This fragment, which potently inhibits Arp2/3-mediated actin assembly in vitro, also effectively reduced actin assembly at cadherin adhesive contacts. Blocking Arp2/3 activity by this strategy profoundly reduced the ability of cells to extend cadherin adhesive contacts but did not affect cell adhesiveness. These findings demonstrate that Arp2/3 activity is necessary for cells to efficiently extend and assemble cadherin-based adhesive contacts.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Tokyo, Inst Med Sci, Div Canc Gen, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, PRESTO, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, CREST, Tokyo 1088639, Japan	University of Queensland; University of Queensland; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	a.yap@imb.uq.edu.au	Shewan, Annette/B-3251-2011; Yap, Alpha S./J-1554-2014	Shewan, Annette/0000-0003-4936-9207; Yap, Alpha S./0000-0002-1038-8956; Den Elzen, Nicole/0000-0003-0223-4954				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Ayscough K, 1998, METHOD ENZYMOL, V298, P18, DOI 10.1016/S0076-6879(98)98004-1; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; EVANGELISTA M, 2001, NAT CELL BIOL, V4, P260; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Grinnell F, 1978, Int Rev Cytol, V53, P65; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; Helwani FM, 2004, J CELL BIOL, V164, P899, DOI 10.1083/jcb.200309034; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Niessen CM, 2002, J CELL BIOL, V156, P389, DOI 10.1083/jcb.200108040; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sako Y, 1998, J CELL BIOL, V140, P1227, DOI 10.1083/jcb.140.5.1227; Sasaki N, 2000, BIOCHEM BIOPH RES CO, V272, P386, DOI 10.1006/bbrc.2000.2785; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; TROXELLML, 1999, AM J PHYSIOL, V276, pC404; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156	38	124	124	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34062	34070		10.1074/jbc.M404814200	http://dx.doi.org/10.1074/jbc.M404814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159390	hybrid			2022-12-25	WOS:000223039700118
J	Araki, S; Ito, M; Soyano, T; Nishihama, R; Machida, Y				Araki, S; Ito, M; Soyano, T; Nishihama, R; Machida, Y			Mitotic cyclins stimulate the activity of c-Myb-like factors for transactivation of G(2)/M phase-specific genes in tobacco	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; B-MYB; TRANSCRIPTIONAL ACTIVATION; S-PHASE; PLANT CYTOKINESIS; KINASE COMPLEX; A-TYPE; EXPRESSION; PHOSPHORYLATION; REPRESSION	Myb transcription factors, which contain three imperfect repeats in the Myb domain, are evolutionarily conserved members of the Myb superfamily. Vertebrate Myb proteins with three repeats, c-Myb, A-Myb, and B-Myb, play important roles at the G(1)/S transition in the cell cycle. In plants, this type of Myb protein controls the G(2)/M phase by activating or repressing the transcription of cyclin B genes and a variety of other G(2)/M phase-specific genes. In tobacco, two genes for Myb activators, NtmybA1 and NtmybA2, are transcriptionally controlled and are expressed specifically at the G(2)/M phase. As we showed here, in addition to the control at the transcriptional level, activity of NtmybA2 is also controlled at the post-translational level. We found that the transactivation potential of NtmybA2 is repressed by a regulatory domain located at its carboxyl terminus and that specific classes of cyclins A and B enhanced NtmybA2 activity possibly by relieving this inhibitory effect. Mutations at the 20 potential sites of phosphorylation by cyclin-dependent kinase (CDK) in NtmybA2 blocked the enhancing effects of the cyclins on NtmybA2 activity. Recombinant NtmybA2 was phosphorylated in vitro by a CDK fraction prepared from tobacco BY2 cells. The kinase activity for NtmybA2 in the CDK fraction was cell cycle-regulated in BY2 cells, peaking at the G(2)/M phase when the level of transcripts of cyclin B is maximal. Taken together, our data suggest that NtmybA2 is phosphorylated by a specific cyclin/CDK complex(es) at G2/M and that this phosphorylation removes the inhibitory effect of its C-terminal region, thereby activating NtmybA2 specifically at G(2)/M.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	Nagoya University; University of Tokyo	Ito, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Regulat Biol Signals, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	masakito@agr.nagoya-u.ac.jp	Nishihama, Ryuichi/X-8623-2019; Ito, Masaki/G-4252-2013	Nishihama, Ryuichi/0000-0002-7032-732X; Ito, Masaki/0000-0002-9635-9709; Soyano, Takashi/0000-0002-0620-6734				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Breeden LL, 2000, CURR BIOL, V10, pR586, DOI 10.1016/S0960-9822(00)00634-5; Breyne P, 2002, P NATL ACAD SCI USA, V99, P14825, DOI 10.1073/pnas.222561199; Chaboute ME, 2002, J BIOL CHEM, V277, P17845, DOI 10.1074/jbc.M200959200; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS DA, 1983, INT REV CYTOL S, V16, P33; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Genschik P, 1998, PLANT CELL, V10, P2063; Guerineau F., 1993, Plant molecular biology labfax., P121; Gutierrez C, 2002, CURR OPIN PLANT BIOL, V5, P480, DOI 10.1016/S1369-5266(02)00301-1; Ito M, 2000, PLANT MOL BIOL, V43, P677, DOI 10.1023/A:1006336005587; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Ito M, 1998, PLANT CELL, V10, P331; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; Kosugi S, 2002, PLANT J, V29, P45, DOI 10.1046/j.1365-313x.2002.01196.x; Kranz H, 2000, PLANT J, V21, P231, DOI 10.1046/j.1365-313x.2000.00666.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lavia P, 1999, BIOESSAYS, V21, P221; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; Menges M, 2002, J BIOL CHEM, V277, P41987, DOI 10.1074/jbc.M207570200; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nakagami H, 2002, PLANT CELL, V14, P1847, DOI 10.1105/tpc.002550; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; Nishihama R, 2002, CELL, V109, P87, DOI 10.1016/S0092-8674(02)00691-8; Okada M, 2002, EMBO J, V21, P675, DOI 10.1093/emboj/21.4.675; Potrykus, 1994, PLANT MOL BIOL MAN A, P1; Reindl A, 1997, PLANT PHYSIOL, V115, P93, DOI 10.1104/pp.115.1.93; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Renaudin JP, 1996, PLANT MOL BIOL, V32, P1003, DOI 10.1007/BF00041384; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Robinson C, 1996, ONCOGENE, V12, P1855; Rosinski JA, 1998, J MOL EVOL, V46, P74, DOI 10.1007/PL00006285; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Schwechheimer C, 1998, PLANT MOL BIOL, V36, P195, DOI 10.1023/A:1005990321918; Setiady YY, 1996, PLANT CELL PHYSIOL, V37, P369, DOI 10.1093/oxfordjournals.pcp.a028955; Setiady YY, 1995, PLANT J, V8, P949, DOI 10.1046/j.1365-313X.1995.8060949.x; Soyano T, 2003, GENE DEV, V17, P1055, DOI 10.1101/gad.1071103; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vandepoele K, 2002, PLANT CELL, V14, P903, DOI 10.1105/tpc.010445; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	53	92	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32979	32988		10.1074/jbc.M403171200	http://dx.doi.org/10.1074/jbc.M403171200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15175336	hybrid			2022-12-25	WOS:000222849700118
J	Lozach, PY; Amara, A; Bartosch, B; Virelizier, JL; Arenzana-Seisdedos, F; Cosset, FL; Altmeyer, R				Lozach, PY; Amara, A; Bartosch, B; Virelizier, JL; Arenzana-Seisdedos, F; Cosset, FL; Altmeyer, R			C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC CELLS; GLYCOPROTEIN E2; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; EFFICIENT INFECTION; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; ENVELOPE PROTEIN; DNA FLAP; B VIRUS	The molecular mechanisms involved in the hepatic tropism of hepatitis C virus (HCV) have not been identified. We have shown previously that liver-expressed C-type lectins L-SIGN and DC-SIGN bind the HCV E2 glycoprotein with high affinity (Lozach, P. Y., Lortat-Jacob, H., de Lacroix de Lavalette, A., Staropoli, I., Foung, S., Amara, A., Houles, C., Fieschi, F., Schwartz, O., Virelizier, J. L., Arenzana-Seisdedos, F., and Altmeyer, R. ( 2003) J. Biol. Chem. 278, 20358-20366). To analyze the functional relevance of this interaction, we generated pseudotyped lentivirus particles presenting HCV glycoproteins E1 and E2 at the virion surface (HCV-pp). High mannose N-glycans are present on E1 and, to a lesser extent, on E2 proteins of mature infectious HCV-pp. Such particles bind to both L-SIGN and DC-SIGN, but they cannot use these receptors for entry into cells. However, infectious virus is transmitted efficiently when permissive Huh-7 cells are cocultured with HCV-pp bound to L-SIGN or to DC-SIGN-positive cell lines. HCV-pp transmission via L-SIGN or DC-SIGN is inhibited by characteristic inhibitors such as the calcium chelator EGTA and monoclonal antibodies directed against lectin carbohydrate recognition domains of both lectins. In support of the biological relevance of this phenomenon, dendritic cells expressing endogenous DC-SIGN transmitted HCV-pp with high efficiency in a DC-SIGN-dependent manner. Our results support the hypothesis that C-type lectins such as the liver sinusoidal endothelial cell-expressed L-SIGN could act as a capture receptor for HCV in the liver and transmit infectious virions to neighboring hepatocytes.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France; Ecole Normale Super Lyon, Inst Federat Rech 74, Lab Vectorol Retrovirale & Therapie Genique, INSERM,U412, F-69364 Lyon 07, France; Univ Hong Kong, Pasteur Res Ctr, Hong Kong, Hong Kong, Peoples R China	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Hong Kong	Altmeyer, R (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.	altmeyer@hkucc.hku.hk	Bartosch, Birke/I-7255-2018; Lozach, Pierre-Yves/H-7072-2015	Bartosch, Birke/0000-0001-6354-4660; AMARA, Ali/0000-0002-0283-1815; Cosset, Francois-Loic/0000-0001-8842-3726; Lozach, Pierre-Yves/0000-0002-9966-1452				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Agnello V, 1998, HEPATOLOGY, V28, P573, DOI 10.1002/hep.510280240; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Amara A, 2003, J VIROL, V77, P2550, DOI 10.1128/JVI.77.4.2550-2558.2003; Barth H, 2003, J BIOL CHEM, V278, P41003, DOI 10.1074/jbc.M302267200; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; BLIGHT K, 1993, AM J PATHOL, V143, P1568; Breiner KM, 2001, HEPATOLOGY, V34, P803, DOI 10.1053/jhep.2001.27810; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Goutagny N, 2003, J INFECT DIS, V187, P1951, DOI 10.1086/375350; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; KEMPKA G, 1988, EXP CELL RES, V176, P38, DOI 10.1016/0014-4827(88)90118-8; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Limmer A, 1998, EUR J IMMUNOL, V28, P2395, DOI 10.1002/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D; Liu WL, 2004, J BIOL CHEM, V279, P18748, DOI 10.1074/jbc.M311227200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Navas MC, 2002, J MED VIROL, V67, P152, DOI 10.1002/jmv.2204; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Royer C, 2003, J HEPATOL, V38, P250, DOI 10.1016/S0168-8278(02)00418-X; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Schwartz AJ, 2002, AIDS RES HUM RETROV, V18, P1021, DOI 10.1089/08892220260235380; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Wu L, 2004, VIROLOGY, V318, P17, DOI 10.1016/j.virol.2003.09.028; Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; YONEYAMA H, 2003, 10 INT M HEP C VIR R, P26; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	48	146	159	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32035	32045		10.1074/jbc.M402296200	http://dx.doi.org/10.1074/jbc.M402296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166245	hybrid, Green Published			2022-12-25	WOS:000222849700007
J	Wang, YQ; Theriault, JR; He, HY; Gong, JL; Calderwood, SK				Wang, YQ; Theriault, JR; He, HY; Gong, JL; Calderwood, SK			Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-1; MOLECULAR CHAPERONES; SPINDLE CHECKPOINT; PROTEIN EXPRESSION; GENE-TRANSCRIPTION; DNA REREPLICATION; MAMMALIAN-CELLS; BREAST-CANCER; C-FOS; ACTIVATION	Recent studies have implicated heat shock proteins (HSP) and heat shock transcription factor 1 (HSF1) in tumor progression. We have examined the role of HSF1 in the malignant phenotype of PC-3 prostate carcinoma cells. We have developed a dominant negative construct of HSF1 that antagonizes transcription from HSP promoters and results in the depletion of intracellular HSP 70. Our studies indicate that expression of DN-HSF1 dramatically alters the DNA content of PC-3 cells ( derived from p53 null prostatic carcinoma) and inhibits aneuploidy in these cells. This effect is due to prolonged expression of DN-HSF1, and transient expression of the dominant negative factor from an inducible promoter failed to cause the effect. Inhibition of aneuploidy in p53 null PC-3 cells by DN-HSF1 expression was recapitulated by expression within the cells of wild type p53. Furthermore, cells expressing DN-HSF1 showed a profound inhibition in the development of aneuploidy when exposed to chemical agents that disrupt the mitotic spindle and prevent progression through metaphase. Inhibition of aneuploidy in PC-3 cells expressing DN-HSF1 was associated with delayed breakdown of cyclin B1 compared with controls, consistent with a role for wild type HSF1 in the regulation of cyclin B1 degradation, a key step in the control of mitosis. Our experiments therefore demonstrate that HSF1 plays a functional role in cancer cells under nonstress conditions and influences cell cycle behavior and progression through mitosis and promotes the development of the aneuploid state.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol,Div Mol & Cellular Biol, 21-27 Burlington Ave,Rm 553B, Boston, MA 02215 USA.			Gong, Jianlin/0000-0003-0910-014X	NCI NIH HHS [CA50642, CA31303, CA47407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047407, P01CA031303, R01CA050642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bruce JL, 1999, CELL STRESS CHAPERON, V4, P36, DOI 10.1054/csac.1999.0005; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Ciocca Daniel R, 2002, Prog Mol Subcell Biol, V28, P205; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cornford PA, 2000, CANCER RES, V60, P7099; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; He HY, 2003, J BIOL CHEM, V278, P35465, DOI 10.1074/jbc.M304663200; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Huang JR, 1997, J BIOL CHEM, V272, P26009, DOI 10.1074/jbc.272.41.26009; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEE KA, 1990, METHOD ENZYMOL, V181, P227; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LI GC, 1980, CANCER RES, V40, P4501; Li RH, 1997, P NATL ACAD SCI USA, V94, P14506, DOI 10.1073/pnas.94.26.14506; Liang P, 1997, J CELL SCI, V110, P1431; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Matzke MA, 1999, BIOESSAYS, V21, P761, DOI 10.1002/(SICI)1521-1878(199909)21:9&lt;761::AID-BIES7&gt;3.0.CO;2-C; Newton EM, 1996, MOL CELL BIOL, V16, P839; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; RATTNER JB, 1991, EXP CELL RES, V195, P110, DOI 10.1016/0014-4827(91)90505-O; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Strik HM, 2000, ANTICANCER RES, V20, P4457; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Wigley WC, 1999, J CELL BIOL, V145, P481; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200; Yano M, 1999, CANCER LETT, V137, P45, DOI 10.1016/S0304-3835(98)00338-3; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	63	58	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32651	32659		10.1074/jbc.M401475200	http://dx.doi.org/10.1074/jbc.M401475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15152009	hybrid			2022-12-25	WOS:000222849700083
J	Ahmad, Z; Senior, AE				Ahmad, Z; Senior, AE			Mutagenesis of residue beta Arg-246 in the phosphate-binding subdomain of catalytic sites of Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACILLUS PS3; MYOSIN MOTOR DOMAIN; ATP SYNTHASE; TRANSITION-STATE; NUCLEOTIDE-BINDING; BETA-SUBUNIT; OXIDATIVE-PHOSPHORYLATION; F1F0-ATP SYNTHASE; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL ATPASE	Residues responsible for phosphate binding in F1F0-ATP synthase catalytic sites are of significant interest because phosphate binding is believed linked to proton gradient-driven subunit rotation. From x-ray structures, a phosphate-binding subdomain is evident in catalytic sites, with conserved betaArg-246 in a suitable position to bind phosphate. Mutations betaR246Q, betaR246K, and betaR246A in Escherichia coli were found to impair oxidative phosphorylation and to reduce ATPase activity of purified F-1 by 100-fold. In contrast to wild type, ATPase of mutants was not inhibited by MgADP-fluoroaluminate or MgADP-fluoroscandium, showing the Arg side chain is required for wild-type transition state formation. Whereas 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) inhibited wild-type ATPase essentially completely, ATPase in mutants was inhibited maximally by similar to 50%, although reaction still occurred at residue betaTyr-297, proximal to betaArg-246 in the phosphate-binding pocket. Inhibition characteristics supported the conclusion that NBD-Cl reacts in betaE ( empty) catalytic sites, as shown previously by x-ray structure analysis. Phosphate protected against NBD-Cl inhibition in wild type but not in mutants. The results show that phosphate can bind in the betaE catalytic site of E. coli F-1 and that betaArg-246 is an important phosphate-binding residue.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu		Ahmad, Zulfiqar/0000-0001-7306-8151	NIGMS NIH HHS [GM25349, R15 GM085771] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM085771, R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; AlShawi MK, 1997, BIOCHEMISTRY-US, V36, P12961, DOI 10.1021/bi971478r; ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; Bockmann RA, 2002, NAT STRUCT BIOL, V9, P198, DOI 10.1038/nsb760; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; de Meis L, 1977, Biochemistry, V16, P4455, DOI 10.1021/bi00639a020; DEMEIS L, 1987, FEBS LETT, V213, P333, DOI 10.1016/0014-5793(87)81517-X; Dittrich M, 2003, BIOPHYS J, V85, P2253, DOI 10.1016/S0006-3495(03)74650-5; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Masaike T, 2002, J BIOL CHEM, V277, P21643, DOI 10.1074/jbc.M110297200; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nadanaciva S, 2000, BIOCHEMISTRY-US, V39, P9583, DOI 10.1021/bi000941o; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P15493, DOI 10.1021/bi9917683; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P7670, DOI 10.1021/bi990663x; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; NOUMI T, 1986, J BIOL CHEM, V261, P9196; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ JA, 1986, FEBS LETT, V198, P113, DOI 10.1016/0014-5793(86)81195-4; RAO R, 1988, J BIOL CHEM, V263, P5569; ROSING J, 1977, J BIOL CHEM, V252, P2478; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; SENIOR AE, 1983, BIOCHEM J, V210, P395, DOI 10.1042/bj2100395; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1992, J BIOL CHEM, V267, P1712; Weber J, 2004, METHOD ENZYMOL, V380, P132; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Yang W, 2003, P NATL ACAD SCI USA, V100, P874, DOI 10.1073/pnas.0337432100	57	47	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31505	31513		10.1074/jbc.M404621200	http://dx.doi.org/10.1074/jbc.M404621200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150266	hybrid			2022-12-25	WOS:000222726800073
J	Mohri, K; Vorobiev, S; Fedorov, AA; Almo, SC; Ono, S				Mohri, K; Vorobiev, S; Fedorov, AA; Almo, SC; Ono, S			Identification of functional residues on Caenorhabditis elegans actin-interacting protein 1 (UNC-78) for disassembly of actin depolymerizing factor/cofilin-bound actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; WD REPEAT; BINDING PROTEINS; COFILIN; DYNAMICS; HOMOLOG; FAMILY; AIP1; UNC-60B; XAIP1	Actin-interacting protein 1 (AIP1) is a WD40 repeat protein that enhances actin filament disassembly in the presence of actin-depolymerizing factor (ADF)/cofilin. AIP1 also caps the barbed end of ADF/cofilin-bound actin filament. However, the mechanism by which AIP1 interacts with ADF/cofilin and actin is not clearly understood. We determined the crystal structure of Caenorhabditis elegans AIP1 ( UNC-78), which revealed 14 WD40 modules arranged in two seven-bladed beta-propeller domains. The structure allowed for the mapping of conserved surface residues, and mutagenesis studies identified five residues that affected the ADF/cofilin-dependent actin filament disassembly activity. Mutations of these residues, which reside in blades 3 and 4 in the N-terminal propeller domain, had significant effects on the disassembly activity but did not alter the barbed end capping activity. These data support a model in which this conserved surface of AIP1 plays a direct role in enhancing fragmentation/depolymerization of ADF/cofilin-bound actin filaments but not in barbed end capping.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Synchrotron Biosci, Bronx, NY 10461 USA	Emory University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ono, S (corresponding author), Emory Univ, Dept Pathol, 615 Michael St,Whitehead Res Bldg,Rm 105N, Atlanta, GA 30322 USA.	sono@emory.edu	Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001979] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41-EB-01979] Funding Source: Medline; NIGMS NIH HHS [GM53807] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; Allwood EG, 2002, PLANT CELL, V14, P2915, DOI 10.1105/tpc.005363; Balcer HI, 2003, CURR BIOL, V13, P2159, DOI 10.1016/S0960-9822(03)00907-2; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Galkin VE, 2003, J CELL BIOL, V163, P1057, DOI 10.1083/jcb.200308144; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; Garcia-Higuera I, 1998, J BIOL CHEM, V273, P9041, DOI 10.1074/jbc.273.15.9041; Gerisch G, 2004, CELL MOTIL CYTOSKEL, V57, P18, DOI 10.1002/cm.10150; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Ketelaar T, 2004, CURR BIOL, V14, P145, DOI 10.1016/j.cub.2004.01.004; Konzok A, 1999, J CELL BIOL, V146, P453, DOI 10.1083/jcb.146.2.453; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Maciver SK, 2002, GENOME BIOL, V3; MBERG DC, 1995, NAT STRUCT BIOL, V2, P28; McGough A, 1999, J MOL BIOL, V291, P513, DOI 10.1006/jmbi.1999.2968; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Mohri K, 2003, J CELL SCI, V116, P4107, DOI 10.1242/jcs.00717; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 2002, J BIOL CHEM, V277, P43011, DOI 10.1074/jbc.M203111200; Ono K, 2003, J CELL SCI, V116, P2073, DOI 10.1242/jcs.00421; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Ono S, 2004, J BIOL CHEM, V279, P14207, DOI 10.1074/jbc.M313418200; Ono S, 1999, J CELL BIOL, V145, P491, DOI 10.1083/jcb.145.3.491; Ono S, 1998, J BIOL CHEM, V273, P3778, DOI 10.1074/jbc.273.6.3778; Ono S, 2001, J CELL BIOL, V152, P1313, DOI 10.1083/jcb.152.6.1313; Ono S, 2001, J BIOL CHEM, V276, P5952, DOI 10.1074/jbc.M007563200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Voegtli WC, 2003, J BIOL CHEM, V278, P34373, DOI 10.1074/jbc.M302773200	42	63	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31697	31707		10.1074/jbc.M403351200	http://dx.doi.org/10.1074/jbc.M403351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150269	hybrid			2022-12-25	WOS:000222726800095
J	Pakneshan, P; Szyf, M; Farias-Eisner, R; Rabbani, SA				Pakneshan, P; Szyf, M; Farias-Eisner, R; Rabbani, SA			Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; IN-VIVO; INHIBITS TUMORIGENESIS; S-ADENOSYLMETHIONINE; EXPRESSION; ANTISENSE; METHYLTRANSFERASE; INVASION; DEMETHYLATION; MECHANISM	Metastasis is a leading cause of mortality and morbidity in cancer. Urokinase (uPA), only expressed by the highly invasive cancer cells, has been implicated in invasion, metastases, and angiogenesis of several malignancies including breast cancer. Because uPA expression is strongly correlated with its hypomethylated state, we utilized the uPA gene in the highly invasive MDA-231 human breast cancer cells as a model system to test the hypothesis that pharmacological reversal of the uPA promoter hypomethylation would result in its silencing and inhibition of metastasis. S-Adenosyl-L-methionine ( AdoMet) has previously been shown to cause hypermethylation and inhibit demethylation. Treatment of MDA-231 cells with AdoMet, but not its unmethylated analogue S-adenosylhomocysteine, significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and metastasis in vivo. The effects of AdoMet on uPA expression were reversed by the demethylating agent 5'-azacytidine, supporting the conclusion that AdoMet effects are caused by hypermethylation. Knockdown of the methyl-binding protein 2 also causes a significant inhibition of uPA expression in vitro and tumor growth and metastasis in vivo. These treatments did not have any effects on estrogen receptor expression, suggesting that inhibition of hypomethylation will not affect genes already silenced by hypermethylation. These data are consistent with the hypothesis that hypomethylation of critical genes like uPA plays a causal role in metastasis. Inhibition of hypomethylation can thus be used as a novel therapeutic approach to silence the pro-metastatic gene uPA and block breast cancer progression into the aggressive and metastatic stages of the disease.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Pharmacol, Montreal, PQ H3A 1A1, Canada; Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA	McGill University; McGill University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, 687 Pine Ave W,Rm H4-67, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca		rabbani, shafaat/0000-0001-5594-3899				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Campbell PM, 2004, CARCINOGENESIS, V25, P499, DOI 10.1093/carcin/bgh045; Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuso A, 2001, FEBS LETT, V508, P337, DOI 10.1016/S0014-5793(01)03030-7; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; Rabbani SA, 1998, INT J ONCOL, V12, P911; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; SIMILE MM, 1994, CANCER LETT, V79, P9, DOI 10.1016/0304-3835(94)90056-6; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; van der Westhuyzen J, 1985, Nutr Cancer, V7, P179; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555	30	152	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31735	31744		10.1074/jbc.M401669200	http://dx.doi.org/10.1074/jbc.M401669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150277	hybrid			2022-12-25	WOS:000222726800099
J	Han, JS; Kang, SY; Kim, SH; Ko, MJ; Hwang, DS				Han, JS; Kang, SY; Kim, SH; Ko, MJ; Hwang, DS			Binding of SeqA protein to hemi-methylated GATC sequences enhances their interaction and aggregation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; TOPOISOMERASE-IV; BIDIRECTIONAL MIGRATION; CHROMOSOME-REPLICATION; DAM METHYLTRANSFERASE; SEGREGATION; ORIGIN; SEQUESTRATION; INITIATION	The SeqA protein regulates chromosome initiation and is involved in segregation in Escherichia coli. One SeqA protein binds to two hemi-methylated GATC sequences to form a stable SeqA-DNA complex. We found that binding induced DNA bending, which was pronounced when the two sequences were on the same face of the DNA. Two SeqA molecules bound cooperatively to each pair of hemi-methylated sites when the spacing between the sites was less than or equal to30 bp. This cooperative binding was able to stabilize the binding of a wild type to a single hemi-methylated site, or mutant form of SeqA protein to hemi-methylated sites, although such binding did not occur without cooperative interaction. Two cooperatively bound SeqA molecules interacted with another SeqA bound up to 185 bp away from the two bound SeqA proteins, and this was followed by aggregation of free SeqA proteins onto the bound proteins. These results suggest that the stepwise interaction of SeqA proteins with hemi-methylated GATC sites enhances their interaction and leads to the formation of SeqA aggregates. Cooperative interaction followed by aggregation may be the driving force for formation of the SeqA foci that appear to be located behind replication forks.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	dshwang@plaza.snu.ac.kr		Kang, Sukhyun/0000-0002-7567-0231				ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Bach T, 2003, EMBO J, V22, P315, DOI 10.1093/emboj/cdg020; Bae SH, 2003, J BIOL CHEM, V278, P45987, DOI 10.1074/jbc.M306038200; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; Brendler T, 2000, EMBO J, V19, P6249, DOI 10.1093/emboj/19.22.6249; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Fossum S, 2003, MOL MICROBIOL, V47, P619, DOI 10.1046/j.1365-2958.2003.t01-1-03329.x; Fujikawa N, 2004, NUCLEIC ACIDS RES, V32, P82, DOI 10.1093/nar/gkh173; Fujikawa N, 2003, BIOCHEM BIOPH RES CO, V300, P699, DOI 10.1016/S0006-291X(02)02891-7; GEIER GE, 1979, J BIOL CHEM, V254, P1408; Guarne A, 2002, NAT STRUCT BIOL, V9, P839, DOI 10.1038/nsb857; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Han JS, 2003, J BIOL CHEM, V278, P34983, DOI 10.1074/jbc.M304923200; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiraga S, 2000, GENES CELLS, V5, P327, DOI 10.1046/j.1365-2443.2000.00334.x; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kang S, 1999, J BIOL CHEM, V274, P11463, DOI 10.1074/jbc.274.17.11463; Kang SH, 2003, J BIOL CHEM, V278, P48779, DOI 10.1074/jbc.M308843200; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KORNBERG A, 1992, DNA REPLICATION, P521; Lee H, 2001, J BIOL CHEM, V276, P34600, DOI 10.1074/jbc.M101339200; Lee H, 2001, MOL GEN GENET, V264, P931, DOI 10.1007/PL00008701; Lee YS, 1997, J BIOL CHEM, V272, P83; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MESSER W, 1996, ESCHERICHIA COLI SAL, P1580; Onogi T, 1999, MOL MICROBIOL, V31, P1775, DOI 10.1046/j.1365-2958.1999.01313.x; Papavassiliou AG., 1994, DNA-protein interactions, P43, DOI 10.1385/0-89603-256-6:43; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawitzke J, 2001, MOL MICROBIOL, V40, P786, DOI 10.1046/j.1365-2958.2001.02350.x; Slominska M, 2001, MOL MICROBIOL, V40, P1371, DOI 10.1046/j.1365-2958.2001.02480.x; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitao T, 2000, EMBO REP, V1, P494; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	39	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30236	30243		10.1074/jbc.M402612200	http://dx.doi.org/10.1074/jbc.M402612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15151991	hybrid			2022-12-25	WOS:000222531900047
J	Karbowniczek, M; Cash, T; Cheung, M; Robertson, GP; Astrinidis, A; Henske, EP				Karbowniczek, M; Cash, T; Cheung, M; Robertson, GP; Astrinidis, A; Henske, EP			Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEINS; SCLEROSIS GENE; CELL-GROWTH; TSC1 GENE; ACTIVATION; PRODUCT; DROSOPHILA; HAMARTIN; MTOR; COMPLEX	Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome with manifestations that can include seizures, mental retardation, autism, and tumors in the brain, retina, kidney, heart, and skin. The products of the TSC1 and TSC2 genes, hamartin and tuberin, respectively, heterodimerize and inhibit the mammalian target of rapamycin ( mTOR). We found that tuberin expression increases p42/44 MAPK phosphorylation and B-Raf kinase activity. Short interfering RNA down-regulation of tuberin decreased the p42/44 MAPK phosphorylation and B-Raf activity. Expression of Rheb, the target of the GTPase-activating domain of tuberin, inhibited wildtype B-Raf kinase but not activated forms of B-Raf. The interaction of endogenous Rheb with B-Raf was enhanced by serum and by Ras overexpression. A farnesylation-defective mutant of Rheb co-immunoprecipitated with and inhibited B-Raf but did not activate ribosomal protein S6 kinase, indicating that farnesylation is not required for B-Raf inhibition by Rheb and that B-Raf inhibition and S6 kinase activation are separable activities of Rheb. Consistent with this, inhibition of B-Raf and p42/44 MAPK by Rheb was resistant to rapamycin in contrast to Rheb activation of S6 kinase, which is rapamycin-sensitive. Taken together these data demonstrate that inhibition of B-Raf kinase via Rheb is an mTOR-independent function of tuberin.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Penn State Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Henske, EP (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	EP_Henske@fccc.edu	Astrinidis, Aristotelis/A-1396-2010; Astreinidis, Aristotelis/ABA-6715-2021; Astreinidis, Aristotelis/AAK-5137-2020; Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997; Astrinidis, Aristotelis/0000-0001-7098-1391	NHLBI NIH HHS [HL 60746] Funding Source: Medline; NIDDK NIH HHS [DK 51052] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051052, R01DK051052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; HIROSE T, 1995, ACTA NEUROPATHOL, V90, P387; HOWE SR, 1995, AM J PATHOL, V146, P1568; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; Kenerson HL, 2002, CANCER RES, V62, P5645; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Liu MY, 2002, CANCER RES, V62, P6475; Mercer K, 2002, ONCOGENE, V21, P347, DOI 10.1038/sj.onc.1205101; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921; Yoon HS, 2004, AM J PHYSIOL-RENAL, V286, pF417, DOI 10.1152/ajprenal.00234.2003; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	48	82	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					29930	29937		10.1074/jbc.M402591200	http://dx.doi.org/10.1074/jbc.M402591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15150271	hybrid			2022-12-25	WOS:000222531900009
J	Nowikovsky, K; Froschauer, EM; Zsurka, G; Samaj, J; Reipert, S; Kolisek, M; Wiesenberger, G; Schweyen, RJ				Nowikovsky, K; Froschauer, EM; Zsurka, G; Samaj, J; Reipert, S; Kolisek, M; Wiesenberger, G; Schweyen, RJ			The LETM1/YOL027 gene family encodes a factor of the mitochondrial K+ homeostasis with a potential role in the Wolf-Hirschhorn syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; WHS CRITICAL REGION; YEAST MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; NA+/H+ ANTIPORTER; PROTEIN IMPORT; K+/H+ ANTIPORT; TRANSPORT; RECONSTITUTION	The yeast open reading frames YOL027 and YPR125 and their orthologs in various eukaryotes encode proteins with a single predicted trans-membrane domain ranging in molecular mass from 45 to 85 kDa. Hemizygous deletion of their human homolog LETM1 is likely to contribute to the Wolf-Hirschhorn syndrome phenotype. We show here that in yeast and human cells, these genes encode integral proteins of the inner mitochondrial membrane. Deletion of the yeast YOL027 gene (yol027Delta mutation) results in mitochondrial dysfunction. This mutant phenotype is complemented by the expression of the human LETM1 gene in yeast, indicating a functional conservation of LetM1/Yol027 proteins from yeast to man. Mutant yol027Delta mitochondria have increased cation contents, particularly K+ and low-membrane-potential DeltaPsi. They are massively swollen in situ and refractory to potassium acetate-induced swelling in vitro, which is indicative of a defect in K+/H+ exchange activity. Thus, YOL027/LETM1 are the first genes shown to encode factors involved in both K+ homeostasis and organelle volume control.	Univ Vienna, Max F Perutz Labs, Dept Genet & Microbiol, A-1030 Vienna, Austria; Univ Vienna, Dept Biochem & Mol Biol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); University of Vienna	Schweyen, RJ (corresponding author), Univ Vienna, Max F Perutz Labs, Dept Genet & Microbiol, Campus Vienna Bioctr, A-1030 Vienna, Austria.	rudolf.schweyen@univie.ac.at	Samaj, Jozef/AAD-4206-2022; Reipert, Siegfried/A-4406-2014	Samaj, Jozef/0000-0003-4750-2123; Wiesenberger, Gerlinde/0000-0002-3788-7974; Reipert, Siegfried/0000-0002-2043-3562; Nowikovsky, Karin/0000-0001-8435-8410; Zsurka, Gabor/0000-0002-6379-849X				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brett CL, 2002, AM J PHYSIOL-CELL PH, V282, pC1031, DOI 10.1152/ajpcell.00420.2001; BRIERLEY GP, 1988, J BIOENERG BIOMEMBR, V20, P193, DOI 10.1007/BF00768394; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Endele S, 1999, GENOMICS, V60, P218, DOI 10.1006/geno.1999.5881; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; GARLID KD, 1986, J BIOL CHEM, V261, P1529; Godinot C, 1979, Methods Enzymol, V55, P112; Gregan J, 2001, GENE DEV, V15, P2229, DOI 10.1101/gad.201301; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; JEZEK P, 1990, J BIOL CHEM, V265, P10522; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; LI XQ, 1990, J BIOL CHEM, V265, P15316; MANON S, 1992, BIOCHIM BIOPHYS ACTA, V1108, P169, DOI 10.1016/0005-2736(92)90022-E; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Schlickum S, 2004, GENOMICS, V83, P254, DOI 10.1016/j.ygeno.2003.08.013; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; WELIHINDA AA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P367, DOI 10.1016/0005-2728(93)90122-V; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; Zollino M, 2003, AM J HUM GENET, V72, P590, DOI 10.1086/367925	32	158	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30307	30315		10.1074/jbc.M403607200	http://dx.doi.org/10.1074/jbc.M403607200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138253	hybrid			2022-12-25	WOS:000222531900056
J	Zachara, NE; O'Donnell, N; Cheung, WD; Mercer, JJ; Marth, JD; Hart, GW				Zachara, NE; O'Donnell, N; Cheung, WD; Mercer, JJ; Marth, JD; Hart, GW			Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress - A survival response of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; CAPACITATIVE CALCIUM-ENTRY; HYPOXIA-INDUCED APOPTOSIS; DEPENDENT NUCLEAR IMPORT; 67-KDA POLYPEPTIDE P67; NITRIC-OXIDE SYNTHASE; MUTATIONAL HOT-SPOT; RNA-POLYMERASE-II; CYTOSOLIC PROTEINS; INSULIN-RESISTANCE	Cellular response to environmental, physiological, or chemical stress is key to survival following injury or disease. Here we describe a unique signaling mechanism by which cells detect and respond to stress in order to survive. A wide variety of stress stimuli rapidly increase nucleocytoplasmic protein modification by O-linked beta-N-acetylglucosamine (O-GlcNAc), an essential post-translational modification of Ser and Thr residues of metazoans. Blocking this post-translational modification, or reducing it, renders cells more sensitive to stress and results in decreased cell survival; and increasing O-GlcNAc levels protects cells. O-GlcNAc regulates both the rates and extent of the stress-induced induction of heat shock proteins, providing a molecular basis for these findings.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Univ Calif San Diego, Dept Cellular & Mol Sci, Glycobiol Res & Training Ctr, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Johns Hopkins University; Howard Hughes Medical Institute; University of California System; University of California San Diego	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	gwhart@jhmi.edu		Hart, Gerald/0000-0001-7812-4351	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028180] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NCI NIH HHS [CA42486] Funding Source: Medline; NHLBI NIH HHS [N01-HV-28180] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreoni G, 1997, EXP NEUROL, V148, P281, DOI 10.1006/exnr.1997.6647; BACHMANN M, 1989, MOL CELL BIOCHEM, V85, P103, DOI 10.1007/BF00577106; Barnes K, 2002, J CELL SCI, V115, P2433; Barros LF, 2001, PFLUG ARCH EUR J PHY, V442, P614; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; CHAKRABORTY A, 1994, INDIAN J BIOCHEM BIO, V31, P236; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DATTA B, 1989, J BIOL CHEM, V264, P20620; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; DUVERGER E, 1993, EXP CELL RES, V207, P197, DOI 10.1006/excr.1993.1181; Duverger E, 1996, GLYCOBIOLOGY, V6, P381, DOI 10.1093/glycob/6.4.381; DUVERGER E, 1995, J CELL SCI, V108, P1325; Dwyer DS, 1999, J CELL PHYSIOL, V178, P93, DOI 10.1002/(SICI)1097-4652(199901)178:1<93::AID-JCP12>3.3.CO;2-L; Federici M, 2002, CIRCULATION, V106, P466, DOI 10.1161/01.CIR.0000023043.02648.51; Fiorentini D, 2001, FREE RADICAL BIO MED, V31, P923, DOI 10.1016/S0891-5849(01)00678-5; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Goldberg HJ, 2002, J BIOL CHEM, V277, P33833, DOI 10.1074/jbc.M112331200; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han I, 1998, J CELL BIOCHEM, V68, P50, DOI 10.1002/(SICI)1097-4644(19980101)68:1<50::AID-JCB5>3.0.CO;2-V; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Ikari A, 2002, J BIOL CHEM, V277, P33338, DOI 10.1074/jbc.M200310200; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Juang YT, 2002, J IMMUNOL, V168, P2865, DOI 10.4049/jimmunol.168.6.2865; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kim HJ, 2002, J BIOL CHEM, V277, P23193, DOI 10.1074/jbc.M201007200; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Lamarre-Vincent N, 2003, J AM CHEM SOC, V125, P6612, DOI 10.1021/ja028200t; Lefebvre T, 2001, BIOCHEM J, V360, P179, DOI 10.1042/0264-6021:3600179; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Liu WL, 2000, AM J PHYSIOL-ENDOC M, V279, pE782, DOI 10.1152/ajpendo.2000.279.4.E782; Luss H, 2002, CARDIOVASC RES, V54, P140, DOI 10.1016/S0008-6363(02)00232-8; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Mer G, 1996, NAT STRUCT BIOL, V3, P45, DOI 10.1038/nsb0196-45; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; Monsigny M, 1999, BIOSCIENCE REP, V19, P125, DOI 10.1023/A:1020114611517; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Pang Y, 2002, DIABETES, V51, P3461, DOI 10.2337/diabetes.51.12.3461; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; PASTERNAK CA, 1991, J CELL PHYSIOL, V149, P324, DOI 10.1002/jcp.1041490221; Pereira C, 2000, EXP NEUROL, V161, P383, DOI 10.1006/exnr.1999.7270; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; RAY MK, 1992, P NATL ACAD SCI USA, V89, P539, DOI 10.1073/pnas.89.2.539; Rivera AA, 1995, AM J PHYSIOL-CELL PH, V269, pC1482, DOI 10.1152/ajpcell.1995.269.6.C1482; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; Sumegi M, 2003, BIOCHEM BIOPH RES CO, V312, P1284, DOI 10.1016/j.bbrc.2003.11.074; Sviderskaya EV, 1996, J MEMBRANE BIOL, V149, P133, DOI 10.1007/s002329900014; Vemuri S, 1999, J BIOL CHEM, V274, P20165, DOI 10.1074/jbc.274.29.20165; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; WARREN AP, 1986, J CELL PHYSIOL, V128, P383, DOI 10.1002/jcp.1041280306; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Wells L, 2002, J BIOL CHEM, V277, P1755, DOI 10.1074/jbc.M109656200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang JZ, 1999, AM J KIDNEY DIS, V34, P189, DOI 10.1016/S0272-6386(99)70131-9	89	423	455	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30133	30142		10.1074/jbc.M403773200	http://dx.doi.org/10.1074/jbc.M403773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138254	hybrid			2022-12-25	WOS:000222531900034
J	Maeda, H; Nagata, S; Wolfgang, CD; Bratthauer, GL; Bera, TK; Pastan, I				Maeda, H; Nagata, S; Wolfgang, CD; Bratthauer, GL; Bera, TK; Pastan, I			The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN-REGULATED GENE; CANCER CELLS; EPITHELIAL-CELLS; MOLECULAR-CLONING; CITRATE METABOLISM; EXPRESSION; MEMBRANE; ANTIGEN; BINDING; TUMORS	We previously showed that mRNA encoding TARP ( T cell receptor gamma chain alternate reading frame protein) is exclusively expressed in the prostate in males and is up-regulated by androgen in LNCaP cells, an androgen-sensitive prostate cancer cell line. We have now developed an anti-TARP monoclonal antibody named TP1, and show that TARP protein is up-regulated by androgen in both LNCaP and MDA-PCa-2b cells. We used TP1 to determine the subcellular localization of TARP by Western blotting following subcellular fractionation and immunocytochemistry. Both methods showed that TARP is localized in the mitochondria of LNCaP cells, MDA-PCa-2b cells, and PC-3 cells transfected with a TARP-expressing plasmid. We also transfected a plasmid encoding TARP fused to green fluorescent protein into LNCaP, MDA-Pca-2b, and PC-3 cells and confirmed its specific mitochondrial localization in living cells. Fractionation of mitochondria shows that TARP is located in the outer mitochondrial membrane. Immunohistochemistry using a human prostate cancer sample showed that TP1 reacted in a dot-like cytoplasmic pattern consistent with the presence of TARP in mitochondria. These data demonstrate that TARP is the first prostate-specific protein localizing in mitochondria and indicate that TARP, an androgen-regulated protein, may act on mitochondria to carry out its biological functions.	NCI, Mol Biol Lab, NIH, Ctr Canc Res, Bethesda, MD 20892 USA; Armed Forces Inst Pathol, Dept Gynecol & Breast Pathol, Washington, DC 20306 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense	Pastan, I (corresponding author), NCI, Mol Biol Lab, NIH, Ctr Canc Res, 37 Convent Dr,Room 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	pastan, ira/P-9319-2019; Nagata, Satoshi/B-5781-2008	pastan, ira/0000-0002-9223-0270; Nagata, Satoshi/0000-0001-9156-5215	NATIONAL CANCER INSTITUTE [ZIABC010298, Z01BC010298] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bander NH, 2003, J UROLOGY, V170, P1717, DOI 10.1097/01.ju.0000091655.77601.0c; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bratthauer G L, 1999, Methods Mol Biol, V115, P203; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chaib H, 2001, CANCER RES, V61, P2390; Costello LC, 1997, UROLOGY, V50, P3, DOI 10.1016/S0090-4295(97)00124-6; Costello LC, 2002, HORM METAB RES, V34, P417, DOI 10.1055/s-2002-33598; Dubbink HJ, 1998, GENOMICS, V51, P434, DOI 10.1006/geno.1998.5393; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; Evdokimov AG, 2000, ACTA CRYSTALLOGR D, V56, P1676, DOI 10.1107/S0907444900013378; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; HASUMURA S, 1986, BIOCHEMISTRY-US, V25, P7881, DOI 10.1021/bi00372a014; Herness EA, 2003, CANCER RES, V63, P329; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kimura K, 2001, CANCER RES, V61, P5611; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Lin BY, 2000, CANCER RES, V60, P858; Lin BY, 2001, CANCER RES, V61, P1611; Maeda H, 2001, CANCER RES, V61, P5432; Murphy GP, 1999, PROSTATE, V39, P54, DOI 10.1002/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Nicholson B, 2003, HISTOL HISTOPATHOL, V18, P275, DOI 10.14670/HH-18.275; Nozawa M, 2000, CANCER RES, V60, P1348; Olsson P, 2001, PROSTATE, V48, P231, DOI 10.1002/pros.1102; Qi H, 2002, CANCER RES, V62, P721; Rhodes DR, 2002, CANCER RES, V62, P4427; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Spector D. L., 1998, CELLS LAB MANUAL CUL, V1; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Staack A, 2003, PROSTATE, V54, P212, DOI 10.1002/pros.10179; Stamey TA, 2001, J UROLOGY, V166, P2171, DOI 10.1016/S0022-5347(05)65528-0; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Tsavaler L, 2001, CANCER RES, V61, P3760; Van de Sande T, 2002, CANCER RES, V62, P642; Vasmatzis G, 1998, P NATL ACAD SCI USA, V95, P300, DOI 10.1073/pnas.95.1.300; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; Wolfgang CD, 2001, CANCER RES, V61, P8122; Xu JC, 2001, CANCER RES, V61, P1563; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Xu LL, 2000, CANCER RES, V60, P6568; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhuang LY, 2002, CANCER RES, V62, P2227	46	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24561	24568		10.1074/jbc.M402492200	http://dx.doi.org/10.1074/jbc.M402492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15150260	hybrid			2022-12-25	WOS:000221702500085
J	Butan, C; van der Zandt, H; Tucker, PA				Butan, C; van der Zandt, H; Tucker, PA			Structure and assembly of the RNA binding domain of bluetongue virus non-structural protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED RNA; INCLUSION-BODIES; RECOGNITION; NS2; REFINEMENT; SYNTHETASE; NSP2; CRYSTALLOGRAPHY; PHOSPHOPROTEIN; MULTIMERS	Bluetongue virus non-structural protein 2 belongs to a class of highly conserved proteins found in orbiviruses of the Reoviridae family. Non-structural protein 2 forms large multimeric complexes and localizes to cytoplasmic inclusions in infected cells. It is able to bind single-stranded RNA non-specifically, and it has been suggested that the protein is involved in the selection and condensation of the Bluetongue virus RNA segments prior to genome encapsidation. We have determined the x-ray structure of the N-terminal domain ( sufficient for the RNA binding ability of non-structural protein 2) to 2.4 Angstrom resolution using anomalous scattering methods. Crystals of this apparently insoluble domain were obtained by in situ proteolysis of a soluble construct. The asymmetric unit shows two monomers related by noncrystallographic symmetry, with each monomer folded as a beta sandwich with a unique topology. The crystal structure reveals extensive monomer-monomer interactions, which explain the ability of the protein to self-assemble into large homomultimeric complexes. Of the entire surface area of the monomer, one-third is used to create the interfaces of the curved multimeric assembly observed in the x-ray structure. The structure reported here shows how the N-terminal domain would be able to bind single-stranded RNA non-specifically protecting the bound regions in a heterogeneous multimeric but not polymeric complex.	Deutsch Elektron Synchrotron, European Mol Biol Lab, D-22603 Hamburg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tucker, PA (corresponding author), Deutsch Elektron Synchrotron, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.	tucker@embl-hamburg.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; BROOKES SM, 1993, J GEN VIROL, V74, P525, DOI 10.1099/0022-1317-74-3-525; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Deo RC, 2002, CELL, V108, P71, DOI 10.1016/S0092-8674(01)00632-8; DEVANEY MA, 1988, VIRUS RES, V11, P151, DOI 10.1016/0168-1702(88)90040-8; EATON BT, 1990, CURR TOP MICROBIOL, V162, P89; Fillmore GC, 2002, J VIROL, V76, P499, DOI 10.1128/JVI.76.2.499-506.2002; Gillian AL, 2000, J VIROL, V74, P5939, DOI 10.1128/JVI.74.13.5939-5948.2000; Gouet P, 1999, CELL, V97, P481, DOI 10.1016/S0092-8674(00)80758-8; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUISMANS H, 1987, J VIROL, V61, P3589, DOI 10.1128/JVI.61.11.3589-3595.1987; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lymperopoulos K, 2003, J BIOL CHEM, V278, P31722, DOI 10.1074/jbc.M301072200; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Taraporewala Z, 1999, J VIROL, V73, P9934, DOI 10.1128/JVI.73.12.9934-9943.1999; Taraporewala ZF, 2002, J VIROL, V76, P7082, DOI 10.1128/JVI.76.14.7082-7093.2002; Taraporewala ZF, 2001, VIROLOGY, V280, P221, DOI 10.1006/viro.2000.0764; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMAS CP, 1990, J GEN VIROL, V71, P2073, DOI 10.1099/0022-1317-71-9-2073; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Wang XQ, 2002, CELL, V110, P501, DOI 10.1016/S0092-8674(02)00873-5; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; ZHAO Y, 1994, J VIROL, V68, P2179, DOI 10.1128/JVI.68.4.2179-2185.1994	40	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2004	279	36					37613	37621		10.1074/jbc.M400502200	http://dx.doi.org/10.1074/jbc.M400502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	849QK	15155766	hybrid			2022-12-25	WOS:000223554600052
J	Akiyoshi, H; Hatakeyama, S; Pitkanen, J; Mouri, Y; Doucas, V; Kudoh, J; Tsurugaya, K; Uchida, D; Matsushima, A; Oshikawa, K; Nakayama, KI; Shimizu, N; Peterson, P; Matsumoto, M				Akiyoshi, H; Hatakeyama, S; Pitkanen, J; Mouri, Y; Doucas, V; Kudoh, J; Tsurugaya, K; Uchida, D; Matsushima, A; Oshikawa, K; Nakayama, KI; Shimizu, N; Peterson, P; Matsumoto, M			Subcellular expression of autoimmune regulator is organized in a spatiotemporal manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE SELECTION; NUCLEAR-BODIES; AIRE; PROTEIN; GENE; LOCALIZATION; ACTIVATION; TOLERANCE; THYMUS; PHD	Autoimmune regulator ( AIRE) is responsible for the development of organ-specific autoimmune disease in a monogenic fashion. Rare and low levels of tissue expression together with the lack of AIRE-expressing cell lines have hampered a detailed analysis of the molecular dynamics of AIRE. Here we have established cell lines stably transfected with AIRE and studied the regulatory mechanisms for its subcellular expression. We found that nuclear body ( NB) formation by AIRE was dependent on the cell cycle. Biochemical fractionation revealed that a significant proportion of AIRE is associated with the nuclear matrix, which directs the functional domains of chromatin to provide sites for gene regulation. Upon proteasome inhibition, AIRE NBs were increased with concomitant reduced expression in the cytoplasm, suggesting that subcellular targeting of AIRE is regulated by a ubiquitin-proteasome pathway. We also found that AIRE NBs compete for cAMP-response element-binding protein-binding protein/p300, a common coactivator of transcription, with the promyelocytic leukemia gene product. These results suggest that the transcriptional regulating activities of AIRE within a cell are controlled and organized in a spatiotemporal manner.	Univ Tokushima, Inst Enzyme Res, Div Mol Immunol, Tokushima 7708503, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Saitama 3320012, Japan; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere 33101, Finland; Inst Jacques Monod, Dept Biol Genomes, F-75251 Paris 05, France; Keio Univ, Sch Med, Dept Mol Biol, Tokyo 1608582, Japan	Tokushima University; Kyushu University; Japan Science & Technology Agency (JST); Tampere University; Tampere University; Tampere University Hospital; UDICE-French Research Universities; Universite Paris Cite; Keio University	Matsumoto, M (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Mol Immunol, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	mitsuru@ier.tokushima-u.ac.jp	Mouri, Yasuhiro/AAF-8953-2021; Peterson, Pärt/A-5788-2009; Hatakeyama, Shigetsugu/C-8333-2012	Peterson, Pärt/0000-0001-6755-791X; Hatakeyama, Shigetsugu/0000-0002-2150-9979				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Doucas V, 2000, BIOCHEM PHARMACOL, V60, P1197, DOI 10.1016/S0006-2952(00)00413-5; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kasai M, 1996, EUR J IMMUNOL, V26, P2101, DOI 10.1002/eji.1830260921; Kumar PG, 2001, J BIOL CHEM, V276, P41357, DOI 10.1074/jbc.M104898200; Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nickerson JA, 2001, J CELL SCI, V114, P463; Oshikawa K, 2003, BIOCHEM BIOPH RES CO, V303, P1209, DOI 10.1016/S0006-291X(03)00501-1; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Pitkanen J, 2003, GENES IMMUN, V4, P12, DOI 10.1038/sj.gene.6363929; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Ramsey C, 2002, HUM MOL GENET, V11, P3299, DOI 10.1093/hmg/11.26.3299; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; TESTA U, 1994, CANCER RES, V54, P4508; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; Wandstrat A, 2001, NAT IMMUNOL, V2, P802, DOI 10.1038/ni0901-802; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zuklys S, 2000, J IMMUNOL, V165, P1976, DOI 10.4049/jimmunol.165.4.1976	37	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33984	33991		10.1074/jbc.M400702200	http://dx.doi.org/10.1074/jbc.M400702200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15150263	hybrid			2022-12-25	WOS:000223039700109
J	Ajenjo, N; Canon, E; Sanchez-Perez, I; Matallanas, D; Leon, J; Perona, R; Crespo, P				Ajenjo, N; Canon, E; Sanchez-Perez, I; Matallanas, D; Leon, J; Perona, R; Crespo, P			Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE KINASE; SIGNAL-REGULATED KINASE; ABL TYROSINE KINASE; RIBOSOMAL S6 KINASE; EPIDERMAL-GROWTH-FACTOR; NUCLEAR EXPORT SIGNAL; MAP KINASE; BCR-ABL; CONSTITUTIVE ACTIVATION	ERKs, mitogen-activated protein kinases, are well characterized as key mediators in the conveyance of signals that promote cell survival in cells of hemopoietic origin, a key factor in the upbringing of leukemogenesis. It is also well known that ERKs phosphorylate a wide array of substrates distributed throughout distinct cellular locations such as the nucleus, cytoplasm, and cell periphery, but the relative contribution of these compartmentalized signal components to the overall survival signal generated by activation of ERKs has yet to be established. To this end, we have utilized constitutively activated forms of ERK2, whose expression is restricted to the nucleus or to the cytoplasm, to investigate the consequences of compartmentalized activation of ERK in the survival of chronic myelogenous leukemia cells subjected to distinct apoptogenic stimuli. We show that cytoplasmic ERK2 activity protected against apoptosis caused by prolonged serum starvation, whereas ERK2 activation restricted to the nucleus antagonized apoptosis induced by the Bcr-Abl inhibitor STI571. On the other hand, neither cytoplasmic nor nuclear ERK2 activities were effective in counteracting apoptosis induced by UV light. These results demonstrate that the protective effects of ERK2 against defined apoptogenic stimuli are strictly dependent on the cellular localization where ERK activation takes place. Furthermore, we present evidence suggesting that the complex IkappaB-NFkappaB participates on ERK2-mediated survival mechanisms, in a fashion dependent on the cellular location where ERK2 is active and on the causative apoptogenic stimulus.	Univ Cantabria, Fac Med, Dept Biol Mol, CSIC,Inst Invest Biomed,Unidad Biomed, Santander 39011, Spain; CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Crespo, P (corresponding author), Univ Cantabria, Fac Med, Dept Biol Mol, CSIC,Inst Invest Biomed,Unidad Biomed, C Cardenal Herrera Oria S-N, Santander 39011, Spain.	pcrespo@iib.uam.es	Leon, Javier/K-4615-2014; Sánchez-Pérez, Isabel/R-4107-2016; gomez, david/U-9465-2019; Crespo, Piero/M-3273-2014	Sánchez-Pérez, Isabel/0000-0002-4829-201X; gomez, david/0000-0002-2360-3141; Ajenjo Diez, Nuria/0000-0002-9435-6467; Crespo, Piero/0000-0003-2825-7783; Leon, Javier/0000-0001-5803-0112				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BEDI A, 1994, BLOOD, V83, P2038; Benito A, 1997, LEUKEMIA, V11, P940, DOI 10.1038/sj.leu.2400699; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; GRENDINER E, 1998, J BIOL CHEM, V2273, P10436; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Henderson C, 2003, DRUG RESIST UPDATE, V6, P247, DOI 10.1016/S1368-7646(03)00067-0; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Lerga A, 1999, BIOCHEM BIOPH RES CO, V260, P256, DOI 10.1006/bbrc.1999.0852; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; OKA H, 1995, CANCER RES, V55, P4182; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RACKE FK, 1997, J BIOL CHEM, V272, P23336; Renault F, 2003, BIOCHEM PHARMACOL, V66, P1581, DOI 10.1016/S0006-2952(03)00514-8; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sanz-Moreno V, 2003, MOL CELL BIOL, V23, P3079, DOI 10.1128/MCB.23.9.3079-3090.2003; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Schramek H, 1997, J BIOL CHEM, V272, P11426; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Viatour P, 2003, J BIOL CHEM, V278, P46541, DOI 10.1074/jbc.M306381200; Wang SJ, 1998, BIOCHEM PHARMACOL, V56, P635, DOI 10.1016/S0006-2952(98)00188-9; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; Yu CR, 2002, CANCER RES, V62, P188; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	77	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32813	32823		10.1074/jbc.M313656200	http://dx.doi.org/10.1074/jbc.M313656200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15173174	hybrid			2022-12-25	WOS:000222849700101
J	Sun, XJ; Zhang, H; Wang, D; Ma, DL; Shen, Y; Shang, YF				Sun, XJ; Zhang, H; Wang, D; Ma, DL; Shen, Y; Shang, YF			DLP, a novel Dim1 family protein implicated in pre-mRNA splicing and cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN PARTICLE; SCHIZOSACCHAROMYCES-POMBE; U5 SNRNP; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; MAMMALIAN HOMOLOG; BINDING PROTEIN; MITOTIC ENTRY; GENE ENCODES; IDENTIFICATION	In eukaryotes, primary transcripts undergo a splicing process that removes intronic sequences by a macromolecular enzyme known as the spliceosome. Both genetic and biochemical studies have revealed that essential components of the spliceosome include five small RNAs, U1, U2, U4, U5, and U6, and as many as 300 distinct proteins. Here we report the molecular cloning and functional analysis of a novel cDNA encoding for a protein of 149 amino acids. This protein has 38% amino acid sequence identity with and is evolutionally related to yeast Dim1 protein. Hence we named this protein DLP for Dim1-like protein. We showed that DLP is required for S/G(2) transition. We also demonstrated that DLP functions in cell nucleus and interacts with the U5-102-kDa protein subunit of the spliceosome, and blocking DLP protein activity led to an insufficient pre-mRNA splicing, suggesting that DLP is yet another protein component involved in pre-mRNA splicing. Collectively, our experiments indicated that DLP is implicated in not only cell cycle progression but also in a more specific molecular process such as pre-mRNA splicing.	Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Chinese Natl Human Genome Ctr, Beijing 100176, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Peking University	Shen, Y (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.	sheny@ms.imicams.ac.cn; jason@bjmu.edu.cn						ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Ajuh P, 2001, J BIOL CHEM, V276, P42370, DOI 10.1074/jbc.M105453200; ALLEY MC, 1988, CANCER RES, V48, P589; Beales M, 2000, YEAST, V16, P1001, DOI 10.1002/1097-0061(200008)16:11<1001::AID-YEA605>3.0.CO;2-6; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Berry LD, 1997, J CELL BIOL, V137, P1337, DOI 10.1083/jcb.137.6.1337; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Chawla G, 2003, NUCLEIC ACIDS RES, V31, P2333, DOI 10.1093/nar/gkg333; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Grabowski PJ, 2001, PROG NEUROBIOL, V65, P289, DOI 10.1016/S0301-0082(01)00007-7; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; Habara Y, 2001, RNA, V7, P671, DOI 10.1017/S1355838201001200; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lei XH, 2000, J CELL SCI, V113, P4523; Lundgren K, 1996, MOL BIOL CELL, V7, P1083, DOI 10.1091/mbc.7.7.1083; Makarov EM, 2000, J MOL BIOL, V298, P567, DOI 10.1006/jmbi.2000.3685; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; Potashkin J, 1998, CURR GENET, V34, P153, DOI 10.1007/s002940050381; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Reuter K, 1999, J MOL BIOL, V294, P515, DOI 10.1006/jmbi.1999.3258; Russell CS, 2000, RNA, V6, P1565, DOI 10.1017/S1355838200000984; Schwelnus W, 2001, EMBO REP, V2, P35, DOI 10.1093/embo-reports/kve009; Shao WL, 2002, MOL CELL BIOL, V22, P3358, DOI 10.1128/MCB.22.10.3358-3372.2002; SHEA JE, 1994, NUCLEIC ACIDS RES, V22, P5555, DOI 10.1093/nar/22.25.5555; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Zhang YZ, 1999, PHYSIOL GENOMICS, V1, P109, DOI 10.1152/physiolgenomics.1999.1.3.109; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	42	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32839	32847		10.1074/jbc.M402522200	http://dx.doi.org/10.1074/jbc.M402522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161931	hybrid			2022-12-25	WOS:000222849700104
J	Yamazaki, T; Nakano, H; Hayakari, M; Tanaka, M; Mayama, J; Tsuchida, S				Yamazaki, T; Nakano, H; Hayakari, M; Tanaka, M; Mayama, J; Tsuchida, S			Differentiation induction of human keratinocytes by phosphatidylethanolamine-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; RAF KINASE; BOVINE BRAIN; INHIBITOR PROTEIN; 23-KDA PROTEIN; ACTIVATION; PATHWAY; EXPRESSION; SEQUENCE	Phosphatidylethanolamine-binding protein ( PEBP) has been demonstrated to bind to Raf-1 and mitogen-activated protein kinase kinase, components of the extracellular signal-regulated protein kinase (ERK) pathway, thereby inhibiting the pathway and resulting in the suppression of cell proliferation. In the present study, we examined whether PEBP is involved in differentiation induction of human keratinocytes. PEBP expression was immunohistochemically examined in normal human skin and skin cancers with different differentiation properties. PEBP was not expressed in the basal layer of the epidermis but was expressed in the spinous and granular layers of normal skin. The protein was expressed in differentiated but not in undifferentiated carcinoma. PEBP expression was also examined in cultured normal human epidermal keratinocytes in which differentiation was induced by calcium treatment. Involucrin was used as a differentiation marker for spinous and granular cells. Northern blotting analysis indicated that both PEBP and involucrin mRNAs were enhanced 6 h after treatment with 2.0 mM CaCl2. The protein amount of PEBP was also increased by this treatment. To investigate whether PEBP is involved in differentiation induction of keratinocytes, HaCaT keratinocytes were transfected with an expression vector. Fluorescent immunostain revealed that cells expressing PEBP exhibited enlarged and flattened cell shape, and induction of involucrin expression was demonstrated by immunoblot analysis. Although the protein amount of ERK was not altered, phosphorylated ERK levels were decreased and cell proliferation was partly inhibited by PEBP expression. These results indicate that PEBP not only inhibits cell proliferation but also induces differentiation of human keratinocytes.	Hirosaki Univ, Sch Med, Dept Biochem 2, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Dermatol, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Pathol 2, Hirosaki, Aomori 0368562, Japan	Hirosaki University; Hirosaki University; Hirosaki University	Tsuchida, S (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem 2, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	tsuchida@cc.hirosaki-u.ac.jp	Tsuchida, Shigeki/L-3382-2013	Tsuchida, Shigeki/0000-0002-4404-5599				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Apostolidis A, 1997, CELL SIGNAL, V9, P439, DOI 10.1016/S0898-6568(97)00034-X; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; BERNIER I, 1984, BIOCHIM BIOPHYS ACTA, V790, P174, DOI 10.1016/0167-4838(84)90221-8; BOLLENGIER F, 1989, J NEUROCHEM, V52, P1123, DOI 10.1111/j.1471-4159.1989.tb01856.x; BOS JL, 1989, CANCER RES, V49, P4682; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCQUOY S, 1994, EUR J BIOCHEM, V225, P1203, DOI 10.1111/j.1432-1033.1994.1203b.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Deucher A, 2002, J BIOL CHEM, V277, P17032, DOI 10.1074/jbc.M109076200; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; GUTHENBERG C, 1979, BIOCHEM BIOPH RES CO, V86, P1304, DOI 10.1016/0006-291X(79)90258-4; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HORI N, 1994, GENE, V140, P293; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HYDER SM, 1994, BIOTECHNIQUES, V17, P478; KajiharaKano H, 1997, BIOCHEM J, V328, P473, DOI 10.1042/bj3280473; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Murphy George F., 1997, P5; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; PERRY ACF, 1994, BIOCHEM J, V301, P235, DOI 10.1042/bj3010235; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	55	23	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32191	32195		10.1074/jbc.M404029200	http://dx.doi.org/10.1074/jbc.M404029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155742	hybrid			2022-12-25	WOS:000222849700025
J	Tondera, D; Santel, A; Schwarzer, R; Dames, S; Giese, K; Klippel, A; Kaufmann, J				Tondera, D; Santel, A; Schwarzer, R; Dames, S; Giese, K; Klippel, A; Kaufmann, J			Knockdown of MTP18, a novel phosphatidylinositol 3-kinase-dependent protein, affects mitochondrial morphology and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; CELL-GROWTH; FISSION; 3-KINASE; ACTIVATION; CLEAVAGE; DIVISION; PATHWAY; KINASE; BAX	We identified a novel human cDNA encoding a mitochondrial protein, MTP18 ( mitochondrial protein, 18 kDa) as a transcriptional downstream target of phosphatidylinositol ( PI) 3-kinase signaling. We demonstrate that MTP18 mRNA as well as protein expression is dependent on PI 3-kinase activity. Confocal microscopy and biochemical fractionation revealed a mitochondrial localization of MTP18. Loss-of-function analysis employing antisense molecules revealed that MTP18 is essential for cell viability in PC-3 and HaCaT cells. We show that knockdown of MTP18 protein level results in a cytochrome c release from mitochondria and consequently leads to apoptosis. In addition, HaCaT cells with reduced levels of MTP18 become more sensitive to apoptotic stimuli. This effect is accompanied by dramatic subcellular alterations. Reduction of MTP18 impairs mitochondrial morphology resulting in the formation of a highly interconnected mitochondrial reticulum in COS-7 cells. Conversely, overexpression of MTP18 induces a punctuate morphology of mitochondria suggesting also a functional role of MTP18 in maintaining the mitochondrial integrity. Hence, our data indicate an unexpected connection of PI 3-kinase signaling, apoptosis and the morphology of mammalian mitochondria.	Atugen AG, D-13125 Berlin, Germany		Kaufmann, J (corresponding author), Atugen AG, Otto Warburg Haus 80,Robert Rossle Str 10, D-13125 Berlin, Germany.	kaufmann@atugen.com		Schwarzer, Rolf/0000-0002-8934-8788				BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Coffer PJ, 1998, BIOCHEM J, V335, P1; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEL PL, 1997, SCIENCE, V278, P687; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kaufmann J, 2004, BIOCHEM SOC T, V32, P355, DOI 10.1042/BST0320355; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Modica-Napolitano Josephine S, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004453; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Santel A, 2001, J CELL SCI, V114, P867; Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Takasawa R, 2003, APOPTOSIS, V8, P291, DOI 10.1023/A:1023629023696; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhu YF, 2002, EXP CELL RES, V280, P97, DOI 10.1006/excr.2002.5621	47	104	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31544	31555		10.1074/jbc.M404704200	http://dx.doi.org/10.1074/jbc.M404704200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155745	hybrid			2022-12-25	WOS:000222726800077
J	Shibagaki, N; Grossman, AR				Shibagaki, N; Grossman, AR			Probing the function of STAS domains of the Arabidopsis sulfate transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ANION TRANSPORTERS; NA+/H+ EXCHANGER; MUTATIONS; FAMILY; RESIDUES; PROTEIN; BINDING; GENE	Sulfate transporters in plants and animals are structurally conserved and have an amino-terminal domain that functions in transport and a carboxyl-terminal region that has been designated the STAS domain. The STAS domain in sulfate transporters has significant similarity to bacterial anti-sigma factor antagonists. To determine if the STAS domain has a role in controlling the activity of sulfate transporters, their stability, or their localization to the plasma membrane, we examined the effect of deleting or modifying the STAS domain of dominant sulfate transporters in roots of Arabidopsis thaliana. The A. thaliana Sultr1;2 and Sultr1; 1 sulfate transporters rescue the methionine-dependent growth phenotype of the yeast sulfate transporter mutant strain CP154-7B. Constructs of Sultr1; 2 in which the STAS domain was deleted (DeltaSTAS) resulted in synthesis of a truncated polypeptide that was unable to rescue the CP154-7B phenotype. The inability of these constructs to rescue the mutant phenotype probably reflected both low level cellular accumulation of the transporter and the inability of the truncated protein to localize to the plasma membrane. Fusing the STAS domain from other sulfate transporters to Sultr1; 2 DeltaSTAS constructs restored elevated accumulation and plasma membrane localization, although the kinetics of sulfate uptake in the transformants were markedly altered with respect to transformants synthesizing wild-type Sultr1; 2 protein. These results suggest that the STAS domain is essential, either directly or indirectly, for facilitating localization of the transporters to the plasma membrane, but it also appears to influence the kinetic properties of the catalytic domain of transporters.	Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Shibagaki, N (corresponding author), Carnegie Inst Washington, Dept Plant Biol, 260 Panama St, Stanford, CA 94305 USA.	snakako@stanford.edu						Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Cherest H, 1997, GENETICS, V145, P627; Chernova MN, 2003, J PHYSIOL-LONDON, V549, P3, DOI 10.1113/jphysiol.2003.039818; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Everett LA, 1999, HUM MOL GENET, V8, P1883, DOI 10.1093/hmg/8.10.1883; Fuglsang AT, 2003, J BIOL CHEM, V278, P42266, DOI 10.1074/jbc.M306707200; Hastbacka J, 1996, ANN NY ACAD SCI, V785, P131; Hawkesford MJ, 2003, PHYSIOL PLANTARUM, V117, P155, DOI 10.1034/j.1399-3054.2003.00034.x; Ho MS, 2003, J BIOL CHEM, V278, P20898, DOI 10.1074/jbc.M302305200; Jahn TP, 2002, J BIOL CHEM, V277, P6353, DOI 10.1074/jbc.M109637200; Jones S, 1998, PROTEIN SCI, V7, P233; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; Khurana OK, 2000, FEBS LETT, V477, P118, DOI 10.1016/S0014-5793(00)01783-X; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Mitsui K, 2004, J BIOL CHEM, V279, P12438, DOI 10.1074/jbc.M310806200; Pang TX, 2002, J BIOL CHEM, V277, P43771, DOI 10.1074/jbc.M208313200; Rose MD., 1990, METHODS YEAST GENETI; Saito K, 2000, CURR OPIN PLANT BIOL, V3, P188, DOI 10.1016/S1369-5266(00)00063-7; Shelden MC, 2003, BIOCHEMISTRY-US, V42, P12941, DOI 10.1021/bi034827s; Shelden MC, 2001, BIOCHEM J, V356, P589, DOI 10.1042/0264-6021:3560589; Shibagaki N, 2002, PLANT J, V29, P475, DOI 10.1046/j.0960-7412.2001.01232.x; SHIBAGAKI N, 2003, SULFUR TRANSPORT ASS, P323; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; SupertiFurga A, 1996, AM J MED GENET, V63, P144, DOI 10.1002/(SICI)1096-8628(19960503)63:1<144::AID-AJMG25>3.0.CO;2-N; Takahashi H, 2000, PLANT J, V23, P171, DOI 10.1046/j.1365-313x.2000.00768.x; Takahashi H., 1999, Plant Physiology, V121, P686; Usami S, 1999, HUM GENET, V104, P188, DOI 10.1007/s004390050933; Wakabayashi S, 1997, BIOCHEMISTRY-US, V36, P12854, DOI 10.1021/bi9715472; Yoshimoto N, 2002, PLANT J, V29, P465, DOI 10.1046/j.0960-7412.2001.01231.x	34	71	73	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30791	30799		10.1074/jbc.M403248200	http://dx.doi.org/10.1074/jbc.M403248200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136568	hybrid			2022-12-25	WOS:000222531900110
J	Xiao, GT; Fong, A; Sun, SC				Xiao, GT; Fong, A; Sun, SC			Induction of p100 processing by NF-kappa B-inducing kinase involves docking I kappa B kinase alpha (IKK alpha) to p100 and IKK alpha-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; NF-KAPPA-B2 P100; MICE DEFICIENT; P50 SUBUNIT; GENE; BAFF; ACTIVATION; PROTEINS; EXPRESSION; PRECURSOR	The processing of the nfkappab2 gene product p100 to generate p52 is a regulated event, which is important for the instrumental function of NF-kappaB. We previously demonstrated that this tightly controlled event is regulated positively by NF-kappaB-inducing kinase (NIK) and its downstream kinase, IkappaB kinase alpha (IKKalpha). However, the precise mechanisms by which NIK and IKKalpha induce p100 processing remain unclear. Here, we show that, besides activating IKKalpha, NIK also serves as a docking molecule recruiting IKKalpha to p100. This novel function of NIK requires two specific amino acid residues, serine 866 and serine 870, of p100 that are known to be essential for inducible processing of p100. We also show that, after being recruited into p100 complex, activated IKKalpha phosphorylates specific serines located in both N- and C-terminal regions of p100 (serines 99, 108, 115, 123, and 872). The phosphorylation of these specific serines is the prerequisite for ubiquitination and subsequent processing of p100 mediated by the beta-TrCP ubiquitin ligase and 26 S proteasome, respectively. These results highlight the critical but different roles of NIK and IKKalpha in regulating p100 processing and shed light on the mechanisms mediating the tight control of p100 processing. These data also provide the first evidence for explaining why overexpression of IKKalpha or its activation by many other stimuli such as tumor necrosis factor and mitogens fails to induce p100 processing.	Rutgers State Univ, Nelson Biol Labs, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Rutgers State University New Brunswick; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Xiao, GT (corresponding author), Rutgers State Univ, Nelson Biol Labs, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu; sxs70@psu.edu			NCI NIH HHS [1R01 CA94922] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LANOIX J, 1994, ONCOGENE, V9, P841; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; THAKUR S, 1994, ONCOGENE, V9, P2335; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; ZHANG JD, 1994, ONCOGENE, V9, P1931	45	218	231	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30099	30105		10.1074/jbc.M401428200	http://dx.doi.org/10.1074/jbc.M401428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140882	hybrid			2022-12-25	WOS:000222531900030
J	Shollar, D; Del Valle, L; Khalili, K; Otte, J; Gordon, J				Shollar, D; Del Valle, L; Khalili, K; Otte, J; Gordon, J			JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						mpnst; polyomavirus; NF2; p53; animal model; JC virus; T-antigen	HUMAN NEUROTROPIC POLYOMAVIRUS; BRAIN-TUMORS; VIRUS; EXPRESSION; PROTEIN; INVOLVEMENT; SUPPRESSOR; MERLIN	The human polyomavirus, JC virus, has recently been associated with several human CNS tumors, including medulloblastomas and a broad range of glial-origin tumors. This ubiquitous virus is the causative agent of the rare demyelinating disease, progressive multifocal leukoencephalopathy in immunocompromised individuals. Expression of the viral protein, T-antigen, which possesses the ability to transform cells of neural origin, has been detected in human CNS tumors. In an effort to further understand the transforming potential of JCV T-antigen, transgenic mice expressing JCV T-antigen under the control of the Mad-4 promoter were generated. As described previously, approximately 50% of the animals developed pituitary tumors by 1 year of age. However, a small subset of the animals developed solid masses arising from the soft tissues surrounding the salivary gland, the sciatic nerve, and along the extremities that histologically resemble malignant peripheral nerve sheath tumors, rare neoplasms that occur in individuals with neurofibromatosis type 1 (NF1). JCV T-antigen was detected in tumor tissue by immunohistochemistry and immunoprecipitation/Western blotting, but not in normal tissues and was colocalized with NF2, the putative tumor suppressor protein associated with neurofibromatosis type 2, in the nucleus of some cells. In addition, T-antigen was co-precipitated with NF2, but not with NF1 protein, although NF1 was detectable in tumor tissue. Furthermore, precipitated immunocomplexes contained T-antigen, NF2, and p53, suggesting that these three proteins may form a ternary complex. The importance of these findings on mechanisms of T-antigen-mediated tumorigenesis and the pathogenesis of neurofibromatosis are discussed.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Gordon, J (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	jennifer.gordon@temple.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Del Valle L, 2001, CANCER RES, V61, P4287; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Enam S, 2002, CANCER RES, V62, P7093; Frank D, 2003, CANCER GENET CYTOGEN, V144, P18, DOI 10.1016/S0165-4608(02)00870-1; Franks RR, 1996, ONCOGENE, V12, P2573; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kim H.S., 2001, HUMAN POLYOMAVIRUSES, P73; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; LOUIS DN, 2000, PATHOLOGY GENETICS T, P219; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2001, BBA-REV CANCER, V1471, pM73, DOI 10.1016/S0304-419X(00)00026-3; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; RESSETAR HG, 1990, LAB INVEST, V62, P287; REY JA, 1993, CANCER GENET CYTOGEN, V66, P28, DOI 10.1016/0165-4608(93)90144-B; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Schmucker B, 1999, HUM MOL GENET, V8, P1561, DOI 10.1093/hmg/8.8.1561; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Testa JR, 1998, CANCER RES, V58, P4505; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; VONDEIMLING A, 2000, PATHOLOGY GENETICS T, P216; Woodruff J.M., 2000, PATHOLOGY GENETICS T, P172; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	38	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5459	5467		10.1038/sj.onc.1207728	http://dx.doi.org/10.1038/sj.onc.1207728			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133494				2022-12-25	WOS:000222588400005
J	Waddell, DS; Liberati, NT; Guo, X; Frederick, JP; Wang, XF				Waddell, DS; Liberati, NT; Guo, X; Frederick, JP; Wang, XF			Casein kinase I epsilon plays a functional role in the transforming growth factor-beta signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATENIN DEGRADATION COMPLEX; TGF-BETA; SUBSTRATE DETERMINANTS; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; CIRCADIAN CLOCK; CULTURED-CELLS; CKI-EPSILON; WNT PATHWAY; PHOSPHORYLATION	The transforming growth factor-beta (TGF-beta) signaling pathway is known to be involved in a wide range of biological events, including development, cellular differentiation, apoptosis, and oncogenesis. The TGF-beta signal is mediated by ligand binding to the type II receptor, leading to the recruitment and activation of the type I receptor, and subsequent activation of a family of intracellular signal transducing proteins called Smads. Here we report a regulatory role for casein kinase Iepsilon (CKIepsilon) in the TGF-beta signaling cascade. We find that CKIepsilon binds to all Smads and the cytoplasmic domains of the type I and type II receptors both in vitro and in vivo. The interaction of CKIepsilon with the type I and type II receptors is independent of TGF-beta stimulation, whereas the CKIepsilon/Smad interaction is transiently disrupted by ligand treatment. Additionally, CKIepsilon is able to phosphorylate the receptor-activated Smads (Smads 1-3 and 5) and the type II receptor in vitro. Transcriptional reporter assays reveal that transient overexpression of wild type CKIepsilon dramatically reduces basal reporter activity but enhances TGF-beta-stimulated transcription. Furthermore, overexpression of a kinase-dead mutant of CKIepsilon inhibits both basal and ligand-induced transcription, whereas inhibition of endogenous CKI catalytic activity with IC261 blocks only TGF-beta-stimulated reporter activity. Finally, knocking down CKIepsilon protein levels results in a significant increase in basal and TGF-beta-induced transcription. These results suggest that CKIepsilon plays a ligand-dependent, differential, and dual regulatory role within the TGF-beta signaling pathway.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, POB 3813, Durham, NC 27710 USA.	wang0011@mc.duke.edu	Waddell, David/AAG-3774-2020; Waddell, David/J-7435-2015	Waddell, David/0000-0001-6749-4461; Waddell, David/0000-0001-6749-4461	NCI NIH HHS [CA83770, CA75368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083770, R01CA075368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Bioukar EB, 1999, J BIOL CHEM, V274, P21457, DOI 10.1074/jbc.274.30.21457; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Frederick JP, 2002, STRUCTURE, V10, P1607, DOI 10.1016/S0969-2126(02)00914-0; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hall FL, 1996, BIOCHEM J, V316, P303, DOI 10.1042/bj3160303; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Marin O, 2002, BIOCHEMISTRY-US, V41, P618, DOI 10.1021/bi0112309; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Preuss F, 2004, MOL CELL BIOL, V24, P886, DOI 10.1128/MCB.24.2.886-898.2004; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Randall RA, 2004, MOL CELL BIOL, V24, P1106, DOI 10.1128/MCB.24.3.1106-1121.2004; Reguly T, 2003, TRENDS CELL BIOL, V13, P216, DOI 10.1016/S0962-8924(03)00075-8; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Tobin AB, 2002, TRENDS PHARMACOL SCI, V23, P337, DOI 10.1016/S0165-6147(02)02043-6; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Warner DR, 2003, FEBS LETT, V539, P167, DOI 10.1016/S0014-5793(03)00155-8; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	67	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29236	29246		10.1074/jbc.M400880200	http://dx.doi.org/10.1074/jbc.M400880200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15133026	hybrid			2022-12-25	WOS:000222445300052
J	Zhang, ZH; Rhodes, KJ; Childers, WE; Argentieri, TM; Wang, Q				Zhang, ZH; Rhodes, KJ; Childers, WE; Argentieri, TM; Wang, Q			"Disinactivation" of N-type inactivation of voltage-gated K channels by an erbstatin analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; TYROSINE PHOSPHORYLATION; KINASE INHIBITOR; BETA-SUBUNITS; ASSOCIATION; RECEPTOR; PEPTIDE	In some A-type voltage-gated K channels, rapid inactivation is achieved through the binding of an N-terminal domain of the pore-forming alpha-subunit or an associated beta-subunit to a cytoplasmic acceptor located at or near the channel pore using the ball-and-chain machinery (1-5). This inactivation involving the N terminus is known as N-type inactivation. Here, we describe an erbstatin (Erb) analogue as a small molecule inhibitor of the N-type inactivation in channels of Kv1.4 and Kv1.1+Kvbeta1. We show that this inhibition of inactivation (designated as "disinactivation") is potent and selective for N-type inactivation in heterologous cells (Chinese hamster ovary and Xenopus oocytes) expressing these A-type channels. In Chinese hamster ovary cells, Erb increased the inactivation time constant of Kv1.4 from 86.5 +/- 9.5 to 150 +/- 10 ms (n = 6, p < 0.01). Similarly, Erb increased the inactivation time constant of Kv1.1 + Kv beta 1 from 10 +/- 0.9 to 49.3 +/- 7 ms (n = 7, p < 0.01). The EC50 for disinactivating Kv1.1 + Kvbeta1 was 10.4 +/- 0.9 muM (n = 2-9). Erb had no effect upon another A-channel, Kv4.3, which does not utilize the ball-and-chain mechanism. The mechanism of Erb-induced disinactivation was also investigated. Neither cysteine oxidation nor tyrosine kinase inhibition was involved. The results demonstrate that Erb can be used as a base structure to identify potent, selective small molecule inhibitors of intracellular protein-protein interactions, and that these disinactivators may offer another therapeutic approach to the treatment of seizure disorders.	Wyeth Ayerst Res, Dept Womens Hlth & Bone, Collegeville, PA 19426 USA; Wyeth Ayerst Res, Dept Med Chem, Princeton, NJ 08543 USA; Wyeth Ayerst Res, Dept Neurosci, Princeton, NJ 08543 USA	Pfizer; Pfizer; Pfizer	Wang, Q (corresponding author), Wyeth Ayerst Res, Dept Womens Hlth & Bone, 500 Arcola Rd, Collegeville, PA 19426 USA.	wangq@wyeth.com						COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; Encinar JA, 2002, BIOCHEMISTRY-US, V41, P12263, DOI 10.1021/bi020188u; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; HEINEMANN S, 1994, J PHYSIOL-PARIS, V88, P173, DOI 10.1016/0928-4257(94)90003-5; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISSHIKI K, 1987, J ANTIBIOT, V40, P1207, DOI 10.7164/antibiotics.40.1207; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Murakoshi H, 1997, MOL PHARMACOL, V52, P821, DOI 10.1124/mol.52.5.821; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; PONGS O, 1992, PHYSL REV S4, V72, P69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Stephens GJ, 1996, PFLUG ARCH EUR J PHY, V431, P435, DOI 10.1007/BF02207283; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; Wang Q, 1999, ANN NY ACAD SCI, V868, P447, DOI 10.1111/j.1749-6632.1999.tb11311.x; Young K. H., 1999, Society for Neuroscience Abstracts, V25, P983; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhang ZH, 2000, PFLUG ARCH EUR J PHY, V440, P784, DOI 10.1007/s004240000360	23	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2004	279	28					29226	29230		10.1074/jbc.M403290200	http://dx.doi.org/10.1074/jbc.M403290200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834XX	15136567	hybrid			2022-12-25	WOS:000222445300050
J	Stamatiou, PB; Chan, CC; Monneret, G; Ethier, D; Rokach, J; Powell, WS				Stamatiou, PB; Chan, CC; Monneret, G; Ethier, D; Rokach, J; Powell, WS			5-oxo-6,8,11,14-eicosatetraenoic acid stimulates the release of the eosinophil survival factor granulocyte/macrophage colony-stimulating factor from monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; IN-VITRO; HUMAN-NEUTROPHILS; HUMAN GRANULOCYTES; MONONUCLEAR-CELLS; POTENT STIMULATOR; HUMAN BLOOD; MACROPHAGE; APOPTOSIS; RECEPTOR	Allergic diseases such as asthma are characterized by tissue eosinophilia induced by the combined effects of chemoattractants and cytokines. Lipid mediators are a major class of endogenous chemoattractants, among which 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is the most potent for human eosinophils. In this study, we investigated the effects of 5-oxo-ETE on eosinophil survival by flow cytometry. We found that this compound could promote eosinophil survival in the presence of small numbers of contaminating monocytes, but not in their absence. The conditioned medium from monocytes treated for 24 h with 5-oxo-ETE also strongly promoted eosinophil survival, whereas the medium from vehicle-treated monocytes had no effect. An antibody against the granulocyte/macrophage colony-stimulating factor (GM-CSF) completely blocked the response of eosinophils to the conditioned medium from 5-oxo-ETE-treated monocytes, whereas an antibody against interleukin-5 had no effect. Furthermore, 5-oxo-ETE stimulated the release of GM-CSF from cultured monocytes in amounts compatible with eosinophil survival activity, with a maximal effect being observed after 24 h. This effect was concentration-dependent and could be observed at concentrations in the picomolar range. 5-Oxo-ETE and leukotriene B-4 had similar effects on GM-CSF release at low concentrations, but 5-oxo-ETE induced a much stronger response at concentrations of 10 nM or higher. This is the first report that 5-oxo-ETE can induce the release of any cytokine, suggesting that it could be an important mediator in allergic and other inflammatory diseases due both to its chemoattractant properties and to its potent effects on the synthesis of the survival factor GM-CSF.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Merck & Company; Merck & Company; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	william.powell@mcgill.ca	Powell, William/AAE-9000-2020	Rokach, Joshu/0000-0003-1814-7505; Powell, William/0000-0002-8507-4038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 69835] Funding Source: Medline; NIDDK NIH HHS [DK 44730] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becler K, 2002, ALLERGY, V57, P1021, DOI 10.1034/j.1398-9995.2002.23620.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bowers RC, 2000, J BIOL CHEM, V275, P29931, DOI 10.1074/jbc.C000502200; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Czech W, 1997, J INVEST DERMATOL, V108, P108, DOI 10.1111/1523-1747.ep12285653; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Guilbert M, 1999, AM J RESP CELL MOL, V21, P97, DOI 10.1165/ajrcmb.21.1.3517; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hevko JM, 2002, J BIOL CHEM, V277, P7037, DOI 10.1074/jbc.M108942200; Hevko JM, 2001, J PHARMACOL EXP THER, V296, P293; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Iversen PO, 1997, AM J RESP CRIT CARE, V156, P1628, DOI 10.1164/ajrccm.156.5.9612097; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Meerschaert J, 2000, AM J RESP CELL MOL, V23, P780, DOI 10.1165/ajrcmb.23.6.4171; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; Muro S, 2003, J ALLERGY CLIN IMMUN, V112, P768, DOI 10.1016/S0091-6749(03)01888-8; O'Flaherty JT, 2000, J IMMUNOL, V164, P3345, DOI 10.4049/jimmunol.164.6.3345; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Park CS, 1998, EUR RESPIR J, V12, P872, DOI 10.1183/09031936.98.12040872; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; POULIOT M, 1994, J IMMUNOL, V152, P851; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1995, J IMMUNOL, V154, P4123; ROLAPLESZCZYNSKI M, 1992, BLOOD, V80, P1004; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; SEEDS EAM, 1995, EUR J PHARM-ENVIRON, V293, P369, DOI 10.1016/0926-6917(95)90057-8; Simon HU, 2000, ALLERGY, V55, P910, DOI 10.1034/j.1398-9995.2000.055010910.x; Sozzani S, 1996, J IMMUNOL, V157, P4664; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; Tohda Y, 1999, CLIN EXP ALLERGY, V29, P1532; Zhang Y, 1996, J LEUKOCYTE BIOL, V59, P847, DOI 10.1002/jlb.59.6.847	49	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28159	28164		10.1074/jbc.M401537200	http://dx.doi.org/10.1074/jbc.M401537200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	832KC	15136573	hybrid			2022-12-25	WOS:000222265400043
J	El Jamali, A; Freund, C; Rechner, C; Scheidereit, C; Dietz, R; Bergmann, MW				El Jamali, A; Freund, C; Rechner, C; Scheidereit, C; Dietz, R; Bergmann, MW			Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3 beta	FASEB JOURNAL			English	Article						cardiac hypertrophy; heart failure; CRE-dependent transcription	ELEMENT-BINDING PROTEIN; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; CARDIAC MYOCYTE APOPTOSIS; CAMP-RESPONSIVE ELEMENT; CYCLIC-AMP; BETA(2)-ADRENERGIC RECEPTORS; TRANSCRIPTION FACTOR; MEDIATED INDUCTION; ANGIOTENSIN-II	In vivo, left ventricular remodeling after myocardial infarction involves hypertrophy generally attributed to increased cardiac workload. We hypothesized that hypoxia/reoxygenation directly induces cardiomyocyte hypertrophy and studied several participating kinases and transcription factors in isolated cardiomyocytes. Hypoxia for 6 h followed by 42 h reoxygenation induced cardiomyocyte hypertrophy assessed by H-3 leucine incorporation and immunohistochemistry. Inhibition of reactive oxygen species (ROS), serine/threonine kinase AKT, and ERK abolished reoxygenation-induced hypertrophy. In addition, a beta2-adrenergic receptor (beta2-AR) antagonist, as well as Gi inhibitor pertussis toxin, blocked reoxygenation- induced hypertrophy. Hypoxia for 6 h increased transcription factors CREB, NF-kappaB, and GATA DNA binding activities. However, only CREB DNA-binding was sustained during reoxygenation. Inhibition of PI3-kinase, ERK, and PKA abrogated reoxygenation- induced CREB DNA-binding without affecting CREB serine-133 phosphorylation. These same pathways were found to regulate hypoxia/reoxygenation-induced GSK3beta kinase activity and CREB serine-129 de-phosphorylation. GSK3beta mutants resistant to phosphorylation blocked the stimulation of CRE-dependent transcription induced by hypoxia/reoxygenation. Transfection of cardiomyocytes with a dominant-negative mutant of CREB abrogated hypoxia/reoxygenation-induced hypertrophy. We suggest that hypoxia/reoxygenation induces cardiomyocyte hypertrophy through CREB activation. Inactivation of GSK3beta by hypoxia/reoxygenation, possibly integrating PI3-kinase and ERK pathways downstream of beta2-AR and ROS, is a prerequisite for CRE-dependent transcription. Transient hypoxia may contribute to cardiac hypertrophy in ischemic heart disease independent of cardiac workload.	HELIOS Klin, Franz Volhard Clin, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Franz-Volhard Clinical Research Center; Helios Kliniken; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bergmann, MW (corresponding author), Franz Volhard Clin, Charite Campus Buch,Wiltbergstr 50, D-13125 Berlin, Germany.	M.Bergmann@mdc-berlin.de						Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bergmann M, 2000, AM J RESP CELL MOL, V22, P582, DOI 10.1165/ajrcmb.22.5.3889; Bergmann MW, 2001, J MOL CELL CARDIOL, V33, P1223, DOI 10.1006/jmcc.2001.1385; Bleeke T, 2004, CIRC RES, V94, P37, DOI 10.1161/01.RES.0000109412.80157.7D; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Funakoshi Y, 2002, J BIOL CHEM, V277, P18710, DOI 10.1074/jbc.M110430200; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Haq S, 2003, P NATL ACAD SCI USA, V100, P4610, DOI 10.1073/pnas.0835895100; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; Matsui T, 2001, CIRCULATION, V104, P330; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; OGAWA Y, 1995, J MOL MED-JMM, V73, P457; Oishi Y, 2003, HYPERTENSION, V41, P814, DOI 10.1161/01.HYP.0000048340.53100.43; Purcell NH, 2001, P NATL ACAD SCI USA, V98, P6668, DOI 10.1073/pnas.111155798; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schafer M, 2003, FASEB J, V17, P449, DOI 10.1096/fj.02-0398fje; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tomita H, 2003, CIRC RES, V93, P12, DOI 10.1161/01.RES.0000079794.57578.F1; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xuan YT, 1999, CIRC RES, V84, P1095, DOI 10.1161/01.RES.84.9.1095; Yaoita H, 2002, CIRCULATION, V105, P975, DOI 10.1161/hc0802.104503	49	50	52	2	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1096	+		10.1096/fj.03-1054fje	http://dx.doi.org/10.1096/fj.03-1054fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155564				2022-12-25	WOS:000221883200005
J	Benarroch, D; Egloff, MP; Mulard, L; Guerreiro, C; Romette, JL; Canard, B				Benarroch, D; Egloff, MP; Mulard, L; Guerreiro, C; Romette, JL; Canard, B			A structural basis for the inhibition of the NS5 dengue virus mRNA 2 '-O-Methyltransferase domain by ribavirin 5 '-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEST NILE VIRUS; CRYSTAL-STRUCTURE; DEHYDROGENASE; MECHANISMS	Ribavirin is one of the few nucleoside analogues currently used in the clinic to treat RNA virus infections, but its mechanism of action remains poorly understood at the molecular level. Here, we show that ribavirin 5'-triphosphate inhibits the activity of the dengue virus 2'-O-methyltransferase NS5 domain (NS5MTase(DV)). Along with several other guanosine 5'-triphosphate analogues such as acyclovir, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR), and a series of ribose-modified ribavirin analogues, ribavirin 5'-triphosphate competes with GTP to bind to NS5MTaseDV. A structural view of the binding of ribavirin 5'-triphosphate to this enzyme was obtained by determining the crystal structure of a ternary complex consisting of NS5MTaseDV, ribavirin 5'-triphosphate, and S-adenosyl-L-homocysteine at a resolution of 2.6 Angstrom. These detailed atomic interactions provide the first structural insights into the inhibition of a viral enzyme by ribavirin 5'-triphosphate, as well as the basis for rational drug design of antiviral agents with improved specificity against the emerging flaviviruses.	CNRS, F-13288 Marseille 9, France; Univ Aix Marseille 1, UMR 6098, Ecole Super Ingenieurs Luminy, F-13288 Marseille 9, France; Univ Aix Marseille 2, UMR 6098, Ecole Super Ingenieurs Luminy, F-13288 Marseille 9, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Canard, B (corresponding author), CNRS, Case 925,163 Ave Luminy, F-13288 Marseille 9, France.	bruno@afmb.cnrs-mrs.fr	Benarroch-Popivker, Delphine/T-1990-2019; Benarroch, Delphine/E-9983-2017	Canard, Bruno/0000-0003-4924-1991				Anderson JF, 1999, SCIENCE, V286, P2331, DOI 10.1126/science.286.5448.2331; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALZARINI J, 1993, J BIOL CHEM, V268, P24591; Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Gallois-Montbrun S, 2003, MOL PHARMACOL, V63, P538, DOI 10.1124/mol.63.3.538; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; Hong Zhi, 2002, Prog Drug Res, V59, P41; Jordan I, 2000, J INFECT DIS, V182, P1214, DOI 10.1086/315847; KOFF WC, 1982, ANTIVIR RES, V2, P69, DOI 10.1016/0166-3542(82)90027-4; KORNBERG A, 1992, DNA REPLICATION, P54; Leyssen P, 2001, VIROLOGY, V279, P27, DOI 10.1006/viro.2000.0723; Matsuo H, 2000, J AM CHEM SOC, V122, P2417, DOI 10.1021/ja9926820; Neyts J, 1996, ANTIVIR RES, V30, P125, DOI 10.1016/0166-3542(96)89697-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTERSON JL, 1990, REV INFECT DIS, V12, P1139; Prosise GL, 2002, J BIOL CHEM, V277, P50654, DOI 10.1074/jbc.M208330200; ROUSSEL A, 1991, SILICON GRAPHICS DIR, P97; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; Young KC, 2003, HEPATOLOGY, V38, P869, DOI 10.1053/jhep.2003.50445	25	126	136	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35638	35643		10.1074/jbc.M400460200	http://dx.doi.org/10.1074/jbc.M400460200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15152003	hybrid			2022-12-25	WOS:000223303400060
J	Solovyov, A; Xiao, RY; Gilbert, HF				Solovyov, A; Xiao, RY; Gilbert, HF			Sulfhydryl oxidation, not disulfide isomerization, is the principal function of protein disulfide isomerase in yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BOND FORMATION; DOMAINS	Protein disulfide isomerase (PDI) is an essential protein folding assistant of the eukaryotic endoplasmic reticulum that catalyzes both the formation of disulfides during protein folding ( oxidase activity) and the isomerization of disulfides that may form incorrectly ( isomerase activity). Catalysis of thiol-disulfide exchange by PDI is required for cell viability in Saccharomyces cerevisiae, but there has been some uncertainty as to whether the essential role of PDI in the cell is oxidase or isomerase. We have studied the ability of PDI constructs with high oxidase activity and very low isomerase activity to complement the chromosomal deletion of PDI1 in S. cerevisiae. A single catalytic domain of yeast PDI (PDIa') has 50% of the oxidase activity but only 5% of the isomerase activity of wild-type PDI in vitro. Titrating the expression of PDI using the inducible/repressible GAL1-10 promoter shows that the amount of wild-type PDI protein needed to sustain a normal growth rate is 60% or more of the amount normally expressed from the PDI1 chromosomal location. A single catalytic domain (PDIa') is needed in molar amounts that are approximately twice as high as those required for wild-type PDI, which contains two catalytic domains. This comparison suggests that high (> 60%) PDI oxidase activity is critical to yeast growth and viability, whereas less than 6% of its isomerase activity is needed.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Baylor College of Medicine; Karolinska Institutet	Gilbert, HF (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, 1 Baylor Plaza, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu			NIGMS NIH HHS [GM 40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Guthrie C, 1991, GUIDE YEAST GENETICS; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; Jung GM, 1999, J BIOCHEM-TOKYO, V126, P1; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; SIKORSKI RS, 1989, GENETICS, V122, P19; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200; Zhan XM, 1999, BIOTECHNOL PROGR, V15, P1033, DOI 10.1021/bp990083r	19	28	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34095	34100		10.1074/jbc.M405640200	http://dx.doi.org/10.1074/jbc.M405640200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15175335	hybrid			2022-12-25	WOS:000223134800005
J	Ichida, F; Nishimura, R; Hata, K; Matsubara, T; Ikeda, F; Hisada, K; Yatani, H; Cao, X; Komori, T; Yamaguchi, A; Yoneda, T				Ichida, F; Nishimura, R; Hata, K; Matsubara, T; Ikeda, F; Hisada, K; Yatani, H; Cao, X; Komori, T; Yamaguchi, A; Yoneda, T			Reciprocal roles of Msx2 in regulation of osteoblast and adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RECEPTOR-GAMMA; BONE-FORMATION; HOMEOBOX GENE; CELLS; MICE; PROTEIN; BINDING; MARROW; CBFA1	Mice deficient in the Msx2 gene manifest defects in skull ossification and a marked reduction in bone formation associated with decreases in osteoblast numbers, thus suggesting that Msx2 is involved in bone formation. However, the precise role of Msx2 during osteoblast differentiation is not fully understood. In the present study, we investigated the role of Msx2 in the regulation of osteoblast differentiation in the multipotent mesenchymal cell lines C3H10T1/2 and C2C12 and in murine primary osteoblasts. Introduction of Msx2 induced alkaline phosphatase activity in C3H10T1/2 and C2C12 cells and promoted the calcification of murine primary osteoblasts. This effect of Msx2 was also observed in mesenchymal cells isolated from Runx2-deficient mice. Interestingly the expression of Msx2 was induced by bone morphogenetic protein 2 treatment in Runx2-deficient mesenchymal cells. In contrast, Msx2 diminished peroxisome proliferator-activated receptor gamma (PPARgamma) expression and adipogenesis of the preadipocytic cell line 3T3-F442A. Moreover Msx2 inhibited the transcriptional activity of PPARgamma, CCAAT/enhancer-binding protein beta (C/EBPbeta), and C/EBPdelta and blocked adipocyte differentiation of mesenchymal cells induced by overexpression of PPARgamma, C/EBPalpha, C/EBPbeta, or C/EBPdelta. These data indicate that Msx2 promotes osteoblast differentiation independently of Runx2 and negatively regulates adipocyte differentiation through inhibition of PPARgamma and the C/EBP family.	Osaka Univ, Grad Sch Dent, Dept Biochem, Osaka 5650871, Japan; Univ Alabama, Sch Med, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Osaka Univ, Sch Med, Dept Mol Med, Osaka 5650871, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Oral Pathol & Bone Metab, Nagasaki 8528588, Japan	Osaka University; University of Alabama System; University of Alabama Birmingham; Osaka University; Nagasaki University	Nishimura, R (corresponding author), Osaka Univ, Grad Sch Dent, Dept Biochem, 1-8 Yamadaoka, Osaka 5650871, Japan.	rikonisi@dent.osaka-u.ac.jp	Matsubara, Takuma/B-5031-2019; Ikeda, Fumiyo/AAD-3770-2020	Matsubara, Takuma/0000-0002-8505-0431; Ikeda, Fumiyo/0000-0003-0407-2768; Nishimura, Riko/0000-0001-7279-8363				AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756-3282(87)90015-9; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756-3282(03)00054-1; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MEUNIER P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086-197110000-00021; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORIKAWA M, 1986, J CELL PHYSIOL, V128, P293, DOI 10.1002/jcp.1041280222; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756-3282(02)00826-8; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224; Winograd J, 1997, HUM MOL GENET, V6, P369, DOI 10.1093/hmg/6.3.369; Wuyts W, 2000, HUM MOL GENET, V9, P1251, DOI 10.1093/hmg/9.8.1251; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200	33	157	161	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34015	34022		10.1074/jbc.M403621200	http://dx.doi.org/10.1074/jbc.M403621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175325	hybrid			2022-12-25	WOS:000223039700113
J	Kim, HS; Kang, TS; Hyun, JS; Kang, HS				Kim, HS; Kang, TS; Hyun, JS; Kang, HS			Regulation of penicillin G acylase gene expression in Escherichia coli by repressor PaaX and the cAMP-cAMP receptor protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; PAC GENE; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; PHENYLACETIC ACID; AMIDASE; ACTIVATION; PROMOTER; IDENTIFICATION; MATURATION	The pga gene of Escherichia coli W ATCC11105 encodes a penicillin G acylase whose expression is regulated at both the transcriptional and post-transcriptional level. In this work we have shown that PaaX is the repressor of pga expression, and we have identified its binding consensus as TGATTC(N-27)GAATCA. We conclude that the process of "PAA induction" actually involves relief of pga from repression by PaaX. Other features of the pga promoter have also been characterized. (i) It has a native class III cAMP-receptor protein (CRP)-dependent promoter with two CRP-binding sites. (ii) The downstream CRP-binding site II has higher affinity. (iii) Binding of cAMP-CRP to both sites (I + II) is required for maximal expression. We have also shown that the PaaX-binding site overlaps with the CRP-binding site I. This implies that PaaX and the cAMP-CRP compete for binding to the region around the CRP-binding site I and therefore have antagonistic effects on pga expression.	Seoul Natl Univ, Dept Microbiol, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Kang, HS (corresponding author), Seoul Natl Univ, Dept Microbiol, Sch Biol Sci, San 56-1,Shillim Dong, Seoul 151742, South Korea.	khslab@snu.ac.kr	kang, taesun/AAJ-2957-2020; kang, tae sun/K-2099-2015	kang, taesun/0000-0001-5939-6247; kang, tae sun/0000-0001-5939-6247				BARBERO JL, 1986, GENE, V49, P69, DOI 10.1016/0378-1119(86)90386-0; Beatty CM, 2003, J BACTERIOL, V185, P5148, DOI 10.1128/JB.185.17.5148-5157.2003; BOMSTEIN J, 1965, ANAL CHEM, V37, P576, DOI 10.1021/ac60223a034; Browning DF, 2004, MOL MICROBIOL, V51, P241, DOI 10.1046/j.1365-2958.2003.03824.x; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; Chou CF, 1999, BIOTECHNOL PROGR, V15, P439, DOI 10.1021/bp990036z; Dai MH, 2001, EUR J BIOCHEM, V268, P1298, DOI 10.1046/j.1432-1327.2001.01994.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Ferrandez A, 2000, J BIOL CHEM, V275, P12214, DOI 10.1074/jbc.275.16.12214; Ferrandez A, 1998, J BIOL CHEM, V273, P25974, DOI 10.1074/jbc.273.40.25974; GANG DM, 1976, BIOCHIM BIOPHYS ACTA, V425, P110, DOI 10.1016/0005-2787(76)90220-3; Gust B, 2003, P NATL ACAD SCI USA, V100, P1541, DOI 10.1073/pnas.0337542100; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Ignatova Z, 2002, BIOCHEM BIOPH RES CO, V291, P146, DOI 10.1006/bbrc.2002.6420; Jiang L, 1997, GENET ANAL-BIOMOL E, V14, P51, DOI 10.1016/S1050-3862(97)00011-9; Jiang Q. L, 1992, CHIN J BIOTECHNOL, V8, P213; Kasche V, 1999, BBA-PROTEIN STRUCT M, V1433, P76, DOI 10.1016/S0167-4838(99)00155-7; Kim H. G., 1995, THESIS SEOUL NATL U; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee H, 2000, BIOCHEM BIOPH RES CO, V272, P199, DOI 10.1006/bbrc.2000.2729; Lin WJ, 2001, BIOTECHNOL BIOENG, V73, P484, DOI 10.1002/bit.1083; Ljubijankic G, 1992, DNA Seq, V3, P195, DOI 10.3109/10425179209034017; Luengo JM, 2001, MOL MICROBIOL, V39, P1434, DOI 10.1046/j.1365-2958.2001.02344.x; MAHMOOD ZA, 1991, FOLIA MICROBIOL, V36, P444, DOI 10.1007/BF02884063; MARTIN L, 1995, FEMS MICROBIOL LETT, V125, P287, DOI 10.1016/0378-1097(94)00510-X; MAYER H, 1979, PLASMIDS MED ENV COM, P459; MERINO E, 1992, MOL MICROBIOL, V6, P2175, DOI 10.1111/j.1365-2958.1992.tb01391.x; MEYER TL, 1992, FEBS LETT, V307, P62; OH SJ, 1987, GENE, V56, P87; OHASHI H, 1988, APPL ENVIRON MICROB, V54, P2603, DOI 10.1128/AEM.54.11.2603-2607.1988; Oinonen C, 2000, PROTEIN SCI, V9, P2329, DOI 10.1110/ps.9.12.2329; Pan KL, 2003, J BACTERIOL, V185, P3020, DOI 10.1128/JB.185.10.3020-3030.2003; Radoja S, 1999, GENET ANAL-BIOMOL E, V15, P235, DOI 10.1016/S1050-3862(99)00030-3; Roa A, 1997, FEMS MICROBIOL LETT, V151, P9, DOI 10.1016/S0378-1097(97)00117-1; Roa A, 1999, FEMS MICROBIOL LETT, V177, P7, DOI 10.1016/S0378-1097(99)00281-5; Sambrook J, 2001, MOL CLONING LAB MANU; SCHERRER S, 1994, APPL MICROBIOL BIOT, V42, P85; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Stojcevic N, 2001, BIOMOL ENG, V17, P113, DOI 10.1016/S1389-0344(00)00074-5; SUDHAKARAN VK, 1992, PROCESS BIOCHEM, V27, P131, DOI 10.1016/0032-9592(92)87001-W; SZENTIRMAI A, 1964, APPL MICROBIOL, V12, P185, DOI 10.1128/AEM.12.3.185-187.1964; VALLE F, 1986, GENE, V50, P119, DOI 10.1016/0378-1119(86)90316-1; VALLE F, 1991, TRENDS BIOCHEM SCI, V16, P36, DOI 10.1016/0968-0004(91)90014-M; Verhaert RMD, 1997, APPL ENVIRON MICROB, V63, P3412, DOI 10.1128/AEM.63.9.3412-3418.1997; Virden R, 1990, BIOTECHNOL GENET, V8, P189, DOI [10.1080/02648725.1990.10647869, DOI 10.1080/02648725.1990.10647869]; VOJTISEK V, 1975, FOLIA MICROBIOL, V20, P298, DOI 10.1007/BF02878111; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Yang YG, 2000, ACTA BIOCH BIOPH SIN, V32, P163	52	14	16	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33253	33262		10.1074/jbc.M404348200	http://dx.doi.org/10.1074/jbc.M404348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15159386	hybrid			2022-12-25	WOS:000223039700031
J	Spagnolo, L; Toro, I; D'Orazio, M; O'Neill, P; Pedersen, JZ; Oliviero, CG; Rotilio, G; Battistoni, A; Djinovic-Carugo, K				Spagnolo, L; Toro, I; D'Orazio, M; O'Neill, P; Pedersen, JZ; Oliviero, CG; Rotilio, G; Battistoni, A; Djinovic-Carugo, K			Unique features of the sodC-encoded superoxide dismutase from Mycobacterium tuberculosis, a fully functional copper-containing enzyme lacking zinc in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ERYTHROCUPREIN; BINDING SITE; PH; MECHANISM; REFINEMENT; DISTANCE; PROGRAM; ION	The sodC-encoded Mycobacterium tuberculosis superoxide dismutase ( SOD) shows high sequence homology to other members of the copper/zinc-containing SOD family. Its three-dimensional structure is reported here, solved by x-ray crystallography at 1.63-Angstrom resolution. Metal analyses of the recombinant protein indicate that the native form of the enzyme lacks the zinc ion, which has a very important structural and functional role in all other known enzymes of this class. The absence of zinc within the active site is due to significant rearrangements in the zinc subloop, including deletion or mutation of the metal ligands His(115) and His(123). Nonetheless, the enzyme has a catalytic rate close to the diffusion limit; and unlike all other copper/zinc-containing SODs devoid of zinc, the geometry of the copper site is pH-independent. The protein shows a novel dimer interface characterized by a long and rigid loop, which confers structural stability to the enzyme. As the survival of bacterial pathogens within their host critically depends on their ability to recruit zinc in highly competitive environments, we propose that the observed structural rearrangements are required to build up a zinc-independent but fully active and stable copper-containing SOD.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Nazl Fis Mat, I-00133 Rome, Italy; Sincrotrone Trieste, ELETTRA, Struct Biol Lab, I-34012 Trieste, Italy; Ist Nazl Fis Mat, Natl Lab Technol Avanzate & Nanosci, I-34012 Trieste, Italy; MRC, Radiat & Genome Unit, Didcot OX11 0RD, Oxon, England; Univ Pavia, Dept Gen Chem, I-27100 Pavia, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Elettra Sincrotrone Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; MRC Harwell; University of Pavia	Battistoni, A (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	andrea.battistoni@uniroma2.it; kristina.djinovic@elettra.trieste.it	Battistoni, Andrea/A-4778-2016; Spagnolo, Laura/A-4600-2011; Djinovic-Carugo, Kristina/AAW-1167-2021	Battistoni, Andrea/0000-0003-4085-7917; Spagnolo, Laura/0000-0002-0794-566X; Djinovic-Carugo, Kristina/0000-0003-0252-2972				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Battistoni A, 2003, BIOCHEM SOC T, V31, P1326; Battistoni A, 2001, J BIOL CHEM, V276, P30315, DOI 10.1074/jbc.M010527200; Blencowe DK, 2003, FEMS MICROBIOL REV, V27, P291, DOI 10.1016/S0168-6445(03)00041-X; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; BORDO D, 2001, HDB METALLOPROTEINS, P1284; Carugo O, 2002, J MOL BIOL, V315, P887, DOI 10.1006/jmbi.2001.5250; Carugo O, 2001, PROTEIN SCI, V10, P1470, DOI 10.1110/ps.690101; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COOPER JB, 1995, J MOL BIOL, V246, P531, DOI 10.1006/jmbi.1994.0105; Crow JP, 1997, J NEUROCHEM, V69, P1945; CUDD A, 1982, J BIOL CHEM, V257, P1443; D'Orazio M, 2001, BIOCHEM J, V359, P17, DOI 10.1042/0264-6021:3590017; DeLano W, 2002, PYMOL 0 99; DJINOVIC K, 1992, J MOL BIOL, V226, P227, DOI 10.1016/0022-2836(92)90135-7; Edwards KM, 2001, AM J RESP CRIT CARE, V164, P2213, DOI 10.1164/ajrccm.164.12.2106093; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; FIELDEN EM, 1974, BIOCHEM J, V139, P49, DOI 10.1042/bj1390049; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Grishin NV, 1997, J MOL EVOL, V45, P359, DOI 10.1007/PL00006241; Hough MA, 2003, STRUCTURE, V11, P937, DOI 10.1016/S0969-2126(03)00155-2; JOHNSON MS, 1990, J MOL EVOL, V30, P43, DOI 10.1007/BF02102452; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; MCADAM ME, 1977, BIOCHEM J, V167, P271, DOI 10.1042/bj1670271; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; ONEILL P, 1988, BIOCHEM J, V251, P41, DOI 10.1042/bj2510041; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P1717, DOI 10.1021/ja00370a045; PANTOLIANO MW, 1982, J INORG BIOCHEM, V17, P325, DOI 10.1016/S0162-0134(00)80093-8; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P6310, DOI 10.1021/ja00387a027; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pesce A, 2000, J MOL BIOL, V302, P465, DOI 10.1006/jmbi.2000.4074; Piddington DL, 2001, INFECT IMMUN, V69, P4980, DOI 10.1128/IAI.69.8.4980-4987.2001; Polticelli F, 1998, PROTEIN SCI, V7, P2354, DOI 10.1002/pro.5560071112; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; Sasin JM, 2003, BIOINFORMATICS, V19, pi252, DOI 10.1093/bioinformatics/btg1035; Shi LB, 2003, P NATL ACAD SCI USA, V100, P241, DOI 10.1073/pnas.0136863100; Stroppolo ME, 1998, BIOCHEMISTRY-US, V37, P12287, DOI 10.1021/bi980563b; Stroppolo ME, 1998, BIOCHEM BIOPH RES CO, V249, P579, DOI 10.1006/bbrc.1998.9199; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VALENTINE JS, 1979, P NATL ACAD SCI USA, V76, P4245, DOI 10.1073/pnas.76.9.4245; Zahrt TC, 2003, MICROBES INFECT, V5, P159, DOI 10.1016/S1286-4579(02)00083-7	59	71	73	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33447	33455		10.1074/jbc.M404699200	http://dx.doi.org/10.1074/jbc.M404699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15155722	hybrid			2022-12-25	WOS:000223039700053
J	Boudsocq, F; Kokoska, RJ; Plosky, BS; Vaisman, A; Ling, H; Kunkel, TA; Yang, W; Woodgate, R				Boudsocq, F; Kokoska, RJ; Plosky, BS; Vaisman, A; Ling, H; Kunkel, TA; Yang, W; Woodgate, R			Investigating the role of the little finger domain of Y-family DNA polymerases in low fidelity synthesis and translesion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SOLFATARICUS P2; SYN THYMINE DIMER; LESION-BYPASS; ERROR-PRONE; CRYSTAL-STRUCTURE; XERODERMA-PIGMENTOSUM; ADAPTIVE MUTATION; ESCHERICHIA-COLI; GENE ENCODES; ETA	Dpo4 and Dbh are Y-family polymerases that originate from two closely related strains of Sulfolobaceae. Quite surprisingly, however, the two polymerases exhibit different enzymatic properties in vitro. For example, Dpo4 can replicate past a variety of DNA lesions, yet Dbh does so with a much lower efficiency. When replicating undamaged DNA, Dpo4 is prone to make base pair substitutions, whereas Dbh predominantly makes single-base deletions. Overall, the two proteins are 54% identical, but the greatest divergence is found in their respective little finger (LF) domains, which are only 41% identical. To investigate the role of the LF domain in the fidelity and lesion-bypassing abilities of Y-family polymerases, we have generated chimeras of Dpo4 and Dbh in which their LF domains have been interchanged. Interestingly, by replacing the LF domain of Dbh with that of Dpo4, the enzymatic properties of the chimeric enzyme are more Dpo4-like in that the enzyme is more processive, can bypass an abasic site and a thymine-thymine cyclobutane pyrimidine dimer, and predominantly makes base pair substitutions when replicating undamaged DNA. The converse is true for the Dpo4-LF-Dbh chimera, which is more Dbh-like in its processivity and ability to bypass DNA adducts and generate single-base deletion errors. Our studies indicate that the unique but variable LF domain of Y-family polymerases plays a major role in determining the enzymatic and biological properties of each individual Y-family member.	NICHD, Sect DNA Replicat Repair & Mutagenesis, Lab Genom Integr, NIH, Bethesda, MD 20892 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Woodgate, R (corresponding author), NICHD, Sect DNA Replicat Repair & Mutagenesis, Lab Genom Integr, NIH, Bethesda, MD 20892 USA.	woodgate@nih.gov	Yang, Wei/ABB-4785-2020; Vaisman, Alexandra/C-3766-2013; Ling, Hong/E-3729-2010; Yang, Wei/D-4926-2011; Kunkel, Thomas A./D-5088-2019	Yang, Wei/0000-0002-3591-2195; Vaisman, Alexandra/0000-0002-2521-1467; Yang, Wei/0000-0002-3591-2195; Kunkel, Thomas A./0000-0002-9900-1788; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036119, Z01DK036119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gruz P, 2001, J BIOL CHEM, V276, P47394, DOI 10.1074/jbc.M107213200; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McCulloch SD, 2004, NATURE, V428, P97, DOI 10.1038/nature02352; McDonald JP, 1998, P NATL ACAD SCI USA, V95, P1478, DOI 10.1073/pnas.95.4.1478; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohashi E, 2000, GENE DEV, V14, P1589; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Potapova O, 2002, J BIOL CHEM, V277, P28157, DOI 10.1074/jbc.M202607200; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tompkins JD, 2003, J BACTERIOL, V185, P3469, DOI 10.1128/JB.185.11.3469-3472.2003; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Yeiser B, 2002, P NATL ACAD SCI USA, V99, P8737, DOI 10.1073/pnas.092269199; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	35	109	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32932	32940		10.1074/jbc.M405249200	http://dx.doi.org/10.1074/jbc.M405249200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155753	hybrid			2022-12-25	WOS:000222849700113
J	Doeven, MK; Abele, R; Tampe, R; Poolman, B				Doeven, MK; Abele, R; Tampe, R; Poolman, B			The binding specificity of OppA determines the selectivity of the oligopeptide ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; ABC TRANSPORTERS; SYSTEM; PROTEIN; MECHANISM; PEPTIDES; RECONSTITUTION; SEQUENCE; RECEPTOR	The purification and functional reconstitution of a five-component oligopeptide ATP-binding cassette transporter with a remarkably wide substrate specificity are described. High-affinity peptide uptake was dependent on liganded substrate-binding protein OppA, which interacts with the translocator OppBCDF with higher affinity than unliganded OppA. Transport screening with combinatorial peptide libraries revealed that (i) the Opp transporter is not selective with respect to amino acid side chains of the transported peptides; (ii) any peptide that can bind to OppA is transported via Opp, including very long peptides up to 35 residues long; and (iii) the binding specificity of OppA largely determines the overall transport selectivity.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Goethe Univ Frankfurt, Inst Biochem, Bioctr, D-60439 Frankfurt, Germany	University of Groningen; Goethe University Frankfurt	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@chem.rug.nl	Tampé, Robert/H-2953-2015; Poolman, Bert/D-1882-2012	Tampé, Robert/0000-0002-0403-2160; 				Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Charbonnel P, 2003, J BIOL CHEM, V278, P14832, DOI 10.1074/jbc.M212454200; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; DEAN DA, 1992, MOL MICROBIOL, V6, P2033, DOI 10.1111/j.1365-2958.1992.tb01376.x; Detmers FJM, 2000, P NATL ACAD SCI USA, V97, P12487, DOI 10.1073/pnas.220308797; Detmers FJM, 1998, BIOCHEMISTRY-US, V37, P16671, DOI 10.1021/bi981712t; Detmers FJM, 2001, RES MICROBIOL, V152, P245, DOI 10.1016/S0923-2508(01)01196-2; Helinck S, 2003, J APPL MICROBIOL, V94, P900, DOI 10.1046/j.1365-2672.2003.01922.x; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Kunji ERS, 2003, BBA-BIOMEMBRANES, V1610, P97, DOI 10.1016/S0005-2736(02)00712-5; Kunji ERS, 1996, MOL MICROBIOL, V21, P123, DOI 10.1046/j.1365-2958.1996.6231339.x; Lanfermeijer FC, 2000, EMBO J, V19, P3649, DOI 10.1093/emboj/19.14.3649; Lanfermeijer FC, 1999, BIOCHEMISTRY-US, V38, P14440, DOI 10.1021/bi9914715; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOWRY OH, 1951, J BIOL CHEM, V193, P275; MERINO G, 1995, J THEOR BIOL, V177, P171, DOI 10.1006/jtbi.1995.0236; Patzlaff JS, 2003, J BIOL CHEM, V278, P29546, DOI 10.1074/jbc.M304796200; Picon A, 2000, J BACTERIOL, V182, P1600, DOI 10.1128/JB.182.6.1600-1608.2000; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; van der Heide T, 2002, EMBO REP, V3, P938, DOI 10.1093/embo-reports/kvf201; van Montfort BA, 2002, BBA-BIOENERGETICS, V1555, P111, DOI 10.1016/S0005-2728(02)00264-5	27	63	63	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32301	32307		10.1074/jbc.M404343200	http://dx.doi.org/10.1074/jbc.M404343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169767	Green Published, hybrid			2022-12-25	WOS:000222849700040
J	Hsu, JM; Lee, YCG; Yu, CTR; Huang, CYF				Hsu, JM; Lee, YCG; Yu, CTR; Huang, CYF			Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; CELL-CYCLE; F-BOX; MULTISITE PHOSPHORYLATION; HIF-ALPHA; IDENTIFICATION; KINASE; FAMILY; DEGRADATION; EXPRESSION	F-box proteins, components of SCF ubiquitin-ligase complexes, are believed to be responsible for substrate recognition and recruitment in SCF-mediated proteolysis. F-box proteins that have been identified to function in the SCF complexes to date mostly have substrate-binding motifs, such as WD repeats or leucine-rich repeats in their C termini. However, many F-box proteins lack recognizable substrate-binding modules; whether they can function in the SCF complexes remains unclear. We show here that Fbx7, an F-box protein without WD repeats and leucine-rich repeats, is required for the proteasome-mediated proteolysis of the hepatoma upregulated protein (HURP). Depletion of Fbx7 by small interfering RNA leads to depression of HURP ubiquitination and accumulation of HURP abundance. In the SCFFbx7 complex, Fbx7 recruits HURP through its C-terminal proline-rich region in a Cdk1-cyclin B-phosphorylation dependent manner. Mutation of the multiple Cdk1-cyclin B phosphorylation sites on HURP or the proline-rich region of Fbx7 abolishes the association between Fbx7 and HURP. Thus, Fbx7 is a functional adaptor of the SCF complex with a proline-rich region as the substrate-binding module. In addition to Fbx7, data base analyses reveal two putative mammalian proline-rich region-containing F-box proteins, KIAA1783 and RIKEN cDNA 2410015K21. Taken together, these findings further expound the diverse substrate-recognition abilities of the SCF complexes.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Taipei Med Univ, Grad Inst Med Informat, Taipei 110, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Natl Taiwan Univ, Dept Comp Sci & Informat Engn, Taipei 106, Taiwan	National Health Research Institutes - Taiwan; Taipei Medical University; National Yang Ming Chiao Tung University; National Taiwan University	Huang, CYF (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	chiying@nhri.org.tw	Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chiu AW, 2002, UROLOGY, V60, P181, DOI 10.1016/S0090-4295(02)01672-2; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Deng MQ, 2000, BIOL REPROD, V62, P873, DOI 10.1095/biolreprod62.4.873; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; Ferrell JE, 2001, NATURE, V414, P498, DOI 10.1038/35107180; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang YL, 2003, ANTICANCER RES, V23, P2729; Ilyin GP, 2000, GENOMICS, V67, P40, DOI 10.1006/geno.2000.6211; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ke PY, 2003, BIOCHEM J, V370, P265, DOI 10.1042/BJ20021335; Kim J, 2002, J BIOL CHEM, V277, P24530, DOI 10.1074/jbc.M201612200; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Malecz N, 1996, J BIOL CHEM, V271, P8203, DOI 10.1074/jbc.271.14.8203; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Thom G, 2003, BIOCHEM J, V370, P91, DOI 10.1042/BJ20021462; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Tsou AP, 2003, ONCOGENE, V22, P298, DOI 10.1038/sj.onc.1206129; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yoshida Y, 2003, J BIOL CHEM, V278, P43877, DOI 10.1074/jbc.M304157200; ZARRINPAR A, 2003, SCI STKE; Zhao J, 2000, J CELL SCI, V113, P4363; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	47	88	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32592	32602		10.1074/jbc.M404950200	http://dx.doi.org/10.1074/jbc.M404950200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15145941	hybrid			2022-12-25	WOS:000222849700076
J	Inacio, A; Silva, AL; Pinto, J; Ji, XJ; Morgado, A; Almeida, F; Faustino, P; Lavinha, J; Liebhaber, SA; Romao, L				Inacio, A; Silva, AL; Pinto, J; Ji, XJ; Morgado, A; Almeida, F; Faustino, P; Lavinha, J; Liebhaber, SA; Romao, L			Nonsense mutations in close proximity to the initiation codon fail to trigger full nonsense-mediated mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; PREMATURE TERMINATION CODONS; PROTEIN ALPHA-CP; SPLICE-SITE; TRANSLATION; EXON; SURVEILLANCE; PHOSPHORYLATION; POSITION; CELLS	Nonsense-mediated mRNA decay (NMD) is a surveillance mechanism that degrades mRNAs containing premature translation termination codons. In mammalian cells, a termination codon is ordinarily recognized as "premature" if it is located greater than 50-54 nucleotides 5' to the final exon-exon junction. We have described a set of naturally occurring human beta-globin gene mutations that apparently contradict this rule. The corresponding beta-thalassemia genes contain nonsense mutations within exon 1, and yet their encoded mRNAs accumulate to levels approaching wild-type beta-globin (beta(WT)) mRNA. In the present report we demonstrate that the stabilities of these mRNAs with nonsense mutations in exon 1 are intermediate between beta(WT) mRNA and beta-globin mRNA carrying a prototype NMD-sensitive mutation in exon 2 (codon 39 nonsense; beta39). Functional analyses of these mRNAs with 5'-proximal nonsense mutations demonstrate that their relative resistance to NMD does not reflect abnormal RNA splicing or translation re-initiation and is independent of promoter identity and erythroid specificity. Instead, the proximity of the nonsense codon to the translation initiation AUG constitutes a major determinant of NMD. Positioning a termination mutation at the 5' terminus of the coding region blunts mRNA destabilization, and this effect is dominant to the "50-54 nt boundary rule." These observations impact on current models of NMD.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Instituto Nacional de Saude Dr. Ricardo Jorge; University of Pennsylvania; University of Pennsylvania	Romao, L (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Av Padre Cruz, P-1649016 Lisbon, Portugal.	luisa.romao@insa.min-saude.pt	Faustino, Paula/E-4546-2010; Romão, Luísa/A-2289-2016	Faustino, Paula/0000-0002-6269-4867; Romão, Luísa/0000-0002-5061-5287; Inacio, Angela/0000-0003-0396-6743; Silva, Ana Luisa/0000-0002-4839-8279; Lavinha, Joao/0000-0002-7474-6871; Morgado, Ana/0000-0002-8909-3615	NHLBI NIH HHS [R01-HL 65449] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065449] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asselta R, 2001, BLOOD, V98, P3685, DOI 10.1182/blood.V98.13.3685; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Buzina A, 1999, MOL BIOL CELL, V10, P515, DOI 10.1091/mbc.10.3.515; Couttet P, 2004, NUCLEIC ACIDS RES, V32, P488, DOI 10.1093/nar/gkh218; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; Denecke J, 2004, HUM MUTAT, V23, P477, DOI 10.1002/humu.20026; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; HALL GW, 1994, BLOOD, V83, P2031; He F, 1997, MOL CELL BIOL, V17, P1580, DOI 10.1128/MCB.17.3.1580; HINNEBUSCH AG, 1993, MOL MICROBIOL, V10, P215, DOI 10.1111/j.1365-2958.1993.tb01947.x; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Janzen DM, 2002, MOL CELL BIOL, V22, P8562, DOI 10.1128/MCB.22.24.8562-8570.2002; Ji XJ, 2003, MOL CELL BIOL, V23, P899, DOI 10.1128/MCB.23.3.899-907.2003; Kataoka N, 2004, J BIOL CHEM, V279, P7009, DOI 10.1074/jbc.M307692200; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Kong J, 2003, MOL CELL BIOL, V23, P1125, DOI 10.1128/MCB.23.4.1125-1134.2003; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Liebhaber SA, 1996, MOL CELL BIOL, V16, P2637; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; MAQUAT LE, 1995, RNA, V1, P453; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; ORKIN SH, 1984, BLOOD, V64, P311; ORKIN SH, 1982, NATURE, V300, P768, DOI 10.1038/300768a0; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Romao L, 2000, BLOOD, V96, P2895; Schell T, 2003, BIOCHEM J, V373, P775, DOI 10.1042/BJ20021920; Serin G, 2001, MOL CELL BIOL, V21, P209, DOI 10.1128/MCB.21.1.209-223.2001; Stevens A, 2002, P NATL ACAD SCI USA, V99, P12741, DOI 10.1073/pnas.192442399; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; THEIN SL, 1990, P NATL ACAD SCI USA, V87, P3924, DOI 10.1073/pnas.87.10.3924; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Wagner E, 2002, J CELL SCI, V115, P3033; Wang J, 2002, EMBO REP, V3, P274, DOI 10.1093/embo-reports/kvf036; YANG KG, 1989, BRIT J HAEMATOL, V72, P73, DOI 10.1111/j.1365-2141.1989.tb07655.x; Yu X, 2001, J BIOL CHEM, V276, P33821, DOI 10.1074/jbc.M103772200; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	56	95	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32170	32180		10.1074/jbc.M405024200	http://dx.doi.org/10.1074/jbc.M405024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15161914	hybrid			2022-12-25	WOS:000222849700023
J	Mishra, SK; Talukder, AH; Guraraj, AE; Yang, ZB; Singh, RR; Mahoney, MG; Franci, C; Vadlamudi, RK; Kumar, R				Mishra, SK; Talukder, AH; Guraraj, AE; Yang, ZB; Singh, RR; Mahoney, MG; Franci, C; Vadlamudi, RK; Kumar, R			Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN EXPRESSION; MTA1 MESSENGER-RNA; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; PROTEIN; COMPLEX; CANCER; SNAIL; ROLES; OVEREXPRESSION	Although recent studies have shown a role of estrogen receptor-alpha (ER) in the regulation of epithelial-to-mesenchymal transition via MTA3, the role of upstream determinants of ER regulation of MTA3 and the underlying molecular mechanism remains unknown. Here we show that MTA3 gene regulation by ER is influenced by dynamic changes in levels of nuclear coregulators. MTA3 promoter has a functional ER element half-site with which MTA1 and HDACs interact under basal conditions. Upon estrogen stimulation, these corepressors are derecruited with concomitant recruitment of ER, leading to increased MTA3 transcription and expression. Genetic inactivation of MTA1 pathway promotes the ability of ER to up-regulate MTA3 expression, whereas knockdown of ER enhances MTA1 association with MTA3 gene. Modulation of ER functions, by corepressors (i.e. MTA1 and MTA1s) or coactivators (i.e. AIB1 and PELP1/MNAR), alters ER recruitment to MTA3 chromatin, MTA3 transcription, and expression of downstream epithelial-to-mesenchymal transition components. These studies provide novel insights into the transregulation of the MTA3 gene and reveal novel roles of upstream determinants in modifying the outcome of MTA3 axis and cell differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular Mol, Barcelona 08003, Spain	University of Texas System; UTMD Anderson Cancer Center; Jefferson University; Pompeu Fabra University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Mahoney, My/A-2716-2009	Mishra, Sandip/0000-0002-0776-6581	NCI NIH HHS [R01 CA090970, CA098823, CA90970, CA095681, R01 CA095681, R01 CA098823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095681, R01CA098823, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Liao L, 2002, J STEROID BIOCHEM, V83, P3, DOI 10.1016/S0960-0760(02)00254-6; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mercer JA, 2000, SEMIN CELL DEV BIOL, V11, P309, DOI 10.1006/scdb.2000.0181; Sasaki H, 2002, LUNG CANCER-J IASLC, V35, P149, DOI 10.1016/S0169-5002(01)00329-4; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; TATA JR, 1993, J STEROID BIOCHEM, V46, P105, DOI 10.1016/0960-0760(93)90286-6; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	28	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32709	32715		10.1074/jbc.M402942200	http://dx.doi.org/10.1074/jbc.M402942200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15169784	hybrid, Green Accepted			2022-12-25	WOS:000222849700090
J	Zhou, WD; Ryan, JJ; Zhou, HL				Zhou, WD; Ryan, JJ; Zhou, HL			Global analyses of sumoylated proteins in Saccharomyces cerevisiae - Induction of protein sumoylation by cellular stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SUMO-1 MODIFICATION; CONJUGATING ENZYME; UBIQUITIN; YEAST; SMT3P; GENE; IDENTIFICATION; ACTIVATION; MODIFIERS	We have undertaken a global analysis of sumoylated proteins in Saccharomyces cerevisiae by tandem mass spectrometry. Exposure of cells to oxidative and ethanol stresses caused large increases in protein sumoylation. A large number of new sumoylated proteins were identified in untreated, hydrogen peroxide-treated, and ethanol-treated cells. These proteins are known to be involved in diverse cellular processes, including gene transcription, protein translation, DNA replication, chromosome segregation, metabolic processes, and stress responses. Additionally, the known enzymes, including E1, E2, and E3 of the sumoylation cascade were found to be auto-sumoylated. Taken together, these results show that protein sumoylation is broadly involved in many cellular functions and this mass spectrometry-based proteomic approach is useful in studying the regulation of protein sumoylation in the cells.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Zhou, HL (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, 9500 Gilman Dr,CMM-E,Rm 3050, La Jolla, CA 92093 USA.	huzhou@ucsd.edu		Zhou, Huilin/0000-0002-1350-4430; Ryan, Jennifer/0000-0001-6324-9186	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG002604] Funding Source: NIH RePORTER; NHGRI NIH HHS [K22 HG002604-02, K22 HG002604] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARNOLD JE, 1990, BIOCHEM J, V267, P751, DOI 10.1042/bj2670751; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Kurepa J, 2003, J BIOL CHEM, V278, P6862, DOI 10.1074/jbc.M209694200; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yoon HJ, 1999, P NATL ACAD SCI USA, V96, P13208, DOI 10.1073/pnas.96.23.13208	35	249	270	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32262	32268		10.1074/jbc.M404173200	http://dx.doi.org/10.1074/jbc.M404173200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166219	hybrid, Green Accepted			2022-12-25	WOS:000222849700034
J	Atshaves, BP; McIntosh, AM; Lyuksyutova, OI; Zipfel, W; Webb, WW; Schroeder, F				Atshaves, BP; McIntosh, AM; Lyuksyutova, OI; Zipfel, W; Webb, WW; Schroeder, F			Liver fatty acid-binding protein gene ablation inhibits branched-chain fatty acid metabolism in cultured primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; NBD-STEARATE UPTAKE; PHYTANIC ACID; RAT-LIVER; PEROXISOME PROLIFERATORS; CYTOPLASMIC DIFFUSION; LIPID-COMPOSITION; MICE LACKING; PPAR-ALPHA; L-FABP	Whereas the role of liver fatty acid-binding protein (L-FABP) in the uptake, transport, mitochondrial oxidation, and esterification of normal straight-chain fatty acids has been studied extensively, almost nothing is known regarding the function of L-FABP in peroxisomal oxidation and metabolism of branched-chain fatty acids. Therefore, phytanic acid ( most common dietary branched-chain fatty acid) was chosen to address these issues in cultured primary hepatocytes isolated from livers of L-FABP gene- ablated (-/-) and wild type (+/+) mice. These studies provided three new insights: First, L-FABP gene ablation reduced maximal, but not initial, uptake of phytanic acid 3.2-fold. Initial uptake of phytanic acid uptake was unaltered apparently due to concomitant 5.3-, 1.6-, and 1.4-fold up-regulation of plasma membrane fatty acid transporter/translocase proteins ( glutamic-oxaloacetic transaminase, fatty acid transport protein, and fatty acid translocase, respectively). Second, L-FABP gene ablation inhibited phytanic acid peroxisomal oxidation and microsomal esterification. These effects were consistent with reduced cytoplasmic fatty acid transport as evidenced by multiphoton fluorescence photobleaching recovery, where L-FABP gene ablation reduced the cytoplasmic, but not membrane, diffusional component of NBD-stearic acid movement 2-fold. Third, lipid analysis of the L-FABP gene- ablated hepatocytes revealed an altered fatty acid phenotype. Free fatty acid and triglyceride levels were decreased 1.9- and 1.6-fold, respectively. In summary, results with cultured primary hepatocytes isolated from L-FABP (+/+) and L- FABP (-/-) mice demonstrated for the first time a physiological role of L- FABP in the uptake and metabolism of branched-chain fatty acids.	Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA; Cornell Univ, Dept Appl & Engn Phys, Ithaca, NY 14853 USA	Texas A&M University System; Texas A&M University College Station; Cornell University	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu	Webb, Watt W./B-5905-2011; Zipfel, Warren/B-4059-2016	Zipfel, Warren/0000-0003-2640-329X	NIDDK NIH HHS [DK41402] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atshaves BP, 2004, MOL CELL BIOCHEM, V259, P115, DOI 10.1023/B:MCBI.0000021357.97765.f2; Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 2003, J LIPID RES, V44, P1751, DOI 10.1194/jlr.M300141-JLR200; Atshaves BP, 2002, AM J PHYSIOL-CELL PH, V283, pC688, DOI 10.1152/ajpcell.00586.2001; Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Atshaves BP, 1998, AM J PHYSIOL-CELL PH, V274, pC633, DOI 10.1152/ajpcell.1998.274.3.C633; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown EB, 1999, BIOPHYS J, V77, P2837, DOI 10.1016/S0006-3495(99)77115-8; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Erol E, 2003, FASEB J, V17, P347, DOI 10.1096/fj.03-0330fje; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; GLATZ JFC, 1995, PROSTAG LEUKOTR ESS, V52, P121, DOI 10.1016/0952-3278(95)90010-1; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Heyliger CE, 1996, MOL CELL BIOCHEM, V155, P113; Heyliger CE, 1997, MOL CELL BIOCHEM, V176, P281, DOI 10.1023/A:1006817632484; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Huang H, 2004, BIOCHEMISTRY-US, V43, P2484, DOI 10.1021/bi0352318; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; LANFORD RE, 1989, IN VITRO CELL DEV B, V25, P174; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; Martin GG, 2003, BIOCHEMISTRY-US, V42, P11520, DOI 10.1021/bi0346749; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; MARZO A, 1971, CLIN CHEM, V17, P145; McArthur MJ, 1999, J LIPID RES, V40, P1371; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Milliano MT, 2001, HEPATOLOGY, V33, P413, DOI 10.1053/jhep.2001.21999; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; PAHAN K, 1995, J LIPID RES, V36, P986; Paulussen R J, 1990, Subcell Biochem, V16, P175; REUBSAET FAG, 1990, FEBS LETT, V267, P229, DOI 10.1016/0014-5793(90)80931-8; Richieri GV, 2000, BIOCHEMISTRY-US, V39, P7197, DOI 10.1021/bi000314z; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SPENER F, 1989, FEBS LETT, V244, P1, DOI 10.1016/0014-5793(89)81149-4; Steinberg D, 1990, METABOLIC BASIS INHE, P1533; Steinberg D., 1983, METABOLIC BASIS INHE, P731; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Thigpen JE, 1999, ENVIRON HEALTH PERSP, V107, pA182, DOI 10.2307/3434577; Thigpen JE, 1999, LAB ANIM SCI, V49, P530; VEERKAMP JH, 1993, MOL CELL BIOCHEM, V123, P101, DOI 10.1007/BF01076480; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Weisiger RA, 1996, COMP BIOCHEM PHYS B, V115, P319, DOI 10.1016/S0305-0491(96)00179-4; Weisiger RA, 1996, HEPATOLOGY, V24, P1288; White AL, 1997, CLIN GENET, V52, P326; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u; Wolfrum C, 1999, J LIPID RES, V40, P708; WOODFORD JK, 1993, BIOCHIM BIOPHYS ACTA, V1145, P257, DOI 10.1016/0005-2736(93)90297-D; ZENGERHAIN J, 1992, PROG CLIN BIOL RES, V375, P399	67	84	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30954	30965		10.1074/jbc.M313571200	http://dx.doi.org/10.1074/jbc.M313571200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155724	hybrid			2022-12-25	WOS:000222726800008
J	Cho, YS; Chennathukuzhi, VM; Handel, MA; Eppig, J; Hecht, NB				Cho, YS; Chennathukuzhi, VM; Handel, MA; Eppig, J; Hecht, NB			The relative levels of translin-associated factor X (TRAX) and testis brain RNA-binding protein determine their nucleocytoplasmic distribution in male germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; TB-RBP; MESSENGER-RNAS; CHROMOSOMAL TRANSLOCATIONS; INTERCELLULAR BRIDGES; GENE-EXPRESSION; DNA ENDS; SPERMATOGENESIS; RECOMBINATION; CYTOPLASM	Testis brain RNA-binding protein (TB-RBP), the mouse orthologue of human translin, is an RNA and single-stranded DNA-binding protein abundant in testis and brain. Translin-associated factor X ( TRAX) was identified as a protein that interacts with TB-RBP and is dependent upon TB-RBP for stabilization. Using immunohistochemistry to investigate the subcellular locations of TB-RBP and TRAX during spermatogenesis, both proteins localize in nuclei in meiotic pachytene spermatocytes and in the cytoplasm of subsequent meiotic and post-meiotic cells. An identical subcellular distribution is seen in female germ cells. Western blot analysis of germ cell protein extracts reveals an increased ratio of TRAX to TB-RBP in meiotic pachytene spermatocytes compared with the post-meiotic round and elongated spermatids. Using COS-1 cells and mouse embryonic fibroblasts derived from TB-RBP null mice as model systems to examine the shuttling of TB-RBP and TRAX, we demonstrate that TRAX contains a functional nuclear localization signal and TB-RBP contains a functional nuclear export signal. Coexpression of both proteins in COS-1 cells and TB-RBP-deficient mouse embryonic fibroblasts reveals that the ratio of TRAX to TB-RBP determines their subcellular locations, i.e. increased TRAX to TB-RBP ratios lead to nuclear localizations, whereas TRAX remains in the cytoplasm when TB-RBP levels are elevated. These subcellular distributions require interaction between TB-RBP and TRAX. We propose that the subcellular locations of TB-RBP and TRAX in male germ cells are modulated by the relative ratios of TRAX and TB-RBP.	Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Pennsylvania; Pennsylvania Medicine; Jackson Laboratory	Hecht, NB (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, 1310 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	nhecht@mail.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD033816] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063593] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 33816, HD 28832] Funding Source: Medline; NIGMS NIH HHS [GM63593] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki K, 1999, FEBS LETT, V443, P363, DOI 10.1016/S0014-5793(99)00010-1; Aoki K, 1997, FEBS LETT, V401, P109, DOI 10.1016/S0014-5793(96)01444-5; AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Braun RE, 2000, INT J ANDROL, V23, P92, DOI 10.1046/j.1365-2605.2000.00027.x; Chennathukuzhi V, 2003, P NATL ACAD SCI USA, V100, P15566, DOI 10.1073/pnas.2536695100; Chennathukuzhi V, 2003, MOL CELL BIOL, V23, P6419, DOI 10.1128/MCB.23.18.6419-6434.2003; Chennathukuzhi VM, 2001, J BIOL CHEM, V276, P13256, DOI 10.1074/jbc.M009707200; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; Erdemir T, 2002, MOL MICROBIOL, V46, P947, DOI 10.1046/j.1365-2958.2002.03224.x; Erdemir T, 2002, J CELL SCI, V115, P207; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Finkenstadt PM, 2000, J NEUROCHEM, V75, P1754, DOI 10.1046/j.1471-4159.2000.0751754.x; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; Gasca S, 2002, P NATL ACAD SCI USA, V99, P11199, DOI 10.1073/pnas.172383099; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gu W, 1998, MOL REPROD DEV, V49, P219, DOI 10.1002/(SICI)1098-2795(199803)49:3&lt;219::AID-MRD1&gt;3.0.CO;2-R; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Han MK, 2002, BIOCHEMISTRY-US, V41, P3468, DOI 10.1021/bi015901e; Harley VR, 2003, P NATL ACAD SCI USA, V100, P7045, DOI 10.1073/pnas.1137864100; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Ishida R, 2002, FEBS LETT, V525, P105, DOI 10.1016/S0014-5793(02)03095-8; Kasai M, 1997, J BIOL CHEM, V272, P11402; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Lee SP, 2001, BIOCHEMISTRY-US, V40, P14081, DOI 10.1021/bi010302t; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MACARA IG, 2001, MOL BIOL REV, V65, P1; Macho B, 2002, SCIENCE, V298, P2388, DOI 10.1126/science.1077265; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Morales CR, 1998, DEV BIOL, V201, P113, DOI 10.1006/dbio.1998.8967; Morales CR, 2002, DEV BIOL, V246, P480, DOI 10.1006/dbio.2002.0679; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Sengupta K, 2002, BIOCHEMISTRY-US, V41, P15315, DOI 10.1021/bi026378m; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Travis AJ, 1998, MOL BIOL CELL, V9, P263, DOI 10.1091/mbc.9.2.263; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; VanLoock MS, 2001, J STRUCT BIOL, V135, P58, DOI 10.1006/jsbi.2001.4383; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vera Y, 2002, J ANDROL, V23, P622; Wu XQ, 1999, BIOCHEMISTRY-US, V38, P11261, DOI 10.1021/bi990573s; Wu XQ, 2000, BIOL REPROD, V62, P720, DOI 10.1095/biolreprod62.3.720; Wu XQ, 1998, NUCLEIC ACIDS RES, V26, P1675, DOI 10.1093/nar/26.7.1675; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Yang SC, 2004, J BIOL CHEM, V279, P12605, DOI 10.1074/jbc.M313133200; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200	54	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31514	31523		10.1074/jbc.M401442200	http://dx.doi.org/10.1074/jbc.M401442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15138261	hybrid			2022-12-25	WOS:000222726800074
J	Gu, D; Zhou, YZ; Kallhoff, V; Baban, B; Tanner, JJ; Becker, DF				Gu, D; Zhou, YZ; Kallhoff, V; Baban, B; Tanner, JJ; Becker, DF			Identification and characterization of the DNA-binding domain of the multifunctional PutA flavoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE DEHYDROGENASE DOMAIN; FLAVIN REDOX STATE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; ARC REPRESSOR; ALANINE SUBSTITUTIONS; MET REPRESSOR; MNT REPRESSOR; PLASMID RK2	The PutA flavoprotein from Escherichia coli is a transcriptional repressor and a bifunctional enzyme that regulates and catalyzes proline oxidation. PutA represses transcription of genes putA and putP by binding to the control DNA region of the put regulon. The objective of this study is to define and characterize the DNA binding domain of PutA. The DNA binding activity of PutA, a 1320 amino acid polypeptide, has been localized to N-terminal residues 1 - 261. After exploring a potential DNA-binding region and an N-terminal deletion mutant of PutA, residues 1 - 90 (PutA90) were determined to contain DNA binding activity and stabilize the dimeric structure of PutA. Cell-based transcriptional assays demonstrate that PutA90 functions as a transcriptional repressor in vivo. The dissociation constant of PutA90 with the put control DNA was estimated to be 110 nM, which is slightly higher than that of the PutA-DNA complex (K-d similar to 45 nM). Primary and secondary structure analysis of PutA90 suggested the presence of a ribbon-helix-helix DNA binding motif in residues 1 - 47. To test this prediction, we purified and characterized PutA47. PutA47 is shown to purify as an apparent dimer, to exhibit in vivo transcriptional activity, and to bind specifically to the put control DNA. In gel-mobility shift assays, PutA47 was observed to bind cooperatively to the put control DNA with an overall dissociation constant of 15 nM for the PutA47-DNA complex. Thus, N-terminal residues 1 - 47 are critical for DNA-binding and the dimeric structure of PutA. These results are consistent with the ribbon-helix-helix family of transcription factors.	Univ Nebraska, Dept Biochem, Beadle Ctr N258, Lincoln, NE 68588 USA; Univ Missouri, Dept Chem & Biochem, St Louis, MO 63121 USA; Univ Missouri, Dept Chem, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Nebraska System; University of Nebraska Lincoln; University of Missouri System; University of Missouri Saint Louis; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Becker, DF (corresponding author), Univ Nebraska, Dept Biochem, Beadle Ctr N258, Lincoln, NE 68588 USA.	dbecker3@unl.edu		ZHOU, Yuzhen/0000-0003-3964-4359; Tanner, John/0000-0001-8314-113X	NCRR NIH HHS [P20 RR017675, P20-RR-01767502] Funding Source: Medline; NIGMS NIH HHS [R01 GM061068, GM65546, R01 GM065546, R01 GM065546-03, GM61068] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065546, R01GM061068] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; Becker DF, 2001, BIOCHEMISTRY-US, V40, P4714, DOI 10.1021/bi0019491; Berggrun A, 2001, P NATL ACAD SCI USA, V98, P2301, DOI 10.1073/pnas.041612198; Brown BM, 1999, P NATL ACAD SCI USA, V96, P1983, DOI 10.1073/pnas.96.5.1983; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BROWN ED, 1993, J BIOL CHEM, V268, P8972; CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; CHEN LM, 1991, J BACTERIOL, V173, P783, DOI 10.1128/jb.173.2.783-790.1991; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; Golovanov AP, 2003, MOL MICROBIOL, V50, P1141, DOI 10.1046/j.1365-2958.2003.03750.x; Gomis-Ruth FX, 1998, EMBO J, V17, P7404, DOI 10.1093/emboj/17.24.7404; Lee YH, 2003, NAT STRUCT BIOL, V10, P109, DOI 10.1038/nsb885; LING MF, 1994, J MOL BIOL, V243, P950, DOI 10.1006/jmbi.1994.1696; MALOY SR, 1983, J BACTERIOL, V154, P561, DOI 10.1128/JB.154.2.561-568.1983; MENZEL R, 1981, J MOL BIOL, V148, P21, DOI 10.1016/0022-2836(81)90233-3; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P3344, DOI 10.1021/bi00010a025; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; Nooren IMA, 1999, NAT STRUCT BIOL, V6, P755; Oberer M, 2002, BIOCHEM J, V361, P41, DOI 10.1042/0264-6021:3610041; OSTROVSKY PC, 1995, GENE DEV, V9, P2034, DOI 10.1101/gad.9.16.2034; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROBERTS RC, 1993, J BIOL CHEM, V268, P27109; Schreiter ER, 2003, NAT STRUCT BIOL, V10, P794, DOI 10.1038/nsb985; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Soto MJ, 2000, J BACTERIOL, V182, P1935, DOI 10.1128/JB.182.7.1935-1941.2000; Straub PF, 1996, APPL ENVIRON MICROB, V62, P221, DOI 10.1128/AEM.62.1.221-229.1996; SUZUKI M, 1995, PROTEIN ENG, V8, P1, DOI 10.1093/protein/8.1.1; Vilchez S, 2000, APPL ENVIRON MICROB, V66, P5221, DOI 10.1128/AEM.66.12.5221-5225.2000; Vinod MP, 2002, BIOCHEMISTRY-US, V41, P6525, DOI 10.1021/bi025706f; WOOD JM, 1981, J BACTERIOL, V146, P895, DOI 10.1128/JB.146.3.895-901.1981; Zhu WD, 2003, BIOCHEMISTRY-US, V42, P5469, DOI 10.1021/bi0272196; Zhu WD, 2002, ARCH BIOCHEM BIOPHYS, V408, P131, DOI 10.1016/S0003-9861(02)00535-0	39	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31171	31176		10.1074/jbc.M403701200	http://dx.doi.org/10.1074/jbc.M403701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155740	Green Accepted, hybrid			2022-12-25	WOS:000222726800034
J	Hsiao, YS; Jogl, G; Tong, L				Hsiao, YS; Jogl, G; Tong, L			Structural and biochemical studies of the substrate selectivity of carnitine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED MOLECULAR REPLACEMENT; PALMITOYLTRANSFERASE; MACROMOLECULES; ENZYMOLOGY; TRANSPORT; SYSTEM; MODELS	Carnitine acyltransferases catalyze the exchange of acyl groups between coenzyme A (CoA) and carnitine. They have important roles in many cellular processes, especially the oxidation of long-chain fatty acids, and are attractive targets for drug discovery against diabetes and obesity. These enzymes are classified based on their substrate selectivity for short-chain, medium-chain, or long-chain fatty acids. Structural information on carnitine acetyltransferase suggests that residues Met-564 and Phe-565 may be important determinants of substrate selectivity with the side chain of Met-564 located in the putative binding pocket for acyl groups. Both residues are replaced by glycine in carnitine palmitoyltransferases. To assess the functional relevance of this structural observation, we have replaced these two residues with small amino acids by mutagenesis, characterized the substrate preference of the mutants, and determined the crystal structures of two of these mutants. Kinetic studies confirm that the M564G or M564A mutation is sufficient to increase the activity of the enzyme toward medium-chain substrates with hexanoyl-CoA being the preferred substrate for the M564G mutant. The crystal structures of the M564G mutant, both alone and in complex with carnitine, reveal a deep binding pocket that can accommodate the larger acyl group. We have determined the crystal structure of the F565A mutant in a ternary complex with both the carnitine and CoA substrates at a 1.8-Angstrom resolution. The F565A mutation has minor effects on the structure or the substrate preference of the enzyme.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	tong@como.bio.columbia.edu	Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315; Tong, Liang/0000-0002-0563-6468	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK67238] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; Evans AM, 2003, CLIN PHARMACOKINET, V42, P941, DOI 10.2165/00003088-200342110-00002; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lenhard JM, 2002, ADV DRUG DELIVER REV, V54, P1199, DOI 10.1016/S0169-409X(02)00092-3; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramsay RR, 2003, TRENDS BIOCHEM SCI, V28, P343, DOI 10.1016/S0968-0004(03)00137-3; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; RAMSAY RR, 1987, BIOCHEM J, V244, P271, DOI 10.1042/bj2440271; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X	20	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31584	31589		10.1074/jbc.M403484200	http://dx.doi.org/10.1074/jbc.M403484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155726	hybrid			2022-12-25	WOS:000222726800081
J	Huang, YM; Chen, SU; Goodman, SD; Wu, SH; Kao, JT; Lee, CN; Cheng, WC; Tsai, KS; Fang, WH				Huang, YM; Chen, SU; Goodman, SD; Wu, SH; Kao, JT; Lee, CN; Cheng, WC; Tsai, KS; Fang, WH			Interaction of nick-directed DNA mismatch repair and loop repair in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NUCLEAR EXTRACTS; SINGLE-STRANDED LOOPS; MAMMALIAN-CELLS; ESCHERICHIA-COLI; HETERODUPLEX DNA; SACCHAROMYCES-CEREVISIAE; REPLICATION FIDELITY; RECOMBINATION; INSTABILITY; CLEAVAGE	In human cells, large DNA loop heterologies are repaired through a nick-directed pathway independent of mismatch repair. However, a 3'-nick generated by bacteriophage fd gene II protein heterology is not capable of stimulating loop repair. To evaluate the possibility that a mismatch near a loop could induce both repair types in human cell extracts, we constructed and tested a set of DNA heteroduplexes, each of which contains a combination of mismatches and loops. We have demonstrated that a strand break generated by restriction endonucleases 3' to a large loop is capable of provoking and directing loop repair. The repair of 3'-heteroduplexes in human cell extracts is very similar to that of 5'-heteroduplex repair, being strand-specific and highly biased to the nicked strand. This observation suggests that the loop repair pathway possesses bidirectional repair capability similar to that of the bacterial loop repair system. We also found that a nick 5' to a coincident mismatch and loop can apparently stimulate the repair of both. In contrast, 3'-nick-directed repair of a G-G mismatch was reduced when in the vicinity of a loop (33 or 46 bp between two sites). Increasing the distance separating the G-G mismatch and loop by 325 bp restored the efficiency of repair to the level of a single base-base mismatch. This observation suggests interference between 3'-nick-directed large loop repair and conventional mismatch repair systems when a mispair is near a loop. We propose a model in which DNA repair systems avoid simultaneous repair at adjacent sites to avoid the creation of double-stranded DNA breaks.	Natl Taiwan Univ, Coll Med, Sch Med Technol, Taipei 10063, Taiwan; Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 10063, Taiwan; Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 10063, Taiwan; Univ So Calif, Sch Dent, Div Diagnost Sci, Los Angeles, CA 90089 USA	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; University of Southern California	Fang, WH (corresponding author), Natl Taiwan Univ, Coll Med, Sch Med Technol, 7 Chung Shan S Rd, Taipei 10063, Taiwan.	whfang@ha.mc.ntu.edu.tw	Goodman, Steven/C-5732-2013	Wu, Shang-Hsin/0000-0002-6204-7950; KAO, JAU-TSUEN/0000-0003-1918-0366; FANG, WOEI-HORNG/0000-0003-4728-5931; TSAI, KEH-SUNG/0000-0001-8528-1566; CHEN, SHEE-UAN/0000-0001-7592-3238				AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; Bill CA, 2001, MUTAT RES-DNA REPAIR, V485, P255, DOI 10.1016/S0921-8777(01)00065-9; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Corrette-Bennett SE, 2001, NUCLEIC ACIDS RES, V29, P4134, DOI 10.1093/nar/29.20.4134; Corrette-Bennett SE, 1999, J BIOL CHEM, V274, P17605, DOI 10.1074/jbc.274.25.17605; Fang WH, 2003, J BIOL CHEM, V278, P22446, DOI 10.1074/jbc.M302585200; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FANG WH, 1993, COLD SPRING HARB SYM, V58, P597, DOI 10.1101/SQB.1993.058.01.066; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GREENSTEIN D, 1989, J BIOL CHEM, V264, P12627; HASTINGS PJ, 1988, GENETIC RECOMBINATIO, P397; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; McCulloch SD, 2003, J BIOL CHEM, V278, P50803, DOI 10.1074/jbc.M309025200; McCulloch SD, 2003, J BIOL CHEM, V278, P3891, DOI 10.1074/jbc.M210687200; MESELSON M, 1988, RECOMBINATION GENETI, P91; MEYER TF, 1979, J BIOL CHEM, V254, P2642; MIRET JJ, 1993, J BIOL CHEM, V268, P3507; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SU SS, 1988, J BIOL CHEM, V263, P6829; Taghian DG, 1998, GENETICS, V148, P1257; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Wang HX, 2003, J BIOL CHEM, V278, P28686, DOI 10.1074/jbc.M302844200; Wang HX, 2002, J BIOL CHEM, V277, P26136, DOI 10.1074/jbc.M200357200; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619; Wierdl M, 1997, GENETICS, V146, P769	37	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30228	30235		10.1074/jbc.M401675200	http://dx.doi.org/10.1074/jbc.M401675200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15151992	hybrid			2022-12-25	WOS:000222531900046
J	Ray, S; Lu, Y; Kaufmann, SH; Gustafson, WC; Karp, JE; Boldogh, I; Fields, AP; Brasier, AR				Ray, S; Lu, Y; Kaufmann, SH; Gustafson, WC; Karp, JE; Boldogh, I; Fields, AP; Brasier, AR			Genomic mechanisms of p210(BCR-ABL) signaling - Induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PROTEIN-KINASE-C; ABL-MEDIATED RESISTANCE; HEAT-SHOCK PROTEINS; TRANSCRIPTION FACTOR; CELL-DEATH; ACTIVATION; EXPRESSION; GENE; INHIBITION	Chronic myelogenous leukemia (CML) results from a t(9,22) translocation, producing the p210(BCR-ABL) oncoprotein, a tyrosine kinase that causes transformation and chemotherapy resistance. To further understand mechanisms mediating chemotherapy resistance, we identified 556 differentially regulated genes in HL-60 cells stably expressing p210(BCR-ABL) versus those expressing an empty vector using cDNA macro- and oligonucleotide microarrays. These BCR-ABL-regulated gene products play diverse roles in cellular function including apoptosis, cell cycle regulation, intracellular signaling, transcription, and cellular adhesion. In particular, we identified up-regulation of the inducible form of heat shock protein 70 (Hsp70), and further explored the mechanism for its up-regulation. In HL-60/BCR-ABL and K562 cells (expressing p210(BCR-ABL)), abundant cytoplasmic Hsp70 expression was detected by immunoblot analysis. Moreover, cells isolated from bone marrow aspirates of patients in different stages of CML (chronic, aggressive, and blast crisis) express Hsp70. Expression of p210(BCR-ABL) in BCR-ABL negative cells induced transcription of the proximal Hsp70 promoter. Mutational analysis mapped the major p210(BCR-ABL) responsive element to a high affinity 5'(A/T)GATA(A/G)-3' "GATA" response element (GATA-RE) that binds GATA-1 in CML cells. The GATA-RE was sufficient to confer p210(BCR-ABL)- and p185(BCR-ABL)-mediated trans-activation to an inert promoter. Short interfering RNA mediated "knockdown" of Hsp70 expression in K562 cells induced marked sensitivity to paclitaxel-induced apoptosis. Together these findings indicate that BCR-ABL confers chemotherapeutic resistance through intracellular signaling to the GATA-RE element found in the promoter region of the anti-apoptotic Hsp70 protein. We suggest that down-regulation of the GATA-Hsp70 pathway may be useful in the treatment of chemotherapy-resistant CML.	Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, Galveston, TX 77555 USA; Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA	University of Texas System; University of Texas Medical Branch Galveston; Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Medical Branch Galveston; Mayo Clinic	Brasier, AR (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Endocrinol, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu	Ray, Sutapa/D-3272-2012	Ray, Sutapa/0000-0003-4234-2124; Kaufmann, Scott/0000-0002-4900-7145; Brasier, Allan/0000-0002-5012-4090	NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040218, R44AI056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline; NIAID NIH HHS [R44 AI056869, AI40218] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; BRASIER AR, 1990, CURRENT PROTOCOLS MO; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DRUKER B, 1992, BLOOD, V79, P2215; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jena N, 2002, CANCER RES, V62, P535; KAUFMANN SH, 1991, CANCER RES, V51, P3534; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salesse S, 2003, MOL CANCER THER, V2, P173; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SIRARD C, 1994, BLOOD, V83, P1575; Snapyan M, 2003, PROTEOMICS, V3, P647, DOI 10.1002/pmic.200300390; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Zhang YH, 2001, J VIROL, V75, P9044, DOI 10.1128/JVI.75.19.9044-9058.2001; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	60	50	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35604	35615		10.1074/jbc.M401851200	http://dx.doi.org/10.1074/jbc.M401851200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15155749	hybrid			2022-12-25	WOS:000223303400056
J	Xu, X; Zhao, JY; Xu, Z; Peng, BZ; Huang, QH; Arnold, E; Ding, JP				Xu, X; Zhao, JY; Xu, Z; Peng, BZ; Huang, QH; Arnold, E; Ding, JP			Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; CRYSTAL-STRUCTURE; CELLULAR DEFENSE; FATTY-ACIDS; PHOSPHORYLATION; ENZYME; DAMAGE; SITE; KINASE/PHOSPHATASE; INACTIVATION	Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, and regulation of the enzymatic activity of IDHs is crucial for their biological functions. Bacterial IDHs are reversibly regulated by phosphorylation of a strictly conserved serine residue at the active site. Eukaryotic NADP-dependent IDHs (NADP-IDHs) have been shown to have diverse important biological functions; however, their regulatory mechanism remains unclear. Structural studies of human cytosolic NADP-IDH (HcIDH) in complex with NADP and in complex with NADP, isocitrate, and Ca2+ reveal three biologically relevant conformational states of the enzyme that differ substantially in the structure of the active site and in the overall structure. A structural segment at the active site that forms a conserved alpha-helix in all known NADP-IDH structures assumes a loop conformation in the open, inactive form of HcIDH; a partially unraveled alpha-helix in the semi-open, intermediate form; and an alpha-helix in the closed, active form. The side chain of Asp(279) of this segment occupies the isocitrate-binding site and forms hydrogen bonds with Ser(94) ( the equivalent of the phosphorylation site in bacterial IDHs) in the inactive form and chelates the metal ion in the active form. The structural data led us to propose a novel self-regulatory mechanism for HcIDH that mimics the phosphorylation mechanism used by the bacterial homologs, consistent with biochemical and biological data. This mechanism might be applicable to other eukaryotic NADP-IDHs. The results also provide insights into the recognition and specificity of substrate and cofactor by eukaryotic NADP-IDHs.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Prote, Shanghai 200031, Peoples R China; Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Gen, Shanghai 200025, Peoples R China; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Ding, JP (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Prote, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jpding@sibs.ac.cn	Xu, Xiang/G-5528-2012	ding, jian ping/0000-0001-7029-7346	NIAID NIH HHS [AI27690] Funding Source: Medline; NIGMS NIH HHS [GM 66671] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027690, R37AI027690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066671] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benderdour M, 2003, J BIOL CHEM, V278, P45154, DOI 10.1074/jbc.M306285200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; FARRELL HM, 1990, J BIOL CHEM, V265, P17637; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JENNINGS GT, 1994, J BIOL CHEM, V269, P23128; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SY, 2003, FREE RADICAL RES, V37, P309, DOI 10.1080/1071576021000050429; LAPORTE DC, 1993, J CELL BIOCHEM, V51, P14, DOI 10.1002/jcb.240510104; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; Nekrutenko A, 1998, MOL BIOL EVOL, V15, P1674, DOI 10.1093/oxfordjournals.molbev.a025894; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; SEERY VL, 1990, J BIOL CHEM, V265, P17644; Singh SK, 2002, J BIOL CHEM, V277, P7567, DOI 10.1074/jbc.M107908200; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; Yang ES, 2002, FREE RADICAL BIO MED, V33, P927, DOI 10.1016/S0891-5849(02)00981-4; Yoshihara T, 2001, J HISTOCHEM CYTOCHEM, V49, P1123, DOI 10.1177/002215540104900906	35	281	300	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33946	33957		10.1074/jbc.M404298200	http://dx.doi.org/10.1074/jbc.M404298200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173171	hybrid			2022-12-25	WOS:000223039700105
J	Anindya, R; Savithri, HS				Anindya, R; Savithri, HS			Potyviral NIa proteinase, a proteinase with novel deoxyribonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO ETCH POTYVIRUS; TURNIP MOSAIC POTYVIRUS; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; CATALYTIC-ACTIVITY; STRUCTURAL BASIS; RNASE ACTIVITY; CLEAVAGE SITE; PROTEASE	The NIa proteinase from pepper vein banding virus (PVBV) is a sequence-specific proteinase required for processing of viral polyprotein in the cytoplasm. It accumulates in the nucleus of the infected plant cell and forms inclusion bodies. The function of this protein in the nucleus is not clear. The purified recombinant NIa proteinase was active, and the mutation of the catalytic residues His-46, Asp-81, and Cys-151 resulted in complete loss of activity. Most interesting, the PVBV NIa proteinase exhibited previously unidentified activity, namely nonspecific double-stranded DNA degradation. This DNase activity of the NIa proteinase showed an absolute requirement for Mg2+. Site-specific mutational analysis showed that of the three catalytic residues, Asp-81 was the crucial residue for DNase activity. Mutation of His-46 and Cys-151 had no effect on the DNase activity, whereas mutant D81N was partially active, and D81G was completely inactive. Based on kinetic analysis and molecular modeling, a metal ion-dependent catalysis similar to that observed in other nonspecific DNases is proposed. Similar results were obtained with glutathione S-transferase-fused PVBV NIa proteinase and tobacco etch virus NIa proteinase, confirming that the DNase function is an intrinsic property of potyviral NIa proteinase. The NIa protein present in the infected plant nuclear extract also showed the proteinase and the DNase activities, suggesting that the PVBV NIa protein that accumulates in the nucleus late in the infection cycle might serve to degrade the host DNA. Thus the dual function of the NIa proteinase could play an important role in the life cycle of the virus.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Savithri, HS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	bchss@biochem.iisc.ernet.in	Anindya, Roy/ABD-1326-2020; Anindya, Roy/F-8241-2012	Anindya, Roy/0000-0001-8561-907X; Anindya, Roy/0000-0001-8561-907X				Anindya R, 2004, ARCH VIROL, V149, P625, DOI 10.1007/s00705-003-0236-0; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CARRINGTON JC, 1989, EMBO J, V8, P365, DOI 10.1002/j.1460-2075.1989.tb03386.x; CARRINGTON JC, 1988, P NATL ACAD SCI USA, V85, P3391, DOI 10.1073/pnas.85.10.3391; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CARRINGTON JC, 1993, J VIROL, V67, P6995, DOI 10.1128/JVI.67.12.6995-7000.1993; CHEAH KSE, 1977, BIOCHEM J, V163, P141, DOI 10.1042/bj1630141; Daros JA, 1997, VIROLOGY, V237, P327, DOI 10.1006/viro.1997.8802; DOUGHERTY WG, 1988, EMBO J, V7, P1281, DOI 10.1002/j.1460-2075.1988.tb02942.x; GARCIA JA, 1990, J GEN VIROL, V71, P2773, DOI 10.1099/0022-1317-71-12-2773; Gautier-Bert K, 2003, MOL BIOL REP, V30, P1, DOI 10.1023/A:1022261925117; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; Hajimorad MR, 1996, VIROLOGY, V224, P368, DOI 10.1006/viro.1996.0544; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hull R., 2002, MATTHEWS PLANT VIROL; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; Joseph J, 1999, ARCH VIROL, V144, P1679, DOI 10.1007/s007050050696; Joseph J, 2000, ARCH VIROL, V145, P2493, DOI 10.1007/s007050070004; Kim DH, 1996, VIROLOGY, V221, P245, DOI 10.1006/viro.1996.0372; Kim DH, 1996, VIROLOGY, V226, P183, DOI 10.1006/viro.1996.0645; KNUHTSEN H, 1974, VIROLOGY, V61, P200, DOI 10.1016/0042-6822(74)90254-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CL, 2003, EMBO J, V22, P4014, DOI 10.1093/emboj/cdg377; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; Patel D, 2001, BIOTECHNIQUES, V31, P1194, DOI 10.2144/01315dd04; Petit F, 1997, MOL BIOL REP, V24, P113, DOI 10.1023/A:1006886911852; Phan J, 2002, J BIOL CHEM, V277, P50564, DOI 10.1074/jbc.M207224200; POUCH MN, 1995, J BIOL CHEM, V270, P22023, DOI 10.1074/jbc.270.37.22023; Rashid N, 1997, NUCLEIC ACIDS RES, V25, P719, DOI 10.1093/nar/25.4.719; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; Schaad MC, 1996, J VIROL, V70, P7039, DOI 10.1128/JVI.70.10.7039-7048.1996; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6	37	29	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32159	32169		10.1074/jbc.M404135200	http://dx.doi.org/10.1074/jbc.M404135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15163663	Green Accepted, hybrid			2022-12-25	WOS:000222849700022
J	Forrest, ST; Barringhaus, KG; Perlegas, D; Hammarskjold, ML; McNamara, CA				Forrest, ST; Barringhaus, KG; Perlegas, D; Hammarskjold, ML; McNamara, CA			Intron retention generates a novel Id3 isoform that inhibits vascular lesion formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE CELL-PROLIFERATION; ATHEROSCLEROTIC PLAQUE RUPTURE; ARTERIAL EXPRESSION; TYROSINE KINASE; GROWTH; PROTEINS; GENE; APOPTOSIS; INJURY; AUTOINHIBITOR	The expression of intron-containing messages has been shown to occur in a variety of diseases including lactic acidosis, Cowden Syndrome, and several cancers. However, it is unknown whether these intron-containing messages result in protein production in vivo. Indeed, intron-containing RNAs are typically retained in the nucleus, targeted for degradation, or are repressed translationally. Here, we show that during vascular lesion formation in rats, an alternative isoform of the helix-loop-helix transcription factor Id3 (Id3a) generated by intron retention is abundantly expressed. We demonstrate that Id3 is expressed early in lesion formation when the proliferative index of the neointima is highest and that Id3 promotes smooth muscle cell (SMC) proliferation and S-phase entry and inhibits transcription of the cell-cycle inhibitor p21(Cip1). Using an Id3a-specific antibody developed by our laboratory, we show that Id3a protein is induced during vascular lesion formation and that Id3a expression peaks late when the proliferative index is low or declining and extensive apoptosis is observed. Furthermore, Id3a fails to promote SMC growth and S-phase entry or to inhibit p21(Cip1) promoter transactivation. In contrast, Id3a stimulates SMC apoptosis and inhibits endogenous Id3 production. Adenoviral delivery of Id3a inhibited lesion formation in balloon-injured rat carotid arteries in vivo. These data describe a novel feedback loop whereby intron retention generates an Id3 isoform that acts to limit SMC growth during vascular lesion formation, providing the first evidence that regulated intron retention can modulate a pathologic process in vivo.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Myles H Thaler Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	McNamara, CA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA.	cam8c@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA097095] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007355, T32HL007284, P01HL055798, R01HL062522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054335, R01AI034721] Funding Source: NIH RePORTER; NCI NIH HHS [CAA097095] Funding Source: Medline; NHLBI NIH HHS [T32HL007355, T32HL007284, P01 HL55798, R01 HL062522] Funding Source: Medline; NIAID NIH HHS [AI054335, AI34721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bennett MR, 1999, CARDIOVASC RES, V41, P361, DOI 10.1016/S0008-6363(98)00212-0; Braganza DM, 2001, POSTGRAD MED J, V77, P94, DOI 10.1136/pmj.77.904.94; CLOWES AW, 1983, LAB INVEST, V49, P327; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DUBIN D, 1995, ARTERIOSCL THROM VAS, V15, P1958, DOI 10.1161/01.ATV.15.11.1958; Dytrych L, 1998, J BIOL CHEM, V273, P5794, DOI 10.1074/jbc.273.10.5794; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Goodison S, 1998, AM J PATHOL, V153, P1221, DOI 10.1016/S0002-9440(10)65666-0; HAN DKM, 1995, AM J PATHOL, V147, P267; HANKE H, 1990, CIRC RES, V67, P651, DOI 10.1161/01.RES.67.3.651; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jhabvala-Romero F, 2003, ONCOGENE, V22, P8178, DOI 10.1038/sj.onc.1206912; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Kantor B, 1999, Cardiovasc Radiat Med, V1, P48, DOI 10.1016/S1522-1865(98)00005-5; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Matsumura ME, 2001, ARTERIOSCL THROM VAS, V21, P752, DOI 10.1161/01.ATV.21.5.752; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Suzuki JI, 1997, NAT MED, V3, P900, DOI 10.1038/nm0897-900; Tsukamoto Y, 2001, AM J PATHOL, V158, P1685, DOI 10.1016/S0002-9440(10)64124-7; Wallner K, 2002, ATHEROSCLEROSIS, V161, P75, DOI 10.1016/S0021-9150(01)00627-X	27	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32897	32903		10.1074/jbc.M404882200	http://dx.doi.org/10.1074/jbc.M404882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15159391	hybrid			2022-12-25	WOS:000222849700109
J	Takano, A; Isojima, Y; Nagai, K				Takano, A; Isojima, Y; Nagai, K			Identification of mPer1 phosphorylation sites responsible for the nuclear entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN-KINASE-I; DROSOPHILA CLOCK GENE; CKI-EPSILON; DOUBLE-TIME; PERIOD; PROTEINS; MUTATION; ENCODES; CLONING	Casein kinase 1 epsilon (CK1epsilon) is an essential component of the circadian clock in mammals and Drosophila. The phosphorylation of Period (Per) proteins by CK1epsilon is believed to be implicated in their subcellular localization and degradation, but the precise mechanism by which CK1epsilon affects Per proteins has not been determined. In this study, three putative CK1epsilon phosphorylation motif clusters in mouse Per1 (mPer1) were identified, and the phosphorylation status of serine and threonine residues in these clusters was examined. Phosphorylation of residues within a region defined by amino acids 653-663 and in particular of Ser-661 and Ser-663, was identified as responsible for the nuclear translocation of mPer1. Furthermore, phosphorylation of these residues may influence the nuclear translocation of a clock protein complex containing mPer1. These findings indicate that mPer1 phosphorylation is a critical aspect of the circadian clock mechanism.	Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan	Osaka University	Takano, A (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Metab, 3-2 Yamada Oka, Suita, Osaka 5650871, Japan.	atsuko@protein.osaka-u.ac.jp						Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Harmer SL, 2001, ANNU REV CELL DEV BI, V17, P215, DOI 10.1146/annurev.cellbio.17.1.215; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	27	61	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32578	32585		10.1074/jbc.M403433200	http://dx.doi.org/10.1074/jbc.M403433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148313	hybrid			2022-12-25	WOS:000222849700074
J	Barros, MH; Johnson, A; Tzagoloff, A				Barros, MH; Johnson, A; Tzagoloff, A			COX23, a homologue of COX17, is required for cytochrome oxidase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER METALLOCHAPERONE COX17; SACCHAROMYCES-CEREVISIAE; C-OXIDASE; MITOCHONDRIAL-MEMBRANE; PROTEIN; PURIFICATION; EXPRESSION; VECTORS; STRAINS; SHUTTLE	Deletion of reading frame YHR116W of the Saccharomyces cerevisiae nuclear genome elicits a respiratory deficiency. The encoded product, here named Cox23p, is shown to be required for the expression of cytochrome oxidase. Cox23p is homologous to Cox17p, a water-soluble copper protein previously implicated in the maturation of the Cu-A center of cytochrome oxidase. The respiratory defect of a cox23 null mutant is rescued by high concentrations of copper in the medium but only when the mutant harbors COX17 on a high copy plasmid. Overexpression of Cox17p by itself is not a sufficient condition to rescue the mutant phenotype. Cox23p, like Cox17p, is detected in the intermembrane space of mitochondria and in the postmitochondrial supernatant fraction, the latter consisting predominantly of cytosolic proteins. Because Cox23p and Cox17p are not part of a complex, the requirement of both for cytochrome oxidase assembly suggests that they function in a common pathway with Cox17p acting downstream of Cox23p.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Estadual Paulista, Inst Biociencias Botucatu, Dept Genet, BR-18607741 Sao Paulo, Brazil	Columbia University; Instituto de Botanica - Sao Paulo; Universidade Estadual Paulista	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario H/B-8118-2012; Barros, Mario/Q-6358-2019	Barros, Mario/0000-0003-2977-9815	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050187, GM 50187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Beinert H, 1997, EUR J BIOCHEM, V245, P521, DOI 10.1111/j.1432-1033.1997.t01-1-00521.x; Brachmann CB, 1998, YEAST, V14, P115; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Chinenov YV, 2000, J MOL MED, V78, P239, DOI 10.1007/s001090000110; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Nobrega MP, 2002, J BIOL CHEM, V277, P40206, DOI 10.1074/jbc.M207348200; Punter FA, 2003, J BIOL CHEM, V278, P30875, DOI 10.1074/jbc.M302358200; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	29	69	70	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31943	31947		10.1074/jbc.M405014200	http://dx.doi.org/10.1074/jbc.M405014200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145942	hybrid			2022-12-25	WOS:000222726800122
J	Froderberg, L; Houben, ENG; Baars, L; Luirink, J; de Gier, JW				Froderberg, L; Houben, ENG; Baars, L; Luirink, J; de Gier, JW			Targeting and translocation of two lipoproteins in Escherichia coli via the SRP/Sec/YidC pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; OUTER-MEMBRANE LIPOPROTEIN; TRIGGER FACTOR; PRESECRETORY PROTEINS; UBIQUINOL OXIDASE; 4.5S RNA; INSERTION; YIDC; GENE; SECY	In Escherichia coli, two main protein targeting pathways to the inner membrane exist: the SecB pathway for the essentially posttranslational targeting of secretory proteins and the SRP pathway for cotranslational targeting of inner membrane proteins (IMPs). At the inner membrane both pathways converge at the Sec translocase, which is capable of both linear transport into the periplasm and lateral transport into the lipid bilayer. The Sec-associated YidC appears to assist the lateral transport of IMPs from the Sec translocase into the lipid bilayer. It should be noted that targeting and translocation of only a handful of secretory proteins and IMPs have been studied. These model proteins do not include lipoproteins. Here, we have studied the targeting and translocation of two secretory lipoproteins, the murein lipoprotein and the bacteriocin release protein, using a combined in vivo and in vitro approach. The data indicate that both murein lipoprotein and bacteriocin release protein require the SRP pathway for efficient targeting to the Sec translocase. Furthermore, we show that YidC plays an important role in the targeting/translocation of both lipoproteins.	Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; BioCentrum Amsterdam, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands	Stockholm University; University of Amsterdam	de Gier, JW (corresponding author), Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	degier@dbb.su.se	Luirink, Joen/AAB-8658-2021; Houben, Edith N.G./B-2110-2015	Houben, Edith N.G./0000-0002-8805-2002; Froderberg Roth, Linda/0000-0002-2684-3650; Luirink, J./0000-0001-8431-0804				Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein KD, 2001, J BACTERIOL, V183, P2187, DOI 10.1128/JB.183.7.2187-2197.2001; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Drew D, 2003, BBA-BIOMEMBRANES, V1610, P3, DOI 10.1016/S0005-2736(02)00707-1; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; HAYASHI S, 1985, J BACTERIOL, V161, P949, DOI 10.1128/JB.161.3.949-954.1985; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; JENSEN CG, 1994, J BACTERIOL, V176, P7148, DOI 10.1128/JB.176.23.7148-7154.1994; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LUIRINK J, 1991, MOL MICROBIOL, V5, P393, DOI 10.1111/j.1365-2958.1991.tb02121.x; Ma JX, 1997, BIOCHEMISTRY-US, V36, P11298, DOI 10.1021/bi9709710; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; OUDEGA B, 1993, J BACTERIOL, V175, P1543, DOI 10.1128/JB.175.5.1543-1547.1993; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; PETERSON JH, 2003, J BIOL CHEM; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Schierle CF, 2003, J BACTERIOL, V185, P5706, DOI 10.1128/JB.185.19.5706-5713.2003; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; Shu W, 2000, J MOL BIOL, V299, P1101, DOI 10.1006/jmbi.2000.3776; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; SUGAI M, 1992, J BACTERIOL, V174, P2511, DOI 10.1128/jb.174.8.2511-2516.1992; TIAN GL, 1989, J BACTERIOL, V171, P1987, DOI 10.1128/jb.171.4.1987-1997.1989; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; VANDENELZEN PJM, 1983, NUCLEIC ACIDS RES, V11, P2465, DOI 10.1093/nar/11.8.2465; vanderWal FJ, 1995, FEMS MICROBIOL REV, V17, P381, DOI 10.1016/0168-6445(95)00022-4; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988	56	42	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31026	31032		10.1074/jbc.M403229200	http://dx.doi.org/10.1074/jbc.M403229200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140892	Green Published, hybrid			2022-12-25	WOS:000222726800016
J	Okubo, S; Hara, F; Tsuchida, Y; Shimotakahara, S; Suzuki, S; Hatanaka, H; Yokoyama, S; Tanaka, H; Yasuda, H; Shindo, H				Okubo, S; Hara, F; Tsuchida, Y; Shimotakahara, S; Suzuki, S; Hatanaka, H; Yokoyama, S; Tanaka, H; Yasuda, H; Shindo, H			NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; JUNCTION RESOLVASE; CRYSTAL-STRUCTURE; NUCLEAR; RECEPTOR; FAMILY; ACTIVATION; ATTACHMENT; UBIQUITIN; PROGRAM	A member of the PIAS ( protein inhibitor of activated STAT) family of proteins, PIAS1, have been reported to serve as an E3-type SUMO ligase for tumor suppressor p53 and its own. It also was proposed that the N-terminal domain of PIAS1 interacts with DNA as well as p53. Extensive biochemical studies have been devoted recently to understand sumoylations and its biological implications, whereas the structural aspects of the PIAS family and the mechanism of its interactions with various factors are less well known to date. In this study, the three-dimensional structure of the N-terminal domain ( residues 1 - 65) of SUMO ligase PIAS1 was determined by NMR spectroscopy. The structure revealed a unique four-helix bundle with a topology of an up-down-extended loop-down-up, a part of which the helix-extended loop-helix represented the SAP (SAF-A/B, Acinus, and PIAS) motif. Thus, this N-terminal domain may be referred to as a four-helix SAP domain. The glutathione S-transferase pull-down assay demonstrated that this domain possesses a binding ability to tumor suppressor p53, a target protein for sumoylation by PIAS1, whereas gel mobility assays showed that it has a strong affinity toward A/T-rich DNA. An NMR analysis of the four-helix SAP domain complexed with the 16-bp-long DNA demonstrated that one end of the four-helix bundle is the binding site and may fit into the minor groove of DNA. The three-dimensional structure and its binding duality are discussed in conjunction with the biological functions of PIAS1 as a SUMO ligase.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan; RIKEN Genom Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; SPring 8, RIKEN Harima Inst, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1100033, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 1920392, Japan	Tokyo University of Pharmacy & Life Sciences; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Shindo, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan.	shindo@ps.toyaku.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Ahn JS, 2003, J BIOL CHEM, V278, P29121, DOI 10.1074/jbc.M302314200; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Ceschini S, 2001, EMBO J, V20, P6601, DOI 10.1093/emboj/20.23.6601; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kracklauer Martin P, 2003, Mol Cancer, V2, P39, DOI 10.1186/1476-4598-2-39; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Zhang ZM, 2001, J BIOL CHEM, V276, P38231	43	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31455	31461		10.1074/jbc.M403561200	http://dx.doi.org/10.1074/jbc.M403561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133049	hybrid			2022-12-25	WOS:000222726800067
J	Pineda, AO; Carrell, CJ; Bush, LA; Prasad, S; Caccia, S; Chen, ZW; Mathews, FS; Di Cera, E				Pineda, AO; Carrell, CJ; Bush, LA; Prasad, S; Caccia, S; Chen, ZW; Mathews, FS; Di Cera, E			Molecular dissection of Na+ binding to thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN ALPHA-THROMBIN; MONOVALENT CATION SPECIFICITY; ACTIVE-SITE GEOMETRY; SERINE PROTEASES; CRYSTAL-STRUCTURE; SUBSTRATE-SPECIFICITY; CATALYTIC-ACTIVITY; STRUCTURAL BASIS; DIALKYLGLYCINE DECARBOXYLASE; ANTICOAGULANT ACTIVITY	Na+ binding near the primary specificity pocket of thrombin promotes the procoagulant, prothrombotic, and signaling functions of the enzyme. The effect is mediated allosterically by a communication between the Na+ site and regions involved in substrate recognition. Using a panel of 78 Ala mutants of thrombin, we have mapped the allosteric core of residues that are energetically linked to Na+ binding. These residues are Asp-189, Glu-217, Asp-222, and Tyr-225, all in close proximity to the bound Na+. Among these residues, Asp-189 shares with Asp-221 the important function of transducing Na+ binding into enhanced catalytic activity. None of the residues of exosite I, exosite II, or the 60-loop plays a significant role in Na+ binding and allosteric transduction. X-ray crystal structures of the Na+-free ( slow) and Na+-bound ( fast) forms of thrombin, free or bound to the active site inhibitor H-D-Phe-Pro-Arg-chloromethyl-ketone, document the conformational changes induced by Na+ binding. The slow 3 fast transition results in formation of the Arg-187:Asp-222 ion pair, optimal orientation of Asp-189 and Ser-195 for substrate binding, and a significant shift of the side chain of Glu-192 linked to a rearrangement of the network of water molecules that connect the bound Na+ to Ser-195 in the active site. The changes in the water network and the allosteric core explain the thermodynamic signatures linked to Na+ binding and the mechanism of thrombin activation by Na+. The role of the water network uncovered in this study establishes a new paradigm for the allosteric regulation of thrombin and other Na+-activated enzymes involved in blood coagulation and the immune response.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu	Caccia, Sonia/G-5938-2014	Caccia, Sonia/0000-0003-0829-5379	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R29HL049413, R01HL073813, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL58141, HL73813] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006; Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; Banner DW, 1997, THROMB HAEMOSTASIS, V78, P512; BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; Berg DT, 1996, SCIENCE, V273, P1389, DOI 10.1126/science.273.5280.1389; BODE W, 1992, PROTEIN SCI, V1, P426; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Colwell NS, 1998, BIOCHEMISTRY-US, V37, P15057, DOI 10.1021/bi980925f; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEGEN SJF, 1995, THROMB HAEMOSTASIS, V73, P203; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Esmon CT, 2003, CHEST, V124, p26S, DOI 10.1378/chest.124.3_suppl.26S; Friedrich R, 2003, NATURE, V425, P535, DOI 10.1038/nature01962; Frisch C, 2001, J MOL BIOL, V308, P69, DOI 10.1006/jmbi.2001.4577; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Greenspan NS, 1999, NAT BIOTECHNOL, V17, P936, DOI 10.1038/13590; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8757, DOI 10.1021/bi00195a017; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Henriksen RA, 1998, BLOOD, V91, P2026, DOI 10.1182/blood.V91.6.2026.2026_2026_2031; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Huntington JA, 2003, STRUCTURE, V11, P469, DOI 10.1016/S0969-2126(03)00049-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Krem MM, 1998, PROTEINS, V30, P34, DOI 10.1002/(SICI)1097-0134(19980101)30:1<34::AID-PROT3>3.0.CO;2-K; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Krem MM, 2002, J BIOL CHEM, V277, P40260, DOI 10.1074/jbc.M206173200; Krishnan R, 2000, ACTA CRYSTALLOGR D, V56, P406, DOI 10.1107/S0907444900001487; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; LANDIS BH, 1981, J BIOL CHEM, V256, P4604; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIU LW, 1991, J BIOL CHEM, V266, P16977; Mann KG, 2003, CHEST, V124, p4S, DOI 10.1378/chest.124.3_suppl.4S; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; McGee M, 2003, ARTERIOSCL THROM VAS, V23, P1921, DOI 10.1161/01.ATV.0000090673.96120.67; MCGRATH ME, 1992, BIOCHEMISTRY-US, V31, P3059, DOI 10.1021/bi00127a005; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN WG, 1995, BIOCHEMISTRY-US, V34, P9277, DOI 10.1021/bi00029a001; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pletnev VZ, 2000, PROTEINS, V41, P8, DOI 10.1002/1097-0134(20001001)41:1<8::AID-PROT30>3.0.CO;2-2; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Sanschagrin PC, 1998, PROTEIN SCI, V7, P2054, DOI 10.1002/pro.5560071002; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sichler K, 2002, J MOL BIOL, V322, P591, DOI 10.1016/S0022-2836(02)00747-7; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Yu EW, 2001, P NATL ACAD SCI USA, V98, P9517, DOI 10.1073/pnas.161239298; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	101	159	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31842	31853		10.1074/jbc.M401756200	http://dx.doi.org/10.1074/jbc.M401756200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15152000	hybrid			2022-12-25	WOS:000222726800111
J	Sol-Foulon, N; Esnault, CC; Percherancier, Y; Porrot, F; Metais-Cunha, P; Bachelerie, F; Schwartz, O				Sol-Foulon, N; Esnault, CC; Percherancier, Y; Porrot, F; Metais-Cunha, P; Bachelerie, F; Schwartz, O			The effects of HIV-1 nef on CD4 surface expression and viral infectivity in lymphoid cells are independent of rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; LIPID RAFTS; DOWN-REGULATION; T-CELLS; PROTEIN PALMITOYLATION; DENDRITIC CELLS; SUBCELLULAR-LOCALIZATION; ENVELOPE GLYCOPROTEIN; MEMBRANE DOMAINS	The HIV-1 Nef protein is a critical virulence factor that exerts multiple effects during viral replication. Nef modulates surface expression of various cellular proteins including CD4 and MHC-I, enhances viral infectivity, and affects signal transduction pathways. Nef has been shown to partially associate with rafts, where it can prime T cells for activation. The contribution of rafts during Nef-induced CD4 down-regulation and enhancement of viral replication remains poorly understood. We show here that Nef does not modify the palmitoylation state of CD4 or its partition within rafts. Moreover, CD4 mutants lacking palmitoylation or unable to associate with rafts are efficiently down-regulated by Nef. In HIV-infected cells, viral assembly and budding occurs from rafts, and Nef has been suggested to increase this process. However, using T cells acutely infected with wild-type or nef-deleted HIV, we did not observe any impact of Nef on raft segregation of viral structural proteins. We have also designed a palmitoylated mutant of Nef (NefG3C), which significantly accumulates in rafts. Interestingly, the efficiency of NefG3C to down-regulate CD4 and MHC-I, and to promote viral replication was not increased when compared with the wild-type protein. Altogether, these results strongly suggest that rafts are not a key element involved in the effects of Nef on trafficking of cellular proteins and on viral replication.	Inst Pasteur, Virus & Immun Grp, CNRS, URA 1930, F-75724 Paris 15, France; Inst Pasteur, Unite Immunol Virale, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schwartz, O (corresponding author), Inst Pasteur, Virus & Immun Grp, CNRS, URA 1930, 28 Rue Dr Roux, F-75724 Paris 15, France.	schwartz@pasteur.fr	Schwartz, Olivier/AAZ-3765-2021; BACHELERIE, FRANCOISE/F-8823-2013	Schwartz, Olivier/0000-0002-0729-1475; BACHELERIE, FRANCOISE/0000-0002-0399-3277; Sol-Foulon, Nathalie/0000-0002-2643-0311; percherancier, yann/0000-0002-2410-5806				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Alexander M, 2004, J VIROL, V78, P1685, DOI 10.1128/JVI.78.4.1685-1696.2004; Alonso MA, 2001, J CELL SCI, V114, P3957; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Briggs JAG, 2003, J GEN VIROL, V84, P757, DOI 10.1099/vir.0.18779-0; Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003; CINEK T, 1995, IMMUNOGENETICS, V41, P110, DOI 10.1007/BF00182321; Cohen GB, 2000, J BIOL CHEM, V275, P23097, DOI 10.1074/jbc.M000536200; CRISE B, 1992, J BIOL CHEM, V267, P13593; del Real G, 2002, J EXP MED, V196, P293, DOI 10.1084/jem.20020308; DERONDE A, 1992, VIROLOGY, V188, P391, DOI 10.1016/0042-6822(92)90772-H; Ding LM, 2003, J VIROL, V77, P1916, DOI 10.1128/JVI.77.3.1916-1926.2003; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Holm K, 2003, J VIROL, V77, P4805, DOI 10.1128/JVI.77.8.4805-4817.2003; Janardhan A, 2004, PLOS BIOL, V2, P65, DOI 10.1371/journal.pbio.0020006; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004; Lama J, 2000, J VIROL, V74, P9396, DOI 10.1128/JVI.74.20.9396-9402.2000; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Li M, 2002, J VIROL, V76, P11845, DOI 10.1128/JVI.76.23.11845-11852.2002; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Lundquist CA, 2002, J VIROL, V76, P4625, DOI 10.1128/JVI.76.9.4625-4633.2002; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Marechal V, 1998, J VIROL, V72, P2208; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nozawa N, 2003, J VIROL, V77, P3204, DOI 10.1128/JVI.77.5.3204-3216.2003; Ochsenbauer-Jambor C, 2001, J VIROL, V75, P11544, DOI 10.1128/JVI.75.23.11544-11554.2001; Olsen KEP, 1999, J VIROL, V73, P8975, DOI 10.1128/JVI.73.11.8975-8981.1999; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Petit C, 2001, VIROLOGY, V286, P225, DOI 10.1006/viro.2001.0984; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Rousso I, 2000, P NATL ACAD SCI USA, V97, P13523, DOI 10.1073/pnas.240459697; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; SALGHETTI S, 1995, P NATL ACAD SCI USA, V92, P349, DOI 10.1073/pnas.92.2.349; Sanfridson A, 1997, P NATL ACAD SCI USA, V94, P873, DOI 10.1073/pnas.94.3.873; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; SCHWARTZ O, 1993, J VIROL, V67, P3274, DOI 10.1128/JVI.67.6.3274-3280.1993; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211; Suomalainen M, 2002, TRAFFIC, V3, P705, DOI 10.1034/j.1600-0854.2002.31002.x; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; Swingler S, 2003, NATURE, V424, P213, DOI 10.1038/nature01749; Tobiume M, 2003, J VIROL, V77, P10645, DOI 10.1128/JVI.77.19.10645-10650.2003; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Venkatesan S, 2003, MOL BIOL CELL, V14, P3305, DOI 10.1091/mbc.e02-11-0714; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Walk SF, 2001, J VIROL, V75, P834, DOI 10.1128/JVI.75.2.834-843.2001; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Wei BL, 2003, CURR HIV RES, V1, P41, DOI 10.2174/1570162033352057; Witte V, 2004, MOL CELL, V13, P179, DOI 10.1016/S1097-2765(04)00004-8; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871; Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000; Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8; Zheng YH, 2003, P NATL ACAD SCI USA, V100, P8460, DOI 10.1073/pnas.1437453100	95	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31398	31408		10.1074/jbc.M401621200	http://dx.doi.org/10.1074/jbc.M401621200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133044	hybrid			2022-12-25	WOS:000222726800061
J	Thornton, C; Tang, KC; Phamluong, K; Luong, K; Vagts, A; Nikanjam, D; Yaka, R; Ron, D				Thornton, C; Tang, KC; Phamluong, K; Luong, K; Vagts, A; Nikanjam, D; Yaka, R; Ron, D			Spatial and temporal regulation of RACK1 function and N-methyl-D-aspartate receptor activity through WD40 motif-mediated dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NMDA RECEPTOR; CRYSTAL-STRUCTURE; SCAFFOLD PROTEIN; GENE-EXPRESSION; BETA; BINDING; INTERACTS; SUBUNIT; ASSOCIATION	Efficient signaling requires accurate spatial and temporal compartmentalization of proteins. RACK1 is a scaffolding protein that fulfils this role through interaction of binding partners with one of its seven WD40 domains. We recently identified the kinase Fyn and the NR2B subunit of the N-methyl-D-Aspartate receptor ( NMDAR) as binding partners of RACK1. Scaffolding of Fyn near its substrate NR2B by RACK1 inhibits Fyn phosphorylation of NR2B and thereby negatively regulates channel function. We found that Fyn and NR2B share the same binding site on RACK1; however, their binding to RACK1 is not mutually exclusive (Yaka, R., Thornton, C., Vagts, A. J., Phamluong, K., Bonci, A., and Ron, D. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5710 5715). We therefore tested the hypothesis that RACK1 forms a homodimer that allows the simultaneous binding of Fyn and NR2B. We found that RACK1 binds to itself both in vitro and in the brain. Deletion analyses identified a RACK1-RACK1 dimer-binding site within the 4th WD40 repeat, and application of the 4th WD40 repeat or a peptide derivative to hippocampal slices inhibited NMDAR activity. We further found that in hippocampal slices, both RACK1 and NR2B associated with another WD40 protein, the beta-subunit of G protein (Gbeta), previously shown to heterodimerize with RACK1 in vitro ( Dell, E. J., Connor, J., Chen, S., Stebbins, E. G., Skiba, N. P., Mochly- Rosen, D., and Hamm, H. E. ( 2002) J. Biol. Chem. 277, 49888 - 49895). However, activation of the pituitary adenylate cyclase polypeptide ( 1 - 38) G protein-coupled receptor, previously found to induce the dissociation of RACK1 from the NMDAR complex ( Yaka, R., He, D. Y., Phamluong, K., and Ron, D. ( 2003) J. Biol. Chem. 278, 9630 - 9638), attenuated the association of Gbeta with RACK1 and NR2B. Based on these results, we propose that WD40-mediated homo- and heterodimerization of RACK1 mediate the formation of a transient signaling complex that includes the NMDAR, a G protein and Fyn.	Ernest Gallo Res Ctr, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Ron, D (corresponding author), 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	dorit@itsa.ucsf.edu						Angenstein F, 2002, J NEUROSCI, V22, P8827; Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Chen SH, 2004, J BIOL CHEM, V279, P17861, DOI 10.1074/jbc.M313727200; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Fagni Laurent, 2002, Sci STKE, V2002, pre8, DOI 10.1126/stke.2002.137.re8; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KIELY PA, 2002, J BIOL CHEM, V8, P6; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Liedtke CM, 2004, AM J PHYSIOL-CELL PH, V286, pC1037, DOI 10.1152/ajpcell.00222.2003; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Mourton T, 2001, J BIOL CHEM, V13, P13; Pei L, 2004, J NEUROSCI, V24, P1149, DOI 10.1523/JNEUROSCI.3922-03.2004; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Thornton C, 2003, J BIOL CHEM, V278, P23823, DOI 10.1074/jbc.M302389200; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Wilson SE, 1998, NUCLEIC ACIDS RES, V26, P2457, DOI 10.1093/nar/26.10.2457; Yaka R, 2003, J NEUROSCI, V23, P3623; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	36	62	67	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31357	31364		10.1074/jbc.M402316200	http://dx.doi.org/10.1074/jbc.M402316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140893	hybrid			2022-12-25	WOS:000222726800056
J	Blois, JT; Mataraza, JM; Mecklenbrauker, I; Tarakhovsky, A; Chiles, TC				Blois, JT; Mataraza, JM; Mecklenbrauker, I; Tarakhovsky, A; Chiles, TC			B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; NF-KAPPA-B; TRANSCRIPTION FACTOR; SURFACE-IMMUNOGLOBULIN; FACTOR CREB; SH2 DOMAIN; PKC-DELTA; PHOSPHORYLATION; PATHWAY; BLNK	The cAMP-response element-binding protein ( CREB) is activated by phosphorylation on Ser-133 and plays a key role in the proliferative and survival responses of mature B cells to B cell receptor (BCR) signaling. The signal link between the BCR and CREB activation depends on a phorbol ester (phorbol 12-myristate 13-acetate)-sensitive protein kinase C (PKC) activity and not protein kinase A or calmodulin kinase; however, the identity and role of the PKC(s) activity has not been elucidated. We found the novel PKCdelta (nPKCdelta) activator bistratene A is sufficient to induce CREB phosphorylation in murine splenic B cells. The pharmacological inhibitor Go6976, which targets conventional PKCs and PKC mu, has no effect on CREB phosphorylation, whereas the nPKCdelta inhibitor rottlerin blocks CREB phosphorylation following BCR cross-linking. Bryostatin 1 selectively prevents nPKCdelta depletion by phorbol 12-myristate 13-acetate when coapplied, coincident with protection of BCR-induced CREB phosphorylation. Ectopic expression of a kinase-inactive nPKCdelta blocks BCR-induced CREB phosphorylation in A20 B cells. In addition, BCR-induced CREB phosphorylation is significantly diminished in nPKCdelta-deficient splenic B cells in comparison with wild type mice. Consistent with the essential role for Bruton's tyrosine kinase and phospholipase Cgamma2 in mediating PKC activation, Bruton's tyrosine kinase- and phospholipase Cgamma2-deficient B cells display defective CREB phosphorylation by the BCR. We also found that p90 RSK directly phosphorylates CREB on Ser-133 following BCR cross-linking and is positioned downstream of nPKCdelta. Taken together, these results suggest a model in which BCR engagement leads to the phosphorylation of CREB via a signaling pathway that requires nPKCdelta and p90 RSK in mature B cells.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA; Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10021 USA	Boston College; Rockefeller University	Chiles, TC (corresponding author), Boston Coll, Dept Biol, 414 Higgings Hall, Chestnut Hill, MA 02467 USA.	ChilesT@bc.edu			NIAID NIH HHS [AI34586] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034586, R29AI034586] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amato SF, 1996, J IMMUNOL, V157, P146; Antony P, 2003, EXP CELL RES, V291, P11, DOI 10.1016/S0014-4827(03)00338-0; Barbazuk SM, 1999, IMMUNOL LETT, V69, P259, DOI 10.1016/S0165-2478(99)00090-5; Bhushan A, 2001, EUR J IMMUNOL, V31, P653, DOI 10.1002/1521-4141(200102)31:2<653::AID-IMMU653>3.0.CO;2-D; Cariappa A, 1999, J IMMUNOL, V162, P4417; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; FEURSTEIN N, 1996, J IMMUNOL, V156, P4582; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Frissora F, 2003, EUR J IMMUNOL, V33, P907, DOI 10.1002/eji.200323657; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Gubina E, 2001, J IMMUNOL, V167, P4303, DOI 10.4049/jimmunol.167.8.4303; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Ishiai M, 1999, J IMMUNOL, V163, P1746; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1991, J IMMUNOL, V147, P3981; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; MORENO CS, 1995, J IMMUNOL, V155, P4313; Muthusamy N, 1998, J BIOL CHEM, V273, P22841, DOI 10.1074/jbc.273.35.22841; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; PONGUBALA JMR, 1995, J BIOL CHEM, V270, P10304, DOI 10.1074/jbc.270.17.10304; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Stevens S, 2000, J IMMUNOL, V164, P6372, DOI 10.4049/jimmunol.164.12.6372; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Swart JM, 2000, J IMMUNOL, V164, P2311, DOI 10.4049/jimmunol.164.5.2311; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Watters D, 1996, EXP CELL RES, V229, P327, DOI 10.1006/excr.1996.0378; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xie HJ, 1996, CELL IMMUNOL, V169, P264, DOI 10.1006/cimm.1996.0117; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhang CY, 2002, J BIOL CHEM, V277, P48359, DOI 10.1074/jbc.M209329200	62	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30123	30132		10.1074/jbc.M402793200	http://dx.doi.org/10.1074/jbc.M402793200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15138267	hybrid			2022-12-25	WOS:000222531900033
J	Bresson, D; Pugniere, M; Roquet, F; Rebuffat, SA; N-Guyen, B; Cerutti, M; Guo, J; McLachlan, SM; Rapoport, B; Estienne, V; Ruf, J; Chardes, T; Peraldi-Roux, S				Bresson, D; Pugniere, M; Roquet, F; Rebuffat, SA; N-Guyen, B; Cerutti, M; Guo, J; McLachlan, SM; Rapoport, B; Estienne, V; Ruf, J; Chardes, T; Peraldi-Roux, S			Directed mutagenesis in region 713-720 of human thyroperoxidase assigns (KFPED717)-K-713 residues as being involved in the B domain of the discontinuous immunodominant region recognized by human autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; CELL-MEDIATED CYTOTOXICITY; IMMUNOGLOBULIN GENE USAGE; POLYMERASE CHAIN-REACTION; AUTOIMMUNE-DISEASE; CONFORMATIONAL EPITOPES; HASHIMOTOS-THYROIDITIS; 3-DIMENSIONAL MODEL; ANTIBODIES; ANTIGEN	Autoantibodies (aAbs) to thyroid peroxidase (TPO), the hallmark of autoimmune thyroid disease (AITD), recognize conformational epitopes restricted to an immunodominant region (IDR), divided into two overlapping domains A and B. Despite numerous efforts aimed at localizing the IDR and identifying aAb-interacting residues on TPO, only two critical amino acids, Lys(713) and Tyr(772), have been characterized. Precise and complete delineation of the other residues involved in the IDR remains to be defined. By using a recombinant anti-TPO aAb T13, we demonstrated that four regions on TPO are part of the IDR/B; one of them, located between amino acids 713 and 720, is particularly important for the binding of sera from patients suffering from AITD. To precisely define critical residues implicated in the binding of aAb to human TPO, we used directed mutagenesis and expressed the mutants in stably transfected CHO cells. Then we assessed the kinetic parameters involved in the interactions between anti-TPO aAbs and mutants by real-time analysis. We identified (i) the minimal epitope 713-717 recognized by mAb 47 (a reference antibody) and (ii) the amino acids used as contact points for two IDR-specific human monoclonal aAbs TR1.9 (Pro(715) and Asp(717)) and T13 (Lys(713), Phe(714), Pro(715), and Glu(716)). Using a rational strategy to identify complex epitopes on proteins showing a highly convoluted architecture, this study definitively identifies the amino acids Lys(713)-Asp(717) as being the key residues recognized by IDR/B-specific anti-TPO aAbs in AITD.	Fac Pharm Montpellier, Ctr Pharmacol & Biotechnol Sante, CNRS, UMR 5160, F-34093 Montpellier 5, France; INRA, Stn Rech Pathol Comparee, CNRS, FRE 2689, F-30380 St Christol Les Ales, France; Cedars Sinai Res Inst, Autoimmune Dis Unit, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA; Fac Med Marseille, Lab Biochim Endocrinienne & Metab, INSERM, U555, F-13385 Marseille 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); INRAE; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Peraldi-Roux, S (corresponding author), Fac Pharm Montpellier, Ctr Pharmacol & Biotechnol Sante, CNRS, UMR 5160, 15 Ave Charles Flahault,BP 14491, F-34093 Montpellier 5, France.	sylvie.roux@ibph.pharma.univ-montp1.fr	Ruf, Jean/E-3963-2016; Chardès, Thierry/B-5420-2019; PUGNIERE, Martine/AAD-4315-2020; Pugniere, Martine/T-1355-2017	Ruf, Jean/0000-0003-4300-8048; Chardès, Thierry/0000-0002-1836-7439; PUGNIERE, Martine/0000-0002-2049-2909; Pugniere, Martine/0000-0002-2049-2909; Rebuffat, Sandra/0000-0002-1102-4935				Arscott PL, 1996, J BIOL CHEM, V271, P4966; BANGA JP, 1990, AUTOIMMUNITY, V6, P257, DOI 10.3109/08916939008998418; Bes C, 2003, J BIOL CHEM, V278, P14265, DOI 10.1074/jbc.M210694200; Blanchin S, 2002, BIOCHEM BIOPH RES CO, V295, P1118, DOI 10.1016/S0006-291X(02)00827-6; Bresson D, 2003, J BIOL CHEM, V278, P9560, DOI 10.1074/jbc.M211930200; Bresson Damien, 2001, Human Antibodies, V10, P109; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CHAZENBALK GD, 1993, J CLIN ENDOCR METAB, V77, P1715, DOI 10.1210/jc.77.6.1715; CHIOVATO L, 1993, J CLIN ENDOCR METAB, V77, P1700, DOI 10.1210/jc.77.6.1700; Christen U, 2004, MOL IMMUNOL, V40, P1113, DOI 10.1016/j.molimm.2003.11.014; Czarnocka B, 1997, J CLIN ENDOCR METAB, V82, P2639, DOI 10.1210/jc.82.8.2639; Dai Y, 1999, J IMMUNOL, V162, P6987; Estienne V, 1998, J BIOL CHEM, V273, P8056, DOI 10.1074/jbc.273.14.8056; Estienne V, 2002, INT IMMUNOL, V14, P359, DOI 10.1093/intimm/14.4.359; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; EWINS DL, 1992, AUTOIMMUNITY, V11, P141, DOI 10.3109/08916939209035148; Fairweather D, 2002, NAT IMMUNOL, V3, P338, DOI 10.1038/ni0402-338; FINKE R, 1990, J CLIN ENDOCR METAB, V71, P53, DOI 10.1210/jcem-71-1-53; Flodstrom-Tullberg M, 2003, MICROBES INFECT, V5, P911, DOI 10.1016/S1286-4579(03)00161-8; FRORATH B, 1992, J BIOCHEM-TOKYO, V111, P633, DOI 10.1093/oxfordjournals.jbchem.a123810; Gardas A, 2000, REDOX REP, V5, P237, DOI 10.1179/135100000101535681; Gardas A, 1997, BIOCHEM BIOPH RES CO, V234, P366, DOI 10.1006/bbrc.1997.6600; Guo J, 1997, J CLIN ENDOCR METAB, V82, P925, DOI 10.1210/jc.82.3.925; Guo J, 1998, CLIN EXP IMMUNOL, V111, P408; Guo J, 2002, J BIOL CHEM, V277, P40189, DOI 10.1074/jbc.M205524200; Guo J, 2000, CLIN EXP IMMUNOL, V119, P38, DOI 10.1046/j.1365-2249.2000.01087.x; Guo J, 2001, J IMMUNOL, V166, P1327, DOI 10.4049/jimmunol.166.2.1327; Hendry E, 1999, J ENDOCRINOL, V160, pR13, DOI 10.1677/joe.0.160R013; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobby P, 2000, ENDOCRINOLOGY, V141, P2018, DOI 10.1210/en.141.6.2018; Jones FG, 1999, AUTOIMMUNITY, V30, P157, DOI 10.3109/08916939908993850; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; LIBERT F, 1991, J CLIN ENDOCR METAB, V73, P857, DOI 10.1210/jcem-73-4-857; McLachlan S M, 2000, Int Rev Immunol, V19, P587, DOI 10.3109/08830180009088514; Metcalfe RA, 1997, AUTOIMMUNITY, V25, P65, DOI 10.3109/08916939708996272; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; NISHIKAWA T, 1993, ENDOCRINOLOGY, V133, P2496, DOI 10.1210/en.133.6.2496; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V79, P1648, DOI 10.1210/jc.79.6.1648; PARKES AB, 1994, J CLIN ENDOCR METAB, V79, P395, DOI 10.1210/jc.79.2.395; PORTOLANO S, 1992, J CLIN INVEST, V90, P720, DOI 10.1172/JCI115943; Regner M, 2001, NAT IMMUNOL, V2, P185, DOI 10.1038/85228; Rodien P, 1996, J CLIN ENDOCR METAB, V81, P2595, DOI 10.1210/jc.81.7.2595; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tong JC, 2002, ANN NY ACAD SCI, V958, P182; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; von Herrath MG, 2000, J NEUROIMMUNOL, V107, P154, DOI 10.1016/S0165-5728(00)00227-7; ZANELLI E, 1993, CELL MOL BIOL, V39, P491; ZANELLI E, 1992, CLIN EXP IMMUNOL, V87, P80; Zinkernagel RM, 2002, ANN NY ACAD SCI, V958, P3	50	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2004	279	37					39058	39067		10.1074/jbc.M403897200	http://dx.doi.org/10.1074/jbc.M403897200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	851KN	15150267	hybrid			2022-12-25	WOS:000223684100121
J	Horn, NA; Hurst, GB; Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB				Horn, NA; Hurst, GB; Mayasundari, A; Whittemore, NA; Serpersu, EH; Peterson, CB			Assignment of the four disulfides in the N-terminal somatomedin B domain of native vitronectin isolated from human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CYSTINE-KNOT; CELL-ADHESION; ALPHA-SUBUNIT; PROTEINS; BINDING; PAI-1; RESOLUTION; BRIDGES; BONDS	The primary sequence of the N-terminal somatomedin B (SMB) domain of native vitronectin contains 44 amino acids, including a framework of four disulfide bonds formed by 8 closely spaced cysteines in sequence patterns similar to those found in the cystine knot family of proteins. The SMB domain of vitronectin was isolated by digesting the protein with endoproteinase Glu-C and purifying the N-terminal 1-55 peptide by reverse-phase high performance liquid chromatography. Through a combination of techniques, including stepwise reduction and alkylation at acidic pH, peptide mapping with matrix-assisted laser desorption ionization mass spectrometry and NMR, the disulfide bonds contained in the SMB domain have been determined to be Cys(5):Cys(9), Cys(19):Cys(31), Cys(21):Cys(32), and Cys(25):Cys(39). This pattern of disulfides differs from two other connectivities that have been reported previously for recombinant forms of the SMB domain expressed in Escherichia coli. This arrangement of disulfide bonds in the SMB domain from native vitronectin forms a rigid core around the Cys(19):Cys(31) and Cys(21):Cys(32) disulfides. A small positively charged loop is created at the N terminus by the Cys(5):Cys(9) cystine. The most prominent feature of this disulfide-bonding pattern is a loop between Cys(25) and Cys(39) similar to cystine-stabilized alpha-helical structures commonly observed in cystine knots. This alpha-helix has been confirmed in the solution structure determined for this domain using NMR (Mayasundari, A., Whittemore, N. A., Serpersu, E. H., and Peterson, C. B. (2004) J. Biol. Chem. 279, 29359-29366). It confers function on the SMB domain, comprising the site for binding to plasminogen activator inhibitor type-1 and the urokinase receptor.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Excellence Struct Biol, Knoxville, TN 37996 USA; Oak Ridge Natl Lab, Div Chem Sci, Oak Ridge, TN 37831 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory	Peterson, CB (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, M407 Walters Life Sci Bldg, Knoxville, TN 37996 USA.	cynthia_peterson@utk.edu		Serpersu, Engin H./0000-0003-1420-455X; Hurst, Gregory/0000-0002-7650-8009	NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Avsian-Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003-0227; Calabro V, 1997, J PEPT RES, V50, P39; Cemazar M, 2004, J BIOL CHEM, V279, P16697, DOI 10.1074/jbc.M312328200; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; Daly NL, 2003, J BIOL CHEM, V278, P6314, DOI 10.1074/jbc.M210492200; Darling RJ, 2000, J BIOL CHEM, V275, P15413, DOI 10.1074/jbc.275.20.15413; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Escoubas P, 2004, TOXICON, V43, P555, DOI 10.1016/j.toxicon.2004.02.007; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Hiro'oka T, 2000, ENDOCRINOLOGY, V141, P4751, DOI 10.1210/en.141.12.4751; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kamikubo Y, 2004, BIOCHEMISTRY-US, V43, P6519, DOI 10.1021/bi049647c; Kamikubo Y, 2002, J BIOL CHEM, V277, P27109, DOI 10.1074/jbc.M200354200; KARL R, 1999, ANAL CHEM, V71, P2871; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Mayasundari A, 2004, J BIOL CHEM, V279, P29359, DOI 10.1074/jbc.M401279200; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Mousa Shaker A, 2002, Curr Opin Investig Drugs, V3, P1191; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; Schroeck F, 2002, BIOL CHEM, V383, P1143, DOI 10.1515/BC.2002.125; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; Taylor WR, 2003, COMPUT BIOL CHEM, V27, P11, DOI 10.1016/S1476-9271(02)00099-3; Vitt UA, 2001, MOL ENDOCRINOL, V15, P681, DOI 10.1210/me.15.5.681; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wechsler-Reya RJ, 2001, TRENDS NEUROSCI, V24, P680, DOI 10.1016/S0166-2236(00)02058-0; Wilken JA, 2004, BIOCHEMISTRY-US, V43, P5109, DOI 10.1021/bi049856x; Wu Jiang, 2002, Methods Mol Biol, V194, P1; Xu D, 2001, PROTEINS, V44, P312, DOI 10.1002/prot.1096; Yen TY, 2002, J MASS SPECTROM, V37, P15, DOI 10.1002/jms.241; Young Y, 1999, J PEPT RES, V54, P514, DOI 10.1034/j.1399-3011.1999.00126.x; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhu Q, 2002, BIOCHEMISTRY-US, V41, P11488, DOI 10.1021/bi026136m; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	59	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 20	2004	279	34					35867	35878		10.1074/jbc.M405716200	http://dx.doi.org/10.1074/jbc.M405716200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	846GJ	15173163	hybrid, Green Published			2022-12-25	WOS:000223303400088
J	Davis, HR; Zhu, LJ; Hoos, LM; Tetzloff, G; Maguire, M; Liu, JJ; Yao, XR; Iyer, SPN; Lam, MH; Lund, EG; Detmers, PA; Graziano, MP; Altmann, SW				Davis, HR; Zhu, LJ; Hoos, LM; Tetzloff, G; Maguire, M; Liu, JJ; Yao, XR; Iyer, SPN; Lam, MH; Lund, EG; Detmers, PA; Graziano, MP; Altmann, SW			Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSORPTION INHIBITOR; DIETARY-CHOLESTEROL; MESSENGER-RNA; EZETIMIBE; IDENTIFICATION; POTENT; ABCG5; EXPRESSION; DISCOVERY; EFFLUX	Niemann-Pick C1 Like 1 (NPC1L1) is a protein localized in jejunal enterocytes that is critical for intestinal cholesterol absorption. The uptake of intestinal phytosterols and cholesterol into absorptive enterocytes in the intestine is not fully defined on a molecular level, and the role of NPC1L1 in maintaining whole body cholesterol homeostasis is not known. NPC1L1 null mice had substantially reduced intestinal uptake of cholesterol and sitosterol, with dramatically reduced plasma phytosterol levels. The NPC1L1 null mice were completely resistant to diet-induced hypercholesterolemia, with plasma lipoprotein and hepatic cholesterol profiles similar to those of wild type mice treated with the cholesterol absorption inhibitor ezetimibe. Cholesterol/cholate feeding resulted in down-regulation of intestinal NPC1L1 mRNA expression in wild type mice. NPC1L1 deficiency resulted in up-regulation of intestinal hydroxymethylglutaryl-CoA synthase mRNA and an increase in intestinal cholesterol synthesis, down-regulation of ABCA1 mRNA, and no change in ABCG5 and ABCG8 mRNA expression. NPC1L1 is required for intestinal uptake of both cholesterol and phytosterols and plays a major role in cholesterol homeostasis. Thus, NPC1L1 may be a useful drug target for the treatment of hypercholesterolemia and sitosterolemia.	Schering Plough Corp, Res Inst, Dept Cardiovasc Metab Dis, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Discovery Technol, Kenilworth, NJ 07033 USA; Merck Res Labs, Dept Cardiovasc Dis, Rahway, NJ 07065 USA; Merck Res Labs, Dept Immunol, Rahway, NJ 07065 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Merck & Company	Davis, HR (corresponding author), Schering Plough Corp, Res Inst, Dept Cardiovasc Metab Dis, K15-2-2600,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	harry.davis@spcorp.com						Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; Altmann SW, 2002, BBA-MOL CELL BIOL L, V1580, P77, DOI 10.1016/S1388-1981(01)00190-1; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; BURRIER RE, 1994, BIOCHEM PHARMACOL, V47, P1545, DOI 10.1016/0006-2952(94)90530-4; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Davis HR, 2001, ARTERIOSCL THROM VAS, V21, P2032, DOI 10.1161/hq1201.100260; Davis HR, 2001, METABOLISM, V50, P1234, DOI 10.1053/meta.2001.26737; Gagne C, 2002, AM J CARDIOL, V90, P1084, DOI 10.1016/S0002-9149(02)02774-1; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Repa JJ, 2002, J LIPID RES, V43, P1864, DOI 10.1194/jlr.M200144-JLR200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rosenblum SB, 1998, J MED CHEM, V41, P973, DOI 10.1021/jm970701f; Salen G, 2004, CIRCULATION, V109, P966, DOI 10.1161/01.CIR.0000116766.31036.03; Sudhop T, 2002, CIRCULATION, V106, P1943, DOI 10.1161/01.CIR.0000034044.95911.DC; van Heek M, 2003, BRIT J PHARMACOL, V138, P1459, DOI 10.1038/sj.bjp.0705187; van Heek M, 2001, EUR J PHARMACOL, V415, P79, DOI 10.1016/S0014-2999(01)00825-1; van Heek M, 2001, BRIT J PHARMACOL, V134, P409, DOI 10.1038/sj.bjp.0704260; VanHeek M, 1997, J PHARMACOL EXP THER, V283, P157; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	22	525	549	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33586	33592		10.1074/jbc.M405817200	http://dx.doi.org/10.1074/jbc.M405817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15173162	hybrid			2022-12-25	WOS:000223039700067
J	Midwinter, RG; Peskin, AV; Vissers, MCM; Winterbourn, CC				Midwinter, RG; Peskin, AV; Vissers, MCM; Winterbourn, CC			Extracellular oxidation by taurine chloramine activates ERK via the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; HYDROGEN PEROXIDE-CHLORIDE; HYPOCHLOROUS ACID; ENDOTHELIAL-CELLS; NITRIC-OXIDE; KINASE-ACTIVITY; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; INFLAMMATORY MEDIATORS; SIGNAL-TRANSDUCTION	Taurine is present in high concentrations in neutrophils, and when the cells are stimulated taurine can react with hypochlorous acid (HOCl) to form taurine-chloramine (Tau-Cl). This compound retains oxidant activity and can affect the neutrophil itself or surrounding tissue cells. We have investigated the effects of Tau-Cl on MAPK signaling in human umbilical vein endothelial cells ( HUVEC). Tau-Cl caused no loss in intracellular glutathione or inactivation of the thiol-sensitive enzyme glyceral-dehyde-3-phosphate dehydrogenase, indicating that it had not entered the cells. However, stimulation of HUVEC with Tau-Cl (20-100 muM) induced the rapid activation of ERK within 10 min. This activation was abolished by inhibition of MEK by U0126, indicating that it was not because of direct oxidation of ERK. No activation of p38 was detected. These results suggest that Tau-Cl reacts with a cell membrane target that results in intracellular ERK activation. Tau-Cl over the same concentration range and time scale stimulated epidermal growth factor (EGF) receptor tyrosine phosphorylation in A431 cells and HUVEC. The EGF receptor inhibitor PD158780 significantly attenuated Tau-Cl-induced phosphorylation of both the EGF receptor and ERK. This implicates the EGF receptor in the upstream activation of ERK. The Src tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolol[3,4-d]pyrimidine had no effect on Tau-Cl-induced EGF receptor or ERK activation. We propose that Tau-Cl acts on an oxidant-sensitive target on the cell surface, this being either the EGF receptor itself or another target that can interact with the EGF receptor, with consequential activation of ERK.	Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, Christchurch 8001, New Zealand	University of Otago	Midwinter, RG (corresponding author), Christchurch Sch Med & Hlth Sci, Free Rad Res Grp, Dept Pathol, POB 4345, Christchurch 8001, New Zealand.	robyn.midwinter@chmeds.ac.nz	Peskin, alexander/R-6457-2019; Vissers, Margreet C M/T-4159-2017	peskin, alexander/0000-0001-9890-6043				Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; Beutler E., 1984, RED CELL METABOLISM, P51; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chorazy M, 2002, AMINO ACIDS, V23, P407, DOI 10.1007/s00726-002-0204-0; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Englert RP, 2002, J BIOL CHEM, V277, P20518, DOI 10.1074/jbc.M200212200; FUKUDA K, 1982, CLIN CHEM, V28, P1758; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; GRISHAM MB, 1984, J BIOL CHEM, V259, P6676; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Liu Y, 2003, ADV EXP MED BIOL, V526, P365; Marcinkiewicz J, 2003, IMMUNOL LETT, V89, P187, DOI 10.1016/S0165-2478(03)00140-8; Marcinkiewicz J, 1995, J LEUKOCYTE BIOL, V58, P667, DOI 10.1002/jlb.58.6.667; Midwinter RG, 2001, ARCH BIOCHEM BIOPHYS, V394, P13, DOI 10.1006/abbi.2001.2530; Milligan SA, 1998, ARCH BIOCHEM BIOPHYS, V352, P255, DOI 10.1006/abbi.1998.0603; NAITO Y, 1997, J CLIN GASTRONETE S1, V25, P179; Oliveira CJR, 2003, FREE RADICAL BIO MED, V35, P381, DOI 10.1016/S0891-5849(03)00311-3; PARK E, 1995, J IMMUNOL, V154, P4778; Park S, 2001, BIOCHEM PHARMACOL, V62, P1107, DOI 10.1016/S0006-2952(01)00741-9; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597, DOI 10.1152/ajpheart.1994.267.4.H1597; Thomas E L, 1986, Methods Enzymol, V132, P569; Thomas E L, 1986, Methods Enzymol, V132, P585; THOMAS EL, 1979, INFECT IMMUN, V25, P110, DOI 10.1128/IAI.25.1.110-116.1979; Thomas EL, 2000, REDOX REP, V5, P191, DOI 10.1179/135100000101535744; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; Vissers MCM, 2001, J BIOL CHEM, V276, P46835, DOI 10.1074/jbc.M107664200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199	52	40	40	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32205	32211		10.1074/jbc.M402070200	http://dx.doi.org/10.1074/jbc.M402070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166244	hybrid			2022-12-25	WOS:000222849700027
J	Mironova, GD; Negoda, AE; Marinov, BS; Paucek, P; Costa, ADT; Grigoriev, SM; Skarga, YY; Garlid, KD				Mironova, GD; Negoda, AE; Marinov, BS; Paucek, P; Costa, ADT; Grigoriev, SM; Skarga, YY; Garlid, KD			Functional distinctions between the mitochondrial ATP-dependent K+ channel (mitoK(ATP)) and its inward rectifier subunit (mitoKIR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; HEART-MITOCHONDRIA; CATION-TRANSPORT; LIGHT-SCATTERING; INNER MEMBRANE; RECONSTITUTION; ACTIVATION; MECHANISM; COA	The ATP-sensitive potassium channel from the inner mitochondrial membrane ( mitoKATP) is a highly selective conductor of K+ ions. When isolated in the presence of nonionic detergent and reconstituted in liposomes, mitoK(ATP) is inhibited with high affinity by ATP (K-1/2 = 20-30 muM). We have suggested that holo-mitoK(ATP) is a heteromultimer consisting of an inwardly rectifying K+ channel (mitoKIR) and a sulfonylurea receptor (Grover, G. J., and Garlid, K. D. ( 2000) J. Mol. Cell. Cardiol. 32, 677-695). Here, we show that a 55-kDa protein isolated by ethanol extraction and reconstituted in bilayer lipid membranes and liposomes is the mitoKIR. This protein, which lacks the sulfonylurea receptor subunit, is inhibited with low affinity by ATP, with K-1/2 similar to 550 muM. ATP inhibition of both mitoKIR and holo-mitoK(ATP) is reversed by UDP (K-1/2 = 10-15 muM). Holo-mitoK(ATP) is opened by cromakalim and diazoxide, and the flux through the open channel is inhibited by glibenclamide and 5-hydroxydecanoate. None of these agents has any effect upon mitoKIR. We have identified two compounds that act specifically on mitoKIR. p-diethylaminoethylbenzoate reverses inhibition of mitoKIR by ATP and ADP at micromolar concentrations and also opens mitoK(ATP) in isolated mitochondria. Tetraphenylphosphonium inhibits K+ flux through both mitoKIR and mitoK(ATP) with the same apparent affinity. These findings support the hypothesis that the 55-kDa mitoKIR is the channel component of mitoK(ATP).	Portland State Univ, Dept Biol, Portland, OR 97207 USA; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142290, Moscow Region, Russia	Portland State University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics	Garlid, KD (corresponding author), Portland State Univ, Dept Biol, POB 751, Portland, OR 97207 USA.	garlid@pdx.edu	Costa, Alexandre Dias Tavares/ABB-1896-2021; Costa, Alexandre Augusto da/HCJ-0140-2022; Mironova, Galina D/Y-3702-2019	Costa, Alexandre Dias Tavares/0000-0001-8434-2152; Costa, Alexandre Augusto da/0000-0001-7558-5435; Mironova, Galina D/0000-0001-7432-0902; Garlid, Keith/0000-0002-6777-1235	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL067842] Funding Source: NIH RePORTER; FIC NIH HHS [TW01116] Funding Source: Medline; NHLBI NIH HHS [HL67842, HL36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Bajgar R, 2001, J BIOL CHEM, V276, P33369, DOI 10.1074/jbc.M103320200; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Branstrom R, 1997, J BIOL CHEM, V272, P17390, DOI 10.1074/jbc.272.28.17390; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; Dos Santos P, 2002, AM J PHYSIOL-HEART C, V283, pH284, DOI 10.1152/ajpheart.00034.2002; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Garlid KD, 2000, BASIC RES CARDIOL, V95, P275, DOI 10.1007/s003950070046; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 2001, IUBMB LIFE, V52, P153, DOI 10.1080/15216540152845948; GARLID KD, 1985, J BIOL CHEM, V260, P3434; Garlid KD, 1997, CIRC RES, V81, P1072; Garlid KD, 1996, BBA-BIOENERGETICS, V1275, P123, DOI 10.1016/0005-2728(96)00061-8; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Garlid Keith D., 1996, Biophysical Journal, V70, pA311; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Grigoriev SM, 1999, BBA-BIOENERGETICS, V1410, P91, DOI 10.1016/S0005-2728(98)00179-0; Grover GJ, 2000, J MOL CELL CARDIOL, V32, P677, DOI 10.1006/jmcc.2000.1111; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLIB MA, 1984, METHOD PHARMACOL, V5, P25; Mironova G. D., 1981, Biophysics, V26, P458; Mironova G D, 1997, Membr Cell Biol, V10, P583; Mironova GD, 1999, J BIOENERG BIOMEMBR, V31, P159, DOI 10.1023/A:1005408029549; MIRONOVA GD, 1996, MEMBR CELL BIOL, V10, P429; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Paucek P, 1996, J BIOL CHEM, V271, P32084, DOI 10.1074/jbc.271.50.32084; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; YarovYarovoy V, 1997, BBA-BIOENERGETICS, V1321, P128, DOI 10.1016/S0005-2728(97)00051-0; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	43	71	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32562	32568		10.1074/jbc.M401115200	http://dx.doi.org/10.1074/jbc.M401115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15138282	hybrid			2022-12-25	WOS:000222849700072
J	Estabrook, RA; Lipson, R; Hopkins, B; Reich, N				Estabrook, RA; Lipson, R; Hopkins, B; Reich, N			The coupling of tight DNA binding and base flipping - Identification of a conserved structural motif in base flipping enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HHAI METHYLTRANSFERASE; ESCHERICHIA-COLI; TARGET BASE; CRYSTAL-STRUCTURE; MECHANISM; GLYCOSYLASE; METHYLATION; CATALYSIS; CYTOSINE; DYNAMICS	Val(121) is positioned immediately above the extrahelical cytosine in HhaI DNA C-5-cytosine methyltransferase, and replacement with alanine dramatically interferes with base flipping and catalysis. DNA binding and k(cat) are decreased 10(5)-fold for the Val(121) --> Ala mutant that has a normal circular dichroism spectrum and AdoMet affinity. The magnitude of this loss of function is comparable with removal of the essential catalytic Cys(81). Surprisingly, DNA binding is completely recovered ( increase of 10(5)-fold) with a DNA substrate lacking the target cytosine base (abasic). Thus, interfering with the base flipping transition results in a dramatic loss of binding energy. Our data support an induced fit mechanism in which tight DNA binding is coupled to both base flipping and protein loop rearrangement. The importance of the proximal protein segment ( His(127) Thr(132)) in maintaining this critical interaction between Val(121) and the flipped cytosine was probed with single site alanine substitutions. None of these mutants are significantly altered in secondary structure, AdoMet or DNA affinity, k(methylation), k(inactivation), or k(cat). Although Val(121) plays a critical role in both extrahelical base stabilization and catalysis, its position and mobility are not influenced by individual residues in the adjacent peptide region. Structural comparisons with other DNA methyltransferases and DNA repair enzymes that stabilize extrahelical nucleotides reveal a motif that includes a positively charged or polar side chain and a hydrophobic residue positioned adjacent to the target DNA base and either the 5'- or 3'-phosphate.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Reich, N (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	reich@chem.ucsb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046333] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46333] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1999, J BIOL CHEM, V274, P19269, DOI 10.1074/jbc.274.27.19269; Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Banavali NK, 2002, J MOL BIOL, V319, P141, DOI 10.1016/S0022-2836(02)00194-8; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Blumenthal RM, 2001, NAT STRUCT BIOL, V8, P101, DOI 10.1038/84072; Bruice TC, 2002, ACCOUNTS CHEM RES, V35, P139, DOI 10.1021/ar0001665; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOUGLAS KT, 1987, MED RES REV, V7, P441, DOI 10.1002/med.2610070405; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; FERSHT A, 1999, STRUCTURE MECH PROTE, P332; GABBARA S, 1995, BIOCHEMISTRY-US, V34, P8914, DOI 10.1021/bi00027a044; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; Gueron M, 1995, METHOD ENZYMOL, V261, P383; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Huang N, 2003, P NATL ACAD SCI USA, V100, P68, DOI 10.1073/pnas.0135427100; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Lariviere L, 2002, J MOL BIOL, V324, P483, DOI 10.1016/S0022-2836(02)01091-4; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau EY, 1999, J MOL BIOL, V293, P9, DOI 10.1006/jmbi.1999.3120; Lau EY, 1998, J AM CHEM SOC, V120, P12387, DOI 10.1021/ja9827447; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Perakyla M, 1998, J AM CHEM SOC, V120, P12895, DOI 10.1021/ja981405a; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Sankpal UT, 2002, NUCLEIC ACIDS RES, V30, P2628, DOI 10.1093/nar/gkf380; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Solstad T, 2003, EUR J BIOCHEM, V270, P929, DOI 10.1046/j.1432-1033.2003.03455.x; Sutcliffe MJ, 2002, EUR J BIOCHEM, V269, P3096, DOI 10.1046/j.1432-1033.2002.03020.x; TAKUSAGAWA F, 1998, S ADENOSYLMETHIONINE, P1; Vilkaitis G, 2000, J BIOL CHEM, V275, P38722, DOI 10.1074/jbc.M005278200; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; Wang PY, 2000, J AM CHEM SOC, V122, P12422, DOI 10.1021/ja001989s; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; WU JC, 1987, J BIOL CHEM, V262, P4778; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	54	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31419	31428		10.1074/jbc.M402950200	http://dx.doi.org/10.1074/jbc.M402950200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15143064	hybrid			2022-12-25	WOS:000222726800063
J	Hisanaga, Y; Ago, H; Nakagawa, N; Hamada, K; Ida, K; Yamamoto, M; Hori, T; Arii, Y; Sugahara, M; Kuramitsu, S; Yokoyama, S; Miyano, M				Hisanaga, Y; Ago, H; Nakagawa, N; Hamada, K; Ida, K; Yamamoto, M; Hori, T; Arii, Y; Sugahara, M; Kuramitsu, S; Yokoyama, S; Miyano, M			Structural basis of the substrate-specific two-step catalysis of long chain fatty acyl-CoA synthetase dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE MOVEMENT; FIREFLY LUCIFERASE; ESCHERICHIA-COLI; ACID; ENZYME; ACYLATION; BINDING	Long chain fatty acyl-CoA synthetases are responsible for fatty acid degradation as well as physiological regulation of cellular functions via the production of long chain fatty acyl-CoA esters. We report the first crystal structures of long chain fatty acyl-CoA synthetase homodimer (LC-FACS) from Thermus thermophilus HB8 (ttLC-FACS), including complexes with the ATP analogue adenosine 5'-(beta,gamma-imido) triphosphate (AMP-PNP) and myristoyl-AMP. ttLC-FACS is a member of the adenylate forming enzyme superfamily that catalyzes the ATP-dependent acylation of fatty acid in a two-step reaction. The first reaction step was shown to propagate in AMP-PNP complex crystals soaked with myristate solution. Myristoyl-AMP was identified as the intermediate. The AMP-PNP and the myristoyl-AMP complex structures show an identical closed conformation of the small C-terminal domains, whereas the uncomplexed form shows a variety of open conformations. Upon ATP binding, the fatty acid-binding tunnel gated by an aromatic residue opens to the ATP-binding site. The gated fatty acid-binding tunnel appears only to allow one-way movement of the fatty acid during overall catalysis. The protein incorporates a hydrophobic branch from the fatty acid-binding tunnel that is responsible for substrate specificity. Based on these high resolution crystal structures, we propose a unidirectional Bi Uni Uni Bi Ping-Pong mechanism for the two-step acylation by ttLC-FACS.	RIKEN, Harima Inst SPring, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring, Highthroughput Factory, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring, Structurome Res Grp, Sayo, Hyogo 6795148, Japan; RIKEN, Harima Inst SPring, Coherent Xray Opt Lab, Sayo, Hyogo 6795148, Japan; Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan	RIKEN; RIKEN; RIKEN; RIKEN; Osaka University; Yokohama City University	Miyano, M (corresponding author), RIKEN, Harima Inst SPring, Struct Biophys Lab, 8 Kouto, Sayo, Hyogo 6795148, Japan.	ago@spring8.or.jp; miyano@spring8.or.jp	Yokoyama, Shigeyuki/N-6911-2015; Yamamoto, Masaki/B-7844-2015; Miyano, Masashi/R-2785-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yamamoto, Masaki/0000-0002-1311-1768; Miyano, Masashi/0000-0003-2253-6175; Ago, Hideo/0000-0002-9040-488X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTANA J, 1973, BIOCHEM J, V135, P411, DOI 10.1042/bj1350411; BARTANA J, 1973, BIOCHEM J, V131, P199, DOI 10.1042/bj1310199; BERG P, 1956, J BIOL CHEM, V222, P991; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Black PN, 2000, J BIOL CHEM, V275, P38547, DOI 10.1074/jbc.M006413200; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERSHT A, 1999, STRUCTURE MECH PROTE, P245; Fraisl P, 2004, BIOCHEM J, V377, P85, DOI 10.1042/BJ20031062; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; GURANOWSKI A, 1994, J BACTERIOL, V176, P2986, DOI 10.1128/JB.176.10.2986-2990.1994; HOSAKA K, 1979, EUR J BIOCHEM, V93, P197, DOI 10.1111/j.1432-1033.1979.tb12811.x; Jogl G, 2004, BIOCHEMISTRY-US, V43, P1425, DOI 10.1021/bi035911a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; Kumasaka T, 2002, STRUCTURE, V10, P1205, DOI 10.1016/S0969-2126(02)00830-4; LAI JCK, 1993, RES COMMUN CHEM PATH, V82, P331; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li ZN, 2001, J GEN VIROL, V82, P1085, DOI 10.1099/0022-1317-82-5-1085; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; May JJ, 2002, P NATL ACAD SCI USA, V99, P12120, DOI 10.1073/pnas.182156699; MISHINA M, 1978, EUR J BIOCHEM, V89, P321, DOI 10.1111/j.1432-1033.1978.tb12533.x; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oba Y, 2003, FEBS LETT, V540, P251, DOI 10.1016/S0014-5793(03)00272-2; OBRIEN WJ, 1977, J BACTERIOL, V132, P532, DOI 10.1128/JB.132.2.532-540.1977; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PHILIPP DP, 1979, J BIOL CHEM, V254, P785; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Saunders C, 1996, BIOCHEM J, V313, P849, DOI 10.1042/bj3130849; SCHOMBURG D, 2001, SPRINGER HDB ENZYMES, V2, P186; Schomburg I, 2004, NUCLEIC ACIDS RES, V32, pD431, DOI 10.1093/nar/gkh081; TAKAO S, 1987, AGR BIOL CHEM TOKYO, V51, P145, DOI 10.1080/00021369.1987.10868004; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Weimar JD, 2002, J BIOL CHEM, V277, P29369, DOI 10.1074/jbc.M107022200; Yokoyama S, 2000, NAT STRUCT BIOL, V7, P943, DOI 10.1038/80712; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	56	163	166	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31717	31726		10.1074/jbc.M400100200	http://dx.doi.org/10.1074/jbc.M400100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145952	hybrid			2022-12-25	WOS:000222726800097
J	Hong, M; Zhou, FF; You, GF				Hong, M; Zhou, FF; You, GF			Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; SITE	Human organic anion transporter 1 (hOAT1) belongs to a superfamily of organic anion transporters, which play critical roles in the body disposition of clinically important drugs, including anti-human immunodeficiency virus therapeutics, anti-tumor drugs, antibiotics, anti-hypertensives, and anti-inflammatories. Previously we suggested that the predicted transmembrane domain 1 (TM1) of hOAT1 might be important for its function. In the present study, we examined the role of each residue within TM1 of hOAT1 in substrate recognition and transport. Alanine scanning was used to construct mutants of hOAT1, and the uptake of model substrate para-aminohippurate was studied in COS-7 cells expressing the mutant transporters. This approach led to the discovery of two critical amino acid residues, Leu-30 and Thr-36. A substitution of Leu-30 or Thr-36 with alanine resulted in a complete loss of transport activities. We then further characterized Leu-30 and Thr-36 by mutagenizing these residues to amino acids with different physicochemical properties. Leu-30 was replaced with amino acids with varying sizes of side chains, including glycine, valine, and isoleucine. We showed that progressively smaller side chains at position 30 increasingly impaired hOAT1 function mainly because of the impaired surface expression of the transporter. Thr-36, another critical amino acid in TM1, was replaced by serine and cysteine. Similar to the substitution of Thr-36 by alanine, substitution by serine and cysteine at this position abolished transport activity without affecting the surface expression of the transporter. The fact that Thr-36 cannot be substituted with serine and that the side chains of alanine, serine, and cysteine are smaller than that of threonine by a methyl group indicate that both the methyl group and the hydroxyl group of Thr-36 could be critical for hOAT1 activity. Together we conclude that Leu-30 and Thr-36 play distinct roles in hOAT1 function. Leu-30 is important in targeting the transporter to the plasma membrane. In contrast, Thr-36 is critical for substrate recognition. The present study provided the first molecular evidence that transmembrane domain 1 is a critical determinant of hOAT1 function and may provide important insights into the structure-function relationships of the organic anion transporter family.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	You, GF (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, 160 Frelinhuysen Rd, Piscataway, NJ 08854 USA.	gyou@cop.rutgers.edu	Zhou, Fanfan/M-4404-2013; Zhou, Fanfan/J-2327-2019	Zhou, Fanfan/0000-0002-1982-1541; Zhou, Fanfan/0000-0002-1982-1541; Hong, Mei/0000-0001-9219-2844	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060034] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 60034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Diez-Sampedro A, 2001, J BIOL CHEM, V276, P49188, DOI 10.1074/jbc.M108286200; Ekaratanawong S, 2004, J PHARMACOL SCI, V94, P297, DOI 10.1254/jphs.94.297; Leu YJ, 2003, J BIOL CHEM, V278, P7300, DOI 10.1074/jbc.M206701200; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Witt H, 2002, BIOCHEMISTRY-US, V41, P8557, DOI 10.1021/bi025822i; You GF, 2004, CURR DRUG METAB, V5, P55, DOI 10.2174/1389200043489207; You GF, 2002, MED RES REV, V22, P602, DOI 10.1002/med.10019	8	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31478	31482		10.1074/jbc.M404686200	http://dx.doi.org/10.1074/jbc.M404686200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145940	hybrid			2022-12-25	WOS:000222726800070
J	Koo, BM; Yoon, MJ; Lee, CR; Nam, TW; Choe, YJ; Jaffe, H; Peterkofsky, A; Seok, YJ				Koo, BM; Yoon, MJ; Lee, CR; Nam, TW; Choe, YJ; Jaffe, H; Peterkofsky, A; Seok, YJ			A novel fermentation/respiration switch protein regulated by enzyme IIA(Glc) in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYL TRANSFER COMPLEX; GLOBAL REPRESSOR MLC; GLUCOSE-TRANSPORTER; INDUCER EXCLUSION; TERMINAL DOMAIN; GLYCEROL KINASE; SALMONELLA-TYPHIMURIUM; GLYCOGEN-PHOSPHORYLASE; ALLOSTERIC REGULATION	The bacterial phosphoenolpyruvate: sugar phosphotransferase system regulates a variety of physiological processes as well as effecting sugar transport. The crr gene product (enzyme IIA(Glc) (IIA(Glc))) mediates some of these regulatory phenomena. In this report, we characterize a novel IIA(Glc)-binding protein from Escherichia coli extracts, discovered using ligand-fishing with surface plasmon resonance spectroscopy. This protein, which we named FrsA ( fermentation/respiration switch protein), is the 47-kDa product of the yafA gene, previously denoted as "function unknown." FrsA forms a 1: 1 complex specifically with the unphosphorylated form of IIA(Glc), with the highest affinity of any protein thus far shown to interact with IIA(Glc). Orthologs of FrsA have been found to exist only in facultative anaerobes belonging to the gamma-proteobacterial group. Disruption of frsA increased cellular respiration on several sugars including glucose, while increased FrsA expression resulted in an increased fermentation rate on these sugars with the concomitant accumulation of mixed-acid fermentation products. These results suggest that IIA(Glc) regulates the flux between respiration and fermentation pathways by sensing the available sugar species via a phosphorylation state-dependent interaction with FrsA.	Seoul Natl Univ, Sch Biol Sci, Lab Macromol Interact, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; NINDS, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Seok, YJ (corresponding author), Seoul Natl Univ, Sch Biol Sci, Lab Macromol Interact, Seoul 151742, South Korea.	yjseok@plaza.snu.ac.kr		Choe, Young Jun/0000-0003-3062-057X; Koo, Byoung-Mo/0000-0003-1001-6367; Seok, Yeong-Jae/0000-0003-0379-3619	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bochner BR, 2001, GENOME RES, V11, P1246, DOI 10.1101/gr.186501; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CLARKE PM, 1983, ANAL BIOCHEM, V130, P402, DOI 10.1016/0003-2697(83)90607-3; DEAN DA, 1990, J BIOL CHEM, V265, P21005; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Hogema BM, 1998, MOL MICROBIOL, V30, P487, DOI 10.1046/j.1365-2958.1998.01053.x; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; Jaffe H, 1998, BIOCHEMISTRY-US, V37, P3931, DOI 10.1021/bi972518u; Koo BM, 2001, J MICROBIOL, V39, P24; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LEVY S, 1990, GENE, V86, P27, DOI 10.1016/0378-1119(90)90110-D; LUX R, 1995, P NATL ACAD SCI USA, V92, P11583, DOI 10.1073/pnas.92.25.11583; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; NYSTROM T, 1994, MOL MICROBIOL, V12, P833, DOI 10.1111/j.1365-2958.1994.tb01069.x; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Pettigrew DW, 1998, BIOCHEMISTRY-US, V37, P4875, DOI 10.1021/bi971634u; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; SAIER MH, 1983, J BACTERIOL, V155, P1351, DOI 10.1128/JB.155.3.1351-1357.1983; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Seok YJ, 1996, P NATL ACAD SCI USA, V93, P347, DOI 10.1073/pnas.93.1.347; Seok YJ, 2001, J MOL MICROB BIOTECH, V3, P385; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; TITGEMEYER F, 1994, J BACTERIOL, V176, P543, DOI 10.1128/JB.176.2.543-546.1994; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhou L, 2003, J BACTERIOL, V185, P4956, DOI 10.1128/JB.185.16.4956-4972.2003	34	57	61	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31613	31621		10.1074/jbc.M405048200	http://dx.doi.org/10.1074/jbc.M405048200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15169777	hybrid			2022-12-25	WOS:000222726800085
J	Munir, S; Xu, GX; Wu, YJ; Yang, B; Lala, PK; Peng, C				Munir, S; Xu, GX; Wu, YJ; Yang, B; Lala, PK; Peng, C			Nodal and ALK7 inhibit proliferation and induce apoptosis in human trophoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; RECEPTOR SERINE/THREONINE KINASE; CYCLIN-DEPENDENT KINASES; TGF-BETA; EXPRESSION; ACTIVIN; MECHANISM; PATHWAYS; CRIPTO; SMADS	Nodal, a member of the transforming growth factor-beta superfamily, is known to play critical roles in early vertebrate development, but its functions in extraembryonic tissues are unclear. ALK7 is a type I receptor for Nodal. Recently, we demonstrated that Nodal mRNA and several ALK7 transcripts are expressed in human placenta throughout pregnancy (Roberts, H. J., Hu, S., Qiu, Q., Leung, P. C. K., Cannigia, I., Gruslin, A., Tsang, B., and Peng, C. ( 2003) Biol. Reprod. 68, 1719 - 1726). In this study, we determined the role of Nodal and ALK7 in trophoblast cell proliferation and apoptosis. Overexpression of Nodal in normal trophoblast cells (HTR8/ SVneo) and several choriocarcinoma cell lines resulted in a significant decrease in the number of metabolically active cells. The effect of Nodal could be mimicked by constitutively active ALK7 (ALK7-ca), but was blocked by kinase-deficient ALK7. The growth inhibitory effect of Nodal was also blocked by dominant-negative Smad2/3. Overexpression of Nodal and ALK7-ca induced apoptosis in trophoblast cells as determined by Hoechst staining, flow cytometry, and caspase-3 Western blotting. In addition, Nodal and ALK7-ca decreased the number of proliferating cells as measured by bromodeoxyuridine assays. Furthermore, overexpression of Nodal or ALK7-ca increased p27 expression, but reduced the levels of Cdk2 and cyclin D-1. Taken together, this study demonstrates for the first time that Nodal, acting through ALK7 and Smad2/3, inhibits proliferation and induces apoptosis in human trophoblast cells. Our findings also suggest that the Nodal-ALK7 pathway inhibits cell proliferation by inducing G(1) cell cycle arrest and that this effect is mediated in part by the p27-cyclin E/Cdk2 pathway.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	York University - Canada; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Western University (University of Western Ontario)	Peng, C (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	cpeng@yorku.ca						Aboagye-Mathiesen G, 1996, Early Pregnancy, V2, P102; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Brennan J, 2002, GENE DEV, V16, P2339, DOI 10.1101/gad.1016202; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; Eimon PM, 2002, DEVELOPMENT, V129, P3089; GRAHAM CH, 1992, BIOL REPROD, V46, P561, DOI 10.1095/biolreprod46.4.561; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; GRAHAM CH, 1991, J CELL PHYSIOL, V148, P228, DOI 10.1002/jcp.1041480207; GRANA X, 1995, ONCOGENE, V11, P211; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; Jornvall H, 2001, J BIOL CHEM, V276, P5140, DOI 10.1074/jbc.M005200200; Kim BC, 2004, J BIOL CHEM, V279, P28458, DOI 10.1074/jbc.M313277200; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Luo S, 2002, MOL HUM REPROD, V8, P318, DOI 10.1093/molehr/8.4.318; Ma GT, 2001, DEV BIOL, V236, P124, DOI 10.1006/dbio.2001.0334; Massague J, 2000, GENE DEV, V14, P627; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Peng Chun, 2003, J Obstet Gynaecol Can, V25, P834; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Roberts HJ, 2003, BIOL REPROD, V68, P1719, DOI 10.1095/biolreprod.102.013045; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Watanabe R, 1999, BIOCHEM BIOPH RES CO, V254, P707, DOI 10.1006/bbrc.1998.0118; Wieser R, 2001, CURR OPIN ONCOL, V13, P70, DOI 10.1097/00001622-200101000-00014; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu DN, 2001, MOL CELL ENDOCRINOL, V175, P111, DOI 10.1016/S0303-7207(01)00397-5; Xu GX, 2003, BIOCHEM BIOPH RES CO, V300, P383, DOI 10.1016/S0006-291X(02)02845-0; Xu GX, 2002, BIOCHEM BIOPH RES CO, V294, P1079, DOI 10.1016/S0006-291X(02)00605-8; Xu GX, 2001, BIOCHEM BIOPH RES CO, V287, P47, DOI 10.1006/bbrc.2001.5533; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	48	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31277	31286		10.1074/jbc.M400641200	http://dx.doi.org/10.1074/jbc.M400641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15150278	hybrid			2022-12-25	WOS:000222726800047
J	Seow, HA; Penketh, PG; Belcourt, MF; Tomasz, M; Rockwell, S; Sartorelli, AC				Seow, HA; Penketh, PG; Belcourt, MF; Tomasz, M; Rockwell, S; Sartorelli, AC			Nuclear overexpression of NAD(P)H : quinone oxidoreductase 1 in Chinese hamster ovary cells increases the cytotoxicity of mitomycin C under aerobic and hypoxic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; DT-DIAPHORASE; REDUCTIVE ACTIVATION; DNA-ADDUCTS; XANTHINE DEHYDROGENASE; NADPH-CYTOCHROME-P-450 REDUCTASE; DRUG-METABOLISM; P-450 REDUCTASE; CROSS-LINKING; BIOACTIVATION	The effects of the subcellular localization of overexpressed bioreductive enzyme NAD(P) H: quinone oxidoreductase 1 (NQO1) on the activity of the antineoplastic agent mitomycin C ( MC) under aerobic and hypoxic conditions were examined. Chinese hamster ovary ( CHO-K1/ dhfr(-)) cells were transfected with NQO1 cDNA to produce cells that overexpressed NQO1 activity in the nucleus (148-fold) or the cytosol (163-fold) over the constitutive level of the enzyme in parental cells. Subcellular localization of the enzyme was confirmed using antibody-assisted immunofluorescence. Nuclear localization of transfected NQO1 activity increased the cytotoxicity of MC over that produced by overexpression in the cytosol under both aerobic and hypoxic conditions, with greater cytotoxicity being produced under hypoxia. The greater cytotoxicity of nuclear localized NQO1 was not attributable to greater metabolic activation of MC but instead was the result of activation of the drug in close proximity to its target, nuclear DNA. A positive relationship existed between the degree of MC-induced cytotoxicity and the number of MC-DNA adducts produced. The findings indicate that activation of MC proximal to nuclear DNA by the nuclear localization of transfected NQO1 increases the cytotoxic effects of MC regardless of the degree of oxygenation and support the concept that the mechanism of action of MC involves alkylation of DNA.	Yale Univ, Sch Med, Dept Pharmacol, Yale Canc Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Therapeut Radiol, Yale Canc Ctr, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dev Therapeut Program, Yale Canc Ctr, New Haven, CT 06520 USA; CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA	Yale University; Yale University; Yale University; City University of New York (CUNY) System; Hunter College (CUNY)	Sartorelli, AC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Yale Canc Ctr, 333 Cedar St, New Haven, CT 06520 USA.	alan.sartorelli@yale.edu	Rockwell, Sara/B-8458-2009		NCI NIH HHS [CA-80845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; Baumann RP, 2001, CANCER RES, V61, P7770; BEGLEITER A, 1992, MOL PHARMACOL, V41, P677; Belcourt M. F., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P599; Belcourt MF, 1996, BIOCHEM PHARMACOL, V51, P1669, DOI 10.1016/0006-2952(96)00143-8; Belcourt MF, 1998, J BIOL CHEM, V273, P8875, DOI 10.1074/jbc.273.15.8875; Belcourt MF, 1996, P NATL ACAD SCI USA, V93, P456, DOI 10.1073/pnas.93.1.456; Belcourt MF, 1998, ADV ENZYME REGUL, V38, P111, DOI 10.1016/S0065-2571(97)00009-5; BIZANEK R, 1993, CANCER RES, V53, P5127; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; Fisher J., 1982, DEV BIOCHEM, V21, P240; GARGIULO D, 1995, NUCL ACIDS S SER, V34, P169; GUSTAFSON DL, 1992, JNCI-J NATL CANCER I, V84, P1180, DOI 10.1093/jnci/84.15.1180; GUSTAFSON DL, 1992, CANCER RES, V52, P6936; HODNICK WF, 1993, CANCER RES, V53, P4907; Holtz KM, 2003, J BIOL CHEM, V278, P5029, DOI 10.1074/jbc.M209722200; IYER VN, 1963, P NATL ACAD SCI USA, V50, P355, DOI 10.1073/pnas.50.2.355; IYER VN, 1964, SCIENCE, V145, P55, DOI 10.1126/science.145.3627.55; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Jiang HB, 2000, BIOCHEM PHARMACOL, V60, P571, DOI 10.1016/S0006-2952(00)00346-4; Jiang HB, 2001, LIFE SCI, V68, P1677, DOI 10.1016/S0024-3205(01)00959-6; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KENNEDY KA, 1980, CANCER RES, V40, P2356; KEYES SR, 1991, CANCER COMMUN-US, V3, P351, DOI 10.3727/095535491820873812; KEYES SR, 1984, CANCER RES, V44, P5638; KOMIYAMA T, 1979, J PHARMACOBIO-DYNAM, V2, P407, DOI 10.1248/bpb1978.2.407; Kumar GS, 1997, BIOCHEMISTRY-US, V36, P14128, DOI 10.1021/bi971394i; MCHUGH KM, 1988, NUCLEIC ACIDS RES, V16, P4167, DOI 10.1093/nar/16.9.4167; MURRAY RDH, 1982, NATURAL COUMARINS OC, P241; Palom Y, 2001, BIOCHEM PHARMACOL, V61, P1517, DOI 10.1016/S0006-2952(01)00609-8; Palom Y, 1998, ONCOL RES, V10, P509; Palom Y, 2000, CHEM RES TOXICOL, V13, P479, DOI 10.1021/tx000024j; PAN SS, 1988, MOL PHARMACOL, V34, P223; PAN SS, 1984, J BIOL CHEM, V259, P959; Penketh PG, 2001, J BIOL CHEM, V276, P34445, DOI 10.1074/jbc.M104263200; Phillips RM, 2000, CANCER RES, V60, P6384; PRITSOS CA, 1994, ONCOL RES, V6, P477; PRITSOS CA, 1986, CANCER RES, V46, P3528; PRITSOS CA, 1985, ANAL BIOCHEM, V150, P294, DOI 10.1016/0003-2697(85)90513-5; RAUTH AM, 1983, CANCER RES, V43, P4154; SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019; SIEGEL D, 1990, CANCER RES, V50, P7483; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tomasz M, 1997, PHARMACOL THERAPEUT, V76, P73, DOI 10.1016/S0163-7258(97)00088-0; TOMASZ M, 1987, SCIENCE, V235, P1204, DOI 10.1126/science.3103215; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANCUROVA I, 1994, BIOCHEM BIOPH RES CO, V205, P529, DOI 10.1006/bbrc.1994.2697; WAKAKI S., 1958, ANTIBIOT AND CHEMOTHER, V8, P228; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YUBISUI T, 1982, J BIOCHEM, V91, P1467, DOI 10.1093/oxfordjournals.jbchem.a133838	51	23	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31606	31612		10.1074/jbc.M404910200	http://dx.doi.org/10.1074/jbc.M404910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155746	hybrid			2022-12-25	WOS:000222726800084
J	Srinivasan, S; Bolick, DT; Hatley, ME; Natarajan, R; Reilly, KB; Yeh, M; Chrestensen, C; Sturgill, TW; Hedrick, CC				Srinivasan, S; Bolick, DT; Hatley, ME; Natarajan, R; Reilly, KB; Yeh, M; Chrestensen, C; Sturgill, TW; Hedrick, CC			Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGER FIRM ADHESION; VASCULAR ENDOTHELIUM; MONOCYTE ADHESION; MAP KINASE; MONOCYTE/ENDOTHELIAL INTERACTIONS; ATHEROSCLEROTIC LESIONS; FLOW CONDITIONS; TNF-ALPHA; DISEASE; ATHEROGENESIS	We have shown that chronic elevated glucose ( 25 mM) increases monocyte adhesion to human aortic endothelial cells (EC). This increased adhesion is mediated primarily through induction of interleukin (IL)-8 via activation of the transcription factor AP-1 ( Srinivasan, S., Yeh, M., Danziger, E. C., Hatley, M. E., Riggan, A. E., Leitinger, N., Berliner, J. A., and Hedrick, C. C. ( 2003) Circ. Res. 92, 371 - 377). In the current study, we identified the elements in the AP-1 transcriptional complex that are activated by glucose. These elements include c-Jun, c-Fos, and Fra-1. AP-1 is activated by cellular oxidative stress, and we have reported significant production of ROS by high glucose-cultured cells. We examined signaling pathways upstream of AP-1 in EC that lead to AP-1 activation by HG. EC cultured in 25 mM glucose had a 2-fold increase in p38 phosphorylation compared with control normal glucose-cultured EC. Inhibition of the p38 pathway using 5 muM SB203580 significantly reduced glucose-mediated IL-8 mRNA production by 60%. Furthermore, blocking p38 pathway activation using a dominant-negative p38 construct significantly reduced glucose-mediated monocyte adhesion by 50%. Thus, glucose-stimulated monocyte adhesion is primarily regulated through phosphorylation of p38 with subsequent activation of AP-1, leading to IL-8 production. To study this pathway in the setting of diabetes, we used the db/db mouse. P38 phosphorylation was increased in diabetic db/db mice compared with control mice. We found a dramatic elevation in plasma levels of KC, the mouse ortholog of IL-8 in diabetic db/db mice ( 1800 +/- 100 pg/ml KC in db/db versus 300 +/- 75 pg/ml in C57BL/6J control mice, p < 0.0001). Inhibition of the p38 pathway in diabetic db/db mice significantly reduced monocyte adhesion by 50%. Taken together, these data indicate that chronic elevated glucose in diabetes activates the p38 MAP kinase pathway to increase inflammatory IL-8 gene induction and monocyte/endothelial adhesion.	Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, Charlottesville, VA 22908 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA; Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of Virginia	Hedrick, CC (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, POB 801394,415 Lane Rd,MR5 Rm G123, Charlottesville, VA 22908 USA.	cch6n@virginia.edu	Bolick, David/A-3467-2017; Hedrick, Catherine/D-1106-2012		NHLBI NIH HHS [P01 HL55798-09] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; BERLINER JA, 2001, VASCULAR ADHESION IN, P239; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Conti P, 2001, ALLERGY ASTHMA PROC, V22, P133, DOI 10.2500/108854101778148737; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; GERRITY RG, 1981, AM J PATHOL, V103, P191; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Lahti A, 2002, EUR J PHARMACOL, V454, P115, DOI 10.1016/S0014-2999(02)02490-1; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LEY K, 1995, J IMMUNOL, V155, P525; Luscinskas FW, 2000, ANN NY ACAD SCI, V902, P288; McEvoy LM, 1997, J EXP MED, V185, P2069, DOI 10.1084/jem.185.12.2069; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Reilly KB, 2004, J BIOL CHEM, V279, P9440, DOI 10.1074/jbc.M303857200; REILLY KB, 2003, J BIOL CHEM; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Shi WB, 2000, CIRC RES, V86, P1078, DOI 10.1161/01.RES.86.10.1078; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Srinivasan S, 2003, CIRC RES, V92, P371, DOI 10.1161/01.RES.0000061714.74668.5C; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Thulaseedharan N, 1995, Indian Heart J, V47, P471; Tkac I, 1997, ARTERIOSCL THROM VAS, V17, P3633, DOI 10.1161/01.ATV.17.12.3633; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; UUSITUPA MIJ, 1990, CIRCULATION, V82, P27, DOI 10.1161/01.CIR.82.1.27; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Yeh M, 2001, ARTERIOSCL THROM VAS, V21, P1585, DOI 10.1161/hq1001.097027; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322	39	52	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31930	31936		10.1074/jbc.M400753200	http://dx.doi.org/10.1074/jbc.M400753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145956	hybrid			2022-12-25	WOS:000222726800120
J	Hemers, H; Verrijdt, G; Organe, S; Claessens, F; Heyns, W; Verhoeven, G; Swinnen, JV				Hemers, H; Verrijdt, G; Organe, S; Claessens, F; Heyns, W; Verhoeven, G; Swinnen, JV			Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CANCER CELLS; IN-VIVO; SCAP; EXPRESSION; MECHANISM; PROGESTERONE; MEMBRANES; PROSTATE; PATHWAY	Sterol regulatory element-binding proteins (SREBPs) are transcription regulators that play a pivotal role in intracellular lipid homeostasis. They are synthesized as inactive precursor proteins in the endoplasmic reticulum, where they are retained by SREBP cleavage-activating protein (SCAP), a sterol sensing protein that in turn is linked to a retention protein complex. Low intracellular sterol concentrations weaken the interaction of SCAP with its retention proteins and allow translocation of the SREBP.SCAP complex to the Golgi compartment where SREBP is proteolytically cleaved and activated. Previous studies on the mechanisms by which androgens provoke a coordinated activation of lipogenic pathways in prostate cancer cells have suggested an alternative pathway of activation in which androgens increase the expression of SCAP and favor translocation of the SREBP.SCAP complex to the Golgi apparatus by disturbing the balance between SCAP and its retention proteins. Here we show that the SCAP gene contains an androgen-responsive region located in intron 8. This region interacts directly with the androgen receptor and confers androgen responsiveness to promoter-reporter constructs transfected in LNCaP cells. It contains a noncanonical androgen response element GGAAGAaaaTGTACC that interacts not only with the androgen receptor but also with the glucocorticoid receptor and that also confers glucocorticoid responsiveness. The identification of a steroid response element in intron 8 of the SCAP gene further supports the contention that SCAP is a direct target for steroid hormone action.	Katholieke Univ Leuven, Onderwijs & Navorsing, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Onderwijs & Navorsing, Fac Med, Div Biochem, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Swinnen, JV (corresponding author), Onderwijs & Navorsing, LEGENDO, Herestr 49, B-3000 Louvain, Belgium.	johan.swinnen@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022; Claessens, Frank/M-8565-2016	Swinnen, Johannes V/0000-0002-7720-5077; Claessens, Frank/0000-0002-8676-7709				Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; Heemers H, 2003, MOL CELL ENDOCRINOL, V205, P21, DOI 10.1016/S0303-7207(03)00205-3; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Jiang F, 2003, ENDOCRINOLOGY, V144, P1257, DOI 10.1210/en.2002-220718; JUDGE SM, 1983, CANCER RES, V43, P4407; Lacasa D, 2001, J BIOL CHEM, V276, P11512, DOI 10.1074/jbc.M008556200; Leake R. E., 1987, STEROID HORMONES PRA, P213; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; Nakajima T, 1999, J HUM GENET, V44, P402, DOI 10.1007/s100380050187; Rosignoli C, 2003, EXP DERMATOL, V12, P480, DOI 10.1034/j.1600-0625.2003.00014.x; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	23	56	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30880	30887		10.1074/jbc.M401615200	http://dx.doi.org/10.1074/jbc.M401615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15133039	hybrid			2022-12-25	WOS:000222531900122
J	Hynes, TR; Tang, LN; Mervine, SM; Sabo, JL; Yost, EA; Devreotes, PN; Berlot, CH				Hynes, TR; Tang, LN; Mervine, SM; Sabo, JL; Yost, EA; Devreotes, PN; Berlot, CH			Visualization of g protein beta gamma dimers using bimolecular fluorescence complementation demonstrates roles for both beta and gamma in subcellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; ADENYLYL-CYCLASE; CRYSTAL-STRUCTURE; NUCLEAR-LOCALIZATION; SUBUNIT COMPOSITION; PHOSPHOLIPASE-C; SF9 CELLS; RECEPTOR; ALPHA; ASSOCIATION	To investigate the role of subcellular localization in regulating the specificity of G protein betagamma signaling, we have applied the strategy of bimolecular fluorescence complementation (BiFC) to visualize betagamma dimers in vivo. We fused an amino-terminal yellow fluorescent protein fragment to beta and a carboxyl-terminal yellow fluorescent protein fragment to gamma. When expressed together, these two proteins produced a fluorescent signal in human embryonic kidney 293 cells that was not obtained with either subunit alone. Fluorescence was dependent on betagamma assembly in that it was not obtained using beta(2) and gamma(1), which do not form a functional dimer. In addition to assembly, BiFC betagamma complexes were functional as demonstrated by more specific plasma membrane labeling than was obtained with individually tagged fluorescent beta and gamma subunits and by their abilities to potentiate activation of adenylyl cyclase by alpha(s) in COS-7 cells. To investigate isoform-dependent targeting specificity, the localization patterns of dimers formed by pair-wise combinations of three different beta subunits with three different gamma subunits were compared. BiFC betagamma complexes containing either beta(1) or beta(2) localized to the plasma membrane, whereas those containing beta(5) accumulated in the cytosol or on intracellular membranes. These results indicate that the beta subunit can direct trafficking of the gamma subunit. Taken together with previous observations, these results show that the G protein alpha, beta, and gamma subunits all play roles in targeting each other. This method of specifically visualizing betagamma dimers will have many applications in sorting out roles for particular betagamma complexes in a wide variety of cell types.	Weis Ctr Res, Geisinger Clin, Danville, PA 17822 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Berlot, CH (corresponding author), Weis Ctr Res, Geisinger Clin, 100 N Acad Ave, Danville, PA 17822 USA.	chberlot@geisinger.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050369, R01GM050369] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50369] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano T, 1999, J BIOL CHEM, V274, P21425, DOI 10.1074/jbc.274.30.21425; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chatterjee TK, 2003, J BIOL CHEM, V278, P30261, DOI 10.1074/jbc.M212687200; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Figler RA, 1997, BIOCHEMISTRY-US, V36, P16288, DOI 10.1021/bi972000q; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Lo W, 1998, BIOTECHNIQUES, V25, P94, DOI 10.2144/98251st05; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Mirshahi T, 2002, J BIOL CHEM, V277, P7348, DOI 10.1074/jbc.M109999200; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; ROBISHAW JD, 2003, HDB CELL SIGNALING, V2, P623; Rojkova AM, 2003, J BIOL CHEM, V278, P12507, DOI 10.1074/jbc.M207302200; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Ueda H, 1997, J CELL SCI, V110, P1503; UEDA N, 1994, J BIOL CHEM, V269, P4388; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575; Zhou JY, 2003, J PHARMACOL EXP THER, V305, P460, DOI 10.1124/jpet.102.048637	56	85	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30279	30286		10.1074/jbc.M401432200	http://dx.doi.org/10.1074/jbc.M401432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15136579	hybrid			2022-12-25	WOS:000222531900053
J	Worm, J; Christensen, C; Gronbaek, K; Tulchinsky, E; Guldberg, P				Worm, J; Christensen, C; Gronbaek, K; Tulchinsky, E; Guldberg, P			Genetic and epigenetic alterations of the APC gene in malignant melanoma	ONCOGENE			English	Article						melanoma; APC; Wnt signalling; DNA methylation; beta-catenin; RNAi	ADENOMATOUS-POLYPOSIS-COLI; CELL-CYCLE PROGRESSION; BETA-CATENIN GENE; SOMATIC MUTATIONS; EXON 3; SIGNALING PATHWAY; COLORECTAL-CANCER; DNA METHYLATION; S-PHASE; PROMOTER	High levels of beta-catenin and activating mutations in the beta-catenin gene (CTNNB1) have been demonstrated in malignant melanomas, implicating dysregulated Wnt signalling in the pathogenesis of this malignancy. We systematically examined melanoma cell lines for activating CTNNB1 mutations as well as genetic and epigenetic alterations of the adenomatous polyposis coli gene (APC), another key component of the Wnt signalling transduction pathway. Of 40 cell lines tested, one carried a truncating APC mutation and loss of the corresponding wild-type allele, and one carried a CTNNB1 missense mutation. Hypermethylation of APC promoter 1A was present in five of the cell lines (13%) and in nine of 54 melanoma biopsies (17%). Cells with truncating APC or activating CTNNB1 mutations showed increased transcription from endogenous and ectopic beta-catenin/T-cell factor (Tcf)responsive target genes, consistent with the known effects of these alterations on beta-catenin stability and Tcf transactivation. In contrast, cell lines with APC promoter 1A hypermethylation did not show increased Wnt signalling, probably due to residual APC activity expressed from promoter 1B. Suppression of APC transcripts in melanoma cells by stable expression of short hairpin RNAs led to a Wnt signalling-independent increase in cell proliferation, but also reduced the invasive growth in collagen type I. Collectively, our data suggest that the tumour-suppressive function of APC in melanocytic cells is dose dependent. We propose that epigenetic silencing of promoter 1A may contribute to the development of malignant melanoma by reducing the expression of APC to a level that promotes cell proliferation without compromising the invasive capacity.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 7RH, Leics, England	Danish Cancer Society; University of Leicester	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	perg@cancer.dk	Tulchinsky, Eugene/ABD-7070-2021	Gronbaek, Kirsten/0000-0002-1535-9601				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Chen C, 2001, J BIOL CHEM, V276, P320, DOI 10.1074/jbc.M007096200; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Cremonesi L, 1997, BIOTECHNIQUES, V22, P326, DOI 10.2144/97222rr01; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Esteller M, 2000, CANCER RES, V60, P4366; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Guldberg P, 1997, CANCER RES, V57, P3660; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Oda H, 1996, CANCER RES, V56, P3320; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Pollock PM, 2002, MELANOMA RES, V12, P183, DOI 10.1097/00008390-200204000-00013; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Worm J, 2001, CLIN CHEM, V47, P1183; Wu R, 2001, CANCER RES, V61, P8247; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; ZEKI K, 1994, J CLIN ENDOCR METAB, V79, P1317, DOI 10.1210/jc.79.5.1317; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	48	81	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5215	5226		10.1038/sj.onc.1207647	http://dx.doi.org/10.1038/sj.onc.1207647			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15133491				2022-12-25	WOS:000222382500011
J	Jia, YZ; Qi, C; Kashireddi, P; Surapureddi, S; Zhu, YJ; Rao, MS; Le Roith, D; Chambon, P; Gonzalez, FJ; Reddy, JK				Jia, YZ; Qi, C; Kashireddi, P; Surapureddi, S; Zhu, YJ; Rao, MS; Le Roith, D; Chambon, P; Gonzalez, FJ; Reddy, JK			Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPAR alpha-regulated gene expression in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; NUCLEAR RECEPTORS; BINDING-PROTEIN; EMBRYONIC-DEVELOPMENT; INTERACTING PROTEIN; TRAP220 COMPONENT; LIGAND METABOLISM; BETA-OXIDATION; NORMAL GROWTH; MOUSE-LIVER	Nuclear receptor coactivator PBP (peroxisome proliferator-activated receptor (PPAR)-binding protein) functions as a coactivator for PPARs and other nuclear receptors. PBP serves as an anchor for TRAP ( thyroid hormone receptor-associated proteins)/mediator multi-subunit cofactor transcription complex. Disruption of the PBP/TRAP220 gene results in embryonic lethality around embryonic day 11.5 by affecting placental, cardiac, hepatic, and bone marrow development. Because PPAR isoforms alpha, gamma, and beta/delta function as important regulators of lipid homeostasis in mammals, it becomes important to assess the requirement of coactivator PBP in the regulation of PPAR functions in vivo. Sustained activation of PPARalpha by structurally diverse classes of chemicals of biological importance, designated peroxisome proliferators, leads to proliferation of peroxisomes in liver, induction of PPARalpha target genes including those involved in fatty acid oxidation, and the eventual development of liver tumors. Here, we show that targeted deletion of PBP in liver parenchymal cells, using the Cre-loxP system, results in the near abrogation of PPARalpha ligand-induced peroxisome proliferation and liver cell proliferation, as well as the induction of PPARalpha-regulated genes in PBP-deficient liver cells. In contrast, scattered PBP+/+ hepatocytes in these livers showed DNA synthesis and were markedly hypertrophic with peroxisome proliferation in response to PPARalpha ligands. Chromatin immunoprecipitation data suggest that in PBP conditional null livers, there appears to be reduced association of cofactors, especially of CBP and TRAP150, to the mouse enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase gene promoter. These observations suggest that PBP is required for the stabilization of multiprotein cofactor complexes. In essence, the absence of PBP in hepatocytes in vivo appears to mimic the absence of PPARalpha, indicating that coactivator PBP is essential for PPARalpha-regulated gene expression in liver parenchymal cells.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; NIH, Diabet Branch, Bethesda, MD 20892 USA; Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS INSERM, F-67404 Illkirch Graffenstaden, France; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu			NCI NIH HHS [CA104578] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104578, Z01BC005708, ZIABC005708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; CHU RY, 1995, J BIOL CHEM, V270, P29636; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GEHLIN M, 2002, MOL CELL BIOL, V22, P5923; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Jain S, 1998, AM J PATHOL, V153, P349, DOI 10.1016/S0002-9440(10)65577-0; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Landles C, 2003, MOL ENDOCRINOL, V17, P2418, DOI 10.1210/me.2003-0097; LASKO M, 1996, P NATL ACAD SCI USA, V93, P5860; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Melnick RL, 2001, ENVIRON HEALTH PERSP, V109, P437, DOI 10.2307/3454700; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Qi C, 1999, J BIOL CHEM, V274, P15775, DOI 10.1074/jbc.274.22.15775; Qi C, 2003, J BIOL CHEM, V278, P25281, DOI 10.1074/jbc.C300175200; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1979, CANCER RES, V39, P152; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 2004, IN PRESS AM J PATHOL; Roeder RG, 2003, NAT MED, V9, P1239, DOI 10.1038/nm938; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Watkins RE, 2003, J MOL BIOL, V331, P815, DOI 10.1016/S0022-2836(03)00795-2; WEGLARZ TC, 1941, CARCINOGENESIS, V25, P107; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	56	94	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 4	2004	279	23					24427	24434		10.1074/jbc.M402391200	http://dx.doi.org/10.1074/jbc.M402391200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	824RA	15150259	hybrid			2022-12-25	WOS:000221702500069
J	Garden, GA; Guo, WQ; Jayadev, S; Tun, C; Balcaitis, S; Choi, J; Montine, TJ; Moller, T; Morrison, RS				Garden, GA; Guo, WQ; Jayadev, S; Tun, C; Balcaitis, S; Choi, J; Montine, TJ; Moller, T; Morrison, RS			HIV associated neurodegeneration requires p53 in neurons and microglia	FASEB JOURNAL			English	Article						AIDS; apoptosis; caspase; chemokine receptors; dementia	HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-SUPPRESSOR P53; CELL-DEATH; GLYCOPROTEIN COMPLEX; QUINOLINIC ACID; MOUSE MODEL; APOPTOSIS; ACTIVATION; EXPRESSION; PROTEIN	HIV infection of the central nervous system leads to HIV-associated dementia ( HAD) in a substantial subset of infected individuals. The pathogenesis of neuronal dysfunction in HAD is not well understood, but previous studies have demonstrated evidence for activation of apoptotic pathways. The tumor suppressor transcription factor p53 is an apical mediator of neuronal apoptosis following a variety of injurious stimuli. To determine whether p53 participates in HAD, we exposed cerebrocortical cultures from wild-type and p53 deficient mice to the neurotoxic HIV envelope protein gp120. Using neuron/microglia co-culture of mixed p53 genotype, we observed that both neurons and microglia require p53 for gp120 induced neuronal apoptosis. Additionally, accumulation of p53 protein in neurons was recently reported in postmortem cortical tissue from a small group of HAD patients. Using a much larger cohort of HAD cases, we extend this finding and report that p53 protein also increases in non-neuronal cells, including microglia. Taken together these findings demonstrate a novel role for p53 in the microglial response to gp120. Additionally, these findings, in conjunction with a recent report that monocytes expressing HIV-Tat also secrete neurotoxins that promote p53 activation, suggest that distinct HIV proteins may converge on the p53 pathway to promote neurotoxicity.	Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Garden, GA (corresponding author), Univ Washington, Dept Neurol, Box 356465, Seattle, WA 98195 USA.	gagarden@u.washington.edu	Jayadev, Suman/B-6362-2019; Garden, Gwenn/CAF-9344-2022	Garden, Gwenn/0000-0002-8753-6515	NIMH NIH HHS [U01 MH083545] Funding Source: Medline; NINDS NIH HHS [NS02063, NS45528, NS44337, NS35533] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH083545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044337, R01NS035533, R01NS045528] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; Adle-Biassette H, 1999, NEUROPATH APPL NEURO, V25, P123; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; ChengMayer C, 1997, J VIROL, V71, P1657, DOI 10.1128/JVI.71.2.1657-1661.1997; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; de la Monte SM, 1998, LAB INVEST, V78, P401; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Doughty ML, 2000, J NEUROSCI, V20, P3687; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Garden GA, 2002, GLIA, V40, P240, DOI 10.1002/glia.10155; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; Genini D, 2001, FASEB J, V15, P5; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/S0306-4522(96)00174-1; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Hung CS, 1999, J VIROL, V73, P8216, DOI 10.1128/JVI.73.10.8216-8226.1999; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan-Sciutto KL, 2000, AM J PATHOL, V157, P497, DOI 10.1016/S0002-9440(10)64561-0; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kawahara K, 2001, NEUROSCI LETT, V310, P89, DOI 10.1016/S0304-3940(01)02079-1; Klockel BJ, 2002, CELL DEATH DIFFER, V9, P1063, DOI 10.1038/sj.cdd.4401067; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kuntz C, 2000, EXP NEUROL, V165, P184, DOI 10.1006/exnr.2000.7464; Letendre SL, 1999, J INFECT DIS, V180, P310, DOI 10.1086/314866; Manes S, 2003, J EXP MED, V198, P1381, DOI 10.1084/jem.20030580; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MATAS D, 2004, CELL DEATH DIFFER; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 1996, J NEUROSCI, V16, P1337; Prudlo J, 2000, BRAIN RES, V879, P183, DOI 10.1016/S0006-8993(00)02745-1; Puig B, 2001, ACTA NEUROPATHOL, V102, P207; Saito N, 2000, J NEUROTRAUM, V17, P173, DOI 10.1089/neu.2000.17.173; Sakhi S, 1997, EXP NEUROL, V145, P81, DOI 10.1006/exnr.1997.6451; Shahbazian MD, 2001, NEUROBIOL DIS, V8, P974, DOI 10.1006/nbdi.2001.0444; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Silva C, 2003, ANN NEUROL, V54, P605, DOI 10.1002/ana.10729; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Su JH, 2000, EXP NEUROL, V163, P9, DOI 10.1006/exnr.2000.7340; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Wang JB, 2002, J INFECT DIS, V185, P885, DOI 10.1086/339522; WESSELINGH SL, 1994, ADV NEUROIMMUNOL, V4, P199, DOI 10.1016/S0960-5428(06)80258-5; Xiang H, 1996, J NEUROSCI, V16, P6753; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yeh MW, 2000, J IMMUNOL, V164, P4265, DOI 10.4049/jimmunol.164.8.4265; Yeung MC, 1998, AIDS, V12, P349, DOI 10.1097/00002030-199804000-00002	56	99	103	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2004	18	7					1141	+		10.1096/fj.04-1676fje	http://dx.doi.org/10.1096/fj.04-1676fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	827EZ	15155568				2022-12-25	WOS:000221883200001
J	Yamada, M; Mattaj, IW; Yoneda, Y				Yamada, M; Mattaj, IW; Yoneda, Y			An ATP-dependent activity that releases RanGDP from NTF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSPORT FACTOR-2; GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN IMPORT; PORE COMPLEX; STRUCTURAL BASIS; GTP HYDROLYSIS; GDP-RAN; RCC1; REGULATOR; IDENTIFICATION	The small GTPase Ran functions in several critical processes in eukaryotic cells including nuclear transport, nuclear envelope formation, and spindle formation. A RanGDP-binding protein, NTF2, facilitates translocation of RanGDP through the nuclear pore complex and also acts to stabilize RanGDP against nucleotide exchange. Here, we identify a novel activity that stimulates release of GDP from Ran in the presence of NTF2. Hydrolyzable ATP enhances the GDP dissociation activity, and this enhancement is inhibited by nonhydrolyzable ATP analogues. In contrast, neither hydrolyzable ATP nor nonhydrolyzable ATP analogues affect GDP dissociation from Ran catalyzed by recombinant RCC1 or inhibition of GDP dissociation from Ran by recombinant NTF2. The ATP-dependent RanGDP dissociation activity therefore has the properties of a RanGDP dissociation inhibitor (GDI) displacement factor (RanGDF) where the GDI is NTF2. A protein phosphatase inhibitor mixture stimulates the RanGDF activity, suggesting the activity is regulated by phosphorylation. We propose that the ATP-dependent NTF2 releasing factor may have a role in the RanGDP/GTP cycle.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka, Japan	European Molecular Biology Laboratory (EMBL); Osaka University	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	mattaj@embl-heidelberg.de		Mattaj, Iain/0000-0002-5537-8284				Avis JM, 1996, J CELL SCI, V109, P2423; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Kunzler M, 2001, J CELL SCI, V114, P3233; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; Paschal BM, 1997, J BIOL CHEM, V272, P21534, DOI 10.1074/jbc.272.34.21534; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2000, J MOL BIOL, V299, P213, DOI 10.1006/jmbi.2000.3733; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Yamada M, 1998, CURR BIOL, V8, P1339, DOI 10.1016/S0960-9822(07)00566-0	38	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 27	2004	279	35					36228	36234		10.1074/jbc.M403101200	http://dx.doi.org/10.1074/jbc.M403101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	848FS	15155737	hybrid			2022-12-25	WOS:000223453600010
J	Trujillo, M; Budde, H; Pineyro, MD; Stehr, M; Robello, C; Flohe, L; Radi, R				Trujillo, M; Budde, H; Pineyro, MD; Stehr, M; Robello, C; Flohe, L; Radi, R			Trypanosoma brucei and Trypanosoma cruzi tryparedoxin peroxidases catalytically detoxify peroxynitrite via oxidation of fast reacting thiols.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX-SENSITIVE OLIGOMERIZATION; NITRIC-OXIDE SYNTHASE; HUMAN SERUM-ALBUMIN; HYDROGEN-PEROXIDE; MEDIATED CYTOTOXICITY; MACROPHAGE ACTIVATION; LEISHMANIA-CHAGASI; METABOLISM; SUPEROXIDE; PEROXIREDOXINS	Macrophage activation is one of the hallmarks observed in trypanosomiasis, and the parasites must cope with the resulting oxidative burden, which includes the production of peroxynitrite, an unusual peroxo-acid that acts as a strong oxidant and trypanocidal molecule. Cytosolic tryparedoxin peroxidase (cTXNPx) has been recently identified as essential for oxidative defense in trypanosomatids. This peroxiredoxin decomposes peroxides using tryparedoxin (TXN) as electron donor, which in turn is reduced by dihydrotrypanothione. In this work, we studied the kinetics of the reaction of peroxynitrite with the different thiol-containing components of the cytosolic tryparedoxin peroxidase system in T. brucei (Tb) and T. cruzi (Tc), namely trypanothione, TXN, and cTXNPx. We found that whereas peroxynitrite reacted with dihydrotrypanothione and TbTXN at moderate rates (7200 and 3500 M-1 s(-1), respectively, at pH 7.4 and 37 degreesC) and within the range of typical thiols, the second order rate constants for the reaction of peroxynitrite with reduced TbcTXNPx and TccTXNPx were 9 x 10(5) and 7.2 x 10(5) M-1 s(-1) at pH 7.4 and 37 degreesC, respectively. This reactivity was dependent on a highly reactive cTXNPx thiol group identified as cysteine 52. Competition experiments showed that TbcTXNPx inhibited other fast peroxynitrite-mediated processes, such as the oxidation of Mn3+-porphyrins. Moreover, steady-state kinetic studies indicate that peroxynitrite-dependent TbcTXNPx and TccTXNPx oxidation is readily reverted by TXN, supporting that these peroxiredoxins would be not only a preferential target for peroxynitrite reactivity but also be able to act catalytically in peroxynitrite decomposition in vivo.	Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Republica, Fac Med, Ctr Free Rad & Bioomed Res, Montevideo 11800, Uruguay; Tech Univ Carolo Wilhelmina Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; MOLISA GmbH, D-39106 Magdeburg, Germany	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Braunschweig University of Technology	Radi, R (corresponding author), Univ Republica, Fac Med, Dept Bioquim, Avda Gral Flores 2125, Montevideo 11800, Uruguay.	rradi@fmed.edu.uy	ROBELLO, CARLOS/M-5609-2019	ROBELLO, CARLOS/0000-0001-6985-6171				Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Alvarez MN, 2002, METHOD ENZYMOL, V359, P353; Barr SD, 2003, J BIOL CHEM, V278, P10816, DOI 10.1074/jbc.M212990200; Barr SD, 2001, J BIOL CHEM, V276, P34279, DOI 10.1074/jbc.M104406200; BOHN H, 1989, J CARDIOVASC PHA S11, V14, P6; BOVERIS A, 1977, EXPERIENTIA, V33, P1306, DOI 10.1007/BF01920148; Britto PJ, 2002, J BIOL CHEM, V277, P29018, DOI 10.1074/jbc.M204263200; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Budde H, 2003, BIOL CHEM, V384, P619, DOI 10.1515/BC.2003.069; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; CARDONI RL, 1990, CELL IMMUNOL, V128, P11, DOI 10.1016/0008-8749(90)90002-9; Cardoni RL, 1997, AM J TROP MED HYG, V56, P329, DOI 10.4269/ajtmh.1997.56.329; CELENTANO AM, 1992, PARASITE IMMUNOL, V14, P155, DOI 10.1111/j.1365-3024.1992.tb00458.x; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chandrasekar B, 2000, CLIN EXP IMMUNOL, V121, P112, DOI 10.1046/j.1365-2249.2000.01258.x; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; DOCAMPO R, 1986, FED PROC, V45, P2471; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Espenson J. H., 1995, CHEM KINETICS REACTI, P46; Ferrer-Sueta G, 2003, J BIOL CHEM, V278, P27432, DOI 10.1074/jbc.M213302200; Finzi JK, 2004, MOL BIOCHEM PARASIT, V133, P37, DOI 10.1016/j.molbiopara.2003.08.011; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; FONTECAVE M, 1987, J BIOL CHEM, V262, P12332; GROSSKINSKY CM, 1983, INFECT IMMUN, V39, P1080, DOI 10.1128/IAI.39.3.1080-1086.1983; Guerrero SA, 2000, APPL MICROBIOL BIOT, V53, P410, DOI 10.1007/s002530051634; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; Jaeger T, 2004, ARCH BIOCHEM BIOPHYS, V423, P182, DOI 10.1016/j.abb.2003.11.021; Keita M, 2000, EXP PARASITOL, V95, P19, DOI 10.1006/expr.2000.4505; Kelm M, 1997, J BIOL CHEM, V272, P9922; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Machado FS, 2000, CIRCULATION, V102, P3003, DOI 10.1161/01.CIR.102.24.3003; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Souza JM, 1998, ARCH BIOCHEM BIOPHYS, V360, P187, DOI 10.1006/abbi.1998.0932; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Thomson L, 2003, ARCH BIOCHEM BIOPHYS, V412, P55, DOI 10.1016/S0003-9861(02)00745-2; Trujillo M, 2002, ARCH BIOCHEM BIOPHYS, V397, P91, DOI 10.1006/abbi.2001.2619; VINCENDEAU P, 1992, EXP PARASITOL, V75, P353, DOI 10.1016/0014-4894(92)90220-5; VINCENDEAU P, 1999, PROGR HUMAN AFRICAN, P137; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2003, J BIOL CHEM, V278, P31640, DOI 10.1074/jbc.M303035200; Wilkinson SR, 2002, P NATL ACAD SCI USA, V99, P13453, DOI 10.1073/pnas.202422899; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m	54	104	110	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34175	34182		10.1074/jbc.M404317200	http://dx.doi.org/10.1074/jbc.M404317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15155760	hybrid			2022-12-25	WOS:000223134800015
J	Alric, J; Yoshida, M; Nagashima, KVP; Hienerwadel, R; Parot, P; Vermeglio, A; Chen, SWW; Pellequer, JL				Alric, J; Yoshida, M; Nagashima, KVP; Hienerwadel, R; Parot, P; Vermeglio, A; Chen, SWW; Pellequer, JL			Two distinct binding sites for high potential iron-sulfur protein and cytochrome C on the reaction center-bound cytochrome of Rubrivivax gelatinosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; REACTION-CENTER COMPLEX; ELECTRON-TRANSFER; PURPLE BACTERIUM; RHODOPSEUDOMONAS-VIRIDIS; CRYSTAL-STRUCTURE; SUBUNIT; RESOLUTION; SUBSTRATE; HIPIP	The photosynthetic cyclic electron transfer of the purple bacterium Rubrivivax gelatinosus, involving the cytochrome bc(1) complex and the reaction center, can be carried out via two pathways. A high potential iron-sulfur protein (HiPIP) acts as the in vivo periplasmic electron donor to the reaction center (RC)-bound cytochrome when cells are grown under anaerobic conditions in the light, while cytochrome c(8) is the soluble electron carrier for cells grown under aerobic conditions in the dark. A spontaneous reversion of R. gelatinosus C244, a defective mutant in synthesis of the RC-bound cytochrome by insertion of a Km(r) cassette leading to gene disruption with a slow growth rate, restores the normal photosynthetic growth. This revertant, designated C244-P1, lost the Kmr cassette but synthesized a RC-bound cytochrome with an external 77-amino acid insertion derived from the cassette. We characterized the RC-bound cytochrome of this mutant by EPR, time-resolved optical spectroscopy, and structural analysis. We also investigated the in vivo electron transfer rates between the two soluble electron donors and this RC-bound cytochrome. Our results demonstrated that the C244-P1 RC-bound cytochrome is still able to receive electrons from HiPIP, but it is no longer reducible by cytochrome c(8). Combining these experimental and theoretical protein-protein docking results, we conclude that cytochrome c(8) and HiPIP bind the RC-bound cytochrome at two distinct but partially overlapping sites.	CEA Valrho, Ctr Marcoule, DSV, DIEP,SBTN, F-30207 Bagnols Sur Ceze, France; CEA Aix Marseille 2, Lab Genet & Biophys Plantes, CNRS, UMR 6191, F-13288 Marseille, France; UMR 6191 CNRS CEA Aix Marseille 2, CEA Cadarache, Direct Sci Vivant, Dept Ecophysiol Vegetale & Microbiol,Lab Bioenerg, F-13108 St Paul Les Durance, France; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan	CEA; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; CEA; Tokyo Metropolitan University	Pellequer, JL (corresponding author), CEA Valrho, Ctr Marcoule, DSV, DIEP,SBTN, BP 17171, F-30207 Bagnols Sur Ceze, France.	jlpellequer@cea.fr	PAROT, Pierre/C-1742-2017; Pellequer, Jean-Luc/L-6855-2013; Nagashima, Kenji V. P./M-2208-2017; Parot, Pierre/Q-4444-2019; Alric, Jean/E-3538-2013; PAROT, Pierre/B-3959-2012	Pellequer, Jean-Luc/0000-0002-8944-2715; Nagashima, Kenji V. P./0000-0002-4526-6625; Alric, Jean/0000-0003-3574-2234; 				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; Axelrod HL, 2002, J MOL BIOL, V319, P501, DOI 10.1016/S0022-2836(02)00168-7; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chen SWW, 2004, CURR MED CHEM, V11, P595, DOI 10.2174/0929867043455891; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Gonzalez A, 2003, ACTA CRYSTALLOGR D, V59, P1582, DOI 10.1107/S0907444903014604; Hochkoeppler A, 1996, P NATL ACAD SCI USA, V93, P6998, DOI 10.1073/pnas.93.14.6998; Kerfeld CA, 1996, BIOCHEMISTRY-US, V35, P7812, DOI 10.1021/bi952731v; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Masuda S, 1999, J BIOL CHEM, V274, P10795, DOI 10.1074/jbc.274.16.10795; Masuda S, 2002, BIOCHEMISTRY-US, V41, P11211, DOI 10.1021/bi0258492; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Menin L, 1999, BIOCHEMISTRY-US, V38, P15238, DOI 10.1021/bi991146h; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 2001, HDB METALLOPROTEINS, V1, P33; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nagashima KVP, 1996, FEBS LETT, V385, P209, DOI 10.1016/0014-5793(96)00382-1; Nagashima KVP, 2002, BIOCHEMISTRY-US, V41, P14028, DOI 10.1021/bi026511a; Nagashima KVP, 1997, PLANT CELL PHYSIOL, V38, P1249, DOI 10.1093/oxfordjournals.pcp.a029112; Nagashima KVP, 1998, PHOTOSYNTH RES, V55, P349, DOI 10.1023/A:1005912810674; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1100, P49; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; Nogi T, 2001, J BIOCHEM-TOKYO, V130, P319, DOI 10.1093/oxfordjournals.jbchem.a002989; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Roussel A., 1989, SILICON GRAPHICS GEO; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHOEPP B, 1995, BIOCHEMISTRY-US, V34, P11736, DOI 10.1021/bi00037a010; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Venturoli G, 2004, BIOCHEMISTRY-US, V43, P437, DOI 10.1021/bi035384v; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; Vermeglio A, 2002, BIOCHEMISTRY-US, V41, P8868, DOI 10.1021/bi012037h; Yoshida M, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P897; Yoshida MT, 2001, BBA-BIOENERGETICS, V1506, P23, DOI 10.1016/S0005-2728(01)00177-3	46	7	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32545	32553		10.1074/jbc.M401784200	http://dx.doi.org/10.1074/jbc.M401784200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155756	Green Published, hybrid			2022-12-25	WOS:000222849700070
J	Erikson, E; Haystead, TAJ; Qian, YW; Maller, JL				Erikson, E; Haystead, TAJ; Qian, YW; Maller, JL			A feedback loop in the polo-like kinase activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS CDC25 PHOSPHATASE; PROTEIN-KINASE; CELL-CYCLE; PHOSPHORYLATION SITES; PLX1; TRANSITION; PLK1; BOX; IDENTIFICATION; AMPLIFICATION	The Xenopus polo-like kinase Plx1 plays important roles during entry into and exit from mitosis ( M phase). Previous studies revealed that Plx1 is activated by phosphorylation on serine and threonine residues, and purification of an activating enzyme from mitotic Xenopus egg extracts led to cloning and characterization of Xenopus polo-like kinase kinase (xPlkk1), which can phosphorylate and activate Plx1 in vitro. In the present study, a positive feedback loop between Plx1 and xPlkk1 was shown to result in each kinase phosphorylating and activating the other. Sequencing of radiolabeled xPlkk1 after phosphorylation by Plx1 in vitro identified three phosphorylation sites each spaced three amino acids apart, two of which have the consensus acidic-X-pSer-hydrophobic described for other polo-like kinase substrates. In addition, endogenous xPlkk1 in oocytes was phosphorylated on these sites in M phase but not in interphase. A mutant xPlkk1 in which these three amino acids were changed to alanine (xPlkk1(SA3)) was unable to be phosphorylated or activated in vitro by Plxl. Depletion of Plx1 from oocyte extracts prior to stimulation of the G(2)/M transition blocked the activation of xPlkk1, but depletion of xPlkk1 before stimulation did not block Plx1 activation. These results indicate that xPlkk1 may function downstream as a target of Plx1 rather than as an upstream activating kinase during the G(2)/M transition.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Duke University	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA.	Jim.Maller@uchsc.edu			NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NIDDK NIH HHS [DK52378-08] Funding Source: Medline; NIGMS NIH HHS [GM26743-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Donaldson MM, 2001, J CELL SCI, V114, P2357; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gross SD, 2001, J BIOL CHEM, V276, P46099, DOI 10.1074/jbc.C100496200; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Liu JJ, 2004, J BIOL CHEM, V279, P21367, DOI 10.1074/jbc.M400482200; LIU X, 2004, IN PRESS J CELL SCI; MacDonald JA, 2002, MOL CELL PROTEOMICS, V1, P314, DOI 10.1074/mcp.M200002-MCP200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Perdiguero E, 2004, CELL CYCLE, V3, P733; Perdiguero E, 2003, EMBO J, V22, P5746, DOI 10.1093/emboj/cdg559; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SUL HS, 1982, J BIOL CHEM, V257, P3484; Tavares AAM, 1996, EMBO J, V15, P4873, DOI 10.1002/j.1460-2075.1996.tb00868.x; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	44	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32219	32224		10.1074/jbc.M403840200	http://dx.doi.org/10.1074/jbc.M403840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166215	hybrid			2022-12-25	WOS:000222849700029
J	Friedman, YE; O'Brian, MR				Friedman, YE; O'Brian, MR			The ferric uptake regulator (Fur) protein from Bradyrhizobium japonicum is an iron-responsive transcriptional repressor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; BINDING; IDENTIFICATION; IRR; AUTOREGULATION; EXPRESSION; PROMOTER; HEME; GENE	The Fur protein represses transcription of iron-responsive genes in bacteria. The discovery that Fur is a zinc metalloprotein and the use of surrogate metals for Fe2+ for in vitro studies question whether Fur is a direct iron sensor. In the present study, we show that the affinity of Fur from Bradyrhizobium japonicum (BjFur) for its target DNA increases 30-fold in the presence of metal, with a K-d value of about 2 nM. DNase I footprinting experiments showed that BjFur protected its binding site within the irr gene promoter in the presence of Fe2+ but not in the absence of metal, showing that DNA binding is Fe2+-dependent. BjFur did not inhibit in vitro transcription from the irr promoter using purified components in the absence of metal, but BjFur repressed transcription in the presence of Fe2+. Thus, BjFur is an iron-responsive transcriptional repressor in vitro. A regulatory Fe2+-binding site (site 1) and a structural Zn2+-binding site (site 2) inferred from the recent crystal structure of Fur from Pseudomonas aeruginosa are composed of amino acids highly conserved in many Fur proteins, including BjFur. BjFur mutants containing substitutions in site 1 (BjFurS1) or site 2 (BjFurS2) bound DNA with high affinity and repressed transcription in vitro in an Fe2+-dependent manner. Interestingly, only a single dimer of BjFurS2 occupied the irr promoter, whereas the wild type and BjFurS1 displayed one- or two-dimer occupancy. We suggest that the putative functions for metal-binding sites deduced from the structure of P. aeruginosa Fur cannot be extrapolated to bacterial Fur proteins as a whole.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	O'Brian, MR (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall, Buffalo, NY 14214 USA.	mrobrian@buffalo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-067966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bsat N, 1999, J BACTERIOL, V181, P4299, DOI 10.1128/JB.181.14.4299-4307.1999; de Peredo AG, 1999, BIOCHEMISTRY-US, V38, P8582, DOI 10.1021/bi9902283; Delany I, 2003, MOL MICROBIOL, V50, P1329, DOI 10.1046/j.1365-2958.2003.03757.x; Delany I, 2002, MOL MICROBIOL, V46, P1107, DOI 10.1046/j.1365-2958.2002.03227.x; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Friedman YE, 2003, J BIOL CHEM, V278, P38395, DOI 10.1074/jbc.M306710200; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; Hamza I, 1999, J BACTERIOL, V181, P5843, DOI 10.1128/JB.181.18.5843-5846.1999; Hamza I, 1998, J BIOL CHEM, V273, P21669, DOI 10.1074/jbc.273.34.21669; Hamza I, 2000, MICROBIOL-SGM, V146, P669, DOI 10.1099/00221287-146-3-669; Hassett DJ, 1996, J BACTERIOL, V178, P3996, DOI 10.1128/jb.178.14.3996-4003.1996; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; Lewin AC, 2002, MICROBIOL-SGM, V148, P2449, DOI 10.1099/00221287-148-8-2449; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; OCHSNER UA, 1995, J BACTERIOL, V177, P7194, DOI 10.1128/jb.177.24.7194-7201.1995; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; Touati D, 2000, ARCH BIOCHEM BIOPHYS, V373, P1, DOI 10.1006/abbi.1999.1518	25	41	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32100	32105		10.1074/jbc.M404924200	http://dx.doi.org/10.1074/jbc.M404924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15148310	hybrid			2022-12-25	WOS:000222849700015
J	Peng, J; Mao, XO; Stevenson, FF; Hsu, M; Andersen, JK				Peng, J; Mao, XO; Stevenson, FF; Hsu, M; Andersen, JK			The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVIRONMENTAL RISK-FACTORS; N-TERMINAL KINASE; PARKINSONS-DISEASE; C-JUN; PROTEIN-KINASE; CELL-DEATH; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION; WELL WATER; EXPOSURE	Environmental exposure to the oxidant-producing herbicide paraquat has been implicated as a risk factor in Parkinson's disease. Although intraperitoneal paraquat injections in mice cause a selective loss of dopaminergic neurons in the substantia nigra pars compacta, the exact mechanism involved is still poorly understood. Our data show that paraquat induces the sequential phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun and the activation of caspase-3 and sequential neuronal death both in vitro and in vivo. These effects are diminished by the specific JNK inhibitor SP600125 and the antioxidant manganese(III) tetrakis (4-benzoic acid) porphyrin in vitro. Furthermore, JNK pathway inhibitor CEP-11004 effectively blocks paraquat-induced dopaminergic neuronal death in vivo. These results suggest that the JNK signaling cascade is a direct activator of the paraquat-mediated nigral dopaminergic neuronal apoptotic machinery and provides a molecular linkage between oxidative stress and neuronal apoptosis.	Buck Inst Age Res, Novato, CA 94945 USA; Univ So Calif, Dept Biol Sci, Program Mol Biol, Los Angeles, CA 90089 USA	Buck Institute for Research on Aging; University of Southern California	Andersen, JK (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	jandersen@buckinstitute.org		Andersen, Julie/0000-0003-1324-4875; Hsu, Mike/0000-0001-7086-1808	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012077] Funding Source: NIH RePORTER; NIEHS NIH HHS [U54 ES12077] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BURKITT MJ, 1993, MOL PHARMACOL, V43, P257; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; CLEJAN L, 1989, BIOCHEM PHARMACOL, V38, P1779, DOI 10.1016/0006-2952(89)90412-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han MJ, 2003, MOL CELLS, V15, P94; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HERTZMAN C, 1990, AM J IND MED, V17, P349, DOI 10.1002/ajim.4700170307; HUBBLE JP, 1993, NEUROLOGY, V43, P1693, DOI 10.1212/WNL.43.9.1693; JIMENEZJIMENEZ FJ, 1992, MOVEMENT DISORD, V7, P149, DOI 10.1002/mds.870070209; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Maroney AC, 1999, J NEUROCHEM, V73, P1901; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; Murakata C, 2002, BIOORG MED CHEM LETT, V12, P147, DOI 10.1016/S0960-894X(01)00690-4; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Peng J, 2002, J BIOL CHEM, V277, P44285, DOI 10.1074/jbc.M207407200; Peng J, 2003, IUBMB LIFE, V55, P267, DOI 10.1080/1521654031000121666; PRASAD KN, 1994, IN VITRO CELL DEV-AN, V30A, P596; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Stephenson J, 2000, JAMA-J AM MED ASSOC, V283, P3055, DOI 10.1001/jama.283.23.3055; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298	42	169	179	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32626	32632		10.1074/jbc.M404596200	http://dx.doi.org/10.1074/jbc.M404596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155744	hybrid			2022-12-25	WOS:000222849700080
J	Zhao, L; Liao, H; Tsai, MD				Zhao, L; Liao, H; Tsai, MD			The catalytic role of aspartate in a short strong hydrogen bond of the Asp(274)-His(32) catalytic dyad in phosphatidylinositol-specific phospholipase C can be substituted by a chloride ion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SERINE PROTEASES; ENZYMATIC CATALYSIS; BACILLUS-CEREUS; ACTIVE-SITE; TRIAD; MECHANISM; HISTIDINE; NMR; CHYMOTRYPSIN	Phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis catalyzes the cleavage of the phosphorus-oxygen bond in phosphatidylinositol. The focus of this work is to dissect the roles of the carboxylate side chain of Asp(274) in the Asp(274)-His(32) dyad, where a short strong hydrogen bond (SSHB) was shown to exist based on NMR criteria. A regular hydrogen bond (HB) was observed in D274N, and no low field proton resonance was detected for D274E and D274A. Comparison of the activity of wild type, D274N, and D274A suggested that the regular HB contributes significantly (similar to4 kcal/mol) to catalysis, whereas the SSHB contributes only an additional 2 kcal/mol. The mutant D274E displays high activity similar to wild type, suggesting that the negative charge is sufficient for the catalytic role of Asp(274). To further support this interpretation and rule out possible contribution of regular HB or SSHB in D274E, we showed that the activity of D274G can be rescued by exogenous chloride ions to a level comparable with that of D274E. Comparison between different anions suggested that the ability of an anion to rescue the activity is due to the size and the charge of the anion not the property as a HB acceptor. In conclusion, a major fraction of the functional role of Asp(274) in the Asp(274)-His(32) dyad can be attributed to a negative charge (as in D274E and D274G-Cl-), and the SSHB in the wild type enzyme provides minimal contribution to catalysis. These results represent novel insight for an Asp-His catalytic dyad and for the mechanism of phosphatidylinositol-specific phospholipase C.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	Ohio State University; Ohio State University; Ohio State University; Academia Sinica - Taiwan	Tsai, MD (corresponding author), Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.	tsai.7@osu.edu	Tsai, Ming-Daw/G-4689-2019	Tsai, Ming-Daw/0000-0003-1374-0414	NIGMS NIH HHS [GM57568] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; Bachovchin WW, 2001, MAGN RESON CHEM, V39, pS199, DOI 10.1002/mrc.951; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Gassler CS, 1997, BIOCHEMISTRY-US, V36, P12802, DOI 10.1021/bi971102d; Gerlt JA, 1997, CHEM BIOL, V4, P259, DOI 10.1016/S1074-5521(97)90069-7; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Hondal RJ, 1998, BIOCHEMISTRY-US, V37, P4568, DOI 10.1021/bi972646i; Hondal RJ, 1997, BIOCHEMISTRY-US, V36, P6633, DOI 10.1021/bi962866g; HUNKAPILLER MW, 1973, BIOCHEMISTRY-US, V12, P4732, DOI 10.1021/bi00747a028; Kravchuk AV, 2001, BIOCHEMISTRY-US, V40, P5433, DOI 10.1021/bi002372q; Kubiak RJ, 2001, BIOCHEMISTRY-US, V40, P5422, DOI 10.1021/bi002371y; Kubiak RJ, 1999, J AM CHEM SOC, V121, P488, DOI 10.1021/ja9834677; KUMAR A, 1994, PROTEIN SCI, V3, P2082, DOI 10.1002/pro.5560031121; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Poi MJ, 2003, J MOL BIOL, V329, P997, DOI 10.1016/S0022-2836(03)00512-6; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; Ryan M, 2001, BIOCHEMISTRY-US, V40, P9743, DOI 10.1021/bi010958m; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; Stratton JR, 2001, BIOCHEMISTRY-US, V40, P10411, DOI 10.1021/bi015542n; TOBIN JB, 1995, BIOCHEMISTRY-US, V34, P6919, DOI 10.1021/bi00021a002; VOLWERK JJ, 1989, FEMS MICROBIOL LETT, V61, P237, DOI 10.1111/j.1574-6968.1989.tb03629.x; YATES BF, 1988, J AM CHEM SOC, V110, P6327, DOI 10.1021/ja00227a008	29	8	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					31995	32000		10.1074/jbc.M404184200	http://dx.doi.org/10.1074/jbc.M404184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15155721	hybrid			2022-12-25	WOS:000222849700002
J	Page, JL; Wang, X; Sordillo, LM; Johnson, SE				Page, JL; Wang, X; Sordillo, LM; Johnson, SE			MEKK1 signaling through p38 leads to transcriptional inactivation of E47 and repression of skeletal Myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HELIX-LOOP-HELIX; ACTIVATED PROTEIN-KINASE; MUSCLE GENE-EXPRESSION; MAP KINASE; OXIDATIVE STRESS; AVIAN MYOGENESIS; C2C12 MYOGENESIS; PATHWAYS; DIFFERENTIATION	Activation of the Raf kinase signal transduction pathway in skeletal myoblasts causes a complete cessation of myofiber formation and muscle gene expression. The negative impacts of the signaling pathway are realized through downstream activation of mitogen and extracellular kinase (MEK) phosphorylation-dependent events and MEK-independent signal transmission. MEKK1, a kinase that can physically associate with Raf, may contribute to the MEK-independent signaling in response to elevated Raf activity. Myogenic cells overexpressing activated Raf and kinase-defective MEKK1 remain differentiation-defective, suggesting that MEKK1 does not contribute to the inhibitory actions of Raf. However, constitutive activation of MEKK1 dramatically inhibits biochemical and morphological measures of muscle formation. MEKK1 inhibits MyoD-directed transcriptional activity without altering the ability of the protein to form heterodimers with E2A proteins or bind DNA. By contrast, the transcriptional activity of E47, the preferred dimer partner of the myogenic regulatory factors, is severely compromised by MEKK1-initiated signaling. Inhibition of MEK1/2 and JNK1/2 function did not reinstate E47-directed transcription, indicating that these two downstream kinases likely are not involved in the MEKK1-controlled transcriptional block. Inhibition of p38 signaling overcame the negative effects exerted by MEKK1 on the amino terminus of E47. Closer examination indicates that E47 is phosphorylated in vitro by p38, and deletion analysis predicts that the critical amino acid(s) phosphorylated by p38 lie outside of the minimal transcriptional activation domains. Thus, modification of E47 by p38 likely disrupts higher order protein complex formation that is necessary for muscle gene transcription.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA; Michigan State Univ, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Michigan State University	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, 206 Henning, University Pk, PA 16802 USA.	sej4@psu.edu		Sordillo, Lorraine/0000-0001-8873-3134	NIAMS NIH HHS [1R01 AR048830-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048830] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Becker JR, 2001, EXP CELL RES, V267, P135, DOI 10.1006/excr.2001.5249; Boldt S, 2003, EXP CELL RES, V283, P80, DOI 10.1016/S0014-4827(02)00018-6; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 2000, J BIOL CHEM, V275, P27481; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Johnson SE, 2002, J BIOL CHEM, V277, P28742, DOI 10.1074/jbc.M203680200; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li FQ, 1996, J CELL BIOL, V135, P1043, DOI 10.1083/jcb.135.4.1043; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Mitin N, 2001, ONCOGENE, V20, P1276, DOI 10.1038/sj.onc.1204223; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Puri PL, 2000, GENE DEV, V14, P574; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Schlesinger TK, 2002, J BIOL CHEM, V277, P10283, DOI 10.1074/jbc.M106885200; Suelves M, 2004, EMBO J, V23, P365, DOI 10.1038/sj.emboj.7600056; Waas WF, 2001, J BIOL CHEM, V276, P5676, DOI 10.1074/jbc.M008787200; Wang X, 2004, J BIOL CHEM, V279, P2528, DOI 10.1074/jbc.M306489200; Winter B, 2000, J CELL SCI, V113, P4211; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	47	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30966	30972		10.1074/jbc.M402224200	http://dx.doi.org/10.1074/jbc.M402224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159407	hybrid			2022-12-25	WOS:000222726800009
J	Chen, HH; Mullett, SJ; Stewart, AFR				Chen, HH; Mullett, SJ; Stewart, AFR			Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha(1)-adrenergic activation of gene expression in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; MUSCLE-SPECIFIC TRANSCRIPTION; CAT BINDING-FACTOR; PROTEIN-KINASE-C; SKELETAL-MUSCLE; DROSOPHILA-MELANOGASTER; WING FORMATION; FACTOR RTEF-1; ELEMENTS; TEF-1	Cardiac and skeletal muscle genes are regulated by the transcriptional enhancer factor (TEF-1) family of transcription factors. In skeletal muscle, TEF-1 factors interact with a skeletal muscle-specific cofactor called Vestigial-like 2 (Vgl-2) that is related to the Drosophila protein Vestigial. Here, we characterize Vgl-4, the only member of the Vestigial-like family expressed in the heart. Unlike other members of the Vgl family that have a single TEF-1 interaction domain called the tondu (TDU) motif, Vgl-4 has two TDU motifs in its carboxyl-terminal domain. Like other Vgl factors, Vgl-4 physically interacts with TEF-1 in an immunoprecipitation assay. Vgl-4 functionally interacts with TEF-1 and also with myocyte enhancer factor 2 in a mammalian two-hybrid assay. Overexpression of Vgl-4 in cardiac myocytes interfered with the basal expression and alpha(1)-adrenergic receptor-dependent activation of a TEF-1-dependent skeletal alpha-actin promoter. In cardiac myocytes cultured in serum and in serum-free medium, a myc-tagged Vgl-4 protein was located in the nucleus and cytoplasm but was exported from the nucleus when cells were treated with alpha(1)-adrenergic receptor agonist. A chimeric nuclear-retained Vgl-4 protein inhibited alpha(1)-adrenergic receptor-dependent activation. In contrast, deletion of the TDU motifs of Vgl-4 prevented Vgl-4 nuclear localization, relieved Vgl-4 interference of basal activity, and enhanced alpha(1)-adrenergic up-regulation of the skeletal alpha-actin promoter. Nuclear export of Vgl-4 is dependent on the nuclear exportin CRM-1. These results suggest that Vgl-4 modulates the activity of TEF-1 factors and counteracts alpha(1)-adrenergic activation of gene expression in cardiac myocytes.	Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stewart, AFR (corresponding author), Univ Pittsburgh, Cardiovasc Inst, 1704-3 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	stewartaf@upmc.edu	Stewart, Alexandre F.R./A-5677-2011	Stewart, Alexandre/0000-0003-2673-9164; Chen, Hsiao-Huei/0000-0003-2914-6057				Bate Michael, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1047; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Brown CO, 2004, J BIOL CHEM, V279, P10659, DOI 10.1074/jbc.M301648200; Busk PK, 2002, CARDIOVASC RES, V56, P64, DOI 10.1016/S0008-6363(02)00510-2; Butler AJ, 1999, MOL CELL BIOL, V19, P296; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Halder G, 1998, GENE DEV, V12, P3900, DOI 10.1101/gad.12.24.3900; Halder G, 2001, DEVELOPMENT, V128, P3295; Huey KA, 2003, AM J PHYSIOL-CELL PH, V284, pC738, DOI 10.1152/ajpcell.00389.2002; JACQUEMIN P, 1994, DNA CELL BIOL, V13, P1037, DOI 10.1089/dna.1994.13.1037; JIANG SW, 1994, J BIOL CHEM, V269, P10384; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Maeda T, 2002, J BIOL CHEM, V277, P24346, DOI 10.1074/jbc.M201171200; Maeda T, 2002, BIOCHEM BIOPH RES CO, V294, P791, DOI 10.1016/S0006-291X(02)00556-9; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; McLean BG, 2003, J MOL CELL CARDIOL, V35, P461, DOI 10.1016/S0022-2828(03)00049-X; Mielcarek M, 2002, MECH DEVELOP, V119, pS269, DOI 10.1016/S0925-4773(03)00127-8; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Paumard-Rigal S, 1998, DEV GENES EVOL, V208, P440, DOI 10.1007/s004270050201; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; Stewart AFR, 1996, GENOMICS, V37, P68, DOI 10.1006/geno.1996.0522; Stewart AFR, 1998, CIRC RES, V83, P43, DOI 10.1161/01.RES.83.1.43; Sudarsan V, 2001, DEV CELL, V1, P829, DOI 10.1016/S1534-5807(01)00089-2; Tsika RW, 2002, AM J PHYSIOL-CELL PH, V283, pC1761, DOI 10.1152/ajpcell.00278.2002; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; Vara D, 2003, J BIOL CHEM, V278, P21388, DOI 10.1074/jbc.M212612200; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	43	84	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2004	279	29					30800	30806		10.1074/jbc.M400154200	http://dx.doi.org/10.1074/jbc.M400154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	836CD	15140898	hybrid			2022-12-25	WOS:000222531900111
J	Qiu, ZH; Hyman, BT; Rebeck, GW				Qiu, ZH; Hyman, BT; Rebeck, GW			Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PEPTIDE; METHYL-D-ASPARTATE; GROWTH CONE MOTILITY; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; ALZHEIMERS-DISEASE; SIGNALING PATHWAY; CALCIUM RESPONSES; ALPHA(2)-MACROGLOBULIN; CREB	Several ligands of the endocytic low density lipoprotein receptor-related protein (LRP), such as apoE-containing lipoproteins and activated alpha2-macroglobulin (alpha2M*), promote neurite outgrowth, suggesting that LRP may have signaling functions. In this study, we found that the treatment of neurons with alpha2M* significantly increased the individual length (by 71%) and numbers (by 139%) of neurites of primary mouse cortical neurons. These effects were blocked by the LRP antagonist, the receptor-associated protein. We found similar neurite outgrowth with purified apoE3 and a tandem apoE peptide containing only the receptor-binding domain. To investigate the intracellular pathway of the LRP signaling involved in neurite outgrowth, we tested the effects of alpha2M* on the phosphorylation of the mitogen-activated protein (MAP) extracellular signal-regulated kinases 1 and 2 (ERK1/2). We found that 1) phospho-MAP kinase levels were altered within 30 min after treatment with alpha2M*, 2) the MAP kinase inhibitor, PD98059, specifically blocked the alpha2M*-induced neurite outgrowth, 3) manipulating intracellular calcium by BayK or BAPTA altered the neurite outgrowth and associated changes in the phospho-MAP kinase levels, which were blunted by alpha2M*, 4) alpha2M* promoted the phosphorylation of the transcription factor CREB through MAP kinase, and 5) LRP-specific antibodies increased levels of phosphorylated MAP kinase and phosphorylated CREB. The effects of alpha2M*, apoE3, and apoE peptides increased LRP levels in the cortical neurons, whereas LRP receptor-associated protein reduced dendritic LRP expression. These results demonstrate that p44/42 MAP kinase plays an important role in LRP-mediated neurite outgrowth with activation involving the effects on calcium homeostasis and downstream effects involving the activation of gene transcription through CREB.	Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA	Georgetown University; Harvard University; Massachusetts General Hospital	Rebeck, GW (corresponding author), Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA.	gwr2@georgetown.edu	Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X	NIA NIH HHS [R37 AG 12406, R01 AG 14773] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG012406] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Du YS, 1998, J NEUROCHEM, V70, P1182; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; GOMEZ TM, 1995, NEURON, V14, P1233, DOI 10.1016/0896-6273(95)90270-8; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Kater S. B., 1995, Current Opinion in Neurobiology, V5, P68, DOI 10.1016/0959-4388(95)80089-1; KATER SB, 1991, J NEUROSCI, V11, P891; Kim SN, 2000, J CELL BIOCHEM, V76, P386, DOI 10.1002/(SICI)1097-4644(20000301)76:3<386::AID-JCB6>3.0.CO;2-9; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Kolkova K, 2000, J NEUROSCI, V20, P2238; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Larsen JO, 1998, J NEUROSCI METH, V85, P107, DOI 10.1016/S0165-0270(98)00129-0; Lautermilch NJ, 2000, J NEUROSCI, V20, P315, DOI 10.1523/JNEUROSCI.20-01-00315.2000; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; MATTSON MP, 1988, NEURON, V1, P865, DOI 10.1016/0896-6273(88)90134-1; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Narita M, 1997, J NEUROCHEM, V68, P587; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Narita M, 1997, J NEUROCHEM, V69, P1904; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Perron JC, 1999, MOL CELL NEUROSCI, V13, P362, DOI 10.1006/mcne.1999.0753; Postuma RB, 1998, FEBS LETT, V428, P13, DOI 10.1016/S0014-5793(98)00475-X; Przewlocki R, 1999, J NEUROSCI, V19, P9705; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Qiu ZH, 2003, J NEUROIMMUNOL, V139, P51, DOI 10.1016/S0165-5728(03)00158-9; Qiu ZH, 2001, J NEUROPATH EXP NEUR, V60, P430, DOI 10.1093/jnen/60.5.430; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Schmid RS, 2000, J NEUROSCI, V20, P4177; SOLEM M, 1995, J NEUROSCI, V15, P5966; Spitzer NC, 1997, SCIENCE, V277, P1060, DOI 10.1126/science.277.5329.1060; Stadheim TA, 1998, BIOCHEM BIOPH RES CO, V245, P266, DOI 10.1006/bbrc.1998.8410; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; Thal DR, 1997, BRAIN RES, V777, P223, DOI 10.1016/S0006-8993(97)01021-4; Tolar M, 1997, J NEUROSCI, V17, P5678; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Veinbergs I, 2001, EXP NEUROL, V170, P15, DOI 10.1006/exnr.2001.7684; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Zhao LX, 2003, J NEUROSCI, V23, P4228	64	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 13	2004	279	33					34948	34956		10.1074/jbc.M401055200	http://dx.doi.org/10.1074/jbc.M401055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	844CL	15169786	hybrid			2022-12-25	WOS:000223134800106
J	Nishio, M; Fukumoto, S; Furukawa, K; Ichimura, A; Miyazaki, H; Kusunoki, S; Urano, T; Furukawa, K				Nishio, M; Fukumoto, S; Furukawa, K; Ichimura, A; Miyazaki, H; Kusunoki, S; Urano, T; Furukawa, K			Overexpressed GM1 suppresses nerve growth factor (NGF) signals by modulating the intracellular localization of NGF receptors and membrane fluidity in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; LIPID RAFTS; NEUROTROPHIN RECEPTORS; BRAIN GANGLIOSIDES; MAP KINASES; TRK; PROTEIN; CAVEOLAE; RAS; PHOSPHORYLATION	Ganglioside GM1 has been considered to have a neurotrophic factor-like activity. To analyze the effects of endogenously generated GM1, the rat pheochromocytoma cell line PC12 was transfected with the GM1/GD1b/ GA1 synthase gene and showed increased expression levels of GM1. To our surprise, GM1(+)-transfectant cells (GM1(+) cells) showed no neurite formation after stimulation with nerve growth factor (NGF). Autophosphorylation of NGF receptor TrkA and activation of ERK1/2 after NGF treatment were scarcely detected in GM1(+) cells. Binding of I-125-NGF to PC12 cells was almost equivalent between GM1(+) cells and controls. However, dimer formation of TrkA upon NGF treatment was markedly suppressed in GM1(+) cells in both cross-linking analysis with Bis(sulfosuccinimidyl) suberate 3 and I-125-NGF binding assay. The sucrose density gradient fractionation of the cell lysate revealed that TrkA primarily located in the lipid raft fraction moved to the non-raft fraction in GM1(+) cells. p75(NTR) and Ras also moved from the raft to non-raft fraction in GM1(+) cells, whereas flotillin and GM1 persistently resided in the lipid raft. TrkA kinase activity was differentially regulated when GM1 was added to the kinase assay system in vitro, suggesting suppressive/enhancing effects of GM1 on NGF signals based on the concentration. Measurement of fluorescence recovery after photobleaching revealed that the membrane fluidity was reduced in GM1(+) cells. These results suggested that overexpressed GM1 suppresses the differentiation signals mediated by NGF/ TrkA by modulating the properties of the lipid raft and the intracellular localization of NGF receptors and relevant signaling molecules.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528588, Japan; Kinki Univ, Sch Med, Dept Neurol, Osaka 5898511, Japan	Nagoya University; Nagasaki University; Kindai University (Kinki University)	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp		Urano, Takeshi/0000-0003-3383-3554; Fukumoto, Satoshi/0000-0002-5046-6891				Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen SY, 1996, ALCOHOL, V13, P589; Duchemin AM, 2002, J NEUROCHEM, V81, P696, DOI 10.1046/j.1471-4159.2002.00831.x; Farooqui T, 1997, J NEUROCHEM, V68, P2348; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Ge GX, 2001, BIOCHEM BIOPH RES CO, V282, P511, DOI 10.1006/bbrc.2001.4600; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huang C, 1999, J BIOL CHEM, V274, P36707, DOI 10.1074/jbc.274.51.36707; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KARPIAK SE, 1986, CLIN NEUROPHARMACOL, V9, P338; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; Masserini M, 2001, BBA-MOL CELL BIOL L, V1532, P149, DOI 10.1016/S1388-1981(01)00128-7; MILJAN EA, 2002, SCI STKE; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Notterpek L, 2003, TRENDS NEUROSCI, V26, P232, DOI 10.1016/S0166-2236(03)00099-7; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Peiro S, 2000, J BIOL CHEM, V275, P37846, DOI 10.1074/jbc.M000487200; RABIN SJ, 1995, J NEUROCHEM, V65, P347; Rabin SJ, 2002, J BIOL CHEM, V277, P49466, DOI 10.1074/jbc.M203240200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SCHENGRUND CL, 1990, BRAIN RES BULL, V24, P131, DOI 10.1016/0361-9230(90)90297-D; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUZUKI K, 1965, J NEUROCHEM, V12, P969, DOI 10.1111/j.1471-4159.1965.tb10256.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TERNBERG PW, 1999, NAT CELL BIOL, V1, pE35; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUI Z, 1990, In Vivo (Attiki), V4, P205; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	53	97	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33368	33378		10.1074/jbc.M403816200	http://dx.doi.org/10.1074/jbc.M403816200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15145933	hybrid			2022-12-25	WOS:000223039700044
J	Nofer, JR; Herminghaus, G; Brodde, M; Morgenstern, E; Rust, S; Engel, T; Seedorf, U; Assmann, G; Bluethmann, H; Kehrel, BE				Nofer, JR; Herminghaus, G; Brodde, M; Morgenstern, E; Rust, S; Engel, T; Seedorf, U; Assmann, G; Bluethmann, H; Kehrel, BE			Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER 1; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; GLYCOPROTEIN-VI; PROCOAGULANT ACTIVITY; LIPID-COMPOSITION; THROMBIN-BINDING; APOPTOTIC CELLS; BLOOD PLATELETS; SCOTT-SYNDROME	ATP binding cassette transporter A1 (ABCA1) is involved in regulation of intracellular lipid trafficking and export of cholesterol from cells to high density lipoproteins. ABCA1 defects cause Tangier disease, a disorder characterized by absence of high density lipoprotein and thrombocytopenia. In the present study we have demonstrated that ABCA1 is expressed in human platelets and that fibrinogen binding and CD62 surface expression in response to collagen and low concentrations of thrombin, but not to ADP, are defective in platelets from Tangier patients and ABCA1-deficient animals. The expression of platelet membrane receptors such as GPVI, alpha(2)beta(1) integrin, and GPIIb/IIIa, the collagen-induced changes in phosphatidylserine and cholesterol distribution, and the collagen-induced signal transduction examined by phosphorylation of LAT and p72(syk) and by intracellular Ca2+ mobilization were unaltered in Tangier platelets. The electron microscopy of Tangier platelets revealed reduced numbers of dense bodies and the presence of giant granules typically encountered in platelets from Chediak-Higashi syndrome. Further studies demonstrated impaired release of dense body content in platelets from Tangier patients and ABCA1-deficient animals. In addition, Tangier platelets were characterized by defective surface exposure of dense body and lysosomal markers (CD63, LAMP-1, LAMP-2, CD68) during collagen- and thrombin-induced stimulation and by abnormally high lysosomal pH. We conclude that intact ABCA1 function is necessary for proper maturation of dense bodies in platelets. The impaired release of the content of dense bodies may explain the defective activation of Tangier platelets by collagen and low concentrations of thrombin, but not by ADP.	Univ Munster, Inst Klin Chem & Lab Med, D-48129 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48149 Munster, Germany; Univ Munster, Klin & Poliklin Anaesthesiol & Operat Intens Med, D-48129 Munster, Germany; Univ Saarland, D-66421 Homburg, Germany; F Hoffmann La Roche, Roche Ctr Med Gen, CH-4070 Basel, Switzerland	University of Munster; University of Munster; University of Munster; Saarland University; Roche Holding	Nofer, JR (corresponding author), Univ Munster, Inst Klin Chem & Lab Med, Albert Schweitzer Str 33, D-48129 Munster, Germany.	nofer@uni-muenster.de		Seedorf, Udo/0000-0003-4652-5358				ARDLIE NG, 1986, THROMB RES, V42, P115, DOI 10.1016/0049-3848(86)90288-4; ASSMAN G, 2000, METABOLIC MOL BASES, P2053; Atkinson BT, 2001, EUR J BIOCHEM, V268, P5242, DOI 10.1046/j.0014-2956.2001.02448.x; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Dachary-Prigent J, 1997, BRIT J HAEMATOL, V99, P959, DOI 10.1046/j.1365-2141.1997.5003302.x; Dean M, 2001, J LIPID RES, V42, P1007; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARMON JT, 1986, BLOOD, V68, P498; Heijnen HFG, 1998, BLOOD, V91, P2313, DOI 10.1182/blood.V91.7.2313.2313_2313_2325; Hirano K, 2000, FEBS LETT, V484, P275, DOI 10.1016/S0014-5793(00)02171-2; Huizing M, 2001, THROMB HAEMOSTASIS, V86, P233, DOI 10.1055/s-0037-1616221; Kehrel B, 1998, BLOOD, V91, P491; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; LEGRAND C, 1985, THROMB HAEMOSTASIS, V54, P603; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; MCINTYRE JC, 1999, BIOCHEMISTRY-US, V32, P12420; MORGENSTERN E, 1987, EUR J CELL BIOL, V43, P273; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Nofer JR, 1997, J BIOL CHEM, V272, P32861, DOI 10.1074/jbc.272.52.32861; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Oram JF, 2002, TRENDS MOL MED, V8, P168, DOI 10.1016/S1471-4914(02)02289-X; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P1007, DOI 10.1161/01.ATV.11.4.1007; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SHASTRI KM, 1980, J LIPID RES, V21, P467; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; VERGANI CG, 1984, EUR J CLIN INVEST, V14, P49, DOI 10.1111/j.1365-2362.1984.tb00703.x; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x	40	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					34032	34037		10.1074/jbc.M405174200	http://dx.doi.org/10.1074/jbc.M405174200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15163665	hybrid			2022-12-25	WOS:000223039700115
J	Ono, S; Sone, N; Yoshida, M; Suzuki, T				Ono, S; Sone, N; Yoshida, M; Suzuki, T			ATP synthase that lacks F-0 alpha-subunit - Isolation, properties, and indication of F(0)b(2)-subunits as an anchor rail of a rotating c-ring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING PROTON MOVEMENTS; ESCHERICHIA-COLI; CROSS-LINKING; THERMOPHILIC BACTERIUM; EPSILON-SUBUNIT; ROTARY MOTOR; F-0 COMPLEX; ADENOSINE-TRIPHOSPHATASE; MOLECULAR ARCHITECTURE; F1F0-ATP SYNTHASE	In a rotary motor F1F0-ATP synthase, F-0 works as a proton motor; the oligomer ring of F(0)c-subunits (c-ring) rotates relative to the F(0)ab(2) domain as protons pass through F-0 down the gradient. F(0)ab(2) must exert dual functions during rotation, that is, sliding the c-ring ( motor drive) while keeping the association with the c-ring ( anchor rail). Here we have isolated thermophilic F1F0(- a) which lacks F(0)a. F1F0(-a) has no proton transport activity, and F-0(-a) does not work as a proton channel. Interestingly, ATPase activity of F1F0(-a) is greatly suppressed, even though its F-1 sector is intact. Most likely, F(0)b(2) associates with the c-ring as an anchor rail in the intact F1F0; without F(0)a, this association prevents rotation of the c-ring ( and hence the gamma-subunit), which disables ATP hydrolysis at F-1. Functional F1F0 is easily reconstituted from purified F(0)a and F1F0(-a), and thus F(0)a can bind to its proper location on F1F0( - a) without a large rearrangement of other-subunits.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, ERATO, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp						Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aksimentiev A, 2004, BIOPHYS J, V86, P1332, DOI 10.1016/S0006-3495(04)74205-8; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Greie JC, 2000, J BIOENERG BIOMEMBR, V32, P357, DOI 10.1023/A:1005523902800; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; MITOME N, 2004, IN PRESS P NATL ACAD; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OKAMOTO H, 1977, J BIOL CHEM, V252, P6125; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SONE N, 1977, J BIOL CHEM, V252, P2956; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Suzuki T, 2003, J BIOL CHEM, V278, P46840, DOI 10.1074/jbc.M307165200; Suzuki T, 2002, J BIOL CHEM, V277, P13281, DOI 10.1074/jbc.M111210200; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1987, J BIOL CHEM, V262, P8340; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	38	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33409	33412		10.1074/jbc.M404993200	http://dx.doi.org/10.1074/jbc.M404993200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15175330	hybrid			2022-12-25	WOS:000223039700048
J	Mohan, S; Bruns, JR; Weixel, KM; Edinger, RS; Bruns, JB; Kleyman, TR; Johnson, JP; Weisz, OA				Mohan, S; Bruns, JR; Weixel, KM; Edinger, RS; Bruns, JB; Kleyman, TR; Johnson, JP; Weisz, OA			Differential current decay profiles of epithelial sodium channel subunit combinations in polarized renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; APICAL MEMBRANE; A6 CELLS; XENOPUS OOCYTES; GAMMA-SUBUNIT; ALPHA-SUBUNIT; BETA-SUBUNIT; ENAC; EXPRESSION; ALDOSTERONE	In many epithelial tissues in the body, the rate of Na+ reabsorption is governed by the activity of the epithelial sodium channel (ENaC). The assembly, trafficking, and turnover of the three ENaC subunits (alpha, beta, and gamma) is complex and not well understood. Recent experiments suggest that ENaC must be proteolytically cleaved for maximal activity and may explain the discrepancies reported in prior biochemical approaches focused on quantitating the trafficking and half-life of full-length subunits. As an alternative approach to examining the dynamics of ENaC subunits, we have generated doxycycline-repressible replication-defective recombinant adenoviruses encoding individual epitope-tagged mouse ENaC subunits and expressed these in polarized MDCK I cells. Co-infection with these viruses encoding all three subunits generates robust amiloride-sensitive currents in polarized MDCK cells. Significant current was also observed in cells expressing alpha- and gamma-mENaC in the absence of beta-mENaC. These currents did not appear to result from association with endogenous canine beta-ENaC. Treatment of alphabetagamma-expressing cells with cycloheximide (CHX) resulted in the rapid inhibition (within 3 h) of similar to50-80% of the initial current; however, a sizable fraction of the initial current remained even after 6 h of CHX. By contrast, CHX addition to cells expressing only alpha- and gamma-mENaC resulted in rapid decay in current with no residual fraction. Our data suggest that ENaC channels of differing stoichiometries are differentially trafficked and degraded and provide support for the possibility that noncoordinate trafficking of ENaC subunits may function in vivo as a mechanism to modulate ENaC activity.	Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK061296, R01DK065161, R01DK057718] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK57718, R01 DK65161, T32-DK61296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2001, J AM SOC NEPHROL, V12, P1114, DOI 10.1681/ASN.V1261114; Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; Booth RE, 2003, AM J PHYSIOL-RENAL, V284, pF938, DOI 10.1152/ajprenal.00373.2002; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hill WG, 2002, J BIOL CHEM, V277, P33541, DOI 10.1074/jbc.C200309200; Hughey RP, 2004, J BIOL CHEM, V279, P18111, DOI 10.1074/jbc.C400080200; Hughey RP, 2003, J BIOL CHEM, V278, P37073, DOI 10.1074/jbc.M307003200; Kleyman TR, 2001, AM J PHYSIOL-RENAL, V281, pF213, DOI 10.1152/ajprenal.2001.281.2.F213; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Weisz OA, 2003, AM J PHYSIOL-RENAL, V285, pF833, DOI 10.1152/ajprenal.00088.2003; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	29	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2004	279	31					32071	32078		10.1074/jbc.M405091200	http://dx.doi.org/10.1074/jbc.M405091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	840HW	15166222	hybrid			2022-12-25	WOS:000222849700011
J	Chaudhary, K; Darling, JA; Fohl, LM; Sullivan, WJ; Donald, RGK; Pfefferkorn, ER; Ullman, B; Roos, DS				Chaudhary, K; Darling, JA; Fohl, LM; Sullivan, WJ; Donald, RGK; Pfefferkorn, ER; Ullman, B; Roos, DS			Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE ANALOG; ADENOSINE KINASE; ADENINE PHOSPHORIBOSYLTRANSFERASE; PLASMODIUM-FALCIPARUM; CRYSTAL-STRUCTURES; OPPORTUNISTIC INFECTIONS; RECOMBINANT EXPRESSION; SELECTABLE MARKER; EIMERIA-TENELLA	We have exploited a variety of molecular genetic, biochemical, and genomic techniques to investigate the roles of purine salvage enzymes in the protozoan parasite Toxoplasma gondii. The ability to generate defined genetic knockouts and target transgenes to specific loci demonstrates that T. gondii uses two ( and only two) pathways for purine salvage, defined by the enzymes hypoxanthine-xanthine-guanine phosphoribosyltransferase (HXGPRT) and adenosine kinase (AK). Both HXGPRT and AK are single-copy genes, and either one can be deleted, indicating that either one of these pathways is sufficient to meet parasite purine requirements. Fitness defects suggest both pathways are important for the parasite, however, and that the salvage of adenosine is more important than salvage of hypoxanthine and other purine nucleobases. HXGPRT and AK cannot be deleted simultaneously unless one of these enzymes is provided in trans, indicating that alternative routes of functionally significant purine salvage are lacking. Despite previous reports to the contrary, we found no evidence of adenine phosphoribosyltransferase (APRT) activity when parasites were propagated in APRT-deficient host cells, and no APRT ortholog is evident in the T. gondii genome. Expression of Leishmania donovani APRT in transgenic T. gondii parasites yielded low levels of activity but did not permit genetic deletion of both HXGPRT and AK. A detailed comparative genomic study of the purine salvage pathway in various apicomplexan species highlights important differences among these parasites.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Dartmouth Coll Sch Med, Dept Microbiol, Hanover, NH 03755 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	University of Pennsylvania; Dartmouth College; Oregon Health & Science University	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu	Donald, Robert George Konrad/GNP-4958-2022; Darling, John/B-5451-2014	Darling, John/0000-0002-4776-9533; Roos, David Siker/0000-0001-6725-4089				Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; Brooks R. G., 1987, Antimicrobial Agents Annual, V2, P297; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHANG CH, 1980, J BIOL CHEM, V255, P2366; Chiang CW, 1999, J BIOL CHEM, V274, P35255, DOI 10.1074/jbc.274.49.35255; Conner R.L., 1973, P123; DARE E, 1992, EXP CELL RES, V203, P336, DOI 10.1016/0014-4827(92)90007-U; Darling JA, 1999, MOL BIOCHEM PARASIT, V103, P15, DOI 10.1016/S0166-6851(99)00109-7; De Koning HP, 2003, INT J PARASITOL, V33, P821, DOI 10.1016/S0020-7519(03)00091-2; DEJONG JW, 1980, ANAL BIOCHEM, V101, P407, DOI 10.1016/0003-2697(80)90206-7; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Doyle PS, 1998, EXP PARASITOL, V89, P9, DOI 10.1006/expr.1998.4263; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; Fohl LM, 2003, MOL MICROBIOL, V50, P1319, DOI 10.1046/j.1365-2958.2003.03756.x; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; HILL DL, 1967, J CELL PHYSIOL, V69, P321, DOI 10.1002/jcp.1040690308; Kicska GA, 2002, J BIOL CHEM, V277, P3226, DOI 10.1074/jbc.M105906200; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Kissinger JC, 2003, NUCLEIC ACIDS RES, V31, P234, DOI 10.1093/nar/gkg072; KRUG EC, 1989, J BIOL CHEM, V264, P10601; LAFON SW, 1985, MOL BIOCHEM PARASIT, V14, P11, DOI 10.1016/0166-6851(85)90101-X; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; LAUGHON BE, 1991, J INFECT DIS, V164, P244, DOI 10.1093/infdis/164.2.244; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; Matrajt M, 2002, MOL BIOCHEM PARASIT, V120, P285, DOI 10.1016/S0166-6851(02)00014-2; MILLER RL, 1983, MOL BIOCHEM PARASIT, V7, P41, DOI 10.1016/0166-6851(83)90115-9; MILLER RL, 1979, J BIOL CHEM, V254, P2346; PEROTTO J, 1971, J PROTOZOOL, V18, P470; PFEFFERKORN ER, 1983, CIBA F SYMP, V99, P74; POLLACK Y, 1985, EXP PARASITOL, V60, P270, DOI 10.1016/0014-4894(85)90031-1; Pongsaensook P, 1997, MUTAT RES-FUND MOL M, V377, P27, DOI 10.1016/S0027-5107(97)00055-9; Puiu D, 2004, NUCLEIC ACIDS RES, V32, pD329, DOI 10.1093/nar/gkh050; QUEEN SA, 1989, BIOCHIM BIOPHYS ACTA, V996, P160, DOI 10.1016/0167-4838(89)90242-2; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; SAVARESE TM, 1987, BIOCHEM PHARMACOL, V36, P1881, DOI 10.1016/0006-2952(87)90484-9; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Schumacher MA, 1998, EMBO J, V17, P3219, DOI 10.1093/emboj/17.12.3219; SCHWAB JC, 1995, MOL BIOCHEM PARASIT, V70, P59, DOI 10.1016/0166-6851(95)00005-L; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Striepen B, 2004, P NATL ACAD SCI USA, V101, P3154, DOI 10.1073/pnas.0304686101; Striepen B, 2002, P NATL ACAD SCI USA, V99, P6304, DOI 10.1073/pnas.092525699; Sullivan WJ, 1999, MOL BIOCHEM PARASIT, V103, P1, DOI 10.1016/S0166-6851(99)00114-0; THOMAS CB, 1973, J BIOL CHEM, V248, P2529; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; VASANTHAKUMAR G, 1990, GENE, V91, P63, DOI 10.1016/0378-1119(90)90163-L; WANG CC, 1981, P NATL ACAD SCI-BIOL, V78, P6618, DOI 10.1073/pnas.78.11.6618; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	53	80	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31221	31227		10.1074/jbc.M404232200	http://dx.doi.org/10.1074/jbc.M404232200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15140885	hybrid			2022-12-25	WOS:000222726800041
J	Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ				Dong, MQ; Pinon, DI; Cox, RF; Miller, LJ			Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; AFFINITY HORMONE-BINDING; PARATHYROID-HORMONE; EXTRACELLULAR DOMAIN; SECRETIN RECEPTOR; SPATIAL APPROXIMATION; DIRECT IDENTIFICATION; CRITICAL DETERMINANTS; PHOTOLABILE RESIDUE; GLUCAGON RECEPTOR	The calcitonin receptor is a member of the class B family of G protein-coupled receptors, which contains numerous potentially important drug targets. Delineation of themes for agonist binding and activation of these receptors will facilitate the rational design of receptor-active drugs. We reported previously that a photolabile residue within the carboxyl-terminal half ( residue 26) and mid-region ( residue 16) of calcitonin covalently label the extracellular amino-terminal domain of this receptor ( Dong, M., Pinon, D. I., Cox, R. F., and Miller, L. J. ( 2004) J. Biol. Chem. 279, 1167 - 1175). Chimeric receptor studies support the importance of this region and suggest important contributions of extracellular loop domains. To examine whether other parts of the ligand may contact those loops, we developed another probe that has its photolabile site of labeling within the amino-terminal half in position 8 of the ligand. This probe was a full agonist (EC50 = 563 +/- 67 pM), stimulating cAMP accumulation in receptor-bearing human embryonic kidney 293 cells in a concentration-dependent manner. It bound specifically and saturably (K-i = 14.3 +/- 1.9 nM) and was able to efficiently label the calcitonin receptor. By purification, specific cleavage, and sequencing of labeled wild-type and mutant calcitonin receptors, the site of attachment was identified as residue Leu(368) within the third extracellular loop of the receptor, a domain distinct from that labeled by previous probes. These data are consistent with a common ligand binding mechanism for receptors in this important family.	Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA; GlaxoSmithKline, Res Triangle Pk, NC 27709 USA	Mayo Clinic; Mayo Clinic Phoenix; GlaxoSmithKline	Dong, MQ (corresponding author), Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Johnson Res Blgd,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	dongmq@mayo.edu			NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chauvin S, 2000, MOL PHARMACOL, V57, P625, DOI 10.1124/mol.57.3.625; DeAlmeida VI, 1998, MOL ENDOCRINOL, V12, P750, DOI 10.1210/me.12.5.750; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2004, J BIOL CHEM, V279, P1167, DOI 10.1074/jbc.M305719200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; EPAND RM, 1986, BIOCHEMISTRY-US, V25, P1964, DOI 10.1021/bi00356a019; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Gourlet P, 1996, EUR J BIOCHEM, V239, P349, DOI 10.1111/j.1432-1033.1996.0349u.x; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hashimoto H, 1997, MOL PHARMACOL, V52, P128, DOI 10.1124/mol.52.1.128; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Perret J, 2002, BIOCHEM J, V362, P389, DOI 10.1042/0264-6021:3620389; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Pham V, 2004, J BIOL CHEM, V279, P6720, DOI 10.1074/jbc.M307214200; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; Runge S, 2003, BRIT J PHARMACOL, V138, P787, DOI 10.1038/sj.bjp.0705120; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sexton PM, 1999, CURR MED CHEM, V6, P1067; SEXTON PM, 1991, MOL NEUROBIOL, V5, P251, DOI 10.1007/BF02935550; Sohn J, 2003, J BIOL CHEM, V278, P47868, DOI 10.1074/jbc.M307751200; Sohn J, 2002, J BIOL CHEM, V277, P50165, DOI 10.1074/jbc.M207646200; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Suva LJ, 1997, J PHARMACOL EXP THER, V283, P876; Sydow S, 1999, EUR J BIOCHEM, V259, P55, DOI 10.1046/j.1432-1327.1999.00007.x; Unson CG, 2002, BIOCHEMISTRY-US, V41, P11795, DOI 10.1021/bi025711j; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	60	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31177	31182		10.1074/jbc.M404113200	http://dx.doi.org/10.1074/jbc.M404113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15155765	hybrid			2022-12-25	WOS:000222726800035
J	Grabar, TB; Cain, BD				Grabar, TB; Cain, BD			Genetic complementation between mutant b subunits in F1F0 ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1F0-ATPASE; 2ND STALK; DIMERIZATION DOMAIN; MUTAGENIC ANALYSIS; MEMBRANE DOMAIN; EPSILON-SUBUNIT; F-0 SUBUNITS; H+-ATPASE; F-1-ATPASE; IDENTIFICATION	In Escherichia coli, a parallel homodimer of identical b subunits constitutes the peripheral stalk of F1F0 ATP synthase. Although the two b subunits have long been viewed as a single functional unit, the asymmetric nature of the enzyme complex suggested that the functional roles of each b subunit should not necessarily be considered equivalent. Previous mutagenesis studies of the peripheral stalk suffered from the fact that mutations in the uncF( b) gene affected both of the b subunits. We developed a system to express and study F1F0 ATP synthase complexes containing two different b subunits. Two mutations already known to inactivate the F1F0 ATP synthase complex have been studied using this experimental system. An evolutionarily conserved arginine, b(Arg-36), was known to be crucial for F1F0 ATP synthase function, and the last four C-terminal amino acids had been shown to be important for enzyme assembly. Experiments expressing one of the mutants with a wild type b subunit demonstrated the presence of heterodimers in F1F0 ATP synthase complexes. Activity assays suggested that the heterodimeric F1F0 complexes were functional. When the two defective b subunits were expressed together and in the absence of any wild type b subunit, an active F1F0 ATP synthase complex was assembled. This mutual complementation between fully defective b subunits indicated that each of the two b subunits makes a unique contribution to the functions of the peripheral stalk, such that one mutant b subunit is making up for what the other is lacking.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	bcain@biochem.med.ufl.edu			NIGMS NIH HHS [R01GM43495] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altendorf K, 2000, J EXP BIOL, V203, P19; ARIS JP, 1985, J BIOL CHEM, V260, P1207; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Deckers-Hebestreit G, 2000, BBA-BIOENERGETICS, V1458, P364, DOI 10.1016/S0005-2728(00)00087-6; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dimroth P, 2000, BBA-BIOENERGETICS, V1458, P374, DOI 10.1016/S0005-2728(00)00088-8; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 1999, NOVART FDN SYMP, V221, P218; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Grabar TB, 2003, J BIOL CHEM, V278, P34751, DOI 10.1074/jbc.M303361200; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Hardy AW, 2003, J BIOENERG BIOMEMBR, V35, P389, DOI 10.1023/A:1027363012727; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Nath Sunil, 2002, Adv Biochem Eng Biotechnol, V74, P65; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; Turina P, 2000, J BIOENERG BIOMEMBR, V32, P373, DOI 10.1023/A:1005528003709	36	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31205	31211		10.1074/jbc.M404420200	http://dx.doi.org/10.1074/jbc.M404420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15159387	hybrid			2022-12-25	WOS:000222726800039
J	Reverter-Branchat, G; Cabiscol, E; Tamarit, J; Ros, J				Reverter-Branchat, G; Cabiscol, E; Tamarit, J; Ros, J			Oxidative damage to specific proteins in replicative and chronological-aged Saccharomyces cerevisiae - Common targets and prevention by calorie restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY-PHASE; LIFE-SPAN; STRESS; LONGEVITY; EXTENDS; DISEASE; ENZYME; CELLS; IDENTIFICATION; RESISTANCE	Oxidative modifications of cellular components have been described as one of the main contributions to aged phenotype. In Saccharomyces cerevisiae, two distinct life spans can be considered, replicative and chronological. The relationship between both aging models is still not clear despite suggestions that these phenomena may be related. In this work, we show that replicative and chronological-aged yeast cells are affected by an oxidative stress situation demonstrated by increased protein carbonylation when compared with young cells. The data on the identification of these oxidatively modified proteins gives clues to better understand cellular dysfunction that occurs during aging. Strikingly, although in both aging models metabolic differences are important, major targets are almost the same. Common targets include stress resistance proteins (Hsp60 and Hsp70) and enzymes involved in glucose metabolism such as enolase, glyceraldehydes-3-P dehydrogenase, fructose-1,6-biphosphate aldolase, pyruvate decarboxylase, and alcohol dehydrogenase. In both aging models, calorie restriction results in decreased damage to these proteins. In addition, chronological-aged cells grown under glucose restriction displayed lowered levels of lipid peroxidation product lipofuscin. Intracellular iron concentration is kept almost unchanged, whereas in non-restricted cells, the values increase up 4 - 5 times. The pro-oxidant effects of such increased iron concentration would account for the damage observed. Also, calorie-restricted cells show undamaged catalase, which clearly appears carbonylated in cells grown at a high glucose concentration. These results may explain lengthening of the viability of chronological-aged cells and could have an important role in replicative life span extension by calorie restriction.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25008, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Montserrat Roig 2, Lleida 25008, Spain.	joaquim.ros@cmb.udl.es	ROS, Joaquim/ABG-7487-2020; Cabiscol, Elisa/A-4584-2009; Tamarit, Jordi/C-6316-2008; Ros, Joaquim/A-7507-2010	ROS, Joaquim/0000-0003-0901-8648; Cabiscol, Elisa/0000-0003-2795-7999; Tamarit, Jordi/0000-0003-3227-6928; 				Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Ashrafi K, 1999, P NATL ACAD SCI USA, V96, P9100, DOI 10.1073/pnas.96.16.9100; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bitterman KJ, 2003, MICROBIOL MOL BIOL R, V67, P376, DOI 10.1128/MMBR.67.3.376-399.2003; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brown RK, 1996, FREE RADICALS PRACTI, P119; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Butterfield DA, 2004, BRAIN RES, V1000, P1, DOI 10.1016/j.brainres.2003.12.012; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Cabiscol E, 2002, J BIOL CHEM, V277, P44531, DOI 10.1074/jbc.M206525200; Choi J, 2004, FREE RADICAL BIO MED, V36, P1155, DOI 10.1016/j.freeradbiomed.2004.02.002; Costa WMV, 2002, FREE RADICAL BIO MED, V33, P1507, DOI 10.1016/S0891-5849(02)01086-9; Fabrizio P, 2003, GENETICS, V163, P35; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GELLER BL, 1984, METHOD ENZYMOL, V105, P105; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Harris N, 2003, FREE RADICAL BIO MED, V34, P1599, DOI 10.1016/S0891-5849(03)00210-7; Harris N, 2001, MOL GENET GENOMICS, V265, P258, DOI 10.1007/s004380000409; Herman PK, 2002, CURR OPIN MICROBIOL, V5, P602, DOI 10.1016/S1369-5274(02)00377-6; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; LARDINOIS OM, 1995, FREE RADICAL RES, V22, P251, DOI 10.3109/10715769509147544; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MacLean M, 2001, YEAST, V18, P499, DOI 10.1002/yea.701; MAITRA PK, 1971, J BIOL CHEM, V246, P475; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Park PU, 2002, METHOD ENZYMOL, V351, P468; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; Shanmuganathan A, 2004, FEBS LETT, V556, P253, DOI 10.1016/S0014-5793(03)01428-5; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993	52	170	177	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31983	31989		10.1074/jbc.M404849200	http://dx.doi.org/10.1074/jbc.M404849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15166233	hybrid, Green Published			2022-12-25	WOS:000222726800127
J	Sheng, SH; Perry, CJ; Kleyman, TR				Sheng, SH; Perry, CJ; Kleyman, TR			Extracellular Zn2+ activates epithelial Na+ channels by eliminating Na+ self-inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SODIUM-CHANNEL; HISTIDINE-RESIDUES; CONVERTING-ENZYME; GAMMA-SUBUNIT; ALPHA-SUBUNIT; ION CHANNELS; ENAC; HYPERTENSION; BINDING	Inhibition of epithelial Na+ channel ( ENaC) activity by high concentrations of extracellular Na+ is referred to as Na+ self-inhibition. We investigated the effects of external Zn2+ on whole cell Na+ currents and on the Na+ self-inhibition response in Xenopus oocytes expressing mouse alphabetagamma ENaC. Na+ self-inhibition was examined by analyzing inward current decay from a peak current to a steady-state current following a fast switching of a low Na+ (1 mM) bath solution to a high Na+ (110 mM) solution. Our results indicate that external Zn2+ rapidly and reversibly activates ENaC in a dose-dependent manner with an estimated EC50 of 2 muM. External Zn2+ in the high Na+ bath also prevents or reverses Na+ self-inhibition with similar affinity. Zn2+ activation is dependent on extracellular Na+ concentration and is absent in ENaCs containing gammaH239 mutations that eliminate Na+ self-inhibition and in alphaS580Cbetagamma following covalent modification by a sulfhydryl-reactive reagent that locks the channels in a fully open state. In contrast, external Ni2+ inhibition of ENaC currents appears to be additive to Na+ self-inhibition when Ni2+ is present in the high Na+ bath. Pretreatment of oocytes with Ni2+ in a low Na+ bath also prevents the current decay following a switch to a high Na+ bath but rendered the currents below the control steady-state level measured in the absence of Ni2+ pretreatment. Our results suggest that external Zn2+ activates ENaC by relieving the channel from Na+ self-inhibition, and that external Ni2+ mimics or masks Na+ self-inhibition.	Univ Pittsburgh, Div Renal Electrolyte, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sheng, SH (corresponding author), Univ Pittsburgh, Div Renal Electrolyte, Dept Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	shaohu@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Solvi, Cwyn/0000-0003-2517-6179	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Amuzescu B, 2003, PFLUG ARCH EUR J PHY, V446, P69, DOI 10.1007/s00424-002-0998-3; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Buchman AL, 1998, J AM COLL NUTR, V17, P124, DOI 10.1080/07315724.1998.10718737; Campbell JD, 2003, EMBO REP, V4, P1038, DOI 10.1038/sj.embor.7400003; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Cucu D, 2003, J MEMBRANE BIOL, V194, P33, DOI 10.1007/s00232-003-2023-y; Ekmekci OB, 2003, BIOL TRACE ELEM RES, V95, P203, DOI 10.1385/BTER:95:3:203; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOOD DW, 1984, AM J PHYSIOL, V246, pF609, DOI 10.1152/ajprenal.1984.246.5.F609; Hu JX, 2002, CHEM COMMUN, P1810, DOI 10.1039/b204321c; JACKSON MJ, 1989, ZINC HUMAN BIOL, P1; Kellenberger S, 2002, J PHYSIOL-LONDON, V543, P413, DOI 10.1113/jphysiol.2002.022020; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; POCOCK G, 1999, HUMAN PHYSL BASIS ME, P361; Quinteiro-Blondin S, 2001, GEN PHYSIOL BIOPHYS, V20, P331; Reifarth FW, 1999, BBA-BIOMEMBRANES, V1417, P63, DOI 10.1016/S0005-2736(98)00257-0; Riordan JF, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-225; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Schafer JA, 2002, AM J PHYSIOL-RENAL, V283, pF221, DOI 10.1152/ajprenal.00068.2002; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHOLTZ E, 1988, PFLUG ARCH EUR J PHY, V413, P174, DOI 10.1007/BF00582528; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Sheng SH, 2004, J BIOL CHEM, V279, P9743, DOI 10.1074/jbc.M311952200; Sheng SH, 2002, J BIOL CHEM, V277, P50098, DOI 10.1074/jbc.M209975200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; Song YL, 2003, J GEN PHYSIOL, V122, P511, DOI 10.1085/jgp.200308866; TURNHEIM K, 1991, PHYSIOL REV, V71, P429, DOI 10.1152/physrev.1991.71.2.429; VANDRIESSCHE W, 1985, PHYSIOL REV, V65, P833, DOI 10.1152/physrev.1985.65.4.833; Vasilyev A, 2002, J MEMBRANE BIOL, V185, P237, DOI 10.1007/s00232-001-0126-x; Wagner CA, 2000, CELL PHYSIOL BIOCHEM, V10, P1, DOI 10.1159/000016341; ZOZAYA JLG, 1985, RES COMMUN CHEM PATH, V48, P445; Zozaya JLG, 2000, J HUM HYPERTENS, V14, pS100, DOI 10.1038/sj.jhh.1000995	37	42	45	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31687	31696		10.1074/jbc.M405224200	http://dx.doi.org/10.1074/jbc.M405224200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145943	hybrid			2022-12-25	WOS:000222726800094
J	Vyas, S; Juin, P; Hancock, D; Suzuki, Y; Takahashi, R; Triller, A; Evan, G				Vyas, S; Juin, P; Hancock, D; Suzuki, Y; Takahashi, R; Triller, A; Evan, G			Differentiation-dependent sensitivity to apoptogenic factors in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CASPASE ACTIVATION; SYMPATHETIC NEURONS; SERINE-PROTEASE; STRUCTURAL BASIS; APOPTOSIS; DEATH; MITOCHONDRIA; RELEASE; XIAP	We have investigated the role of the mitochondrial pathway during cell death following serum and nerve growth factor (NGF)/dibutyryl cyclic AMP (Bt(2)cAMP) withdrawal in undifferentiated or NGF/Bt(2)cAMP-differentiated PC12 cells, respectively. Holocytochrome c, Smac/DIABLO, and Omi/ HtrA2 are released rapidly following trophic factor deprivation in PC12 cells. Bcl-2 and Akt inhibited this release. The protection, however, persisted longer in differentiated PC12 cells. In differentiated, but not undifferentiated cells, Bcl-2 and Akt also inhibited apoptosis downstream of holocytochrome c release. Thus, undifferentiated PC12 cells showed marked sensitivity to induction of apoptosis by microinjected cytochrome c even in the presence of NGF, Bcl-2, or Akt. In contrast, in differentiated cells these factors suppressed cell death. Consistent with these observations, in vitro processing of procaspase 9 in response to cytochrome c was observed in extracts from undifferentiated but not differentiated cells expressing Akt or Bcl-2. Endogenous caspase 9 was cleaved during cell death, whereas dominant negative caspase 9 inhibited cell death. The results from determining the role of inhibitors of apoptosis (IAPs) suggest that acquisition of inhibition by IAPs is part of the differentiation program. Ubiquitin-DeltaN-AVPI Smac/DIABLO induced cell death in differentiated cells only. c-IAP-2 is unregulated in differentiated cells, whereas X-linked IAP levels decreased in these cells coincident with cell death. Moreover, expressing X-linked IAP rendered undifferentiated cells resistant to microinjected cytochrome c. Overall, the inhibitory regulation, of cell death at the level of release of mitochondrial apoptogenic factors and at post-mitochondrial activation of caspase 9 observed in differentiated PC12 cells, is reduced or absent in the undifferentiated counterparts.	Ecole Normale Super, INSERM, U497, F-75005 Paris, France; INSERM, U419, F-44035 Nantes, France; Canc Res UK, Signal Transduct Lab, London WC2A 3PX, England; RIKEN, Brain Sci Inst, Lab Motor Syst Neurodegenerat, Wako, Saitama 3510198, Japan; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); Cancer Research UK; RIKEN; University of California System; University of California San Francisco	Vyas, S (corresponding author), Ecole Normale Super, INSERM, U497, 46 Rue Ulm, F-75005 Paris, France.	vyas@wotan.ens.fr	JUIN, Philippe P/H-3636-2014; JUIN, Philippe/Q-1338-2019; Vyas, Sheela/M-4460-2017	JUIN, Philippe P/0000-0002-4997-3888; JUIN, Philippe/0000-0002-4997-3888; TRILLER, Antoine/0000-0002-7530-1233				Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2002, J NEUROSCI, V22, P8018; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; JIN S, 2003, GENE DEV, V17, P1; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; MICHEL PP, 1995, EUR J NEUROSCI, V7, P251, DOI 10.1111/j.1460-9568.1995.tb01061.x; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Potts PR, 2003, J CELL BIOL, V163, P789, DOI 10.1083/jcb.200307130; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stefanis L, 1997, J NEUROCHEM, V69, P1425; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 1997, J NEUROSCI, V17, P1911; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vyas S, 2002, MOL CELL NEUROSCI, V21, P1, DOI 10.1006/mcne.2002.1170; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001	52	34	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					30983	30993		10.1074/jbc.M400692200	http://dx.doi.org/10.1074/jbc.M400692200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15133027	hybrid			2022-12-25	WOS:000222726800011
J	Wang, YJ; Schattenberg, JM; Rigolo, RM; Storz, P; Czaja, MJ				Wang, YJ; Schattenberg, JM; Rigolo, RM; Storz, P; Czaja, MJ			Hepatocyte resistance to oxidative stress is dependent on protein kinase C-mediated down-regulation of c-Jun/AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATION LOOP SER(744); JUN NH2-TERMINAL KINASE; TYROSINE PHOSPHORYLATION; SENSITIZES HEPATOCYTES; INDUCED APOPTOSIS; TUMOR-NECROSIS; INTACT-CELLS; TNF-ALPHA; EXPRESSION	The prevention of injury from reactive oxygen species is critical for cellular resistance to many death stimuli. Resistance to death from the superoxide generator menadione in the hepatocyte cell line RALA255-10G is dependent on down-regulation of the c-Jun N-terminal kinase (JNK)/AP-1 signaling pathway by extracellular signal-regulated kinase 1/2 (ERK1/2). Because protein kinase C (PKC) regulates both oxidant stress and JNK signaling, the ability of PKC to modulate hepatocyte death from menadione through effects on AP-1 was examined. PKC inhibition with Ro-31-8425 or bisindolylmaleimide I sensitized this cell line to death from menadione. Menadione treatment led to activation of PKCmu, or protein kinase D (PKD), but not PKCalpha/beta, PKCzeta/lambda, or PKCdelta/theta. Menadione induced phosphorylation of PKD at Ser-744/748, but not Ser-916, and translocation of PKD to the nucleus. PKC inhibition blocked menadione-induced phosphorylation of PKD, and expression of a constitutively active PKD prevented death from Ro-31-8425/ menadione. PKC inhibition led to a sustained overactivation of JNK and c-Jun in response to menadione as determined by in vitro kinase assay and immunoblotting for the phosphorylated forms of both proteins. Cell death from PKC inhibition and menadione treatment resulted from c-Jun activation, since death was blocked by adenoviral expression of the c-Jun dominant negative TAM67. PKC and ERK1/2 independently down-regulated JNK/c-Jun, since inhibition of either kinase failed to affect activation of the other kinase, and simultaneous inhibition of both pathways caused additive JNK/c-Jun activation and cell death. Resistance to death from superoxide therefore requires both PKC/PKD and ERK1/2 activation in order to down-regulate proapoptotic JNK/c-Jun signaling.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School	Czaja, MJ (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	czaja@aecom.yu.edu	Schattenberg, Jörn M./C-1301-2013	Schattenberg, Jörn M./0000-0002-4224-4703	NIDDK NIH HHS [DK44234, R01 DK044234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; CHOU JY, 1987, CANCER RES, V47, P5415; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; Czaja MJ, 2003, HEPATOLOGY, V37, P1405, DOI 10.1053/jhep.2003.50233; Czaja MJ, 2003, AM J PHYSIOL-GASTR L, V284, pG875, DOI 10.1152/ajpgi.00549.2002; Czaja MJ, 2002, ANTIOXID REDOX SIGN, V4, P759, DOI 10.1089/152308602760598909; Duke RC, 1992, CURR PROT IMMUNOL S3, V17, P1; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Jones BE, 2000, AM J PHYSIOL-GASTR L, V278, pG693, DOI 10.1152/ajpgi.2000.278.5.G693; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Lee SK, 1998, J BIOL CHEM, V273, P19829, DOI 10.1074/jbc.273.31.19829; LIU H, 2002, AM J PHYSIOL, V2582, pG257; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Liu HL, 2000, J BIOL CHEM, V275, P40155, DOI 10.1074/jbc.M001565200; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Meier UT, 1996, J BIOL CHEM, V271, P19376; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; THOR H, 1982, J BIOL CHEM, V257, P2419; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	48	68	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 23	2004	279	30					31089	31097		10.1074/jbc.M404170200	http://dx.doi.org/10.1074/jbc.M404170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	838QA	15145937	hybrid			2022-12-25	WOS:000222726800024
